Regression O
of O
the O
ROP B-outcome ['Physiological-Clinical']
was O
assessed O
for O
a O
minimum O
period O
of O
6 O
months O
. O
['Physiological-Clinical']

OBJECTIVE O
We O
investigated O
, O
in O
humans O
, O
the O
relation O
between O
past O
use O
of O
ecstasy O
and O
cognitive O
performance O
as O
well O
as O
serotonergic O
function O
. O
[]

Patients O
were O
evaluated O
1 O
month O
after O
the O
first O
visit O
. O
[]

The O
authors O
studied O
20 O
patients O
, O
ASA O
I-II O
, O
aged O
20-54 O
, O
both O
sexes O
, O
scheduled O
for O
abdominal O
surgery O
. O
[]

First O
analgesic B-outcome ['Resource-use']
time I-outcome ['Resource-use']
was O
similar O
in O
the O
two O
groups O
. O
['Resource-use']

There O
were O
no O
statistically O
significant O
changes O
from O
baseline O
for O
eye B-outcome ['Physiological-Clinical']
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
visual O
analog O
pain B-outcome ['Physiological-Clinical']
scale O
; O
VAS O
) O
and O
opiate B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
( O
ketobemidon B-outcome ['Resource-use']
) O
were O
evaluated O
during O
five O
postoperative O
days O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

Effects O
of O
single O
dose O
intranasal O
oxytocin O
on O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
in O
schizophrenia O
. O
['Life-Impact']

A O
multivariate O
model O
showed O
a O
significant O
regression O
in O
histopathology B-outcome ['Physiological-Clinical']
score O
as O
a O
function O
of O
the O
square O
of O
H B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
negative O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Some O
studies O
have O
suggested O
that O
rituximab O
is O
associated O
with O
excessive O
toxicity B-outcome ['Adverse-effects']
in O
HIV-associated O
NHL O
, O
and O
that O
infusional O
chemotherapy O
may O
be O
more O
effective O
. O
['Adverse-effects']

After O
2 O
years O
of O
follow-up O
, O
the O
differences O
narrowed O
. O
[]

Cardiovascular O
complications O
to O
treatment O
of O
prostate O
cancer O
with O
estramustine O
phosphate O
( O
Estracyt O
) O
or O
conventional O
estrogen O
. O
[]

OBJECTIVES O
We O
compared O
the O
efficacy O
of O
2 O
palatal O
surgical O
procedures O
in O
the O
treatment O
of O
patients O
with O
mild O
sleep-disordered O
breathing O
( O
SDB O
) O
. O
[]

DISCUSSION O
This O
trial O
will O
provide O
robust O
evidence O
to O
support O
the O
effectiveness O
of O
different O
designs O
of O
virtual O
patients O
, O
based O
on O
student B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
evaluation O
. O
['Life-Impact']

Early O
morning O
sleep O
deprivation O
( O
patient O
awake O
from O
0200 O
to O
2200 O
hours O
) O
produces O
a O
same-day O
antidepressant B-outcome ['Resource-use']
effect O
in O
approximately O
one-half O
of O
patients O
with O
major O
depression O
. O
['Resource-use']

To O
evaluate O
whether O
the O
inhibitory O
control O
of O
TSH B-outcome ['Physiological-Clinical']
and O
the O
stimulatory B-outcome ['Physiological-Clinical']
control O
of O
prolactin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
secretion B-outcome ['Physiological-Clinical']
exerted O
by O
endogenous O
serotonin O
was O
altered O
in O
obesity O
, O
22 O
obese O
men O
and O
10 O
normal O
controls O
were O
tested O
with O
TRH O
( O
200 O
micrograms O
IV O
bolus O
) O
in O
the O
presence O
( O
experimental O
test O
) O
and O
absence O
( O
control O
test O
) O
of O
the O
serotonergic O
agonist O
fenfluramine O
( O
60 O
mg O
PO O
90 O
min O
before O
TRH O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

We O
report O
three O
experiments O
carried O
out O
in O
the O
development O
of O
DTkid O
-- O
interactive O
computer O
simulation O
software O
that O
presents O
SIMon O
, O
a O
realistic O
virtual O
child O
with O
whom O
novice O
tutors O
can O
learn O
and O
practise O
DTT O
techniques O
. O
[]

The O
results O
from O
this O
study O
demonstrated O
that O
Cappra O
( O
? O
) O
[]

From O
the O
nutritional O
supplement O
database O
, O
22 O
subjects O
had O
an O
on-trial O
average O
supplementary O
vitamin O
E O
intake O
of O
> O
or O
= O
100 O
IU O
per O
day O
( O
high O
users O
) O
and O
29 O
subjects O
had O
an O
average O
on-trial O
supplementary O
vitamin O
C O
intake O
of O
> O
or O
= O
250 O
mg O
per O
day O
( O
high O
users O
) O
. O
[]

Effects O
of O
pioglitazone O
and O
glimepiride O
on O
glycemic O
control O
and O
insulin O
sensitivity O
in O
Mexican O
patients O
with O
type O
2 O
diabetes O
mellitus O
: O
A O
multicenter O
, O
randomized O
, O
double-blind O
, O
parallel-group O
trial O
. O
[]

This O
study O
compared O
the O
incidence O
of O
gastric O
ulcers O
after O
treatment O
with O
risedronate O
, O
a O
pyridinyl O
bisphosphonate O
, O
or O
alendronate O
, O
a O
primary O
amino O
bisphosphonate O
, O
in O
healthy O
postmenopausal O
women O
stratified O
by O
Helicobacter O
pylori O
status O
. O
[]

0.049 O
G/L O
) O
. O
[]

The O
pain B-outcome ['Physiological-Clinical']
reported O
by O
the O
patients O
was O
subdivided O
into O
four O
severity O
grades O
, O
and O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
recorded O
. O
['Physiological-Clinical', 'Resource-use']

Early O
educational O
intervention O
for O
very O
low O
birth O
weight O
infants O
: O
results O
from O
the O
Infant O
Health O
and O
Development O
Program O
. O
[]

69.2 O
kg O
, O
359.1 O
? O
[]

Elucidating O
the O
neural O
basis O
of O
the O
overlap O
between O
ASD O
and O
ADHD O
is O
likely O
to O
inform O
aetiological O
investigation O
and O
clinical O
assessment O
. O
[]

INTERVENTIONS O
Management O
guided O
by O
a O
clinical O
pathway O
( O
55 O
patients O
) O
or O
established O
standard O
of O
care O
( O
control O
group O
, O
56 O
patients O
) O
. O
[]

KC O
11458 O
slightly O
worsened O
( O
P O
= O
0.04 O
) O
upper B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
when O
compared O
with O
placebo O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
is O
the O
first O
study O
to O
test O
whether O
remission O
from O
geriatric O
depression O
depends O
on O
lesion O
volume O
by O
ROI O
in O
an O
outpatient O
sample O
. O
[]

Patients O
received O
single-needle O
acupuncture O
with O
a O
0.2 O
x O
13 O
mm O
disposable O
acupuncture O
needle O
( O
Suzhou O
Medical O
Appliances O
, O
China O
) O
, O
10-mm O
deep O
either O
at O
Chengjiang O
( O
midline O
between O
lower O
lip O
and O
chin O
) O
or O
superficially O
at O
a O
sham O
point O
( O
tip O
of O
the O
chin O
) O
during O
TEE O
or O
no O
acupuncture O
for O
alleviating O
gag O
reflex O
. O
[]

The O
patients O
of O
group O
2 O
( O
24 O
heels O
) O
continued O
nonsurgical O
treatment O
( O
iontophoresis O
with O
diclofenac O
and O
an O
oral O
nonsteroidal O
anti-inflammatory O
drug O
) O
for O
12 O
weeks O
. O
[]

We O
have O
compared O
this O
method O
with O
two O
other O
methods O
based O
on O
ultrasonic O
waves O
to O
identify O
the O
IJV O
and O
the O
carotid O
artery O
( O
CA O
) O
( O
even O
in O
atypical O
positions O
) O
. O
[]

No O
statistical O
difference O
in O
mortality B-outcome ['Mortality']
rate O
was O
seen O
among O
the O
3 O
fluid O
resuscitation O
groups O
. O
['Mortality']

Approximately O
160 O
patients O
are O
recruited O
in O
two O
care O
units O
at O
Psychiatrie-Zentrum O
Hard O
Embrach O
and O
two O
care O
units O
at O
Klinik O
Schlosstal O
Winterthur O
. O
[]

METHODS O
A O
total O
of O
107 O
American O
Society O
of O
Anaesthesiologists O
physical O
status O
grade O
I O
and O
II O
patients O
between O
18 O
and O
65 O
years O
of O
age O
who O
were O
scheduled O
to O
undergo O
elective O
anterior O
crucial O
ligament O
( O
ACL O
) O
reconstruction O
with O
hamstring O
autografts O
were O
enrolled O
in O
the O
study O
. O
[]

The O
total O
nocturnal B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
was O
, O
however O
, O
significantly O
reduced O
by O
octreotide O
( O
TSH O
AUC O
562+/-136 O
mU/l O
x O
h O
during O
octreotide O
and O
851+/-185 O
mU/l O
x O
h O
during O
saline O
; O
p O
< O
0.05 O
) O
, O
thus O
suggesting O
that O
100 O
microg O
of O
octreotide O
should O
be O
sufficient O
to O
inhibit O
also O
the O
pinealocytes O
if O
their O
function O
were O
regulated O
by O
somatostatin O
. O
['Physiological-Clinical']

We O
determined O
whether O
a O
pamphlet O
alone O
could O
be O
used O
by O
parents O
to O
help O
their O
child O
's O
insomnia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

if O
the O
C O
( O
2 O
) O
level O
was O
?60 O
ng/mL O
( O
T2 O
group O
) O
. O
[]

Effect O
of O
aliskiren O
on O
proteinuria B-outcome ['Physiological-Clinical']
in O
non-diabetic O
chronic O
kidney O
disease O
: O
a O
double-blind O
, O
crossover O
, O
randomised O
, O
controlled O
trial O
. O
['Physiological-Clinical']

Somnolence B-outcome ['Physiological-Clinical']
, O
the O
most O
frequently O
reported O
adverse O
event O
, O
was O
noted O
in O
72.5 O
% O
versus O
7.7 O
% O
of O
subjects O
( O
risperidone O
vs O
placebo O
) O
and O
seemed O
manageable O
with O
dose/dose-schedule O
modification O
. O
['Physiological-Clinical']

RESULTS O
Fluvoxamine O
and O
clomipramine O
both O
resulted O
in O
marked O
improvements O
; O
there O
were O
no O
statistically O
significant O
differences O
between O
them O
on O
the O
17-item O
HAMD O
total O
score O
, O
the O
clinical B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
or O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
items O
or O
the O
Montgomery-Asberg O
depression B-outcome ['Life-Impact']
rating O
scale O
, O
at O
any O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Of O
these O
5 O
tasks O
, O
the O
coin-in-the-hand O
, O
when O
administered O
in O
conjunction O
with O
the O
autobiographical O
interview O
, O
identified O
95 O
per O
cent O
of O
the O
simulators O
without O
misclassifying O
any O
of O
the O
memory-impaired O
or O
normal O
participants O
. O
[]

One-half O
of O
the O
patients O
was O
either O
prescribed O
an O
AmF/SnF2-containing O
mouthrinse O
( O
test O
mouthrinse O
) O
or O
a O
control O
mouthrinse O
in O
addition O
to O
mechanical O
plaque O
control O
for O
12 O
weeks O
. O
[]

Analyses O
of O
covariance O
showed O
that O
likely O
confounding O
variables O
including O
recent O
exposure O
to O
ecstasy O
, O
psychosocial O
profiles O
and O
use O
of O
other O
drugs O
did O
not O
explain O
the O
differences O
found O
between O
the O
groups O
. O
[]

BACKGROUND O
Diltiazem O
, O
a O
calcium O
channel O
blocker O
, O
has O
been O
shown O
to O
be O
safe O
and O
effective O
in O
the O
treatment O
of O
patients O
in O
atrial O
fibrillation O
and/or O
atrial O
flutter O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
a O
control O
group O
, O
who O
received O
the O
usual O
care O
or O
to O
an O
experimental O
group O
, O
who O
received O
a O
weekly O
telephone O
call O
intervention O
in O
addition O
to O
the O
usual O
care O
. O
[]

METHODS O
The O
study O
was O
a O
randomized O
controlled O
clinical O
study O
evaluating O
a O
'fast O
track O
' O
appointment O
with O
a O
6-week O
target O
waiting O
time O
against O
an O
'ordinary O
' O
appointment O
in O
the O
main O
city O
out-patient O
clinic O
of O
the O
rheumatology O
service O
for O
the O
Lothian O
and O
Borders O
region O
( O
population O
approximately O
1 O
million O
) O
. O
[]

This O
improvement O
was O
greater O
than O
with O
individual O
physiotherapy B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
exercises I-outcome ['Life-Impact']
alone O
( O
P O
< O
.001 O
) O
. O
['Life-Impact']

We O
compared O
patient-provider O
communication O
for O
the O
2 O
groups O
using O
audio O
recordings O
of O
the O
visit O
analyzed O
with O
the O
Roter O
Interaction O
Analysis O
System O
. O
[]

Of O
the O
53 O
patients O
enrolled O
in O
the O
crossover O
study O
, O
32 O
( O
age O
60 O
? O
[]

Measures O
of O
adherence B-outcome ['Life-Impact']
, O
activities O
of O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
, O
and O
emotional B-outcome ['Life-Impact']
impact O
were O
completed O
at O
the O
first O
and O
last O
intervention O
sessions O
and O
again O
at O
8 O
weeks O
and O
6 O
months O
post O
intervention O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
mean O
( O
sd O
) O
arterial O
pressure B-outcome ['Physiological-Clinical']
( O
mmHg O
) O
was O
significantly O
lower O
in O
group O
KG O
( O
67.4 O
[ O
2.07 O
] O
) O
than O
in O
groups O
TC O
( O
75.6 O
[ O
2.23 O
] O
) O
and O
KM O
( O
81.0 O
[ O
2.16 O
] O
) O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
time B-outcome ['Life-Impact']
between I-outcome ['Life-Impact']
stroke I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
beginning I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
was O
not O
significantly O
different O
between O
both O
groups O
. O
['Life-Impact']

Humoral O
parameters O
were O
analyzed O
at O
D0 O
, O
D15 O
, O
and O
M12 O
. O
[]

In O
the O
remaining O
patients O
extremely O
angulated O
, O
uneasy O
projection O
was O
often O
required O
to O
get O
a O
correct O
fluoroscopic B-outcome ['Resource-use']
image I-outcome ['Resource-use']
. O
['Resource-use']

CONCLUSIONS O
Patients O
undergoing O
FOB O
under O
adequate O
midazolam-alfentanil O
sedation O
do O
not O
develop O
excessive O
sympathetic O
drive O
that O
may O
lead O
to O
cardiac O
stress O
. O
[]

The O
preparation O
of O
homeopathic O
drugs O
is O
based O
on O
potentiation O
. O
[]

Combined O
topical O
and O
oral O
therapy O
with O
ofloxacin O
may O
be O
beneficial O
in O
the O
treatment O
of O
bleb-associated O
infections O
. O
[]

METHODS O
AND O
MATERIALS O
Between O
January O
2010 O
and O
January O
2012 O
, O
44 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
( O
FIGO O
2009 O
) O
stage O
IIB-IIIB O
squamous O
cell O
carcinoma O
of O
the O
cervix O
were O
randomized O
to O
receive O
50.4 O
Gy O
in O
28 O
fractions O
delivered O
via O
either O
WP-CRT O
or O
WP-IMRT O
with O
concurrent O
weekly O
cisplatin O
40 O
mg/m O
( O
2 O
) O
. O
[]

METHODS O
A O
10-month O
three-armed O
cluster-randomized O
controlled O
trial O
compared O
DCM O
and O
VPM O
with O
control O
. O
[]

BACKGROUND O
This O
study O
investigated O
the O
effects O
of O
oral O
dimercapto O
succinic O
acid O
( O
DMSA O
) O
therapy O
on O
the O
behavioural O
symptoms O
of O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
ages O
3-8 O
years O
. O
[]

There O
were O
7 O
systemic O
reactions B-outcome ['Adverse-effects']
with O
the O
monomer O
and O
none O
with O
the O
polymer O
. O
['Adverse-effects']

This O
points O
at O
C O
fibers O
, O
but O
the O
effects O
of O
pharmacologically O
stimulating O
C O
fibers O
have O
not O
been O
studied O
. O
[]

Atenolol O
was O
shown O
to O
be O
an O
effective O
anti-anginal O
agent O
when O
given O
once O
daily O
, O
and O
there O
were O
no O
major O
differences O
between O
the O
doses O
studied O
. O
[]

Patients O
with O
asymmetric O
diseases O
also O
were O
randomized O
for O
treatment O
in O
the O
threshold O
eye O
. O
[]

Mood B-outcome ['Life-Impact']
remained O
unchanged O
after O
rTMS O
. O
['Life-Impact']

Some O
effects O
were O
moderated O
by O
location O
and O
risk O
level O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
various O
anaesthetic O
procedures O
on O
the O
endocrine O
stress O
responses O
during O
ear O
microsurgical O
operations O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
clot-lysis I-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
, O
activated B-outcome ['Physiological-Clinical']
TAFI I-outcome ['Physiological-Clinical']
( O
TAFIa B-outcome ['Physiological-Clinical']
) O
-dependent O
prolongation O
of O
clot-lysis B-outcome ['Physiological-Clinical']
and O
TAFI B-outcome ['Physiological-Clinical']
levels O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
raises O
doubts O
about O
the O
clinical O
effectiveness O
of O
HDPM O
in O
autistic O
disorder O
. O
[]

Parents O
reported O
a O
high O
level O
of O
satisfaction B-outcome ['Life-Impact']
with O
the O
intervention O
. O
['Life-Impact']

The O
dose O
of O
risperidone O
was O
titrated O
up O
to O
3 O
mg/d O
and O
memantine O
was O
titrated O
to O
20 O
mg/d O
. O
[]

Three O
smaller O
studies O
also O
demonstrated O
that O
diltiazem O
effectively O
reduces O
ambulatory B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
; O
however O
, O
results O
with O
nifedipine O
are O
conflicting O
, O
with O
several O
studies O
showing O
no O
benefit O
. O
['Physiological-Clinical']

Blinding O
was O
maintained O
and O
the O
practitioner O
was O
able O
to O
maintain O
meditation B-outcome ['Life-Impact']
for O
both O
tactile O
and O
non-tactile O
LKM O
interventions O
as O
reflected O
in O
significantly O
reduced O
RR B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Both O
techniques O
were O
performed O
using O
a O
27G O
pencil O
point O
needle O
, O
an O
18G O
Tuohy O
needle O
, O
and O
a O
20G O
multiport O
epidural O
catheter O
from O
the O
same O
manufacturer O
. O
[]

MVO B-outcome ['Physiological-Clinical']
( O
2 O
) O
was O
measured O
before O
and O
after O
CCM O
therapy O
. O
['Physiological-Clinical']

All O
cavities O
received O
the O
same O
adhesive O
system O
and O
were O
restored O
with O
flowable O
composite O
according O
to O
manufacturer O
's O
instructions O
. O
[]

Results O
At O
month O
12 O
, O
zoledronic O
acid O
significantly O
increased O
LS O
BMD O
versus O
risedronate O
in O
patients O
? O
[]

CONCLUSION O
In O
MBC O
, O
longer O
epirubicin-based O
regimens O
are O
better O
in O
terms O
of O
response O
duration O
and O
TTP B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
renin-angiotensin O
system O
played O
a O
part O
in O
maintenance O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
only O
with O
severe O
salt O
restriction O
and O
in O
a O
small O
proportion O
of O
cases O
. O
['Physiological-Clinical']

Significantly O
enhanced O
power O
output B-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
groups O
post-arthroplasty O
; O
however O
, O
the O
new O
design O
implant O
group O
demonstrated O
a O
greater O
change O
in O
power O
output B-outcome ['Physiological-Clinical']
than O
the O
traditional O
implant O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Association O
of O
efavirenz O
hypersusceptibility O
with O
virologic O
response O
in O
ACTG O
368 O
, O
a O
randomized O
trial O
of O
abacavir O
( O
ABC O
) O
in O
combination O
with O
efavirenz O
( O
EFV O
) O
and O
indinavir O
( O
IDV O
) O
in O
HIV-infected O
subjects O
with O
prior O
nucleoside O
analog O
experience O
. O
[]

Combination O
treatment O
decreased O
the O
TC B-outcome ['Physiological-Clinical']
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
levels O
by O
28 O
% O
, O
38 O
% O
, O
and O
39 O
% O
respectively O
, O
and O
increased O
the O
HDL-C B-outcome ['Physiological-Clinical']
level O
by O
23 O
% O
( O
all O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
double-blind O
, O
double-dummy O
controlled O
, O
multicenter O
trial O
was O
conducted O
that O
involved O
554 O
antiretroviral-naive O
human O
immunodeficiency O
virus-infected O
adults O
( O
plasma O
HIV O
type O
1 O
[ O
HIV-1 O
] O
RNA O
level O
, O
> O
or=400 O
copies/mL O
; O
CD4 O
( O
+ O
) O
cell O
count O
, O
> O
100 O
cells/mm O
( O
3 O
) O
) O
and O
compared O
a O
300-mg O
once-daily O
( O
q.d O
. O
) O
[]

Modest O
antihypertensive O
effect O
of O
epanolol O
, O
a O
beta O
1-selective O
receptor O
blocker O
with O
beta O
1 O
agonist O
activity O
: O
an O
acute O
and O
long-term O
hemodynamic O
study O
at O
rest O
and O
during O
exercise O
and O
double O
crossover O
comparison O
with O
atenolol O
on O
ambulatory O
blood O
pressure O
. O
[]

Exploratory O
analyses O
suggested O
a O
survival B-outcome ['Mortality']
advantage O
for O
ASC O
plus O
vinorelbine O
compared O
with O
ASC O
alone O
( O
HR O
0.80 O
[ O
0.63-1.02 O
] O
; O
p=0.08 O
) O
, O
with O
a O
median O
survival B-outcome ['Mortality']
of O
9.5 O
months O
. O
['Mortality', 'Mortality']

DISCUSSION O
This O
study O
will O
investigate O
the O
effect O
of O
Nordic O
Walking O
on O
pain O
and O
function O
in O
a O
population O
of O
people O
with O
chronic O
LBP O
. O
[]

[ O
The O
problems O
of O
prophylactic O
chemotherapy O
, O
the O
second-look O
operation O
and O
the O
maintenance O
of O
the O
remission O
in O
the O
treatment O
of O
ovarian O
cancer O
( O
author O
's O
transl O
) O
] O
. O
[]

The O
pharmacokinetic/pharmacodynamic O
model O
showed O
that O
the O
QTcI B-outcome ['Physiological-Clinical']
slope O
for O
vilazodone O
was O
not O
different O
from O
0.0 O
and O
that O
the O
predicted O
increase O
from O
baseline O
in O
the O
QTc B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
Cmax I-outcome ['Physiological-Clinical']
for O
the O
highest O
therapeutic O
dose O
( O
156 O
ng/ml O
after O
40 O
mg/day O
) O
was O
< O
1 O
ms O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
within-practice O
[]

The O
purpose O
of O
this O
study O
was O
to O
gather O
data O
on O
the O
safety O
of O
lasalocid O
when O
fed O
to O
Chinese O
ring-necked O
pheasants O
at O
one O
, O
two O
, O
and O
three O
times O
the O
recommended O
high O
dose O
of O
lasalocid O
used O
for O
prevention O
of O
coccidiosis O
in O
other O
poultry O
at O
three O
times O
the O
normal O
treatment O
period O
. O
[]

Subjective O
and O
blinded O
physician O
dyschromia O
scores O
improved O
26 O
and O
38 O
% O
, O
respectively O
, O
3 O
months O
after O
the O
final O
IPL O
treatment O
, O
but O
only O
by O
7 O
and O
29 O
% O
, O
respectively O
, O
with O
Er O
: O
YAG O
. O
[]

Times B-outcome ['Resource-use']
to I-outcome ['Resource-use']
discharge I-outcome ['Resource-use']
were O
269 O
+/- O
62 O
minutes O
( O
C O
) O
, O
284 O
+/- O
62 O
( O
L O
) O
, O
and O
357 O
+/- O
71 O
( O
M O
) O
. O
['Resource-use']

RESULTS O
Eyes O
treated O
with O
10 O
Gy O
for O
occult O
CNV O
( O
n O
= O
12 O
) O
were O
subject O
to O
severe B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
41.6 O
% O
of O
the O
cases O
compared O
to O
38.5 O
% O
in O
the O
control O
group O
( O
n O
= O
13 O
) O
at O
12 O
months O
of O
follow-up O
. O
['Physiological-Clinical']

Relationship O
between O
baseline O
blood O
pressure O
parameters O
( O
including O
mean O
pressure O
, O
pulse O
pressure O
, O
and O
variability O
) O
and O
early O
outcome O
after O
stroke O
: O
data O
from O
the O
Tinzaparin O
in O
Acute O
Ischaemic O
Stroke O
Trial O
( O
TAIST O
) O
. O
[]

RESULTS O
Simvastatin O
, O
but O
not O
placebo O
, O
administered O
to O
these O
patients O
reduced O
plasma B-outcome ['Physiological-Clinical']
levels/activity O
of I-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
( O
from O
3.5 O
? O
['Physiological-Clinical']

This O
study O
sought O
to O
evaluate O
physical O
activity O
in O
women O
at O
moderate O
risk O
for O
breast O
cancer O
, O
the O
correlates O
of O
engaging O
in O
regular O
physical O
activity O
, O
and O
whether O
physical O
activity O
relates O
to O
psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
. O
['Life-Impact']

Schools O
were O
randomly O
assigned O
to O
the O
health-education O
package O
, O
which O
included O
a O
cartoon O
video O
, O
or O
to O
a O
control O
package O
, O
which O
involved O
only O
the O
display O
of O
a O
health-education O
poster O
. O
[]

BACKGROUND O
Pruritus O
in O
HIV-1+ O
patients O
is O
common O
and O
increases O
with O
disease O
progression O
. O
[]

In O
Phase O
2 O
, O
the O
two O
groups O
of O
children O
swapped O
over O
. O
[]

Histamine O
tests O
were O
performed O
before O
drug O
intake O
on O
days O
1 O
and O
5 O
, O
and O
then O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
, O
14 O
, O
and O
24 O
hours O
after O
drug O
intake O
on O
day O
5 O
. O
[]

Groups O
I O
, O
II O
, O
III O
, O
IV O
, O
and O
V O
consisted O
of O
roots O
in O
which O
the O
canal O
was O
filled O
with O
gutta-percha O
along O
with O
either O
Roth O
's O
sealer O
, O
AH26 O
, O
Sealapex O
, O
CRCS O
, O
or O
Nogenol O
sealer O
, O
respectively O
. O
[]

DEBR O
alone O
showed O
reductions O
in O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
and O
PPD O
and O
a O
significantly O
smaller O
gain O
in O
CPAL O
than O
in O
presplint O
teeth O
treated O
with O
BRG O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
observe O
the O
effects O
of O
Shuxuening O
Injection O
( O
SI O
) O
on O
the O
levels O
of O
serum B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
metalloproteinase-9 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MMP-9 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
tissue B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metalloproteinase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TIMP-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
acute O
exacerbated O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eighty-eight O
postmenopausal O
women O
with O
metastatic O
breast O
cancer O
, O
in O
whom O
estrogen O
receptors O
( O
ER O
) O
were O
positive O
or O
unknown O
, O
were O
treated O
on O
a O
controlled O
trial O
to O
determine O
the O
effectiveness O
of O
tamoxifen O
and O
to O
assess O
the O
therapeutic B-outcome ['Physiological-Clinical']
advantage O
of O
sequentially O
adding O
low-dose O
cyclophosphamide-methotrexate-5-fluorouracil O
( O
CMF O
) O
chemotherapy O
in O
tamoxifen O
responders O
. O
['Physiological-Clinical']

The O
PD O
effects O
were O
also O
assessed O
according O
the O
presence O
or O
absence O
of O
high B-outcome ['Physiological-Clinical']
on-treatment I-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Several O
studies O
have O
demonstrated O
that O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
can O
improve O
cognitive O
processing O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
then O
controlled O
after O
5 O
, O
10 O
, O
15 O
, O
20 O
, O
30 O
, O
45 O
, O
60 O
, O
120 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Thirty-eight O
patients O
with O
post-operative O
pain O
following O
hip O
replacement O
surgery O
were O
given O
IM O
or O
IV O
morphine O
10 O
mg O
at O
a O
specified O
pain O
level O
. O
[]

Brief O
, O
high-impact O
exercise O
increases O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
but O
the O
optimal O
frequency O
of O
such O
exercise O
and O
the O
location O
of O
bone O
accrual O
is O
unknown O
. O
['Physiological-Clinical']

With O
corrections O
applied O
for O
baseline O
and O
placebo O
, O
nitrendipine O
( O
10 O
to O
40 O
mg/d O
) O
, O
with O
the O
possible O
addition O
of O
enalapril O
( O
5 O
to O
20 O
mg/d O
) O
and/or O
hydrochlorothiazide O
( O
12.5 O
to O
25 O
mg/d O
) O
, O
reduced O
( O
P O
< O
.001 O
) O
these O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
values O
by O
16.6/7.3 O
and O
9.8/4.7 O
mm O
Hg O
, O
respectively O
. O
['Physiological-Clinical']

Aztreonam O
versus O
gentamicin O
for O
short-term O
prophylaxis O
in O
biliary O
and O
gastric O
surgery O
. O
[]

A O
significant O
relationship O
exists O
between O
higher O
levels O
( O
> O
or O
= O
125/microL O
) O
of O
CD19 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
longer O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Mortality']

Day O
0 O
was O
defined O
as O
the O
day O
that O
the O
animal O
first O
received O
treatment O
. O
[]

The O
intervention O
, O
Qigong O
Sensory O
Training O
( O
QST O
) O
, O
is O
a O
qigong O
massage O
intervention O
based O
in O
Chinese O
medicine O
. O
[]

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
these O
agents O
as O
antifungal O
prophylaxis O
. O
['Adverse-effects']

We O
will O
recruit O
patients O
with O
diabetes O
or O
hypertension O
; O
these O
patients O
will O
be O
randomly O
assigned O
to O
receive O
all O
of O
their O
medications O
with O
improved O
labels O
or O
to O
receive O
prescriptions O
with O
standard O
labels O
. O
[]

METHODS O
AND O
RESULTS O
Of O
140 O
patients O
randomized O
to O
three O
argatroban O
dose O
groups O
( O
ARG250 O
, O
ARG300 O
, O
and O
ARG350 O
with O
250 O
, O
300 O
, O
or O
350 O
?g/kg O
bolus O
, O
followed O
by O
15 O
, O
20 O
, O
or O
25 O
?g/kg/min O
infusion O
) O
and O
one O
unfractionated O
heparin O
( O
UFH O
) O
group O
( O
70-100 O
IU/kg O
bolus O
) O
, O
138 O
patients O
were O
analyzed O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
characterize O
the O
PK O
and O
PK/DPP-4 O
inhibition O
relationship O
of O
linagliptin O
in O
Japanese O
patients O
with O
T2DM O
using O
a O
population O
PK/DPP-4 O
model O
and O
to O
support O
the O
rationale O
for O
the O
therapeutic O
dose O
in O
Japanese O
patients O
by O
simulation O
. O
[]

The O
scores O
on O
awakening O
and O
after O
10 O
minutes O
were O
significantly O
lower O
in O
the O
bupivacaine O
group O
( O
P O
< O
0.05 O
, O
Mann-Whitney O
U O
test O
) O
. O
[]

The O
baseline O
characteristics O
, O
complications B-outcome ['Adverse-effects']
, O
and O
survival B-outcome ['Mortality']
of O
489 O
black O
and O
6,890 O
non-black O
patients O
with O
acute O
coronary O
syndromes O
were O
studied O
. O
['Adverse-effects', 'Mortality']

Esomeprazole O
resolves O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
in O
patients O
without O
erosive O
oesophagitis O
. O
['Physiological-Clinical']

After O
5 O
weeks O
of O
treatment O
, O
the O
largest O
decrease O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
observed O
in O
group O
3 O
( O
the O
mean O
change O
from O
baseline O
in O
seated B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SDBP B-outcome ['Physiological-Clinical']
) O
and O
seated B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SSBP B-outcome ['Physiological-Clinical']
) O
, O
respectively O
, O
were O
: O
-2.0 O
and O
-11.5 O
mmHg O
in O
group O
1 O
; O
-7.6 O
and O
-15.4 O
mmHg O
in O
group O
2 O
; O
-12.6 O
and O
-21.6 O
mmHg O
in O
group O
3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
general O
, O
the O
changes O
in O
standing B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
stabilized I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
similar O
to O
those O
seen O
in O
supine O
measurements O
. O
['Physiological-Clinical', 'Physiological-Clinical']

10?/L O
vs. O
9.6 O
? O
[]

Patients O
in O
the O
diastolic O
HF O
group O
tended O
to O
be O
older O
( O
p O
< O
0.08 O
) O
, O
with O
more O
women O
( O
p O
< O
0.006 O
) O
and O
with O
greater O
body O
mass O
indexes O
( O
p O
< O
0.02 O
) O
, O
than O
those O
in O
the O
systolic O
HF O
group O
. O
[]

An O
open-label O
, O
randomized O
controlled O
study O
was O
conducted O
at O
a O
tertiary O
care O
teaching O
hospital O
to O
compare O
efficacy O
and O
safety O
of O
intravenous O
sodium O
valproate O
versus O
diazepam O
infusion O
for O
control O
of O
refractory O
status O
epilepticus O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
also O
differently O
affected O
the O
power O
distribution O
< O
1 O
Hz O
in O
non-rapid B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
movement B-outcome ['Physiological-Clinical']
sleep B-outcome ['Physiological-Clinical']
between O
caffeine O
sensitive O
and O
insensitive O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RS O
had O
no O
clinical O
effect O
on O
adenomas O
. O
[]

CONCLUSIONS O
There O
is O
a O
strong O
association O
between O
non-accidental B-outcome ['Physiological-Clinical']
falls O
and O
cardioinhibitory O
CSH O
. O
['Physiological-Clinical']

CONCLUSION O
For O
this O
population O
of O
low-risk O
patients O
, O
there O
was O
no O
significant O
difference O
in O
outcome O
after O
applications O
of O
a O
single O
intraoperative O
dose O
of O
beta O
radiation O
. O
[]

Participants O
A O
total O
of O
59 O
children O
, O
aged O
3-5 O
years O
, O
attending O
two O
early O
childhood O
intervention O
centres O
in O
Melbourne O
, O
Australia O
. O
[]

RESULTS O
The O
intensity O
of O
LBP B-outcome ['Physiological-Clinical']
decreased O
significantly O
more O
( O
39 O
% O
) O
in O
the O
TG O
than O
in O
CG O
at O
12 O
months O
. O
['Physiological-Clinical']

Previous O
studies O
have O
found O
that O
angiotensin-converting O
enzyme O
inhibitors O
( O
ACEi O
) O
may O
improve O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
older O
people O
. O
['Life-Impact']

STUDY O
DESIGN O
A O
randomized O
, O
placebo-controlled O
trial O
in O
which O
patients O
received O
either O
usual O
care O
by O
a O
general O
practitioner O
( O
information O
and O
analgesics O
) O
, O
or O
placebo O
physiotherapy O
given O
by O
a O
physiotherapist O
, O
or O
exercise O
therapy O
given O
by O
a O
physiotherapist O
. O
[]

Patients O
in O
the O
BENEFIT-EXT O
study O
received O
extended O
criteria O
donor O
kidneys O
and O
a O
more O
intensive O
( O
MI O
) O
or O
less O
intensive O
( O
LI O
) O
belatacept O
immunosuppression O
regimen O
, O
or O
cyclosporine O
A O
( O
CsA O
) O
. O
[]

BACKGROUND O
Symptoms O
of O
allergic O
rhinitis O
are O
mediated O
in O
part O
by O
cysteinyl O
leukotrienes O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
thyroid O
hormone O
excess O
and O
deficiency O
on O
TAFI O
levels O
and O
function O
. O
[]

Visual O
and O
kinesthetic O
locomotor O
imagery O
training O
integrated O
with O
auditory O
step O
rhythm O
for O
walking O
performance O
of O
patients O
with O
chronic O
stroke O
. O
[]

METHODS O
Forty O
autistic O
children O
aged O
2-12 O
, O
who O
were O
scheduled O
for O
stem O
cell O
transplantation O
via O
lumbar O
puncture O
under O
anesthesia O
, O
were O
randomized O
for O
a O
double-blind O
study O
. O
[]

5 O
sec O
) O
, O
n O
= O
35 O
. O
[]

A O
secondary O
aim O
was O
to O
evaluate O
toxicity O
. O
[]

METHODS O
Forty O
pregnant O
women O
were O
randomly O
allocated O
to O
control O
or O
treatment O
groups O
. O
[]

STUDY O
DESIGN O
First O
a O
randomised O
trial O
, O
later O
periconception O
care O
including O
in O
total O
12225 O
females O
. O
[]

RESULTS O
At O
end O
point O
, O
reductions O
in O
ADHD B-outcome ['Life-Impact']
, O
depressive B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Evidence-based O
narratives O
to O
improve O
recall B-outcome ['Life-Impact']
of O
opioid O
prescribing O
guidelines O
: O
a O
randomized O
experiment O
. O
['Life-Impact']

CONCLUSION O
All O
women O
become O
menopausal O
, O
and O
many O
of O
them O
seek O
medical O
advice O
on O
ways O
to O
improve O
quality O
of O
life O
; O
little O
evidence-based O
information O
exists O
. O
[]

PURPOSE O
To O
study O
the O
impact O
of O
clinical O
predisposing O
factors O
on O
rectal O
normal O
tissue O
complication O
probability O
modeling O
using O
the O
updated O
results O
of O
the O
Dutch O
prostate O
dose-escalation O
trial O
. O
[]

Fifty-two O
patients O
with O
severe O
rheumatoid O
arthritis O
( O
RA O
) O
from O
four O
Australian O
centres O
were O
randomised O
to O
receive O
cyclosporin O
A O
( O
CSA O
) O
( O
n O
= O
25 O
) O
or O
azathioprine O
( O
AZA O
) O
( O
n O
= O
27 O
) O
for O
six O
months O
. O
[]

As O
demonstrated O
by O
in O
vitro O
studies O
, O
cisplatin O
( O
CDDP O
) O
is O
able O
to O
down-regulate O
the O
AGAT O
activity O
, O
suggesting O
that O
CDDP O
could O
enhance O
the O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
TMZ I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
a O
further O
3 O
and O
12 O
months O
, O
they O
were O
assessed O
in O
exactly O
the O
same O
way O
as O
the O
treatment O
group O
. O
[]

METHODS O
This O
trial O
extended O
a O
13-week O
, O
Phase O
III O
multicenter O
placebo-controlled O
, O
double-blind O
outpatient O
trial O
for O
an O
additional O
40 O
weeks O
. O
[]

Nordic O
walking O
and O
chronic O
low O
back O
pain O
: O
design O
of O
a O
randomized O
clinical O
trial O
. O
[]

Fake O
bad O
test O
response O
bias O
effects O
on O
the O
test O
of O
variables O
of O
attention B-outcome ['Life-Impact']
. O
['Life-Impact']

S-adenosylmethionine O
significantly O
( O
P O
less O
than O
0.01 O
) O
improved O
subjective O
symptoms B-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
pruritus I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
feeling O
of O
['Physiological-Clinical', 'Physiological-Clinical']

Late O
attendance O
for O
the O
second O
surveillance O
test O
was O
higher O
in O
women O
who O
were O
younger O
, O
smokers O
, O
had O
children O
and O
attended O
late O
for O
the O
first O
test O
. O
[]

Determining O
the O
trough-to-peak O
ratio O
in O
parallel-group O
trials O
. O
[]

The O
presentation O
of O
the O
research O
design O
includes O
discussions O
of O
data O
collection O
and O
patient O
sampling O
methods O
; O
the O
measurement O
of O
patient O
outcomes O
, O
including O
measures O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
utilization B-outcome ['Life-Impact']
, O
patient B-outcome ['Physiological-Clinical']
functional I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
quality O
of O
life O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
verify O
the O
effectiveness O
and O
safety O
of O
an O
n-BCA/Tantalum O
Powder/Ethiodized O
Oil O
mixture O
, O
compared O
with O
conventional O
treatment O
( O
Trufill O
polyvinyl O
alcohol O
[ O
PVA O
] O
) O
for O
preoperative O
embolization O
of O
cerebral O
AVM O
. O
[]

RESULTS O
Patients O
treated O
with O
fluoxetine O
and O
those O
treated O
with O
venlafaxine O
showed O
similar O
improvement O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Radiotherapy O
treatment O
was O
completed O
in O
78 O
% O
( O
47/60 O
) O
of O
the O
RT O
group O
and O
89 O
% O
( O
58/65 O
) O
of O
the O
CRT O
group O
( O
P=0.10 O
) O
. O
[]

Association O
between O
weight O
loss B-outcome ['Physiological-Clinical']
and O
improvement O
of O
ventricular B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
advanced O
heart O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
( O
16 O
% O
) O
patients O
in O
the O
LC O
group O
required O
conversion O
to O
OC O
, O
in O
most O
because O
severe B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
distorted O
the O
anatomy O
of O
Calot O
's O
triangle O
. O
['Physiological-Clinical']

The O
subjects O
gained O
an O
average O
of O
5.1 O
kg O
. O
[]

The O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
scores O
and O
requirement B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
was O
significantly O
less O
in O
the O
stapled O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

However O
, O
the O
time O
of O
recovery O
showed O
a O
significant O
decrease O
only O
in O
the O
LED O
group O
( O
p O
= O
0.003 O
) O
. O
[]

The O
relative O
increase O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
most O
successful B-outcome ['Physiological-Clinical']
method O
was O
to O
leave O
the O
laryngoscope O
in O
the O
mouth O
and O
rotate O
the O
tube O
to O
-90 O
degrees O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
Australia O
and O
New O
Zealand O
Clinical O
Trials O
Register O
( O
ANZCTR O
) O
: O
ACTRN12606000344594 O
. O
[]

Falls B-outcome ['Life-Impact']
were O
documented O
using O
diaries O
. O
['Life-Impact']

Safety O
of O
an O
astaxanthin-rich O
Haematococcus O
pluvialis O
algal O
extract O
: O
a O
randomized O
clinical O
trial O
. O
[]

The O
effects O
of O
a O
multi-component O
higher-functioning O
autism O
anti-stigma O
program O
on O
adolescent O
boys O
. O
[]

The O
present O
study O
was O
undertaken O
to O
determine O
the O
optimal O
timing O
of O
autologous O
blood O
reinfusion O
in O
elective O
spinal O
surgery O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
to O
recommend O
no O
snacks O
vs O
three O
snacks O
per O
day O
on O
1-year O
weight O
loss O
. O
[]

RESULTS O
After O
6 O
mo O
, O
im O
TU O
increased O
T B-outcome ['Physiological-Clinical']
and O
free- O
T B-outcome ['Physiological-Clinical']
levels O
( O
p O
< O
0.0001 O
) O
, O
and O
improved O
metabolic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
[ O
reduction O
in O
Homeostasis B-outcome ['Physiological-Clinical']
Model O
Assessment O
( O
HOMA B-outcome ['Physiological-Clinical']
) O
index O
, O
p O
< O
0.0001 O
; O
waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
and O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
p O
< O
0.001 O
, O
respectively O
] O
, O
in O
International O
Index O
of O
Erectile B-outcome ['Life-Impact']
Function-5 O
and O
Aging O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

METHODS O
Blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
fibrinolytic I-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
were O
measured O
in O
both O
forearms O
of O
eight O
healthy O
males O
who O
received O
unilateral O
brachial O
artery O
infusions O
of O
the O
endothelium-dependent O
vasodilators O
substance O
P O
( O
2 O
to O
8 O
pmol/min O
) O
and O
bradykinin O
( O
100 O
to O
1,000 O
pmol/min O
) O
, O
and O
the O
endothelium-independent O
vasodilator O
sodium O
nitroprusside O
( O
2 O
to O
8 O
microg/min O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
treatment O
for O
12 O
to O
18 O
months O
, O
cyclosporin O
A O
caused O
significant O
reductions O
in O
the O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
before O
drug O
withdrawal O
, O
cyclosporin O
97 O
+/- O
18 O
vs O
placebo O
125 O
+/- O
16 O
ml O
min-1 O
1.73-m-2 O
, O
p O
less O
than O
0.05 O
) O
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
454 O
+/- O
83 O
vs O
536 O
+/- O
70 O
ml O
min-1 O
1.73-m-2 O
, O
p O
less O
than O
0.05 O
) O
, O
and O
lithium B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( O
17 O
+/- O
3 O
vs O
28 O
+/- O
5 O
ml O
min-1 O
1.73-m-2 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
post O
hoc O
analysis O
of O
the O
Treating O
to O
New O
Targets O
( O
TNT O
) O
trial O
examined O
whether O
the O
observed O
decrease O
in O
HF O
hospitalizations O
with O
high- O
compared O
to O
low-dose O
atorvastatin O
could O
be O
related O
to O
improvements O
in O
kidney O
function O
. O
[]

Patients O
receive O
hyperbaric O
oxygen O
therapy O
every O
day O
for O
6 O
weeks O
during O
the O
treatment O
phase O
and O
are O
provided O
ongoing O
wound O
care O
and O
weekly O
assessments O
. O
[]

Abnormalities O
in O
the O
serotonin O
neurotransmitter O
system O
have O
been O
identified O
in O
some O
persons O
with O
autism O
. O
[]

RESULTS O
No O
differences O
in O
rocuronium B-outcome ['Physiological-Clinical']
PK I-outcome ['Physiological-Clinical']
parameters O
were O
observed O
between O
study O
groups O
. O
['Physiological-Clinical']

Subjects O
were O
treated O
for O
3 O
months O
, O
with O
follow-up O
visits O
at O
2 O
, O
4 O
, O
6 O
, O
and O
12 O
weeks O
. O
[]

RESULTS O
Compared O
to O
the O
normal O
group O
, O
the O
levels O
of O
MDA B-outcome ['Physiological-Clinical']
in O
all O
of O
the O
hypertension B-outcome ['Physiological-Clinical']
patient O
groups O
were O
higher O
, O
SOD B-outcome ['Physiological-Clinical']
was O
lower O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
results O
suggest O
that O
a O
comprehensive O
health O
care O
program O
is O
one O
way O
to O
bring O
about O
better O
outcomes O
for O
both O
adolescent O
mothers O
and O
their O
infants O
. O
[]

ME-609 O
treatment O
offers O
additional O
therapeutic O
benefit O
compared O
with O
therapy O
with O
topical O
acyclovir O
alone O
. O
[]

Longitudinally O
, O
these O
correlations O
were O
lower O
( O
coefficients O
ranged O
from O
0.17 O
to O
0.54 O
) O
but O
were O
still O
significant O
. O
[]

Patients O
with O
symptomatic O
paroxysmal O
or O
persistent O
AF O
who O
had O
converted O
to O
sinus O
rhythm O
( O
SR O
) O
were O
randomly O
assigned O
aprindine O
( O
40 O
mg/day O
) O
, O
digoxin O
( O
0.25 O
mg/day O
) O
or O
placebo O
and O
followed O
up O
on O
an O
outpatient O
basis O
every O
2 O
weeks O
for O
6 O
months O
. O
[]

Nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
and O
safety O
assessments O
were O
performed O
during O
the O
24-h O
recovery O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cases O
of O
renal O
stone O
regardless O
of O
stone O
size O
and O
configuration O
, O
having O
pre-operative O
negative O
urine O
culture O
, O
no O
coagulopathy O
, O
and O
no O
visible O
residual O
stone O
in O
intra-operative O
fluoroscopy O
, O
were O
included O
. O
[]

We O
investigated O
the O
visual O
information O
and O
the O
control O
strategies O
used O
to O
guide O
both O
the O
head O
and O
the O
hand O
on O
approach O
to O
a O
target O
in O
a O
locomotion-to-reach O
task O
. O
[]

METHODS O
In O
groups O
of O
20 O
, O
60 O
women O
were O
randomly O
assigned O
to O
one O
of O
three O
treatments O
: O
oral O
calcium O
, O
1000 O
mg/day O
; O
oral O
calcium O
plus O
oral O
clodronate O
, O
400 O
mg/day O
; O
oral O
calcium O
plus O
oral O
clodronate O
, O
400 O
mg/day O
for O
30 O
days O
, O
followed O
by O
a O
60-day O
period O
of O
calcium O
supplement O
alone O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
these O
drugs O
and O
times O
for O
the O
plasma O
concentration O
to O
decrease O
by O
50 O
% O
( O
t50 O
) O
and O
80 O
% O
( O
t80 O
) O
after O
cessation O
of O
the O
infusion O
were O
determined O
. O
['Physiological-Clinical']

RESULTS O
Sixty O
one O
children O
completed O
the O
study O
. O
[]

The O
effect O
variables O
were O
daily O
levels O
of O
pain O
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
palpation B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and O
isokinetic B-outcome ['Physiological-Clinical']
quadriceps I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Demographic O
data O
are O
presented O
for O
the O
study O
population O
, O
including O
an O
analysis O
of O
potential O
biased O
selection O
of O
patients O
electing O
to O
participate O
in O
random O
assignment O
. O
[]

Radiation-induced O
brachial O
plexopathy O
occurs O
mainly O
as O
diffuse O
damage O
to O
the O
brachial O
plexus O
. O
[]

The O
median O
follow-up O
was O
8.5 O
years O
. O
[]

CONCLUSION O
Our O
data O
indicate O
that O
the O
beneficial O
effect O
of O
the O
multiple O
risk O
intervention O
programme O
was O
confined O
to O
those O
patients O
with O
echolucent O
plaques O
. O
[]

CNS O
disease O
included O
meningeal O
disease O
or O
CNS O
parenchymal O
masses O
with O
or O
without O
cranial O
neuropathies O
( O
CSF+/Mass O
; O
CNPs O
) O
in O
36 O
patients O
and O
isolated O
CNPs O
in O
13 O
. O
[]

Six O
children O
enrolled O
in O
a O
double-blind O
, O
placebo-controlled O
crossover O
study O
in O
which O
each O
child O
was O
its O
own O
control O
. O
[]

In O
this O
double-blind O
, O
randomized O
crossover O
study O
, O
we O
compared O
spinal O
2-CP O
( O
30 O
mg O
) O
with O
and O
without O
clonidine O
( O
15 O
microg O
) O
in O
eight O
volunteers O
. O
[]

Subjects O
in O
both O
practice O
and O
no-practice O
groups O
reported O
less O
anxiety B-outcome ['Life-Impact']
and O
exhibited O
more O
cooperative B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
during O
inoculation O
than O
subjects O
in O
the O
control O
group O
, O
and O
those O
who O
were O
guided O
and O
prompted O
to O
actively O
practice O
derived O
greater O
benefit O
. O
['Life-Impact', 'Life-Impact']

Fifty O
patients O
completed O
the O
crossover O
trial O
and O
47 O
completed O
the O
open-label O
phase O
. O
[]

Adjuvant O
portal O
infusion O
did O
not O
influence O
the O
occurrence O
of O
liver B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
but O
reduced O
the O
overall O
recurrence B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

26 O
were O
operated O
on O
under O
neuroleptanaesthesia O
( O
NA O
group O
) O
and O
24 O
under O
continuous O
epidural O
combined O
with O
a O
light O
general O
anaesthesia O
( O
epidural O
group O
) O
. O
[]

[ O
Effect O
on O
pressure O
after O
instillation O
of O
a O
drop O
of O
depot-pilocarpine O
. O
[]

0.3 O
) O
( O
P O
= O
0.015 O
) O
. O
[]

METHODS O
Pronuclear-stage O
human O
embryos O
were O
randomly O
divided O
and O
cultured O
in O
human O
tubal O
fluid O
medium O
( O
HTF O
) O
supplemented O
with O
either O
HSA O
( O
5 O
mg/mL O
) O
or O
Plasmatein O
( O
10 O
% O
, O
v/v O
; O
5 O
mg/ml O
) O
as O
a O
means O
of O
indirectly O
assessing O
the O
effect O
alpha- O
and O
beta-globulins O
have O
on O
embryonic O
development O
. O
[]

After O
adjusting O
for O
child O
demographic O
characteristics O
and O
non-ASD-associated O
illnesses O
, O
ASD O
was O
associated O
with O
$ O
3020 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
$ O
1017- O
$ O
4259 O
) O
higher O
health O
care O
costs O
and O
$ O
14,061 O
( O
95 O
% O
CI O
: O
$ O
4390- O
$ O
24,302 O
) O
higher O
aggregate O
non-health O
care O
costs O
, O
including O
$ O
8610 O
( O
95 O
% O
CI O
: O
$ O
6595- O
$ O
10,421 O
) O
higher O
school O
costs O
. O
[]

After O
excluding O
women O
with O
sexually O
transmitted O
infections O
and O
other O
exclusions O
, O
61 O
% O
( O
53/87 O
) O
had O
cervicitis B-outcome ['Physiological-Clinical']
of O
unknown O
etiology O
. O
['Physiological-Clinical']

Evaluations O
were O
at O
baseline O
, O
3- O
, O
and O
6-months O
. O
[]

OBJECTIVES O
To O
establish O
the O
effect O
of O
the O
atypical O
neuroleptic O
clozapine O
on O
chorea O
, O
voluntary O
motor O
performance O
, O
and O
functional O
disability O
in O
patients O
with O
Huntington O
's O
disease O
. O
[]

BACKGROUND O
Azimilide O
dihydrochloride O
( O
azimilide O
) O
is O
an O
investigational O
antiarrhythmic O
drug O
that O
has O
been O
tested O
in O
patients O
with O
a O
variety O
of O
arrhythmias O
. O
[]

Therefore O
, O
it O
is O
probable O
that O
these O
changes O
are O
membrane-related O
. O
[]

However O
, O
potassium O
titanyl O
phosphate O
laser O
required O
slightly O
more O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
caused O
more O
late B-outcome ['Physiological-Clinical']
post-operative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
than O
the O
bipolar O
radiofrequency O
technique O
. O
['Life-Impact', 'Physiological-Clinical']

METHOD O
Thirty-four O
children O
and O
adolescents O
with O
ASD O
( O
age O
range O
8-17 O
years O
; O
IQ O
> O
75 O
) O
were O
enrolled O
in O
a O
10-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
donepezil O
( O
doses O
of O
5 O
and O
10 O
mg O
) O
, O
followed O
by O
a O
10-week O
open O
label O
trial O
for O
placebo O
nonresponders O
. O
[]

Significant O
changes O
over O
time O
were O
also O
noted O
in O
the O
visual O
analog O
pain B-outcome ['Physiological-Clinical']
and O
functional O
scales O
and O
the O
mid-patella O
girth O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
multicenter O
, O
randomized O
, O
double-blind O
study O
was O
designed O
to O
compare O
the O
efficacy O
and O
safety O
of O
once-daily O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
( O
220 O
micrograms/day O
) O
with O
placebo O
in O
relieving O
the O
symptoms O
of O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
due O
to O
ragweed O
. O
['Physiological-Clinical']

This O
study O
investigated O
the O
efficacy O
and O
safety O
of O
transdermal O
clonidine O
in O
reducing O
hyperarousal O
behaviors O
associated O
with O
autism O
. O
[]

Intrauterine O
catheter-tip O
transducers O
can O
be O
used O
reliably O
to O
measure O
uterine B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
third O
stage O
of O
labour O
although O
there O
may O
be O
minor O
contraction O
by O
contraction O
differences O
in O
recordings O
of O
individual B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
a O
single O
injection O
of O
intravenous O
secretin O
results O
in O
measurable O
improvements O
in O
socialization O
and/or O
communication O
skills O
in O
children O
with O
autism O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
efficacy O
of O
SJW O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
. O
['Life-Impact']

Weak O
resting-state O
inhibition O
was O
associated O
with O
an O
overall O
lower O
manual O
motor O
performance O
. O
[]

All O
assessments O
were O
double-blinded O
. O
[]

TRIAL O
REGISTRATION O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
ACTRN12610000087055 O
. O
[]

Results O
for O
oxitropium O
bromide O
treatment O
were O
significantly O
better O
than O
the O
run-in O
values O
( O
p O
less O
than O
0.005 O
) O
and O
the O
placebo O
period O
( O
p O
less O
than O
0.02 O
) O
. O
[]

In O
a O
secondary O
analysis O
, O
outcome O
variables O
were O
compared O
with O
the O
nonrandomized O
patients O
without O
previous O
statin O
therapy O
( O
n O
= O
126 O
) O
. O
[]

In O
addition O
, O
students O
who O
used O
TeachTown O
: O
Basics O
demonstrated O
significant O
progress B-outcome ['Physiological-Clinical']
overall I-outcome ['Physiological-Clinical']
in O
the O
['Physiological-Clinical']

CONTEXT O
It O
is O
uncertain O
whether O
intensified O
heart O
failure O
therapy O
guided O
by O
N-terminal O
brain O
natriuretic O
peptide O
( O
BNP O
) O
is O
superior O
to O
symptom-guided O
therapy O
. O
[]

Physical O
health O
-- O
a O
cluster O
randomized O
controlled O
lifestyle O
intervention O
among O
persons O
with O
a O
psychiatric O
disability O
and O
their O
staff O
. O
[]

A O
receiver O
operating O
characteristic O
( O
ROC O
) O
curve O
analysis O
was O
done O
of O
sensitivity O
and O
specificity O
of O
biopsy O
indications O
through O
PSA O
and O
PSA O
corrected O
for O
the O
volumes O
measured O
with O
transrectal O
ultrasound O
. O
[]

Randomized O
, O
controlled O
, O
crossover O
trial O
of O
methylphenidate O
in O
pervasive O
developmental O
disorders O
with O
hyperactivity O
. O
[]

There O
was O
no O
significant O
difference O
between O
losartan O
and O
enalapril O
with O
respect O
to O
their O
impact O
on O
proteinuria B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical']

Following O
maintenance O
evaluations O
, O
the O
drug O
was O
tapered O
down O
over O
2 O
weeks O
. O
[]

0.41 O
IU/mL O
for O
dalteparin O
( O
P O
= O
0.1 O
) O
, O
indicating O
clinically O
important O
accumulation O
for O
both O
drugs O
. O
[]

Treatment O
was O
associated O
with O
32 O
days O
longer B-outcome ['Physiological-Clinical']
gestation I-outcome ['Physiological-Clinical']
for O
the O
23 O
participants O
who O
had O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
spontaneous I-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
( O
P= O
0.024 O
, O
Mann-Whitney O
U O
test O
) O
and O
significantly O
fewer O
infants O
had O
a O
birthweight O
below O
2,500 O
g B-outcome ['Physiological-Clinical']
( O
secondary O
outcome O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
. O
[]

CONCLUSIONS O
Left O
internal O
thoracic O
artery-radial O
artery O
composite O
grafts O
proved O
to O
be O
a O
safe O
procedure O
in O
elderly O
patients O
. O
[]

Seventy-eight O
children O
presenting O
with O
typical O
and O
extraesophageal O
symptoms O
of O
gastroesophageal O
reflux O
disease O
underwent O
a O
multichannel O
intraluminal O
impedance O
and O
pH O
monitoring O
( O
MII/pH O
) O
. O
[]

The O
authors O
report O
a O
randomized O
, O
controlled O
study O
of O
21 O
hospitalized O
trauma O
patients O
to O
assess O
the O
analgesic O
efficacy O
of O
virtual O
reality O
hypnosis O
( O
VRH O
) O
-hypnotic O
induction O
and O
analgesic O
suggestion O
delivered O
by O
customized O
virtual O
reality O
( O
VR O
) O
hardware/software O
. O
[]

The O
results O
showed O
small O
nonsignificant O
changes O
in O
the O
total O
scores O
of O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
after O
3- O
and O
6-month O
treatment O
. O
['Life-Impact']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
diethylpropion O
on O
a O
long-term O
basis O
, O
with O
emphasis O
in O
cardiovascular O
and O
psychiatric O
safety O
aspects O
. O
[]

Primary O
RP O
were O
screened O
and O
assigned O
to O
either O
the O
nifedipine O
SR O
group O
( O
Group O
N O
) O
or O
the O
Ginkgo O
biloba O
extract O
group O
( O
Group O
G O
) O
in O
the O
ratio O
of O
2:1 O
. O
[]

After O
treatment O
, O
the O
experimental O
group O
significantly O
improved O
in O
measures O
of O
[]

ET O
vs. O
BMV O
) O
. O
[]

RESULTS O
Data O
were O
successfully O
obtained O
from O
the O
12 O
of O
18 O
subjects O
who O
completed O
the O
study O
( O
11 O
males O
, O
age O
range O
2 O
to O
15.25 O
years O
, O
mean O
5.47 O
, O
SD O
3.6 O
) O
. O
[]

Participants O
were O
trained O
to O
adopt O
a O
generally O
positive O
or O
negative O
poststressor O
appraisal O
style O
using O
a O
series O
of O
scripted O
vignettes O
after O
having O
been O
exposed O
to O
highly O
distressing O
film O
clips O
. O
[]

Transverse O
paddle O
orientation O
resulted O
in O
a O
significantly O
( O
P O
< O
0.01 O
) O
higher O
TTI O
than O
longitudinal O
orientation O
at O
all O
paddle O
forces O
below O
12 O
kg O
force O
. O
[]

At O
a O
regional O
conference O
, O
emergency O
physicians O
( O
EPs O
) O
were O
randomized O
to O
read O
either O
a O
summary O
of O
the O
guideline O
( O
control O
) O
or O
a O
narrative O
( O
intervention O
) O
. O
[]

Circulating B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
and O
glucagon B-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Eligibility O
for O
acute O
beta-blocker O
therapy O
was O
determined O
on O
the O
basis O
of O
readily O
available O
, O
noninvasive O
tests O
. O
[]

Four O
of O
110 O
patients O
in O
the O
atrial O
group O
developed O
grade O
2 O
to O
3 O
AV O
block B-outcome ['Physiological-Clinical']
that O
required O
upgrading O
of O
the O
pacemaker O
( O
0.6 O
% O
per O
year O
) O
. O
['Physiological-Clinical']

The O
clinical O
importance O
of O
this O
finding O
needs O
further O
investigation O
. O
[]

Nephrotoxicity B-outcome ['Physiological-Clinical']
was O
defined O
as O
an O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
to O
greater O
than O
25 O
% O
over O
baseline O
with O
an O
absolute O
rise O
of O
at O
least O
0.5 O
mg/100 O
ml O
to O
a O
value O
greater O
than O
or O
equal O
to O
1.3 O
mg/100 O
ml O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
& O
PARTICIPANTS O
Italian O
uremic O
patients O
without O
diabetes O
older O
than O
70 O
years O
with O
glomerular O
filtration O
rate O
of O
5 O
to O
7 O
mL/min O
( O
0.08 O
to O
0.12 O
mL/s O
) O
. O
[]

8/16 O
'short-treated O
' O
and O
18/39 O
'long-treated O
' O
patients O
remained O
in O
remission B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

64 O
cases O
had O
not O
been O
treated O
with O
total O
androgen O
ablation O
( O
e.g O
. O
[]

Oxytocin O
increases O
retention O
of O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
in O
autism O
. O
['Life-Impact']

Induction O
treatment O
with O
3 O
g O
of O
IV O
methylprednisolone O
( O
MP O
) O
followed O
by O
either O
IV O
monthly O
cyclophosphamide O
( O
Cy O
) O
versus O
IV O
MP O
bimonthly O
every O
4 O
months O
for O
1 O
year O
and O
then O
IV O
Cy O
or O
IV O
MP O
every O
3 O
months O
for O
another O
year O
. O
[]

Clinicians O
of O
the O
same O
ethnicity O
as O
the O
client O
may O
be O
more O
likely O
to O
understand O
the O
culture-specific O
values O
, O
norms O
, O
and O
attitudes O
and O
, O
therefore O
, O
the O
intervention O
may O
be O
more O
effective O
. O
[]

Safety O
assessment O
included O
vital O
signs O
, O
electrocardiogram O
, O
electroencephalogram O
, O
adverse O
events O
, O
laboratory O
tests O
, O
extrapyramidal O
symptoms O
and O
the O
side O
effects O
. O
[]

The O
visual O
analog O
scale O
( O
VAS O
) O
score O
and O
Lysholm O
knee B-outcome ['Physiological-Clinical']
score O
were O
used O
to O
evaluate O
the O
therapeutic O
effects O
. O
['Physiological-Clinical']

METHODS O
Randomized O
, O
controlled O
, O
split-face O
comparison O
of O
anesthesia O
was O
performed O
on O
12 O
volunteers O
. O
[]

The O
infants O
were O
divided O
into O
three O
groups O
: O
Group O
A O
and O
B O
received O
a O
dose O
of O
1.6 O
x O
10 O
( O
8 O
) O
cells O
of O
B. O
breve O
supplement O
twice O
a O
day O
, O
commencing O
either O
from O
several O
hours O
after O
birth O
( O
group O
A O
) O
or O
24 O
h O
after O
birth O
( O
group O
B O
) O
. O
[]

RESULTS O
Overall O
, O
873 O
patients O
were O
randomly O
assigned O
to O
receive O
sunitinib O
( O
n O
= O
584 O
) O
or O
placebo O
( O
n O
= O
289 O
) O
. O
[]

There O
has O
been O
minimal O
interest O
in O
plaque O
accumulation O
on O
occlusal O
surfaces O
despite O
the O
predilection O
for O
caries O
at O
these O
sites O
. O
[]

Verification O
was O
obtained O
by O
phlebography O
in O
86 O
% O
of O
the O
patients O
. O
[]

Although O
exercise O
may O
be O
used O
by O
some O
to O
decrease O
distress O
, O
little O
is O
known O
about O
how O
it O
may O
contribute O
to O
stress O
management O
( O
SM O
) O
among O
patients O
receiving O
chemotherapy O
. O
[]

Moreover O
, O
usage B-outcome ['Life-Impact']
of O
bronchodilators B-outcome ['Resource-use']
( O
theophylline O
and O
aerosol O
beta-stimulants O
combined O
) O
declined O
significantly O
( O
p O
less O
than O
0.001 O
) O
during O
sodium O
cromoglycate O
treatment O
compared O
to O
placebo O
. O
['Life-Impact', 'Resource-use']

METHODS O
Patients O
12 O
years O
of O
age O
and O
older O
with O
acne O
vulgaris O
( O
N O
= O
3010 O
) O
participated O
in O
two O
identically-designed O
12-week O
, O
randomized O
, O
double-blind O
studies O
of O
twice-daily O
monotherapy O
with O
dapsone O
gel O
, O
5 O
% O
, O
versus O
a O
vehicle O
gel O
. O
[]

The O
CGI-I O
scores O
show O
significant O
improvement O
in O
the O
amantadine O
group O
compared O
to O
the O
placebo O
group O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
, O
side O
effects O
and O
acceptability B-outcome ['Life-Impact']
of O
sublingual O
and O
vaginal O
misoprostol O
for O
second O
trimester O
medical O
abortion O
. O
['Life-Impact']

Initial O
parameters O
failed O
to O
distinguish O
the O
first O
two O
groups O
, O
but O
Lennox-Gastaut O
syndrome O
( O
the O
third O
group O
) O
was O
distinct O
from O
both O
groups O
of O
myoclonic O
astatic O
epilepsy O
from O
the O
onset O
. O
[]

RESULTS O
The O
age-standardized O
prevalences O
of O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
were O
16.2 O
% O
, O
32.2 O
% O
, O
and O
28.3 O
% O
in O
men O
and O
26.8 O
% O
, O
37.2 O
% O
, O
and O
34.6 O
% O
in O
women O
, O
according O
to O
the O
definitions O
of O
the O
NCEP O
2004 O
, O
NCEP O
2005 O
, O
and O
IDF O
, O
respectively O
. O
['Physiological-Clinical']

Increased O
platelet O
5-HT O
levels O
were O
found O
in O
40 O
% O
of O
the O
autistic O
population O
, O
suggesting O
that O
hyperserotonaemia O
may O
be O
a O
pathologic O
factor O
in O
infantile O
autism O
. O
[]

These O
are O
among O
the O
first O
randomized O
controlled O
data O
to O
suggest O
that O
short-term O
parent-mediated O
interventions O
can O
have O
important O
effects O
on O
core O
impairments O
in O
toddlers O
with O
autism O
. O
[]

1 O
. O
[]

The O
deperitonealized O
areas O
( O
N O
= O
205 O
) O
of O
all O
sidewalls O
were O
divided O
into O
three O
groups O
: O
less O
than O
100 O
mm2 O
, O
N O
= O
72 O
; O
100-1000 O
mm2 O
, O
N O
= O
95 O
; O
and O
more O
than O
1000 O
mm2 O
, O
N O
= O
38 O
. O
[]

13.0 O
) O
] O
( O
t O
= O
-4.28 O
-- O
5.67 O
, O
P O
< O
0.05 O
) O
. O
[]

Pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
decreased O
by O
66 O
% O
with O
gabapentin O
compared O
to O
33 O
% O
with O
placebo O
. O
['Physiological-Clinical']

There O
was O
increased O
substitution O
of O
affricates B-outcome ['Life-Impact']
by I-outcome ['Life-Impact']
fricatives I-outcome ['Life-Impact']
for O
children O
using O
NLFC O
, O
compared O
to O
children O
using O
conventional O
amplification O
. O
['Life-Impact']

Performance B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
improved O
linearly O
by O
0.8 O
% O
per O
4 O
wk O
. O
['Life-Impact']

The O
first O
method O
evaluated O
the O
current O
survival B-outcome ['Mortality']
data O
taking O
into O
account O
the O
issue O
of O
repeated O
significance O
testing O
. O
['Mortality']

The O
rates O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
( O
placebo O
versus O
steroid O
, O
respectively O
) O
: O
CMV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
25 O
% O
versus O
33 O
% O
( O
p O
= O
0.336 O
) O
, O
post-transplant B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
30 O
% O
versus O
53 O
% O
( O
p O
= O
0.024 O
) O
, O
hypertension B-outcome ['Physiological-Clinical']
39 O
% O
versus O
52 O
% O
( O
p O
= O
0.248 O
) O
, O
hypercholesterolemia B-outcome ['Physiological-Clinical']
10 O
% O
versus O
41 O
% O
( O
p O
= O
0.002 O
) O
and O
hypertriglyceridemia B-outcome ['Physiological-Clinical']
32 O
% O
versus O
54 O
% O
( O
p O
= O
0.046 O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomised O
, O
controlled O
crossover O
trial O
involving O
19 O
patients O
with O
a O
first-ever O
diagnosis O
of O
OSAS O
measured O
the O
effect O
of O
conventional O
heated O
humidification O
added O
to O
CPAP O
compared O
with O
a O
controlled O
heated O
breathing O
tube O
humidifier O
( O
ThermoSmart O
( O
R O
) O
; O
Fisher O
and O
Paykel O
Healthcare O
, O
Auckland O
, O
New O
Zealand O
) O
on O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
deprecate O
their O
use O
in O
athletics O
but O
can O
suggest O
no O
way O
of O
stopping O
it O
. O
[]

Children O
with O
autistic O
spectrum O
disorders O
. O
[]

Secondary O
endpoints O
included O
the O
profile O
of O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
during O
titration O
and O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
calcium B-outcome ['Physiological-Clinical']
, O
and O
calcium B-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Ca I-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
Exposure O
to O
atole O
before O
, O
but O
not O
after O
, O
age O
3 O
years O
was O
associated O
with O
higher O
hourly B-outcome ['Life-Impact']
wages I-outcome ['Life-Impact']
, O
but O
only O
for O
men O
. O
['Life-Impact']

on O
days O
1 O
to O
4 O
or O
cisplatin O
( O
20 O
mg/m2 O
) O
, O
ifosfamide O
( O
1.2 O
g/m2 O
) O
, O
and O
etoposide O
( O
75 O
mg/m2 O
) O
( O
VIP O
) O
all O
given O
i.v O
. O
[]

Home O
sleep O
studies O
in O
the O
assessment O
of O
sleep B-outcome ['Physiological-Clinical']
apnea/hypopnea I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
two O
types O
of O
intervention O
: O
a O
) O
Minimal O
Intervention O
( O
MI O
) O
. O
[]

CD4+FOXP3+ O
regulatory O
T O
cell O
depletion O
by O
low-dose O
cyclophosphamide O
prevents O
recurrence B-outcome ['Physiological-Clinical']
in O
patients O
with O
large O
condylomata O
acuminata O
after O
laser O
therapy O
. O
['Physiological-Clinical']

DESIGN O
OF O
STUDY O
Randomised O
controlled O
trial O
. O
[]

DESIGN O
Field O
experiment O
, O
two-way O
analysis O
of O
variance O
with O
one O
between O
group O
( O
short- O
versus O
long-stay O
) O
and O
one O
repeated O
measures O
factor O
( O
admission O
, O
then O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
months O
post-admission O
) O
. O
[]

Chronic O
disease O
prevalence O
and O
severity O
, O
preadmission O
functional O
status O
, O
clinical O
presentation O
, O
and O
vascular O
history O
were O
used O
to O
test O
the O
risk-adjusted O
effect O
of O
race O
and O
ethnicity O
on O
rates O
of O
primary O
and O
repeat B-outcome ['Resource-use']
amputation I-outcome ['Resource-use']
. O
['Resource-use']

The O
diabetic O
patients O
treated O
with O
Mydriasert O
had O
less O
mydriasis B-outcome ['Physiological-Clinical']
than O
those O
treated O
with O
eyedrops O
after O
20 O
and O
40 O
minutes O
, O
and O
diabetic O
patients O
showed O
less O
mydriasis O
than O
the O
nondiabetic O
patients O
after O
60 O
and O
90 O
minutes O
. O
['Physiological-Clinical']

Comparison O
of O
inhaled O
albuterol O
powder O
and O
aerosol O
in O
asthma O
. O
[]

Both O
frequency O
and O
function O
of O
communicative B-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
in O
toddlerhood O
were O
positively O
associated O
with O
later O
['Life-Impact']

The O
number O
of O
patients O
who O
required O
a O
continuous O
supply O
of O
oxygen B-outcome ['Resource-use']
2 O
hours O
after O
returning O
to O
the O
ward O
was O
significantly O
lower O
in O
the O
propofol O
group O
( O
midazolam O
18 O
; O
propofol O
6 O
; O
P O
= O
0.010 O
) O
. O
['Resource-use']

There O
was O
the O
suggestion O
that O
nimodipine O
might O
attenuate O
the O
severity O
of O
some O
cocaine-induced O
brain O
deficits O
, O
as O
detected O
by O
evaluation O
of O
smooth B-outcome ['Life-Impact']
pursuit I-outcome ['Life-Impact']
eye I-outcome ['Life-Impact']
movement I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Life-Impact']

Secondary O
outcome O
variables O
included O
OA O
pain O
in O
the O
target O
joint O
, O
patient O
's O
and O
physician O
's O
global O
assessments O
of O
disease O
activity O
, O
Short O
Arthritis O
assessment O
Scale O
( O
SAS O
) O
total O
score O
, O
rescue O
medication O
use O
, O
and O
safety O
and O
tolerability O
. O
[]

METHODS O
AND O
RESULTS O
CLAS O
was O
an O
arterial O
imaging O
trial O
in O
which O
nonsmoking O
40- O
to O
59-year-old O
men O
with O
previous O
coronary O
artery O
bypass O
graft O
surgery O
were O
randomized O
to O
colestipol/niacin O
plus O
diet O
or O
placebo O
plus O
diet O
. O
[]

OBJECTIVE O
To O
determine O
whether O
moxifloxacin O
penetrates O
the O
uterine O
tissue O
and O
accumulates O
at O
levels O
sufficient O
to O
eradicate O
the O
major B-outcome ['Physiological-Clinical']
pathogens I-outcome ['Physiological-Clinical']
causing O
pelvic O
inflammatory O
disease O
( O
PID O
) O
. O
['Physiological-Clinical']

RESULTS O
Intake O
of O
calories O
, O
carbohydrates O
, O
and O
fat O
were O
in O
the O
average O
range O
; O
protein O
intake O
was O
increased O
( O
211 O
% O
of O
RDA O
) O
. O
[]

The O
high O
level O
of O
[]

SUBJECTS O
A O
total O
of O
36 O
obese O
nondiabetic O
volunteers O
with O
hyperinsulinemia O
( O
10 O
males/26 O
females O
, O
aged O
34-65 O
y O
, O
BMI O
28-43 O
kg/m O
( O
2 O
) O
, O
fasting O
insulin O
12-45 O
mU/l O
) O
. O
[]

Moreover O
, O
in O
SH O
patients O
both O
QT B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
and O
QTc B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
were O
positively O
related O
to O
TSH O
( O
r=0.64 O
and O
r=0.63 O
, O
P O
< O
0.001 O
for O
both O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

2 O
mg O
, O
well O
below O
doses O
that O
induced O
serum O
IFN-? O
or O
led O
to O
clinical O
adverse O
events O
. O
[]

The O
apoptotic B-outcome ['Physiological-Clinical']
index O
( O
AI B-outcome ['Physiological-Clinical']
) O
and O
an O
MIB-1 B-outcome ['Physiological-Clinical']
index O
( O
MI B-outcome ['Physiological-Clinical']
) O
were O
also O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
included O
clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
5 O
to O
9 O
days O
after O
therapy O
and O
, O
for O
trimethoprim-sulfamethoxazole-treated O
women O
, O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
stratified O
by O
the O
trimethoprim-sulfamethoxazole O
susceptibility O
of O
the O
uropathogen O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Small-dose O
selective O
spinal O
anesthesia O
for O
short-duration O
outpatient O
laparoscopy O
: O
recovery O
characteristics O
compared O
with O
desflurane O
anesthesia O
. O
[]

The O
Fast O
Fourier O
Transform O
was O
used O
to O
calculate O
power O
spectral O
densities O
for O
each O
EEG O
recording O
. O
[]

BACKGROUND O
This O
randomized O
clinical O
trial O
compared O
early O
outcomes O
after O
radiofrequency O
ablation O
( O
RFA O
) O
and O
conventional O
surgery O
for O
varicose O
veins O
. O
[]

CONCLUSIONS O
Adjunctive O
intravenous O
streptokinase O
therapy O
does O
not O
enhance O
early O
preservation O
of O
ventricular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
improve O
arterial O
patency O
rates O
, O
or O
lower O
restenosis O
rates O
after O
PTCA O
therapy O
of O
acute O
MI O
. O
['Physiological-Clinical']

105 O
patients O
admitted O
for O
cataract O
surgery O
were O
treated O
pre-operatively O
with O
polyvinylpyrrolidone-iodine O
( O
PVP-I O
) O
as O
a O
disinfectant O
, O
and O
consecutive O
bacterial O
cultures O
were O
obtained O
before O
initiating O
surgery O
and O
at O
the O
end O
of O
the O
operation O
. O
[]

RESULTS O
Patients O
who O
registered O
in O
a O
screened O
area O
felt O
significantly O
more O
able O
to O
[]

The O
pre-pPCI B-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
( O
55+/-21.4 O
% O
vs O
42.4+/-18.2 O
% O
, O
p=0.005 O
) O
, O
TIMI B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
grade O
3 O
( O
29 O
% O
vs O
7 O
% O
, O
p=0.042 O
) O
, O
corrected O
TIMI B-outcome ['Physiological-Clinical']
frame O
count O
( O
58.4+/-32.7 O
vs O
78.9+/-28.4 O
frame O
, O
p=0.018 O
) O
% B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
( O
76.3 O
/63.5-100/ O
vs O
100 O
/73.5-100/ O
; O
median O
/interquartile O
range/ O
, O
p=0.023 O
) O
, O
were O
significantly O
higher O
in O
Group O
1 O
vs O
Group O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Design O
and O
subject O
characteristics O
in O
the O
federally-funded O
citalopram O
trial O
in O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

Then O
an O
endoscope O
was O
placed O
in O
the O
duodenum O
without O
premedication O
, O
and O
basal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duodenal I-outcome ['Physiological-Clinical']
peristaltic I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

An O
open-label O
extension O
study O
of O
the O
safety O
and O
efficacy O
of O
risperidone O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

Both O
symptom B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
are O
important O
clinical O
treatment O
targets O
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
Exenatide O
improves O
postprandial O
glycemic B-outcome ['Physiological-Clinical']
excursions I-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

Thus O
, O
the O
program O
may O
be O
capable O
of O
promoting O
discharge O
of O
[]

Our O
primary O
objective O
was O
to O
compare O
whether O
tinzaparin O
and O
dalteparin O
differentially O
accumulate O
in O
HD O
patients O
. O
[]

METHODS O
AND O
MATERIALS O
Between O
1995 O
and O
1996 O
, O
100 O
patients O
were O
randomized O
to O
receive O
a O
prophylactic O
therapy O
for O
prevention O
of O
heterotopic O
ossification O
. O
[]

CONCLUSIONS O
This O
study O
provides O
the O
first O
evidence O
that O
oxytocin O
nasal O
spray O
improves O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
in O
young O
people O
diagnosed O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

METHODS O
Between O
1993 O
and O
1998 O
, O
20 O
consecutive O
patients O
were O
found O
by O
multiplane O
transesophageal O
echocardiography O
( O
TEE O
) O
to O
have O
non-obstructive O
PVT O
. O
[]

The O
challenge O
induced O
the O
reappearance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
insomnia I-outcome ['Life-Impact']
and O
agitated B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
all O
except O
one O
child O
. O
['Life-Impact', 'Life-Impact']

Kawasaki O
disease O
is O
now O
the O
most O
common O
cause O
of O
acquired O
heart O
disease O
in O
America O
's O
children O
. O
[]

We O
found O
a O
wide O
variability O
in O
analgesic O
requirements O
where O
11 O
% O
of O
patients O
required O
no O
opioids O
and O
16 O
% O
required O
more O
than O
15 O
mg O
i.v O
. O
[]

BACKGROUND O
Seasonal O
allergic O
rhinitis O
( O
SAR O
) O
is O
a O
risk O
factor O
for O
asthma O
in O
affected O
individuals O
. O
[]

Study O
patients O
were O
randomized O
to O
the O
two O
treatment O
arms O
, O
Er O
: O
YAG O
( O
3.8 O
J/cm O
( O
2 O
) O
, O
30 O
% O
pattern O
overlap O
, O
0 O
% O
interpulse O
overlap O
, O
15 O
microm O
per O
pass O
with O
no O
coagulation O
) O
and O
IPL O
( O
560-nm O
filter O
, O
30 O
J/cm O
( O
2 O
) O
, O
2.4/4.0-ms O
pulse O
with O
10-ms O
delay O
) O
, O
each O
receiving O
three O
sequential O
treatments O
spaced O
1 O
month O
apart O
. O
[]

Standard O
PN O
does O
not O
improve O
antioxidant O
status O
compared O
with O
administration O
of O
micronutrients O
alone O
. O
[]

The O
necessity O
of O
luteal-phase O
supplementation O
in O
an O
IVF O
programme O
is O
of O
continuing O
interest O
. O
[]

The O
patients O
were O
randomized O
to O
undergo O
the O
second O
colonoscopy O
by O
the O
same O
or O
a O
different O
endoscopist O
and O
in O
the O
same O
or O
different O
position O
. O
[]

IHC B-outcome ['Physiological-Clinical']
( O
n O
= O
84 O
) O
, O
ELISAs O
of O
blood/BM O
sera O
( O
n O
= O
41 O
) O
, O
and O
microarray O
data O
for O
mRNA O
levels O
( O
n O
= O
261 O
) O
were O
performed O
. O
['Physiological-Clinical']

After O
8 O
weeks O
, O
the O
TC B-outcome ['Physiological-Clinical']
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
in O
the O
atorvastatin B-outcome ['Physiological-Clinical']
group O
decreased O
by O
19 O
% O
, O
26 O
% O
, O
and O
17 O
% O
respectively O
compared O
with O
the O
baseline O
values O
( O
all O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
variable O
had O
a O
c-index O
> O
0.70 O
, O
and O
few O
had O
values O
> O
0.60 O
; O
c-indices O
were O
lower O
for O
composite O
outcomes O
than O
for O
mortality O
. O
[]

In O
contrast O
, O
smokers O
showed O
less O
BOP B-outcome ['Physiological-Clinical']
at O
baseline O
but O
also O
less O
improvement O
in O
BOP B-outcome ['Physiological-Clinical']
through O
direct O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparative O
study O
of O
actinic O
keratosis O
treatment O
with O
3 O
% O
diclofenac O
sodium O
and O
5 O
% O
5-fluorouracil O
. O
[]

STUDY O
OBJECTIVE O
Comparison O
of O
tamoxifen O
and O
mastectomy O
in O
treatment O
of O
breast O
cancer O
in O
elderly O
patients O
. O
[]

Sixty-three O
percent O
of O
patients O
without O
spontaneous O
regrowth O
of O
hair B-outcome ['Physiological-Clinical']
regrew I-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
after O
DNCB O
application O
. O
['Physiological-Clinical']

METHODS O
Thirty O
patients O
, O
17 O
female O
and O
13 O
male O
, O
with O
CSX O
were O
enrolled O
in O
the O
study O
. O
[]

Association O
of O
severity O
of O
coexisting O
patellofemoral O
disease O
with O
increased O
impairments O
and O
functional O
limitations O
in O
patients O
with O
knee O
osteoarthritis O
. O
[]

The O
baseline O
characteristics O
was O
comparable O
between O
the O
two O
groups O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
2,802 O
men O
50 O
years O
or O
older O
with O
a O
clinical O
diagnosis O
of O
benign O
prostatic O
hyperplasia O
, O
no O
history O
of O
prostate O
cancer O
, O
PSA O
1.5 O
to O
10 O
ng/ml O
, O
prostate O
volume O
30 O
cc O
or O
greater O
, O
an O
American O
Urological O
Association O
symptom O
score O
of O
12 O
or O
greater O
and O
peak O
urinary O
flow O
rate O
15 O
ml O
per O
second O
or O
less O
were O
randomized O
to O
0.5 O
mg O
dutasteride O
daily O
or O
matching O
placebo O
for O
24 O
months O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
rates O
of O
oocyte B-outcome ['Physiological-Clinical']
fertilization I-outcome ['Physiological-Clinical']
and O
cleavage B-outcome ['Physiological-Clinical']
between O
these O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

20.7 O
, O
34 O
female O
) O
. O
[]

Findings O
revealed O
one O
child O
( O
engagement O
) O
, O
one O
teacher O
( O
exhaustion O
) O
, O
two O
intervention O
quality O
( O
IEP O
quality O
for O
targeted O
and O
not O
targeted O
elements O
) O
, O
and O
no O
implementation O
quality O
variables O
accounted O
for O
variance O
in O
child O
outcomes O
when O
analyzed O
separately O
. O
[]

The O
patients O
received O
oral O
GCV O
for O
between O
12 O
days O
and O
14 O
weeks O
. O
[]

Forty O
volunteers O
were O
randomized O
( O
ten O
each O
) O
to O
three O
different O
pill O
regimens O
or O
to O
nonsteroidal O
contraception O
. O
[]

In O
conclusion O
, O
esmolol O
blunted O
the O
CBFV B-outcome ['Physiological-Clinical']
increase O
during O
emergence O
, O
confirming O
that O
sympathetic O
overactivity O
contributes O
to O
cerebral B-outcome ['Physiological-Clinical']
hyperemia I-outcome ['Physiological-Clinical']
during O
neurosurgical O
recovery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
two-group O
quasi-experimental O
design O
. O
[]

RESULTS O
More O
than O
half O
of O
the O
patients O
had O
ischemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
; O
95 O
% O
of O
these O
were O
silent O
. O
['Physiological-Clinical']

Paracervical O
anesthesia O
for O
outpatient B-outcome ['Resource-use']
hysteroscopy I-outcome ['Resource-use']
. O
['Resource-use']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
propofol O
, O
isoflurane O
, O
and O
sevoflurane O
on O
middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
during O
open O
heart O
surgery O
, O
and O
the O
relationship O
between O
these O
effects O
and O
hemodynamic O
parameters O
. O
['Physiological-Clinical']

Medical O
schools O
worldwide O
are O
moving O
away O
from O
dissection O
and O
lectures O
to O
a O
more O
integrated O
course O
, O
where O
basic O
science O
and O
clinical O
skills O
are O
taught O
simultaneously O
. O
[]

We O
therefore O
evaluated O
the O
effect O
of O
clonidine O
on O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Resource-use']
requirements O
during O
ophthalmic O
surgery O
when O
given O
as O
premedication O
in O
type O
2 O
diabetic O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
included O
sedation O
and O
fatigue B-outcome ['Physiological-Clinical']
during O
the O
first O
2 O
weeks O
of O
clonidine O
treatment O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
median O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
to O
random O
assignment O
was O
217 O
( O
139 O
, O
335 O
) O
minutes O
in O
the O
PCI O
group O
and O
210 O
( O
145 O
, O
334 O
) O
minutes O
in O
the O
SK O
group O
. O
['Physiological-Clinical']

OBJECTIVES O
This O
study O
was O
designed O
to O
compare O
the O
safety O
and O
efficacy O
of O
two O
cycled O
dosing O
regimens O
of O
imiquimod O
5 O
% O
cream O
for O
treatment O
of O
superficial O
basal O
cell O
carcinoma O
( O
sBCC O
) O
. O
[]

But O
they O
can O
provoke O
gastrointestinal O
side-effects O
. O
[]

Interactive O
effects O
of O
indomethacin O
, O
angiotensin O
II O
and O
frusemide O
on O
renal O
haemodynamics O
and O
natriuresis O
in O
man O
. O
[]

Analgesics B-outcome ['Resource-use']
were O
required O
earlier O
in O
patients O
receiving O
remifentanil O
; O
median O
time O
0.5 O
vs O
1.08 O
hr O
, O
P O
< O
0.001 O
. O
['Resource-use']

METHODS O
A O
modified O
resuscitation O
manikin O
was O
used O
to O
measure O
variation O
in O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
during O
3-min O
periods O
of O
mask O
ventilation O
. O
['Resource-use']

Fifty-nine O
episodes O
of O
atrial O
flutter O
in O
54 O
patients O
who O
failed O
to O
terminate O
with O
an O
intravenous O
infusion O
of O
ibutilide O
, O
procainamide O
, O
or O
placebo O
alone O
underwent O
attempts O
at O
pacing O
termination O
using O
a O
standard O
protocol O
of O
burst O
atrial O
overdrive O
pacing O
. O
[]

CONCLUSION O
Inversion O
ankle B-outcome ['Physiological-Clinical']
sprains I-outcome ['Physiological-Clinical']
during O
parachute O
training O
can O
be O
significantly O
reduced O
by O
using O
an O
outside-the-boot O
ankle O
brace O
, O
with O
no O
increase O
in O
risk O
for O
other O
injuries O
. O
['Physiological-Clinical']

PURPOSE O
This O
study O
evaluated O
the O
bond O
strength O
of O
two O
etch-and-rinse O
adhesive O
systems O
( O
two- O
and O
three-step O
) O
and O
a O
self-etching O
system O
to O
coronal B-outcome ['Physiological-Clinical']
and O
root B-outcome ['Physiological-Clinical']
canal I-outcome ['Physiological-Clinical']
dentin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

B-type B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
( O
TNF O
) O
were O
measured O
at O
baseline O
, O
6 O
weeks O
, O
and O
12 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
SH O
herbs O
may O
be O
an O
alternative O
for O
the O
third O
anti-retroviral O
agent O
in O
the O
triple O
drug O
regimen O
for O
the O
treatment O
of O
HIV O
infected O
patients O
in O
countries O
with O
limited O
resources O
. O
[]

We O
evaluated O
the O
effects O
of O
concurrent O
strength O
and O
aerobic O
endurance O
training O
on O
cardiovascular O
and O
cardiorespiratory O
adaptations O
in O
college O
athletes O
and O
compared O
two O
concurrent O
exercise O
( O
CE O
) O
protocols O
. O
[]

However O
, O
the O
effect O
of O
an O
active O
pectoral O
can O
on O
atrial O
defibrillation O
is O
unknown O
. O
[]

CONTEXT O
Maternal O
vitamin O
A O
deficiency O
is O
a O
public O
health O
concern O
in O
the O
developing O
world O
. O
[]

One O
patient O
in O
the O
standard O
group O
showed O
a O
positive O
Trendelenburg O
gait B-outcome ['Life-Impact']
ten O
days O
postoperatively O
; O
it O
had O
disappeared O
completely O
at O
the O
twelve-week O
time O
point O
. O
['Life-Impact']

SIB O
produced O
wide O
variation O
and O
unacceptably O
high O
TV B-outcome ['Physiological-Clinical']
and O
MV B-outcome ['Physiological-Clinical']
in O
experienced O
hands O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
each O
group O
, O
the O
incidence O
of O
histologically B-outcome ['Physiological-Clinical']
proven I-outcome ['Physiological-Clinical']
CMV I-outcome ['Physiological-Clinical']
interstitial I-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
during O
the O
first O
110 O
days O
post O
BMT O
was O
recorded O
. O
['Physiological-Clinical']

Blood O
samples O
were O
drawn O
at O
day O
0 O
and O
day O
90 O
for O
measuring O
above O
parameters O
. O
[]

No O
significant B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
due O
to O
the O
combined O
administration O
of O
HCFU O
were O
recognized O
. O
['Adverse-effects']

In O
the O
292 O
fractures O
which O
were O
followed O
for O
six O
months O
, O
the O
incidence O
of O
nonunion B-outcome ['Physiological-Clinical']
was O
independent O
of O
the O
type O
of O
cast O
used O
. O
['Physiological-Clinical']

The O
targeted O
mechanism O
of O
factor O
Xa O
inhibition O
has O
been O
studied O
extensively O
, O
initially O
as O
prophylaxis O
for O
venous O
thromboembolism O
( O
VTE O
) O
in O
the O
orthopedic O
surgical O
setting O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
measured O
using O
an O
automatic B-outcome ['Physiological-Clinical']
oscillometric I-outcome ['Physiological-Clinical']
technique I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
derived O
from O
the O
ECG O
, O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
was O
measured O
by O
pulse O
oximetry O
, O
and O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
by O
a O
thoracic O
bioimpedance O
technique O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
In O
a O
large O
cluster O
randomized O
control O
trial O
of O
insecticide-treated O
bed O
nets O
( O
ITN O
) O
in O
Western O
Myanmar O
the O
malaria O
protective B-outcome ['Physiological-Clinical']
effect O
of O
ITN O
was O
found O
to O
be O
highly O
variable O
and O
, O
in O
aggregate O
, O
the O
effect O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

In O
one O
patient O
a O
decrease O
in O
some O
palpebral B-outcome ['Physiological-Clinical']
xanthelasmas B-outcome ['Physiological-Clinical']
was O
observed O
after O
two O
months O
of O
treatment O
with O
the O
active O
drug O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
have O
monitored O
the O
effect O
of O
cyclosporin O
administered O
during O
a O
planned O
programme O
of O
third-party O
blood O
transfusions O
on O
the O
development O
of O
both O
cytotoxic B-outcome ['Physiological-Clinical']
and O
anti-idiotypic B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Families O
who O
used O
> O
20 O
hours O
per O
week O
of O
conventional O
services O
were O
more O
likely O
to O
use O
CAM O
, O
including O
potentially O
unsafe O
or O
disproven O
CAM O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
a O
subhypnotic O
dose O
of O
propofol O
with O
the O
conventional O
antiemetics O
droperidol O
and O
metoclopramide O
for O
the O
prophylaxis O
of O
PONV O
after O
breast O
cancer O
surgery O
in O
Japanese O
patients O
. O
[]

This O
reduction O
in O
steroid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
obtained O
without O
altering O
clinical O
status O
and O
without O
significant O
complication O
. O
['Resource-use']

The O
absorption B-outcome ['Physiological-Clinical']
of O
intramuscular B-outcome ['Physiological-Clinical']
phenobarbitone B-outcome ['Physiological-Clinical']
7 O
mg.kg-1 O
was O
studied O
in O
11 O
Karen O
children O
aged O
between O
1.7 O
and O
11 O
y O
with O
severe O
falciparum O
malaria O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
laser O
treatment O
was O
carried O
out O
in O
only O
one O
eye O
chosen O
at O
random O
, O
and O
the O
fellow O
eye O
was O
used O
as O
a O
control O
. O
[]

Bile O
acid O
replacement O
therapy O
might O
therefore O
be O
of O
clinical O
benefit O
, O
provided O
that O
diarrhoea O
is O
not O
aggravated O
by O
therapy O
. O
[]

Twenty O
four-hour O
urine O
samples O
were O
collected O
for O
6-beta-hydroxycortisol O
measurements O
, O
before O
and O
after O
14 O
days O
of O
ticlopidine O
. O
[]

There O
was O
a O
tendency O
for O
the O
immunized O
groups O
to O
enjoy O
a O
slightly O
longer O
recurrence-free B-outcome ['Physiological-Clinical']
period O
. O
['Physiological-Clinical']

METHODS O
We O
investigated O
the O
mechanisms O
by O
which O
PSK O
influences O
immunological B-outcome ['Physiological-Clinical']
parameters O
such O
as O
Th1 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
IFN-gamma-positive B-outcome ['Physiological-Clinical']
CD4 I-outcome ['Physiological-Clinical']
( O
+ O
) O
T B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OFC O
and O
rACC O
activation O
to O
the O
misleading O
cue O
were O
also O
associated O
with O
less O
aversive B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
that I-outcome ['Physiological-Clinical']
taste I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Outcome O
of O
CNS O
disease O
at O
diagnosis O
in O
disseminated O
small O
noncleaved-cell O
lymphoma O
and O
B-cell O
leukemia O
: O
a O
Children O
's O
Cancer O
Group O
study O
. O
[]

Triacylglycerol B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
the O
CLO O
group O
only O
. O
['Physiological-Clinical']

Median O
survival B-outcome ['Mortality']
was O
16 O
versus O
20 O
months O
with O
a O
nonsignificant O
trend O
in O
favor O
of O
doxorubicin O
( O
P O
= O
0.09 O
) O
. O
['Mortality']

After O
a O
10-week O
treatment O
with O
enalapril O
or O
eprosartan O
, O
the O
sitting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
in O
both O
the O
enalapril O
group O
( O
from O
152.2 O
+/- O
18.7 O
mmHg O
to O
141.9 O
+/- O
23.5 O
mmHg O
, O
P O
< O
0.05 O
) O
and O
eprosartan O
group O
( O
from O
151 O
+/- O
10.0 O
mmHg O
to O
142.3 O
+/- O
12.9 O
mmHg O
, O
P O
< O
0.05 O
) O
was O
significantly O
reduced O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
administered O
131I-activity B-outcome ['Physiological-Clinical']
was O
170 O
MBq O
( O
45-1269 O
) O
in O
the O
rhTSH O
group O
and O
559 O
MBq O
( O
245-3530 O
) O
in O
the O
placebo O
group O
( O
70 O
% O
reduction O
, O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
secretin B-outcome ['Physiological-Clinical']
at O
14 O
days O
after O
birth O
was O
significantly O
higher O
than O
that O
at O
1 O
or O
2 O
days O
and O
7 O
days O
after O
birth O
in O
the O
early O
feeding O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

From O
randomization O
until O
end O
of O
follow-up O
( O
mean O
duration O
, O
7.1 O
years O
) O
, O
25 O
women O
( O
20 O
% O
) O
in O
the O
usual O
care O
and O
8 O
women O
( O
7 O
% O
) O
in O
the O
stress O
reduction O
died O
, O
yielding O
an O
almost O
3-fold O
protective O
effect O
of O
the O
intervention O
( O
odds O
ratio O
, O
0.33 O
; O
95 O
% O
CI O
, O
0.15 O
to O
0.74 O
; O
P=0.007 O
) O
. O
[]

Eighteen O
patients O
completed O
1-year O
and O
7.5-year O
follow-up O
. O
[]

About O
half O
( O
56.4 O
% O
) O
of O
the O
subjects O
were O
successfully O
located O
by O
using O
either O
Canada411 O
or O
InfoSpace O
. O
[]

CONCLUSION O
( O
S O
) O
A O
flexible O
protocol O
of O
0.25 O
mg O
of O
cetrorelix O
for O
IUI O
cycles O
appears O
to O
suppress O
the O
rate O
of O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
during O
ovarian O
stimulation O
with O
letrozole O
and O
gonadotropins O
. O
['Physiological-Clinical']

This O
residual O
tumor O
was O
used O
as O
control O
. O
[]

Free B-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
decreased O
in O
53.85 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
37.5 O
% O
of O
women O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

After O
upper O
gastrointestinal O
endoscopy O
, O
H. O
pylori-infected O
patients O
with O
a O
gastric O
ulcer O
and/or O
a O
duodenal O
ulcer O
were O
randomly O
assigned O
to O
a O
PAC7 O
group O
( O
omeprazole O
20 O
mg O
or O
equivalent O
dose O
of O
other O
PPIs O
, O
amoxicillin O
1000 O
mg O
, O
and O
clarithromycin O
500 O
mg O
twice O
daily O
for O
7 O
days O
) O
or O
to O
a O
PAC14 O
group O
( O
the O
same O
regimen O
as O
the O
PAC7 O
group O
but O
for O
14 O
days O
) O
. O
[]

Successful O
appraisal O
induction O
was O
verified O
using O
novel O
vignettes O
and O
via O
change O
scores O
on O
the O
post O
traumatic O
cognitions O
inventory O
. O
[]

All O
patients O
received O
preperitoneal O
abdominal O
wall O
infiltration O
with O
0.25 O
per O
cent O
bupivacaine O
to O
control O
parietal O
( O
somatic O
) O
abdominal O
pain O
. O
[]

kg O
( O
-1 O
) O
? O
[]

CONCLUSIONS O
This O
is O
the O
first O
study O
to O
demonstrate O
that O
rhTSH O
not O
only O
increases O
the O
thyroid B-outcome ['Physiological-Clinical']
131I I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
, O
but O
per O
se O
potentiates O
the O
effect O
of O
131I-therapy O
, O
allowing O
a O
major O
reduction O
of O
the O
131I-activity B-outcome ['Physiological-Clinical']
without O
compromising O
efficacy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
2.5 O
mg O
dose O
group O
, O
steady-state O
DPP-4 O
inhibition O
of O
> O
80 O
% O
was O
not O
maintained O
over O
24 O
hours O
( O
observed O
and O
simulated O
) O
. O
[]

FUNDING O
Novartis O
Pharmaceuticals O
and O
Pfizer O
Inc O
. O
[]

Radiation-induced O
xerostomia O
can O
result O
in O
the O
rapid O
onset O
and O
progression O
of O
dental O
caries O
in O
head O
and O
neck O
cancer O
patients O
. O
[]

Forty-three O
subjects O
were O
allocated O
to O
sublingual O
immunotherapy O
, O
with O
three O
different O
induction O
protocols O
( O
8- O
, O
15- O
and O
20-day O
, O
respectively O
) O
. O
[]

Atrial O
natriuretic O
factor O
15 O
pmol O
kg-1 O
min-1 O
or O
placebo O
( O
P O
) O
was O
concomitantly O
administered O
against O
a O
background O
infusion O
of O
either O
AVP O
0.003 O
pmol O
kg-1 O
min-1 O
or O
P O
; O
thus O
the O
combinations O
P O
+ O
P O
, O
AVP O
+ O
P O
, O
P O
+ O
ANF O
and O
AVP O
+ O
ANF O
were O
studied O
. O
[]

METHODS O
Two O
hundred O
seven O
consecutive O
coronary O
artery O
bypass O
patients O
( O
mean O
age O
62 O
+/- O
11 O
years O
) O
were O
randomized O
to O
receive O
sotalol O
alone O
( O
80 O
mg O
twice O
daily O
for O
5 O
days O
starting O
from O
the O
morning O
of O
the O
first O
postoperative O
day O
) O
( O
group O
S O
) O
, O
magnesium O
alone O
( O
1.5 O
g O
daily O
for O
6 O
days O
starting O
in O
the O
operating O
room O
just O
before O
cardiopulmonary O
bypass O
) O
( O
group O
M O
) O
, O
both O
pharmacologic O
agents O
at O
the O
same O
dosages O
( O
group O
S+M O
) O
, O
or O
no O
antiarrhythmic O
agents O
( O
group O
CTR O
) O
. O
[]

Pimecrolimus O
cream O
and O
Tacrolimus O
ointment O
in O
the O
treatment O
of O
atopic B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
: O
a O
pilot O
study O
on O
patient O
preference O
. O
['Physiological-Clinical']

This O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
lowering O
blood O
pressure O
by O
angiotensin O
II-receptor O
blockers O
( O
ARB O
) O
has O
more O
beneficial O
effects O
than O
by O
conventional O
calcium O
channel O
blockers O
( O
CCB O
) O
on O
the O
frequency O
of O
paroxysmal O
AF O
with O
hypertension O
. O
[]

6.4 O
days O
, O
13.4 O
? O
[]

CONCLUSION O
At O
12 O
months O
, O
exemestane O
was O
associated O
with O
fewer O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
and O
less O
vaginal B-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
than O
tamoxifen O
, O
but O
with O
more O
vaginal B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
, O
bone/muscle B-outcome ['Physiological-Clinical']
aches I-outcome ['Physiological-Clinical']
, O
and O
difficulty B-outcome ['Physiological-Clinical']
sleeping I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
'The O
Body O
& O
Cancer O
Trial O
' O
. O
[]

The O
meals O
contained O
either O
oat O
powder O
( O
62 O
g O
, O
of O
which O
2.7 O
soluble O
fibre O
) O
, O
rye O
bran O
( O
31 O
g O
, O
of O
which O
1.7 O
g O
soluble O
fibre O
) O
, O
sugar O
beet O
fibre O
( O
19 O
g O
, O
of O
which O
5 O
g O
soluble O
fibre O
) O
, O
a O
mixture O
of O
these O
three O
fibres O
( O
74 O
g O
, O
of O
which O
1.7 O
g O
soluble O
fibre O
from O
each O
source O
, O
giving O
5 O
g O
soluble O
fibre O
) O
or O
no O
added O
fibre O
( O
control O
) O
and O
were O
all O
adjusted O
to O
contain O
the O
same O
total O
amount O
of O
available O
carbohydrates O
. O
[]

The O
Studies O
to O
Advance O
Autism O
Research O
and O
Treatment O
Network O
conducted O
a O
randomized O
trial O
with O
citalopram O
in O
children O
with O
Pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
therapeutic O
effect O
of O
Compound O
Xuanju O
Capsule O
on O
type O
III O
prostatitis O
. O
[]

Luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
LH B-outcome ['Physiological-Clinical']
) O
, O
follicle B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
FSH B-outcome ['Physiological-Clinical']
) O
, O
dehydroepiandrostendione B-outcome ['Physiological-Clinical']
sulfate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DHEAS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
total O
testosterone B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
and O
insulin B-outcome ['Resource-use']
levels O
were O
measured O
at O
baseline O
and O
after O
the O
first O
cycle O
, O
as O
well O
as O
body O
mass O
index O
( O
BMI O
) O
, O
cervical B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
, O
and O
pregnancy B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Median O
peak O
headache B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
was O
1 O
( O
range O
0-9 O
) O
after O
valproate O
compared O
to O
4.5 O
( O
range O
0-8 O
) O
after O
placebo O
( O
P O
= O
0.120 O
) O
. O
['Physiological-Clinical']

During O
the O
sleep-deprivation O
day O
, O
both O
mean O
24-h O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
mean O
24-h O
heart O
rate O
were O
higher O
in O
comparison O
with O
those O
recorded O
during O
the O
routine O
workday O
, O
the O
difference O
being O
more O
pronounced O
during O
the O
nighttime O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

On O
HS O
diet O
, O
E O
' O
and O
RBF B-outcome ['Physiological-Clinical']
were O
higher O
than O
on O
LS O
diet O
( O
E O
' O
14.0 O
+/- O
1.2 O
vs O
12.6 O
+/- O
1.0 O
cm/s O
, O
P O
= O
0.02 O
; O
RBF O
596 O
+/- O
24 O
vs O
563 O
+/- O
26 O
mL/min O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Primary O
intracoronary O
stent O
placement O
after O
successfully O
crossing O
chronic O
total O
coronary O
occlusions O
may O
decrease O
the O
high O
restenosis O
rate O
at O
long-term O
follow-up O
compared O
with O
conventional O
balloon O
angioplasty O
. O
[]

Healthy O
Bodies O
, O
Healthy O
Souls O
( O
HBHS O
) O
is O
a O
church-based O
, O
community-participatory O
, O
cluster-randomized O
health O
intervention O
trial O
conducted O
in O
Baltimore O
City O
to O
reduce O
diabetes O
risk O
among O
urban O
African O
Americans O
by O
promoting O
healthy O
dietary O
intake O
, O
increased O
physical O
activity O
and O
improvement O
to O
the O
church O
food O
environment O
. O
[]

Second O
examinations O
showed O
significantly O
lower O
mean O
PIPP O
scores O
after O
examination O
( O
1 O
min O
( O
P=0.003 O
) O
and O
5 O
min O
( O
P=0.025 O
) O
) O
, O
regardless O
of O
the O
type O
of O
drop O
used O
. O
[]

PURPOSE O
We O
examined O
the O
effects O
of O
Positive O
Action O
( O
PA O
) O
, O
a O
school-based O
social-emotional O
learning O
and O
health O
promotion O
program O
, O
on O
the O
emotional O
health O
of O
predominately O
low-income O
and O
ethnic O
minority O
urban O
youth O
. O
[]

[ O
Isometric O
hip O
muscle O
strength O
in O
posttraumatic O
below-knee O
amputees O
] O
. O
[]

Our O
findings O
thus O
suggest O
that O
verapamil O
may O
have O
potential O
utility O
as O
an O
adjunct O
to O
lithium O
. O
[]

Administration O
of O
RG-CMH O
was O
associated O
with O
a O
significant O
reduction O
in O
levels O
of O
leucocytes B-outcome ['Physiological-Clinical']
from O
31?5 O
% O
for O
the O
placebo O
group O
to O
13?4 O
% O
for O
the O
RG-CMH O
group O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
mean O
HR O
during O
the O
recovery O
with O
and O
without O
music O
. O
[]

Postoperative O
magnesium O
sulphate O
infusion O
reduces O
analgesic O
requirements O
in O
spinal O
anaesthesia O
. O
[]

Our O
results O
indicate O
increased O
platelet B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
and O
decreased O
fibrinolysis B-outcome ['Physiological-Clinical']
in O
patients O
with O
acute O
atherosclerotic O
ischemic O
stroke O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
description O
of O
the O
clinical O
characteristics O
at O
baseline O
of O
patients O
recruited O
into O
the O
Carvedilol O
or O
Metoprolol O
European O
Trial O
( O
COMET O
) O
. O
[]

ClinicalTrials.gov O
number O
, O
NCT00479375 O
[ O
ClinicalTrials.gov O
] O
. O
) O
. O
[]

Those O
patients O
not O
surgically O
staged O
with O
only O
LAG O
for O
lymph O
node O
evaluation O
were O
less O
accurately O
staged O
, O
as O
reflected O
by O
a O
statistically O
significant O
reduced O
survival O
and O
earlier O
metastases O
. O
[]

Ten O
males O
and O
nine O
females O
( O
age O
range O
20-33 O
years O
) O
were O
studied O
in O
a O
double-blind O
, O
randomized O
, O
cross-over O
trial O
. O
[]

Patients O
who O
were O
identified O
as O
requiring O
pedicled O
flap O
reconstruction O
were O
potential O
candidates O
for O
the O
study O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
introducing O
intensive O
diabetes O
management O
[ O
intensive O
insulin O
therapy O
( O
IIT O
) O
and O
'Sweet O
Talk O
' O
text-messaging O
support O
] O
produces O
measurable O
improvements O
in O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Thirty O
health O
care O
practitioners O
participated O
in O
a O
clinical O
trial O
using O
a O
20-minute O
videotape O
to O
instruct O
them O
in O
motivational O
interviewing O
. O
[]

On O
the O
other O
hand O
, O
both O
clodronate-treated O
groups O
had O
increased O
levels O
of O
lumbar O
bone O
mass O
compared O
with O
controls O
, O
both O
after O
6 O
and O
12 O
months O
of O
therapy O
. O
[]

Trimetazidine O
has O
a O
direct O
anti-ischaemic B-outcome ['Physiological-Clinical']
effect O
on O
the O
myocardium O
without O
altering O
the O
rate O
x O
pressure O
product O
or O
coronary B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
in O
number O
of O
verbal B-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
or O
number O
of O
correct B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
were O
noted O
between O
groups O
following O
treatment O
. O
['Life-Impact', 'Life-Impact']

The O
initial O
complete B-outcome ['Physiological-Clinical']
response O
rate O
( O
CR O
) O
was O
79 O
% O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
study O
objective O
was O
to O
identify O
factors O
associated O
with O
death O
and O
cardiac O
transplantation O
in O
infants O
undergoing O
the O
Norwood O
procedure O
and O
to O
determine O
differences O
in O
associations O
that O
might O
favor O
the O
modified O
Blalock-Taussig O
shunt O
or O
a O
right O
ventricle-to-pulmonary O
artery O
shunt O
. O
[]

Investigations O
from O
the O
last O
decade O
established O
that O
extent O
of O
ICH-mediated O
brain O
injury O
relates O
directly O
to O
blood O
clot O
volume O
and O
duration O
of O
blood O
exposure O
to O
brain O
tissue O
. O
[]

Pain O
intensity O
( O
rest O
and O
passive O
mobilisation O
) O
was O
recorded O
after O
recovery O
and O
after O
1,2,4 O
, O
and O
24 O
hours O
( O
Numeric O
Rating O
Scale O
) O
; O
the O
use O
of O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
( O
piritramide B-outcome ['Resource-use']
by O
patient B-outcome ['Resource-use']
controlled I-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
) O
was O
noted O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Seventy-six O
healthy O
postmenopausal O
women O
were O
randomly O
assigned O
to O
placebo O
or O
800 O
IU O
( O
20 O
?g O
) O
, O
2000 O
IU O
( O
50 O
?g O
) O
, O
or O
4000 O
IU O
( O
100 O
?g O
) O
vitamin O
D? O
for O
8 O
wk O
. O
[]

The O
lactobacilli O
tablet O
was O
found O
to O
be O
better O
than O
the O
pH O
tablet O
in O
preventing O
BV O
in O
healthy O
subjects O
. O
[]

In O
this O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
study O
, O
patients O
received O
a O
single O
50-mg O
oral O
dose O
of O
a O
5-HT O
( O
1D O
) O
agonist O
, O
PNU-142633 O
( O
n O
= O
34 O
) O
, O
or O
matching O
placebo O
( O
n O
= O
35 O
) O
during O
an O
acute O
migraine O
attack O
. O
[]

CONCLUSIONS O
Students O
taught O
on O
a O
traditional O
course O
have O
a O
higher O
level O
of O
anatomical B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
than O
those O
taught O
on O
an O
integrated O
course O
. O
['Life-Impact']

In O
the O
negative O
feedback O
condition O
, O
increases O
in O
the O
EI O
caused O
the O
number O
of O
stimuli B-outcome ['Life-Impact']
in O
the O
array O
to O
decrease O
while O
decreases O
in O
the O
EI O
caused O
the O
number O
of O
stimuli O
to O
increase O
. O
['Life-Impact']

The O
primary O
outcome O
was O
10-wk O
continuous O
smoking B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
effect O
is O
restricted O
to O
tuberculin O
skin O
test-positive O
persons O
. O
[]

In O
a O
study O
of O
retinopathy O
during O
one O
year O
of O
tight O
blood O
glucose O
control O
45 O
type O
I O
( O
insulin O
dependent O
) O
diabetics O
without O
proliferative O
retinopathy O
were O
randomised O
to O
receive O
either O
continuous O
subcutaneous O
insulin O
infusion O
, O
multiple O
insulin O
injections O
, O
or O
conventional O
insulin O
treatment O
( O
controls O
) O
. O
[]

Safety O
was O
good O
, O
with O
minimal O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
considered O
unrelated O
to O
the O
products O
. O
['Adverse-effects']

In O
addition O
, O
compared O
to O
the O
No O
Intervention O
group O
, O
the O
CAI O
group O
scored O
significantly O
higher O
on O
the O
scales O
measuring O
[]

There O
were O
no O
significant O
differences O
between O
the O
etanercept O
and O
control O
groups O
in O
the O
rates O
of O
sustained B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
69.7 O
percent O
vs. O
75.3 O
percent O
, O
P=0.39 O
) O
, O
sustained O
periods O
of O
low-level O
disease I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
86.5 O
percent O
vs. O
90.6 O
percent O
, O
P=0.32 O
) O
, O
or O
the O
time O
required O
to O
achieve O
those O
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Immunogenicity O
was O
evaluated O
using O
VZV O
interferon-gamma O
( O
IFN-? O
) O
enzyme-linked O
immunospot O
( O
ELISPOT O
) O
assay O
and O
VZV O
glycoprotein O
enzyme-linked O
immunosorbent O
antibody O
( O
gpELISA O
) O
assay O
. O
[]

An O
evaluation O
of O
vitamin B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
prior O
to O
the O
study O
found O
that O
the O
autistic O
children O
had O
substantially O
elevated O
levels O
of O
B6 O
compared O
to O
a O
control O
group O
of O
typical O
children O
( O
75 O
% O
higher O
, O
p O
< O
0.0000001 O
) O
. O
['Physiological-Clinical']

Comparison O
of O
thiopentone/guaifenesin O
, O
ketamine/guaifenesin O
and O
ketamine/midazolam O
for O
the O
induction O
of O
horses O
to O
be O
anaesthetised O
with O
isoflurane O
. O
[]

BACKGROUND O
Acute O
phase O
protein O
production O
is O
a O
hallmark O
of O
severe O
burns O
. O
[]

RESULTS O
Equally O
significant O
improvements O
were O
apparent O
for O
all O
outcomes O
after O
WB O
exercise O
and O
NWB O
exercise O
, O
except O
for O
reposition B-outcome ['Physiological-Clinical']
error I-outcome ['Physiological-Clinical']
, O
for O
which O
improvement O
was O
greater O
in O
the O
WB O
exercise O
group O
. O
['Physiological-Clinical']

They O
also O
had O
some O
poorer O
psychosocial B-outcome ['Life-Impact']
outcomes O
; O
for O
example O
, O
they O
were O
more O
worried O
about O
fetal B-outcome ['Physiological-Clinical']
wellbeing I-outcome ['Physiological-Clinical']
antenatally I-outcome ['Physiological-Clinical']
and O
coping B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
baby I-outcome ['Life-Impact']
postnatally I-outcome ['Life-Impact']
, O
and O
they O
had O
more O
negative O
attitudes B-outcome ['Life-Impact']
to O
their O
babies O
, O
both O
in O
pregnancy O
and O
postnatally O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Serotonergic O
( O
5-HT O
) O
abnormalities O
have O
been O
documented O
in O
autism O
. O
[]

This O
sustained O
secretion O
of O
both O
GH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
in O
uremia O
could O
be O
attributed O
to O
reduced O
kidney O
clearance O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
late O
hemodynamic O
effects O
of O
preserving O
the O
papillary O
muscles O
during O
mitral O
valve O
replacement O
have O
not O
been O
evaluated O
. O
[]

BACKGROUND O
Analgesics O
are O
an O
essential O
component O
of O
the O
treatment O
of O
cancer-associated O
pain O
. O
[]

A O
growing O
literature O
suggests O
that O
the O
self-face O
is O
involved O
in O
processing O
the O
facial O
expressions O
of O
others O
. O
[]

RESULTS O
Three O
of O
four O
subjects O
reacted O
to O
much O
smaller O
doses O
of O
peanut B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
re-challenge I-outcome ['Physiological-Clinical']
( O
mean O
dose O
equivalence O
- O
23 O
times O
less O
peanut O
) O
with O
the O
lower O
fat O
recipe O
. O
['Physiological-Clinical']

METHODS O
From O
March O
of O
1999 O
to O
March O
of O
2001 O
, O
70 O
adult O
patients O
who O
underwent O
immediate O
reconstruction O
for O
traumatic O
injuries O
of O
the O
digits O
were O
prospectively O
randomized O
into O
two O
groups O
. O
[]

PATIENTS O
AND O
METHODS O
From O
January O
2000 O
to O
April O
2002 O
, O
132 O
patients O
were O
enrolled O
on O
the O
study O
. O
[]

The O
role O
of O
somatostatin O
( O
octreotide O
) O
in O
the O
regulation O
of O
melatonin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
healthy O
volunteers O
and O
in O
patients O
with O
primary O
hypothyroidism O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
examine O
whether O
a O
Web-based O
health O
and O
leadership O
development O
program O
-- O
designed O
specifically O
for O
managers O
-- O
was O
associated O
with O
changes O
in O
self-reported O
and O
biometric B-outcome ['Physiological-Clinical']
indicators I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
within O
the O
context O
of O
a O
randomized O
control O
trial O
. O
['Physiological-Clinical']

RESULTS O
One O
hundred O
seventy-five O
eligible O
patients O
( O
mean O
age O
73 O
+/- O
10 O
years O
; O
60 O
% O
women O
) O
were O
randomized O
to O
the O
trial O
: O
pacemaker O
87 O
; O
controls O
88 O
. O
[]

MATERIALS O
AND O
METHODS O
Forty-eight O
osteoporotic O
patients O
with O
prostate O
cancer O
, O
treated O
with O
3-month O
depot O
triptorelina O
, O
were O
enrolled O
and O
randomly O
assigned O
to O
two O
different O
treatment O
groups O
: O
group O
A O
( O
n O
= O
24 O
) O
was O
treated O
with O
a O
daily O
calcium O
and O
cholecalciferol O
supplement O
( O
500 O
mg O
of O
elemental O
calcium O
and O
400 O
IU O
cholecalciferol O
) O
, O
and O
group O
B O
( O
n O
= O
24 O
) O
received O
in O
addition O
to O
the O
same O
daily O
calcium O
and O
cholecalciferol O
supplement O
, O
25 O
mg O
of O
neridronate O
given O
intramuscularly O
every O
month O
. O
[]

Thus O
, O
though O
our O
numbers O
are O
small O
, O
there O
appears O
to O
be O
some O
advantage O
of O
laser-assisted O
drainage O
in O
terms O
of O
a O
lower O
incidence O
of O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Both O
the O
drug O
and O
the O
transdermal O
system O
were O
generally O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
under O
the O
study O
conditions O
. O
['Life-Impact']

Two O
intact O
classes O
were O
randomly O
assigned O
to O
groups O
, O
one O
of O
whom O
used O
lighter O
balls O
during O
skills O
progressions O
while O
a O
second O
used O
regulation O
balls O
. O
[]

MAIN O
MEASURES O
PTSD B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
was O
the O
primary O
outcome O
. O
['Physiological-Clinical']

The O
dependent O
variables O
were O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
and O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Postoperative B-outcome ['Physiological-Clinical']
infectious I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
were O
demonstrated O
in O
15 O
of O
197 O
( O
7.6 O
% O
) O
, O
25 O
of O
203 O
( O
12.3 O
% O
) O
and O
43 O
of O
199 O
( O
21.6 O
% O
) O
patients O
in O
the O
study O
groups O
, O
respectively O
. O
['Physiological-Clinical']

PURPOSE O
To O
report O
data O
regarding O
the O
safety O
of O
intravitreous O
fomivirsen O
for O
treatment O
of O
cytomegalovirus O
( O
CMV O
) O
retinitis O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
. O
[]

Linear O
regression O
was O
used O
to O
examine O
the O
cross-sectional O
associations O
of O
plasma B-outcome ['Physiological-Clinical']
FGF23 I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
with O
BMI O
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Acute B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
the O
bladder O
and O
bowel O
were O
significantly O
worse O
after O
photon O
therapy O
. O
['Adverse-effects']

Raters O
were O
blind O
to O
treatment O
condition O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
outcome O
measure O
was O
a O
change O
in O
neuropathy B-outcome ['Physiological-Clinical']
between O
baseline O
and O
week O
48 O
, O
demonstrated O
by O
the O
Neuropathy B-outcome ['Physiological-Clinical']
Impairment B-outcome ['Life-Impact']
Score O
for O
the O
Lower O
Limbs O
, O
compared O
between O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

There O
were O
no O
significant O
differences O
in O
the O
implant B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rate O
as O
determined O
by O
radiographic O
['Physiological-Clinical']

However O
, O
the O
treatment O
time O
tends O
to O
be O
relatively O
long O
and O
insufflation O
and O
manipulation O
of O
the O
endoscope O
can O
increase O
pain O
and O
discomfort O
. O
[]

Future O
research O
will O
investigate O
whether O
abnormalities O
in O
these O
mechanisms O
play O
a O
role O
in O
disorders O
of O
diastolic O
function O
. O
[]

Indices O
of O
respiratory O
muscle O
strength O
, O
pulmonary O
function O
, O
and O
pulmonary O
diffusing O
capacity O
were O
measured O
in O
11 O
malnourished O
children O
( O
age O
10 O
to O
17 O
years O
) O
with O
cystic O
fibrosis O
, O
before O
and O
after O
improvement O
of O
nutritional O
status O
with O
supplemental O
parenteral O
nutrients O
for O
1 O
month O
. O
[]

Upper B-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
reported O
by O
18 O
( O
5.7 O
% O
) O
subjects O
in O
the O
risedronate O
group O
( O
19 O
events O
) O
and O
28 O
( O
8.8 O
% O
) O
subjects O
in O
the O
alendronate O
group O
( O
32 O
events O
) O
. O
['Physiological-Clinical']

A O
randomized O
crossover O
study O
investigating O
the O
influence O
of O
ranitidine O
or O
omeprazole O
on O
the O
pharmacokinetics O
of O
cephalexin B-outcome ['Physiological-Clinical']
monohydrate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Chlorhexidine-based O
antiseptic O
solution O
vs O
alcohol-based O
povidone-iodine O
for O
central O
venous O
catheter O
care O
. O
[]

Retinal B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
were O
measured O
with O
a O
retinal O
vessel O
analyzer O
, O
and O
retinal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
was O
assessed O
by O
bi-directional O
laser O
Doppler O
velocimetry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

p.o. O
, O
n=198 O
) O
or O
corresponding O
placebo O
( O
n=202 O
) O
, O
for O
24 O
weeks O
as O
an O
add-on O
to O
conventional O
antianginal O
therapy O
and O
for O
4 O
additional O
weeks O
as O
monotherapy O
-- O
the O
latter O
after O
withdrawal O
of O
standard O
treatment O
with O
calcium O
antagonists O
and/or O
beta-blockers O
and/or O
long-acting O
( O
prophylactic O
) O
nitrates O
. O
[]

BACKGROUND O
Allergic O
conjunctivitis O
is O
one O
of O
the O
most O
frequent O
allergic O
diseases O
of O
the O
anterior O
eye O
segment O
. O
[]

RESULTS O
One O
hundred O
twenty O
eligible O
patients O
were O
randomized O
. O
[]

RESULTS O
Inter-rater O
reliability O
( O
intraclass O
correlation O
coefficient O
[ O
ICC O
] O
= O
.79 O
) O
and O
temporal B-outcome ['Life-Impact']
stability I-outcome ['Life-Impact']
( O
average O
ICC B-outcome ['Resource-use']
= O
.86 O
) O
were O
excellent O
. O
['Life-Impact', 'Resource-use']

This O
trial O
is O
registered O
at O
ClinicalTrials.gov O
, O
NCT00655473 O
. O
[]

BACKGROUND O
Young O
children O
are O
not O
participating O
in O
recommended O
levels O
of O
physical O
activity O
and O
exhibit O
high O
levels O
of O
sedentary O
behaviour O
. O
[]

Coenzyme O
Q10 O
and O
exercise O
training O
in O
chronic O
heart O
failure O
. O
[]

However O
, O
DAS28 O
remission O
rates O
were O
higher O
( O
even O
when O
using O
the O
lower O
cut O
point O
) O
than O
the O
SDAI O
and O
CDAI O
remission O
rates O
. O
[]

Central B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
assessed O
by O
use O
of O
the O
Auditory B-outcome ['Physiological-Clinical']
Steady I-outcome ['Physiological-Clinical']
State I-outcome ['Physiological-Clinical']
Response O
( O
ASSR O
) O
and O
Bispectral B-outcome ['Physiological-Clinical']
Index O
( O
BIS O
) O
analysis O
of O
electrooculogram O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
an O
intravenous O
infusion O
of O
synthetic O
human O
secretin O
improves O
language B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

PURPOSE O
In O
this O
study O
, O
we O
sought O
to O
1 O
) O
describe O
elements O
of O
the O
financial O
and O
quality-of-life O
burden O
of O
dysfunctional O
uterine O
bleeding O
( O
DUB O
) O
from O
the O
perspective O
of O
women O
who O
agreed O
to O
obtain O
surgical O
treatment O
; O
2 O
) O
explore O
associations O
between O
DUB O
symptom O
characteristics O
and O
the O
financial O
and O
quality-of-life O
burden O
; O
3 O
) O
estimate O
the O
annual O
dollar O
value O
of O
the O
financial O
burden O
; O
and O
4 O
) O
estimate O
the O
most O
that O
could O
be O
spent O
on O
surgery O
to O
eliminate O
DUB O
symptoms O
for O
which O
medical O
treatment O
has O
been O
unsuccessful O
that O
would O
result O
in O
a O
$ O
50,000/quality-adjusted O
life-year O
incremental O
cost-effectiveness O
ratio O
. O
[]

The O
intervention O
was O
feasible B-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
to O
both O
support O
persons O
and O
smokers O
. O
['Life-Impact', 'Life-Impact']

Complete O
blood O
counts O
, O
differential O
, O
and O
platelet O
counts O
were O
obtained O
, O
and O
tibial O
bone O
marrow O
aspirate O
was O
performed O
on O
day O
8 O
. O
[]

RESULTS O
The O
decreased O
levels O
of O
serum B-outcome ['Physiological-Clinical']
trace I-outcome ['Physiological-Clinical']
elements I-outcome ['Physiological-Clinical']
, O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
and O
increased O
malondialdehyde B-outcome ['Physiological-Clinical']
, O
glutathion B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
was O
observed O
in O
cervical O
cancer O
patients O
when O
compared O
to O
healthy O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Subjects O
who O
were O
H B-outcome ['Physiological-Clinical']
pylori B-outcome ['Physiological-Clinical']
negative O
had O
14.8 O
% O
more O
regression O
and O
13.7 O
% O
less O
progression B-outcome ['Physiological-Clinical']
than O
patients O
who O
were O
positive O
at O
12 O
years O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
median O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
the O
laser O
group O
of O
55 O
patients O
was O
4.6 O
milliliters O
at O
, O
and O
within O
, O
24 O
hours O
after O
operation O
compared O
with O
30.1 O
milliliters O
in O
the O
cold O
knife O
group O
of O
55 O
patients O
. O
['Physiological-Clinical']

Effect O
of O
indomethacin O
phonophoresis O
on O
the O
relief O
of O
temporomandibular O
joint O
pain O
. O
[]

Patients O
with O
pulmonary O
embolism O
or O
deep O
venous O
thrombosis O
were O
randomly O
assigned O
to O
receive O
either O
intermittent O
or O
continuous O
intravenous O
heparin O
therapy O
. O
[]

One O
or O
2 O
units O
of O
blood O
were O
transfused O
to O
patients O
in O
both O
groups O
according O
to O
postoperative O
Hb O
level O
( O
between O
60 O
and O
70 O
g/L O
or O
betweeen O
50 O
and O
60 O
g/L O
, O
respectively O
) O
. O
[]

There O
was O
a O
clear O
tendency O
for O
the O
problems O
to O
be O
more O
common O
after O
CRT O
than O
after O
RT O
. O
[]

The O
primary O
endpoints O
were O
hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
, O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
length O
of O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
. O
['Mortality', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

Altered O
accuracy O
of O
saccadic O
eye O
movements O
in O
children O
with O
fetal O
alcohol O
spectrum O
disorder O
. O
[]

CONCLUSIONS O
The O
findings O
of O
this O
study O
indicate O
that O
flexion O
of O
the O
knee O
to O
30? O
with O
the O
leg O
elevated O
30? O
at O
the O
hip O
after O
total O
knee O
arthroplasty O
may O
mitigate O
knee O
swelling O
and O
provide O
other O
beneficial O
results O
during O
the O
early O
rehabilitation O
following O
TKA O
. O
[]

High O
levels O
of O
fibrinogen O
and O
clotting O
factor O
VII O
are O
associated O
with O
an O
increased O
risk O
for O
subsequent O
death B-outcome ['Mortality']
and O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
apparently O
healthy O
individuals O
. O
['Mortality', 'Physiological-Clinical']

BACKGROUND O
There O
is O
increasing O
evidence O
that O
fatty O
acid O
deficiencies O
or O
imbalances O
may O
contribute O
to O
childhood O
neurodevelopmental O
disorders O
. O
[]

The O
scales O
were O
compared O
with O
the O
original O
SWAT O
scale O
in O
terms O
of O
sensitivity B-outcome ['Physiological-Clinical']
and O
pretask O
procedure O
completion O
time O
when O
performing O
arithmetic O
tasks O
. O
['Physiological-Clinical']

Usual O
secondary O
efficacy O
endpoints O
were O
assessed O
. O
[]

Our O
study O
demonstrates O
a O
reversible O
depression O
of O
myocardial B-outcome ['Physiological-Clinical']
contractility I-outcome ['Physiological-Clinical']
and O
hemodynamic B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
during O
rapid O
permissive O
hypercapnia O
which O
were O
attenuated O
by O
buffering O
with O
THAM O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
probability O
of O
patients O
remaining O
in O
the O
study O
over O
time O
without O
developing O
signs O
of O
exacerbating B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
fluticasone O
propionate O
groups O
than O
in O
the O
placebo O
group O
( O
P O
= O
.001 O
) O
. O
['Physiological-Clinical']

The O
use O
of O
a O
DNAemia O
cut-off O
avoids O
unnecessary O
antiviral O
treatment O
. O
[]

system O
, O
compared O
to O
standard O
moist O
wound O
therapy O
( O
MWT O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
physical O
therapy O
for O
osteoarthritis O
of O
the O
knee O
, O
applied O
by O
experienced O
physical O
therapists O
with O
formal O
training O
in O
manual O
therapy O
. O
[]

CONCLUSION O
Cryobiopsy O
is O
safe O
and O
increases O
the O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
in O
endobronchial O
tumor O
lesions O
. O
['Life-Impact']

Sildenafil O
is O
a O
selective O
phosphodiesterase-5 O
inhibitor O
and O
causes O
vasodilatation O
, O
particularly O
in O
pulmonary O
circulation O
. O
[]

Furthermore O
, O
symmetrical B-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
resulted O
after O
morning O
and O
evening O
administration O
of O
the O
test O
formulation O
. O
['Physiological-Clinical']

This O
study O
compares O
a O
moisture-vapour-permeable O
film O
( O
MVPF O
) O
with O
silver O
sulphadiazine O
in O
a O
randomized O
prospective O
manner O
for O
the O
treatment O
of O
outpatient O
burns O
. O
[]

Randomized O
controlled O
trial O
of O
acellular O
diphtheria O
, O
pertussis O
and O
tetanus O
vaccines B-outcome ['Resource-use']
in O
southern O
Ghana O
. O
['Resource-use']

The O
patients O
in O
the O
stapled O
group O
returned B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
routine I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
earlier O
( O
ie O
, O
within O
8.12 O
days O
[ O
2.48 O
] O
) O
as O
compared O
with O
17.62 O
( O
5.59 O
) O
in O
the O
open O
group O
. O
['Life-Impact']

Despite O
its O
advantages O
, O
complications O
such O
as O
anal O
canal O
stenosis O
, O
hemorrhage O
and O
anastomosis O
leak O
with O
eventual O
intrapelvic O
sepsis O
can O
cause O
serious O
postoperative O
problems O
. O
[]

The O
major O
difference O
between O
the O
two O
groups O
was O
an O
increased O
incidence O
of O
enterococcal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
the O
cefoxitin-treated O
patients O
. O
['Physiological-Clinical']

Many O
new O
hypotheses O
are O
proposed O
to O
explain O
the O
same O
. O
[]

Clinical O
stages O
II3+A O
and O
IIB O
received O
either O
six O
cycles O
of O
MOPP O
( O
H O
72 O
) O
, O
three O
cycles O
of O
MOPP O
, O
or O
three O
cycles O
of O
CCNU O
, O
vinblastine O
, O
procarbazine O
, O
and O
prednisone O
( O
CVPP O
) O
( O
H O
77 O
) O
and O
subsequently O
had O
a O
laparotomy O
followed O
by O
supradiaphragmatic O
radiotherapy O
and O
a O
lumboaortic O
field O
if O
results O
of O
laparotomy O
were O
positive O
. O
[]

METHODS O
Two O
hundred O
two O
patients O
with O
PPLs O
and O
positive O
EBUS O
findings O
were O
enrolled O
. O
[]

Also O
, O
the O
mitogen-stimulated B-outcome ['Physiological-Clinical']
interferon-gamma I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
increased O
from O
121 O
to O
269 O
pg/mL O
( O
p O
< O
.05 O
) O
in O
patients O
treated O
with O
ranitidine O
, O
but O
not O
in O
patients O
treated O
with O
placebo O
. O
['Physiological-Clinical']

RESULTS O
Women O
in O
both O
the O
intervention O
( O
OR O
1.70 O
; O
1.31 O
, O
2.21 O
, O
p O
< O
0.001 O
) O
and O
control O
groups O
( O
OR O
1.38 O
; O
1.04 O
, O
1.82 O
, O
p O
= O
0.025 O
) O
significantly O
increased O
cervical B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
rates O
within O
risk O
appropriate O
guidelines O
. O
['Life-Impact']

Prolongation O
of O
intrauterine O
time O
after O
the O
onset O
of O
uterine O
contractions O
was O
seen O
in O
women O
receiving O
tocolysis O
( O
105.2 O
+/- O
157 O
hours O
versus O
62.1 O
+/- O
77 O
hours O
, O
p O
= O
0.06 O
) O
. O
[]

METHODS O
Two O
hundred O
twenty-four O
patients O
with O
MBC O
and O
no O
prior O
therapy O
for O
metastatic O
disease O
were O
randomized O
to O
receive O
either O
TLC O
D-99 O
( O
75 O
mg/m O
( O
2 O
) O
) O
or O
doxorubicin O
( O
75 O
mg/m O
( O
2 O
) O
) O
every O
3 O
weeks O
, O
in O
the O
absence O
of O
disease O
progression O
or O
unacceptable O
toxicity O
. O
[]

Of O
particular O
note O
, O
drowsiness B-outcome ['Physiological-Clinical']
was O
reported O
twice O
as O
often O
by O
diazepam O
patients O
as O
by O
ketazolam O
patients O
. O
['Physiological-Clinical']

Polymorphisms O
of O
ADORA2A O
modulate O
psychomotor O
vigilance O
and O
the O
effects O
of O
caffeine O
on O
neurobehavioural B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
sleep B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
after O
sleep O
deprivation O
. O
['Life-Impact', 'Physiological-Clinical']

AIMS O
To O
investigate O
the O
usefulness O
of O
these O
parameters O
as O
predictors O
of O
the O
response O
to O
tamoxifen O
in O
premenopausal O
women O
with O
breast O
cancer O
. O
[]

To O
overcome O
these O
methodological O
shortcomings O
, O
this O
study O
evaluated O
the O
effects O
of O
EEG-biofeedback O
in O
ASD O
in O
a O
randomized O
pretest-posttest O
control O
group O
design O
with O
blinded O
active O
comparator O
and O
six O
months O
follow-up O
. O
[]

Toothpaste O
was O
supplied O
to O
the O
children O
's O
homes O
, O
and O
its O
use O
was O
unsupervised O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Pain B-outcome ['Physiological-Clinical']
Rating O
Index O
, O
Roland-Morris O
Disability O
Questionnaire O
( O
RMDQ B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

We O
used O
linear O
regression O
models O
, O
adjusting O
for O
potentially O
confounding O
factors O
, O
to O
assess O
the O
relation O
between O
economic O
variables O
and O
exposure O
to O
atole O
or O
fresco O
at O
specific O
ages O
between O
birth O
and O
7 O
years O
. O
[]

The O
role O
of O
glucose-insulin-potassium O
( O
GIK O
) O
infusion O
in O
the O
management O
of O
acute B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
is O
not O
well O
established O
. O
['Physiological-Clinical']

Enrollment O
occurred O
from O
December O
1998 O
through O
April O
2001 O
. O
[]

Hypoxic O
exercise O
training O
reduces O
senescent B-outcome ['Physiological-Clinical']
T-lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
double-blind O
clinical O
trial O
. O
[]

Neither O
enalapril O
alone O
( O
+59 O
+/- O
46 O
mL/min O
, O
P O
= O
0.21 O
) O
nor O
eprosartan O
alone O
( O
+113 O
+/- O
51 O
mL/min O
, O
P O
= O
0.06 O
) O
had O
a O
clear-cut O
significant O
effect O
on O
RPF B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PoC O
tests O
measured O
( O
and O
devices O
used O
) O
in O
the O
trial O
were O
haemoglobin B-outcome ['Physiological-Clinical']
A1c I-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
: O
creatinine B-outcome ['Physiological-Clinical']
ratio O
( O
DCA B-outcome ['Physiological-Clinical']
2000 I-outcome ['Physiological-Clinical']
) O
, O
lipids B-outcome ['Physiological-Clinical']
( O
Cholestech B-outcome ['Physiological-Clinical']
LDX I-outcome ['Physiological-Clinical']
) O
and O
international O
normalized O
ratio O
( O
CoaguChek O
S O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Preventive O
treatment O
of O
serotonin-migraine O
with O
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo O
( O
b O
, O
f O
) O
pyrazino- O
( O
1,2 O
-- O
d O
) O
- O
( O
1,4 O
) O
-oxazepine O
hydrogen O
maleate O
( O
Org O
GC O
94 O
) O
. O
[]

Hemiarthroplasty O
compared O
to O
internal O
fixation O
with O
percutaneous O
cannulated O
screws O
as O
treatment O
of O
displaced O
femoral O
neck O
fractures O
in O
the O
elderly O
: O
cost-utility O
analysis O
performed O
alongside O
a O
randomized O
, O
controlled O
trial O
. O
[]

Collagen O
cross-linking O
with O
photoactivated O
riboflavin O
( O
PACK-CXL O
) O
for O
the O
treatment O
of O
advanced O
infectious O
keratitis O
with O
corneal O
melting O
. O
[]

The O
stroke B-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
increased O
in O
the O
experimental O
group O
during O
the O
training O
period O
. O
['Physiological-Clinical']

Although O
the O
use O
of O
antibiotics O
in O
the O
treatment O
of O
acute O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
is O
largely O
accepted O
, O
controversy O
remains O
regarding O
whether O
the O
choice O
of O
antibiotic O
has O
any O
impact O
on O
outcome O
. O
[]

The O
regimen O
was O
well O
tolerated B-outcome ['Life-Impact']
with O
rash B-outcome ['Physiological-Clinical']
and O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
being O
most O
common O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
risk O
of O
a O
recurrence B-outcome ['Physiological-Clinical']
( O
adjusted O
for O
initial O
CD4 O
cell O
count O
) O
was O
3.25 O
times O
higher O
in O
the O
pentamidine O
group O
( O
P O
< O
0.001 O
, O
95 O
percent O
confidence O
interval O
, O
1.72 O
to O
6.16 O
) O
. O
['Physiological-Clinical']

When O
TPN O
became O
necessary O
, O
patients O
who O
received O
GLN O
orally O
were O
given O
TPN O
with O
GLN O
( O
0.57 O
g/kg O
) O
. O
[]

SETTING O
Clinical O
research O
center O
. O
[]

During O
enrollment O
and O
the O
2-year O
follow-up O
, O
608 O
women O
had O
a O
histopathologic O
diagnosis O
of O
CIN3 O
and O
PCR-based O
HPV O
genotyping O
results O
on O
cervical O
specimens O
. O
[]

There O
were O
no O
significant O
changes O
in O
metabolic O
measures O
compared O
with O
placebo O
in O
either O
group O
. O
[]

It O
is O
also O
associated O
with O
ritualistic O
and O
stereotypical O
behaviour O
. O
[]

PARTICIPANTS O
109 O
patients O
with O
radiographic O
and O
symptomatic O
hip O
OA O
with O
mild O
to O
moderate O
symptoms O
. O
[]

The O
mean O
arterial B-outcome ['Physiological-Clinical']
carboxyhemoglobin I-outcome ['Physiological-Clinical']
level O
was O
1.52 O
percent O
in O
the O
air O
control O
period O
and O
decreased O
from O
1.47 O
to O
1.34 O
per O
cent O
after O
purified O
air O
( O
P O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

Randomised O
multicentre O
trial O
of O
circular O
stapling O
devices O
. O
[]

At O
visit O
2 O
, O
patients O
in O
the O
azithromycin O
group O
demonstrated O
significant O
improvements O
in O
MG B-outcome ['Physiological-Clinical']
plugging I-outcome ['Physiological-Clinical']
, O
MG B-outcome ['Physiological-Clinical']
secretions I-outcome ['Physiological-Clinical']
, O
and O
eyelid B-outcome ['Physiological-Clinical']
redness I-outcome ['Physiological-Clinical']
as O
compared O
with O
the O
compress O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
seven-day O
course O
of O
metronidazole O
was O
not O
found O
by O
statistical O
analysis O
to O
be O
significantly O
superior O
to O
single-dose O
therapy O
when O
considering O
initial O
cure O
rates O
by O
clinical O
or O
Gram-stained O
smear O
criteria O
or O
recurrence O
rates O
. O
( O
[]

The O
safety O
and O
efficacy O
of O
terazosin O
in O
the O
treatment O
of O
essential O
hypertension O
in O
blacks O
. O
[]

SETTING O
The O
Central O
Medical O
Unit O
( O
CMU O
) O
-- O
a O
freestanding O
primary O
care O
medical O
clinic O
staffed O
by O
physicians O
and O
nurse O
practitioners O
. O
[]

Tapered O
, O
roughened-surface O
Southern O
implants O
were O
placed O
using O
a O
standardized O
technique O
, O
and O
implant O
level O
bone O
impressions O
were O
made O
. O
[]

The O
scores O
from O
5-items O
questionnaires O
and O
6-items O
clinical O
score O
were O
significantly O
associated O
with O
the O
physician-diagnosed O
groups O
( O
i.e. O
, O
controlled O
, O
partly O
controlled O
and O
uncontrolled O
groups O
) O
. O
[]

Omitting O
radiotherapy O
in O
early O
positron O
emission O
tomography-negative O
stage O
I/II O
Hodgkin O
lymphoma O
is O
associated O
with O
an O
increased O
risk O
of O
early O
relapse O
: O
Clinical O
results O
of O
the O
preplanned O
interim O
analysis O
of O
the O
randomized O
EORTC/LYSA/FIL O
H10 O
trial O
. O
[]

The O
following O
double-blind O
placebo-controlled O
study O
examined O
the O
role O
of O
the O
VSCCB O
nimodipine O
in O
attenuating O
cocaine O
craving O
in O
66 O
recently O
abstinent O
cocaine-dependent O
patients O
on O
an O
inpatient O
substance O
abuse O
treatment O
unit O
utilizing O
an O
intensive O
12-step O
milieu-oriented O
psychosocial O
therapy O
. O
[]

Also O
, O
both O
of O
the O
peribulbar O
and O
topical O
anesthesia O
procedures O
showed O
similar O
efficiency O
. O
[]

The O
effect O
of O
trandolapril O
and O
its O
fixed-dose O
combination O
with O
verapamil O
on O
circulating O
adhesion O
molecules O
levels O
in O
hypertensive O
patients O
with O
type O
2 O
diabetes O
. O
[]

However O
, O
83 O
% O
/87 O
% O
( O
setting O
II/III O
) O
of O
the O
additionally-delivered O
inspiratory O
volume O
during O
pressure-limited O
NPPV O
was O
also O
lost O
via O
leakage O
. O
[]

RESULTS O
After O
oral O
dosing O
, O
moxifloxacin B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
reached O
a O
maximum O
( O
C O
( O
max O
) O
) O
of O
3.38 O
? O
['Physiological-Clinical']

DESIGN O
Randomised O
, O
double-blind O
, O
placebo-controlled O
sequential O
trial O
. O
[]

The O
remaining O
66 O
patients O
were O
followed O
up O
for O
3-24 O
months O
after O
randomization O
. O
[]

OBJECTIVE O
To O
test O
the O
effectiveness O
of O
customized O
, O
family-oriented O
reminder O
letters O
in O
activating O
patients O
to O
seek O
appropriate O
preventive O
services O
. O
[]

CONCLUSION O
In O
our O
study O
, O
both O
concomitant O
and O
sequential O
therapy O
, O
but O
not O
hybrid O
therapy O
, O
reached O
high O
eradication B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical']

In O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
study O
, O
39 O
patients O
with O
depression O
with O
somatic O
symptoms O
were O
treated O
with O
hypericum O
extract O
LI O
160 O
. O
[]

In O
group O
1 O
there O
were O
5 O
patients O
with O
significant O
disability O
, O
compared O
with O
only O
1 O
in O
group O
2 O
. O
[]

Behavioral B-outcome ['Life-Impact']
and O
physiological O
effects O
of O
remifentanil O
and O
alfentanil O
in O
healthy O
volunteers O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
The O
DSRL O
group O
used O
50 O
% O
more O
training O
time O
than O
the O
SRL O
group O
( O
p O
< O
0.001 O
) O
. O
[]

Therefore O
, O
we O
undertook O
a O
randomised O
, O
parallel O
, O
double-blind O
clinical O
trial O
of O
ALA-PDT O
versus O
placeboPDT O
for O
recalcitrant O
foot O
and O
hand O
warts O
. O
[]

The O
incidence O
of O
shivering B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
misoprostol O
group O
whilst O
that O
of O
vomiting O
was O
significantly O
higher O
in O
the O
syntometrine O
group O
. O
['Physiological-Clinical']

With O
dacarbazine O
4/51 O
patients O
obtained O
a O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
8 O
% O
) O
and O
5/51 O
patients O
a O
partial B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
10 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
in O
[]

BACKGROUND O
Vitamin O
D O
insufficiency O
is O
a O
common O
public O
health O
problem O
nationwide O
. O
[]

Depression B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
were O
at O
clinical O
levels O
premenstrually O
in O
the O
PMS O
and O
PME O
groups O
; O
following O
treatment O
they O
remitted O
in O
the O
PMS O
group O
but O
not O
in O
the O
PME O
leuprolide O
subjects O
. O
['Life-Impact']

Efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
donepezil O
in O
vascular O
dementia O
: O
positive O
results O
of O
a O
24-week O
, O
multicenter O
, O
international O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
. O
['Life-Impact']

Nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAID O
) O
may O
interfere O
with O
aspirin O
( O
acetylsalicylic O
acid O
) O
and O
increase O
the O
risk O
for O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
are O
patients O
with O
an O
isolated O
solitary O
extracranial O
metastasis O
who O
have O
improved O
outcomes O
compared O
with O
those O
with O
cranial O
or O
multiple O
metastases O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Benefits O
, O
morbidity B-outcome ['Physiological-Clinical']
, O
and O
mortality B-outcome ['Mortality']
associated O
with O
long-term O
administration O
of O
oral O
anticoagulant O
therapy O
to O
patients O
with O
peripheral O
arterial O
bypass O
procedures O
: O
a O
prospective O
randomized O
study O
. O
['Physiological-Clinical', 'Mortality']

These O
analyses O
yield O
information O
on O
the O
processes O
involved O
in O
the O
manner O
in O
which O
drug O
use O
changes O
as O
a O
result O
of O
abstinent-contingent O
housing O
and O
work O
. O
[]

An O
increase O
in O
IL-2 B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
mononuclear I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
significant O
rises O
in O
numbers O
of O
Leu11 B-outcome ['Physiological-Clinical']
( O
CD16 B-outcome ['Physiological-Clinical']
) O
+ O
, O
OKM1 B-outcome ['Physiological-Clinical']
( O
CD11 B-outcome ['Physiological-Clinical']
) O
+ O
and O
OKIa1 B-outcome ['Physiological-Clinical']
( O
HLA-DR B-outcome ['Physiological-Clinical']
) O
+ O
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Triple O
therapy O
regimens O
including O
two O
antibiotics O
plus O
acid O
suppression O
have O
become O
the O
new O
standard O
therapy O
in O
Helicobacter O
pylori O
eradication O
because O
of O
success O
rates O
of O
about O
90 O
% O
. O
[]

METHODS O
This O
was O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
clinical O
trial O
of O
patients O
with O
acute O
extremity O
pain O
who O
were O
discharged O
home O
from O
the O
ED O
, O
comparing O
a O
3-day O
supply O
of O
oral O
hydrocodone/acetaminophen O
( O
5 O
mg/500 O
mg O
) O
to O
oral O
codeine/acetaminophen O
( O
30 O
mg/300 O
mg O
) O
. O
[]

More O
patients O
in O
the O
recumbent O
group O
required O
augmentations O
with O
oxytocic B-outcome ['Resource-use']
drugs I-outcome ['Resource-use']
. O
['Resource-use']

We O
compared O
the O
ocular O
hypotensive O
effect O
for O
24 O
hours O
and O
the O
tolerability O
of O
latanoprost O
stored O
at O
4 O
degrees O
C O
and O
30 O
degrees O
C. O
Seventeen O
healthy O
volunteers O
were O
included O
in O
this O
crossover O
trial O
. O
[]

In O
this O
open-label O
, O
multicenter O
, O
phase O
II O
study O
, O
eligible O
patients O
( O
N O
= O
112 O
) O
were O
randomized O
2:1 O
to O
lapatinib O
plus O
vinorelbine O
[ O
( O
N O
= O
75 O
) O
1,250 O
mg O
orally O
once O
daily O
( O
QD O
) O
continuously O
plus O
20 O
mg/m O
( O
2 O
) O
/day O
intravenously O
] O
or O
lapatinib O
plus O
capecitabine O
[ O
( O
N O
= O
37 O
) O
1,250 O
mg O
orally O
QD O
continuously O
plus O
2,000 O
mg/m O
( O
2 O
) O
/day O
orally O
, O
2 O
doses O
] O
. O
[]

Role O
of O
diltiazem O
in O
the O
treatment O
of O
silent O
myocardial O
ischemia O
. O
[]

Data O
were O
available O
for O
1971 O
of O
1998 O
patients O
in O
these O
families O
. O
[]

A O
randomized O
controlled O
study O
was O
performed O
to O
evaluate O
the O
efficacy O
of O
intrapleural O
and O
systemic O
administration O
of O
OK-432 O
, O
streptococcus O
preparation O
, O
in O
patients O
with O
cancerous O
pleurisy O
. O
[]

Elaborated O
Intrusion O
theory O
( O
EI O
theory O
; O
Kavanagh O
, O
Andrade O
, O
& O
May O
, O
2005 O
) O
posits O
two O
main O
cognitive O
components O
in O
craving B-outcome ['Life-Impact']
: O
associative O
processes O
that O
lead O
to O
intrusive O
thoughts O
about O
the O
craved O
substance O
or O
activity O
, O
and O
elaborative O
processes O
supporting O
mental O
imagery O
of O
the O
substance O
or O
activity O
. O
['Life-Impact']

The O
treated O
group O
had O
a O
mean O
pupillary B-outcome ['Physiological-Clinical']
decrease O
of O
1.88 O
mm O
and O
the O
control O
group O
had O
a O
decrease O
of O
1.57 O
mm O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
D-dimer O
offers O
a O
useful O
laboratory O
tool O
for O
assessing O
early O
and O
late O
clinical O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
SAH I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
significant O
differences O
noted O
at O
baseline O
between O
groups O
. O
[]

Migraine B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
of O
initially O
7-8 O
was O
reduced O
to O
1-2 O
attacks/month O
. O
['Physiological-Clinical']

Airway B-outcome ['Physiological-Clinical']
seal I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
cm O
H O
( O
2 O
) O
O O
) O
for O
LTS O
and O
PLMA O
was O
20 O
+/- O
8.6 O
and O
24.1 O
+/- O
10.8 O
, O
respectively O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

EMG-EMG O
coherence O
analyses O
revealed O
that O
elbow B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
significantly O
reduced O
intermuscular B-outcome ['Physiological-Clinical']
coherence O
between O
distal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pooling O
all O
seven O
trials O
, O
a O
risk O
ratio O
was O
found O
for O
persons O
treated O
with O
isoniazid O
for O
developing O
tuberculosis O
of O
0.58 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
0.43-0.80 O
] O
and O
0.94 O
( O
95 O
% O
CI O
, O
0.83-1.07 O
) O
for O
death B-outcome ['Mortality']
. O
['Mortality']

The O
future O
development O
of O
fondaparinux O
resides O
primarily O
in O
three O
therapeutic O
areas O
: O
prevention O
of O
VTE O
, O
treatment O
of O
VTE O
, O
and O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndromes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Most O
patients O
had O
been O
treated O
with O
long-term O
topical O
2 O
% O
minoxidil O
for O
1 O
year O
or O
more O
prior O
to O
the O
study O
. O
[]

Providing O
an O
EAA+CHO O
solution O
postexercise O
can O
further O
increase O
muscle O
protein O
synthesis O
. O
[]

Endoscopically O
, O
the O
ulcer O
had O
healed B-outcome ['Physiological-Clinical']
at O
14 O
days O
in O
38.8 O
% O
( O
M O
) O
and O
in O
34.9 O
% O
( O
T O
) O
and O
at O
28 O
days O
in O
80.0 O
% O
( O
M O
) O
and O
74.7 O
% O
( O
T O
) O
, O
respectively O
. O
['Physiological-Clinical']

[ O
Effect O
of O
alpha O
dihydroergocryptine O
in O
patients O
with O
fibrocystic O
breast O
disease O
] O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
similar O
; O
and O
, O
at O
5 O
years O
, O
the O
survival B-outcome ['Mortality']
rate O
was O
33 O
% O
alive O
on O
the O
ALL-2 O
arm O
versus O
27 O
% O
on O
the O
L-20 O
. O
['Mortality', 'Mortality']

BACKGROUND O
Allergen O
vaccination O
is O
effective O
in O
mite-allergic O
asthma O
. O
[]

Concomitant O
, O
sequential O
, O
and O
hybrid O
therapy O
for O
H. O
pylori B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
: O
a O
pilot O
study O
. O
['Physiological-Clinical']

If O
prognostic O
factors O
have O
to O
be O
taken O
into O
account O
, O
the O
Cox O
model O
provides O
tests O
of O
Ho O
, O
and O
a O
useful O
confidence O
interval O
for O
the O
adjusted O
relative O
derived O
from O
the O
regression O
parameter O
for O
the O
treatment O
indicator O
. O
[]

The O
seizures O
were O
blindly O
rated O
for O
duration O
of O
motor B-outcome ['Physiological-Clinical']
convulsion I-outcome ['Physiological-Clinical']
, O
duration O
of O
electroencephalogram B-outcome ['Resource-use']
( O
['Physiological-Clinical', 'Resource-use']

Patients O
were O
given O
a O
250-mL O
bolus O
of O
Voluven O
( O
6 O
% O
hydroxyethyl O
starch O
130/0.4 O
in O
0.9 O
% O
sodium O
chloride O
) O
until O
the O
stroke O
volume O
no O
longer O
increased O
by O
10 O
% O
, O
then O
received O
either O
dopexamine O
( O
0.5 O
?g O
? O
[]

Eligible O
subjects O
in O
a O
multicenter O
, O
double-masked O
, O
randomized O
, O
parallel-group O
, O
placebo-controlled O
, O
natural O
exposure O
clinical O
trial O
were O
randomly O
assigned O
to O
either O
BBOS O
1.5 O
% O
or O
placebo O
eyedrops O
on O
a O
1:1 O
basis O
and O
instilled O
1 O
drop O
of O
the O
test O
agent O
into O
both O
eyes O
twice O
daily O
for O
2 O
weeks O
. O
[]

In O
the O
placebo O
group O
, O
none O
of O
the O
cases O
showed O
undetectable O
[]

Febrile B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in O
the O
48 O
h O
preceding O
the O
reaction O
were O
generally O
not O
observed O
in O
this O
group O
. O
['Physiological-Clinical']

DESIGN O
Randomised O
controlled O
trial O
to O
include O
400 O
women O
in O
each O
arm O
of O
the O
trial O
. O
[]

A O
single O
prophylactic O
intraoperative O
dose O
of O
intravenous O
amiodarone O
decreased O
post B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
arrhythmia I-outcome ['Physiological-Clinical']
in O
this O
study O
in O
comparison O
to O
the O
control O
group O
. O
['Physiological-Clinical']

Leukocyte-mediated O
reperfusion O
injury O
is O
partly O
responsible O
for O
decreased O
graft B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
after O
prolonged O
graft O
ischemia O
. O
['Physiological-Clinical']

A O
no-intervention O
control O
group O
was O
also O
assessed O
. O
[]

No O
significant O
differences O
were O
detected O
between O
the O
treatment O
and O
the O
placebo O
groups O
after O
8 O
weeks O
of O
supplementation O
with O
the O
algal O
extract O
in O
the O
parameters O
analyzed O
, O
except O
for O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
, O
total O
protein B-outcome ['Physiological-Clinical']
, O
and O
eosinophils B-outcome ['Physiological-Clinical']
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
include O
VAS O
change O
scores O
at O
10 O
, O
60 O
, O
90 O
and O
120 O
min O
, O
analgesia B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
mode O
of O
birth B-outcome ['Physiological-Clinical']
and O
maternal B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

Noninfiltrative O
anesthesia O
for O
transrectal O
prostate O
biopsy O
: O
a O
randomized O
prospective O
study O
comparing O
lidocaine-prilocaine O
cream O
and O
lidocaine-ketorolac O
gel O
. O
[]

Adapalene O
gel O
is O
a O
tretinoin O
derivative O
and O
has O
a O
lower O
incidence O
of O
irritation B-outcome ['Physiological-Clinical']
compared O
with O
other O
topical O
retinoid O
products O
. O
['Physiological-Clinical']

METHODS O
AND O
FINDINGS O
We O
identified O
57,857 O
middle O
and O
high O
school O
students O
( O
13-18 O
year O
olds O
) O
from O
a O
Korean O
nationally O
representative O
survey O
, O
which O
was O
surveyed O
in O
2009 O
. O
[]

RESULTS O
Wind-up O
occurred O
only O
with O
the O
2 O
Hz O
train O
in O
the O
UO O
and O
hand O
( O
both O
p=0.01 O
) O
. O
[]

Public O
and O
private O
heart O
rate O
feedback O
in O
social O
phobia O
: O
a O
manipulation O
of O
anxiety B-outcome ['Life-Impact']
visibility I-outcome ['Life-Impact']
. O
['Life-Impact']

Eleven O
patients O
with O
well-documented O
hepatorenal O
syndrome O
were O
studied O
by O
measurement O
of O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
renin B-outcome ['Physiological-Clinical']
substrate O
concentration O
, O
and O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Higher O
costs O
for O
personal B-outcome ['Resource-use']
care/waiver I-outcome ['Resource-use']
services I-outcome ['Resource-use']
were O
partially O
offset O
by O
savings O
in O
other O
Medicaid O
services O
, O
particularly O
those O
related O
to O
long-term O
care O
. O
['Resource-use']

In O
the O
present O
study O
, O
we O
aimed O
to O
investigate O
the O
effect O
of O
exercise O
, O
training O
, O
and O
glycogen O
availability O
, O
factors O
known O
to O
affect O
IL-6 O
, O
on O
the O
regulation O
of O
gene O
expression O
of O
the O
IL-6R O
in O
human O
skeletal O
muscle O
. O
[]

RESULTS O
Twenty-five O
patients O
received O
101 O
cycles O
of O
therapy O
( O
median O
two O
cycles O
, O
range O
1-15 O
) O
. O
[]

DESIGN O
Multicentre O
randomised O
clinical O
study O
. O
[]

The O
slope O
of O
the O
regression O
line O
for O
the O
delta O
melanin B-outcome ['Resource-use']
index O
against O
delta O
erythema B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

RESULTS O
Changes O
in O
the O
DAS28 O
, O
the O
SDAI O
score O
, O
and O
the O
CDAI B-outcome ['Physiological-Clinical']
score O
among O
patients O
receiving O
tocilizumab O
were O
significantly O
higher O
than O
those O
among O
patients O
receiving O
placebo O
, O
and O
the O
magnitude O
of O
these O
changes O
was O
similar O
for O
the O
SDAI O
and O
the O
CDAI B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Few O
women O
reported O
sexual O
activity O
during O
the O
previous O
month O
. O
[]

No O
operative O
deaths B-outcome ['Mortality']
occurred O
. O
['Mortality']

DESIGN O
A O
total O
of O
766 O
low-income O
adolescents O
( O
79 O
% O
participation O
rate O
) O
, O
including O
610 O
foreign-born O
, O
were O
recruited O
. O
[]

A O
group O
of O
10 O
subjects O
had O
plaque O
scored O
by O
index O
and O
area O
after O
suspending O
toothcleaning O
for O
48 O
h. O
Subjects O
were O
then O
randomly O
allocated O
to O
brush O
or O
not O
brush O
their O
teeth O
and O
plaque O
rescored O
. O
[]

The O
questionnaire O
was O
completed O
prior O
to O
treatment O
and O
after O
1 O
, O
6 O
, O
12 O
, O
24 O
, O
36 O
and O
48 O
months O
. O
[]

Risedronate O
5 O
mg O
reduced O
the O
risk O
of O
new O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
by O
49 O
% O
over O
3 O
years O
compared O
with O
control O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Compared O
to O
the O
placebo O
group O
, O
the O
olanzapine O
group O
had O
a O
lower O
incidence O
of O
( O
59.2 O
% O
versus O
91.1 O
% O
, O
p O
< O
0.001 O
) O
and O
a O
longer O
time O
to O
( O
46 O
versus O
15 O
days O
, O
p O
< O
0.001 O
) O
symptomatic B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
of O
any O
kind O
. O
['Physiological-Clinical']

All O
children O
were O
assessed O
before O
and O
after O
treatment O
on O
two O
behavioral O
measures O
, O
the O
Vineland O
Maladaptive B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Domain O
and O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
. O
['Life-Impact', 'Life-Impact']

degree O
C-1 O
. O
[]

Subjects O
with O
a O
negative O
history O
for O
HZ O
were O
randomized O
1:1 O
to O
receive O
one O
dose O
of O
either O
formulation O
. O
[]

Strictly O
controlled O
isocaloric O
diets O
with O
36 O
% O
of O
energy O
from O
test O
fats O
were O
served O
in O
random O
order O
for O
3 O
weeks O
separated O
by O
wash-out O
period O
( O
s O
) O
. O
[]

CONCLUSION O
TTS-scopolamine O
offers O
effective O
prophylaxis B-outcome ['Resource-use']
against O
PONV B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
auriculoemetic I-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

During O
each O
condition O
, O
systemic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
regional I-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

RESULTS O
The O
proton O
pump O
inhibitors O
and O
roxithromycin O
did O
not O
alter O
the O
blood B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
of O
each O
other O
. O
['Physiological-Clinical']

We O
recently O
showed O
that O
resistance O
exercise O
and O
ingestion O
of O
essential O
amino O
acids O
with O
carbohydrate O
( O
EAA+CHO O
) O
can O
independently O
stimulate O
mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
signaling O
and O
muscle O
protein O
synthesis O
in O
humans O
. O
[]

Balance O
was O
perturbed O
in O
11 O
healthy O
participants O
by O
a O
movable O
platform O
that O
suddenly O
translated O
forward O
or O
backward O
. O
[]

METHODS O
Two O
consecutive O
same O
day O
colonoscopies O
were O
performed O
in O
183 O
patients O
. O
[]

AIM O
This O
study O
compares O
the O
effects O
of O
laparoscopic O
lymphadenectomy O
versus O
those O
of O
abdominal O
lymphadenectomy O
in O
patients O
with O
endometrial O
cancer O
. O
[]

Tolerability O
was O
assessed O
by O
recording O
adverse O
events O
and O
change O
on O
the O
Arizona O
Sexual O
Experience O
Scale O
. O
[]

The O
Third O
National O
Wilms O
' O
Tumor O
Study O
sought O
to O
reduce O
treatment O
for O
low-risk O
patients O
and O
find O
better O
chemotherapy O
for O
those O
at O
high O
risk O
for O
relapse O
. O
[]

The O
proportions O
of O
infants O
in O
the O
vitamin O
A O
group O
and O
the O
control O
group O
who O
had O
signs O
of O
potential O
vitamin B-outcome ['Adverse-effects']
A I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
were O
similar O
. O
['Adverse-effects']

II O
. O
[]

CONCLUSION O
Our O
results O
indicate O
that O
supplementation O
of O
a O
combination O
of O
vitamin O
E O
, O
selenium O
, O
vitamin O
C O
and O
coenzyme-Q10 O
does O
not O
affect O
serum B-outcome ['Physiological-Clinical']
level O
of I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
. O
['Physiological-Clinical']

Both O
peak O
VO B-outcome ['Physiological-Clinical']
( O
2 O
) O
and O
endothelium-dependent B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
of O
the O
brachial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
( O
EDDBA B-outcome ['Physiological-Clinical']
) O
improved O
significantly O
after O
CoQ O
( O
10 O
) O
and O
after O
ET O
as O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIM O
OF O
THE O
STUDY O
To O
determine O
whether O
different O
induction O
regimens O
affect O
the O
outcome O
of O
sublingual O
immunotherapy O
. O
[]

Forty-three O
men O
and O
22 O
women O
with O
severe O
COAD O
were O
randomly O
allocated O
for O
8 O
weeks O
to O
one O
of O
three O
types O
of O
psychotherapy O
or O
to O
an O
untreated O
control O
group O
, O
and O
were O
followed O
up O
six O
months O
later O
. O
[]

Hemodynamics B-outcome ['Physiological-Clinical']
, O
rate O
of O
cesarean B-outcome ['Resource-use']
delivery I-outcome ['Resource-use']
, O
sensory B-outcome ['Physiological-Clinical']
block O
level O
, O
Bromage O
motor B-outcome ['Life-Impact']
scale I-outcome ['Life-Impact']
scores O
, O
instrument-assisted B-outcome ['Resource-use']
delivery I-outcome ['Resource-use']
, O
oxytocin B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
visual O
analog O
scale O
( O
VAS O
) O
scores O
, O
Apgar B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
, O
umbilical B-outcome ['Physiological-Clinical']
cord B-outcome ['Physiological-Clinical']
artery B-outcome ['Physiological-Clinical']
gas O
analysis O
, O
and O
maternal B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
including O
nausea B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

Session O
analysis O
showed O
significantly O
more O
and I-outcome ['Life-Impact']
lengthier O
events O
of O
eye B-outcome ['Life-Impact']
contact I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
turn-taking I-outcome ['Life-Impact']
in O
improvisational O
music O
therapy O
than O
play O
sessions O
. O
['Life-Impact']

The O
effectiveness O
of O
treatment O
does O
not O
compensate O
for O
the O
long-lasting O
and O
intense O
treatment O
protocol O
. O
[]

The O
primary O
end O
point O
was O
the O
percentage O
of O
attacks O
in O
which O
headache O
improved O
from O
severe O
or O
moderate O
before O
treatment O
to O
mild O
or O
absent O
at O
1 O
hour O
after O
the O
first O
injection O
. O
[]

The O
present O
study O
was O
designed O
to O
identify O
optimal O
patient O
positioning O
for O
the O
induction O
of O
general O
anesthesia O
that O
minimizes O
the O
risk O
of O
hypoxemia O
in O
these O
patients O
. O
[]

A O
randomized O
double-blind O
trial O
was O
used O
to O
assess O
endurance B-outcome ['Life-Impact']
, O
resistance B-outcome ['Life-Impact']
, O
strength B-outcome ['Life-Impact']
and O
coordination B-outcome ['Life-Impact']
in O
26 O
athletes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O
[]

Prophylactic O
budesonide O
did O
not O
prevent O
ipilimumab-induced O
bowel O
inflammation O
. O
[]

In O
this O
controlled O
randomized O
study O
, O
we O
investigated O
the O
influence O
of O
statin O
pretreatment O
and O
its O
withdrawal O
on O
the O
outcome O
of O
acute O
ischemic O
stroke O
patients O
. O
[]

APU B-outcome ['Physiological-Clinical']
decreased O
during O
the O
first O
6 O
months O
of O
treatment O
, O
but O
had O
returned O
to O
its O
baseline O
value O
after O
24 O
months O
and O
remained O
unchanged O
throughout O
the O
rest O
of O
the O
study O
. O
['Physiological-Clinical']

No O
differences O
in O
scar B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

The O
immunogenicity B-outcome ['Physiological-Clinical']
of O
three O
Haemophilus O
influenzae O
type O
B O
conjugate O
vaccines O
after O
a O
primary O
vaccination O
series O
in O
Philippine O
infants O
. O
['Physiological-Clinical']

Median O
duration O
of O
follow-up O
was O
7.0 O
years O
. O
[]

All O
patients O
received O
6-thioguanine O
during O
intensification O
courses O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
and O
['Physiological-Clinical', 'Resource-use']

DISCUSSION O
This O
study O
has O
the O
potential O
to O
determine O
whether O
outpatient O
movement O
strategy O
training O
combined O
with O
falls O
prevention O
education O
or O
progressive O
resistance O
strength O
training O
combined O
with O
falls O
prevention O
education O
are O
effective O
for O
reducing O
falls B-outcome ['Life-Impact']
and O
improving B-outcome ['Life-Impact']
mobility I-outcome ['Life-Impact']
and O
life B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
in O
people O
with O
Parkinson O
's O
disease O
who O
live O
at O
home O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
evaluated O
the O
associations O
of O
BMI O
with O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
incidence O
, O
adenoma B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
and O
cancer B-outcome ['Physiological-Clinical']
in O
the O
context O
of O
a O
large O
screening O
trial O
, O
in O
which O
cases O
and O
controls O
had O
an O
equal O
chance O
for O
disease O
detection O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Ovulation O
( O
89.09 O
% O
) O
and O
pregnancy O
( O
54.55 O
% O
) O
rates O
were O
higher O
in O
group O
B. O
Ovulation O
( O
74.55 O
% O
) O
and O
pregnancy O
( O
29.09 O
% O
) O
rates O
were O
also O
satisfactory O
in O
group O
C O
but O
a O
dose O
of O
rFSH O
requirement O
was O
significantly O
higher O
( O
P O
= O
0.000 O
) O
. O
[]

Patients O
also O
received O
pegfilgrastim O
6 O
mg O
as O
a O
single O
subcutaneous O
injection O
on O
day O
2 O
of O
each O
cycle O
. O
[]

38 O
male O
youths O
( O
7-16 O
years O
old O
) O
with O
autism O
spectrum O
disorders O
were O
administered O
24 O
or O
12 O
international O
units O
( O
depending O
on O
weight O
) O
intranasal O
placebo O
or O
oxytocin O
once O
daily O
over O
four O
consecutive O
days O
. O
[]

Employees O
from O
intervention O
work O
sites O
who O
were O
in O
preaction O
stages O
at O
baseline O
were O
much O
more O
likely O
to O
shift O
into O
action O
and O
maintenance O
stages O
than O
controls O
. O
[]

The O
clinical O
registrations O
were O
mirrored O
by O
a O
statistically O
significant O
decrease O
( O
p O
< O
0.05 O
) O
in O
the O
[]

In O
conclusion O
, O
smooth O
and O
predictable O
concentration/time B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
were O
achieved O
, O
enabling O
an O
efficacious O
and O
safe O
therapy O
of O
asthma O
. O
['Physiological-Clinical']

In O
a O
subgroup O
of O
patients O
, O
there O
is O
a O
second O
randomization O
to O
energy O
levels O
of O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
or O
4 O
steps O
above O
implant O
DFT++ O
for O
conversion O
testing O
of O
3 O
induced O
ventricular O
fibrillation O
episodes O
at O
prehospital O
discharge O
, O
3 O
months O
, O
and O
12 O
months O
after O
implant O
. O
[]

Bone B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
was O
less O
common O
in O
the O
SL O
group O
( O
14 O
% O
) O
than O
the O
LAG O
group O
( O
27 O
% O
) O
( O
p O
= O
0.003 O
) O
. O
['Physiological-Clinical']

1.43 O
mg/L O
and O
1.03 O
h O
( O
0.75-2.50 O
) O
, O
respectively O
. O
[]

0.47 O
kg O
, O
P O
< O
0.0005 O
) O
groups O
during O
the O
beverage O
arm O
. O
[]

[ O
Restorative O
proctectomy O
, O
reconstruction O
of O
continuity O
with O
or O
without O
colon O
J O
pouch O
] O
. O
[]

This O
is O
a O
model O
for O
acute O
GHD O
without O
the O
alterations O
in O
body O
composition O
associated O
with O
GHD O
. O
[]

PURPOSE O
To O
investigate O
and O
compare O
the O
effects O
of O
a O
dental O
cream O
containing O
complexes O
of O
casein O
phosphoprotein-amorphous O
calcium O
phosphate O
( O
CPP-ACP O
) O
and O
fluoride O
mouthwashes O
on O
the O
regression O
of O
white O
spot O
lesions O
( O
WSL O
) O
. O
[]

BACKGROUND O
The O
metastatic O
potential O
of O
tumors O
is O
dependent O
on O
the O
cell O
to O
cell O
adhesion O
by O
cell O
surface O
carbohydrate O
antigens O
. O
[]

Etanercept O
plus O
standard O
therapy O
for O
Wegener O
's O
granulomatosis O
. O
[]

Drug-induced O
, O
or O
chemical O
cystitis O
was O
observed O
in O
13 O
( O
16.7 O
% O
) O
of O
78 O
BCG-treated O
patients O
and O
in O
12 O
( O
13.8 O
% O
) O
of O
87 O
MMC-treated O
patients O
. O
[]

Influence O
of O
asimadoline O
, O
a O
new O
kappa-opioid O
receptor O
agonist O
, O
on O
tubular O
water O
absorption O
and O
vasopressin O
secretion O
in O
man O
. O
[]

Ototoxicity B-outcome ['Physiological-Clinical']
was O
assessed O
in O
patients O
who O
completed O
two O
audiograms O
and O
were O
not O
receiving O
ototoxic O
agents O
( O
n O
= O
63 O
) O
. O
['Physiological-Clinical']

TBS O
was O
followed O
by O
physical O
therapy O
for O
10 O
working O
days O
. O
[]

OBJECTIVE O
We O
performed O
a O
randomized O
, O
prospective O
trial O
to O
assess O
the O
impact O
of O
fibrin O
glue O
on O
the O
incidence O
of O
lymphocysts O
after O
systematic O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
in O
patients O
with O
gynecologic O
malignancies O
. O
[]

did O
not O
achieve O
statistically O
significant O
increases O
( O
P O
= O
0.25 O
) O
. O
[]

We O
also O
measured O
the O
concentration O
of O
infusions B-outcome ['Resource-use']
prepared O
by O
a O
pharmacist O
and O
a O
pharmaceutical O
company O
. O
['Resource-use']

moderate O
and O
severe O
. O
[]

METHODS O
One-hundred O
and O
nineteen O
introductory O
psychology O
students O
who O
either O
had O
two O
episodes O
of O
heavy O
episodic O
drinking O
in O
the O
past O
month O
or O
scored O
?8 O
on O
the O
AUDIT O
participated O
in O
this O
randomized O
controlled O
trial O
for O
course O
credit O
. O
[]

But O
further O
research O
examining O
efficacy O
of O
tailored O
nutrition O
education O
in O
comparison O
to O
other O
nutrition O
education O
methods O
and O
across O
a O
wider O
range O
of O
dietary O
behaviours O
is O
needed O
. O
[]

Etoposide O
was O
administered O
until O
Day O
22 O
. O
[]

Sodium O
cromoglycate O
was O
superior O
to O
placebo O
in O
improving O
breathlessness B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.001 O
) O
, O
breathlessness B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
and O
the O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.001 O
) O
, O
and O
also O
in O
improving O
the O
morning O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow O
rate O
value O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
at O
4 O
weeks O
was O
33 O
% O
for O
ketoconazole O
and O
29 O
% O
for O
griseofulvin O
, O
and O
at O
8 O
weeks O
was O
53 O
% O
and O
57 O
% O
respectively O
. O
['Physiological-Clinical']

Efficacy O
of O
different O
gonadotropin O
combinations O
to O
support O
ovulation B-outcome ['Physiological-Clinical']
induction I-outcome ['Physiological-Clinical']
in O
WHO O
type O
I O
anovulation O
infertility O
: O
clinical O
evidences O
of O
human O
recombinant O
FSH/human O
recombinant O
LH O
in O
a O
2:1 O
ratio O
and O
highly O
purified O
human O
menopausal O
gonadotropin O
stimulation O
protocols O
. O
['Physiological-Clinical']

Eleven O
subjects O
using O
insulin O
plus O
10 O
mg O
glyburide O
before O
breakfast O
had O
lower O
mean O
fasting O
glucose O
at O
10-16 O
weeks O
than O
10 O
subjects O
using O
insulin O
with O
placebo O
( O
mean O
+/- O
SEM O
; O
5.9 O
+/- O
0.3 O
versus O
7.5 O
+/- O
0.7 O
mmol/L O
; O
p O
less O
than O
0.05 O
) O
, O
and O
had O
a O
greater O
decrement O
of O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin B-outcome ['Physiological-Clinical']
from O
baseline O
values O
( O
1.3 O
+/- O
0.1 O
versus O
0.8 O
+/- O
0.2 O
% O
A1 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
modified O
CIMT O
group O
received O
1-hour O
daily O
physical O
rehabilitation O
sessions O
for O
2 O
weeks O
. O
[]

Magnesium O
sulphate O
only O
slightly O
reduces O
the O
shivering B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

This O
report O
describes O
the O
design O
, O
recruitment O
, O
enrolment O
and O
baseline O
results O
of O
the O
Treatment O
of O
Lead-Exposed O
Children O
( O
TLC O
) O
trial O
, O
a O
randomised O
, O
multicentre O
, O
placebo-controlled O
, O
double-blind O
clinical O
trial O
of O
the O
effects O
of O
treating O
lead-exposed O
children O
with O
succimer O
, O
a O
drug O
that O
enhances O
urinary O
excretion O
of O
lead O
, O
on O
cognitive O
, O
behavioural O
and O
physical O
development O
. O
[]

HDPM O
at O
an O
average O
dose O
of O
638.9 O
mg O
of O
pyridoxine O
and O
216.3 O
mg O
of O
magnesium O
oxide O
was O
ineffective O
in O
ameliorating B-outcome ['Life-Impact']
autistic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
as O
assessed O
by O
the O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
, O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
, O
and O
the O
NIMH O
Global B-outcome ['Life-Impact']
Obsessive I-outcome ['Life-Impact']
Compulsive I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
educational O
brochure O
seems O
to O
represent O
the O
most O
convenient O
and O
least O
costly O
method O
to O
increase O
knowledge B-outcome ['Life-Impact']
about O
breast O
cancer O
and O
screening O
among O
women O
who O
present O
for O
screening O
mammography O
. O
['Life-Impact']

Ascaris O
and O
growth O
rates O
: O
a O
randomized O
trial O
of O
treatment O
. O
[]

Previous O
research O
has O
shown O
that O
listeners O
can O
use O
lexical O
information O
to O
guide O
their O
interpretation O
of O
atypical O
sounds O
in O
speech O
( O
Norris O
, O
McQueen O
, O
& O
Cutler O
, O
2003 O
) O
. O
[]

There O
was O
a O
poor O
correlation O
between O
microscopy O
and O
culture O
of O
the O
bile O
for O
bacteria B-outcome ['Physiological-Clinical']
and O
there O
was O
no O
increase O
in O
['Physiological-Clinical']

Interruption O
of O
treatment O
in O
the O
TOTO O
group O
did O
not O
result O
in O
a O
better O
gain O
in O
height B-outcome ['Physiological-Clinical']
standard I-outcome ['Physiological-Clinical']
deviation O
score O
H-SDSCA B-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
TTOO O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Capsaicin O
jelly O
against O
migraine B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
minimal O
bleeding O
event O
rate O
is O
higher O
than O
reported O
but O
does O
not O
seem O
to O
affect O
adherence O
to O
treatment O
. O
[]

Secondary O
measures O
included O
the O
ABC O
stereotypy O
subscale O
, O
Repetitive B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Scale-Revised O
, O
and O
Social B-outcome ['Life-Impact']
Responsiveness I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

These O
measures O
were O
compared O
between O
the O
healthy O
controls O
and O
chronic O
pancreatitis O
patients O
. O
[]

By O
contrast O
, O
no O
difference O
in O
FFS O
was O
observed O
when O
patients O
were O
stratified O
by O
EBER-ISH O
. O
[]

Biomarker B-outcome ['Physiological-Clinical']
studies I-outcome ['Physiological-Clinical']
confirmed O
the O
superiority O
of O
letrozole O
in O
centrally O
assessed O
estrogen O
receptor-positive O
( O
ER+ O
) O
tumors O
and O
found O
a O
strong O
relationship O
with O
the O
degree O
of O
['Physiological-Clinical']

The O
development O
of O
anaesthesia O
was O
fastest O
following O
the O
largest O
dose O
, O
but O
the O
large O
number O
of O
central O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
makes O
that O
dosage O
less O
suitable O
for O
clinical O
work O
. O
['Adverse-effects']

The O
changes O
of O
scores O
of O
IQ B-outcome ['Life-Impact']
were O
determined O
with O
Gesell O
and O
WPPSI O
or O
WISC-R O
. O
['Life-Impact']

Postconceptional O
age O
was O
36 O
to O
45 O
weeks O
at O
the O
time O
of O
treatment O
. O
[]

The O
hypothyroid O
men O
all O
had O
elevated O
[]

Normothermic O
patients O
were O
warmed O
to O
36.5-37.0 O
degrees O
C O
after O
an O
initial O
temperature O
decrease O
, O
and O
hypothermic O
patients O
were O
cooled O
to O
35 O
degrees O
C. O
In O
the O
hypothermic O
group O
temperatures O
were O
allowed O
to O
drift O
to O
34.5 O
degrees O
C O
before O
rewarming O
was O
initiated O
. O
[]

However O
, O
that O
treatment O
may O
be O
related O
to O
potential O
pro-arrhythmia O
, O
lack O
of O
efficacy O
or O
the O
exceptionally O
high O
cost O
of O
a O
compound O
used O
. O
[]

Magnocellular O
visual O
evoked O
potential O
delay O
with O
high O
autism O
spectrum O
quotient O
yields O
a O
neural O
mechanism O
for O
altered B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Changes O
between O
pre- O
and O
post-treatment O
were O
examined O
using O
clinical O
interviews O
as O
well O
as O
child- O
, O
parent- O
and O
teacher-report O
measures O
. O
[]

Lead-time O
in O
the O
European O
Randomised O
Study O
of O
Screening O
for O
Prostate O
Cancer O
. O
[]

Glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate O
deteriorated O
significantly O
in O
the O
placebo O
group O
after O
24 O
months O
( O
p O
< O
0.025 O
) O
but O
showed O
no O
significant O
change O
in O
the O
lovastatin-treated O
patients O
. O
['Physiological-Clinical']

Recent O
studies O
have O
suggested O
an O
uneven O
profile O
of O
executive O
dysfunction O
in O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

These O
patients O
had O
duplex B-outcome ['Resource-use']
doppler I-outcome ['Resource-use']
scans I-outcome ['Resource-use']
between O
the O
fifth O
and O
seventh O
postoperative O
days O
. O
['Resource-use']

The O
average O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
about O
5 O
weeks O
. O
['Life-Impact']

We O
recorded O
patients O
' O
temperatures B-outcome ['Physiological-Clinical']
on O
their O
arrival O
in O
the O
PACU O
and O
at O
30 O
minutes O
after O
arrival B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

PATIENT O
( O
S O
) O
Sixty-one O
patients O
were O
randomly O
assigned O
into O
two O
letrozole O
and O
gonadotropin-treated O
groups O
. O
[]

All O
children O
received O
two O
20-min O
sessions O
a O
week O
over O
a O
6-week O
period O
. O
[]

The O
effects O
of O
acute O
administration O
per O
os O
of O
30 O
mg O
camazepam O
and O
the O
same O
dose O
of O
temazepam O
, O
were O
compared O
with O
placebo O
in O
8 O
young O
male O
volunteers O
, O
fully O
adapted O
to O
the O
laboratory O
environment O
by O
6 O
nights O
of O
adaptation O
. O
[]

Abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
after O
injection O
of O
low-dose O
gentamicin O
was O
similar O
to O
that O
of O
control O
. O
['Physiological-Clinical']

The O
comparison O
acupuncture O
treatment O
group O
had O
no O
significant O
change O
in O
severity O
from O
baseline O
over O
the O
treatment O
phase O
. O
[]

SUBJECTS O
Forty-one O
subjects O
with O
T2DM O
were O
treated O
with O
metformin O
or O
diet O
, O
having O
good O
glycemic O
control O
with O
glycosylated O
hemoglobin O
values O
of O
6.2-7.5 O
% O
. O
[]

Folic O
acid O
fortification O
has O
produced O
a O
dramatic O
increase O
in O
blood O
folate O
concentrations O
among O
reproductive O
age O
women O
, O
and O
a O
reduction O
in O
neural O
tube O
defect O
( O
NTD O
) O
-affected O
pregnancies O
. O
[]

We O
conclude O
there O
is O
no O
difference O
between O
OG O
( O
using O
local O
anesthesia O
) O
and O
PEG O
with O
regard O
to O
morbidity B-outcome ['Physiological-Clinical']
, O
mortality B-outcome ['Mortality']
, O
or O
tube B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Mortality', 'Life-Impact']

Prediction O
of O
metabolic O
and O
cardiopulmonary O
responses O
to O
maximum O
cycle O
ergometry O
: O
a O
randomised O
study O
. O
[]

Colonization B-outcome ['Physiological-Clinical']
was O
limited O
to O
infants O
who O
were O
not O
on O
antibiotics O
within O
7 O
days O
of O
treatment O
with O
LGG O
. O
['Physiological-Clinical']

RESULTS O
Nineteen O
patients O
from O
group O
A O
and O
23 O
patients O
from O
group O
B O
completed O
the O
study O
. O
[]

Attenuation O
values O
of O
the O
bilateral O
internal B-outcome ['Physiological-Clinical']
carotid I-outcome ['Physiological-Clinical']
arteries B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
in O
the O
treatment O
group O
received O
2.0 O
clinical O
units O
of O
secretin O
per O
kilogram O
of O
body O
weight O
as O
a O
single O
intravenous O
dose O
. O
[]

RESULTS O
Groups O
were O
comparable O
at O
baseline O
in O
age O
, O
sex O
, O
tumor O
type O
, O
weight O
loss O
, O
and O
performance O
status O
. O
[]

The O
findings O
also O
indicated O
that O
girls O
reported O
a O
higher O
level O
of O
anxiety O
than O
boys O
and O
children O
in O
higher O
grades O
reported O
lower O
anxiety O
relative O
to O
younger O
children O
in O
both O
studies O
. O
[]

RESULTS O
After O
12 O
weeks O
of O
therapy O
with O
placebo O
, O
there O
was O
no O
change O
in O
total O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
, O
parasympathetically B-outcome ['Physiological-Clinical']
governed I-outcome ['Physiological-Clinical']
high I-outcome ['Physiological-Clinical']
frequency O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
or O
sympathetically B-outcome ['Physiological-Clinical']
influenced I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
frequency O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
Blood O
coagulation O
at O
the O
site O
of O
microvascular O
injury O
was O
assessed O
in O
26 O
males O
with O
CAD O
before O
and O
after O
treatment O
with O
quinapril O
( O
10 O
mg O
day-1 O
; O
n=13 O
) O
or O
atorvastatin O
( O
40 O
mg O
day-1 O
; O
n=13 O
) O
for O
4 O
weeks O
and O
an O
additional O
4 O
weeks O
of O
combined O
therapy O
( O
quinapril+atorvastatin O
) O
. O
[]

From O
July O
1986 O
to O
July O
1988 O
, O
146 O
children O
less O
than O
5 O
years O
of O
age O
were O
referred O
by O
their O
physicians O
to O
our O
university O
sleep O
clinic O
for O
continual O
waking O
and O
crying O
during O
sleep O
hours O
. O
[]

One-year O
follow-up O
of O
the O
outcome O
of O
a O
randomized O
controlled O
trial O
of O
a O
home-based O
intervention O
programme O
for O
children O
with O
autism O
and O
developmental O
delay O
and O
their O
families O
. O
[]

Zidovudine O
was O
discontinued O
in O
group O
A O
patients O
before O
instituting O
GM-CSF O
treatment O
and O
was O
restarted O
in O
a O
graduated O
fashion O
over O
4 O
weeks O
. O
[]

Mixed-effects O
modelling O
showed O
that O
a O
decrease O
in O
patients O
' O
anxiety O
was O
linked O
with O
screening O
questions O
( O
P O
= O
0.045 O
) O
, O
physicians O
' O
satisfaction B-outcome ['Life-Impact']
about O
support O
given O
( O
P O
= O
0.004 O
) O
and O
with O
patients O
' O
distress O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact']

RESULT O
( O
S O
) O
Compared O
with O
group O
I O
, O
the O
rate O
of O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
was O
statistically O
significantly O
lower O
for O
group O
II O
( O
43.4 O
% O
[ O
13/30 O
] O
vs. O
19.4 O
% O
[ O
6/31 O
] O
) O
, O
but O
the O
amount B-outcome ['Resource-use']
of I-outcome ['Resource-use']
gonadotropins I-outcome ['Resource-use']
used O
was O
statistically O
significantly O
higher O
( O
817.5 O
+/- O
28.5 O
vs. O
907.5 O
+/- O
27.3 O
IU O
) O
. O
['Physiological-Clinical', 'Resource-use']

The O
apical O
paddle O
is O
often O
placed O
in O
a O
transverse O
orientation O
. O
[]

There O
was O
no O
difference O
in O
the O
rate O
of O
[]

In O
Study O
1 O
, O
TOM O
test O
scores O
of O
normal O
children O
( O
n O
= O
70 O
) O
correlated O
positively O
with O
their O
performance O
on O
other O
theory O
of O
mind O
tasks O
. O
[]

The O
concentration O
of O
5-fluorouracil B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
5-FU I-outcome ['Physiological-Clinical']
) O
in O
tumor B-outcome ['Physiological-Clinical']
tissue B-outcome ['Physiological-Clinical']
was O
measured O
by O
chemical B-outcome ['Physiological-Clinical']
assay O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Insight B-outcome ['Physiological-Clinical']
was O
clinically O
significantly O
improved O
( O
risk O
ratio=1.15 O
, O
95 O
% O
CI O
1.01-1.31 O
) O
. O
['Physiological-Clinical']

At O
all O
doses O
, O
rhuGM-CSF O
was O
well O
tolerated O
, O
and O
there O
was O
no O
evidence O
of O
grade O
III B-outcome ['Physiological-Clinical']
or O
IV B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Cox O
regression O
analyses O
were O
performed O
to O
evaluate O
the O
relations O
between O
BMI O
and O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
PCSM B-outcome ['Mortality']
, O
and O
nonprostate B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality', 'Mortality', 'Mortality']

The O
greatest O
effect O
of O
valaciclovir O
on O
CMV B-outcome ['Physiological-Clinical']
disease O
was O
seen O
in O
patients O
who O
were O
PCR-positive O
in O
blood O
at O
baseline O
( O
P O
= O
.002 O
) O
, O
although O
a O
significant O
effect O
was O
also O
seen O
in O
those O
who O
were O
PCR-negative O
in O
urine O
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

This O
may O
arise O
from O
an O
underlying O
impairment O
in O
which O
individuals O
with O
ASD O
have O
difficulty O
perceiving O
the O
temporal O
relationship O
between O
cross-modal O
inputs O
, O
an O
important O
cue O
for O
multisensory O
integration O
. O
[]

Multiple O
logistic O
regression O
analyses O
of O
potential O
risk O
factors O
for O
12-month O
point-prevalent O
smoking O
and O
for O
persistent O
smoking O
( O
point-prevalent O
smoking O
at O
both O
follow-ups O
) O
following O
treatment O
were O
conducted O
for O
men O
and O
women O
combined O
and O
separately O
. O
[]

Lactobacillus O
plantarum O
CECT7315 O
and O
CECT7316 O
stimulate O
immunoglobulin B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
after O
influenza O
vaccination O
in O
elderly O
. O
['Physiological-Clinical']

plasma B-outcome ['Physiological-Clinical']
renin B-outcome ['Physiological-Clinical']
activity B-outcome ['Life-Impact']
, O
leptin B-outcome ['Physiological-Clinical']
and O
interleukin-6 B-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Greater O
decreases O
were O
also O
seen O
in O
community-specific B-outcome ['Physiological-Clinical']
microfilarial I-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
with O
combined O
therapy O
( O
mean O
reductions O
91.1 O
% O
and O
69.8 O
% O
, O
respectively O
; O
p O
= O
0.0047 O
) O
. O
['Physiological-Clinical']

The O
benzodiazepines O
are O
typified O
by O
a O
profile O
of O
side O
effects O
which O
includes O
drowsiness B-outcome ['Physiological-Clinical']
, O
ataxia B-outcome ['Physiological-Clinical']
and O
incoordination B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

mCPP O
raised O
prolactin B-outcome ['Physiological-Clinical']
and O
temperature B-outcome ['Physiological-Clinical']
as O
compared O
to O
placebo O
, O
but O
did O
not O
affect O
plasma B-outcome ['Physiological-Clinical']
homovanillic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
indicate O
that O
GSSTP O
is O
a O
promising O
intervention O
for O
a O
mixed-disability O
group O
. O
[]

Assessing O
the O
benefit O
of O
a O
personalized O
EHR-generated O
informed O
consent O
in O
a O
dental O
school O
setting O
. O
[]

Baseline O
risk O
factors O
for O
SH O
were O
evaluated O
over O
12 O
months O
of O
follow-up O
using O
proportional O
hazards O
regression O
. O
[]

CONCLUSIONS O
There O
were O
no O
significant O
differences O
in O
efficacy O
or O
safety O
between O
20 O
and O
50 O
mg O
of O
arzoxifene O
. O
[]

Clinical O
parameters O
were O
assessed O
to O
determine O
potential O
sources O
of O
bias O
. O
[]

We O
sought O
to O
determine O
whether O
exposure O
to O
low-level O
light O
contamination O
during O
the O
dark O
phase O
influenced O
the O
normally O
entrained O
circadian O
rhythms O
of O
various O
substances O
in O
plasma O
. O
[]

The O
authors O
describe O
neuropsychological O
outcomes O
in O
people O
with O
Parkinson O
's O
disease O
( O
PD O
) O
after O
their O
participation O
in O
an O
NIH-sponsored O
, O
randomized O
, O
controlled O
trial O
of O
cognitive-behavioral O
treatment O
for O
depression O
. O
[]

Program O
reach O
was O
low O
, O
which O
may O
reflect O
inaccuracies O
in O
church O
attendance O
rather O
than O
study O
implementation O
issues O
. O
[]

Cooperative O
Study O
Group O
of O
Surgical O
Adjuvant O
Chemotherapy O
of O
Colorectal O
Cancer O
in O
Japan O
] O
. O
[]

Results O
showed O
parents O
reporting O
fewer O
and O
lower O
intensity O
of O
problem B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
and O
increased O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
at O
4 O
weeks O
and O
3 O
months O
. O
['Life-Impact', 'Life-Impact']

Subjects O
were O
evaluated O
at O
enrollment O
and O
1 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
initial O
diagnosis O
of O
T1D O
. O
[]

Cow O
's O
milk O
was O
excluded O
from O
their O
diet O
. O
[]

Delay O
in O
absorption O
of O
cephalexin O
resulted O
in O
a O
decrease O
in O
the O
percentage O
of O
T O
> O
MIC B-outcome ['Physiological-Clinical']
( O
90 O
) O
for O
certain O
acid-suppressive O
regimens O
and O
pathogen O
combinations O
. O
['Physiological-Clinical']

On O
two O
separate O
occasions O
at O
the O
same O
time O
of O
day O
, O
concentration-response O
studies O
with O
inhaled O
histamine O
or O
methacholine O
, O
or O
a O
sham O
challenge O
with O
normal O
saline O
were O
carried O
out O
in O
a O
blinded O
, O
randomized O
manner O
. O
[]

Survival B-outcome ['Mortality']
rates O
for O
cases O
of O
squamous O
cell O
carcinoma O
, O
small O
cell O
carcinoma O
, O
and O
adrenocarcinoma O
were O
the O
same O
after O
both O
regimens O
of O
therapy O
. O
['Mortality']

OBJECTIVE O
To O
determine O
whether O
docosahexaenoic O
acid O
will O
slow O
the O
course O
of O
retinal O
degeneration O
in O
subgroups O
of O
patients O
with O
retinitis O
pigmentosa O
who O
are O
receiving O
vitamin O
A O
. O
[]

The O
emergence O
of O
behavioral O
control O
in O
some O
instances O
seemed O
to O
be O
marked O
by O
reduction O
of O
complexity O
of O
the O
impulse O
response O
to O
one O
dominated O
by O
the O
zeroth-order O
lag O
, O
leading O
to O
dynamically O
simpler O
responses O
compared O
to O
control O
. O
[]

morphine O
self-administered O
by O
the O
patient O
via O
the O
patient-controlled O
analgesia O
device O
( O
PCA O
) O
is O
used O
to O
study O
the O
interaction O
between O
EM O
and O
2-CP O
. O
[]

An O
uncompleted O
randomised O
controlled O
trial O
of O
463 O
women O
. O
[]

INTERVENTIONS O
Five O
weeks O
of O
SMT O
or O
NSAID O
therapy O
in O
combination O
with O
supervised O
trunk O
exercise O
, O
followed O
by O
and O
additional O
6 O
wk O
of O
supervised O
exercise O
alone O
. O
[]

Thirty O
cases O
in O
treatment O
group O
with O
49 O
eyes O
were O
transplanted O
with O
irradiated O
drug-containing O
( O
ofloxacin O
, O
acetyl O
cysteine O
and O
reduced O
glutathione O
) O
porcine-cornea O
. O
[]

A O
total O
of O
1161 O
subjects O
were O
randomized O
to O
OCT O
and O
1163 O
to O
placebo O
; O
over O
80 O
% O
returned O
for O
a O
repeat O
13C-urea O
breath O
test O
on O
at O
least O
one O
occasion O
. O
[]

The O
effect O
of O
prophylactic O
calcium O
and O
magnesium O
infusions O
on O
the O
incidence O
of O
neurotoxicity O
and O
clinical O
outcome O
of O
oxaliplatin-based O
systemic O
treatment O
in O
advanced O
colorectal O
cancer O
patients O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
ST I-outcome ['Physiological-Clinical']
segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
increased O
to O
341 O
+/- O
148 O
from O
296 O
+/- O
154 O
seconds O
( O
p O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
analgesic B-outcome ['Resource-use']
efficacy O
of O
hydrogen O
peroxide O
( O
H2O2 O
) O
mouth O
rinse O
with O
control O
for O
post-tonsillectomy B-outcome ['Resource-use']
pain I-outcome ['Resource-use']
management I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use']

Patients O
who O
received O
radiotherapy O
alone O
had O
a O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rate O
of O
100 O
% O
, O
the O
TTF B-outcome ['Life-Impact']
was O
90 O
% O
at O
5 O
years O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
at O
5 O
years O
was O
90 O
% O
with O
no O
statistical O
difference O
when O
compared O
with O
patients O
who O
received O
combined O
therapy O
[ O
100 O
, O
80 O
and O
95 O
% O
, O
respectively O
( O
P O
= O
0.5 O
) O
] O
. O
['Physiological-Clinical', 'Life-Impact', 'Mortality']

Short-term O
aerobic O
exercise O
training O
in O
obese O
humans O
with O
type O
2 O
diabetes O
mellitus O
improves O
whole-body O
insulin O
sensitivity O
through O
gains O
in O
peripheral O
, O
not O
hepatic O
insulin O
sensitivity O
. O
[]

Subjects O
received O
3 O
years O
of O
grass O
AIT O
( O
n O
= O
157 O
) O
or O
placebo O
( O
n O
= O
126 O
) O
, O
followed O
by O
1 O
year O
of O
follow-up O
. O
[]

Group O
3 O
wore O
a O
functioning O
HMD O
without O
any O
additional O
aids O
. O
[]

They O
had O
, O
however O
, O
a O
high O
incidence O
of O
[]

The O
impact O
of O
information O
about O
autism O
on O
these O
ratings O
was O
investigated O
as O
well O
as O
age O
and O
gender O
effects O
. O
[]

Implant B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
revision I-outcome ['Physiological-Clinical']
surgery I-outcome ['Physiological-Clinical']
was O
necessary O
in O
2 O
patients O
after O
an O
additional O
adequate O
trauma O
. O
['Physiological-Clinical']

A O
total O
of O
950 O
men O
and O
women O
aged O
40-74 O
years O
were O
randomized O
and O
are O
being O
followed O
for O
5 O
years O
at O
a O
single O
center O
. O
[]

On O
all O
measures O
group O
variability O
in O
scores O
increased O
with O
age O
. O
[]

CONCLUSIONS O
Fluorescence O
diagnosis O
is O
significantly O
superior O
to O
conventional O
white O
light O
transurethral O
resection O
with O
respect O
to O
the O
residual O
tumor B-outcome ['Physiological-Clinical']
rate O
and O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

BACKGROUND O
AND O
OBJECTIVE O
This O
study O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
monthly O
alternating O
ABVD/MOPP O
compared O
to O
ABVD/OPP O
regimens O
in O
patients O
with O
advanced O
stage O
Hodgkin O
's O
disease O
( O
HD O
) O
, O
as O
well O
as O
in O
early O
stage O
patients O
with O
systemic O
symptoms O
and/or O
bulky O
disease O
. O
['Adverse-effects']

BACKGROUND O
Clomethiazole O
( O
CLO O
) O
has O
been O
shown O
to O
be O
effective O
in O
treating O
alcohol B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
( O
AWS B-outcome ['Physiological-Clinical']
) O
. O
['Life-Impact', 'Physiological-Clinical']

Secondary O
outcomes O
were O
changes O
on O
the O
10-item O
version O
of O
the O
Neuropsychiatric O
Inventory O
Questionnaire O
( O
NPI-Q O
) O
, O
the O
Cornell O
Scale O
for O
Depression B-outcome ['Life-Impact']
in O
Dementia O
( O
CSDD O
) O
and O
the O
Quality O
of O
Life O
in O
Late-Stage O
Dementia B-outcome ['Physiological-Clinical']
( O
QUALID O
) O
scale O
. O
['Life-Impact', 'Physiological-Clinical']

Needles O
on O
the O
4 O
extremities O
were O
withdrawn O
first O
after O
30 O
minutes O
, O
needles O
on O
head O
were O
remained O
during O
behavior O
training O
. O
[]

The O
results O
indicate O
successful B-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
of O
the O
HBHS O
program O
. O
['Life-Impact']

fludarabine O
with O
once O
daily O
i.v O
. O
[]

Mean O
follow-up O
was O
22.5 O
months O
( O
SD O
9.0 O
) O
. O
[]

Evaluation O
of O
25-gauge O
Quincke O
and O
24-gauge O
Gertie O
Marx O
needles O
for O
spinal O
anaesthesia O
for O
caesarean O
section O
. O
[]

14 O
mm O
in O
diameter O
( O
P O
< O
0.007 O
) O
and O
serum B-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
levels O
( O
P O
< O
0.001 O
) O
on O
the O
day O
of O
hCG O
were O
lower O
in O
the O
Early O
versus O
the O
Late O
hCG O
groups O
. O
['Physiological-Clinical']

Both O
the O
NIH-CPSI B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
and O
the O
improvement O
of O
complications B-outcome ['Adverse-effects']
were O
significantly O
higher O
in O
the O
experimental O
than O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

A O
limited O
sampling O
method O
for O
the O
estimation O
of O
flunarizine O
area O
under O
the O
curve O
( O
AUC O
) O
and O
maximum B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomisation O
was O
done O
with O
a O
computer-generated O
randomisation O
code O
and O
was O
stratified O
by O
centre O
. O
[]

Open O
or O
uncontrolled O
studies O
have O
suggested O
that O
providing O
cancer O
patients O
with O
audiotapes O
of O
their O
clinical O
interviews O
can O
improve O
information O
recall B-outcome ['Life-Impact']
and O
reduce O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Therapeutic O
effects O
of O
combined O
treatment O
using O
tetracycline-immobilized O
collagen O
film O
and O
root O
planing O
in O
periodontal O
furcation O
pockets O
. O
[]

Recovery B-outcome ['Physiological-Clinical']
after O
prolonged O
anaesthesia O
for O
acoustic O
neuroma O
surgery O
: O
desflurane O
versus O
isoflurane O
. O
['Physiological-Clinical']

Effect O
of O
finasteride O
treatment O
on O
suburethral O
prostatic O
microvessel O
density O
in O
patients O
with O
hematuria O
related O
to O
benign O
prostate O
hyperplasia O
. O
[]

Supplemental O
oxygen O
appears O
to O
be O
an O
effective O
intervention O
to O
reduce O
SSI B-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
colon O
or O
rectal O
surgery O
. O
['Physiological-Clinical']

METHODS O
Patients O
received O
CDDP O
75 O
mg/m O
( O
2 O
) O
plus O
DCT O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
weeks O
( O
arm O
A O
) O
or O
CDDP O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
plus O
VNR O
30 O
mg/m O
( O
2 O
) O
day O
1 O
and O
8 O
every O
3 O
weeks O
( O
arm O
B O
) O
. O
[]

Among O
the O
70 O
patients O
, O
24 O
had O
angina O
only O
at O
rest O
. O
[]

Yet O
, O
in O
the O
motivation O
condition O
, O
both O
typical O
and O
autistic O
adults O
donated O
significantly O
more O
to O
the O
observer O
when O
watched O
, O
although O
this O
effect O
was O
significantly O
attenuated O
in O
autistic O
individuals O
. O
[]

The O
patients O
were O
compared O
to O
20 O
age- O
und O
sex-matched O
healthy O
controls O
. O
[]

There O
were O
no O
serious O
adverse O
events O
. O
[]

Results O
reveal O
that O
explicit O
instruction O
group O
patients O
demonstrated O
more O
improved O
memory B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
using O
semantic O
clustering O
, O
suggesting O
that O
explicit O
and O
direct O
teaching O
facilitates O
patients O
' O
learning O
of O
information O
. O
['Life-Impact']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
the O
Ramsay O
sedation O
score O
( O
RSS O
) O
, O
and O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
all O
children O
were O
continuously O
monitored O
and O
recorded O
during O
the O
entire O
procedure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

They O
were O
assigned O
randomly O
to O
active O
warming O
or O
passive O
insulation O
on O
day O
1 O
and O
given O
alternative O
treatment O
during O
the O
subsequent O
visit O
. O
[]

They O
underwent O
comprehensive O
neuropsychological O
testing O
to O
determine O
treatment O
effects O
on O
cognitive O
functioning O
. O
[]

Patients O
were O
divided O
into O
four O
groups O
( O
20 O
patients O
for O
each O
) O
: O
dexmedetomidine O
and O
topical O
anesthesia O
, O
dexmedetomidine O
and O
peribulbar O
anesthesia O
, O
midazolam+fentanyl O
and O
topical O
anesthesia O
, O
and O
midazolam+fentanyl O
and O
peribulbar O
anesthesia O
. O
[]

Ninety O
six O
patients O
with O
nocturnal O
asthma O
, O
( O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV1 O
) O
60-90 O
% O
of O
predicted O
value O
, O
reversibility O
> O
or O
= O
15 O
% O
, O
at O
least O
two O
nocturnal O
awakenings O
per O
week O
) O
were O
eligible O
for O
a O
multicentre O
, O
double-blind O
, O
double-dummy O
cross-over O
study O
( O
14-day O
run-in O
, O
two O
successive O
28-day O
treatment O
periods O
) O
. O
[]

In O
experiment O
2 O
, O
the O
osteotomy B-outcome ['Physiological-Clinical']
shape I-outcome ['Physiological-Clinical']
was O
varied O
. O
['Physiological-Clinical']

INTERVENTION O
Screening O
for O
high O
risk O
and O
provision O
of O
social O
work-based O
case O
management O
. O
[]

BACKGROUND O
Whether O
early O
detection O
and O
treatment O
of O
prostate O
cancer O
( O
PCa O
) O
will O
reduce O
disease-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
remains O
uncertain O
. O
['Mortality']

Enhanced B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
in O
a O
milk-based O
formulation O
of O
wolfberry O
( O
Gou O
Qi O
Zi O
; O
Fructus O
barbarum O
L. O
) O
. O
['Physiological-Clinical']

Experimental O
hyaline O
membrane O
disease O
in O
the O
premature O
monkey O
: O
effects O
of O
antenatal O
dexamethasone O
. O
[]

Moreover O
, O
11 O
patients O
in O
the O
control O
arm O
suffered O
from O
fever B-outcome ['Physiological-Clinical']
> O
37.5 O
degrees O
C O
for O
at O
least O
3 O
days O
as O
compared O
to O
1 O
patient O
in O
the O
antibiotic O
prophylaxis O
group O
; O
the O
postoperative B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
13.3 O
+/- O
4.3 O
and O
9.0 O
+/- O
1.6 O
in O
the O
control O
and O
antibiotic O
arm O
respectively O
. O
['Physiological-Clinical', 'Resource-use']

PURPOSE O
To O
assess O
a O
single O
dose O
of O
intraoperative O
beta O
radiation O
used O
to O
enhance O
the O
success O
rate O
of O
trabeculectomy O
in O
a O
population O
of O
low-risk O
glaucoma O
patients O
in O
whom O
antimetabolites O
might O
not O
be O
indicated O
. O
[]

We O
conclude O
that O
oral O
methotrexate O
did O
not O
slow O
down O
progression O
of O
muscle B-outcome ['Physiological-Clinical']
weakness I-outcome ['Physiological-Clinical']
but O
decreased O
serum B-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
trial O
examined O
the O
efficacy O
of O
pemetrexed-cisplatin O
for O
SCCHN O
. O
[]

Inhibition O
of O
histamine-induced O
skin O
wheal O
and O
flare O
after O
5 O
days O
of O
mizolastine O
. O
[]

The O
significant O
mean O
loss O
in O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
group O
A O
during O
therapy O
reversed O
slowly O
and O
had O
not O
returned O
to O
baseline O
at O
the O
final O
follow-up O
visit O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
rates O
at O
6 O
months O
follow-up O
were O
similar O
in O
the O
2 O
groups O
( O
61 O
of O
117 O
, O
52.1 O
% O
vs. O
62 O
of O
116 O
, O
53.4 O
% O
; O
P=0.8 O
) O
. O
['Mortality']

METHODS O
We O
evaluated O
the O
effects O
of O
calcitriol O
( O
1alpha,25-dihydroxyvitamin O
D3 O
) O
on O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
76 O
patients O
( O
26 O
men O
and O
50 O
women O
) O
with O
cirrhosis O
who O
were O
assigned O
randomly O
to O
receive O
calcitriol O
( O
0.5 O
mg O
twice O
per O
day O
) O
or O
not O
. O
['Physiological-Clinical']

One O
hundred O
milliliter O
venous O
blood O
was O
drawn O
from O
each O
patient O
, O
and O
was O
mixed O
with O
100 O
ml O
( O
35 O
?g/ml O
) O
medical O
ozone O
and O
then O
was O
returned O
the O
blood O
to O
the O
patient O
intravenously O
, O
once O
every O
other O
day O
for O
20 O
days O
. O
[]

Production O
and O
use O
of O
CFCs O
, O
except O
for O
certain O
critical O
exemptions O
, O
has O
been O
prohibited O
by O
the O
Montreal O
Protocol O
. O
[]

Comparative O
studies O
proved O
a O
local B-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
5-HT3 I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
antagonist I-outcome ['Physiological-Clinical']
, O
tropisetron B-outcome ['Physiological-Clinical']
( O
Navoban B-outcome ['Physiological-Clinical']
( O
R O
) O
) O
, O
to O
be O
more O
effective O
than O
an O
injection O
of O
the O
local O
anesthetic O
prilocaine O
in O
treating O
periarthropathies O
of O
different O
localizations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
DMI O
and O
gain O
: O
feed O
showed O
cubic O
( O
P O
< O
.10 O
) O
responses O
to O
increasing O
dietary O
level O
of O
RPLM O
. O
[]

We O
collected O
blood O
pre-exposure O
, O
7 O
, O
and O
22 O
hours O
after O
exposure O
initiation O
and O
measured O
the O
complete O
blood B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
differential O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
free O
radicals O
( O
FR O
) O
generation O
after O
ischaemic O
preconditioning O
and O
cardiopulmonary O
bypass O
and O
during O
reperfusion O
in O
CABG O
patients O
, O
and O
the O
role O
of O
ischaemic O
preconditioning O
. O
[]

Adverse B-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
associated O
with O
doses O
and O
schedules O
used O
clinically O
can O
be O
managed O
successfully O
with O
medical O
therapy O
. O
['Physiological-Clinical']

RESULTS O
Women O
in O
the O
treatment O
condition O
compared O
to O
the O
control O
condition O
reported O
significant O
gains O
in O
attitudes B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

PATIENTS O
AND O
METHODS O
Patients O
with O
advanced O
solid O
tumours O
were O
randomised O
at O
cycle-1 O
to O
placebo O
or O
aflibercept O
( O
4 O
mg/kg O
) O
on O
day O
1 O
then O
irinotecan-LV5FU2 O
on O
days O
1 O
and O
2 O
. O
[]

On O
three O
trial O
days O
, O
patients O
inhaled O
, O
in O
random O
order O
, O
40 O
micrograms O
ipratropium O
bromide O
, O
200 O
micrograms O
fenoterol O
hydrobromide O
, O
or O
a O
combination O
of O
40 O
micrograms O
ipratropium O
and O
100 O
micrograms O
fenoterol O
from O
a O
powder O
inhaler O
, O
followed O
by O
a O
second O
dose O
of O
the O
same O
drug O
after O
60 O
min O
. O
[]

Dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
was O
twice O
as O
frequent O
in O
the O
clonidine-treated O
patients O
, O
but O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
all O
side O
effects O
or O
the O
number O
of O
withdrawals B-outcome ['Life-Impact']
from O
the O
study O
because O
of O
side O
effects O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Life-Impact']

CONCLUSIONS O
Supplementary O
vitamin O
E O
intake O
appears O
to O
be O
effective O
in O
reducing O
the O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
in O
subjects O
not O
treated O
with O
lipid-lowering O
drugs O
while O
the O
process O
is O
still O
confined O
to O
the O
arterial O
wall O
( O
early O
preintrusive O
atherosclerosis O
) O
. O
['Physiological-Clinical']

Efficacy O
indexes O
were O
1.09 O
for O
ZAR O
patients O
and O
0.95 O
for O
Planoscan O
patients O
. O
[]

PURPOSE O
A O
prospective O
randomized O
trial O
was O
conducted O
to O
determine O
whether O
the O
addition O
of O
concurrent O
cisplatin O
to O
preoperative O
or O
definitive O
radiation O
therapy O
in O
patients O
with O
muscle-invasive O
bladder O
cancer O
improved O
local O
control O
or O
survival B-outcome ['Mortality']
. O
['Mortality']

In O
the O
first O
100 O
days O
, O
1 O
patient O
died O
of O
pneumonia O
, O
and O
1 O
of O
liver O
GVHD O
. O
[]

Pharmacokinetic O
properties O
of O
YM17E O
, O
an O
inhibitor O
of O
acyl O
coenzyme O
A O
: O
cholesterol O
acyl O
transferase O
, O
and O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

AS O
is O
the O
preferred O
method O
of O
arterial O
closure O
after O
cardiac O
catheterization O
. O
[]

RESULTS O
The O
pooled O
database O
included O
538 O
patients O
. O
[]

Of O
these O
, O
109 O
( O
71.2 O
% O
) O
completed O
the O
first O
questionnaire O
1 O
week O
after O
consultation O
, O
whereas O
95 O
( O
62.1 O
% O
) O
completed O
the O
6-month O
follow-up O
questionnaire O
. O
[]

Eligible O
patients O
were O
18-75 O
years O
old O
with O
CKD O
stage O
5 O
maintained O
on O
haemodialysis O
. O
[]

In O
addition O
, O
a O
regression O
analysis O
was O
conducted O
to O
determine O
whether O
changes O
in O
social O
interaction O
skills O
were O
associated O
with O
language O
development O
. O
[]

Nephrotoxicity B-outcome ['Physiological-Clinical']
was O
assessed O
in O
patients O
who O
did O
not O
receive O
nephrotoxic O
agents O
( O
n O
= O
76 O
) O
. O
['Physiological-Clinical']

The O
mean O
VAS O
scores O
8 O
and O
24 O
hours O
after O
surgery O
were O
significantly O
lower O
in O
group O
2 O
than O
in O
group O
1 O
( O
P O
= O
0.001 O
) O
. O
[]

METHODS O
Sixty-eight O
consecutively O
recruited O
, O
premenopausal O
, O
omnivorous O
women O
of O
all O
races O
and O
ethnicities O
between O
the O
ages O
of O
25 O
years O
and O
55 O
years O
were O
admitted O
to O
the O
study O
and O
randomized O
to O
an O
experimental O
group O
supplemented O
with O
soy O
( O
40 O
mg O
genistein O
per O
day O
) O
or O
to O
a O
control O
group O
that O
consumed O
a O
placebo O
for O
a O
12-week O
period O
. O
[]

OBJECTIVE O
To O
assess O
the O
mechanism O
of O
long-term O
LDL-C-lowering O
effect O
of O
ezetimibe-plus-statin O
. O
[]

PURPOSE O
Different O
outcome O
results O
have O
been O
published O
in O
trials O
comparing O
maximal O
androgen O
blockade O
( O
MAB O
) O
with O
chemical O
or O
surgical O
castration O
alone O
. O
[]

INTERVENTIONS O
Volunteers O
received O
a O
single O
200-mg O
oral O
dose O
of O
itraconazole O
or O
itraconazole O
with O
concomitant O
oral O
ddI O
300 O
mg O
( O
two O
150-mg O
tablets O
) O
dispersed O
in O
240 O
ml O
water O
. O
[]

How O
does O
Cash O
and O
Counseling O
affect O
costs O
? O
[]

OBJECTIVE O
This O
prospective O
randomized O
study O
aims O
at O
evaluation O
and O
comparison O
of O
the O
prophylactic O
effects O
of O
amiodarone O
versus O
digoxin O
and O
metoprolol O
combination O
in O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Lp B-outcome ['Physiological-Clinical']
( O
a O
) O
showed O
no O
significant O
change O
in O
both O
groups O
. O
['Physiological-Clinical']

A O
prospective O
, O
randomized O
, O
controlled O
study O
on O
cefotiam O
. O
[]

The O
echocamera O
provided O
improved O
localization O
of O
the O
IJV O
and O
the O
CA O
in O
comparison O
with O
the O
Doppler O
ultrasound O
. O
( O
[]

The O
changes O
in O
nocturnal B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
coincided O
with O
significant O
decreases O
in O
the O
severity B-outcome ['Physiological-Clinical']
and O
frequency O
of O
narcolepsy B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
ambulatory O
monitoring O
showed O
that O
lisinopril O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
final O
value O
and O
maintained B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
to O
a O
greater O
degree O
than O
captopril O
throughout O
24-h O
periods O
of O
observation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
this O
trial O
period O
, O
the O
treatment O
was O
discontinued O
by O
16 O
patients O
taking O
CSA O
( O
mainly O
because O
of O
loss O
of O
efficacy O
) O
and O
by O
4 O
taking O
MTX O
. O
[]

The O
[]

Upper O
endoscopies O
were O
performed O
before O
and O
at O
the O
end O
of O
the O
treatment O
period O
, O
and O
gastroduodenal B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
graded O
using O
a O
predefined B-outcome ['Physiological-Clinical']
scoring I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
study O
results O
suggest O
that O
telmisartan O
results O
in O
a O
greater O
reduction O
of O
urinary B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
than O
does O
enalapril O
and O
that O
this O
effect O
occurs O
by O
a O
mechanism O
independent O
of O
blood O
pressure O
reduction O
. O
['Physiological-Clinical']

METHODS O
Sixty-three O
patients O
were O
randomized O
into O
mitoxantrone O
and O
doxorubicin O
groups O
. O
[]

All O
data O
were O
subjected O
to O
covariance O
analysis O
including O
the O
age O
factor O
. O
[]

Sulfasalazine O
is O
an O
inhibitor O
of O
their O
synthesis O
in O
the O
mucosa O
. O
[]

To O
evaluate O
the O
effects O
of O
hydrocortisone O
on O
the O
balance O
between O
proinflammatory O
and O
antiinflammation O
, O
40 O
patients O
with O
septic O
shock O
were O
randomized O
in O
a O
double-blind O
crossover O
study O
to O
receive O
either O
the O
first O
100 O
mg O
of O
hydrocortisone O
as O
a O
loading O
dose O
and O
10 O
mg O
per O
hour O
until O
Day O
3 O
( O
n O
= O
20 O
) O
or O
placebo O
( O
n O
= O
20 O
) O
, O
followed O
by O
the O
opposite O
medication O
until O
Day O
6 O
. O
[]

The O
primary O
outcome O
variables O
are O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
intensity O
, O
disability B-outcome ['Life-Impact']
, O
and O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Levels O
of O
fibrinogen B-outcome ['Physiological-Clinical']
, O
activated B-outcome ['Physiological-Clinical']
factor O
VII B-outcome ['Physiological-Clinical']
, O
and O
factor O
VII B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
were O
not O
significantly O
influenced O
by O
hormone O
replacement O
therapy O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
falls O
in O
the O
CSF B-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
colony I-outcome ['Physiological-Clinical']
counts O
were O
4.7 O
and O
5.0 O
log10 O
colony-forming O
units/ml O
, O
respectively O
. O
['Physiological-Clinical']

The O
cultures O
obtained O
from O
the O
conjunctival O
sac O
of O
the O
control O
group O
principally O
showed O
growth O
of O
Staph O
. O
[]

By O
multivariable O
analysis O
side O
branch O
occlusion O
was O
an O
independent O
predictor O
of O
NQMI B-outcome ['Physiological-Clinical']
( O
OR O
4.45 O
; O
95 O
% O
CI O
[ O
1.82 O
, O
10.85 O
] O
) O
. O
['Physiological-Clinical']

Actigraphy O
and O
parent O
questionnaires O
were O
collected O
at O
baseline O
and O
1 O
month O
after O
treatment O
. O
[]

RESULTS O
Analyses O
controlled O
for O
the O
effect O
of O
chronological O
age O
, O
verbal O
intelligence O
, O
gender O
and O
DVD O
viewing O
time O
on O
outcomes O
. O
[]

For O
multivariable O
analysis O
, O
Cox O
's O
proportional O
hazards O
regression O
models O
were O
performed O
. O
[]

The O
H-reflex B-outcome ['Physiological-Clinical']
provides O
a O
measure O
of O
alpha O
motorneuron O
( O
neuromuscular O
) O
excitability O
in O
the O
sensory-motor O
pathway O
of O
the O
respective O
muscle O
and O
nerve O
. O
['Physiological-Clinical']

The O
incidences O
of O
any O
Common O
Terminology O
Criteria O
for O
Adverse B-outcome ['Adverse-effects']
Events I-outcome ['Adverse-effects']
grade O
3 O
and O
4 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs B-outcome ['Adverse-effects']
) O
were O
87 O
% O
and O
72 O
% O
in O
the O
panitumumab O
and O
control O
groups O
, O
respectively O
. O
['Adverse-effects', 'Adverse-effects', 'Adverse-effects']

INTRODUCTION O
There O
is O
debate O
about O
the O
type O
and O
intensity O
of O
early O
childhood O
intervention O
that O
is O
most O
helpful O
for O
children O
with O
developmental O
problems O
. O
[]

OBJECTIVE O
To O
evaluate O
pentoxifylline O
for O
the O
treatment O
of O
recurrent O
aphthous O
stomatitis O
. O
[]

Most O
AEs O
were O
mild O
to O
moderate O
and O
failed O
to O
interfere O
with O
therapeutic O
changes O
; O
there O
were O
no O
unanticipated O
AEs O
. O
[]

Comparison O
of O
enoxaparin O
and O
standard O
heparin O
in O
gynaecologic O
oncologic O
surgery O
: O
a O
randomised O
prospective O
double-blind O
clinical O
study O
. O
[]

Effect O
of O
addition O
of O
single O
dose O
of O
oral O
montelukast O
to O
standard O
treatment O
in O
acute O
moderate O
to O
severe O
asthma O
in O
children O
between O
5 O
and O
15 O
years O
of O
age O
: O
a O
randomised O
, O
double-blind O
, O
placebo O
controlled O
trial O
. O
[]

We O
conclude O
that O
antibiotic O
therapy O
is O
not O
needed O
in O
moderately O
ill O
patients O
with O
exacerbations O
of O
chronic O
bronchitis O
. O
[]

The O
prolongation B-outcome ['Physiological-Clinical']
of O
QS2c B-outcome ['Physiological-Clinical']
after O
oral O
nifedipine O
is O
suggestive O
of O
a O
negative O
['Physiological-Clinical', 'Physiological-Clinical']

Four O
groups O
of O
patients O
with O
increasingly O
severe O
liver O
disease O
were O
compared O
: O
( O
A O
) O
bridging O
fibrosis O
( O
Ishak O
3 O
and O
4 O
) O
with O
platelet O
counts O
> O
125,000/mm3 O
( O
n O
= O
559 O
) O
; O
( O
B O
) O
bridging O
fibrosis O
with O
platelet O
counts O
< O
or O
=125,000/mm3 O
( O
n O
= O
96 O
) O
; O
( O
C O
) O
cirrhosis O
( O
Ishak O
5 O
and O
6 O
) O
with O
platelet O
counts O
> O
125,000/mm3 O
( O
n O
= O
198 O
) O
; O
and O
( O
D O
) O
cirrhosis O
with O
platelet O
counts O
< O
or O
=125,000/mm3 O
( O
n O
= O
193 O
) O
. O
[]

Modest O
visceral O
fat O
gain O
causes O
endothelial O
dysfunction O
in O
healthy O
humans O
. O
[]

3 O
. O
[]

In O
the O
pre-trial O
period O
( O
treatment O
as O
needed O
) O
there O
were O
an O
average O
of O
35 O
bleedings B-outcome ['Physiological-Clinical']
per O
two O
months O
. O
['Physiological-Clinical']

METHODS O
A O
randomized O
, O
double-masked O
, O
two-way O
crossover O
study O
was O
performed O
in O
14 O
healthy O
volunteers O
. O
[]

This O
is O
the O
first O
truly O
objective O
( O
randomized O
) O
study O
demonstrating O
the O
beneficial O
effect O
of O
supporting O
the O
luteal O
phase O
in O
an O
IVF O
programme O
. O
[]

Nineteen O
participants O
received O
gelcaps O
with O
an O
algal O
extract O
in O
safflower O
oil O
, O
containing O
2 O
mg O
of O
astaxanthin O
each O
( O
treatment O
) O
; O
16 O
participants O
received O
gelcaps O
containing O
safflower O
oil O
only O
( O
placebo O
) O
. O
[]

However O
, O
these O
findings O
were O
not O
statistically O
significant O
( O
P=0.99 O
) O
. O
[]

CONCLUSION O
Treatment O
with O
sevoflurane O
before O
coronary O
occlusion O
seem O
effective O
in O
reducing O
functional B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
due O
to O
ischemia O
. O
['Physiological-Clinical']

Biochemical O
markers O
as O
predictors O
of O
bone O
mineral O
density O
changes O
after O
GnRH O
agonist O
treatment O
. O
[]

In O
the O
current O
study O
, O
we O
attempted O
to O
address O
this O
question O
by O
categorizing O
stimuli O
as O
high O
, O
middle O
, O
and O
low O
preference O
based O
on O
the O
results O
of O
a O
choice O
assessment O
, O
and O
then O
comparing O
the O
reinforcing O
effectiveness O
of O
these O
stimuli O
using O
a O
concurrent O
operants O
paradigm O
. O
[]

Fifty-six O
patients O
were O
assigned O
to O
5 O
days O
of O
perioperative O
antibiotic O
prophylaxis O
. O
[]

RESULTS O
Compliance O
to O
target O
numbers O
and O
types O
of O
F O
& O
V O
was O
broadly O
met O
and O
verified O
by O
dietary O
records O
, O
and O
plasma B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Evaluation O
was O
carried O
out O
by O
means O
of O
a O
standardised O
questionnaire O
( O
BMS O
) O
and O
a O
concentration O
test O
( O
d2 O
Aufmerksamkeits-Belastungs-Test O
) O
. O
[]

Psychological O
well-being O
correlates O
with O
free O
thyroxine O
but O
not O
free O
3,5,3'-triiodothyronine O
levels O
in O
patients O
on O
thyroid O
hormone O
replacement O
. O
[]

Relationships O
between O
age O
at O
diagnosis O
, O
clinical O
features O
, O
and O
outcome O
of O
therapy O
in O
children O
treated O
in O
the O
Medical O
Research O
Council O
AML O
10 O
and O
12 O
trials O
for O
acute O
myeloid O
leukemia O
. O
[]

Surgical O
time O
was O
reduced O
in O
the O
custom-fit O
group O
( O
12 O
min O
less O
; O
p O
= O
0.001 O
) O
. O
[]

This O
study O
is O
a O
prospective O
assessment O
of O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
in O
patients O
on O
long-term O
therapy O
for O
acute O
venous O
thromboembolism O
who O
have O
active O
cancer O
. O
['Physiological-Clinical']

Core B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
tympanic O
membrane O
and O
mean O
skin B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
determined O
from O
four O
sites O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
preceded O
by O
a O
2-week O
run-in O
when O
ICS O
were O
discontinued O
and O
salmeterol O
started O
, O
and O
used O
on O
a O
regular O
basis O
throughout O
the O
study O
. O
[]

Long-term O
follow-up O
of O
a O
randomized O
trial O
of O
fludarabine-mitoxantrone O
, O
compared O
with O
cyclophosphamide O
, O
doxorubicin O
, O
vindesine O
, O
prednisone O
( O
CHVP O
) O
, O
as O
first-line O
treatment O
of O
elderly O
patients O
with O
advanced O
, O
low-grade O
non-Hodgkin O
's O
lymphoma O
before O
the O
era O
of O
monoclonal O
antibodies O
. O
[]

Current O
evidence O
on O
the O
effectiveness O
of O
patient O
reminders O
for O
all O
types O
of O
immunisation O
programmes O
is O
largely O
based O
on O
North O
American O
studies O
. O
[]

Using O
initial O
assessment O
data O
from O
46 O
clients O
of O
a O
clinical O
psychology O
alcohol O
problems O
service O
( O
30 O
men O
, O
16 O
women O
) O
, O
an O
attempt O
was O
made O
to O
operationalize O
the O
concepts O
of O
dependence O
and O
personal O
persuasion O
using O
a O
variety O
of O
indicators O
of O
each O
. O
[]

Little O
covariation O
was O
detected O
within O
or O
between O
other O
diet B-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
domains O
suggesting O
that O
interventions O
to O
improve O
these O
behaviors O
in O
adolescents O
need O
to O
include O
specific O
program O
components O
for O
each O
target O
behavior O
of O
interest O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
AND O
FINDINGS O
During O
18 O
y O
of O
follow-up O
of O
14,916 O
men O
initially O
free O
of O
diagnosed O
cancer O
, O
we O
identified O
1,066 O
men O
with O
incident O
prostate O
cancer O
( O
including O
496 O
with O
aggressive O
disease O
, O
defined O
as O
stage O
C O
or O
D O
, O
Gleason O
7-10 O
, O
metastatic O
, O
and O
fatal O
prostate O
cancer O
) O
and O
1,618 O
cancer-free O
, O
age- O
and O
smoking-matched O
control O
participants O
in O
the O
Physicians O
' O
Health O
Study O
. O
[]

The O
over-all B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
28 O
% O
in O
patients O
treated O
with O
LMW-heparin O
and O
39 O
% O
in O
those O
given O
dextran O
, O
a O
non-significant O
difference O
. O
['Physiological-Clinical']

OUTCOMES O
& O
MEASUREMENTS O
Mortality B-outcome ['Mortality']
, O
hospitalization B-outcome ['Resource-use']
, O
and O
metabolic B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Resource-use', 'Physiological-Clinical']

During O
aortic O
cross-clamping O
Group O
II O
patients O
received O
dopexamine O
infusion O
, O
at O
a O
dose O
of O
1 O
microgram/kg/m O
, O
and O
at O
a O
dose O
of O
0.5 O
micrograms/kg/m O
from O
declamping O
to O
the O
end O
of O
the O
surgery O
. O
[]

The O
acute O
effects O
of O
fluid O
intake O
on O
urine O
specific O
gravity O
and O
fluid O
retention O
in O
a O
mildly O
dehydrated O
state O
. O
[]

Eight O
hours O
after O
the O
start O
of O
the O
loading O
dose O
infusion O
, O
the O
first O
maintenance O
dose O
( O
120 O
mg O
) O
was O
administered O
over O
60 O
minutes O
. O
[]

MATERIALS O
AND O
METHODS O
45 O
participants O
without O
any O
visual O
impairment O
were O
randomly O
assigned O
to O
3 O
groups O
and O
completed O
a O
variety O
of O
tasks O
during O
a O
simulated O
working O
day O
. O
[]

Chronic B-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
did O
not O
matter O
. O
['Physiological-Clinical']

In O
this O
study O
, O
19 O
subjects O
received O
the O
influenza O
vaccine O
, O
20 O
subjects O
the O
combination O
of O
influenza O
and O
pneumococcal O
vaccine O
. O
[]

CONCLUSION O
The O
use O
of O
large O
biopsy O
forceps O
to O
perform O
TBLB O
via O
rigid O
bronchoscope O
can O
significantly O
increase O
diagnostic O
yield O
in O
the O
pathological O
diagnosis O
of O
diffuse O
infiltrative O
lung O
disease O
. O
[]

Abrasive B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
on O
eroded O
root O
dentine O
after O
different O
periods O
of O
exposure O
to O
saliva O
in O
situ O
. O
['Physiological-Clinical']

With O
sotalol O
, O
as O
compared O
with O
the O
other O
drugs O
combined O
, O
there O
were O
lower O
risks O
of O
[]

Accordingly O
, O
we O
investigated O
the O
effects O
on O
ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
of O
aspirin O
administered O
at O
different O
times O
of O
the O
day O
in O
prehypertension O
. O
['Physiological-Clinical']

During O
acute O
attacks O
, O
the O
porphyrin O
precursors O
5-aminolevulinic O
acid O
and O
porphobilinogen O
accumulate O
and O
are O
excreted O
at O
high O
concentrations O
in O
the O
urine O
. O
[]

RESULTS O
In O
the O
trimethoprim-sulfamethoxazole O
group O
( O
n O
= O
154 O
) O
there O
were O
14 O
recurrences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCP I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
36 O
recurrences O
( O
including O
1 O
extrapulmonary O
recurrence O
) O
in O
the O
aerosolized-pentamidine O
group O
( O
n O
= O
156 O
) O
. O
['Physiological-Clinical']

The O
purpose O
of O
the O
study O
described O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
cognitive O
behavioural O
intervention O
for O
anger O
management O
with O
children O
diagnosed O
with O
Asperger O
syndrome O
. O
[]

Immunoglobulin O
treatment O
for O
whooping O
cough O
( O
pertussis O
) O
is O
widely O
believed O
to O
be O
ineffective O
although O
there O
are O
sound O
reasons O
for O
regarding O
the O
condition O
as O
a O
toxin-induced O
disease O
. O
[]

Results O
confirmed O
our O
hypothesis O
that O
patients O
who O
received O
either O
relaxation O
and O
imagery O
alone O
or O
patients O
who O
received O
the O
package O
of O
cognitive-behavioral O
coping O
skills O
would O
report O
less O
pain B-outcome ['Physiological-Clinical']
than O
patients O
in O
the O
other O
2 O
groups O
. O
['Physiological-Clinical']

The O
mean O
MMDAI O
score O
at O
baseline O
was O
7.9 O
; O
62 O
% O
of O
patients O
had O
a O
score O
> O
or O
=8.0 O
( O
moderate O
disease O
) O
. O
[]

The O
data O
suggest O
that O
various O
clinical O
background O
variables O
may O
influence O
individual O
and O
summed O
amplitudes O
of O
OPs O
differently O
. O
[]

randomly O
. O
[]

By O
multiple O
linear O
regressions O
, O
240 O
SNPs O
in O
twenty-four O
candidate O
genes O
were O
investigated O
for O
SNP O
main O
and O
SNP-diet O
interaction O
effects O
on O
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
LDL-cholesterol B-outcome ['Physiological-Clinical']
, O
HDL-cholesterol B-outcome ['Physiological-Clinical']
and O
TAG B-outcome ['Physiological-Clinical']
after O
an O
8-week O
low-energy O
diet O
( O
only O
main O
effect O
) O
, O
and O
a O
6-month O
ad O
libitum O
weight O
maintenance O
diet O
, O
with O
different O
contents O
of O
dietary O
protein O
or O
glycaemic O
index O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Further O
imaging O
was O
recommended O
more O
often O
after O
CT O
( O
25 O
of O
71 O
patients O
, O
35 O
% O
) O
than O
after O
DSA O
( O
nine O
of O
66 O
patients O
, O
14 O
% O
; O
P O
= O
.003 O
) O
. O
[]

It O
is O
hypothesized O
that O
patients O
who O
receive O
the O
multi O
modular O
structured O
intervention O
will O
have O
less O
patient O
related O
barriers O
and O
a O
better O
self O
management O
of O
cancer B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
patients O
were O
treated O
with O
either O
20 O
mg O
Mitoxantrone O
or O
40 O
mg O
mitomycin O
C O
weekly O
for O
8 O
weeks O
and O
two O
other O
instillations O
every O
15 O
days O
in O
50 O
ml O
saline O
solution O
. O
[]

In O
all O
groups O
, O
there O
is O
a O
statistically O
significant O
decrease O
in O
BChE B-outcome ['Physiological-Clinical']
( O
p O
= O
0.03 O
, O
p O
= O
0.02 O
) O
and O
leptin B-outcome ['Physiological-Clinical']
( O
p O
= O
0.002 O
) O
, O
insulin B-outcome ['Resource-use']
and O
HOMA-IR B-outcome ['Physiological-Clinical']
levels O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

We O
conclude O
that O
rizatriptan O
10 O
mg O
has O
a O
rapid O
onset O
of O
action O
and O
relieves O
headache O
and O
associated O
symptoms O
more O
effectively O
than O
sumatriptan O
100 O
mg O
. O
[]

OBJECTIVES O
Thrombolysis O
is O
the O
treatment O
of O
choice O
for O
patients O
with O
ST-elevation O
myocardial O
infarction O
( O
STEMI O
) O
living O
in O
rural O
areas O
with O
long O
transfer O
delays O
to O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

In O
contrast O
, O
they O
chose O
amphetamine O
either O
as O
often O
as O
or O
more O
often O
than O
placebo O
. O
[]

New O
coated O
and O
closed O
loop O
circuit O
systems O
may O
reduce O
this O
inflammation B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
improve O
the O
surgical B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
zoledronic O
acid O
on O
disseminated O
tumour O
cells O
in O
women O
with O
locally O
advanced O
breast O
cancer O
: O
an O
open O
label O
, O
randomised O
, O
phase O
2 O
trial O
. O
[]

A O
decrease O
in O
PPD O
( O
5.4 O
mm O
, O
SD O
1.4 O
mm O
) O
and O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
( O
DDM-horizontal O
257 O
microns O
, O
SD O
60 O
microns O
) O
and O
a O
gain O
of O
CPAL O
( O
5.1 O
mm O
, O
SD O
1.4 O
mm O
) O
were O
seen O
following O
the O
use O
of O
BRG O
in O
presplint O
teeth O
. O
['Physiological-Clinical']

Eight O
previously O
characterized O
patients O
with O
recurrent O
NMS O
( O
five O
females O
and O
three O
males O
; O
34+/-2 O
yr O
) O
were O
recruited O
from O
the O
Vanderbilt O
Syncope O
Unit O
and O
eight O
age-matched O
controls O
underwent O
initial O
administration O
of O
clonidine O
( O
CLO O
) O
or O
yohimbine O
( O
YHO O
) O
. O
[]

However O
, O
little O
is O
known O
about O
subclinical O
inflammation O
or O
the O
effect O
of O
lifestyle O
intervention O
on O
inflammation O
in O
early O
stages O
of O
OSA O
. O
[]

METHODS O
This O
was O
a O
parallel-group O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Healthcare B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
differences O
between O
sustained O
quitters O
and O
a O
sample O
of O
community-dwelling O
smokers O
, O
matched O
to O
these O
quitters O
on O
the O
basis O
of O
health O
services O
use O
around O
the O
time O
trial O
participant O
enrolled O
and O
by O
demographics O
, O
were O
also O
examined O
. O
['Resource-use']

Disorders O
of O
autonomic O
regulation O
are O
common O
in O
patients O
with O
Parkinson O
's O
disease O
( O
PD O
) O
. O
[]

Markedly B-outcome ['Physiological-Clinical']
abnormal I-outcome ['Physiological-Clinical']
Fridericia I-outcome ['Physiological-Clinical']
's O
correction B-outcome ['Physiological-Clinical']
of O
QT O
values O
( O
500 O
milliseconds O
or O
greater O
) O
were O
observed O
in O
only O
a O
small O
number O
of O
subjects O
by O
treatment O
group O
, O
that O
is O
2 O
( O
less O
than O
1 O
% O
) O
in O
the O
pooled O
degarelix O
group O
and O
2 O
( O
1 O
% O
) O
in O
the O
leuprolide O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Before O
operation O
( O
T O
( O
1 O
) O
) O
, O
10 O
min O
after O
recovery O
of O
two-lung O
ventilation O
( O
T O
( O
2 O
) O
) O
, O
and O
24 O
h O
( O
T O
( O
3 O
) O
) O
and O
48 O
h O
( O
T O
( O
4 O
) O
) O
after O
operation O
, O
the O
venous O
blood O
sample O
was O
taken O
from O
the O
internal O
jugular O
vein O
and O
the O
plasma O
was O
separated O
and O
stored O
at O
-70 O
degrees O
C O
for O
later O
analysis O
of O
IL-6 O
and O
IL-8 O
with O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O
[]

PARTICIPANTS O
A O
total O
of O
135 O
patients O
with O
signs O
and O
symptoms O
of O
seasonal O
allergic O
conjunctivitis O
participated O
. O
[]

Women O
selecting O
this O
treatment O
were O
assigned O
to O
a O
group O
that O
received O
both O
mail O
and O
telephone O
reminders O
or O
to O
a O
second O
group O
that O
received O
only O
a O
scheduled O
appointment O
at O
the O
time O
of O
the O
previous O
injection O
. O
[]

Immune O
reconstitution O
after O
allogeneic O
marrow O
transplantation O
compared O
with O
blood O
stem O
cell O
transplantation O
. O
[]

BACKGROUND O
Although O
precordial O
contrast O
echocardiography O
is O
widely O
used O
to O
diagnose O
patent O
foramen O
ovale O
, O
this O
method O
is O
limited O
by O
poor O
sensitivity O
. O
[]

Children O
were O
eligible O
for O
TLC O
if O
they O
were O
between O
12 O
and O
33 O
months O
of O
age O
, O
had O
a O
confirmed O
blood O
lead O
concentration O
between O
20 O
and O
44 O
micrograms/dL O
and O
lived O
in O
a O
residence O
suitable O
for O
lead O
dust O
reduction O
. O
[]

Sample O
size O
was O
based O
on O
80 O
% O
power O
to O
reject O
the O
null O
hypothesis O
that O
the O
cost/QALY O
gained O
would O
not O
exceed O
$ O
50,000 O
. O
['Resource-use']

The O
experience O
of O
pleasure O
before O
and O
after O
hearing O
rehabilitation O
. O
[]

The O
Intraclass O
Correlation O
Coefficient O
( O
ICC O
) O
for O
the O
interobserver O
reliability O
of O
determining O
the O
echo-types O
I+II O
was O
0.95 O
. O
[]

The O
use O
of O
the O
transition O
zone O
volume O
for O
this O
correction O
results O
in O
a O
higher O
discriminatory O
potential O
when O
compared O
to O
the O
use O
of O
the O
total O
prostate O
volume O
; O
however O
, O
the O
observed O
difference O
was O
not O
statistically O
significant O
. O
[]

At O
T1 O
there O
were O
no O
differences O
in O
biochemical B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
anthropometric I-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
between O
the O
groups O
, O
whereas O
at O
T2 O
group O
C O
presented O
a O
higher O
level O
of O
HDL O
( O
48.7 O
+/- O
2.4 O
vs. O
45.00 O
+/- O
5.6 O
; O
P O
= O
0.01 O
) O
and O
a O
lower O
LDL O
: O
HDL O
ratio O
( O
2.41 O
+/- O
0.8 O
vs. O
3.1 O
+/- O
0.8 O
; O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

A O
randomised O
controlled O
trial O
of O
a O
CBT O
intervention O
for O
anxiety O
in O
children O
with O
Asperger B-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
. O
['Life-Impact']

At O
walking B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
the O
HI O
group O
was O
significantly O
younger O
than O
the O
C O
group O
( O
p=0.011 O
) O
. O
['Life-Impact']

The O
dose O
of O
topiramate O
was O
titrated O
up O
to O
200 O
mg/day O
depending O
on O
weight O
( O
100 O
mg/day O
for O
< O
30 O
kg O
and O
200 O
mg/day O
for O
> O
30 O
kg O
) O
. O
[]

One O
hundred O
and O
twenty-nine O
patients O
examined O
within O
a O
median O
of O
72 O
h O
, O
lying O
on O
the O
left O
side O
resulted O
in O
slightly O
lower O
SaO B-outcome ['Physiological-Clinical']
( O
2 O
) O
than O
lying O
on O
the O
right O
side O
, O
which O
was O
statistically O
significant O
in O
the O
patients O
with O
a O
right O
( O
n O
= O
66 O
) O
, O
but O
not O
left O
, O
hemiparesis O
. O
['Physiological-Clinical']

RESULTS O
The O
LTS-D O
was O
inserted O
significantly O
faster O
than O
the O
ET O
tube O
( O
15 O
s O
vs. O
44 O
s O
, O
respectively O
, O
p O
< O
0.01 O
) O
. O
[]

No O
objective B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
subjective I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
noted O
, O
and O
no O
substantial B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
, O
pulse B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
or O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fourty-four O
DES-exposed O
offspring O
had O
their O
vaginal O
adenosis O
treated O
with O
the O
carbon O
dioxide O
laser O
( O
group O
I O
) O
, O
and O
the O
remaining O
35 O
DES-exposed O
offspring O
( O
group O
II O
) O
did O
not O
receive O
any O
specific O
treatment O
for O
this O
condition O
. O
[]

Adding O
social O
engagement O
targets O
to O
intervention O
improves O
short-term O
outcome O
at O
no O
additional O
cost O
to O
the O
intervention O
. O
[]

Active O
drug O
and O
placebo O
control O
were O
applied O
twice O
daily O
on O
the O
affected O
areas O
, O
and O
follow-up O
visits O
were O
performed O
on O
days O
14 O
and O
28 O
. O
[]

We O
conclude O
that O
the O
gum O
elastic O
bougie-guided O
insertion O
has O
a O
higher O
success O
rate O
and O
causes O
less O
trauma O
than O
the O
insertion O
tool O
insertion O
technique O
after O
failed O
digital O
insertion O
of O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
. O
[]

n O
= O
1679 O
) O
or O
placebo O
( O
n O
= O
837 O
) O
for O
12 O
wk O
. O
[]

No O
such O
group O
difference O
was O
found O
for O
focused O
attention O
. O
[]

PURPOSE O
To O
investigate O
the O
efficacy O
and O
safety O
of O
corneal O
collagen O
cross-linking O
( O
CXL O
) O
with O
photoactivated O
riboflavin O
( O
photoactivated O
chromophore O
for O
infectious O
keratitis O
[ O
PACK O
] O
-CXL O
) O
in O
the O
management O
of O
infectious O
keratitis O
with O
corneal O
melting O
. O
[]

Basal O
nitric O
oxide O
synthesis O
of O
the O
renal B-outcome ['Physiological-Clinical']
vasculature I-outcome ['Physiological-Clinical']
was O
assessed O
by O
the O
decrease O
in O
RPF B-outcome ['Physiological-Clinical']
after O
inhibition O
of O
nitric O
oxide O
synthase O
with O
NG-monomethyl-L-arginine O
( O
L-NMMA O
; O
4.25 O
mg/kg O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomization O
process O
provided O
a O
suitable O
opportunity O
to O
compare O
the O
effects O
of O
these O
two O
administered O
steroid O
on O
surrogate O
markers O
of O
adipocyte O
activity O
( O
leptin O
) O
and O
hyperinsulinaemia/insulin O
resistance O
( O
SHBG O
) O
. O
[]

Enteric O
alendronate O
has O
a O
similar O
action O
to O
the O
conventional O
tablets O
on O
biochemical B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Neither O
amantadine O
nor O
pemoline O
enhances O
cognitive O
performance O
in O
MS O
compared O
with O
placebo O
. O
[]

RESULTS O
Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
was O
significantly O
shorter O
in O
the O
navigated O
group O
( O
stratified O
log O
rank O
test O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
patients O
in O
the O
control O
group O
received O
an O
equivalent O
volume O
of O
normal O
saline O
. O
[]

TC B-outcome ['Physiological-Clinical']
was O
measured O
by O
the O
pharmacist O
during O
the O
study O
visit O
using O
the O
enzymatic O
dry O
method O
. O
['Physiological-Clinical']

Experiment O
1 O
showed O
that O
after O
training O
with O
the O
procedure O
described O
by O
Sloutsky O
and O
Fisher O
( O
2008 O
) O
, O
only O
a O
minority O
of O
adults O
showed O
evidence O
of O
context-dependent O
responding O
in O
the O
selective O
induction O
test O
. O
[]

Most O
of O
the O
patients O
were O
discharged O
on O
the O
second O
postoperative O
day O
. O
[]

These O
results O
indicated O
that O
porcine O
expanded O
blastocysts O
can O
be O
cryopreserved O
using O
the O
MVAC O
method O
without O
potential O
pathogen O
contamination O
from O
LN? O
. O
[]

METHOD O
Three O
hundred O
and O
fifty-three O
women O
within O
one O
year O
of O
diagnosis O
with O
primary O
breast O
cancer O
were O
randomly O
assigned O
to O
receive O
supportive-expressive O
group O
therapy O
or O
to O
an O
education O
control O
condition O
. O
[]

RESULTS O
Pelvic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cramps I-outcome ['Physiological-Clinical']
were O
associated O
with O
activity B-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
and O
tiredness B-outcome ['Physiological-Clinical']
was O
associated O
with O
a O
lower O
health B-outcome ['Life-Impact']
utility I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

RESULTS O
Response O
rates O
in O
the O
20 O
mg O
arm O
were O
numerically O
higher O
than O
the O
50-mg O
arm O
according O
to O
the O
investigator O
( O
40.5 O
% O
versus O
36.4 O
% O
) O
and O
the O
independent O
review O
panel O
( O
42.9 O
% O
versus O
27.3 O
% O
) O
. O
[]

The O
synthesis O
of O
this O
internal O
standard O
includes O
the O
biosynthetic O
conversion O
of O
11-hydroxy-9,15-diketoprostanoic O
acid O
to O
PGE-M O
by O
the O
rabbit O
. O
[]

METHODS O
Seventy-two O
OSM O
patients O
were O
assigned O
to O
2 O
groups O
by O
a O
randomizing O
digital O
table O
, O
the O
treated O
group O
and O
the O
control O
group O
, O
they O
were O
treated O
respectively O
by O
ZJC1 O
and O
Wuzi O
Yanzong O
Pill O
( O
WYP O
) O
. O
[]

Long-stay O
versus O
short-stay O
hospital O
treatment O
of O
children O
suffering O
from O
severe O
protein-energy O
malnutrition O
. O
[]

The O
PIPP O
score O
was O
significantly O
lower O
in O
infants O
given O
sucrose O
than O
in O
those O
given O
sterile O
water O
( O
mean O
5?8 O
, O
95 O
% O
CI O
3?7-7?8 O
vs O
8?5 O
, O
7?3-9?8 O
; O
p=0?02 O
) O
and O
significantly O
more O
infants O
had O
no O
change O
in O
facial O
expression O
after O
sucrose O
administration O
( O
seven O
of O
20 O
[ O
35 O
% O
] O
vs O
none O
of O
24 O
; O
p O
< O
0?0001 O
) O
. O
[]

A O
case-control O
study O
] O
. O
[]

Optimum O
frequency O
of O
exercise O
for O
bone B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
: O
randomised O
controlled O
trial O
of O
a O
high-impact O
unilateral O
intervention O
. O
['Physiological-Clinical']

BACKGROUND O
Compliance O
studies O
have O
shown O
that O
patients O
with O
reflux O
symptoms O
generally O
take O
their O
medication O
only O
when O
experiencing O
these O
symptoms O
. O
[]

RESULTS O
During O
the O
radiofrequency O
exposure O
session O
, O
SkBF B-outcome ['Physiological-Clinical']
increased O
( O
vs. O
baseline O
) O
more O
than O
during O
the O
sham O
exposure O
session O
. O
['Physiological-Clinical']

Secondary B-outcome ['Physiological-Clinical']
endpoints I-outcome ['Physiological-Clinical']
were O
changes O
in O
biochemical O
parameters O
related O
to O
androgens O
and O
insulin O
. O
['Physiological-Clinical']

In O
this O
new O
analysis O
of O
the O
Anandron O
European O
Study O
, O
independent O
prognostic O
factors O
have O
been O
evaluated O
in O
order O
to O
identify O
those O
which O
could O
influence O
the O
study O
outcome O
and O
the O
impact O
of O
the O
treatment O
. O
[]

These O
results O
do O
not O
support O
a O
beneficial O
or O
harmful O
effect O
of O
antioxidants B-outcome ['Resource-use']
or O
zinc B-outcome ['Physiological-Clinical']
and O
copper B-outcome ['Resource-use']
on O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

CONCLUSIONS O
Although O
the O
main O
findings O
were O
similar O
to O
those O
from O
other O
brief-intervention O
studies O
in O
Western O
cultures O
, O
findings O
here O
also O
suggest O
that O
intervention O
may O
have O
differential O
benefits O
for O
specific O
subgroups O
of O
patients O
in O
the O
ED O
, O
an O
area O
of O
research O
that O
may O
warrant O
additional O
study O
of O
brief O
intervention O
in O
the O
ED O
setting O
. O
[]

Using O
logistic O
regression O
, O
there O
was O
no O
association O
between O
virologic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
and O
either O
baseline O
ABC O
resistance B-outcome ['Life-Impact']
or O
regimen B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
score O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Patients O
with O
SH O
and O
control O
subjects O
underwent O
a O
full O
history O
, O
physical O
examination O
, O
standard O
12-lead O
ECG O
, O
and O
24-h O
ambulatory O
ECG O
monitoring O
. O
[]

DESCRIPTION O
OF O
STUDY O
Fifty-two O
patients O
with O
newly O
diagnosed O
breast O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
arms O
: O
usual O
care O
or O
usual O
care O
plus O
exercise O
. O
[]

The O
suction O
needle O
was O
repeatedly B-outcome ['Life-Impact']
reusable I-outcome ['Life-Impact']
and O
considerably O
cheaper O
than O
the O
sheathed O
needle O
, O
which O
may O
be O
used O
once O
only O
. O
['Life-Impact']

Also O
, O
on O
days O
30 O
, O
60 O
, O
and O
90 O
, O
mean O
flea B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
in O
selamectin-treated O
cats O
were O
reduced O
by O
92.5 O
, O
98.3 O
, O
and O
99.3 O
% O
, O
and O
mean O
flea B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
in O
pyrethrin-treated O
cats O
were O
reduced O
by O
66.4 O
, O
73.9 O
, O
and O
81.3 O
% O
, O
respectively O
, O
compared O
with O
day O
0 O
counts O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Using O
3 O
different O
genotypic O
scoring O
systems O
, O
EFV-HS O
was O
significantly O
associated O
with O
reduced O
virologic O
failure O
at O
week O
16 O
, O
independent O
of O
treatment O
assignment O
. O
[]

The O
No O
Pres O
group O
had O
similar O
cardiac B-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
after O
exercise O
because O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
( O
P O
< O
.005 O
by O
rm O
ANOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
In O
the O
doses O
and O
schedules O
we O
studied O
, O
megestrol O
acetate O
provided O
superior O
anorexia O
palliation O
among O
advanced O
cancer O
patients O
compared O
with O
dronabinol O
alone O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
effectiveness O
of O
combination O
hydrocodone O
7.5 O
mg O
and O
ibuprofen O
200 O
mg O
with O
that O
of O
combination O
codeine O
30 O
mg O
and O
acetaminophen O
300 O
mg O
for O
the O
treatment O
of O
chronic O
pain O
. O
[]

Systemic O
chemotherapy O
did O
not O
affect O
the O
generation O
of O
CEA-specific B-outcome ['Physiological-Clinical']
T-cell I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
following O
vaccination O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHOD O
The O
data O
of O
the O
questionnaire O
responses O
and O
spirometric O
results O
from O
20 O
randomized O
asthmatic O
patients O
in O
the O
clinic O
including O
the O
record O
of O
3 O
visits O
for O
each O
subject O
. O
[]

This O
is O
slowing O
clinical O
application O
of O
the O
neuropeptide O
. O
[]

The O
suppositories O
have O
a O
distinct O
laxative B-outcome ['Physiological-Clinical']
effect O
and O
we O
aim O
to O
explore O
this O
effect O
in O
further O
clinical O
trials O
. O
['Physiological-Clinical']

0.3 O
) O
, O
12 O
weeks O
( O
7.0 O
? O
[]

BACKGROUND O
The O
most O
dominant O
feature O
in O
chronic O
pancreatitis O
is O
intense O
abdominal O
pain O
. O
[]

Both O
the O
degree O
and O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
groups O
. O
['Physiological-Clinical']

The O
incidence O
of O
pertussis O
in O
the O
vaccine O
groups O
and O
prevalence O
of O
pertussis O
in O
children O
under O
5 O
years O
of O
age O
in O
the O
study O
area O
were O
also O
determined O
. O
[]

The O
predischarge O
angiogram O
showed O
the O
presence O
of O
TIMI B-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
in O
96 O
% O
of O
patients O
who O
received O
PCI O
and O
65 O
% O
of O
patients O
who O
received O
SK O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
two O
beta-blocking O
drugs O
on O
endogenous O
insulin O
secretion O
and O
insulin O
sensitivity O
were O
investigated O
in O
a O
double-blind O
cross-over O
study O
in O
13 O
hypertensive O
patients O
. O
[]

2 O
randomized O
, O
controlled O
, O
factorial O
design O
trial O
. O
[]

[ O
Complaints O
in O
the O
postoperative O
phase O
related O
to O
anesthetics O
] O
. O
[]

However O
, O
only O
questionnaires O
from O
control O
group O
children O
who O
had O
a O
positive O
result O
at O
a O
subsequent O
screening O
were O
retained O
for O
analysis O
. O
[]

ICP B-outcome ['Physiological-Clinical']
was O
measured O
continuously O
subdurally O
with O
a O
22-gauge O
canula O
connected O
to O
a O
transducer O
. O
['Physiological-Clinical']

INTERVENTION O
( O
S O
) O
The O
effect O
of O
treatments O
was O
assessed O
after O
6 O
months O
of O
therapy O
. O
[]

A O
baseline O
determination O
of O
the O
minimum O
alveolar O
concentration O
of O
isoflurane O
( O
MACISO O
) O
was O
made O
for O
each O
animal O
. O
[]

METHODS O
We O
identified O
independent O
predictors O
of O
inhospital O
ventricular O
fibrillation O
( O
VF O
) O
and O
ventricular O
tachycardia O
( O
VT O
) O
and O
compared O
30-day O
and O
1-year O
mortality O
rates O
of O
patients O
who O
did O
( O
n O
= O
1121 O
) O
and O
did O
not O
( O
n O
= O
13,921 O
) O
have O
these O
arrhythmias O
during O
the O
index O
hospitalization O
. O
[]

Outcome O
measures O
will O
be O
assessed O
before O
and O
after O
the O
6 O
month O
intervention O
period O
. O
[]

Mean O
+/- O
s.d O
. O
[]

PURPOSE O
To O
investigate O
the O
effect O
of O
adjunctive O
mitomycin O
C O
on O
primary O
glaucoma O
triple O
procedure O
in O
patients O
with O
primary O
open-angle O
glaucoma O
with O
and O
without O
one O
or O
more O
of O
the O
prognostic O
factors O
for O
filtration O
failure O
of O
primary O
glaucoma O
triple O
procedure O
. O
[]

Overall O
, O
acetate B-outcome ['Physiological-Clinical']
, O
butyrate B-outcome ['Physiological-Clinical']
, O
and O
total O
SCFA B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
higher O
when O
participants O
consumed O
RS O
compared O
with O
entry O
and O
NSP O
diets O
, O
but O
individual O
responses O
varied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
hematocrit O
of O
the O
subjects O
( O
26.23?2.03 O
% O
) O
at O
the O
end O
of O
the O
study O
was O
also O
higher O
, O
p O
< O
0.001 O
. O
[]

In O
the O
ward O
, O
patients O
in O
Group O
I O
( O
CEI O
) O
were O
maintained O
by O
continuous O
infusion O
of O
0.125 O
% O
levobupivacaine O
with O
morphine O
0.0125 O
mg/ml O
( O
4 O
ml/hr O
) O
, O
Group O
II O
( O
CFNB O
) O
were O
maintained O
by O
0.125 O
% O
levobupivacaine O
( O
8 O
ml/hr O
) O
. O
[]

Accuracy O
in O
a O
baseline O
condition O
was O
compared O
to O
accuracy O
with O
a O
differential O
observing O
response O
procedure O
. O
[]

Active O
treatment O
produced O
similar O
relative O
risk O
reductions O
for O
the O
primary O
outcome O
, O
major B-outcome ['Physiological-Clinical']
macrovascular I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
death B-outcome ['Mortality']
and O
renal B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
across O
age O
groups O
( O
all O
P O
heterogeneity O
> O
0.3 O
) O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Seventeen O
patients O
received O
adjuvant O
chemotherapy O
consisting O
of O
doxorubicin O
( O
less O
than O
or O
equal O
to O
550 O
mg/m2 O
) O
, O
cyclophosphamide O
( O
less O
than O
or O
equal O
to O
5500 O
mg/m2 O
) O
, O
and O
methotrexate O
( O
less O
than O
or O
equal O
to O
1000 O
mg/kg O
) O
. O
[]

RESULTS O
The O
median O
time B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
was O
5 O
minutes O
and O
28 O
seconds O
for O
morcellation O
compared O
with O
10 O
minutes O
and O
12 O
seconds O
for O
electrosurgical O
resection O
( O
P O
< O
.001 O
) O
. O
['Life-Impact']

Overall O
51 O
% O
( O
1447/2837 O
) O
of O
all O
bites B-outcome ['Physiological-Clinical']
recorded O
were O
between O
6 O
pm O
and O
8 O
pm O
. O
['Physiological-Clinical']

RESULTS O
2656 O
patients O
in O
the O
intervention O
arm O
and O
2239 O
in O
the O
control O
arm O
required O
[]

The O
participants O
consumed O
the O
probiotic O
during O
3 O
months O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
safety O
profile O
of O
MEDI-545 O
, O
a O
fully O
human O
anti-IFN-alpha O
monoclonal O
antibody O
and O
to O
explore O
its O
effect O
on O
the O
involvement O
of O
type O
I O
IFN-alpha O
activity O
in O
the O
maintenance O
of O
established O
plaque O
psoriasis O
. O
[]

We O
noted O
a O
prevalence O
of O
early-stage B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
in O
patients O
treated O
with O
furosemide O
or O
mometasone O
, O
whereas O
patients O
who O
did O
not O
receive O
any O
treatment O
experienced O
more O
severe O
grades O
of O
chronic B-outcome ['Physiological-Clinical']
hyperplastic I-outcome ['Physiological-Clinical']
sinusitis I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
polyposis I-outcome ['Physiological-Clinical']
( O
P O
< O
.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
difference O
was O
noted O
between O
the O
two O
treatment O
groups O
in O
response O
to O
test O
drug O
( O
P O
= O
.66 O
) O
. O
[]

The O
intervention O
comprised O
matched O
children O
savings O
accounts O
, O
financial O
management O
workshops O
and O
mentorship O
. O
[]

The O
intervention O
effect O
was O
maintained O
at O
6-month O
follow-up O
. O
[]

Consultations O
with O
a O
cancer O
patient O
were O
recorded O
. O
[]

In O
this O
article O
, O
we O
give O
description O
of O
open O
and O
double-blind O
studies O
of O
naltrexone O
in O
autism O
. O
[]

The O
patient O
education O
component O
included O
written O
and O
videotaped O
materials O
on O
the O
care O
of O
low O
back O
pain O
. O
[]

More O
is O
not O
necessarily O
better O
: O
Examining O
the O
nature O
of O
the O
temporal O
reference O
memory O
component O
in O
timing O
. O
[]

The O
outcome O
measures O
were O
infant O
's O
hemoglobin B-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
months I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
value-congruence O
model O
of O
memory O
for O
emotional B-outcome ['Life-Impact']
experiences I-outcome ['Life-Impact']
: O
an O
explanation O
for O
cultural O
differences O
in O
emotional O
self-reports O
. O
['Life-Impact']

Gabapentin O
alleviates O
and/or O
prevents O
acute B-outcome ['Physiological-Clinical']
nociceptive I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
both O
in O
animals O
and O
volunteers O
, O
especially O
when O
given O
before O
trauma O
. O
['Physiological-Clinical']

There O
were O
also O
no O
statistical O
differences O
between O
the O
two O
groups O
for O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
weaning I-outcome ['Physiological-Clinical']
[ O
IMVG O
: O
1 O
day O
( O
1-6 O
) O
vs. O
SIMVG O
: O
1 O
day O
( O
1-6 O
) O
; O
p O
= O
0.262 O
] O
or O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
[ O
IMVG O
: O
8 O
days O
( O
2-22 O
) O
vs. O
SIMVG O
: O
6 O
days O
( O
3-20 O
) O
; O
p O
= O
0.113 O
] O
. O
['Physiological-Clinical', 'Resource-use']

Similar O
dosage O
and O
fractionation O
of O
RT O
was O
administered O
in O
both O
arms O
. O
[]

Serum O
concentrations O
of O
pantoprazole O
and O
digoxin O
were O
determined O
on O
day O
5 O
. O
[]

MAIN O
OUTCOMES O
AND O
MEASURES O
Using O
functional O
magnetic O
resonance O
imaging O
, O
we O
examined O
effects O
of O
oxytocin O
on O
behavioral B-outcome ['Life-Impact']
neural I-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
of O
the O
participants O
to O
a O
social O
psychological O
task O
. O
['Life-Impact']

RESULTS O
Systemic O
leaks O
> O
or O
= O
1 O
% O
from O
the O
perfusion O
circuit O
occurred O
in O
six O
patients O
who O
received O
TNF/IFN/M O
and O
in O
four O
who O
received O
M O
alone O
. O
[]

Further O
study O
of O
telephone O
interventions O
is O
recommended O
using O
ethnically O
and O
economically O
heterogeneous O
samples O
. O
[]

Reasons O
for O
discontinuation O
of O
part O
I O
included O
loss O
of O
efficacy O
( O
N=5 O
) O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
N=1 O
) O
. O
['Adverse-effects']

Among O
subjects O
with O
recurrent O
adenomas O
, O
the O
mean O
( O
+/-SE O
) O
number O
of O
such O
lesions B-outcome ['Physiological-Clinical']
was O
1.85+/-0.08 O
in O
the O
intervention O
group O
and O
1.84+/-0.07 O
in O
the O
control O
group O
. O
['Physiological-Clinical']

12 O
of O
15 O
patients O
( O
80 O
% O
) O
were O
cured B-outcome ['Physiological-Clinical']
with O
metronidazole O
given O
for O
an O
average O
period O
of O
7 O
days O
( O
range O
4 O
to O
14 O
days O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Significant O
efforts O
were O
made O
to O
recruit O
racial/ O
ethnic O
minorities O
into O
PLCO O
, O
and O
these O
efforts O
resulted O
in O
enrollment O
levels O
that O
were O
comparable O
to O
those O
seen O
in O
many O
recent O
cancer O
screening O
or O
prevention O
trials O
. O
[]

Supervisor O
tolerance-responsiveness O
, O
referring O
to O
the O
attitudes O
and O
behaviors O
associated O
with O
either O
ignoring O
or O
taking O
proactive O
steps O
with O
troubled O
employees O
, O
was O
investigated O
in O
two O
studies O
. O
[]

BACKGROUND O
AND O
STUDY O
AIMS O
Endoscopic O
injection O
sclerotherapy O
( O
EIS O
) O
and O
endoscopic O
variceal O
ligation O
( O
EVL O
) O
are O
used O
worldwide O
as O
the O
treatment O
for O
esophageal O
varices O
. O
[]

Twenty O
healthy O
men O
, O
aged O
18-55 O
years O
participated O
in O
a O
14-day O
skiing O
tour O
through O
the O
Swedish O
mountains O
, O
carrying O
a O
pack O
load O
of O
30 O
kg O
, O
and O
spending O
each O
night O
in O
self-dug O
igloos O
( O
ambient O
temp O
-10 O
degrees O
to O
-25 O
degrees O
C O
) O
, O
and O
were O
randomized O
to O
2 O
food O
regimens O
having O
30 O
or O
40 O
energy O
percent O
of O
fat O
. O
[]

Alternative O
voice O
after O
laryngectomy O
using O
a O
sound-producing O
voice O
prosthesis O
. O
[]

At O
7 O
days O
post O
treatment O
, O
all O
three O
formulations O
reduced O
flea B-outcome ['Physiological-Clinical']
populations I-outcome ['Physiological-Clinical']
within O
6 O
and O
24 O
hours O
by O
68.4 O
% O
and O
99.4 O
% O
, O
respectively O
. O
['Physiological-Clinical']

The O
control O
group O
received O
group O
support O
only O
. O
[]

These O
consisted O
of O
the O
administration O
in O
interrupted O
doses O
of O
chemotherapy O
which O
consisted O
of O
vincristine O
associated O
for O
the O
one O
part O
with O
cyclophosphamide O
and O
5-fluoro-uracil O
and O
on O
the O
other O
hand O
with O
doxorubicine O
or/and O
with O
methotrexate O
. O
[]

The O
amount O
of O
hypertonic B-outcome ['Physiological-Clinical']
and O
normal B-outcome ['Physiological-Clinical']
saline I-outcome ['Physiological-Clinical']
given O
during O
dialysis O
was O
markedly O
reduced O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Two O
hundred O
sixteen O
male O
and O
female O
CABG O
patients O
were O
assigned O
randomly O
either O
to O
view O
one O
of O
the O
two O
videotapes O
before O
discharge O
from O
the O
hospital O
or O
to O
receive O
only O
the O
standard O
discharge O
preparation O
provided O
by O
the O
hospital O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
in O
autistic O
children O
. O
['Physiological-Clinical']

RESULTS O
An O
interim O
analysis O
with O
505 O
assessable O
patients O
and O
a O
median O
follow-up O
of O
23 O
months O
showed O
a O
significant O
inferiority O
( O
according O
to O
sequential O
monitoring O
strategy O
) O
of O
the O
COPP/ABVD O
regimen O
in O
progression B-outcome ['Physiological-Clinical']
rate O
and O
freedom O
from O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
FFTF O
) O
compared O
with O
the O
pooled O
results O
of O
both O
BEACOPP O
variants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
adding O
vancomycin O
to O
central O
venous O
catheter O
( O
CVC O
) O
flush O
solution O
would O
significantly O
reduce O
the O
incidence O
of O
bacteremia O
attributable O
to O
luminal O
colonization O
with O
vancomycin-susceptible O
organisms O
. O
[]

Changes O
in O
airway O
calibre O
were O
followed O
as O
FEV1 B-outcome ['Physiological-Clinical']
and O
agonist O
responsiveness O
expressed O
as O
the O
provocative O
concentration O
causing O
a O
20 O
% O
fall O
in O
FEV1 B-outcome ['Physiological-Clinical']
( O
PC20 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
evaluate O
the O
beneficial O
effect O
of O
human O
chorionic O
gonadotrophin O
( O
HCG O
) O
supplementation O
, O
we O
performed O
a O
multicentre O
, O
double-blind O
, O
randomized O
study O
with O
HCG O
( O
193 O
transfers O
) O
against O
placebo O
( O
194 O
transfers O
) O
. O
[]

Patient O
and O
graft O
survival B-outcome ['Mortality']
exceeded O
98 O
% O
in O
both O
groups O
. O
['Mortality']

Outpatient O
management O
of O
asthma O
with O
regular O
nebulized O
beta O
agonists O
: O
comparison O
of O
bitolterol O
mesylate O
and O
isoproterenol O
. O
[]

Preterm O
neonates O
without O
other O
risk O
factors O
for O
infection O
admitted O
in O
the O
first O
12h O
of O
life O
were O
randomised O
to O
receive O
routine O
antibiotics O
or O
to O
a O
control O
group O
( O
no O
antibiotics O
unless O
clinically O
indicated O
) O
. O
[]

OBJECTIVES O
To O
estimate O
the O
Minimal O
Clinically O
Important O
Change O
( O
MCIC O
) O
of O
the O
pain O
intensity O
numerical O
rating O
scale O
( O
PI-NRS O
) O
, O
the O
Quebec O
Back O
Pain O
Disability O
Scale O
( O
QBPDS O
) O
, O
and O
the O
Euroqol O
( O
EQ O
) O
in O
patients O
with O
low O
back O
pain O
. O
[]

Tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
is O
thought O
to O
induce O
cachexia O
in O
subjects O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
, O
and O
it O
has O
been O
suggested O
that O
HIV-seropositive O
patients O
would O
benefit O
from O
treatment O
with O
pentoxifylline O
, O
a O
known O
suppressor O
of O
TNF-alpha O
production O
. O
[]

Therefore O
, O
TISSEEL O
VH O
S/D O
is O
at O
least O
as O
efficacious O
as O
TISSEEL O
VH O
. O
[]

Profound O
differences O
were O
discovered O
in O
the O
therapists O
' O
success O
with O
the O
patients O
in O
their O
case O
loads O
. O
[]

Bulky O
disease O
always O
received O
40 O
Gy O
. O
[]

For O
the O
majority O
of O
the O
patients O
, O
sufficient O
pain O
relief O
can O
be O
obtained O
if O
adequate O
treatment O
is O
provided O
. O
[]

NSAID O
ionisation O
in O
the O
management O
of O
soft-tissue O
rheumatism O
: O
role O
played O
by O
the O
drug O
, O
electrical O
stimulation O
and O
suggestion O
. O
[]

Annual O
transmission B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
decreased O
by O
between O
75.7 O
% O
and O
98.8 O
% O
in O
combined-therapy O
communities O
and O
between O
75.6 O
% O
and O
79.4 O
% O
in O
communities O
given O
diethylcarbamazine O
alone O
. O
['Physiological-Clinical']

The O
coagulation O
inhibitors O
antithrombin B-outcome ['Physiological-Clinical']
, O
protein B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
, O
and O
protein B-outcome ['Physiological-Clinical']
S O
, O
but O
not O
tissue B-outcome ['Physiological-Clinical']
factor O
pathway B-outcome ['Physiological-Clinical']
inhibitor B-outcome ['Physiological-Clinical']
, O
decreased O
significantly O
from O
baseline O
in O
the O
hormone O
replacement O
therapy O
group O
at O
both O
3 O
and O
12 O
months O
as O
compared O
with O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
interval O
from O
exposure O
to O
bulls O
until O
subsequent O
calving O
did O
not O
differ O
( O
P O
= O
0.16 O
) O
among O
PRE O
( O
298 O
+/- O
2.3 O
d O
) O
, O
POST O
( O
303 O
+/- O
2.6 O
d O
) O
, O
and O
control O
( O
304 O
+/- O
2.3 O
d O
) O
cows O
. O
[]

CONCLUSIONS/SIGNIFICANCE O
The O
present O
study O
confirms O
that O
chronic O
pancreatitis O
patients O
show O
signs O
of O
altered O
central O
processing O
of O
nociception O
compared O
to O
healthy O
controls O
. O
[]

Wards O
( O
villages O
) O
were O
randomly O
assigned O
to O
either O
a O
standard O
care O
group O
or O
a O
standard O
care O
plus O
green O
banana O
group O
where O
mothers O
were O
instructed O
to O
add O
cooked O
green O
banana O
to O
the O
diets O
of O
diarrhoeal O
children O
. O
[]

The O
present O
study O
examined O
which O
other O
working O
memory O
components O
( O
visual O
, O
spatial O
, O
and O
phonological O
) O
influence O
visual B-outcome ['Life-Impact']
selective I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
. O
['Life-Impact']

[ O
No O
effect O
of O
spironolactone O
on O
bulimia O
nervosa O
symptoms O
] O
. O
[]

METHODS O
Patients O
with O
stage O
II/III O
LARC O
received O
capecitabine O
1250 O
mg/m O
( O
2 O
) O
twice O
daily O
for O
2 O
weeks O
followed O
by O
intravenous O
cetuximab O
400 O
mg/m O
( O
2 O
) O
at O
week O
3 O
, O
then O
weekly O
intravenous O
250 O
mg/m O
( O
2 O
) O
cetuximab O
plus O
CRT O
including O
capecitabine O
825 O
mg/m O
( O
2 O
) O
twice O
daily O
( O
including O
weekends O
during O
radiotherapy O
) O
with O
radiotherapy O
of O
45 O
Gy O
( O
25 O
x O
1.8 O
Gy O
) O
, O
5 O
days O
a O
week O
for O
5 O
weeks O
. O
[]

RESULTS O
After O
an O
average O
weight O
gain O
of O
4.1 O
kg O
, O
fat O
gainers O
significantly O
increased O
their O
total O
, O
visceral B-outcome ['Physiological-Clinical']
, O
and I-outcome ['Physiological-Clinical']
subcutaneous I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
physical O
activity O
group O
also O
had O
reductions O
in O
depressive O
symptoms O
( O
p=.044 O
) O
, O
daytime O
sleepiness O
( O
p=.02 O
) O
and O
improvements O
in O
vitality O
( O
p=.017 O
) O
compared O
to O
baseline O
scores O
. O
[]

Following O
a O
starting O
dose O
of O
either O
2.5 O
mg O
once-daily O
quinapril O
, O
or O
6.25 O
mg O
twice-daily O
captopril O
, O
patients O
were O
reviewed O
at O
two-weekly O
intervals O
, O
and O
following O
clinical O
assessment O
a O
decision O
was O
made O
either O
to O
titrate O
up O
to O
the O
next O
medication O
stage O
or O
to O
enter O
the O
patient O
into O
the O
16-week O
maintenance O
phase O
. O
[]

Ten O
subjects O
served O
as O
controls O
and O
received O
symptomatic O
treatments O
. O
[]

Brain B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
correlates O
differentially O
with O
increasing O
temporal O
complexity O
of O
rhythms O
during O
initialisation O
, O
synchronisation O
, O
and O
continuation O
phases O
of O
paced O
finger O
tapping O
. O
['Physiological-Clinical']

CONCLUSION O
[]

BACKGROUND O
AND O
PURPOSE O
Following O
our O
phase O
II O
experience O
, O
a O
randomised O
trial O
was O
undertaken O
to O
evaluate O
the O
efficacy O
of O
adding O
chemotherapy O
to O
radiotherapy O
in O
patients O
with O
unresectable O
squamous O
cell O
cancer O
of O
the O
esophagus O
. O
[]

Transesophageal O
echocardiography O
in O
quantification O
of O
emboli O
during O
femoral O
nailing O
: O
reamed O
versus O
unreamed O
techniques O
. O
[]

Lens B-outcome ['Physiological-Clinical']
wettability I-outcome ['Physiological-Clinical']
was O
excellent O
, O
and O
there O
were O
no O
clinically O
relevant O
deposits O
. O
['Physiological-Clinical']

RESULTS O
The O
median O
time B-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
ED I-outcome ['Life-Impact']
discharge O
to O
follow-up O
was O
26 O
hours O
( O
interquartile O
range O
[ O
IQR O
] O
= O
24 O
to O
39 O
hours O
) O
. O
['Life-Impact']

Group O
3 O
showed O
significant O
hypersensitivity B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
at O
one O
week O
onward O
. O
['Physiological-Clinical']

Itraconazole O
solution O
and O
fluconazole O
provide O
effective O
prophylaxis O
against O
Candida O
but O
itraconazole O
affords O
greater O
protection O
against O
fatal O
aspergillosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
dose-ranging O
study O
of O
pramipexole O
for O
the O
symptomatic O
treatment O
of O
restless O
legs O
syndrome O
: O
polysomnographic O
evaluation O
of O
periodic B-outcome ['Physiological-Clinical']
leg I-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
and O
sleep O
disturbance O
. O
['Physiological-Clinical']

The O
clinical O
status O
and O
CT O
were O
assessed O
prior O
to O
shunting O
, O
14 O
days O
and O
3 O
and O
6 O
months O
after O
the O
operation O
. O
[]

The O
five-year O
crude O
rates O
of O
first B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
according O
to O
site O
in O
the O
radiotherapy-first O
and O
chemotherapy-first O
groups O
, O
respectively O
, O
were O
5 O
percent O
and O
14 O
percent O
for O
local O
recurrence O
and O
32 O
percent O
and O
20 O
percent O
for O
distant O
or O
regional O
recurrence O
or O
both O
. O
['Physiological-Clinical']

The O
endpoints O
included O
refractory B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
pectoris I-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
death B-outcome ['Mortality']
, O
emergency B-outcome ['Resource-use']
PTCA I-outcome ['Resource-use']
and O
CABG B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Resource-use', 'Physiological-Clinical']

positive O
) O
subgroup O
of O
the O
randomised O
cohort O
, O
YAP1 O
expression O
was O
inversely O
correlated O
to O
histological O
grade O
and O
proliferation O
( O
p O
= O
0.001 O
and O
p O
= O
0.016 O
, O
respectively O
) O
whereas O
in O
the O
ER- O
( O
Estrogen O
Receptor O
? O
[]

METHODS O
Patients O
were O
admitted O
to O
the O
laboratory O
for O
three O
consecutive O
nights O
. O
[]

Adverse O
effects O
of O
rHuEPO O
therapy O
, O
such O
as O
hypertension B-outcome ['Physiological-Clinical']
, O
thrombosis B-outcome ['Physiological-Clinical']
or O
neurologic B-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
, O
are O
mostly O
reported O
in O
patients O
with O
terminal B-outcome ['Physiological-Clinical']
kidney I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
developed O
a O
scoring O
system O
to O
predict O
the O
artery O
responsible O
for O
an O
acute O
myocardial O
infarction O
( O
AMI O
) O
using O
ST-segment O
and O
T-wave O
changes O
on O
the O
initial O
electrocardiogram O
( O
ECG O
) O
using O
data O
from O
228 O
patients O
( O
development O
set O
) O
with O
symptoms O
compatible O
with O
AMI O
and O
tested O
in O
a O
similar O
group O
of O
223 O
patients O
( O
test O
set O
) O
from O
the O
Thrombolysis O
and O
Angioplasty O
in O
Myocardial O
Infarction O
( O
TAMI-5 O
) O
Trial O
. O
[]

Interestingly O
however O
, O
when O
segregated O
on O
the O
Choi O
criteria O
, O
cytotoxic O
drugs O
alone O
showed O
a O
non-significant O
trend O
in O
improved O
survival O
( O
74 O
% O
versus O
55 O
% O
, O
p O
0.32 O
) O
as O
well O
as O
event-free O
survival O
( O
44 O
% O
versus O
40 O
% O
, O
p O
0.42 O
) O
for O
the O
germinal O
centre O
as O
opposed O
to O
the O
activated O
B-cell O
subtype O
. O
[]

PATIENTS O
AND O
METHODS O
Thirty O
one O
colorectal O
cancer O
patients O
were O
prospectively O
studied O
and O
sentinel O
lymph O
node O
was O
identified O
in O
100 O
% O
of O
the O
cases O
utilizing O
either O
patent O
blue O
alone O
, O
or O
in O
association O
with O
radiotracer O
based O
on O
technetium O
99m O
colloid O
solution O
in O
a O
randomized O
fashion O
. O
[]

Blood B-outcome ['Physiological-Clinical']
bismuth I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
during O
the O
study O
had O
a O
range O
of O
less O
than O
or O
equal O
to O
3 O
to O
33 O
micrograms/l O
. O
['Physiological-Clinical']

Group O
1 O
participated O
in O
6 O
weekly O
education O
program O
sessions O
immediately O
following O
baseline O
assessment O
, O
and O
Group O
2 O
started O
the O
program O
following O
Group O
1 O
's O
program O
completion O
. O
[]

Change O
in O
CT O
number O
between O
unenhanced O
and O
contrast-enhanced O
images O
per O
gram O
of O
iodine O
and O
maximum O
hepatic O
enhancement O
( O
MHE O
) O
adjusted O
for O
iodine O
dose O
were O
examined O
for O
correlation O
with O
TBW O
, O
LBW O
, O
and O
BV O
by O
using O
linear O
regression O
analysis O
. O
[]

they O
did O
not O
differ O
significantly O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
yoga O
on O
mood O
status O
and O
quality O
of O
life O
among O
women O
undergoing O
detoxification O
for O
heroin O
dependence O
in O
China O
. O
[]

Because O
the O
process O
for O
learning O
new O
or O
unfamiliar O
stimuli O
( O
elaboration O
) O
in O
particular O
may O
be O
impaired O
under O
general O
anesthesia O
, O
more O
memory O
priming O
was O
expected O
for O
familiar O
than O
for O
unfamiliar O
material O
. O
[]

Six O
of O
the O
nine O
women O
also O
received O
a O
dose O
of O
200 O
mg O
. O
[]

We O
aimed O
to O
assess O
effectiveness O
and O
safety O
of O
all O
four O
treatments O
. O
[]

A O
trial O
with O
3'-azido-2',3'-dideoxythymidine O
and O
human O
interferon-? O
in O
cats O
naturally O
infected O
with O
feline O
leukaemia O
virus O
. O
[]

Behaviourally O
, O
there O
were O
no O
significant O
differences O
between O
the O
two O
groups O
. O
[]

There O
was O
no O
significant O
statistical O
difference O
in O
mortality O
rate O
among O
three O
groups O
. O
[]

All O
patients O
with O
an O
ejection O
fraction O
less O
than O
0.40 O
were O
excluded O
. O
[]

Augmentation O
of O
preoperative O
blood O
donation O
by O
therapy O
with O
recombinant O
human O
erythropoietin O
( O
rHuEPO O
) O
has O
been O
described O
in O
animal O
models O
and O
in O
patients O
. O
[]

BACKGROUND O
Heightened O
central O
sympathetic O
nervous O
outflow O
is O
common O
in O
essential O
hypertension O
, O
contributing O
to O
hypertension O
development O
and O
perhaps O
also O
to O
complications O
. O
[]

Patients O
were O
followed O
up O
for O
outcomes O
of O
death B-outcome ['Mortality']
, O
hepatocellular B-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
and O
hepatic B-outcome ['Physiological-Clinical']
decompensation I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
normalized O
in O
the O
combination O
group O
in O
67 O
% O
of O
patients O
, O
a O
significantly O
higher O
proportion O
than O
either O
trandolapril O
( O
63 O
% O
) O
or O
HCTZ O
( O
60 O
% O
; O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Significant O
improvement O
occurred O
following O
three O
months O
of O
outpatient O
treatment O
using O
a O
behavioural O
approach O
and O
either O
Senokot O
, O
placebo O
or O
no O
medication O
. O
[]

The O
study O
was O
supplemented O
by O
a O
meta-analysis O
of O
accomplished O
comparative O
studies O
of O
group O
vs. O
individual O
CBT O
for O
OCD O
. O
[]

This O
increased O
morbidity O
mainly O
seemed O
to O
be O
caused O
by O
symptoms O
usually O
associated O
with O
respiratory O
tract O
infection O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
11.4 O
versus O
9.8 O
months O
for O
arms O
A O
and O
B O
, O
respectively O
; O
estimated O
1-year O
survival O
, O
47.7 O
% O
versus O
39.3 O
% O
; O
and O
objective O
response O
rate O
, O
29.6 O
% O
versus O
25 O
% O
. O
['Mortality']

Speech B-outcome ['Life-Impact']
Alone I-outcome ['Life-Impact']
, O
Simultaneous O
Presentation O
, O
and O
Alternating B-outcome ['Life-Impact']
Presentation I-outcome ['Life-Impact']
condition I-outcome ['Life-Impact']
facilitated O
more O
child-initiated O
speech O
during O
treatment O
than O
did O
the O
Sign O
Alone O
condition O
. O
['Life-Impact', 'Life-Impact']

METHODS O
Three O
hundred O
cases O
of O
VVC O
were O
recruited O
. O
[]

BACKGROUND O
Decreased O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
has O
been O
described O
in O
HIV-infected O
patients O
initiating O
antiretroviral O
therapy O
( O
ART O
) O
, O
but O
the O
contributions O
of O
ART O
and O
immunologic O
and/or O
virologic O
factors O
remain O
unclear O
. O
['Physiological-Clinical']

Dysfunction O
of O
multiple O
brain O
systems O
in O
progressive O
supranuclear O
palsy O
( O
PSP O
) O
has O
complicated O
attempts O
to O
treat O
the O
disease O
. O
[]

Clinical O
and O
radiographic O
evaluation O
of O
guided O
tissue O
regeneration O
in O
the O
treatment O
of O
class O
II O
furcation O
defects O
. O
[]

DESIGN O
Randomized O
, O
assessor-blind O
, O
( O
3 O
x O
4 O
) O
mixed-model O
repeated O
measures O
. O
[]

RESULTS O
Nurses O
were O
more O
likely O
to O
use O
open-ended O
questions O
, O
back-channel O
responses O
, O
friendly B-outcome ['Life-Impact']
jokes I-outcome ['Life-Impact']
, O
and O
checks O
for O
understanding B-outcome ['Life-Impact']
on O
the O
telephone O
compared O
to O
videophone O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
The O
two O
premedications O
appear O
equally O
effective O
in O
the O
performance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ERCP I-outcome ['Life-Impact']
. O
['Life-Impact']

single O
doses O
of O
tegaserod O
( O
0.8 O
mg O
to O
20 O
mg O
) O
or O
placebo O
. O
[]

Azelnidipine O
and O
amlodipine O
anti-coronary O
atherosclerosis O
trial O
in O
hypertensive O
patients O
undergoing O
coronary O
intervention O
by O
serial O
volumetric O
intravascular O
ultrasound O
analysis O
in O
Juntendo O
university O
( O
ALPS-J O
) O
. O
[]

Cow O
BW O
( O
538 O
+/- O
13 O
kg O
) O
and O
BCS O
( O
5.4 O
+/- O
0.13 O
) O
did O
not O
differ O
among O
treatments O
at O
any O
time O
during O
the O
experiment O
. O
[]

A O
significant O
decrease O
in O
attainment O
of O
protective B-outcome ['Life-Impact']
antibody I-outcome ['Life-Impact']
titer I-outcome ['Life-Impact']
( O
titer O
of O
1:40 O
or O
greater O
) O
against O
A/Texas O
in O
subjects O
with O
non-protective O
baseline O
antibody O
titer O
was O
recorded O
following O
DHEA O
treatment O
compared O
to O
placebo O
( O
52 O
vs. O
84 O
% O
, O
P O
< O
0.05 O
) O
. O
['Life-Impact']

One O
quadrant O
sub-Tenon O
's O
capsule O
anesthesia O
in O
anterior O
segment O
surgery O
. O
[]

A O
randomised O
double-blind O
trial O
of O
cyclosporin O
and O
azathioprine O
in O
refractory O
rheumatoid O
arthritis O
. O
[]

The O
average O
time O
of O
observation O
was O
34.5 O
months O
. O
[]

Healthcare O
costs O
around O
the O
time O
of O
smoking O
cessation O
. O
[]

In O
group O
A O
, O
endothelium O
dependent O
[ O
( O
12 O
+/- O
5 O
) O
% O
vs O
( O
9 O
+/- O
5 O
) O
% O
, O
t O
= O
2.9 O
, O
P O
< O
0.01 O
] O
and O
independent O
[ O
( O
18 O
+/- O
4 O
) O
% O
vs O
( O
12 O
+/- O
5 O
) O
% O
, O
t O
= O
3.4 O
, O
P O
< O
0.01 O
] O
vasodilatation B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
significantly O
increased O
after O
treatment O
, O
no O
significant O
changes O
were O
observed O
in O
group O
B. O
Endothelium O
dependent O
[ O
( O
9 O
+/- O
6 O
) O
% O
, O
t O
= O
2.8 O
, O
P O
< O
0.01 O
] O
and O
independent O
[ O
( O
12 O
+/- O
5 O
) O
% O
, O
t O
= O
3.5 O
, O
P O
< O
0.01 O
] O
['Physiological-Clinical']

We O
expected O
to O
find O
post-TMS O
differences O
in O
amplitude O
and O
latency O
of O
early O
and O
late O
ERP O
components O
. O
[]

Primary O
outcome O
was O
severity O
of O
autism B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
( O
a O
total O
score O
of O
social B-outcome ['Life-Impact']
communication B-outcome ['Life-Impact']
algorithm O
items O
from O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Concerning O
the O
three O
different O
techniques O
, O
TBNA O
showed O
the O
highest B-outcome ['Physiological-Clinical']
diagnostic I-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
( O
62.5 O
% O
) O
in O
comparison O
to O
TBB O
( O
48.9 O
% O
) O
and O
to O
BW O
( O
19.8 O
% O
) O
. O
['Physiological-Clinical']

Predefined O
study O
endpoints O
are O
gastric B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
precancerous B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
( O
dysplasia B-outcome ['Physiological-Clinical']
, O
adenoma B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
concluded O
that O
the O
application O
of O
a O
chlorhexidine O
varnish O
significantly O
improved O
the O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
of O
T O
subjects O
for O
up O
to O
three O
months O
. O
['Physiological-Clinical']

The O
best O
angiographic O
surrogate O
of O
TVR O
was O
the O
50 O
% O
follow-up O
DS O
obtained O
from O
the O
ribbon+margin O
analysis O
( O
ROC O
area O
0.806 O
) O
. O
[]

Of O
households O
with O
untested O
wells O
, O
93 O
% O
in O
both O
intervention O
groups O
HE O
and O
HELM B-outcome ['Physiological-Clinical']
purchased I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
As I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
, O
whereas O
only O
53 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

At O
that O
time O
, O
the O
echocardiographic O
and O
gated O
blood O
pool O
studies O
were O
repeated O
both O
on O
and O
after O
subsequent O
withdrawal O
of O
the O
study O
medications O
. O
[]

Adjudication O
of O
end O
points O
is O
blinded O
to O
drug O
assignment O
. O
[]

Using O
analysis O
of O
covariance O
to O
control O
for O
baseline O
measures O
and O
demographic O
characteristics O
, O
no O
difference O
in O
outcome O
measures O
was O
found O
between O
intervention O
and O
assessment O
conditions O
. O
[]

Thirty O
women O
were O
randomly O
divided O
into O
three O
groups O
. O
[]

Using O
daily O
transtelephonic O
monitoring O
, O
we O
examined O
asymptomatic O
and O
symptomatic O
paroxysmal B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
episodes O
during O
a O
maximum O
1 O
year O
treatment O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
urinary B-outcome ['Physiological-Clinical']
and O
sexual B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of O
vaginal O
delivery O
compared O
with O
Caesarean O
section O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
groups O
of O
tuberculin O
skin O
test-positive O
and O
negative O
persons O
, O
the O
risk O
ratio O
of O
tuberculosis O
was O
0.40 O
( O
95 O
% O
CI O
, O
0.24-0.65 O
) O
and O
0.84 O
( O
95 O
% O
CI O
, O
0.54-1.30 O
) O
, O
respectively O
, O
and O
the O
difference O
in O
the O
effectiveness O
of O
isoniazid O
versus O
placebo O
between O
these O
groups O
was O
statistically O
significant O
( O
P O
= O
0.03 O
, O
for O
the O
difference O
of O
summary O
estimates O
) O
. O
[]

rhNGF O
Clinical O
Investigator O
Group O
. O
[]

Furthermore O
, O
three O
parents O
in O
the O
local O
services O
group O
commenced O
intensive O
, O
home-based O
behavioural O
intervention O
during O
the O
course O
of O
the O
study O
. O
[]

METHODS O
Adverse O
ocular O
events O
reported O
by O
clinician O
investigators O
were O
listed O
using O
terms O
modified O
from O
the O
COSTART O
dictionary O
. O
[]

RESULTS O
The O
average O
ridge B-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
decreased O
by O
0.50 O
mm O
for O
both O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

The O
mean O
change O
in O
lag O
time O
was O
-7 O
+/- O
14 O
min O
( O
-7.2 O
% O
) O
in O
the O
PUFA-diet O
group O
and O
+4 O
+/- O
16 O
min O
( O
+4.0 O
% O
) O
in O
the O
MUFA-diet O
group O
( O
P O
= O
0.029 O
, O
PUFA-diet O
group O
vs O
MUFA-diet O
group O
) O
. O
[]

There O
was O
no O
difference O
in O
median O
progression-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
between O
the O
two O
arms O
( O
5.5 O
versus O
5.0 O
months O
, O
p O
= O
0.19 O
) O
. O
['Physiological-Clinical', 'Mortality']

There O
were O
no O
group O
variabilities O
with O
regard O
to O
MAP B-outcome ['Physiological-Clinical']
and O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
AND O
LIMITATIONS O
Of O
285 O
women O
, O
144 O
had O
the O
U-type O
method O
and O
141 O
had O
the O
H-type O
method O
. O
[]

This O
study O
has O
shown O
heart O
failure O
to O
be O
as O
well O
controlled O
by O
once-daily O
quinapril O
as O
by O
twice-daily O
captopril O
, O
with O
comparable O
effects O
on O
first-dose B-outcome ['Physiological-Clinical']
blood-pressure I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Anti-angiogenic O
effect O
of O
tamoxifen O
combined O
with O
epirubicin O
in O
breast O
cancer O
patients O
. O
[]

The O
safety O
profile O
of O
Ar O
+ O
Ep O
was O
also O
studied O
by O
investigating O
the O
stability O
of O
cardiovascular O
parameters O
. O
[]

The O
sensitivity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
using O
clinician-collected O
samples O
and O
cervical O
cytology O
did O
not O
differ O
by O
treatment O
status O
. O
['Physiological-Clinical']

Imidafenacin O
was O
non-inferior O
to O
fesoterodine O
, O
and O
the O
lower O
limit O
of O
95 O
% O
two-sided O
confidence O
intervals O
was O
-0.53 O
. O
[]

METHODS O
Children O
younger O
than O
16 O
years O
and O
experiencing O
moderate O
to O
severe O
blunt O
head O
injury O
were O
randomized O
to O
receive O
phenytoin O
or O
placebo O
within O
60 O
minutes O
of O
presentation O
at O
3 O
pediatric O
trauma O
centers O
. O
[]

Comparison O
of O
the O
two O
groups O
showed O
that O
tipping B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
molar I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
premolar I-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
in O
the O
banded O
group O
was O
significantly O
more O
than O
in O
the O
bonded O
group O
( O
P O
< O
0.01 O
and O
P O
< O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical']

METHODS O
Community-dwelling O
people O
aged O
? O
[]

Arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
analysis O
of O
the O
serum O
propofol O
and O
clonidine O
concentrations O
were O
taken O
immediately O
before O
verbal O
commands O
were O
given O
. O
['Physiological-Clinical']

Baseline O
mean O
( O
SD O
) O
values O
for O
sitting B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
SiDBP B-outcome ['Physiological-Clinical']
were O
152.0 O
( O
12.2 O
) O
mm O
Hg O
and O
98.1 O
( O
5.6 O
) O
mm O
Hg O
, O
respectively O
, O
for O
the O
amlodipine O
maleate O
group O
and O
153.4 O
( O
14.0 O
) O
mm O
Hg O
and O
98.1 O
( O
5.5 O
) O
mm O
Hg O
, O
respectively O
, O
for O
the O
amlodipine O
besylate O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
, O
controlled O
trial O
of O
Behavioral O
Family O
Systems O
Therapy O
for O
Diabetes O
: O
maintenance O
and O
generalization O
of O
effects O
on O
parent-adolescent O
communication O
. O
[]

Recently O
, O
a O
new O
form O
of O
treatment O
based O
on O
porphobilinogen O
deaminase O
enzyme O
replacement O
therapy O
has O
been O
shown O
to O
be O
effective O
in O
an O
acute O
intermittent O
porphyria O
mouse O
model O
which O
, O
during O
phenobarbital O
( O
phenobarbitone O
) O
induction O
of O
haem O
biosynthesis O
, O
mimics O
the O
biochemical O
pattern O
of O
acute O
porphyric O
attacks O
. O
[]

RESULTS O
The O
indices O
of O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
significantly O
after O
6 O
months O
' O
treatment O
in O
trial O
group O
( O
P O
< O
0.05 O
) O
; O
TCC B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
neutrophil B-outcome ['Physiological-Clinical']
count O
decreased O
significantly O
compared O
with O
baseline O
in O
the O
trial O
group O
( O
P O
< O
0.05 O
) O
; O
Sputum B-outcome ['Physiological-Clinical']
IL-8 I-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
dropped O
significantly O
after O
6 O
months O
' O
treatment O
, O
from O
a O
mean O
of O
5.216 O
+/- O
2.914 O
microg/L O
to O
4.222 O
+/- O
2.140 O
microg/L O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
the O
effects O
of O
epinephrine O
on O
ventilation O
in O
patients O
with O
panic O
disorder O
and O
in O
social O
phobics O
, O
analyses O
were O
performed O
on O
pooled O
data O
from O
two O
previous O
infusion O
studies O
. O
[]

INTERVENTIONS O
Mastectomy O
group O
received O
wedge O
mastectomy O
plus O
excision O
of O
symptomatic O
axillary O
lymph O
nodes O
. O
[]

The O
second O
outcomes O
including O
ICU B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rate O
, O
duration O
of O
ICU B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
rate O
and O
neurologic B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
at O
6 O
months O
follow-up O
. O
['Physiological-Clinical', 'Resource-use', 'Mortality', 'Physiological-Clinical']

No O
serious B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
detected O
. O
['Adverse-effects']

METHODOLOGY/PRINCIPAL O
FINDINGS O
As O
part O
of O
a O
cluster O
randomised O
controlled O
trial O
, O
we O
assessed O
the O
baseline O
prevalence O
of O
, O
and O
risk O
factors O
for O
, O
active O
trachoma B-outcome ['Physiological-Clinical']
and O
ocular O
C. O
trachomatis O
infection O
in O
randomly O
selected O
children O
aged O
0-5 O
years O
from O
48 O
Gambian O
and O
36 O
Tanzanian O
communities O
. O
['Physiological-Clinical']

METHODS O
Fifty O
otoplasty O
patients O
were O
studied O
; O
half O
of O
them O
received O
randomly O
and O
in O
double-blind O
fashion O
a O
transdermal O
therapeutic O
system O
( O
patch O
) O
of O
scopolamine O
( O
TTS-scopolamine O
) O
as O
prophylaxis O
against O
PONV O
before O
general O
anesthesia O
. O
[]

SUBJECTS O
AND O
METHODS O
Randomized O
, O
double-blind O
, O
double-dummy O
study O
with O
three O
parallel O
treatment O
arms O
[ O
oral O
TU O
; O
transdermal O
placebo O
gel O
( O
P O
) O
; O
im O
TU O
] O
administration O
for O
12 O
months O
( O
mo O
) O
. O
[]

Significant O
differential O
effects O
of O
omega-3 O
fatty O
acids O
and O
fenofibrate O
in O
patients O
with O
hypertriglyceridemia O
. O
[]

Changes O
in O
H O
reflex O
and O
V O
wave O
following O
short-term O
endurance O
and O
strength O
training O
. O
[]

After O
a O
washout O
period O
of O
at O
least O
4 O
weeks O
, O
the O
procedure O
was O
repeated O
with O
placebo O
challenge O
( O
diluent O
) O
. O
[]

Evaluations O
performed O
pre O
and O
post-treatment O
: O
state B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
was O
assessed O
with O
the O
State-Trait B-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory I-outcome ['Life-Impact']
, O
QoL O
with O
the O
IBD O
Questionnaire O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Main O
outcome O
measures O
were O
body O
mass O
index O
( O
BMI O
) O
, O
serum O
leptin O
and O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
. O
[]

The O
effect O
of O
oral O
steroids O
with O
and O
without O
vitamin O
D3 O
on O
early O
efficacy O
of O
immunotherapy O
in O
asthmatic O
children O
. O
[]

This O
drug O
therefore O
appears O
to O
be O
effective O
in O
the O
management O
of O
patients O
with O
frequent O
attacks O
of O
angina B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ultrasound O
therapy O
for O
recalcitrant B-outcome ['Physiological-Clinical']
diabetic I-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
: O
results O
of O
a O
randomized O
, O
double-blind O
, O
controlled O
, O
multicenter O
study O
. O
['Physiological-Clinical']

DESIGN O
Twenty-six O
pregnant O
women O
with O
increased O
3-HIA O
excretion O
were O
studied O
in O
a O
randomized O
, O
placebo-controlled O
trial O
; O
10 O
women O
were O
studied O
during O
early O
pregnancy O
( O
6-17 O
wk O
gestation O
) O
and O
16 O
women O
during O
late O
pregnancy O
( O
21-37 O
wk O
gestation O
) O
. O
[]

The O
analgesic B-outcome ['Resource-use']
efficacy O
of O
EMLA O
cream O
was O
compared O
with O
infiltration O
with O
1 O
% O
carbocaine O
in O
13 O
bilateral O
vasectomies O
. O
['Resource-use']

In O
the O
first O
three O
cycles O
, O
it O
was O
134 O
% O
( O
median O
) O
in O
cohort O
1 O
and O
200 O
% O
in O
cohorts O
2 O
and O
3 O
( O
P O
< O
.0001 O
) O
. O
[]

Twenty-six O
postmenopausal O
women O
participated O
in O
a O
double-blind O
trial O
involving O
treatment O
according O
to O
a O
Latin O
square O
design O
with O
either O
( O
i O
) O
dl-norgestrel O
alone O
( O
0.075 O
mg/day O
) O
continuously O
for O
two O
cycles O
, O
( O
ii O
) O
estradiol-17 O
beta O
alone O
( O
1 O
mg O
on O
25 O
of O
28 O
days O
) O
for O
two O
cycles O
, O
or O
( O
iii O
) O
the O
combined O
hormones O
for O
six O
cycles O
. O
[]

RESULTS O
In O
this O
population O
, O
only O
a O
modest O
proportion O
of O
children O
whose O
symptoms O
warranted O
a O
medication O
increase O
actually O
had O
a O
scheduled O
visit O
to O
reevaluate O
their O
asthma O
treatment O
. O
[]

Comparison O
between O
obtained O
mydriasis O
in O
type O
2 O
diabetics O
and O
non-diabetic O
patients O
. O
[]

Propofol O
and O
isoflurane O
have O
been O
reported O
recently O
to O
offer O
better O
sedation B-outcome ['Life-Impact']
than O
alternative O
agents O
in O
patients O
who O
require O
long-term O
ventilation O
in O
the O
Intensive O
Care O
Unit O
. O
['Life-Impact']

CONCLUSIONS O
Patient O
coaching O
offers O
promise O
as O
a O
means O
of O
reducing O
racial/ethnic O
disparities O
in O
pain B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Its O
role O
in O
the O
treatment O
of O
HPRC O
remains O
to O
be O
elucidated O
in O
an O
appropriate O
phase O
III O
setting O
. O
[]

CONCLUSION O
Addition O
of O
MgSO4 O
to O
conventional O
therapy O
helps O
in O
achieving O
earlier O
improvement O
in O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
and O
PEFR B-outcome ['Physiological-Clinical']
in O
patients O
not O
responding O
to O
conventional O
therapy O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
compares O
doxepin O
with O
placebo O
, O
and O
a O
marital O
therapy O
designed O
to O
enhance O
intimacy O
through O
facilitating O
self-disclosure O
between O
spouses O
with O
a O
more O
supportive O
and O
educational O
therapeutic O
approach O
. O
[]

CONCLUSION O
The O
results O
of O
our O
study O
demonstrate O
the O
efficacy O
of O
the O
modes O
of O
intervention O
developed O
by O
us O
and O
serve O
as O
a O
new O
training O
tool O
for O
future O
health O
care O
professionals O
with O
regard O
to O
stigma B-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
. O
['Life-Impact']

These O
levels O
were O
in O
close O
agreement O
with O
values O
published O
previously O
. O
[]

In O
each O
subject O
, O
positron B-outcome ['Resource-use']
emission I-outcome ['Resource-use']
tomographic I-outcome ['Resource-use']
images I-outcome ['Resource-use']
of O
regional O
cerebral B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
with O
[ O
18F O
] O
fluorodeoxyglucose O
were O
obtained O
in O
two O
conditions O
in O
the O
morning O
on O
different O
days O
: O
about O
3min O
after O
approximately O
1-2mg O
of O
nasal O
nicotine O
spray O
and O
after O
an O
equivalent O
volume O
of O
an O
active O
placebo O
spray O
of O
oleoresin O
of O
pepper O
in O
a O
random O
counterbalanced O
design O
. O
['Resource-use', 'Physiological-Clinical']

[ O
Clinical O
study O
on O
retarding B-outcome ['Physiological-Clinical']
aging I-outcome ['Physiological-Clinical']
effect O
of O
tongbu O
recipe O
to O
traditional O
Chinese O
medicine O
] O
. O
['Physiological-Clinical']

Safety O
and O
efficacy O
of O
irinotecan O
plus O
high-dose O
leucovorin O
and O
intravenous O
bolus O
5-fluorouracil O
for O
metastatic O
colorectal O
cancer O
: O
pooled O
analysis O
of O
two O
consecutive O
southern O
Italy O
cooperative O
oncology O
group O
trials O
. O
[]

The O
effect O
of O
eradication O
of O
Helicobacter O
pylori O
upon O
the O
duodenal B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
-- O
a O
24 O
month O
follow-up O
study O
. O
['Physiological-Clinical']

The O
only O
difference O
in O
treatment O
lay O
in O
the O
position O
of O
fixation O
in O
plaster O
. O
[]

OUTCOME O
MEASURES O
Volume O
and O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
, O
physician O
, O
case B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
, O
and O
['Resource-use', 'Life-Impact']

Transdermal O
nitroglycerin O
in O
angina O
pectoris O
: O
efficacy O
of O
intermittent O
application O
. O
[]

Circadian O
rhythms O
in O
dietary O
and O
water O
intake O
and O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
total O
fatty B-outcome ['Physiological-Clinical']
acids B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
statistically O
significant O
relationships O
between O
stool O
consistency O
and O
dietary O
intake O
were O
observed O
. O
[]

According O
to O
this O
model O
, O
frequency O
discrimination O
is O
based O
on O
a O
change O
in O
the O
relative O
output O
levels O
of O
two O
auditory O
filters O
, O
one O
centered O
below O
and O
the O
other O
above O
the O
frequency O
of O
the O
tone O
. O
[]

METHODS O
Sixty-six O
patients O
with O
gastric O
carcinoma O
scheduled O
for O
gastrectomy O
were O
randomly O
divided O
into O
3 O
groups O
, O
namely O
group O
P O
( O
n=22 O
) O
, O
group O
E O
( O
n=22 O
) O
and O
group O
V O
( O
n=22 O
) O
, O
to O
receive O
preemptive O
epidural O
analgesia O
combined O
with O
postoperative O
epidural O
analgesia O
, O
exclusive O
postoperative O
epidural O
analgesia O
, O
and O
exclusive O
postoperative O
intravenous O
analgesia O
, O
respectively O
. O
[]

Ketorolac O
did O
not O
alter O
the O
[]

BACKGROUND O
Empirical O
treatment O
with O
antifungal O
drugs O
is O
often O
used O
in O
haematology O
patients O
at O
high O
risk O
of O
invasive O
aspergillosis O
. O
[]

A O
randomized O
cross-over O
study O
of O
inhalation O
of O
diesel O
exhaust O
, O
hematological O
indices O
, O
and O
endothelial O
markers O
in O
humans O
. O
[]

Intramedullary O
nailing O
was O
with O
the O
AO/ASIF* O
universal O
reamed O
or O
unreamed O
nail O
. O
[]

Patients O
who O
received O
either O
hypnosis O
or O
CB O
reported O
less O
pain B-outcome ['Physiological-Clinical']
and O
pain-related B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
than O
did O
control O
patients O
and O
less O
pain B-outcome ['Physiological-Clinical']
and O
anxiety B-outcome ['Life-Impact']
than O
at O
their O
own O
baseline O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
was O
measured O
using O
the O
SF12 O
physical B-outcome ['Physiological-Clinical']
and O
mental B-outcome ['Physiological-Clinical']
summary O
component O
T-scores O
and O
pain B-outcome ['Physiological-Clinical']
was O
measured O
with O
a O
100 O
mm O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
clinical O
significance O
of O
Skp2 O
in O
patients O
with O
laryngeal O
squamous O
cell O
carcinoma O
( O
LSCC O
) O
remains O
unknown O
. O
[]

According O
to O
a O
crossover O
design O
, O
they O
were O
randomized O
to O
have O
either O
sleep O
deprivation O
or O
a O
full O
night O
's O
sleep O
1 O
week O
apart O
, O
during O
which O
they O
were O
monitored O
with O
ABPM O
. O
[]

Likewise O
, O
19.5 O
% O
of O
children O
in O
the O
IT O
methotrexate O
group O
had O
a O
Processing B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
Index O
score O
in O
the O
below-average O
range O
compared O
with O
6.9 O
% O
in O
the O
triple O
IT O
therapy O
group O
( O
P O
= O
.02 O
) O
. O
['Life-Impact']

= O
1 O
, O
P O
= O
0.048 O
; O
F O
= O
4.29 O
, O
d.f O
. O
[]

Significant O
improvements O
were O
found O
for O
the O
secondary O
outcome O
WOMAC O
physical B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
( O
P=0.011 O
) O
in O
the O
group O
receiving O
PE+SE O
compared O
to O
the O
group O
receiving O
PE O
only O
. O
['Physiological-Clinical', 'Life-Impact']

Computer-navigated O
versus O
conventional O
total O
knee O
arthroplasty O
a O
prospective O
randomized O
trial O
. O
[]

Forty-seven O
children O
were O
randomly O
assigned O
to O
treatment O
and O
wait-list O
control O
groups O
. O
[]

However O
, O
there O
were O
not O
significantly O
more O
patients O
on O
atomoxetine O
( O
20.9 O
% O
) O
who O
improved O
much O
, O
or O
very O
much O
according O
to O
the O
CGI-I O
, O
than O
on O
placebo O
( O
8.7 O
% O
; O
p O
= O
0.14 O
) O
. O
[]

Total O
and O
appendicular B-outcome ['Physiological-Clinical']
skeletal I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ASM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
percent O
fat B-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
mineralization I-outcome ['Physiological-Clinical']
were O
assessed O
by O
dual O
energy O
X-ray O
absorptiometry O
and O
used O
to O
characterize O
normal O
lean O
( O
NL O
, O
n O
= O
51 O
) O
, O
sarcopenic O
( O
SS O
, O
n O
= O
18 O
) O
, O
sarcopenic O
obese O
( O
SO O
, O
n O
= O
29 O
) O
, O
and O
obese O
( O
OO O
, O
n O
= O
85 O
) O
phenotypes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
the O
periods O
with O
and O
without O
Na+ O
modeling O
: O
no O
differences O
were O
found O
in O
weight O
gained O
interdialysis O
, O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
predialysis I-outcome ['Physiological-Clinical']
and O
postdialysis B-outcome ['Physiological-Clinical']
, O
and O
hemoconcentration B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
primary O
aim O
was O
to O
assess O
and O
compare O
[]

No O
unexpected O
safety O
signals O
were O
noted O
. O
[]

Initiatives O
involving O
health O
educators O
, O
outreach O
workers O
, O
medical O
providers O
, O
health O
care O
insurers O
, O
housing O
agencies O
, O
and O
elected O
officials O
are O
needed O
to O
reduce O
these O
exposures O
. O
[]

An O
intravenous O
bolus O
of O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
was O
administered O
in O
doses O
at O
the O
lower O
( O
0.05 O
microg/kg O
) O
and O
upper O
( O
0.15 O
microg/kg O
) O
range O
of O
the O
dose-response O
curves O
for O
young O
males O
, O
as O
well O
as O
the O
standard O
supramaximal O
dose O
( O
1 O
. O
[]

Intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
will O
provide O
the O
clearest O
evidence O
to O
date O
about O
the O
value O
of O
yoga O
as O
a O
therapeutic O
option O
for O
treating O
chronic B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
if O
the O
results O
are O
positive O
, O
will O
help O
focus O
future O
, O
more O
in-depth O
, O
research O
on O
the O
most O
promising O
potential O
mechanisms O
of O
action O
identified O
by O
this O
study O
. O
['Physiological-Clinical']

Daily O
2g O
IV O
ceftriaxone O
was O
initially O
given O
to O
all O
patients O
. O
[]

The O
partial O
response O
rate O
was O
significantly O
greater O
in O
patients O
who O
received O
CDDP/FU O
versus O
FU O
alone O
( O
25 O
% O
v O
3 O
% O
, O
P O
= O
.001 O
) O
. O
[]

The O
proportion O
of O
chronic O
liver O
disease O
associated O
with O
the O
pre-core O
mutant O
of O
hepatitis O
B O
virus O
( O
HBV O
) O
infection O
is O
increasing O
, O
particularly O
in O
Mediterranean O
Europe O
and O
in O
Asia O
. O
[]

DESIGN O
A O
randomised O
controlled O
trial O
. O
[]

DESIGN O
Multicentre O
randomised O
controlled O
trial O
. O
[]

The O
cholesterol-lowering O
effect O
during O
the O
run-in O
period O
may O
be O
explained O
by O
the O
regression O
to O
the O
mean O
effect O
and O
by O
other O
factors O
related O
to O
study O
participation O
, O
mainly O
nutrient O
displacement O
induced O
by O
the O
protein O
supplement O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
satisfaction B-outcome ['Life-Impact']
rate O
, O
efficacy O
, O
and O
complication B-outcome ['Adverse-effects']
rate O
of O
carbon O
dioxide O
( O
CO O
( O
2 O
) O
) O
versus O
normal O
saline O
as O
a O
uterine O
distension O
medium O
for O
outpatient O
diagnostic O
vaginoscopic O
hysteroscopy O
in O
infertile O
patients O
. O
['Life-Impact', 'Adverse-effects']

All O
patients O
developed O
granulocyte B-outcome ['Physiological-Clinical']
nadirs I-outcome ['Physiological-Clinical']
below O
100/cu O
mm O
. O
['Physiological-Clinical']

Effect O
of O
different O
rates O
of O
infusion O
of O
propofol O
for O
induction O
of O
anaesthesia B-outcome ['Resource-use']
in O
elderly O
patients O
. O
['Resource-use']

A O
pilot O
randomized O
controlled O
trial O
of O
DIR/Floortime? O
parent O
training O
intervention O
for O
pre-school O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

The O
groups O
were O
analysed O
for O
intraoperative O
blood O
loss O
, O
drainage O
, O
transfusion O
requirements O
, O
perioperative O
haemoglobin O
decrease O
, O
wound O
haematoma O
, O
and O
clinical O
deep O
venous O
thrombosis O
. O
[]

To O
investigate O
the O
effect O
of O
cardiopulmonary O
bypass O
on O
the O
shear-induced O
pathway O
, O
a O
double-blind O
study O
of O
preoperative O
aspirin O
treatment O
( O
325 O
mg O
) O
and O
placebo O
was O
conducted O
in O
40 O
patients O
undergoing O
coronary O
artery O
bypass O
grafting O
. O
[]

[ O
Potentials O
of O
monocular O
augmented O
reality O
technology O
in O
automobile O
production O
] O
. O
[]

Patients O
were O
randomized O
to O
receive O
one O
of O
the O
following O
treatments O
: O
( O
a O
) O
concomitant O
therapy O
: O
omeprazole O
20mg O
, O
amoxicillin O
1g O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
for O
5 O
days O
; O
( O
b O
) O
sequential O
therapy O
: O
omeprazole O
20mg O
and O
amoxicillin O
1g O
for O
5 O
days O
followed O
by O
omeprazole O
20mg O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
for O
5 O
days O
; O
( O
c O
) O
hybrid O
therapy O
: O
omeprazole O
20mg O
, O
and O
amoxicillin O
1g O
for O
7 O
days O
followed O
by O
omeprazole O
20mg O
, O
amoxicillin O
1g O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
, O
for O
7 O
days O
. O
[]

The O
duration O
of O
inotropic B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
was O
shorter O
in O
group O
II O
than O
in O
group O
I O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

Large O
doses O
of O
oral O
conjugated O
estrogen O
were O
administered O
for O
a O
three-month O
period O
to O
23 O
premenopausal O
and O
postmenopausal O
inpatient O
women O
. O
[]

The O
primary O
analysis O
of O
the O
population O
for O
survival B-outcome ['Mortality']
was O
by O
intention O
to O
treat O
. O
['Mortality']

Role O
of O
angiotensin-converting O
enzyme O
inhibitors O
in O
early O
antihypertensive O
treatment O
in O
non-insulin O
dependent O
diabetes O
mellitus O
. O
[]

MATERIAL/METHODS O
We O
performed O
a O
post-hoc O
analysis O
on O
307 O
kidney O
transplant O
recipients O
included O
in O
a O
prospective O
randomized O
trial O
comparing O
tacrolimus/mycophenolate O
mofetil O
( O
Tac/MMF O
) O
vs. O
cyclosporine/azathioprine O
( O
CsA/AZA O
) O
, O
both O
used O
with O
antithymocyte O
globulin O
induction O
and O
steroids O
. O
[]

Medical O
rehabilitation O
is O
very O
significant O
for O
the O
muscle O
performance O
improvement O
in O
this O
population O
providing O
their O
social O
reintegration O
. O
[]

The O
probiotic O
approach O
may O
thus O
offer O
a O
new O
direction O
in O
the O
search O
for O
future O
foods O
for O
allergy O
treatment O
and O
prevention O
strategies O
. O
[]

Participants O
were O
randomized O
to O
an O
oral O
dose O
of O
30 O
mg/kg/d O
DHA O
or O
placebo O
plus O
a O
daily O
multivitamin O
. O
[]

The O
primary O
study O
end O
point O
was O
the O
proportion O
of O
DNA B-outcome ['Physiological-Clinical']
aneuploid I-outcome ['Physiological-Clinical']
histograms I-outcome ['Physiological-Clinical']
after O
12 O
months O
. O
['Physiological-Clinical']

The O
clinical O
study O
shows O
that O
the O
polymer O
complex O
( O
Polym O
) O
produced O
a O
prolonged B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
effect O
, O
this O
being O
consistant O
with O
a O
slow O
release O
pattern O
and O
maintained O
a O
more O
effective O
around-the-clock O
control O
than O
pilocarpine O
solution O
. O
['Physiological-Clinical']

However O
, O
the O
choice O
of O
antidepressant O
drug O
is O
critically O
influenced O
by O
its O
safety O
and O
tolerability B-outcome ['Life-Impact']
and O
by O
its O
effect O
on O
concurrent O
pathologies O
. O
['Life-Impact']

METHODS O
Ninety-one O
patients O
were O
enrolled O
in O
this O
prospective O
, O
randomized O
, O
multicentre O
study O
. O
[]

PURPOSE O
To O
evaluate O
and O
compare O
total O
body B-outcome ['Physiological-Clinical']
weight O
( O
TBW O
) O
, O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
weight O
( O
LBW O
) O
, O
and O
estimated O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
BV B-outcome ['Physiological-Clinical']
) O
for O
the O
adjustment O
of O
the O
iodine O
dose O
required O
for O
contrast O
material-enhanced O
multidetector O
computed O
tomography O
( O
CT O
) O
of O
the O
aorta O
and O
liver O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
our O
study O
of O
borderline O
hypertension O
in O
Tecumseh O
, O
white-coat O
hypertension O
is O
present O
in O
7.1 O
% O
of O
the O
whole O
population O
and O
in O
58 O
% O
of O
all O
subjects O
with O
elevated O
blood B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
in O
the O
clinic O
. O
['Physiological-Clinical']

Prospective O
study O
of O
Clostridium B-outcome ['Physiological-Clinical']
difficile I-outcome ['Physiological-Clinical']
intestinal O
colonization O
and O
disease O
following O
single-dose O
antibiotic O
prophylaxis O
in O
surgery O
. O
['Physiological-Clinical']

The O
issue O
of O
clinical O
understaging O
and O
of O
resection O
limit O
positivity O
have O
led O
to O
the O
development O
of O
novel O
management O
practices O
, O
including O
neoadjuvant O
hormonal O
therapy O
( O
NHT O
) O
. O
[]

1.5 O
; O
p O
= O
0.01 O
) O
and O
higher O
inpatient O
opiate O
usage O
( O
hydromorphone O
use O
: O
3.9 O
? O
[]

RESULTS O
Patients O
treated O
with O
either O
dose O
of O
esomeprazole O
were O
two O
to O
three O
times O
more O
likely O
to O
achieve O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
than O
patients O
treated O
with O
placebo O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

According O
to O
the O
American O
College O
of O
Surgeons O
, O
complex O
oral O
surgical O
procedures O
, O
including O
the O
transoral O
placement O
of O
endosseous O
implants O
, O
are O
of O
the O
type O
that O
may O
require O
prophylactic O
antibiotics O
. O
[]

Conditional O
logistic O
regression O
was O
used O
to O
estimate O
adjusted O
odds O
ratios O
( O
OR O
) O
and O
95 O
% O
CI O
. O
[]

No O
first-dose O
side O
effects O
were O
observed O
with O
either O
drug O
. O
[]

No O
significant O
difference O
was O
present O
for O
different O
doses O
within O
the O
same O
contrast O
medium O
group O
. O
[]

CONCLUSIONS O
At O
best O
this O
was O
a O
flawed O
study O
in O
that O
37 O
% O
of O
the O
treated O
cases O
did O
not O
meet O
inclusion O
criteria O
, O
and O
at O
worst O
there O
was O
no O
evidence O
of O
effect O
. O
[]

Clinical O
characteristics O
and O
disease O
progression O
were O
compared O
between O
patients O
with O
spotty O
calcification O
( O
n O
= O
922 O
) O
and O
those O
with O
no O
calcification O
( O
n O
= O
425 O
) O
. O
[]

Profound O
luteinizing O
hormone O
suppression O
after O
stopping O
the O
gonadotropin-releasing O
hormone-agonist O
leuprolide O
acetate O
. O
[]

GOALS O
To O
measure O
visit-to-visit O
intraindividual O
variations O
of O
both O
clinic O
and O
24-h O
mean O
BP O
in O
the O
hypertensive O
patients O
of O
the O
European O
Lacidipine O
Study O
on O
Atherosclerosis O
( O
ELSA O
) O
trial O
treated O
for O
4 O
years O
with O
either O
atenolol O
or O
lacidipine O
, O
and O
to O
check O
whether O
interindividual O
clinic O
and O
24-h O
BP O
variabilities O
during O
treatment O
can O
really O
be O
considered O
a O
surrogate O
of O
intraindividual O
variabilities O
in O
exploring O
differences O
between O
?-blocker O
and O
calcium O
antagonist O
treatments O
. O
[]

Over O
the O
5.4 O
years O
of O
median O
follow-up O
, O
simvastatin O
produced O
changes O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( O
LDL B-outcome ['Physiological-Clinical']
) O
cholesterol B-outcome ['Physiological-Clinical']
, O
and O
high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
of O
-25 O
% O
, O
-35 O
% O
, O
and O
+8 O
% O
, O
respectively O
, O
with O
minimal O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Similar O
improvements O
were O
seen O
in O
group O
A O
patients O
. O
[]

Furthermore O
, O
the O
HR O
, O
double O
product O
and O
Borg O
score O
at O
isotime O
were O
significantly O
lower O
in O
the O
LED O
group O
and O
in O
the O
exercise O
group O
( O
p O
< O
0.05 O
) O
. O
[]

In O
the O
morning O
, O
these O
ratios O
averaged O
0.25 O
systolic O
( O
95 O
% O
confidence O
interval O
, O
0.09 O
to O
0.41 O
) O
and O
0.15 O
diastolic O
( O
95 O
% O
confidence O
interval O
, O
0.00 O
to O
0.31 O
) O
and O
in O
the O
evening O
, O
0.19 O
and O
0.36 O
( O
95 O
% O
confidence O
intervals O
, O
0.00 O
to O
0.38 O
and O
0.14 O
to O
0.56 O
) O
, O
respectively O
. O
[]

However O
, O
few O
attempts O
have O
been O
made O
to O
define O
and O
measure O
this O
symptom O
. O
[]

Our O
findings O
might O
help O
explain O
the O
reduced O
risk O
of O
myocardial O
infarction O
or O
stroke O
in O
patients O
treated O
with O
statins O
and/or O
ACEIs O
and O
the O
lack O
of O
clinical O
benefits O
from O
ACEI O
added O
to O
prior O
statin O
therapy O
in O
patients O
at O
cardiovascular O
risk O
. O
[]

The O
poor O
metabolizer O
demonstrated O
in O
both O
oral O
formulations O
high B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
increased O
AUCs O
and O
prolonged O
terminal O
half-lives O
as O
well O
as O
increased O
renal B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prajmalium I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Patients O
( O
N=60 O
) O
admitted O
to O
our O
department O
postorthopedic O
surgery O
were O
randomly O
assigned O
to O
either O
a O
case O
( O
n=30 O
) O
or O
control O
( O
n=30 O
) O
group O
. O
[]

In O
the O
fixed O
duration O
cautery O
group O
, O
11 O
of O
21 O
polyps O
( O
52 O
% O
) O
were O
eradicated B-outcome ['Physiological-Clinical']
, O
compared O
with O
12 O
of O
14 O
polyps O
( O
86 O
% O
) O
in O
the O
variable O
duration O
cautery O
group O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Large O
individual O
variation O
, O
inadequate O
nutritional O
support O
and O
differences O
in O
admission O
arm O
muscle O
area O
may O
have O
clouded O
these O
results O
. O
[]

All O
pens O
within O
a O
block O
were O
slaughtered O
on O
the O
same O
day O
( O
132.1 O
? O
[]

The O
level O
of O
agreement B-outcome ['Life-Impact']
was O
higher O
in O
the O
controls O
( O
63 O
% O
) O
than O
in O
the O
cord O
complication O
group O
( O
56 O
% O
) O
. O
['Life-Impact']

Mean O
( O
range O
) O
weekly O
doses B-outcome ['Life-Impact']
were O
92.68 O
( O
12.74-398.41 O
) O
IU/kg/wk O
and O
92.58 O
( O
10.53-393.07 O
) O
IU/kg/wk O
for O
patients O
receiving O
epoetin O
zeta O
and O
epoetin O
alfa O
, O
respectively O
( O
95 O
% O
CI O
[ O
test-reference O
] O
: O
-4.67 O
and O
4.29 O
IU/kg/wk O
, O
within O
the O
equivalence O
range O
of O
+/-45.00 O
IU/kg/wk O
) O
. O
['Life-Impact']

Cilazapril O
significantly O
lowered O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
for O
a O
period O
of O
24 O
h O
post O
administration O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
is O
to O
assess O
the O
effectiveness O
and O
acceptability O
of O
a O
multi-component O
physical O
activity O
intervention O
, O
delivered O
by O
childcare O
service O
staff O
, O
in O
increasing O
the O
physical O
activity O
levels O
of O
children O
attending O
long O
day O
care O
services O
. O
[]

CONCLUSION O
Unreamed O
nailing O
in O
patients O
with O
tibial O
shaft O
fractures O
may O
be O
associated O
with O
higher O
rates O
of O
secondary B-outcome ['Resource-use']
operations I-outcome ['Resource-use']
and O
malunions B-outcome ['Physiological-Clinical']
compared O
with O
reamed O
nailing O
. O
['Resource-use', 'Physiological-Clinical']

RATIONALE O
The O
acute O
effect O
of O
secondhand O
smoke O
( O
SHS O
) O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
the O
duration O
of O
system B-outcome ['Physiological-Clinical']
disruption I-outcome ['Physiological-Clinical']
remain O
unknown O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Drowsiness O
differed O
; O
15 O
% O
and O
14 O
% O
were O
drowsy O
in O
Mi+Mo O
versus O
2 O
% O
and O
3 O
% O
in O
Mo O
alone O
respectively O
( O
p O
< O
0.001 O
) O
. O
[]

This O
study O
examined O
the O
[]

Double O
blockade O
decreased O
lung B-outcome ['Physiological-Clinical']
volume-to-heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
transfer O
function O
magnitude B-outcome ['Physiological-Clinical']
( O
P O
< O
0.007 O
) O
and O
increased O
phase O
angle B-outcome ['Physiological-Clinical']
( O
P O
< O
0.02 O
) O
without O
age O
effects O
or O
age-drug O
interactions O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

With O
a O
relative O
dose O
intensity O
of O
paclitaxel O
0.94 O
in O
both O
groups O
, O
neurotoxicity B-outcome ['Physiological-Clinical']
( O
P O
= O
0.025 O
) O
and O
leucopenia B-outcome ['Physiological-Clinical']
( O
P O
= O
0.038 O
) O
were O
more O
pronounced O
in O
group O
B O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thirty-eight O
patients O
were O
randomly O
assigned O
to O
receive O
nateglinide O
( O
270 O
mg/dL O
) O
and O
40 O
to O
control O
group O
( O
no O
treatment O
) O
. O
[]

The O
role O
of O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
of O
at O
least O
6 O
weeks O
duration O
: O
a O
randomised O
( O
unblinded O
) O
controlled O
trial O
. O
[]

BACKGROUND O
Hypertrophied O
anal O
papillae O
and O
fibrous O
anal O
polyps O
are O
frequently O
found O
in O
association O
with O
chronic O
fissure O
in O
ano O
. O
[]

First-time B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
second-time I-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
comparable O
for O
both O
groups O
( O
86 O
vs. O
88 O
% O
and O
96 O
vs. O
98 O
% O
in O
LTS O
and O
PLMA O
groups O
, O
respectively O
) O
. O
['Physiological-Clinical']

CO B-outcome ['Physiological-Clinical']
was O
measured O
noninvasively O
at O
approximately O
two-minute O
intervals O
, O
using O
continuous-wave O
Doppler O
echocardiography O
. O
['Physiological-Clinical']

22.3 O
ng/L O
; O
CRP O
: O
35.0 O
? O
[]

Pregnancy B-outcome ['Physiological-Clinical']
rates O
were O
20 O
, O
13.73 O
and O
12.24 O
% O
, O
respectively O
, O
with O
no O
significant O
difference O
between O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
percentage O
of O
adjudicated O
PMI B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
is O
driven O
by O
the O
MI-definition O
criteria O
and O
biomarker O
type O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
significant O
difference O
in O
gender O
( O
66 O
% O
vs. O
67 O
% O
male O
) O
, O
age O
( O
46+/-11 O
years O
vs. O
45+/-10 O
years O
) O
, O
APACHE O
II O
score O
( O
30 O
vs. O
29 O
) O
, O
TISS-28 O
score O
( O
47 O
vs. O
46 O
) O
, O
and O
Glasgow O
Coma B-outcome ['Physiological-Clinical']
Score O
( O
GCS O
, O
5.3 O
vs. O
5.3 O
) O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Administration O
of O
placebo O
to O
a O
different O
group O
of O
seven O
uremic O
patients O
did O
not O
alter O
GH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Differential O
effects O
of O
angiotensin O
converting O
enzyme O
inhibitors O
on O
the O
vasodepressor O
and O
prostacyclin O
responses O
to O
bradykinin O
. O
[]

Anthropometric B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
parameters O
were O
measured O
when O
the O
study O
was O
initiated O
and O
completed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
assess O
the O
long-term O
effects O
of O
finasteride O
on O
pressure-flow B-outcome ['Physiological-Clinical']
parameters O
in O
men O
with O
urodynamically O
documented O
bladder O
outflow O
obstruction O
( O
BOO O
) O
. O
['Physiological-Clinical']

CGM-measured O
hypoglycemia O
over O
a O
24-h O
span O
is O
highly O
associated O
with O
SH O
the O
following O
day O
( O
P O
< O
0.001 O
) O
, O
but O
the O
PPV O
is O
low O
. O
[]

Cox O
's O
proportional O
hazards O
regression O
models O
proved O
tumor O
budding O
to O
be O
an O
independent O
predictor O
of O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
3.91 O
, O
95 O
% O
confidence O
interval O
1.3-11.77 O
; O
P O
= O
0.02 O
) O
and O
cancer-related O
death O
( O
hazard O
ratio O
5.90 O
, O
95 O
% O
confidence O
interval O
1.62-21.51 O
; O
P O
= O
0.007 O
) O
. O
['Physiological-Clinical']

Caudal O
neostigmine O
with O
bupivacaine O
produces O
a O
dose-independent O
analgesic O
effect O
in O
children O
. O
[]

Visualization O
and O
25 O
W O
short O
burns O
: O
Ablation O
guided O
by O
barium O
visualization O
using O
25 O
W O
and O
short O
burns O
( O
max O
. O
[]

[ O
How O
to O
treat O
the O
relapse B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
NSCLC I-outcome ['Physiological-Clinical']
after O
surgery O
and O
chemotherapy O
? O
['Physiological-Clinical']

While O
the O
employment O
of O
questionnaires O
disclosed O
that O
autistic O
children O
had O
an O
earlier B-outcome ['Physiological-Clinical']
morning I-outcome ['Physiological-Clinical']
awakening I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
and O
multiple B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
night I-outcome ['Physiological-Clinical']
arousals I-outcome ['Physiological-Clinical']
, O
actigraphic O
monitoring O
showed O
that O
with O
the O
exception O
of O
an O
earlier B-outcome ['Physiological-Clinical']
morning I-outcome ['Physiological-Clinical']
arousal I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
p O
= O
.045 O
) O
, O
sleep B-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
of O
autistic O
children O
were O
similar O
to O
that O
of O
normal O
children O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Direct O
trocar O
insertion O
resulted O
in O
fewer O
instrument B-outcome ['Life-Impact']
insertions I-outcome ['Life-Impact']
( O
21.8 O
% O
vs. O
7.8 O
% O
) O
and O
use O
of O
smaller O
volumes O
of O
CO2 B-outcome ['Physiological-Clinical']
( O
2.67 O
vs. O
2.32 O
L O
) O
. O
['Life-Impact', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
( O
P O
> O
.05 O
) O
between O
the O
lidocaine O
and O
mepivacaine O
solutions O
. O
[]

Forty O
consecutive O
patients O
without O
laboratory O
or O
other O
clinical O
signs O
of O
allergy O
but O
with O
severe O
nasal O
polyposis O
were O
included O
in O
the O
study O
. O
[]

Breaking O
it O
down O
is O
better O
: O
haptic O
decomposition O
of O
complex O
movements O
aids O
in O
robot-assisted O
motor B-outcome ['Physiological-Clinical']
learning I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Randomized O
clinical O
trial O
of O
citalopram O
hydrobromide O
for O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
and O
prominent O
repetitive O
behavior O
. O
[]

BACKGROUND O
Coronary-artery O
bypass O
grafting O
( O
CABG O
) O
and O
percutaneous O
transluminal O
coronary O
angioplasty O
( O
PTCA O
) O
are O
alternative O
methods O
of O
revascularization O
in O
patients O
with O
coronary O
artery O
disease O
. O
[]

Patients O
with O
chronic O
stable O
heart O
failure O
were O
recruited O
from O
out-patient O
clinics O
. O
[]

Can O
patient O
coaching O
reduce O
racial/ethnic O
disparities O
in O
cancer O
pain O
control O
? O
[]

In O
mice O
, O
methotrimeprazine O
only O
possessed O
antinociceptive B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
doses O
which O
caused O
marked B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tissue B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
remained O
between O
1.7 O
and O
2.1 O
for O
24 O
hours O
. O
['Physiological-Clinical']

Patients O
also O
received O
oral O
prednisone O
5 O
mg O
twice O
daily O
. O
[]

MEASUREMENTS O
( O
1 O
) O
Report O
of O
patient O
verified O
by O
partner O
as O
to O
number O
of O
coital B-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
per O
month O
; O
( O
2 O
) O
penile-brachial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
index O
determinations O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

An O
additional O
aim O
was O
to O
assess O
sex O
differences O
in O
haemodynamic O
responsiveness O
to O
cardiovascular O
drugs O
in O
male O
and O
female O
healthy O
volunteers O
. O
[]

The O
study O
was O
performed O
twice O
within O
2 O
weeks O
, O
with O
the O
patients O
receiving O
a O
slow O
intravenous O
injection O
of O
either O
clonidine O
( O
225 O
micrograms O
) O
or O
saline O
( O
154 O
mmol/l O
) O
in O
random O
order O
. O
[]

Prognostic O
value O
of O
postoperative O
CEA O
clearance O
in O
rectal O
cancer O
patients O
with O
high O
preoperative O
CEA O
levels O
. O
[]

CONCLUSIONS O
Both O
treatments O
seem O
to O
have O
a O
positive O
influence O
on O
back O
muscle O
function O
by O
improving O
muscle B-outcome ['Physiological-Clinical']
symmetry O
; O
however O
, O
the O
treatments O
had O
no O
effect O
on O
the O
flexion-relaxation B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
after O
1 O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
84 O
elementary O
school O
children O
, O
mean O
age O
6.8 O
years O
. O
[]

Iohexol O
was O
only O
diagnostic B-outcome ['Life-Impact']
in O
74 O
% O
( O
9 O
gI O
) O
and O
81.8 O
% O
( O
12 O
gI O
) O
. O
['Life-Impact']

Endurance B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
significantly O
decreased O
in O
the O
fatigued O
state O
compared O
with O
the O
fresh O
condition O
in O
COPD O
( O
356 O
+/- O
69 O
s O
vs. O
294 O
+/- O
45 O
s O
, O
P O
< O
0.05 O
) O
and O
controls O
( O
450 O
+/- O
74 O
s O
vs. O
340 O
+/- O
45 O
s O
, O
P O
< O
0.05 O
) O
. O
['Life-Impact']

Dropout O
occurred O
significantly O
less O
frequently O
in O
the O
CBT O
group O
. O
[]

Increasing O
participation O
in O
cervical B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
screening O
: O
offering O
a O
HPV O
self-test O
to O
long-term O
non-attendees O
as O
part O
of O
RACOMIP O
, O
a O
Swedish O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

8 O
, O
and O
daily O
mean O
urgency O
or O
urgency O
incontinence O
frequency O
? O
[]

Induction O
of O
labour B-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
in O
the O
treatment O
group O
( O
41 O
% O
) O
than O
in O
the O
control O
group O
( O
15 O
% O
) O
. O
['Physiological-Clinical']

The O
higher O
fat O
recipe O
required O
twice O
as O
much O
peanut O
to O
cause O
50 O
% O
inhibition O
. O
[]

In O
vivo O
evaluation O
includes O
speech O
rate O
, O
maximal O
phonation O
time O
, O
perceptual O
voice O
evaluation O
of O
read-aloud O
prose O
by O
an O
expert O
listener O
, O
speech O
intelligibility O
measurements O
with O
12 O
listeners O
, O
and O
self-assessment O
by O
the O
patients O
. O
[]

The O
distance O
walked O
during O
the O
six-minute O
walking O
test O
improved O
in O
both O
groups O
; O
the O
difference O
between O
the O
treatment O
groups O
was O
not O
statistically O
significant O
. O
[]

A O
reduction O
of O
the O
increase O
of O
scar O
width O
was O
seen O
in O
the O
Contractubex-treated O
group O
as O
compared O
with O
the O
untreated O
group O
. O
[]

No O
association O
was O
noted O
between O
skin B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
and O
other O
markers O
of O
systemic O
toxicity B-outcome ['Adverse-effects']
from O
the O
use O
of O
ICSs O
. O
['Physiological-Clinical', 'Adverse-effects']

This O
study O
retrospectively O
analyzed O
changes O
of O
proteinuria O
over O
4.5 O
yr O
in O
the O
HOPE O
( O
Heart O
Outcomes O
and O
Prevention O
Evaluation O
) O
study O
, O
which O
compared O
ramipril O
's O
effects O
to O
placebo O
in O
9297 O
participants O
, O
including O
3577 O
with O
diabetes O
and O
1956 O
with O
microalbuminuria O
. O
[]

INTERVENTIONS O
After O
a O
screening O
nocturnal O
polysomnograms O
( O
NPSG O
) O
and O
MSLT O
the O
following O
day O
, O
participants O
with O
primary O
insomnia O
were O
randomized O
to O
take O
zolpidem O
10 O
mg O
( O
n O
= O
50 O
) O
or O
placebo O
( O
n O
= O
45 O
) O
nightly O
for O
12 O
months O
. O
[]

In O
randomized O
trials O
, O
stimulation O
parameters O
were O
stochastically O
modulated O
every O
100 O
ms O
in O
a O
range O
of O
+/-15 O
% O
using O
a O
uniform O
probability O
distribution O
. O
[]

All O
PCNL O
procedures O
were O
performed O
by O
the O
same O
surgeon O
. O
[]

There O
was O
a O
trend O
of O
a O
reduced O
proportion O
of O
rapid B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
with O
increased O
exercise B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

With O
frequent O
monitoring O
, O
there O
were O
no O
significant O
differences O
in O
the O
incidence O
of O
serious O
adverse O
events O
, O
a O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
level O
of O
3.0 O
mg O
per O
deciliter O
( O
265 O
?mol O
per O
liter O
) O
or O
higher O
, O
or O
dialysis O
. O
['Physiological-Clinical']

RESULTS O
After O
infusion O
of O
histamine O
pulsatile B-outcome ['Physiological-Clinical']
choroidal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
increased O
by O
5 O
+/- O
3 O
% O
, O
9 O
+/- O
8 O
% O
, O
and O
14 O
+/- O
7 O
% O
( O
P O
= O
0.001 O
, O
ANOVA O
) O
and O
subfoveolar B-outcome ['Physiological-Clinical']
choroidal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
by O
8 O
+/- O
11 O
% O
, O
13 O
+/- O
11 O
% O
, O
and O
13 O
+/- O
12 O
% O
( O
P O
= O
0.003 O
, O
ANOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
suggest O
that O
PTF O
may O
have O
beneficial O
effects O
on O
tubulointerstitial O
damage O
in O
diabetic O
kidney O
disease O
. O
[]

SETTING O
Two O
health O
clinics O
in O
Los O
Angeles O
County O
, O
California O
. O
[]

Twenty-seven O
patients O
( O
A O
) O
received O
10 O
million O
units O
alpha-N1 O
IFN O
i.m O
. O
[]

Experiment O
1 O
compared O
the O
difference O
in O
the O
depth O
of O
the O
osteotomy B-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

TBPI B-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
for O
6 O
h O
after O
PTA O
and O
then O
at O
24 O
h O
, O
1 O
week O
, O
1 O
month O
and O
6 O
months O
. O
['Physiological-Clinical']

Mortality B-outcome ['Mortality']
was O
equivalent O
in O
both O
groups O
. O
['Mortality']

Key O
variables O
included O
perceptions O
of O
neighborhood B-outcome ['Life-Impact']
mobilization I-outcome ['Life-Impact']
by O
youth O
, O
parents O
, O
and O
key O
neighborhood O
leaders O
. O
['Life-Impact']

MATERIAL O
AND O
METHODS O
The O
study O
, O
comprising O
11 O
patients O
with O
at O
least O
two O
screw O
type O
implants O
with O
bleeding B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
( O
BOP B-outcome ['Physiological-Clinical']
) O
, O
probing B-outcome ['Physiological-Clinical']
pocket I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PPD B-outcome ['Physiological-Clinical']
) O
> O
or O
=5 O
mm O
, O
and O
at O
least O
1.5 O
mm O
radiographic O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
exposed O
implant O
threads O
, O
was O
carried O
out O
as O
a O
single O
blind O
randomized O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fewer O
patients O
in O
the O
experimental O
arm O
reported O
both O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
at O
20 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
studied O
434 O
treated O
hypertensive O
patients O
whose O
home O
systolic O
blood O
pressure O
was O
135 O
mmHg O
or O
higher O
. O
[]

Using O
subjective O
questionnaires O
, O
the O
participants O
rated O
difficulties O
with O
two-dimensional O
vision O
and O
coordination B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
instruments I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
estimated O
changes O
in O
heart B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
mean O
values O
of O
pulmonary B-outcome ['Physiological-Clinical']
artery B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
after O
3 O
months O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
use O
of O
enflurane O
versus O
propofol O
for O
maintenance O
of O
anesthesia O
did O
not O
significantly O
prolong O
the O
time B-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
arrival I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
recovery I-outcome ['Life-Impact']
room I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
sitting I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
tolerating I-outcome ['Life-Impact']
oral I-outcome ['Life-Impact']
fluids I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
being I-outcome ['Life-Impact']
judged I-outcome ['Life-Impact']
fit I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVE O
To O
explore O
the O
relationship O
of O
TCM O
type O
with O
serum O
level O
of O
soluble O
CD44v6 O
( O
sCD44v6 O
) O
and O
different O
histologic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
in O
gastric O
carcinoma O
patients O
and O
to O
observe O
the O
influence O
of O
Weitai O
capsule O
( O
WTC O
) O
on O
the O
sCD44v6 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Vilazodone O
had O
no O
significant O
effect O
on O
cardiac B-outcome ['Physiological-Clinical']
repolarization I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
PR B-outcome ['Physiological-Clinical']
or O
QRS B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
or O
ECG B-outcome ['Physiological-Clinical']
morphology I-outcome ['Physiological-Clinical']
in O
healthy O
adult O
participants O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
caffeine O
was O
effective O
in O
non-HT4 O
allele O
carriers O
, O
and O
modafinil O
reduced O
the O
consequences O
of O
prolonged O
waking O
, O
independently O
of O
ADORA2A O
haplotype O
. O
[]

Both O
formulas O
were O
well O
tolerated O
. O
[]

Integrated O
CE O
produced O
discernibly O
larger O
gains O
than O
serial O
CE O
or O
a O
trend O
for O
four O
of O
six O
training O
adaptations O
. O
[]

RESULTS O
Median O
OS B-outcome ['Physiological-Clinical']
was O
7.3 O
months O
in O
the O
pemetrexed-cisplatin O
arm O
and O
6.3 O
months O
in O
the O
placebo-cisplatin O
arm O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.87 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.75-1.02 O
; O
P O
= O
.082 O
) O
. O
['Physiological-Clinical']

Small O
and O
nonsignificant O
treatment O
effects O
were O
found O
with O
regard O
to O
nonsplinted O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Over O
the O
6-month O
post-RTx O
period O
, O
there O
were O
13 O
episodes O
of O
CMV B-outcome ['Physiological-Clinical']
disease O
in O
eight O
( O
66.7 O
% O
) O
patients O
of O
the O
C O
group O
compared O
with O
none O
in O
the O
GAN O
and O
VAL O
groups O
( O
P=0.0005 O
, O
GAN O
vs O
C O
; O
P=0.001 O
, O
VAL O
vs O
C O
) O
. O
['Physiological-Clinical']

MAIN O
RESULTS O
There O
were O
no O
differences O
in O
Pao B-outcome ['Physiological-Clinical']
( O
2 O
) O
values O
among O
the O
5 O
groups O
studied O
and O
at O
the O
different O
time O
points O
. O
['Physiological-Clinical']

INTERVENTIONS O
Continuous O
infusion O
of O
ranitidine O
at O
6.25 O
mg/hr O
( O
n O
= O
9 O
) O
or O
placebo O
( O
n O
= O
11 O
) O
for O
a O
maximum O
of O
5 O
days O
. O
[]

The O
causes O
of O
pruritus O
are O
numerous O
including O
xerosis O
, O
drug O
and O
photoeruptions O
, O
follicular O
and O
papular O
eruptions O
as O
well O
as O
infestations O
and O
infections O
by O
a O
wide O
range O
of O
organisms O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
letrozole O
in O
HER2+ O
breast O
cancer O
was O
confirmed O
by O
fluorescent O
in O
situ O
hybridization O
analysis O
and O
was O
found O
to O
be O
comparable O
to O
that O
of O
HER2- O
cases O
( O
ORR O
71 O
% O
in O
both O
subsets O
) O
. O
['Physiological-Clinical']

These O
effects O
were O
greater O
in O
women O
age O
60 O
to O
79 O
years O
( O
P O
= O
.03 O
for O
interaction O
across O
age O
) O
. O
[]

Follow-ups O
can O
be O
done O
every O
second O
year O
using O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
alone I-outcome ['Physiological-Clinical']
, O
as O
97 O
% O
of O
the O
cancers O
detected O
at O
annual O
follow-up O
by O
DRE O
+ O
PSA O
were O
PSA+ O
. O
['Physiological-Clinical']

Salient O
contours O
within O
this O
complex O
background O
were O
formed O
by O
colinear O
alignment O
of O
nearby O
segments O
. O
[]

Following O
cessation O
of O
raloxifene O
( O
group O
2 O
) O
, O
bone B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
returned O
to O
baseline O
levels O
( O
by O
120 O
weeks O
) O
. O
['Physiological-Clinical']

Patients O
' O
anxiety B-outcome ['Life-Impact']
was O
assessed O
with O
the O
State B-outcome ['Life-Impact']
Trait I-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
before O
and O
after O
a O
consultation O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
compare O
an O
azelastine-fluticasone O
combination O
nasal O
spray O
administered O
in O
a O
single-delivery O
device O
with O
a O
commercially O
available O
azelastine O
nasal O
spray O
and O
fluticasone O
nasal O
spray O
. O
[]

The O
large O
discrepancies O
found O
suggest O
the O
need O
for O
further O
studies O
in O
to O
enable O
women O
and O
health O
care O
providers O
to O
choose O
the O
most O
appropriate O
method O
for O
milk O
expression O
. O
( O
[]

[ O
Advantages O
of O
video O
assisted O
thoracic O
surgery O
in O
the O
treatment O
of O
spontaneous O
pneumothorax O
] O
. O
[]

Asthma B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
scores O
, O
supplemental B-outcome ['Resource-use']
rescue I-outcome ['Resource-use']
albuterol I-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
and O
number O
of O
nighttime B-outcome ['Physiological-Clinical']
awakenings I-outcome ['Physiological-Clinical']
due I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
asthma B-outcome ['Physiological-Clinical']
requiring O
treatment O
also O
improved O
significantly O
with O
all O
fluticasone O
propionate O
treatment O
regimens O
compared O
with O
placebo O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
20 O
% O
attrition O
from O
Helping O
HAND O
( O
attended O
< O
4/6 O
sessions O
) O
. O
[]

A O
thromboprophylactic O
dose O
of O
enoxaparin O
inhibited O
PAI-1 B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
but O
failed O
to O
down-regulate O
coagulation B-outcome ['Physiological-Clinical']
activity O
and O
D-dimer B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
A O
total O
of O
198 O
English-speaking O
women O
, O
with O
no O
personal O
or O
family O
history O
of O
breast O
cancer O
, O
were O
recruited O
and O
randomized O
to O
four O
groups O
when O
they O
presented O
to O
the O
clinic O
for O
a O
screening O
mammogram O
. O
[]

Comparable O
electrocardiographic B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
were O
obtained O
during O
placebo O
and O
tegaserod O
treatment O
. O
['Physiological-Clinical']

The O
rate O
of O
premature B-outcome ['Physiological-Clinical']
deliveries I-outcome ['Physiological-Clinical']
was O
also O
significantly O
lower O
in O
the O
treated O
group O
( O
16.1 O
% O
) O
than O
in O
the O
control O
group O
( O
37.82 O
% O
) O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

RESULTS O
Patients O
receiving O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
, O
220 O
micrograms/day O
, O
had O
significantly O
( O
P O
< O
.05 O
) O
greater O
improvements O
in O
all O
rhinitis B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
at O
weeks O
1 O
and O
2 O
and O
overall O
for O
the O
2-week O
treatment O
period O
compared O
with O
the O
placebo O
group O
. O
['Physiological-Clinical']

Patients O
received O
eight O
courses O
of O
one O
of O
the O
two O
regimens O
after O
stratification O
according O
to O
the O
stage O
. O
[]

A O
comparison O
of O
intermittent O
vaginal O
administration O
of O
misoprostol O
with O
continuous O
dinoprostone O
for O
cervical B-outcome ['Physiological-Clinical']
ripening I-outcome ['Physiological-Clinical']
and O
labor B-outcome ['Physiological-Clinical']
induction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Vaccination O
with O
live O
oral O
heterologous O
rotavirus O
vaccines O
may O
prevent O
rotavirus O
gastroenteritis O
. O
[]

CONCLUSION O
When O
an O
appropriate O
drug O
combination O
is O
used O
, O
diabetic O
patients O
can O
achieve O
mydriasis B-outcome ['Physiological-Clinical']
as O
satisfactory O
as O
non-diabetic O
patients O
, O
allowing O
adequate O
fundus O
examination O
and/or O
retinopathy O
treatment O
. O
['Physiological-Clinical']

No O
troublesome O
side O
effects O
occurred O
. O
[]

Effects O
of O
resistive O
exercise O
on O
skeletal O
muscle O
in O
marrow O
transplant O
recipients O
receiving O
total O
parenteral O
nutrition O
. O
[]

[ O
Clinical O
and O
experimental O
research O
of O
Epimedium O
brevicornum O
in O
relieving O
neuroendocrino-immunological B-outcome ['Physiological-Clinical']
effect O
inhibited O
by O
exogenous O
glucocorticoid O
] O
. O
['Physiological-Clinical']

After O
intake O
of O
amantadine O
, O
a O
significant O
dose-dependent O
decrease O
of O
ICF B-outcome ['Physiological-Clinical']
was O
noticed O
as O
well O
as O
a O
significant O
increase O
of O
L-ICI B-outcome ['Physiological-Clinical']
as O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
radial O
artery O
was O
used O
in O
all O
cases O
as O
a O
composite O
Y-graft O
. O
[]

Parent O
expansions O
of O
child O
verbal O
utterances O
predicted O
spoken B-outcome ['Life-Impact']
vocabulary I-outcome ['Life-Impact']
after O
controlling O
for O
child O
talkativeness O
. O
['Life-Impact']

METHOD O
Comprehensive O
cognitive-behavioural O
therapy O
has O
been O
developed O
for O
patients O
in O
the O
early O
initial O
prodromal O
state O
. O
[]

Triptorelin O
decreased O
uterine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
calculated O
by O
ultrasonography O
, O
by O
26.5 O
% O
in O
group O
A O
, O
whereas O
the O
volume O
remained O
unchanged O
in O
group O
B O
. O
['Physiological-Clinical']

Irregular B-outcome ['Physiological-Clinical']
uterine I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
almost O
entirely O
confined O
to O
the O
earlier O
phase O
of O
the O
study O
and O
was O
substantially O
less O
with O
the O
formulation O
containing O
1 O
mg O
norethisterone O
acetate O
. O
['Physiological-Clinical']

When O
adjusted O
for O
other O
important O
factors O
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rates O
were O
similar O
( O
P O
=.5 O
) O
and O
although O
there O
was O
less O
resistant O
disease O
in O
younger O
children O
( O
P O
=.003 O
) O
, O
this O
was O
partially O
balanced O
by O
a O
slight O
increase O
in O
deaths B-outcome ['Mortality']
during O
induction O
therapy O
in O
younger O
patients O
( O
P O
=.06 O
) O
. O
['Physiological-Clinical', 'Mortality']

Response O
evaluation O
after O
chemotherapy O
was O
possible O
in O
25 O
patients O
: O
2 O
CR O
, O
6 O
PR O
, O
8 O
SD O
and O
9 O
PD O
. O
[]

RESULTS O
One O
year O
recurrence O
amounted O
to O
1 O
out O
of O
48 O
for O
phlebectomy O
and O
12 O
out O
of O
48 O
for O
compression O
sclerotherapy O
( O
P O
< O
0.001 O
) O
; O
at O
2 O
years O
, O
six O
additional O
recurrences B-outcome ['Physiological-Clinical']
were O
found O
, O
but O
then O
solely O
for O
compression O
sclerotherapy O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Reactivation O
of O
unstable B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
after O
the O
discontinuation O
of O
heparin O
. O
['Physiological-Clinical']

Pouch O
construction O
should O
be O
considered O
after O
deep O
rectal O
resection O
, O
as O
it O
seems O
to O
improve O
functional B-outcome ['Life-Impact']
outcome I-outcome ['Life-Impact']
and O
has O
fewer O
local B-outcome ['Physiological-Clinical']
septic I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
than O
straight O
anastomosis O
. O
['Life-Impact', 'Physiological-Clinical']

Similar O
challenge O
vehicle O
recipes O
were O
used O
, O
the O
only O
difference O
being O
the O
lower O
fat O
content O
( O
22.9 O
% O
compared O
with O
31.5 O
% O
) O
. O
[]

Six O
had O
primary O
adrenal O
failure O
( O
PAF O
) O
. O
[]

The O
reduction O
in O
sudden B-outcome ['Mortality']
death I-outcome ['Mortality']
in O
ICD O
patients O
was O
completely O
offset O
by O
increased O
nonarrhythmic B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
which O
were O
greatest O
in O
patients O
receiving O
ICD O
shock O
therapy O
( O
hazard O
ratio O
, O
6.0 O
; O
95 O
% O
confidence O
interval O
, O
2.8 O
to O
12.7 O
) O
. O
['Mortality', 'Mortality']

RESULTS O
Multivariate O
analysis O
indicated O
that O
, O
for O
end-of-treatment O
abstinence B-outcome ['Life-Impact']
, O
patients O
were O
significantly O
more O
likely O
to O
have O
quit B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
if O
they O
were O
older O
( O
OR O
= O
1.06 O
, O
95 O
% O
CI O
: O
1.03-1.10 O
, O
p O
< O
0.05 O
) O
and O
were O
diagnosed O
with O
a O
non-tobacco O
related O
cancer O
( O
OR O
= O
2.54 O
, O
95 O
% O
CI O
: O
1.24-5.20 O
, O
p O
< O
0.05 O
) O
. O
['Life-Impact', 'Life-Impact']

Changing O
sodium O
intake O
in O
children O
. O
[]

Perceived B-outcome ['Life-Impact']
responsibility I-outcome ['Life-Impact']
was O
higher O
and O
struggle B-outcome ['Life-Impact']
was O
lower O
during O
couple-responsible O
episodes O
. O
['Life-Impact', 'Life-Impact']

In O
the O
fourth O
week O
, O
both O
groups O
showed O
equal O
and O
nearly O
normal O
pain B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical']

Future O
therapeutic O
directions O
for O
factor O
Xa O
inhibition O
in O
the O
prophylaxis O
and O
treatment O
of O
thrombotic O
disorders O
. O
[]

However O
, O
it O
can O
not O
be O
concluded O
that O
L-carnitine O
provides O
an O
advantageous O
support O
therapy B-outcome ['Resource-use']
for O
well-compensated O
patients O
requiring O
cardiac O
surgery O
. O
['Resource-use']

Significant O
results O
might O
be O
obtained O
if O
subgroups O
of O
known O
hyperserotoninemic O
autistic O
and O
attention O
deficit O
disorder O
children O
were O
exposed O
to O
negatively O
ionized O
conditions O
. O
[]

There O
was O
no O
difference O
between O
the O
two O
groups O
with O
respect O
to O
mean O
haemoglobin B-outcome ['Physiological-Clinical']
and O
median O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
at O
6 O
, O
9 O
, O
12 O
, O
15 O
, O
and O
18 O
months O
of O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Entomological O
surveys O
were O
carried O
out O
using O
different O
catching O
methods O
to O
identify O
potential O
malaria B-outcome ['Physiological-Clinical']
vector O
species B-outcome ['Physiological-Clinical']
and O
characterise O
their O
biting B-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

AIMS O
To O
investigate O
the O
prevalence O
of O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
and O
its O
components O
in O
both O
rural O
and O
urban O
Chinese O
population O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
A O
selection O
of O
17 O
polymorphisms O
in O
genes O
encoding O
drug O
targets O
, O
pathway B-outcome ['Physiological-Clinical']
molecules I-outcome ['Physiological-Clinical']
and O
detoxification B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
was O
analyzed O
in O
279 O
previously O
untreated O
mCRC O
patients O
treated O
with O
capecitabine O
, O
oxaliplatin O
and O
bevacizumab O
( O
CAPOX-B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
overall O
first O
response O
rate O
was O
43.8 O
% O
( O
42.2 O
% O
in O
206 O
stage O
I O
, O
II O
and O
III O
patients O
treated O
with O
MPH-P O
and O
48.0 O
% O
in O
75 O
stage O
III O
patients O
treated O
with O
combination O
chemotherapy O
, O
P O
= O
NS O
) O
. O
[]

Two O
different O
interpretations O
are O
discussed O
, O
both O
compatible O
with O
the O
idea O
that O
perceptual O
and O
or O
attentional O
abnormalities O
in O
ASDs O
result O
in O
a O
diminished O
level O
of O
expertise O
for O
faces O
. O
[]

On O
treatment O
days O
volunteers O
remained O
recumbent O
for O
4 O
hours O
after O
drug O
administration O
, O
with O
food O
and O
fluid O
intake O
standardized O
over O
this O
period O
. O
[]

Telephone O
( O
n=14 O
) O
and O
videophone O
( O
n=14 O
) O
interactions O
were O
audio O
taped O
and O
analyzed O
using O
the O
Roter O
Interaction O
Analysis O
System O
. O
[]

RESULTS O
No O
significant O
increases O
were O
observed O
in O
the O
anthropometric B-outcome ['Physiological-Clinical']
indices O
of O
the O
subjects O
receiving O
the O
high-calcium O
fortified O
milk O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

Antibody B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
to O
both O
antigens O
were O
similar O
in O
groups O
A O
and O
B O
, O
in O
which O
HA B-outcome ['Physiological-Clinical']
seroprotection B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
( O
> O
or O
= O
20 O
mIU/mL O
) O
were O
respectively O
, O
98.7 O
% O
and O
100 O
% O
at O
day O
28 O
, O
and O
99.1 O
% O
and O
99.0 O
% O
after O
3 O
years O
, O
achieving O
100 O
% O
after O
the O
booster O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
PLA O
should O
be O
considered O
a O
viable O
treatment O
option O
for O
HCC O
? O
[]

An O
allopurinol-controlled O
, O
randomized O
, O
double-dummy O
, O
double-blind O
, O
parallel O
between-group O
, O
comparative O
study O
of O
febuxostat O
( O
TMX-67 O
) O
, O
a O
non-purine-selective O
inhibitor O
of O
xanthine O
oxidase O
, O
in O
patients O
with O
hyperuricemia O
including O
those O
with O
gout O
in O
Japan O
: O
phase O
3 O
clinical O
study O
. O
[]

OBJECTIVE O
To O
assess O
the O
relationship O
between O
inflammation O
and O
joint O
destruction O
in O
rheumatoid O
arthritis O
( O
RA O
) O
patients O
who O
have O
not O
responded O
clinically O
to O
treatment O
. O
[]

RESULTS O
A O
repeated O
measures O
analysis O
of O
variance O
indicated O
no O
significant O
differences O
between O
groups O
or O
between O
baseline O
, O
intervention O
, O
and O
withdrawal O
conditions O
. O
[]

BACKGROUND O
Premedication O
with O
sedatives O
can O
decrease O
the O
discomfort B-outcome ['Physiological-Clinical']
associated O
with O
invasive O
anesthetic O
procedures O
. O
['Physiological-Clinical']

In O
the O
study O
, O
100 O
patients O
experiencing O
primary O
TKA O
were O
randomly O
divided O
into O
study O
group O
, O
receiving O
parecoxib O
sodium O
( O
40 O
mg O
) O
intravenously O
( O
IV O
) O
at O
the O
completion O
of O
surgery O
and O
once O
every O
12 O
h O
for O
totally O
6 O
times O
postoperatively O
, O
and O
placebo O
group O
, O
receiving O
normal O
saline O
2 O
mL O
IV O
at O
the O
same O
time O
points O
. O
[]

Group O
2 O
received O
only O
a O
face-to-face O
presentation O
, O
given O
to O
departmental O
groups O
, O
as O
well O
as O
the O
same O
written O
educational O
materials O
used O
in O
group O
1 O
. O
[]

Objective O
parameters O
were O
used O
to O
evaluate O
therapeutical O
effects O
. O
[]

RESULTS O
Twenty-six O
patients O
were O
included O
( O
infliximab O
group O
: O
n O
= O
12 O
, O
infliximab O
+ O
MTX O
group O
: O
n O
= O
14 O
) O
, O
and O
507 O
serum O
samples O
were O
available O
for O
measurement O
of O
infliximab B-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Neoadjuvant O
chemotherapy O
trials O
have O
consistently O
reported O
lower O
response O
rates O
in O
hormone O
receptor-positive O
( O
HR+ O
) O
breast O
cancer O
when O
compared O
with O
HR- O
cases O
. O
[]

The O
intervention O
consisted O
of O
usual O
care O
plus O
3 O
hours O
contact O
with O
a O
pediatric O
nurse O
practitioner O
( O
PNP O
) O
for O
counseling O
, O
instruction O
, O
and O
assistance O
with O
implementation O
of O
the O
recommended O
treatment O
plan O
. O
[]

Tailoring O
for O
dietary O
intake O
was O
performed O
on O
data O
from O
a O
validated O
63-item O
combination O
FFQ O
designed O
for O
the O
purpose O
2 O
) O
small O
group O
nutrition O
education O
sessions O
( O
GE O
) O
: O
consisting O
of O
two O
90-minute O
dietitian-led O
small O
group O
nutrition O
education O
sessions O
and O
3 O
) O
and O
a O
wait-listed O
control O
( O
C O
) O
group O
who O
completed O
the O
dietary O
measures O
and O
socio-demographic O
questionnaires O
at O
baseline O
and O
3-months O
later O
. O
[]

It O
may O
significantly O
lower O
the O
risk O
of O
refractory O
angina O
pectoris O
compared O
with O
intravenous O
nitroglycerin O
. O
[]

METHODS O
Thirty O
male O
rats O
were O
randomly O
allocated O
into O
three O
groups O
of O
10 O
rats O
each O
: O
1. O
controls O
, O
2. O
diabetes O
( O
D O
) O
and O
3. O
diabetes O
+ O
ginseng O
( O
DG O
) O
. O
[]

In O
this O
study O
, O
we O
compared O
the O
effect O
of O
epidural O
analgesia O
and O
IV O
morphine O
patient-controlled O
analgesia O
( O
PCA O
) O
on O
pain O
relief O
, O
duration O
of O
hospitalization O
, O
oral O
nutrition O
, O
ambulation O
, O
and O
side O
effects O
in O
patients O
undergoing O
a O
major O
surgical O
procedure O
( O
i.e. O
, O
unilateral O
mastectomy O
with O
immediate O
transverse O
rectus O
abdominis O
musculocutaneous O
flap O
reconstruction O
) O
. O
[]

Treatment O
consisted O
of O
bronchodilators O
, O
corticosteroids O
, O
and O
either O
tetracycline O
, O
500 O
mg O
, O
or O
placebo O
by O
mouth O
every O
6 O
hours O
for O
1 O
week O
. O
[]

This O
was O
attributed O
to O
a O
significant O
decrease O
of O
early O
PV O
reconnections O
within O
the O
first O
30 O
min O
in O
17 O
% O
of O
group O
B O
patients O
vs. O
45 O
% O
of O
group O
A O
patients O
( O
p O
< O
0.001 O
) O
. O
[]

Data O
are O
also O
presented O
documenting O
potential O
selection O
bias O
across O
geographically O
determined O
treatment O
groups O
in O
the O
geographic O
area O
design O
arm O
. O
[]

CONCLUSION O
The O
addition O
of O
vancomycin O
to O
heparin O
CVC O
flush O
solution O
did O
not O
reduce O
bacteremia B-outcome ['Physiological-Clinical']
with O
vancomycin-susceptible O
organisms O
. O
['Physiological-Clinical']

Tirasemtiv O
approximately O
doubled O
the O
serum B-outcome ['Physiological-Clinical']
concentration O
of O
riluzole B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

0.003 O
, O
CES-L O
1.011 O
? O
[]

DISCUSSION O
In O
helicopter O
noise O
, O
custom O
made O
ear O
plugs O
may O
provide O
a O
much O
improved O
speech B-outcome ['Life-Impact']
intelligibility I-outcome ['Life-Impact']
over O
conventional O
plugs O
when O
worn O
under O
a O
headset O
, O
while O
maintaining O
improved O
noise O
protection O
over O
the O
headset-alone O
situation O
. O
['Life-Impact']

16.5 O
mm O
Hg O
, O
p O
< O
0.05 O
) O
and O
the O
citrulline O
( O
56.67 O
? O
[]

These O
findings O
further O
reduce O
a O
role O
for O
fear O
of O
bodily O
sensations O
in O
epinephrine-induced O
panic O
attacks O
and O
favor O
a O
biological O
sensitivity O
to O
sympathetic O
stimulation O
. O
[]

In O
conclusion O
, O
there O
was O
a O
significant O
decrease O
from O
baseline O
in O
the O
coronary O
plaque O
volume O
in O
patients O
with O
stable O
angina O
pectoris O
who O
received O
olmesartan O
or O
valsartan O
for O
6 O
months O
. O
[]

Thus O
, O
the O
use O
of O
concentrate O
of O
factor O
IX O
in O
this O
trial O
, O
as O
well O
as O
potentiating O
intravascular B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
, O
was O
inadequate O
as O
replacement O
for O
the O
clotting O
factor O
deficiencies O
. O
['Physiological-Clinical']

BACKGROUND O
Lead-time O
is O
defined O
as O
the O
time O
by O
which O
screening O
advances O
the O
diagnosis O
compared O
with O
absence O
of O
screening O
. O
[]

While O
the O
postoperative B-outcome ['Life-Impact']
catheterization I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
75.7 O
h O
in O
TURP O
group O
, O
it O
was O
found O
to O
be O
42 O
h O
in O
PKRP O
group O
and O
it O
was O
clear O
that O
catheterization B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
significantly O
shorter O
( O
P O
< O
0001 O
) O
. O
['Life-Impact', 'Life-Impact']

At O
the O
end O
of O
each O
treatment O
period O
, O
glucose B-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GIR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
muscle B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MSA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
and O
total O
body B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
radioisotope I-outcome ['Physiological-Clinical']
dilution I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
examined O
during O
euglycemic O
hyperinsulinemic O
clamp O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Bisphosphonates O
are O
effective O
treatment O
for O
osteoporosis O
but O
have O
been O
associated O
with O
gastrointestinal O
( O
GI O
) O
mucosal O
injury O
. O
[]

Initial O
treatment O
should O
be O
directed O
at O
obviating O
occult O
and O
overt O
testicular O
relapse O
. O
[]

The O
addition O
of O
4 O
microg/ml O
fentanyl O
improves O
analgesia O
from O
epidural O
ropivacaine O
. O
[]

OBJECTIVE O
To O
test O
the O
effectiveness O
of O
interventions O
intended O
to O
increase O
rates O
of O
regular B-outcome ['Life-Impact']
breast I-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
, O
according O
to O
recommended O
guidelines O
. O
['Life-Impact']

10 O
min O
in O
duration O
on O
park O
walks O
due O
to O
the O
lack O
of O
interruptions O
in O
walking O
. O
[]

Intramuscular O
inoculation O
with O
the O
inactivated O
vaccine O
induced O
primary B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
IgM I-outcome ['Physiological-Clinical']
, O
IgG1 B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response B-outcome ['Physiological-Clinical']
to O
chemotherapy O
of O
mCRC O
. O
['Physiological-Clinical']

Endocrine O
disorders O
affect O
both O
the O
coagulation O
and O
fibrinolytic O
systems O
, O
and O
have O
been O
associated O
with O
the O
development O
of O
cardiovascular O
diseases O
. O
[]

All O
recurrences O
after O
tension-free O
repairs O
were O
diagnosed O
within O
the O
first O
year O
after O
surgery O
. O
[]

Is O
successful O
rehabilitation O
of O
complex O
regional O
pain O
syndrome O
due O
to O
sustained O
attention O
to O
the O
affected O
limb O
? O
[]

The O
primary O
aim O
was O
to O
test O
whether O
treatment O
with O
LMWH O
, O
started O
within O
30 O
h O
of O
stroke O
onset O
, O
is O
superior O
to O
aspirin O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
during O
the O
first O
14 O
days O
. O
['Physiological-Clinical']

Of O
these O
referrals O
, O
17 O
% O
met O
the O
inclusion O
criteria O
for O
primary O
idiopathic O
frozen O
shoulder O
. O
[]

METHODS O
The O
study O
was O
a O
matched-pair O
, O
cluster-randomized O
controlled O
trial O
involving O
14 O
Chicago O
public O
schools O
. O
[]

The O
study O
purpose O
was O
to O
confirm O
the O
efficacy O
of O
oral O
sodium O
phosphate O
and O
extend O
observations O
to O
include O
castor O
oil O
. O
[]

Patients O
at O
high O
risk O
of O
GER O
were O
excluded O
from O
the O
study O
. O
[]

RESULTS O
The O
effective O
rate O
was O
96.7 O
% O
in O
the O
observation O
group O
which O
was O
better O
than O
86.7 O
% O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
[]

Histologic B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
( O
change O
from O
initially O
favorable O
to O
an O
unfavorable O
subtype O
of O
non-Hodgkin O
's O
lymphoma O
) O
was O
documented O
in O
22/78 O
patients O
( O
28 O
% O
) O
. O
['Physiological-Clinical']

The O
FB O
group O
had O
excessive O
amounts O
of O
omission B-outcome ['Life-Impact']
and O
commission B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
, O
a O
greater O
response O
time O
mean O
( O
i.e. O
, O
slower O
to O
respond O
) O
and O
had O
greater O
variance O
around O
their O
mean O
response O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
These O
results O
suggest O
that O
preoperative O
hemodilution O
using O
4 O
% O
albumin O
on O
a O
1:1 O
volume O
basis O
for O
blood O
substitution O
during O
a O
prolonged O
surgical O
procedure O
with O
reduced O
blood O
losses O
enhances O
the O
extravasation O
rate O
of O
albumin O
and O
fluid O
to O
the O
interstitial O
tissues O
, O
impeding O
the O
maintenance O
of O
isovolemia O
. O
[]

In O
addition O
, O
women O
who O
were O
taking O
soy O
had O
their O
mean O
[]

RESULTS O
In O
the O
39 O
patients O
identified O
with O
DGE O
, O
change O
from O
placebo O
baseline O
( O
CFB B-outcome ['Physiological-Clinical']
) O
for O
percent O
gastric B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
at O
4-hour O
postmeal O
with O
nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
was O
each O
improved O
and O
statistically O
significant O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
between O
treatment O
groups O
in O
the O
percentage O
of O
patients O
who O
experienced O
a O
clinical B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Adverse-effects']

From O
January O
1995 O
until O
July O
1999 O
, O
124 O
patients O
with O
histologically O
proven O
locally O
advanced O
non-nasopharyngeal O
head O
and O
neck O
cancer O
( O
HNC O
) O
were O
randomized O
to O
receive O
either O
RT O
monotherapy O
( O
70 O
Gy O
, O
Group O
A O
) O
or O
the O
same O
RT O
concomitantly O
with O
DDP O
( O
100 O
mg/m2 O
on O
d O
2 O
, O
22 O
, O
42 O
, O
Group O
B O
) O
or O
Cb O
( O
7 O
AUC O
on O
d O
2 O
, O
22 O
, O
42 O
, O
Group O
C O
) O
. O
[]

A O
total O
of O
14 O
patients O
developed O
wound B-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Venofer O
came O
in O
sight O
as O
effective O
drug O
in O
the O
treatment O
of O
pospartal B-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
and O
could O
become O
as O
the O
alternative O
to O
blood O
transfusion O
in O
mid-severe O
cases O
. O
['Physiological-Clinical']

RESULTS O
Before O
application O
of O
saline O
solutions O
, O
mucociliary B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
in O
the O
three O
patient O
treatment O
groups O
were O
found O
to O
be O
significantly O
delayed O
, O
compared O
with O
the O
control O
group O
. O
['Physiological-Clinical']

The O
standardized O
protocol O
for O
cardiopulmonary O
bypass O
was O
maintained O
for O
all O
the O
patients O
. O
[]

METHODS O
Estimates O
of O
hospitalization O
costs O
were O
based O
on O
the O
2003 O
cost O
schedules O
released O
by O
the O
Health O
Funding O
and O
Costing O
Branch O
of O
the O
Alberta O
Health O
and O
Wellness O
, O
as O
well O
as O
on O
the O
Case O
Mix O
Group O
classification O
system O
. O
[]

All O
patients O
completed O
the O
Short O
Form O
12-question O
Health O
Survey O
and O
Harris O
Hip O
Score O
preoperatively O
and O
at O
4 O
weeks O
, O
1 O
month O
, O
3 O
months O
, O
and O
1 O
year O
postoperatively O
. O
[]

AIM O
OF O
THE O
STUDY O
To O
investigate O
the O
effects O
on O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
and O
triglyceride B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
meals O
enriched O
with O
soluble O
dietary O
fibres O
from O
oats O
, O
rye O
bran O
, O
sugar O
beet O
fibre O
or O
a O
mixture O
of O
these O
three O
fibres O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

The O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
score O
and O
side O
effects O
were O
studied O
in O
the O
four O
groups O
. O
['Physiological-Clinical']

Peak O
block O
height B-outcome ['Physiological-Clinical']
was O
similar O
between O
2-CP O
( O
T8 O
[ O
range O
, O
T6 O
to O
L2 O
] O
) O
and O
2-CP O
with O
clonidine O
( O
T8 O
[ O
range O
, O
T4 O
to O
T11 O
] O
) O
( O
P O
= O
0.57 O
) O
. O
['Physiological-Clinical']

Areal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( O
aBMD B-outcome ['Physiological-Clinical']
) O
was O
measured O
at O
baseline O
and O
6 O
, O
12 O
, O
18 O
and O
24 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
Bamako O
, O
132 O
patients O
with O
pyoderma O
, O
diagnosed O
and O
graded O
as O
severe O
on O
clinical O
grounds O
, O
were O
randomly O
assigned O
to O
an O
oral O
treatment O
by O
either O
amoxicillin O
( O
50 O
mg/kg O
per O
day O
) O
or O
erythromycin O
; O
infections O
of O
the O
follicular O
appendage O
were O
excluded O
. O
[]

2 O
Isoprenaline O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
dose-response I-outcome ['Physiological-Clinical']
curves O
showed O
parallel O
shifts O
to O
the O
right O
after O
oral O
prizidilol O
, O
indicating O
antagonism O
by O
this O
compound O
at O
beta-adrenoceptors O
in O
the O
heart O
. O
['Physiological-Clinical']

BACKGROUND O
Evaluating O
the O
effectiveness O
of O
treatments O
such O
as O
brief O
alcohol O
interventions O
among O
Hispanics O
is O
essential O
to O
effectively O
addressing O
their O
treatment O
needs O
. O
[]

C-spine B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
bag-mask I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
was O
82 O
% O
less O
at O
the O
four O
motion O
segments O
studied O
than O
during O
Macintosh O
laryngoscopy O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

diltiazem O
, O
while O
allowing O
diltiazem O
to O
maintain O
its O
efficacy O
. O
[]

It O
is O
concluded O
that O
there O
may O
be O
a O
place O
for O
the O
use O
of O
single-dose O
antibiotic O
therapy O
for O
the O
treatment O
of O
selected O
elderly O
women O
with O
bacteriuria O
, O
but O
larger O
studies O
are O
needed O
. O
[]

However O
, O
chronic O
use O
of O
corticosteroids O
is O
associated O
with O
side-effects O
such O
as O
skin O
atrophy O
and O
telangiectasia O
. O
[]

However O
, O
the O
level O
of O
emergent B-outcome ['Life-Impact']
over-selectivity I-outcome ['Life-Impact']
was O
significantly O
reduced O
by O
a O
mindfulness O
induction O
when O
compared O
to O
a O
no- O
intervention O
control O
group O
. O
['Life-Impact']

The O
effect O
of O
person-centred O
dementia O
care O
to O
prevent O
agitation O
and O
other O
neuropsychiatric O
symptoms O
and O
enhance O
quality O
of O
life O
in O
nursing O
home O
patients O
: O
a O
10-month O
randomized O
controlled O
trial O
. O
[]

RESULTS O
Latent O
variable O
structural O
equation O
modeling O
indicated O
that O
: O
1 O
) O
the O
intervention O
had O
direct O
, O
positive O
effects O
on O
physical O
activity O
and O
factors O
influencing O
enjoyment O
of O
PE O
, O
which O
subsequently O
explained O
the O
effects O
of O
increased O
physical O
activity O
enjoyment O
and O
self-efficacy B-outcome ['Life-Impact']
on O
increased O
physical O
activity O
; O
and O
2 O
) O
an O
additional O
, O
indirect O
effect O
of O
physical O
activity O
enjoyment O
on O
physical O
activity O
operated O
by O
an O
influence O
on O
self-efficacy B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Earlier O
studies O
showed O
that O
cognitive O
therapy O
has O
anti-panic O
effects O
and O
exposure O
has O
anti-agoraphobic O
effects O
while O
other O
studies O
suggest O
that O
agoraphobia O
is O
a O
secondary O
complication O
of O
panic O
disorder O
. O
[]

Contrast O
, O
motion O
, O
perceptual O
integration O
, O
and O
neurocognition O
in O
schizophrenia O
: O
the O
role O
of O
fragile-X O
related O
mechanisms O
. O
[]

Laser O
interferometry O
is O
a O
valuable O
non-invasive O
, O
highly O
sensitive O
and O
specific O
approach O
for O
the O
detection O
of O
pulse O
pressure O
changes O
. O
[]

METHODS O
Four O
hundred O
ninety O
six O
home O
, O
hospital O
, O
and O
hospice O
nurses O
participated O
in O
a O
one-day O
workshop O
or O
two O
half-day O
workshops O
on O
cancer O
pain O
assessment O
and O
management O
. O
[]

RESULTS O
The O
mean O
FVIIa O
activity O
was O
measurable O
for O
up O
to O
at O
least O
72 O
h O
after O
dosing O
, O
and O
the O
overall O
mean O
t O
( O
1/2 O
) O
for O
FVIIa O
activity O
was O
15 O
h. O
The O
pharmacokinetics O
of O
N7-GP O
appeared O
to O
be O
dose-proportional O
in O
the O
dose O
range O
investigated O
. O
[]

The O
Long-term O
Intervention O
with O
Pravastatin O
in O
Ischemic O
Heart O
Disease O
( O
LIPID O
) O
trial O
is O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
evaluating O
the O
long-term O
effect O
of O
pravastatin O
on O
coronary O
mortality O
in O
patients O
with O
a O
previous O
myocardial O
infarction O
or O
unstable O
angina-ischemic O
heart O
disease O
( O
IHD O
) O
. O
[]

An O
initial O
prospective O
, O
randomised O
, O
controlled O
trial O
( O
Study O
1 O
) O
, O
compared O
the O
safety O
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
( O
serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rabies I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
) O
after O
administration O
either O
of O
PHT-Erig O
or O
of O
a O
commercially-available O
, O
equine O
rabies O
immune O
globulin O
( O
Erig O
PMC O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
nucleoside O
analog O
( O
s O
) O
were/was O
infused O
over O
1 O
hour O
once O
daily O
for O
4 O
days O
, O
followed O
on O
each O
day O
by O
Bu O
, O
infused O
over O
3 O
hours O
to O
a O
pharmacokinetically O
targeted O
daily O
area O
under O
the O
curve O
( O
AUC O
) O
of O
6000 O
?Mol-min O
? O
[]

Primary O
and O
secondary O
target O
lesion O
patencies O
were O
determined O
by O
Kaplan-Meier O
analysis O
. O
[]

There O
was O
no O
significant O
difference O
in O
pain B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
overall I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
experienced O
between O
the O
two O
groups O
; O
however O
, O
the O
sensation O
of O
bad B-outcome ['Physiological-Clinical']
taste I-outcome ['Physiological-Clinical']
was O
significantly O
worse O
in O
the O
cophenylcaine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
received O
standardized O
postoperative O
analgesic O
, O
laxative O
and O
antibiotic O
treatment O
. O
[]

Nefazodone O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
, O
and O
the O
number O
of O
patients O
discontinuing O
owing O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
small O
, O
with O
no O
significant O
safety O
issues O
noted O
in O
either O
treatment O
group O
. O
['Life-Impact', 'Adverse-effects']

The O
t- O
and O
U-tests O
were O
used O
for O
statistical O
analyses O
. O
[]

Mild B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
11 O
cases O
( O
3.7 O
% O
) O
, O
moderate B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
3 O
cases O
( O
1.0 O
% O
) O
, O
and O
severe B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
1 O
case O
( O
0.3 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mann-Whitney O
U O
test O
and O
Friedman O
test O
were O
employed O
to O
analyze O
the O
program O
's O
effectiveness O
. O
[]

Headache B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
, O
presence O
or O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
functional B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
were O
assessed O
over O
a O
4-hour O
postdose O
period O
, O
and O
any O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

CONCLUSION O
These O
data O
indicate O
that O
the O
computerized O
WOMAC O
OA O
index O
3.0 O
is O
comparable O
to O
the O
paper O
WOMAC O
in O
all O
three O
dimensions O
. O
[]

RESULTS O
Chlorogenic O
acid O
and O
trigonelline O
ingestion O
significantly O
reduced O
glucose B-outcome ['Physiological-Clinical']
( O
-0.7 O
mmol/l O
, O
P O
= O
0.007 O
, O
and O
-0.5 O
mmol/l O
, O
P O
= O
0.024 O
, O
respectively O
) O
and O
insulin B-outcome ['Resource-use']
( O
-73 O
pmol/l O
, O
P O
= O
0.038 O
, O
and O
-117 O
pmol/l O
, O
P O
= O
0.007 O
) O
concentrations O
15 O
min O
following O
an O
OGTT O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Resource-use']

Interventions O
started O
when O
infants O
were O
stable O
and O
ceased O
when O
routine O
side-lying O
commenced O
. O
[]

This O
prospective O
randomized O
, O
double-blinded O
, O
dose-response O
study O
examined O
the O
anesthetic O
and O
recovery O
profiles O
of O
60- O
and O
80-mg O
doses O
of O
preservative-free O
plain O
mepivacaine O
for O
ambulatory O
spinal O
anesthesia O
. O
[]

Gastric O
biopsies O
were O
obtained O
at O
baseline O
, O
and O
at O
3 O
, O
6 O
, O
and O
12 O
years O
. O
[]

CONCLUSIONS O
This O
multifactorial O
method O
significantly O
decreases O
vaccination O
pain B-outcome ['Physiological-Clinical']
in O
4- O
to O
12-year-old O
children O
. O
['Physiological-Clinical']

Among O
the O
278 O
patients O
who O
completed O
6 O
weeks O
of O
active O
therapy O
, O
mean O
supine B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
from O
pretreatment O
baseline O
were O
5.9 O
, O
9.3 O
, O
9.2 O
, O
11.1 O
, O
and O
13.2 O
mm O
Hg O
in O
the O
placebo O
, O
20- O
, O
50- O
, O
100- O
, O
and O
150-mg O
groups O
, O
respectively O
. O
['Physiological-Clinical']

A O
numerical O
plaque O
index O
( O
0-5 O
) O
is O
described O
based O
on O
the O
presence O
and O
distribution O
of O
plaque O
in O
the O
fissures O
and O
over O
the O
occlusal O
surfaces O
of O
permanent O
molar O
and O
premolar O
teeth O
. O
[]

In O
experiment O
II O
we O
saw O
no O
difference O
in O
plasma B-outcome ['Physiological-Clinical']
Lp I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
after O
diets O
high O
in O
C16 O
and O
C14 O
. O
['Physiological-Clinical']

Campbell O
et O
al O
. O
( O
[]

However O
, O
at O
all O
points O
postsuctioning O
, O
EELV B-outcome ['Physiological-Clinical']
recovered O
more O
slowly O
after O
CS O
than O
after O
OS O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
All-cause O
mortality O
of O
women O
related O
to O
pregnancy O
, O
stillbirth O
, O
and O
infant O
mortality O
to O
12 O
weeks O
( O
84 O
days O
) O
following O
pregnancy O
outcome O
. O
[]

Defibrillation O
electrodes O
were O
positioned O
in O
the O
right O
atrial O
appendage O
and O
distal O
coronary O
sinus O
. O
[]

METHODS O
This O
Phase O
III O
, O
8-week O
, O
prospective O
, O
randomized O
, O
double-blind O
, O
parallel-group O
study O
was O
conducted O
in O
13 O
cardiology O
centers O
across O
the O
Republic O
of O
Korea O
. O
[]

Pentoxifylline O
therapy O
in O
HIV O
seropositive O
subjects O
with O
elevated O
TNF O
. O
[]

CONCLUSION O
The O
results O
suggest O
that O
administration O
of O
oral O
steroids O
before O
primary O
vitrectomy O
in O
eyes O
with O
combined O
RRD O
and O
CD O
improves O
reattachment O
rates O
. O
[]

Sixty-eight O
patients O
who O
completed O
the O
study O
experienced O
a O
significant O
decrease O
in O
bulimic B-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
after O
the O
8 O
weeks O
. O
['Life-Impact']

[ O
Results O
of O
a O
cooperative O
prospective O
study O
of O
treatment O
of O
primary O
digestive O
localizations O
of O
non-Hodgkin O
's O
lymphoma O
] O
. O
[]

CONCLUSIONS O
Initial O
results O
from O
this O
randomized O
, O
designed O
treatment O
study O
suggest O
that O
agroup O
CBT O
intervention O
specifically O
developed O
for O
children O
with O
ASD O
may O
be O
effective O
in O
decreasing O
anxiety O
. O
[]

Exercise O
time O
to O
onset O
of O
angina O
, O
total O
exercise O
duration O
and O
time O
to O
1 O
mm O
ST O
segment O
depression O
were O
all O
significantly O
increased O
after O
initial O
application O
during O
the O
continuous O
and O
intermittent O
treatment O
periods O
. O
[]

Risperidone O
treatment O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
significantly O
improved O
behavioral B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
associated O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Interactions O
between O
morphine O
and O
methotrimeprazine O
have O
been O
studied O
in O
mice O
and O
man O
with O
respect O
to O
analgesia B-outcome ['Resource-use']
or I-outcome ['Resource-use']
antinociceptive I-outcome ['Resource-use']
activity I-outcome ['Resource-use']
, O
respiratory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Erythema O
migrans O
: O
comparison O
of O
treatment O
with O
azithromycin O
, O
doxycycline O
and O
phenoxymethylpenicillin O
. O
[]

Substitution O
of O
physically O
active O
for O
sedentary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
changes O
in O
activity B-outcome ['Life-Impact']
level O
predicted O
6- O
and O
12-month O
z-BMI B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Laryngeal O
preservation O
with O
induction O
chemotherapy O
for O
hypopharyngeal O
squamous O
cell O
carcinoma O
: O
10-year O
results O
of O
EORTC O
trial O
24891 O
. O
[]

METHODS O
This O
was O
a O
prospective O
, O
randomized O
controlled O
experiment O
to O
compare O
whether O
narrative O
versus O
summary O
promoted O
short-term O
recall O
of O
six O
themes O
contained O
in O
the O
ACEP O
opioid O
guideline O
. O
[]

Patients O
with O
diminutive O
polyps O
in O
the O
rectum O
or O
sigmoid O
colon O
were O
randomized O
to O
hot O
biopsy O
treatment O
for O
either O
1 O
) O
electrocautery O
for O
2 O
s O
( O
fixed O
duration O
cautery O
) O
or O
2 O
) O
cautery O
until O
visible O
necrosis O
of O
the O
polyp O
base O
was O
evident O
( O
variable O
duration O
cautery O
) O
. O
[]

CONCLUSION O
For O
postgraduate O
nurses O
, O
daylong O
cancer O
pain O
education O
workshops O
were O
, O
in O
the O
group O
studied O
, O
as O
effective O
as O
hands-on O
experience O
in O
improving O
cancer B-outcome ['Life-Impact']
pain I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
changing O
attitudes B-outcome ['Life-Impact']
. O
['Life-Impact']

Patients O
suffering O
from O
moderate O
to O
severe O
pain O
following O
surgery O
were O
monitored O
for O
up O
to O
8 O
hours O
. O
[]

Our O
findings O
suggest O
one O
potential O
source O
of O
these O
results O
was O
a O
divergence O
between O
student O
and O
educator O
conceptions O
for O
structuring O
the O
practice O
of O
cardiac O
auscultation O
skills O
. O
[]

Furthermore O
, O
the O
effect O
of O
shearing O
on O
thermoregulative B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
sheep O
has O
not O
been O
adequately O
studied O
under O
temperate O
environmental O
conditions O
. O
['Physiological-Clinical']

Patients O
were O
divided O
into O
two O
groups O
on O
the O
basis O
of O
a O
dual-isotope O
mixed-meal O
study O
of O
their O
gastric O
emptying O
( O
GE O
) O
. O
[]

Rest O
periods O
were O
also O
allowed O
if O
necessary O
. O
[]

BACKGROUND O
There O
is O
little O
evidence O
for O
the O
optimal O
form O
of O
nonoperative O
treatment O
in O
the O
management O
of O
frozen O
shoulder O
. O
[]

OBJECTIVES O
To O
compare O
the O
effects O
of O
the O
angiotensin O
receptor O
blocker O
( O
ARB O
) O
valsartan O
versus O
the O
calcium O
channel O
blocker O
amlodipine O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
formation O
by O
monocytes O
, O
C-reactive O
protein O
( O
CRP O
) O
, O
and O
left O
ventricular O
( O
LV O
) O
mass O
were O
studied O
in O
104 O
hypertensive O
patients O
with O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
. O
[]

Mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
as O
well O
as O
work B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
are O
all O
measures O
of O
functioning O
that O
have O
been O
used O
to O
evaluate O
treatment O
strategies O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Participants O
were O
stratified O
on O
the O
basis O
of O
radiation O
exposure O
and O
randomly O
assigned O
to O
treatment O
with O
either O
IFRS O
or O
stannous O
fluoride O
gel O
. O
[]

Treatment O
with O
recombinant O
interleukin O
2 O
prevented O
the O
postoperative O
fall O
in O
both O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
and O
lymphokine-activated B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
cytotoxicity I-outcome ['Physiological-Clinical']
, O
clearly O
demonstrated O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
show O
that O
advance O
knowledge O
about O
the O
nature O
of O
pending O
tasks O
led O
participants O
to O
delay O
visual O
interruption O
tasks O
the O
longest O
, O
which O
allowed O
them O
to O
avoid O
intramodal O
interference O
and O
scanning O
costs O
associated O
with O
performing O
these O
tasks O
concurrently O
with O
ATC O
tasks O
. O
[]

METHODS O
Using O
data O
from O
a O
randomised O
trial O
, O
multivariable O
proportional O
hazards O
models O
were O
generated O
to O
examine O
the O
impact O
of O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
established O
prognostic O
factors O
( O
performance O
status O
, O
calcium O
, O
and O
haemoglobin O
) O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
) O
. O
['Physiological-Clinical', 'Mortality']

RESULTS O
The O
study O
group O
included O
thirty-one O
female O
patients O
and O
twenty-five O
male O
patients O
with O
a O
combined O
average O
age O
of O
fifty O
years O
and O
an O
average O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
of O
30.9 O
. O
['Physiological-Clinical']

Despite O
its O
frequent O
use O
in O
clinical O
practice O
, O
no O
controlled O
clinical O
trial O
on O
the O
efficacy O
of O
bibrocathol O
2 O
% O
eye O
ointment O
has O
been O
performed O
until O
now O
. O
[]

The O
BMD B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lumbar I-outcome ['Physiological-Clinical']
vertebrae I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy B-outcome ['Resource-use']
X-ray I-outcome ['Resource-use']
absorptiometry I-outcome ['Resource-use']
at O
least O
twice O
, O
12-57 O
months O
apart O
. O
['Physiological-Clinical', 'Resource-use']

A O
three-part O
process O
evaluation O
was O
adopted O
to O
evaluate O
implementation O
success B-outcome ['Physiological-Clinical']
: O
an O
in-church O
instrument O
to O
assess O
the O
reach O
, O
dose B-outcome ['Life-Impact']
delivered I-outcome ['Life-Impact']
and O
fidelity B-outcome ['Life-Impact']
of O
interactive O
sessions O
; O
a O
post-intervention O
exposure B-outcome ['Physiological-Clinical']
survey O
to O
assess O
individual-level B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
received O
in O
a O
sample O
of O
congregants O
and O
an O
evaluation O
form O
to O
assess O
the O
church B-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
environment I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Based O
on O
behavioral O
studies O
demonstrating O
the O
potential O
efficacy O
of O
aerobic O
exercise O
for O
improving O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
cognitive B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Artesunate O
plus O
amodiaquine O
is O
a O
coblistered O
ACT O
, O
given O
as O
a O
single O
daily O
intake O
. O
[]

The O
changes O
in O
respiratory O
impedance O
were O
qualitatively O
similar O
for O
all O
three O
drug O
regimens O
, O
but O
larger O
in O
absolute O
terms O
after O
fenoterol O
and O
the O
combination O
regimen O
than O
after O
ipratropium O
. O
[]

In O
the O
ropivacaine O
and O
bupivacaine O
groups O
sensory O
anesthesia O
was O
considered O
adequate O
for O
surgery O
in O
all O
cases O
but O
one O
in O
each O
group O
; O
in O
the O
etidocaine O
group O
, O
however O
60 O
% O
of O
the O
patients O
showed O
[]

CONCLUSIONS O
Our O
study O
failed O
to O
show O
a O
beneficial O
effect O
of O
oral O
corticosteroids O
on O
allergen-specific O
immunotherapy O
. O
[]

Additionally O
, O
efforts O
will O
be O
made O
to O
define O
whether O
noninvasive O
hemodynamic O
parameters O
, O
retinal O
vessel O
measurement O
changes O
, O
or O
biologic B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
may O
predict O
and O
track O
the O
underlying O
vascular B-outcome ['Physiological-Clinical']
morphologic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
physiologic I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
induced O
by O
either O
regimen O
during O
the O
12-month O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Followup O
was O
done O
with O
diuretic O
scanning O
at O
3 O
, O
6 O
, O
9 O
and O
12 O
months O
and O
then O
yearly O
, O
and O
thereafter O
with O
diuretic O
renography O
. O
[]

DESIGN O
Prospective O
randomised O
controlled O
trial O
. O
[]

We O
evaluated O
the O
acute O
effects O
of O
decaffeinated O
coffee O
and O
the O
major O
coffee O
components O
chlorogenic O
acid O
and O
trigonelline O
on O
glucose O
tolerance O
. O
[]

A O
standard O
general O
anesthetic O
technique O
, O
including O
sevoflurane O
and O
air O
in O
oxygen O
, O
was O
used O
. O
[]

An O
analysis O
of O
the O
effects O
of O
test O
order O
yielded O
non-significant O
differences O
for O
basic O
TOVA O
variables O
across O
all O
four O
quarters O
, O
both O
halves O
and O
the O
total O
score O
. O
[]

Urine O
samples O
were O
collected O
at O
intake O
, O
on O
Wednesday O
, O
Friday O
( O
the O
last O
day O
of O
detoxification O
) O
, O
and O
the O
following O
Monday O
. O
[]

Immunogenicity B-outcome ['Physiological-Clinical']
of O
the O
acellular O
vaccines O
, O
persistence O
of O
antibodies O
and O
adverse O
reactions O
were O
compared O
with O
those O
achieved O
with O
a O
whole-cell O
diphtheria-pertussis-tetanus O
( O
DPT O
) O
vaccine O
. O
['Physiological-Clinical']

One-year O
and O
4-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
in O
the O
PRE O
group O
were O
100 O
% O
and O
86 O
% O
respectively O
and O
100 O
% O
and O
60 O
% O
in O
the O
POST O
group O
( O
p O
= O
0.520 O
) O
. O
['Mortality']

The O
purpose O
of O
this O
report O
is O
to O
describe O
in O
greater O
detail O
the O
heterogeneity O
of O
this O
population O
at O
baseline O
with O
particular O
reference O
to O
the O
impact O
of O
symptomatic O
severity O
, O
age O
and O
gender O
on O
patient O
characteristics O
. O
[]

OBJECTIVE O
To O
test O
the O
feasibility B-outcome ['Life-Impact']
and O
effect O
of O
nurse O
run O
epilepsy O
clinics O
in O
primary O
care O
. O
['Life-Impact']

After O
elimination O
of O
carious O
lesions O
, O
a O
prophylaxis O
was O
given O
to O
both O
groups O
. O
[]

RESULTS O
With O
a O
median O
follow-up O
of O
26.3 O
months O
( O
range O
3-74.6 O
months O
) O
, O
59 O
% O
of O
patients O
in O
the O
cisplatin O
arm O
completed O
the O
planned O
concurrent O
chemoradiation O
treatment O
, O
compared O
to O
73 O
% O
in O
the O
carboplatin O
arm O
. O
[]

By O
means O
of O
suitable O
control O
methods O
a O
causal O
non-medicamentously O
conditioned O
decrease O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
could O
be O
excluded O
. O
['Physiological-Clinical']

METHODS O
Pulse O
and O
mean O
arterial O
pressure O
were O
analyzed O
for O
their O
effect O
on O
mortality B-outcome ['Mortality']
, O
adjusting O
for O
other O
modifiers O
of O
risk O
, O
using O
Cox O
proportional O
hazards O
regression O
analysis O
of O
data O
collected O
from O
6,781 O
patients O
randomized O
into O
the O
Studies O
of O
Left O
Ventricular O
Dysfunction O
trials O
. O
['Mortality']

Results O
indicate O
that O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
gains I-outcome ['Life-Impact']
were O
greater O
for O
both O
treatment O
groups O
compared O
with O
the O
control O
group O
, O
and O
results O
could O
not O
be O
explained O
by O
differences O
in O
other O
interventions O
in O
which O
children O
participated O
. O
['Life-Impact']

A O
randomized O
double O
blind O
placebo O
controlled O
trial O
to O
determine O
the O
efficacy O
and O
safety O
of O
combined-herbs O
( O
SH O
) O
given O
with O
zidovudine O
( O
ZDV O
) O
and O
zalcitabine O
( O
ddC O
) O
for O
the O
treatment O
of O
HIV O
infection O
in O
Thai O
adults O
was O
conducted O
in O
3 O
hospitals O
in O
northern O
Thailand O
during O
2002 O
to O
2003 O
. O
[]

A O
highly O
significant O
degree O
of I-outcome ['Physiological-Clinical']
discolouration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
all I-outcome ['Physiological-Clinical']
parts I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
cavity I-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
treated O
with O
CBS O
chewing O
tablets O
, O
whereas O
only O
a O
few O
patients O
treated O
with O
CBS O
coated O
tablets O
experienced O
a O
slight B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tongue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
Gingival O
overgrowth O
associated O
with O
immunosuppression O
following O
liver O
transplantation O
is O
a O
commonly O
recognized O
clinical O
problem O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
test O
results O
after O
placebo O
and O
after O
progesterone O
. O
[]

The O
current O
study O
examined O
the O
predictors O
of O
postpartum O
maternal O
attachment O
in O
a O
sample O
of O
217 O
Latina O
women O
enrolled O
in O
a O
perinatal O
depression O
prevention O
trial O
. O
[]

The O
impact O
of O
glutamine O
substitution O
on O
postoperative O
immunosuppression O
and O
morbidity O
was O
investigated O
in O
patients O
with O
surgical O
interventions O
and O
total O
parenteral O
nutrition O
in O
a O
prospective O
randomized O
trial O
. O
[]

Gefitinib O
or O
placebo O
in O
combination O
with O
tamoxifen O
in O
patients O
with O
hormone B-outcome ['Physiological-Clinical']
receptor-positive I-outcome ['Physiological-Clinical']
metastatic I-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
: O
a O
randomized O
phase O
II O
study O
. O
['Physiological-Clinical']

Risperidone O
in O
the O
treatment O
of O
negative O
symptoms B-outcome ['Life-Impact']
of O
schizophrenia O
: O
a O
meta-analysis O
. O
['Life-Impact']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Concentrations O
of O
itraconazole O
were O
determined O
using O
a O
microbiologic O
assay O
. O
[]

Report O
on O
the O
second O
myelomatosis O
trial O
after O
five O
years O
of O
follow-up O
. O
[]

However O
, O
bronchial O
biopsies O
demonstrated O
that O
cilomilast O
treatment O
was O
associated O
with O
reductions O
in O
CD8+ B-outcome ['Physiological-Clinical']
( O
p O
= O
0.001 O
; O
ANOVA O
) O
and O
CD68+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
; O
ANOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Only O
a O
credentialed O
surgeon O
can O
be O
responsible O
for O
both O
open O
distal O
gastrectomy O
and O
laparoscopy-assisted O
distal O
gastrectomy O
. O
[]

RESULTS O
Both O
treatments O
resulted O
in O
significant O
and O
progressive O
improvement O
in O
overall O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
at O
follow-up O
( O
F O
= O
2 O
, O
97 O
, O
p O
=.007 O
) O
and O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
significantly O
improved O
over O
time O
in O
the O
54 O
% O
of O
principal O
caregivers O
who O
had O
the O
highest O
levels O
of O
mental O
health O
problems O
. O
['Life-Impact', 'Life-Impact']

Patients O
in O
the O
5-fluorouracil O
group O
had O
a O
higher O
risk O
of O
late-onset B-outcome ['Physiological-Clinical']
bleb I-outcome ['Physiological-Clinical']
leaks I-outcome ['Physiological-Clinical']
( O
9 O
% O
nine O
of O
105 O
) O
than O
those O
in O
the O
standard O
filtering O
surgery O
group O
( O
2 O
% O
two O
of O
108 O
) O
( O
P O
= O
.032 O
, O
Fisher O
's O
exact O
test O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
investigate O
the O
short-term O
effects O
of O
nonsurgical O
therapy O
( O
scaling O
and O
root O
planing O
, O
SRP O
) O
on O
the O
subgingival O
microbiota O
in O
chronic O
( O
CP O
) O
and O
aggressive O
( O
AP O
) O
periodontal O
disease O
. O
[]

Neither O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
nor O
survival I-outcome ['Mortality']
in O
these O
subgroups O
was O
significantly O
influenced O
by O
treatment O
. O
['Mortality']

The O
present O
study O
aimed O
to O
observe O
effects O
of O
medical O
ozone O
therapy O
system O
on O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
PRA B-outcome ['Physiological-Clinical']
) O
, O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
( O
AII O
) O
, O
aldosterone B-outcome ['Physiological-Clinical']
( O
ALD B-outcome ['Physiological-Clinical']
) O
, O
renal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
patients O
with O
chronic O
severe O
hepatitis O
and O
explore O
mechanisms O
of O
medical O
ozone O
therapy O
in O
the O
treatment O
of O
severe O
hepatitis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Primary O
outcomes O
were O
18-month O
survival B-outcome ['Mortality']
free I-outcome ['Mortality']
of I-outcome ['Mortality']
all-cause I-outcome ['Mortality']
hospitalizations I-outcome ['Mortality']
and O
quality O
of O
life O
as O
assessed O
by O
structured O
validated O
questionnaires O
. O
['Mortality']

The O
primary O
outcome O
variable O
is O
change O
in O
percent O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Are O
tyrosine O
kinase O
inhibitors O
still O
active O
in O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
previously O
treated O
with O
a O
tyrosine O
kinase O
inhibitor O
and O
everolimus O
? O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
D-cycloserine I-outcome ['Physiological-Clinical']
, O
relevant B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
order O
to O
estimate O
the O
influence O
of O
a O
non-medicamentous O
therapy O
( O
CNT O
) O
on O
the O
consumption O
of O
medicaments O
and O
coronary O
risk O
in O
high O
blood O
pressure O
73 O
hypertensives O
of O
a O
medicamentously O
stabilized O
CNT-group O
were O
examined O
in O
comparison O
to O
a O
group O
of O
the O
same O
size O
of O
patients O
with O
hypertension O
who O
were O
managed O
exclusively O
medicamentously O
for O
behaviour O
of O
blood O
pressure O
, O
need O
of O
antihypertensive O
drugs O
and O
changes O
of O
hypertension-associated O
risk O
factors O
. O
[]

Symptom O
diaries O
were O
filled O
during O
the O
study O
periods O
. O
[]

Pretreatment O
with O
ranitidine O
had O
no O
effect O
on O
the O
disposition O
of O
intravenously B-outcome ['Resource-use']
administered I-outcome ['Resource-use']
triazolam I-outcome ['Resource-use']
but O
significantly O
increased O
the O
area O
under O
the O
serum B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentration-time O
curve O
of O
oral B-outcome ['Physiological-Clinical']
triazolam B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
pilot O
study O
with O
adjuvant O
hormone O
therapy O
in O
FIGO O
stage O
I O
endometrial O
carcinoma O
with O
myometrial O
invasion O
was O
carried O
out O
. O
[]

Both O
eye O
gaze O
and O
arrow O
pointing O
distractors O
resulted O
in O
overt B-outcome ['Life-Impact']
cueing I-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
, O
both O
in O
terms O
of O
increased O
saccadic B-outcome ['Life-Impact']
reaction I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
and O
in O
proportions O
of O
saccades B-outcome ['Life-Impact']
executed I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
cued I-outcome ['Life-Impact']
direction I-outcome ['Life-Impact']
instead O
of O
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
target B-outcome ['Life-Impact']
, O
for O
both O
participant O
groups O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Cellular O
markers O
were O
chosen O
to O
assess O
general B-outcome ['Physiological-Clinical']
pediatric I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
emphasizing B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
and O
activation O
of O
B O
, O
T B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
ovarian O
cancers O
of O
stage O
1 O
and O
stage O
2 O
, O
a O
post-operative O
prophylactic O
chemotherapy O
is O
useful O
only O
in O
cases O
with O
tumor O
cells O
in O
the O
secretions O
of O
the O
pouch O
of O
Douglas O
or O
in O
the O
ascites O
and O
in O
cases O
where O
a O
sensitivity O
to O
the O
chemotherapy O
can O
be O
assumed O
. O
[]

Patients O
with O
short-term O
successful O
and O
unsuccessful O
GHQ O
outcomes O
were O
compared O
for O
mid-term O
maintenance O
of O
success O
, O
1-year O
death O
and O
readmission O
rates O
, O
and O
1-year O
depression O
and O
anxiety O
symptoms O
. O
[]

4 O
. O
[]

However O
, O
it O
is O
not O
known O
whether O
this O
can O
be O
done O
accurately O
. O
[]

METHODS O
Ninety-five O
consecutive O
primary O
carotid O
endarterectomies O
were O
performed O
in O
a O
prospective O
randomized O
fashion O
in O
92 O
patients O
. O
[]

The O
comparison O
between O
the O
two O
groups O
after O
the O
treatment O
showed O
that O
the O
improvement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
FMA I-outcome ['Physiological-Clinical']
score O
in O
the O
observation O
group O
was O
significantly O
better O
than O
the O
control O
group O
( O
P O
< O
0.05 O
or O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Blood O
samples O
were O
obtained O
from O
the O
antecubital O
vein O
before O
each O
exercise O
test O
, O
1 O
min O
after O
completing O
the O
test O
and O
after O
a O
24-hr O
recovery O
period O
. O
[]

The O
mechanisms O
of O
FZ O
in O
the O
treatment O
of O
peptic O
ulcer O
disease O
are O
not O
fully O
understood O
, O
perhaps O
partly O
due O
to O
the O
monoamine B-outcome ['Physiological-Clinical']
oxidase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MAO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
inhibitory I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
and O
partly O
to O
the O
antibacterial B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
( O
HP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
survival O
, O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
and O
rates O
of O
adverse O
events O
( O
AEs O
) O
and O
serious O
AEs O
were O
similar O
between O
groups O
. O
['Physiological-Clinical']

The O
OPTIMA O
study O
. O
[]

They O
were O
divided O
randomly O
by O
a O
physician O
into O
2 O
groups O
of O
30 O
patients O
each O
for O
5 O
sessions O
of O
active O
treatment O
( O
30 O
mg O
of O
ketorolac O
) O
or O
placebo O
( O
5 O
mL O
of O
normal O
saline O
) O
. O
[]

Response O
was O
measured O
clinically B-outcome ['Physiological-Clinical']
and O
by O
computed O
tomography O
of O
the O
brain O
. O
['Physiological-Clinical']

Oxytocin O
might O
reduce O
the O
incidence O
of O
manual B-outcome ['Physiological-Clinical']
lysis I-outcome ['Physiological-Clinical']
of O
the O
['Physiological-Clinical']

A O
Siemens/CTI O
931/08-12 O
scanner O
with O
the O
capability O
of O
15 O
horizontal O
brain O
slices O
was O
used O
. O
[]

Anaesthesia O
was O
standardized O
with O
propofol O
, O
nitrous O
oxide O
and O
enflurane O
. O
[]

22.60 O
) O
pg/ml O
, O
which O
decreased O
significantly O
compared O
with O
those O
before O
treatment O
( O
PRA O
( O
2.23 O
? O
[]

A O
bimodal O
pattern O
appeared O
, O
with O
a O
frequency O
of O
57.1 O
% O
for O
20 O
CA O
repeats O
and O
18.6 O
% O
for O
16 O
CA O
repeats O
. O
[]

Physical O
activity O
in O
first-degree O
relatives O
of O
breast O
cancer O
patients O
. O
[]

RESULTS O
The O
participants O
were O
as O
satisfied B-outcome ['Life-Impact']
with O
the O
Internet-based O
training O
as O
with O
a O
face-to-face O
group O
training O
. O
['Life-Impact']

Two O
subjects O
from O
the O
active O
group O
and O
one O
subject O
from O
the O
placebo O
group O
discontinued O
the O
study O
because O
of O
either O
a O
lack O
of O
efficacy O
or O
side O
effects O
( O
increased O
irritability O
) O
. O
[]

The O
groups O
were O
comparable O
with O
regard O
to O
age O
, O
sex O
and O
prednisone O
dose O
. O
[]

Uncomplicated O
moderate O
coronary O
artery O
dissections O
after O
balloon O
angioplasty O
: O
good O
outcome O
without O
stenting O
. O
[]

The O
most O
commonly O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
all O
with O
incidence O
of O
5 O
% O
or O
less O
) O
among O
patients O
receiving O
rizatriptan O
were O
dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
asthenia/fatigue B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anyway O
we O
think O
that O
in O
severe O
forms O
SLN O
should O
be O
preferred O
for O
the O
shorter O
time O
preceding O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

n=9 O
) O
were O
removed O
( O
Wilcoxon O
test O
: O
P-value=0.031 O
; O
Student O
's O
t-test O
: O
P-value=0.017 O
) O
. O
[]

70 O
tendons O
were O
included O
and O
randomised O
into O
one O
of O
two O
treatment O
groups O
: O
eccentric O
exercises O
with O
a O
night O
splint O
( O
night O
splint O
group O
, O
n O
= O
36 O
) O
or O
eccentric O
exercises O
only O
( O
eccentric O
group O
, O
n O
= O
34 O
) O
. O
[]

Three O
years O
after O
surgery O
, O
the O
rate O
of O
PCO B-outcome ['Physiological-Clinical']
was O
analysed O
using O
the O
evaluation O
of O
posterior O
capsule O
opacification O
computer O
software O
( O
EPCO O
) O
. O
['Physiological-Clinical']

Treatments O
included O
involved O
field O
, O
total O
lymphoid O
, O
or O
whole O
body O
irradiation O
, O
single O
alkylating O
agent O
chemotherapy O
, O
combination O
chemotherapy O
with O
cyclophosphamide O
, O
vincristine O
and O
prednisone O
( O
CVP O
) O
or O
with O
cyclophosphamide O
, O
vincristine O
, O
procarbazine O
, O
and O
prednisone O
( O
C-MOPP O
) O
, O
or O
various O
combinations O
of O
chemotherapy O
and O
irradiation O
. O
[]

Patients O
in O
both O
groups O
were O
similar O
initially O
. O
[]

Their O
median O
age O
at O
referral O
was O
13.5 O
months O
( O
range O
2.5 O
to O
29 O
months O
) O
. O
[]

Hence O
, O
this O
treatment O
should O
be O
continued O
in O
the O
acute O
phase O
of O
ischemic O
stroke O
. O
[]

The O
fifth O
regimen O
was O
a O
single O
local O
application O
( O
LA O
) O
. O
[]

Adverse B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
behavioral O
, O
mild O
, O
and O
transient O
. O
['Adverse-effects']

After O
3 O
months O
, O
similar O
anti-anginal O
efficacy O
was O
observed O
between O
the O
trimetazidine O
( O
n O
= O
71 O
) O
and O
propranolol O
( O
n O
= O
78 O
) O
groups O
. O
['Physiological-Clinical']

Hematologic B-outcome ['Physiological-Clinical']
and O
nonhematologic O
toxicities I-outcome ['Physiological-Clinical']
were O
mild O
to O
moderate O
. O
['Physiological-Clinical']

58 O
participants O
aged O
11-16 O
years-old O
were O
randomly O
assigned O
to O
either O
an O
immediate O
treatment O
or O
waitlist O
comparison O
group O
. O
[]

Subjects O
were O
randomized O
to O
receive O
i.v. O
, O
one O
of O
ondansetron O
4 O
mg O
, O
droperidol O
1.25 O
mg O
, O
perphenazine O
5 O
mg O
, O
metoclopramide O
10 O
mg O
, O
or O
placebo O
prior O
to O
induction O
of O
anesthesia O
. O
[]

The O
mean O
survival B-outcome ['Mortality']
time O
was O
6.6 O
months O
in O
arm O
1 O
and O
7.7 O
months O
in O
arm O
2. O
WHO O
grade O
4 O
toxicity B-outcome ['Adverse-effects']
was O
encountered O
in O
25.5 O
and O
15.8 O
% O
of O
patients O
in O
arm O
1 O
and O
2 O
, O
respectively O
. O
['Mortality', 'Adverse-effects']

Although O
the O
2 O
therapies O
showed O
comparable O
mean O
effects O
for O
decreasing O
LDL-C B-outcome ['Physiological-Clinical']
, O
similar O
adverse O
reaction O
and O
cost O
, O
each O
therapy O
was O
predominantly O
more O
effective O
in O
some O
patients O
than O
in O
others O
. O
['Physiological-Clinical']

1 O
capsule O
on O
morphology B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
motility I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
in O
patients O
with O
oligospermia O
] O
. O
['Physiological-Clinical']

OBJECTIVE O
Hypertension O
is O
a O
chronic O
disorder O
with O
a O
high O
prevalence O
worldwide O
. O
[]

Significant O
and O
equivalent O
decreases O
in O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
high B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
density I-outcome ['Life-Impact']
foods I-outcome ['Life-Impact']
, O
increases O
in O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
fruits B-outcome ['Life-Impact']
and O
vegetables B-outcome ['Life-Impact']
, O
and O
decreases O
in O
standardized O
body O
mass O
index O
( O
z-BMI O
) O
were O
observed O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

in O
health O
care O
settings O
devoted O
to O
cancer O
care O
is O
beginning O
to O
be O
recognised O
but O
their O
content O
, O
form O
and O
effectiveness O
need O
further O
investigation O
. O
[]

PARTICIPANTS O
24 O
practice O
nurses O
, O
trained O
in O
10-year O
cardiovascular O
risk O
assessment O
, O
calculated O
the O
risk O
of O
a O
total O
of O
421 O
patients O
without O
established O
cardiovascular O
diseases O
but O
eligible O
for O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
assessment O
. O
['Physiological-Clinical']

However O
, O
there O
were O
significant O
increases O
in O
the O
weight O
( O
p O
= O
.008 O
) O
, O
body O
mass O
index O
( O
p O
= O
.007 O
) O
, O
and O
waist B-outcome ['Physiological-Clinical']
( O
p O
= O
.018 O
) O
and O
hip B-outcome ['Physiological-Clinical']
( O
p O
= O
.003 O
) O
circumferences B-outcome ['Physiological-Clinical']
of O
the O
subjects O
receiving O
the O
placebo O
drink O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
assess O
and O
compare O
the O
effectiveness O
of O
3 O
% O
diclofenac O
sodium O
associated O
with O
2.5 O
% O
hyaluronic O
acid O
and O
of O
5 O
% O
5-Fluorouracil O
for O
the O
treatment O
of O
actinic O
keratosis O
, O
as O
well O
as O
the O
patient O
's O
degree O
of O
satisfaction O
and O
tolerability O
. O
[]

ANIMALS O
46 O
dogs O
housed O
in O
animal O
shelters O
and O
undergoing O
elective O
orchiectomy O
or O
ovariohysterectomy O
. O
[]

There O
was O
no O
apparent O
impact O
on O
red O
cell O
transfusion O
requirements O
, O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
or O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

We O
examined O
the O
perceptual O
rules O
governing O
contour O
saliency O
to O
determine O
whether O
the O
spatial O
extents O
of O
contextual O
interactions O
and O
horizontal O
connections O
match O
those O
mediating O
saliency O
. O
[]

Compared O
with O
nonsmokers O
, O
smokers O
had O
3-fold O
median O
M-CSF B-outcome ['Physiological-Clinical']
( O
1499 O
vs O
476 O
pg/mL O
) O
, O
2-fold O
CRP B-outcome ['Physiological-Clinical']
( O
1.5 O
vs O
0.8 O
mg/L O
) O
, O
and O
higher O
11-dehydro-TXB B-outcome ['Physiological-Clinical']
2 O
( O
3.6 O
vs O
2.1 O
ng/mg O
creatinine O
, O
P O
< O
.01 O
for O
all O
comparisons O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
distal O
tibiofibular O
joint O
manipulation O
group O
demonstrated O
a O
significant O
increase O
( O
P O
< O
.05 O
) O
in O
soleus B-outcome ['Physiological-Clinical']
H/M I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
at O
all O
post-intervention O
time O
periods O
except O
20 O
min O
post-intervention O
( O
P=.48 O
) O
. O
['Physiological-Clinical']

Each O
slide O
presented O
an O
item O
from O
an O
intelligence O
test O
, O
to O
which O
the O
subjects O
were O
either O
allowed O
to O
answer O
successfully O
( O
success O
) O
or O
not O
( O
failure O
) O
. O
[]

Results O
were O
similar O
for O
pedometer O
measured O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
with O
a O
significant O
overall O
increase O
in O
steps/day O
from O
baseline O
to O
follow-up O
, O
but O
no O
between O
arm O
difference O
in O
change O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
A O
randomized O
phase O
II O
study O
in O
first-line O
MBC O
demonstrated O
superior O
efficacy O
and O
safety O
of O
weekly O
nab-paclitaxel O
compared O
with O
docetaxel O
. O
[]

BACKGROUND O
AND O
STUDY O
AIMS O
A O
prepackaged O
low O
residue O
one-day O
diet O
( O
breakfast O
, O
lunch O
and O
dinner O
) O
has O
been O
recently O
developed O
to O
improve O
patient O
tolerance O
for O
bowel B-outcome ['Physiological-Clinical']
preparation I-outcome ['Physiological-Clinical']
prior O
to O
colonoscopy O
. O
['Physiological-Clinical']

Diets O
were O
identical O
except O
for O
7 O
% O
of O
energy O
provided O
by O
oleic O
acid O
( O
control O
diet O
) O
, O
iTFA O
, O
or O
CLA O
. O
[]

DESIGN O
Data O
from O
a O
randomized O
, O
placebo-controlled O
clinical O
trial O
of O
bupropion O
SR O
were O
submitted O
to O
mediation O
analyses O
. O
[]

The O
subjects O
( O
n O
= O
45 O
) O
were O
randomized O
into O
three O
groups O
without O
regard O
to O
age O
, O
sex O
, O
or O
race O
. O
[]

Effectiveness O
of O
nonpharmacologic O
treatments O
for O
acute O
seasonal O
allergic O
conjunctivitis O
. O
[]

RESULTS O
Patients O
' O
completion O
of O
the O
QLQ-C30 O
and O
SSQ O
exceeded O
95 O
% O
. O
[]

Prolonged O
ECC O
and O
CONC O
training O
equally O
stimulated O
muscle O
hypertrophy O
and O
produced O
increases O
in O
MRTF-A B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
of O
125 O
% O
and O
99 O
% O
, O
respectively O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
The O
efficacy O
of O
the O
vaccine O
had O
begun O
to O
drop O
11 O
years O
after O
immunization O
, O
which O
should O
be O
followed O
up O
further O
to O
reach O
a O
clear O
conclusion O
. O
[]

O O
) O
, O
FIGO O
stage O
( O
96 O
% O
stage O
III O
) O
, O
histology O
( O
serous O
in O
66 O
% O
) O
, O
grade O
( O
2 O
or O
3 O
in O
80 O
% O
) O
, O
and O
residuum O
before O
intravenous O
CT O
( O
> O
1 O
cm O
in O
40 O
% O
) O
. O
[]

However O
, O
the O
actuarial O
risk O
for O
conversion B-outcome ['Life-Impact']
was O
actually O
much O
greater O
( O
60 O
% O
at O
8 O
yr O
) O
. O
['Life-Impact']

The O
effect O
of O
knee O
position O
on O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
range O
of O
motion B-outcome ['Life-Impact']
following O
total O
knee O
arthroplasty O
. O
['Physiological-Clinical', 'Life-Impact']

No O
differences O
were O
seen O
between O
the O
two O
treatment O
groups O
with O
regard O
to O
demographic O
parameters O
and O
clinical O
histories O
. O
[]

Over-correction O
is O
not O
necessary O
. O
[]

While O
previous O
theoretical O
approaches O
to O
understanding O
autism O
have O
emphasized O
social O
impairments O
and O
altered O
interpersonal O
interactions O
, O
there O
is O
a O
recent O
shift O
towards O
understanding O
the O
nature O
of O
the O
representation O
of O
the O
self O
in O
individuals O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

DESIGN O
Prospective O
, O
blinded O
trial O
. O
[]

BACKGROUND O
Even O
though O
there O
is O
research O
demonstrating O
a O
positive O
relationship O
between O
leisure O
participation O
and O
the O
two O
constructs O
of O
quality O
of O
life O
and O
stress O
reduction O
, O
current O
conceptualisation O
of O
leisure O
as O
a O
contributor O
to O
quality O
of O
life O
is O
limited O
. O
[]

Parents O
' O
state O
and O
trait O
anxiety O
: O
relationships O
with O
anxiety B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
and O
treatment O
response O
in O
adolescents O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

At O
the O
same O
times O
the O
controls O
were O
given O
12.5 O
g O
human O
albumin O
each O
. O
[]

Behavioral B-outcome ['Life-Impact']
assessments O
were O
obtained O
before O
and O
at O
12 O
weeks O
of O
treatment O
. O
['Life-Impact']

Low-molecular-weight O
heparin O
offers O
safe O
and O
easily O
administered O
thromboprophylaxis O
in O
total O
hip O
replacement O
. O
[]

No O
significant O
differences O
in O
peak O
[]

The O
subjects O
were O
randomized O
to O
receive O
probiotic O
lactobacilli O
vaginal O
tablets O
( O
L. O
brevis O
CD2 O
, O
L. O
salivarius O
subsp O
. O
[]

Ibutilide O
and O
procainamide O
compared O
with O
placebo O
markedly O
reduced O
( O
p O
< O
0.001 O
) O
the O
incidence O
of O
pacing-induced B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Placebo-controlled O
, O
double-blind O
study O
in O
80 O
patients O
with O
first O
and O
second O
degree O
hemorrhoids O
; O
duration O
of O
treatment O
one O
week O
; O
examinations O
performed O
on O
admission O
and O
on O
days O
3 O
, O
4 O
, O
5 O
and O
8 O
. O
[]

7.87 O
, O
p O
= O
0.003 O
. O
[]

A O
comparison O
of O
laparoscopically O
assisted O
and O
open O
colectomy O
for O
colon O
cancer O
. O
[]

midazolam O
and O
0.98 O
( O
0.82 O
, O
1.17 O
) O
for O
that O
of O
oral O
midazolam O
with O
and O
without O
roflumilast O
. O
[]

Specifically O
, O
it O
is O
proposed O
that O
attitude O
certainty O
can O
be O
conceptualized O
, O
and O
empirically O
separated O
, O
in O
terms O
of O
attitude O
clarity O
( O
the O
subjective O
sense O
that O
one O
knows O
what O
one O
's O
attitude O
is O
) O
and O
attitude O
correctness O
( O
the O
subjective O
sense O
that O
one O
's O
attitude O
is O
correct O
or O
valid O
) O
. O
[]

RESULTS O
Data O
were O
analyzed O
for O
101 O
tumors O
. O
[]

We O
also O
aimed O
to O
monitor O
these O
patients O
' O
renal B-outcome ['Physiological-Clinical']
safety O
, O
and O
to O
compare O
their O
time O
in O
clinic O
to O
receive O
P O
and O
Z O
infusions O
. O
['Physiological-Clinical']

SETTING O
University-affiliated O
hospital O
. O
[]

In O
this O
paper O
, O
a O
novel O
red O
lesion O
detection O
method O
is O
presented O
based O
on O
a O
hybrid O
approach O
, O
combining O
prior O
works O
by O
Spencer O
et O
al O
. O
( O
[]

Second-line O
therapy O
in O
the O
treatment O
failures O
was O
of O
no O
benefit O
. O
[]

BACKGROUND O
The O
primary O
objective O
of O
this O
prospective O
randomized O
controlled O
trial O
was O
to O
compare O
functional B-outcome ['Life-Impact']
and O
quality-of-life B-outcome ['Life-Impact']
indices O
and O
rates O
of O
revision B-outcome ['Physiological-Clinical']
surgery I-outcome ['Physiological-Clinical']
in O
arthroscopic O
rotator O
cuff O
repair O
with O
and O
without O
acromioplasty O
. O
['Life-Impact', 'Physiological-Clinical']

For O
85 O
children O
( O
58.2 O
% O
) O
, O
the O
sleeplessness O
was O
attributed O
to O
inappropriate O
sleep O
habits O
. O
[]

A O
laser-powered O
hydrokinetic O
system O
for O
caries O
removal O
and O
cavity O
preparation O
. O
[]

Although O
the O
REGRESS O
trial O
was O
not O
designed O
to O
evaluate O
combination O
therapy O
, O
the O
results O
suggest O
that O
addition O
of O
CCBs O
to O
HMG-CoA O
reductase O
inhibitor O
therapy O
( O
pravastatin O
) O
acts O
synergistically O
in O
retarding O
the O
progression O
of O
established B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

or O
equivalent O
placebo O
. O
[]

One O
hundred O
and O
twenty O
four O
randomly O
selected O
patients O
with O
DBU O
were O
included O
in O
this O
prospective O
study O
. O
[]

In O
contrast O
to O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
a O
fall O
in O
inflammatory O
activity O
stimulated O
and O
impairment O
of O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
significantly O
decreased O
osteocalcin O
levels O
in O
patients O
with O
RA O
. O
['Physiological-Clinical', 'Life-Impact']

EXPERIMENTAL O
DESIGN O
Patients O
with O
newly O
diagnosed O
metastatic O
breast O
cancer O
or O
locally O
recurrent O
breast O
cancer O
received O
600 O
mg/m O
( O
2 O
) O
( O
P600 O
arm O
) O
or O
900 O
mg/m O
( O
2 O
) O
( O
P900 O
arm O
) O
of O
pemetrexed O
on O
day O
1 O
of O
a O
21-day O
cycle O
. O
[]

Twenty-one O
HIV-seropositive O
patients O
were O
randomized O
to O
receive O
either O
beta-carotene O
, O
180 O
mg/day O
or O
placebo O
for O
4 O
weeks O
, O
and O
then O
crossed O
over O
to O
receive O
the O
alternative O
treatment O
for O
the O
following O
4 O
weeks O
. O
[]

The O
propofol O
plus O
fentanyl O
group O
had O
a O
mean O
TICS O
score O
of O
34.53 O
at O
24 O
hours O
compared O
with O
34.96 O
at O
48 O
hours O
( O
P O
= O
.017 O
) O
. O
[]

Amplitude O
changes O
as O
well O
as O
areas O
under O
the O
curve O
( O
AUCs O
) O
over O
150 O
min O
were O
compared O
for O
the O
four O
treatments O
by O
repeated O
measures O
ANOVA O
( O
significance O
0.05 O
) O
. O
[]

Ranitidine O
pretreatment O
consisted O
of O
five O
150-mg O
oral O
doses O
( O
as O
the O
hydrochloride O
salt O
) O
given O
every O
12 O
hours O
; O
the O
last O
dose O
was O
given O
two O
hours O
before O
triazolam O
was O
administered O
. O
[]

RESULTS O
Mean O
follow-up O
time O
was O
24 O
months O
. O
[]

METHODS O
Thirty O
patients O
undergoing O
lower O
abdominal O
surgery O
were O
randomized O
in O
a O
double-blinded O
manner O
to O
receive O
one O
of O
three O
solutions O
: O
0.2 O
% O
ropivacaine-4 O
microg O
fentanyl O
0.1 O
% O
ropivacaine-2 O
microg O
fentanyl O
, O
or O
0.05 O
% O
ropivacaine-1 O
microg O
fentanyl O
for O
patient-controlled O
epidural O
analgesia O
after O
standardized O
combined O
epidural O
and O
general O
anesthesia O
. O
[]

RESULTS O
A O
total O
of O
74 O
patients O
were O
enrolled O
in O
present O
study O
, O
with O
37 O
patients O
in O
each O
arm O
, O
and O
there O
were O
12 O
cases O
and O
10 O
cases O
who O
received O
preoperative O
radiation O
therapy O
, O
respectively O
. O
[]

Sunbathing O
and O
sunbed O
use O
related O
to O
self-image O
in O
a O
randomized O
sample O
of O
Swedish O
adolescents O
. O
[]

Subjective O
effects O
of O
the O
drugs O
were O
monitored O
using O
the O
Profile O
of O
Mood B-outcome ['Life-Impact']
States O
( O
POMS O
) O
and O
a O
shortened O
version O
of O
the O
Addiction B-outcome ['Life-Impact']
Research O
Center O
Inventory O
( O
ARCI B-outcome ['Physiological-Clinical']
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Matched O
HR O
for O
death B-outcome ['Mortality']
['Mortality']

Both O
doses O
of O
laquinimod O
were O
well O
tolerated O
, O
with O
some O
transient O
and O
dose-dependent O
increases O
in O
[]

The O
results O
of O
this O
study O
show O
that O
high-dose O
fluticasone O
is O
effective O
in O
reducing O
the O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
in O
bronchiectasis O
. O
['Physiological-Clinical']

RESULTS O
Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O
[]

Total O
peripheral B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TPR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate-corrected I-outcome ['Physiological-Clinical']
electromechanical I-outcome ['Physiological-Clinical']
systole I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
QS2c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
preejection B-outcome ['Physiological-Clinical']
period O
( O
PEPc O
) O
were O
assessed O
noninvasively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
spanned O
12 O
months O
, O
with O
assessments O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
months O
. O
[]

Unfortunately O
, O
H. O
pylori O
therapy O
may O
be O
troublesome O
for O
drug O
side O
effects O
and O
inefficacious O
for O
resistance O
to O
antibiotics O
. O
[]

once O
daily O
( O
marketed O
) O
. O
[]

The O
changes O
in O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
were O
consistent O
with O
the O
changes O
in O
biochemical B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
; O
DMPA O
users O
showed O
signs O
of O
increased O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
and O
users O
of O
levonorgestrel O
showed O
increased O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
with O
increased O
levels O
of O
both O
alkaline O
phosphatase O
( O
p O
= O
0.004 O
) O
and O
osteocalcin O
( O
p O
= O
0.007 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
four O
active O
doses O
were O
well O
tolerated O
, O
no O
serious O
adverse O
event O
occurred O
; O
two O
Grade O
II O
reactions B-outcome ['Adverse-effects']
, O
according O
to O
EAACI O
classification O
, O
were O
observed O
, O
one O
in O
each O
of O
the O
160- O
and O
320-?g O
groups O
. O
['Adverse-effects']

Inhibition O
of O
increased O
central O
sympathetic O
vasoconstrictor O
outflow O
is O
one O
mechanism O
by O
which O
nocturnal O
CPAP O
reduces O
awake O
BP B-outcome ['Physiological-Clinical']
in O
HF O
patients O
with O
moderate O
to O
severe O
OSA O
. O
['Physiological-Clinical']

Lack O
of O
therapeutic O
benefit O
and O
increase O
of O
the O
toxicity B-outcome ['Adverse-effects']
from O
aminophylline O
given O
in O
addition O
to O
high O
doses O
of O
salbutamol O
delivered O
by O
metered-dose O
inhaler O
with O
a O
spacer O
. O
['Adverse-effects']

We O
administered O
tests O
of O
cognitive O
performance O
and O
autism O
severity O
to O
both O
groups O
at O
the O
initiation O
of O
the O
study O
and O
after O
6 O
months O
. O
[]

The O
primary O
end O
point O
was O
the O
response O
rate O
( O
RR O
) O
. O
[]

Among O
premenopausal O
patients O
distant B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
occurred O
less O
frequently O
in O
the O
CT O
group O
( O
relative O
hazard O
: O
1.68 O
, O
p O
> O
0.001 O
) O
resulting O
in O
an O
improved O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Mortality']

We O
varied O
the O
direction O
and O
magnitude O
of O
the O
perturbations O
, O
as O
well O
as O
the O
prior O
knowledge O
of O
perturbation O
direction O
. O
[]

Further O
, O
no O
correlation O
was O
found O
between O
the O
maximum O
inhibition O
of O
14C-serotonin O
release O
in O
vivo O
and O
the O
release O
predicted O
from O
in O
vitro O
experiments O
wherein O
the O
effect O
was O
measured O
after O
incubating O
plasma O
containing O
specified O
ASA O
concentrations O
. O
[]

Recorded O
adverse O
events O
were O
within O
safety O
limits O
, O
including O
30-day O
mortality B-outcome ['Mortality']
, O
8 O
% O
; O
symptomatic B-outcome ['Physiological-Clinical']
re-bleeding I-outcome ['Physiological-Clinical']
, O
8 O
% O
; O
and O
bacterial B-outcome ['Physiological-Clinical']
ventriculitis I-outcome ['Physiological-Clinical']
, O
0 O
% O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
CAD O
patients O
, O
atorvastatin O
and O
quinapril O
slowed O
blood O
clotting O
at O
the O
site O
of O
microvascular O
injury O
after O
28 O
days O
of O
therapy O
. O
[]

A O
randomized O
trial O
of O
continuous O
subcutaneous O
insulin O
infusion O
and O
intensive O
injection O
therapy O
in O
type O
1 O
diabetes O
for O
patients O
with O
long-standing O
poor O
glycemic O
control O
. O
[]

This O
effect O
is O
lost O
after O
4 O
days O
, O
suggesting O
that O
a O
regular O
daily O
co-administration O
of O
NSAID O
does O
not O
have O
an O
influence O
on O
platelet B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
by O
aspirin O
. O
['Physiological-Clinical']

In O
addition O
, O
ZH-fed O
steers O
produced O
a O
greater O
( O
P O
< O
0.001 O
) O
percentage O
of O
USDA O
YG O
1 O
carcasses O
( O
25.9 O
vs. O
16.2 O
% O
) O
and O
a O
lesser O
( O
P O
< O
0.001 O
) O
percentage O
of O
YG O
4 O
or O
higher O
carcasses O
( O
1.6 O
vs. O
6.0 O
% O
) O
than O
steers O
fed O
the O
control O
diet O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Over O
the O
last O
few O
decades O
, O
application O
of O
ultrasound O
has O
been O
attempted O
to O
enhance O
transdermal O
transport O
of O
several O
drugs O
, O
a O
method O
referred O
to O
as O
phonophoresis O
. O
[]

DESIGN O
A O
single-site O
, O
unblinded O
randomized O
trial O
in O
New O
York O
City O
with O
3-month O
follow-up O
. O
[]

The O
robust O
detection O
of O
red B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in O
digital O
color O
fundus O
photographs O
is O
a O
critical O
step O
in O
the O
development O
of O
automated O
screening O
systems O
for O
diabetic O
retinopathy O
. O
['Physiological-Clinical']

Randomization O
was O
stratified O
on O
the O
basis O
of O
whether O
patients O
had O
untreated O
or O
relapsed O
retinitis O
. O
[]

Plasma O
kinetics O
of O
zeaxanthin O
and O
3'-dehydro-lutein O
after O
multiple O
oral O
doses O
of O
synthetic O
zeaxanthin O
. O
[]

The O
study O
recruited O
successive O
patients O
with O
unresectable O
grade O
I/II O
head O
and O
neck O
cancer O
who O
were O
not O
suitable O
for O
irradiation O
treatment O
( O
T O
any O
N3 O
or O
T4 O
N2C O
) O
, O
metastatic O
or O
previously O
irradiated O
. O
[]

APO-A1 B-outcome ['Physiological-Clinical']
showed O
a O
4 O
% O
increase O
, O
while O
APO-B O
showed O
a O
3 O
% O
reduction O
. O
['Physiological-Clinical']

3.9 O
days O
vs. O
25.8 O
? O
[]

However O
, O
the O
P/S B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
not O
significantly O
affected O
, O
partly O
because O
the O
relative O
content O
of O
saturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
present O
an O
evaluation O
of O
a O
1.5-year O
follow-up O
of O
an O
Internet-based O
cognitive-behavioral O
intervention O
for O
complicated O
grief O
. O
[]

Inhaled O
fluticasone O
reduces O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
in O
severe O
bronchiectasis O
. O
['Physiological-Clinical']

Holter B-outcome ['Physiological-Clinical']
recordings I-outcome ['Physiological-Clinical']
in O
basal O
conditions O
and O
following O
7 O
days O
of O
ibopamine O
and O
placebo O
treatment O
. O
['Physiological-Clinical']

A O
clinical O
evaluation O
of O
a O
blood O
conservation O
device O
in O
medical O
intensive O
care O
unit O
patients O
. O
[]

25 O
% O
decrease O
in O
Aberrant O
Behavior O
Checklist-irritability O
subscale O
score O
and O
a O
rating O
of O
much O
improved O
or O
very O
much O
improved O
on O
the O
Clinical O
Global O
Impressions-Improvement O
scale O
) O
for O
12 O
consecutive O
weeks O
were O
randomized O
into O
phase O
2 O
to O
continue O
aripiprazole O
or O
switch O
to O
placebo O
. O
[]

Their O
results O
show O
that O
experimentally O
activating O
self-face O
representations O
results O
in O
earlier O
recognition O
of O
dynamically O
emerging O
facial B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
. O
['Life-Impact']

Two O
patients O
in O
the O
coumadin O
group O
( O
5.7 O
% O
) O
experienced O
excessive B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Double-blind O
placebo-controlled O
prospective O
study O
design O
. O
[]

Treating O
the O
substance-abusing O
suicidal O
patient O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
association O
between O
severity O
of O
coexisting O
patellofemoral O
( O
PF O
) O
disease O
with O
lower O
extremity O
impairments O
and O
functional O
limitations O
in O
patients O
with O
tibiofemoral O
( O
TF O
) O
osteoarthritis O
( O
OA O
) O
. O
[]

Of O
those O
, O
27 O
% O
( O
194/715 O
) O
reported O
to O
the O
IVR O
system O
that O
they O
had O
quit B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
and O
were O
therefore O
excluded O
from O
the O
study O
and O
analysis O
. O
['Life-Impact']

CONCLUSION O
The O
measurement O
of O
biliary O
bile O
acids O
is O
superior O
to O
that O
of O
serum O
bile O
acids O
for O
assessing O
the O
compliance O
and O
changes O
in O
the O
circulating O
bile O
acids O
in O
patients O
receiving O
ursodeoxycholic O
acid O
for O
the O
treatment O
of O
primary B-outcome ['Physiological-Clinical']
biliary I-outcome ['Physiological-Clinical']
cirrhosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Bladder O
sensation O
volumes O
and O
detrusor O
contractions O
were O
compared O
. O
[]

OBJECTIVE O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
effectiveness O
of O
an O
applied O
behaviour O
analysis O
( O
ABA O
) O
-based O
intervention O
conducted O
by O
a O
robot O
compared O
to O
an O
ABA-based O
intervention O
conducted O
by O
a O
human O
trainer O
in O
promoting O
self-initiated O
questions O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Effects O
of O
resistance O
versus O
endurance O
training O
on O
serum B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
index O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
vitamin O
A-fortified O
coconut O
cooking O
oil O
on O
the O
serum B-outcome ['Physiological-Clinical']
retinol I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
Filipino O
children O
4-7 O
years O
old O
. O
['Physiological-Clinical']

In O
light O
of O
these O
findings O
CONTRAST O
training O
should O
be O
preferred O
to O
line O
sprint O
training O
in O
the O
short O
term O
in O
young O
elite O
soccer O
players O
when O
the O
aim O
is O
to O
improve O
soccer-specific B-outcome ['Life-Impact']
sprint I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
15 O
m O
) O
during O
the O
competitive O
season O
. O
['Life-Impact']

Iron O
intake O
and O
iron O
nutritional O
status O
of O
infants O
fed O
iron-fortified O
beikost O
with O
meat O
. O
[]

An O
increase O
in O
response O
rate O
for O
patients O
with O
measurable O
disease O
, O
of O
borderline O
statistical O
significance O
( O
P O
= O
0.088 O
, O
P O
for O
trend O
= O
0.018 O
) O
, O
from O
42 O
% O
in O
the O
CEF O
group O
to O
69 O
% O
in O
the O
CEF O
+ O
GM-CSF O
group O
, O
was O
observed O
. O
[]

Follow-up O
was O
every O
3 O
weeks O
to O
21 O
weeks O
after O
randomisation O
, O
and O
every O
8 O
weeks O
thereafter O
. O
[]

This O
study O
investigated O
whether O
or O
not O
children O
with O
autism O
or O
a O
related O
pervasive O
developmental O
disorder O
( O
PDD O
) O
can O
benefit O
from O
regular O
opportunities O
to O
interact O
with O
a O
normally O
developing O
peer O
, O
matched O
as O
to O
sex O
and O
age O
. O
[]

The O
humoral O
and O
cellular O
immune O
responses O
were O
measured O
before O
vaccination O
( O
day O
0 O
) O
; O
6 O
days O
after O
the O
second O
dose O
( O
day O
36 O
) O
; O
6 O
days O
( O
day O
66 O
) O
, O
2 O
months O
( O
day O
120 O
) O
and O
10 O
months O
( O
day O
365 O
) O
after O
the O
third O
dose O
and O
1 O
month O
after O
the O
fourth O
dose O
( O
day O
395 O
) O
. O
[]

13 O
, O
age O
71+/-2 O
yr O
) O
groups O
. O
[]

METHODS O
Twenty-four O
children O
( O
3-11 O
years O
old O
, O
ASA O
PS O
I O
or O
II O
) O
were O
randomized O
to O
receive O
N2O/O2-fentanyl O
or O
N2O/O2-sevoflurane O
( O
one O
MAC O
) O
anesthesia O
. O
[]

Hematopoietic O
progenitors O
collected O
during O
each O
cycle O
were O
reinfused O
on O
day O
3 O
of O
the O
next O
cycle O
. O
[]

CONCLUSIONS O
There O
seems O
to O
be O
no O
obvious O
clinical O
or O
radiographic O
differences O
between O
the O
test O
and O
control O
single-implant O
restorations O
during O
10 O
years O
of O
follow-up O
. O
[]

The O
intervention O
was O
developed O
through O
a O
dynamic O
and O
iterative O
process O
that O
involved O
extensive O
development O
activities O
, O
focus O
groups O
with O
the O
target O
population O
to O
pilot O
individual O
activities O
and O
intervention O
sessions O
, O
and O
later O
, O
pilot O
testing O
of O
the O
entire O
intervention O
. O
[]

Myocardial O
free O
radical O
production O
was O
-0.94 O
( O
1.21 O
) O
in O
the O
allopurinol O
and O
+0.79 O
( O
0.96 O
) O
in O
the O
placebo O
group O
after O
10 O
min O
reperfusion O
, O
the O
difference O
being O
significant O
( O
p O
= O
0.043 O
) O
. O
[]

TMN B-outcome ['Physiological-Clinical']
staging O
at O
baseline O
was O
: O
T4N2 O
, O
11 O
% O
; O
T3N2 O
, O
40 O
% O
; O
T2N2 O
, O
3 O
% O
; O
T3N1 O
, O
35 O
% O
; O
T2N1 O
, O
3 O
% O
and O
T3N0 O
8 O
% O
. O
['Physiological-Clinical']

Forty-seven O
of O
the O
61 O
patients O
completing O
the O
intended O
12 O
or O
more O
months O
of O
initial O
IFN O
treatment O
were O
eventually O
considered O
IFN O
failures O
. O
[]

Nonparametric O
analysis O
of O
variance O
and O
Chi-squared O
analysis O
were O
used O
for O
statistical O
comparisons O
. O
[]

Patients O
were O
assigned O
randomly O
to O
active O
warming O
at O
52 O
degrees O
C O
or O
passive O
insulation O
( O
heater O
not O
activated O
) O
. O
[]

These O
regimens O
are O
associated O
with O
a O
very O
low O
risk O
of O
Grade O
3-4 O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Elevated O
levels O
of O
8-epi-PGF2 O
alpha O
in O
smokers O
may O
be O
modulated O
by O
quitting O
cigarettes O
and O
switching O
to O
nicotine O
patches O
or O
by O
antioxidant O
vitamin O
therapy O
. O
[]

Total O
deaths B-outcome ['Mortality']
were O
54 O
in O
the O
strict-treatment O
group O
vs. O
42 O
in O
the O
mild-treatment O
group O
( O
p=0.22 O
) O
, O
and O
treatment O
was O
withdrawn O
because O
of O
adverse O
events O
in O
36 O
patients O
in O
each O
group O
( O
p=0.99 O
) O
. O
['Mortality']

Split-face O
comparison O
of O
the O
erbium O
micropeel O
with O
intense O
pulsed O
light O
. O
[]

The O
difference O
between O
the O
two O
groups O
in O
the O
frequency O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
not O
significant O
. O
['Adverse-effects']

Opioid B-outcome ['Life-Impact']
usage I-outcome ['Life-Impact']
during O
the O
first O
24 O
hours O
was O
similar O
( O
INB- O
, O
16.7 O
mg O
vs. O
INB+ O
, O
13.2 O
mg O
, O
P O
= O
.7 O
) O
. O
['Life-Impact']

Two O
HBOT O
patients O
and O
four O
control O
patients O
developed O
positive O
bacterial O
cultures O
. O
[]

Although O
the O
incidence O
of O
angiographic O
restenosis O
tended O
to O
be O
lower O
with O
warfarin O
, O
none O
of O
these O
differences O
was O
significant O
. O
[]

Arginine O
vasopressin O
( O
10 O
pressor O
units O
) O
was O
given O
intramuscularly O
at O
the O
same O
time O
. O
[]

In O
the O
IS O
1-2 O
ml O
of O
5 O
% O
phenol O
in O
almond O
oil O
was O
injected O
in O
the O
same O
plane O
in O
each O
pile O
core O
. O
[]

BACKGROUND O
Laparoscopic O
cholecystectomy O
( O
LC O
) O
has O
become O
the O
treatment O
of O
choice O
for O
elective O
cholecystectomy O
, O
but O
controversy O
persists O
over O
use O
of O
this O
approach O
in O
the O
treatment O
of O
acute O
cholecystitis O
. O
[]

Significant O
improvements O
were O
noted O
in O
the O
BL O
periods O
compared O
with O
the O
non-BL O
periods O
for O
self-assessed O
sleepiness B-outcome ['Life-Impact']
at O
10 O
: O
00 O
on O
day-shift O
days O
, O
self-assessment O
of O
night B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
day-shift I-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
and O
for O
fatigue B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Future O
controlled O
trials O
may O
need O
to O
consider O
a O
longer O
treatment O
period O
to O
detect O
significant O
gains O
on O
EF O
measures O
. O
[]

However O
, O
the O
combination O
of O
intraperitoneal O
bupivacaine O
0.25 O
% O
and O
i.v O
. O
[]

The O
two O
populations O
were O
well O
matched O
in O
terms O
of O
age O
, O
gender O
, O
underlying O
disease O
, O
chemotherapy O
received O
, O
oral O
decontamination O
, O
clinical O
and O
bacterial O
documentation O
, O
and O
severity O
and O
duration O
of O
neutropenia O
. O
[]

Forty-eight O
women O
( O
body O
mass O
index O
of O
30 O
to O
44 O
kg/m O
( O
2 O
) O
) O
were O
enrolled O
. O
[]

Milk O
samples O
collected O
7 O
, O
14 O
, O
30 O
, O
and O
60 O
d O
after O
calving O
were O
plated O
for O
bacterial O
isolation O
within O
24 O
h O
after O
collection O
and O
after O
24 O
to O
72 O
h O
of O
storage O
at O
-20 O
degrees O
C. O
Quarters O
were O
defined O
as O
infected O
if O
S. O
aureus O
was O
isolated O
from O
the O
fresh O
and O
frozen O
cultures O
from O
any O
one O
sample O
collected O
before O
drying O
off O
. O
[]

Each O
patient O
was O
evaluated O
with O
two O
lead O
configurations O
with O
the O
order O
of O
testing O
randomized O
. O
[]

Among O
AMP O
patients O
( O
45 O
) O
, O
8 O
had O
significant O
residua O
and O
3 O
died B-outcome ['Mortality']
; O
among O
CB O
patients O
( O
41 O
) O
, O
5 O
had O
residua O
and O
none O
died O
. O
['Mortality']

At O
baseline O
, O
no O
difference O
was O
observed O
between O
the O
two O
groups O
. O
[]

The O
time-points O
at O
which O
the O
patient O
first O
drove O
and O
ambulated O
with O
a O
cane O
, O
without O
a O
cane O
, O
and O
without O
a O
limp O
were O
also O
collected O
. O
[]

Additional O
measurements O
such O
as O
change O
in O
urinary B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
level O
, O
capsule B-outcome ['Life-Impact']
count I-outcome ['Life-Impact']
, O
client O
self O
report O
and O
physician O
estimate O
of O
adherence B-outcome ['Life-Impact']
were O
recorded O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Survival B-outcome ['Mortality']
was O
dependent O
on O
abdominal B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
, O
histologic B-outcome ['Physiological-Clinical']
grade O
according O
to O
the O
new O
working O
formulation O
used O
for O
lymph-node O
lymphomas B-outcome ['Physiological-Clinical']
, O
initial B-outcome ['Physiological-Clinical']
localization I-outcome ['Physiological-Clinical']
( O
gastric O
lymphomas O
have O
the O
best O
survival O
) O
and O
achievement O
of O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CI-AKI O
occurred O
in O
131 O
patients O
( O
13.3 O
% O
) O
. O
[]

The O
modest O
magnitude O
of O
effects O
over O
an O
extended O
period O
of O
program O
implementation O
, O
however O
, O
reflects O
the O
challenges O
of O
both O
mounting O
interventions O
and O
offsetting O
formidable O
risks O
for O
mental O
health O
problems O
in O
such O
environments O
. O
[]

compared O
to O
a O
combination O
of O
slow-release O
theophylline O
and O
ketotifen O
p.o O
. O
( O
[]

Ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
responsive I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
amiodarone I-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
myoblast-treated O
patients O
: O
1 O
( O
placebo O
) O
, O
3 O
( O
low O
dose O
) O
, O
and O
4 O
( O
high O
dose O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
hand-sewn O
and O
stapled O
methods O
in O
esophagogastric O
anastomosis O
. O
[]

The O
effects O
of O
12 O
weeks O
of O
antioxidant O
supplementation O
on O
exercise-induced O
oxidative O
stress O
were O
investigated O
in O
older O
adults O
( O
60 O
( O
SE O
1 O
) O
years O
; O
BMI O
26 O
( O
SE O
1 O
) O
kg/m O
( O
2 O
) O
) O
. O
[]

PURPOSE O
Approximately O
60 O
% O
of O
patients O
with O
small-cell O
lung O
cancer O
( O
SCLC O
) O
develop O
brain O
metastases O
. O
[]

Also O
, O
the O
average O
number O
of O
wet B-outcome ['Physiological-Clinical']
nights I-outcome ['Physiological-Clinical']
in O
group O
1 O
was O
significantly O
lower O
than O
at O
baseline O
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Toxicity O
was O
comparable O
between O
the O
two O
arms O
for O
anemia B-outcome ['Physiological-Clinical']
, O
leukopenia B-outcome ['Physiological-Clinical']
, O
neutropenia B-outcome ['Physiological-Clinical']
, O
thrombocytopenia B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
constipation B-outcome ['Physiological-Clinical']
and O
arthralgias/myalgias B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
isotonic O
training O
( O
5BX O
programme O
) O
and O
isometric O
training O
( O
a O
programme O
of O
isometric O
exercises O
working O
all O
major O
groups O
of O
muscles O
) O
were O
compared O
with O
a O
control O
group O
with O
no O
specific O
workout O
. O
[]

To O
investigate O
the O
existence O
of O
risk O
factors O
, O
the O
incidence O
of O
encephalopathic O
syndromes O
and O
the O
relationship O
between O
the O
development O
of O
different O
types O
of O
encephalopathies O
and O
the O
clinical O
outcome O
was O
studied O
in O
a O
clinical O
trial O
with O
588 O
patients O
under O
treatment O
with O
melarsoprol O
. O
[]

The O
latter O
effect O
occurred O
only O
for O
children O
who O
began O
treatment O
with O
at O
least O
some O
initiating B-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
. O
['Life-Impact']

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
Identifier O
NCT01174225 O
. O
[]

The O
WBC O
count O
in O
P+EN O
group O
was O
significantly O
lower O
than O
that O
in O
PN O
group O
( O
5.9 O
? O
[]

Our O
study O
compared O
the O
ability O
of O
the O
calcium O
blocker O
, O
verapamil O
, O
and O
the O
beta-blocker O
, O
atenolol O
, O
to O
both O
control O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
to O
induce O
regression O
of O
LV B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
in O
older O
hypertensives O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
follow-up O
period O
covered O
up O
to O
24 O
months O
after O
enrollment O
. O
[]

Peritoneal O
equilibration O
tests O
revealed O
subtle B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
solute I-outcome ['Physiological-Clinical']
transport I-outcome ['Physiological-Clinical']
, O
with O
a O
less O
steep B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
equilibration I-outcome ['Physiological-Clinical']
curve O
during O
bicarbonate O
dialysis O
, O
suggesting O
reduced O
peritoneal O
vasodilation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
test O
the O
hypothesis O
of O
a O
therapeutic O
window O
, O
we O
have O
randomly O
assigned O
acutely O
exacerbating O
schizophrenic B-outcome ['Life-Impact']
or O
schizoaffective B-outcome ['Life-Impact']
patients O
to O
one O
of O
three O
plasma O
levels O
of O
haloperidol O
( O
HAL O
) O
: O
2-13 O
, O
13.1-24 O
, O
or O
24.1-35 O
ng/ml O
. O
['Life-Impact', 'Life-Impact']

METHODS O
A O
prospective O
experimental O
observation O
was O
designed O
. O
[]

The O
results O
show O
a O
significant O
improvement O
in O
the O
active O
treatment O
group O
at O
the O
5 O
% O
level O
as O
compared O
to O
placebo O
. O
[]

FEC O
100 O
regimens O
improve O
the O
[]

We O
conclude O
that O
staple O
transection O
of O
the O
esophagus O
is O
as O
safe O
as O
sclerotherapy B-outcome ['Resource-use']
for O
the O
emergency B-outcome ['Physiological-Clinical']
treatment O
of O
['Resource-use', 'Physiological-Clinical']

AIM O
This O
study O
was O
carried O
out O
to O
determine O
the O
effect O
of O
injection O
duration O
on O
bruising O
and O
pain O
following O
the O
administration O
of O
the O
subcutaneous O
injection O
of O
heparin O
. O
[]

Group O
I O
was O
given O
600 O
mg O
ipriflavone O
orally O
daily O
and O
group O
II O
was O
weekly O
injected O
intramuscularly O
with O
20 O
units O
elcatonin O
, O
Asu1-7 O
eel O
calcitonin O
( O
carbocalcitonin O
) O
. O
[]

A O
published O
meta-analysis O
demonstrated O
that O
overall O
, O
producers O
lose O
approximately O
0.35 O
kg O
of O
milk O
per O
parasitized O
cow O
per O
day O
. O
[]

Randomized O
clinical O
trial O
of O
tamoxifen O
plus O
sequential O
CMF O
chemotherapy O
versus O
tamoxifen O
alone O
in O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O
[]

In O
two O
prospective O
, O
randomized O
studies O
conducted O
in O
West O
Germany O
and O
involving O
80 O
patients O
, O
netilmicin-ticarcillin O
was O
compared O
to O
tobramycin-ticarcillin O
in O
the O
treatment O
of O
serious O
systemic O
infections O
. O
[]

Evaluation O
of O
the O
pharmacodynamics O
of O
acetylsalicylic O
acid O
81 O
mg O
with O
or O
without O
esomeprazole O
20 O
mg O
in O
healthy O
volunteers O
. O
[]

The O
present O
study O
assessed O
the O
effects O
of O
topiramate O
plus O
risperidone O
in O
the O
treatment O
of O
autistic O
disorder O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
1.4 O
years O
, O
and O
the O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
was O
33 O
% O
. O
['Mortality', 'Mortality']

The O
intervention O
group O
( O
n O
= O
42 O
) O
was O
trained O
to O
perform O
CVC O
self-care O
. O
[]

The O
Interstitial B-outcome ['Physiological-Clinical']
Cystitis I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Index O
and O
Interstitial B-outcome ['Physiological-Clinical']
Cystitis I-outcome ['Physiological-Clinical']
Problem B-outcome ['Physiological-Clinical']
Index O
mean O
scores O
improved O
by O
71 O
% O
and O
69 O
% O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Peak O
serum B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
were O
determined O
by O
visual O
inspection O
of O
each O
individual O
's O
serum O
concentration-time O
curve O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pharmacokinetic O
analyses O
showed O
a O
linear O
relationship O
between O
dose O
and O
plasma O
concentrations O
, O
with O
a O
Cmax O
of O
828 O
+/- O
19.2 O
ng/mL O
after O
a O
50-mg O
dose O
. O
[]

CONCLUSIONS O
The O
generalized O
use O
of O
exogenous O
PAF O
for O
the O
preparation O
of O
sperm O
in O
unselected O
cases O
of O
mild O
male O
infertility O
does O
not O
improve O
the O
clinical O
outcome O
of O
IUI O
. O
[]

Three-quarters O
were O
African-American O
. O
[]

DESIGN O
Randomized O
, O
multicentre O
, O
double-blind O
, O
double- O
dummy O
, O
parallel O
groups O
study O
. O
[]

A O
10 O
% O
reduction O
in O
cholesterol O
levels O
can O
reduce O
the O
risk O
of O
coronary O
heart O
disease O
by O
15 O
% O
. O
[]

No O
differences O
in O
the O
initial O
values O
were O
found O
between O
the O
two O
groups O
. O
[]

UNLABELLED O
Clonidine O
premedication O
reduces O
the O
intraoperative O
requirement O
for O
opioids O
and O
volatile O
anesthetics O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Before O
and O
10 O
minutes O
after O
administration O
of O
each O
desired O
end-expiratory O
anesthetic O
concentration O
, O
the O
following O
parameters O
were O
determined O
: O
hemodynamic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

All O
patients O
then O
received O
i.v O
. O
[]

the O
action O
performed O
by O
the O
human O
body O
segment O
specifically O
affected O
by O
writer O
's O
cramp O
) O
or O
inanimate O
object O
motion O
( O
a O
moving O
circle O
reaching O
a O
spatial O
target O
) O
. O
[]

METHODS O
At O
six O
centers O
, O
71 O
angiographers O
each O
reviewed O
a O
set O
of O
100 O
angiographic O
sequences O
. O
[]

This O
controlled O
trial O
of O
a O
parent O
management O
intervention O
aimed O
to O
increase O
parental O
competence O
in O
management O
of O
problem O
behaviours O
associated O
with O
Asperger O
syndrome O
. O
[]

METHODS O
The O
Collaborative O
Ocular O
Melanoma O
Study O
( O
COMS O
) O
is O
a O
set O
of O
clinical O
trials O
designed O
to O
compare O
the O
role O
of O
radiotherapy O
and O
enucleation O
in O
the O
treatment O
of O
medium O
and O
large-size O
choroidal O
melanoma O
. O
[]

Patient O
numbers O
were O
as O
follows O
: O
controls O
, O
45 O
; O
allergic O
rhinitis O
, O
21 O
; O
acute O
sinusitis O
, O
24 O
; O
and O
chronic O
sinusitis O
, O
42 O
. O
[]

The O
primary O
end O
point O
of O
this O
study O
was O
response O
at O
day O
+120 O
. O
[]

The O
current O
study O
illustrates O
how O
researchers O
developed O
and O
validated O
a O
cartoon-based O
adaptation O
of O
a O
written O
hostile B-outcome ['Life-Impact']
attributional I-outcome ['Life-Impact']
bias O
measure O
for O
a O
sample O
of O
urban O
, O
low-income O
, O
African O
American O
boys O
. O
['Life-Impact']

Efficacy O
and O
safety O
of O
2 O
risperidone O
doses O
were O
evaluated O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

A O
replication O
and O
extension O
of O
the O
PEERS O
intervention O
: O
examining O
effects O
on O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
in O
adolescents O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact', 'Life-Impact']

We O
re-evaluated O
the O
GHRH O
dose-response O
curve O
in O
patients O
post O
cranial O
irradiation O
and O
in O
controls O
. O
[]

Staphylococcal O
species O
accounted O
for O
40 O
% O
of O
the O
isolates O
with O
an O
equal O
incidence O
of O
Staphylococcus B-outcome ['Physiological-Clinical']
aureus I-outcome ['Physiological-Clinical']
and O
coagulase B-outcome ['Physiological-Clinical']
negative O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Mean O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
was O
higher O
after O
esomeprazole O
than O
rabeprazole O
during O
0-5 O
h O
after O
dosing O
( O
P=0.0001 O
) O
; O
the O
reverse O
was O
true O
from O
14-24 O
h O
( O
P=0.0002 O
) O
. O
['Physiological-Clinical']

Subsequently O
, O
19 O
subjects O
were O
treated O
with O
50 O
mg/d O
and O
14 O
with O
150 O
mg/d O
of O
naltrexone O
hydrochloride O
for O
4 O
weeks O
. O
[]

Accordingly O
, O
antihypertensive O
drugs O
inhibiting O
sympathetic O
outflow O
represent O
a O
theoretically O
attractive O
therapeutic O
option O
. O
[]

Only O
minor O
changes O
were O
seen O
in O
the O
phospholipids B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Safety O
of O
ferumoxytol O
in O
patients O
with O
anemia O
and O
CKD O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
: O
control O
group O
( O
n=15 O
) O
- O
open O
flap O
debridement O
( O
OFD O
) O
+24 O
% O
ethylenediaminetetraacetic O
acid O
( O
EDTA O
) O
conditioning O
; O
test O
group O
( O
n=15 O
) O
- O
OFD+24 O
% O
EDTA O
conditioning+EMD O
application O
. O
[]

Of O
these O
, O
59 O
patients O
were O
treated O
with O
ofloxacin O
and O
33 O
with O
the O
comparator O
drug O
. O
[]

Five O
patients O
in O
each O
group O
were O
lost O
to O
follow-up O
during O
the O
study O
period O
, O
so O
49 O
patients O
in O
each O
group O
were O
analysed O
. O
[]

These O
studies O
used O
both O
new O
and O
commercially O
available O
drugs O
, O
as O
well O
as O
surgery O
and/or O
radiation O
therapy O
in O
1,087 O
patients O
. O
[]

The O
patients O
in O
group O
A O
received O
radiotherapy O
alone O
, O
those O
in O
group O
B O
were O
given O
daily O
Selaginella O
( O
30 O
g O
) O
prepared O
into O
50 O
ml O
decoction O
during O
the O
entire O
course O
of O
radiotherapy O
, O
and O
those O
in O
group O
C O
had O
Selaginella O
30 O
g O
daily O
in O
the O
late O
course O
of O
radiotherapy O
. O
[]

There O
was O
a O
greater O
increase O
of O
prolactin B-outcome ['Physiological-Clinical']
in O
the O
risperidone O
group O
, O
while O
alanine B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ALT I-outcome ['Physiological-Clinical']
) O
had O
further O
increased O
in O
the O
haloperidol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
We O
performed O
the O
following O
studies O
: O
( O
1 O
) O
a O
cross-sectional O
comparison O
of O
smokers O
and O
control O
subjects O
, O
( O
2 O
) O
an O
examination O
of O
the O
dose-response O
relationship O
, O
( O
3 O
) O
an O
exploration O
of O
the O
effect O
of O
smoking O
cessation O
( O
3 O
weeks O
) O
and O
nicotine O
patch O
supplementation O
, O
( O
4 O
) O
the O
effect O
of O
aspirin O
consumption O
, O
and O
( O
5 O
) O
the O
effects O
of O
5 O
days O
' O
dosing O
with O
vitamin O
E O
( O
100 O
and O
800 O
U O
) O
, O
vitamin O
C O
( O
2 O
g O
) O
, O
and O
their O
combination O
. O
[]

and O
vindesine O
( O
3 O
mg/m O
( O
2 O
) O
i.v O
. O
) O
[]

In O
conclusion O
, O
the O
combination O
of O
beclomethasone O
dipropionate O
and O
salmeterol O
improved O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
bronchial B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
earlier O
than O
beclomethasone O
dipropionate O
alone O
, O
while O
nedocromil O
sodium O
improved O
symptoms O
but O
not O
pulmonary O
function O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
pharmacologic O
effect O
was O
apparent O
from O
a O
dose-dependent O
statistically O
significant O
decrease O
in O
the O
mean O
prothrombin O
time O
in O
all O
N7-GP O
groups O
as O
compared O
with O
placebo O
. O
[]

We O
evaluated O
the O
effect O
of O
breathing O
100 O
ppm O
of O
carbon O
monoxide O
versus O
compressed O
, O
purified O
air O
for O
1 O
hour O
on O
exercise B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
in O
10 O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
in O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
. O
['Life-Impact']

Additionally O
, O
parameters O
of O
muscle B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
improved O
significantly O
. O
['Life-Impact']

INTERPRETATION O
We O
conclude O
that O
the O
mechanical O
fixation O
of O
TM O
tibial O
components O
is O
superior O
to O
that O
of O
screw-fixed O
Ti O
tibial O
components O
. O
[]

Overall O
pTBA O
resulted O
in O
an O
absolute O
risk O
reduction O
of O
5.9 O
% O
and O
a O
relative O
risk O
reduction O
of O
10.4 O
% O
unfavorable O
outcome O
( O
P=0.54 O
) O
. O
[]

Folate O
and O
arsenic O
metabolism O
: O
a O
double-blind O
, O
placebo-controlled O
folic O
acid-supplementation O
trial O
in O
Bangladesh O
. O
[]

0.05 O
) O
. O
[]

The O
authors O
conclude O
that O
symptomatic B-outcome ['Physiological-Clinical']
weakness I-outcome ['Physiological-Clinical']
due O
to O
neuropathy O
or O
myopathy O
appears O
in O
a O
predictable O
manner O
during O
intensive O
vincristine/corticosteroid-based O
treatment O
protocols O
. O
['Physiological-Clinical']

Shocks O
were O
delivered O
either O
between O
the O
right O
ventricular O
coil O
and O
proximal O
atrial O
coil O
( O
lead O
) O
or O
between O
the O
right O
ventricular O
coil O
and O
an O
active O
can O
in O
common O
with O
the O
atrial O
coil O
( O
active O
can O
) O
. O
[]

Multiple O
linear O
regression O
analyses O
were O
performed O
following O
a O
backward O
selection O
procedure O
until O
only O
independent O
variables O
with O
p O
< O
0.05 O
remained O
in O
the O
model O
. O
[]

The O
mean O
[]

RESULTS O
The O
VM B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
increased O
in O
the O
HS O
group O
at O
3 O
months O
compared O
to O
1-month O
post O
surgery O
( O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

Women O
not O
using O
HRT O
had O
faster O
[]

OBJECTIVE O
To O
examine O
the O
bioavailability O
of O
methotrexate O
( O
MTX O
) O
in O
the O
presence O
of O
hydroxychloroquine O
( O
HCQ O
) O
, O
and O
vice O
versa O
, O
to O
determine O
a O
possible O
pharmacokinetic O
explanation O
for O
the O
observation O
that O
combination O
treatment O
of O
rheumatoid O
arthritis O
with O
MTX O
and O
HCQ O
has O
been O
shown O
, O
clinically O
, O
to O
be O
more O
potent O
than O
MTX O
used O
alone O
. O
[]

METHODS O
We O
used O
two O
complementary O
study O
designs O
: O
a O
) O
between-groups O
comparisons O
based O
on O
randomized O
stove O
assignment O
, O
and O
b O
) O
before-and-after O
comparisons O
within O
control O
subjects O
who O
used O
open O
fires O
during O
the O
trial O
and O
received O
chimney O
stoves O
after O
the O
trial O
. O
[]

[ O
Local O
treatment O
of O
periarthropathies O
with O
the O
5-HT3-receptor-antagonist O
tropisetron O
] O
. O
[]

However O
, O
fluoxetine O
was O
marginally O
superior O
to O
placebo O
on O
a O
composite O
measure O
of O
global O
effectiveness O
. O
[]

RESULTS O
In O
study O
group O
, O
the O
factors O
and O
total O
scores O
of O
PANSS O
in O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
[ O
( O
12.0 O
? O
[]

The O
children O
were O
examined O
clinically O
and O
radiologically O
each O
year O
. O
[]

A O
total O
of O
2242 O
patients O
with O
mild O
to O
moderate O
hypertension O
( O
diastolic O
pressure O
95-120 O
mmHg O
) O
were O
randomised O
on O
a O
double-blind O
basis O
to O
receive O
a O
single O
dose O
of O
placebo O
, O
5 O
mg O
quinapril O
or O
10 O
mg O
quinapril O
. O
[]

RESULTS O
Of O
the O
60 O
children O
, O
4 O
could O
not O
be O
evaluated O
- O
2 O
received O
secretin O
outside O
the O
study O
, O
and O
2 O
did O
not O
return O
for O
follow-up O
. O
[]

The O
primary O
and O
secondary O
endpoints O
were O
acute B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
and O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
respectively O
. O
['Physiological-Clinical', 'Mortality']

Measurements O
were O
made O
of O
all O
groups O
administering O
simulated O
adult O
CPR O
. O
[]

Ambient O
temperature O
and O
biomarkers O
of O
heart O
failure O
: O
a O
repeated O
measures O
analysis O
. O
[]

There O
was O
no O
difference O
between O
GP O
and O
TC O
in O
3-year O
OS O
( O
HR=0.97 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
: O
0.76-1.25 O
] O
, O
p=0.80 O
) O
or O
response O
rates O
. O
[]

Secondary O
endpoints O
included O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
assessed O
by O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
. O
['Life-Impact', 'Life-Impact']

From O
the O
original O
group O
of O
6 O
participants O
, O
2 O
were O
selected O
subsequently O
to O
participate O
in O
aerobic O
exercise O
immediately O
before O
performing O
a O
community-integrated O
vocational O
task O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
improvisational O
music O
therapy O
on O
joint O
attention O
behaviors O
in O
pre-school O
children O
with O
autism O
. O
[]

After O
a O
median O
follow-up O
of O
8 O
years O
, O
80 O
patients O
( O
52 O
% O
) O
have O
progressed O
with O
no O
difference O
in O
the O
pattern O
of O
relapse B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
and O
75 O
patients O
( O
49 O
% O
) O
have O
died B-outcome ['Mortality']
; O
the O
respective O
hazard O
ratios O
for O
PFS O
and O
OS O
with O
95 O
% O
CI O
are O
0.89 O
( O
0.59-1.33 O
) O
and O
0.82 O
( O
0.52-1.29 O
) O
. O
['Physiological-Clinical', 'Mortality']

A O
randomised O
comparison O
of O
three O
drainage O
systems O
following O
cholecystectomy O
. O
[]

OT O
seems O
to O
modulate O
this O
effect O
by O
enhancing O
activation B-outcome ['Life-Impact']
differences O
between O
allele O
groups O
, O
which O
suggests O
an O
interaction O
between O
genetic B-outcome ['Physiological-Clinical']
makeup I-outcome ['Physiological-Clinical']
and O
OT B-outcome ['Physiological-Clinical']
availability I-outcome ['Physiological-Clinical']
on O
fusiform B-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
showed O
no O
benefit O
of O
preoperatively O
administered O
oral O
ibuprofen O
10 O
mg.kg-1 O
or O
acetaminophen O
15 O
mg.kg-1 O
over O
placebo O
for O
the O
relief O
of O
postoperative O
pain O
in O
children O
undergoing O
BM O
& O
T O
. O
[]

Although O
preliminary O
, O
this O
study O
demonstrates O
how O
a O
controlled O
clinical O
trial O
of O
the O
GFCF O
diet O
can O
be O
conducted O
, O
and O
suggests O
directions O
for O
future O
research O
. O
[]

Combination O
hydrocodone O
and O
ibuprofen O
versus O
combination O
codeine O
and O
acetaminophen O
for O
the O
treatment O
of O
chronic O
pain O
. O
[]

Investigation O
of O
maxillary B-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
sizes I-outcome ['Physiological-Clinical']
in O
patients O
with O
palatal O
canine O
displacement O
. O
['Physiological-Clinical']

The O
individual O
responsiveness O
to O
growth O
hormone O
( O
GH O
) O
treatment O
in O
GH-deficient O
adults O
is O
dependent O
on O
the O
level O
of O
GH-binding O
protein O
, O
body O
mass O
index O
, O
age O
, O
and O
gender O
. O
[]

Scores O
were O
not O
related O
to O
age O
or O
verbal O
ability O
. O
[]

Anti-HLA B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
developed O
in O
3 O
of O
9 O
patients O
in O
group O
1 O
and O
8 O
of O
12 O
patients O
in O
group O
2 O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

SAMPLE O
Thirty-one O
children O
with O
DCD O
aged O
7 O
to O
9 O
years O
participated O
in O
the O
study O
. O
[]

Cilomilast O
( O
Ariflo O
) O
, O
a O
new O
oral O
phosphodiesterase-4 O
selective O
inhibitor O
, O
improves O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Circulating B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
GH B-outcome ['Physiological-Clinical']
, O
IGF-I B-outcome ['Physiological-Clinical']
, O
bioavailable B-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
, O
IGF-binding B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
IGFBP B-outcome ['Physiological-Clinical']
) O
-1 O
, O
IGFBP-3 B-outcome ['Physiological-Clinical']
, O
and O
acid-labile B-outcome ['Physiological-Clinical']
subunit O
were O
analyzed O
upon O
admission O
and O
d O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

c O
) O
. O
[]

Thus O
, O
twice O
daily O
proton O
pump O
inhibitor O
( O
PPI O
) O
-based O
triple O
therapies O
for O
7 O
days O
remain O
as O
the O
choice O
of O
treatment O
in O
children O
. O
[]

Auditory O
integration O
training O
for O
children O
with O
autism B-outcome ['Life-Impact']
: O
no O
behavioral O
benefits O
detected O
. O
['Life-Impact']

OBJECTIVE O
To O
evaluate O
the O
safety O
of O
applying O
follicular-fluid O
meiosis-activating O
sterol O
( O
FF-MAS O
) O
in O
vitro O
to O
immature O
human O
oocytes O
. O
[]

The O
expression O
of O
VEGF B-outcome ['Physiological-Clinical']
and O
VEGFR2 B-outcome ['Physiological-Clinical']
was O
assessed O
on O
tissue O
microarray O
by O
immunohistochemistry O
at O
baseline O
conditions O
and O
after O
treatments O
in O
the O
case O
of O
191 O
patients O
with O
T2-4 O
N0-1 O
breast O
cancer O
enrolled O
in O
a O
randomized O
trial O
comparing O
four O
cycles O
of O
single O
agent O
epirubicin O
versus O
epirubicin O
plus O
tamoxifen O
as O
primary O
systemic O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
impact O
of O
risperidone O
on O
adaptive O
behavior O
in O
children O
with O
autistic O
disorder O
who O
have O
serious O
behavior O
problems O
and O
to O
examine O
different O
methods O
of O
scoring O
the O
Vineland O
Adaptive O
Behavior O
Scales O
to O
measure O
change O
. O
[]

OBJECTIVES O
The O
goals O
of O
the O
study O
were O
to O
determine O
the O
incidence O
of O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
after O
major O
adult O
spinal O
surgery O
and O
the O
optimal O
mode O
of O
prophylaxis O
in O
this O
surgical O
population O
. O
['Physiological-Clinical']

Patients O
responding O
to O
initial O
RTX O
treatment O
could O
receive O
further O
RTX O
courses O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Patients O
were O
clinically O
evaluated O
preoperatively O
and O
at O
6 O
weeks O
, O
1 O
year O
, O
and O
a O
minimum O
of O
2 O
years O
after O
treatment O
. O
[]

and O
celecoxib O
200 O
mg O
o.d O
. O
[]

OBJECTIVES O
To O
compare O
the O
effectiveness O
and O
the O
costs B-outcome ['Resource-use']
of O
multidisciplinary O
home O
based O
care O
in O
multiple O
sclerosis O
with O
hospital O
care O
in O
a O
prospective O
randomised O
controlled O
trial O
with O
a O
one O
year O
follow O
up O
. O
['Resource-use']

Most O
patients O
( O
more O
than O
80 O
% O
) O
achieved O
substantial O
control O
of O
their O
symptoms O
with O
budesonide O
. O
[]

Overall O
lamotrigine O
appeared O
equally O
effective O
but O
better O
tolerated O
compared O
with O
carbamazepine O
. O
[]

The O
positive O
effect O
from O
prior O
drug O
treatment O
began O
to O
dissipate O
after O
three O
years O
postadmission O
. O
[]

A O
randomized O
surveillance O
study O
of O
patients O
with O
pedunculated O
and O
small O
sessile O
tubular O
and O
tubulovillous O
adenomas O
. O
[]

Effect O
of O
light-cured O
filled O
sealant O
on O
shear O
bond O
strength O
of O
metal O
and O
ceramic O
brackets O
bonded O
with O
a O
resin-modified O
glass O
ionomer O
cement O
. O
[]

PATIENTS O
AND O
METHODS O
A O
prospective O
randomized O
comparison O
of O
conventional O
Milligan-Morgan O
haemorrhoidectomy O
and O
stapled O
mucosectomy O
was O
carried O
out O
on O
35 O
consecutive O
patients O
presenting O
with O
acute O
thrombosed O
circumferential O
prolapsed O
haemorrhoids O
. O
[]

METHODS O
Reanalysis O
of O
the O
prediction O
model O
for O
the O
risk O
of O
developing O
POAG O
using O
the O
same O
baseline O
variables O
( O
age O
, O
IOP O
, O
CCT O
, O
VCDR O
, O
and O
PSD O
) O
except O
that O
IOP O
was O
adjusted O
for O
CCT O
using O
correction O
formulae O
. O
[]

These O
findings O
do O
not O
support O
the O
hypothesis O
that O
insulin O
resistance-associated O
hyperinsulinemia O
preferentially O
drives O
endothelin-mediated B-outcome ['Physiological-Clinical']
vasoconstriction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Since O
1988 O
, O
when O
the O
term O
chronic O
fatigue O
syndrome O
( O
CFS O
) O
was O
coined O
, O
considerable O
discussion O
has O
occurred O
about O
stigma O
associated O
with O
this O
diagnostic O
term O
. O
[]

The O
incidence O
of O
adverse O
events O
did O
not O
differ O
between O
the O
two O
treatment O
groups O
. O
[]

Given O
the O
inherent O
risks O
for O
such O
serious O
complications O
, O
systemic O
thrombolysis O
, O
although O
effective O
, O
should O
be O
used O
selectively O
in O
limb-threatening O
thrombotic O
situations O
. O
[]

Neonatal O
naloxone B-outcome ['Resource-use']
['Resource-use']

Home O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring O
: O
advantages O
and O
limitations O
. O
['Physiological-Clinical']

For O
the O
pharmacodynamic O
analysis O
, O
the O
inhibitory O
effect O
of O
bilastine O
( O
inhibition O
of O
histamine-induced O
wheal O
and O
flare O
) O
was O
assessed O
on O
a O
preselected O
time O
schedule O
, O
and O
the O
predicted O
typical O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
( O
based O
on O
the O
pharmacokinetic O
model O
previously O
developed O
) O
was O
used O
. O
['Physiological-Clinical']

When O
contour O
spacing O
was O
beyond O
a O
critical O
range O
( O
about O
2 O
degrees O
) O
, O
however O
, O
the O
detectability O
dropped O
to O
chance O
levels O
, O
regardless O
of O
the O
number O
of O
colinear O
lines O
. O
[]

Serial B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
, O
hematocrit B-outcome ['Physiological-Clinical']
, O
and O
serum B-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
were O
recorded O
from O
maternal O
blood O
and O
from O
cord O
blood O
on O
delivery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
prospective O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
prophylactic O
intravesical O
instillation O
of O
pirarubicin O
( O
THP O
) O
prior O
to O
transurethral B-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TUR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
superficial I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SETTING O
Center O
for O
Tobacco O
Research O
and O
Intervention O
, O
Madison O
, O
WI O
, O
USA O
. O
[]

Influenza O
and O
pneumococcal O
vaccination O
as O
a O
model O
to O
assess O
C-reactive O
protein O
response O
to O
mild O
inflammation O
. O
[]

The O
study O
included O
only O
ACB O
's O
with O
intraoperative O
blood O
flow O
rates O
< O
or O
= O
40 O
ml/min O
as O
it O
is O
just O
these O
ACB O
's O
which O
are O
at O
the O
highest O
risk O
of O
early O
and O
late O
occlusions O
. O
[]

At O
18 O
months O
, O
the O
expert O
system O
resulted O
in O
23.2 O
% O
point O
prevalence O
abstinence B-outcome ['Life-Impact']
, O
which O
was O
33 O
% O
greater O
than O
that O
of O
assessment O
only O
. O
['Life-Impact']

SECONDARY O
OUTCOME O
MEASURES O
Postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
at O
4 O
months O
after O
fracture O
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Resource-use', 'Life-Impact', 'Physiological-Clinical']

Secondary O
outcomes O
included O
changes O
in O
markers B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
N-telopeptide I-outcome ['Physiological-Clinical']
cross-linked I-outcome ['Physiological-Clinical']
collagen I-outcome ['Physiological-Clinical']
type O
I O
) O
and O
formation B-outcome ['Physiological-Clinical']
( O
osteocalcin B-outcome ['Physiological-Clinical']
, O
N-terminal B-outcome ['Physiological-Clinical']
propeptide I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
With O
a O
median O
follow-up O
of O
57 O
months O
, O
the O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
62.3 O
% O
vs. O
48.1 O
% O
vs. O
25 O
% O
and O
the O
5-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
58.6 O
% O
vs. O
52.7 O
% O
vs. O
25 O
% O
among O
groups O
1 O
, O
2 O
, O
and O
3 O
( O
P O
= O
0.014 O
, O
P O
= O
0.027 O
, O
respectively O
) O
in O
patients O
with O
stage O
III O
rectal O
cancer O
. O
['Mortality', 'Mortality']

Children O
were O
randomly O
assigned O
to O
the O
Experimental O
group O
, O
with O
vitamin O
A-fortified O
cooking O
oil O
ration O
; O
to O
Control-1 O
group O
with O
unfortified O
cooking O
oil O
ration O
; O
and O
to O
Control-2 O
group O
without O
cooking O
oil O
ration O
. O
[]

Intravenous O
adenosine O
activates O
pulmonary O
C O
fibers O
and O
induces O
dyspnea O
. O
[]

The O
needle-knife O
group O
were O
treated O
with O
small O
needle-knife O
releasing O
therapy O
, O
blocking O
and O
functional O
training O
. O
[]

Serum B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
also O
increased O
in O
all O
three O
groups O
of O
patients O
( O
mean O
change O
within O
a O
group O
: O
0.28 O
mmol/l O
in O
group O
1 O
, O
P= O
0.28 O
; O
0.48 O
mmol/l O
in O
group O
2 O
, O
P= O
0.0008 O
; O
0.36 O
mmol/l O
in O
group O
3 O
, O
P= O
0.02 O
) O
. O
['Physiological-Clinical']

POPULATION O
Twenty-eight O
patients O
with O
symptomatic O
fibroids O
and O
uterine O
sizes O
ranging O
from O
14 O
to O
24 O
weeks O
of O
gestation O
undergoing O
open O
myomectomy O
. O
[]

The O
third O
group O
of O
patients O
underwent O
acute O
salt O
loading O
. O
[]

Furthermore O
, O
the O
addition O
of O
protein O
to O
a O
carbohydrate O
supplement O
will O
enhance O
the O
insulin O
response O
of O
a O
carbohydrate O
supplement O
. O
[]

Intravenous O
pretreatment O
of O
hypertonic O
saline O
can O
prevent O
systemic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
induced O
by O
spinal O
anesthesia O
. O
['Physiological-Clinical']

Effects O
of O
alcohol O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
morphine O
sulfate O
and O
naltrexone O
hydrochloride O
extended O
release O
capsules O
. O
['Physiological-Clinical']

The O
tumor B-outcome ['Physiological-Clinical']
regression O
rate O
was O
also O
significantly O
greater O
in O
group O
A O
( O
8/17 O
; O
47.1 O
% O
showing O
more O
than O
25 O
% O
tumor O
regression O
) O
than O
in O
group O
B O
( O
1/13 O
; O
7.7 O
% O
showing O
more O
than O
25 O
% O
tumor O
regression O
) O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

that O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
and O
Respimat O
2.5 O
?g O
once O
daily O
are O
non-inferior O
to O
HandiHaler O
in O
terms O
of O
all-cause O
mortality O
, O
and O
2 O
) O
. O
[]

Pain O
relief O
was O
evaluated O
in O
81 O
patients O
with O
acute O
ureteral O
colic O
and O
the O
confirmed O
presence O
of O
a O
calculus O
. O
[]

positive O
reframing O
) O
. O
[]

We O
compared O
the O
effect O
of O
pegvisomant O
with O
that O
of O
placebo O
before O
and O
after O
3 O
d O
of O
fasting O
. O
[]

Despite O
this O
, O
the O
augmentation O
of O
insulin-mediated B-outcome ['Physiological-Clinical']
vasodilation I-outcome ['Physiological-Clinical']
by O
BQ-123 O
was O
not O
different O
between O
groups O
. O
['Physiological-Clinical']

Oxidative O
DNA O
damage O
measured O
in O
human O
lymphocytes O
: O
large O
differences O
between O
sexes O
and O
between O
countries O
, O
and O
correlations O
with O
heart O
disease O
mortality O
rates O
. O
[]

At O
the O
end O
of O
a O
1-month O
washout O
placebo O
period O
, O
using O
a O
double-blind O
crossover O
design O
, O
the O
patients O
were O
randomly O
allocated O
to O
nifedipine O
( O
20 O
mg O
twice O
a O
day O
) O
, O
chlorthalidone O
( O
25 O
mg O
once O
a O
day O
) O
, O
the O
two O
drugs O
combined O
at O
the O
same O
doses O
and O
the O
corresponding O
placebo O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
pharmacodynamic O
response O
to O
a O
neuroactive O
steroid O
, O
pregnanolone O
, O
before O
and O
during O
different O
hormonal O
settings O
of O
postmenopausal O
hormone O
replacement O
therapy O
( O
HRT O
) O
, O
using O
natural O
progesterone O
. O
[]

Statistical O
analysis O
of O
cardiovascular B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
frequency O
) O
, O
respiratory B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
score O
showed O
an O
overlapping O
progression O
among O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Measuring O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
in O
adolescents O
: O
implications O
for O
students O
with O
TBI O
returning O
to O
school O
. O
['Life-Impact']

Neurocognitive B-outcome ['Physiological-Clinical']
outcomes O
in O
off-pump O
versus O
on-pump O
bypass O
surgery O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

One-hundred-twenty-four O
adult O
patients O
, O
ASA O
physical O
status O
I-II O
, O
undergoing O
elective O
surgery O
were O
randomly O
assigned O
into O
4 O
groups O
of O
31 O
each O
. O
[]

After O
completing O
the O
questionnaire O
pupils O
in O
both O
intervention O
conditions O
will O
receive O
three O
computer-tailored O
feedback O
letters O
in O
their O
personal O
e-mail O
box O
. O
[]

In O
all O
stages O
, O
discontinuing O
or O
continuing O
maintenance O
did O
not O
alter O
the O
median O
duration O
of O
first O
response O
. O
[]

PURPOSE O
To O
examine O
the O
effects O
of O
static O
stretching O
during O
the O
recovery O
periods O
of O
field-based O
team O
sports O
on O
subsequent O
repeated B-outcome ['Physiological-Clinical']
sprint I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
( O
RSA B-outcome ['Physiological-Clinical']
) O
and O
change O
of O
direction B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
CODS I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Sixty-six O
PNES O
patients O
were O
randomized O
to O
either O
CBT O
( O
plus O
SMC O
) O
or O
SMC O
alone O
, O
scheduled O
to O
occur O
over O
4 O
months O
. O
[]

Both O
of O
the O
treatments O
caused O
an O
increase O
in O
C-peptide B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
was O
carried O
out O
to O
compare O
patient O
safety O
and O
analgesic B-outcome ['Resource-use']
efficacy O
of O
a O
single O
and O
high O
dose O
of O
morphine O
given O
IM O
or O
IV O
for O
post-operative O
pain O
management O
. O
['Resource-use']

Are O
prenatal O
ultrasound O
scans O
associated O
with O
the O
autism B-outcome ['Life-Impact']
phenotype I-outcome ['Life-Impact']
? O
['Life-Impact']

Dexmedetomidine B-outcome ['Resource-use']
infusion I-outcome ['Resource-use']
did O
not O
completely O
abolish O
the O
need O
for O
isoflurane B-outcome ['Resource-use']
but O
diminished O
its O
requirement O
by O
> O
90 O
% O
( O
P O
= O
0.02 O
) O
. O
['Resource-use']

RESULTS O
The O
groups O
were O
matched O
in O
regard O
to O
patient O
age O
( O
p O
= O
0.84 O
) O
, O
body O
mass O
index O
( O
p O
= O
0.43 O
) O
, O
American O
Society O
of O
Anesthesiologists O
class O
( O
p O
= O
0.81 O
) O
and O
laterality O
( O
p O
= O
0.12 O
) O
. O
[]

The O
changes O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
TGs I-outcome ['Physiological-Clinical']
, O
C1 B-outcome ['Physiological-Clinical']
, O
and O
C2 B-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
the O
WL+FAEE O
group O
than O
in O
the O
WL O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

POPULATION O
Two O
hundred O
and O
twenty-four O
women O
at O
12 O
to O
20 O
weeks O
of O
gestation O
. O
[]

The O
study O
was O
a O
prospective O
trial O
in O
which O
76 O
burn O
scars O
in O
60 O
patients O
were O
objectively O
assessed O
with O
the O
Minolta O
Chromameter O
CR-300 O
for O
erythema O
and O
with O
the O
Dermascan B-outcome ['Resource-use']
C I-outcome ['Resource-use']
for O
thickness O
of O
the O
scar O
over O
a O
period O
of O
3 O
months O
. O
['Resource-use']

CONCLUSIONS O
AND O
CLINICAL O
RELEVANCE O
IM O
injection O
of O
erythromycin O
increased O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
in O
dairy O
calves O
, O
whereas O
low-dose O
and O
high-dose O
gentamicin O
did O
not O
alter O
the O
rate O
of O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
as O
measured O
by O
acetaminophen O
kinetics O
and O
glucose O
absorption O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Today O
, O
endoscopic O
sclerotherapy O
( O
ES O
) O
and O
endoscopic O
ligation O
( O
EL O
) O
are O
the O
accepted O
, O
community O
standards O
of O
endoscopic O
treatment O
of O
patients O
with O
EVH O
. O
[]

The O
early O
group O
had O
no O
flexion O
or O
car O
riding O
restrictions O
. O
[]

FINDINGS O
The O
5.3 O
year O
median O
follow-up O
( O
range O
8 O
months O
to O
8 O
years O
11 O
months O
) O
showed O
44 O
% O
( O
95 O
% O
CI O
7-66 O
) O
risk O
reduction O
for O
recurrence O
in O
the O
recurrence-free O
period O
in O
all O
patients O
receiving O
ASI O
( O
p=0.023 O
) O
. O
[]

The O
amount O
of O
HCW O
gain O
tended O
to O
be O
less O
( O
P O
= O
0.095 O
) O
for O
steers O
of O
the O
TT O
genotype O
( O
12.7 O
kg O
) O
than O
either O
CC O
( O
16.3 O
kg O
) O
or O
CT O
( O
17.0 O
kg O
) O
genotypes O
. O
[]

Results O
support O
the O
ability O
of O
vouchers O
to O
produce O
modest O
improvements O
in O
abstinence B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
rates O
during O
brief O
detoxification O
but O
suggest O
that O
additional O
interventions O
are O
needed O
to O
sustain O
improvements O
. O
['Life-Impact']

It O
is O
suggested O
, O
therefore O
, O
that O
the O
new O
aqueous O
nasal O
spray O
provides O
an O
alternative O
method O
of O
intranasal O
administration O
of O
the O
steroid O
for O
patients O
who O
may O
prefer O
an O
aqueous O
product O
. O
[]

OBJECTIVE O
To O
determine O
whether O
hospital O
report O
cards O
constructed O
using O
linked O
hospital O
and O
prescription O
administrative O
databases O
are O
effective O
for O
improving O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
for O
acute O
myocardial O
infarction O
( O
AMI O
) O
. O
['Life-Impact']

Randomized O
comparison O
of O
the O
efficacy O
and O
safety O
of O
zotarolimus-eluting O
stents O
vs. O
sirolimus-eluting O
stents O
for O
percutaneous O
coronary O
intervention O
in O
chronic O
total O
occlusion O
-- O
CAtholic O
Total O
Occlusion O
Study O
( O
CATOS O
) O
trial O
. O
[]

Participants O
were O
randomly O
assigned O
to O
one O
of O
three O
experimental O
consent O
documents O
( O
traditional O
, O
n O
= O
110 O
; O
binary O
, O
n O
= O
103 O
; O
and O
tiered O
, O
n O
= O
110 O
) O
. O
[]

For O
all O
256 O
carcinomas O
, O
the O
cumulative O
accuracy O
( O
brushing B-outcome ['Resource-use']
cytology I-outcome ['Resource-use']
plus O
biopsy B-outcome ['Resource-use']
) O
reached O
98.8 O
% O
and O
was O
significantly O
better O
( O
P O
less O
than O
.001 O
) O
than O
that O
of O
biopsy B-outcome ['Resource-use']
alone O
( O
93.9 O
% O
) O
or O
cytology B-outcome ['Physiological-Clinical']
alone O
( O
87.9 O
% O
) O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

At O
the O
end O
of O
the O
study O
, O
lanthanum O
carbonate-treated O
patients O
had O
significantly O
lower O
phosphorus B-outcome ['Physiological-Clinical']
levels O
( O
1.6 O
+/- O
0.5 O
mmol/l O
[ O
5.1 O
+/- O
1.5 O
mg/dl O
] O
; O
n=30 O
) O
than O
those O
receiving O
placebo O
( O
2.3 O
+/- O
0.4 O
mmol/l O
[ O
7.2 O
+/- O
1.3 O
mg/dl O
] O
; O
n=31 O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Patients O
were O
randomized O
into O
one O
of O
three O
groups O
to O
receive O
1 O
L O
of O
either O
5 O
% O
dextrose O
( O
50 O
gm O
of O
glucose O
) O
or O
Ringer O
's O
lactate O
or O
isotonic O
saline O
solution O
before O
epidural O
anesthesia O
. O
[]

However O
the O
mutagenic O
studies O
of O
several O
biological O
systems O
indicate O
that O
it O
has O
a O
mutagenic B-outcome ['Physiological-Clinical']
effect O
, O
but O
the O
mutagenic O
and O
carcinogenic B-outcome ['Physiological-Clinical']
effects O
on O
humans O
and O
animals O
remain O
questionable O
, O
because O
FZ O
has O
been O
biotransformed O
into O
other O
metabolites O
. O
['Physiological-Clinical', 'Physiological-Clinical']

aeruginosa B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
between O
the O
4th O
and O
14th O
day O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
the O
mothers O
of O
both O
groups O
observed O
behavioral O
changes O
. O
[]

METHODOLOGY O
A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O
[]

CONCLUSIONS O
The O
success O
of O
improving O
nutrient O
profile O
by O
active O
encouragement O
of O
F O
& O
V O
intake O
in O
an O
intervention O
study O
implies O
the O
need O
for O
a O
more O
hands-on O
public O
health O
approach O
. O
[]

Both O
eyes O
of O
each O
volunteer O
were O
irrigated O
simultaneously O
for O
15 O
minutes O
, O
with O
additional O
discomfort B-outcome ['Physiological-Clinical']
scores O
being O
recorded O
every O
5 O
minutes O
using O
the O
same O
100-mm O
, O
unnumbered O
analog O
discomfort B-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
and O
analgesic O
use O
for O
the O
first O
24 O
hrs O
were O
recorded O
. O
['Physiological-Clinical']

Classroom O
intervention O
for O
illness-related O
problem O
behavior O
in O
children O
with O
developmental O
disabilities O
. O
[]

Possible O
etiology O
of O
improvements O
in O
both O
quality O
of O
life O
and O
overlapping O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
by O
proton O
pump O
inhibitor O
treatment O
in O
a O
prospective O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

Lumbar O
spine O
radiography O
was O
associated O
with O
a O
net O
economic B-outcome ['Resource-use']
loss I-outcome ['Resource-use']
at O
3 O
and O
9 O
months O
. O
['Resource-use']

In O
both O
groups O
, O
clinical B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
improved O
and O
stratum O
corneum B-outcome ['Physiological-Clinical']
hydration I-outcome ['Physiological-Clinical']
increased O
significantly O
during O
the O
study O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
subjects O
had O
seizures B-outcome ['Physiological-Clinical']
( O
one O
taking O
placebo O
) O
, O
but O
these O
were O
considered O
unrelated O
to O
active O
drug O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
percentage O
of O
patients O
[]

MAIN O
OUTCOME O
MEASURES O
The O
rate O
of O
induction O
of O
labour B-outcome ['Physiological-Clinical']
for O
prolonged B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
degree O
of O
association O
between O
BMI O
percentile O
and O
frequency O
of O
RTEC O
consumption O
adjusted O
for O
age O
, O
sex O
, O
ethnicity O
, O
and O
nutrition-related O
parameters O
were O
calculated O
using O
a O
partial O
correlation O
multivariate O
linear O
model O
analysis O
. O
[]

In O
an O
attempt O
to O
develop O
a O
brief O
treatment O
for O
disaster O
survivors O
, O
the O
present O
study O
examined O
the O
effectiveness O
of O
a O
single O
session O
of O
modified O
behavioral O
treatment O
in O
earthquake-related O
posttraumatic O
stress O
disorder O
. O
[]

BACKGROUND O
To O
evaluate O
the O
effectiveness O
of O
intravaginal O
electrical O
stimulation O
( O
ES O
) O
of O
the O
pelvic O
floor O
for O
urinary O
incontinence O
in O
elderly O
women O
, O
and O
to O
determine O
whether O
ES O
of O
the O
pelvic O
floor O
is O
a O
preferable O
treatment O
for O
urinary O
incontinence O
in O
elderly O
women O
. O
[]

Liver B-outcome ['Physiological-Clinical']
and O
kidney B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
significantly O
differed O
with O
both O
treatments O
( O
octreotide O
: O
-71 O
+/- O
57 O
ml O
versus O
+71 O
+/- O
107 O
; O
placebo O
: O
+14 O
+/- O
85 O
ml O
versus O
+162 O
+/- O
114 O
) O
, O
but O
net O
reductions B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
( O
-85 O
+/- O
103 O
ml O
) O
and O
kidney B-outcome ['Physiological-Clinical']
( O
-91 O
+/- O
125 O
ml O
) O
volume B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
on O
octreotide O
versus O
placebo O
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Strength O
of O
hand O
grip O
was O
the O
best O
predictor O
of O
volume O
delivered O
and O
was O
more O
strongly O
correlated O
with O
volumes O
delivered O
by O
one O
rather O
than O
two O
hands O
. O
[]

The O
distribution O
of O
HIF-1alpha B-outcome ['Physiological-Clinical']
genotypes I-outcome ['Physiological-Clinical']
in O
colorectal O
cancer O
patients O
was O
100 O
C/C O
( O
100 O
% O
) O
, O
0 O
C/T O
( O
0 O
% O
) O
, O
and O
0 O
T/T O
( O
0 O
% O
) O
. O
['Physiological-Clinical']

Right O
colon O
adenomas O
were O
missed O
more O
often O
( O
27 O
% O
) O
than O
left O
colon O
adenomas O
( O
21 O
% O
) O
, O
but O
the O
difference O
was O
not O
significant O
. O
[]

Only O
a O
subgroup O
of O
patients O
with O
pronounced B-outcome ['Life-Impact']
negative O
symptoms B-outcome ['Physiological-Clinical']
developed I-outcome ['Physiological-Clinical']
some O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
as O
indicated O
by O
significant O
changes O
in O
the O
GAF-scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Cisplatin O
, O
epirubicin O
, O
leucovorin O
and O
5-fluorouracil O
( O
PELF O
) O
is O
more O
active O
than O
5-fluorouracil O
, O
doxorubicin O
and O
methotrexate O
( O
FAMTX O
) O
in O
advanced O
gastric O
carcinoma O
. O
[]

The O
difference O
in O
the O
median O
annual O
change O
between O
the O
two O
groups O
was O
significant O
( O
P O
= O
0.013 O
) O
. O
[]

In O
order O
to O
evaluate O
any O
beneficial O
effect O
of O
such O
an O
administration O
, O
a O
group O
of O
patients O
with O
recurrent O
gastric O
cancer O
was O
studied O
. O
[]

Treatment O
was O
monitored O
using O
TEE O
. O
[]

CONCLUSIONS O
NT O
201 O
is O
effective O
and O
safe O
in O
inducing O
the O
desired O
paretic O
effect O
. O
[]

A O
significant O
decrease O
in O
number O
of O
tender B-outcome ['Physiological-Clinical']
sites I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
masticatory I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
was O
found O
in O
group O
T O
at O
the O
follow-ups O
. O
['Physiological-Clinical']

In O
the O
second O
phase O
, O
the O
adult O
either O
imitated O
the O
child O
or O
was O
contingently O
responsive O
to O
the O
child O
. O
[]

This O
study O
evaluated O
the O
prognostic O
significance O
of O
SLN O
metastatic O
deposits O
< O
or O
= O
0.2 O
mm O
in O
patients O
treated O
in O
a O
referral O
cancer O
center O
in O
Brazil O
. O
[]

RESULTS O
After O
induction O
treatment O
, O
464 O
patients O
were O
assessable O
for O
the O
consolidation O
phase O
. O
[]

Thirty-five O
children O
diagnosed O
with O
autism O
were O
randomly O
assigned O
to O
either O
a O
joint O
attention O
or O
a O
symbolic O
play O
intervention O
. O
[]

Laboratory O
parameters O
of O
oxidative O
stress O
, O
fibrinolysis O
and O
endothelial O
function O
were O
evaluated O
before O
and O
at O
the O
end O
of O
each O
treatment O
period O
. O
[]

After O
2 O
months O
( O
level O
2 O
) O
, O
nonresponders O
received O
a O
low-dose O
thiazide O
diuretic O
, O
and O
after O
4 O
months O
( O
level O
3 O
) O
, O
amlodipine O
( O
groups O
E O
, O
C O
, O
and O
L O
) O
and O
carvedilol O
( O
group O
A O
) O
. O
[]

Preservation O
of O
insulin O
secretion O
, O
measured O
by O
mixed-meal-stimulated O
C-peptide O
secretion O
, O
was O
compared O
after O
6 O
and O
12 O
months O
of O
treatment O
. O
[]

AIMS O
To O
compare O
an O
activity-based O
, O
health-promotion O
programme O
with O
an O
individual O
programme O
, O
targeting O
the O
elderly O
with O
age-related O
macular O
degeneration O
concerning O
the O
effect O
on O
the O
development O
of O
dependence O
in O
ADL O
, O
general O
health O
, O
and O
self-reported O
health O
problems O
. O
[]

METHODS O
In O
a O
double-blinded O
, O
placebo-controlled O
study O
we O
randomized O
1223 O
mothers O
with O
infants O
at O
high O
risk O
for O
allergy O
to O
receive O
a O
probiotic O
mixture O
( O
2 O
lactobacilli O
, O
bifidobacteria O
, O
and O
propionibacteria O
) O
or O
placebo O
during O
the O
last O
month O
of O
pregnancy O
and O
their O
infants O
to O
receive O
it O
from O
birth O
until O
age O
6 O
months O
. O
[]

A O
recently O
synthesized O
alpha O
1-blocker O
, O
( O
R O
) O
( O
- O
) O
-5- O
[ O
2- O
[ O
[ O
2- O
( O
o-ethoxyphenoxy O
) O
ethyl O
] O
amino O
] O
propyl O
] O
-2- O
methoxybenzenesulfonamide O
hydrochloride O
( O
YM617 O
) O
, O
was O
evaluated O
in O
270 O
patients O
with O
benign O
prostatic O
hypertrophy O
in O
a O
double-blind O
study O
. O
[]

acetaminophen O
seems O
to O
be O
effective O
in O
attenuating O
pain B-outcome ['Physiological-Clinical']
during O
i.v O
. O
['Physiological-Clinical']

If O
BP B-outcome ['Physiological-Clinical']
was O
not O
controlled O
with O
either O
agent O
, O
chlorthalidone O
was O
added O
. O
['Physiological-Clinical']

The O
purposes O
of O
this O
study O
were O
( O
1 O
) O
to O
assess O
baseline O
echocardiographic O
predictors O
of O
clinical O
outcome O
, O
( O
2 O
) O
to O
investigate O
changes O
in O
echocardiographic O
parameters O
, O
and O
( O
3 O
) O
to O
compare O
these O
echocardiographic O
changes O
with O
changes O
in O
plasma O
levels O
of O
b-type O
natriuretic O
peptide O
( O
BNP O
) O
in O
a O
population O
of O
children O
with O
systemic O
ventricular O
dysfunction O
and O
symptomatic O
heart O
failure O
treated O
with O
carvedilol O
or O
placebo O
. O
[]

Granisetron O
given O
at O
20 O
or O
40 O
micrograms/kg O
i.v O
. O
[]

Agreement O
between O
methods O
in O
the O
classification O
of O
clinic O
reactors O
was O
found O
in O
147 O
patients O
( O
78 O
% O
) O
. O
[]

FZYLG O
was O
given O
to O
the O
former O
for O
15 O
days O
. O
[]

This O
study O
suggests O
that O
the O
addition O
of O
TENS O
, O
applied O
continuously O
during O
the O
immediate O
postoperative O
period O
following O
CABG O
with O
ITA O
, O
may O
not O
be O
advantageous O
in O
pain B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
or O
the O
prevention O
of O
pulmonary B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Polish O
patients O
also O
underwent O
pretreatment O
and O
post-treatment O
urodynamic B-outcome ['Physiological-Clinical']
evaluations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
Phenytoin O
is O
an O
effective O
anticonvulsant O
that O
has O
not O
previously O
been O
studied O
prophylactically O
in O
bipolar O
( O
BP O
) O
patients O
. O
[]

The O
number O
of O
children O
who O
achieved O
the O
75th O
percentile O
for O
the O
vegetable O
and O
fruit O
component O
score O
was O
higher O
in O
the O
intervention O
than O
in O
control O
group O
( O
RR O
= O
1.95 O
; O
95 O
% O
CI O
= O
1.31-2.89 O
and O
RR O
= O
1.49 O
; O
95 O
% O
CI O
= O
1.07-2.07 O
, O
respectively O
) O
. O
[]

Comparison O
of O
an O
allograft O
in O
an O
experimental O
putty O
carrier O
and O
a O
bovine-derived O
xenograft O
used O
in O
ridge O
preservation O
: O
a O
clinical O
and O
histologic O
study O
in O
humans O
. O
[]

As O
a O
result O
, O
porfimer O
sodium O
showed O
a O
good O
[]

PURPOSE O
We O
determined O
the O
prognostic O
value O
of O
carcinoembryonic O
antigen O
( O
CEA O
) O
clearance O
after O
tumor O
resection O
with O
serial O
evaluation O
of O
postoperative O
CEA O
levels O
in O
rectal O
cancer O
. O
[]

This O
study O
was O
designed O
to O
determine O
the O
ability O
of O
experienced O
surgeons O
to O
interpret O
haptic B-outcome ['Physiological-Clinical']
feedback I-outcome ['Physiological-Clinical']
with O
respect O
to O
texture B-outcome ['Life-Impact']
, O
shape O
, O
and O
consistency O
of O
an O
object B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

MAIN O
OUTCOME O
MEASURES O
We O
recorded O
the O
number O
of O
transfusions B-outcome ['Resource-use']
, O
the O
number O
of O
donor B-outcome ['Physiological-Clinical']
exposures I-outcome ['Physiological-Clinical']
, O
and O
various O
clinical B-outcome ['Physiological-Clinical']
and O
physiologic B-outcome ['Physiological-Clinical']
outcomes O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Tissue O
microarray O
in O
a O
subset O
of O
South O
African O
patients O
with O
DLBCL O
. O
[]

At O
5 O
years O
, O
the O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
rate O
was O
63 O
% O
+/- O
6 O
% O
, O
and O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
rate O
was O
79 O
% O
+/- O
5 O
% O
, O
compared O
with O
a O
PFS B-outcome ['Mortality']
rate O
of O
19 O
% O
+/- O
3 O
% O
( O
P O
< O
0.0001 O
) O
and O
an O
OS B-outcome ['Mortality']
rate O
of O
22 O
% O
+/- O
3 O
% O
( O
P O
< O
0.0001 O
) O
in O
the O
remainder O
of O
the O
cohort O
. O
['Mortality', 'Mortality', 'Mortality', 'Mortality']

At O
TW24 O
, O
the O
control O
group O
but O
not O
the O
amantadine O
group O
, O
however O
, O
showed O
significant O
deterioration O
of O
the O
modalities B-outcome ['Physiological-Clinical']
depression B-outcome ['Life-Impact']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
vigor B-outcome ['Physiological-Clinical']
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

65 O
of O
the O
patients O
showed O
at O
least O
one O
palatally-displaced O
canine O
. O
[]

After O
participating O
in O
an O
intensive O
skill O
development O
program O
, O
pharmacists O
performed O
in O
an O
interdisciplinary O
team O
in O
a O
rural O
clinic O
. O
[]

Every O
patient O
in O
each O
of O
the O
3 O
groups O
received O
intra-arterial O
heparin O
, O
lidocaine O
and O
diltiazem O
. O
[]

All O
44 O
patients O
were O
contacted O
for O
follow-up O
at O
48 O
to O
72 O
hours O
after O
enrollment O
. O
[]

Adherence B-outcome ['Life-Impact']
was O
assessed O
primarily O
using O
the O
number O
of O
actual B-outcome ['Life-Impact']
administered I-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
reported O
from O
the O
device O
counter O
divided O
by O
the O
number O
of O
scheduled O
doses O
. O
['Life-Impact', 'Life-Impact']

At O
the O
end O
of O
the O
study O
, O
71 O
% O
in O
the O
fluvoxamine O
group O
and O
69 O
% O
in O
the O
clomipramine O
group O
were O
responders O
( O
> O
or= O
50 O
% O
decrease O
in O
17-item O
HAMD O
total O
score O
) O
. O
[]

The O
incidence O
of O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GER I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
tracheal B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
aspiration I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
thoracotomy O
in O
the O
lateral O
position O
is O
unknown O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
independent O
data O
monitoring O
committee O
concluded O
it O
was O
unlikely O
that O
we O
would O
show O
noninferiority O
in O
the O
final O
results O
for O
the O
experimental O
arm O
and O
advised O
stopping O
random O
assignment O
for O
early O
PET-negative O
patients O
. O
[]

The O
parents O
of O
consecutive O
children O
with O
autism O
( O
2 O
( O
1/2 O
) O
-5 O
years O
old O
) O
from O
the O
autism O
assessment O
services O
for O
the O
intervention O
regions O
were O
then O
randomly O
allocated O
to O
either O
a O
20-week O
manual-based O
parent O
education O
and O
behavior O
management O
intervention O
( O
n O
= O
35 O
) O
or O
a O
manual-based O
parent O
education O
and O
counseling O
intervention O
( O
n O
= O
35 O
) O
. O
[]

Additionally O
, O
post-vaccination B-outcome ['Physiological-Clinical']
protective I-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
against O
the O
A/Johannesburg O
strain O
were O
more O
prevalent O
in O
those O
subjects O
who O
were O
never O
vaccinated O
before O
. O
['Physiological-Clinical']

Phase O
III O
trial O
comparing O
whole-pelvic O
versus O
prostate-only O
radiotherapy O
and O
neoadjuvant O
versus O
adjuvant O
combined O
androgen O
suppression O
: O
Radiation O
Therapy O
Oncology O
Group O
9413 O
. O
[]

In O
the O
direct O
comparison O
, O
there O
was O
no O
significant O
difference O
between O
nebivolol O
and O
metoprolol O
. O
[]

During O
the O
first O
cycle O
, O
grade B-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
delayed I-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
3 O
fever B-outcome ['Physiological-Clinical']
were O
the O
DLTs O
at O
the O
dosage O
of O
80 O
mg/m O
( O
2 O
) O
/day O
in O
three O
out O
of O
five O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Compared O
with O
the O
placebo O
phase O
, O
end O
of O
phase O
clinic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
unchanged O
by O
any O
of O
the O
progestogen O
treatments O
. O
['Physiological-Clinical']

On O
the O
other O
hand O
, O
alveolar O
macrophages O
from O
BAL O
showed O
a O
decrease O
in O
the O
ability O
to O
phagocytose B-outcome ['Physiological-Clinical']
unopsonized I-outcome ['Physiological-Clinical']
Candida I-outcome ['Physiological-Clinical']
albicans I-outcome ['Physiological-Clinical']
and O
a O
decrease O
in O
superoxide B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Progression O
of O
PD O
is O
characterized O
by O
the O
emergence O
of O
motor O
deficits O
, O
which O
eventually O
respond O
less O
to O
dopaminergic O
therapy O
and O
pose O
a O
therapeutic O
challenge O
. O
[]

Similarly O
, O
measures O
of O
HR B-outcome ['Physiological-Clinical']
and O
RMSSD B-outcome ['Physiological-Clinical']
remained O
the O
same O
between O
these O
two O
conditions O
; O
however O
, O
PEP B-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
later O
part O
of O
the O
night O
in O
the O
chewing O
condition O
compared O
with O
a O
relative O
increase O
for O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
short-term O
effects O
of O
denopamine O
, O
an O
orally O
available O
beta-stimulant O
, O
on O
exercise O
capacity O
were O
studied O
in O
patients O
with O
chronic O
heart O
failure O
. O
[]

The O
role O
of O
nasal O
IgA O
in O
children O
vaccinated O
with O
live O
attenuated O
influenza O
vaccine O
. O
[]

The O
effect O
of O
Cys O
LT1 O
receptor O
blockade O
on O
airway O
responses O
to O
allergen O
. O
[]

Improving O
access O
to O
primary O
and O
preventive O
care O
for O
lower-income O
patients O
could O
reduce O
amputation B-outcome ['Resource-use']
rates O
among O
African O
Americans O
. O
['Resource-use']

From O
this O
perspective O
, O
awareness O
of O
the O
importance O
of O
studies O
about O
drug O
effectiveness O
on O
treatment O
discontinuation O
rate O
, O
remission O
rate O
, O
and O
improvement O
in O
QOL O
has O
grown O
recently O
. O
[]

There O
were O
no O
statistical O
differences O
between O
the O
two O
groups O
according O
to O
the O
side O
effects O
( O
p O
> O
0.01 O
) O
. O
[]

Experimental O
studies O
suggest O
that O
recombinant O
human O
erythropoietin O
( O
EPO O
) O
independent O
of O
its O
erythropoietic O
effect O
may O
be O
used O
clinically O
as O
an O
anti-inflammatory O
drug O
. O
[]

BACKGROUND O
Due O
to O
dyspnea O
and O
fatigue O
, O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
are O
often O
restricted O
in O
the O
performance O
of O
everyday O
activities O
, O
which O
gradually O
may O
lead O
to O
hypoactivity O
. O
[]

CONCLUSIONS O
AND O
RELEVANCE O
These O
findings O
provide O
the O
first O
neurobiological O
evidence O
for O
oxytocin O
's O
beneficial O
effects O
on O
sociocommunicational O
deficits O
of O
ASD O
and O
give O
us O
the O
initial O
account O
for O
neurobiological O
mechanisms O
underlying O
any O
beneficial O
effects O
of O
the O
neuropeptide O
. O
[]

Impact O
of O
isotonic O
and O
hypertonic O
saline O
solutions O
on O
mucociliary O
activity O
in O
various O
nasal O
pathologies O
: O
clinical O
study O
. O
[]

Eighty O
five O
( O
77 O
% O
) O
had O
follow O
up O
angiography O
at O
five O
months O
. O
[]

Of O
20 O
patients O
receiving O
flecainide O
, O
14 O
of O
17 O
( O
82 O
% O
) O
with O
AF O
converted O
to O
sinus O
rhythm O
, O
but O
in O
3 O
patients O
with O
AFI O
flecainide O
failed O
. O
[]

A O
prospective O
study O
on O
the O
clinical O
performance O
of O
polysiloxane O
soft O
liners O
: O
one-year O
results O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacies O
of O
7-day O
and O
14-day O
PPI-containing O
triple O
therapy O
. O
[]

The O
adjusted O
risk O
of O
pregnancy B-outcome ['Physiological-Clinical']
among O
FemCap O
users O
was O
1.96 O
times O
that O
among O
diaphragm O
users O
, O
with O
an O
upper O
95 O
% O
confidence O
limit O
of O
3.01 O
. O
['Physiological-Clinical']

Brief O
high-impact O
exercise O
may O
have O
a O
role O
in O
reducing O
hip B-outcome ['Physiological-Clinical']
fragility I-outcome ['Physiological-Clinical']
, O
but O
may O
need O
to O
be O
performed O
frequently O
for O
optimal O
response O
. O
['Physiological-Clinical']

Both O
agents O
were O
effective O
in O
producing O
hypotension B-outcome ['Physiological-Clinical']
, O
but O
enflurane O
was O
the O
more O
potent O
hypotensive O
agent O
in O
terms O
of O
MAC O
equivalents O
. O
['Physiological-Clinical']

Participants O
were O
33 O
children O
( O
29 O
boys O
) O
between O
the O
ages O
of O
5 O
and O
13 O
years O
who O
participated O
in O
a O
four-week O
crossover O
trial O
of O
placebo O
and O
increasing O
doses O
of O
methylphenidate O
given O
in O
random O
order O
each O
for O
one O
week O
. O
[]

has O
no O
statistically O
significant O
effect O
on O
the O
improvement O
of O
the O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
the O
fluorescein B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
in O
Behcet O
's O
patients O
with O
CMO O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
use O
of O
a O
weighted O
blanket O
did O
not O
help O
children O
with O
ASD O
sleep O
for O
a O
longer O
period O
of O
time O
, O
fall O
asleep O
significantly O
faster O
, O
or O
wake O
less O
often O
. O
[]

Somatostatin O
and O
ranitidine O
in O
the O
treatment O
of O
non-variceal O
upper O
gastrointestinal O
bleeding O
: O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
controlled O
study O
. O
[]

Our O
observations O
suggest O
that O
a O
fat O
high O
in O
stearic O
acid O
might O
affect O
Lp B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
in O
a O
different O
way O
than O
fats O
high O
in O
palmitic O
and O
myristic+lauric O
acid O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
combined O
spinal-epidural O
technique O
provided O
more O
effective O
analgesia O
during O
labour O
than O
epidural O
analgesia O
alone O
but O
offered O
no O
other O
advantage O
. O
[]

This O
22-year-old O
epileptic O
woman O
was O
treated O
continuously O
by O
carbamazepine O
and O
a O
folic O
acid O
( O
1 O
mg O
) O
-containing O
multivitamin O
from O
the O
20th O
week O
of O
gestation O
. O
[]

To O
characterize O
the O
time O
course O
of O
plasma O
and O
red O
blood O
cell O
( O
RBC O
) O
changes O
after O
n-3 O
polyunsaturated O
fatty O
acid O
( O
PUFA O
) O
supplementation O
, O
20 O
healthy O
male O
volunteers O
were O
randomly O
assigned O
to O
receive O
either O
four O
1-g O
capsules O
of O
n-3 O
PUFA O
ethyl O
esters O
or O
four O
1-g O
capsules O
of O
olive O
oil O
( O
as O
placebo O
) O
for O
a O
period O
of O
4 O
mo O
, O
followed O
by O
a O
3-mo O
washout O
period O
. O
[]

The O
elimination O
half-life O
( O
T1/2 O
) O
of O
rhuGM-CSF O
was O
1.4 O
+/- O
0.8 O
to O
3.9 O
+/- O
2.8 O
hours O
. O
( O
[]

Randomized O
, O
placebo-controlled O
, O
crossover O
study O
of O
methylphenidate O
for O
attention-deficit/hyperactivity O
disorder O
symptoms O
in O
preschoolers O
with O
developmental O
disorders O
. O
[]

METHODS O
After O
hemorrhoidal O
banding O
, O
patients O
were O
randomly O
assigned O
to O
receive O
a O
local O
injection O
of O
bupivacaine O
with O
1:200,000 O
epinephrine O
, O
an O
injection O
of O
normal O
saline O
, O
or O
no O
injection O
, O
just O
superior O
to O
each O
band O
. O
[]

CONCLUSIONS O
Raltegravir O
intensification O
resulted O
in O
a O
rapid O
increase O
in O
the O
level O
of O
2-LTR O
circles O
in O
a O
proportion O
of O
subjects O
, O
indicating O
that O
low-level O
viral O
replication O
persists O
in O
some O
individuals O
even O
after O
long-term O
ART O
. O
[]

Both O
hormonal O
doses O
resulted O
in O
( O
high O
) O
physiological B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
mean O
cumulative O
24-h O
i.v O
. O
[]

Global O
contour O
saliency O
and O
local O
colinear O
interactions O
. O
[]

The O
plates O
were O
incubated O
and O
counted O
. O
[]

The O
interaction O
of O
eptifibatide O
with O
CrCl O
had O
borderline O
significance O
for O
the O
30-day O
outcome O
( O
p O
= O
0.109 O
) O
. O
[]

Modified O
CBT O
interventions O
for O
anxiety O
in O
children O
with O
ASD O
have O
also O
yielded O
promising O
results O
. O
[]

Alpha O
interferon O
clinical O
trial O
for O
multiple O
sclerosis O
: O
design O
considerations O
. O
[]

MATERIAL O
AND O
METHODS O
Data O
from O
246 O
cancer O
patients O
participating O
in O
a O
randomized O
placebo-controlled O
smoking O
cessation O
clinical O
trial O
were O
used O
to O
examine O
baseline O
predictors O
of O
end-of-treatment O
and O
six-month O
postbaseline O
smoking O
cessation O
outcomes O
. O
[]

The O
ability O
to O
predict O
the O
effect O
of O
anthelmintic O
treatment O
on O
milk O
production O
depends O
on O
the O
level O
of O
parasitism O
quantified O
by O
an O
ELISA O
measuring O
milk B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against O
O. O
ostertagi O
, O
and O
reported O
as O
optical B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ODRs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Behavioral B-outcome ['Life-Impact']
ratings O
were O
obtained O
at O
baseline O
and O
after O
4 O
, O
8 O
, O
and O
12 O
weeks O
of O
treatment O
. O
['Life-Impact']

RESULTS O
For O
pramipexole O
recipients O
, O
the O
primary O
outcome O
measure O
, O
PLM O
per O
hour B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bed I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
awake I-outcome ['Physiological-Clinical']
( O
the O
PLM O
index O
, O
or O
PLMI O
) O
, O
decreased O
by O
a O
median O
of O
-26.55 O
to O
-52.70 O
depending O
on O
dosage O
group O
, O
vs. O
-3.00 O
for O
placebo O
( O
p O
< O
0.01 O
or O
0.001 O
for O
each O
group O
vs. O
placebo O
; O
Wilcoxon-Mann-Whitney O
test O
) O
. O
['Physiological-Clinical']

The O
efficacy O
and O
safety O
of O
oral O
enoximone O
were O
also O
studied O
in O
a O
12-week O
, O
double-blind O
randomized O
format O
. O
[]

In O
the O
last O
week O
of O
training O
the O
exercise O
intensity O
in O
the O
group O
of O
patients O
who O
were O
trained O
by O
the O
continuous O
method O
was O
at O
83 O
watts O
, O
and O
at O
20:121 O
watts O
in O
the O
group O
of O
patients O
who O
were O
trained O
by O
interval O
method O
( O
rest O
: O
work O
each O
1:1 O
min O
) O
. O
[]

Patients O
completing O
six O
treatments O
in O
10 O
days O
or O
less O
had O
better O
results O
than O
those O
treated O
over O
a O
longer O
period O
. O
[]

These O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
parameters O
in O
group O
B O
were O
also O
decreased O
as O
compared O
ith O
the O
pretreatment O
level O
brt O
with O
less O
statistical O
significance O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

INTERVENTION O
Using O
the O
data O
sets O
of O
the O
DCCT O
, O
this O
study O
analyzed O
the O
strengths O
of O
the O
associations O
between O
smoking O
and O
macronutrient B-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
, O
hemoglobin B-outcome ['Physiological-Clinical']
A1c I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HbA1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
body O
mass O
index O
( O
BMI O
) O
, O
and O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
at O
the O
study O
baseline O
, O
2 O
years O
, O
and O
4 O
years O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
symptom-specific O
risk O
of O
mortality B-outcome ['Mortality']
was O
significantly O
associated O
with O
diarrhea B-outcome ['Physiological-Clinical']
, O
convulsions B-outcome ['Physiological-Clinical']
, O
and O
other O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Relationship O
between O
endogenous O
estrogen O
concentrations O
and O
serum O
cholesteryl O
ester O
transfer O
protein O
concentrations O
in O
Chinese O
women O
. O
[]

All O
patients O
reported O
their O
average O
and O
worst O
pain B-outcome ['Physiological-Clinical']
levels O
at O
baseline O
and O
2 O
and O
3 O
weeks O
after O
the O
start O
of O
the O
intervention O
. O
['Physiological-Clinical']

Randomised O
children O
received O
up O
to O
three O
26-day O
courses O
of O
succimer O
or O
placebo O
, O
and O
were O
then O
followed O
for O
3 O
years O
. O
[]

Both O
restorations B-outcome ['Physiological-Clinical']
had O
to O
be O
replaced O
. O
['Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
, O
randomized O
study O
is O
described O
of O
an O
assessment O
of O
the O
efficacy O
and O
relative O
safety O
of O
the O
ergot O
alkaloid O
, O
dihydroergocryptine O
, O
on O
52 O
patients O
with O
mild O
organic O
brain O
syndrome O
over O
a O
period O
of O
three O
months O
using O
a O
series O
of O
neurophysiological O
tests O
. O
['Physiological-Clinical']

Mean O
increases O
in O
erythrocyte O
riboflavin O
( O
P O
< O
0.0001 O
) O
and O
plasma B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
( O
P=0.01 O
) O
were O
greater O
in O
the O
FeR O
+ O
VA O
group O
than O
in O
the O
VA O
only O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
At O
1 O
year O
, O
H. O
pylori O
eradication O
is O
beneficial O
in O
preventing O
progression O
of O
pathologic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of O
the O
gastric O
mucosa O
. O
['Physiological-Clinical']

Patients O
in O
the O
assessment O
( O
85 O
% O
) O
and O
intervention O
( O
83 O
% O
) O
conditions O
were O
blindly O
reassessed O
at O
3 O
months O
via O
a O
telephone O
interview O
. O
[]

This O
study O
demonstrates O
the O
potential O
application O
of O
ultrasonic O
embolic O
signal O
detection O
to O
examine O
the O
efficacy O
of O
new O
antiplatelet O
agents O
in O
relatively O
small O
numbers O
of O
patients O
. O
[]

In O
this O
prospective O
, O
randomized O
and O
controlled O
study O
the O
effect O
of O
cefotiam O
for O
the O
prevention O
of O
wound O
infections O
following O
trepanations O
was O
investigated O
. O
[]

A O
large O
portion O
of O
the O
difference O
in O
cost B-outcome ['Resource-use']
was O
related O
to O
the O
greater O
frequency O
of O
outpatient B-outcome ['Resource-use']
visits I-outcome ['Resource-use']
and O
the O
greater O
resources B-outcome ['Resource-use']
used I-outcome ['Resource-use']
in I-outcome ['Resource-use']
self-care I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use', 'Resource-use']

INTERPRETATION O
Initial O
treatment O
with O
either O
an O
NNRTI-based O
regimen O
or O
a O
PI-based O
regimen O
, O
but O
not O
both O
together O
, O
is O
a O
good O
strategy O
for O
long-term O
antiretroviral O
management O
in O
treatment-naive O
patients O
with O
HIV O
. O
[]

Plasma O
levels O
of O
naproxen O
were O
measured O
by O
a O
sensitive O
and O
specific O
HPLC O
method O
. O
[]

Parents O
of O
children O
who O
evidence O
higher O
object O
interest O
may O
require O
greater O
support O
to O
implement O
the O
HMTW O
strategies O
, O
or O
may O
require O
different O
strategies O
than O
those O
provided O
by O
the O
HMTW O
curriculum O
. O
[]

CONCLUSION O
Chlorhexidine-based O
solutions O
should O
be O
considered O
as O
a O
replacement O
for O
povidone-iodine O
( O
including O
alcohol-based O
) O
formulations O
in O
efforts O
to O
prevent O
catheter-related B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Randomized O
clinical O
trial O
. O
[]

The O
survival O
rates O
of O
embryos O
in O
the O
MVAC O
, O
CT O
and O
Control O
groups O
were O
88.9 O
% O
( O
32/36 O
) O
, O
91.7 O
% O
( O
33/36 O
) O
and O
100 O
% O
( O
34/34 O
) O
, O
respectively O
, O
after O
48 O
h O
culture O
, O
and O
the O
hatching B-outcome ['Physiological-Clinical']
rates O
of O
embryos O
after O
48 O
h O
incubation O
were O
69.4 O
% O
( O
25/36 O
) O
, O
63.9 O
% O
( O
23/36 O
) O
and O
94.1 O
% O
( O
32/34 O
) O
, O
respectively O
. O
['Physiological-Clinical']

In O
the O
RA O
group O
the O
simple O
formula O
published O
by O
Cockcroft O
[ O
Clcr O
= O
( O
( O
140 O
- O
age O
) O
x O
body O
weight O
) O
/ O
( O
72 O
x O
Scr O
) O
, O
x O
0.85 O
for O
females O
] O
showed O
the O
best O
correlation O
with O
the O
measured O
Clcr B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Significantly O
more O
patients O
in O
the O
AMX-CL O
group O
than O
in O
the O
CAE O
or O
CEC O
group O
had O
a O
side O
effect O
, O
primarily B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
, O
vomiting O
, O
or O
diaper O
rash O
. O
['Physiological-Clinical']

We O
have O
evaluated O
its O
antiinflammatory O
effects O
in O
59 O
patients O
with O
COPD O
randomized O
to O
receive O
cilomilast O
, O
15 O
mg O
two O
times O
a O
day O
, O
or O
placebo O
for O
12 O
weeks O
. O
['Physiological-Clinical']

The O
trial O
will O
recruit O
at O
least O
1000 O
patients O
who O
will O
be O
followed O
for O
five O
years O
. O
[]

Four-mm-thick O
buildups O
were O
built O
on O
the O
adhesives O
, O
then O
specimens O
were O
sectioned O
in O
accordance O
with O
the O
nontrimming O
technique O
. O
[]

Patients O
who O
completed O
the O
flexibility O
programme O
were O
invited O
to O
cross O
over O
to O
the O
exercise O
programme O
afterwards O
. O
[]

Because O
men O
will O
be O
exposed O
to O
the O
microbicide O
when O
engaging O
in O
vaginal O
intercourse O
, O
safety O
and O
acceptability B-outcome ['Life-Impact']
need O
to O
be O
assessed O
in O
men O
. O
['Life-Impact']

Secondary B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
was O
noticed O
in O
1 O
subject O
of O
the O
TWT O
group O
and O
3 O
subjects O
of O
the O
BET O
group O
. O
['Physiological-Clinical']

We O
developed O
a O
checklist O
containing O
six O
unique O
sets O
of O
yes/no O
variables O
organized O
in O
a O
2 O
x O
3 O
matrix O
of O
exposure O
potential O
versus O
protection O
( O
two O
columns O
) O
at O
the O
levels O
of O
materials O
, O
processes O
, O
and O
human O
interface O
( O
three O
rows O
) O
. O
[]

Flu O
with O
i.v O
. O
[]

High-functioning O
autism O
( O
HFA O
) O
is O
characterized O
by O
persistent O
impairment O
in O
social O
interaction O
despite O
the O
absence O
of O
mental O
retardation O
. O
[]

Processing O
familiar O
and O
unfamiliar O
auditory O
stimuli O
during O
general O
anesthesia O
. O
[]

Although O
not O
statistically O
significant O
, O
relative O
to O
chemotherapy O
alone O
, O
the O
risk O
of O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
was O
0.66 O
( O
95 O
% O
CI O
, O
0.38 O
to O
1.16 O
) O
among O
patients O
treated O
with O
bevacizumab-chemotherapy O
and O
0.72 O
( O
95 O
% O
CI O
, O
0.42 O
to O
1.23 O
) O
among O
patients O
treated O
with O
bevacizumab-erlotinib O
. O
['Physiological-Clinical', 'Mortality']

RESULTS O
There O
were O
no O
significant O
differences O
in O
efficacy O
between O
the O
two O
groups O
. O
[]

Participants O
were O
recruited O
between O
June O
1998 O
and O
January O
2001 O
from O
inner-city O
Atlanta O
( O
Georgia O
, O
U.S. O
) O
neighborhoods O
and O
were O
randomly O
assigned O
to O
one O
of O
two O
enhanced O
gender-specific O
and O
culturally O
specific O
HIV O
intervention O
conditions O
or O
to O
the O
NIDA O
standard O
condition O
. O
[]

CONCLUSION O
Combinative O
assessment O
of O
MSCT O
and O
SAA O
could O
improve O
the O
accuracy O
of O
preoperative O
staging O
, O
and O
thus O
provide O
higher O
predictive O
coincidence O
rate O
of O
operative O
procedures O
. O
[]

No O
significant O
difference O
was O
observed O
after O
6 O
and O
12 O
months O
of O
treatment O
in O
PEF B-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
, O
FEV1 B-outcome ['Physiological-Clinical']
or O
bronchial B-outcome ['Physiological-Clinical']
hyperreactivity I-outcome ['Physiological-Clinical']
in O
the O
NS O
group O
compared O
with O
baseline O
values O
, O
while O
a O
significant O
difference O
was O
observed O
in O
symptom O
score O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
consumption O
of O
the O
probiotic O
began O
between O
three O
and O
four O
months O
after O
the O
vaccination O
. O
[]

It O
has O
been O
suggested O
that O
clarification O
of O
such O
methodologic O
dilemmas O
is O
one O
of O
the O
most O
important O
challenges O
facing O
the O
future O
of O
industry-sponsored O
psychopharmacologic O
drug O
development O
. O
[]

Cytokine O
levels O
in O
the O
perfusate O
and O
systemic O
circulation O
during O
and O
after O
ILP O
were O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
. O
[]

This O
study O
determined O
safety O
of O
tirasemtiv O
when O
given O
at O
doses O
up O
to O
500 O
mg O
daily O
for O
three O
weeks O
. O
[]

Additional O
outcomes O
included O
the O
change O
in O
other O
sputum O
markers O
of O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
, O
symptom B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood O
product O
requirements O
during O
OLT O
were O
tendentiously O
higher O
in O
the O
bolus O
group O
but O
not O
significantly O
so O
. O
[]

Evaluation O
was O
carried O
out O
every O
3 O
weeks O
by O
the O
Migraine B-outcome ['Physiological-Clinical']
Index O
supplying O
a O
general O
assessment O
of O
the O
attacks B-outcome ['Physiological-Clinical']
, O
i.e O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUBJECTS O
Twelve O
male O
, O
obese O
subjects O
( O
age O
36.3+/-5.1 O
y O
; O
body O
weight O
94.6+/-13.9 O
kg O
; O
body O
mass O
index O
, O
BMI O
30.8+/-3.0 O
kg/m2 O
) O
and O
in O
an O
additional O
study O
15 O
lean O
, O
well-trained O
subjects O
( O
age O
36.2+/-7.2 O
y O
; O
body O
weight O
72.2+/-5.9 O
kg O
; O
BMI O
22.3+/-1.7 O
kg/m2 O
) O
participated O
. O
[]

RESULTS O
We O
isolated O
127 O
pathogens O
from O
121 O
( O
60 O
% O
) O
patients O
: O
73 O
( O
57 O
% O
) O
Shigella B-outcome ['Physiological-Clinical']
; O
23 O
( O
18 O
% O
) O
Salmonella B-outcome ['Physiological-Clinical']
; O
18 O
( O
14 O
% O
) O
E. O
coli B-outcome ['Physiological-Clinical']
; O
and O
13 O
( O
10 O
% O
) O
Campylobacter B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Atypical O
antipsychotic O
agents O
, O
which O
block O
postsynaptic O
dopamine O
and O
serotonin O
receptors O
, O
have O
advantages O
over O
traditional O
antipsychotic O
medications O
in O
the O
treatment O
of O
adults O
with O
schizophrenia O
and O
may O
be O
beneficial O
in O
children O
with O
autistic O
disorder O
who O
have O
serious O
behavioral O
disturbances O
. O
[]

The O
median O
OS B-outcome ['Physiological-Clinical']
time O
after O
crossover O
was O
14.3 O
months O
. O
['Physiological-Clinical']

In O
the O
post-therapy O
period O
, O
there O
were O
no O
group O
differences O
in O
special B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
['Life-Impact']

The O
further O
rate O
of I-outcome ['Physiological-Clinical']
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
from O
their O
levels O
at O
the O
end O
of O
the O
DCCT O
remains O
less O
in O
the O
former O
intensive O
treatment O
group O
. O
['Physiological-Clinical']

There O
was O
12 O
% O
progressive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
with O
COPP/ABVD O
and O
6 O
% O
with O
BEACOPP O
pooled O
. O
['Physiological-Clinical']

Perlane O
has O
acceptable O
long-term O
safety O
and O
offers O
a O
longer-lasting O
aesthetic O
improvement O
than O
Zyplast O
. O
[]

CONCLUSIONS O
Clopidogrel O
plus O
acetylsalicylic O
acid O
showed O
significantly O
superior O
antithrombotic O
efficacy O
compared O
with O
extended-release O
dipyridamole O
plus O
acetylsalicylic O
acid O
in O
preventing O
arterial O
thrombogenesis O
in O
humans O
. O
[]

For O
the O
in-hospital O
treatment O
successes O
, O
the O
advantage O
from O
drug O
treatment O
and O
the O
disadvantage O
from O
psychotherapy O
were O
less O
apparent O
. O
[]

Either O
melatonin O
, O
3 O
mg O
, O
or O
placebo O
was O
given O
to O
participants O
for O
2 O
weeks O
and O
then O
alternated O
for O
another O
2 O
weeks O
. O
[]

In O
the O
case O
of O
inadequate O
anesthesia O
, O
patients O
received O
repeated O
doses O
of O
0.1 O
mg/kg O
of O
etomidate O
until O
reaching O
deep O
sedation O
. O
[]

Being O
metabolically O
programmed O
by O
low O
protein O
provision O
in O
utero O
did O
not O
affect O
the O
response O
to O
post-weaning B-outcome ['Physiological-Clinical']
diets I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Chemoradiotherapy O
with O
concurrent O
gemcitabine O
and O
cisplatin O
with O
or O
without O
sequential O
chemotherapy O
with O
gemcitabine/cisplatin O
vs O
chemoradiotherapy O
with O
concurrent O
5-fluorouracil O
in O
patients O
with O
locally O
advanced O
pancreatic O
cancer O
-- O
a O
multi-centre O
randomised O
phase O
II O
study O
. O
[]

Twelve O
patients O
already O
used O
other O
neuroleptic O
medication O
, O
which O
was O
kept O
unchanged O
during O
the O
trial O
period O
. O
[]

Because O
of O
heterogeneity O
in O
the O
relationship O
between O
hsCRP O
and O
clinical O
outcomes O
, O
evaluation O
was O
limited O
to O
patients O
from O
whom O
samples O
were O
collected O
within O
48 O
h O
of O
symptom O
onset O
. O
[]

Long-term B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
measures O
after O
functional O
endoscopic O
sinus O
surgery O
. O
['Life-Impact']

Antagonist O
blockade O
after O
low O
salt O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
three O
patients O
with O
the O
highest O
plasma O
renin O
values O
. O
['Physiological-Clinical']

The O
2 O
groups O
were O
compared O
with O
chi2 O
test O
for O
independence O
of O
categorical O
variables O
. O
[]

Target O
tones O
evoked O
larger O
P3s B-outcome ['Physiological-Clinical']
than O
non-targets O
in O
the O
latter O
group O
but O
not O
in O
the O
former O
, O
in O
particular O
not O
in O
those O
subjects O
that O
actually O
blinked O
rarely O
. O
['Physiological-Clinical']

Volunteers O
in O
the O
verum O
group O
received O
10 O
ml O
of O
an O
ethanolic O
( O
vincamine O
free O
) O
eleutherococcus O
senticosus O
preparation O
, O
3 O
times O
daily O
for O
4 O
weeks O
. O
[]

19.13 O
) O
pg/ml O
, O
ALD O
( O
405.31 O
? O
[]

The O
percent O
improvement O
in O
Group O
N O
was O
50.1 O
% O
at O
8 O
weeks O
after O
treatment O
, O
while O
it O
was O
31.0 O
% O
in O
Group O
G O
( O
p O
= O
0.03 O
) O
. O
[]

We O
found O
that O
the O
natural O
history O
of O
symptomatic O
reflux O
esophagitis O
was O
to O
improve O
with O
either O
antacid O
or O
placebo O
. O
[]

OBJECTIVE O
Evaluation O
of O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
6 O
% O
coriander O
oil O
in O
unguentum O
leniens O
in O
the O
treatment O
of O
interdigital O
tinea O
pedis O
. O
['Life-Impact']

Leucocyte O
depletion O
of O
perioperative O
blood O
transfusion O
does O
not O
affect O
long-term O
survival B-outcome ['Mortality']
and O
recurrence O
in O
patients O
with O
gastrointestinal O
cancer O
. O
['Mortality']

DESIGN O
The O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
over O
12 O
months O
. O
[]

Fatigue B-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
capacity B-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

PATIENTS O
AND O
METHODS O
In O
a O
randomized O
crossover O
study O
, O
26 O
patients O
undergoing O
bilateral O
lower O
third O
molar O
surgery O
at O
two O
visits O
had O
patient-controlled O
sedation O
with O
1 O
mg O
midazolam O
increments O
at O
1-minute O
or O
3-minute O
intervals O
at O
one O
visit O
and O
the O
alternative O
at O
the O
other O
visit O
. O
[]

1 O
. O
[]

Participants O
were O
randomized O
to O
a O
control O
group O
( O
treatment O
as O
usual O
, O
30 O
h O
of O
ABA-based O
therapy O
per O
week O
) O
or O
a O
treatment O
group O
( O
substitution O
of O
30 O
min O
of O
JASPER O
treatment O
, O
twice O
weekly O
during O
their O
regular O
program O
) O
. O
[]

BACKGROUND O
Transfer O
factor O
of O
the O
lung B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
monoxide I-outcome ['Physiological-Clinical']
( O
TLCO B-outcome ['Physiological-Clinical']
) O
was O
measured O
by O
a O
new O
method O
based O
on O
analysis O
of O
the O
ratio O
of O
the O
concentrations O
of O
carbon O
monoxide O
to O
an O
inert O
gas O
( O
methane O
) O
relative O
to O
lung O
volume O
during O
a O
constant O
exhalation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
partly O
blinded O
study O
. O
[]

Gastrointestinal O
tolerance O
and O
diarrhoea O
rate O
were O
similar O
in O
all O
the O
patients O
. O
[]

SICI O
was O
evaluated O
during O
resting O
state O
and O
in O
an O
event-related O
condition O
during O
movement O
preparation O
in O
a O
visually O
triggered O
simple O
reaction O
time O
task O
. O
[]

Plasma O
levels O
of O
1,25 O
( O
OH O
) O
2D O
did O
not O
vary O
by O
season O
. O
[]

Nearly O
13 O
% O
( O
summer/fall O
) O
to O
36 O
% O
( O
winter/spring O
) O
of O
the O
control O
participants O
were O
deficient O
in O
25 O
( O
OH O
) O
D O
( O
< O
20 O
ng/ml O
) O
and O
51 O
% O
( O
summer/fall O
) O
and O
77 O
% O
( O
winter/spring O
) O
had O
insufficient O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
( O
< O
32 O
ng/ml O
) O
. O
['Physiological-Clinical']

The O
children O
were O
separated O
into O
two O
groups O
, O
each O
comprising O
15 O
children O
between O
7 O
and O
11 O
years O
of O
age O
with O
autism O
, O
according O
to O
DSM-IV O
criteria O
. O
[]

There O
were O
three O
babies O
in O
the O
forceps O
group O
with O
unexplained B-outcome ['Physiological-Clinical']
neonatal I-outcome ['Physiological-Clinical']
convulsions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
also O
found O
a O
significant O
depression B-outcome ['Life-Impact']
of O
the O
EMG-response B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

To O
investigate O
the O
clinical O
effects O
of O
a O
novel O
PD O
fluid O
buffered O
with O
34 O
mM O
pure O
bicarbonate O
at O
neutral O
pH O
, O
a O
randomized O
, O
prospective O
, O
crossover O
comparison O
with O
conventional O
, O
acidic O
, O
35 O
mM O
lactate O
PD O
fluid O
was O
performed O
for O
two O
consecutive O
12-wk O
periods O
with O
28 O
children O
( O
age O
, O
6 O
mo O
to O
15 O
yr O
) O
undergoing O
automated O
PD O
( O
APD O
) O
. O
[]

Changes O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
were O
not O
significantly O
different O
( O
P=0.465 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
pentoxifylline O
treatment O
did O
not O
influence O
the O
weight O
, O
temperature B-outcome ['Physiological-Clinical']
, O
well B-outcome ['Physiological-Clinical']
being I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
tiredness I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
subjects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
could O
be O
useful O
in O
the O
diagnosis O
of O
CIN2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Following O
withdrawals O
, O
data O
from O
36 O
patients O
( O
20 O
on O
quinapril O
, O
16 O
on O
captopril O
) O
were O
available O
for O
analysis O
. O
[]

OBJECTIVE O
A O
randomized O
trial O
of O
breast O
self-examination O
( O
BSE O
) O
Program O
was O
carried O
out O
to O
evaluate O
whether O
the O
intensive O
BSE O
could O
reduce O
the O
number O
of O
deaths O
among O
women O
from O
breast O
cancer O
. O
[]

RESULTS O
The O
mean O
total O
ATEC O
scores O
by O
both O
parents O
and O
clinicians O
were O
significantly O
improved O
after O
intervention O
in O
both O
arms O
of O
the O
study O
compared O
to O
the O
score O
before O
intervention O
( O
P O
< O
0.001 O
in O
both O
groups O
by O
parents O
, O
P O
= O
0.015 O
in O
HBOT O
group O
and O
P O
= O
0.004 O
in O
sham O
group O
by O
clinician O
) O
. O
[]

Chemotherapy O
of O
advanced O
gastric O
carcinoma O
( O
stage O
IV O
) O
: O
a O
randomized O
study O
of O
FAM O
versus O
5-FU O
plus O
BCNU O
. O
[]

The O
inhibitory O
effects O
of O
aspirin O
on O
thromboxane B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
and O
on O
collagen-induced B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
remained O
throughout O
the O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lack O
of O
benefit O
of O
intravenous O
synthetic O
human O
secretin O
in O
the O
treatment O
of O
autism O
. O
[]

Only O
10 O
% O
of O
patients O
treated O
with O
imiquimod O
were O
clinically O
diagnosed O
with O
recurrence O
1 O
year O
after O
treatment O
. O
[]

Sustained O
ventricular O
arrhythmias O
and O
mortality O
among O
patients O
with O
acute O
myocardial O
infarction O
: O
results O
from O
the O
GUSTO-III O
trial O
. O
[]

BACKGROUND O
Nonpharmacologic O
interventions O
, O
such O
as O
distraction O
, O
have O
been O
shown O
to O
be O
powerful O
adjuncts O
in O
reducing O
pain O
and O
anxiety O
in O
children O
with O
both O
acute O
and O
chronic O
painful O
conditions O
. O
[]

Palmar-plantar B-outcome ['Physiological-Clinical']
erythrodysesthesia B-outcome ['Physiological-Clinical']
( O
48 O
% O
versus O
2 O
% O
) O
, O
stomatitis B-outcome ['Physiological-Clinical']
( O
22 O
% O
versus O
15 O
% O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Total O
contrast O
dye B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
to O
search O
and O
engage O
the O
CS O
ostium O
was O
0.0 O
ml O
in O
the O
EPA O
group O
versus O
14.3 O
+/- O
3.4 O
ml O
in O
the O
GCA O
group O
p O
< O
0.001 O
. O
['Physiological-Clinical']

Both O
CaCl O
( O
2 O
) O
and O
placebo O
pre-treatment O
groups O
had O
equal O
lowering O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
intervention O
was O
not O
associated O
with O
higher O
smoking B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
rates O
or O
quit B-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Eighty O
children O
, O
3-17 O
years O
of O
age O
, O
with O
autism O
or O
Asperger O
syndrome O
and O
mild O
to O
severe O
distress O
in O
the O
presence O
of O
some O
sounds O
, O
were O
randomly O
allocated O
to O
two O
groups O
. O
[]

Investigation O
of O
the O
effect O
of O
FK506 O
( O
tacrolimus O
) O
and O
cyclosporin O
on O
gingival O
overgrowth O
following O
paediatric O
liver O
transplantation O
. O
[]

Cefixime O
is O
an O
orally O
absorbed O
cephalosporin O
that O
is O
active O
against O
resistant O
gonococci O
and O
has O
pharmacokinetic O
activity O
suitable O
for O
single-dose O
administration O
. O
[]

The O
objective O
was O
to O
explore O
the O
impact O
on O
physical O
health O
of O
a O
lifestyle O
programme O
among O
persons O
with O
psychiatric O
disabilities O
, O
and O
their O
caregivers O
. O
[]

Treatment O
periods O
were O
separated O
by O
a O
5-week O
washout O
. O
[]

60 O
eyes O
of O
59 O
patients O
were O
divided O
into O
two O
groups O
, O
31 O
in O
the O
cord O
serum O
group O
and O
29 O
in O
the O
autologous O
serum O
control O
group O
. O
[]

Pharmacokinetic O
interaction O
between O
proton O
pump O
inhibitors O
and O
roxithromycin O
in O
volunteers O
. O
[]

BACKGROUND O
Blocking O
the O
renin-angiotensin O
system O
( O
RAS O
) O
with O
angiotensin O
receptor O
blockers O
or O
angiotensin-converting O
enzyme O
inhibitors O
protects O
against O
renal O
injury O
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

Overall O
, O
in O
comparison O
with O
propranolol O
, O
nicardipine O
was O
effective O
, O
well-tolerated O
and O
safe O
to O
use O
in O
the O
monotherapy O
of O
mild O
or O
moderate O
essential O
hypertension O
. O
[]

CONCLUSIONS O
Allograft O
mixed O
with O
an O
experimental O
putty O
carrier O
produced O
significantly O
more O
vital O
bone O
fill O
than O
did O
the O
use O
of O
a O
xenograft O
with O
no O
carrier O
material O
. O
[]

After O
bilateral O
operation O
, O
the O
respective O
incidences O
were O
39 O
% O
and O
81 O
% O
( O
P O
< O
.01 O
) O
. O
[]

The O
effects O
of O
0.3 O
and O
0.6 O
mg/kg O
methylphenidate O
were O
analyzed O
in O
a O
double-blind O
, O
placebo-controlled O
, O
cross-over O
study O
in O
which O
17 O
boys O
( O
ages O
7.8-9.9 O
years O
) O
with O
attention O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
played O
in O
baseball O
games O
. O
[]

No O
significant O
differences O
in O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
values O
were O
observed O
between O
group O
A O
( O
P=0.704 O
) O
or O
group O
B O
( O
P=0.270 O
) O
at O
baseline O
, O
or O
at O
5 O
( O
Group O
A O
: O
P=0.340 O
; O
Group O
B O
: O
P=0.559 O
) O
and O
15 O
min O
( O
Group O
A O
: O
P=0.526 O
; O
Group O
B O
: O
P=0.818 O
) O
post O
dose O
. O
['Physiological-Clinical']

The O
authors O
undertook O
this O
study O
to O
further O
evaluate O
the O
level O
of O
adenosine B-outcome ['Physiological-Clinical']
deaminase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ADA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
schizophrenia O
treated O
with O
monotherapy O
of O
haloperidol O
, O
risperidone O
or O
clozapine O
and O
correlation O
between O
the O
ADA O
level O
with O
response O
to O
treatment O
. O
['Physiological-Clinical']

Contingency O
management O
for O
the O
treatment O
of O
antipsychotic-induced O
weight O
gain O
: O
a O
randomized O
controlled O
pilot O
study O
. O
[]

4 O
) O
Lumbar O
spine O
radiography O
is O
not O
cost-effective O
compared O
with O
usual O
care O
without O
lumbar O
spine O
radiography O
. O
[]

PURPOSE O
We O
assessed O
the O
efficacy O
and O
safety O
of O
transurethral O
resection O
and O
vaporization O
with O
bipolar O
PlasmaKinetic O
energy O
. O
[]

Treatment O
arm O
was O
the O
major O
risk O
factor O
influencing O
[]

METHODS O
In O
three O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
parallel O
group O
clinical O
studies O
, O
2516 O
IBS O
patients O
with O
symptoms O
of O
abdominal O
pain O
and O
constipation O
received O
tegaserod O
2 O
or O
6 O
mg O
b.i.d O
. O
( O
[]

This O
investigation O
examined O
the O
effect O
of O
supplementation O
with O
Biostimine O
, O
extract O
from O
Aloe O
arborescens O
Mill O
. O
[]

PATIENTS O
AND O
METHODS O
Six O
hundred O
sixty-two O
patients O
with O
osteosarcoma O
without O
clinically O
detectable O
metastatic O
disease O
and O
whose O
disease O
was O
considered O
resectable O
received O
one O
of O
four O
prospectively O
randomized O
treatments O
. O
[]

The O
applicability O
and O
validity O
of O
regulatory O
requirements O
have O
been O
widely O
criticized O
on O
statistical O
and O
clinical O
relevance O
grounds O
. O
[]

Adverse O
effects O
( O
AEs O
) O
of O
the O
opioids O
include O
constipation O
, O
somnolence O
, O
nausea O
, O
and O
vomiting O
. O
[]

1.14 O
G/L O
, O
respectively O
) O
. O
[]

CONCLUSION O
Sildenafil O
( O
25 O
, O
50 O
, O
and O
100 O
mg O
) O
was O
found O
to O
be O
an O
effective O
, O
safe O
, O
and O
well-tolerated O
treatment O
for O
ED O
in O
the O
present O
study O
population O
of O
Thai O
, O
Malaysian O
, O
and O
Singaporean O
males O
who O
also O
had O
increased O
cardiovascular O
risk O
[]

Eight O
in-office O
tooth O
whitening O
systems O
evaluated O
in O
vivo O
: O
a O
pilot O
study O
. O
[]

The O
primary O
indicator O
was O
the O
proportion O
of O
elderly O
survivors O
of O
AMI O
at O
each O
study O
hospital O
who O
filled O
a O
prescription O
for O
a O
beta-blocker O
within O
30 O
days O
after O
discharge O
. O
[]

Using O
dietetic O
assistants O
to O
improve O
the O
outcome O
of O
hip O
fracture O
: O
a O
randomised O
controlled O
trial O
of O
nutritional O
support O
in O
an O
acute O
trauma O
ward O
. O
[]

Usual O
care O
patients O
( O
n O
= O
58 O
) O
were O
treated O
by O
their O
primary O
care O
physician O
. O
[]

Patients O
were O
excluded O
if O
they O
had O
any O
one O
of O
the O
following O
: O
an O
underlying O
disease O
that O
might O
affect O
cardiopulmonary O
status O
, O
asthma O
, O
recent O
treatment O
with O
steroids O
( O
within O
2 O
weeks O
) O
, O
or O
any O
history O
of O
adverse O
reaction O
to O
steroids O
. O
[]

Eleven O
of O
the O
24 O
children O
improved O
in O
two O
or O
more O
settings O
. O
[]

Postoperative O
pain O
perception O
was O
graded O
using O
the O
modified O
McGill O
pain O
intensity O
scale O
at O
30 O
minutes O
postoperatively O
, O
at O
discharge O
from O
the O
recovery O
room O
, O
and O
the O
next O
morning O
by O
telephone O
interview O
. O
[]

The O
corresponding O
DHA O
doses O
were O
3 O
, O
33 O
, O
333 O
and O
3333 O
mg. O
A O
control O
group O
was O
given O
olive O
oil O
as O
placebo O
for O
the O
entire O
24 O
weeks O
. O
[]

BACKGROUND O
To O
evaluate O
the O
effect O
of O
the O
amino O
acids O
L-arginine O
and O
citrulline O
on O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
in O
stable O
diastolic O
and O
right O
heart O
failure O
using O
photoplethysmography O
. O
['Physiological-Clinical']

AD O
patients O
achieved O
longer O
durations O
of O
cocaine B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
and O
were O
more O
likely O
to O
submit O
a O
cocaine-negative B-outcome ['Life-Impact']
sample I-outcome ['Life-Impact']
at O
follow-up O
than O
non-AD O
patients O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
Treatment O
of O
hirsute O
women O
with O
third O
generation O
OCs O
containing O
desogestrel O
results O
in O
a O
significant O
increase O
in O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
and O
decrease O
in O
free B-outcome ['Physiological-Clinical']
testosterone I-outcome ['Physiological-Clinical']
and O
3alpha-androstanediol B-outcome ['Physiological-Clinical']
glucuronide I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Social O
stories O
: O
mechanisms O
of O
effectiveness O
in O
increasing O
game O
play O
skills O
in O
children O
diagnosed O
with O
autism O
spectrum O
disorder O
using O
a O
pretest O
posttest O
repeated O
measures O
randomized O
control O
group O
design O
. O
[]

RESULTS O
At O
baseline O
, O
patients O
reported O
greater O
anxiety B-outcome ['Life-Impact']
and O
lower O
QoL B-outcome ['Life-Impact']
than O
healthy O
populations O
. O
['Life-Impact', 'Life-Impact']

Pharmacokinetics O
of O
two O
theophylline O
( O
CAS O
58-55-9 O
) O
sustained O
release O
preparations O
( O
T O
: O
Bronchoretard O
Capsules/R O
: O
Capsule O
formulation O
from O
the O
US O
market O
) O
were O
investigated O
in O
an O
open O
randomised O
two-way O
crossover O
design O
. O
[]

Additionally O
, O
knee-specific B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
were O
assessed O
using O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
( O
WOMAC O
) O
and O
the O
Activities O
of O
Daily O
Living O
Scale O
( O
ADLS O
) O
. O
['Physiological-Clinical', 'Life-Impact']

CONCLUSION O
The O
oral O
UFT/LV O
regimen O
failed O
to O
achieve O
improved O
TTP B-outcome ['Physiological-Clinical']
; O
however O
, O
the O
study O
confirms O
significant O
safety O
improvements O
compared O
with O
bolus O
IV O
5-FU/LV O
for O
the O
first-line O
treatment O
of O
metastatic O
CRC O
. O
['Physiological-Clinical']

Osteosarcoma O
: O
the O
addition O
of O
muramyl O
tripeptide O
to O
chemotherapy O
improves O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
-- O
a O
report O
from O
the O
Children O
's O
Oncology O
Group O
. O
['Mortality']

Twenty-eight O
children O
with O
autism O
were O
randomised O
between O
this O
treatment O
and O
routine O
care O
alone O
, O
stratified O
for O
age O
and O
baseline O
severity O
. O
[]

Evaluation O
of O
postural B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
by O
computerised O
posturography O
following O
outpatient O
paediatric O
anaesthesia O
. O
['Physiological-Clinical']

WST-1 O
assay O
was O
employed O
to O
measure O
cell B-outcome ['Physiological-Clinical']
viability I-outcome ['Physiological-Clinical']
and O
a O
luciferase B-outcome ['Physiological-Clinical']
ERE I-outcome ['Physiological-Clinical']
( O
estrogen O
responsive O
element O
) O
construct O
was O
used O
to O
study O
the O
effect O
of O
tamoxifen O
, O
following O
downregulation O
of O
YAP1 O
using O
siRNAs O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Between-group O
comparisons O
demonstrated O
significant O
( O
P O
< O
0.0001 O
) O
reductions O
in O
yellowness B-outcome ['Physiological-Clinical']
and O
redness B-outcome ['Physiological-Clinical']
, O
and O
increased O
brightness B-outcome ['Physiological-Clinical']
favoring I-outcome ['Physiological-Clinical']
the O
peroxide O
strip O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
total O
, O
20 O
ex-smoking O
COPD O
patients O
with O
post-bronchodilator O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV O
( O
1 O
) O
) O
> O
1.20 O
L O
and O
FEV O
( O
1 O
) O
/forced O
vital O
capacity O
< O
70 O
% O
were O
enrolled O
in O
a O
randomised O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

CONCLUSIONS O
Unrecognized O
overnight O
hypoglycaemia O
in O
children O
and O
adolescents O
on O
pituitary O
hormone O
replacement O
is O
uncommon O
but O
BG B-outcome ['Physiological-Clinical']
levels O
quickly O
become O
abnormal O
when O
treatment O
and O
meals O
are O
omitted O
. O
['Physiological-Clinical']

Infusion O
of O
placebo O
or O
TRH O
had O
no O
effect O
on O
leptin B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

With O
these O
limits O
, O
oral O
clodronate O
demonstrated O
some O
efficacy O
in O
symptom O
control O
and O
in O
reducing O
the O
need O
for O
analgesics O
. O
[]

Patients O
aged O
12 O
to O
17 O
years O
received O
rizatriptan O
5 O
mg O
( O
n O
= O
149 O
) O
or O
placebo O
( O
n O
= O
147 O
) O
for O
a O
moderate O
or O
severe O
headache O
and O
for O
up O
to O
two O
recurrences O
. O
[]

In O
the O
remaining O
five O
patients O
gabapentin O
improved O
[]

13.47 O
, O
final O
23.65 O
? O
[]

RESULTS O
The O
subjects O
' O
mean O
straylight B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
were O
0.90 O
+/- O
0.09 O
at O
baseline O
and O
0.95 O
+/- O
0.10 O
with O
the O
clear O
Optima O
38 O
CL O
. O
['Physiological-Clinical']

Placebo-controlled O
acute O
dosage O
naltrexone O
study O
in O
young O
autistic O
children O
. O
[]

To O
date O
, O
only O
one O
double-blind O
, O
placebo-controlled O
study O
of O
subjects O
with O
alcohol O
or O
substance O
abuse O
has O
included O
substantial O
numbers O
of O
suicidal O
patients O
. O
[]

Prophylactic O
labetalol O
gave O
no O
additional O
benefit O
. O
[]

For O
anesthetic O
solution O
deposition O
, O
8 O
% O
of O
the O
subjects O
reported O
moderate B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
12 O
% O
reported O
moderate B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
two O
10-day O
treatment O
periods O
separated O
by O
a O
14-day O
washout O
period O
, O
23 O
healthy O
male O
volunteers O
received O
once-daily O
clopidogrel O
75 O
mg O
plus O
acetylsalicylic O
acid O
75 O
mg O
, O
or O
twice-daily O
extended-release O
dipyridamole O
200 O
mg O
plus O
acetylsalicylic O
acid O
25 O
mg O
. O
[]

[ O
Efficacy O
of O
paliperidone O
extended-release O
tablets O
in O
the O
improvement O
of O
social B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
in O
schizophrenics O
: O
a O
randomized O
and O
controlled O
study O
] O
. O
['Life-Impact']

However O
, O
the O
oral O
hydrocodone/acetaminophen O
failed O
to O
provide O
clinically O
or O
statistically O
superior O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
compared O
to O
oral O
codeine/acetaminophen O
when O
prescribed O
to O
patients O
discharged O
from O
the O
ED O
with O
acute O
extremity O
pain O
. O
['Physiological-Clinical']

Immune B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
infants O
fed O
soy-based O
formulas O
with O
or O
without O
added O
nucleotides O
for O
1 O
year O
: O
part O
2 O
: O
immune O
cell O
populations O
. O
['Physiological-Clinical']

These O
data O
are O
in O
agreement O
with O
current O
knowledge O
on O
skeletal O
muscle O
physiology O
and O
show O
the O
reliability O
of O
the O
proposed O
method O
. O
[]

The O
rate O
of O
leg B-outcome ['Physiological-Clinical']
oedema I-outcome ['Physiological-Clinical']
was O
not O
altered O
, O
but O
the O
frequency O
of O
advanced B-outcome ['Physiological-Clinical']
hydroceles I-outcome ['Physiological-Clinical']
decreased O
by O
47 O
% O
with O
combined O
therapy O
and O
56 O
% O
with O
diethylcarbamazine O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

8.8 O
ml? O
kg O
( O
-1 O
) O
? O
[]

This O
prospective O
randomised O
trial O
is O
designed O
to O
determine O
if O
addition O
of O
brachytherapy O
offers O
any O
advantages O
over O
laser O
therapy O
alone O
. O
[]

The O
effect O
persisted O
for O
2 O
years O
, O
with O
a O
mean O
increase O
of O
1.7 O
percentage O
points O
( O
95 O
% O
CI O
, O
0.7 O
to O
2.7 O
) O
versus O
a O
mean O
decrease O
of O
1.2 O
percentage O
points O
( O
95 O
% O
CI O
, O
-1.8 O
to O
-0.5 O
; O
P O
< O
.001 O
) O
in O
the O
hormone O
and O
placebo O
groups O
, O
respectively O
. O
[]

Second O
, O
within O
this O
overview O
, O
the O
ways O
in O
which O
selected O
results O
informed O
program O
development O
are O
highlighted O
. O
[]

In O
the O
third O
trial O
, O
patients O
with O
advanced O
disease O
no O
longer O
responsive O
to O
hormonal O
treatment O
were O
randomized O
to O
either O
Adriamycin O
or O
Procarbazine O
. O
[]

RESULTS O
. O
[]

Various O
parameters O
such O
as O
Karnofsky O
performance B-outcome ['Physiological-Clinical']
status O
, O
pain O
score O
( O
measured O
by O
a O
visual-analogue O
scale O
) O
and O
analgesic B-outcome ['Resource-use']
requirement O
were O
recorded O
at O
monthly O
intervals O
. O
['Physiological-Clinical', 'Resource-use']

Both O
isotonic O
and O
isometric O
training O
resulted O
in O
significant O
cardiovascular B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
but O
seemed O
inadequate O
to O
improve O
vital B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
and O
flow B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SAMPLE O
The O
sample O
consisted O
of O
53 O
patients O
in O
the O
experimental O
arm O
and O
60 O
in O
the O
control O
arm O
who O
reported O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
at O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Temporal O
discounting O
: O
the O
differential O
effect O
of O
proximal O
and O
distal O
consequences O
on O
confession O
decisions O
. O
[]

This O
was O
an O
open-labeled O
, O
randomized O
, O
comparative O
trial O
. O
[]

filters O
in O
excluding O
the O
large O
particle O
load O
introduced O
by O
i.v O
. O
[]

Patients O
with O
JET O
had O
longer O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
time I-outcome ['Resource-use']
, O
cardiac B-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CICU I-outcome ['Resource-use']
) I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use', 'Resource-use']

METHODS O
Study O
patients O
consisted O
of O
197 O
consecutive O
patients O
with O
primary O
open-angle O
glaucoma O
who O
were O
randomly O
assigned O
to O
receive O
either O
no O
adjunctive O
mitomycin O
C O
( O
101 O
eyes O
of O
101 O
patients O
) O
or O
to O
receive O
adjunctive O
subconjunctival O
mitomycin O
C O
( O
96 O
eyes O
of O
96 O
patients O
) O
during O
the O
primary O
glaucoma O
triple O
procedure O
. O
[]

Early B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
and O
psychomotor B-outcome ['Life-Impact']
recovery I-outcome ['Life-Impact']
was O
studied O
in O
67 O
patients O
undergoing O
colorectal O
surgery O
under O
continuous O
epidural O
anaesthesia O
and O
light O
general O
anaesthesia O
using O
propofol O
, O
halothane O
, O
and O
midazolam/fentanyl O
. O
['Life-Impact', 'Life-Impact']

Eleven O
patients O
died B-outcome ['Mortality']
during O
the O
study O
period O
( O
7 O
in O
group O
A O
[ O
25 O
% O
] O
, O
4 O
in O
group O
B O
[ O
11.8 O
% O
] O
) O
. O
['Mortality']

Epidemiology O
of O
stroke B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Subjective O
assessment B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
infant I-outcome ['Physiological-Clinical']
's O
cry B-outcome ['Physiological-Clinical']
intensity O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
costs B-outcome ['Resource-use']
to I-outcome ['Resource-use']
the I-outcome ['Resource-use']
National I-outcome ['Resource-use']
Health I-outcome ['Resource-use']
Service O
over O
the O
one O
year O
follow O
up O
were O
calculated O
by O
a O
cost O
minimisation O
analysis O
. O
['Resource-use']

Oral O
S-adenosylmethionine O
in O
the O
symptomatic O
treatment O
of O
intrahepatic B-outcome ['Physiological-Clinical']
cholestasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Cortical O
bone O
dimensions O
were O
evaluated O
by O
digital O
x-ray O
radiogrammetry O
of O
the O
metacarpal O
bones O
every O
6 O
months O
. O
[]

The O
relationship O
between O
physical O
activity O
level O
, O
anxiety O
, O
depression O
, O
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
juvenile O
idiopathic O
arthritis O
. O
['Life-Impact']

MATERIAL O
AND O
METHODS O
Randomized O
crossover O
study O
examining O
20 O
patients O
postcardiac B-outcome ['Physiological-Clinical']
surgery O
. O
['Physiological-Clinical']

Fe O
intake O
of O
the O
group O
fed O
the O
nonfortified O
formula O
was O
significantly O
lower O
( O
p O
less O
than O
0.0001 O
) O
. O
[]

Significant O
associations O
were O
found O
between O
addictive O
Internet B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
and O
school O
grade O
, O
parental O
education O
, O
alcohol O
use O
, O
tobacco O
use O
, O
and O
substance O
use O
. O
['Life-Impact']

CONCLUSION O
Intensive O
instruction O
in O
BSE O
did O
not O
seem O
to O
have O
reduced O
the O
mortality B-outcome ['Mortality']
rate O
of O
breast O
cancer O
, O
but O
more O
and O
smaller O
benign B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
lumps I-outcome ['Physiological-Clinical']
could O
be O
detected O
. O
['Mortality', 'Physiological-Clinical']

DATA O
SOURCES/STUDY O
SETTING O
The O
three O
data O
sources O
for O
the O
study O
were O
( O
1 O
) O
the O
generic O
screen O
results O
of O
a O
3 O
percent O
random O
sample O
of O
Medicare O
beneficiaries O
age O
65 O
years O
or O
older O
who O
were O
admitted O
to O
California O
hospitals O
between O
1 O
July O
1987 O
and O
30 O
June O
1988 O
( O
n O
= O
20,136 O
patients O
) O
; O
( O
2 O
) O
the O
1987 O
and O
1988 O
California O
Medicare O
Provided O
Analysis O
and O
Review O
( O
MEDPAR O
) O
data O
files O
; O
and O
( O
3 O
) O
the O
American O
Hospital O
Association O
( O
AHA O
) O
1988 O
Annual O
Survey O
of O
Hospitals O
. O
[]

Performance O
on O
a O
cancellation O
task O
( O
number O
of O
correct B-outcome ['Life-Impact']
detections I-outcome ['Life-Impact']
) O
and O
a O
verbal B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
( O
word B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
) O
was O
better O
on O
risperidone O
than O
on O
placebo O
( O
without O
correction O
for O
multiplicity O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Efficacy O
of O
latanoprost O
when O
stored O
at O
room O
temperature O
. O
[]

CONCLUSIONS O
Febuxostat O
at O
40 O
mg/d O
demonstrated O
more O
potent O
hypouricemic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
than O
allopurinol O
at O
200 O
mg/d O
, O
was O
efficacious O
regardless O
of O
medical O
history O
of O
gout O
, O
and O
is O
considered O
safe O
for O
treatment O
of O
hyperuricemia O
. O
['Physiological-Clinical']

Standard O
assessments O
at O
age O
2 O
did O
not O
predict O
outcome O
at O
age O
7 O
even O
within O
the O
same O
domain O
of O
functioning O
. O
[]

Desonide O
ointment O
has O
demonstrated O
a O
good O
safety O
and O
efficacy O
profile O
during O
the O
many O
years O
it O
has O
been O
used O
in O
treating O
dermatoses O
. O
[]

Extant O
research O
has O
primarily O
modeled O
between-person O
covariation O
between O
postquit O
abstinence O
and O
depressive O
symptom O
trajectories O
. O
[]

The O
study O
utilized O
a O
double-blind O
, O
randomized O
, O
crossover O
design O
with O
two O
treatments O
: O
( O
i O
) O
sugar-free O
gum O
containing O
18.8 O
mg O
of O
CPP-ACP O
, O
and O
( O
ii O
) O
sugar-free O
gum O
not O
containing O
CPP-ACP O
as O
control O
. O
[]

Contrast O
reduction O
was O
maintained O
in O
the O
rotational O
angiography O
group O
compared O
to O
the O
conventional O
technique O
( O
A O
vs O
B O
, O
335.1 O
[ O
192.1 O
] O
vs O
238.5 O
[ O
114.4 O
] O
mL O
; O
P=.02 O
) O
. O
[]

BACKGROUND O
Older O
adult O
cancer O
survivors O
are O
at O
greater O
risk O
of O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
other O
comorbidities O
that O
can O
be O
prevented O
through O
improved O
diet O
and O
weight O
management O
. O
['Physiological-Clinical']

In O
order O
to O
more O
precisely O
measure O
the O
effects O
of O
secretin O
, O
this O
study O
investigated O
the O
effect O
of O
a O
single O
intravenous O
dose O
of O
porcine O
secretin O
on O
12 O
autistic O
children O
through O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

FUNDING O
GlaxoSmithKline O
. O
[]

Coronary B-outcome ['Resource-use']
angiography I-outcome ['Resource-use']
was O
performed O
in O
75 O
% O
of O
the O
90 O
patients O
eligible O
for O
restudy O
. O
['Resource-use']

Polymorphonuclear O
leukocyte O
( O
PMN O
) O
chemotaxis O
is O
thought O
to O
play O
an O
essential O
role O
in O
the O
pathogenesis O
of O
rheumatoid O
arthritis O
. O
[]

In O
those O
aged O
from O
3 O
to O
6 O
years O
of O
age O
, O
dosage O
of O
midazolam O
was O
2.09 O
, O
with O
deviation O
of O
0.36 O
, O
and O
of O
ketamine O
1.78 O
, O
with O
deviation O
of O
0.27 O
, O
following O
use O
of O
the O
bispectral O
index O
, O
compared O
to O
2.89 O
with O
deviation O
of O
0.28 O
, O
and O
2.62 O
with O
deviation O
of O
0.69 O
respectively O
, O
when O
the O
bispectral O
index O
was O
not O
used O
, O
these O
again O
being O
significant O
differences O
( O
p O
= O
0.033 O
and O
p O
= O
0.04 O
) O
. O
[]

There O
were O
four O
recurrent B-outcome ['Physiological-Clinical']
meningeal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
the O
patients O
taking O
placebo O
, O
but O
none O
in O
those O
taking O
fluconazole O
( O
mean O
duration O
of O
follow-up O
, O
164 O
days O
) O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

Percutaneous O
coronary O
intervention O
in O
patients O
with O
previous O
coronary O
artery O
bypass O
grafting O
( O
from O
the O
j-Cypher O
Registry O
) O
. O
[]

CONCLUSION O
This O
re-analysis O
confirmed O
the O
antipsychotic O
effect O
and O
absence O
of O
extrapyramidal O
effects O
for O
sertindole O
and O
, O
in O
addition O
, O
showed O
a O
clinically O
significant O
antidepressant O
effect O
. O
[]

In O
the O
management O
of O
wounds O
, O
sometimes O
it O
is O
recommended O
to O
give O
an O
adult-type O
tetanus-diphtheria O
( O
Td O
) O
vaccine O
dose O
plus O
tetanus O
immune O
globulin O
( O
TIG O
) O
. O
[]

Although O
dissecting O
the O
ureter O
at O
the O
beginning O
of O
the O
operation O
did O
not O
produce O
a O
significant O
discrepancy B-outcome ['Physiological-Clinical']
in O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
hospitalization B-outcome ['Resource-use']
day I-outcome ['Resource-use']
and O
ureter B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
control O
group O
, O
the O
uterine O
arteries O
, O
however O
, O
may O
be O
confidently O
desiccated O
once O
the O
path O
of O
the O
ureter O
near O
the O
uterosacral O
ligament O
is O
identified O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

The O
percentage O
of O
sites O
per O
subject O
with O
scores O
of O
two O
or O
three O
at O
the O
baseline O
were O
balanced O
between O
study O
groups O
( O
3.7 O
+/- O
7.1 O
for O
T O
; O
1.8 O
+/- O
3.2 O
for O
C O
; O
p O
= O
0.08 O
) O
. O
[]

The O
policy O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

3 O
) O
does O
this O
effect O
depend O
on O
prior O
knowledge O
of O
the O
perturbation O
direction O
? O
; O
[]

ApoA-I O
induction O
as O
a O
potential O
cardioprotective O
strategy O
: O
rationale O
for O
the O
SUSTAIN O
and O
ASSURE O
studies O
. O
[]

A O
multicenter O
, O
placebo-controlled O
, O
randomized O
, O
double-blind O
trial O
compared O
the O
preventive B-outcome ['Physiological-Clinical']
effect O
of O
aprindine O
and O
digoxin O
on O
the O
recurrence O
of O
atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
placebo O
, O
and O
also O
compare O
the O
effectiveness O
of O
these O
2 O
drugs O
in O
the O
prevention B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
compare O
the O
postoperative O
pain-relieving B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
of O
a O
ropivacaine O
0.1 O
% O
-clonidine O
mixture O
to O
that O
of O
plain O
ropivacaine O
0.2 O
% O
following O
caudal O
administration O
in O
children O
. O
['Physiological-Clinical']

DESIGN O
The O
study O
is O
a O
randomized O
research O
in O
an O
open O
randomized O
clinical O
trial O
. O
[]

Trial O
of O
( O
+ O
) O
-cyanidanol-3 O
in O
patients O
with O
hepatitis O
B O
chronic O
liver O
disease O
. O
[]

Medication B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
were O
17.0 O
times O
less O
likely O
when O
pre-filled O
syringes O
were O
used O
( O
95 O
% O
CI O
5.2-55.5 O
) O
, O
and O
infusions O
prepared O
by O
pharmacy O
and O
industry O
were O
significantly O
more O
likely O
to O
contain O
the O
expected O
concentration O
( O
P O
< O
0.001 O
for O
norepinephrine O
and O
P=0.001 O
for O
epinephrine O
) O
. O
['Life-Impact']

Interleukin-2 B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
reductions I-outcome ['Life-Impact']
were O
required O
in O
7 O
patients O
, O
and O
no O
patient O
discontinued O
therapy O
secondary O
to O
toxicity B-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Secondary O
outcomes O
included O
resolution B-outcome ['Physiological-Clinical']
of O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
measured O
by O
the O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
( O
PSQI O
) O
questionnaire O
, O
and O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
measured O
by O
the O
Work B-outcome ['Life-Impact']
Productivity I-outcome ['Life-Impact']
and O
Activity B-outcome ['Life-Impact']
Impairment I-outcome ['Life-Impact']
Questionnaire O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Modifications O
of O
the O
patch O
system O
may O
perhaps O
make O
it O
possible O
to O
achieve O
higher O
[]

CONCLUSIONS O
Preserving O
chordal O
attachments O
enhanced O
the O
late O
hemodynamic O
recovery O
after O
mitral O
valve O
replacement O
for O
mitral O
regurgitation O
. O
[]

Across O
intervention O
group O
, O
effects O
were O
tested O
using O
ANCOVA O
with O
post O
hoc O
pairwise O
comparisons O
. O
[]

Then O
they O
were O
sent O
to O
the O
Department O
of O
Nuclear O
Medicine O
in O
Ostrava O
in O
the O
Czech O
Republic O
. O
[]

CONCLUSIONS O
The O
current O
analysis O
demonstrates O
that O
nasal O
IgA O
contributes O
to O
the O
efficacy O
of O
LAIV O
and O
can O
provide O
evidence O
of O
vaccine-induced O
immunity O
. O
[]

Changes O
( O
mean O
+/- O
SE O
) O
in O
standing B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
baseline O
were O
-7.9 O
+/- O
2.0 O
mm O
Hg O
for O
terazosin O
alone O
, O
-15.1 O
+/- O
2.1 O
mm O
Hg O
for O
terazosin O
plus O
2.5 O
mg O
of O
methyclothiazide O
, O
and O
-15.0 O
+/- O
2.0 O
mm O
Hg O
for O
terazosin O
plus O
5 O
mg O
of O
methyclothiazide O
. O
['Physiological-Clinical']

BACKGROUND O
Anorexia O
nervosa O
is O
an O
often O
chronic O
disorder O
with O
high O
morbidity O
and O
mortality O
. O
[]

Drug O
dosing O
was O
established O
by O
the O
following O
algorithm O
based O
on O
calculated O
creatinine O
clearance O
( O
CrCl O
) O
: O
CrCl O
= O
[ O
( O
140-age O
) O
x O
body O
weight O
] O
/ O
( O
72 O
x O
Cr O
) O
x O
0.85 O
for O
women O
that O
is O
, O
CrCl O
> O
50 O
ml/min O
, O
1000 O
mg O
every O
8 O
hr O
; O
CrCl O
of O
25-50 O
ml/min O
, O
1000 O
mg O
every O
24 O
hr O
; O
CrCl O
of O
10-24 O
ml/ O
min O
, O
500 O
mg O
every O
day O
; O
CrCl O
< O
10 O
ml/min O
( O
or O
on O
dialysis O
) O
, O
500 O
mg O
every O
other O
day O
after O
dialysis O
. O
[]

OBJECTIVE O
The O
advent O
of O
dental O
lasers O
has O
raised O
another O
possible O
treatment O
option O
for O
dentine B-outcome ['Physiological-Clinical']
hypersensitivity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
has O
become O
a O
research O
interest O
in O
the O
last O
decades O
. O
['Physiological-Clinical']

3 O
. O
[]

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
recorded O
. O
['Adverse-effects']

The O
usefulness O
of O
caffeine O
, O
metoclopramide O
and O
pyridoxine O
as O
adjuncts O
to O
tolfenamic O
acid O
was O
tested O
in O
acute B-outcome ['Physiological-Clinical']
migraine I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
in O
ten O
patients O
. O
['Physiological-Clinical']

Thromboprophylaxis O
( O
dextran-70 O
, O
low O
molecular O
weight O
heparin O
and O
graded O
elastic O
stockings O
) O
was O
given O
during O
the O
first O
week O
after O
operation O
. O
[]

Anxiety B-outcome ['Life-Impact']
and O
fear B-outcome ['Life-Impact']
are O
often O
associated O
with O
chronic O
conditions O
such O
as O
cancer O
. O
['Life-Impact', 'Life-Impact']

Results O
were O
analyzed O
at O
1 O
year O
( O
previously O
published O
) O
and O
5 O
years O
postoperatively O
( O
the O
subject O
of O
this O
report O
) O
. O
[]

In O
patients O
with O
no O
contraindication O
to O
beta-blockers O
, O
these O
drugs O
appeared O
to O
be O
safe O
. O
( O
[]

The O
supplement O
group O
had O
significantly O
greater O
improvements O
than O
did O
the O
placebo O
group O
on O
the O
PGI-R O
Average O
Change O
. O
[]

The O
extent O
of O
ON O
was O
estimated O
on O
the O
basis O
of O
abnormal O
signal O
intensity O
in O
the O
weight-bearing O
portion O
of O
the O
femoral O
head O
as O
determined O
from O
a O
combination O
of O
coronal O
and O
sagittal O
MRIs O
. O
[]

Headache B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
reported O
1 O
hour O
after O
the O
first O
injection O
in O
a O
mean O
of O
78 O
% O
of O
attacks O
( O
83 O
% O
in O
the O
first O
3 O
months O
and O
76 O
% O
in O
the O
second O
3 O
months O
) O
. O
['Physiological-Clinical']

Carotid O
sinus O
hypersensitivity O
should O
be O
considered O
in O
all O
older O
adults O
who O
have O
non-accidental O
falls O
. O
[]

The O
net O
trough-to-peak O
ratios O
were O
first O
determined O
from O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
profiles O
( O
12 O
hours O
) O
with O
1-hour O
precision O
, O
synchronized O
by O
the O
morning O
and O
evening O
doses O
of O
the O
double-blind O
medication O
. O
['Physiological-Clinical']

A O
randomized O
, O
controlled O
study O
on O
the O
influence O
of O
acetaminophen O
, O
diclofenac O
, O
or O
naproxen O
on O
aspirin-induced O
inhibition O
of O
platelet B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTION O
49 O
patients O
were O
treated O
with O
cryotherapy O
plus O
subcutaneously O
administered O
interferon O
alpha-2a O
, O
and O
48 O
received O
cryotherapy O
plus O
placebo O
. O
[]

0.53 O
kg O
) O
after O
consuming O
the O
solid O
fruits O
and O
vegetables O
whereas O
the O
overweight/obese O
group O
had O
lower O
compensation O
and O
significant O
weight O
gain O
during O
the O
solid O
arm O
( O
46 O
% O
, O
1.77 O
? O
[]

No O
significant O
side-effects O
or O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
encountered O
. O
['Adverse-effects']

METHODS/DESIGN O
Guided O
by O
a O
multi-level O
, O
conceptual O
framework O
that O
emphasizes O
changes O
in O
provider O
beliefs O
and O
organizational O
characteristics O
as O
drivers O
of O
improvement O
in O
tobacco O
treatment O
delivery O
, O
the O
current O
protocol O
will O
use O
a O
cluster O
, O
randomized O
design O
and O
multiple O
data O
sources O
( O
patient O
exit O
interviews O
, O
provider O
surveys O
, O
site O
observations O
, O
chart O
audits O
, O
and O
semi-structured O
provider O
interviews O
) O
to O
study O
the O
process O
of O
implementing O
clinical O
practice O
guidelines O
for O
treating O
tobacco O
dependence O
in O
18 O
public O
dental O
care O
clinics O
in O
New O
York O
City O
. O
[]

There O
were O
significantly O
more O
cases O
of O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
the O
placebo O
group O
during O
the O
first O
four O
postoperative O
days O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

It O
is O
common O
to O
combine O
forceps O
biopsy O
with O
cytology O
methods O
to O
increase O
the O
diagnostic O
yield O
. O
[]

Based O
on O
our O
data O
, O
we O
conclude O
that O
20 O
Gy O
is O
sufficient O
in O
EF/IF O
of O
intermediate-stage O
HD O
following O
four O
cycles O
of O
modern O
polychemotherapy O
. O
[]

In O
conclusion O
, O
fee-based B-outcome ['Resource-use']
As I-outcome ['Resource-use']
testing I-outcome ['Resource-use']
with O
household B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
is O
effective O
in O
the O
increasing O
demand O
for O
As O
['Resource-use', 'Life-Impact']

RESULTS O
DMSA O
greatly O
increased O
the O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lead I-outcome ['Physiological-Clinical']
, O
substantially O
increased O
excretion O
of O
tin O
and O
bismuth B-outcome ['Physiological-Clinical']
, O
and O
somewhat O
increased O
the O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thallium I-outcome ['Physiological-Clinical']
, O
mercury B-outcome ['Physiological-Clinical']
, O
antimony B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
TMP O
test O
group O
( O
425 O
children O
) O
had O
significantly O
higher O
caries B-outcome ['Physiological-Clinical']
increments I-outcome ['Physiological-Clinical']
than O
the O
MFP O
control O
group O
. O
['Physiological-Clinical']

SUBJECTS O
A O
total O
of O
323 O
consecutive O
patients O
presenting O
with O
dyspnoea O
. O
[]

Because O
of O
interassay O
variability O
the O
results O
were O
considered O
as O
dichotomous O
variables O
( O
proliferation O
versus O
non-proliferation O
) O
for O
further O
data O
analysis O
. O
[]

5.3 O
) O
, O
( O
32.5 O
? O
[]

The O
role O
of O
NO O
was O
investigated O
by O
administering O
N O
( O
G O
) O
-nitro-l-arginine O
methyl O
ester O
hydrochloride O
( O
L-NAME O
, O
20 O
mM O
) O
, O
an O
NO O
synthase O
inhibitor O
or O
Ringer O
's O
solution O
( O
control O
site O
) O
, O
via O
intradermal O
microdialysis O
( O
protocol O
1 O
; O
n=7 O
) O
. O
[]

CONCLUSIONS O
Triple O
tourniquets O
are O
effective O
in O
reducing O
bleeding O
and O
transfusion B-outcome ['Resource-use']
rates O
. O
['Physiological-Clinical', 'Resource-use']

The O
Southwest O
Oncology O
Group O
in O
a O
prospective O
randomized O
study O
compared O
one O
year O
of O
adjuvant O
combination O
chemotherapy O
with O
continuous O
CMFVP O
( O
cyclophosphamide O
, O
methotrexate O
, O
5-fluorouracil O
, O
vincristine O
, O
and O
prednisone O
) O
to O
two O
years O
of O
intermittent O
L-phenylalanine O
mustard O
( O
L-PAM O
) O
in O
women O
with O
operable O
breast O
cancer O
with O
histologically O
positive O
axillary O
lymph O
nodes O
. O
[]

METHODS O
We O
conducted O
a O
double-blind O
, O
randomized O
, O
noninferiority O
, O
clinical O
intervention O
trial O
in O
the O
Minneapolis O
Veterans O
Affairs O
Medical O
Center O
. O
[]

RESULTS O
Forty-seven O
patients O
( O
51 O
% O
) O
were O
treated O
with O
fibrin O
glue O
and O
46 O
( O
49 O
% O
) O
were O
not O
. O
[]

RESULTS O
There O
was O
a O
consistent O
tendency O
for O
RSA B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
to O
be O
slower O
after O
the O
static O
stretching O
intervention O
, O
which O
was O
supported O
by O
statistical O
significance O
for O
three O
performance O
variables O
( O
MST O
0-5 O
m O
set O
2 O
, O
MST O
0-20 O
m O
set O
2 O
, O
and O
TST O
set O
2 O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Practice O
was O
shown O
to O
have O
a O
powerful O
effect O
on O
antisaccade B-outcome ['Life-Impact']
direction I-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
. O
['Life-Impact']

IQ B-outcome ['Life-Impact']
and O
ACRT B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
improved O
. O
['Life-Impact', 'Life-Impact']

The O
endophenotype O
of O
autism O
includes O
neuropsychological O
deficits O
, O
for O
instance O
a O
lack O
of O
Theory O
of O
Mind O
and O
problems O
recognizing O
facial O
affect O
. O
[]

Can O
acupuncture O
ease O
the O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
menopause I-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical']

BACKGROUND O
AND O
AIMS O
Calcium-containing O
phosphate O
binders O
have O
been O
shown O
to O
increase O
the O
progression O
of O
vascular B-outcome ['Physiological-Clinical']
calcification I-outcome ['Physiological-Clinical']
in O
hemodialysis O
patients O
. O
['Physiological-Clinical']

RESULTS O
The O
GMC O
of O
non-and-low O
response O
children O
in O
group O
A O
( O
before O
booster O
) O
, O
group O
B O
( O
after O
1 O
dose O
booster O
) O
and O
group O
C O
( O
after O
3 O
dose O
booster O
) O
were O
18.66 O
mIUml O
, O
88.82 O
mIU/ml O
, O
178.24 O
mIU/ml O
respectively O
; O
the O
proportion O
of O
non-responders O
in O
three O
groups O
were O
20.4 O
% O
, O
9.1 O
% O
, O
1.9 O
% O
respectively O
. O
[]

METHODS O
The O
treatment O
regimen O
consisted O
of O
nitrous O
oxide/oxygen O
inhalation O
in O
conjunction O
with O
oral O
administration O
of O
either O
diazepam O
0.3 O
mg/kg O
or O
midazolam O
0.5 O
mg/kg O
in O
a O
cross-over O
design O
study O
of O
13 O
subjects O
aged O
5.8 O
to O
14.7 O
years O
. O
[]

It O
is O
hoped O
that O
, O
if O
this O
inhibition O
can O
be O
mitigated O
, O
it O
will O
be O
possible O
to O
assist O
the O
compromised O
immune O
system O
and O
maintain O
a O
certain O
level O
of O
immune O
performance O
which O
will O
prevent O
recurrence O
and O
improve O
survival B-outcome ['Mortality']
rate O
. O
['Mortality']

For O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
APV I-outcome ['Physiological-Clinical']
AUC O
( O
0-tau O
) O
, O
C B-outcome ['Physiological-Clinical']
( O
max O
) O
, O
and O
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tau I-outcome ['Physiological-Clinical']
) O
were O
26 O
, O
48 O
, O
and O
32 O
% O
higher O
, O
respectively O
, O
and O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
RTV I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Since O
treatment O
decisions O
are O
often O
made O
or O
modified O
at O
the O
first O
outpatient O
clinic O
visit O
, O
this O
study O
was O
designed O
to O
evaluate O
the O
importance O
of O
post-hospital O
data O
on O
mortality O
prediction O
after O
a O
first O
myocardial O
infarction O
( O
MI O
) O
. O
[]

Exhaled O
carbon-monoxide O
( O
CO O
) O
monitoring O
was O
used O
to O
validate O
exposure O
in O
both O
groups O
. O
[]

These O
findings O
can O
help O
to O
determine O
an O
effective O
hypoxic O
exercise O
regimen O
to O
minimize O
immune O
dysfunction O
by O
retarding O
T-lymphocyte O
senescence O
. O
[]

After O
random O
assignment O
of O
20 O
schizophrenia O
patients O
to O
either O
an O
explicit O
or O
normal O
instruction O
group O
, O
the O
Japanese O
Verbal O
Learning O
Test O
was O
administered O
to O
them O
. O
[]

At O
this O
exercise O
training O
that O
lasted O
for O
20 O
min O
the O
acute O
response O
of O
heart B-outcome ['Physiological-Clinical']
rate O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
rate-pressure O
product O
, O
glucose B-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
and O
catecholamines B-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty-one O
children O
with O
ASD O
( O
9-16 O
years O
) O
were O
compared O
to O
typically O
developing O
matched O
groups O
. O
[]

The O
primary O
endpoint O
was O
the O
ADHD B-outcome ['Life-Impact']
Rating O
Scale O
( O
ADHD-RS O
) O
score O
; O
secondary O
endpoints O
were O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
of O
ADHD-Improvement O
( O
CGI-I O
) O
and O
the O
Conners O
Teacher O
Rating O
Scale-Revised O
: O
Short O
Form O
( O
CTRS-R O
: O
S O
) O
score O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
130 O
children O
( O
mean O
[ O
+/-SD O
] O
age O
, O
8.3+/-3.3 O
years O
) O
were O
enrolled O
; O
63 O
were O
randomly O
assigned O
to O
receive O
transfusions O
and O
67 O
to O
receive O
standard O
care O
. O
[]

Radical O
operation O
during O
the O
remission O
appears O
to O
be O
very O
important O
for O
survival B-outcome ['Mortality']
of O
the O
patient O
. O
['Mortality']

RESULTS O
The O
median O
duration O
of O
ART B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
was O
3.8 O
years O
. O
['Physiological-Clinical']

The O
conventional O
methods O
of O
IPC O
use O
low O
pressure O
and O
slow O
inflation O
of O
the O
air O
bladder O
on O
the O
leg O
to O
augment O
venous O
return O
. O
[]

Implications O
of O
the O
results O
and O
directions O
for O
future O
research O
are O
discussed O
. O
[]

An O
inferomedial O
injection O
location O
requires O
[]

Efficacy O
of O
outpatient O
induction O
with O
low-dose O
intravaginal O
prostaglandin O
E2 O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Normothermic O
CPB O
was O
not O
associated O
with O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
on O
postoperative B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
high-sensitive I-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
hsCRP B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

The O
one-year O
survival B-outcome ['Mortality']
was O
37 O
% O
for O
group O
A O
and O
44 O
% O
for O
group O
B O
( O
P O
= O
0.35 O
) O
. O
['Mortality']

European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
International O
Antimicrobial O
Therapy O
Cooperative O
Group O
and O
the O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
. O
[]

Subjects O
also O
had O
significant O
reductions O
in O
RR B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
['Physiological-Clinical']

Lornoxicam O
8 O
mg O
demonstrated O
significant O
analgesic B-outcome ['Resource-use']
efficacy O
as O
compared O
with O
placebo O
. O
['Resource-use']

The O
prognostic O
role O
of O
OPN O
was O
most O
prominent O
in O
intermediate-risk O
AML O
. O
[]

Comparative O
efficacy O
of O
intravenous O
ibutilide O
versus O
procainamide O
for O
enhancing O
termination O
of O
atrial O
flutter O
by O
atrial O
overdrive O
pacing O
. O
[]

Beta-adrenoceptor O
blockade O
did O
not O
affect O
the O
pressor B-outcome ['Physiological-Clinical']
response O
the O
cold B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
multivariable O
analysis O
, O
DeltaBNP O
and O
DeltaNT-ANP O
were O
independent O
predictors O
of O
DeltaESV O
and O
DeltaEDV O
, O
whereas O
DeltaBNP O
also O
predicted O
DeltaEF O
( O
all O
p O
< O
0.0001 O
) O
. O
[]

Lithium O
and O
granulocytopenia O
during O
induction O
therapy O
of O
acute O
myelogenous O
leukemia O
. O
[]

BACKGROUND O
This O
study O
evaluated O
the O
relative O
effects O
on O
compliance O
with O
recommended O
lifestyle O
changes O
of O
two O
experimental O
videotapes O
that O
involved O
different O
approaches O
for O
preparing O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
patients O
for O
the O
posthospital O
recovery O
period O
. O
[]

The O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
shorter O
in O
the O
stapled O
group O
24.28 O
minutes O
( O
4.25 O
) O
versus O
45.21 O
minutes O
( O
5.36 O
) O
in O
the O
Milligan-Morgan O
group O
( O
P O
< O
.001 O
) O
. O
['Life-Impact']

CONCLUSIONS O
There O
is O
no O
significant O
difference O
in O
the O
survival B-outcome ['Mortality']
rates O
between O
the O
two O
groups O
. O
['Mortality']

Its O
prevention O
may O
improve O
maternal O
and O
infant O
survival O
. O
[]

Transthoracic O
versus O
transesophageal O
cardioversion O
of O
atrial O
fibrillation O
under O
light O
sedation O
: O
a O
prospective O
randomized O
trial O
. O
[]

Nineteen O
patients O
were O
randomised O
, O
9 O
to O
the O
intravenous O
and O
10 O
to O
the O
intra-arterial O
arms O
. O
[]

Effect O
of O
vitamin O
K2 O
on O
the O
recurrence B-outcome ['Physiological-Clinical']
in O
patients O
with O
hepatocellular O
carcinoma O
. O
['Physiological-Clinical']

MCA O
was O
performed O
on O
all O
clinical O
and O
EEG O
parameters O
, O
first O
throughout O
follow-up O
, O
then O
restricted O
to O
the O
first O
year O
of O
the O
disease O
. O
[]

While O
there O
were O
no O
significant O
group O
differences O
in O
sex O
, O
age O
, O
intellectual O
disability O
, O
language O
level O
, O
or O
baseline O
ADHD O
symptoms O
, O
autistic O
symptoms O
tended O
to O
be O
more O
prevalent O
in O
the O
IED O
group O
( O
according O
to O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule-2 O
criteria O
) O
. O
['Life-Impact']

There O
was O
no O
alteration O
in O
psychometric B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
non-TIPS O
patients O
after O
glutamine O
when O
LOLA O
was O
given O
but O
when O
placebo O
was O
given O
, O
glutamine O
caused O
prolongation O
of O
CRT B-outcome ['Physiological-Clinical']
( O
p=0.02 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

In O
the O
group O
of O
Futraful O
alone O
the O
survival B-outcome ['Mortality']
and O
disease-free B-outcome ['Physiological-Clinical']
rate O
were O
improved O
in O
three O
years O
after O
operation O
, O
especially O
marked O
in O
patients O
with O
the O
advanced O
stage O
. O
['Mortality', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
A O
total O
of O
90 O
eyes O
of O
90 O
patients O
with O
primary O
open-angle O
glaucoma O
or O
pseudoexfoliative O
glaucoma O
underwent O
deep O
sclerectomy O
. O
[]

By O
assessing O
combined O
status O
of O
BRAF O
and O
MSI O
, O
it O
seemed O
that O
BRAF-mutated O
MSS O
( O
microsatellite O
stable O
) O
tumor O
was O
an O
unfavorable O
subtype O
, O
whereas O
BRAF O
wild-type O
MSI-high O
tumor O
was O
a O
favorable O
subtype O
, O
and O
BRAF-mutated O
MSI-high O
tumor O
and O
BRAF O
wild-type O
MSS O
tumor O
were O
intermediate O
subtypes O
. O
[]

All O
treatments O
were O
well-tolerated B-outcome ['Life-Impact']
, O
with O
minor B-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
and O
oral B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
representing O
the O
most O
common O
findings O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
monitored O
with O
and O
without O
CPRV O
for O
60 O
min O
. O
['Physiological-Clinical']

Individuals O
were O
treated O
on O
each O
occasion O
with O
100 O
mg O
aspirin O
daily O
in O
combination O
with O
either O
3 O
x O
1 O
g O
acetaminophen O
, O
3 O
x O
50 O
mg O
diclofenac O
, O
3 O
x O
250 O
mg O
naproxen O
, O
or O
3 O
x O
1 O
placebo O
. O
[]

When O
compared O
with O
the O
no-treatment O
group O
, O
the O
combined-treatment O
group O
had O
significantly O
fewer O
subjects O
admitted B-outcome ['Resource-use']
to I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
( O
0 O
compared O
with O
5 O
, O
P O
= O
0.03 O
) O
, O
fewer O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
( O
0 O
compared O
with O
74 O
, O
P O
= O
0.041 O
) O
, O
and O
a O
longer O
time O
to O
hospital O
admission O
( O
P O
= O
0.017 O
) O
. O
['Resource-use', 'Resource-use']

Each O
treatment O
was O
well O
tolerated O
. O
[]

DESIGN O
Eighty-three O
technically O
successful O
PTA O
procedures O
were O
studied O
. O
[]

Mean O
injury B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
score O
was O
32.7 O
for O
HSD O
and O
32.6 O
for O
NS O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Cohort O
study O
. O
[]

WBRT O
( O
10 O
fractions O
of O
3 O
Gy O
) O
had O
to O
start O
within O
3 O
weeks O
from O
the O
start O
of O
chemotherapy O
. O
[]

We O
tried O
a O
infusion O
of O
interleukin-2 O
( O
IL-2 O
) O
of O
a O
relatively O
low O
dose O
via O
an O
intrasplenic O
arterial O
catheter O
connected O
to O
a O
chronometric O
infusion O
( O
IS-IL-2 O
) O
. O
[]

After O
4 O
days O
of O
treatment O
platelet B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
was O
similarly O
inhibited O
by O
all O
combinations O
. O
['Physiological-Clinical']

10 O
volunteers O
( O
61-78 O
years O
) O
with O
minor O
impairment O
of O
brain O
function O
were O
given O
placebo O
, O
40 O
mg O
and O
60 O
mg O
nimodipine O
( O
Nimotop O
) O
in O
single O
doses O
with O
intervals O
of O
3 O
medication-free O
days O
between O
medications O
under O
double-blind O
conditions O
. O
[]

CONCLUSION O
Local O
estrogen O
either O
alone O
or O
with O
androgen O
is O
highly O
effective O
in O
relieving O
symptoms O
of O
[]

BACKGROUND O
In O
2005 O
, O
the O
European O
Resuscitation O
Council O
and O
the O
American O
Heart O
Association O
published O
new O
guidelines O
for O
Advanced O
Life O
Support O
. O
[]

These O
improvements O
corresponded O
to O
small O
to O
large O
between-groups O
effect O
sizes O
( O
Cohen O
's O
d O
) O
at O
posttreatment O
for O
disability B-outcome ['Life-Impact']
( O
d O
= O
.88 O
) O
, O
anxiety B-outcome ['Life-Impact']
( O
d O
= O
.38 O
) O
, O
depression B-outcome ['Life-Impact']
( O
d O
= O
.66 O
) O
, O
and O
average O
pain B-outcome ['Physiological-Clinical']
( O
d O
= O
.64 O
) O
, O
respectively O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

METHODS O
This O
was O
a O
randomized O
clinical O
trial O
that O
enrolled O
children O
aged O
28 O
days O
to O
4 O
years O
who O
were O
admitted O
to O
a O
PICU O
between O
October O
of O
2005 O
and O
June O
of O
2007 O
and O
put O
on O
mechanical O
ventilation O
( O
MV O
) O
for O
more O
than O
48 O
hours O
. O
[]

Effect O
of O
clinical O
context O
on O
simulator-based O
assessment O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
taking O
- O
a O
pilot O
randomized O
study O
. O
['Physiological-Clinical']

The O
enlarged O
blood-buffering O
capacity O
after O
infusion O
of O
Bicarb O
eliminated O
metabolic O
acidosis O
during O
maximal O
exercise O
but O
that O
did O
not O
affect O
the O
cerebral O
lactate O
uptake O
and O
, O
therefore O
, O
the O
decrease O
in O
the O
cerebral O
metabolic O
ratio O
. O
[]

[ O
Physical O
performance O
and O
sedation O
: O
comparative O
study O
of O
the O
effects O
of O
a O
benzodiazepine O
( O
temazepam O
) O
and O
of O
a O
non-benzodiazepine O
hypnotic O
( O
zolpidem O
) O
] O
. O
[]

Primary O
outcome O
, O
assessed O
at O
week O
8 O
, O
was O
recurrence O
of O
visible O
warts O
. O
[]

A O
total O
of O
406 O
previously O
untreated O
CHC O
patients O
, O
including O
98 O
( O
24 O
% O
) O
IVDUs O
, O
were O
studied O
for O
compliance O
( O
presentation O
at O
the O
end O
of O
treatment O
) O
, O
complete O
response O
( O
alanine O
aminotransferase O
within O
normal O
limits O
and O
serum O
hepatitis O
C O
virus O
polymerase O
chain O
reaction O
negative O
) O
at O
the O
end O
of O
therapy O
and O
sustained O
virological O
response O
( O
SVR O
) O
. O
[]

Patient O
characteristics O
similar O
in O
the O
two O
groups O
and O
all O
under O
care O
of O
one O
surgical O
team O
. O
[]

With O
respect O
to O
the O
tolerability B-outcome ['Life-Impact']
therapy O
with O
the O
combination O
is O
more O
beneficial O
in O
comparison O
to O
the O
alternative O
therapy O
. O
['Life-Impact']

The O
effect O
of O
expertise O
training O
with O
faces O
was O
studied O
in O
adults O
with O
ASD O
who O
showed O
initial O
impairment O
in O
face O
recognition O
. O
[]

Intention-to-treat O
analysis O
of O
the O
entire O
study O
population O
of O
1,214 O
patients O
showed O
that O
primary O
endpoint O
events O
( O
ipsilateral O
stroke O
or O
death O
between O
randomisation O
and O
day O
30 O
) O
occurred O
in O
6.92 O
% O
of O
the O
CAS O
group O
and O
6.45 O
% O
of O
the O
CEA O
group O
. O
[]

Forty O
patients O
had O
both O
their O
trachea O
and O
oesophagus O
intubated O
, O
each O
patient O
was O
studied O
twice O
. O
[]

Thus O
, O
56 O
children O
( O
28 O
in O
each O
group O
) O
completed O
the O
study O
. O
[]

A O
comparison O
of O
high O
and O
low O
fat O
meals O
on O
postprandial O
esophageal O
acid O
exposure O
. O
[]

BACKGROUND O
Recently O
, O
amlodipine O
maleate O
was O
developed O
and O
tested O
in O
preclinical O
and O
Phase O
I O
clinical O
trials O
in O
Korea O
. O
[]

There O
was O
no O
difference O
between O
ischemic O
and O
nonischemic O
etiology O
. O
[]

Of O
the O
total O
7788 O
participants O
entered O
into O
the O
DIG O
trial O
, O
only O
97 O
participants O
( O
1.2 O
% O
) O
could O
not O
have O
their O
vital B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
as O
of O
December O
31 O
, O
1995 O
determined O
. O
['Physiological-Clinical']

Ipratropium O
bromide O
nasal O
spray O
for O
treatment O
of O
rhinorrhea O
in O
the O
laryngectomized O
patient O
: O
a O
pilot O
study O
. O
[]

In O
the O
trial O
group O
, O
skin O
incision O
parallel O
to O
the O
thenar O
crease O
was O
made O
up O
to O
2.5 O
cm O
in O
length O
, O
under O
an O
operating O
microscope O
and O
endoscopic O
transillumination O
. O
[]

Previous O
clinical O
series O
and O
experimental O
studies O
have O
not O
examined O
this O
aspect O
of O
distal O
radius O
loading O
after O
harvesting O
the O
bone O
graft O
. O
[]

CONCLUSION O
Malnutrition B-outcome ['Physiological-Clinical']
was O
highly O
prevalent O
in O
this O
setting O
of O
patients O
. O
['Physiological-Clinical']

Cardiac B-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
I O
( O
cTnI O
) O
was O
assayed O
preoperatively O
, O
and O
then O
4 O
hours O
, O
8 O
hours O
, O
12 O
hours O
, O
20 O
hours O
, O
and O
48 O
hours O
after O
persistent O
reperfusion O
. O
['Physiological-Clinical']

The O
benefits O
of O
visual O
biofeedback O
by O
forceplate O
system O
training O
suggest O
particular O
improvement O
of O
anticipation O
equilibrium O
with O
conventional O
therapy O
. O
[]

PATIENTS O
AND O
METHODS O
In O
all O
, O
202 O
consecutive O
patients O
from O
the O
hospital O
waiting O
list O
were O
randomized O
to O
undergo O
TURP O
using O
either O
a O
bipolar O
system O
( O
Surgmaster O
TURis O
, O
Olympus O
, O
Tokyo O
, O
Japan O
) O
or O
a O
monopolar O
system O
( O
24 O
F O
, O
Storz O
, O
T?bingen O
, O
Germany O
) O
. O
[]

Allergic O
mothers O
had O
significantly O
lower O
amounts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
breast-milk O
compared O
with O
non-allergic O
mothers O
[ O
median O
1.3 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
IQR O
22.4-3.0 O
x O
10 O
( O
3 O
) O
) O
vs. O
5.6 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
1.8 O
x O
10 O
( O
3 O
) O
-1.8 O
x O
10 O
( O
4 O
) O
) O
, O
respectively O
, O
( O
P=0.004 O
) O
] O
, O
and O
their O
infants O
had O
concurrently O
lower O
counts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
feces O
[ O
3.9 O
x O
10 O
( O
8 O
) O
bacterial O
cells/g O
( O
IQR O
6.5 O
x O
10 O
( O
6 O
) O
-1.5 O
x O
10 O
( O
9 O
) O
) O
in O
infants O
of O
allergic O
mothers O
, O
vs. O
2.5 O
x O
10 O
( O
9 O
) O
bacterial O
cells/g O
( O
6.5 O
x O
10 O
( O
8 O
) O
-3.2 O
x O
10 O
( O
10 O
) O
) O
in O
infants O
of O
non-allergic O
mothers O
, O
P=0.013 O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Majority O
of O
myocardial B-outcome ['Physiological-Clinical']
infarctions I-outcome ['Physiological-Clinical']
were O
asymptomatic O
or O
unrecognized O
. O
['Physiological-Clinical']

However O
, O
supramaximal O
doses O
of O
GHRH O
were O
used O
and O
the O
response O
may O
decline O
with O
time O
after O
radiotherapy O
. O
[]

There O
was O
a O
significant O
[]

The O
purpose O
of O
this O
study O
was O
to O
measure O
the O
degree O
of O
anesthesia B-outcome ['Resource-use']
following O
the O
administration O
of O
3.6 O
ml O
of O
2 O
% O
lidocaine O
solutions O
with O
either O
1:50,000 O
, O
1:80,000 O
, O
or O
1:100,000 O
for O
inferior O
alveolar O
nerve O
block O
and O
to O
compare O
the O
results O
with O
those O
obtained O
following O
the O
administration O
of O
1.8 O
ml O
of O
the O
same O
solutions O
( O
1 O
) O
. O
['Resource-use']

OBJECTIVE O
To O
prospectively O
compare O
two O
commonly O
used O
methods O
for O
percutaneous O
dilational O
tracheostomy O
( O
PDT O
) O
in O
critically O
ill O
patients O
. O
[]

Randomisation O
was O
planned O
so O
that O
50 O
% O
of O
the O
patients O
in O
each O
subgroup O
were O
assigned O
for O
16 O
weeks O
to O
treatment O
with O
citalopram O
and O
the O
remaining O
50 O
% O
were O
assigned O
to O
treatment O
with O
reboxetine O
. O
[]

PATIENTS O
AND O
METHODS O
Of O
462 O
patients O
with O
disseminated O
disease O
, O
49 O
( O
10.6 O
% O
) O
had O
CNS O
disease O
at O
diagnosis O
( O
CNS+ O
) O
. O
[]

The O
interaction O
of O
antimicrobial O
therapy O
and O
acid O
suppression O
is O
not O
yet O
well O
elucidated O
. O
[]

PATIENT O
( O
S O
) O
A O
total O
of O
119 O
women O
were O
taken O
into O
the O
study O
. O
[]

The O
diets O
did O
not O
differ O
in O
sodium O
content O
( O
approximately O
3 O
g/day O
) O
. O
[]

The O
primary O
outcome O
measure O
was O
an O
instrument O
rating O
six O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
: O
need B-outcome ['Life-Impact']
to O
know B-outcome ['Life-Impact']
, O
repeating B-outcome ['Life-Impact']
, O
ordering B-outcome ['Life-Impact']
, O
need B-outcome ['Life-Impact']
to O
tell/ask B-outcome ['Life-Impact']
, O
self-injury B-outcome ['Life-Impact']
, O
and O
touching B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

One O
group O
( O
n O
= O
10 O
; O
4 O
men O
and O
6 O
women O
; O
51.4 O
+/- O
2.8 O
years O
of O
age O
) O
agreed O
to O
physical O
training O
using O
bicycle O
ergometer O
exercise O
with O
the O
intensity O
at O
blood O
lactate O
threshold O
for O
60 O
minutes O
three O
times O
a O
week O
for O
10 O
weeks O
, O
while O
the O
other O
group O
( O
n O
= O
10 O
; O
4 O
men O
and O
6 O
women O
; O
51.0 O
+/- O
2.9 O
years O
of O
age O
) O
did O
no O
particular O
physical O
training O
and O
was O
followed O
once O
a O
week O
as O
the O
control O
. O
[]

This O
phase O
II O
study O
assessed O
neoadjuvant O
cetuximab O
with O
capecitabine-based O
CRT O
in O
LARC O
. O
[]

Two O
groups O
of O
9 O
male O
patients O
( O
age O
: O
59 O
+/- O
4 O
and O
56 O
+/- O
6 O
years O
, O
resp O
. O
) O
[]

METHODS O
Prospectively O
enrolled O
patients O
with O
rectal O
cancer O
from O
October O
2007 O
to O
October O
2008 O
. O
[]

This O
idea O
can O
explain O
the O
experimental O
results O
that O
frequency O
discrimination O
is O
relatively O
unaffected O
by O
randomization O
of O
stimulus O
level O
. O
[]

Cephalometric B-outcome ['Physiological-Clinical']
measures I-outcome ['Physiological-Clinical']
showed O
a O
significant O
decrease O
in O
anterior B-outcome ['Physiological-Clinical']
lower O
facial B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
showed O
that O
the O
parent-delivered O
program O
was O
effective O
in O
improving O
measures O
of O
autism O
( O
medium O
effect O
size O
) O
and O
sensory B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulatory I-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
( O
large O
effect O
size O
) O
. O
['Life-Impact']

The O
duration O
of O
the O
study O
was O
6 O
months O
. O
[]

There O
were O
intervals O
of O
4 O
weeks O
without O
medication O
between O
the O
treatment O
periods O
. O
[]

However O
, O
there O
were O
broad O
interindividual O
differences O
in O
the O
erythropoietic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
possibly O
due O
to O
limitations O
in O
iron O
availability O
. O
['Physiological-Clinical']

17 O
beta-Oestradiol O
( O
9 O
mg O
) O
or O
progesterone O
( O
300 O
mg O
) O
were O
given O
before O
the O
second O
test O
, O
after O
a O
first O
test O
with O
placebo O
. O
[]

RESULTS O
Women O
in O
the O
pilot O
group O
had O
significantly O
more O
continuity O
of O
care B-outcome ['Life-Impact']
throughout O
each O
of O
the O
three O
periods O
, O
were O
generally O
more O
satisfied B-outcome ['Life-Impact']
with O
their O
care O
, O
felt O
that O
they O
had O
more O
choice B-outcome ['Life-Impact']
over O
a O
variety O
of O
aspects O
of O
care B-outcome ['Life-Impact']
and O
experienced O
no O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Geometric O
mean O
titres O
( O
GMTs O
) O
, O
measured O
by O
ELISA B-outcome ['Resource-use']
, O
to O
pertussis B-outcome ['Physiological-Clinical']
toxin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
filamentous B-outcome ['Physiological-Clinical']
haemagglutinin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FHA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
the O
acellular O
vaccine O
groups O
than O
in O
the O
whole-cell O
DPT O
( O
WCDPT O
) O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
and O
severity O
of O
adverse O
effects O
were O
also O
comparable O
whether O
or O
not O
low-dose O
bupivacaine O
infusion O
was O
used O
. O
[]

Late B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
in O
the O
form B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
( O
5 O
% O
vs. O
15 O
% O
odds O
ratio O
0.29 O
, O
95 O
% O
CI O
0.08-1.11 O
, O
P=0.08 O
) O
and O
strictures B-outcome ['Physiological-Clinical']
( O
13 O
% O
vs. O
28 O
% O
, O
odds O
ratio O
0.40 O
, O
95 O
% O
CI O
0.16-1.01 O
, O
P=0.05 O
) O
was O
observed O
in O
the O
RT O
and O
CRT O
groups O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
efficacy O
of O
maternal O
vitamin O
A O
or O
beta O
carotene O
supplementation O
in O
reducing O
pregnancy-related O
and O
infant O
mortality O
. O
[]

RESULTS O
Patients O
who O
received O
IT O
methotrexate O
had O
a O
mean O
Processing B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
Index O
that O
was O
3.6 O
points O
lower O
, O
about O
one O
fourth O
of O
a O
standard O
deviation O
, O
than O
those O
who O
received O
triple O
IT O
therapy O
( O
P O
= O
.04 O
) O
after O
analysis O
was O
adjusted O
for O
age O
, O
sex O
, O
and O
time O
since O
diagnosis O
. O
['Life-Impact']

RESULTS O
The O
overall O
miss B-outcome ['Physiological-Clinical']
rate O
for O
adenomas O
was O
24 O
% O
, O
27 O
% O
for O
adenomas O
< O
or O
= O
5 O
mm O
, O
13 O
% O
for O
adenomas O
6-9 O
mm O
, O
and O
6 O
% O
for O
adenomas O
> O
or O
= O
1 O
cm O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
left O
ventricular O
ejection O
fraction O
less O
than O
45 O
% O
after O
AMI O
were O
randomly O
assigned O
stem O
cell O
delivery O
via O
intramyocardial O
injection O
and O
intracoronary O
infusion O
3-6 O
weeks O
or O
3-4 O
months O
after O
AMI O
. O
[]

Final O
report O
of O
a O
randomized O
controlled O
study O
with O
streptococcal O
preparation O
OK-432 O
as O
a O
supplementary O
immunopotentiator O
for O
laryngeal O
cancer O
. O
[]

The O
study O
was O
a O
randomized O
, O
double-blind O
, O
cross-over O
trial O
preceded O
by O
a O
placebo O
run-in O
period O
. O
[]

RESULTS O
We O
enrolled O
20 O
patients O
with O
a O
mean O
( O
SD O
) O
Acute B-outcome ['Physiological-Clinical']
Physiology I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Chronic I-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
Evaluation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APACHE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
score O
of O
32 O
( O
10.2 O
) O
; O
14 O
were O
insulin-dependent O
pre-ICU O
, O
and O
all O
were O
medical O
admissions O
. O
['Physiological-Clinical']

INTRODUCTION O
The O
most O
suitable O
antihypertensive O
drug O
to O
reduce O
the O
risk O
of O
cardiovascular O
disease O
in O
patients O
with O
hypertension O
and O
diabetes O
is O
unclear O
. O
[]

The O
reduction O
in O
incontinence B-outcome ['Physiological-Clinical']
during O
the O
follow-up O
period O
resulted O
in O
some O
small O
savings O
in O
laundry B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
supplies O
used O
, O
and O
some O
quantitatively O
unmeasurable O
but O
detectable O
improvement O
in O
psychosocial B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
among O
the O
trainees O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

Full B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
achieved O
in O
8-9 O
minutes O
. O
['Physiological-Clinical']

Results O
of O
previous O
reports O
about O
the O
effects O
of O
ischemic O
postconditioning O
on O
myocardial B-outcome ['Physiological-Clinical']
protection I-outcome ['Physiological-Clinical']
in O
animals O
and O
humans O
are O
very O
encouraging O
. O
['Physiological-Clinical']

Regarding O
safety O
, O
35 O
dogs O
in O
each O
group O
experienced O
at O
least O
one O
adverse B-outcome ['Adverse-effects']
event O
. O
['Adverse-effects']

Cardiovascular O
safety O
and O
gastrointestinal B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
etoricoxib O
vs O
diclofenac O
in O
a O
randomized O
controlled O
clinical O
trial O
( O
The O
MEDAL O
study O
) O
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Adult O
patients O
with O
chronic O
renal O
failure O
( O
CRF O
) O
often O
show O
symptoms O
as O
fatigue O
, O
wasting O
, O
and O
reduced O
working O
capacity O
with O
concomitant O
findings O
of O
reduced O
cardiac O
performance O
and O
muscle O
mass O
. O
[]

Non-linear O
mixed O
models O
were O
used O
to O
estimate O
the O
cumulative O
effect O
of O
H O
pylori O
clearance O
on O
histopathology B-outcome ['Physiological-Clinical']
scores O
adjusted O
for O
follow O
up O
time O
, O
interventions O
, O
and O
confounders O
. O
['Physiological-Clinical']

This O
decrease O
was O
caused O
by O
a O
significant O
decrease O
in O
CBF B-outcome ['Physiological-Clinical']
associated O
with O
a O
significant O
increase O
in O
AVDO2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Nightblind O
pregnant O
women O
were O
randomly O
assigned O
to O
receive O
, O
6 O
d/wk O
under O
supervision O
for O
6 O
wk O
, O
a O
vitamin O
A-fortified O
rice O
curry O
dish O
providing O
850 O
microg O
retinal O
activity O
equivalents/d O
with O
either O
a O
30-mg O
Fe O
and O
6-mg O
riboflavin O
( O
FeR O
+ O
VA O
) O
capsule O
or O
a O
placebo O
control O
( O
VA O
only O
) O
capsule O
. O
[]

In O
general O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
similar O
in O
both O
study O
groups O
. O
['Adverse-effects']

Furthermore O
, O
there O
were O
identical O
shortening O
of O
inspiratory O
time O
and O
prolongation O
of O
duty O
ratio O
( O
inspiratory O
time/duration O
of O
a O
breath O
) O
in O
the O
two O
groups O
. O
[]

TRIAL O
REGISTRATION O
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html O
Identifier O
: O
UKF001272 O
. O
[]

CONCLUSIONS O
We O
found O
no O
effect O
of O
the O
Resperate O
on O
BP B-outcome ['Physiological-Clinical']
or O
QoL B-outcome ['Life-Impact']
compared O
with O
the O
control O
group O
. O
['Physiological-Clinical', 'Life-Impact']

Comparison O
between O
three O
contrast O
media O
. O
[]

INTERVENTION O
Comparison O
of O
isoniazid B-outcome ['Physiological-Clinical']
with O
placebo O
or O
no B-outcome ['Resource-use']
prophylaxis I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

In O
both O
groups O
, O
patients O
received O
continuous O
infusion O
FU O
1,000 O
mg/m2/d O
for O
5 O
consecutive O
days O
every O
4 O
weeks O
. O
[]

This O
is O
the O
first O
phase O
III O
randomised O
trial O
to O
evaluate O
maintenance O
immunotherapy O
in O
metastatic O
renal O
cell O
cancer O
( O
mRCC O
) O
. O
[]

In O
the O
second O
group O
( O
propranolol O
group O
= O
75 O
cases O
) O
, O
before O
the O
beginning O
of O
oxytocin O
, O
2 O
mg O
propranolol O
was O
slowly O
injected O
intravenously O
then O
the O
oxytocin O
was O
initiated O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
morning O
stiffness O
, O
walking O
time O
, O
erythrocyte O
sedimentation O
rate O
, O
C-reactive O
protein O
, O
or O
rheumatoid O
factor O
between O
the O
groups O
. O
[]

METHODS O
This O
multicenter O
, O
open-label O
, O
randomised O
trial O
with O
a O
2?2 O
factorial O
design O
first O
compared O
two O
chemotherapy O
strategies O
( O
PRE O
versus O
PERI O
) O
, O
then O
two O
chemotherapy O
regimens O
( O
gemcitabine-cisplatin O
[ O
GP O
] O
versus O
paclitaxel-carboplatin O
[ O
TC O
] O
) O
. O
[]

DISCUSSION O
Changes O
in O
objective O
ophthalmological O
investigation O
parameters O
were O
not O
observed O
. O
[]

The O
FemCap O
Investigators O
' O
Group O
. O
[]

METHODS O
In O
a O
prospective O
, O
randomized O
trial O
, O
100 O
adult O
patients O
received O
either O
conscious O
analgesia/sedation O
( O
Sedation O
group O
) O
or O
total O
intravenous O
anesthesia O
( O
TIVA O
group O
) O
. O
[]

CONCLUSIONS O
Post-discharge O
pharmacy O
directed O
home O
medication O
review O
appeared O
to O
have O
no O
effect O
on O
mortality O
and O
health O
care O
utilisation O
above O
that O
achieved O
with O
standard O
care O
. O
[]

Seventy-eight O
patients O
were O
able O
to O
be O
evaluated O
for O
efficacy O
, O
28 O
receiving O
clarithromycin O
, O
28 O
roxithromycin O
, O
and O
22 O
erythromycin O
stearate O
. O
[]

RESULTS O
( O
a O
) O
Intraoperative O
findings O
and O
distribution O
of O
cervical O
dilatation O
in O
the O
two O
treatment O
groups O
. O
[]

Of O
these O
, O
62 O
took O
part O
in O
the O
treatment O
program O
and O
43 O
served O
as O
controls O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
relationships O
between O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
level O
and O
anxiety B-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
juvenile O
idiopathic O
arthritis O
( O
JIA O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

During O
phase O
2 O
, O
the O
effect O
of O
room O
assignment O
and O
the O
intervention O
of O
standing O
orders O
in O
common O
obstetric O
problems O
were O
utilized O
. O
[]

While O
insulin B-outcome ['Resource-use']
remained O
nearly O
constant O
( O
41 O
( O
45 O
; O
38 O
) O
microU/ml O
) O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
dropped O
by O
about O
14 O
% O
and O
reached O
a O
steady O
state O
of O
89 O
( O
134 O
; O
45 O
) O
mg/dl O
. O
['Resource-use', 'Physiological-Clinical']

Enhancing O
implementation O
of O
tobacco O
use O
prevention O
and O
cessation O
counselling O
guideline O
among O
dental O
providers O
: O
a O
cluster O
randomised O
controlled O
trial O
. O
[]

Randomisation O
was O
done O
by O
minimisation O
, O
with O
stratification O
for O
WHO O
performance O
status O
, O
histology O
, O
and O
centre O
. O
[]

Outcome O
measures O
included O
improvements O
in O
severity O
and O
behavioral O
features O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( O
stereotypies B-outcome ['Life-Impact']
, O
lethargy B-outcome ['Life-Impact']
, O
irritability B-outcome ['Life-Impact']
, O
hyperactivity B-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
reciprocity I-outcome ['Life-Impact']
, O
sharing B-outcome ['Life-Impact']
pleasures I-outcome ['Life-Impact']
) O
and O
improvements O
in O
language B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
socialization B-outcome ['Life-Impact']
, O
and I-outcome ['Life-Impact']
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
noted O
after O
12 O
weeks O
( O
the O
end O
of O
a O
4-week O
maintenance O
phase O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

One O
cohort O
received O
75 O
U/kg O
rhAT O
, O
and O
the O
other O
received O
normal O
saline O
. O
[]

However O
, O
results O
from O
the O
Conners O
' O
[]

Four O
children O
from O
the O
placebo O
group O
versus O
only O
one O
child O
from O
the O
S. O
boulardii O
group O
had O
persisting B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Interrater O
reliability O
was O
excellent O
. O
[]

Exercise O
stress O
test O
was O
performed O
and O
body O
mass O
index O
( O
BMI O
) O
, O
waist-to-hip O
ratio O
( O
WHR O
) O
, O
waist O
circumference O
and O
plasma O
leptin O
levels O
were O
measured O
at O
the O
beginning O
and O
end O
of O
the O
study O
. O
[]

There O
was O
a O
correspondence O
in O
6 O
of O
the O
7 O
patients O
with O
positive O
reaction O
in O
aR O
between O
both O
methods O
. O
[]

In O
phase O
2 O
, O
DA O
predicted O
a O
differential O
response O
in O
the O
medication O
only O
arm O
, O
but O
not O
in O
the O
two O
psychotherapy O
+ O
medication O
conditions O
. O
[]

Local O
anesthetic O
solutions O
used O
were O
0.5 O
per O
cent O
bupivacaine O
HCl O
, O
2 O
per O
cent O
lidocaine O
HCl O
, O
and O
lidocaine-bupivacaine O
mixtures O
in O
the O
ratios O
of O
1:3 O
, O
1:1 O
or O
3:1 O
by O
volume O
. O
[]

CONCLUSION O
: O
Combination O
therapy O
containing O
NFV O
+ O
RTV O
+ O
ddI O
appears O
more O
efficacious O
in O
NRTI-experienced O
children O
than O
a O
regimen O
containing O
NFV O
+ O
NVP O
+ O
d4T O
. O
[]

Ciprofloxacin O
and O
rifampicin O
versus O
doxycycline O
and O
rifampicin O
in O
the O
treatment O
of O
brucellosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additionally O
40 O
euthyroid O
controls O
were O
studied O
. O
[]

This O
figure O
was O
48.9 O
% O
in O
the O
fenretinide O
arm O
and O
41.9 O
% O
in O
the O
control O
arm O
( O
odds O
ratio O
, O
1.16 O
; O
95 O
% O
confidence O
interval O
, O
0.44-3.07 O
) O
. O
[]

The O
75 O
% O
Awassi O
crosses O
were O
least O
profitable B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
remaining O
71 O
patients O
( O
mean O
age O
, O
60 O
y O
; O
49 O
men O
) O
with O
suboptimal O
PTA O
results O
were O
eventually O
randomized O
: O
36 O
to O
the O
CBA O
arm O
and O
35 O
to O
the O
HPBA O
arm O
. O
[]

at O
week O
8 O
if O
mean O
GH O
> O
2.5 O
microg/l O
on O
GH O
day O
curves O
; O
pretreatment O
group O
, O
Group O
1 O
) O
or O
to O
transsphenoidal O
surgery O
( O
direct O
surgery O
group O
, O
Group O
2 O
) O
. O
[]

RFA O
was O
applied O
using O
our O
new O
stepwise O
hook O
extension O
technique O
in O
patients O
of O
group O
1 O
, O
and O
the O
full O
extension O
method O
in O
group O
2 O
. O
[]

The O
percentage O
of O
tumor B-outcome ['Physiological-Clinical']
nuclei I-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
positive O
( O
PSP O
) O
was O
quantified O
manually O
or O
by O
image O
analysis O
, O
and O
the O
per-sample O
mean O
intensity O
score O
( O
MIS O
) O
was O
quantified O
by O
image O
analysis O
. O
['Physiological-Clinical']

Eligibility O
included O
primary O
insomnia O
for O
at O
least O
3 O
months O
, O
habitual O
sleep O
duration O
< O
6.5h O
and O
a O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
score O
> O
5 O
. O
[]

There O
was O
no O
significant O
difference O
in O
response O
rates O
( O
p=0.784 O
) O
. O
[]

There O
were O
significant O
changes O
from O
baseline O
potassium B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
both O
within O
and O
between O
treatments O
in O
the O
early O
postinjection O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Gross B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
scores O
on O
the O
TGMD-2 O
were O
measured O
and O
statistically O
analyzed O
using O
a O
within-subjects O
repeated-measures O
ANOVA O
. O
['Physiological-Clinical']

A O
placebo-controlled O
, O
double-blind O
, O
randomized O
toxicity O
trial O
of O
tamoxifen O
was O
conducted O
among O
postmenopausal O
women O
with O
node O
negative O
breast O
cancer O
. O
[]

The O
mean O
+/- O
SD O
change O
from O
baseline O
in O
total O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
was O
-4.2 O
+/- O
5.3 O
for O
silodosin O
vs O
-2.3 O
+/- O
4.4 O
for O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
one O
patient O
with O
a O
CrCl O
of O
23.8 O
ml/min O
, O
the O
Cmin O
and O
Cmax O
were O
0.32 O
and O
0.7 O
microg/ml O
, O
respectively O
, O
with O
an O
AUC0-24 O
of O
10.7 O
microg O
x O
hr/ml O
. O
[]

Statistical O
differences O
between O
the O
two O
closure O
techniques O
were O
assessed O
by O
Wilcoxon O
signed O
rank O
test O
. O
[]

There O
was O
a O
significant O
correlation O
between O
the O
decrease O
in O
FMD B-outcome ['Physiological-Clinical']
and O
the O
increase O
in O
visceral B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
gain O
( O
rho=-0.42 O
, O
p=0.004 O
) O
, O
but O
not O
with O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
gain O
( O
rho=-0.22 O
, O
p=0.15 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Toxicity B-outcome ['Adverse-effects']
was O
comparable O
in O
the O
2 O
arms O
, O
although O
patients O
with O
a O
baseline O
CD4 B-outcome ['Physiological-Clinical']
count O
less O
than O
50/microL O
had O
a O
high O
infectious B-outcome ['Mortality']
death I-outcome ['Mortality']
rate O
in O
the O
concurrent O
arm O
. O
['Adverse-effects', 'Physiological-Clinical', 'Mortality']

Miss O
rates O
are O
low O
for O
adenomas O
> O
or O
= O
1 O
cm O
. O
[]

In O
Experiment O
1 O
participants O
watched O
a O
video O
, O
before O
a O
cued-recall O
test O
for O
which O
they O
were O
either O
instructed O
to O
close O
their O
eyes O
, O
or O
received O
no-instructions O
. O
[]

These O
findings O
suggest O
MASSI O
is O
a O
feasible B-outcome ['Life-Impact']
treatment O
program O
and O
further O
evaluation O
is O
warranted O
. O
['Life-Impact']

Angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
block O
degradation O
of O
bradykinin O
and O
bradykinin O
stimulates O
prostacyclin O
production O
. O
[]

Thus O
, O
supplementation O
with O
either O
RRR-AT O
or O
all-rac-AT O
resulted O
in O
similar O
increases O
in O
plasma O
and O
LDL O
AT O
levels O
at O
equivalent O
IU O
doses O
, O
and O
the O
degree O
of O
protection O
against O
copper-catalyzed O
LDL O
oxidation O
was O
only O
evident O
at O
doses O
> O
or O
= O
400 O
IU/d O
for O
both O
forms O
. O
[]

Dirithromycin O
, O
in O
the O
regimen O
used O
, O
shows O
little O
promise O
in O
the O
treatment O
of O
patients O
with O
H. O
pylori O
infection O
. O
[]

No O
relevant O
bradycardia B-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

Only O
pigs O
that O
were O
without O
passively O
acquired O
antibody O
at O
the O
time O
they O
were O
inoculated O
with O
virulent O
virus O
appeared O
to O
have O
complete B-outcome ['Physiological-Clinical']
protective I-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
against O
challenge O
exposure O
, O
as O
evidenced O
by O
lack O
of O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pseudorabies I-outcome ['Physiological-Clinical']
and O
lack O
of O
virus B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MgSO4 O
) O
in O
children O
with O
acute O
severe O
asthma O
not O
responding O
to O
conventional O
therapy O
. O
[]

These O
two O
methods O
, O
as O
well O
as O
other O
considerations O
led O
to O
the O
recommendation O
to O
discontinue O
the O
trial O
. O
[]

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical']

1 O
. O
[]

Additionally O
, O
because O
prolonged O
breath O
holding O
is O
not O
required O
, O
measurements O
can O
readily O
be O
made O
in O
dyspnoeic O
patients O
. O
[]

Can O
analysis O
of O
the O
bispectral O
index O
prove O
helpful O
when O
monitoring O
titration O
of O
doses O
of O
midazolam O
and O
ketamine O
for O
sedation O
during O
paediatric B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
catheterization I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
determine O
whether O
educating O
diabetic O
patients O
to O
'eat O
vegetables O
before O
carbohydrate O
' O
was O
as O
effective O
on O
long-term B-outcome ['Physiological-Clinical']
glycemic I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
as O
a O
traditional O
exchange-based O
meal O
plan O
. O
['Physiological-Clinical']

Minimal O
follow-up O
length O
was O
6 O
months O
( O
mean O
9 O
? O
[]

In O
the O
multiple-dose O
studies O
, O
127 O
healthy O
subjects O
received O
bilastine O
10 O
, O
20 O
, O
40 O
, O
50 O
, O
80 O
, O
100 O
, O
140 O
or O
200 O
mg/day O
as O
multiple O
doses O
during O
a O
4- O
, O
7- O
or O
14-day O
period O
. O
[]

METHOD O
Eleven O
5-7 O
year-old O
children O
participated O
in O
a O
CBT-group O
while O
parents O
participated O
in O
psychoeducation O
. O
[]

The O
injecting O
physician O
assessed O
severity O
of O
pain B-outcome ['Physiological-Clinical']
and O
ease B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
injection I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

There O
was O
some O
evidence O
that O
the O
parent O
training O
group O
made O
more O
progress O
in O
language B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
than O
the O
local O
services O
group O
. O
['Life-Impact']

The O
median O
follow-up O
was O
13 O
years O
. O
[]

OBJECTIVES O
Childhood O
asthma O
is O
a O
growing O
public O
health O
concern O
in O
low-income O
urban O
communities O
. O
[]

METHOD O
In O
this O
study O
, O
46 O
children O
, O
3-7 O
years O
of O
age O
diagnosed O
with O
an O
ASD O
were O
randomly O
assigned O
to O
double-blind O
treatment O
with O
20 O
mg/kg/day O
BH4 O
or O
placebo O
for O
16 O
weeks O
. O
[]

They O
received O
12 O
1-h O
weekly O
sessions O
of O
therapy O
and O
daily O
1-h O
home O
intervention O
delivered O
by O
parents O
. O
[]

METHODS O
Outcomes O
7.5 O
months O
after O
randomisation O
were O
acceptability B-outcome ['Life-Impact']
of O
randomisation O
, O
overall B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
of O
and O
satisfaction B-outcome ['Life-Impact']
with O
conservative B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
, O
impact O
on O
quality O
of O
life O
, O
perceived B-outcome ['Life-Impact']
need I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
further I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
and O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
defined O
a O
priori O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Latanoprost O
0.005 O
% O
( O
Xalatan O
) O
was O
stored O
at O
4 O
degrees O
C O
or O
30 O
degrees O
C O
for O
4 O
weeks O
in O
the O
dark O
. O
[]

CONCLUSION O
The O
changes O
in O
24 O
h B-outcome ['Physiological-Clinical']
substrate I-outcome ['Physiological-Clinical']
utilization B-outcome ['Physiological-Clinical']
in O
the O
obese O
, O
as O
well O
as O
in O
the O
well-trained O
group O
, O
suggest O
that O
endurance O
training O
increased O
the O
reliance O
on O
['Physiological-Clinical', 'Physiological-Clinical']

Factors O
associated O
with O
exclusive O
breastfeeding O
included O
maternal B-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
( O
OR=3.92 O
; O
p-value O
< O
0.001 O
) O
, O
planned B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
( O
OR=2.42 O
, O
p-value=0.010 O
) O
, O
intention B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
breastfeed I-outcome ['Life-Impact']
( O
OR=3.28 O
; O
p-value=0.043 O
) O
, O
source O
of O
maternal B-outcome ['Life-Impact']
emotional I-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
( O
OR=1.87 O
, O
p-value=0.039 O
) O
and O
the O
use B-outcome ['Life-Impact']
the O
postpartum O
support O
video B-outcome ['Physiological-Clinical']
, O
the O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
purpose O
of O
this O
report O
is O
to O
summarize O
and O
integrate O
the O
findings O
of O
the O
Diabetes O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
, O
a O
randomized O
controlled O
clinical O
trial O
, O
and O
the O
succeeding O
observational O
follow-up O
of O
the O
DCCT O
cohort O
in O
the O
Epidemiology O
of O
Diabetes O
Interventions O
and O
Complications O
( O
EDIC O
) O
study O
, O
regarding O
the O
effects O
of O
intensive O
treatment O
on O
the O
microvascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
of O
type O
1 O
diabetes O
mellitus O
. O
['Physiological-Clinical']

At O
2 O
years O
, O
there O
was O
no O
difference O
in O
major O
adverse O
cardiac O
events O
( O
98.0 O
% O
for O
ETT O
and O
97.7 O
% O
for O
MPI O
; O
P=0.59 O
) O
. O
[]

The O
incidence O
of O
proximal O
deep-vein O
thrombosis O
as O
assessed O
by O
Doppler O
ultrasonography O
was O
23 O
% O
in O
the O
control O
group O
and O
0 O
% O
in O
those O
using O
the O
device O
( O
p O
less O
than O
0.01 O
) O
. O
[]

Medical O
records O
for O
children O
< O
36 O
months O
of O
age O
were O
abstracted O
before O
, O
during O
, O
and O
after O
the O
intervention O
periods O
for O
specific O
documentation O
elements O
. O
[]

The O
study O
failed O
to O
show O
a O
significant O
association O
between O
experienced O
back O
pain O
and O
EMG O
parameters O
. O
[]

Using O
a O
multivariate O
model O
, O
a O
trend O
was O
seen O
towards O
a O
greater O
benefit O
from O
CHART O
in O
the O
lower O
Ki-67 O
tumours O
( O
P O
= O
0.08 O
) O
; O
this O
became O
significant O
by O
pooling O
the O
low O
and O
intermediate O
Ki-67 O
groups O
in O
comparison O
with O
the O
high O
Ki-67 O
group O
( O
P O
= O
0.032 O
) O
. O
[]

3 O
. O
[]

These O
results O
suggest O
that O
multimodal O
pain O
therapy O
with O
COX-2 O
inhibitors O
may O
have O
a O
role O
in O
outpatient O
inguinal O
hernia O
repair O
. O
[]

Continuous O
event O
recorders O
did O
not O
affect O
anxiety B-outcome ['Life-Impact']
or O
quality O
of O
life O
in O
patients O
with O
palpitations O
. O
['Life-Impact']

CBT O
also O
outperformed O
the O
waitlist O
on O
diagnostic O
outcomes O
and O
parent O
reports O
of O
child B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
but O
not O
children O
's O
self-reports O
. O
['Life-Impact']

Unlike O
intracoronary O
brachytherapy O
, O
there O
was O
no O
evidence O
of O
negative O
edge O
effects O
, O
unhealed B-outcome ['Physiological-Clinical']
dissections I-outcome ['Physiological-Clinical']
, O
or I-outcome ['Physiological-Clinical']
late I-outcome ['Physiological-Clinical']
stent-vessel I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
mechanisms O
underlying O
these O
changes O
and O
their O
modulation O
by O
steroid O
prophylaxis O
have O
not O
been O
clarified O
. O
[]

All O
three O
studies O
used O
a O
multiple O
baseline O
across O
participants O
. O
[]

In O
the O
onion-treated O
skin O
sites O
the O
wheal B-outcome ['Physiological-Clinical']
areas I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
( O
20 O
IU O
: O
control O
: O
108 O
+/- O
53 O
mm2 O
; O
onion O
69 O
+/- O
42 O
mm2 O
, O
P O
less O
than O
0.05 O
; O
200 O
IU O
anti-IgE O
: O
control O
: O
152 O
+/- O
25 O
mm2 O
, O
onion O
: O
138 O
+/- O
26 O
mm2 O
, O
P O
less O
than O
0.02 O
) O
. O
['Physiological-Clinical']

AIMS O
The O
study O
aimed O
to O
determine O
the O
extent O
to O
which O
parents O
and O
teachers O
, O
with O
guidance O
, O
can O
assist O
in O
the O
management O
of O
children O
with O
DCD O
; O
whether O
children O
with O
DCD O
are O
helped O
in O
this O
way O
and O
how O
this O
may O
contribute O
to O
our O
understanding O
of O
the O
condition O
. O
[]

Severity O
of O
symptoms O
was O
rated O
using O
the O
CARS O
( O
Childhood O
Autism O
Rating O
Scale O
) O
. O
[]

Group O
3 O
( O
n=92 O
) O
was O
the O
control O
group O
with O
no O
antiarrhythmic O
prophylaxis O
. O
[]

One O
method O
of O
myocardial O
protection O
during O
cardiac O
surgery O
is O
the O
use O
of O
blood O
cardioplegia O
. O
[]

Regarding O
overall O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
there O
was O
a O
significant O
difference O
between O
the O
NSAID O
group O
and O
the O
7 O
Gy O
group O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Logistic O
regression O
results O
indicated O
an O
11.2 O
times O
higher O
odds O
for O
re-enrollment O
of O
the O
intervention O
group O
than O
the O
control O
group O
( O
p O
< O
.001 O
) O
. O
[]

The O
pattern O
of O
remission O
rates O
and O
odds O
ratios O
was O
similar O
when O
patients O
were O
classified O
as O
having O
high O
DWMH O
, O
PVH O
or O
total O
volume O
suggesting O
that O
lesion O
location O
may O
not O
be O
critical O
. O
[]

The O
primary O
outcome O
was O
the O
Western O
Ontario O
Rotator O
Cuff O
( O
WORC O
) O
index O
. O
[]

IFN-alpha O
does O
not O
appear O
to O
be O
significantly O
involved O
in O
the O
maintenance O
of O
established O
plaque O
psoriasis O
. O
[]

The O
vital O
status O
of O
identified O
women O
was O
confirmed O
using O
Wisconsin O
state O
death O
records O
. O
[]

After O
a O
follow-up O
period O
of O
approximately O
4 O
months O
, O
both O
groups O
had O
similar O
event O
rates O
and O
comparable O
hemodynamic O
parameters O
( O
P O
= O
not O
significant O
) O
. O
[]

To O
assess O
the O
ability O
to O
manage O
events O
, O
we O
reviewed O
treatments O
given O
for O
two O
events O
( O
anterior O
chamber O
inflammation O
, O
increased O
intraocular O
pressure O
) O
in O
one O
trial O
. O
[]

Longterm O
safety O
, O
efficacy O
, O
and O
[]

The O
data O
suggest O
that O
CHG O
does O
not O
offer O
increased O
protection O
against O
perirectal O
infections O
in O
patients O
undergoing O
intensive O
chemotherapy O
, O
nor O
is O
it O
more O
irritating O
than O
a O
nonmedicated O
skin O
cleanser O
. O
[]

In O
this O
multicenter O
, O
randomized O
, O
double-blind O
study O
comparing O
the O
efficacy O
and O
safety O
of O
aerosolized O
albuterol O
with O
the O
dry O
powder O
formulation O
, O
231 O
patients O
with O
chronic O
reversible O
obstructive O
airway O
disease O
were O
randomly O
allocated O
to O
receive O
either O
placebo O
albuterol O
aerosol O
followed O
immediately O
by O
active O
albuterol O
powder O
( O
200 O
micrograms O
) O
or O
active O
albuterol O
aerosol O
( O
two O
puffs O
, O
180 O
micrograms O
) O
followed O
immediately O
by O
placebo O
lactose O
powder O
four O
times O
a O
day O
for O
a O
period O
of O
12 O
weeks O
. O
[]

Enriched O
sensorimotor O
environments O
enable O
rodents O
to O
compensate O
for O
a O
wide O
range O
of O
neurological O
challenges O
, O
including O
those O
induced O
in O
animal O
models O
of O
autism O
. O
[]

RESULTS O
Sixty O
women O
were O
studied O
. O
[]

Intervention O
patients O
also O
experienced O
greater O
rates O
of O
depression B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
( O
72.3 O
% O
v O
10.4 O
% O
of O
EUC O
patients O
; O
P O
< O
.0001 O
) O
and O
significantly O
better O
quality-of-life B-outcome ['Life-Impact']
outcomes O
, O
including O
social/family O
( O
adjusted O
mean O
difference O
between O
groups O
, O
2.7 O
; O
95 O
% O
CI O
, O
1.22 O
to O
4.17 O
; O
P O
< O
.001 O
) O
, O
emotional B-outcome ['Life-Impact']
( O
adjusted O
mean O
difference O
, O
1.29 O
; O
95 O
% O
CI O
, O
0.26 O
to O
2.22 O
; O
P O
= O
.01 O
) O
, O
functional B-outcome ['Life-Impact']
( O
adjusted O
mean O
difference O
, O
1.34 O
; O
95 O
% O
CI O
, O
0.08 O
to O
2.59 O
; O
P O
= O
.04 O
) O
, O
and O
physical B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
( O
adjusted O
mean O
difference O
, O
2.79 O
; O
95 O
% O
CI O
, O
0.49 O
to O
5.1 O
; O
P O
= O
.02 O
) O
. O
['Resource-use', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Lanthanum O
carbonate O
( O
Fosrenol O
) O
is O
a O
new O
non-aluminum O
, O
non-calcium O
phosphate O
binder O
developed O
for O
the O
treatment O
of O
hyperphosphatemia O
in O
patients O
with O
end-stage O
renal O
disease O
( O
ESRD O
) O
. O
[]

The O
intensity O
of O
skin B-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
was O
evaluated O
once O
per O
week O
by O
non-invasive O
instrumental O
reflectance O
spectrophotometry O
in O
comparison O
with O
a O
visual O
scoring O
system O
. O
['Physiological-Clinical']

Final O
analysis O
was O
done O
1 O
year O
after O
the O
last O
patient O
was O
enrolled O
. O
[]

Bone O
turnover O
markers O
and O
bone O
density O
( O
BMD O
) O
were O
measured O
throughout O
the O
study O
. O
[]

INTRODUCTION O
Helicobacter O
pylori O
screening O
and O
treatment O
has O
been O
proposed O
as O
a O
cost-effective O
method O
of O
preventing O
gastric O
cancer O
. O
[]

The O
effects O
of O
these O
two O
training O
forms O
are O
almost O
equivalent O
. O
[]

We O
assessed O
the O
effect O
of O
oral O
daily O
0.3 O
and O
0.6 O
mg O
laquinimod O
on O
MRI-monitored O
disease B-outcome ['Physiological-Clinical']
activity O
in O
a O
36-week O
double-blind O
, O
placebo-controlled O
phase O
IIb O
study O
. O
['Physiological-Clinical']

After O
10 O
, O
20 O
, O
60 O
, O
150 O
and O
240 O
min O
, O
nasal B-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
and O
nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
were O
assessed O
using O
a O
standardized O
visual O
analogue O
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

s.e.m O
. O
[]

Communication O
was O
evaluated O
from O
videotaped O
samples O
of O
seminaturalistic O
parent-child O
interaction O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
orally O
administered O
17 O
beta-oestradiol O
and O
progesterone O
on O
finger B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
before O
and O
during O
heat O
and O
cold O
challenge O
in O
17 O
healthy O
normotensive O
women O
and O
in O
12 O
women O
with O
Raynaud O
's O
phenomenon O
. O
['Physiological-Clinical']

The O
3-month O
leuprolide O
depot O
11.25- O
and O
30-mg O
formulations O
are O
newly O
approved O
treatment O
options O
. O
[]

Large O
forceps O
obtained O
significantly O
more O
tissue B-outcome ['Physiological-Clinical']
than O
the O
small O
forceps O
; O
the O
biopsy O
specimen O
taken O
with O
normal O
forcep O
measured O
in O
average O
1.4 O
x O
1.0 O
mm O
and O
the O
larger O
biopsy O
taken O
with O
jumbo O
forcep O
measured O
in O
average O
2.5 O
x O
1.9 O
mm O
( O
p O
< O
0.005 O
) O
. O
['Physiological-Clinical']

We O
investigated O
the O
use O
of O
oral O
sildenafil O
as O
a O
possible O
substitute O
for O
intracavernosal O
agents O
. O
[]

Interobserver O
variability O
: O
All O
4 O
obstetricians O
agreed O
in O
47 O
of O
100 O
evaluations O
. O
[]

Hence O
treatment O
with O
pegIFNalpha O
2a O
relative O
to O
IFNalpha O
2b/RBV O
minimizes O
the O
adverse O
impact O
of O
therapy O
on O
health-related B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
. O
['Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Pulmonary O
vein O
re-isolation O
for O
atrial O
fibrillation O
using O
duty-cycled O
phased O
radiofrequency O
ablation O
: O
safety O
and O
efficacy O
of O
a O
primary O
2:1 O
bipolar/unipolar O
ablation O
mode O
. O
[]

In O
Study O
2 O
, O
71 O
healthy O
volunteers O
received O
40 O
IU O
kg O
( O
-1 O
) O
via O
the O
intramuscular O
route O
of O
either O
Erig O
PMC O
( O
n O
= O
36 O
) O
or O
PHT-Erig O
( O
n O
= O
35 O
) O
on O
D0 O
, O
in O
association O
with O
five O
doses O
of O
PVRV O
on O
D0 O
, O
D3 O
, O
D7 O
, O
D14 O
and O
D28 O
. O
[]

During O
the O
early O
postoperative O
period O
, O
1 O
, O
2 O
and O
24 O
h O
after O
surgery O
, O
only O
cortisol B-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical']

RESULTS O
IgG B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IgM I-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
as O
soon O
as O
D15 O
in O
both O
groups O
( O
?35 O
% O
, O
?26 O
% O
, O
and O
?35 O
% O
respectively O
, O
vs. O
D0 O
) O
. O
['Physiological-Clinical']

While O
the O
sport O
has O
gained O
considerable O
recognition O
, O
to O
date O
there O
is O
little O
or O
no O
scientific O
research O
regarding O
training B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
to O
snowshoeing O
as O
a O
form O
of O
exercise O
. O
['Life-Impact']

Patients O
were O
randomised O
to O
group O
1 O
, O
CIT O
only O
( O
n=28 O
) O
; O
group O
2 O
, O
CIT O
and O
Sweet O
Talk O
( O
n=33 O
) O
; O
or O
group O
3 O
, O
IIT O
and O
Sweet O
Talk O
( O
n=31 O
) O
. O
[]

Frequency O
of O
nasal B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Activation O
of O
the O
carotid O
chemoreflex O
secondary O
to O
muscle B-outcome ['Physiological-Clinical']
metaboreflex I-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
in O
men O
. O
['Physiological-Clinical']

However O
, O
positive O
effects O
on O
symptoms B-outcome ['Physiological-Clinical']
, O
knowledge B-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
the O
intervention O
were O
found O
in O
both O
the O
short O
and O
the O
long O
version O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

MAIN O
OUTCOME O
MEASURES O
Cytology B-outcome ['Physiological-Clinical']
and O
histology B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
endocervical I-outcome ['Physiological-Clinical']
sampling I-outcome ['Physiological-Clinical']
compared O
with O
cone B-outcome ['Physiological-Clinical']
biopsy I-outcome ['Physiological-Clinical']
histology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
largest O
dosage O
was O
80 O
- O
100 O
microg/min O
. O
[]

METHODS O
A O
retrospective O
, O
cross-sectional O
study O
using O
hospital O
discharge O
and O
billing O
data O
from O
the O
2005 O
Nationwide O
Inpatient O
Sample O
for O
54 O
686 O
Medicare O
beneficiaries O
admitted O
to O
US O
community O
hospitals O
who O
met O
the O
study O
's O
eligibility O
criteria O
. O
[]

Patients O
in O
groups O
A O
, O
B O
and O
C O
received O
amphotericin O
B O
( O
AMB O
) O
in O
a O
dose O
of O
1 O
mg/kg O
body O
weight O
( O
bw O
) O
/day O
, O
0.75 O
mg/kg O
bw/day O
and O
0.5 O
mg/kg O
bw/day O
for O
20 O
days O
respectively O
. O
[]

A O
total O
of O
2771 O
pregnant O
women O
with O
gestational O
age O
estimated O
by O
ultrasound O
measurement O
of O
the O
fetal O
biparietal O
diameter O
( O
BPD O
) O
before O
the O
22nd O
week O
of O
gestation O
were O
re-examined O
by O
ultrasound O
in O
the O
32nd O
and O
37th O
week O
of O
pregnancy O
at O
which O
time O
the O
fetal O
BPD O
and O
abdominal O
diameter O
( O
AD O
) O
were O
measured O
. O
[]

Because O
no O
benefit O
was O
observed O
with O
the O
use O
of O
an O
active O
pectoral O
electrode O
for O
atrial O
defibrillation O
, O
programmable O
shock O
vectors O
may O
be O
useful O
for O
dual-chamber O
implantable O
cardioverter O
defibrillators O
. O
[]

Mean O
change O
in O
A1C B-outcome ['Physiological-Clinical']
level O
from O
baseline O
to O
12 O
months O
was O
-0.4 O
+/- O
0.6 O
% O
( O
P O
< O
0.001 O
) O
in O
subjects O
with O
baseline O
A1C O
> O
or=7.0 O
% O
. O
['Physiological-Clinical']

The O
IO O
group O
had O
the O
greatest O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
the O
IOPO O
group O
the O
greatest O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
cohort O
study O
was O
conducted O
involving O
2166 O
women O
, O
aged O
20-59 O
, O
with O
recent O
low-grade O
cervical O
cytology O
taken O
within O
the O
NHS O
Cervical O
Screening O
Programmes O
in O
Scotland O
and O
England O
, O
and O
managed O
by O
6-monthly O
cytology O
in O
primary O
care O
. O
[]

General O
anaesthesia O
for O
caesarean O
section O
in O
severe O
pre-eclampsia O
. O
[]

Major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
were O
4.4 O
times O
more O
frequent O
with O
the O
Griggs O
PDT O
kit O
. O
['Physiological-Clinical']

We O
present O
the O
rationale O
, O
design O
and O
sample O
characteristics O
of O
the O
citalopram O
trial O
. O
[]

METHODS O
AND O
RESULTS O
In O
18 O
countries O
, O
4809 O
patients O
undergoing O
PCI O
with O
stent O
implantation O
were O
randomized O
to O
tirofiban O
or O
abciximab O
. O
[]

METHOD O
Ten O
patients O
with O
chronic O
stroke O
( O
7 O
males O
; O
mean O
age O
, O
61.4+/-3.02 O
years O
; O
age O
range O
, O
48 O
to O
79 O
years O
; O
mean O
time O
since O
stroke O
, O
28.5 O
months O
; O
range O
, O
13 O
to O
42 O
months O
) O
exhibiting O
stable O
, O
affected O
arm O
motor O
deficits O
were O
administered O
mCIT O
, O
consisting O
of O
: O
( O
1 O
) O
structured O
therapy O
emphasizing O
affected O
arm O
use O
in O
functional O
activities O
3 O
days/week O
for O
10 O
weeks O
; O
and O
( O
2 O
) O
less O
affected O
arm O
restraint O
5 O
days/week O
for O
5 O
hours O
. O
[]

STUDY O
DESIGN O
This O
was O
a O
parallel O
group O
, O
randomized O
controlled O
trial O
of O
infants O
unresponsive O
to O
stimulation O
who O
received O
bag O
and O
mask O
ventilation O
as O
part O
of O
their O
resuscitation O
at O
birth O
and O
infants O
who O
did O
not O
require O
any O
resuscitation O
born O
in O
rural O
communities O
in O
India O
, O
Pakistan O
, O
and O
Zambia O
. O
[]

The O
secondary O
outcome O
measure O
was O
the O
median O
change O
( O
preintervention O
minus O
postintervention O
) O
in O
a O
standardized O
amount O
of O
benzodiazepines O
prescribed O
per O
physician O
. O
[]

Use O
of O
a O
postural O
support O
roll O
improves O
shoulder B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
up O
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

Plasma O
levels O
of O
IL-5 O
increased O
after O
allergen O
challenge O
( O
8.7 O
+/- O
2.9 O
to O
14.5 O
+/- O
3.9 O
pg/mL O
, O
P O
= O
0.001 O
) O
, O
and O
the O
increase O
in O
plasma O
IL-5 O
was O
positively O
correlated O
with O
the O
rise O
in O
sputum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
in O
a O
subgroup O
of O
'responders O
' O
( O
n O
= O
12 O
, O
r O
= O
0.71 O
, O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

FINDINGS O
256 O
episodes O
of O
rotavirus O
gastroenteritis O
occurred O
at O
any O
time O
during O
the O
study O
; O
65 O
were O
among O
1191 O
RRV-TV O
recipients O
, O
and O
191 O
among O
1207 O
placebo O
recipients O
( O
vaccine O
efficacy O
66 O
% O
[ O
95 O
% O
CI O
55-74 O
] O
; O
intention-to-treat O
analysis O
) O
. O
[]

Occurrence O
and O
needed O
days O
for O
healing B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
RAS I-outcome ['Physiological-Clinical']
were O
recorded O
during O
the O
two O
phases O
and O
compared O
. O
['Physiological-Clinical']

These O
results O
were O
consistent O
with O
a O
hypothesized O
dopaminergic O
mechanism O
of O
action O
of O
ascorbic O
acid O
. O
[]

To O
compare O
the O
efficacy O
of O
emergency O
percutaneous O
transluminal O
coronary O
angioplasty O
and O
intracoronary O
streptokinase O
in O
preventing O
exercise-induced O
periinfarct O
ischemia O
, O
28 O
patients O
presenting O
within O
12 O
hours O
of O
the O
onset O
of O
symptoms O
of O
acute O
myocardial O
infarction O
were O
prospectively O
randomized O
. O
[]

Clinical O
trial O
: O
once-daily O
mesalamine O
granules O
for O
maintenance O
of O
remission O
of O
ulcerative O
colitis O
- O
a O
6-month O
placebo-controlled O
trial O
. O
[]

This O
depression B-outcome ['Life-Impact']
was O
observed O
in O
the O
conditioning-testing O
intervals O
of O
400 O
, O
500 O
, O
and O
600 O
msec O
during O
the O
ipsilateral O
backward O
arm O
swing O
and O
at O
the O
onset O
of O
the O
ipsilateral O
arm O
forward O
swing O
. O
['Life-Impact']

Right O
ventricular O
function O
during O
high-frequency O
oscillatory O
ventilation O
in O
adults O
with O
acute O
respiratory O
distress O
syndrome O
. O
[]

CONCLUSIONS O
These O
results O
indicate O
that O
proteinuria O
is O
reduced O
by O
low O
doses O
of O
losartan O
or O
enalapril O
. O
[]

The O
treatment O
efficacy O
of O
single O
dose O
mebendazole O
in O
children O
did O
not O
differ O
significantly O
from O
placebo O
, O
with O
a O
reduction O
in O
mean O
eggs O
per O
gram B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
feces I-outcome ['Physiological-Clinical']
relative O
to O
placebo O
of O
31 O
% O
( O
95 O
% O
CI O
-9 O
to O
56 O
% O
, O
P O
= O
0.1 O
) O
. O
['Physiological-Clinical']

The O
practitioner O
had O
more O
than O
10 O
years O
' O
experience O
with O
loving-kindness O
meditation O
( O
LKM O
) O
, O
a O
form O
of O
NVCC O
. O
[]

Economic B-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
of O
a O
nursing-led O
inpatient O
unit O
: O
the O
impact O
of O
findings O
on O
management O
decisions O
of O
service O
utility O
and O
sustainability O
. O
['Physiological-Clinical']

Late O
hemodynamic O
effects O
of O
the O
preserved O
papillary O
muscles O
during O
mitral O
valve O
replacement O
. O
[]

Adjustments O
in O
spatial B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
were O
evident O
in O
improved O
ball O
catching B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
a O
task O
requiring O
visual O
tracking O
and O
eye-hand O
coordination O
. O
['Life-Impact', 'Life-Impact']

One O
month O
after O
the O
withdrawal O
of O
ACE O
inhibitors O
, O
5 O
patients O
were O
free O
from O
cough B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
BK O
did O
not O
cause O
cough B-outcome ['Physiological-Clinical']
up O
to O
10 O
( O
-5 O
) O
M O
in O
these O
patients O
, O
except O
for O
one O
who O
coughed O
at O
10 O
( O
-9 O
) O
M O
, O
without O
changes O
in O
responses O
to O
citric O
acid O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ALA O
was O
left O
for O
4 O
h O
( O
BCC O
) O
or O
6 O
h O
( O
BD O
) O
. O
[]

Therefore O
, O
we O
investigated O
verapamil O
, O
used O
alone O
or O
as O
an O
adjunctive O
treatment O
, O
in O
manic O
patients O
who O
did O
not O
respond O
to O
an O
initial O
adequate O
trial O
of O
lithium O
. O
[]

In O
particular O
, O
patients O
with O
CFS O
have O
felt O
that O
this O
term O
trivializes O
the O
serious O
nature O
of O
this O
disorder O
. O
[]

METHODS O
Fifty-six O
consecutive O
patients O
scheduled O
for O
knee O
arthroscopy O
were O
enrolled O
. O
[]

Tractography O
was O
conducted O
to O
isolate O
the O
superior O
longitudinal O
fasciculus O
and O
investigate O
whether O
the O
exercise O
intervention O
affected O
WMI O
in O
this O
region O
. O
[]

Subjective O
parameters O
also O
showed O
more O
improvement O
in O
the O
MPA O
group O
than O
in O
the O
patients O
given O
CT O
alone O
. O
[]

This O
study O
compared O
the O
efficacy O
and O
safety O
of O
thrombolysis O
and O
heparin O
treatment O
in O
these O
patients O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
Randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
trial O
at O
8 O
National O
Cancer O
Institute O
( O
NCI O
) O
-funded O
cooperative O
research O
networks O
that O
enrolled O
231 O
patients O
who O
were O
25 O
years O
or O
older O
being O
treated O
at O
community O
and O
academic O
settings O
between O
April O
2008 O
and O
March O
2011 O
. O
[]

Infusion O
sites O
were O
assessed O
daily O
. O
[]

CONCLUSIONS O
When O
using O
the O
bispectral O
index O
for O
monitoring O
sedation O
during O
catheterization O
in O
children O
, O
we O
noted O
decreased O
need O
for O
doses O
of O
midazolam B-outcome ['Resource-use']
and O
ketamine B-outcome ['Physiological-Clinical']
, O
a O
lower O
need O
for O
respiratory B-outcome ['Resource-use']
support I-outcome ['Resource-use']
and O
less O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects']

Given O
the O
ease O
of O
use O
, O
decreased O
morbidity O
to O
the O
patient O
, O
and O
cost-effectiveness O
, O
FloSeal O
hemostatic O
matrix O
could O
change O
clinical O
practice O
in O
managing O
this O
common O
condition O
. O
[]

Twelve O
( O
80 O
% O
) O
of O
15 O
women O
with O
major O
depression O
in O
the O
study O
group O
were O
fully B-outcome ['Physiological-Clinical']
recovered I-outcome ['Physiological-Clinical']
after O
the O
intervention O
compared O
to O
4 O
( O
25 O
% O
) O
of O
16 O
in O
the O
control O
group O
. O
['Physiological-Clinical']

CONCLUSION O
At O
mean O
5-year O
angiography O
in O
largely O
asymptomatic O
patients O
, O
the O
selection O
of O
arterial O
or O
venous O
conduit O
for O
the O
second O
graft O
has O
not O
significantly O
affected O
patency O
. O
[]

Economic B-outcome ['Resource-use']
outcomes O
were O
assessed O
using O
a O
state-transition O
Markov O
model O
, O
which O
predicted O
the O
progress O
of O
participants O
through O
five O
health O
states O
relating O
to O
physical O
activity O
and O
dietary O
improvement O
, O
for O
ten O
years O
after O
recruitment O
. O
['Resource-use']

OBJECTIVE O
The O
common O
goals O
of O
new O
surgical O
treatment O
for O
benign B-outcome ['Physiological-Clinical']
prostatic I-outcome ['Physiological-Clinical']
hyperplasia I-outcome ['Physiological-Clinical']
( O
BPH O
) O
are O
to O
improve O
subjective O
and O
objective O
symptoms O
, O
to O
decrease O
the O
risk O
of O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
and O
short O
hospitalization O
. O
['Physiological-Clinical', 'Adverse-effects']

Before O
treatment O
, O
there O
was O
no O
statistical O
difference O
in O
organism B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
between O
the O
groups O
. O
['Physiological-Clinical']

Under O
the O
given O
conditions O
, O
the O
children O
failed O
to O
learn O
on O
either O
haloperidol O
or O
placebo O
. O
[]

The O
only O
difference O
in O
social O
support O
was O
a O
significant O
decline O
in O
perceived O
support O
reciprocity B-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
( O
F O
= O
5.94 O
, O
P O
= O
.004 O
) O
. O
['Physiological-Clinical']

For O
abdominal O
scars O
, O
there O
was O
no O
difference O
in O
the O
patient O
or O
surgeon O
ratings O
. O
[]

Pain B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
iliac I-outcome ['Physiological-Clinical']
crest I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
during O
the O
first O
12 O
postoperative O
hours O
in O
local O
anaesthetic O
groups O
compared O
to O
the O
control O
group O
. O
['Physiological-Clinical']

RESULTS O
Baseline O
spontaneous O
activity O
in O
all O
subjects O
showed O
both O
high- O
and O
low-frequency O
components O
; O
in O
three O
patients O
with O
UC O
, O
the O
low-frequency O
activity O
was O
of O
high O
amplitude O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
survival B-outcome ['Mortality']
, O
tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Two-week O
indwelling O
did O
not O
increase O
the O
risk O
of O
infection B-outcome ['Physiological-Clinical']
compared O
with O
1-week O
indwelling O
at O
any O
of O
the O
sites O
in O
critically O
ill O
patients O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
findings O
confirm O
an O
increased O
cancer O
risk O
associated O
with O
the O
G84E O
mutation O
in O
the O
Finnish O
population O
, O
particularly O
for O
early-onset O
prostate O
cancer O
and O
cases O
with O
substantially O
elevated O
PSA O
. O
[]

Thus O
, O
the O
use O
of O
random O
SD O
platelet O
transfusions O
postponed O
alloimmunization O
. O
[]

Comparison O
with O
computed O
tomography O
of O
two O
ultrasound O
devices O
for O
diagnosis O
of O
abdominal O
aortic O
aneurysm O
. O
[]

RESULTS O
No O
significant O
differences O
were O
found O
between O
ECD/CD O
, O
ECD/NMI O
and O
TCT/CD O
, O
suggesting O
that O
ECD O
registration O
can O
be O
done O
with O
either O
CD O
or O
NMI O
, O
and O
that O
TCT O
registration O
using O
CD O
is O
equally O
as O
accurate O
as O
ECD O
registration O
. O
[]

Ten-year O
results O
of O
a O
randomised O
trial O
comparing O
cisplatin O
with O
cisplatin O
and O
cyclophosphamide O
in O
advanced O
, O
suboptimally O
debulked O
ovarian O
cancer O
. O
[]

Seventy-three O
eligible O
patients O
were O
assigned O
to O
treatment O
with O
cytarabine O
and O
infusional O
daunorubicin O
with O
or O
without O
intravenous O
CsA O
. O
[]

METHODS O
A O
prospective O
clinical O
trial O
was O
conducted O
on O
epistaxis O
patients O
whose O
nasal O
hemorrhage O
persisted O
despite O
adequate O
nasal O
packing O
by O
the O
otolaryngology-head O
and O
neck O
surgery O
team O
. O
[]

The O
greatest O
reduction O
in O
otorrhea B-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
with O
bilateral O
effusion O
at O
the O
time O
of O
surgery O
. O
['Physiological-Clinical']

Although O
there O
were O
5 O
patients O
who O
needed O
cardioversion B-outcome ['Physiological-Clinical']
or O
ablation B-outcome ['Physiological-Clinical']
because O
of O
frequent O
episodes O
of O
PAF/PAFL O
( O
2 O
in O
25 O
mg/BID O
, O
1 O
in O
50 O
mg/BID O
, O
and O
2 O
in O
100 O
mg/BID O
of O
flecainide O
) O
, O
neither O
death B-outcome ['Mortality']
nor O
ventricular B-outcome ['Physiological-Clinical']
proarrhythmic I-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
was O
reported O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

The O
uncrowded O
logMAR B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
test O
significantly O
overestimated O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
logMAR B-outcome ['Physiological-Clinical']
crowded I-outcome ['Physiological-Clinical']
Kay I-outcome ['Physiological-Clinical']
picture I-outcome ['Physiological-Clinical']
test O
( O
P O
< O
0.005 O
) O
by O
a O
mean O
of O
0.088+/-0.008 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Children O
's O
Cancer O
Group O
1952 O
( O
CCG-1952 O
) O
clinical O
trial O
studied O
the O
substitution O
of O
oral O
6-thioguanine O
( O
TG O
) O
for O
6-mercaptopurine O
( O
MP O
) O
and O
triple O
intrathecal O
therapy O
( O
ITT O
) O
for O
intrathecal O
methotrexate O
( O
IT-MTX O
) O
in O
the O
treatment O
of O
standard-risk O
acute O
lymphoblastic O
leukemia O
. O
[]

29.88 O
) O
pg/ml O
, O
t O
= O
4.67 O
- O
14.23 O
, O
P O
< O
0.01 O
) O
, O
also O
lower O
than O
those O
of O
control O
group O
20 O
days O
after O
the O
treatment O
( O
PRA O
( O
2.02 O
? O
[]

After O
the O
treatment O
, O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
in O
the O
GLP O
group O
, O
BCVA B-outcome ['Physiological-Clinical']
had O
improved O
by O
0.19 O
, O
0.22 O
, O
0.21 O
, O
and O
0.20 O
logMAR O
, O
CMT B-outcome ['Physiological-Clinical']
had O
decreased O
by O
40 O
% O
, O
41.3 O
% O
, O
40.5 O
% O
, O
and O
42 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
caries-preventive O
effects O
of O
two O
toothpastes O
were O
tested O
in O
a O
3-year O
clinical O
trial O
involving O
1319 O
children O
aged O
11-13 O
years O
. O
['Physiological-Clinical']

There O
was O
also O
no O
significant O
improvement O
in O
memory B-outcome ['Life-Impact']
, O
the O
primary O
outcome O
measure O
, O
or O
in O
secondary O
measures O
of O
language B-outcome ['Life-Impact']
, O
attention/executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
behavior B-outcome ['Life-Impact']
, O
and O
overall B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
CX516-treated O
subjects O
compared O
to O
placebo O
. O
['Life-Impact', 'Life-Impact']

Evaluation O
of O
an O
aquatics O
programme O
on O
fitness B-outcome ['Physiological-Clinical']
parameters O
of O
individuals O
with O
a O
brain O
injury O
. O
['Physiological-Clinical']

Concerning O
sleep B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
temazepam O
induces O
a O
statistically O
significant O
reduction O
of O
: O
phase O
shifts O
; O
number O
of O
awakenings O
; O
percent O
duration O
of O
sleep O
stages O
I O
and O
IV O
. O
['Physiological-Clinical']

Primary O
end O
points O
were O
frequency O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
safety O
) O
and O
changes O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
and O
Minnesota O
Living O
With O
HF O
score O
( O
efficacy O
) O
. O
['Adverse-effects', 'Life-Impact']

Checklist O
ratings O
did O
not O
show O
significant O
changes O
. O
[]

Analgesic B-outcome ['Resource-use']
efficacy O
of O
caudal O
block O
versus O
diclofenac O
suppository O
and O
local O
anesthetic O
infiltration O
following O
pediatric O
laparoscopy O
. O
['Resource-use']

A O
small O
proportion O
of O
patients O
( O
7 O
% O
) O
treated O
with O
ofloxacin O
suffered O
mild O
adverse O
effects O
( O
nausea O
, O
vomiting O
, O
headache O
, O
hypotension O
and O
rash O
) O
. O
[]

Patients O
were O
randomized O
to O
receive O
a O
clear O
liquid O
diet O
and O
the O
PEG O
4L O
regimen O
( O
106 O
patients O
) O
or O
the O
low O
residue O
test O
meals O
and O
the O
PEG O
4L O
regimen O
( O
TM-PEG O
4L O
, O
108 O
patients O
) O
. O
[]

CONCLUSIONS O
Gabapentin O
reduces O
temporal O
summation O
of O
[]

There O
is O
no O
information O
, O
however O
, O
regarding O
the O
effect O
of O
oral O
clonidine O
premedication O
on O
the O
propofol O
blood O
concentrations O
required O
for O
loss O
of O
consciousness O
, O
and O
the O
interaction O
between O
propofol O
and O
clonidine O
. O
[]

Remission B-outcome ['Physiological-Clinical']
periods I-outcome ['Physiological-Clinical']
after O
stopping O
the O
treatment O
were O
1.5 O
+/- O
0.5 O
weeks O
( O
n O
= O
2 O
) O
with O
Re O
, O
10.5 O
+/- O
11.4 O
weeks O
( O
n O
= O
6 O
) O
with O
Re-PUVA O
, O
and O
one O
year O
( O
n O
= O
1 O
) O
with O
PUVA O
. O
['Physiological-Clinical']

Group O
A O
received O
an O
educational O
leaflet O
with O
general O
information O
about O
osteoporosis O
; O
group O
B O
followed O
current O
practice O
. O
[]

In O
a O
randomised O
phase O
III O
study O
, O
we O
aimed O
to O
compare O
LTA O
with O
the O
abdominal-transhiatal O
approach O
( O
TH O
) O
in O
the O
treatment O
of O
these O
tumours O
. O
[]

PURPOSE O
Periprostatic O
local O
anesthesia O
for O
prostate O
biopsy O
requires O
2 O
or O
more O
extra O
needle O
punctures O
and O
injection O
of O
the O
local O
anesthetic O
through O
the O
highly O
colonized O
rectum O
. O
[]

Unconsciousness B-outcome ['Physiological-Clinical']
was O
associated O
with O
reductions O
in O
ASSR B-outcome ['Physiological-Clinical']
( O
0.10 O
+/- O
0.08 O
microV O
[ O
awake O
baseline O
0.32 O
+/- O
0.18 O
microV O
] O
, O
P O
< O
0.001 O
) O
and O
BIS B-outcome ['Physiological-Clinical']
( O
55.7 O
+/- O
8.8 O
[ O
awake O
baseline O
92.4 O
+/- O
3.9 O
] O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
subjects O
are O
individually O
guided O
to O
increase O
their O
level O
of O
physical O
activity O
. O
[]

CONCLUSION O
Provision O
of O
parenteral O
nutrition O
( O
versus O
fluid O
therapy O
) O
in O
critically O
ill O
neonates O
> O
32 O
weeks O
did O
not O
significantly O
affect O
netilmicin B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
and O
therefore O
does O
not O
require O
modification O
of O
recommended O
netilmicin O
dosage O
regimens O
. O
['Physiological-Clinical']

INTERVENTIONS O
EPO O
( O
epoetin O
alfa O
, O
500 O
IU/kg O
intravenously O
, O
n O
= O
22 O
) O
or O
placebo O
( O
n O
= O
21 O
) O
was O
administered O
12 O
to O
18 O
hours O
preoperatively O
and O
again O
at O
the O
induction O
of O
anesthesia O
. O
[]

Average O
caffeine O
level O
in O
saliva O
90 O
minutes O
after O
ingestion O
was O
6.6+/-1.6 O
( O
SD O
) O
microg/dL O
. O
[]

However O
there O
was O
substantial O
inter-participant O
variability O
, O
with O
individual B-outcome ['Physiological-Clinical']
deficiencies I-outcome ['Physiological-Clinical']
( O
< O
80 O
% O
of O
DRI O
) O
in O
the O
intake O
of O
calcium B-outcome ['Physiological-Clinical']
( O
9 O
of O
20 O
participants O
) O
, O
pantothenic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
6 O
of O
20 O
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
prospective O
, O
double-blind O
study O
. O
[]

The O
major O
side-effect O
of O
CA O
was O
diarrhea B-outcome ['Physiological-Clinical']
( O
present O
in O
13 O
% O
of O
CA O
patients O
versus O
7 O
% O
of O
placebo O
, O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Parental O
state O
anxiety O
correlated O
with O
severity O
of O
adolescent O
anxiety O
, O
and O
trait O
anxiety O
in O
parents O
correlated O
with O
parent-reported O
adolescent O
internalizing O
and O
externalizing O
symptoms O
. O
[]

In O
univariate O
survival O
( O
Cox O
) O
analysis O
, O
no O
significant O
difference O
in O
regression O
was O
obtained O
between O
p16 O
( O
INK4a O
) O
-negative O
and O
-positive O
CIN2 O
lesions O
( O
adjusted O
HR O
= O
1.1 O
; O
95 O
% O
CI O
0.6-2.0 O
) O
. O
[]

There O
was O
no O
significant O
difference O
( O
P O
> O
.05 O
) O
between O
the O
topical O
and O
placebo O
groups O
. O
[]

The O
between-treatment O
differences O
were O
significant O
for O
many O
of O
the O
scores O
particularly O
in O
the O
first O
24 O
weeks O
of O
treatment O
. O
[]

METHODS O
Thirteen O
female O
patients O
( O
6 O
in O
the O
United O
States O
and O
7 O
in O
Poland O
) O
with O
IC O
according O
to O
the O
criteria O
of O
the O
National O
Institute O
of O
Diabetes O
, O
Digestive O
and O
Kidney O
Disease O
were O
included O
. O
[]

Equivalence O
study O
of O
a O
topical O
diclofenac O
solution O
( O
pennsaid O
) O
compared O
with O
oral O
diclofenac O
in O
symptomatic O
treatment O
of O
osteoarthritis O
of O
the O
knee O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
efficacy O
of O
metronidazole O
and O
tinidazole O
has O
been O
compared O
in O
31 O
patients O
with O
hepatic O
amoebiasis O
. O
[]

For O
all O
statistics O
CLIP O
staging O
system O
had O
a O
better O
prognostic O
ability O
. O
[]

We O
conclude O
that O
a O
significant O
placebo O
effect O
is O
present O
in O
the O
treatment O
of O
gastroesophageal O
reflux O
. O
[]

Two O
doses O
of O
dabigatran O
( O
110 O
and O
150 O
mg O
BID O
) O
are O
being O
evaluated O
. O
[]

The O
ability O
to O
discriminate O
between O
subjects O
with O
different O
levels O
of O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
was O
somewhat O
better O
for O
the O
SGRQ O
. O
['Physiological-Clinical']

METHOD O
Thirty-seven O
outpatients O
( O
11 O
men O
and O
26 O
women O
) O
meeting O
DSM-III-R O
criteria O
for O
major O
depressive O
disorder O
were O
randomly O
assigned O
to O
receive O
either O
placebo O
or O
4 O
mg/day O
of O
oral O
dexamethasone O
for O
4 O
days O
. O
[]

Prospective O
trial O
of O
intraoperative O
mitomycin O
C O
in O
the O
treatment O
of O
primary O
pterygium O
. O
[]

BACKGROUND O
Psoralen O
plus O
ultraviolet O
A O
( O
PUVA O
) O
is O
the O
standard O
treatment O
for O
early O
stages O
of O
mycosis O
fungoides O
. O
[]

Yoga O
is O
an O
increasingly O
popular O
mind-body O
CAM O
therapy O
often O
used O
for O
relieving B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
several O
small O
studies O
have O
found O
yoga O
effective O
for O
this O
condition O
. O
['Physiological-Clinical']

Antisecretory O
reflux O
treatment O
improves O
extraesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Exercise O
showed O
benefit O
in O
the O
MENQOL O
physical O
domain O
score O
at O
12 O
weeks O
( O
P O
= O
.02 O
) O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
percentage O
reduction O
in O
direct B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
LDL-C. O
Ezetimibe O
reduced O
direct B-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
by O
a O
mean O
of O
17.7 O
% O
from O
baseline O
to O
endpoint O
, O
compared O
with O
an O
increase O
of O
0.8 O
% O
with O
placebo O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
prothrombin O
time O
( O
PT O
) O
ratio O
( O
patient O
PT O
divided O
by O
control O
PT O
) O
between O
1.3 O
and O
2.5 O
was O
considered O
to O
be O
in O
the O
therapeutic O
range O
. O
[]

Cognitive B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
outcome O
measures O
were O
administered O
prior O
to O
treatment O
, O
at O
the O
end O
of O
treatment O
, O
and O
2 O
weeks O
posttreatment O
. O
['Life-Impact', 'Life-Impact']

The O
present O
study O
is O
the O
first O
to O
test O
the O
outcome O
of O
repeated O
doses O
and O
to O
examine O
whether O
there O
is O
a O
subgroup O
of O
children O
who O
are O
more O
likely O
to O
achieve O
positive O
effects O
. O
[]

In O
the O
same O
groups O
, O
the O
cumulative O
12-month O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
was O
13.3 O
% O
, O
0.0 O
% O
, O
and O
3.5 O
% O
( O
P O
= O
.01 O
) O
, O
of O
severe O
underweight B-outcome ['Physiological-Clinical']
was O
15.0 O
% O
, O
22.5 O
% O
, O
and O
16.9 O
% O
( O
P O
= O
.71 O
) O
, O
and O
of O
severe B-outcome ['Physiological-Clinical']
wasting I-outcome ['Physiological-Clinical']
was O
1.8 O
% O
, O
1.9 O
% O
, O
and O
1.8 O
% O
( O
P O
> O
.99 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
relationships O
between O
VPW B-outcome ['Physiological-Clinical']
, O
positive O
end-expiratory O
pressure O
( O
PEEP O
) O
, O
cumulative O
fluid O
['Physiological-Clinical']

Adequacy B-outcome ['Life-Impact']
of O
pharmacotherapy O
was O
assessed O
with O
an O
algorithm O
based O
on O
a O
review O
of O
efficacy O
studies O
. O
['Life-Impact']

Analyses O
were O
by O
intention O
to O
treat O
. O
[]

No O
circadian B-outcome ['Physiological-Clinical']
variation I-outcome ['Physiological-Clinical']
was O
found O
in O
the O
efficacy O
of O
diltiazem O
. O
['Physiological-Clinical']

From O
December O
1986 O
to O
August O
1989 O
, O
patients O
with O
small O
choroidal O
melanoma O
, O
not O
large O
enough O
to O
be O
eligible O
for O
the O
COMS O
clinical O
trials O
, O
were O
offered O
participation O
in O
a O
nonrandomized O
prospective O
follow-up O
study O
. O
[]

Following O
baseline O
measurements O
in O
VO2max B-outcome ['Physiological-Clinical']
, O
running O
time O
to O
exhaustion O
( O
RTE O
) O
, O
and O
anthropometry B-outcome ['Physiological-Clinical']
, O
17 O
subjects O
( O
10 O
snowshoers O
and O
7 O
runners O
) O
participated O
in O
a O
six O
week O
conditioning O
program O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Multivariable O
analyses O
showed O
neuralgia B-outcome ['Physiological-Clinical']
( O
P O
< O
.0005 O
) O
adversely O
affected O
all O
PRO O
, O
and O
recurrence O
( O
P O
< O
.05 O
) O
affected O
patient-reported B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
activity B-outcome ['Life-Impact']
, O
and O
satisfaction B-outcome ['Life-Impact']
, O
but O
not O
the O
score O
for O
the O
Medical B-outcome ['Physiological-Clinical']
Outcomes O
Study O
Short O
Form O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Conventional O
advice O
on O
immediate O
treatment O
of O
honey-bee O
stings O
has O
emphasised O
that O
the O
sting O
should O
be O
scraped O
off O
, O
never O
pinched O
. O
[]

BACKGROUND O
Angiotensin-converting O
enzyme O
inhibitor O
therapy O
may O
exert O
a O
beneficial O
effect O
on O
the O
endogenous O
fibrinolytic O
balance O
. O
[]

Ciclesonide O
is O
an O
intranasal O
corticosteroid O
approved O
for O
the O
treatment O
of O
allergic O
rhinitis O
. O
[]

The O
control O
group O
received O
two O
injections O
of O
a O
placebo O
at O
8 O
and O
4 O
wk O
before O
calving O
. O
[]

The O
hazard O
ratio O
for O
AC O
versus O
AT O
was O
1.02 O
( O
95 O
% O
CI O
for O
DFS O
, O
0.86 O
to O
1.22 O
; O
P O
= O
.78 O
) O
. O
[]

TEN O
versus O
TPN O
following O
major O
abdominal O
trauma O
-- O
reduced O
septic O
morbidity O
. O
[]

UNLABELLED O
Web-based O
screening O
and O
brief O
interventions O
that O
include O
personalized O
feedback O
about O
their O
alcohol O
use O
have O
proven O
to O
be O
particularly O
promising O
for O
reducing O
hazardous O
drinking O
among O
university O
students O
. O
[]

Furthermore O
, O
a O
higher O
percentage O
of O
patients O
in O
the O
azithromycin O
group O
rated O
overall B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
as O
excellent O
or O
good O
. O
['Physiological-Clinical']

INTERVENTION O
Comparison O
of O
a O
behavioral O
plus O
nutrition O
education O
intervention O
with O
a O
nutrition O
education O
intervention O
alone O
. O
[]

The O
risk O
for O
falls B-outcome ['Life-Impact']
decreased O
for O
exercise O
participants O
with O
low O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
.51 O
) O
but O
increased O
for O
exercise O
participants O
with O
high O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
3.51 O
) O
. O
['Life-Impact']

CONCLUSION O
The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
in O
tongue O
acupuncture O
group O
is O
apparently O
superior O
to O
that O
in O
conventional O
training O
group O
, O
ETTAA O
combined O
with O
conventional O
training O
have O
a O
better O
curative B-outcome ['Physiological-Clinical']
effect O
in O
the O
treatment O
of O
autism O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cats O
were O
assessed O
by O
a O
veterinarian O
on O
five O
occasions O
and O
the O
owner O
completed O
an O
assessment O
form O
at O
the O
same O
time O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
a O
nonexercising O
control O
group O
, O
a O
cycle O
training O
group O
( O
cycle O
) O
, O
or O
one O
of O
the O
two O
HCT O
groups O
. O
[]

Cycles O
were O
repeated O
every O
3 O
weeks O
. O
[]

Efforts O
to O
prevent O
this O
complication O
should O
be O
undertaken O
. O
[]

At O
3 O
, O
10 O
, O
and O
20 O
minutes O
following O
allergen O
challenge O
, O
subjects O
graded B-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
and O
were O
assessed O
for O
hyperemia B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
conjunctival I-outcome ['Physiological-Clinical']
, O
ciliary B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thirty-seven O
children O
between O
3 O
and O
11 O
years O
of O
age O
with O
a O
diagnosis O
of O
autism O
and/or O
pervasive O
developmental O
disorder O
were O
gender O
and O
age O
matched O
and O
randomly O
assigned O
to O
receive O
either O
placebo O
or O
dimethylglycine O
for O
4 O
weeks O
. O
[]

CONCLUSION O
After O
three O
months O
of O
follow-up O
, O
changes O
in O
cardiac B-outcome ['Physiological-Clinical']
structure I-outcome ['Physiological-Clinical']
were O
comparable O
between O
patients O
with O
BB O
and O
PTFE O
AVFs O
. O
['Physiological-Clinical']

PATIENTS O
Individuals O
free O
from O
tuberculosis O
, O
2367 O
persons O
in O
the O
intervention O
and O
2162 O
in O
the O
control O
groups O
. O
[]

RESULTS O
During O
the O
active O
weight O
loss O
phase O
, O
the O
MR O
( O
n O
= O
45 O
) O
and O
RCD O
( O
n O
= O
43 O
) O
groups O
lost O
a O
significant O
amount O
of O
weight B-outcome ['Physiological-Clinical']
, O
although O
no O
significant O
difference O
was O
found O
between O
the O
groups O
( O
mean O
+/- O
standard O
error O
= O
4.90 O
+/- O
0.30 O
kg O
MR O
versus O
4.30 O
+/- O
0.30 O
kg O
RCD O
; O
P O
= O
.16 O
) O
. O
['Physiological-Clinical']

High O
levels O
of O
acceptance B-outcome ['Life-Impact']
and O
compliance B-outcome ['Life-Impact']
by O
subjects/caregivers O
were O
maintained O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
Using O
custom-fit O
pin O
guides O
reduces O
blood O
drainage O
, O
but O
not O
the O
estimated O
Hb O
loss O
in O
minimally O
invasive O
TKA O
and O
does O
not O
affect O
transfusion O
rate O
. O
[]

In O
order O
to O
overcome O
the O
problems O
associated O
with O
the O
oral O
and O
intravenous O
application O
of O
physostigmine O
, O
and O
to O
improve O
patients O
' O
compliance B-outcome ['Life-Impact']
, O
a O
transdermal O
therapeutic O
system O
was O
developed O
. O
['Life-Impact']

BACKGROUND/AIM O
OF O
STUDY O
Laser O
therapy O
is O
effective O
in O
relieving O
malignant B-outcome ['Physiological-Clinical']
dysphagia I-outcome ['Physiological-Clinical']
, O
but O
repeated O
treatments O
at O
4 O
to O
6 O
week O
intervals O
are O
usually O
required O
. O
['Physiological-Clinical']

Forty-one O
patients O
had O
active O
leukemia O
at O
the O
time O
of O
transplant O
, O
and O
35 O
achieved O
CR O
( O
85 O
% O
) O
. O
[]

No O
significant O
change O
occurred O
in O
the O
mean O
ALT B-outcome ['Physiological-Clinical']
and O
GGT B-outcome ['Physiological-Clinical']
levels O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Statistical O
analysis O
was O
performed O
with O
ANOVA O
. O
[]

2 O
factorial O
arrangement O
of O
treatments O
to O
examine O
the O
effects O
of O
0.5 O
g/d O
of O
Saccaromyces O
cervisiae O
boulardii O
CNCM O
1079-Levucell O
SB O
( O
LEV O
) O
, O
or O
3 O
g/d O
of O
AMF O
with O
2 O
corn O
sources O
, O
dry O
whole-shelled O
corn O
or O
high O
moisture O
corn O
, O
on O
growth O
and O
carcass O
characteristics O
. O
[]

Subjects O
received O
pretreatment O
with O
orally O
administered O
nifedipine O
( O
20 O
mg O
) O
, O
intravenously O
administered O
verapamil O
( O
10 O
mg O
bolus O
followed O
by O
a O
continuous O
infusion O
) O
, O
or O
appropriate O
placebos O
in O
a O
randomized O
, O
double-blind O
fashion O
. O
[]

Each O
trial O
lasted O
4 O
weeks O
with O
a O
2-week O
washout O
period O
between O
treatment O
phases O
. O
[]

During O
the O
whole O
experimental O
period O
, O
dietary O
choline O
had O
no O
significant O
effects O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
egg B-outcome ['Physiological-Clinical']
weight O
, O
and O
egg B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
P O
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

And O
3 O
months O
was O
taken O
as O
one O
observation O
cycle O
. O
[]

The O
objective O
of O
this O
trial O
was O
to O
evaluate O
the O
potential O
advantages O
of O
the O
combination O
of O
piperacillin O
and O
tazobactam O
in O
the O
control O
of O
fever B-outcome ['Physiological-Clinical']
in O
neutropenic O
patients O
. O
['Physiological-Clinical']

A O
per-protocol O
analysis O
did O
not O
show O
appreciably O
different O
results O
. O
[]

Group O
B O
received O
the O
same O
treatment O
but O
with O
pulsed O
ultrasound O
( O
100 O
Hz O
, O
20 O
% O
duty O
cycle O
) O
. O
[]

Advice O
or O
exercise O
for O
chronic O
whiplash O
disorders O
? O
[]

High O
levels O
of O
parent O
, O
child B-outcome ['Physiological-Clinical']
and O
staff B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
were O
reported O
, O
along O
with O
high O
levels O
of O
treatment O
fidelity B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

RESULTS O
This O
technique O
interrupted O
3 O
to O
14 O
( O
mean O
, O
7 O
) O
incompetent O
perforating O
veins O
per O
patient O
. O
[]

No O
dyskinesias B-outcome ['Physiological-Clinical']
, O
adverse B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
or O
seizures B-outcome ['Physiological-Clinical']
occurred O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitor O
enalapril O
and O
diuretic O
indapamide O
on O
the O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
the O
central B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
Chinese O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
the O
trial O
, O
significantly O
more O
nefazodone-treated O
patients O
( O
50 O
% O
) O
than O
placebo-treated O
patients O
( O
29 O
% O
) O
had O
responded O
, O
as O
indicated O
by O
their O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
( O
p O
= O
.021 O
) O
or O
by O
a O
> O
or O
= O
50 O
% O
reduction O
in O
their O
HAM-D-17 O
scores O
( O
p O
= O
.017 O
) O
. O
['Physiological-Clinical']

Isoflurane O
and O
propofol O
for O
long-term O
sedation O
in O
the O
intensive O
care O
unit O
. O
[]

DESIGN O
Repeated O
measures O
design O
with O
independent O
variables O
, O
treatment O
( O
cryotherapy O
and O
control O
) O
, O
and O
time O
( O
baseline O
, O
immediately O
post O
treatment O
, O
15 O
minutes O
post O
treatment O
, O
and O
30 O
minutes O
post O
treatment O
) O
. O
[]

Main O
outcome O
measures O
, O
derived O
actigraphically O
, O
were O
sleep O
latency O
, O
total O
sleep O
time O
, O
wake O
after O
sleep O
onset O
and O
number O
of O
awakenings O
. O
[]

Four O
of O
the O
variants O
used O
the O
continuous O
SWAT O
subscales O
while O
one O
used O
the O
discrete O
SWAT O
subscale O
. O
[]

A O
prospective O
, O
double-blind O
study O
of O
392 O
patients O
randomized O
into O
four O
groups O
was O
performed O
to O
establish O
whether O
diagnostic O
intravenous O
urograms O
could O
be O
obtained O
with O
a O
lower O
dose O
of O
iodine O
when O
using O
the O
dimeric O
, O
non-ionic O
contrast O
medium O
iodixanol O
compared O
with O
the O
monomeric O
, O
non-ionic O
iohexol O
. O
[]

CONCLUSIONS O
Postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

Both O
groups O
decreased O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
E O
% O
( O
energy O
percent O
) O
fat O
and O
increased O
E B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
fiber B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
but O
there O
was O
no O
differences O
between O
the O
groups O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
dropout O
rate O
was O
significantly O
higher O
in O
the O
Web-based O
intervention O
group O
( O
53 O
% O
) O
compared O
to O
the O
print-delivered O
intervention O
( O
39 O
% O
, O
P O
< O
.001 O
) O
. O
[]

830 O
N O
) O
but O
not O
for O
12HL O
( O
2538 O
? O
[]

The O
clearance B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
AmB I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
dextrose I-outcome ['Physiological-Clinical']
( O
0.039 O
+/- O
0.016 O
liter O
. O
['Physiological-Clinical']

Brief O
report O
: O
effects O
of O
cognitive O
behavioral O
therapy O
on O
parent-reported O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
school-age O
children O
with O
high-functioning O
autism O
. O
['Life-Impact']

This O
study O
was O
performed O
to O
assess O
the O
cost-effectiveness O
of O
concomitant O
ablation O
surgery O
( O
AS O
) O
compared O
to O
regular O
cardiac O
surgery O
in O
atrial O
fibrillation O
( O
AF O
) O
patients O
over O
a O
one-year O
follow-up O
. O
[]

Autism O
is O
commonly O
associated O
with O
sensory B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulatory I-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
present O
research O
identifies O
2 O
aspects O
of O
attitude O
certainty O
and O
provides O
evidence O
for O
the O
distinctness O
of O
the O
constructs O
. O
[]

Tumor O
necrosis O
factor O
?-stimulated O
expression O
of O
CD69 O
and O
NFlB O
subunit O
p50 O
was O
significantly O
blunted O
after O
4 O
days O
of O
sulfasalazine O
treatment O
but O
not O
after O
no O
treatment O
. O
[]

Data O
obtained O
at O
a O
3-month O
follow-up O
assessment O
showed O
that O
girls O
who O
received O
the O
HIV-related O
intervention O
improved O
their O
HIV-related B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
enhanced O
their O
motivation B-outcome ['Life-Impact']
for O
risk O
reduction O
compared O
to O
girls O
who O
received O
a O
control O
( O
health O
promotion O
) O
intervention O
. O
['Life-Impact', 'Life-Impact']

The O
Na+ O
program O
was O
changed O
weekly O
at O
random O
. O
[]

We O
assessed O
the O
activity O
of O
the O
synthetic O
retinoid O
fenretinide O
in O
superficial O
bladder O
cancer O
using O
DNA O
flow O
cytometry O
and O
conventional O
cytology O
as O
surrogate O
biomarkers O
. O
[]

The O
intranasal O
application O
of O
oxytocin O
( O
OT O
) O
has O
been O
shown O
to O
influence O
behavioral B-outcome ['Life-Impact']
and O
neural O
correlates O
of O
social B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
in O
the O
doxorubicin O
group O
was O
30 O
% O
( O
95 O
% O
CI O
: O
19.8 O
% O
-38.8 O
% O
) O
, O
while O
it O
was O
27.3 O
% O
( O
95 O
% O
CI O
: O
17.5 O
% O
-36.8 O
% O
) O
in O
the O
mitoxantrone O
group O
. O
['Physiological-Clinical']

BACKGROUND O
Postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
is O
still O
a O
common O
and O
major O
complication O
for O
surgical O
patients O
, O
which O
may O
delay O
post-anesthetic O
care O
unit O
discharge O
, O
prolong O
hospital O
stay O
and O
thus O
increase O
the O
cost O
of O
hospitalization O
. O
[]

After O
treatment O
11 O
group O
1 O
patients O
( O
78.6 O
% O
) O
had O
a O
partial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
posterior O
tibial O
nerve O
stimulation O
but O
only O
2 O
( O
14.3 O
% O
) O
in O
group O
2 O
had O
a O
partial B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
The O
efficacies O
were O
similar O
in O
three O
HT-managed O
groups O
, O
but O
was O
better O
than O
in O
group O
D O
, O
although O
the O
latter O
was O
also O
effective O
in O
alleviating O
menopausal O
symptoms O
. O
[]

AIM O
To O
compare O
the O
effects O
of O
single O
doses O
of O
three O
oral O
medications O
on O
postoperative O
pain B-outcome ['Physiological-Clinical']
following O
instrumentation O
of O
root O
canals O
in O
teeth O
with O
irreversible O
pulpitis O
. O
['Physiological-Clinical']

A O
shift O
in O
Wolfe O
classification O
from O
lower O
to O
greater O
parenchymal B-outcome ['Physiological-Clinical']
density O
was O
noted O
in O
24 O
% O
of O
subjects O
( O
P O
= O
.016 O
) O
. O
['Physiological-Clinical']

Beclomethasone O
dipropionate O
( O
200 O
micrograms O
) O
was O
administered O
twice O
daily O
for O
a O
treatment O
period O
of O
2 O
weeks O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SVR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
unaltered O
. O
['Physiological-Clinical']

Correlation O
of O
quantitative O
measures O
with O
the O
modified O
Ashworth O
scale O
in O
the O
assessment O
of O
plantar O
flexor O
spasticity O
in O
patients O
with O
traumatic O
brain O
injury O
. O
[]

RESULTS O
In O
the O
MI O
, O
23.8 O
% O
were O
abstinent B-outcome ['Life-Impact']
at O
15 O
days O
; O
the O
same O
percentage O
at O
one O
month O
and O
3 O
months O
; O
19 O
% O
at O
6 O
months O
; O
and O
14.3 O
% O
remained O
abstinent B-outcome ['Life-Impact']
after O
a O
year O
. O
['Life-Impact', 'Life-Impact']

Sham B-outcome ['Physiological-Clinical']
rTMS B-outcome ['Physiological-Clinical']
showed O
a O
trend O
for O
improvement O
over O
time O
on O
positive O
and O
negative O
subscales O
of O
PANSS O
and O
MADRS B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
goal O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
mild O
exercise O
training O
or O
statin O
therapy O
on O
forearm O
endothelial O
function O
in O
CAD O
patients O
with O
average O
cholesterol O
levels O
. O
[]

METHODS O
Thirty O
patients O
were O
randomized O
prospectively O
to O
postoperative O
diclofenac O
in O
one O
eye O
and O
ketorolac O
in O
the O
other O
. O
[]

Serum B-outcome ['Physiological-Clinical']
bactericidal I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
and O
comparative O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
meropenem O
and O
imipenem-cilastatin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Our O
findings O
suggest O
that O
this O
23 O
% O
incidence O
of O
false-negative O
biopsies O
represents O
significant O
cancer O
. O
[]

Results O
suggest O
that O
a O
single O
triamcinolone O
acetonide O
injection O
followed O
by O
lid O
massage O
is O
almost O
as O
effective O
as O
incision O
and O
curettage O
in O
the O
treatment O
of O
chalazia O
and O
with O
similar O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
and O
less O
pain B-outcome ['Physiological-Clinical']
and O
patient B-outcome ['Life-Impact']
inconvenience I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
effect O
of O
cognitive-behavioral O
therapy O
versus O
treatment O
as O
usual O
for O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
, O
controlled O
trial O
. O
['Life-Impact']

DESIGN O
Randomized O
, O
comparative O
study O
. O
[]

Lead-time B-outcome ['Physiological-Clinical']
was O
estimated O
as O
the O
time O
required O
to O
accumulate O
a O
similar O
cumulative O
risk O
of O
prostate O
cancer O
in O
the O
control O
arm O
to O
the O
detection O
rate O
in O
the O
intervention O
arm O
, O
i.e O
. O
['Physiological-Clinical']

To O
assess O
blinding O
, O
subjects O
were O
asked O
after O
the O
interventions O
what O
the O
practitioner O
was O
doing O
during O
each O
period O
( O
reading O
, O
touch O
, O
or O
something O
else O
) O
. O
[]

PaO2 B-outcome ['Physiological-Clinical']
in O
the O
CPAP O
group O
showed O
a O
significant O
increase O
by O
the O
end O
of O
the O
initial O
study O
; O
whereas O
intrapulmonary B-outcome ['Physiological-Clinical']
shunt I-outcome ['Physiological-Clinical']
and O
alveolar-arterial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
tension I-outcome ['Physiological-Clinical']
gradient I-outcome ['Physiological-Clinical']
AaDO2 I-outcome ['Physiological-Clinical']
revealed O
simultaneously O
a O
significant O
reduction O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
evaluated O
PU O
action O
on O
the O
symptoms B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
quality O
of O
life O
with O
application O
of O
questionnaires B-outcome ['Physiological-Clinical']
IPSS I-outcome ['Physiological-Clinical']
and O
QoL B-outcome ['Life-Impact']
( O
BS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

RATIONALE O
Subjects O
who O
view O
experimental O
procedures O
as O
worthwhile O
are O
more O
likely O
to O
participate O
in O
clinical O
trials O
and O
comply O
with O
study O
procedures O
. O
[]

No O
significant O
difference O
in O
median O
CD4 B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
from O
baseline O
to O
week O
48 O
was O
found O
( O
3 O
% O
versus O
1 O
% O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
hydraulic O
circuit O
training O
( O
HCT O
) O
on O
cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
assessed O
in O
32 O
healthy O
middle-aged O
males O
( O
X O
age O
= O
42.2 O
+/- O
2.1 O
yr O
) O
. O
['Physiological-Clinical']

This O
study O
contributes O
to O
the O
growing O
literature O
supporting O
adapted O
CBT O
approaches O
for O
treating O
anxiety O
in O
youth O
with O
ASD O
. O
[]

If O
the O
formula O
was O
used O
to O
compute O
a O
change O
in O
total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
, O
the O
agreement O
between O
both O
methods O
remained O
good O
. O
['Physiological-Clinical']

EGFr O
is O
often O
overexpressed O
in O
HNSCC O
and O
has O
been O
related O
to O
the O
repopulation O
taking O
place O
during O
radiotherapy O
. O
[]

These O
findings O
suggest O
the O
intervention O
improves O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
with O
ASD O
. O
['Life-Impact']

METHODS O
Eighty-four O
children O
of O
autism O
were O
randomly O
divided O
into O
a O
tongue O
acupuncture O
group O
( O
group O
A O
) O
and O
a O
conventional O
training O
group O
( O
group O
B O
) O
, O
42 O
cases O
in O
each O
group O
. O
[]

In O
infancy O
, O
increased O
total O
IgE B-outcome ['Physiological-Clinical']
is O
more O
affected O
by O
factors O
increasing O
risk O
of O
intercurrent O
infection O
and O
non-specific O
airway O
inflammation O
, O
such O
as O
environmental O
tobacco O
smoke O
exposure O
( O
p O
< O
0.001 O
) O
and O
the O
use O
of O
gas O
cookers O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

Heartburn B-outcome ['Physiological-Clinical']
improved O
in O
50 O
% O
of O
patients O
who O
received O
bismuth O
compared O
with O
17 O
% O
of O
those O
given O
placebo O
. O
['Physiological-Clinical']

Statistical O
analysis O
proved O
significant O
effects O
concerning O
dysfunctional B-outcome ['Life-Impact']
parenting I-outcome ['Life-Impact']
, O
parental O
stress O
and O
child B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
as O
well O
as O
little O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
a O
positive O
acceptance B-outcome ['Life-Impact']
of O
stepping O
stones O
by O
the O
families O
. O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact']

STUDY O
DESIGN O
We O
conducted O
a O
12-week O
3 O
? O
[]

It O
was O
also O
noted O
tha O
with O
the O
addition O
of O
antidepressant O
fluoxetine O
, O
the O
manifestations O
of O
depression B-outcome ['Life-Impact']
ere O
alleviated O
as O
shown O
by O
Hamilton O
depression B-outcome ['Life-Impact']
( O
HAMD O
) O
scale O
. O
['Life-Impact', 'Life-Impact']

The O
Randomised O
Intervention O
Treatment O
of O
Angina O
( O
RITA O
) O
Trial O
is O
a O
prospective O
, O
randomised O
study O
to O
compare O
the O
short O
term O
and O
long O
term O
effects O
of O
percutaneous O
transluminal O
coronary O
angioplasty O
and O
coronary O
artery O
bypass O
surgery O
. O
[]

The O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stomatitis I-outcome ['Physiological-Clinical']
and O
mucositis B-outcome ['Physiological-Clinical']
was O
0.6 O
% O
in O
the O
mitoxantrone O
group O
and O
8.4 O
% O
in O
the O
doxorubicin O
group O
( O
P O
= O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
PECS O
was O
more O
successful O
than O
RPMT O
in O
increasing O
the O
number O
of O
nonimitative B-outcome ['Life-Impact']
spoken I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
and O
the O
number O
of O
different B-outcome ['Physiological-Clinical']
nonimitative I-outcome ['Physiological-Clinical']
words I-outcome ['Physiological-Clinical']
used I-outcome ['Physiological-Clinical']
at O
the O
posttreatment O
period O
. O
['Life-Impact', 'Physiological-Clinical']

Growth O
hormone O
effects O
on O
cortical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
in O
young O
adults O
with O
childhood-onset O
growth O
hormone O
deficiency O
. O
['Physiological-Clinical']

Providing O
live O
supervision O
via O
teleconferencing O
improves O
acquisition O
of O
motivational B-outcome ['Life-Impact']
interviewing I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
after O
workshop O
attendance O
. O
['Life-Impact']

The O
global B-outcome ['Physiological-Clinical']
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
45 O
% O
higher O
with O
EC O
, O
though O
not O
significant O
( O
32 O
vs. O
22 O
% O
, O
p O
= O
0.075 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

In O
serum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
no O
change O
was O
observed O
in O
the O
low O
dose O
budesonide O
group O
, O
but O
a O
marked O
decrease O
in O
the O
high-dose O
budesonide O
group O
( O
P=0.008 O
; O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

RESULTS O
Forty O
patients O
were O
assigned O
to O
laparoscopic O
lymphadenectomy O
and O
40 O
patients O
to O
abdominal O
lymphadenectomy O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
In O
a O
multicenter O
randomized O
clinical O
trial O
, O
436 O
children O
and O
adults O
with O
type O
1 O
diabetes O
were O
randomized O
to O
a O
treatment O
group O
that O
used O
CGM O
( O
N O
= O
224 O
) O
, O
or O
a O
control O
group O
that O
used O
standard O
home O
blood O
glucose O
monitoring O
( O
N O
= O
212 O
) O
and O
completed O
12 O
months O
of O
follow-up O
. O
[]

UTC O
categorises O
four O
different O
echotypes B-outcome ['Physiological-Clinical']
that O
represent O
( O
I O
) O
highly O
stable B-outcome ['Physiological-Clinical']
; O
( O
II O
) O
medium O
stable O
; O
( O
III O
) O
highly O
variable B-outcome ['Physiological-Clinical']
and O
( O
IV O
) O
constantly O
low O
intensity O
and O
variable O
distribution O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
were O
sufficiently O
ill O
to O
require O
hospitalization O
although O
none O
needed O
ventilatory O
support O
; O
the O
presence O
of O
pneumonia O
was O
excluded O
. O
[]

Administration O
of O
conjugated O
equine O
estrogens O
resulted O
in O
decreased O
levels O
of O
Lp B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
only O
in O
group O
B O
after O
treatment O
. O
['Physiological-Clinical']

CONCLUSION O
This O
strategy O
did O
not O
compromise O
disease O
control O
or O
survival O
( O
that O
remained O
poor O
) O
and O
allowed O
more O
than O
half O
of O
the O
survivors O
to O
retain O
their O
larynx O
. O
[]

Epidural O
analgesia O
compared O
with O
intravenous O
morphine O
patient-controlled O
analgesia O
: O
postoperative O
outcome O
measures O
after O
mastectomy O
with O
immediate O
TRAM O
flap O
breast O
reconstruction O
. O
[]

PATIENTS O
A O
total O
of O
100 O
patients O
who O
were O
admitted O
to O
the O
medical O
ICU O
, O
required O
arterial O
line O
monitoring O
for O
clinical O
purposes O
, O
and O
were O
managed O
by O
the O
ICU O
medical O
service O
. O
[]

The O
primary O
end O
point O
was O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
change O
from O
baseline O
to O
last O
observation O
. O
['Physiological-Clinical']

PATIENTS O
AND O
OTHER O
PARTICIPANTS O
Smokers O
recruited O
from O
among O
the O
health O
centre O
users O
through O
the O
preventive O
activities O
and O
health O
promotion O
programme O
. O
[]

RESULTS O
Some O
of O
the O
patients O
lost O
follow-up O
. O
[]

Compared O
with O
the O
control O
group O
, O
diets O
supplemented O
with O
425 O
or O
850 O
mg O
of O
choline/kg O
significantly O
( O
P O
< O
0.01 O
) O
improved O
[]

[ O
Radiotherapy O
for O
choroidal O
neovascularization O
in O
age-related O
macular O
degeneration O
. O
[]

Although O
biopsy O
fragmentation O
was O
commoner O
with O
the O
suction O
needle O
, O
the O
length O
and O
volume O
of O
the O
largest O
core O
obtained O
was O
similar O
to O
results O
with O
the O
sheathed O
needle O
. O
[]

BACKGROUND O
Recent O
economic O
analyses O
have O
showed O
that O
nursing-led O
inpatient O
units O
are O
associated O
with O
increased O
costs O
of O
care O
with O
length O
of O
stay O
as O
the O
main O
driver O
of O
inpatient O
costs O
. O
[]

Argatroban O
dose-dependently O
prolonged O
activated O
clotting O
time O
( O
ACT O
) O
with O
more O
patients O
reaching O
the O
minimum O
target O
ACT O
after O
the O
initial O
bolus O
injection O
( O
ARG250 O
: O
86.1 O
% O
, O
ARG300 O
: O
89.5 O
% O
, O
and O
ARG350 O
: O
96.8 O
% O
) O
compared O
to O
45.5 O
% O
in O
UFH O
( O
p O
< O
0.001 O
) O
. O
[]

American O
College O
of O
Cardiology/American O
Heart O
Association O
type O
C B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
diabetic O
patients O
( O
17 O
% O
versus O
15 O
% O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
group O
receiving O
Magnesium O
Oxide O
had O
statistically O
significant O
fewer O
subjects O
who O
developed O
hypertension B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
multiple O
regression O
analysis O
did O
not O
provide O
any O
comprehensibility O
in O
the O
relationship O
between O
masticatory B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
chewing I-outcome ['Physiological-Clinical']
experience I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Length O
of O
procedure O
times O
and O
adolescent O
reactions O
were O
also O
recorded O
to O
inform O
clinical O
utility O
. O
[]

Symptom O
score O
, O
peak O
expiratory O
flow O
( O
PEF O
) O
maximal O
amplitude O
, O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV1 O
) O
, O
and O
methacholine O
reactivity O
were O
measured O
at O
the O
baseline O
and O
at O
intervals O
of O
3 O
months O
up O
to O
12 O
months O
. O
[]

The O
gluten-free O
, O
casein-free O
diet O
in O
autism O
: O
results O
of O
a O
preliminary O
double O
blind O
clinical O
trial O
. O
[]

PURPOSE O
To O
determine O
the O
efficacy O
and O
safety O
of O
subconjunctival O
5- O
fluorouracil O
injections O
after O
trabeculectomy O
in O
patients O
with O
poor O
prognoses O
, O
to O
determine O
risk O
factors O
for O
surgical O
failure O
and O
to O
examine O
the O
relationship O
of O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
visual B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Virtual O
reality O
intervention O
for O
older O
women O
with O
breast O
cancer O
. O
[]

PARTICIPANTS O
Six O
hundred O
seven O
newly O
diagnosed O
glaucoma O
patients O
. O
[]

Adjuvant O
chemotherapy O
may O
not O
be O
useful O
. O
[]

METHODS O
A O
total O
of O
71 O
patients O
with O
confirmed O
severe O
acute O
pancreatitis O
from O
March O
2009 O
to O
September O
2011 O
in O
the O
Department O
of O
Critical O
Care O
Medicine O
of O
Huizhou O
Municipal O
Central O
Hospital O
, O
Guangdong O
, O
China O
were O
enrolled O
in O
this O
study O
. O
[]

Observational O
measures O
of O
certain O
aspects O
of O
children O
's O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
self-regulation B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Phase O
II O
study O
of O
efficacy O
and O
safety O
of O
bevacizumab O
in O
combination O
with O
chemotherapy O
or O
erlotinib O
compared O
with O
chemotherapy O
alone O
for O
treatment O
of O
recurrent O
or O
refractory O
non O
small-cell O
lung O
cancer O
. O
[]

This O
may O
be O
explained O
by O
the O
development O
of O
tolerance O
in O
patients O
who O
received O
the O
infusion O
of O
morphine O
. O
[]

A O
comparison O
of O
21 O
patients O
with O
a O
DSV O
and O
the O
patients O
with O
DP O
valves O
, O
evaluated O
by O
measuring O
the O
reduction O
of O
the O
Evans O
Index O
, O
revealed O
a O
distinctly O
higher O
percentage O
of O
significant O
regressions O
in O
the O
DP O
valve O
collective O
, O
without O
doubt O
due O
to O
chronic O
overdrainage O
. O
[]

Treatments O
were O
compared O
after O
2 O
weeks O
( O
strip O
use O
) O
and O
12 O
weeks O
( O
dentifrice O
use O
) O
using O
analysis O
of O
covariance O
. O
[]

The O
2 O
treatment O
groups O
were O
well O
matched O
. O
[]

Peer O
and O
adolescent O
substance O
use O
are O
highly O
correlated O
, O
but O
this O
relationship O
is O
not O
fully O
understood O
. O
[]

This O
12-week O
, O
randomized O
, O
double-blind O
, O
forced-titration O
study O
compared O
the O
efficacy O
of O
3 O
angiotensin O
receptor O
blockers O
. O
[]

Disopyramide O
was O
given O
to O
each O
patient O
both O
with O
placebo O
and O
with O
active O
pyridostigmine O
. O
[]

All O
were O
homosexual O
males O
, O
except O
one O
female O
in O
group O
A O
who O
was O
the O
sex O
partner O
of O
a O
bisexual O
male O
with O
AIDS O
. O
[]

Open-label O
reports O
suggest O
that O
the O
serotonin2A-dopamine O
D2 O
antagonist O
risperidone O
may O
be O
safe O
and O
effective O
in O
reducing O
the O
interfering O
symptoms O
of O
patients O
with O
autism O
. O
[]

Aspiration O
was O
performed O
transvaginally O
between O
day O
9 O
and O
day O
17 O
in O
the O
unstimulated O
group O
and O
on O
day O
8 O
or O
day O
9 O
in O
the O
FSH-primed O
group O
after O
FSH O
deprivation O
for O
2 O
or O
3 O
days O
. O
[]

Data O
were O
collected O
at O
three O
points O
over O
30 O
weeks O
. O
[]

Changes O
in O
sleep B-outcome ['Physiological-Clinical']
architecture I-outcome ['Physiological-Clinical']
were O
measured O
using O
centrally O
scored O
nocturnal O
polysomnograms O
. O
['Physiological-Clinical']

A O
dose B-outcome ['Life-Impact']
level I-outcome ['Life-Impact']
was O
considered O
tolerable B-outcome ['Life-Impact']
if O
no O
more O
than O
2 O
patients O
experienced O
grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
. O
['Life-Impact', 'Life-Impact', 'Adverse-effects']

Mean O
change O
from O
baseline O
in O
PJD O
over O
5 O
years O
was O
greater O
in O
PBO-randomized O
versus O
RTX-randomized O
patients O
( O
5.51 O
vs O
3.21 O
) O
. O
[]

Quality O
of O
life O
was O
not O
influenced O
by O
either O
treatment O
, O
and O
there O
was O
no O
relevant O
change O
in O
flow-mediated O
dilatation O
in O
patients O
treated O
with O
nebivolol O
or O
metoprolol O
( O
P=0.16 O
) O
. O
[]

Moreover O
, O
it O
facilitated O
ulcer B-outcome ['Physiological-Clinical']
scarring I-outcome ['Physiological-Clinical']
and O
had O
beneficial O
effect O
on O
dynamics O
of O
serum B-outcome ['Physiological-Clinical']
LF I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Patient O
age O
, O
gender O
, O
and O
cancer-type O
may O
be O
important O
factors O
to O
consider O
when O
developing O
and O
implementing O
smoking O
cessation O
interventions O
for O
cancer O
patients O
. O
[]

The O
plasma O
levels O
of O
epinephrine O
and O
norepinephrine O
demonstrate O
a O
direct O
response O
to O
stress O
followed O
by O
a O
secondary O
change O
in O
glucose B-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
and O
free B-outcome ['Physiological-Clinical']
glycerol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

TACTIC O
) O
study O
is O
a O
multicentre O
randomized O
controlled O
trial O
evaluating O
the O
short-term O
benefits O
of O
LD O
versus O
non-LD O
RBC O
transfusions O
. O
[]

In O
prenatal O
women O
, O
neither O
approach O
was O
effective O
. O
[]

However O
, O
it O
properties O
were O
unable O
to O
be O
put O
into O
use O
if O
there O
were O
the O
surgical O
sites O
were O
not O
infested O
with O
bacterial O
. O
[]

Children O
in O
the O
experimental O
group O
were O
enrolled O
in O
day O
care O
and O
their O
parents O
and O
child O
care O
workers O
received O
a O
12-week O
intervention O
consisting O
of O
lectures O
and O
on-site O
consultations O
to O
day-care O
centers O
. O
[]

When O
compared O
with O
placebo+TRT O
, O
the O
TENS+TRT O
group O
produced O
earlier O
and O
greater O
reduction O
of O
plantarflexor B-outcome ['Physiological-Clinical']
spasticity I-outcome ['Physiological-Clinical']
and O
improvement O
in O
ankle B-outcome ['Physiological-Clinical']
dorsiflexion I-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
at O
week O
2 O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
early O
group O
were O
faster O
to O
ambulate B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
only I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
cane I-outcome ['Life-Impact']
( O
P=.03 O
) O
, O
without O
a O
cane B-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
and O
without O
a O
limp B-outcome ['Life-Impact']
( O
P=.003 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Changes O
on O
the O
DD-CGAS O
correlated O
with O
changes O
on O
the O
[]

A O
prospective O
, O
randomized O
, O
double O
dummy O
, O
placebo-controlled O
trial O
of O
oral O
cefditoren O
pivoxil O
400mg O
once O
daily O
as O
switch O
therapy O
after O
intravenous O
ceftriaxone O
in O
the O
treatment O
of O
acute O
pyelonephritis O
. O
[]

METHOD O
Raters O
from O
five O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
( O
RUPP O
) O
Autism O
Network O
were O
trained O
to O
reliability O
. O
[]

The O
captopril O
group O
included O
12 O
patients O
and O
the O
propranolol O
group O
seven O
. O
[]

Eighteen O
patients O
were O
then O
withdrawn O
from O
the O
study O
. O
[]

Forty-three O
ovarian O
cancer O
cases O
, O
25 O
fatal O
, O
would O
have O
been O
detected O
earlier O
with O
ROCA O
, O
with O
a O
median O
( O
minimum O
) O
advance O
time O
for O
fatal B-outcome ['Mortality']
cases I-outcome ['Mortality']
of O
344 O
( O
147 O
) O
days O
. O
['Mortality']

Further O
evaluation O
of O
PN O
formulations O
to O
support O
patients O
undergoing O
high-dose O
chemotherapy O
and O
BMT O
are O
needed O
. O
[]

Neuromuscular O
transmission O
was O
allowed O
to O
recover O
spontaneously O
. O
[]

Errors O
during O
the O
preparation O
of O
drug O
infusions O
: O
a O
randomized O
controlled O
trial O
. O
[]

Although O
the O
incidence O
of O
HCMV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
comparable O
in O
DNAemia O
and O
antigenemia O
arms O
( O
34 O
% O
vs O
42 O
% O
, O
respectively O
, O
P O
= O
.259 O
) O
, O
the O
number O
of O
patients O
treated B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
DNAemia O
arm O
( O
18 O
% O
vs O
31 O
% O
, O
P O
= O
.026 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
review O
of O
impressions O
of O
the O
graft O
materials O
indicated O
a O
decided O
preference O
for O
PTFE O
grafts O
. O
[]

OBJECTIVE O
Our O
purpose O
was O
to O
determine O
whether O
a O
protocol O
for O
outpatient O
induction O
is O
safe O
and O
effective O
for O
initiating O
labor O
. O
[]

The O
epinephrine-containing O
local O
anesthetic O
significantly O
reduced O
the O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
concentration O
10 O
min O
after O
injection B-outcome ['Physiological-Clinical']
, O
by O
0.16 O
+/- O
0.20 O
mmol/L O
( O
mean O
+/- O
SD O
) O
, O
and O
increased O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
at O
10 O
, O
20 O
, O
and O
30 O
min O
( O
by O
0.46 O
+/- O
0.37 O
, O
0.63 O
+/- O
0.45 O
, O
and O
0.56 O
+/- O
0.28 O
mmol/L O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
a O
co-administration O
of O
NSAID O
and O
aspirin O
may O
interfere O
with O
platelet B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
at O
the O
beginning O
of O
a O
treatment O
with O
an O
increase O
of O
naproxen O
and O
a O
decrease O
of O
diclofenac O
. O
['Physiological-Clinical']

METHOD O
Thirty-nine O
subjects O
( O
intent O
to O
treat O
; O
5-19 O
years O
old O
; O
IQ O
> O
35 O
) O
had O
autism O
diagnosed O
according O
to O
DSM-IV O
and O
ICD-10 O
criteria O
using O
the O
Autism O
Diagnostic O
Interview-Revised O
and O
the O
Autism O
Diagnostic O
Observation O
Schedule-Generic O
. O
[]

The O
patients O
in O
both O
groups O
were O
instructed O
as O
to O
the O
prophylactic O
hygienic O
care O
of O
the O
limb O
. O
[]

Childcare O
services O
provide O
access O
to O
large O
numbers O
of O
young O
children O
for O
prolonged O
periods O
, O
yet O
there O
is O
limited O
experimental O
evidence O
regarding O
the O
effectiveness O
of O
physical O
activity O
interventions O
implemented O
in O
this O
setting O
. O
[]

The O
efficacy O
of O
treatment O
was O
evaluated O
by O
the O
degree O
of O
early B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
( O
pulmonary O
angiograms O
were O
performed O
30 O
to O
48 O
hours O
after O
initiation O
of O
thrombolytic O
treatment O
and O
analysed O
blindly O
by O
four O
independent O
vascular O
radiologists O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
Comparisons O
of O
two O
3-year O
protocols O
, O
one O
20-week O
protocol O
of O
mitomycin O
C O
instillation O
and O
one O
3-year O
protocol O
of O
doxorubicin O
instillation O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
and O
progression B-outcome ['Physiological-Clinical']
in O
patients O
whose O
superficial O
bladder O
tumors O
had O
been O
removed O
by O
transurethral O
resection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
for O
open O
surgery O
( O
P O
< O
0.001 O
) O
and O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
significantly O
greater O
for O
laparoscopic O
surgery O
( O
P O
= O
0.020 O
) O
, O
and O
return O
to O
diet O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
longer O
for O
open O
surgery O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use']

Fifteen O
Italian O
hypertension O
units O
studied O
142 O
hypertensive O
patients O
( O
76 O
men O
, O
66 O
women O
; O
mean O
age O
59 O
+/- O
5.9 O
years O
) O
treated O
with O
different O
antihypertensive O
drugs O
: O
71 O
patients O
were O
randomized O
to O
aspirin O
and O
71 O
served O
as O
controls O
. O
[]

Metoclopramide O
( O
10 O
mg O
slow O
i.v O
. O
) O
[]

The O
intervention O
started O
at O
the O
first O
week O
of O
life O
and O
involved O
8 O
weeks O
of O
daily O
passive O
extension O
and O
flexion O
range-of-motion O
exercise O
of O
the O
upper O
and O
lower O
extremities O
. O
[]

Furthermore O
, O
the O
combination O
of O
the O
two O
drugs O
was O
shown O
to O
enhance O
the O
antihypertensive B-outcome ['Resource-use']
effect O
of O
the O
two O
compounds O
alone O
. O
['Resource-use']

OBJECTIVES O
To O
assess O
cervical B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
among O
underserved O
women O
participating O
in O
an O
intervention O
designed O
to O
increase O
mammography O
use O
. O
['Life-Impact']

catheters O
( O
long O
lines O
) O
was O
also O
performed O
. O
[]

All O
adverse O
events O
resolved O
within O
72 O
h. O
Induction O
of O
chemokines/cytokines O
and O
IFN-stimulated O
genes O
were O
seen O
at O
GS-9620 O
doses O
? O
[]

This O
article O
reports O
the O
psychometric O
properties O
of O
two O
scales O
for O
rating O
positive O
and O
negative O
schizophrenic O
signs O
and O
symptoms O
. O
[]

After O
3 O
months O
the O
control O
group O
were O
given O
the O
same O
treatment O
. O
[]

Both O
drugs O
were O
well O
tolerated B-outcome ['Life-Impact']
and O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
or O
clinically O
relevant O
alterations O
in O
vital O
signs O
or O
clinical O
laboratory O
parameters O
were O
observed O
during O
treatment O
. O
['Life-Impact', 'Adverse-effects']

RESULTS O
After O
the O
intervention O
, O
CGs O
reported O
better O
self-rated B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
and O
emotional B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
which O
was O
related O
to O
less O
burden O
and O
bother O
with O
their O
caregiving O
role O
than O
for O
CGs O
not O
receiving O
the O
intervention O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Antiarrhythmic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
neoton O
manifested O
on O
MI O
day O
2 O
. O
['Physiological-Clinical']

Following O
endodontic O
treatment O
, O
the O
teeth O
were O
randomly O
assigned O
to O
four O
groups O
: O
cast O
Ni-Cr O
alloy O
dowel-core O
with O
no O
ferrule O
( O
Group O
A1 O
) O
, O
cast O
Ni-Cr O
alloy O
dowel-core O
with O
2.0 O
mm O
ferrule O
( O
Group O
A2 O
) O
, O
prefabricated O
carbon O
fiber-reinforced O
dowel-resin O
core O
with O
no O
ferrule O
( O
Group O
B1 O
) O
and O
carbon O
fiber-reinforced O
dowel-resin O
core O
with O
2.0 O
mm O
ferrule O
( O
Group O
B2 O
) O
. O
[]

The O
placebo O
group O
( O
n=30 O
) O
received O
20cc O
saline O
without O
bupivacaine O
, O
installed O
into O
the O
gallbladder O
bed O
. O
[]

Participants O
assigned O
the O
three-class O
strategy O
were O
significantly O
more O
likely O
to O
discontinue B-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
because O
of O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
than O
were O
those O
assigned O
to O
the O
two-class O
strategies O
( O
HR O
1.58 O
; O
p O
< O
0.0001 O
) O
. O
['Life-Impact', 'Adverse-effects']

CONCLUSION O
Although O
hs-CRP B-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
CC O
genotype O
patients O
of O
ATR1 O
polymorphisms O
E O
and/or O
L O
reduced O
hs-CRP O
and O
increased O
TA O
regardless O
of O
the O
RAS O
genotype O
. O
['Physiological-Clinical']

This O
report O
deals O
only O
with O
amonafide O
as O
a O
Phase O
II O
agent O
. O
[]

STUDY O
DESIGN O
Post O
hoc O
assessment O
of O
the O
data O
from O
a O
double-blind O
, O
randomized O
study O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
vertical B-outcome ['Physiological-Clinical']
migration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
device I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
between O
the O
implants O
used O
( O
p O
= O
0.3 O
) O
. O
['Physiological-Clinical']

We O
analysed O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
as O
one O
of O
our O
secondary O
endpoints O
. O
['Mortality']

The O
most O
important O
methods O
of O
regional O
chemotherapy O
are O
exemplified O
by O
657 O
cases O
of O
primary O
and O
secondary O
liver O
only O
malignancies O
. O
[]

No O
differences O
between O
study O
arms O
were O
observed O
with O
respect O
to O
hepatotoxicity B-outcome ['Physiological-Clinical']
or O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Height B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
HV O
and O
total O
height B-outcome ['Physiological-Clinical']
gain I-outcome ['Physiological-Clinical']
were O
assessed O
during O
the O
4-year O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Few O
clinical O
problems O
were O
observed O
, O
and O
the O
overall O
average O
marginal O
bone O
loss O
was O
0.26 O
mm O
( O
SD O
0.64 O
) O
during O
10 O
years O
in O
function O
. O
[]

Compared O
with O
LP-supplemented O
infants O
, O
those O
given O
FS50 O
gained O
a O
mean O
of O
100 O
g O
more O
weight O
and O
0.8 O
cm O
more O
length B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Random-effects O
regression O
models O
over O
the O
first O
4 O
years O
after O
randomization O
revealed O
that O
, O
although O
the O
intervention O
did O
not O
affect O
the O
frequency O
of O
patient O
behavioral O
problems O
, O
it O
did O
significantly O
reduce O
caregivers B-outcome ['Life-Impact']
' O
reaction B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact']

METHODS O
Twenty O
adult O
severely O
burned O
patients O
with O
sepsis O
were O
studied O
. O
[]

This O
may O
have O
applicability O
to O
the O
clinical O
strategy O
of O
permissive O
hypercapnia O
and O
allow O
the O
benefit O
of O
decreased O
airway B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
to O
be O
realized O
while O
minimizing O
the O
adverse O
hemodynamic O
effects O
of O
hypercapnic O
acidosis O
. O
['Physiological-Clinical']

Stress O
reduction O
and O
analgesia O
in O
patients O
exposed O
to O
calming O
music O
postoperatively O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
control O
group O
received O
standardized O
information O
on O
controlling O
pain O
. O
[]

Clinical O
benefit O
with O
docetaxel O
plus O
fluorouracil O
and O
cisplatin O
compared O
with O
cisplatin O
and O
fluorouracil O
in O
a O
phase O
III O
trial O
of O
advanced O
gastric O
or O
gastroesophageal O
cancer O
adenocarcinoma O
: O
the O
V-325 O
Study O
Group O
. O
[]

The O
Mini-Mental O
State I-outcome ['Life-Impact']
Examination O
( O
MMS O
) O
and O
the O
Geriatric O
Depression B-outcome ['Life-Impact']
Scale O
( O
GDS O
) O
were O
applied O
to O
evaluate O
the O
effect O
of O
maprotiline O
on O
cognitive O
and O
depressive O
symptoms O
. O
['Life-Impact', 'Life-Impact']

There O
were O
no O
within-pair O
differences O
in O
height O
, O
weight O
, O
or O
calcium O
intake O
at O
baseline O
. O
[]

Emotional B-outcome ['Life-Impact']
, O
motivational B-outcome ['Life-Impact']
and O
interpersonal B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
of O
children O
with O
autism O
in O
improvisational O
music O
therapy O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Groups O
met O
for O
seven O
50-minute O
treatment O
sessions O
during O
a O
three-week O
period O
. O
[]

Several O
case O
studies O
published O
recently O
have O
indicated O
that O
5 O
% O
imiquimod O
cream O
, O
currently O
licensed O
for O
the O
treatment O
of O
genital O
warts O
, O
may O
be O
an O
effective O
treatment O
for O
AK O
. O
[]

METHODS O
The O
provocative O
antigen O
challenge O
model O
was O
used O
in O
this O
randomized O
, O
double-blind O
, O
single-center O
, O
crossover O
study O
. O
[]

Thereafter O
, O
clinical O
and O
radiographic O
data O
were O
collected O
and O
compared O
between O
the O
two O
groups O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
following O
appendicectomy O
: O
the O
placebo O
effect O
. O
[]

BACKGROUND O
Less O
microbial O
exposure O
in O
early O
childhood O
is O
associated O
with O
more O
allergic O
disease O
later O
. O
[]

DESIGN O
AND O
METHOD O
Reported O
are O
the O
results O
of O
a O
randomized O
control O
design O
evaluating O
the O
program O
's O
effectiveness O
. O
[]

OBJECTIVE O
To O
identify O
the O
determinants O
of O
improvement O
in O
walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
following O
therapeutic O
exercise O
in O
chronic O
stroke O
survivors O
. O
['Life-Impact']

Outcomes O
in O
a O
nursing O
home O
transition O
case-management O
program O
targeting O
new O
admissions O
. O
[]

RESULTS O
Compared O
to O
the O
patients O
who O
received O
TAU O
only O
, O
patients O
in O
the O
COMET O
+ O
TAU O
condition O
showed O
significant O
improvement O
with O
large O
effect O
sizes O
on O
indices O
of O
self-esteem B-outcome ['Life-Impact']
, O
['Life-Impact']

For O
the O
maintenance O
of O
the O
remission O
continuous O
chemotherapy O
for O
at O
least O
2 O
years O
following O
treatment O
by O
operation O
and O
radiotherapy O
is O
necessary O
. O
[]

The O
results O
of O
this O
study O
indicate O
that O
propranolol O
treatment O
can O
significantly O
affect O
bone B-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Rye O
bran O
bread O
intake O
elevates O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ferulic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
in O
humans O
, O
but O
does O
not O
affect O
the O
susceptibility O
of O
LDL B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
ex O
vivo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Expression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Ki-67 I-outcome ['Physiological-Clinical']
was O
examined O
by O
immunohistochemical B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Screen-and-treat O
cervical O
cancer O
prevention O
programs O
based O
on O
high-risk O
human O
papillomavirus O
( O
HPV O
) O
testing O
and O
cryotherapy O
have O
been O
shown O
to O
be O
effective O
in O
resource-limited O
settings O
. O
[]

PURPOSE O
To O
determine O
the O
effectiveness O
of O
the O
Alleviating O
Depression O
Among O
Patients O
With O
Cancer O
( O
ADAPt-C O
) O
collaborative O
care O
management O
for O
major O
depression O
or O
dysthymia O
. O
[]

We O
conclude O
that O
, O
for O
cardiovascular O
and O
cardiorespiratory O
adaptations O
in O
athletes O
, O
strength O
and O
endurance O
training O
are O
compatible O
and O
that O
exercise O
timing O
and O
sequence O
significantly O
influence O
training O
adaptations O
, O
complimenting O
our O
previous O
similar O
conclusions O
for O
strength B-outcome ['Physiological-Clinical']
, O
muscle B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
pre-core O
mutant O
HBV O
is O
unable O
to O
produce O
hepatitis O
B O
e O
antigen O
( O
HBeAg O
) O
, O
so O
that O
patients O
with O
this O
variant O
do O
not O
present O
with O
HBV O
characterised O
by O
HBeAg B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Trunk O
muscle B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
was O
equally O
increased O
( O
SP O
: O
23+/-4 O
% O
, O
MX O
: O
25+/-5 O
% O
) O
, O
but O
arms B-outcome ['Physiological-Clinical']
endurance B-outcome ['Physiological-Clinical']
was O
improved O
significantly O
more O
after O
MX O
( O
50+/-11 O
% O
) O
compared O
to O
SP O
( O
11+/-14 O
% O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Some O
of O
the O
children O
showed O
improvement O
in O
tests O
of O
cognitive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
although O
the O
results O
did O
not O
achieve O
overall O
statistical O
significance O
. O
['Life-Impact']

Also O
, O
economically O
our O
partnership O
is O
[]

Ninety-two O
percent O
of O
eyes O
( O
83 O
of O
90 O
) O
were O
within O
1.00 O
D O
of O
intended O
correction O
and O
76 O
% O
of O
eyes O
( O
68 O
of O
90 O
) O
were O
within O
0.50 O
D O
of O
intended O
correction O
. O
[]

OBJECTIVE O
To O
investigate O
if O
intraperitoneal O
( O
IP O
) O
insulin O
infusion O
via O
programmable O
implantable O
pumps O
is O
a O
potential O
alternative O
to O
subcutaneous O
( O
SC O
) O
insulin O
via O
multiple O
injections O
. O
[]

We O
designed O
a O
randomized O
phase O
II O
study O
to O
evaluate O
and O
compare O
the O
activity O
and O
safety O
profile O
of O
the O
combination O
versus O
single-agent O
TMZ O
in O
patients O
with O
advanced O
melanoma O
. O
[]

A O
Phase O
II O
, O
4-week O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
was O
conducted O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
the O
Ampakine O
compound O
CX516 O
as O
a O
potential O
treatment O
for O
the O
underlying O
disorder O
in O
fragile O
X O
syndrome O
( O
FXS O
) O
. O
[]

In O
the O
present O
study O
, O
we O
assessed O
hemostatic B-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
associated O
with O
clinical O
status O
and O
outcome O
of O
SAH O
. O
['Physiological-Clinical']

The O
study O
fills O
a O
critical O
gap O
in O
our O
understanding O
of O
the O
role O
of O
depressive O
symptoms O
during O
pregnancy O
in O
shaping O
mothers O
' O
early O
attachment O
to O
their O
infants O
. O
[]

The O
initial O
dose O
of O
sertraline O
was O
50 O
mg/day O
with O
increases O
of O
50 O
mg/day O
every O
3 O
weeks O
permitted O
after O
the O
fourth O
week O
of O
treatment O
( O
dosing O
was O
flexible O
up O
to O
a O
maximum O
of O
200 O
mg/day O
) O
. O
[]

Additional O
evidence O
for O
intravascular O
coagulation O
came O
from O
the O
changes O
observed O
in O
factor O
VIII O
levels O
which O
, O
although O
initially O
high O
in O
all O
patients O
, O
fell O
subsequently O
, O
particularly O
in O
those O
given O
concentrate O
alone O
. O
[]

Effect O
of O
prophylactic O
transluminal O
balloon O
angioplasty O
on O
cerebral B-outcome ['Physiological-Clinical']
vasospasm I-outcome ['Physiological-Clinical']
and O
outcome O
in O
patients O
with O
Fisher O
grade O
III O
subarachnoid O
hemorrhage O
: O
results O
of O
a O
phase O
II O
multicenter O
, O
randomized O
, O
clinical O
trial O
. O
['Physiological-Clinical']

Expiratory B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
higher O
in O
setting O
II O
compared O
to O
setting O
III O
( O
both O
p O
< O
0.001 O
) O
, O
indicating O
the O
presence O
of O
significant O
expiratory O
leakage O
. O
['Physiological-Clinical']

Participants O
attended O
their O
local O
practice O
and O
H. O
pylori O
status O
was O
determined O
by O
13C-urea O
breath O
test O
. O
[]

Fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
SCFAs I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
over O
the O
first O
3 O
mo O
. O
['Physiological-Clinical']

In O
a O
phase O
II O
study O
119 O
patients O
with O
disseminated O
malignant O
melanoma O
were O
randomized O
to O
receive O
treatment O
with O
dacarbazine O
alone O
or O
in O
combination O
with O
vindesine O
. O
[]

To O
analyze O
immune O
competence O
, O
the O
expression O
of O
CD3 O
, O
CD4 O
, O
and O
CD8 O
on O
lymphocytes O
and O
of O
HLA-DR O
and O
CD14 O
on O
monocytes O
as O
well O
as O
the O
plasma O
levels O
of O
IL-6 O
and O
IL-10 O
was O
evaluated O
before O
, O
1 O
, O
2 O
, O
4 O
, O
and O
7 O
days O
after O
surgery O
. O
[]

Comparison O
of O
arch O
dimension O
changes O
in O
1-phase O
vs O
2-phase O
treatment O
of O
Class O
II O
malocclusion O
. O
[]

Side O
effects O
including O
flushing B-outcome ['Physiological-Clinical']
and O
headache B-outcome ['Physiological-Clinical']
, O
were O
common O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
group O
received O
botulinum O
toxin O
to O
confirm O
the O
trigger O
sites O
; O
controls O
received O
saline O
injections O
. O
[]

Furthermore O
, O
24-h O
proteinuria B-outcome ['Physiological-Clinical']
was O
reduced O
by O
23 O
% O
( O
mean O
95 O
% O
CI O
; O
2?44 O
) O
by O
treatment O
with O
aliskiren O
( O
150 O
mg O
) O
, O
by O
36 O
% O
( O
95 O
% O
CI O
, O
17?55 O
; O
P O
< O
0.001 O
) O
with O
aliskiren O
( O
300 O
mg O
) O
, O
by O
7.1 O
% O
( O
95 O
% O
CI O
, O
11?26 O
) O
with O
perindopril O
( O
5 O
mg O
) O
and O
by O
25 O
% O
( O
95 O
% O
CI O
, O
11?39 O
; O
P O
< O
0.05 O
) O
with O
perindopril O
( O
10 O
mg O
) O
, O
compared O
to O
placebo O
. O
['Physiological-Clinical']

The O
behavioural O
evaluation O
was O
conducted O
using O
the O
specific O
BSE O
and O
CARS O
rating O
scales O
NAL O
treatment O
produced O
a O
significant O
reduction O
of O
the O
autistic B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
seven O
( O
responders O
) O
out O
of O
12 O
children O
. O
['Life-Impact']

Progressive O
relaxation O
markedly O
reduced O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
but O
did O
not O
favorably O
influence O
performance O
or O
affect O
in O
response O
to O
acute O
stress O
. O
['Physiological-Clinical']

5-Fluorouracil O
, O
adriamycin O
, O
cyclophosphamide O
( O
FAC O
) O
vs. O
5-fluorouracil O
, O
epirubicin O
, O
cyclophosphamide O
( O
FEC O
) O
in O
metastatic O
breast O
cancer O
. O
[]

A O
single-blind O
, O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
vacuum-compression B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VCT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
for O
the O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Because O
of O
the O
methodological O
deficiencies O
in O
this O
area O
of O
research O
, O
it O
is O
impossible O
to O
make O
any O
valid O
conclusions O
about O
whether O
hypnosis O
itself O
is O
effective O
in O
the O
treatment O
of O
cigarette O
habituation O
. O
[]

Responses O
were O
evaluated O
at O
2 O
, O
4 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
baseline O
. O
[]

In O
irradiated O
subjects O
there O
was O
an O
incremental O
rise O
in O
GH B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
with O
increasing O
doses O
of O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
( O
median O
AUC O
: O
122mU/l.min O
vs O
179mU/l.min O
vs O
268mU/l.min O
; O
P=0.007 O
) O
reflecting O
altered O
pituitary B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
and O
reduced O
responsiveness B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
estimated O
energy O
expenditure O
was O
determined O
by O
: O
estTEE O
= O
( O
BMR O
+ O
EEPA O
) O
x O
1.10 O
. O
[]

Results O
of O
the O
Erectile O
Dysfunction O
and O
Statins O
Trial O
[ O
ISRCTN66772971 O
] O
. O
[]

Three O
hundred O
and O
sixty-nine O
patients O
with O
histological O
proof O
of O
adenocarcinoma O
, O
who O
had O
received O
no O
more O
than O
a O
single O
regimen O
of O
5-fluorouracil-based O
chemotherapy O
, O
were O
randomised O
to O
receive O
either O
marimastat O
( O
10 O
mg O
b.d O
. O
) O
[]

To O
test O
the O
effectiveness O
of O
a O
special O
health O
care O
program O
for O
adolescent O
mothers O
( O
17 O
years O
old O
or O
younger O
) O
and O
their O
infants O
, O
243 O
mother-infant O
pairs O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

From O
1989 O
to O
1997 O
, O
68 O
patients O
diagnosed O
with O
previously O
untreated O
PMBCL O
, O
aged O
18-65 O
years O
and O
negative O
for O
immunodeficiency O
virus O
test O
, O
were O
considered O
candidates O
to O
receive O
either O
conventional O
chemotherapy O
with O
CEOP-Bleo O
( O
cyclophosphamide O
750 O
mg/m O
( O
2 O
) O
, O
vincristine O
1.4 O
mg/m O
( O
2 O
) O
, O
prednisone O
40 O
mg/m O
( O
2 O
) O
, O
epirubicin O
70 O
mg/m O
( O
2 O
) O
, O
and O
bleomycin O
10 O
mg/m O
( O
2 O
) O
) O
or O
mega O
CEOP-Bleo O
( O
cyclophosphamide O
1000 O
mg/m O
( O
2 O
) O
, O
epirubicin O
120 O
mg/m O
( O
2 O
) O
, O
vincristine O
, O
prednisone O
, O
and O
bleomycin O
at O
the O
same O
doses O
) O
every O
21 O
days O
for O
six O
cycles O
, O
followed O
by O
radiotherapy O
to O
the O
mediastinum O
with O
the O
mantle O
technique O
( O
35-45 O
Gy O
, O
mean O
38 O
Gy O
) O
. O
[]

Infarct B-outcome ['Physiological-Clinical']
size O
, O
occurrence O
of O
major B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
TLT-related O
complications B-outcome ['Adverse-effects']
, O
in-hospital O
and O
6-month O
mortality B-outcome ['Mortality']
rates O
were O
investigated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Mortality']

If O
shown O
to O
be O
safe O
and O
effective O
in O
decreasing O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
, O
this O
novel O
approach O
will O
impact O
the O
treatment O
paradigm O
for O
heart O
failure O
. O
['Physiological-Clinical', 'Mortality']

DESIGN O
A O
secondary O
analysis O
was O
performed O
of O
baseline O
data O
from O
the O
Reach O
Out O
to O
Enhance O
Wellness B-outcome ['Physiological-Clinical']
( O
RENEW O
) O
trial O
, O
a O
diet O
and O
exercise O
intervention O
among O
overweight O
, O
long-term O
( O
?5 O
years O
) O
, O
older O
survivors O
of O
colorectal O
, O
breast O
, O
and O
prostate O
cancer O
. O
['Physiological-Clinical']

Treatment O
groups O
were O
comparable O
with O
respect O
to O
age O
and O
baseline O
granulocyte O
counts O
. O
[]

= O
.71 O
, O
.50 O
respectively O
) O
. O
[]

Renal B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
was O
reduced O
by O
each O
active O
treatment O
with O
the O
most O
prominent O
reduction O
in O
the O
combination O
phase O
. O
['Physiological-Clinical']

Enhancement O
of O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
lowering O
effect O
of O
a O
sulfonylurea O
when O
coadministered O
with O
an O
ACE O
inhibitor O
: O
results O
of O
a O
glucose-clamp O
study O
. O
['Physiological-Clinical']

Rapid O
sequential O
intravenous O
infusions O
of O
human O
corticotrophin O
releasing O
factor O
100 O
micrograms O
, O
growth O
hormone O
releasing O
factor O
100 O
micrograms O
, O
luteinising O
hormone O
releasing O
hormone O
100 O
micrograms O
, O
and O
thyrotrophin O
releasing O
hormone O
200 O
micrograms O
were O
administered O
. O
[]

The O
patients O
of O
each O
group O
were O
given O
1 O
drop O
into O
each O
eye O
: O
1 O
drop O
every O
12 O
hours O
for O
Polym O
, O
1 O
drop O
every O
6 O
hours O
for O
Plc O
. O
[]

The O
trial O
was O
complete O
with O
28 O
patients O
randomized O
. O
[]

The O
10 O
patients O
who O
completed O
the O
study O
reported O
a O
33.5 O
% O
improvement O
( O
from O
16.7 O
+/- O
3.2 O
to O
11.1 O
+/- O
4 O
; O
P O
< O
0.001 O
) O
of O
the O
6-item O
IRLS O
scores O
during O
levodopa O
SR O
treatment O
and O
a O
73.5 O
% O
improvement O
( O
from O
16.6 O
+/- O
2.8 O
to O
4.4 O
+/- O
3.8 O
; O
P O
< O
0.001 O
) O
during O
ropinirole O
treatment O
. O
[]

Electrocardiogram B-outcome ['Resource-use']
( O
['Resource-use']

They O
consumed O
less O
vitamin B-outcome ['Life-Impact']
D I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
supplements I-outcome ['Life-Impact']
( O
2.15 O
( O
sd O
5.24 O
) O
?g/d O
( O
86 O
( O
sd O
210 O
) O
IU/d O
) O
v. O
4.55 O
( O
sd O
8.48 O
) O
?g/d O
( O
188 O
( O
sd O
344 O
) O
IU/d O
) O
, O
P O
= O
0.003 O
) O
. O
['Life-Impact']

The O
most O
common O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
were O
fluid O
retention O
, O
nausea B-outcome ['Physiological-Clinical']
, O
fatigue O
, O
skin O
rash O
, O
gastrointestinal O
complaints O
, O
and O
myalgia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
economic O
evaluation O
was O
based O
on O
a O
European O
clinical O
trial O
( O
LIDO O
) O
, O
in O
which O
203 O
patients O
with O
severe O
heart O
failure O
randomly O
received O
a O
24 O
h O
infusion O
with O
either O
levosimendan O
or O
dobutamine O
. O
[]

CONCLUSION O
A O
green O
banana-supplemented O
diet O
hastened O
recovery O
of O
acute O
and O
prolonged O
childhood O
diarrhoea O
managed O
at O
home O
in O
rural O
Bangladesh O
. O
[]

Scopolamine-induced O
cognitive O
impairment O
was O
used O
in O
healthy O
men O
to O
evaluate O
the O
central O
nervous O
system O
activity O
of O
the O
new O
cholinomimetic O
SDZ O
ENS-163 O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
ketorolac O
tromethamine O
10 O
mg O
and O
30 O
mg O
suppositories O
in O
comparison O
to O
placebo O
, O
after O
single O
dose O
administration O
in O
patients O
suffering O
from O
post-operative O
pain O
after O
cholecystectomy O
. O
['Life-Impact']

Comparison O
of O
nitinol O
tipless O
stone O
baskets O
in O
an O
in O
vitro B-outcome ['Physiological-Clinical']
caliceal O
model O
. O
['Physiological-Clinical']

These O
results O
should O
be O
generalized O
cautiously O
owing O
to O
the O
small O
sample O
size O
and O
participant O
selection O
process O
. O
[]

Secondary O
outcomes O
were O
mean O
BP B-outcome ['Physiological-Clinical']
and O
TC B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma O
pharmacokinetic O
profile O
was O
approximately O
linear O
. O
[]

The O
proportion O
of O
HLA-sensitized O
patients O
decreased O
in O
the O
Tac/MMF O
group O
( O
15.9 O
% O
at O
D0 O
and O
6.7 O
% O
at O
M12 O
, O
p=0.02 O
) O
and O
remained O
stable O
in O
the O
CsA/AZA O
group O
( O
10.3 O
% O
at O
D0 O
and O
8.9 O
% O
at O
M12 O
, O
p=0.5 O
) O
. O
[]

A O
prospective O
, O
randomised O
study O
of O
82 O
patients O
having O
postoperative O
epidural O
analgesia O
was O
performed O
to O
determine O
whether O
the O
tunnelling O
of O
an O
epidural O
catheter O
influences B-outcome ['Physiological-Clinical']
its I-outcome ['Physiological-Clinical']
migration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Abdominal O
ultrasonography O
and O
dynamic O
CT O
were O
performed O
at O
3-month O
intervals O
. O
[]

Vietnam O
is O
participating O
in O
a O
global O
de-worming O
effort O
that O
aims O
to O
treat O
650 O
million O
school O
children O
regularly O
by O
2010 O
. O
[]

Among O
22 O
autistic O
children O
, O
12 O
were O
reported O
as O
having O
sleep O
problems O
and O
8 O
patients O
completed O
72 O
hours O
actigraphy O
. O
[]

No O
late O
arising O
QOL B-outcome ['Life-Impact']
issues O
were O
observed O
. O
['Life-Impact']

METHOD O
A O
double-blind O
, O
placebo-crossover O
study O
with O
transdermal O
clonidine O
was O
performed O
in O
nine O
autistic O
males O
( O
aged O
5 O
to O
33 O
years O
) O
. O
[]

Mild O
side O
effects O
including O
cough O
( O
n O
= O
9 O
) O
and O
sore O
throat O
( O
n O
= O
6 O
) O
did O
not O
require O
discontinuation O
of O
therapy O
. O
[]

Hypertensive O
patients O
were O
randomized O
to O
measure O
HBP O
for O
2 O
weeks O
or O
ABP O
for O
24 O
h. O
The O
alternative O
measurement O
was O
then O
performed O
. O
[]

OBJECTIVE O
To O
assess O
whether O
three-dimensional O
imaging O
of O
the O
Achilles O
tendon O
by O
ultrasonographic O
tissue O
characterisation O
( O
UTC O
) O
can O
differentiate O
between O
symptomatic O
and O
asymptomatic O
tendons O
. O
[]

Serial O
EEGs O
, O
obtained O
in O
parallel O
with O
psychometric O
and O
circulation O
time O
tests O
, O
demonstrated O
a O
marked O
increase O
in O
the O
8-10 O
[]

Pre-operatively O
, O
and O
2 O
h O
after O
commencing O
their O
post-operative O
feeds O
, O
rates O
of O
whole-body B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
and O
breakdown B-outcome ['Life-Impact']
were O
measured O
over O
a O
9-h O
period O
following O
intravenous O
injection O
of O
a O
single O
tracer O
dose O
of O
15N-glycine O
by O
the O
ammonia O
and O
urea O
end-product O
methods O
. O
['Physiological-Clinical', 'Life-Impact']

Randomised O
participants O
are O
allocated O
to O
receive O
a O
four O
or O
single O
intradermal O
needle O
SWI O
technique O
. O
[]

RESULTS O
Elderly O
depressed O
patients O
manifested O
significantly O
more O
severe O
hyperintensity B-outcome ['Physiological-Clinical']
ratings O
in O
the O
subcortical O
gray O
matter O
than O
age-matched O
comparison O
subjects O
. O
['Physiological-Clinical']

Therefore O
, O
we O
decided O
to O
study O
these O
findings O
by O
using O
a O
randomized O
, O
double-blind O
, O
placebo O
controlled O
study O
design O
. O
[]

Nicotine O
challenge O
was O
used O
to O
demonstrate O
that O
decreased O
rsFC O
in O
identified O
circuits O
reflects O
addiction O
trait O
and O
is O
not O
affected O
by O
pharmacological O
state O
. O
[]

METHODS O
We O
studied O
50 O
children O
undergoing O
laparoscopy O
for O
diagnostic O
and O
therapeutic O
purposes O
. O
[]

Both O
groups O
showed O
improvements O
in O
the O
FSFI O
desire B-outcome ['Life-Impact']
score O
, O
but O
with O
statistical O
significance O
only O
for O
EE20/LNG100 O
group O
. O
['Life-Impact']

Factors O
that O
influence O
cancer O
patients O
' O
anxiety B-outcome ['Life-Impact']
following O
a O
medical O
consultation O
: O
impact O
of O
a O
communication O
skills O
training O
programme O
for O
physicians O
. O
['Life-Impact']

Ropinirole O
as O
a O
treatment O
of O
restless O
legs O
syndrome O
in O
patients O
on O
chronic O
hemodialysis O
: O
an O
open O
randomized O
crossover O
trial O
versus O
levodopa O
sustained O
release O
. O
[]

The O
costs B-outcome ['Resource-use']
of O
the O
research O
component O
of O
the O
DCCT O
were O
not O
included O
. O
['Resource-use']

Omeprazole O
significantly O
decreased O
aspirin-induced B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
, O
Wilcoxon O
signed-rank O
test O
) O
. O
['Physiological-Clinical']

After O
the O
initial O
12-week O
treatment O
with O
tamoxifen O
alone O
, O
60 O
% O
of O
ER O
positive O
patients O
achieved O
complete B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
as O
did O
35 O
% O
in O
whom O
ER O
were O
unknown O
. O
['Physiological-Clinical']

The O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
for O
those O
assigned O
to O
trimethoprim-sulfamethoxazole O
( O
P O
= O
0.017 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
objective O
of O
this O
randomized O
open-label O
clinical O
trial O
was O
to O
compare O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
pimecrolimus O
in O
comparison O
with O
a O
potent O
corticosteroid O
( O
betamethasone O
17-valerate O
) O
in O
the O
treatment O
of O
seborrhoeic O
dermatitis O
. O
['Life-Impact']

Symptom-limited O
exercise O
testing O
( O
ramp O
protocol O
) O
on O
a O
bicycle O
ergometer O
with O
gas O
exchange O
analysis O
was O
conducted O
1 O
hour O
after O
oral O
administration O
of O
either O
20 O
mg O
denopamine O
or O
placebo O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
terms O
of O
the O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
and O
mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
differences O
in O
estimated O
5-year O
patencies O
were O
6.6 O
% O
( O
radial O
minus O
right O
internal O
thoracic O
artery O
) O
in O
group O
1 O
and O
2.9 O
% O
( O
radial O
minus O
saphenous O
vein O
graft O
) O
in O
group O
2 O
. O
[]

Mann-Whitney O
U-test O
was O
used O
to O
compare O
relative O
increase O
between O
the O
measured O
cardiac B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
for O
the O
two O
groups O
. O
['Physiological-Clinical']

Whole B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
lean I-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
increased O
( O
P O
< O
0.05 O
) O
with O
strength O
training O
, O
but O
leg B-outcome ['Physiological-Clinical']
fat-free I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
did O
not O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
reach O
of O
the O
same O
tailored B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( O
PA O
) O
intervention O
in O
a O
printed O
or O
Web-based O
delivery O
mode O
differed O
between O
sociodemographic O
subgroups O
of O
participants O
over O
50 O
years O
of O
age O
. O
['Life-Impact']

In O
the O
case O
of O
acute O
otitis O
externa O
, O
treatment O
measures O
focus O
on O
the O
reduction O
of O
pain B-outcome ['Physiological-Clinical']
and O
swelling B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
nine O
patients O
died B-outcome ['Mortality']
. O
['Mortality']

Treatment O
of O
Alzheimer O
's O
disease O
sometimes O
uses O
combinations O
of O
drugs O
because O
dementia O
is O
frequently O
associated O
with O
behavioral O
symptoms O
. O
[]

Effects O
of O
a O
common O
variant O
in O
the O
CD38 O
gene O
on O
social B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
an O
oxytocin O
challenge O
study O
: O
possible O
links O
to O
autism O
. O
['Life-Impact']

Post-treatment O
measurement O
of O
the O
number O
of O
picture B-outcome ['Life-Impact']
exchanges I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
far-transfer I-outcome ['Life-Impact']
, O
assessment O
context O
favored O
the O
PECS O
intervention O
. O
['Life-Impact']

Clinician O
rating O
of O
severity O
of O
the O
sleep O
disorder O
and O
improvement O
from O
baseline O
, O
along O
with O
caregiver B-outcome ['Life-Impact']
ratings I-outcome ['Life-Impact']
of O
global O
functioning O
and O
family O
stress O
were O
also O
obtained O
. O
['Life-Impact']

The O
fertilization B-outcome ['Physiological-Clinical']
rate O
was O
51 O
% O
( O
92/182 O
oocytes O
) O
. O
['Physiological-Clinical']

Clinical O
data O
show O
that O
lamivudine O
is O
an O
effective O
treatment O
for O
patients O
with O
pre-core O
mutant O
hepatitis O
B O
. O
[]

Every O
patient O
evaluated O
the O
information O
received O
at O
the O
end O
of O
the O
preoperative O
visit O
and O
in O
the O
postoperative O
period O
. O
[]

Therefore O
, O
the O
present O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
wool O
coverage O
on O
water B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
in O
relation O
to O
thermoregulation O
in O
sheep O
by O
using O
the O
deuterium O
dilution O
technique O
to O
predict O
total O
water O
intake O
before O
and O
after O
shearing O
. O
['Physiological-Clinical']

Preservative-free O
ocular O
hydrating O
agents O
in O
symptomatic O
contact O
lens O
wearers O
: O
saline O
versus O
PVP O
solution O
. O
[]

After O
3 O
weeks O
, O
the O
average O
and O
worst O
pain O
experienced O
by O
patients O
randomized O
to O
the O
clinical O
intervention O
group O
was O
significantly O
inferior O
to O
the O
average O
pain O
experienced O
by O
patients O
in O
the O
control O
group O
( O
2.9/10 O
vs. O
4.4/10 O
and O
4.2/10 O
vs. O
5.5/10 O
, O
respectively O
) O
. O
[]

Effect O
of O
diltiazem O
on O
symptomatic O
and O
asymptomatic O
episodes O
of O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
occurring O
during O
daily O
life O
and O
during O
exercise O
. O
['Physiological-Clinical']

We O
therefore O
evaluated O
a O
new O
quadruple O
therapy O
, O
because O
theoretically O
a O
shorter O
duration O
of O
treatment O
may O
result O
in O
reduced O
costs O
, O
fewer O
side-effects O
, O
and O
possibly O
in O
a O
lower O
potential O
for O
antibiotic O
resistances O
. O
[]

Treatment O
of O
acute O
otitis O
media O
in O
children O
under O
2 O
years O
of O
age O
. O
[]

Visual O
Analogue O
Scale O
and O
Real O
Life O
Rating O
Scale O
were O
used O
to O
register O
changes O
in O
behaviour O
. O
[]

A O
higher O
incidence O
of O
noticing O
a O
smell O
of O
gas O
was O
registered O
for O
the O
group O
without O
an O
extractor O
( O
87 O
% O
vs O
11 O
% O
in O
the O
extractor O
group O
, O
P=.003 O
) O
. O
[]

Prophylaxis O
with O
Calcium O
entry O
blocker O
Flunarizine O
( O
Sibelium O
) O
or O
Thromboxane O
A O
inhibitor O
Acetylsalicylic O
acid O
( O
ASS O
) O
was O
carried O
out O
in O
a O
double O
blind O
design O
for O
3 O
months O
. O
[]

BACKGROUND O
Intravenous O
nicorandil O
, O
a O
hybrid O
compound O
of O
ATP-sensitive O
potassium O
channel O
opener O
and O
nitric O
oxide O
donor O
, O
has O
been O
reported O
to O
ameliorate O
early O
functional O
and O
clinical O
problems O
in O
patients O
with O
acute O
myocardial O
infarction O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
measurements O
were O
carried O
out O
before O
infusion O
( O
T1 O
) O
and O
at O
30 O
min O
( O
T2 O
) O
, O
2 O
h O
( O
T3 O
) O
, O
and O
12 O
h O
( O
T4 O
) O
after O
initiation O
of O
treatment O
in O
the O
intensive O
care O
unit O
. O
['Physiological-Clinical']

The O
rate O
of O
new O
or O
recurrent B-outcome ['Physiological-Clinical']
carious I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
group I-outcome ['Physiological-Clinical']
treated O
with O
the O
fluoride O
gel O
was O
slightly O
lower O
than O
in O
the O
IFRS O
group O
, O
based O
on O
carious O
lesions O
at O
the O
baseline O
examination O
( O
Poisson O
mean O
number O
of O
new O
or O
recurrent O
carious O
lesions O
for O
the O
control O
group=0.55 O
per O
year O
vs. O
0.83 O
per O
year O
for O
the O
study O
group O
, O
p=0.705 O
; O
odds O
ratio O
of O
the O
occurrence O
of O
any O
new O
or O
recurrent B-outcome ['Physiological-Clinical']
caries B-outcome ['Physiological-Clinical']
during O
follow-up O
for O
control O
group O
vs. O
the O
study O
group=0.80 O
; O
p=0.781 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
Use O
of O
an O
inspiratory O
impedance O
threshold O
device O
( O
ITD O
) O
significantly O
increases O
coronary O
perfusion O
pressures O
and O
survival O
in O
patients O
ventilated O
with O
an O
endotracheal O
tube O
( O
ETT O
) O
during O
active O
compression-decompression O
cardiopulmonary O
resuscitation O
. O
[]

DESIGN O
A O
3-year O
, O
multicenter O
, O
randomized O
, O
historically O
controlled O
trial O
of O
the O
0.59-mg O
FA O
intravitreous O
implant O
in O
110 O
patients O
and O
the O
2.1-mg O
FA O
intravitreous O
implant O
in O
168 O
patients O
. O
[]

The O
difference O
was O
not O
statistically O
significant O
( O
chi-square O
= O
0.037 O
, O
p O
> O
0.8 O
) O
. O
[]

The O
most O
frequently O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
pyrexia B-outcome ['Physiological-Clinical']
( O
18 O
% O
) O
, O
hypokalemia B-outcome ['Physiological-Clinical']
( O
15 O
% O
) O
, O
and O
hypophosphatemia B-outcome ['Physiological-Clinical']
( O
15 O
% O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
, O
total O
( O
sum O
of O
six O
sprints O
) O
, O
first O
, O
and O
best B-outcome ['Life-Impact']
sprint I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
( O
MST O
, O
TST O
, O
FST O
, O
and O
BST O
, O
respectively O
) O
were O
recorded O
for O
each O
set O
. O
['Life-Impact']

In O
the O
clinical O
range O
of O
torsion O
, O
the O
implant-bone B-outcome ['Physiological-Clinical']
construct I-outcome ['Physiological-Clinical']
never O
failed O
or O
was O
deformed O
. O
['Physiological-Clinical']

Pre- O
and O
post-treatment O
pain O
levels O
and O
pain O
sensitivity O
were O
assessed O
with O
visual O
analogue O
scales O
( O
VAS O
) O
and O
pressure B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PPT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Each O
anti-HER2 O
therapy O
was O
given O
alone O
for O
6 O
wk O
, O
followed O
by O
12 O
wk O
of O
the O
same O
therapy O
plus O
weekly O
paclitaxel O
. O
[]

Callus O
formation O
was O
arbitrarily O
classified O
as O
rich O
, O
intermediate O
, O
or O
poor O
. O
[]

for O
24 O
wk O
( O
total O
dose O
: O
720 O
million O
units O
) O
; O
21 O
( O
B O
) O
received O
9 O
million O
units O
alpha-2a O
IFN O
i.m O
. O
[]

METHOD O
A O
randomised O
controlled O
trial O
was O
conducted O
in O
a O
large O
hospital O
with O
a O
was O
conducted O
in O
a O
large O
hospital O
with O
a O
sample O
of O
101 O
patients O
with O
schizophrenia O
and O
their O
families O
. O
[]

A O
sheathed O
needle O
( O
Tru-Cut O
) O
was O
compared O
with O
a O
suction O
biopsy O
needle O
( O
Menghini O
) O
in O
a O
randomised O
prospective O
trial O
over O
18 O
months O
to O
determine O
whether O
the O
former O
offered O
any O
special O
advantages O
in O
routine O
percutaneous O
liver O
biopsy O
. O
[]

Changes O
in O
dietary O
stage O
of O
change O
were O
associated O
with O
decreases O
in O
fat B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
increases O
in O
fiber B-outcome ['Physiological-Clinical']
, O
fruit B-outcome ['Life-Impact']
and O
vegetable B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Limitations O
of O
the O
study O
, O
along O
with O
areas O
for O
future O
research O
, O
are O
also O
discussed O
. O
[]

Within O
each O
stage O
, O
responsive O
patients O
were O
randomised O
between O
receiving O
additional O
therapy O
only O
until O
maximal O
tumour O
reduction O
was O
reached O
( O
plateau O
phase O
) O
and O
continuing O
induction O
therapy O
indefinitely O
until O
relapse O
. O
[]

RESULTS O
Clinically O
and O
statistically O
significant O
improvements O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distance B-outcome ['Physiological-Clinical']
and O
WOMAC O
score O
at O
4 O
weeks O
and O
8 O
weeks O
were O
seen O
in O
the O
treatment O
group O
but O
not O
the O
placebo O
group O
. O
['Life-Impact', 'Physiological-Clinical']

Butyrate O
and O
other O
SCFA O
produced O
by O
bacterial O
fermentation O
of O
resistant O
starch O
( O
RS O
) O
or O
nonstarch O
polysaccharides O
( O
NSP O
) O
promote O
human B-outcome ['Physiological-Clinical']
colonic I-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Our O
study O
is O
preliminary O
and O
large-scale O
trials O
are O
needed O
to O
determine O
whether O
VK2 O
is O
of O
benefit O
to O
decrease O
the O
[]

SETTING O
St O
Vincent O
's O
Hospital O
, O
Melbourne O
, O
Victoria O
( O
a O
tertiary O
referral O
, O
university O
teaching O
hospital O
) O
, O
1 O
October O
1997 O
to O
30 O
November O
1998 O
. O
[]

PURPOSE O
The O
effects O
of O
morphine O
on O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
investigated O
in O
patients O
who O
underwent O
hysterectomy O
. O
['Physiological-Clinical']

At O
14 O
days O
, O
there O
were O
no O
differences O
in O
the O
P2Y B-outcome ['Physiological-Clinical']
( O
12 O
) O
reactivity B-outcome ['Physiological-Clinical']
index O
as O
assessed O
by O
vasodilator-stimulated O
phosphoprotein O
phosphorylation O
between O
treatment O
groups O
( O
primary O
endpoint O
; O
p O
= O
0.93 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tamoxifen O
group O
received O
continuous O
treatment O
with O
tamoxifen O
20 O
mg O
twice O
daily O
. O
[]

There O
was O
no O
difference O
between O
the O
two O
groups O
concerning O
operative O
time O
, O
hospital O
stay O
and O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Tamsulone-FS O
-- O
a O
novel O
Russian O
alpha1A/D-adrenoblocker O
( O
Farm-Syntez O
) O
-- O
was O
studied O
in O
a O
randomized O
multicenter O
comparative O
trial O
in O
patients O
with O
prostatic O
adenoma O
. O
[]

There O
were O
3 O
cases O
of O
eclampsia B-outcome ['Physiological-Clinical']
, O
all O
in O
the O
Placebo O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
explore O
the O
effect O
of O
antidepressant O
treatment O
on O
antihypertensive O
therapy O
of O
senile O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Symptom B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
and O
spirometry B-outcome ['Resource-use']
did O
not O
differ O
between O
the O
crossover O
trials O
, O
and O
overall O
clinical O
status O
was O
not O
altered O
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
In O
this O
study O
, O
100 O
patients O
with O
stage O
I O
hypertension O
are O
characterized O
at O
baseline O
before O
being O
treated O
for O
1 O
year O
to O
obtain O
a O
goal O
BP O
of O
less O
than O
140/90 O
mm O
Hg O
as O
defined O
by O
Joint O
National O
Committee O
( O
JNC O
) O
-7 O
. O
[]

METHODS O
In O
a O
placebo-controlled O
, O
randomised O
, O
double-blind O
crossover O
design O
we O
studied O
the O
effects O
of O
single O
oral O
doses O
of O
1 O
, O
5 O
, O
and O
10 O
mg O
of O
asimadoline O
, O
in O
24 O
healthy O
volunteers O
. O
[]

BACKGROUND O
Nasotracheal O
intubation O
( O
NTI O
) O
has O
greater O
potential O
for O
trauma O
of O
nasopharyngeal O
mucosa O
than O
orotracheal O
intubation O
. O
[]

RESULTS O
Among O
300 O
cases O
of O
VVC O
, O
uncomplicated O
, O
complicated O
and O
recurrent O
VVC O
were O
56.0 O
% O
, O
44.0 O
% O
and O
9.7 O
% O
( O
29/300 O
) O
respectively O
. O
[]

The O
pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
cervical B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
also O
higher O
in O
that O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
screening O
for O
exclusion O
, O
only O
55 O
patients O
were O
included O
in O
the O
first O
3-hour O
investigation O
period O
. O
[]

This O
trial O
demonstrates O
the O
variability O
in O
responsiveness O
to O
GH O
administration O
in O
GH-deficient O
adults O
. O
[]

Thirteen O
healthy O
volunteers O
( O
aged O
38.6 O
+/- O
4 O
years O
) O
entered O
a O
2 O
week O
crossover O
design O
study O
( O
week O
1 O
, O
high O
sodium O
diet O
[ O
HS O
] O
> O
200 O
mmol O
Na/day O
; O
week O
2 O
, O
low O
sodium O
diet O
[ O
LS O
] O
, O
< O
10 O
mmol O
Na/day O
) O
to O
investigate O
the O
influence O
of O
dietary O
sodium O
and O
Ang O
II O
on O
myocardial O
relaxation O
and O
renal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
was O
proposed O
to O
investigate O
the O
effect O
of O
donor-site O
bone O
loss O
on O
the O
strength O
of O
the O
radius O
under O
torsional O
( O
rotational O
) O
loading O
. O
[]

Humans O
have O
a O
remarkable O
ability O
to O
understand O
spoken O
language O
despite O
the O
large O
amount O
of O
variability O
in O
speech O
. O
[]

Collaborative O
Group O
of O
the O
Primary O
Prevention O
Project O
( O
PPP O
) O
-- O
Hypertension O
study O
. O
[]

BACKGROUND O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
3-year O
clinical O
outcome O
in O
patients O
enrolled O
in O
the O
Primary O
Stenting O
of O
Totally O
Occluded O
Native O
Coronary O
Arteries O
II O
study O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Delivery B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rate O
, O
maternal B-outcome ['Physiological-Clinical']
perineal I-outcome ['Physiological-Clinical']
and O
vaginal B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
, O
maternal B-outcome ['Physiological-Clinical']
anaesthetic I-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
, O
neonatal B-outcome ['Physiological-Clinical']
scalp I-outcome ['Physiological-Clinical']
and O
facial B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
overall O
survival B-outcome ['Mortality']
, O
PLD O
was O
significantly O
superior O
to O
topotecan O
( O
P O
=.008 O
) O
, O
with O
a O
median O
of O
108 O
weeks O
versus O
71.1 O
weeks O
. O
['Mortality']

BACKGROUND O
Most O
clinical O
trials O
for O
acute O
leukemia O
have O
reported O
results O
after O
2-3 O
years O
of O
follow-up O
. O
[]

There O
were O
32 O
males O
and O
19 O
females O
, O
with O
a O
median O
age O
of O
45 O
years O
( O
range O
: O
6-59 O
) O
. O
[]

Cortical O
venous O
reflux O
( O
CVR O
) O
was O
demonstrated O
in O
two O
cases O
out O
of O
three O
patients O
with O
CVR O
. O
[]

Few O
( O
12-13 O
% O
) O
participants O
tested O
negative O
on O
Monday O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
fall O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
Ganda O
1.0/0.2 O
( O
8.87 O
mm O
Hg O
) O
and O
Timolol O
0.25 O
per O
cent O
( O
8.24 O
mm O
Hg O
) O
. O
['Physiological-Clinical']

A O
total O
of O
1000 O
ml O
of O
normal O
saline O
and O
1 O
mCi O
of O
Tc-99m O
SC O
was O
infused O
intraperitoneally O
for O
IDI O
. O
[]

RPMT O
facilitated O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
in O
the O
posttreatment O
period O
. O
['Life-Impact']

Combined O
statin O
with O
niacin O
may O
produce O
a O
more O
global O
and O
effective O
improvement O
in O
lipid B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
levels O
than O
monotherapy O
and O
is O
generally O
safe O
and O
well B-outcome ['Life-Impact']
tolerable I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

We O
present O
a O
study O
of O
the O
ghostwritten O
archival O
report O
of O
an O
industry-sponsored O
trial O
comparing O
antidepressant O
treatments O
for O
bipolar B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
: O
GlaxoSmithKline O
( O
GSK O
) O
paroxetine O
study O
352 O
. O
['Life-Impact']

All O
patients O
, O
irrespective O
of O
training O
form O
, O
were O
able O
to O
exercise O
to O
maximal O
intensity O
( O
80-90 O
% O
of O
estimated O
maximal O
heart O
rate O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
This O
randomized O
controlled O
trial O
was O
designed O
to O
evaluate O
, O
first O
, O
whether O
intra- O
or O
postoperative O
music O
therapy O
could O
influence O
stress O
and O
immune B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
and O
after O
general O
anaesthesia O
and O
second O
, O
if O
there O
was O
a O
different O
response O
between O
patients O
exposed O
to O
music O
intra- O
or O
postoperatively O
. O
['Physiological-Clinical']

Complication O
rates O
, O
and O
['Adverse-effects']

Since O
its O
introduction O
in O
1996 O
, O
it O
has O
been O
used O
for O
subcutaneous O
infiltration O
; O
epidural O
, O
intrathecal O
, O
and O
peripheral O
nerve O
block O
surgery O
; O
and O
postoperative O
analgesia O
. O
[]

h-1 O
. O
[]

However O
, O
ROCA O
could O
still O
show O
a O
significant O
effect O
in O
other O
screening O
trials O
, O
including O
UKCTOCS O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
impact O
of O
a O
1-year O
, O
senior O
center-based O
chronic B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
self-management O
and O
disability O
prevention O
program O
on O
health O
, O
functioning O
, O
and O
healthcare O
utilization O
in O
frail O
older O
adults O
. O
['Physiological-Clinical']

This O
study O
was O
registered O
with O
the O
Dutch O
Trial O
Register O
and O
has O
the O
International O
Standard O
Randomised O
Clinical O
Trial O
number O
ISRCTN72675518 O
. O
[]

Bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
following O
cessation O
of O
raloxifene O
therapy O
at O
96 O
weeks O
was O
greater O
than O
in O
the O
control O
group O
, O
suggesting O
accelerated O
bone O
loss O
. O
['Physiological-Clinical']

Future O
research O
should O
focus O
on O
attrition O
in O
order O
to O
enhance O
the O
overall O
effectiveness O
of O
training O
. O
[]

Duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
, O
as O
well O
as O
the O
requirement O
of O
additional O
analgesics O
, O
were O
noted O
. O
['Life-Impact']

The O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
( O
less O
than O
0.5 O
x O
10 O
( O
9 O
) O
/L O
) O
was O
similar O
between O
controls O
( O
median O
22.5 O
days O
) O
and O
patients O
treated O
with O
lithium O
( O
median O
24 O
days O
) O
. O
['Physiological-Clinical']

Based O
on O
per O
protocol O
repeated O
measures O
analysis O
, O
data O
for O
26 O
diet O
children O
and O
29 O
controls O
were O
available O
at O
12 O
months O
. O
[]

It O
is O
associated O
with O
a O
decreased O
incidence O
of O
rectal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
presumably O
due O
to O
decreased O
patient O
discomfort O
. O
['Physiological-Clinical']

Delayed O
t O
[]

Two O
interim O
analyses O
were O
planned O
. O
[]

Significant O
group O
by O
phase O
interactions O
were O
found O
for O
total O
scores O
and O
also O
sensory B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
scores O
indicating O
a O
reduction O
in O
symptom B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
associated O
with O
the O
ascorbic O
acid O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
6 O
months O
, O
study O
outcomes O
included O
days O
of O
alcohol B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
measured O
using O
the O
time-line O
follow-back O
method O
. O
['Life-Impact']

The O
speed O
of O
kill O
of O
selamectin O
, O
imidacloprid O
, O
and O
fipronil- O
( O
S O
) O
-methoprene O
against O
Ctenocephalides O
felis O
infestations O
on O
cats O
for O
one O
month O
following O
a O
single O
treatment O
was O
evaluated O
. O
[]

METHODS O
Patients O
with O
AS O
patients O
who O
had O
predominantly O
axial O
symptoms O
were O
randomised O
to O
receive O
infliximab O
alone O
( O
infusions O
of O
5 O
mg/kg O
at O
weeks O
0 O
, O
2 O
, O
6 O
, O
12 O
and O
18 O
) O
or O
infliximab O
combined O
with O
MTX O
( O
10 O
mg/week O
) O
. O
[]

The O
risk O
of O
a O
second O
primary O
malignancy O
, O
however O
, O
was O
doubled O
in O
the O
RT O
group O
( O
p O
> O
0.01 O
) O
. O
[]

Primary O
outcomes O
were O
death O
, O
CHF B-outcome ['Resource-use']
hospitalisation I-outcome ['Resource-use']
and O
length O
of O
hospital O
stay O
. O
['Resource-use']

AIM O
During O
the O
last O
decade O
laparoscopic O
techniques O
have O
been O
applied O
to O
the O
treatment O
of O
inguinal B-outcome ['Physiological-Clinical']
hernia I-outcome ['Physiological-Clinical']
to O
combine O
tension-free O
technique O
, O
esthetic O
, O
and O
functional O
benefits O
of O
mini-invasive O
surgery O
. O
['Physiological-Clinical']

Forty-six O
age- O
and O
IQ-matched O
ASD O
children O
were O
randomly O
assigned O
to O
receive O
group O
training O
in O
Nei O
Yang O
Gong O
( O
experimental O
group O
) O
or O
PMR O
( O
control O
group O
) O
twice O
per O
week O
for O
four O
weeks O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
preoperative O
intentional O
hemodilution O
with O
4 O
% O
albumin O
solution O
on O
the O
extravasation O
rate O
of O
intravascular O
albumin O
and O
fluid O
in O
surgical O
patients O
. O
[]

This O
difference O
is O
statistically O
significant O
( O
p O
= O
0.023 O
) O
. O
[]

They O
were O
randomized O
to O
double-blind O
supplementation O
for O
6 O
weeks O
with O
Abalon O
( O
soy O
protein O
[ O
50 O
g/day O
] O
with O
high O
levels O
of O
isoflavones O
[ O
minimum O
165 O
mg/day O
] O
and O
cotyledon O
fiber O
[ O
20 O
g/day O
] O
) O
or O
placebo O
( O
casein O
[ O
50 O
g/day O
] O
and O
cellulose O
[ O
20 O
g/day O
] O
) O
, O
separated O
by O
a O
3-week O
wash-out O
period O
. O
[]

We O
hypothesized O
that O
re-training O
reduces O
the O
impaired O
performance O
on O
neurosensory O
tests O
of O
tactile O
function O
that O
is O
commonly O
observed O
post-surgically O
. O
[]

Extra O
virgin O
olive O
oil O
( O
EVOO O
) O
consumption O
and O
antioxidant B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
healthy O
institutionalized O
elderly O
humans O
. O
['Physiological-Clinical']

OBJECTIVE O
Weight O
gain O
is O
common O
for O
individuals O
with O
serious O
mental O
illness O
( O
SMI O
) O
receiving O
antipsychotic O
drug O
therapy O
. O
[]

OBJECTIVES O
Forty-eight O
weeks O
of O
peginterferon O
alfa-2a O
is O
the O
approved O
regimen O
for O
chronic O
hepatitis O
B O
( O
CHB O
) O
. O
[]

Part O
2 O
: O
Phase O
I O
study O
. O
[]

DESIGN O
A O
cross-sectional O
survey O
of O
women O
in O
the O
18th O
week O
of O
pregnancy O
. O
[]

Lesions O
were O
semi-automatically O
segmented O
on O
each O
interval O
image O
series O
and O
supervised O
by O
a O
radiologist O
. O
[]

BACKGROUND O
Clinical O
trials O
addressing O
the O
acneiform O
rash O
associated O
with O
epidermal O
growth O
factor O
receptor O
inhibitors O
are O
lacking O
. O
[]

and O
PUVA O
vs. O
PUVA O
alone O
in O
patients O
with O
stage O
IB O
and O
IIA O
mycosis O
fungoides O
( O
MF O
) O
. O
[]

A O
loading O
dose O
of O
T3 O
was O
administered O
: O
( O
a O
) O
at O
release O
of O
the O
aortic O
cross-clamp O
, O
( O
b O
) O
whenever O
the O
patient O
became O
CPB O
dependent O
, O
( O
c O
) O
if O
the O
patient O
exhibited O
low O
cardiac O
output O
after O
discontinuing O
CPB O
and O
( O
d O
) O
as O
pretreatment O
before O
initiating O
CPB O
. O
[]

Often O
subjects O
have O
been O
instructed O
to O
refrain O
from O
blinking O
lest O
their O
evoked O
EEG O
potentials O
should O
be O
distorted O
. O
[]

The O
data O
were O
recorded O
and O
analyzed O
using O
ANOVA O
and O
Fisher O
's O
exact O
tests O
, O
with O
alpha O
= O
0.05 O
. O
[]

The O
rate O
of O
definite B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
engraftment I-outcome ['Physiological-Clinical']
was O
1.7-fold O
higher O
in O
marrow O
recipients O
( O
P O
=.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
Both O
treatments O
had O
no O
significant O
effect O
on O
induced O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cells O
, O
although O
there O
was O
a O
trend O
for O
a O
reduction O
in O
sputum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
first O
( O
n O
= O
17 O
) O
and O
second O
( O
n O
= O
24 O
) O
groups O
were O
treated O
with O
E O
( O
E O
( O
+ O
) O
: O
10 O
mg/d O
) O
and O
L O
( O
L O
( O
+ O
) O
: O
50 O
mg/d O
) O
alone O
, O
respectively O
. O
[]

To O
date O
, O
there O
has O
been O
no O
randomised O
, O
blinded O
trial O
of O
100 O
% O
oxygen O
administered O
at O
hyperbaric O
pressure O
. O
[]

No O
statistically O
significant O
differences O
were O
found O
in O
fasting O
glucose O
, O
insulin O
, O
and O
C-peptide B-outcome ['Physiological-Clinical']
, O
or O
in O
the O
glucose B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
rate O
and O
in O
any O
of O
the O
parameters O
for O
insulin B-outcome ['Resource-use']
and O
C-peptide B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
i.v O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

This O
study O
aimed O
to O
compare O
the O
efficacy O
, O
tolerability B-outcome ['Life-Impact']
and O
first-dose B-outcome ['Physiological-Clinical']
blood-pressure I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
once-daily O
quinapril O
and O
twice-daily O
captopril O
when O
added O
to O
diuretic O
therapy O
in O
elderly O
patients O
with O
heart O
failure O
. O
['Life-Impact', 'Physiological-Clinical']

The O
efficacy O
of O
PPIs O
is O
superior O
to O
that O
of O
H O
( O
2 O
) O
RAs O
in O
these O
children O
. O
[]

These O
data O
suggest O
a O
potential O
synergism O
of O
these O
two O
drugs O
. O
[]

They O
had O
normal O
psychiatric O
consultation O
and O
the O
Glombock O
Rast O
Sexual B-outcome ['Life-Impact']
Satisfactory I-outcome ['Life-Impact']
Test O
( O
GRISS O
) O
psychiatric O
test O
were O
in O
accordance O
with O
premature O
ejaculation O
. O
['Life-Impact']

LIMITATIONS O
Further O
experimental O
investigations O
are O
needed O
to O
clarify O
the O
specific O
biological O
roles O
played O
by O
HMGB1 O
in O
IL-10-mediated O
regulation O
of O
neuropathic O
pain O
. O
[]

There O
were O
no O
clinical O
predictors O
of O
the O
atrial O
DFT O
. O
[]

Polyunsaturated O
fatty O
acids O
arachidonic O
acid O
( O
ARA O
) O
and O
docosahexaenoic O
acid O
( O
DHA O
) O
may O
have O
key O
role O
in O
brain O
network O
maturation O
. O
[]

After O
the O
induction O
of O
anesthesia O
with O
halothane O
, O
69 O
ambulatory O
surgical O
patients O
( O
1 O
mo O
to O
< O
17 O
yr O
old O
) O
, O
received O
propofol O
without O
EDTA O
( O
n O
= O
33 O
) O
or O
propofol O
with O
EDTA O
( O
n O
= O
36 O
) O
. O
[]

Among O
women O
treated O
with O
goserelin O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
proportion O
of O
menstruating B-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
, O
1 O
year O
after O
completed O
treatment O
compared O
to O
at O
24 O
months O
of O
treatment O
( O
P O
= O
0.006 O
) O
, O
in O
contrast O
to O
all O
other O
treatment O
groups O
, O
who O
were O
unchanged O
or O
more O
often O
amenorrheic B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
glycerol I-outcome ['Physiological-Clinical']
levels O
, O
which O
were O
in O
the O
physiological O
range O
with O
glucose O
as O
the O
osmotic O
agent O
, O
reached O
a O
peak O
80-fold O
greater O
at O
4.3 O
+/- O
0.8 O
mmol/l O
during O
dialysis O
with O
fluid O
containing O
glycerol O
at O
272 O
mmol/l O
and O
eightfold O
higher O
at O
0.42 O
+/- O
0.09 O
mmol/l O
with O
glycerol O
at O
92 O
mmol/l O
. O
['Physiological-Clinical']

The O
randomized O
, O
double-blinded O
, O
crossover O
study O
comprised O
30 O
healthy O
children O
. O
[]

Improved O
responsiveness O
of O
PCOS O
patients O
to O
clomiphene O
after O
CYP17a O
inhibitor O
. O
[]

There O
is O
experimental O
evidence O
to O
suggest O
that O
hypercholesterolaemia O
may O
play O
a O
pathogenetic O
role O
in O
progressive O
glomerular O
injury O
. O
[]

Control O
groups O
received O
a O
similar O
desflurane O
anesthetic O
( O
placebo O
) O
or O
a O
propofol-infusion-based O
( O
active O
control O
) O
anesthetic O
. O
[]

Small-diameter O
hysteroscopy O
with O
Versapoint O
versus O
resectoscopy O
with O
a O
unipolar O
knife O
for O
the O
treatment O
of O
septate O
uterus O
: O
a O
prospective O
randomized O
study O
. O
[]

5.5 O
kg O
, O
age O
: O
24.6 O
? O
[]

V O
diagnosis O
of O
severe O
mental O
illness O
from O
psychiatric O
disability O
from O
10 O
supported O
housing O
facilities O
and O
41 O
of O
their O
caregivers O
participated O
in O
this O
12-month O
study O
during O
2005-2006 O
in O
Sweden O
. O
[]

Results O
. O
[]

METHODS O
Patients O
will O
be O
randomized O
in O
2 O
arms O
. O
[]

RESULTS O
Ninety O
seven O
per O
cent O
of O
subjects O
were O
H B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
positive O
at O
baseline O
, O
and O
53 O
% O
were O
positive O
at O
12 O
years O
. O
['Physiological-Clinical']

Patients O
also O
were O
evaluated O
for O
presence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Thirty-eight O
percent O
of O
women O
receiving O
a O
letter O
and O
study O
information O
from O
their O
physicians O
contacted O
the O
study O
office O
about O
participation O
. O
[]

CONCLUSION O
Early O
acupuncture O
is O
a O
key O
for O
achieving O
the O
best O
therapeutic O
effect O
on O
facial O
paralysis O
. O
[]

INTRODUCTION O
In O
the O
present O
study O
we O
evaluated O
the O
effect O
of O
short-term O
finasteride O
treatment O
on O
microvessel O
density O
( O
MVD O
) O
which O
is O
an O
indicator O
of O
prostatic O
angiogenesis O
in O
patients O
with O
hematuria O
secondary O
to O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
. O
[]

A O
subset O
of O
individuals O
with O
autism O
, O
known O
as O
musical O
savants O
, O
is O
also O
known O
to O
possess O
absolute O
pitch O
. O
[]

At O
12 O
months O
, O
there O
were O
104 O
treated O
patients O
and O
63 O
placebo O
patients O
that O
had O
follow-up O
. O
[]

METHODS O
In O
this O
study O
, O
90 O
medical O
students O
without O
previous O
experience O
in O
laparoscopic O
techniques O
were O
randomly O
assigned O
to O
undergo O
one O
of O
three O
procedures O
: O
CLS O
, O
SPLS O
using O
two O
pre-bent O
instruments O
( O
SPLS-pp O
) O
, O
or O
SPLS O
using O
one O
pre-bent O
and O
one O
straight O
laparoscopic O
instrument O
( O
SPLS-ps O
) O
. O
[]

The O
goal O
of O
this O
pilot O
study O
was O
to O
assess O
the O
feasibility O
of O
using O
oral O
N-acetylcysteine O
( O
NAC O
) O
, O
a O
glutamatergic O
modulator O
and O
an O
antioxidant O
, O
in O
the O
treatment O
of O
behavioral O
disturbance O
in O
children O
with O
autism O
. O
[]

However O
, O
albumen O
height B-outcome ['Physiological-Clinical']
and O
Haugh O
units O
increased O
linearly O
( O
P O
< O
0.01 O
and O
P O
< O
0.05 O
, O
respectively O
) O
as O
choline O
increased O
during O
phase O
2 O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
10 O
term O
infants O
were O
recruited O
after O
parental O
consent O
and O
ethics O
approval O
. O
[]

The O
effect O
of O
lossy O
compression O
on O
the O
sensitivity O
and O
specificity O
for O
detection O
of O
diagnostic O
features O
was O
determined O
. O
[]

Analysis O
of O
deeper O
pockets O
( O
i.e. O
, O
> O
5 O
mm O
at O
baseline O
) O
showed O
the O
same O
relationship O
for O
PPD O
, O
but O
with O
larger O
differences O
between O
groups O
. O
[]

RESULTS O
The O
two O
test O
groups O
were O
demographically O
similar O
. O
[]

The O
effectiveness O
of O
fentanyl O
and O
ketorolac O
in O
providing O
analgesia O
for O
day-case O
gynaecological O
procedures O
was O
evaluated O
in O
55 O
healthy O
volunteers O
in O
a O
single O
blinded O
fashion O
. O
[]

Human O
motor O
responses O
to O
simultaneous O
aversive O
stimulation O
and O
failure O
on O
a O
valued O
task O
. O
[]

Findings O
from O
the O
randomized O
, O
intent-to-treat O
design O
over O
the O
first O
18 O
months O
of O
operations O
show O
virtually O
no O
overall O
impacts O
on O
hospital O
or O
emergency O
room O
( O
ER O
) O
use O
, O
Medicare B-outcome ['Resource-use']
expenditures I-outcome ['Resource-use']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
or O
prescription B-outcome ['Resource-use']
drug I-outcome ['Resource-use']
use I-outcome ['Resource-use']
for O
the O
33,000 O
enrollees O
. O
['Resource-use', 'Life-Impact', 'Resource-use']

CONCLUSIONS O
Oral O
dexamethasone O
therapy O
does O
not O
affect O
the O
clinical O
course O
of O
children O
hospitalized O
with O
bronchiolitis O
and O
therefore O
can O
not O
be O
recommended O
in O
this O
clinical O
situation O
. O
[]

RESULTS O
The O
MCIC B-outcome ['Physiological-Clinical']
of O
the O
PI-NRS O
ranged O
from O
3.5 O
to O
4.7 O
points O
in O
( O
sub O
) O
acute O
patients O
and O
2.5 O
to O
4.5 O
points O
in O
chronic O
patients O
with O
low O
back O
pain O
. O
['Physiological-Clinical']

Teacher O
data O
on O
measures O
of O
autism O
were O
confirmed O
by O
parent O
data O
. O
[]

Influence O
of O
exercise O
training O
on O
leptin B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
stable O
coronary O
artery O
disease O
: O
A O
pilot O
study O
. O
['Physiological-Clinical']

Our O
findings O
suggest O
that O
sulfasalazine O
therapy O
is O
not O
the O
optimal O
anti-inflammatory O
treatment O
for O
reversing O
endothelial O
dysfunction O
in O
cardiovascular O
disease O
. O
[]

CONCLUSIONS O
Administration O
of O
L-arginine O
and O
citrulline O
to O
patients O
with O
HFpEF O
improved O
right O
ventricular O
function O
by O
increasing O
right O
ventricular O
ejection O
fraction O
, O
and O
probably O
decreasing O
systolic O
pulmonary O
artery O
pressure O
. O
[]

Gastric O
emptying O
and O
hormones O
were O
analyzed O
for O
300 O
min O
postmeal O
. O
[]

Acute B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
in O
a O
randomized O
trial O
of O
conventional O
versus O
hypofractionated O
three-dimensional O
conformal O
radiotherapy O
for O
prostate O
cancer O
. O
['Adverse-effects']

METHODS O
Thirty-six O
patients O
with O
COPD O
were O
divided O
into O
trial O
group O
( O
18 O
cases O
) O
and O
control O
group O
( O
18 O
cases O
) O
randomly O
. O
[]

The O
hi-fi O
plug O
was O
somewhat O
better O
than O
foam O
plugs O
, O
and O
the O
custom O
made O
ear O
plug O
provided O
a O
speech B-outcome ['Life-Impact']
intelligibility I-outcome ['Life-Impact']
close O
to O
the O
headset-only O
situation O
. O
['Life-Impact']

RESULTS O
Following O
8 O
weeks O
of O
SXB O
treatment O
, O
study O
patients O
demonstrated O
significant O
dose-related O
increases O
in O
the O
duration O
of O
stage O
3 O
and O
4 O
sleep B-outcome ['Physiological-Clinical']
, O
reaching O
a O
median O
increase O
of O
52.5 O
minutes O
in O
patients O
receiving O
9 O
g O
nightly O
. O
['Physiological-Clinical']

There O
were O
no O
convulsions B-outcome ['Physiological-Clinical']
subsequent O
to O
treatment O
, O
although O
the O
study O
was O
too O
small O
to O
assess O
anticonvulsant O
efficacy O
. O
['Physiological-Clinical']

Whether O
somatostatin O
has O
regulatory O
influence O
on O
melatonin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
man O
has O
never O
been O
unequivocally O
shown O
. O
['Physiological-Clinical']

No O
significant O
change O
in O
the O
ratio O
of O
the O
FEV1 B-outcome ['Physiological-Clinical']
and O
the O
FVC B-outcome ['Physiological-Clinical']
was O
demonstrated O
in O
either O
the O
iopamidol O
or O
the O
sodium O
iothalamate O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Other O
end O
points O
included O
changes O
in O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
weight O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
safety O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

In O
the O
transchoroidal O
needle O
drainage O
procedures O
( O
25 O
eyes O
) O
, O
subretinal B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
occurred O
in O
three O
eyes O
and O
retinal O
incarceration O
in O
one O
. O
['Physiological-Clinical']

Only O
88.1 O
% O
of O
patients O
were O
satisfied B-outcome ['Life-Impact']
by O
the O
open O
method O
compared O
with O
97.6 O
% O
after O
the O
stapled O
technique O
. O
['Life-Impact']

Heparin O
was O
given O
in O
a O
loading O
dose O
of O
15 O
000 O
IU O
and O
a O
maintenance O
dose O
of O
20 O
000-50 O
000 O
IU/day O
. O
[]

RESULTS O
Sixty O
( O
60 O
) O
autistic O
children O
, O
mean O
age O
4.67 O
+/- O
1.82 O
, O
were O
recruited O
. O
[]

We O
conclude O
that O
ofloxacin O
in O
both O
oral O
and O
parenteral O
forms O
is O
an O
effective O
and O
safe O
drug O
in O
the O
treatment O
of O
lower O
respiratory O
tract O
infections O
. O
[]

Index O
of O
biochemistry B-outcome ['Physiological-Clinical']
and O
virology B-outcome ['Physiological-Clinical']
were O
studied O
at O
initial O
and O
post-treatment O
8 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
difference O
in O
the O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
statistically O
different O
( O
P O
= O
.039 O
) O
. O
['Physiological-Clinical']

METHODS O
Nine O
patients O
underwent O
NCE O
4D O
MRA O
for O
the O
evaluation O
of O
DAVF O
in O
the O
transverse O
sinus O
at O
3 O
T. O
One O
patient O
was O
examined O
twice O
, O
once O
before O
and O
once O
after O
the O
interventional O
treatment O
. O
[]

Recent O
advances O
in O
echocardiography O
imaging O
have O
allowed O
sophisticated O
evaluation O
of O
myocardial B-outcome ['Physiological-Clinical']
tissue O
properties O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
between O
the O
active O
treatment O
and O
sham O
groups O
in O
any O
of O
the O
outcome O
measures O
. O
[]

Ibuprofen O
provided O
greater O
temperature B-outcome ['Physiological-Clinical']
decrement I-outcome ['Physiological-Clinical']
and O
longer O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
antipyresis I-outcome ['Resource-use']
than O
acetaminophen O
when O
the O
two O
drugs O
were O
administered O
in O
approximately O
equal O
doses O
. O
['Physiological-Clinical', 'Resource-use']

Effect O
of O
hydrochlorothiazide O
therapy O
on O
cardiac B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
in O
African-American O
men O
with O
systemic O
hypertension O
and O
moderate O
to O
severe O
left O
ventricular O
hypertrophy O
. O
['Physiological-Clinical']

In O
addition O
, O
concomitant O
treatment O
was O
given O
to O
dogs O
presenting O
with O
pulmonary O
oedema O
and/or O
ascites O
, O
supraventricular O
tachyarrhythmia O
and/or O
dilated O
cardiomyopathy O
. O
[]

OBJECTIVE O
To O
determine O
whether O
culture O
at O
a O
more O
physiologically O
cooler O
temperature O
, O
as O
suggested O
by O
limited O
human O
and O
animal O
data O
, O
would O
improve O
blastulation O
and O
pregnancy O
rates O
in O
human O
clinical O
IVF O
. O
[]

With O
the O
15 O
mm O
aperture O
, O
the O
patients O
had O
a O
greater O
breathing B-outcome ['Physiological-Clinical']
frequency O
( O
f O
) O
than O
did O
the O
normal O
subjects O
( O
21 O
+/- O
5 O
[ O
SD O
] O
vs. O
14 O
+/- O
4 O
breaths/min O
, O
P O
less O
than O
0.01 O
) O
as O
well O
as O
a O
smaller O
mean O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
azithromycin O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
erythema O
migrans O
, O
further O
studies O
will O
be O
needed O
to O
determine O
the O
optimal O
dosage O
and O
duration O
of O
therapy O
. O
[]

Laser O
therapy O
combined O
with O
brachytherapy O
for O
the O
palliation O
of O
malignant O
dysphagia O
. O
[]

METHODS O
This O
randomized O
, O
double-blind O
, O
single-dose-escalation O
study O
evaluated O
the O
safety O
, O
pharmacokinetics O
, O
and O
pharmacodynamics O
of O
0.1 O
, O
0.3 O
, O
1 O
, O
3 O
, O
and O
10 O
mg/kg O
ponezumab O
( O
n O
= O
4 O
, O
4 O
, O
4 O
, O
6 O
, O
and O
8 O
, O
respectively O
) O
versus O
placebo O
( O
n O
= O
11 O
) O
after O
a O
2-hour O
intravenous O
infusion O
in O
subjects O
with O
mild-to-moderate O
AD O
. O
[]

In O
both O
study O
arms O
, O
the O
initial O
daily O
tacrolimus O
dose O
was O
0.2 O
mg/kg O
. O
[]

CONCLUSIONS O
For O
patients O
with O
retinitis O
pigmentosa O
beginning O
vitamin O
A O
therapy O
, O
addition O
of O
docosahexaenoic O
acid O
, O
1200 O
mg/d O
, O
slowed O
the O
course O
of O
disease O
for O
2 O
years O
. O
[]

Some O
variation O
was O
found O
in O
the O
fraction O
size O
. O
[]

The O
relative B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
prajmalium O
bitartrate O
from O
the O
tablet O
amounted O
to O
112 O
% O
. O
['Physiological-Clinical']

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
10 O
and O
11.9 O
months O
for O
CP O
and O
cisplatin O
, O
respectively O
( O
non-significant O
) O
. O
['Mortality']

Participants O
in O
both O
groups O
received O
instructions O
and O
demonstration O
on O
the O
use O
of O
the O
devices O
, O
and O
were O
requested O
to O
perform O
the O
respective O
intervention O
twice O
a O
day O
for O
6 O
months O
. O
[]

In O
the O
present O
study O
we O
investigated O
the O
effects O
of O
topical O
agents O
used O
as O
supportive O
care O
to O
minimise O
radiation-induced B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
using O
an O
instrumental O
method O
. O
['Physiological-Clinical']

The O
postoperative B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
( O
diclofenac O
sodium O
) O
was O
significantly O
higher O
in O
group O
1 O
( O
263 O
mg O
) O
than O
in O
group O
2 O
( O
120 O
mg O
; O
P O
= O
0.02 O
) O
. O
['Resource-use']

After O
5 O
years O
, O
the O
cumulative O
risk O
for O
relapse B-outcome ['Physiological-Clinical']
in O
bulky O
sites O
is O
10 O
% O
, O
despite O
40 O
Gy O
of O
radiation O
. O
['Physiological-Clinical']

BACKGROUND O
Compression O
of O
digital O
coronary O
angiograms O
facilitates O
playback O
of O
images O
and O
decreases O
cost O
. O
[]

Two O
patients O
in O
group O
A O
died O
after O
[]

ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
[]

The O
explanation O
may O
be O
part O
that O
BCAH O
preceded O
PTFE O
grafts O
into O
clinical O
use O
, O
and O
inexperience O
in O
the O
operating O
room O
and O
in O
the O
dialysis O
unit O
had O
an O
effect O
on O
BCAH O
results O
. O
[]

Artificial O
tears O
combined O
with O
CC O
reduced O
hyperemia B-outcome ['Physiological-Clinical']
more O
than O
other O
treatments O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
1380 O
families O
approached O
, O
313 O
were O
enrolled O
, O
263 O
were O
excluded O
because O
we O
could O
not O
find O
or O
contact O
a O
family O
member O
( O
FDR O
or O
parent O
) O
, O
331 O
did O
not O
have O
eligible O
family O
members O
, O
and O
473 O
refused O
. O
[]

Outcome O
was O
measured O
at O
12 O
months O
from O
commencement O
of O
intervention O
, O
using O
standardised O
instruments O
. O
[]

Additional O
linear O
radiofrequency O
lesions O
increase O
the O
risk O
of O
ESUL O
development O
. O
[]

Statistical O
analyses O
were O
conducted O
using O
Fisher O
exact O
test O
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
analyzed O
using O
Cox O
modeling O
. O
['Mortality']

Overall O
, O
the O
therapy O
improved O
the O
sleep B-outcome ['Physiological-Clinical']
of O
47 O
children O
and O
was O
effective O
in O
reducing O
family B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
This O
study O
was O
carried O
out O
to O
examine O
the O
efficacy O
of O
a O
12-week O
, O
low-intensity O
( O
1-hour/wk O
of O
therapist O
contact O
) O
, O
parent-delivered O
intervention O
for O
toddlers O
at O
risk O
for O
autism O
spectrum O
disorders O
( O
ASD O
) O
aged O
14 O
to O
24 O
months O
and O
their O
families O
. O
[]

The O
CAPEDP O
project O
, O
involving O
440 O
women O
and O
their O
families O
, O
took O
place O
in O
Paris O
and O
its O
inner O
suburbs O
from O
2006 O
to O
2011 O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
extent O
of O
sensory B-outcome ['Resource-use']
block I-outcome ['Resource-use']
, O
percentage O
of O
patients O
with O
motor O
block B-outcome ['Physiological-Clinical']
or O
incidence O
of O
['Resource-use', 'Physiological-Clinical']

Seventy-eight O
women O
were O
randomized O
to O
receive O
45 O
mg O
of O
hyperbaric O
1.5 O
% O
lidocaine O
with O
or O
without O
10 O
microg O
of O
fentanyl O
. O
[]

One O
vaccine O
contained O
the O
Hib-specific O
capsular O
polysaccharide O
, O
PRP O
; O
the O
second O
vaccine O
contained O
PRP O
combined O
with O
pertussis O
vaccine O
, O
PRP-P. O
A O
third O
vaccine O
, O
DTP O
, O
was O
administered O
to O
a O
control O
group O
for O
each O
age O
. O
[]

METHODS O
A O
prospective O
randomized O
study O
was O
performed O
among O
80 O
patients O
randomly O
assigned O
to O
laparoscopic O
lymphadenectomy O
and O
to O
abdominal O
lymphadenectomy O
in O
the O
treatment O
of O
endometrial O
cancer O
. O
[]

OBJECTIVES O
We O
intended O
to O
investigate O
whether O
ischemic O
preconditioning O
( O
IP O
) O
enhances O
myocardial B-outcome ['Physiological-Clinical']
performance O
in O
patients O
who O
undergo O
off-pump O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
. O
['Physiological-Clinical']

Remission B-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
was O
defined O
as O
a O
24-item O
Hamilton O
Rating O
Scale O
for O
Depression B-outcome ['Life-Impact']
score O
? O
['Life-Impact', 'Life-Impact']

Using O
minimally-invasive O
surgery O
plus O
recombinant O
tissue O
plasminogen O
activator O
( O
rtPA O
) O
, O
MISTIE O
investigators O
explored O
aggressive O
avenues O
to O
treat O
ICH O
. O
[]

The O
use O
of O
trichloroacetic O
acid O
( O
TCA O
) O
as O
a O
periorbital O
and O
eyelid O
peel O
for O
skin O
rejuvenation O
is O
gaining O
significant O
acceptance O
among O
oculoplastic O
surgeons O
, O
dermatologists O
, O
and O
other O
surgery O
groups O
. O
[]

PATIENTS O
AND O
METHODS O
We O
used O
data O
from O
EORTC O
22881-10882 O
trial O
, O
with O
median O
follow-up O
of O
77.4 O
months O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
between O
the O
drug O
groups O
for O
the O
measured O
variables O
in O
either O
the O
parallel O
or O
crossover O
phase O
of O
the O
study O
. O
[]

INTERPRETATION O
Use O
of O
aspergillus O
galactomannan O
and O
PCR O
to O
direct O
treatment O
reduced O
use O
of O
empirical O
antifungal O
treatment O
. O
[]

RESULTS O
The O
self-reported O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
various I-outcome ['Life-Impact']
methods I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
was O
low O
. O
['Life-Impact']

Non-inferiority O
was O
defined O
as O
an O
upper O
95 O
% O
confidence O
limit O
( O
CL O
) O
for O
the O
difference O
in O
success O
of O
eradication O
in O
the O
amoxicillin O
and O
penicillin O
V O
treatment O
groups O
of O
< O
or=10 O
% O
. O
[]

In O
a O
double-blind O
study O
, O
24 O
CAPD O
patients O
with O
LVH O
[ O
left O
ventricular O
mass O
index O
( O
LVMi O
) O
> O
110 O
g/m2 O
for O
women O
and O
LVMi O
> O
137 O
g/m2 O
for O
men O
] O
were O
randomized O
to O
12 O
months O
' O
administration O
of O
either O
the O
ARB O
valsartan O
( O
n O
= O
14 O
) O
or O
a O
placebo O
( O
n O
= O
10 O
) O
. O
[]

After O
a O
therapeutic O
wash-out O
period O
corresponding O
to O
5 O
times O
the O
half-life O
of O
previous O
anti-arrhythmic O
drugs O
, O
patients O
with O
more O
than O
100 O
premature O
ventricular O
contractions O
( O
PVC O
) O
per O
hour O
in O
two O
24 O
hour O
Holter O
records O
obtained O
at O
an O
interval O
of O
7 O
days O
were O
treated O
in O
succession O
and O
after O
randomised O
by O
C O
( O
390 O
mg/day O
in O
3 O
divided O
doses O
) O
and O
P O
( O
900 O
mg/day O
in O
3 O
divided O
doses O
) O
for O
a O
period O
of O
two O
weeks O
, O
each O
active O
sequence O
being O
followed O
by O
a O
two O
week O
wash-out O
period O
. O
[]

The O
children O
tolerated O
well O
a O
daily O
intake O
of O
2 O
g O
of O
GOS O
. O
[]

Naltrexone O
, O
1.0 O
mg/kg O
, O
was O
given O
daily O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
design O
. O
[]

Preoperative O
irradiation O
versus O
the O
use O
of O
nonsteroidal O
anti-inflammatory O
drugs O
for O
prevention O
of O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
following O
total O
hip O
replacement O
: O
the O
results O
of O
a O
randomized O
trial O
. O
['Physiological-Clinical']

The O
tracheal O
tube O
was O
advanced O
into O
the O
nasal O
cavity O
and O
passed O
into O
the O
pharynx O
without O
CTSC O
guidance O
. O
[]

Continuous O
cediranib O
therapy O
was O
associated O
with O
sustained O
antivascular O
effects O
up O
to O
16 O
weeks O
, O
with O
significant O
reductions O
in O
DCE-MRI B-outcome ['Physiological-Clinical']
parameters O
and O
CT B-outcome ['Physiological-Clinical']
EnF I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
AND O
SETTING O
Forty-seven O
patients O
( O
> O
/=70 O
years O
old O
) O
with O
the O
diagnosis O
of O
unilateral O
posterior O
semicircular O
canal O
BPPV O
formed O
the O
study O
population O
. O
[]

CONCLUSIONS O
Two O
out O
of O
three O
indicators O
for O
acceptance-satisfaction B-outcome ['Life-Impact']
and O
dropout O
attrition-provide O
comparable O
results O
between O
the O
Internet-based O
training O
and O
a O
face-to-face O
group O
training O
. O
['Life-Impact', 'Life-Impact']

Before O
and O
3 O
months O
after O
treatment O
, O
a O
nutritional O
and O
biochemical O
study O
was O
performed O
. O
[]

PURPOSE O
To O
determine O
the O
effectiveness O
of O
a O
multicomponent O
clinical O
intervention O
to O
reduce O
pain O
in O
outpatients O
with O
cancer O
. O
[]

Coronary O
sinus O
release O
of O
creatinine B-outcome ['Physiological-Clinical']
phosphokinase-MB I-outcome ['Physiological-Clinical']
5 O
minutes O
after O
reperfusion O
was O
significantly O
less O
in O
group O
II O
( O
1.65 O
EU/min O
) O
than O
in O
group O
I O
( O
3.83 O
units/min O
; O
p O
= O
0.05 O
) O
. O
['Physiological-Clinical']

Three O
investigations O
were O
included O
in O
each O
of O
three O
treatment O
periods O
. O
[]

Rates O
of O
drug B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
self-report I-outcome ['Life-Impact']
were O
highest O
in O
the O
workplace O
interview O
condition O
and O
lowest O
in O
the O
overall O
group O
questionnaire O
condition O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
Two O
hundred O
eighty-eight O
cancer O
patients O
, O
referred O
to O
complementary O
therapy O
services O
with O
clinical O
anxiety O
and/or O
depression O
, O
were O
allocated O
randomly O
to O
a O
course O
of O
aromatherapy O
massage O
or O
usual O
supportive O
care O
alone O
. O
[]

For O
each O
specific O
documentation O
element O
, O
a O
GEE O
model O
gave O
p-values O
of O
> O
0.2 O
in O
independent O
tests O
, O
indicating O
no O
evidence O
of O
significant O
change O
in O
documentation O
after O
the O
intervention O
. O
[]

For O
prediction O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
at O
180 O
days O
, O
the O
model O
c-index O
using O
all O
variables O
was O
0.72 O
and O
for O
the O
simplified O
model O
, O
also O
0.72 O
. O
['Mortality']

Effects O
of O
ezetimibe O
, O
a O
new O
cholesterol O
absorption O
inhibitor O
, O
on O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
patients O
with O
primary O
hypercholesterolemia O
. O
['Physiological-Clinical']

Both O
medicaments O
excerted O
an O
identical O
analgetic O
efficiency O
. O
['Physiological-Clinical']

Analysis O
of O
the O
results O
in O
relation O
to O
stone O
location O
showed O
that O
the O
two O
treatment O
groups O
were O
comparable O
for O
upper O
and O
middle O
ureteric O
calculi O
. O
[]

A O
second O
dose O
of O
ZV O
was O
generally O
safe O
, O
but O
did O
not O
boost O
VZV-specific O
immunity O
beyond O
levels O
achieved O
postdose O
1 O
. O
[]

METHODS O
Volunteers O
with O
H. O
pylori O
infection O
( O
by O
13C-urea O
breath O
test O
) O
were O
randomly O
assigned O
to O
2-week O
treatment O
regimens O
. O
[]

Approval O
summary O
: O
imatinib O
mesylate B-outcome ['Physiological-Clinical']
in O
the O
treatment O
of O
metastatic O
and/or O
unresectable O
malignant O
gastrointestinal B-outcome ['Physiological-Clinical']
stromal I-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Increased O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
is O
associated O
with O
increased O
breast O
cancer O
risk O
and O
reduced O
sensitivity O
of O
screening O
mammography O
and O
is O
related O
to O
hormone O
exposure O
. O
['Physiological-Clinical']

METHODS O
The O
trial O
was O
a O
prospective O
, O
8-week O
, O
double O
blind O
study O
of O
parallel O
groups O
of O
patients O
with O
chronic O
schizophrenia O
. O
[]

In O
the O
early O
stages O
of O
the O
trial O
, O
a O
relatively O
large O
number O
of O
discrepancies O
( O
29-37 O
% O
) O
were O
identified O
on O
central O
review O
. O
[]

RESULTS O
Malnutrition B-outcome ['Physiological-Clinical']
was O
present O
in O
55 O
% O
of O
the O
patients O
, O
with O
19 O
% O
of O
the O
patients O
severely O
malnourished O
. O
['Physiological-Clinical']

Short-term O
metformin O
treatment O
for O
clomiphene O
citrate-resistant O
women O
with O
polycystic O
ovary O
syndrome O
. O
[]

In O
this O
group O
, O
APC O
correctly O
predicted O
positive O
response O
to O
interferon B-outcome ['Resource-use']
in O
75 O
% O
of O
cases O
. O
['Resource-use']

Endoscopic O
ligation O
compared O
with O
sclerotherapy O
for O
bleeding B-outcome ['Physiological-Clinical']
esophageal I-outcome ['Physiological-Clinical']
varices I-outcome ['Physiological-Clinical']
in O
children O
with O
extrahepatic O
portal O
venous O
obstruction O
. O
['Physiological-Clinical']

Randomized O
Phase O
II O
trial O
assessing O
estramustine O
and O
vinblastine O
combination O
chemotherapy O
vs O
estramustine O
alone O
in O
patients O
with O
progressive O
hormone-escaped O
metastatic O
prostate O
cancer O
. O
[]

Six O
of O
the O
seven O
secondary B-outcome ['Physiological-Clinical']
efficacy O
measures O
( O
total O
comedones B-outcome ['Physiological-Clinical']
, O
open B-outcome ['Physiological-Clinical']
comedones I-outcome ['Physiological-Clinical']
, O
closed B-outcome ['Physiological-Clinical']
comedones B-outcome ['Physiological-Clinical']
, O
papules B-outcome ['Physiological-Clinical']
, O
pustules B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Between O
60 O
% O
and O
80 O
% O
of O
patients O
who O
undergo O
mastectomy O
( O
with O
axillary O
dissection O
) O
experience O
PONV B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
secondary O
endpoints O
of O
time O
to O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
quality O
of O
life O
. O
['Mortality', 'Physiological-Clinical']

RESULTS O
Cigarette B-outcome ['Life-Impact']
, O
cigar B-outcome ['Life-Impact']
, O
or O
pipe B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
at O
each O
time O
interval O
correlated O
with O
significantly O
increased O
caloric B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
in O
males O
but O
not O
in O
females O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
Generic O
discharge O
screens O
based O
on O
inadequate O
discharge O
planning O
, O
[]

Comparison O
of O
non-invasive O
methods O
for O
the O
assessment O
of O
haemodynamic O
drug O
effects O
in O
healthy O
male O
and O
female O
volunteers O
: O
sex O
differences O
in O
cardiovascular O
responsiveness O
. O
[]

Allogeneic O
peripheral O
blood O
stem O
cell O
grafts O
contain O
about O
10 O
times O
more O
T O
and O
B O
cells O
than O
marrow O
grafts O
. O
[]

Female O
students O
in O
girls O
' O
schools O
were O
more O
likely O
to O
use B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
addictively I-outcome ['Life-Impact']
than O
those O
in O
coeducational O
schools O
. O
['Life-Impact']

Using O
a O
laryngeal O
tube O
suction-device O
( O
LTS-D O
) O
reduces O
the O
no O
flow B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
a O
single O
rescuer O
manikin O
study O
. O
['Physiological-Clinical']

Pretreatment O
with O
valproate O
as O
compared O
to O
placebo O
reduced O
the O
velocity B-outcome ['Physiological-Clinical']
in O
both O
middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Peroxisome O
proliferator-activated O
receptor-gamma O
( O
PPAR O
gamma O
) O
agonists O
( O
thiazolidinediones O
[ O
TZDs O
] O
) O
are O
used O
for O
the O
treatment O
of O
diabetes O
. O
[]

In O
those O
infected O
at O
birth O
, O
response O
rates O
are O
lower O
. O
[]

Cytokines O
released O
by O
injured O
endothelium O
promote O
vascular O
interactions O
with O
leukocytes O
and O
platelets O
. O
[]

STUDY O
OBJECTIVE O
We O
determine O
the O
efficacy O
of O
prophylactic O
phenytoin O
in O
preventing O
early O
posttraumatic O
seizures O
in O
children O
with O
moderate O
to O
severe O
blunt O
head O
injury O
. O
[]

Some O
patient O
variables O
were O
associated O
with O
delayed B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
or O
ulcer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

QUESTIONS/PURPOSES O
We O
studied O
different O
dosages O
, O
timings O
, O
and O
modes O
of O
administration O
to O
identify O
the O
most O
effective O
regimen O
of O
tranexamic O
acid O
in O
achieving O
maximum O
reduction O
of O
blood O
loss O
in O
TKA O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
Intraperitoneal O
administration O
of O
a O
local O
anaesthetic O
in O
combination O
with O
an O
opioid O
, O
for O
the O
relief O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
has O
already O
been O
reported O
except O
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

Beneficial O
recovery O
of O
microvascular O
organ O
perfusion O
could O
partly O
explain O
the O
perioperative O
advantages O
reported O
for O
MECC O
. O
[]

Evaluation O
of O
oral O
beclomethasone O
dipropionate O
for O
prevention O
of O
acute O
graft-versus-host O
disease O
. O
[]

The O
effects O
of O
10 O
weeks O
of O
either O
treatment O
on O
endothelium-dependent O
and O
independent O
vasodilation O
of O
forearm O
resistance O
vessels O
was O
assessed O
by O
plethysmography O
. O
[]

A O
tendency O
toward O
improved O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
apparent O
among O
patients O
treated O
with O
chemotherapy O
( O
P O
= O
0.018 O
) O
, O
but O
there O
was O
no O
statistically O
significant O
improvement O
in O
overall B-outcome ['Mortality']
actuarial I-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
= O
0.46 O
) O
. O
['Mortality', 'Mortality']

The O
overall B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
infant I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
increased O
during O
medium O
intervention O
when O
compared O
to O
the O
control O
group O
. O
['Life-Impact']

These O
results O
suggest O
that O
the O
haloperidol O
doses O
used O
in O
clinical O
practice O
may O
be O
higher O
than O
necessary O
. O
[]

Griseofulvin O
( O
n O
= O
20 O
) O
was O
tested O
in O
a O
randomized O
double-blind O
study O
versus O
placebo O
( O
m O
= O
19 O
) O
during O
one O
year O
in O
patients O
with O
rheumatoid O
arthritis O
of O
mild-moderate O
activity O
. O
[]

However O
, O
there O
does O
appear O
to O
be O
a O
significant O
lens-solution B-outcome ['Physiological-Clinical']
effect O
on O
volunteers O
' O
discomfort O
scores O
, O
with O
LR O
having O
significantly O
lower O
discomfort O
scores O
when O
used O
for O
ocular O
irrigation O
with O
the O
MTL O
. O
['Physiological-Clinical']

Two O
hundred O
and O
twenty-nine O
adult O
patients O
with O
differentiated O
thyroid O
cancer O
requiring O
radioiodine O
WBS O
were O
studied O
. O
[]

Compared O
to O
the O
non-screened O
, O
a O
higher O
proportion O
of O
screened B-outcome ['Resource-use']
individuals O
were O
women O
( O
OR=4.51 O
; O
CI O
: O
4.28-4.75 O
) O
, O
lived O
in O
better O
housing O
( O
OR=1.35 O
; O
CI O
: O
1.25-1.41 O
) O
, O
had O
television/radio O
( O
OR=1.50 O
; O
CI O
: O
1.43-1.58 O
) O
and O
were O
tobacco O
and O
alcohol O
users O
( O
OR=2.75 O
; O
CI O
: O
2.57-2.95 O
) O
. O
['Resource-use']

This O
disparity O
may O
, O
in O
part O
, O
reflect O
more O
miscommunication O
between O
minority O
patients O
and O
their O
physicians O
. O
[]

Taken O
together O
, O
these O
data O
show O
that O
the O
combination O
of O
nifedipine O
+ O
chlorthalidone O
does O
not O
exert O
any O
additive B-outcome ['Resource-use']
antihypertensive I-outcome ['Resource-use']
effect O
compared O
with O
nifedipine O
alone O
. O
['Resource-use']

As O
calcium O
is O
important O
in O
the O
regulation O
of O
gastric O
acid O
secretion O
and O
gastrin O
release O
, O
we O
have O
examined O
the O
effect O
of O
the O
calcium O
antagonist O
nifedipine O
on O
these O
processes O
in O
man O
. O
[]

Ten O
healthy O
males O
and O
ten O
healthy O
females O
aged O
21.5 O
+/- O
3.2 O
years O
( O
mean O
+/- O
s O
) O
participated O
in O
the O
study O
, O
which O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
sensory O
level-high O
volt O
pulsed O
electrical O
current O
( O
HVPC O
) O
on O
delayed-onset B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
soreness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DOMS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Of O
55 O
patients O
in O
the O
chemotherapy O
arm O
, O
four O
( O
7 O
% O
) O
had O
a O
complete O
response O
( O
CR O
) O
and O
23 O
( O
42 O
% O
) O
a O
partial O
response O
( O
PR O
) O
following O
the O
induction O
regimen O
. O
[]

In O
phase O
2 O
, O
49 O
participants O
were O
randomly O
assigned O
in O
a O
double-blind O
design O
to O
receive O
an O
additional O
6 O
rounds O
of O
either O
DMSA O
or O
placebo O
. O
[]

In O
these O
syndromes O
urinary O
peptide O
abnormalities O
, O
derived O
from O
gluten O
, O
gliadin O
, O
and O
casein O
, O
are O
reported O
. O
[]

PURPOSE O
This O
study O
examined O
short-term O
predictive O
associations O
between O
5 O
different O
types O
of O
parent O
verbal O
responsiveness O
and O
later O
spoken O
vocabulary O
for O
32 O
young O
children O
with O
a O
confirmed O
diagnosis O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Parameters O
were O
determined O
before O
the O
treatment O
, O
at O
the O
end O
of O
the O
eighth O
week O
course O
of O
treatment O
( O
week O
8 O
) O
, O
and O
eighth O
( O
week O
8 O
) O
after O
the O
end O
of O
treatment O
. O
[]

Women O
in O
group O
1 O
( O
n O
= O
12 O
cycles O
) O
received O
no O
stimulation O
and O
women O
in O
group O
2 O
( O
n O
= O
24 O
cycles O
) O
received O
150 O
iu O
recombinant O
FSH O
day O
( O
-1 O
) O
for O
3 O
days O
, O
initiated O
on O
day O
3 O
after O
menstruation O
. O
[]

A O
standard O
CBT O
program O
was O
augmented O
with O
multiple O
treatment O
components O
designed O
to O
accommodate O
or O
remediate O
the O
social O
and O
adaptive O
skill O
deficits O
of O
children O
with O
ASD O
that O
could O
pose O
barriers O
to O
anxiety B-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
We O
conducted O
a O
single-blind O
, O
unmatched O
, O
cluster-randomized O
intervention O
trial O
involving O
1718 O
children O
, O
9 O
to O
10 O
years O
of O
age O
, O
in O
38 O
schools O
over O
the O
course O
of O
1 O
school O
year O
. O
[]

Effects O
of O
soy O
intake O
on O
sex B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
premenopausal O
women O
. O
['Physiological-Clinical']

A O
significant O
survival B-outcome ['Mortality']
benefit O
was O
identified O
at O
study O
completion O
in O
the O
pre-defined O
sub-group O
of O
123 O
patients O
who O
had O
received O
prior O
chemotherapy O
( O
P=0.045 O
, O
hazard O
ratio=1.53 O
( O
1.00-2.34 O
) O
) O
. O
['Mortality']

Controlled-release O
melatonin O
, O
singly O
and O
combined O
with O
cognitive O
behavioural O
therapy O
, O
for O
persistent O
insomnia B-outcome ['Physiological-Clinical']
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

LIMITATIONS O
The O
study O
addressed O
only O
IFN-alpha O
and O
chronic O
psoriatic O
lesions O
. O
[]

or O
piperacillin O
12 O
g/day O
plus O
tazobactam O
1.5 O
g/day O
( O
4 O
g+0.5 O
g O
t.i.d O
. O
) O
[]

The O
pre-embolization O
therapy O
goals O
were O
determined O
in O
terms O
of O
the O
number O
of O
pedicles O
to O
be O
embolized O
and O
the O
percent O
of O
nidus O
reduction O
expected O
. O
[]

The O
mean O
decrease O
in O
inflammatory B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
from O
baseline O
to O
cycle O
6 O
was O
11.8 O
( O
62.0 O
% O
) O
versus O
7.6 O
( O
38.6 O
% O
) O
( O
p O
= O
0.0001 O
) O
, O
and O
the O
mean O
decrease O
in O
total O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
was O
29.1 O
( O
53.1 O
% O
) O
versus O
14.1 O
( O
26.8 O
% O
) O
( O
p O
= O
0.0001 O
) O
in O
the O
OC O
and O
placebo O
groups O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Care O
managers O
received O
supervision O
from O
a O
psychiatrist O
. O
[]

When O
the O
results O
obtained O
with O
a O
particularly O
promising O
new O
drug O
or O
procedure O
are O
presented O
early O
in O
the O
course O
of O
study O
( O
within O
1-2 O
years O
) O
, O
the O
investigators O
should O
strongly O
consider O
a O
repeat O
evaluation O
after O
an O
additional O
3-5 O
years O
of O
follow-up O
. O
[]

Analyses O
of O
the O
data O
by O
the O
Reliable B-outcome ['Life-Impact']
Change I-outcome ['Life-Impact']
Index O
indicated O
improvement O
of O
clinical O
significance O
occurred O
in O
non-verbal B-outcome ['Life-Impact']
areas I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Comparison O
of O
0.25 O
% O
S O
( O
- O
) O
-bupivacaine O
with O
0.25 O
% O
RS-bupivacaine O
for O
epidural O
analgesia B-outcome ['Resource-use']
in O
labour O
. O
['Resource-use']

METHODS O
Each O
study O
phase O
lasted O
three O
weeks O
. O
[]

Treatment O
of O
bladder O
cancer O
with O
intravesical O
instillation O
of O
adriamycin O
. O
[]

AIM O
To O
evaluate O
CDP571 O
, O
a O
humanized O
antibody O
to O
tumour O
necrosis O
factor-alpha O
, O
for O
the O
treatment O
of O
steroid-dependent O
Crohn O
's O
disease O
. O
[]

METHODS O
Randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
patients O
( O
n=209 O
MG O
, O
n=96 O
placebo O
) O
with O
UC O
in O
remission O
[ O
revised O
Sutherland O
Disease B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Index O
( O
['Physiological-Clinical']

The O
efficacy O
and O
safety O
of O
esmolol O
, O
a O
short-acting O
intravenous O
beta-adrenergic-blocking O
agent O
, O
and O
placebo O
were O
compared O
in O
patients O
with O
supraventricular O
tachyarrhythmias O
( O
heart O
rate O
greater O
than O
120 O
bpm O
) O
in O
a O
multicenter O
, O
double-blind O
, O
partial-crossover O
study O
. O
[]

Altered O
shear-induced O
pathway O
. O
[]

Although O
melatonin O
and O
cognitive-behavioural O
therapy O
have O
shown O
efficacy O
in O
treating O
sleep O
disorders O
in O
children O
with O
autism O
spectrum O
disorders O
, O
little O
is O
known O
about O
their O
relative O
or O
combined O
efficacy O
. O
[]

Remission O
in O
rheumatoid B-outcome ['Physiological-Clinical']
arthritis I-outcome ['Physiological-Clinical']
patients O
treated O
with O
etanercept O
monotherapy O
: O
clinical O
practice O
and O
clinical O
trial O
experience O
. O
['Physiological-Clinical']

RESULTS O
Early B-outcome ['Physiological-Clinical']
reactivation I-outcome ['Physiological-Clinical']
occurred O
in O
14 O
of O
the O
107 O
patients O
who O
received O
heparin O
alone O
, O
as O
compared O
with O
only O
5 O
patients O
in O
each O
of O
the O
other O
three O
study O
groups O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Patients O
were O
recruited O
from O
December O
2005 O
to O
September O
2006 O
, O
and O
both O
groups O
were O
followed O
for O
8 O
months O
. O
[]

A O
double-blinded O
protocol O
was O
used O
to O
investigate O
the O
patients O
at O
baseline O
and O
one O
month O
after O
recovery O
with O
the O
stimulator O
turned O
on O
and O
off O
( O
1-month O
periods O
) O
. O
[]

We O
investigated O
subpopulations O
of O
T O
lymphocytes B-outcome ['Physiological-Clinical']
, O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
number I-outcome ['Physiological-Clinical']
and O
cytotoxic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
14 O
chronic O
uremic O
patients O
on O
regular O
hemodialysis O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
compared O
side-effect B-outcome ['Adverse-effects']
profiles O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact']

Pairwise O
comparisons O
showed O
the O
mitomycin O
protocol O
with O
short-term O
intensive O
( O
weekly O
) O
combined O
with O
long-term O
maintenance O
instillation O
to O
have O
a O
highly O
beneficial O
effect O
compared O
to O
long-term O
maintenance O
instillation O
only O
especially O
for O
patients O
entering O
the O
study O
with O
recurrent O
tumors O
( O
RR O
= O
0.06 O
, O
95 O
% O
CI O
: O
[ O
0.008 O
, O
0.506 O
] O
. O
[]

Differential O
response O
of O
seven O
subjects O
with O
autistic O
disorder O
to O
clomipramine O
and O
desipramine O
. O
[]

RESULTS O
after O
statistical O
analysis O
it O
was O
observed O
that O
there O
was O
a O
greater O
development O
in O
the O
total O
scores O
and O
in O
the O
areas O
of O
language B-outcome ['Life-Impact']
, O
psycho-social B-outcome ['Life-Impact']
and O
relational B-outcome ['Life-Impact']
for O
the O
TG O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Comparison O
of O
tocainide O
and O
prajmalium O
bitartrate O
for O
the O
treatment O
of O
ventricular O
arrhythmias O
. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
largely O
gastrointestinal B-outcome ['Physiological-Clinical']
( O
n O
= O
30 O
) O
and O
hematologic B-outcome ['Physiological-Clinical']
( O
n O
= O
24 O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Free O
radical-induced O
oxidative O
damage O
is O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
diseases O
associated O
with O
cigarette O
smoking O
. O
[]

UNLABELLED O
We O
evaluated O
the O
preemptive O
analgesic O
effect O
of O
a O
small O
dose O
of O
ketamine O
given O
before O
or O
immediately O
after O
surgery O
in O
a O
randomized O
, O
double-blinded O
study O
performed O
in O
128 O
women O
undergoing O
total O
mastectomy O
. O
[]

The O
appearance O
during O
treatment O
of O
febrile B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
( O
RR O
11.5 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
RR O
2.5 O
) O
, O
bullous B-outcome ['Physiological-Clinical']
eruptions I-outcome ['Physiological-Clinical']
( O
RR O
4.5 O
) O
and O
systolic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
( O
RR O
2.6 O
) O
were O
associated O
with O
an O
increased O
risk O
for O
the O
occurrence O
of O
encephalopathic O
syndromes O
especially O
of O
the O
coma O
type O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
These O
findings O
indicate O
that O
moderate-to-high O
doses O
of O
ICSs O
result O
in O
an O
increased O
incidence O
of O
easy B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
and O
impairment O
in O
skin B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
in O
middle-aged O
to O
elderly O
persons O
with O
COPD O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
was O
terminated O
on O
recommendation O
of O
the O
Policy O
and O
Data O
Monitoring O
Board O
9 O
months O
before O
the O
scheduled O
closing O
date O
. O
[]

The O
swimmers O
performed B-outcome ['Life-Impact']
substantially O
better O
in O
evenings O
versus O
mornings O
and O
in O
competition O
versus O
training O
. O
['Life-Impact']

The O
purpose O
of O
the O
double-blind O
study O
was O
the O
demonstration O
of O
possible O
effects O
on O
the O
cellular B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
as O
determined O
by O
quantitative B-outcome ['Resource-use']
flow I-outcome ['Resource-use']
cytometry I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

The O
double-blind O
, O
placebo-controlled O
trial O
was O
of O
eight O
weeks O
' O
duration O
and O
included O
127 O
patients O
, O
randomized O
in O
two O
groups O
. O
[]

OBJECTIVE O
To O
describe O
and O
evaluate O
long-term O
efficacy O
( O
18 O
months O
from O
the O
end O
of O
treatment O
) O
of O
a O
new O
cognitive O
short-term O
weight O
reducing O
treatment O
program O
for O
obese O
patients O
. O
[]

The O
two O
groups O
were O
well O
matched O
for O
age O
, O
sex O
, O
stone O
size O
, O
stone O
laterality O
, O
and O
number O
of O
previous O
renal O
procedures O
. O
[]

Prostaglandins O
( O
PGs O
) O
of O
the O
E-type O
are O
potent O
vasodilators O
in O
most O
species O
and O
in O
most O
vascular O
beds O
. O
[]

This O
procedure O
is O
associated O
with O
significantly O
less O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
shorter O
hospitalization B-outcome ['Resource-use']
; O
however O
, O
it O
is O
associated O
with O
significantly O
longer O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

After O
clinical O
exclusion O
of O
symptomatic O
headache O
4 O
weeks O
were O
documented O
by O
means O
of O
a O
migraine O
diary O
. O
[]

DESIGN O
This O
study O
was O
designed O
as O
within-subject O
, O
quasi-experimental O
research O
. O
[]

The O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
training I-outcome ['Resource-use']
was O
the O
equivalent O
of O
about O
one O
hour O
of O
nursing O
aide O
time O
per O
patient O
day O
. O
['Resource-use']

This O
Phase O
II O
study O
has O
been O
undertaken O
to O
establish O
the O
efficacy O
and O
safety O
of O
ebrotidine O
, O
administered O
in O
four O
dosages O
as O
a O
single O
evening O
dose O
versus O
placebo O
in O
the O
treatment O
of O
duodenal O
ulcer O
. O
[]

A O
randomized O
controlled O
trial O
recently O
demonstrated O
that O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
effectively O
decreases O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
children O
presenting O
to O
Ghanaian O
district O
hospitals O
with O
respiratory O
distress O
. O
['Physiological-Clinical']

OUTCOME O
MEASURES O
Four O
10-cm O
visual O
analogue O
scales O
( O
VAS O
) O
were O
used O
to O
measure O
menstrual B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
, O
daily B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
, O
and I-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
intercourse I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
; O
these O
measurements O
were O
recorded O
weekly O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
On O
first O
month O
and O
first O
year O
follow O
up O
between O
the O
groups O
, O
there O
was O
no O
significant O
statistical O
difference O
in O
I-PSS B-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
average O
flow B-outcome ['Physiological-Clinical']
, O
residual O
urine B-outcome ['Physiological-Clinical']
and O
size O
of O
the O
prostate B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

High-pressure O
, O
rapid-inflation O
pneumatic O
compression O
may O
offer O
additional O
protection O
from O
thrombotic O
complications O
on O
the O
basis O
of O
an O
improved O
hemodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
both O
in O
healthy O
volunteers O
and O
in O
patients O
who O
were O
post-thrombotic O
. O
['Physiological-Clinical']

The O
incremental B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
per O
life-year O
saved O
( O
LYS O
) O
was O
3205 O
at O
the O
European O
level O
; O
in O
the O
individual O
countries O
the O
cost O
per O
LYS O
ranged O
between O
3091 O
and O
3331 O
. O
['Resource-use']

No O
significant O
differences O
were O
found O
between O
the O
two O
groups O
for O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
redness B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
postoperatively O
( O
P O
= O
0.609 O
and O
P O
= O
0.123 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
central B-outcome ['Physiological-Clinical']
IBS I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
improved O
substantially O
from O
treatment O
in O
both O
studies O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
educational O
interventions O
studied O
did O
not O
improve O
ED O
documentation O
of O
cases O
of O
possible O
physical O
child O
abuse O
. O
[]

High-sensitivity O
C-reactive O
protein O
( O
hs-CRP O
) O
and O
total O
antioxidant O
( O
TA O
) O
inflammatory O
and O
antioxidative O
markers O
were O
measured O
after O
2 O
months O
. O
[]

The O
short O
period O
of O
this O
trial O
limits O
inferences O
about O
adverse O
effects O
such O
as O
tardive O
dyskinesia O
. O
[]

METHOD O
Twenty-four O
children O
with O
autism O
, O
3.0 O
to O
8.3 O
years O
old O
( O
mean O
5.1 O
) O
who O
were O
living O
at O
home O
and O
attending O
appropriate O
school O
programs O
, O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
trial O
. O
[]

The O
haemoglobin B-outcome ['Physiological-Clinical']
level O
was O
significantly O
higher O
( O
p=0.0069 O
) O
during O
and O
after O
the O
perfusion O
in O
the O
ECC.O O
group O
. O
['Physiological-Clinical']

However O
, O
in O
the O
made-in-Japan O
scenario O
condition O
, O
European O
Americans O
were O
less O
accurate O
than O
were O
Asian O
Americans O
. O
[]

OBJECTIVE O
Up O
to O
87 O
% O
of O
patients O
with O
whiplash O
associated O
disorder O
( O
WAD O
) O
have O
some O
degree O
of O
muscle O
spasm O
that O
is O
contributory O
to O
both O
pain O
and O
dysfunction O
. O
[]

Treatment O
with O
clindamycin-BPO O
2.5 O
% O
gel O
significantly O
improved O
participant-reported O
[]

A O
limited O
number O
of O
studies O
have O
used O
a O
double O
blind O
approach O
to O
evaluate O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
in O
the O
treatment O
of O
diabetic O
ulcers O
. O
[]

The O
sVLPD O
is O
a O
vegan O
diet O
( O
35 O
kcal O
; O
proteins O
, O
0.3 O
g/kg O
body O
weight O
daily O
) O
supplemented O
with O
keto-analogues O
, O
amino O
acids O
, O
and O
vitamins O
. O
[]

However O
, O
kidney O
disease O
results O
in O
elevated O
BNP O
levels O
independently O
of O
CHF O
. O
[]

TSAb B-outcome ['Physiological-Clinical']
was O
undetectable O
in O
24/55 O
patients O
at O
the O
end O
of O
treatment O
. O
['Physiological-Clinical']

We O
evaluated O
whether O
an O
educational O
intervention O
that O
was O
effective O
in O
reducing O
childhood O
diarrhea O
also O
improved O
childhood B-outcome ['Physiological-Clinical']
nutritional I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Reactogenicity O
events O
were O
monitored O
for O
11 O
days O
after O
each O
dose O
. O
[]

Three O
undertook O
the O
pilot O
study O
, O
33 O
were O
allocated O
to O
three O
groups O
: O
no O
screening O
( O
control O
) O
, O
screening O
followed O
by O
intensive O
treatment O
( O
IT O
) O
and O
screening O
plus O
routine O
care O
( O
RC O
) O
in O
an O
unbalanced O
( O
1:3:3 O
) O
randomisation O
. O
[]

Atropine O
decreased O
LOSP B-outcome ['Physiological-Clinical']
significantly O
at O
5 O
min O
after O
i.v O
. O
['Physiological-Clinical']

RESULTS O
Results O
showed O
no O
significant O
differences O
between O
the O
two O
groups O
in O
mean O
and O
maximum B-outcome ['Physiological-Clinical']
VPA I-outcome ['Physiological-Clinical']
, O
nor O
in O
latency O
of O
['Physiological-Clinical']

We O
conclude O
that O
Grenz O
ray O
therapy O
is O
a O
useful O
treatment O
modality O
for O
scalp B-outcome ['Physiological-Clinical']
psoriasis I-outcome ['Physiological-Clinical']
, O
but O
that O
the O
addition O
of O
a O
topical O
corticosteroid O
has O
only O
a O
minor O
effect O
. O
['Physiological-Clinical']

Improvement O
was O
rated O
by O
a O
blinded O
independent O
evaluator O
. O
[]

METHODS O
Nine O
patients O
, O
with O
two O
comparable O
Class O
II O
furcation O
defects O
were O
included O
in O
the O
study O
. O
[]

In O
man O
, O
however O
, O
routine O
pre-transplantation O
blood O
transfusions O
have O
recently O
become O
controversial O
, O
principally O
because O
of O
the O
adverse O
effect O
of O
transfusion-induced O
sensitisation O
on O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
rates O
. O
['Life-Impact']

Metabolism O
of O
enflurane O
resulted O
in O
plasma B-outcome ['Physiological-Clinical']
inorganic I-outcome ['Physiological-Clinical']
fluoride I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
max O
15 O
mumol O
litre O
-1 O
) O
which O
were O
well O
below O
the O
toxic O
value O
. O
['Physiological-Clinical']

METHODS O
Exhalation B-outcome ['Physiological-Clinical']
TLCO I-outcome ['Physiological-Clinical']
( O
TLCO B-outcome ['Physiological-Clinical']
, O
ex O
) O
was O
compared O
with O
the O
standard O
( O
Jones O
and O
Meade O
) O
10 O
second O
breath O
holding O
TLCO B-outcome ['Physiological-Clinical']
( O
TLCO B-outcome ['Physiological-Clinical']
, O
bh B-outcome ['Physiological-Clinical']
) O
in O
100 O
consecutive O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
116 O
patients O
were O
evaluable O
. O
[]

AIM O
To O
determine O
the O
effect O
of O
parent O
education O
on O
adaptive B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
cognitive/language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
of O
young O
children O
with O
autistic O
disorder O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

However O
, O
the O
median O
[]

CONCLUSIONS O
It O
is O
essential O
that O
the O
median O
length O
of O
follow-up O
be O
clearly O
stated O
in O
any O
clinical O
trial O
. O
[]

Immunohistochemistry B-outcome ['Physiological-Clinical']
was O
used O
to O
measure O
VEGF O
and O
HIF-1 O
?. O
HIF-1 O
? O
['Physiological-Clinical']

This O
superiority O
might O
be O
due O
to O
an O
abnormally O
high O
sensitivity O
to O
fine-grained O
pitch O
differences O
in O
sounds O
. O
[]

No O
such O
changes O
were O
observed O
in O
the O
control O
group O
. O
[]

RESULTS O
A O
smoker O
was O
present O
in O
37.5 O
% O
of O
homes O
. O
[]

Thus O
, O
further O
development O
of O
CS O
is O
warranted O
as O
a O
potential O
method O
to O
prevent O
HIV B-outcome ['Physiological-Clinical']
transmission I-outcome ['Physiological-Clinical']
and O
acquisition B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
therapeutic O
modalities O
were O
followed O
by O
a O
continuous O
T3 O
infusion O
. O
[]

No O
significant O
changes O
in O
baseline O
parameters O
occurred O
in O
the O
control O
group O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
impact O
of O
video-based O
interactive O
crisis O
resource O
management O
( O
CRM O
) O
training O
on O
no-flow O
time O
( O
NFT O
) O
and O
on O
proportions O
of O
team B-outcome ['Life-Impact']
member I-outcome ['Life-Impact']
verbalisations I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
TMV I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
during O
simulated O
cardiopulmonary O
resuscitation O
( O
CPR O
) O
. O
['Life-Impact']

CONCLUSIONS O
Our O
findings O
suggest O
that O
dialysis O
with O
polyamide O
membranes O
with O
different O
flux O
characteristics O
did O
not O
modify O
the O
inflammatory O
indices O
and O
lipid O
profile O
in O
stable O
HD O
patients O
; O
however O
, O
a O
seemingly O
beneficial O
effect O
on O
aortic O
stiffness O
was O
noted O
for O
patients O
who O
were O
maintained O
on O
high-flux O
polyamide O
membrane O
. O
[]

Safety O
and O
immunogenicity O
of O
an O
oral O
, O
inactivated O
, O
whole-cell O
vaccine O
for O
Shigella O
sonnei O
: O
preclinical O
studies O
and O
a O
Phase O
I O
trial O
. O
[]

METHODS O
One O
hundred O
and O
ten O
consecutive O
TKA O
patients O
were O
randomized O
into O
flexion O
group O
and O
extension O
group O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
the O
percentage O
of O
patients O
with O
steroid B-outcome ['Physiological-Clinical']
sparing I-outcome ['Physiological-Clinical']
, O
defined O
as O
discontinuation O
of O
steroid O
therapy O
without O
a O
disease O
flare O
( O
Crohn O
's O
Disease O
Activity O
Index O
score O
> O
or O
=220 O
points O
) O
at O
week O
36 O
. O
['Physiological-Clinical']

This O
study O
involving O
novices O
in O
a O
dry O
lab O
compared O
task B-outcome ['Life-Impact']
performances I-outcome ['Life-Impact']
between O
conventional O
laparoscopic O
surgery O
( O
CLS O
) O
and O
single-port O
laparoscopic O
surgery O
( O
SPLS O
) O
using O
newly O
designed O
pre-bent O
instruments O
. O
['Life-Impact']

Group O
I O
or O
the O
amiodarone O
group O
( O
n=28 O
) O
received O
amiodarone O
( O
3 O
mg/kg O
in O
100 O
ml O
normal O
saline O
) O
and O
group O
II O
or O
the O
control O
group O
received O
same O
volume O
of O
normal O
saline O
. O
[]

During O
each O
period O
all O
subjects O
were O
given O
a O
15-g O
supplement O
of O
fish O
oil O
and O
either O
0 O
( O
placebo O
) O
, O
100 O
, O
200 O
, O
or O
400 O
mg O
alpha-tocopheryl O
acetate O
daily O
. O
[]

In O
the O
comprehensive O
and O
Weight O
Watchers-only O
groups O
, O
weight O
loss B-outcome ['Physiological-Clinical']
was O
significantly O
related O
to O
frequency O
of O
attendance O
at O
Weight O
Watchers O
meetings O
, O
and O
attendance O
was O
more O
frequent O
in O
the O
comprehensive O
group O
. O
['Physiological-Clinical']

Gases O
were O
extracted O
from O
the O
room O
for O
1 O
group O
and O
were O
not O
extracted O
for O
the O
other O
group O
( O
n=12 O
in O
each O
group O
) O
. O
[]

Secondary O
outcomes O
included O
the O
number O
of O
deaths B-outcome ['Mortality']
, O
attendance O
at O
hospital B-outcome ['Resource-use']
outpatient I-outcome ['Resource-use']
clinics I-outcome ['Resource-use']
and O
general O
practice O
and O
proportion O
of O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
over O
the O
follow-up O
period B-outcome ['Physiological-Clinical']
, O
together O
with O
patients O
' O
general B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
satisfaction B-outcome ['Life-Impact']
with O
the O
service O
and O
knowledge B-outcome ['Life-Impact']
of O
and O
adherence B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
prescribed I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
. O
['Mortality', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Six O
patients O
in O
each O
group O
received O
either O
apalcillin O
, O
azlocillin O
, O
mezlocillin O
or O
piperacillin O
during O
the O
operation O
. O
[]

RESULTS O
Mean O
daily B-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
symptom B-outcome ['Physiological-Clinical']
scores O
were O
significantly O
reduced O
with O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
The O
combination O
of O
paclitaxel O
and O
carboplatin O
has O
become O
a O
widely O
used O
regimen O
in O
NSCLC O
due O
to O
phase O
II O
reports O
of O
moderate O
toxicity O
, O
reasonable O
activity O
and O
easy O
outpatient O
administration O
. O
[]

The O
mean O
volume O
of O
saline B-outcome ['Resource-use']
irrigation I-outcome ['Resource-use']
during O
the O
PlasmaKinetic O
procedure O
was O
significantly O
lower O
than O
that O
of O
hyperosmolar O
solution O
irrigation O
during O
TURP O
( O
p O
< O
0.05 O
) O
. O
['Resource-use']

Significantly O
fewer O
patients O
on O
ketazolam O
dropped O
out O
of O
the O
study O
due O
to O
ineffective O
medication O
than O
on O
the O
other O
3 O
treatments O
. O
[]

All O
the O
patients O
came O
from O
the O
hospitals O
of O
the O
cooperative O
research O
group O
and O
were O
randomized O
into O
chemotherapy O
and O
control O
groups O
. O
[]

Additionally O
, O
a O
prospective O
clinical O
study O
was O
conducted O
in O
77 O
patients O
with O
CDAD O
to O
demonstrate O
the O
safety O
of O
consuming O
anti-CD O
WPC O
to O
prevent O
relapse O
of O
the O
infection O
. O
[]

Minor B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
slight B-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
were O
encountered O
more O
often O
in O
the O
streptokinase O
than O
in O
the O
heparin O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
this O
effect O
was O
clearly O
seen O
in O
329 O
patients O
with O
a O
mutated O
NPM1 O
gene O
( O
NPM1+ O
) O
, O
but O
not O
in O
319 O
patients O
without O
a O
NPM1 O
mutation O
( O
wtNPM1 O
) O
. O
[]

During O
attacks O
of O
mild- O
to O
moderate-intensity O
, O
> O
50 O
% O
improvement O
was O
obtained O
in O
11/17 O
with O
capsaicin O
and O
in O
one O
with O
vaseline O
. O
[]

RESULTS O
After O
induction O
of O
anesthesia O
, O
the O
decrease O
in O
pupil B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
between O
the O
two O
groups O
( O
P O
= O
0.112 O
) O
, O
but O
for O
the O
next O
two O
stages O
, O
it O
was O
significantly O
less O
in O
the O
diclofenac O
group O
( O
P O
= O
0.012 O
and O
P O
= O
0.003 O
, O
respectively O
) O
. O
['Physiological-Clinical']

The O
intervention O
group O
showed O
a O
significant O
improvement O
in O
mood O
status O
and O
quality O
of O
life O
over O
time O
compared O
with O
their O
counterparts O
in O
the O
control O
group O
. O
[]

We O
used O
both O
parametric O
and O
nonparametric O
techniques O
to O
examine O
changes O
in O
cost B-outcome ['Resource-use']
and O
parametric O
analyses O
to O
examine O
changes O
in O
effectiveness O
. O
['Resource-use']

A O
convenience O
sample O
of O
140 O
patients O
presenting O
with O
acute O
bronchitis O
were O
tested O
for O
M O
pneumoniae O
, O
91 O
of O
whom O
were O
treated O
with O
either O
erythromycin O
250 O
mg O
four O
times O
daily O
for O
10 O
days O
or O
an O
identical-appearing O
placebo O
. O
[]

We O
applied O
a O
structural O
equation O
model O
to O
data O
on O
the O
relationships O
between O
medication O
adherence O
, O
AA O
meeting O
attendance O
and O
abstinent B-outcome ['Physiological-Clinical']
outcome O
to O
clarify O
whether O
medication O
adherence O
or O
AA O
meeting O
attendance O
better O
explains O
the O
positive-outcome O
adherence B-outcome ['Life-Impact']
effect O
we O
observed O
. O
['Physiological-Clinical', 'Life-Impact']

Reduction O
of O
the O
proportion O
of O
linoleate B-outcome ['Physiological-Clinical']
by O
clofibrate O
but O
not O
by O
niceritrol O
. O
['Physiological-Clinical']

Effects O
of O
vitamin O
A O
or O
beta O
carotene O
supplementation O
on O
pregnancy-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
infant B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
rural O
Bangladesh O
: O
a O
cluster O
randomized O
trial O
. O
['Mortality', 'Mortality']

Randomized O
trial O
of O
high-dose O
cytarabine O
versus O
amsacrine O
in O
acute O
myelogenous O
leukemia O
in O
relapse O
: O
a O
Leukemia O
Intergroup O
Study O
. O
[]

RESULTS O
Group O
C O
had O
significantly O
higher O
incidences O
of O
symptomatic O
( O
26.0 O
% O
vs O
6.1 O
% O
; O
P O
< O
.015 O
) O
and O
laboratory O
( O
44.0 O
% O
vs O
14.3 O
% O
; O
P O
< O
.015 O
) O
hypocalcemia B-outcome ['Physiological-Clinical']
than O
the O
group O
without O
CND O
. O
['Physiological-Clinical']

Additional O
positive O
non-SLN O
after O
CLND O
, O
and O
disease O
outcome O
were O
evaluated O
. O
[]

Five-year O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
rates O
were O
16 O
% O
in O
group O
A O
and O
16 O
% O
in O
group O
B O
( O
p O
= O
0.9096 O
) O
, O
and O
corresponding O
distant O
failure O
rates O
were O
23 O
% O
in O
group O
A O
and O
19 O
% O
in O
group O
B O
( O
p O
= O
0.2955 O
) O
. O
['Physiological-Clinical']

This O
low-tilt O
waveform O
was O
compared O
with O
a O
conventional O
waveform O
of O
equivalent O
duration O
and O
voltage O
in O
patients O
with O
AF O
. O
[]

Propranolol O
in O
acute O
myocardial O
infarction O
: O
the O
MILIS O
experience O
. O
[]

[ O
Simvastatin O
versus O
gemfibrozil O
in O
the O
treatment O
of O
primary O
hypercholesterolemia O
in O
hypertensive O
patients O
treated O
with O
hydrochlorothiazide O
] O
. O
[]

There O
is O
little O
robust O
evidence O
of O
effectiveness O
of O
speech-language O
interventions O
which O
target O
the O
language O
, O
pragmatic O
or O
social O
communication O
needs O
of O
these O
children O
. O
[]

The O
LCT O
group O
consisted O
of O
50 O
subjects O
( O
34 O
men O
and O
16 O
women O
) O
, O
while O
the O
MLCT O
group O
consisted O
of O
51 O
subjects O
( O
33 O
men O
and O
18 O
women O
) O
who O
completed O
the O
study O
. O
[]

treatment O
with O
no O
statistical O
benefit O
regarding O
survival B-outcome ['Mortality']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

However O
, O
the O
number O
of O
donors O
to O
whom O
the O
infants O
were O
exposed O
was O
not O
significantly O
different O
( O
2.8 O
+/- O
2.5 O
vs O
2.2 O
+/- O
2.0 O
) O
. O
[]

However O
, O
systolic O
BP O
remained O
significantly O
lower O
in O
PR-STENT O
than O
in O
NO-STENT O
( O
140.1 O
? O
[]

There O
were O
no O
significant O
differences O
between O
treatment O
groups O
with O
regard O
to O
patient O
demographics O
, O
surgery O
type O
, O
or O
awakening O
time O
. O
[]

Patients O
with O
infections O
were O
more O
likely O
to O
have O
low O
levels O
of O
CD19+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Spotty O
calcification O
as O
a O
marker O
of O
accelerated O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
: O
insights O
from O
serial O
intravascular O
ultrasound O
. O
['Physiological-Clinical']

Since O
GABAA-mediated O
intracortical O
inhibition O
has O
been O
shown O
to O
underlie O
plastic O
changes O
throughout O
the O
lifespan O
from O
development O
to O
aging O
, O
here O
, O
the O
aging O
motor O
system O
was O
used O
as O
a O
model O
to O
analyze O
the O
interdependence O
of O
plastic O
alterations O
within O
the O
inhibitory O
motorcortical O
network O
and O
level O
of O
behavioral O
performance O
. O
[]

Pioglitazone O
therapy O
was O
associated O
with O
significant O
increases O
in O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
reduced O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
) O
, O
whereas O
glimepiride O
had O
no O
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
' O
surgical O
wounds O
in O
the O
study O
group O
were O
dressed O
with O
TOISD O
combination O
and O
the O
patient O
's O
surgical O
wounds O
in O
the O
control O
group O
received O
the O
conventional O
method O
of O
no O
dressing O
. O
[]

PATIENTS O
AND O
METHODS O
Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O
[]

Limitations O
include O
small O
sample O
size O
and O
the O
crossover O
design O
of O
the O
study O
. O
[]

If O
the O
threshold-age O
for O
boost O
treatment O
were O
set O
at O
40 O
years O
, O
8.4 O
% O
of O
the O
study O
population O
would O
receive O
a O
boost O
, O
resulting O
in O
a O
5-year O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
of O
6.1 O
% O
in O
the O
study O
population O
. O
['Physiological-Clinical']

There O
were O
no O
treatment-related B-outcome ['Mortality']
deaths I-outcome ['Mortality']
in O
either O
arm O
. O
['Mortality']

DESIGN O
Randomized O
, O
crossover O
, O
unblinded O
single-dose O
pharmacokinetic O
study O
in O
healthy O
volunteers O
. O
[]

RESULTS O
Of O
the O
36 O
eyes O
that O
underwent O
simple O
excision O
, O
14 O
( O
38.8 O
% O
) O
exhibited O
recurrences B-outcome ['Physiological-Clinical']
whereas O
only O
one O
of O
30 O
eyes O
( O
3.33 O
% O
) O
treated O
with O
excision O
and O
intraoperative O
application O
of O
mitomycin O
C O
had O
recurrence B-outcome ['Physiological-Clinical']
( O
p O
= O
0.0006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Ninety-nine O
ASA O
I-II O
children O
less O
than O
10 O
yr O
old O
scheduled O
for O
elective O
sub-umbilical O
surgery O
were O
randomized O
to O
receive O
caudal O
block O
with O
bupivacaine O
0.25 O
% O
, O
ropivacaine O
0.25 O
% O
or O
levobupivacaine O
0.25 O
% O
. O
[]

The O
risk O
with O
the O
lower-dose O
monophasic O
pill O
was O
comparable O
to O
that O
with O
the O
multiphasic O
pill O
( O
RR O
1.3 O
, O
95 O
% O
CI O
0.5-3.6 O
; O
P O
= O
.56 O
) O
. O
[]

Patients O
rated O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
RLS I-outcome ['Physiological-Clinical']
by O
means O
of O
a O
6-item O
questionnaire O
developed O
by O
the O
International O
Restless O
Legs O
Study O
Group O
( O
6-item O
IRLS O
) O
, O
by O
the O
Clinical O
Global O
Impression O
( O
CGI O
) O
scale O
, O
and O
by O
sleep O
diaries O
. O
['Physiological-Clinical']

In O
spite O
of O
the O
high O
dropout O
rate O
, O
91 O
% O
of O
the O
mothers O
were O
located O
for O
the O
18 O
month O
follow-up O
interview O
. O
[]

Tailored O
, O
iterative O
, O
printed O
dietary O
feedback O
is O
as O
effective O
as O
group O
education O
in O
improving O
dietary O
behaviours O
: O
results O
from O
a O
randomised O
control O
trial O
in O
middle-aged O
adults O
with O
cardiovascular O
risk O
factors O
. O
[]

We O
describe O
indoor O
environmental O
conditions O
related O
to O
asthma O
triggers O
among O
a O
low-income O
urban O
population O
in O
Seattle/King O
County O
, O
Washington O
, O
as O
well O
as O
caregiver O
knowledge O
and O
resources O
related O
to O
control O
of O
these O
triggers O
. O
[]

Artesunate O
plus O
primaquine O
( O
group O
IV O
) O
cleared O
parasitemia B-outcome ['Physiological-Clinical']
faster O
than O
the O
other O
3 O
regimens O
. O
['Physiological-Clinical']

Double-blind O
placebo-controlled O
trial O
of O
aprindine O
and O
digoxin O
for O
the O
prevention O
of O
symptomatic B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
decreased O
significantly O
( O
p O
< O
0.01 O
) O
only O
in O
the O
metformin O
group O
, O
but O
this O
was O
not O
significantly O
different O
from O
the O
placebo O
group O
( O
p O
< O
0.12 O
) O
; O
further O
, O
there O
were O
no O
significant O
differences O
in O
the O
change O
in O
plasminogen O
activator O
inhibitor O
1 O
. O
['Physiological-Clinical']

PATIENTS O
The O
study O
population O
was O
aged O
45 O
to O
85 O
years O
. O
[]

Further O
studies O
are O
clearly O
warranted O
to O
evaluate O
the O
efficacy O
of O
various O
pharmacotherapeutic O
agents O
and O
various O
psychotherapies O
in O
the O
treatment O
of O
substance-abusing O
suicidal O
patients O
. O
[]

Scores O
of O
left-colon B-outcome ['Physiological-Clinical']
cleansing I-outcome ['Physiological-Clinical']
for O
flexible O
sigmoidoscopy O
were O
equally O
high O
for O
the O
three O
methods O
. O
['Physiological-Clinical']

CONCLUSION O
Naphcon O
eye O
drop O
is O
an O
effective O
agent O
to O
prevent O
conjunctival O
bleeding O
. O
[]

Using O
the O
demand-control O
model O
of O
job O
strain O
to O
predict O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
and O
caregiver O
satisfaction O
in O
the O
informal O
caregivers O
of O
heart O
failure O
patients O
. O
['Life-Impact']

In O
one O
patient O
in O
each O
group O
, O
there O
was O
staining B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
oropharynx I-outcome ['Physiological-Clinical']
with O
blue O
dye O
at O
the O
end O
of O
surgery O
. O
['Physiological-Clinical']

Intraumbilical O
vein O
injection O
of O
prostaglandin O
F2 O
alpha O
in O
retained O
placenta O
. O
[]

Hemodynamic O
parameters O
and O
the O
requirements O
for O
propofol O
, O
sevoflurane O
, O
and O
the O
postoperative O
need O
for O
ketobemidone O
were O
noted O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
longer-term O
effects O
of O
combined O
medical O
and O
surgical O
therapy O
for O
CRS O
on O
overall O
health O
status O
and O
QOL O
. O
[]

Participants O
received O
concomitant O
mycophenolate O
mofetil O
and O
steroids O
. O
[]

CONCLUSION O
These O
findings O
suggest O
that O
fever B-outcome ['Physiological-Clinical']
is O
associated O
with O
worsened O
outcome O
in O
surgical O
subarachnoid O
hemorrhage O
patients O
, O
although O
, O
because O
the O
association O
between O
fever B-outcome ['Physiological-Clinical']
and O
the O
primary O
outcome O
measure O
for O
the O
trial O
is O
dependent O
on O
the O
covariates O
used O
in O
the O
analysis O
( O
particularly O
operative O
events O
and O
delayed B-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
) O
, O
we O
can O
not O
rule O
out O
the O
possibility O
that O
fever B-outcome ['Physiological-Clinical']
is O
a O
marker O
for O
other O
events O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Salbutamol O
or O
mist O
in O
acute O
bronchiolitis O
. O
[]

In O
these O
settings O
, O
Streptococcus O
pyogenes O
is O
considered O
to O
be O
the O
main O
etiological O
agent O
. O
[]

All O
patients O
had O
normal O
lung O
function/bronchial O
hyper-responsiveness O
out O
of O
season O
and O
a O
negative O
asthma/wheezing O
history O
. O
[]

The O
maximum O
drug O
concentration O
in O
serum O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
was O
reduced O
from O
7.22 O
+/- O
4.0 O
to O
3.51 O
+/- O
1.9 O
microM O
, O
and O
the O
area O
under O
the O
concentration-time O
curve O
from O
0 O
h O
to O
infinity O
( O
AUC0 O
-- O
> O
infinity O
) O
was O
reduced O
from O
22.5 O
+/- O
14 O
to O
14 O
+/- O
5.7 O
microM.h O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
antifibrinolytic O
tranexamic O
acid O
reduces O
surgical O
blood O
loss O
, O
but O
studies O
have O
not O
identified O
an O
optimal O
regimen O
. O
[]

All O
tibial O
components O
migrated B-outcome ['Life-Impact']
initially O
. O
['Life-Impact']

This O
study O
was O
extended O
to O
7,350 O
men O
using O
serum O
PSA O
and O
DRE O
as O
first O
approach O
, O
followed O
by O
TRUS O
only O
when O
1 O
of O
these O
2 O
tests O
was O
abnormal O
. O
[]

CONCLUSIONS O
The O
VIDSUN O
questionnaire O
provides O
an O
initial O
tool O
to O
identify O
postmenopausal O
women O
at O
high O
or O
low O
risk O
of O
VDI O
. O
[]

In O
the O
former O
group O
, O
the O
survival B-outcome ['Mortality']
rates O
at O
12 O
and O
24 O
months O
were O
33 O
percent O
and O
10 O
percent O
, O
respectively O
, O
whereas O
they O
were O
50 O
percent O
and O
38 O
percent O
in O
the O
patients O
receiving O
combined O
therapy O
( O
P O
less O
than O
0.001 O
) O
. O
['Mortality']

TRIAL O
DESIGN O
We O
developed O
an O
evidence-based O
prescription O
label O
that O
addresses O
both O
content O
and O
format O
. O
[]

Underreporting O
was O
a O
widespread O
problem O
( O
approximately O
26 O
% O
) O
for O
all O
modes O
in O
this O
sample O
. O
[]

We O
investigated O
31 O
children O
with O
autistic O
spectrum O
disorders O
in O
an O
8-week O
, O
double-blinded O
study O
to O
determine O
if O
800 O
mg O
L-carnosine O
daily O
would O
result O
in O
observable O
changes O
versus O
placebo O
. O
[]

With O
long O
plateau B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
( O
T O
: O
17.3 O
h O
) O
and O
small O
peak-trough B-outcome ['Physiological-Clinical']
fluctuations I-outcome ['Physiological-Clinical']
( O
T O
: O
49.0 O
% O
) O
, O
established O
quality O
criteria O
for O
high O
quality O
theophylline O
preparations O
were O
fulfilled O
by O
the O
test O
formulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.003 O
) O
. O
[]

Recurrence B-outcome ['Physiological-Clinical']
rates O
by I-outcome ['Physiological-Clinical']
Gram-stained I-outcome ['Physiological-Clinical']
smear I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
between O
patient O
and O
partner O
treatment O
groups O
at O
five O
and O
eight O
weeks O
after O
initiation O
of O
treatment O
were O
also O
not O
significantly O
different O
between O
the O
two O
patient O
regimens O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
the O
Childhood B-outcome ['Life-Impact']
Autism B-outcome ['Life-Impact']
Rating O
Scale O
, O
the O
Gilliam O
Autism B-outcome ['Life-Impact']
Rating O
Scale O
, O
the O
Expressive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
Receptive I-outcome ['Life-Impact']
One-Word I-outcome ['Life-Impact']
Picture I-outcome ['Life-Impact']
Vocabulary I-outcome ['Life-Impact']
tests O
, O
and O
Clinical O
Global O
Impressions O
of O
Change O
. O
['Life-Impact']

Between O
groups O
2 O
and O
3 O
, O
there O
were O
significant O
differences O
at O
two O
and O
four O
weeks O
. O
[]

Thus O
the O
rise O
in O
pressure B-outcome ['Physiological-Clinical']
was O
related O
to O
the O
muscular O
activity O
required O
for O
cuff O
inflation O
. O
['Physiological-Clinical']

Sputum B-outcome ['Physiological-Clinical']
IL-5 I-outcome ['Physiological-Clinical']
was O
undetectable O
in O
all O
patients O
. O
['Physiological-Clinical']

METHODS O
Eighty O
patients O
( O
38 O
males O
and O
42 O
females O
, O
mean O
+/- O
SD O
age O
19.7 O
+/- O
5.9 O
years O
) O
were O
randomized O
in O
a O
1 O
: O
2 O
ratio O
to O
receive O
C/BPO O
alone O
or O
in O
combination O
with O
PDL O
treatment O
( O
wavelength O
585 O
nm O
, O
energy O
fluence O
3 O
J O
cm O
( O
-2 O
) O
, O
pulse O
duration O
0.35 O
ms O
, O
spot O
size O
7 O
mm O
) O
. O
[]

Heifers O
were O
stratified O
by O
weaning O
weight O
and O
allotted O
randomly O
to O
treatment O
before O
breeding O
( O
May O
to O
July O
) O
. O
[]

MC-1 O
( O
pyridoxal O
5'-phosphate O
) O
is O
a O
novel O
agent O
that O
has O
shown O
promise O
in O
reducing O
myocardial O
necrosis O
by O
reducing O
cellular O
calcium O
overload O
after O
percutaneous O
coronary O
intervention O
and O
CABG O
surgery O
in O
high-risk O
patients O
undergoing O
these O
procedures O
. O
[]

There O
were O
no O
significant O
changes O
in O
spirometry B-outcome ['Resource-use']
( O
p O
> O
0.05 O
) O
or O
any O
reported O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
either O
group O
. O
['Resource-use', 'Adverse-effects']

METHODS/DESIGN O
This O
is O
to O
be O
a O
randomized O
controlled O
feasibility O
trial O
recruiting O
50 O
individuals O
with O
upper-limb O
motor O
impairment O
after O
stroke O
. O
[]

at O
the O
dose O
of O
200 O
mg/week O
for O
1 O
year O
. O
[]

A O
randomized O
, O
controlled O
trial O
of O
the O
efficacy O
of O
a O
heparin O
and O
vancomycin O
solution O
in O
preventing O
central B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
children O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
between O
the O
groups O
in O
terms O
of O
total O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
P O
= O
0.55 O
) O
. O
['Adverse-effects']

CONCLUSION O
Ixabepilone O
, O
with O
or O
without O
estramustine O
phosphate O
, O
is O
well O
tolerated B-outcome ['Life-Impact']
and O
has O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
patients O
with O
castrate O
metastatic O
prostate O
cancer O
. O
['Life-Impact', 'Physiological-Clinical']

The O
per-protocol O
, O
as-treated O
primary O
analysis O
was O
designed O
to O
determine O
whether O
rivaroxaban O
was O
noninferior O
to O
warfarin O
for O
the O
primary O
end O
point O
of O
stroke B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
We O
introduced O
and O
evaluated O
an O
optimized O
patient O
care O
program O
for O
patients O
undergoing O
open O
infrarenal O
aortic O
aneurysm O
repair O
which O
showed O
a O
significant O
advantage O
for O
fast-track O
patients O
in O
terms O
of O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
patients O
were O
examined O
within O
72 O
h O
after O
stroke O
onset O
. O
[]

Bevacizumab O
plus O
irinotecan O
, O
fluorouracil O
, O
and O
leucovorin O
for O
metastatic O
colorectal O
cancer O
. O
[]

BACKGROUND O
Endovascular O
aneurysm O
repair O
( O
EVAR O
) O
to O
exclude O
abdominal O
aortic O
aneurysm O
( O
AAA O
) O
was O
introduced O
for O
patients O
of O
poor O
health O
status O
considered O
unfit O
for O
major O
surgery O
. O
[]

Benign O
Prostatic O
Hyperplasia O
Treatment O
Outcomes O
Study O
Group O
. O
[]

CONCLUSION O
In O
conclusion O
, O
RV O
pacing O
results O
in O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
LV O
mass O
, O
and O
worsening B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
recent O
donor O
motivation O
studies O
highlight O
the O
importance O
of O
anxiety B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
, O
and O
perceived B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
cope I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
donation I-outcome ['Life-Impact']
( O
i.e. O
, O
self-efficacy O
) O
as O
crucial O
determinants O
of O
donation O
intention O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
investigated O
the O
relationship O
between O
serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
and O
circulating B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
and O
the O
pharmacokinetics O
of O
rhG-CSF O
for O
patients O
with O
lung O
cancer O
who O
had O
been O
treated O
with O
myelosuppressive O
chemotherapy O
and O
then O
with O
subcutaneous O
rhG-CSF O
( O
lenograstim O
, O
2 O
micrograms O
per O
kg O
of O
body O
weight O
per O
day O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
histology O
, O
22 O
cases O
were O
squamous O
cell O
carcinoma O
, O
1 O
adenocarcinoma O
and O
2 O
squamous O
adenocarcinoma O
. O
[]

OBJECTIVE O
The O
efficacy O
of O
atomoxetine O
as O
treatment O
of O
symptoms O
of O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
in O
patients O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
has O
not O
been O
established O
. O
[]

CONCLUSIONS O
We O
conclude O
that O
ursodeoxycholic O
acid O
given O
over O
4 O
weeks O
had O
no O
influence O
on O
functional B-outcome ['Life-Impact']
score O
['Life-Impact']

The O
Nuelin O
Retard O
preparation O
appears O
to O
provide O
smooth O
, O
sustained O
serum B-outcome ['Physiological-Clinical']
theophylline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
within O
the O
therapeutic O
range O
and O
the O
simple O
, O
twice-daily O
dosage O
should O
result O
in O
improved O
patient O
compliance O
. O
['Physiological-Clinical']

The O
study O
was O
conducted O
at O
80 O
study O
centers O
in O
Europe O
and O
Australia O
. O
[]

The O
amount O
of O
glucose O
infused O
at O
steady-state O
to O
maintain O
stable O
blood O
glucose O
[ O
90 O
mg/dl O
( O
4.95 O
mmol/l O
) O
] O
was O
used O
to O
calculate O
several O
indices O
of O
insulin O
sensitivity O
. O
[]

A O
bronchial O
provocation O
challenge O
test O
was O
conducted O
with O
30 O
subjects O
using O
metacholin O
. O
[]

Maternal O
fecal O
and O
breast-milk O
bifidobacterial O
counts O
impacted O
on O
the O
infants O
' O
fecal O
Bifidobacterium O
levels O
. O
[]

In O
addition O
, O
ORG-2766 O
treatment O
increased O
[]

Hysteroscopic O
morcellation O
compared O
with O
electrical O
resection O
of O
endometrial O
polyps O
: O
a O
randomized O
controlled O
trial O
. O
[]

Non-compartmental O
pharmacokinetic B-outcome ['Physiological-Clinical']
analyses I-outcome ['Physiological-Clinical']
were O
used O
to O
describe O
the O
disposition O
of O
linezolid O
. O
['Physiological-Clinical']

A O
comparative O
study O
of O
a O
new O
food O
supplement O
, O
ViviScal O
, O
with O
fish O
extract O
for O
the O
treatment O
of O
hereditary O
androgenic O
alopecia O
in O
young O
males O
. O
[]

In O
the O
control O
group O
, O
there O
were O
no O
significant O
changes O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P=0.89 O
) O
or O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.70 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

Treatment O
was O
successful O
in O
controlling B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
68 O
% O
of O
eyes O
after O
12 O
months O
follow-up O
( O
p O
= O
0.004 O
) O
. O
['Physiological-Clinical']

The O
efficacy O
of O
SI O
vaccines O
is O
well O
established O
under O
experimental O
conditions O
, O
but O
information O
about O
field O
efficacy O
is O
scarce O
. O
[]

RESULTS O
Comparative O
analysis O
of O
the O
first O
conducted O
and O
randomly O
assigned O
55 O
cases O
revealed O
a O
significantly O
higher O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
for O
cryobiopsy B-outcome ['Resource-use']
compared O
with O
forceps O
biopsy O
( O
89.1 O
% O
vs O
65.5 O
% O
, O
P O
< O
.05 O
) O
. O
['Life-Impact', 'Resource-use']

Prophylactic O
catheter O
ablation O
should O
therefore O
be O
considered O
before O
implantation O
of O
a O
cardioverter O
defibrillator O
in O
such O
patients O
. O
[]

The O
oils O
were O
included O
in O
bread O
. O
[]

Oral O
ISDN O
thus O
has O
a O
dose-dependent O
effect O
on O
the O
frequency O
of O
angina B-outcome ['Physiological-Clinical']
and O
ischaemia B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
during O
ergometric O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoints O
were O
the O
VZV B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
geometric O
mean O
titer O
( O
GMT B-outcome ['Physiological-Clinical']
; O
day O
28 O
) O
, O
the O
VZV B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
geometric O
mean O
rise O
( O
GMR B-outcome ['Physiological-Clinical']
; O
days O
1 O
to O
28 O
) O
, O
and O
the O
incidence O
of O
vaccine-related B-outcome ['Adverse-effects']
serious I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
( O
AEs O
) O
over O
28 O
days O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

We O
investigated O
whether O
adjuvant O
active O
specific O
immunotherapy O
( O
ASI O
) O
with O
an O
autologous O
tumour O
cell-BCG O
vaccine O
with O
surgical O
resection O
was O
more O
beneficial O
than O
resection O
alone O
in O
stage O
II O
and O
III O
colon O
cancer O
. O
[]

One-year O
patient B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
85.7 O
% O
( O
placebo O
) O
and O
88.8 O
% O
( O
steroid O
) O
( O
p O
= O
0.572 O
) O
. O
['Mortality']

If O
thyroglobulin B-outcome ['Physiological-Clinical']
levels O
were O
low O
and O
WBSs B-outcome ['Physiological-Clinical']
were O
negative O
, O
patients O
were O
followed O
up O
in O
the O
Department O
of O
Nuclear O
Medicine O
in O
Martin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twenty-four O
adolescents O
with O
persistent O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
elevation O
( O
greater O
than O
95th O
% O
) O
on O
placebo O
were O
randomized O
double O
blind O
to O
clonidine O
or O
hydrochlorothiazide O
treatment O
. O
['Physiological-Clinical']

RESULTS O
No O
differences O
in O
effects O
were O
detected O
in O
the O
between-group O
comparisons O
at O
any O
of O
the O
follow-up O
assessments O
. O
[]

Anti-Xa O
effect O
of O
a O
low O
molecular O
weight O
heparin O
( O
dalteparin O
) O
does O
not O
accumulate O
in O
extended O
duration O
therapy O
for O
venous O
thromboembolism O
in O
cancer O
patients O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
fish O
oil O
affects O
cardiovascular O
risk O
factors O
during O
the O
adolescent O
growth O
spurt O
. O
[]

Motion O
style O
acupuncture O
treatment O
( O
MSAT O
) O
is O
a O
non-traditional O
acupuncture O
treatment O
requiring O
a O
patient O
to O
exercise O
while O
receiving O
acupuncture O
. O
[]

In O
Group O
General O
Anesthesia O
( O
GA O
) O
, O
patients O
received O
, O
fentanyl O
intravenous O
( O
i.v O
. O
[]

When O
both O
groups O
were O
compared O
, O
we O
did O
not O
find O
a O
significant O
difference O
in O
ICAM B-outcome ['Physiological-Clinical']
and O
E-selectin B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
heart O
failure O
( O
HF O
) O
, O
longitudinal O
changes O
in O
ventricular O
ejection O
fraction O
are O
poorly O
studied O
. O
[]

At O
intermediate O
spacing O
, O
saliency O
built O
up O
progressively O
with O
a O
greater O
number O
of O
colinear O
lines O
, O
extending O
up O
to O
30 O
degrees O
. O
[]

Trial O
of O
prophylactic O
administration O
of O
TXA2 O
synthetase O
inhibitor O
, O
ozagrel O
hydrochloride O
, O
for O
preeclampsia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

At O
6 O
months O
, O
the O
change O
in O
average O
scores O
for O
the O
enriched O
group O
was O
11.3 O
points O
higher O
than O
that O
for O
the O
control O
group O
. O
[]

The O
child O
received O
placebo O
for O
3 O
weeks O
and O
buspirone O
for O
3 O
weeks O
; O
there O
was O
a O
1-week O
interval O
between O
the O
2 O
treatments O
. O
[]

BACKGROUND O
Osteoporosis O
is O
associated O
with O
cirrhosis O
of O
the O
liver O
, O
but O
the O
effects O
of O
therapy O
for O
osteoporosis B-outcome ['Physiological-Clinical']
associated O
with O
cirrhosis O
are O
still O
controversial O
. O
['Physiological-Clinical']

The O
trial O
is O
a O
randomized O
, O
double-blind O
, O
double O
dummy O
, O
event-driven O
, O
parallel O
group O
study O
. O
[]

Physiologic O
modeling O
of O
the O
intravenous B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
tolerance O
test O
in O
type O
2 O
diabetes O
: O
a O
new O
approach O
to O
the O
insulin O
compartment O
. O
['Resource-use']

PURPOSE O
To O
evaluate O
the O
efficacy O
of O
diltiazem O
versus O
placebo O
in O
patients O
with O
stable O
angina O
. O
[]

The O
aim O
of O
this O
prospective O
randomized O
controlled O
study O
was O
to O
evaluate O
the O
efficacy O
of O
absorbable O
clips O
in O
elective B-outcome ['Physiological-Clinical']
laparoscopic I-outcome ['Physiological-Clinical']
cholecystectomy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
have O
determined O
whether O
oral O
estrogen O
reduces O
the O
biological O
effects O
of O
growth O
hormone O
( O
GH O
) O
in O
GH-deficient O
( O
GHD O
) O
women O
compared O
with O
transdermal O
estrogen O
treatment O
. O
[]

The O
primary O
efficacy O
analysis O
was O
based O
on O
children O
who O
received O
three O
doses O
of O
RRV-TV O
( O
n=1128 O
) O
or O
placebo O
( O
n=1145 O
) O
. O
[]

RESULTS O
Age- O
and O
gender-standardized O
weight O
increased O
after O
6 O
months O
of O
treatment O
( O
gross O
: O
mean=5.6 O
kg O
[ O
SD=3.9 O
] O
; O
standardized O
: O
mean=0.6 O
z O
[ O
SD=0.5 O
] O
) O
and O
was O
positively O
correlated O
with O
weight O
gained O
after O
1 O
month O
. O
[]

All O
variables O
were O
recorded O
at O
15 O
minutes O
, O
2 O
hours O
and O
24 O
hours O
postoperatively O
. O
[]

Extrapyramidal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
as O
assessed O
by O
the O
SARS O
, O
were O
no O
more O
common O
for O
drug O
than O
placebo O
, O
although O
drooling O
was O
reported O
more O
often O
in O
the O
risperidone O
group O
. O
['Physiological-Clinical']

Parents O
are O
seeking O
treatment O
with O
secretin O
despite O
the O
absence O
of O
empirical O
investigations O
demonstrating O
amelioration O
in O
autism O
symptomology O
. O
[]

The O
simulation O
predicted O
that O
for O
the O
5 O
mg O
dose O
group O
the O
trough O
DPP-4 B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
at O
steady-state O
was O
84.2 O
% O
, O
which O
is O
higher O
than O
the O
target O
inhibition O
( O
?80 O
% O
) O
for O
an O
effective O
dose O
of O
DPP-4 O
inhibitor O
. O
['Physiological-Clinical']

The O
median O
duration O
of O
the O
tunnelled O
catheters O
was O
224 O
days O
with O
a O
range O
of O
25-846 O
days O
which O
was O
significantly O
longer O
than O
that O
of O
conventional O
catheters O
( O
39.5 O
days O
, O
range O
9-228 O
days O
) O
. O
[]

METHOD O
Forty O
individuals O
comprised O
the O
simulating O
and O
control O
group O
and O
all O
participants O
were O
randomly O
assigned O
to O
the O
simulating O
and O
control O
groups O
. O
[]

Initial O
studies O
have O
demonstrated O
that O
persons O
performing O
Nordic O
Walking O
are O
able O
to O
exercise O
longer O
and O
harder O
compared O
to O
normal O
walking O
thereby O
increasing O
their O
cardiovascular O
metabolism O
. O
[]

A O
57 O
% O
response O
rate O
was O
seen O
in O
the O
combined-modality O
arm O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
43 O
% O
to O
69 O
% O
) O
, O
and O
a O
22 O
% O
response O
rate O
was O
seen O
in O
the O
teniposide-alone O
arm O
( O
95 O
% O
CI O
, O
12 O
% O
to O
34 O
% O
) O
( O
P O
< O
.001 O
) O
. O
[]

PURPOSE O
To O
compare O
three-drug O
chemotherapy O
with O
cisplatin O
, O
doxorubicin O
, O
and O
methotrexate O
with O
four-drug O
chemotherapy O
with O
cisplatin O
, O
doxorubicin O
, O
methotrexate O
, O
and O
ifosfamide O
for O
the O
treatment O
of O
osteosarcoma O
. O
[]

The O
corresponding O
risk-group O
pattern O
for O
the O
inadequately O
treated O
hypertensives O
( O
n O
= O
737 O
) O
was O
5.5 O
, O
48.3 O
, O
11.1 O
and O
35.2 O
% O
, O
respectively O
. O
[]

40 O
subjects O
participated O
in O
this O
parallel O
, O
randomized O
, O
double O
blind O
, O
prospective O
longitudinal O
clinical O
study O
following O
active O
peridontal O
therapy O
. O
[]

[ O
Diphtheria O
antitoxin O
level O
2 O
years O
after O
booster O
vaccination O
] O
. O
[]

No O
effects O
of O
naltrexone O
on O
social O
and O
stereotypic O
behavior O
could O
be O
demonstrated O
. O
[]

Presence O
or O
absence O
of O
a O
contrast O
condition O
, O
where O
couples O
reported O
on O
one O
therapist O
process O
after O
already O
experiencing O
its O
opposite O
, O
led O
to O
main O
effects O
for O
responsibility O
and O
struggle O
, O
and O
mediated O
effects O
of O
struggle O
and O
cooperation O
. O
[]

One O
group O
was O
subjected O
to O
EC O
and O
the O
other O
to O
IS O
. O
[]

This O
report O
examined O
the O
effect O
of O
methylphenidate O
on O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
in O
children O
with O
pervasive O
developmental O
disorders O
and O
hyperactivity O
in O
a O
secondary O
analysis O
of O
RUPP O
Autism O
Network O
data O
. O
['Life-Impact']

OBJECTIVE O
The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
whether O
an O
IVF O
protein O
supplement O
prepared O
from O
human O
serum O
albumin O
( O
HSA O
) O
and O
human O
globulins O
would O
retain O
performance B-outcome ['Life-Impact']
characteristics O
equivalent O
to O
those O
reported O
for O
the O
commercial O
plasma O
expanders O
, O
Plasmatein O
( O
Alpha O
Therapeutics O
, O
Los O
Angeles O
, O
California O
) O
and O
Plasmanate O
( O
Cutter O
Biological O
, O
Miles O
Inc. O
, O
Elkhart O
, O
Indiana O
) O
. O
['Life-Impact']

RESULTS O
Of O
the O
121 O
patients O
who O
participated O
, O
59 O
received O
C/A O
and O
62 O
received O
H/A O
. O
[]

Clomipramine O
versus O
haloperidol O
in O
the O
treatment O
of O
autistic O
disorder O
: O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

The O
anthracycline-treated O
cohort O
consisted O
of O
21 O
men O
and O
21 O
women O
with O
a O
mean O
age O
of O
55 O
? O
[]

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
huIFN-?2a O
, O
AZT O
and O
a O
combination O
of O
both O
drugs O
in O
cats O
infected O
naturally O
with O
FeLV O
in O
a O
placebo-controlled O
double-blinded O
trial O
. O
[]

Significant O
differences O
were O
observed O
among O
swim B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
with O
Cr O
subjects O
swimming O
significantly O
faster O
than O
P O
subjects O
following O
supplementation O
in O
Heat O
1 O
and O
significantly O
decreasing O
swim B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
in O
the O
second O
100-m O
sprint O
. O
['Life-Impact', 'Life-Impact']

In O
addition O
, O
patients O
in O
the O
case O
group O
were O
asked O
to O
observe O
video O
clips O
showing O
daily O
actions O
and O
to O
imitate O
them O
afterward O
. O
[]

Markers O
of O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
-- O
serum O
total O
alkaline B-outcome ['Physiological-Clinical']
phosphatase B-outcome ['Physiological-Clinical']
, O
bone-specific B-outcome ['Physiological-Clinical']
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
tartrate-resistant B-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
osteocalcin B-outcome ['Physiological-Clinical']
, O
intact B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Women O
with O
a O
Bishop O
score O
< O
or O
= O
6 O
at O
38 O
to O
40 O
weeks O
' O
gestation O
were O
administered O
either O
2 O
mg O
of O
intravaginal O
prostaglandin O
E2 O
gel O
or O
placebo O
for O
5 O
consecutive O
days O
as O
outpatients O
while O
undergoing O
fetal O
monitoring O
. O
[]

Fifty O
pairs O
of O
sheep O
tibiae O
were O
utilized O
in O
the O
experiment O
. O
[]

Best O
response O
rates O
and O
median O
time O
to O
tumor B-outcome ['Physiological-Clinical']
progression B-outcome ['Physiological-Clinical']
for O
high O
versus O
low O
thymidine O
phosphorylase O
expression O
were O
27.6 O
% O
versus O
6.3 O
% O
( O
P O
= O
0.023 O
) O
and O
5.4 O
versus O
1.9 O
months O
( O
P O
= O
0.076 O
) O
, O
and O
for O
folylpolyglutamate O
synthetase O
were O
37.5 O
% O
versus O
10.0 O
% O
( O
P O
= O
0.115 O
) O
and O
8.6 O
versus O
3.0 O
months O
( O
P O
= O
0.019 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Treatment O
with O
parenteral O
iron O
and O
low-dose O
rHuEPO-? O
in O
bilateral O
TKRA O
effectively O
attenuated O
anemia O
and O
decreased O
transfusion O
requirements O
in O
iron-deficient O
patients O
. O
[]

Endothelin-1 B-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
and O
12 O
weeks O
. O
['Physiological-Clinical']

RESULTS O
We O
found O
that O
during O
the O
postoperative O
period O
of O
1-8 O
h O
, O
patients O
in O
Group O
D O
reported O
a O
lower O
incidence O
of O
PONV B-outcome ['Physiological-Clinical']
( O
24 O
% O
) O
than O
those O
in O
Group O
P O
( O
39 O
% O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

We O
measured O
the O
brachial O
and O
central O
( O
carotid O
) O
blood O
pressure O
simultaneously O
using O
a O
validated O
device O
, O
and O
the O
B-type O
natriuretic O
peptide O
at O
baseline O
and O
at O
the O
sixth O
month O
of O
treatment O
. O
[]

For O
their O
second O
and O
third O
infusions O
, O
patients O
were O
randomized O
to O
receive O
Z O
then O
P O
or O
P O
then O
Z O
, O
and O
questioned O
on O
their O
preferences O
. O
[]

BACKGROUND O
Tailored O
nutrition O
interventions O
have O
been O
shown O
to O
be O
more O
effective O
than O
non-tailored O
materials O
in O
changing O
dietary O
behaviours O
, O
particularly O
fat O
intake O
and O
fruit O
and O
vegetable O
intake O
. O
[]

FINDINGS O
Mechanical O
efficiency O
increased O
and O
metabolic B-outcome ['Physiological-Clinical']
cost I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
experimental O
group O
compared O
to O
the O
control O
group O
. O
['Physiological-Clinical']

Polar O
body-extruded O
oocytes O
from O
the O
IVO O
and O
IVM O
groups O
were O
processed O
for O
chromosomal O
analysis O
. O
[]

All O
subjects O
had O
at O
least O
one O
gastric O
lesion O
except O
for O
two O
individuals O
taking O
ibuprofen-arginate O
. O
[]

Befriending O
as O
an O
intervention O
for O
chronic O
depression O
among O
women O
in O
an O
inner O
city O
. O
[]

Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
in O
children O
and O
adolescents O
by O
a O
once O
daily O
6-day O
treatment O
with O
or O
without O
a O
proton O
pump O
inhibitor O
in O
a O
double-blind O
randomized O
trial O
. O
['Physiological-Clinical']

6.74 O
, O
p O
= O
0.007 O
at O
60-90 O
s. O
Post-ischemia O
: O
basal O
L-arginine O
36.60 O
? O
[]

MPIS B-outcome ['Physiological-Clinical']
and O
forced B-outcome ['Physiological-Clinical']
expiratory B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
A O
randomized O
, O
double-blind O
controlled O
trial O
. O
[]

RESULTS O
The O
reduction O
of O
AVM B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
( O
79.4 O
% O
in O
the O
n-BCA O
group O
and O
86.9 O
% O
in O
the O
PVA O
group O
) O
and O
the O
mean O
number O
of O
vessels B-outcome ['Physiological-Clinical']
embolized I-outcome ['Physiological-Clinical']
( O
2.2 O
in O
the O
n-BCA O
group O
and O
2.1 O
in O
the O
PVA O
group O
) O
was O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
captopril O
( O
C O
) O
( O
50 O
mg O
, O
three O
times O
daily O
for O
3 O
days O
) O
on O
arterial O
pressure O
( O
AP O
) O
, O
O2 O
consumption O
( O
VO2 O
) O
, O
variations O
in O
auricular O
natriuretic O
factor O
( O
ANF O
) O
, O
renin O
, O
angiotensin O
II O
( O
AII O
) O
plasma O
levels O
, O
as O
well O
as O
glomerular O
filtration O
rate O
( O
GFR O
) O
and O
microalbuminuria O
( O
MA O
) O
were O
evaluated O
. O
[]

Confocal O
microscopy O
assessments O
correlated O
well O
with O
the O
histologic O
diagnosis O
. O
[]

Correlations O
with O
other O
measures O
of O
repetitive O
behavior O
ranged O
from O
r O
= O
0.11 O
to O
r O
= O
0.28 O
and O
were O
similar O
to O
correlations O
with O
measures O
of O
irritability B-outcome ['Life-Impact']
( O
r O
= O
0.24 O
) O
and O
hyperactivity B-outcome ['Life-Impact']
( O
r O
= O
0.25 O
) O
. O
['Life-Impact', 'Life-Impact']

With O
LIS O
the O
response O
was O
18.8 O
( O
15.0-22.5 O
) O
/14.6 O
( O
12.0-17.1 O
) O
mmHg O
for O
men O
and O
12.4 O
( O
8.7-16.2 O
) O
/7.7 O
( O
5.1-10.2 O
) O
mmHg O
for O
women O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
a O
carbohydrate O
restricted O
versus O
a O
low O
fat O
diet O
on O
weight O
loss O
, O
metabolic O
markers O
, O
body O
composition O
, O
and O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests I-outcome ['Physiological-Clinical']
in O
severely O
obese O
adolescents O
. O
['Physiological-Clinical']

Subgroup O
analysis O
found O
some O
significant O
interactions O
between O
intervention O
and O
secondary O
outcomes O
. O
[]

Patients O
who O
developed O
worsening O
dysphagia O
during O
follow-up O
were O
offered O
further O
treatment O
as O
appropriate O
. O
[]

Both O
patients O
and O
physicians O
reported O
a O
greater O
overall O
improvement O
in O
symptoms O
for O
the O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
group O
. O
[]

RESULTS O
On O
most O
measures O
( O
systolic O
blood O
pressure O
, O
heart O
rate O
, O
hand O
steadiness O
, O
reaction O
time O
, O
fatigue O
, O
and O
tension O
) O
, O
drug O
administration O
instructions O
did O
not O
significantly O
influence O
caffeine B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
donepezil O
for O
relieving O
symptoms O
of O
dementia O
in O
VaD O
. O
[]

The O
data O
were O
compiled O
in O
a O
computer O
program O
designed O
for O
this O
study O
and O
evaluated O
by O
the O
statisticians O
. O
[]

This O
study O
was O
designed O
to O
compare O
stapled O
technique O
with O
the O
well-accepted O
conventional O
Milligan O
Morgan O
hemorrhoidectomy O
. O
[]

All O
patients O
were O
followed O
up O
for O
24 O
weeks O
( O
W24 O
) O
. O
[]

The O
energy O
percent O
of O
fat O
in O
the O
food O
had O
no O
differential O
impact O
. O
[]

The O
response O
rates O
for O
control O
of O
pleural B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
were O
73.4 O
% O
in O
the O
N-CWS O
group O
and O
46.1 O
% O
in O
the O
N-CWS O
group O
. O
['Physiological-Clinical']

They O
were O
divided O
randomly O
into O
experimental O
group O
and O
control O
one O
, O
and O
respectively O
received O
auditory O
integrative O
training O
and O
no O
training O
based O
on O
the O
multiple O
therapies O
. O
[]

A O
3 O
day O
balance O
was O
performed O
at O
the O
end O
of O
each O
period O
, O
and O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
collected O
. O
['Physiological-Clinical']

Moreover O
, O
during O
quadruple O
therapy O
, O
a O
higher O
prevalence O
and O
intensity O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
than O
in O
each O
one O
of O
the O
groups O
submitted O
to O
the O
first-line O
triple O
therapy O
was O
observed O
. O
['Adverse-effects']

AIM O
To O
compare O
the O
efficacy O
of O
two O
second-line O
therapies O
for O
persistent O
H. O
pylori O
infection O
. O
[]

The O
reductions O
achieved O
in O
each O
of O
the O
nifedipine O
SR O
groups O
were O
statistically O
significant O
versus O
baseline O
values O
( O
p O
less O
than O
0.001 O
) O
. O
[]

RESULTS O
A O
2x2x19 O
analysis O
of O
variance O
was O
conducted O
with O
main O
effects O
of O
treatment O
condition B-outcome ['Physiological-Clinical']
, O
cohort O
, O
and O
baseline O
distress B-outcome ['Physiological-Clinical']
and O
their O
interactions B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Previous O
studies O
suggest O
that O
less O
costly O
, O
pulsed O
doses O
of O
antifungal O
medications O
may O
be O
as O
effective O
as O
standard O
, O
continuous O
doses O
. O
[]

Late O
left O
atrial O
remodeling O
depended O
on O
the O
type O
of O
atrial O
[]

While O
there O
was O
no O
change O
in O
inflammatory B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
or O
lipid B-outcome ['Physiological-Clinical']
parameters O
, O
cardiovascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
by O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
after O
exercise O
improved O
with O
MET O
and O
worsened O
in O
placebo O
( O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
mean O
age O
of O
patients O
was O
46.02 O
years O
( O
SD O
, O
12.33 O
) O
in O
the O
stapled O
group O
and O
48.64 O
years O
( O
14.57 O
) O
in O
the O
open O
group O
. O
[]

From O
the O
registries O
, O
90 O
residents O
, O
aged O
20 O
to O
49 O
years O
old O
, O
were O
randomly O
selected O
to O
represent O
each O
sex O
from O
each O
area O
. O
[]

Pathogens O
were O
identified O
with O
16S B-outcome ['Physiological-Clinical']
rRNA I-outcome ['Physiological-Clinical']
oligodeoxynucleotide I-outcome ['Physiological-Clinical']
probes I-outcome ['Physiological-Clinical']
and O
dot-blot O
hybridization O
before O
and O
at O
days O
2 O
, O
3 O
, O
4 O
, O
7 O
, O
10 O
, O
and O
21 O
of O
healing O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
different O
clodronate O
regimens O
in O
postmenopausal O
osteoporosis O
. O
[]

In O
the O
first O
group O
of O
19 O
patients O
, O
main O
trunk O
of O
the O
inferior O
thyroid O
artery O
was O
ligated O
and O
in O
the O
second O
one O
consisting O
of O
18 O
patients O
, O
only O
the O
branches O
of O
this O
artery O
were O
ligated O
. O
[]

In O
REGRESS O
, O
patients O
in O
the O
pravastatin O
group O
had O
significantly O
less O
progression B-outcome ['Physiological-Clinical']
if O
cotreated O
with O
CCBs O
as O
compared O
with O
those O
with O
no O
CCB O
cotreatment O
, O
whereas O
in O
the O
placebo O
( O
no O
pravastatin O
) O
group O
no O
effect O
of O
CCB O
treatment O
was O
observed O
. O
['Physiological-Clinical']

TZD O
increased O
the O
SDF-1-induced B-outcome ['Physiological-Clinical']
migratory I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
to O
146 O
+/- O
9 O
% O
per O
EPC O
number O
( O
P O
< O
0.05 O
) O
and O
upregulated O
the O
clonogenic B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
of O
EPCs B-outcome ['Physiological-Clinical']
, O
increasing O
the O
colony-forming B-outcome ['Physiological-Clinical']
units O
to O
172 O
+/- O
12 O
% O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
relationship O
between O
peer O
and O
adolescent B-outcome ['Life-Impact']
substance I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
were O
assessed O
in O
parallel O
processes O
as O
part O
of O
an O
autoregressive O
latent O
trajectory O
model O
. O
['Life-Impact']

RESULTS O
The O
authors O
demonstrated O
that O
total O
and O
conjugated B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
alanine B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
, O
aspartate B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
and O
cholinesterase B-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
during O
the O
5-days O
observation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
132 O
patients O
with O
hematological O
malignancy O
in O
complete O
remission O
without O
any O
main O
organ O
dysfunction O
who O
had O
been O
treated O
between O
April O
1983 O
and O
December O
1997 O
. O
[]

After O
stratifying O
for O
parity O
, O
we O
compared O
rates O
of O
urinary B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
UI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
sexual B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
at O
3 O
months O
postpartum O
in O
women O
who O
had O
a O
VB O
with O
the O
rates O
in O
women O
who O
had O
a O
CS O
. O
['Physiological-Clinical', 'Life-Impact']

In O
group O
I O
, O
thrombolysis O
was O
successful O
in O
all O
patients O
, O
without O
complications B-outcome ['Adverse-effects']
, O
within O
6-72 O
h. O
In O
group O
II O
, O
heparin O
treatment O
was O
successful O
in O
six O
patients O
in O
3-32 O
days O
. O
['Adverse-effects']

RESULTS O
The O
percentage O
of O
ursodeoxycholic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bile I-outcome ['Physiological-Clinical']
increased O
by O
42 O
% O
in O
the O
UDCA O
group O
( O
n O
= O
61 O
) O
compared O
with O
8 O
% O
in O
the O
placebo O
group O
( O
n O
= O
57 O
) O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Actuarial O
3-year O
overall O
survival O
in O
the O
chemotherapy O
arm O
was O
82 O
% O
, O
compared O
to O
61 O
% O
in O
the O
no-chemotherapy O
arm O
( O
P O
= O
0.18 O
) O
. O
[]

On O
day O
16 O
, O
a O
higher O
mean O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
a O
lower O
proportion O
of O
patients O
with O
severe O
( O
< O
500/microL O
) O
neutropenia B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
standard O
group O
included O
restrictions O
to O
avoid O
hip O
flexion O
> O
90 O
degrees O
and O
avoidance O
of O
riding O
in O
a O
car O
for O
the O
first O
postoperative O
month O
. O
[]

Psychological O
factors O
influence O
the O
course O
of O
the O
disease O
and O
should O
be O
targeted O
for O
intervention O
. O
[]

The O
mean O
duration O
of O
treatment O
at O
home O
each O
day O
was O
126 O
minutes O
( O
11 O
to O
496 O
) O
. O
[]

This O
study O
sought O
to O
test O
the O
clinical B-outcome ['Physiological-Clinical']
effectiveness O
of O
PD O
pharmacotherapy O
embedded O
in O
a O
disease O
management O
framework O
of O
collaborative O
care O
( O
CC O
) O
. O
['Physiological-Clinical']

Operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
significantly O
shorter O
in O
the O
thermal O
destruction O
group O
( O
24 O
+/- O
4 O
minutes O
vs O
37 O
+/- O
6 O
minutes O
) O
. O
['Life-Impact']

PURPOSE O
The O
European O
Intergroup O
Cooperative O
Ewing O
's O
Sarcoma O
Study O
investigated O
whether O
cyclophosphamide O
has O
a O
similar O
efficacy O
as O
ifosfamide O
in O
standard-risk O
( O
SR O
) O
patients O
and O
whether O
the O
addition O
of O
etoposide O
improves O
survival B-outcome ['Mortality']
in O
high-risk O
( O
HR O
) O
patients O
. O
['Mortality']

Data O
were O
analysed O
using O
repeated O
measures O
anova O
; O
P O
< O
0.05 O
was O
statistically O
significant O
. O
[]

Fifty-two O
patients O
undergoing O
coronary O
artery O
bypass O
on O
cardiopulmonary O
bypass O
were O
divided O
randomly O
into O
3 O
groups O
: O
the O
first O
group O
received O
100 O
microg O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
propofol O
, O
the O
other O
groups O
received O
one O
minimum O
alveolar O
concentration O
of O
sevoflurane O
or O
isoflurane O
for O
anesthesia O
maintenance O
. O
[]

There O
were O
three O
responses O
among O
77 O
patients O
crossed O
over O
to O
mitoxantrone O
after O
initial O
treatment O
with O
doxorubicin O
. O
[]

No O
differences O
were O
detected O
on O
teacher-rated O
measures O
. O
[]

Ten O
( O
38 O
% O
) O
relapsed B-outcome ['Physiological-Clinical']
despite O
local O
testicular O
irradiation O
and O
systemic O
re-treatment O
; O
six O
of O
the O
10 O
died B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Individuals O
with O
Asperger O
's O
syndrome O
( O
AS O
) O
often O
have O
difficulties O
with O
social O
interactions O
and O
conversations O
. O
[]

for O
16 O
and O
12 O
wk O
separated O
by O
a O
6-month O
interval O
[ O
756 O
million O
units O
] O
) O
. O
[]

The O
evidence O
appears O
to O
suggest O
the O
possibility O
that O
the O
presence O
of O
a O
patient O
's O
husband O
as O
a O
supportive O
figure O
may O
of O
itself O
be O
a O
potent O
therapeutic O
manoeuvre O
in O
the O
treatment O
of O
dysthymic O
women O
. O
[]

RESULTS O
The O
average O
number O
of O
lesions B-outcome ['Physiological-Clinical']
in O
the O
diclofenac O
sodium O
group O
before O
and O
after O
treatment O
was O
13.6 O
and O
6.6 O
( O
p O
< O
0,001 O
) O
, O
respectively O
, O
while O
it O
was O
17.4 O
and O
3.15 O
( O
p O
< O
0.001 O
) O
in O
the O
5-Fluorouracil O
group O
. O
['Physiological-Clinical']

A O
sensory O
integration O
therapy O
program O
on O
sensory O
problems O
for O
children O
with O
autism O
. O
[]

PATIENTS O
100 O
patients O
with O
bilateral O
endometriomas O
. O
[]

A O
comparison O
of O
propranolol O
and O
nadolol O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
clinical O
effects O
in O
thyrotoxicosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Emerging O
technologies O
require O
robust O
evaluation O
before O
routine O
use O
. O
[]

These O
results O
indicate O
a O
significant O
effect O
of O
sexual B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sodium-potassium I-outcome ['Physiological-Clinical']
pump I-outcome ['Physiological-Clinical']
in O
children O
. O
['Physiological-Clinical']

EEG O
mapping O
and O
psychopharmacological O
studies O
with O
denbufylline O
in O
SDAT O
and O
MID O
. O
[]

This O
agent O
improved O
overall O
survival O
in O
a O
phase O
III O
trial O
in O
previously O
treated O
patients O
with O
advanced O
melanoma O
. O
[]

The O
predominant O
organisms O
included O
gram-positive O
cocci O
( O
53.0 O
percent O
) O
, O
gram-negative O
bacilli O
( O
22.4 O
percent O
) O
, O
and O
candida O
species O
( O
16.0 O
percent O
) O
. O
[]

The O
SGRQ O
Total O
score O
and O
[]

BNP-guided O
vs O
symptom-guided O
heart O
failure O
therapy O
: O
the O
Trial O
of O
Intensified O
vs O
Standard O
Medical O
Therapy O
in O
Elderly O
Patients O
With O
Congestive O
Heart O
Failure O
( O
TIME-CHF O
) O
randomized O
trial O
. O
[]

HAI O
FUDR O
treatment O
was O
inferior O
as O
compared O
to O
HAI O
or O
i.v O
. O
[]

Co-morbid O
medical O
conditions O
are O
common O
among O
breast O
cancer O
survivors O
. O
[]

Vitreous O
specimens O
were O
obtained O
by O
biopsy O
with O
a O
20-gauge O
vitrectomy O
cutting O
instrument O
or O
by O
needle O
tap O
with O
a O
22-27-gauge O
needle O
. O
[]

Prophylaxis O
was O
continued O
until O
the O
patient O
achieved O
complete O
remission O
or O
was O
treated O
for O
8 O
weeks O
without O
antileukemic O
response O
. O
[]

No O
bladder B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
occurred O
in O
either O
group O
and O
there O
were O
no O
significant O
differences O
in O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
, O
postoperative B-outcome ['Physiological-Clinical']
microhematuria I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
, O
endometritis B-outcome ['Physiological-Clinical']
, O
or O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

In O
experimental O
studies O
, O
activation O
of O
the O
inflammatory O
regulator O
, O
nuclear O
factor O
kappa O
B O
( O
NFlB O
) O
, O
contributes O
to O
endothelial O
activation O
and O
reduced O
nitric O
oxide O
production O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
, O
using O
a O
microdialysis O
technique O
, O
whether O
modifications O
in O
the O
proportion O
of O
fat O
in O
the O
diet O
influence O
lipid B-outcome ['Life-Impact']
mobilization I-outcome ['Life-Impact']
from O
adipose O
tissue O
in O
situ O
. O
['Life-Impact']

In O
conclusion O
, O
long-term O
anticoagulant O
therapy O
may O
be O
recommended O
after O
acute O
myocardial O
infarction O
. O
[]

Controversy O
exists O
regarding O
the O
extent O
and O
possible O
causal O
relationship O
between O
gastrointestinal O
symptoms O
and O
autism O
. O
[]

The O
training O
was O
performed O
for O
45 O
min O
twice O
a O
week O
for O
6 O
months O
at O
intensities O
between O
85 O
% O
and O
90 O
% O
maximal O
heart O
rate O
( O
HRmax O
) O
. O
[]

Famotidine O
treatment O
of O
children O
with O
autistic O
spectrum O
disorders O
: O
pilot O
research O
using O
single O
subject O
research O
design O
. O
[]

The O
results O
presented O
here O
are O
based O
on O
data O
collected O
4 O
months O
following O
treatment O
, O
which O
shows O
an O
86 O
% O
response O
rate O
. O
[]

In O
vivo O
effect O
of O
clarithromycin O
on O
multiple O
cytochrome O
P450s O
. O
[]

Comparison O
of O
gonadotropin-releasing O
hormone O
agonists O
and O
antagonists O
in O
assisted O
reproduction O
cycles O
of O
polycystic O
ovarian O
syndrome O
patients O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
Abeta I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
decreased O
in O
a O
dose-dependent O
manner O
over O
a O
6-hour O
interval O
following O
drug O
administration O
, O
with O
a O
maximum O
decrease O
of O
approximately O
40 O
% O
relative O
to O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
randomized O
, O
open-labeled O
, O
prospective O
controlled O
trial O
comparing O
sequential O
vs. O
standard O
triple-drug O
therapy O
was O
carried O
out O
at O
Lokmanya O
Tilak O
Municipal O
General O
Hospital O
, O
Mumbai O
. O
[]

Abstinence B-outcome ['Life-Impact']
rates O
did O
not O
differ O
by O
study O
group O
among O
subjects O
who O
took O
at O
least O
75 O
% O
of O
their O
study O
medication O
. O
['Life-Impact']

Following O
consent O
, O
patients O
were O
randomized O
into O
two O
groups O
. O
[]

The O
differences O
in O
changes O
between O
the O
groups O
were O
statistically O
significant O
only O
for O
global B-outcome ['Physiological-Clinical']
fibrinolysis I-outcome ['Physiological-Clinical']
( O
serum O
D-dimer O
, O
P=.046 O
) O
. O
['Physiological-Clinical']

In O
all O
experiments O
, O
5 O
g O
arginine O
were O
given O
iv O
as O
a O
bolus O
dose O
30 O
min O
before O
the O
end O
of O
the O
study O
, O
and O
plasma B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
and O
glucagon B-outcome ['Physiological-Clinical']
levels O
were O
determined O
to O
assess O
islet O
cell O
function O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pearson O
coefficients O
for O
correlation O
of O
quantitative O
spasticity O
measures O
with O
TTT B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
lower O
but O
also O
significant O
( O
P O
< O
or O
= O
0.07 O
) O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
trial O
comparing O
pre-operative O
vs. O
postoperative O
radiochemotherapy O
in O
rectal O
cancer O
patients O
. O
[]

Evidence-based O
medications O
of O
myocardial O
infarction O
were O
seldom O
started O
and O
cardiologist O
was O
consulted O
in O
12 O
patients O
( O
16.9 O
% O
) O
. O
[]

Drug O
use O
was O
measured O
with O
multiple O
weekly O
urine O
toxicologies O
. O
[]

The O
study O
did O
not O
demonstrate O
any O
difference O
between O
DOPEG O
and O
MOPEG O
for O
most O
of O
the O
experimental O
factors O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
scheduled O
to O
undergo O
ESD O
for O
early O
gastric O
cancer O
or O
adenoma O
were O
randomly O
assigned O
to O
sedation O
with O
midazolam O
or O
propofol O
, O
and O
consciousness O
level O
was O
evaluated O
by O
bispectral O
index O
( O
BIS O
) O
monitoring O
. O
[]

CONCLUSION O
In O
mild-to-moderate O
hypertensive O
patients O
, O
visit-to-visit O
BP O
variability O
does O
not O
differ O
substantially O
between O
?-blocker O
and O
calcium O
antagonist O
treatment O
. O
[]

Stratification O
was O
made O
by O
gross O
motor O
function O
classification O
system O
levels O
, O
and O
allocation O
was O
concealed O
. O
[]

Therefore O
, O
a O
total O
of O
534 O
patients O
were O
evaluable O
( O
226 O
patients O
with O
IFN/HU O
and O
308 O
patients O
with O
HU O
) O
. O
[]

Fifty O
patients O
were O
recruited O
in O
the O
school O
's O
Urgent O
Care O
Clinic O
and O
divided O
evenly O
into O
two O
groups O
: O
one O
( O
control O
) O
receiving O
the O
standard O
consent O
, O
with O
the O
second O
receiving O
a O
SmartConsent O
. O
[]

RESULTS O
A O
significant O
improvement O
of O
the O
clinical B-outcome ['Physiological-Clinical']
WSL-scores O
was O
found O
over O
time O
in O
both O
groups O
, O
but O
there O
was O
a O
statistically O
significant O
difference O
( O
p O
< O
0.01 O
) O
concerning O
the O
number O
of O
sites O
that O
totally O
disappeared B-outcome ['Physiological-Clinical']
after O
12 O
months O
in O
favour O
of O
the O
CPP-ACP O
regime O
, O
63 O
% O
compared O
with O
25 O
% O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Midazolam O
2 O
mg O
or O
ondansetron O
4 O
mg O
were O
administered O
intravenously O
30 O
min O
before O
the O
end O
of O
surgery O
. O
[]

The O
effect O
of O
magnesium O
added O
to O
levobupivacaine O
for O
femoral O
nerve O
block O
on O
postoperative O
analgesia O
in O
patients O
undergoing O
ACL O
reconstruction O
. O
[]

Retrieved O
immature O
oocyte O
cumulus O
complexes O
were O
cultured O
for O
30 O
or O
36 O
hours O
in O
one O
of O
six O
IVM O
culture O
conditions O
containing O
FF-MAS O
( O
range O
, O
0.1-20 O
microM O
) O
. O
[]

Serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
treatment O
due O
to O
psychiatric O
conditions O
were O
associated O
with O
AR-R15896AR O
( O
3 O
vs. O
0 O
) O
. O
['Adverse-effects']

We O
conclude O
that O
measuring O
individual O
biochemical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
can O
help O
to O
predict O
the O
bone B-outcome ['Physiological-Clinical']
effect O
of O
an O
increase O
in O
the O
circulating O
estradiol O
in O
women O
with O
ovarian O
deficiency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
the O
LDMI O
condition O
, O
1RM O
values O
were O
lower O
( O
on O
average O
-4 O
% O
) O
than O
in O
the O
other O
4 O
conditions O
( O
345.6 O
? O
[]

BACKGROUND/AIMS O
Helicobacter O
pylori O
( O
H. O
pylori O
) O
infection O
is O
one O
of O
the O
most O
common O
gastrointestinal O
diseases O
. O
[]

However O
, O
responses B-outcome ['Physiological-Clinical']
were O
of O
short O
duration O
( O
16-91 O
days O
) O
. O
['Physiological-Clinical']

The O
SCATA O
was O
used O
to O
measure O
communicative O
ability O
longitudinally O
in O
two O
samples O
of O
toddlers O
with O
autism O
spectrum O
disorder O
. O
[]

According O
uroflowmetry O
, O
peak O
flow B-outcome ['Physiological-Clinical']
rate O
after O
6 O
months O
of O
treatment O
was O
increased O
by O
more O
than O
50 O
% O
. O
['Physiological-Clinical']

Postinjection O
, O
12 O
% O
and O
18 O
% O
of O
the O
subjects O
experienced O
temporary B-outcome ['Physiological-Clinical']
numbness/paresthesia I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
incisive I-outcome ['Physiological-Clinical']
papilla I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
and O
mepivacaine O
solutions O
, O
respectively O
. O
['Physiological-Clinical']

From O
these O
results O
, O
we O
conclude O
that O
relaxation O
and O
imagery O
training O
reduces O
cancer B-outcome ['Physiological-Clinical']
treatment-related O
['Physiological-Clinical']

5 O
% O
frequency O
in O
the O
total O
group O
) O
AEs O
were O
increased O
appetite O
( O
11 O
% O
[ O
n=9 O
] O
) O
; O
increased O
weight O
and O
vomiting O
( O
9 O
% O
[ O
n=7 O
] O
each O
) O
; O
sedation O
, O
pyrexia O
, O
and O
upper O
respiratory O
tract O
infection O
( O
8 O
% O
[ O
n=6 O
] O
each O
) O
; O
nasopharyngitis O
( O
6 O
% O
[ O
n=5 O
] O
) O
; O
and O
somnolence O
and O
fatigue O
( O
5 O
% O
[ O
n=4 O
] O
each O
) O
. O
[]

To O
detect O
trends O
in O
confidence O
, O
confidence O
scores O
were O
plotted O
over O
time O
, O
and O
multiple O
linear O
regression O
analysis O
was O
performed O
. O
[]

In O
a O
limited O
study O
of O
adhesion O
molecule O
expression O
, O
down-regulation O
of O
E-selectin B-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule-1 I-outcome ['Physiological-Clinical']
was O
observed O
after O
treatment O
with O
IL-1Ra O
150 O
mg/day O
, O
but O
not O
after O
IL-1Ra O
30 O
mg/day O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
recommended O
that O
in O
nephrectomies O
undertaken O
for O
primary O
renal O
cell O
carcinoma O
at O
least O
one O
random O
block O
of O
renal O
cortex O
should O
be O
examined O
to O
confirm O
or O
exclude O
intraglomerular O
metastases O
. O
[]

However O
, O
the O
cortisol B-outcome ['Physiological-Clinical']
response O
to O
weaning B-outcome ['Physiological-Clinical']
was O
increased O
in O
LP O
piglets O
( O
P O
< O
0.05 O
) O
, O
and O
in O
HP O
offspring O
the O
basal B-outcome ['Physiological-Clinical']
plasma B-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
describes O
the O
safety O
and O
efficacy O
of O
inhaled O
treprostinil O
in O
children O
with O
PAH O
. O
[]

Metronidazole O
is O
an O
agent O
with O
reported O
success O
in O
the O
treatment O
of O
anaerobic O
periodontal O
infections O
. O
[]

Skill B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
retention B-outcome ['Life-Impact']
were O
shown O
to O
be O
high O
following O
either O
training O
method O
, O
with O
no O
significant O
difference O
between O
the O
performance B-outcome ['Life-Impact']
of O
either O
group O
( O
chi O
2 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Repeat O
SEPS O
was O
successful O
in O
25 O
of O
these O
96 O
patients O
, O
and O
deep O
valve O
repair O
was O
successful O
in O
4 O
patients O
. O
[]

RESULTS O
Night B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
and O
potassium B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
increased O
( O
urinary O
Na O
( O
+ O
) O
, O
P O
< O
0.05 O
; O
urinary O
K O
( O
+ O
) O
, O
P O
< O
0.01 O
) O
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowered O
by O
5.3 O
mm O
Hg/1.8 O
mm O
Hg O
in O
average O
from O
the O
baseline O
in O
the O
supplementary O
group O
two O
years O
after O
potassium O
and O
calcium O
supplementation O
, O
as O
compared O
with O
that O
in O
the O
control O
group O
increased O
by O
( O
1.3/1.7 O
) O
mm O
Hg O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
visual O
supports O
on O
performance B-outcome ['Life-Impact']
of O
the O
TGMD-2 O
for O
children O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

0.05 O
, O
0.43 O
? O
[]

CONCLUSION O
A O
relatively O
small O
and O
central O
capsulorhexis O
allowing O
for O
the O
complete O
covering O
of O
the O
IOL O
optics O
by O
the O
rhexis O
edges O
seems O
to O
protect O
against O
PCO B-outcome ['Physiological-Clinical']
in O
cataract O
surgery O
, O
with O
both O
round-edged O
silicone O
IOLs O
and O
sharp-edged O
hydrophobic O
acrylic O
IOLs O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
, O
single-blinded O
, O
with O
12-week O
follow-up O
. O
[]

There O
were O
no O
significant O
changes O
in O
the O
control O
group O
. O
[]

OBJECTIVE O
We O
investigated O
the O
changes O
in O
the O
temporomandibular O
joint O
( O
TMJ O
) O
after O
bilateral O
sagittal O
split O
osteotomy O
of O
the O
mandible O
for O
orthognathic O
surgery O
and O
the O
influence O
of O
positioning O
of O
the O
condylar O
process O
in O
the O
centre O
of O
the O
articular O
fossa O
before O
and O
during O
the O
operation O
for O
preventing O
changes O
in O
the O
TMJ O
postoperatively O
. O
[]

After O
adjustment O
for O
these O
factors O
, O
receiving O
an O
ICD O
was O
associated O
with O
a O
decreased O
risk O
of O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
hazard O
ratio O
, O
0.33 O
; O
95 O
% O
confidence O
interval O
, O
0.15 O
to O
0.71 O
) O
but O
an O
increase O
in O
nonarrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
hazard O
ratio O
, O
1.70 O
; O
95 O
% O
confidence O
interval O
, O
1.00 O
to O
2.80 O
) O
. O
['Mortality', 'Mortality']

This O
randomized O
, O
double-blind O
, O
triple-dummy O
, O
parallel-groups O
study O
compared O
rizatriptan O
5 O
mg O
, O
rizatriptan O
10 O
mg O
, O
sumatriptan O
100 O
mg O
, O
and O
placebo O
in O
1268 O
outpatients O
treating O
a O
single O
migraine O
attack O
. O
[]

CONCLUSION O
Our O
findings O
suggest O
that O
the O
hypofractionation O
regimen O
used O
in O
our O
study O
is O
safe O
, O
with O
only O
a O
slight O
, O
nonsignificant O
increase O
in O
tolerable O
and O
temporary O
acute B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
compared O
with O
the O
conventional O
fractionation O
schedule O
. O
['Life-Impact', 'Adverse-effects']

OBJECTIVE O
To O
compare O
transperitoneal O
, O
extraperitoneal O
and O
laparoscopic O
pelvic O
lymphadenectomy O
in O
terms O
of O
feasibility B-outcome ['Life-Impact']
and O
morbidity B-outcome ['Physiological-Clinical']
in O
patients O
affected O
by O
cervical O
cancer O
undergoing O
radical O
hysterectomy O
. O
['Life-Impact', 'Physiological-Clinical']

PURPOSE O
We O
determined O
whether O
the O
decrease O
in O
serum O
PSA O
seen O
with O
5alpha-reductase O
inhibitors O
affects O
the O
clinical O
usefulness O
of O
PSA O
for O
prostate O
cancer O
screening O
using O
data O
from O
2 O
dutasteride O
benign O
prostatic O
hyperplasia O
studies O
. O
[]

Long-term O
effects O
. O
[]

RESULTS O
DHA O
supplementation O
increased O
the O
DHA B-outcome ['Physiological-Clinical']
concentration O
in O
plasma B-outcome ['Physiological-Clinical']
by O
76 O
% O
( O
P O
< O
0.0001 O
) O
and O
the O
proportion O
in O
erythrocyte B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
by O
58 O
% O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
was O
a O
phase O
III O
, O
multicenter O
study O
designed O
to O
evaluate O
the O
effectiveness O
of O
placebo O
versus O
empiric O
antibiotic O
treatment O
for O
clinical O
cure O
of O
MPC B-outcome ['Physiological-Clinical']
of O
unknown O
etiology O
at O
2-month O
follow-up O
. O
['Physiological-Clinical']

Treatment O
gains O
were O
maintained O
at O
3-month O
follow-up O
. O
[]

Contrary O
to O
prior O
research O
, O
this O
study O
found O
that O
reminder O
postcards O
did O
not O
improve O
response O
rates O
or O
rates O
[]

Relative O
risks O
for O
mortality O
in O
the O
vitamin O
A O
and O
beta O
carotene O
groups O
were O
1.15 O
( O
95 O
% O
CI O
, O
0.75-1.76 O
) O
and O
1.21 O
( O
95 O
% O
CI O
, O
0.81-1.81 O
) O
, O
respectively O
. O
[]

Groups O
did O
not O
differ O
on O
intent O
to O
diet B-outcome ['Life-Impact']
measured O
at O
post-exposure O
. O
['Life-Impact']

METHODS O
One O
hundred O
and O
fifty O
ASA O
I-II O
patients O
undergoing O
general O
anaesthesia O
were O
randomly O
allocated O
into O
three O
groups O
. O
[]

Execution O
of O
these O
skills O
in O
social O
interactions O
supports O
both O
the O
exchange O
of O
social O
knowledge O
and O
also O
the O
development O
and O
maintenance O
of O
personal O
relationships O
. O
[]

Osteoporosis O
and O
gait O
and O
balance O
disturbances O
in O
older O
sarcopenic O
obese O
New O
Zealanders O
. O
[]

The O
most O
common O
reason O
for O
unacceptable O
errors O
in O
the O
intervention O
group O
: O
vaccine O
was O
given O
too O
early O
; O
in O
the O
control O
group O
: O
vaccine O
was O
postponed O
to O
next O
visit O
. O
[]

PURPOSE O
To O
determine O
the O
appropriate O
irradiation O
dose O
after O
four O
cycles O
of O
modern O
combination O
chemotherapy O
in O
nonbulky O
involved O
field O
( O
IF/BF O
) O
and O
noninvolved O
extended-field O
( O
EF/IF O
) O
sites O
in O
patients O
with O
intermediate-stage O
Hodgkin O
's O
disease O
( O
HD O
) O
. O
[]

MATERIALS O
AND O
METHODS O
Twenty O
normotensive O
postmenopausal O
women O
( O
median O
age O
53 O
years O
) O
participated O
in O
the O
study O
which O
used O
a O
double-blind O
crossover O
design O
. O
[]

High O
doses O
of O
dexamethasone O
( O
50 O
mg/d O
for O
3 O
days O
weekly O
or O
every O
other O
week O
) O
were O
also O
prescribed O
. O
[]

Importantly O
, O
the O
number O
of O
deaths B-outcome ['Mortality']
related I-outcome ['Mortality']
to I-outcome ['Mortality']
infections I-outcome ['Mortality']
was O
significantly O
greater O
in O
the O
low O
versus O
high O
CD19 O
group O
( O
P O
< O
.0202 O
) O
. O
['Mortality']

morphine O
1 O
h O
after O
the O
surgery O
. O
[]

0.4 O
% O
; O
P O
= O
0.004 O
) O
and O
GTN-induced O
dilatation O
( O
16.6 O
? O
[]

In O
the O
subgroup O
of O
allogeneic O
SCT O
patients O
, O
HAI O
showed O
that O
the O
response O
rate O
to O
the O
influenza B-outcome ['Resource-use']
B I-outcome ['Resource-use']
vaccine I-outcome ['Resource-use']
was O
significantly O
higher O
in O
the O
treatment O
group O
( O
P O
< O
.05 O
) O
. O
['Resource-use']

RESULTS O
Raw O
scores O
, O
age-equivalents O
, O
and O
special O
norm O
percentile O
scores O
all O
showed O
significant O
increases O
in O
adaptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
areas I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
daily O
living B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact']

The O
initial O
cognitive O
therapy O
produced O
a O
significant O
reduction O
in O
panic B-outcome ['Life-Impact']
frequency I-outcome ['Life-Impact']
, O
while O
associative O
therapy O
did O
not O
affect O
panic O
. O
['Life-Impact']

Individual O
( O
OP-1 O
, O
OP-2 O
, O
OP-3 O
) O
and O
summed O
( O
OP-sum O
) O
amplitudes O
of O
oscillatory O
potentials O
( O
OPs O
) O
of O
electroretinography O
were O
recorded O
at O
study O
start O
and O
7-years O
later O
in O
45 O
patients O
( O
the O
Oslo O
study O
) O
. O
[]

It O
treats O
the O
cause O
of O
the O
disease O
. O
[]

A O
grade O
3 O
difficult O
intubation O
was O
simulated O
in O
patients O
with O
a O
laryngoscope O
. O
[]

Weights B-outcome ['Physiological-Clinical']
and O
heights B-outcome ['Physiological-Clinical']
were O
measured O
at O
the O
tri-monthly O
treatment O
visits O
for O
a O
period O
of O
one O
year O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
eprosartan O
on O
RPF O
are O
mediated O
, O
at O
least O
in O
part O
, O
by O
an O
increased O
bioavailability O
of O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
in O
the O
renal O
vasculature O
. O
['Physiological-Clinical']

The O
values O
of O
EC B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
50 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
k B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
eo I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastrin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
increased O
with O
multiple O
doses O
of O
rabeprazole O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Severe B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
44 O
percent O
and O
20 O
percent O
, O
respectively O
, O
of O
the O
patients O
who O
received O
combined O
therapy O
, O
as O
compared O
with O
25 O
percent O
and O
3 O
percent O
of O
those O
treated O
with O
radiation O
alone O
. O
['Adverse-effects']

When O
participants O
were O
given O
inclusion O
recall O
instructions O
to O
report O
studied O
items O
as O
well O
as O
related O
items O
, O
they O
still O
reported B-outcome ['Physiological-Clinical']
critical I-outcome ['Physiological-Clinical']
lures I-outcome ['Physiological-Clinical']
less O
often O
after O
picture O
encoding O
than O
they O
did O
after O
word O
encoding O
. O
['Physiological-Clinical']

Bronchial O
challenge O
with O
both O
agonists O
failed O
to O
alter O
significantly O
the O
airway B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
salbutamol O
, O
with O
the O
deltaFEV1 O
% O
init O
mean O
value O
( O
range O
) O
being O
16.9 O
% O
( O
9.0-31.9 O
) O
and O
17.5 O
% O
( O
11.6-31.2 O
) O
on O
the O
sham O
and O
histamine/methacholine O
challenge O
day O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
consider O
that O
RTD O
would O
be O
a O
promising O
polliative O
method O
for O
HCC O
. O
[]

Arch O
dimensions O
were O
followed O
; O
maxillary O
and O
mandibular O
alginate O
impressions O
were O
taken O
at O
baseline O
, O
end O
of O
early O
Class O
II O
treatment O
or O
observation O
, O
beginning O
of O
fixed O
appliance O
treatment O
, O
end O
of O
orthodontic O
treatment O
, O
and O
approximately O
3 O
years O
posttreatment O
. O
[]

OBJECTIVE O
This O
study O
aims O
to O
assess O
user O
characteristics O
related O
to O
participation B-outcome ['Life-Impact']
and O
attrition B-outcome ['Life-Impact']
when O
comparing O
Web-based O
and O
print-delivered O
tailored O
interventions O
containing O
similar O
content O
and O
thereby O
to O
provide O
recommendations O
in O
choosing O
the O
appropriate O
delivery O
mode O
for O
a O
particular O
target O
audience O
. O
['Life-Impact']

In O
the O
same O
period O
, O
27.6 O
% O
of O
the O
control O
group O
( O
n=312 O
) O
claimed O
attendance O
. O
[]

METHODS O
In O
this O
prospective O
double-blind O
, O
placebo-controlled O
study O
, O
30 O
subjects O
( O
20 O
boys O
, O
10 O
girls O
) O
6-20 O
years O
of O
age O
with O
PDD O
and O
significant O
aggression O
were O
randomized O
and O
received O
treatment O
with O
valproate O
( O
VPA O
) O
or O
placebo O
( O
PBO O
) O
for O
8 O
weeks O
as O
outpatients O
. O
[]

At O
2 O
, O
4 O
, O
and O
6 O
wk O
, O
the O
cumulative O
percent O
healed O
on O
antacid O
was O
33 O
% O
, O
64 O
% O
, O
and O
80 O
% O
, O
and O
on O
cimetidine O
it O
was O
25 O
% O
, O
62 O
% O
, O
and O
86 O
% O
. O
[]

METHODS O
Pharmacokinetic O
studies O
were O
carried O
out O
in O
23 O
patients O
who O
were O
either O
a O
recipient O
of O
an O
organ O
transplant O
or O
on O
hemodialysis O
. O
[]

The O
QLQ-C30 O
incorporates O
five O
functional O
scales O
, O
three O
symptom O
scales O
, O
a O
global O
health O
and O
quality-of O
life O
scale O
and O
some O
single O
symptom O
measures O
. O
['Life-Impact']

RESULTS O
For O
Hispanics O
who O
received O
brief O
motivational O
intervention O
, O
an O
ethnic O
match O
between O
patient O
and O
provider O
resulted O
in O
a O
significant O
reduction O
[]

The O
relative O
risks O
of O
0.67 O
and O
0.74 O
were O
clinically O
similar O
and O
the O
difference O
between O
them O
did O
not O
reach O
statistical O
significance O
. O
[]

Acquired O
nystagmus O
occurs O
frequently O
in O
patients O
with O
multiple O
sclerosis O
and O
is O
often O
the O
cause O
of O
illusory O
motion O
of O
the O
environment O
( O
oscillopsia O
) O
, O
and O
blurring O
of O
vision O
. O
[]

The O
majority O
of O
adverse O
events O
were O
mild O
in O
severity O
; O
the O
most O
commonly O
reported O
treatment-related O
events O
were O
dizziness B-outcome ['Physiological-Clinical']
( O
7.7 O
% O
) O
and O
tinnitus B-outcome ['Physiological-Clinical']
( O
2.9 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eltrombopag O
for O
management O
of O
chronic O
immune O
thrombocytopenia O
( O
RAISE O
) O
: O
a O
6-month O
, O
randomised O
, O
phase O
3 O
study O
. O
[]

The O
difference O
between O
the O
ultimate O
cure B-outcome ['Physiological-Clinical']
in O
the O
three O
groups O
was O
significant O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Ipilimumab O
is O
a O
fully O
human O
, O
monoclonal O
antibody O
that O
blocks O
cytotoxic O
T-lymphocyte O
antigen-4 O
to O
potentiate O
an O
antitumor O
T-cell O
response O
. O
[]

OBJECTIVE O
Structured O
multidisciplinary O
patient O
group O
education O
has O
positive O
effects O
on O
symptoms O
, O
health-related O
quality O
of O
life O
, O
and O
disease-related O
knowledge O
in O
patients O
with O
irritable O
bowel O
syndrome O
( O
IBS O
) O
, O
but O
few O
studies O
comparing O
different O
forms O
of O
educational O
interventions O
are O
available O
. O
[]

The O
distance O
from O
the O
vestibular B-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
plate I-outcome ['Physiological-Clinical']
to O
the O
palatal O
root O
of O
these O
teeth O
( O
1.17 O
and O
1.23 O
mm O
for O
the O
right O
premolars O
, O
2.46 O
and O
1.09 O
mm O
for O
the O
left O
premolars O
, O
2.75 O
and O
0.64 O
mm O
for O
the O
right O
molars O
, O
2.23 O
and O
0.96 O
mm O
for O
the O
left O
molars O
in O
the O
banded O
and O
bonded O
groups O
, O
respectively O
) O
increased O
( O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Better O
effects O
on O
the O
pathological O
results O
of O
the O
cervix O
and O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hTERT I-outcome ['Physiological-Clinical']
were O
obtained O
in O
the O
treatment O
group O
after O
treatment O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Objective O
and O
[]

The O
SBP B-outcome ['Physiological-Clinical']
was O
significantly O
lowered O
after O
treatment O
with O
either O
ISDN O
, O
155 O
mmHg O
to O
138 O
mmHg O
, O
or O
NTG O
, O
160 O
mmHg O
to O
130 O
mmHg O
. O
['Physiological-Clinical']

The O
primary O
outcome O
( O
i.e O
. O
[]

24 O
( O
18 O
% O
) O
patients O
receiving O
eltrombopag O
needed O
rescue B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
compared O
with O
25 O
( O
40 O
% O
) O
patients O
receiving O
placebo O
( O
p=0?001 O
) O
. O
['Resource-use']

Long-term O
follow-up O
of O
the O
Stockholm O
randomized O
trials O
of O
postoperative O
radiation O
therapy O
versus O
adjuvant O
chemotherapy O
among O
'high O
risk O
' O
pre- O
and O
postmenopausal O
breast O
cancer O
patients O
. O
[]

Debriefing O
in O
follow-up O
visits O
provided O
participants O
a O
detailed O
review O
of O
all O
consent O
types O
and O
the O
chance O
to O
change O
data O
sharing O
choices O
or O
decline O
genome O
study O
participation O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
Cavitron O
ultrasonic O
surgical O
aspirator O
( O
CUSA O
) O
with O
bipolar O
cautery O
( O
BP O
) O
to O
CUSA O
with O
a O
radiofrequency O
coagulator O
[ O
TissueLink O
( O
TL O
) O
] O
in O
terms O
of O
efficacy O
and O
safety O
for O
hepatic O
transection O
in O
living O
donor O
liver O
transplantation O
. O
[]

The O
improvements O
found O
in O
higher-level O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
encourage O
further O
studies O
into O
the O
therapeutic O
potential O
of O
oxytocin O
in O
schizophrenia O
. O
['Life-Impact']

I O
. O
[]

Blood O
samples O
were O
withdrawn O
before O
and O
two O
hours O
after O
surgery O
and O
on O
postoperative O
days O
one O
and O
two O
to O
determine O
the O
blood O
NK O
cell O
activity O
using O
a O
chromium O
release O
assay O
with O
K562 O
cells O
as O
targets O
, O
plasma O
catecholamines O
and O
cortisol O
levels O
. O
[]

The O
Fluorouracil O
Filtering O
Surgery O
Study O
Group O
. O
[]

13.5 O
to O
50.2 O
? O
[]

1 O
. O
[]

Large O
individual O
differences O
characterize O
the O
changes O
induced O
by O
sleep O
deprivation O
on O
neurobehavioral O
functions O
and O
rhythmic O
brain O
activity O
. O
[]

Drug O
effects O
on O
cognition O
were O
mild O
. O
[]

The O
total O
sample O
size O
was O
398 O
patients O
. O
[]

For O
drugs O
used O
on O
a O
multiple-dose O
basis O
, O
Cmax B-outcome ['Physiological-Clinical']
and O
Tmax B-outcome ['Physiological-Clinical']
evaluations O
become O
redundant O
since O
the O
average O
plateau B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
is O
not O
affected O
by O
these O
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
negative O
clinical O
results O
do O
not O
support O
a O
significant O
role O
of O
endogenous O
opioid O
systems O
in O
the O
pathophysiology O
of O
motor B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
in O
Parkinson O
's O
disease O
. O
['Life-Impact']

RESULTS O
Fracture B-outcome ['Physiological-Clinical']
union I-outcome ['Physiological-Clinical']
was O
achieved O
in O
all O
patients O
in O
the O
operative O
group O
, O
whereas O
nonunion B-outcome ['Physiological-Clinical']
was O
observed O
in O
3 O
of O
30 O
patients O
of O
the O
nonoperative O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
surgical O
team O
was O
the O
same O
for O
both O
procedures O
. O
[]

dose O
appeared O
to O
be O
a O
safe O
H2 O
antagonist O
and O
was O
as O
effective O
as O
ranitidine O
in O
the O
treatment O
of O
duodenal O
and O
gastric O
ulceration O
. O
[]

BACKGROUND O
Cardiovascular O
diseases O
account O
for O
nearly O
20 O
% O
of O
all O
hospitalizations O
in O
Canada O
and O
consume O
12 O
% O
of O
the O
total O
cost O
of O
all O
illnesses O
. O
[]

Spirometric O
testing O
was O
performed O
immediately O
before O
inhalation O
of O
treatment O
and O
after O
2 O
h. O
A O
dose-response B-outcome ['Physiological-Clinical']
curve O
to O
inhaled B-outcome ['Physiological-Clinical']
salbutamol B-outcome ['Resource-use']
was O
then O
constructed O
using O
doses O
of O
100 O
, O
100 O
, O
200 O
microg O
and O
400 O
microg O
-- O
that O
is O
, O
a O
total O
cumulative O
dose O
of O
800 O
microg O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Analyses O
were O
by O
intention O
to O
treat O
and O
included O
all O
enrolled O
patients O
. O
[]

The O
effects O
of O
piracetam O
( O
Nootropil O
, O
UCB6215 O
) O
on O
mental B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
and O
on O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
rCBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
investigated O
in O
eight O
patients O
in O
the O
presenile O
age O
who O
displayed O
symptoms O
of O
moderate O
dementia O
. O
['Life-Impact', 'Physiological-Clinical']

Acute O
elevations O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
commonly O
follow O
extracapsular O
cataract O
extraction O
and O
lens O
implant O
in O
glaucoma O
patients O
. O
['Physiological-Clinical']

We O
conclude O
that O
low-dose O
clonidine O
is O
effective O
in O
the O
treatment O
of O
mild O
or O
moderate O
hypertension O
. O
[]

Chronopharmacology O
of O
enalapril O
in O
hypertensive O
patients O
. O
[]

Forty-three O
patients O
were O
in O
the O
standard O
group O
and O
38 O
patients O
were O
in O
the O
early O
group O
. O
[]

Teacher O
evaluations O
showed O
that O
treated O
children O
had O
significant O
classroom O
improvement O
of O
social B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
reduction O
in O
autistic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
compared O
with O
wait-list O
control O
participants O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Two O
hundred O
ninety O
patients O
were O
accrued O
to O
this O
trial O
. O
[]

BACKGROUND O
Actinic B-outcome ['Physiological-Clinical']
keratoses I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AKs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
are O
precancerous O
epidermal O
lesions O
found O
most O
frequently O
on O
areas O
of O
the O
skin O
exposed O
to O
the O
sun O
. O
['Physiological-Clinical']

Three-year O
OS O
did O
not O
differ O
between O
the O
two O
groups O
( O
67.4 O
% O
and O
67.7 O
% O
, O
respectively O
; O
hazard O
ratio O
( O
HR O
) O
=1.01 O
[ O
0.79-1.30 O
] O
, O
p=0.92 O
) O
, O
nor O
did O
3-year O
disease-free O
survival O
, O
response O
rates O
, O
toxicity O
, O
or O
postoperative O
mortality O
. O
[]

Additionally O
, O
the O
improvement O
in O
urinary B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
study O
was O
similar O
for O
both O
groups O
( O
from O
16.5 O
+/- O
6.1 O
to O
8.5 O
+/- O
2.4 O
for O
E O
group O
and O
from O
15.8 O
+/- O
7.8 O
to O
8.8 O
+/- O
2.7 O
for O
P O
group O
; O
P O
< O
0.01 O
versus O
basal O
) O
; O
however O
, O
those O
women O
in O
group O
E O
reached O
significant O
improvement O
on O
urinary B-outcome ['Physiological-Clinical']
complaints I-outcome ['Physiological-Clinical']
since O
the O
first O
month O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.03 O
) O
. O
[]

Belatacept O
patients O
experienced O
a O
higher O
incidence O
( O
MI O
: O
22 O
% O
, O
LI O
: O
17 O
% O
and O
cyclosporine O
: O
7 O
% O
) O
and O
grade O
of O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Double-dummy O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
. O
[]

METHODS O
Experiments O
were O
performed O
with O
12 O
subjects O
with O
type O
1 O
diabetes O
and O
hypoglycemia O
unawareness O
. O
[]

Omega-3/omega-6 O
fatty O
acids O
for O
attention B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
hyperactivity I-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
: O
a O
randomized O
placebo-controlled O
trial O
in O
children O
and O
adolescents O
. O
['Life-Impact']

Two O
groups O
of O
five O
preterm O
infants O
were O
fed O
a O
diet O
containing O
12.5 O
mg/L O
of O
zinc O
and O
either O
0.9 O
mg/L O
or O
2.1 O
mg/L O
of O
copper O
. O
[]

At O
4 O
weeks O
in O
group O
B O
patients O
, O
ABI B-outcome ['Physiological-Clinical']
was O
significantly O
improved O
in O
legs O
injected O
with O
bone O
marrow-mononuclear O
cells O
compared O
with O
those O
injected O
with O
peripheral O
blood-mononuclear O
cells O
( O
difference O
0.09 O
[ O
95 O
% O
CI O
0.06-0.11 O
] O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Naltrexone O
was O
superior O
to O
placebo O
according O
to O
blind O
Clinical O
Global B-outcome ['Physiological-Clinical']
Consensus I-outcome ['Physiological-Clinical']
Ratings O
( O
unpublished O
scale O
) O
. O
['Physiological-Clinical']

The O
medium O
term O
results O
confirmed O
the O
efficacity O
noted O
in O
the O
short O
term O
survey O
. O
[]

Improved O
prognostic O
risk O
stratification O
may O
assist O
in O
the O
design O
of O
future O
trials O
and O
in O
patient O
management O
. O
[]

Information O
is O
still O
needed O
, O
however O
, O
to O
determine O
if O
only O
subgroups O
of O
girls O
with O
the O
disorder O
are O
responsive O
to O
L-carnitine O
and O
the O
appropriate O
duration O
of O
therapy O
. O
[]

METHODS O
Patients O
with O
a O
diagnosis O
of O
HP O
gastritis O
or O
peptic O
ulcer O
disease O
confirmed O
using O
endoscopy O
and O
stool O
antigen O
testing O
were O
eligible O
for O
inclusion O
in O
this O
study O
. O
[]

Repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
are O
a O
core O
symptom O
domain O
in O
autism O
that O
has O
been O
linked O
to O
alterations O
in O
the O
serotonin O
system O
. O
['Life-Impact']

BACKGROUND O
Similar O
to O
cardiac O
surgery O
patients O
, O
medical-surgical O
critically O
ill O
patients O
may O
benefit O
from O
intensive O
insulin O
therapy O
. O
[]

A O
histopathology B-outcome ['Physiological-Clinical']
score O
was O
utilised O
to O
document O
changes O
in O
gastric B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Once-daily O
versus O
twice-daily O
intravenous O
administration O
of O
vancomycin O
for O
infections O
in O
hospitalized O
patients O
. O
[]

4 O
. O
[]

A O
second O
treatment O
period O
of O
3 O
months O
was O
given O
to O
those O
patients O
who O
were O
not O
symptom-free O
after O
3 O
months O
. O
[]

The O
effects O
of O
therapeutic O
instrumental O
music O
performance O
on O
endurance O
level O
, O
self-perceived O
fatigue O
level O
, O
and O
self-perceived O
exertion O
of O
inpatients O
in O
physical O
rehabilitation O
. O
[]

Fifty-four O
patients O
were O
treated O
with O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAID O
) O
( O
Voltaren O
resinat O
2 O
x O
75 O
mg/day O
for O
2 O
weeks O
) O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
the O
HSV-1 B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
copy I-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tears I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
saliva I-outcome ['Physiological-Clinical']
among O
any O
of O
the O
three O
treatment O
groups O
. O
['Physiological-Clinical']

The O
effect O
of O
RPMT O
on O
growth O
rate O
of O
child-initiated B-outcome ['Life-Impact']
comments I-outcome ['Life-Impact']
( O
i.e. O
, O
the O
most O
common O
type O
of O
initiating O
joint O
attention O
) O
varied O
by O
pretreatment O
measures O
of O
that O
variable O
. O
['Life-Impact']

Improving O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
with O
CBT O
in O
young O
children O
with O
high O
functioning O
autism O
spectrum O
disorders O
: O
a O
pilot O
study O
. O
['Life-Impact']

Further O
studies O
comparing O
costs O
and O
resource O
utilization O
in O
this O
patient O
population O
are O
needed O
. O
[]

Patients O
were O
assigned O
to O
a O
target O
dose O
of O
losartan O
50 O
mg/day O
and O
captopril O
50 O
mg O
t.i.d. O
, O
as O
tolerated O
. O
[]

In O
both O
the O
normal O
and O
high O
bilirubin O
groups O
, O
minimum B-outcome ['Physiological-Clinical']
TSB I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
were O
recorded O
4 O
h O
after O
the O
supper O
. O
['Physiological-Clinical']

Histamine-rich O
foods O
such O
as O
cheese O
, O
sausages O
, O
sauerkraut O
, O
tuna O
, O
tomatoes O
, O
and O
alcoholic O
beverages O
may O
contain O
histamine O
up O
to O
500 O
mg/kg O
. O
[]

PATIENTS O
AND O
METHODS O
Twenty-five O
patients O
with O
small-cell O
lung O
cancer O
( O
SCLC O
) O
were O
treated O
with O
six O
cycles O
of O
ifosfamide O
, O
carboplatin O
, O
and O
etoposide O
( O
ICE O
) O
with O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
300 O
micrograms/d O
subcutaneously O
( O
SC O
) O
on O
days O
4 O
to O
15 O
. O
[]

Girls O
were O
randomly O
assigned O
to O
group O
A O
( O
4 O
IU/m O
( O
2 O
) O
.d O
; O
approximately O
0.045 O
mg/kg/d O
) O
, O
group O
B O
( O
first O
year O
, O
4 O
IU/m O
( O
2 O
) O
.d O
; O
thereafter O
6 O
IU/m O
( O
2 O
) O
.d O
) O
, O
or O
group O
C O
( O
first O
year O
, O
4 O
IU/m O
( O
2 O
) O
.d O
; O
second O
year O
, O
6 O
IU/m O
( O
2 O
) O
.d O
; O
thereafter O
, O
8 O
IU/m O
( O
2 O
) O
.d O
) O
. O
[]

The O
ischaemia B-outcome ['Physiological-Clinical']
response O
in O
the O
ECG O
revealed O
a O
dose-dependent O
reduction O
by O
28 O
% O
( O
5 O
mg O
ISDN O
) O
, O
43 O
% O
( O
20 O
mg O
) O
, O
60 O
% O
( O
40 O
mg O
) O
and O
73 O
% O
( O
80 O
mg O
) O
. O
['Physiological-Clinical']

All O
active O
agents O
were O
significantly O
superior O
to O
placebo O
with O
regard O
to O
headache B-outcome ['Physiological-Clinical']
relief O
and O
pain B-outcome ['Physiological-Clinical']
freedom I-outcome ['Physiological-Clinical']
at O
2 O
hours O
( O
P O
< O
or O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
Canada411 O
could O
find O
significantly O
more O
subjects O
than O
InfoSpace O
, O
the O
number O
of O
potential O
matches B-outcome ['Physiological-Clinical']
returned O
by O
Canada411 O
was O
also O
higher O
, O
which O
meant O
that O
a O
longer O
list O
of O
potential O
matches O
had O
to O
be O
examined O
before O
a O
true O
match O
could O
be O
found O
. O
['Physiological-Clinical']

Randomized O
phase O
II O
trial O
of O
high-dose O
4'-epi-doxorubicin O
+ O
cyclophosphamide O
versus O
high-dose O
4'-epi-doxorubicin O
+ O
cisplatin O
in O
previously O
untreated O
patients O
with O
extensive O
small O
cell O
lung O
cancer O
. O
[]

Despite O
the O
effects O
on O
conceptual O
understanding O
, O
the O
current O
study O
does O
not O
indicate O
strong O
evidence O
for O
the O
effectiveness O
of O
a O
ToM O
treatment O
on O
the O
daily O
life O
mindreading O
skills O
. O
[]

CONCLUSION O
TISSEEL O
VH O
S/D O
is O
safe O
and O
effective O
for O
use O
as O
an O
adjunct O
to O
hemostasis O
in O
patients O
undergoing O
cardiac O
surgery O
. O
[]

This O
sample O
was O
not O
employing O
adequate O
sun O
protection O
behaviors O
( O
83 O
% O
did O
not O
often O
avoid O
the O
sun O
during O
midday O
and O
only O
45 O
% O
often O
used O
sunscreen O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
Since O
the O
efficacy O
of O
the O
standard O
triple O
therapies O
for O
Helicobacter O
pylori O
eradication O
has O
decreased O
, O
novel O
antibiotic O
regimens O
have O
been O
introduced O
, O
including O
concomitant O
, O
sequential O
, O
and O
hybrid O
therapies O
. O
[]

Other O
untoward B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
morphine O
either O
could O
not O
be O
observed O
or O
occurred O
with O
an O
incidence O
unaffected O
by O
either O
dose O
of O
droperidol O
. O
['Adverse-effects']

CONCLUSIONS O
Although O
heparin O
is O
beneficial O
in O
treating O
unstable O
angina O
, O
the O
disease O
process O
may O
be O
reactivated B-outcome ['Physiological-Clinical']
within O
hours O
of O
the O
discontinuation O
of O
this O
drug O
. O
['Physiological-Clinical']

Four O
different O
methods-microscopy O
of O
Gram B-outcome ['Resource-use']
stained I-outcome ['Resource-use']
mucosal I-outcome ['Resource-use']
smear I-outcome ['Resource-use']
, O
specific B-outcome ['Physiological-Clinical']
culture I-outcome ['Physiological-Clinical']
, O
biopsy O
urease B-outcome ['Physiological-Clinical']
test O
, O
histology O
of O
H O
& O
E O
staining-were O
taken O
for O
identifying O
colonization O
of O
H. O
pylori O
before O
treatment O
, O
and O
for O
finding O
the O
eradication O
of O
H. O
pylori O
4 O
weeks O
after O
completion O
of O
therapy O
in O
each O
treatment O
group O
( O
cometidine O
, O
omeprazole O
, O
colloidal O
bismuth O
subcitrate O
( O
CBS O
) O
, O
CBS O
and O
metronidazole O
double O
therapy O
, O
CBS O
, O
metronidazole O
and O
amoxicillin O
triple O
therapy O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

To O
reduce O
peristomal O
infections O
, O
we O
designed O
a O
new O
method O
of O
gastrostomy O
by O
extracorporeal O
approach O
under O
endoscopic O
observation O
, O
named O
as O
extra-corporeal O
PEG O
( O
E-PEG O
) O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
were O
measured O
by O
caregiver O
who O
completed O
somnologs O
and O
wrist O
actigraphs O
. O
['Physiological-Clinical']

Predicting O
the O
effect O
of O
anthelmintic O
treatment O
on O
milk O
production O
of O
dairy O
cattle O
in O
Canada O
using O
an O
Ostertagia O
ostertagi O
ELISA O
from O
individual O
milk O
samples O
. O
[]

Thirty-nine O
( O
66 O
% O
) O
of O
the O
participants O
experienced O
urogenital B-outcome ['Physiological-Clinical']
AE I-outcome ['Physiological-Clinical']
judged O
as O
probably O
or O
possibly O
related O
to O
gel O
. O
['Physiological-Clinical']

RESULTS O
All-cause B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
occurred O
in O
1636 O
( O
rate O
, O
4233/10,000 O
person-years O
) O
and O
1587 O
( O
rate O
, O
3733/10,000 O
person-years O
) O
patients O
respectively O
, O
with O
and O
without O
CKD O
( O
matched O
hazard O
ratio O
[ O
HR O
] O
for O
CKD O
, O
1.18 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.08-1.29 O
; O
P O
< O
0.0001 O
) O
. O
['Resource-use']

Dialysate O
magnesium O
was O
0.375 O
mM/L O
for O
the O
hemodialysis O
and O
0.25 O
mM/L O
for O
the O
CAPD O
patients O
. O
[]

Effect O
of O
upper O
arm O
brachial O
basilic O
and O
prosthetic O
forearm O
arteriovenous O
fistula O
on O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
effect O
of O
valaciclovir O
on O
cytomegalovirus B-outcome ['Physiological-Clinical']
viremia I-outcome ['Physiological-Clinical']
and O
viruria O
detected O
by O
polymerase O
chain O
reaction O
in O
patients O
with O
advanced O
human O
immunodeficiency O
virus O
disease O
. O
['Physiological-Clinical']

Only O
one O
condition O
( O
P O
, O
LD O
, O
or O
HD O
) O
was O
presented O
per O
day O
and O
the O
condition O
order O
was O
randomized O
. O
[]

BACKGROUND O
Induction O
therapy O
for O
adults O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
is O
similar O
across O
essentially O
all O
regimens O
, O
comprised O
of O
vincristine O
, O
corticosteroids O
, O
and O
anthracyclines O
intensified O
with O
cyclophosphamide O
, O
asparaginase O
, O
or O
both O
. O
[]

The O
patients O
were O
randomly O
assigned O
into O
two O
groups O
: O
MSCT O
and O
SAA O
combined O
group O
: O
both O
MSCT O
and O
SAA O
combinative O
assessment O
were O
performed O
for O
preoperative O
evaluation O
; O
MSCT O
group O
: O
only O
MSCT O
was O
performed O
preoperatively O
for O
tumor O
staging O
. O
[]

The O
procedure O
was O
then O
repeated O
on O
the O
finger O
pulps O
. O
[]

The O
efficacy O
and O
safety O
of O
cyclosporine O
reduction O
in O
de O
novo O
renal O
allograft O
patients O
receiving O
sirolimus O
and O
corticosteroids O
: O
results O
from O
an O
open-label O
comparative O
study O
. O
[]

Cost-effectiveness O
of O
combined O
manipulation O
, O
stabilizing O
exercises O
, O
and O
physician O
consultation O
compared O
to O
physician O
consultation O
alone O
for O
chronic O
low O
back O
pain O
: O
a O
prospective O
randomized O
trial O
with O
2-year O
follow-up O
. O
[]

Inflammation O
is O
critical O
for O
atherosclerosis O
development O
and O
may O
be O
a O
target O
for O
risk-reduction O
therapy O
. O
[]

Mean O
total O
doses B-outcome ['Life-Impact']
of O
alfentanil O
, O
fentanyl O
and O
sufentanil O
were O
443 O
, O
45 O
and O
4.4 O
micrograms O
kg-1 O
, O
respectively O
. O
['Life-Impact']

The O
change O
in O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
in O
the O
exercise O
limb O
( O
adjusted O
for O
change O
in O
the O
control O
limb O
and O
baseline O
BMD O
) O
differed O
between O
groups O
( O
p=0.015 O
) O
, O
being O
-0.3 O
% O
( O
-1.2 O
to O
0.6 O
) O
, O
0.0 O
% O
( O
-1.0 O
to O
1.0 O
) O
, O
0.9 O
% O
( O
-0.1 O
to O
2.0 O
) O
and O
1.8 O
% O
( O
0.8 O
to O
2.8 O
) O
in O
those O
exercising O
0 O
, O
2 O
, O
4 O
and O
7 O
days O
per O
week O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSIONS O
Treatment O
of O
coexisting O
OSA O
by O
CPAP O
in O
HF O
patients O
lowers O
daytime B-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
and O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

at O
least O
it O
retarded B-outcome ['Physiological-Clinical']
the O
patients O
' O
complaints B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Improvement O
in O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
was O
dramatic O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SETTING O
University O
hospital O
outpatient O
surgery O
center O
. O
[]

Retinetion O
of O
verbal O
[]

However O
, O
several O
laboratories O
have O
reported O
that O
protein O
ingestion O
does O
not O
result O
in O
an O
increase O
in O
the O
circulating B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
people O
with O
or O
without O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

Neuropsychological O
effects O
of O
risperidone O
in O
children O
with O
pervasive O
developmental O
disorders O
: O
a O
blinded O
discontinuation O
study O
. O
[]

A O
single O
oral O
dose O
of O
1500 O
mg O
mefloquine O
hydrochloride O
was O
administered O
to O
11 O
patients O
and O
5 O
volunteers O
and O
750 O
mg O
was O
given O
to O
16 O
patients O
and O
5 O
volunteers O
. O
[]

H. O
pylori B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
cured B-outcome ['Physiological-Clinical']
in O
10 O
( O
55.6 O
% O
) O
patients O
with O
the O
second-line O
regimen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
SEPS O
group O
( O
n O
= O
25 O
) O
had O
significantly O
reduced O
AVP B-outcome ['Physiological-Clinical']
( O
P O
< O
.01 O
) O
compared O
with O
the O
control O
group O
( O
n O
= O
26 O
) O
. O
['Physiological-Clinical']

Results O
combining O
the O
P-values O
of O
both O
studies O
indicate O
that O
the O
relative O
risk O
of O
having O
persistent O
disease O
was O
2.9 O
times O
greater O
for O
patients O
who O
received O
chemotherapy O
. O
[]

For O
the O
group O
as O
a O
whole O
, O
both O
younger O
child O
age O
at O
the O
start O
of O
intervention O
and O
a O
greater O
number O
of O
intervention B-outcome ['Life-Impact']
hours I-outcome ['Life-Impact']
were O
positively O
related O
to O
the O
degree O
of O
improvement O
in O
children O
's O
behavior O
for O
most O
variables O
. O
['Life-Impact']

Hypotensive B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cramps I-outcome ['Physiological-Clinical']
decreased O
50 O
% O
with O
Na+ O
modeling O
. O
['Physiological-Clinical']

Cows O
were O
enrolled O
from O
24 O
dairy O
herds O
from O
three O
geographical O
regions O
of O
Canada O
. O
[]

There O
was O
also O
a O
very O
limited O
relationship O
( O
r O
( O
2 O
) O
< O
0.026 O
) O
between O
visit-to-visit O
and O
within O
24-h O
ambulatory O
BP O
variabilities O
, O
the O
latter O
being O
two O
to O
three O
times O
greater O
than O
the O
former O
. O
[]

Stability O
, O
tipping O
and O
relapse O
of O
bone-borne O
versus O
tooth-borne O
surgically O
assisted O
rapid O
maxillary O
expansion O
; O
a O
prospective O
randomized O
patient O
trial O
. O
[]

AIMS O
To O
compare O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
trichloroacetic O
acid O
peel O
20 O
% O
vs O
. O
['Physiological-Clinical']

Primary O
end O
point O
was O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
rate O
after O
9 O
months O
. O
['Mortality']

RESULTS O
Urinary B-outcome ['Physiological-Clinical']
magnesium I-outcome ['Physiological-Clinical']
increased O
after O
the O
administration O
of O
magnesium O
( O
change O
: O
36.38 O
mg/d O
after O
magnesium O
compared O
with O
0.72 O
mg/d O
after O
placebo O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

g/mL O
fentanyl O
when O
combined O
with O
0.125 O
% O
ropivacaine O
in O
parturients O
undergoing O
labor O
during O
epidural O
analgesia O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
fell O
by O
5 O
% O
during O
two O
cycles O
of O
treatment O
with O
either O
dl-norgestrel O
alone O
( O
229 O
+/- O
11 O
vs. O
242 O
+/- O
10 O
mg/dl O
, O
n O
= O
25 O
, O
P O
< O
0.02 O
) O
or O
combination O
therapy O
( O
233 O
+/- O
11 O
vs. O
246 O
+/- O
10 O
, O
n O
= O
25 O
, O
P O
< O
0.05 O
) O
versus O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
patients O
in O
each O
group O
experienced O
hypotension B-outcome ['Physiological-Clinical']
during O
the O
5 O
h O
following O
the O
first O
dose O
of O
medication O
. O
['Physiological-Clinical']

Because O
the O
mechanism O
of O
action O
for O
ipilimumab O
is O
thought O
to O
be O
HLA O
independent O
, O
most O
trials O
enrolled O
patients O
without O
regard O
to O
HLA O
subtype O
. O
[]

At O
that O
time O
, O
10 O
% O
of O
the O
prochlorperazine O
and O
25 O
% O
of O
the O
octreotide O
patients O
had O
experienced O
some O
headache B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( O
P O
= O
.1 O
) O
. O
['Physiological-Clinical']

Performance O
on O
the O
timing O
task O
was O
analysed O
measuring O
the O
absolute O
value O
of O
timing O
error O
, O
the O
coefficient O
of O
variability O
and O
the O
percentage O
of O
anticipation O
responses O
. O
[]

No O
effect O
of O
the O
diet B-outcome ['Life-Impact']
composition I-outcome ['Life-Impact']
was O
found O
in O
the O
increases O
of O
EGC B-outcome ['Physiological-Clinical']
in O
response O
to O
isoprenaline O
( O
area O
under O
the O
curve O
[ O
AUC O
] O
: O
HFD O
, O
1,534 O
+/- O
370 O
micromol/90 O
min O
; O
HCD O
, O
1,108 O
+/- O
465 O
micromol/90 O
min O
; O
not O
significant O
[ O
NS O
] O
) O
or O
epinephrine B-outcome ['Physiological-Clinical']
stimulations I-outcome ['Physiological-Clinical']
( O
AUC O
: O
HFD O
, O
190 O
+/- O
92 O
micromol/30 O
min O
; O
HCD O
, O
251 O
+/- O
298 O
micromol/30 O
min O
; O
NS O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Our O
data O
suggest O
that O
LTD4 O
recruits O
eosinophils B-outcome ['Physiological-Clinical']
into O
the O
airways O
of O
asthmatics O
in O
vivo O
, O
possibly O
by O
virtue O
of O
direct O
or O
indirect O
chemotactic O
properties O
, O
whereas O
an O
additional O
effect O
of O
vigourous B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
narrowing I-outcome ['Physiological-Clinical']
per O
se O
can O
not O
be O
excluded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Internet-based O
searches O
represent O
a O
potentially O
useful O
approach O
to O
tracing O
subjects O
in O
epidemiologic O
studies O
. O
[]

A O
significant O
reduction O
in O
mesangial B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
mesangial B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
occurred O
in O
the O
candesartan O
group O
, O
although O
changes O
in O
morphological B-outcome ['Physiological-Clinical']
parameters O
were O
similar O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
the O
phosphodiesterase O
( O
PDE O
) O
inhibitor O
pentoxifylline O
on O
platelet B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
profiles O
in O
patients O
receiving O
dual O
antiplatelet O
therapy O
( O
DAPT O
) O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
81 O
cases O
of O
autistic O
children O
were O
selected O
through O
the O
standard O
of O
DSM-4 O
and O
clinical O
case O
study O
was O
used O
. O
[]

2 O
) O
The O
LKSS B-outcome ['Physiological-Clinical']
: O
The O
post-treatment O
LKSS B-outcome ['Physiological-Clinical']
was O
higher O
than O
that O
before O
treatment O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
patient O
reported O
any O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
during O
treatment O
. O
['Adverse-effects']

Harmonic O
imaging O
remained O
the O
most O
accurate O
approach O
. O
[]

Recent O
studies O
have O
demonstrated O
that O
the O
calcium O
channel O
blocking O
agents O
can O
inhibit O
experimentally B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
bronchoconstriction I-outcome ['Physiological-Clinical']
in O
asthmatics O
, O
but O
their O
protective O
action O
has O
been O
variable O
. O
['Physiological-Clinical']

However O
, O
to O
our O
knowledge O
, O
there O
have O
been O
no O
studies O
using O
all O
these O
measures O
together O
as O
an O
adjuvant O
antidepressant O
strategy O
. O
[]

The O
usual O
combination O
is O
foam O
ear O
plugs O
under O
headset O
or O
helmet O
muffs O
. O
[]

Effect O
of O
age O
and O
radiation O
dose O
on O
local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
after O
breast O
conserving O
treatment O
: O
EORTC O
trial O
22881-10882 O
. O
['Physiological-Clinical']

These O
results O
do O
not O
support O
the O
empirical O
addition O
of O
vancomycin O
to O
initial O
antibiotic O
therapy O
in O
cancer O
patients O
with O
fever O
and O
granulocytopenia O
. O
[]

An O
additional O
twenty O
healthy O
people O
were O
enrolled O
in O
the O
study O
( O
normal O
group O
) O
. O
[]

The O
extent O
of O
late O
skin B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
was O
slightly O
, O
but O
not O
significantly O
reduced O
. O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
observed O
in O
six O
of O
ten O
sites O
treated O
with O
Re-PUVA O
, O
two O
of O
ten O
with O
Re O
, O
and O
one O
of O
ten O
sites O
with O
PUVA O
within O
12 O
weeks O
. O
['Physiological-Clinical']

Succinate O
sumatriptan O
evaluation O
by O
Doppler O
echocardiography O
in O
patients O
with O
migraine O
. O
[]

Montelukast O
conferred O
significant O
( O
P O
< O
0.05 O
) O
improvements O
as O
change O
from O
post O
run-in O
compared O
with O
placebo O
in O
methacholine O
PD20 O
, O
FEV1 B-outcome ['Physiological-Clinical']
% O
predicted O
, O
FEF25-75 B-outcome ['Physiological-Clinical']
% O
predicted O
, O
diurnal B-outcome ['Physiological-Clinical']
peak O
expiratory B-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
, O
symptoms B-outcome ['Physiological-Clinical']
and O
salbutamol B-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

We O
present O
a O
range O
of O
MCIC O
values O
and O
advocate O
the O
choice O
of O
a O
single O
MCIC O
value O
according O
to O
the O
specific O
context O
. O
[]

METHODS O
In O
a O
double-blind O
fashion O
, O
40 O
patients O
( O
ASA O
physical O
status O
III-IV O
) O
scheduled O
for O
elective O
cardioversion O
were O
randomly O
assigned O
to O
receive O
either O
0.015 O
mg/kg O
midazolam O
or O
placebo O
90 O
s O
before O
the O
injection O
of O
0.3 O
mg/kg O
etomidate O
. O
[]

A O
unicenter O
, O
single-blind O
, O
randomized O
study O
was O
conducted O
on O
283 O
patients O
with O
active O
duodenal O
ulcer O
to O
compare O
possible O
factors O
that O
may O
affect O
healing O
and O
relapse O
in O
patients O
treated O
with O
a O
potent O
antisecretory O
agent O
, O
cimetidine O
, O
or O
a O
site-protective O
and O
cytoprotective O
agent O
, O
sucralfate O
. O
[]

TSAb B-outcome ['Physiological-Clinical']
determined O
again O
during O
follow-up O
was O
negative O
in O
each O
of O
the O
18 O
patients O
in O
remission O
, O
and O
positive O
in O
8/10 O
patients O
at O
the O
time O
of O
relapse O
, O
whatever O
its O
level O
at O
the O
end O
of O
the O
drug O
course O
. O
['Physiological-Clinical']

Percutaneous O
tracheostomy O
in O
critically O
ill O
patients O
: O
a O
prospective O
, O
randomized O
comparison O
of O
two O
techniques O
. O
[]

However O
, O
as O
gabapentin O
is O
not O
a O
selective O
GABAergic O
agent O
, O
vigabatrin O
, O
a O
pure O
GABAergic O
medication O
, O
and O
gabapentin O
, O
were O
compared O
in O
a O
single O
blind O
cross O
over O
trial O
in O
eight O
patients O
with O
definite O
multiple O
sclerosis O
. O
[]

The O
present O
proof-of-principle O
study O
examined O
whether O
a O
nonexplicit O
, O
systematic O
computerized O
training O
in O
reappraisal O
style O
following O
a O
stressful O
event O
( O
a O
highly O
distressing O
film O
) O
could O
reduce O
intrusive O
memories O
of O
the O
film O
, O
and O
symptoms O
associated O
with O
posttraumatic O
distress O
over O
the O
subsequent O
week O
. O
[]

These O
observations O
suggest O
that O
the O
cardiovascular O
events O
associated O
with O
both O
agents O
result O
from O
hypogonadism O
rather O
than O
a O
direct O
drug O
effect O
. O
[]

The O
groups O
given O
2000 O
and O
1500 O
mg O
demonstrated O
significant O
reductions O
in O
values O
of O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
-26 O
% O
and O
-19.3 O
% O
, O
respectively O
) O
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
-18.4 O
% O
and O
-13.3 O
% O
) O
, O
and O
total O
cholesterol-high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
-20.4 O
% O
and O
-19.4 O
% O
) O
when O
compared O
with O
diet- O
and O
placebo-treated O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anesthesia O
was O
maintained O
with O
N O
( O
2 O
) O
O/O O
( O
2 O
) O
, O
isoflurane O
0.5 O
MAC O
and O
remifentanil O
0.2 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
or O
fentanyl O
0.04 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
. O
[]

Results O
favored O
a O
higher O
dose O
, O
with O
larger B-outcome ['Physiological-Clinical']
cyst I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
on O
MRI O
at O
90 O
and O
180 O
days O
and O
higher O
albendazole O
sulfoxide O
levels O
in O
plasma O
. O
['Physiological-Clinical']

Fever B-outcome ['Physiological-Clinical']
( O
> O
or O
=38.5 O
degrees O
C O
) O
and O
other O
complications B-outcome ['Adverse-effects']
( O
including O
infections B-outcome ['Physiological-Clinical']
) O
occurring O
between O
admission O
and O
discharge O
( O
or O
death B-outcome ['Mortality']
) O
were O
recorded O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Mortality']

INTERVENTION O
Randomization O
to O
an O
sVLPD O
( O
diet O
group O
) O
or O
dialysis O
. O
[]

Mixed B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
fractional I-outcome ['Physiological-Clinical']
synthetic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
FSR B-outcome ['Physiological-Clinical']
) O
was O
measured O
using O
stable O
isotope O
techniques O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
animals O
included O
19 O
purebred O
or O
crossbred O
Collies O
( O
Bearded O
, O
Border O
, O
and O
unspecified O
) O
. O
[]

A O
study O
extension O
protocol O
was O
done O
for O
long-term O
followup O
of O
these O
patients O
. O
[]

CONCLUSIONS O
Clinical O
outcome O
up O
to O
3 O
years O
after O
implantation O
of O
SESs O
for O
total O
coronary O
occlusions O
continues O
to O
demonstrate O
a O
significant O
reduction O
in O
adverse O
clinical O
events O
compared O
with O
BMSs O
without O
the O
evidence O
for O
either O
disproportionate O
late O
restenosis O
or O
late O
stent O
thrombosis O
. O
[]

METHODS O
AND O
RESULTS O
We O
conducted O
a O
prospective O
, O
nested O
case-control O
study O
in O
the O
Cholesterol O
and O
Recurrent O
Events O
( O
CARE O
) O
trial O
, O
a O
randomized O
placebo-controlled O
trial O
of O
pravastatin O
in O
4159 O
patients O
with O
myocardial O
infarction O
and O
average O
LDL O
concentrations O
at O
baseline O
( O
115 O
to O
174 O
mg/dL O
, O
mean O
139 O
mg/dL O
) O
. O
[]

METHODS O
In O
this O
preliminary O
study O
, O
33 O
adults O
and O
30 O
children O
( O
aged O
8-11 O
years O
) O
with O
no O
known O
history O
of O
listening O
difficulties O
were O
tested O
. O
[]

BACKGROUND O
Nosocomial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
are O
a O
major O
cause O
of O
morbidity O
and O
mortality O
in O
premature O
infants O
. O
['Physiological-Clinical']

Single O
gram-positive O
bacteremias O
responded O
in O
29 O
( O
43 O
% O
) O
of O
68 O
patients O
treated O
with O
CA O
and O
in O
48 O
( O
72 O
% O
) O
of O
67 O
treated O
with O
CAV O
( O
P O
= O
.001 O
) O
. O
[]

Treatment-induced O
effects O
were O
assessed O
with O
the O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
every O
third O
month O
. O
['Life-Impact']

In O
a O
pilot O
study O
we O
examined O
the O
usefulness O
of O
the O
TAMS O
for O
intubations O
of O
actual O
patients O
in O
a O
hospital O
emergency O
department O
. O
[]

A O
randomised O
controlled O
study O
. O
[]

METHODS O
A O
randomized O
, O
blinded O
trial O
in O
217 O
postmenopausal O
women O
with O
hot O
flushes O
randomized O
to O
5 O
or O
10 O
g/day O
of O
MF101 O
or O
placebo O
for O
12 O
weeks O
. O
[]

Male O
and O
female O
patients O
aged O
18-70 O
years O
and O
weighing O
50-100 O
kg O
were O
included O
in O
the O
study O
. O
[]

A O
randomized O
clinical O
trial O
of O
clinician O
feedback O
to O
improve O
quality O
of O
care O
for O
inner-city O
children O
with O
asthma O
. O
[]

There O
were O
no O
differences O
between O
off-pump O
and O
on-pump O
groups O
in O
the O
incidence O
of O
cognitive B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
at O
2 O
months O
or O
6 O
months O
, O
with O
the O
exception O
that O
fewer O
off-pump O
patients O
showed O
impairment O
on O
one O
test O
of O
verbal B-outcome ['Life-Impact']
fluency I-outcome ['Life-Impact']
at O
6 O
months O
. O
['Life-Impact', 'Life-Impact']

The O
proportions O
of O
eicosapentaenoic B-outcome ['Physiological-Clinical']
and O
docosahexaenoic B-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
increased O
in O
the O
fatty O
fish O
group O
only O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
hazard O
ratio O
of O
death B-outcome ['Mortality']
for O
LTA B-outcome ['Physiological-Clinical']
compared O
with O
TH O
was O
1.36 O
( O
0.89-2.08 O
, O
p=0.92 O
) O
. O
['Mortality', 'Physiological-Clinical']

Mycologic B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rate O
of O
3 O
day O
, O
6 O
day O
and O
7 O
day O
miconazole O
courses O
for O
uncomplicated O
VVC O
at O
day O
14 O
was O
96.0 O
% O
, O
93.5 O
% O
and O
98.0 O
% O
, O
respectively O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Intravenous O
beta-blockers O
are O
an O
effective O
means O
of O
controlling O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
during O
electroconvulsive O
therapy O
( O
ECT O
) O
, O
but O
have O
been O
shown O
to O
decrease O
seizure O
duration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
National O
Institutes O
of O
Health O
Stroke O
Scale O
score O
at O
presentation O
was O
7.3 O
( O
SD O
6.2 O
) O
points O
. O
[]

A O
double-blind O
placebo-controlled O
study O
to O
evaluate O
valacyclovir O
alone O
and O
with O
aspirin O
for O
asymptomatic O
HSV-1 O
DNA O
shedding O
in O
human O
tears O
and O
saliva O
. O
[]

The O
influence O
of O
ventricular O
fibrillation O
duration O
on O
defibrillation B-outcome ['Physiological-Clinical']
efficacy O
using O
biphasic O
waveforms O
in O
humans O
. O
['Physiological-Clinical']

This O
may O
explain O
some O
of O
the O
beneficial O
effects O
of O
this O
fixed O
dosed O
combination O
that O
are O
non-related O
to O
its O
antihypertensive O
effects O
. O
[]

Initial O
antibacterial O
therapy O
was O
successful B-outcome ['Physiological-Clinical']
( O
apyrexia O
at O
72 O
h O
, O
without O
antibiotic O
change O
) O
more O
frequently O
( O
P O
= O
0.008 O
) O
with O
the O
regimen O
containing O
piperacillin/tazobactam O
( O
54.4 O
% O
) O
than O
with O
the O
one O
including O
ceftazidime O
( O
37.6 O
% O
) O
. O
['Physiological-Clinical']

Treatment O
groups O
were O
similar O
in O
incidence O
of O
variceal B-outcome ['Physiological-Clinical']
rebleeding I-outcome ['Physiological-Clinical']
( O
41.9 O
% O
vs. O
42.9 O
% O
) O
, O
variceal B-outcome ['Physiological-Clinical']
obliteration I-outcome ['Physiological-Clinical']
( O
41.9 O
% O
vs. O
40.0 O
% O
) O
, O
hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
, O
blood B-outcome ['Resource-use']
transfusions I-outcome ['Resource-use']
, O
shunt B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
and O
survival B-outcome ['Mortality']
( O
71.0 O
% O
vs. O
60.0 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use', 'Mortality']

It O
was O
determined O
that O
the O
size O
of O
the O
bruising B-outcome ['Physiological-Clinical']
was O
smaller O
in O
the O
30-second O
injection O
. O
['Physiological-Clinical']

A O
protocol-planned O
exploratory O
analysis O
stratified O
patients O
according O
to O
baseline O
activity O
; O
this O
analysis O
showed O
that O
patients O
with O
high O
levels O
of O
disease O
activity O
in O
the O
valacyclovir O
treatment O
group O
( O
n O
= O
17 O
) O
developed O
fewer O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
per O
scan O
than O
did O
those O
in O
the O
placebo O
treatment O
group O
( O
n O
= O
11 O
) O
. O
['Physiological-Clinical']

In O
a O
first O
study O
, O
the O
extent O
of O
absorption O
was O
similar O
for O
a O
syrup O
, O
for O
Theo-dur O
, O
and O
for O
the O
experimental O
formulation O
of O
theophylline O
with O
70 O
% O
drum-dried O
corn O
starch O
as O
the O
sustained-release O
agent O
( O
DDCS-70 O
) O
. O
[]

Our O
purpose O
was O
to O
compare O
nitrogen O
, O
mineral O
, O
and O
zinc O
balance O
in O
preterm O
infants O
fed O
standard O
infant O
formulas O
, O
Similac O
With O
Iron O
and O
Similac O
With O
Whey O
+ O
Iron O
. O
[]

Of O
samples O
taken O
from O
the O
abdominal O
cavity O
for O
bacteriologic O
study O
, O
53 O
% O
were O
culture O
positive O
. O
[]

The O
treatment O
group O
received O
tailored O
materials O
, O
including O
personalized O
risk O
feedback O
, O
and O
the O
control O
group O
received O
general O
educational O
materials O
. O
[]

The O
three-year O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
for O
all O
patients O
( O
N O
= O
73 O
) O
was O
84 O
% O
; O
for O
COMP O
( O
N O
= O
42 O
) O
was O
85 O
% O
, O
and O
for O
LSA2-L2 O
( O
N O
= O
31 O
) O
was O
84 O
% O
. O
['Mortality']

14.4 O
vs. O
73.1 O
? O
[]

Secondary O
measures O
included O
WOMAC O
, O
knee B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scale O
, O
SF-36 O
, O
assessment O
of O
quality O
of O
life O
index O
, O
quadriceps B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
and O
balance B-outcome ['Life-Impact']
test O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
one O
technique O
, O
used O
routinely O
in O
this O
department O
, O
employed O
a O
conventional O
daily O
fractionation O
schedule O
while O
the O
other O
used O
a O
high-dose O
weekly O
fractionation O
regimen O
. O
[]

Standard O
methods O
of O
myocardial O
preservation O
for O
heart O
transplantation O
have O
generally O
provided O
good O
results O
. O
[]

With O
dacarbazine-vindesine O
8/59 O
patients O
obtained O
a O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
13 O
% O
) O
and O
7/59 O
patients O
a O
partial B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
12 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Among O
the O
children O
in O
the O
secretin O
group O
, O
the O
mean O
total O
score O
on O
the O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
at O
base O
line O
was O
59.0 O
( O
range O
of O
possible O
values O
, O
0 O
to O
158 O
, O
with O
a O
larger O
value O
corresponding O
to O
greater O
impairment O
) O
, O
and O
among O
those O
in O
the O
placebo O
group O
it O
was O
63.2 O
. O
['Life-Impact']

We O
investigated O
the O
benefit O
of O
adding O
all-trans O
retinoic O
acid O
( O
ATRA O
) O
to O
chemotherapy O
for O
younger O
patients O
with O
nonacute O
promyelocytic O
acute O
myeloid O
leukemia O
and O
high-risk O
myelodysplastic O
syndrome O
, O
and O
considered O
interactions O
between O
treatment O
and O
molecular O
markers O
. O
[]

Smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
rates O
were O
statistically O
significantly O
better O
in O
the O
smokeless O
tobacco O
group O
than O
in O
the O
control O
group O
during O
the O
first O
7 O
weeks O
. O
['Life-Impact']

CONCLUSION O
Although O
there O
was O
a O
greater O
reduction O
in O
the O
number O
of O
sites B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
BOP I-outcome ['Physiological-Clinical']
following O
treatment O
with O
the O
Vector O
system O
than O
following O
instrumentation O
with O
carbon O
fiber O
curettes O
, O
there O
was O
no O
significant O
difference O
between O
the O
two O
methods O
. O
['Physiological-Clinical']

This O
indicated O
an O
imbalance O
in O
bone B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
with O
a O
high B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Diminished O
neuromuscular O
excitability O
is O
one O
potential O
factor O
that O
may O
limit O
muscular O
recovery O
following O
injury O
or O
surgery O
. O
[]

After O
1 O
year O
of O
treatment O
, O
lumbar B-outcome ['Physiological-Clinical']
and O
total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
decreased I-outcome ['Physiological-Clinical']
significantly O
in O
patients O
treated O
only O
with O
calcium O
and O
cholecalciferol O
( O
group O
A O
) O
, O
whereas O
it O
did O
not O
change O
significantly O
at O
any O
skeletal O
site O
in O
patients O
treated O
also O
with O
neridronate O
( O
group O
B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
vitamin/mineral O
supplement O
was O
generally O
well-tolerated B-outcome ['Life-Impact']
, O
and O
individually O
titrated O
to O
optimum O
benefit O
. O
['Life-Impact']

Leak O
compensation O
resulted O
in O
a O
decrease O
in O
leakage-induced B-outcome ['Physiological-Clinical']
dyspnea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
so-called O
post-laparoscopic O
algesia O
is O
a O
specific O
impairment O
of O
about O
63 O
% O
of O
the O
patients O
who O
undergo O
laparoscopic O
surgical O
operations O
. O
[]

The O
prophylactic O
antiemetic O
efficacy O
of O
intravenous O
( O
i.v O
. O
) O
[]

A O
comparative O
randomized O
trial O
. O
[]

No O
significant O
reduction O
in O
mean O
wart O
area O
was O
observed O
for O
the O
168 O
Wenzhou O
protocol O
compliant O
subjects O
who O
also O
received O
VLP O
immunotherapy O
. O
[]

Each O
subject O
was O
randomized O
( O
1:1:3 O
) O
to O
receive O
either O
oral O
TU O
( O
2 O
capsules O
of O
40 O
mg/twice O
per O
day O
at O
breakfast O
and O
dinner O
, O
equalling O
a O
total O
dose O
of O
160 O
mg/day O
; O
no.=10 O
) O
for O
6 O
mo O
and O
continued O
with O
im O
TU O
for O
further O
6 O
mo O
, O
or O
P O
( O
3-4 O
g/day O
; O
no.=10 O
) O
and O
im O
TU O
( O
1000 O
mg/12 O
weeks O
from O
week O
6 O
; O
no.=32 O
) O
for O
12 O
mo O
. O
[]

They O
were O
randomized O
to O
undergo O
either O
laparoscopic O
or O
open O
appendectomy O
( O
OA O
) O
. O
[]

2.1 O
years O
) O
performed O
a O
6-minute O
run O
at O
peak O
oxygen O
consumption O
speed O
( O
predetermined O
from O
the O
VO O
( O
2 O
) O
max O
test O
) O
. O
[]

This O
study O
demonstrates O
that O
the O
speed O
of O
kill O
of O
residual O
flea B-outcome ['Resource-use']
products I-outcome ['Resource-use']
on O
cats O
decreases O
throughout O
the O
month O
following O
application O
. O
['Resource-use']

The O
null O
hypothesis O
is O
that O
both O
surface O
treatments O
can O
generate O
similar O
bond B-outcome ['Physiological-Clinical']
strengths I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ninety-five O
percent O
limits O
of O
agreement O
( O
mean O
+/- O
SD O
) O
were O
wide O
for O
all O
comparisons O
. O
[]

However O
, O
only O
limited O
information O
is O
available O
on O
the O
ability O
of O
patients O
with O
dystonia O
to O
process O
the O
time-dependent O
features O
( O
e.g O
. O
[]

Only O
10 O
of O
18 O
patients O
( O
56 O
% O
) O
were O
considered O
compliant O
in O
their O
usage O
of O
metronidazole O
. O
[]

We O
quantified O
the O
embolic O
load O
to O
the O
lungs O
created O
with O
two O
different O
techniques O
of O
femoral O
nailing O
. O
[]

A O
second O
trial O
( O
Study O
2 O
) O
simulated O
post-exposure O
rabies O
prophylaxis O
by O
using O
a O
reference O
cell O
culture O
vaccine O
, O
the O
purified O
Vero-cell O
rabies O
vaccine O
( O
PVRV O
) O
, O
administered O
in O
association O
with O
either O
Erig O
PMC O
or O
PHT-Erig O
. O
[]

Radiographic O
progression O
was O
much O
greater O
in O
patients O
receiving O
MTX O
plus O
placebo O
than O
in O
patients O
receiving O
infliximab O
plus O
MTX O
, O
irrespective O
of O
[]

The O
results O
do O
not O
support O
any O
suggestion O
that O
information O
about O
the O
existence O
of O
a O
placebo O
condition O
dramatically O
influences O
conclusions O
drawn O
about O
drug O
responses O
in O
placebo-controlled O
trials O
. O
[]

RESULTS O
Forty-seven O
children O
completed O
either O
the O
CBT O
or O
TAU O
condition O
. O
[]

The O
second O
biopsy O
confirmed O
a O
clear O
increase O
of O
PgR B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
in O
8/11 O
cases O
( O
75 O
% O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
HF O
patients O
with O
chronic O
postinfarction O
cardiomyopathy O
, O
transcatheter O
administration O
of O
myoblasts O
in O
doses O
of O
400 O
to O
800 O
million O
cells O
is O
feasible O
and O
may O
lead O
to O
important O
clinical O
benefits O
. O
[]

Lovastatin O
treatment O
was O
not O
associated O
with O
significant O
elevations B-outcome ['Physiological-Clinical']
in O
liver B-outcome ['Physiological-Clinical']
or O
muscle B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
oral O
brovincamine O
on O
visual O
field O
damage O
in O
patients O
with O
normal-tension O
glaucoma O
with O
low-normal O
intraocular O
pressure O
. O
[]

BACKGROUND O
The O
treatment O
of O
distal O
femoral O
fractures O
remains O
a O
significant O
surgical O
challenge O
. O
[]

BACKGROUND O
After O
major O
burns O
, O
patients O
can O
develop O
nutritional O
deficiencies O
including O
trace B-outcome ['Physiological-Clinical']
element I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
deficiencies O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
measure O
was O
pain-free B-outcome ['Physiological-Clinical']
status O
at O
2 O
hours O
postdose O
. O
['Physiological-Clinical']

Side O
effects O
were O
restricted O
to O
an O
occasional O
mild O
hypokalaemia O
( O
3.0-3.5 O
mM O
l O
( O
-1 O
) O
K O
( O
+ O
) O
) O
that O
was O
treated O
with O
supplemental O
potassium O
. O
[]

IMPLICATIONS O
The O
results O
of O
the O
trial O
favor O
, O
at O
present O
, O
the O
indication O
of O
prophylactic O
cranial O
irradiation O
for O
patients O
who O
are O
in O
complete O
remission O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
prosthodontic O
and O
aesthetic O
peri-implant O
mucosal O
outcomes O
of O
immediately O
restored O
, O
Southern O
single-tapered O
implants O
in O
the O
anterior O
maxilla O
after O
1 O
year O
. O
[]

Clinical O
variables O
, O
including O
stomatitis B-outcome ['Physiological-Clinical']
, O
and O
laboratory O
parameters O
, O
such O
as O
CD4 O
( O
+ O
) O
and O
CD8 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
FeLV I-outcome ['Physiological-Clinical']
p I-outcome ['Physiological-Clinical']
27 I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
were O
recorded O
throughout O
the O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Methodologically O
, O
we O
demonstrate O
the O
importance O
of O
analysing O
mortality O
separately O
for O
the O
breast O
cancer O
cases O
as O
well O
as O
for O
the O
entire O
population O
in O
a O
trial O
. O
[]

Exploratory O
analyses O
demonstrated O
no O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.28 O
; O
95 O
% O
CI O
, O
0.92 O
to O
1.76 O
; O
P O
= O
.14 O
) O
or O
OS B-outcome ['Mortality']
benefit O
( O
HR O
, O
1.24 O
; O
95 O
% O
CI O
, O
0.90 O
to O
1.71 O
; O
P O
= O
.18 O
) O
from O
gefitinib O
for O
344 O
patients O
with O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
wild-type O
tumors O
. O
['Mortality', 'Mortality']

Before O
and O
after O
the O
12 O
week O
supplementation O
period O
, O
subjects O
cycled O
for O
45 O
min O
at O
submaximal O
intensity O
( O
50 O
% O
maximal O
workload O
capacity O
) O
. O
[]

Predictors O
evaluated O
against O
child B-outcome ['Life-Impact']
IEP I-outcome ['Life-Impact']
goal I-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
included O
child O
, O
teacher O
, O
intervention O
practice O
, O
and O
implementation O
practice O
variables O
based O
on O
an O
implementation O
science O
framework O
( O
Dunst O
and O
Trivette O
in O
J O
Soc O
Sci O
8:143-148 O
, O
2012 O
) O
. O
['Life-Impact']

METHODS O
STEPs O
was O
a O
3-month O
randomised O
controlled O
trial O
with O
a O
pre O
and O
post-test O
design O
. O
[]

Cholesterol-lowering O
therapy O
may O
retard O
the O
progression O
of O
diabetic O
nephropathy O
. O
[]

RESULTS O
Age O
, O
obesity O
, O
and O
presence O
of O
symptoms O
accompanying O
AF O
were O
inversely O
associated O
with O
baseline O
exercise O
capacity O
, O
but O
these O
factors O
accounted O
for O
only O
10 O
% O
of O
the O
variance O
in O
exercise O
capacity O
. O
[]

OBJECTIVE O
To O
investigate O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
effects O
of O
methadone O
on O
behaviour B-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vasopressin I-outcome ['Physiological-Clinical']
in O
healthy O
dogs O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

radiography O
or O
no O
radiography O
) O
do O
not O
have O
better O
outcomes O
than O
those O
randomised O
to O
a O
treatment O
group O
. O
( O
[]

OBJECTIVE O
To O
determine O
the O
efficacy O
of O
stanol O
esters O
in O
lowering O
cholesterol O
in O
a O
US O
population O
. O
[]

A O
follow-up O
assessment O
was O
conducted O
3 O
weeks O
after O
the O
injection O
. O
[]

Hydrogen O
peroxide O
mouth O
rinse O
: O
an O
analgesic O
post-tonsillectomy O
. O
[]

The O
primary O
endpoint O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
; O
secondary O
endpoints O
were O
time B-outcome ['Mortality']
from I-outcome ['Mortality']
first I-outcome ['Mortality']
progression I-outcome ['Mortality']
to I-outcome ['Mortality']
death I-outcome ['Mortality']
( I-outcome ['Mortality']
TFPTD I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
tolerability B-outcome ['Life-Impact']
. O
['Mortality', 'Mortality', 'Life-Impact']

Delta O
Research O
Group O
. O
[]

These O
results O
reveal O
that O
6 O
mg O
of O
astaxanthin O
per O
day O
from O
a O
H. O
pluvialis O
algal O
extract O
can O
be O
safely O
consumed O
by O
healthy O
adults O
. O
[]

Patients O
were O
then O
randomized O
to O
either O
levofloxacin O
, O
omeprazole O
, O
nitazoxanide O
, O
and O
doxycycline O
( O
LOAD O
) O
therapy O
for O
7 O
days O
( O
LOAD-7 O
) O
or O
10 O
days O
( O
LOAD-10 O
) O
, O
including O
levofloxacin O
250 O
mg O
with O
breakfast O
, O
omeprazole O
40 O
mg O
before O
breakfast O
, O
nitazoxanide O
( O
Alina O
) O
500 O
mg O
twice O
daily O
with O
meals O
and O
doxycycline O
100 O
mg O
at O
dinner O
, O
or O
lansoprozole O
, O
amoxicillin O
, O
and O
clarithromycin O
( O
LAC O
) O
therapy O
for O
10 O
days O
, O
which O
included O
lansoprozole O
30 O
mg O
, O
amoxicillin O
1 O
g O
with O
breakfast O
and O
dinner O
, O
and O
clarithromycin O
500 O
mg O
with O
breakfast O
and O
dinner O
. O
[]

The O
restorations O
were O
clinically O
rated O
using O
modified O
United O
States O
Public O
Health O
Service O
( O
USPHS O
) O
criteria O
at O
baseline O
, O
6 O
and O
12 O
months O
after O
placement O
. O
[]

Clinical O
research O
evaluating O
the O
effects O
of O
preventive O
perirectal O
skin O
care O
is O
scarce O
. O
[]

To O
test O
the O
relative O
importance O
of O
these O
two O
mechanisms O
, O
we O
have O
randomly O
studied O
22 O
patients O
with O
alopecia O
areata O
to O
whom O
either O
DNCB O
or O
croton O
oil O
was O
applied O
topically O
. O
[]

The O
association O
between O
treatment O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
nonmelanoma I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
and O
between O
treatment O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
multiple I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
overall O
and O
within O
subgroups O
, O
defined O
by O
baseline O
characteristics O
, O
was O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Electroacupuncture O
can O
effectively O
improve O
the O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
knee O
joint O
's O
motor B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
knee I-outcome ['Life-Impact']
joints I-outcome ['Life-Impact']
in O
patients O
with O
knee O
osteoarthritis O
, O
as O
well O
as O
the O
synergistic O
effects O
on O
the O
treatment O
of O
knee O
osteoarthritis O
after O
arthroscopic O
debridement O
, O
leading O
to O
a O
much O
better O
long-term O
therapeutic O
effect O
with O
respect O
of O
improving O
the O
function O
of O
knee O
joint O
. O
['Physiological-Clinical', 'Life-Impact']

Oral O
sildenafil O
to O
control O
pulmonary B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
after O
congenital O
heart O
surgery O
. O
['Physiological-Clinical']

METHODS O
Totally O
180 O
patients O
with O
NPC O
were O
divided O
equally O
into O
3 O
groups O
with O
the O
same O
radiotherapeutic O
protocols O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
porphobilinogen I-outcome ['Physiological-Clinical']
and O
5-aminolevulinic B-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
analysed O
using O
a O
novel O
liquid O
chromatography-tandem O
mass O
spectrometry O
method O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
were O
randomly O
divided O
into O
two O
post-ICU O
management O
groups O
: O
geriatric O
ward O
and O
standard O
care O
. O
[]

BACKGROUND O
Subclinical O
hyperthyroidism O
is O
associated O
with O
cardiovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
patients O
were O
divided O
into O
two O
groups O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

Following O
impressions O
for O
the O
test O
group O
, O
all O
subjects O
brushed O
twice O
daily O
with O
a O
regular O
dentifrice O
and O
toothbrush O
for O
a O
four-week O
acclimation O
phase O
to O
standardize O
oral O
conditions O
( O
while O
trays O
were O
fabricated O
) O
prior O
to O
initiating O
the O
treatment O
phase O
. O
[]

A O
comparison O
of O
three O
highly O
active O
antiretroviral O
treatment O
strategies O
consisting O
of O
non-nucleoside O
reverse O
transcriptase O
inhibitors O
, O
protease O
inhibitors O
, O
or O
both O
in O
the O
presence O
of O
nucleoside O
reverse O
transcriptase O
inhibitors O
as O
initial O
therapy O
( O
CPCRA O
058 O
FIRST O
Study O
) O
: O
a O
long-term O
randomised O
trial O
. O
[]

METHODS O
We O
included O
patients O
older O
than O
18 O
years O
, O
expected O
to O
be O
in O
ICU O
for O
more O
than O
72 O
hours O
, O
with O
a O
glucose O
value O
of O
more O
than O
10 O
mmol/L O
within O
48 O
hours O
of O
ICU O
admission O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
strict O
glycemic O
control O
by O
nateglinide O
on O
common O
carotid B-outcome ['Physiological-Clinical']
far I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetic O
patients O
who O
were O
already O
under O
good O
glycemic O
control O
. O
['Physiological-Clinical']

The O
main O
outcome O
measures O
were O
mood B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
noted O
on O
a O
daily O
rating O
scale O
. O
['Life-Impact']

We O
tested O
the O
hypothesis O
that O
in O
selected O
patients O
with O
multivessel O
disease O
suitable O
for O
treatment O
with O
either O
procedure O
, O
an O
initial O
strategy O
of O
PTCA O
does O
not O
result O
in O
a O
poorer O
five-year O
clinical O
outcome O
than O
CABG O
. O
[]

Cytology B-outcome ['Physiological-Clinical']
( O
at O
a O
cutoff O
of O
atypical O
squamous O
cells O
of O
undetermined O
significance O
or O
greater O
) O
detected O
76 O
% O
of O
cases O
among O
both O
treated O
and O
untreated O
women O
. O
['Physiological-Clinical']

RESULTS O
Independent O
of O
the O
preexercise O
meal O
, O
2.8 O
mg?kg O
BM O
of O
PSE O
did O
not O
significantly O
improve O
cycling O
TT O
performance O
. O
[]

Experiment O
1 O
showed O
that O
spending O
10 O
min O
constructing O
shapes O
from O
modeling O
clay O
( O
plasticine O
) O
reduced O
participants O
' O
craving B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
chocolate I-outcome ['Life-Impact']
compared O
with O
spending O
10 O
min O
'letting O
your O
mind O
wander O
' O
. O
['Life-Impact']

Using O
these O
parameters O
retinal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
calculated O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
reduction O
in O
morbidity O
on O
any O
measured O
postoperative O
day O
. O
[]

Measures O
of O
functional O
emotional O
development O
and O
symptom O
severity O
were O
taken O
. O
[]

Conversely O
, O
L-arginine O
restored O
a O
physiological O
profile O
of O
all O
endothelial B-outcome ['Physiological-Clinical']
variables O
compared O
with O
control O
subjects O
. O
['Physiological-Clinical']

Impacts O
of O
a O
disease O
management O
program O
for O
dually O
eligible O
beneficiaries O
. O
[]

122 O
were O
assigned O
the O
standard O
diagnostic O
strategy O
and O
118 O
the O
biomarker-based O
diagnostic O
strategy O
. O
[]

The O
Volpe-Manhold B-outcome ['Physiological-Clinical']
calculus I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
was O
used O
to O
quantify O
the O
distribution O
and O
amount O
of O
calculus O
deposition O
on O
the O
lingual O
aspect O
of O
the O
mandibular O
6 O
anterior O
teeth O
at O
baseline O
. O
['Physiological-Clinical']

Most O
responses O
returned O
to O
the O
baseline O
values O
within O
24 O
h. O
[]

The O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
telomerase I-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
transcriptase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
hTERT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
detected O
from O
fresh O
tissues O
of O
the O
cervical O
lesion O
. O
['Physiological-Clinical']

The O
goal O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
single- O
and O
multi-dose O
( O
5-day O
) O
clindamycin O
therapy O
for O
the O
prevention O
of O
inflammatory O
complications O
in O
patients O
undergoing O
lower O
third O
molar O
surgical O
extraction O
with O
bone O
removal O
. O
[]

On O
day O
1 O
, O
a O
first O
bronchoalveolar O
lavage O
( O
BAL O
) O
was O
performed O
to O
assess O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
by O
unstimulated O
and O
lipopolysaccharide O
( O
LPS O
) O
stimulated O
AM O
. O
['Physiological-Clinical']

Mean O
( O
SD O
) O
time O
taken O
for O
complete O
healing O
with O
combination O
treatment O
[ O
1.9 O
( O
0.6 O
) O
weeks O
] O
was O
significantly O
shorter O
than O
that O
with O
minoxidil O
alone O
( O
3.1 O
[ O
1.7 O
] O
weeks O
; O
p=0.001 O
) O
or O
with O
lignocaine O
alone O
( O
3.3 O
[ O
0.8 O
] O
weeks O
; O
p=0.002 O
) O
. O
[]

Comparison O
of O
active-learning O
strategies O
for O
motivational B-outcome ['Life-Impact']
interviewing I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

AIM O
The O
study O
aimed O
to O
test O
simultaneously O
our O
understanding O
of O
the O
effects O
of O
bupropion O
sustained-release O
( O
SR O
) O
treatment O
on O
putative O
mediators O
and O
our O
understanding O
of O
determinants O
of O
post-quit O
abstinence O
, O
including O
withdrawal O
distress O
, O
cigarette O
craving O
, O
positive O
affect O
and O
subjective O
reactions O
to O
cigarettes O
smoked O
during O
a O
lapse O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
overweight O
patients O
who O
underwent O
OA O
than O
in O
those O
treated O
with O
the O
laparoscopic O
technique O
. O
['Physiological-Clinical']

BACKGROUND O
Immunisation O
against O
influenza O
is O
an O
effective O
intervention O
that O
reduces O
serologically O
confirmed O
cases O
by O
between O
60 O
% O
and O
70 O
% O
. O
[]

The O
median O
follow-up O
duration O
is O
26 O
months O
. O
[]

Effect O
of O
2 O
weeks O
of O
theophylline O
on O
glucose B-outcome ['Physiological-Clinical']
counterregulation I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
1 O
diabetes O
and O
unawareness O
of O
hypoglycemia O
. O
['Physiological-Clinical']

In O
a O
family-based O
analysis O
by O
The O
International O
Consortium O
for O
Prostate O
Cancer O
Genetics O
( O
ICPCG O
) O
, O
the O
G84E O
mutation O
was O
most O
prevalent O
in O
families O
from O
the O
Nordic O
countries O
of O
Finland O
( O
22.4 O
% O
) O
and O
Sweden O
( O
8.2 O
% O
) O
. O
[]

The O
intention-to-treat O
analysis O
showed O
no O
difference O
over O
the O
intervention O
year O
in O
the O
number O
of O
symptom B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
, O
yet O
there O
was O
a O
trend O
toward O
fewer O
days O
of O
limited O
activity O
and O
a O
significant O
decrease O
in O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
by O
the O
intervention O
group O
compared O
with O
controls O
. O
['Physiological-Clinical', 'Resource-use']

Pooled O
analysis O
of O
VACT1/VACT2 O
demonstrated O
greater O
PGART B-outcome ['Physiological-Clinical']
( O
p=0.023 O
) O
with O
rofecoxib O
25 O
mg O
( O
56.1 O
% O
) O
than O
celecoxib O
( O
49.8 O
% O
) O
at O
6 O
weeks O
and O
greater O
response O
to O
all O
other O
PGART O
and O
WOMAC O
endpoints O
, O
and O
confirmed O
superiority O
of O
COX-2 O
inhibitors O
to O
acetaminophen O
. O
['Physiological-Clinical']

In O
a O
2 O
? O
[]

METHODS O
The O
present O
study O
was O
a O
long-term O
effectiveness O
study O
under O
healthcare O
setting O
in O
Japan O
. O
[]

OBJECTIVES O
The O
goal O
of O
these O
studies O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
dapsone O
gel O
, O
5 O
% O
in O
the O
treatment O
of O
acne O
. O
[]

The O
actuarial O
probability O
of O
a O
recurrence B-outcome ['Life-Impact']
of O
arrhythmia B-outcome ['Physiological-Clinical']
after O
a O
prediction O
of O
drug O
efficacy O
by O
either O
strategy O
was O
significantly O
lower O
for O
patients O
treated O
with O
sotalol O
than O
for O
patients O
treated O
with O
the O
other O
drugs O
( O
risk O
ratio O
, O
0.43 O
; O
95 O
percent O
confidence O
interval O
, O
0.29 O
to O
0.62 O
; O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Patients O
fed O
EPA+GLA O
had O
a O
significant O
reduction O
in O
BALF B-outcome ['Physiological-Clinical']
ceruloplasmin I-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
during O
the O
study O
as O
compared O
with O
patients O
fed O
the O
control O
diet O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
intravenous O
adrenaline O
there O
was O
a O
good O
clinical B-outcome ['Physiological-Clinical']
and O
biochemical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
but O
after O
endotracheal O
adrenaline O
there O
was O
no O
change O
in O
serum B-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
and O
no O
measurable O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
last O
decade O
a O
new O
class O
of O
drugs O
-- O
the O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drugs O
-- O
has O
been O
developed O
. O
[]

METHODS O
The O
132 O
subjects O
in O
this O
randomized O
, O
controlled O
trial O
were O
in O
the O
age O
range O
of O
40-79 O
years O
. O
[]

Levels O
of O
complement B-outcome ['Physiological-Clinical']
factor O
C3a B-outcome ['Physiological-Clinical']
( O
851 O
( O
791-959 O
) O
ng/ml O
[ O
median O
with O
quartiles O
] O
in O
group O
C O
, O
497 O
( O
476-573 O
) O
ng/ml O
in O
group O
HC O
, O
p O
< O
0.001 O
) O
, O
Terminal B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
randomized O
study O
. O
[]

The O
introduction O
of O
artemisinin-based O
combination O
therapy O
in O
sub-Saharan O
Africa O
has O
prompted O
calls O
for O
increased O
use O
of O
parasitologic O
diagnosis O
for O
malaria O
. O
[]

The O
optimum O
treatment O
conditions O
of O
interferon O
( O
IFN O
) O
alpha O
therapy O
in O
chronic O
myeloid O
leukemia O
( O
CML O
) O
are O
still O
controversial O
. O
[]

The O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
lowest O
in O
the O
ketazolam O
group O
. O
['Adverse-effects']

OBJECTIVE O
To O
compare O
the O
effect O
of O
visual O
and O
kinesthetic O
locomotor O
imagery O
training O
on O
walking B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
to O
determine O
the O
clinical B-outcome ['Life-Impact']
feasibility I-outcome ['Life-Impact']
of O
incorporating O
auditory O
step O
rhythm O
into O
the O
training O
. O
['Life-Impact', 'Life-Impact']

Concurrent O
naloxone O
attenuated O
the O
opioid B-outcome ['Physiological-Clinical']
agonist I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
buprenorphine O
. O
['Physiological-Clinical']

BACKGROUND O
The O
upright O
sitting O
or O
beachchair O
position O
is O
associated O
with O
hypotension B-outcome ['Physiological-Clinical']
, O
risk O
of O
cerebral B-outcome ['Physiological-Clinical']
hypoperfusion I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Within O
the O
limitations O
of O
this O
study O
and O
in O
comparison O
to O
untreated O
control O
teeth O
, O
Linkmax O
treatment O
resulted O
in O
a O
significant O
reduction O
in O
tooth B-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
over O
1 O
week O
( O
P=.02 O
) O
, O
whereas O
RelyX O
ARC O
did O
not O
( O
P=.066 O
) O
. O
['Physiological-Clinical']

Comparison O
of O
7-day O
and O
14-day O
proton O
pump O
inhibitor-containing O
triple O
therapy O
for O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
: O
neither O
treatment O
duration O
provides O
acceptable O
eradication O
rate O
in O
Korea O
. O
['Physiological-Clinical']

We O
found O
that O
early O
treatment O
was O
important O
, O
since O
the O
effect O
on O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
whoops I-outcome ['Physiological-Clinical']
was O
most O
pronounced O
when O
disease O
duration O
before O
treatment O
was O
less O
than O
or O
equal O
to O
7 O
days O
. O
['Physiological-Clinical']

Despite O
a O
relative O
lack O
of O
published O
data O
antazoline O
has O
been O
marketed O
in O
Poland O
and O
widely O
used O
in O
cardiology O
wards O
and O
emergency O
rooms O
for O
many O
years O
due O
to O
its O
efficacy O
, O
safety O
and O
rapid O
onset O
of O
action O
within O
minutes O
of O
administration O
. O
[]

In O
the O
first O
study O
, O
the O
8 O
and O
16 O
mg O
ondansetron O
groups O
had O
a O
significantly O
lower O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
the O
0-24 O
h O
period O
following O
recovery O
from O
anaesthesia O
than O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
These O
overall O
findings O
suggest O
that O
a O
limited O
bias O
is O
introduced O
by O
drug O
administration O
instructions O
. O
[]

To O
determine O
whether O
increased O
sorafenib O
doses O
cause O
incremental O
increases O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
we O
measured O
12-h O
ambulatory O
BP O
in O
41 O
normotensive O
advanced O
solid O
tumor O
patients O
in O
a O
randomized O
dose-escalation O
study O
. O
['Physiological-Clinical']

Subjects O
who O
fulfill O
selection O
criteria O
will O
be O
randomly O
assigned O
to O
receive O
intravenously O
either O
antazoline O
or O
placebo O
in O
divided O
doses O
and O
observed O
for O
1.5 O
hours O
after O
conversion O
to O
sinus O
rhythm O
or O
after O
the O
last O
i.v O
. O
[]

Twelve O
hour O
fasting O
blood O
samples O
, O
taken O
at O
the O
initiation O
and O
on O
the O
third O
month O
of O
therapy O
, O
were O
analyzed O
for O
the O
levels O
of O
malondialdehyde B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MDA B-outcome ['Physiological-Clinical']
) O
, O
nitrite+nitrate B-outcome ['Physiological-Clinical']
( O
NOx O
) O
, O
and O
the O
activity O
of O
myeloperoxidase B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MPO I-outcome ['Physiological-Clinical']
) O
, O
superoxide B-outcome ['Physiological-Clinical']
dismutase B-outcome ['Physiological-Clinical']
( O
SOD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
controlled O
trial O
of O
acidic O
washout O
solution O
, O
normal O
saline O
washout O
, O
or O
standard O
care O
. O
[]

Treatment O
time O
was O
60s O
for O
GaAlAs O
laser O
and O
30s O
for O
Er O
, O
Cr O
: O
YSGG O
laser O
. O
[]

Educational O
intervention O
for O
altering O
water-sanitation O
behavior O
to O
reduce O
childhood O
diarrhea B-outcome ['Physiological-Clinical']
in O
urban O
Bangladesh O
: O
impact O
on O
nutritional O
status O
. O
['Physiological-Clinical']

Treatment O
groups O
were O
comparable O
concerning O
other O
safety O
parameters O
and O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions B-outcome ['Adverse-effects']
. O
['Adverse-effects', 'Adverse-effects']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

METHODS/DESIGN O
The O
study O
is O
a O
randomized O
, O
waitlist O
controlled O
, O
single-blinded O
trial O
. O
[]

In O
conclusion O
, O
in O
treated O
patients O
with O
heart O
failure O
, O
increasing O
NT-ANP O
and O
BNP O
over O
time O
predict O
a O
decreasing O
EF B-outcome ['Physiological-Clinical']
and O
ventricular B-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
, O
while O
increasing O
NT-ANP O
and O
norepinephrine O
independently O
predict O
greater O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Likewise O
, O
there O
was O
no O
significant O
difference O
in O
the O
details O
of O
the O
operative O
procedure O
when O
compared O
as O
a O
group O
for O
the O
early O
versus O
delayed O
reinfusion O
groups O
. O
[]

METHODS O
A O
total O
of O
27 O
patients O
aged O
18 O
to O
40 O
years O
with O
positive O
skin-prick O
tests O
and O
mild O
asthma O
underwent O
repetitive O
high-dose O
allergen O
challenges O
with O
household O
dust O
mites O
for O
four O
consecutive O
days O
. O
[]

DESIGN O
Double-blind O
randomised O
controlled O
trial O
. O
[]

Comparison O
of O
the O
in O
vitro O
and O
in O
vivo O
release O
of O
digoxin B-outcome ['Resource-use']
from O
four O
different O
soft O
gelatin O
capsule O
formulations O
. O
['Resource-use']

Patients O
in O
both O
groups O
were O
well-matched O
with O
baseline O
disease O
characteristics O
. O
[]

Twenty-four O
Helicobacter O
pylori-negative O
subjects O
were O
randomized O
to O
treatment O
with O
ibuprofen O
or O
ibuprofen-arginate O
( O
each O
600 O
mg/6 O
hr O
during O
3 O
days O
) O
. O
[]

Evidence O
of O
antitumour O
activity O
was O
observed O
, O
with O
significant O
sustained O
effects O
upon O
imaging O
vascular O
parameters O
. O
[]

The O
incidence O
of O
laboratory O
and O
clinical O
serious O
adverse O
events O
in O
both O
mothers O
and O
their O
babies O
was O
similar O
between O
groups O
. O
[]

Modified O
Boyarsky O
score O
decreased O
significantly O
with O
a O
mean O
of O
-6.7 O
( O
SD O
4.0 O
) O
points O
in O
the O
beta-sitosterol-treated O
group O
versus O
-2.1 O
( O
3.2 O
) O
points O
in O
the O
placebo O
group O
p O
< O
0.01 O
. O
[]

Infliximab B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
2 O
hours O
after O
each O
infusion O
and O
at O
1 O
, O
3 O
, O
4 O
, O
5 O
, O
8 O
, O
10 O
, O
14 O
and O
18 O
weeks O
. O
['Physiological-Clinical']

Thus O
, O
at O
least O
two O
androgen-treated O
patients O
had O
increases O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
without O
ever O
increasing O
their O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
induction O
of O
complete O
remission O
, O
patients O
were O
randomized O
to O
the O
bestatin O
group O
( O
30 O
mg/bw O
per O
os O
( O
po O
) O
daily O
) O
and O
the O
control O
group O
. O
[]

Baseline O
characteristics O
were O
evenly O
distributed O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
modified O
CIMT O
on O
improving O
paretic O
arm O
function O
in O
poststroke O
patients O
during O
a O
subacute O
rehabilitation O
period O
. O
[]

CP O
subjects O
were O
treated O
by O
scaling O
and O
root O
planing O
along O
with O
placebo O
tablets O
. O
[]

A O
chest B-outcome ['Physiological-Clinical']
sweating I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of O
40 O
g.m-2.h-1 O
was O
considered O
significant O
. O
['Physiological-Clinical']

Male O
well-informed O
patients O
with O
primary O
monolateral O
inguinal O
hernia O
( O
ASA O
I-II O
) O
were O
divided O
into O
2 O
groups O
and O
consecutively O
treated O
; O
group O
A O
was O
treated O
with O
laparoscopic O
transabdominal O
preperitoneal O
approach O
( O
TAPP O
) O
( O
median O
age O
47+/-7 O
years O
, O
57 O
patients O
) O
, O
group O
B O
with O
open O
mesh O
herniorrhaphy O
( O
45+/-6 O
years O
, O
64 O
patients O
) O
. O
[]

Patients O
receiving O
prophylactic O
amnioinfusion O
had O
a O
significant O
decrease O
in O
both O
the O
frequency O
and O
severity O
of O
variable O
decelerations B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
of O
labor B-outcome ['Physiological-Clinical']
( O
P O
= O
.006 O
) O
and O
in O
the O
average O
total O
number O
of O
variable O
decelerations O
in O
the O
first O
and O
second O
stages O
of O
labor O
( O
P O
= O
.01 O
) O
compared O
with O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
heat O
retention O
or O
warming O
therapy O
, O
patients O
received O
either O
low-flow O
anesthesia O
only O
( O
control O
, O
n O
= O
10 O
) O
, O
low-flow O
anesthesia O
with O
additional O
reflective O
blankets O
( O
blanket O
, O
n O
= O
10 O
) O
, O
or O
low-flow O
anesthesia O
with O
active O
forced-air O
warming O
( O
forced-air O
, O
n O
= O
10 O
) O
. O
[]

After O
Actovegin B-outcome ['Physiological-Clinical']
parietal I-outcome ['Physiological-Clinical']
P300 I-outcome ['Physiological-Clinical']
scalp I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
increased O
, O
while O
frontal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
temporal I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
decreased O
as O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

intervals O
over O
the O
next O
2 O
hours O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Type-4a B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
was O
diagnosed O
in O
208/2121 O
patients O
( O
9.8 O
% O
) O
when O
cTn O
was O
used O
( O
CK-MB O
mass O
if O
cTn O
not O
available O
) O
, O
and O
in O
93/2121 O
of O
patients O
( O
4.4 O
% O
) O
when O
CK-MB O
mass O
was O
used O
( O
cTn O
if O
CK-MB O
mass O
not O
available O
) O
. O
['Physiological-Clinical']

RESULTS O
We O
found O
the O
DB O
group?s O
VAS O
scores O
to O
be O
lower O
than O
the O
control O
group O
and O
block O
group?s O
( O
p O
< O
0.05 O
) O
values O
at O
postoperative O
1st O
, O
2nd O
, O
6th O
and O
12th O
hours O
. O
[]

Transurethral O
resection O
was O
repeated O
5 O
to O
6 O
weeks O
later O
to O
evaluate O
the O
residual O
tumor O
rate O
. O
[]

Low O
attending O
infants O
attended B-outcome ['Life-Impact']
more O
in O
medium O
and O
high O
intervention O
than O
in O
the O
low O
condition O
, O
while O
high O
attending O
infants O
were O
unaffected O
by O
intervention O
. O
['Life-Impact']

Removal O
of O
inflammatory O
cytokines O
and O
endotoxin O
by O
veno-venous O
continuous O
renal O
replacement O
therapy O
for O
burned O
patients O
with O
sepsis O
. O
[]

Comparison O
of O
propofol/alfentanil/N2O O
anaesthesia O
with O
thiopentone/halothane/N2O O
anaesthesia O
. O
[]

A O
negative O
experience B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
caregiving I-outcome ['Life-Impact']
predicted O
carer O
MH O
status O
. O
['Life-Impact']

Three O
days O
of O
fasting O
as O
well O
as O
pegvisomant O
alone O
decreased O
serum B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
levels O
( O
1.0 O
+/- O
0.15 O
vs. O
0.31 O
+/- O
0.05 O
ng/ml O
and O
0.86 O
+/- O
0.23 O
vs. O
0.46 O
+/- O
0.23 O
ng/ml O
, O
respectively O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Genital O
infection O
with O
human O
papillomavirus O
, O
the O
cause O
of O
genital O
warts O
, O
is O
one O
of O
the O
most O
common O
sexually O
transmitted O
diseases O
. O
[]

We O
expect O
long-term B-outcome ['Life-Impact']
implant I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
to O
be O
better O
with O
the O
TM O
tibial O
component O
. O
['Life-Impact']

Importantly O
, O
no O
potentiation O
of O
IgE B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
environmental I-outcome ['Physiological-Clinical']
allergens I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
which I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
participants I-outcome ['Physiological-Clinical']
were I-outcome ['Physiological-Clinical']
sensitized I-outcome ['Physiological-Clinical']
was O
seen O
. O
['Physiological-Clinical']

Fewer O
nefazodone-treated O
than O
placebo-treated O
patients O
discontinued O
owing O
to O
lack O
of O
efficacy O
. O
[]

Data O
collection O
occurred O
in O
a O
simulated O
situation O
. O
[]

For O
the O
seven O
round O
group O
, O
the O
degree O
of O
improvement O
on O
the O
assessment O
measures O
could O
be O
partially O
explained O
by O
a O
regression O
analysis O
based O
on O
excretion O
of O
toxic B-outcome ['Physiological-Clinical']
metals I-outcome ['Physiological-Clinical']
and O
changes O
in O
glutathione B-outcome ['Physiological-Clinical']
( O
adjusted O
R2 O
of O
0.28-0.75 O
, O
p O
< O
0.02 O
in O
all O
cases O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
with O
NAL O
, O
PRE O
resulted O
in O
greater O
improvement O
of O
specific O
symptoms O
in O
the O
areas O
of O
anxiety B-outcome ['Life-Impact']
, O
['Life-Impact']

We O
aimed O
to O
compare O
the O
short-term O
and O
long-term O
effectiveness O
of O
three O
antimalarial O
regimens O
in O
children O
from O
Kampala O
, O
Uganda O
. O
[]

The O
dose O
of O
haloperidol O
and O
cyproheptadine O
was O
titrated O
up O
to O
0.05 O
and O
0.2 O
mg/kg/day O
respectively O
. O
[]

Active O
warming O
, O
not O
passive O
heat O
retention O
, O
maintains O
normothermia B-outcome ['Physiological-Clinical']
during O
combined O
epidural-general O
anesthesia O
for O
hip O
and O
knee O
arthroplasty O
. O
['Physiological-Clinical']

SETTING O
Emergency O
Department O
, O
University O
Hospital O
of O
Wales O
. O
[]

After O
either O
spontaneous O
recovery O
or O
a O
fixed-duration O
wait O
of O
45 O
min O
( O
when O
appropriate O
) O
, O
the O
subjects O
received O
2x100 O
microg O
of O
salbutamol O
from O
a O
metered O
dose O
inhaler O
with O
a O
spacer O
. O
[]

CONCLUSIONS O
Iontophoresis O
treatment O
was O
well O
[]

Functional O
tests O
included O
the O
chair O
stand O
test O
and O
the O
timed O
up O
and O
go O
test O
. O
[]

Light-for-gestational B-outcome ['Physiological-Clinical']
age O
( O
LGA O
) O
was O
suspected O
if O
the O
estimated O
birth-weight O
was O
less O
than O
85 O
% O
of O
the O
expected O
mean O
birthweight O
. O
['Physiological-Clinical']

The O
area O
under O
the O
ROC B-outcome ['Physiological-Clinical']
curve O
for O
the O
home O
study-derived O
parameters O
was O
between O
0.84 O
and O
0.89 O
, O
compared O
with O
polysomnography O
. O
['Physiological-Clinical']

Clinical O
trials O
of O
intrasplenic O
arterial O
infusion O
of O
interleukin-2 O
( O
IS-IL-2 O
) O
to O
patients O
with O
advanced O
cancer O
. O
[]

The O
degree O
of O
eicosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
EPA O
, O
20:5n-3 O
) O
enrichment O
( O
fish-oil O
group O
) O
was O
dramatically O
greater O
in O
the O
ether-containing O
plasmenylethanolamine O
( O
13.5 O
mol O
% O
of O
fatty O
acids O
; O
mol O
% O
of O
fatty O
acids O
= O
moles O
per O
100 O
moles O
of O
total O
fatty O
acids O
) O
than O
in O
phosphatidylethanolamine O
( O
2.8 O
mol O
% O
) O
or O
phosphatidylcholine O
( O
2.9 O
mol O
% O
) O
. O
['Physiological-Clinical']

The O
patients O
were O
treated O
with O
hepatic O
artery O
ligation O
( O
HAL O
) O
and O
repeated O
transient O
dearterialization O
( O
RTD O
) O
respectively O
. O
[]

Major O
outcome O
was O
resolution B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
at O
72 O
h. O
Total O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Of O
204 O
patients O
with O
cLBP O
whose O
Oswestry O
Disability O
Index O
( O
ODI O
) O
was O
at O
least O
16 O
% O
, O
102 O
were O
randomized O
into O
a O
combined O
manipulative O
treatment O
, O
exercise O
, O
and O
physician O
consultation O
group O
( O
i.e. O
, O
a O
combination O
group O
) O
, O
and O
102 O
to O
a O
consultation O
alone O
group O
. O
[]

RESULTS O
Freedom-from-treatment-failure B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FFTF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
( O
SV O
) O
curves O
showed O
no O
differences O
between O
the O
20- O
, O
30- O
, O
and O
40-Gy O
groups O
. O
['Physiological-Clinical', 'Mortality']

PURPOSE O
Isolated O
limb O
perfusion O
( O
ILP O
) O
with O
tumor O
necrosis O
factor O
( O
TNF O
) O
, O
interferon O
gamma O
, O
and O
melphalan O
( O
M O
) O
has O
been O
reported O
to O
result O
in O
high O
response O
rates O
for O
extremity O
melanoma O
and O
sarcoma O
. O
[]

Intervention O
group O
patients O
reported O
higher O
levels O
of O
satisfaction O
than O
controls O
in O
five O
of O
six O
domains O
( O
all O
p O
< O
.05 O
) O
. O
[]

METHODS O
Our O
study O
was O
a O
prospective O
, O
randomised O
control O
trial O
. O
[]

3 O
. O
[]

LPL O
showed O
a O
statistically O
significant O
longer O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Life-Impact']

This O
double-blind O
, O
randomized O
, O
placebo O
crossover O
study O
was O
used O
to O
evaluate O
the O
effects O
of O
a O
cholinesterase O
inhibitor O
-- O
slow-release O
pyridostigmine O
( O
180 O
mg O
orally O
every O
12 O
hours O
) O
-- O
on O
the O
anticholinergic B-outcome ['Physiological-Clinical']
and O
antiarrhythmic B-outcome ['Physiological-Clinical']
properties O
of O
disopyramide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
An O
examiner-blind O
clinical O
trial O
was O
conducted O
among O
30 O
subjects O
with O
moderate O
to O
advanced O
periodontitis O
who O
were O
randomized O
to O
SRP O
alone O
or O
SRP O
combined O
with O
prescription O
custom-tray O
application O
( O
Perio O
Tray O
) O
of O
1.7 O
% O
hydrogen O
peroxide O
gel O
( O
Perio O
Gel O
) O
for O
a O
period O
of O
three O
months O
, O
then O
extended O
to O
six O
months O
. O
[]

Grade O
4 O
neutropaenia B-outcome ['Physiological-Clinical']
, O
grade O
3/4 O
anaemia B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Pharmacokinetics O
of O
naproxen O
after O
oral O
administration O
of O
two O
tablet O
formulations O
in O
healthy O
volunteers O
. O
[]

Closed O
Loop O
Stimulation O
did O
not O
result O
in O
additional O
echocardiographic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
; O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
distribution I-outcome ['Physiological-Clinical']
was O
significantly O
wider O
with O
CLS O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
sponsorships O
provide O
visibility O
for O
Healthway O
and O
positive O
health O
messages O
. O
[]

Yet O
, O
these O
results O
are O
not O
applicable O
for O
competitive O
athletes O
, O
who O
can O
use O
music O
only O
during O
warm-up O
or O
recovery O
from O
exercise O
. O
[]

Eberconazole O
1 O
% O
cream O
is O
an O
effective O
and O
safe O
alternative O
for O
dermatophytosis O
treatment O
: O
multicenter O
, O
randomized O
, O
double-blind O
, O
comparative O
trial O
with O
miconazole O
2 O
% O
cream O
. O
[]

Randomised O
controlled O
study O
of O
clinical O
outcome O
following O
trophic O
feeding O
. O
[]

Endurance O
training O
has O
little O
effect O
on O
active O
muscle O
free B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
or O
triglyceride B-outcome ['Physiological-Clinical']
net O
balances O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
single O
broad-spectrum O
antibiotic O
given O
for O
24 O
hour O
perioperatively O
effectively O
controls O
SWI O
. O
[]

The O
stimulus O
control O
computer O
produced O
no O
improvement O
, O
resulting O
in O
20 O
% O
worse O
cessation B-outcome ['Life-Impact']
rates O
than O
the O
assessment O
only O
condition O
. O
['Life-Impact']

PARTICIPANTS O
Ten O
male O
volunteers O
aged O
18-28 O
( O
mean O
22 O
) O
years O
. O
[]

CONCLUSIONS O
This O
pilot O
study O
is O
the O
first O
to O
prospectively O
investigate O
the O
efficacy O
and O
safety O
of O
a O
combination O
of O
0.45 O
% O
ketorolac O
eyedrops O
three O
times O
a O
day O
and O
intravitreal O
ranibizumab O
injections O
in O
patients O
with O
CNV O
, O
and O
suggests O
that O
topical O
ketorolac O
supplements O
the O
activity O
of O
intravitreal O
ranibizumab O
in O
reducing O
CMT O
in O
CNV O
. O
[]

Both O
treatment O
regimens O
-- O
cefoxitin O
given O
alone O
and O
clindamycin O
and O
gentamicin O
given O
together O
-- O
resulted O
in O
similar O
infection B-outcome ['Physiological-Clinical']
rates O
, O
drug B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
, O
and O
costs O
. O
['Physiological-Clinical', 'Adverse-effects', 'Resource-use']

DPP-4 O
inhibitor O
treatment O
improved O
the O
[]

FMD B-outcome ['Physiological-Clinical']
decreased O
in O
fat O
gainers O
( O
9.1+/-3 O
% O
vs. O
7.8+/-3.2 O
% O
, O
p=0.003 O
) O
but O
recovered O
to O
baseline O
when O
subjects O
shed O
the O
gained O
weight O
. O
['Physiological-Clinical']

BACKGROUND O
Because O
of O
its O
enhanced O
pharmacokinetic B-outcome ['Physiological-Clinical']
characteristics O
, O
ibuprofen O
arginate O
might O
be O
expected O
to O
provide O
faster O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
than O
standard O
ibuprofen O
formulations O
in O
patients O
experiencing O
acute O
pain O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcome O
measures O
included O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
and O
complete O
( O
clinical B-outcome ['Physiological-Clinical']
plus O
mycological B-outcome ['Physiological-Clinical']
) O
cure B-outcome ['Physiological-Clinical']
of O
the O
target O
toenail B-outcome ['Physiological-Clinical']
and O
complete B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
all O
10 O
toenails B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fifty-four O
children O
completed O
the O
assessments O
12 O
months O
after O
conclusion O
of O
the O
intervention O
. O
[]

Finally O
, O
ACE O
inhibitor O
resulted O
in O
decreased O
GFR B-outcome ['Physiological-Clinical']
( O
p O
= O
115 O
+/- O
5.8 O
ml/mn-1 O
, O
C O
= O
91.1 O
+/- O
4 O
, O
p O
< O
0.05 O
) O
with O
exercise O
without O
modification O
of O
MA O
. O
['Physiological-Clinical']

Patients O
were O
randomized O
to O
receive O
either O
clodronate O
1,600 O
mg/day O
for O
one O
year O
or O
identical O
placebo-containing O
tablets O
. O
[]

Being O
a O
current B-outcome ['Life-Impact']
smoker I-outcome ['Life-Impact']
was O
not O
associated O
with O
an O
increase O
in O
risk O
, O
and O
was O
consistent O
across O
all O
fracture O
types O
. O
['Life-Impact']

DESIGN O
Oral O
testosterone O
undecanoate O
( O
40 O
mg O
daily O
for O
women O
, O
80 O
mg O
twice O
daily O
for O
men O
) O
and O
an O
oral O
nutritional O
supplement O
( O
475 O
kcal/d O
) O
were O
administered O
, O
alone O
or O
combined O
, O
for O
1 O
y O
to O
49 O
community-dwelling O
, O
undernourished O
people O
[ O
Mini O
Nutritional O
Assessment O
score O
< O
24 O
and O
low O
body O
weight O
( O
body O
mass O
index O
, O
in O
kg/m O
( O
2 O
) O
: O
< O
22 O
) O
or O
recent O
weight O
loss O
( O
> O
7.5 O
% O
over O
3 O
mo O
) O
] O
aged O
> O
65 O
y O
( O
mean O
age O
: O
77 O
y O
; O
26 O
women O
and O
23 O
men O
) O
. O
[]

Video-trained O
teachers O
, O
however O
, O
were O
less O
likely O
to O
use O
[]

RESULTS O
During O
a O
mean O
4.3-year O
follow-up O
, O
1799 O
( O
16.1 O
% O
) O
patients O
experienced O
a O
major O
event O
. O
[]

CONCLUSIONS O
A O
dual-coil O
, O
active O
pectoral O
lead O
system O
reduces O
defibrillation B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
compared O
with O
a O
single-coil O
, O
unipolar O
configuration O
. O
['Physiological-Clinical']

Effects O
on O
behaviour B-outcome ['Life-Impact']
were O
measured O
using O
the O
Autism B-outcome ['Life-Impact']
Treatment O
Evaluation O
Checklist O
score O
( O
ATEC O
) O
and O
clinical B-outcome ['Physiological-Clinical']
improvement O
was O
measured O
with O
the O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CGI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
system O
; O
in O
particular O
the O
clinical B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
( O
CGIC O
) O
and O
severity O
( O
CGIS O
) O
sub-scores O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Labetalol O
exerted O
a O
net O
inhibitory O
effect O
on O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
which O
was O
related O
to O
basal O
renin O
values O
and O
was O
already O
maximal O
at O
the O
lowest O
doses O
. O
['Physiological-Clinical']

Benefits O
and O
costs O
of O
home-based O
pulmonary O
rehabilitation O
in O
chronic O
obstructive O
pulmonary O
disease O
- O
a O
multi-centre O
randomised O
controlled O
equivalence O
trial O
. O
[]

antibiotics O
were O
randomly O
allocated O
to O
receive O
their O
drugs O
either O
through O
an O
in-line O
filter O
using O
a O
drug-free O
infusate O
or O
with O
no O
filter O
and O
an O
infusate O
containing O
heparin O
500 O
units O
and O
hydrocortisone O
10 O
mg/L O
. O
[]

Cost-effectiveness O
was O
expressed O
as O
the O
incremental O
cost-effectiveness O
ratio O
, O
and O
bootstrap O
methods O
were O
used O
to O
estimate O
the O
joint O
distribution O
of O
costs O
and O
effectiveness O
. O
[]

We O
tested O
the O
efficacy O
, O
tolerability O
and O
pharmacokinetics O
of O
2 O
combination O
therapies O
containing O
an O
NRTI O
, O
protease O
inhibitors O
+/- O
a O
nonnucleoside O
reverse O
transcription O
inhibitor O
( O
NNRTI O
) O
. O
[]

Staphylococcus O
epidermidis O
and O
Enterobacter O
species O
were O
isolated O
from O
sites O
of O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
the O
aztreonam O
group O
; O
Escherichia O
coli O
( O
two O
isolates O
) O
, O
Pseudomonas O
aeruginosa O
( O
two O
isolates O
) O
, O
Enterobacter O
species O
, O
Klebsiella O
species O
, O
Enterococcus O
faecalis O
, O
and O
Aeromonas O
hydrophila O
were O
isolated O
from O
the O
gentamicin O
group O
. O
['Physiological-Clinical']

A O
sample O
was O
selected O
of O
85 O
children O
with O
LD O
, O
with O
age O
range O
between O
8 O
years O
and O
10 O
years O
( O
age O
, O
M=111.02 O
, O
SD=9.6 O
) O
, O
whose O
spelling O
performance O
was O
two O
years O
below O
grade O
level O
. O
[]

A O
number O
of O
studies O
have O
attempted O
to O
evaluate O
the O
effect O
of O
low-power O
laser O
on O
radiotherapy- O
and O
chemotherapy-induced B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

PARTICIPANTS O
Patients O
aged O
65 O
or O
older O
of O
primary O
care O
physicians O
in O
a O
large O
provider O
organization O
bearing O
financial O
risk O
for O
their O
care O
( O
n O
= O
6409 O
) O
. O
[]

Step-down O
approach O
using O
either O
cyclosporin O
A O
or O
methotrexate O
as O
maintenance O
therapy O
in O
early O
rheumatoid O
arthritis O
. O
[]

A O
double-blind O
, O
randomized O
, O
controlled O
, O
multicenter O
study O
to O
assess O
the O
safety O
and O
cardiovascular B-outcome ['Physiological-Clinical']
effects O
of O
skeletal O
myoblast O
implantation O
by O
catheter O
delivery O
in O
patients O
with O
chronic O
heart O
failure O
after O
myocardial O
infarction O
. O
['Physiological-Clinical']

BACKGROUND O
Gastrointestinal O
( O
GI O
) O
symptoms O
and O
abnormalities O
in O
stool O
consistency O
are O
frequently O
reported O
by O
parents O
of O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

Length O
of O
[]

Cases O
of O
cicatricial O
ectropion O
have O
been O
reported O
in O
phenol-peeled O
patients O
, O
and O
lower O
eyelid O
ectropion O
has O
reportedly O
occurred O
in O
patients O
undergoing O
deep O
eyelid O
peel O
in O
conjunction O
with O
a O
blepharoplasty O
( O
1,2 O
) O
. O
[]

CONCLUSIONS O
Femoral O
vein O
contrast O
delivery O
significantly O
enhances O
the O
ability O
of O
precordial O
contrast O
echocardiography B-outcome ['Resource-use']
to O
diagnose O
patent O
foramen O
['Resource-use']

Clinical B-outcome ['Physiological-Clinical']
outcome O
was O
measured O
using O
Barthel O
Index O
, O
a O
functional O
status O
measure O
. O
['Physiological-Clinical']

Roles O
of O
adapalene O
in O
the O
treatment O
of O
pityriasis O
versicolor O
. O
[]

As O
a O
result O
, O
tools O
are O
needed O
to O
facilitate O
informed O
decision B-outcome ['Life-Impact']
making I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
A O
prospective O
, O
randomized O
parallel O
group O
multicenter O
trial O
was O
conducted O
. O
[]

Lactoferrin O
supplementation O
had O
no O
effect O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
body O
weight O
, O
average O
daily O
gain O
, O
heart O
girth O
, O
body O
temperature O
, O
fecal O
scores O
, O
respiratory O
scores O
, O
or O
haptoglobin O
concentrations O
. O
['Life-Impact']

Survival O
curve O
analyses O
revealed O
little O
difference O
between O
these O
groups O
for O
major O
vascular B-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
, O
total O
mortality B-outcome ['Mortality']
, O
all O
amputations B-outcome ['Resource-use']
, O
or O
myocardial B-outcome ['Physiological-Clinical']
infarctions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Resource-use', 'Physiological-Clinical']

Before O
transurethral O
prostatectomy O
the O
patients O
were O
randomized O
into O
3 O
groups O
: O
group O
1 O
-- O
197 O
patients O
given O
single-dose O
ceftriaxone O
( O
2 O
gm O
. O
) O
, O
[]

GTN B-outcome ['Physiological-Clinical']
evoked I-outcome ['Physiological-Clinical']
migraine B-outcome ['Physiological-Clinical']
fulfilling O
IHS O
criteria O
1.1 O
in O
6 O
patients O
after O
placebo O
and O
in O
2 O
patients O
after O
valproate O
( O
P O
= O
0.125 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
must O
therefore O
be O
interpreted O
with O
caution O
. O
[]

The O
study O
consists O
of O
two O
study O
populations O
: O
a O
hypertensive O
one O
( O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
> O
or O
= O
90.0 O
mm O
Hg O
at O
the O
time O
of O
randomization O
) O
and O
a O
normotensive O
one O
( O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
80.0-89.0 O
mm O
Hg O
at O
the O
time O
of O
randomization O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Objective O
parameters O
( O
heart O
rate O
, O
blood O
pressure O
, O
skin O
temperature O
, O
peak O
flow O
) O
as O
well O
as O
a O
total O
clinical O
symptom O
score O
using O
a O
standardized O
protocol O
were O
recorded O
at O
baseline O
, O
10 O
, O
20 O
, O
40 O
, O
80 O
minutes O
, O
and O
24 O
hours O
. O
[]

The O
usual O
logrank O
test O
has O
to O
be O
modified O
to O
test O
whether O
the O
true O
value O
r O
of O
the O
ratio O
of O
hazard O
rates O
in O
two O
treatment O
groups O
is O
at O
least O
equal O
to O
a O
limit O
value O
r0 O
. O
[]

Sixty-seven O
completed O
the O
intervention O
and O
59 O
completed O
a O
24-month O
follow-up O
assessment O
. O
[]

Effect O
of O
oral O
diuretics O
on O
pulmonary O
mechanics O
in O
infants O
with O
chronic O
bronchopulmonary O
dysplasia O
: O
results O
of O
a O
double-blind O
crossover O
sequential O
trial O
. O
[]

Supplementation O
with O
larger O
ARA O
doses O
added O
to O
DHA O
may O
therefore O
mitigate O
social O
impairment O
. O
[]

RESULTS O
Results O
showed O
no O
effect O
of O
aroma O
on O
galvanic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
relaxation O
. O
['Physiological-Clinical']

HR-HPV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
was O
performed O
by O
the O
end O
of O
the O
1st O
menstruation O
after O
3 O
menstrual O
cycles O
. O
['Physiological-Clinical']

All O
were O
from O
the O
same O
subculture O
. O
[]

A O
high O
proportion O
of O
first-time O
donors O
indicated O
that O
they O
had O
experienced O
a O
reaction O
to O
blood O
donation O
. O
[]

Sensitivity B-outcome ['Physiological-Clinical']
was O
over O
90 O
% O
in O
all O
projects O
. O
['Physiological-Clinical']

Median O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
was O
reduced O
by O
-5.00 O
to O
-11.75min O
in O
the O
pramipexole O
groups O
, O
vs. O
-2.00 O
for O
placebo O
( O
p O
< O
0.05 O
for O
all O
groups O
except O
0.25mg/d O
) O
. O
['Physiological-Clinical']

Children O
were O
assessed O
for O
social O
communication O
skills O
pre- O
and O
post-treatment O
, O
and O
followed O
up O
at O
3 O
months O
. O
[]

Penile B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
circumference I-outcome ['Physiological-Clinical']
as O
well O
as O
angle B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
erection I-outcome ['Physiological-Clinical']
, O
before O
and O
after O
each O
medication O
, O
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Not O
surprisingly O
, O
owner O
compliance O
can O
be O
poor O
resulting O
in O
apparent O
treatment O
failure O
. O
[]

Use O
of O
Interceed O
( O
TC7 O
) O
absorbable O
adhesion O
barrier O
to O
reduce O
postoperative B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
reformation I-outcome ['Physiological-Clinical']
in O
infertility O
and O
endometriosis O
surgery O
. O
['Physiological-Clinical']

All O
participants O
were O
inpatients O
, O
in O
the O
active O
phase O
of O
illness O
, O
and O
met O
DSM-IV-TR O
criteria O
for O
schizophrenia O
. O
[]

We O
explored O
the O
hypothesis O
that O
RAS O
activation O
by O
diuretic O
therapy O
might O
therefore O
worsen O
hypoxic O
pulmonary O
vasoconstriction O
via O
the O
effects O
of O
ANG O
II O
on O
the O
pulmonary O
vascular O
bed O
. O
[]

Residual O
postoperative B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
was O
also O
assessed O
. O
['Physiological-Clinical']

Forty O
subjects O
, O
aged O
8-56 O
years O
( O
mean=22 O
) O
, O
all O
with O
mental O
retardation O
and O
36 O
with O
autism O
spectrum O
disorders O
participated O
in O
this O
22-week O
crossover O
study O
, O
with O
24 O
weeks O
of O
open O
maintenance O
thereafter O
. O
[]

With O
the O
switch O
strategy O
used O
in O
IES O
, O
the O
on O
treatment O
adverse B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
exemestane O
are O
reversed O
. O
['Physiological-Clinical']

Secondary O
analyses O
revealed O
that O
the O
WSTP O
had O
greater O
effects O
on O
confidence O
in O
areas O
related O
to O
maneuvering O
around O
the O
physical O
environment O
, O
knowledge O
and O
problem O
solving O
, O
advocacy O
, O
and O
managing O
emotions O
than O
in O
areas O
related O
to O
performing O
activities O
and O
behaving O
in O
social O
situations O
. O
[]

The O
2 O
groups O
were O
similar O
at O
baseline O
in O
clinical O
and O
demographic O
characteristics O
, O
including O
the O
proportion O
of O
patients O
at O
therapeutic O
goals O
for O
BP B-outcome ['Physiological-Clinical']
, O
TC B-outcome ['Physiological-Clinical']
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
follow O
up O
of O
infants O
born O
preterm O
4 O
years O
postnatally O
indicated O
that O
extending O
gestational O
age O
did O
not O
increase O
the O
number O
of O
sequelae O
. O
[]

Although O
capable O
of O
inducing O
an O
anabolic O
state O
after O
surgery O
, O
parenteral O
nutrition O
, O
including O
glucose O
, O
leads O
to O
hyperglycemia O
. O
[]

PURPOSE O
To O
compare O
multi-detector O
row O
computed O
tomographic O
( O
CT O
) O
angiography O
and O
digital O
subtraction O
angiography O
( O
DSA O
) O
prior O
to O
revascularization O
in O
patients O
with O
symptomatic O
peripheral O
arterial O
disease O
for O
the O
purpose O
of O
assessing O
recommendations O
for O
additional O
imaging O
and O
physician O
confidence O
ratings O
for O
chosen O
therapy O
. O
[]

METHODS O
Generalized O
linear O
regression O
models O
were O
used O
to O
analyze O
healthcare B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
data O
on O
individuals O
enrolled O
in O
a O
comparative O
effectiveness O
trial O
of O
cessation O
therapies O
between O
October O
2005 O
and O
May O
2007 O
( O
1346 O
total O
participants O
; O
1338 O
with O
requisite O
data O
for O
further O
analysis O
) O
. O
['Resource-use']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
ozone O
and O
sodium O
ascorbate O
on O
resin-dentin O
microtensile O
bond O
strength O
( O
?TBS O
) O
. O
[]

[ O
Efficacy O
of O
combination O
with O
granisetron O
and O
methylprednisolone O
for O
nausea O
, O
vomiting O
and O
appetite O
loss O
in O
remission O
induction O
chemotherapy O
of O
acute O
myeloid O
leukemia O
-- O
a O
randomized O
comparative O
trial O
between O
granisetron O
alone O
and O
granisetron O
plus O
methylprednisolone O
] O
. O
[]

The O
present O
study O
demonstrated O
that O
the O
perioperative O
administration O
of O
parecoxib O
after O
primary O
TKA O
resulted O
in O
significantly O
improved O
postoperative O
analgesic O
management O
as O
defined O
by O
reduction O
in O
opioid O
requirement O
, O
lower O
pain O
scores O
and O
ROM O
, O
and O
significantly O
lowered O
local O
inflammation O
factors O
PGE2 O
and O
IL-6 O
. O
[]

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
dysfunction O
in O
three O
core O
behavioral O
domains O
: O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
social O
deficits O
, O
and O
language O
abnormalities O
. O
['Life-Impact']

In O
a O
subset O
of O
acute O
respiratory O
distress O
syndrome O
patients O
from O
this O
trial O
, O
we O
performed O
a O
preliminary O
examination O
of O
the O
potential O
mechanisms O
underlying O
these O
clinical O
improvements O
by O
retrospectively O
testing O
the O
hypothesis O
that O
enteral O
feeding O
with O
EPA+GLA O
could O
reduce O
alveolar-capillary O
membrane O
protein O
permeability O
and O
the O
production O
of O
interleukin O
( O
IL O
) O
-8 O
, O
IL-6 O
, O
tumor O
necrosis O
factor-alpha O
, O
and O
leukotriene O
B4 O
that O
are O
responsible O
, O
in O
part O
, O
for O
pulmonary O
inflammation O
. O
[]

Participants O
were O
given O
postcards O
at O
their O
final O
study O
visit O
to O
be O
completed O
and O
mailed O
on O
or O
after O
January O
1 O
, O
1996 O
. O
[]

We O
performed O
a O
randomized O
controlled O
trial O
to O
compare O
recurrence O
rates O
of O
varicose O
veins O
and O
complications O
after O
compression O
sclerotherapy O
and O
ambulatory O
phlebectomy O
. O
[]

No O
significant O
difference O
was O
observed O
in O
perioperative O
blood O
loss O
, O
the O
amount O
of O
morphine O
used O
, O
or O
FFD O
in O
the O
early O
postoperative O
period O
or O
in O
ROM O
and O
FFD O
at O
6 O
weeks O
postoperatively O
. O
[]

METHODS O
In O
total O
of O
71 O
type O
2 O
diabetics O
completed O
the O
study O
. O
[]

There O
appeared O
to O
be O
no O
significant O
differences O
between O
the O
non-pregnant O
and O
pregnant O
women O
in O
either O
the O
plasma O
concentrations O
or O
pharmacokinetic O
parameters O
of O
RU O
486 O
and O
its O
metabolites O
. O
[]

Changes O
in O
selected O
fitness B-outcome ['Physiological-Clinical']
parameters O
following O
six O
weeks O
of O
snowshoe O
training O
. O
['Physiological-Clinical']

CONCLUSION O
Clinical O
progression O
of O
chronic O
hepatitis O
C O
and O
maintenance O
peginterferon O
therapy O
led O
to O
worsening O
of O
symptoms B-outcome ['Physiological-Clinical']
, O
HRQOL B-outcome ['Life-Impact']
and O
, O
in O
men O
, O
sexual B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
in O
a O
large O
patient O
cohort O
followed O
up O
over O
4 O
years O
( O
NCT00006164 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

DESIGN O
Randomised O
controlled O
trial O
. O
[]

3.2 O
? O
[]

INTRODUCTION O
Few O
combinations O
of O
highly O
active O
antiretrovirals O
have O
been O
studied O
in O
nucleoside O
reverse O
transcription O
inhibitor O
( O
NRTI O
) O
-experienced O
, O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-infected O
children O
. O
[]

Serious O
adverse O
events O
were O
reported O
by O
27 O
of O
106 O
( O
25 O
% O
) O
patients O
in O
the O
ganitumab O
group O
and O
nine O
of O
49 O
( O
18 O
% O
) O
patients O
in O
the O
placebo O
group O
. O
[]

The O
primary O
end O
point O
of O
the O
trial O
was O
to O
compare O
114-day O
grades B-outcome ['Mortality']
2-4 I-outcome ['Mortality']
acute I-outcome ['Mortality']
GVHD-free I-outcome ['Mortality']
survival I-outcome ['Mortality']
using O
an O
intention-to-treat O
analysis O
of O
304 O
randomized O
subjects O
. O
['Mortality']

A O
randomized O
clinical O
study O
was O
conducted O
to O
compare O
the O
effect O
of O
conventional O
antiaggregation O
therapy O
( O
ASA O
plus O
dipyridamole O
) O
versus O
indobufen O
in O
patients O
after O
aortocoronary O
bypass O
( O
ACB O
) O
surgery O
. O
[]

Stepping O
Stones O
Triple O
P O
is O
a O
behavioural O
parenting O
training O
for O
families O
with O
a O
handicapped O
child O
, O
which O
has O
already O
been O
successfully O
evaluated O
in O
its O
country O
of O
origin O
, O
Australia O
. O
[]

Baseline O
and O
posttreatment O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
and O
arterial B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Among O
women O
under O
instruction O
, O
864 O
breast O
cancers O
detected O
and O
133 O
breast O
cancer O
deaths O
occurred O
while O
896 O
breast O
cancers O
were O
detected O
and O
130 O
deaths O
recorded O
in O
the O
control O
group O
. O
[]

The O
light O
source O
was O
a O
150-W O
halogen O
lamp O
beam O
. O
[]

METHODS O
26 O
morbidly O
obese O
patients O
( O
body O
mass O
index-BMI O
56 O
+/- O
3 O
) O
were O
randomly O
assigned O
to O
one O
of O
three O
positions O
for O
induction O
of O
anesthesia O
: O
1 O
) O
30 O
degrees O
Reverse O
Trendelenburg O
; O
2 O
) O
Supine-Horizontal O
; O
3 O
) O
30 O
degrees O
Back O
Up O
Fowler O
. O
[]

RESULTS O
By O
completion O
of O
the O
adjuvant O
chemotherapy O
, O
10 O
( O
28 O
% O
) O
interferon O
recipients O
and O
16 O
( O
43 O
% O
) O
placebo O
recipients O
experienced O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
tumor B-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
of O
the O
TACE+HIFU O
group O
was O
21.1 O
% O
, O
not O
significantly O
different O
from O
that O
of O
the O
TACE O
group O
( O
33.3 O
% O
, O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Positive O
studies O
were O
semiquantitatively O
graded O
from O
+1 O
( O
minimal O
left O
ventricular O
opacification O
) O
to O
+4 O
( O
intense O
left O
ventricular O
opacification O
) O
. O
[]

TRIAL O
REGISTRATION O
ACTRN12609000964213 O
. O
[]

RESULTS O
The O
results O
show O
statistically O
significant O
differences O
between O
the O
intervention O
and O
control O
groups O
; O
intervention O
group O
participants O
had O
lower O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
levels I-outcome ['Life-Impact']
than O
control O
participants O
after O
the O
intervention O
. O
['Life-Impact']

Diarrhea B-outcome ['Physiological-Clinical']
was O
the O
most O
common O
AE B-outcome ['Adverse-effects']
, O
and O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
occurred O
in O
109 O
patients O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

The O
aims O
of O
this O
randomised O
double-blind O
study O
were O
to O
investigate O
whether O
25 O
micrograms O
of O
fentanyl O
administered O
prophylactically O
by O
the O
epidural O
route O
would O
influence O
the O
incidence O
of O
shivering B-outcome ['Physiological-Clinical']
in O
parturients O
who O
underwent O
elective O
Caesarean O
section O
under O
epidural O
analgesia O
and O
whether O
it O
would O
affect O
the O
axillary O
and O
calf O
temperatures O
. O
['Physiological-Clinical']

Although O
the O
follow O
up O
is O
still O
short O
, O
no O
superiority O
of O
the O
other O
drugs O
over O
Stilboestrol O
had O
appeared O
so O
far O
with O
regard O
to O
either O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
or O
significant B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
apart O
from O
gynaecomastia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

The O
diamorphine O
group O
had O
better O
analgesia B-outcome ['Resource-use']
than O
the O
control O
group O
for O
the O
first O
24 O
hours O
postoperatively O
. O
['Resource-use']

The O
internal O
consistency O
was O
good O
for O
both O
questionnaires O
( O
Cronbach O
's O
alpha O
coefficients O
> O
/= O
0.84 O
for O
the O
CRQ O
and O
> O
/= O
0.76 O
for O
the O
SGRQ O
) O
. O
[]

For O
those O
with O
stage O
II O
rectal O
cancer O
, O
the O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
of O
group O
1 O
was O
significantly O
better O
than O
groups O
2 O
and O
3 O
( O
88.8 O
% O
vs. O
74.1 O
% O
, O
respectively O
, O
P O
= O
0.021 O
) O
. O
['Mortality']

In O
this O
paper O
, O
we O
explore O
a O
two-filter O
model O
, O
the O
simplest O
version O
of O
multi-channel O
models O
for O
frequency O
discrimination B-outcome ['Physiological-Clinical']
of O
simple O
tones O
. O
['Physiological-Clinical']

These O
rats O
( O
defect O
rats O
) O
were O
randomly O
divided O
into O
groups O
that O
were O
given O
propranolol O
or O
a O
saline O
carrier O
for O
19 O
consecutive O
days O
. O
[]

Under O
60 O
mg O
nimodipine O
both O
subgroups O
showed O
a O
shift B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
results O
demonstrated O
that O
both O
drugs O
were O
safe O
and O
well O
tolerated O
in O
the O
treatment O
of O
AD O
. O
[]

No O
significant O
side-effects O
were O
noted O
with O
SJW O
. O
[]

Mean O
adherence B-outcome ['Life-Impact']
rates O
based O
on O
self-reports O
were O
also O
significantly O
better O
( O
P O
< O
0.001 O
) O
with O
MF-DPI O
400 O
microg O
QD O
PM O
( O
97.2 O
% O
) O
than O
with O
MF-DPI O
200 O
microg O
twice-daily O
( O
95.3 O
% O
) O
. O
['Life-Impact']

It O
also O
reduces O
the O
hospitalization B-outcome ['Resource-use']
time I-outcome ['Resource-use']
, O
the O
use O
of O
analgesic O
drugs O
post O
surgery O
, O
decreases O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
the O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

Other O
clinical O
outcomes O
, O
such O
as O
frequency O
and O
severity B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
, O
development O
of O
pneumonia B-outcome ['Physiological-Clinical']
or O
infection B-outcome ['Physiological-Clinical']
, O
in-hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
and O
response O
rate O
were O
similar O
in O
the O
two O
groups O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

These O
six O
patients O
had O
significantly O
higher O
peak O
systemic B-outcome ['Physiological-Clinical']
TNF I-outcome ['Physiological-Clinical']
levels O
during O
and O
after O
perfusion O
than O
patients O
without O
a O
leak O
( O
2.8 O
and O
8.2 O
ng/mL O
v O
0.7 O
and O
2.0 O
ng/mL O
, O
respectively O
; O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

After O
adjustment O
for O
differences O
in O
sexual O
maturation O
the O
observed O
significant O
difference O
disappeared O
. O
[]

The O
secondary O
objective O
is O
to O
determine O
equivalency O
of O
the O
effects O
of O
a O
calcium O
channel O
blocker O
( O
nisoldipine O
) O
and O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
enalapril O
) O
as O
a O
first-line O
antihypertensive O
agent O
in O
the O
prevention O
and/or O
progression O
of O
these O
diabetic O
vascular O
complications O
. O
[]

RESULTS O
Most O
female O
heroin O
addicts O
were O
young O
and O
single O
, O
with O
a O
low O
education O
level O
. O
[]

Intervention O
participants O
gave O
more O
positive O
evaluations O
of O
the O
materials O
than O
control O
participants O
. O
[]

The O
lead-in O
that O
suggested O
normality O
yielded O
the O
best O
performance O
. O
[]

Mean O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
in O
group O
0 O
was O
8.57 O
and O
8.73 O
in O
group O
1 O
. O
['Physiological-Clinical']

We O
investigated O
the O
effect O
of O
short-term O
permissive O
hypercapnia O
on O
myocardial O
contractility O
and O
hemodynamics O
in O
patients O
with O
ARDS O
. O
[]

CDAI B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
CDAI?2.8 O
) O
and O
sustained O
remission O
( O
?6 O
months O
) O
were O
determined O
through O
year O
3 O
by O
treatment O
group O
, O
study O
, O
time O
to O
remission O
, O
and O
disease O
severity O
. O
['Physiological-Clinical']

Forty-two O
students O
with O
autism O
, O
varying O
in O
age O
and O
expressive O
communication O
ability O
, O
were O
randomly O
assigned O
to O
the O
experimental O
conditions O
. O
[]

In O
conclusion O
, O
oral O
ganciclovir O
and O
valacyclovir O
are O
equally O
safe O
and O
effective O
in O
the O
prophylaxis O
of O
CMV O
disease O
after O
RTx O
. O
[]

METHODS O
AND O
RESULTS O
Multiplex O
tandem O
RT-PCR O
was O
used O
to O
determine O
the O
mRNA O
levels O
of O
genes O
involved O
in O
ATP O
production O
and O
mitochondrial O
biogenesis O
in O
muscle O
tissue O
. O
[]

Oozing O
and O
need B-outcome ['Resource-use']
for I-outcome ['Resource-use']
pressure I-outcome ['Resource-use']
bandage I-outcome ['Resource-use']
at O
the O
puncture O
site O
were O
observed O
in O
37 O
AS O
patients O
and O
57 O
SC O
patients O
( O
25 O
% O
vs. O
38 O
% O
, O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Resource-use']

The O
results O
were O
compared O
with O
those O
from O
DSA O
and/or O
CEMRA O
. O
[]

In O
the O
second O
study O
, O
the O
average O
length O
of O
delay B-outcome ['Physiological-Clinical']
of O
standard O
treatment B-outcome ['Resource-use']
was O
longer O
than O
in O
the O
first O
study O
( O
95 O
days O
vs. O
66 O
days O
; O
P O
less O
than O
.02 O
) O
. O
['Physiological-Clinical', 'Resource-use']

In O
a O
preliminary O
feasibility O
study O
, O
we O
are O
assessing O
the O
acceptability O
of O
the O
trial O
design O
to O
patients O
and O
the O
suitability O
of O
two O
standard O
quality-of-life B-outcome ['Life-Impact']
instruments O
in O
mesothelioma O
. O
['Life-Impact']

Thus O
, O
long-term O
treatment O
with O
MET O
may O
provide O
a O
means O
to O
ameliorate O
the O
cardio-metabolic B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
adolescent I-outcome ['Physiological-Clinical']
obesity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
10 O
Hz O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
on O
clinical O
global O
impression O
in O
chronic O
schizophrenia O
. O
[]

This O
is O
the O
first O
demonstration O
of O
reduction O
by O
any O
agent O
of O
airway B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
characteristic O
of O
COPD O
. O
['Physiological-Clinical']

In O
this O
study O
the O
effects O
of O
anticholinergic O
drugs O
on O
VO2 O
and O
EE O
( O
calculated O
from O
the O
measured O
rates O
of O
VO2 O
and O
carbon O
dioxide O
production O
[ O
VCO2 O
] O
: O
EE O
[ O
kcal/d O
] O
= O
3.581 O
x O
VO2 O
[ O
L/d O
] O
+ O
1.448 O
x O
VCO2 O
[ O
L/d O
] O
- O
32.4 O
) O
were O
measured O
in O
six O
healthy O
female O
volunteers O
. O
[]

Some O
of O
the O
most O
important O
items O
: O
personality O
, O
motivation O
, O
diet O
history O
, O
bodyweight O
, O
blood O
lipids O
and O
blood O
sugar O
anti-smoking O
advice O
given O
individually O
to O
all O
smokers O
in O
the O
intervention O
group O
advice O
that O
smoking O
cessation O
was O
expected O
to O
be O
of O
special O
importance O
for O
those O
with O
elevated O
blood O
lipids O
. O
[]

CONCLUSIONS O
Results O
provided O
some O
support O
for O
models O
of O
bupropion O
SR O
treatment O
and O
relapse O
and O
suggested O
that O
motivational O
processes O
may O
partially O
account O
for O
bupropion O
SR O
efficacy O
. O
[]

Before O
and O
after O
intervention O
, O
the O
foot B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
area O
was O
estimated O
stereologically O
, O
based O
on O
Cavalieri O
's O
principle O
. O
['Physiological-Clinical']

METHODS O
Thirty-seven O
patients O
with O
at O
least O
one O
newly O
developed O
DLE O
lesion O
were O
randomized O
- O
19 O
to O
the O
R-salbutamol O
cream O
0.5 O
% O
and O
18 O
to O
placebo O
- O
and O
treated O
twice O
daily O
for O
8 O
weeks O
. O
[]

Haematological B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
mainly O
cumulative O
anaemia B-outcome ['Physiological-Clinical']
and O
thrombocytopenia B-outcome ['Physiological-Clinical']
, O
was O
manageable O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
[]

The O
peritoneal B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
carcinogen I-outcome ['Physiological-Clinical']
antigen-125 I-outcome ['Physiological-Clinical']
increased O
twofold O
during O
bicarbonate O
APD O
( O
29 O
+/- O
15 O
versus O
15 O
+/- O
8 O
U/ml O
per O
4 O
h O
, O
P O
< O
0.01 O
) O
, O
which O
is O
consistent O
with O
recovery O
of O
the O
mesothelial O
cell O
layer O
. O
['Physiological-Clinical']

Surprisingly O
, O
the O
group O
that O
was O
given O
the O
infusion O
of O
morphine O
received O
as O
much O
supplementary O
morphine O
as O
the O
control O
group O
during O
the O
first O
24 O
hours O
and O
appreciably O
more O
during O
the O
24 O
hours O
after O
the O
infusion O
had O
been O
withdrawn O
. O
[]

The O
disease O
specific O
formula O
should O
therefore O
be O
the O
preferred O
option O
to O
be O
used O
by O
diabetic O
and O
hyperglycemic O
patients O
in O
need O
of O
nutritional O
support O
. O
[]

Protocol-driven O
costs O
were O
excluded O
. O
[]

Similar O
results O
were O
obtained O
for O
dysphagia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
In O
this O
single-center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
, O
two-arm O
study O
, O
40 O
patients O
with O
persistent O
AR O
were O
randomized O
to O
receive O
either O
montelukast O
and/or O
levocetirizine O
or O
placebo O
( O
n O
= O
20 O
) O
or O
to O
receive O
treatment O
with O
montelukast O
and/or O
desloratadine O
or O
placebo O
( O
n O
= O
20 O
) O
. O
[]

Two O
patients O
who O
received O
phenoxymethylpenicillin O
and O
two O
given O
doxycycline O
subsequently O
developed O
major O
manifestations O
of O
Lyme B-outcome ['Physiological-Clinical']
borreliosis I-outcome ['Physiological-Clinical']
; O
these O
did O
not O
occur O
in O
patients O
receiving O
azithromycin O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
pilot O
study O
was O
to O
test O
the O
feasibility O
of O
using O
a O
culturally O
modified O
version O
of O
DASH O
among O
African O
Americans O
in O
an O
underresourced O
community O
. O
[]

METHODS O
This O
good O
, O
clinical O
practice O
compliant O
, O
multicentre O
study O
( O
EFFIC O
study O
) O
enrolled O
142 O
client-owned O
dogs O
and O
was O
conducted O
in O
20 O
locations O
in O
France O
, O
Belgium O
and O
Germany O
. O
[]

Tocilizumab-treated O
patients O
with O
DAS28 O
remission O
but O
without O
CDAI O
remission O
had O
significantly O
higher O
swollen O
joint O
counts O
but O
lower O
erythrocyte O
sedimentation O
rates O
( O
ESRs O
) O
compared O
with O
patients O
with O
SDAI O
or O
CDAI O
remission O
. O
[]

Double-blind O
comparison O
of O
liquid O
antacid O
and O
placebo O
in O
the O
treatment O
of O
symptomatic O
reflux O
esophagitis O
. O
[]

OBJECTIVE O
To O
compare O
the O
use O
of O
in-line O
filtration O
with O
the O
addition O
of O
heparin/hydrocortisone O
( O
hep/hc O
) O
to O
the O
infusate O
for O
both O
phlebitis O
prevention O
and O
intravenous O
( O
i.v O
. O
) O
[]

HOMA-S B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
changed O
18.0 O
% O
for O
pioglitazone O
and O
-7.9 O
% O
for O
glimepiride O
( O
P O
< O
0.001 O
) O
, O
QUICKI O
values O
changed O
a O
respective O
0.013 O
and O
-0.007 O
( O
P O
< O
0.001 O
) O
, O
and O
FSI O
values O
were O
-21.1 O
and O
15.1 O
pmol/L O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

In O
contrast O
, O
obese O
men O
were O
divided O
into O
two O
groups O
: O
nine O
in O
whom O
the O
TRH-induced B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
was O
higher O
than O
normal O
( O
group O
I O
: O
mean O
peak O
= O
16.5 O
+/- O
0.5 O
mU/L O
) O
and O
13 O
in O
whom O
it O
was O
normal O
( O
group O
II O
: O
mean O
peak O
= O
10.6 O
+/- O
0.7 O
mU/L O
) O
. O
['Physiological-Clinical']

The O
population O
pharmacokinetic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
of O
oral O
clonidine O
was O
characterized O
in O
newborns O
with O
neonatal O
abstinence O
syndrome O
, O
and O
significant O
covariates O
affecting O
its O
PK O
parameters O
were O
identified O
. O
['Physiological-Clinical']

4 O
. O
[]

Mecamylamine O
increased O
several O
measures O
of O
cigarette O
smoking O
, O
including O
number O
of O
cigarettes B-outcome ['Physiological-Clinical']
, O
number O
of O
puffs B-outcome ['Life-Impact']
per I-outcome ['Life-Impact']
cigarette I-outcome ['Life-Impact']
, O
and O
expired B-outcome ['Physiological-Clinical']
air I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
monoxide I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Longitudinal O
research O
has O
demonstrated O
that O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
reliably O
predict O
subsequent O
language B-outcome ['Life-Impact']
gains I-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact', 'Life-Impact']

Quantity O
of O
alcohol O
consumed O
per O
week O
and O
heavy B-outcome ['Life-Impact']
episodic I-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
one O
month O
later O
were O
the O
primary O
dependent O
variables O
. O
['Life-Impact']

Safety O
assessments O
were O
conducted O
from O
baseline O
through O
2-weeks O
post-treatment O
. O
[]

Children O
were O
grouped O
into O
trios O
matched O
by O
age O
and O
communication O
level O
and O
then O
randomly O
assigned O
to O
one O
of O
three O
treatment O
groups O
: O
biologic O
secretin O
( O
2 O
CU/kg O
) O
, O
synthetic O
secretin O
( O
0.4 O
microg/kg O
) O
, O
and O
placebo O
. O
[]

RESULTS O
There O
was O
a O
significant O
positive O
relationship O
between O
the O
frequency O
of O
[]

The O
number O
of O
repetitions B-outcome ['Physiological-Clinical']
in O
each O
test O
was O
recorded O
as O
an O
outcome O
. O
['Physiological-Clinical']

The O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
of O
patients O
with O
any O
type O
of O
gastrointestinal O
cancer O
was O
50.8 O
per O
cent O
in O
the O
LD O
group O
and O
45.8 O
per O
cent O
in O
the O
non-LD O
group O
( O
P O
= O
0.191 O
) O
. O
['Mortality']

To O
ensure O
accurate O
comparisons O
between O
consecutive O
cardiac O
output O
measurements O
, O
the O
researchers O
recommend O
that O
the O
position O
in O
which O
the O
cardiac O
output O
measurements O
are O
performed O
be O
documented O
and O
the O
cardiac O
output O
measurements O
be O
conducted O
in O
a O
uniform O
position O
. O
[]

There O
were O
no O
significant O
changes O
in O
anthropometric B-outcome ['Physiological-Clinical']
measures O
, O
plasma B-outcome ['Physiological-Clinical']
A1C I-outcome ['Physiological-Clinical']
, O
and O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
significant O
reduction O
in O
the O
mean O
of O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Although O
there O
were O
no O
ECG B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
, O
one O
patient O
given O
pancuronium O
developed O
severe B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
associated O
with O
tachycardia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
2 O
years O
post O
EOT O
, O
BMD B-outcome ['Physiological-Clinical']
changes O
from O
baseline O
were O
similar O
with O
both O
treatment O
strategies O
. O
['Physiological-Clinical']

In O
the O
control O
group O
46 O
( O
85 O
% O
) O
patients O
were O
improved O
by O
at O
least O
1 O
angina O
class O
and O
31 O
( O
57 O
% O
) O
were O
symptom O
free O
; O
the O
exercise B-outcome ['Life-Impact']
test O
was O
positive O
in O
11 O
( O
21 O
% O
) O
patients O
and O
the O
angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
rate O
was O
33 O
% O
per O
lesion O
and O
37 O
% O
per O
patient O
. O
['Life-Impact', 'Physiological-Clinical']

One O
month O
after O
surgery O
, O
group O
1 O
patients O
( O
n O
= O
97 O
) O
started O
treatment O
with O
intranasal O
furosemide O
, O
group O
2 O
( O
n O
= O
40 O
) O
received O
no O
therapeutic O
treatment O
, O
and O
group O
3 O
( O
n O
= O
33 O
) O
were O
treated O
with O
mometasone O
. O
[]

OUTCOME O
MEASURES O
Thermodilution B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Studies O
of O
vector-parasite O
relations O
of O
Wuchereria O
bancrofti O
suggest O
that O
a O
reduction O
in O
the O
microfilarial O
reservoir O
by O
mass O
chemotherapy O
may O
interrupt O
transmission O
and O
thereby O
eliminate O
infection O
. O
[]

Concerning O
secondary O
endpoints O
, O
we O
observed O
significant O
improvements O
in O
quadriceps B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
of O
8 O
% O
, O
a O
decrease O
in O
body B-outcome ['Physiological-Clinical']
sway I-outcome ['Physiological-Clinical']
of O
28 O
% O
, O
and O
a O
decrease O
in O
time B-outcome ['Life-Impact']
needed I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
perform I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
TUG I-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
of O
11 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Transurethral O
electrovaporization O
of O
the O
prostate O
( O
TUVP O
) O
is O
a O
new O
, O
minimally O
invasive O
and O
a O
promising O
alternative O
to O
standard O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
in O
the O
treatment O
of O
BPH O
. O
[]

Thirty-three O
children O
with O
autism O
between O
the O
ages O
of O
3 O
and O
6 O
years O
participated O
in O
the O
study O
with O
their O
classroom O
teachers O
( O
n O
= O
14 O
) O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
present O
study O
is O
to O
investigate O
whether O
differences O
exist O
between O
a O
30 O
minute O
brisk O
walk O
taken O
in O
two O
different O
environments O
in O
order O
to O
determine O
which O
environment O
best O
facilitates O
current O
physical O
activity O
guidelines O
: O
park O
or O
urban O
. O
[]

During O
phase O
II O
( O
charcoal O
) O
, O
subjects O
ingested O
3 O
g O
acetaminophen O
, O
followed O
one O
hour O
later O
by O
60 O
g O
activated O
charcoal O
and O
a O
supranormal O
loading O
dose O
of O
N-acetylcysteine O
( O
235 O
mg/kg O
) O
. O
[]

Additionally O
, O
PRE O
cows O
were O
grouped O
with O
controls O
after O
calving O
, O
and O
POST O
cows O
were O
grouped O
with O
control O
cows O
before O
calving O
, O
so O
that O
corn O
germ-supplemented O
cows O
received O
the O
control O
supplement O
in O
the O
alternate O
feeding O
period O
. O
[]

CONCLUSIONS O
The O
P-ASA O
injection O
of O
1.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
or O
3 O
% O
mepivacaine O
, O
administered O
with O
the O
Wand O
Plus O
, O
has O
the O
potential O
to O
be O
a O
painful O
injection O
. O
[]

PERSPECTIVE O
This O
study O
showed O
that O
KC O
has O
a O
significant O
effect O
on O
reducing O
autonomic O
pain O
responses O
in O
preterm O
infants O
. O
[]

The O
changes O
in O
isometric B-outcome ['Physiological-Clinical']
trunk I-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
favored O
the O
STG O
( O
P O
=.016 O
) O
during O
the O
first O
2 O
months O
. O
['Physiological-Clinical']

Recent O
anecdotal O
evidence O
, O
supported O
by O
its O
efficacy O
in O
the O
treatment O
of O
Chlamydia O
trachomatis O
infection O
in O
humans O
, O
has O
suggested O
that O
azithromycin O
may O
offer O
an O
alternative O
by O
allowing O
less O
frequent O
dosing O
for O
a O
shorter O
duration O
. O
[]

Risk O
of O
infection O
after O
penetrating O
abdominal O
trauma O
. O
[]

Clinical O
assessments O
were O
performed O
at O
baseline O
and O
at O
weeks O
1 O
, O
2 O
, O
4 O
, O
6 O
, O
and O
8 O
. O
[]

Twenty-three O
patients O
were O
followed O
in O
a O
protocol O
of O
intensified O
prenatal O
care O
and O
randomized O
assignment O
of O
antihypertensive O
agents O
: O
placebo O
, O
hydralazine O
, O
or O
methyldopa O
. O
[]

Locomoting-to-reach O
: O
information O
variables O
and O
control O
strategies O
for O
nested O
actions O
. O
[]

We O
observed O
a O
highly O
significant O
correlation O
between O
central B-outcome ['Physiological-Clinical']
HER2 I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
HER2 B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
measured O
by O
kinetic O
['Physiological-Clinical', 'Physiological-Clinical']

High O
density O
lipoprotein O
cholesterol O
was O
lower O
in O
the O
intervention O
group O
( O
p O
< O
0.05 O
) O
. O
[]

CONCLUSION O
Performing O
a O
pre-transplant O
tacrolimus O
C O
( O
2 O
) O
does O
not O
significantly O
increase O
the O
high O
proportion O
of O
subjects O
achieving O
10 O
ng/mL O
tacrolimus O
concentrations O
by O
day O
3 O
using O
routine O
protocols O
. O
[]

We O
evaluated O
efficacy O
and O
safety O
of O
lapatinib O
plus O
vinorelbine O
, O
compared O
with O
lapatinib O
plus O
capecitabine O
, O
in O
women O
with O
HER2-positive O
MBC O
. O
[]

Multivariate O
analysis O
identified O
saphenous O
vein O
grafts O
as O
independent O
predictors O
for O
graft B-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
and O
angina B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

According O
to O
a O
randomized O
, O
single-blind O
cross-over O
design O
, O
the O
patients O
were O
treated O
with O
MZ O
( O
20 O
mg/day O
) O
or O
CL O
( O
50 O
mg/day O
) O
for O
the O
duration O
of O
4 O
weeks O
. O
[]

Our O
findings O
suggested O
such O
analysis O
to O
be O
useful O
in O
devising O
countermeasures O
against O
medical O
errors O
. O
[]

Severe B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
receiving O
surgery O
were O
noted O
in O
4 O
patients O
( O
A O
: O
1 O
; O
B O
: O
3 O
) O
, O
i.e. O
, O
small O
intestine O
3 O
and O
sigmoid O
colon O
1 O
patient O
. O
['Adverse-effects']

In O
all O
three O
experiments O
subjects O
received O
presentations O
of O
a O
standard O
duration O
at O
the O
beginning O
of O
a O
trial O
block O
and O
then O
had O
to O
judge O
whether O
each O
of O
a O
number O
of O
comparison O
stimuli O
was O
or O
was O
not O
the O
standard O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
compare O
defibrillation O
thresholds O
with O
lead O
systems O
consisting O
of O
an O
active O
left O
pectoral O
electrode O
and O
either O
single O
or O
dual O
transvenous O
coils O
. O
[]

RESULTS O
As O
previously O
published O
, O
the O
intent-to-treat O
( O
ITT O
) O
clearance O
rate O
was O
50 O
% O
( O
54/109 O
) O
in O
the O
imiquimod-treated O
group O
and O
11 O
% O
( O
11/100 O
) O
in O
the O
vehicle-treated O
group O
( O
P O
< O
0.0001 O
) O
. O
[]

Changes O
in O
MD O
( O
standard O
error O
[ O
SE O
] O
) O
during O
the O
study O
period O
were O
-0.778 O
( O
0.178 O
) O
and O
-0.071 O
( O
0.195 O
) O
dB/year O
in O
the O
control O
and O
brovincamine O
groups O
, O
respectively O
; O
change O
in O
the O
control O
group O
was O
significantly O
more O
negative O
than O
in O
the O
brovincamine O
group O
. O
[]

CONTEXT O
Short-term O
aerobic O
exercise O
training O
can O
improve O
whole-body B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
in O
humans O
with O
type O
2 O
diabetes O
mellitus O
; O
however O
, O
the O
contributions O
of O
peripheral O
and O
hepatic O
tissues O
to O
these O
improvements O
are O
not O
known O
. O
['Physiological-Clinical']

The O
T2 O
group O
achieved O
tacrolimus O
trough O
levels O
of O
?10 O
ng/mL O
significantly O
faster O
than O
the O
control O
group O
( O
100 O
% O
achievement O
in O
14 O
days O
( O
Control O
) O
versus O
4 O
days O
( O
T2 O
) O
; O
P=0.01 O
) O
. O
[]

CONCLUSIONS O
BRAF O
mutation O
is O
associated O
with O
inferior O
survival B-outcome ['Mortality']
in O
stage O
III O
colon O
cancer O
. O
['Mortality']

Compared O
with O
placebo O
, O
8 O
weeks O
of O
treatment O
with O
inhaled O
mometasone O
led O
to O
less O
improvement O
in O
methacholine B-outcome ['Physiological-Clinical']
PC I-outcome ['Physiological-Clinical']
( O
20 O
) O
( O
0.5 O
vs O
5.5 O
doubling O
concentrations O
, O
95 O
% O
CI O
of O
difference O
1.1 O
to O
9.1 O
; O
p O
= O
0.018 O
) O
and O
asthma B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
( O
0.2 O
vs O
1.0 O
points O
, O
95 O
% O
CI O
of O
difference O
0.27 O
to O
1.43 O
; O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Clinical O
evaluation O
of O
Er O
, O
Cr O
: O
YSGG O
and O
GaAlAs O
laser O
therapy O
for O
treating O
dentine B-outcome ['Physiological-Clinical']
hypersensitivity I-outcome ['Physiological-Clinical']
: O
A O
randomized O
controlled O
clinical O
trial O
. O
['Physiological-Clinical']

These O
findings O
demonstrate O
a O
role O
for O
adenosine O
A O
( O
2A O
) O
receptors O
in O
the O
effects O
of O
prolonged O
wakefulness O
on O
vigilant O
attention O
and O
the O
sleep O
EEG O
. O
[]

Interdigestive B-outcome ['Physiological-Clinical']
fundus I-outcome ['Physiological-Clinical']
motility I-outcome ['Physiological-Clinical']
was O
recorded O
by O
barostat O
( O
maximum O
capacity O
of O
intragastric O
bag O
1200 O
ml O
) O
during O
basal O
and O
peptide O
periods O
of O
60 O
minutes O
each O
. O
['Physiological-Clinical']

The O
subjects O
were O
randomly O
assigned O
to O
three O
groups O
each O
having O
a O
different O
procedure O
of O
requesting O
the O
completion O
of O
the O
survey O
and O
providing O
the O
questionnaires O
: O
( O
1 O
) O
Postal O
Group O
, O
( O
2 O
) O
Telephone O
Group O
, O
and O
( O
3 O
) O
Face-to-face O
Group O
. O
[]

Muscle B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
and O
4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
during O
exercise O
were O
significantly O
reduced O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Orally O
delivered O
, O
inactivated O
whole-cell O
vaccines O
are O
safe O
methods O
of O
inducing O
local O
and O
systemic O
immunity O
. O
[]

Double O
blind O
, O
placebo O
controlled O
study O
of O
metronidazole O
as O
a O
disease O
modifying O
agent O
in O
the O
treatment O
of O
rheumatoid O
arthritis O
. O
[]

Serum B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
after O
6 O
months O
on O
glibenclamide O
remains O
higher O
than O
during O
insulin O
treatment O
. O
['Physiological-Clinical']

SETTING O
Six O
general O
practices O
in O
the O
South O
Thames O
region O
. O
[]

For O
patients O
in O
the O
late O
initial O
prodromal O
state O
the O
atypical O
neuroleptic O
amisulpride O
is O
explored O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
of O
men O
aged O
> O
or O
= O
50 O
years O
, O
after O
a O
28-day O
placebo O
run-in O
period O
, O
patients O
were O
randomized O
to O
receive O
alfuzosin O
10 O
mg O
q.d O
. O
[]

Arterial B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
was O
87 O
% O
at O
6 O
months O
, O
and O
coronary B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
was O
present O
in O
38 O
% O
of O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
were O
randomly O
assigned O
to O
two O
different O
treatment O
protocols O
with O
the O
aim O
of O
remineralising O
the O
lesions O
: O
A O
) O
daily O
topical O
applications O
of O
a O
dental O
cream O
containing O
CPP-ACP O
( O
Topacal O
) O
for O
3 O
months O
followed O
by O
a O
3-month O
period O
of O
daily O
toothbrushing O
with O
fluoridated O
dentifrice O
, O
or O
B O
) O
daily O
0.05 O
% O
sodium O
fluoride O
mouthwash O
combined O
with O
fluoridated O
dentifrice O
for O
6 O
months O
. O
[]

RESULTS O
In O
the O
added O
treatment O
group O
, O
the O
brachial B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
successfully O
reduced O
, O
but O
the O
central B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
increased O
significantly O
, O
whereas O
the O
other O
blood O
pressure O
parameters O
did O
not O
change O
from O
the O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

and O
does O
hepatitis O
B O
virus O
( O
HBV O
) O
related O
PAN O
require O
treatment O
? O
[]

However O
, O
levels O
between O
0.5 O
and O
1 O
microg/ml O
( O
within O
the O
IC50 O
of O
most O
cytomegalovirus O
isolates O
) O
could O
be O
achieved O
with O
tolerable O
oral O
doses O
. O
[]

Vascular O
endothelial O
growth O
factor O
A O
( O
VEGF-A O
) O
and O
vascular O
endothelial O
growth O
factor O
receptor O
2 O
( O
VEGFR2 O
) O
are O
the O
key O
factors O
mediating O
neo-vascularization O
. O
[]

Primary O
outcome O
measure O
was O
the O
proportion O
of O
eligible O
( O
aged O
< O
/= O
80 O
and O
symptom O
onset O
< O
/= O
6 O
hours O
) O
stroke O
patients O
referred O
to O
a O
stroke O
unit O
( O
SU O
) O
. O
[]

Chronic B-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
was O
present O
in O
81 O
% O
patients O
. O
['Physiological-Clinical']

Combined O
administration O
of O
amino O
acids O
and O
glucose O
decreased O
endogenous B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
( O
P=.001 O
) O
and O
stimulated O
insulin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
( O
P=.001 O
) O
to O
a O
greater O
extent O
than O
the O
administration O
of O
amino O
acids O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Children O
with O
core O
autism O
( O
aged O
2 O
years O
to O
4 O
years O
and O
11 O
months O
) O
were O
randomly O
assigned O
in O
a O
one-to-one O
ratio O
to O
a O
parent-mediated O
communication-focused O
( O
Preschool O
Autism O
Communication O
Trial O
[ O
PACT O
] O
) O
intervention O
or O
treatment O
as O
usual O
at O
three O
specialist O
centres O
in O
the O
UK O
. O
[]

Contour B-outcome ['Physiological-Clinical']
detectability I-outcome ['Physiological-Clinical']
was O
measured O
using O
a O
2-interval-forced-choice O
design O
. O
['Physiological-Clinical']

RESULTS O
Baseline O
mean O
ADHD-RS O
scores O
for O
atomoxetine O
versus O
placebo O
were O
40.7 O
and O
38.6 O
; O
after O
8 O
weeks O
, O
mixed-effect O
model O
repeated-measure O
means O
were O
31.6 O
( O
95 O
% O
confidence O
interval O
29.2-33.9 O
) O
and O
38.3 O
( O
36.0-40.6 O
) O
, O
respectively O
, O
with O
a O
difference O
in O
least O
square O
means O
of O
-6.7 O
( O
-10.0 O
to O
-3.4 O
; O
p O
< O
.001 O
) O
. O
['Life-Impact']

In O
the O
oat O
cereal O
group O
, O
a O
trend O
was O
observed O
for O
a O
lower O
total O
insulin B-outcome ['Resource-use']
response B-outcome ['Physiological-Clinical']
to O
a O
glucose O
load O
, O
suggesting O
improved O
insulin O
sensitivity O
. O
['Resource-use', 'Physiological-Clinical']

In O
absolute O
terms O
this O
improvement O
, O
however O
, O
was O
greater O
in O
the O
good O
prognostic O
group O
. O
[]

The O
studies O
were O
performed O
in O
healthy O
subjects O
with O
MAO O
less O
than O
30 O
mmol/h O
and O
in O
duodenal O
ulcer O
patients O
with O
MAO O
greater O
than O
35 O
mmol/h O
. O
[]

Antibiotics O
( O
clarithromycin O
and O
amoxicillin O
) O
were O
given O
on O
days O
1-4 O
, O
days O
4-7 O
, O
or O
days O
1-7 O
. O
[]

Risperidone O
improves O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
children O
with O
autism O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
['Life-Impact']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Data O
gathered O
included O
: O
age O
; O
gender O
; O
ICU O
discharge O
status O
; O
the O
duration O
of O
ICU O
stay O
; O
time O
in O
the O
study O
; O
volume O
of O
all O
blood O
drawn O
, O
discarded O
, O
or O
lost O
due O
to O
leakage O
; O
hemoglobin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
; O
blood O
transfusions O
; O
and O
accidental B-outcome ['Physiological-Clinical']
needle I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
are O
no O
significant O
differences O
within O
each O
group O
in O
preoperative O
comorbidity O
, O
age O
, O
or O
urgency O
. O
[]

30 O
patients O
( O
Group O
A O
) O
were O
treated O
with O
operation O
alone O
and O
30 O
patients O
( O
Group O
B O
) O
were O
treated O
with O
xeloda O
and O
radiotherapy O
before O
operation O
. O
[]

Prophylactic B-outcome ['Physiological-Clinical']
effect O
of O
phenytoin O
in O
bipolar O
disorder O
: O
a O
controlled O
study O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
study O
examines O
the O
cognitive B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
outcomes O
of O
children O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
over O
a O
5-year O
period O
after O
receiving O
targeted O
early O
interventions O
that O
focused O
on O
joint O
attention O
and O
play O
skills O
. O
['Life-Impact']

Acute B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
graded O
according O
to O
the O
Common O
Terminology O
Criteria O
for O
Adverse B-outcome ['Adverse-effects']
Events I-outcome ['Adverse-effects']
, O
version O
3.0 O
, O
and O
late B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
graded O
according O
to O
the O
Radiation O
Therapy O
Oncology O
Group O
system O
. O
['Adverse-effects', 'Adverse-effects', 'Adverse-effects']

From O
each O
die O
, O
the O
manufacturer O
's O
authorized O
milling O
centers O
supplied O
5 O
copings O
per O
group O
without O
applying O
any O
dying O
technique O
to O
the O
ceramic O
base O
material O
. O
[]

METHODS O
On O
23 O
migraineurs O
showing O
pain O
at O
pressure O
on O
scalp O
arteries O
, O
we O
administered O
topical O
capsaicin O
0.1 O
% O
or O
vaseline O
jelly O
on O
painful O
arteries O
in O
absence O
of O
migraine O
attack O
. O
[]

BACKGROUND O
Intake O
of O
fish O
and O
long-chain O
n-3 O
fatty O
acids O
has O
been O
of O
wide O
interest O
due O
to O
their O
beneficial O
effects O
on O
cardiovascular O
risk O
factors O
and O
lower O
coronary O
heart O
disease O
( O
CHD O
) O
risk O
. O
[]

Supplemental O
perioperative O
oxygen O
and O
the O
risk O
of O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

AIMS O
High O
serum O
phosphorus O
levels O
are O
a O
common O
problem O
in O
patients O
receiving O
long-term O
dialysis O
treatment O
. O
[]

The O
clinical O
course O
of O
the O
postoperative O
period O
of O
diffuse O
peritonitis O
with O
cytoflavin O
included O
in O
intensive O
therapy O
is O
characterized O
by O
shorter O
terms O
of O
artificial B-outcome ['Resource-use']
lung I-outcome ['Resource-use']
ventilation B-outcome ['Life-Impact']
, O
shorter O
time O
of O
staying O
in O
['Resource-use', 'Life-Impact']

CONCLUSIONS O
High O
doses O
of O
beta-endorphin O
induce O
hypotensive O
and O
beneficial O
hormonal O
effects O
in O
humans O
, O
which O
are O
enhanced O
in O
essential O
hypertension O
and O
are O
mediated O
by O
opioid O
receptors O
. O
[]

The O
respective O
five-year O
survival B-outcome ['Mortality']
rates O
free I-outcome ['Mortality']
from I-outcome ['Mortality']
Q-wave I-outcome ['Mortality']
myocardial I-outcome ['Mortality']
infarction I-outcome ['Mortality']
were O
80.4 O
percent O
and O
78.7 O
percent O
. O
['Mortality']

[ O
Tension-free O
laparoscopic O
versus O
open O
inguinal O
hernia O
repair O
] O
. O
[]

PARTICIPANTS O
Ninety-five O
primary O
insomniacs O
, O
32-64 O
years O
old O
and O
55 O
age- O
and O
sex-matched O
general O
population-based O
, O
representative O
controls O
. O
[]

An O
increasing O
number O
of O
patients O
with O
main-stem O
and O
main-stem-equivalent O
stenosis O
are O
treated O
by O
stent O
implantation O
, O
which O
appears O
to O
be O
safe O
in O
the O
short-term O
follow-up O
. O
[]

The O
training O
focused O
on O
stimulating O
joint O
attention O
and O
language O
skills O
and O
was O
based O
on O
the O
intervention O
described O
by O
Drew O
et O
al O
. O
( O
[]

A O
phase O
IIb O
dose-ranging O
study O
of O
the O
oral O
JAK O
inhibitor O
tofacitinib O
( O
CP-690,550 O
) O
versus O
placebo O
in O
combination O
with O
background O
methotrexate O
in O
patients O
with O
active O
rheumatoid O
arthritis O
and O
an O
inadequate O
response O
to O
methotrexate O
alone O
. O
[]

A O
significant O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
levels O
was O
seen O
at O
36 O
and O
60 O
h O
after O
treatment O
compared O
with O
Control O
groups O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Eltrombopag O
is O
an O
oral O
thrombopoietin O
receptor O
agonist O
for O
the O
treatment O
of O
thrombocytopenia O
. O
[]

RESULTS O
Down O
syndrome O
children O
without O
Autism O
Spectrum O
Disorder O
had O
better O
communication B-outcome ['Life-Impact']
and O
socialization B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
than O
children O
with O
Down O
syndrome O
with O
Autism O
Spectrum O
Disorder O
. O
['Life-Impact', 'Life-Impact']

Acute O
effect O
of O
pegvisomant O
on O
cardiovascular O
risk O
markers O
in O
healthy O
men O
: O
implications O
for O
the O
pathogenesis O
of O
atherosclerosis O
in O
GH O
deficiency O
. O
[]

PURPOSE O
To O
measure O
changes O
and O
predictors O
of O
change O
in O
mammograms O
obtained O
in O
postmenopausal O
women O
undergoing O
continuous O
combined O
hormonal O
replacement O
therapy O
( O
HRT O
) O
. O
[]

No O
differences O
in O
power O
emerged O
. O
[]

Effect O
of O
whole-body O
mild-cold O
exposure O
on O
arterial B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
haemodynamics I-outcome ['Physiological-Clinical']
: O
a O
randomised O
, O
cross-over O
trial O
in O
healthy O
men O
and O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Factors O
significantly O
associated O
with O
longer O
TTF B-outcome ['Life-Impact']
and O
longer O
survival B-outcome ['Mortality']
were O
as O
follows O
: O
one O
or O
two O
organs O
with O
metastases O
( O
TTF O
, O
P O
less O
than O
0.0001 O
; O
survival O
, O
P O
less O
than O
0.0001 O
) O
; O
dominant O
site O
other O
than O
soft O
tissue O
( O
TTF O
, O
P O
less O
than O
0.0001 O
; O
survival O
, O
P O
= O
0.05 O
) O
; O
and O
an O
initial O
good O
performance O
status O
( O
TTF O
, O
P O
= O
0.007 O
; O
survival O
, O
P O
= O
0.02 O
) O
. O
['Life-Impact', 'Mortality']

OBJECTIVES O
To O
evaluate O
the O
efficacy O
of O
topical O
racemic O
adrenaline O
( O
RA O
) O
( O
Micronefrin O
; O
Bird O
Products O
, O
Palm O
Springs O
, O
CA O
, O
USA O
) O
in O
the O
control O
of O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
the O
prevention O
of O
postoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
laryngeal B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
adenoidectomy O
among O
children O
< O
6 O
years O
of O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Verapamil O
, O
although O
primarily O
known O
as O
a O
calcium O
channel O
blocker O
, O
also O
has O
PKC O
inhibitory O
activity O
. O
[]

The O
clinically B-outcome ['Life-Impact']
driven I-outcome ['Life-Impact']
postprocedural I-outcome ['Life-Impact']
observation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
5.5 O
+/- O
5.1 O
days O
( O
range O
19 O
hours O
and O
one O
Cr O
value O
to O
25.7 O
days O
and O
18 O
values O
) O
. O
['Life-Impact']

BACKGROUND O
Neoadjuvant O
chemoradiotherapy O
( O
CRT O
) O
reduces O
local O
tumor O
recurrence O
in O
locally O
advanced O
rectal O
cancer O
( O
LARC O
) O
. O
[]

CONCLUSIONS O
Therapeutic O
steady O
state O
concentrations O
of O
roflumilast O
and O
its O
N-oxide O
do O
not O
alter O
the O
[]

MAIN O
OUTCOME O
MEASURES O
Serum B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
debriefing O
, O
53.1 O
% O
chose O
public B-outcome ['Physiological-Clinical']
data O
release B-outcome ['Physiological-Clinical']
, O
33.1 O
% O
chose O
restricted B-outcome ['Physiological-Clinical']
( O
controlled B-outcome ['Physiological-Clinical']
access I-outcome ['Physiological-Clinical']
database O
) O
release B-outcome ['Physiological-Clinical']
, O
and O
13.7 O
% O
opted B-outcome ['Life-Impact']
out I-outcome ['Life-Impact']
of O
data O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

REVAMP O
comprised O
two O
phases O
: O
1 O
) O
a O
12-week O
open-label O
antidepressant O
trial O
and O
2 O
) O
, O
a O
subsequent O
phase O
, O
in O
which O
phase O
1 O
non-remitters O
( O
N O
= O
491 O
) O
were O
randomized O
to O
either O
receive O
an O
ongoing O
medication O
algorithm O
alone O
, O
medication O
plus O
cognitive O
behavioral O
analysis O
system O
of O
psychotherapy O
, O
or O
medication O
plus O
brief O
supportive O
psychotherapy O
. O
[]

METHODS O
We O
examined O
management O
of O
post-CABG O
AF O
in O
the O
PREVENT-IV O
trial O
, O
and O
we O
explored O
patterns O
of O
use O
of O
postoperative O
rhythm O
versus O
rate O
control O
and O
anticoagulation O
for O
AF B-outcome ['Physiological-Clinical']
by O
geographic O
region O
and O
type O
of O
site O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Fifty-five O
children O
with O
cancer O
and O
eight O
children O
given O
total O
parenteral O
nutrition O
by O
the O
surgery O
or O
nutrition O
support O
services O
were O
randomly O
assigned O
to O
receive O
a O
heparin O
CVC O
flush O
solution O
( O
n O
= O
31 O
) O
or O
a O
heparin-vancomycin O
CVC O
flush O
solution O
( O
n O
= O
32 O
) O
. O
[]

RESULTS O
The O
incidence O
of O
AF B-outcome ['Physiological-Clinical']
was O
24 O
% O
. O
['Physiological-Clinical']

This O
study O
reports O
the O
baseline O
data O
from O
a O
five-year O
randomized O
, O
controlled O
, O
prospective O
, O
population-based O
study O
in O
general O
practices O
in O
Ebeltoft O
, O
Denmark O
. O
[]

To O
examine O
variation O
in O
fecal B-outcome ['Physiological-Clinical']
variables O
, O
especially O
butyrate B-outcome ['Physiological-Clinical']
, O
among O
individuals O
and O
the O
response O
to O
these O
fibers O
, O
a O
randomized O
cross-over O
study O
was O
conducted O
that O
compared O
the O
effects O
of O
foods O
supplying O
25 O
g O
of O
NSP O
or O
25 O
g O
of O
NSP O
plus O
22 O
g O
of O
RS/d O
over O
4 O
wk O
in O
46 O
healthy O
adults O
( O
16 O
males O
, O
30 O
females O
; O
age O
31-66 O
y O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
reported O
in O
either O
group O
. O
['Adverse-effects']

Indeed O
, O
it O
is O
not O
uncommon O
for O
such O
studies O
to O
conclude O
with O
uninterpretable O
results O
, O
due O
in O
part O
to O
such O
methodological O
pitfalls O
. O
[]

Results O
on O
word-learning B-outcome ['Life-Impact']
tests O
and O
Sternberg O
Memory B-outcome ['Life-Impact']
Scanning I-outcome ['Life-Impact']
Tests O
were O
not O
significantly O
impaired O
. O
['Life-Impact', 'Life-Impact']

Demonstration O
enrollees O
included O
those O
eligible O
for O
PCS O
( O
in O
Arkansas O
) O
, O
those O
assessed O
to O
receive O
such O
services O
( O
in O
New O
Jersey O
) O
, O
and O
recipients O
of O
Medicaid O
HCBS O
( O
in O
Florida O
) O
. O
[]

Moreover O
, O
most O
studies O
have O
related O
to O
type O
2 O
diabetes O
subjects O
whose O
diabetes O
was O
relatively O
mild O
in O
terms O
of O
therapeutic O
requirements O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
the O
treatment O
groups O
with O
antacid O
containing O
Mg O
and O
Al O
hydroxide O
( O
M O
) O
( O
4 O
X O
70 O
mmol/day O
; O
n O
= O
86 O
) O
or O
to O
the O
group O
receiving O
cimetidine O
( O
T O
) O
( O
1000 O
mg/day O
; O
n O
= O
85 O
) O
. O
[]

Modified O
Navy O
Plaque O
Index O
were O
randomly O
assigned O
to O
treatment O
sequence O
. O
[]

Participants O
were O
52 O
families O
of O
children O
diagnosed O
with O
an O
Autism O
Spectrum O
Disorder O
, O
Down O
syndrome O
, O
Cerebral O
Palsy O
, O
or O
an O
intellectual O
disability O
. O
[]

Differences O
in O
the O
changes O
in O
PF O
and O
FEV1 B-outcome ['Physiological-Clinical']
between O
betaxolol O
and O
timolol O
as O
well O
as O
betaxolol O
and O
carteolol O
groups O
were O
statistically O
significant O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
loteprednol O
etabonate O
( O
LE O
) O
0.2 O
% O
in O
reducing O
the O
signs O
and O
symptoms O
of O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
conjunctivitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
DESIGN O
Group O
randomised O
, O
controlled O
trial O
( O
3 O
groups O
: O
immediate O
treatment O
, O
delayed O
treatment O
, O
no O
treatment O
) O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
evaluate O
the O
effectiveness O
of O
5 O
% O
lidocaine O
( O
ELA-Max O
) O
cream O
applied O
after O
erbium O
: O
yttrium-aluminum-garnet O
( O
Er O
: O
YAG O
) O
laser O
ablation O
of O
the O
stratum O
corneum O
. O
[]

In O
Arm O
2 O
, O
patients O
will O
undergo O
TORS O
along O
with O
selective O
neck O
dissections O
, O
which O
may O
be O
staged O
. O
[]

In O
patients O
with O
MDS O
or O
in O
the O
remission-induction O
phase O
of O
chemotherapy O
, O
the O
numbers O
of O
cases O
with O
probable B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
possible I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
lower O
in O
the O
itraconazole O
group O
than O
in O
the O
fluconazole O
group O
, O
whereas O
no O
difference O
was O
seen O
in O
patients O
with O
AML O
or O
in O
the O
consolidation O
phase O
of O
therapy O
. O
['Physiological-Clinical']

Thoracic B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
index O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
contrast O
early O
discharge O
versus O
attempted O
full O
nutritional O
rehabilitation O
in O
hospital O
of O
children O
suffering O
from O
severe O
protein-energy O
malnutrition O
( O
PEM O
) O
. O
[]

People O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
show O
reduced O
interest O
towards O
social O
aspects O
of O
the O
environment O
and O
a O
lesser O
tendency O
to O
follow O
other O
people O
's O
gaze B-outcome ['Physiological-Clinical']
in O
the O
real O
world O
. O
['Physiological-Clinical']

The O
increased O
screening-coverage O
rate O
in O
the O
intervention O
zone O
was O
similar O
to O
that O
of O
the O
control O
zone O
( O
43.6 O
vs. O
34.9 O
% O
, O
p=0.119 O
) O
; O
however O
, O
there O
was O
a O
borderline O
significant O
increase O
in O
the O
intervention O
zone O
compared O
with O
baseline O
( O
36.7 O
to O
43.6 O
% O
, O
p=0.070 O
) O
. O
[]

In O
Group O
I O
, O
plasma O
lysozyme O
levels O
in O
arterial O
and O
venous O
blood O
samples O
did O
not O
show O
significant O
changes O
during O
the O
surgery O
. O
[]

DATA O
EXTRACTION O
METHODS O
Each O
state O
supplied O
claims O
data O
for O
demonstration O
enrollees O
. O
[]

Practical O
implications O
for O
laterality O
research O
are O
also O
discussed O
. O
[]

Using O
participatory O
action O
research O
is O
an O
effective O
means O
for O
developing O
electronic O
algorithms O
acceptable O
to O
both O
clinicians O
and O
patients O
. O
[]

Oral O
amoxicillin O
vs. O
oral O
erythromycin O
in O
the O
treatment O
of O
pyoderma B-outcome ['Physiological-Clinical']
in O
Bamako O
, O
Mali O
: O
an O
open O
randomized O
trial O
. O
['Physiological-Clinical']

METHODS O
Study O
subjects O
were O
identified O
by O
enzyme-linked O
immunosorbent O
assay O
and O
immunoblot O
in O
a O
family O
screening O
project O
. O
[]

Patients O
use O
the O
local O
medication O
daily O
for O
the O
first O
3 O
weeks O
and O
twice-weekly O
thereafter O
. O
[]

The O
overall O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
obtained O
was O
63 O
p. O
100 O
( O
51 O
patients O
) O
with O
17 O
patients O
in O
relapse B-outcome ['Physiological-Clinical']
within O
6 O
to O
40 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analyses O
were O
by O
intention O
to O
treat O
. O
[]

METHODS O
Four O
hundred O
patients O
with O
chronic O
stable O
angina O
pectoris O
and O
a O
positive O
treadmill O
exercise O
test O
were O
randomized O
to O
receive O
either O
modified O
release O
dipyridamole O
( O
200 O
mg O
b.i.d O
. O
[]

Mortality B-outcome ['Mortality']
occurred O
in O
5 O
patients O
, O
including O
1 O
with O
TLA O
and O
4 O
with O
RLA O
, O
during O
the O
6-year O
followup O
. O
['Mortality']

SESSION O
A O
A O
short O
acupuncture O
needle O
, O
( O
Seirin O
no O
3 O
, O
& O
emptyv O
; O
0.20x15 O
mm O
) O
was O
inserted O
perpendicular O
into O
the O
earpoint O
, O
Lu O
1 O
, O
in O
the O
left O
inferior O
hemi-conchae O
. O
[]

Eighty-seven O
children O
with O
central O
nervous O
system O
( O
CNS O
) O
leukemia O
were O
randomized O
to O
receive O
either O
induction O
intrathecal O
chemotherapy O
( O
ITC O
) O
and O
cranial O
irradiation O
( O
CRT O
) O
plus O
maintenance O
ITC O
, O
or O
induction O
ITC O
and O
craniospinal O
irradiation O
( O
CSpRT O
) O
with O
no O
maintenance O
ITC O
. O
[]

Compliance O
rates O
were O
similar O
between O
groups O
, O
with O
mean O
( O
SD O
) O
compliance B-outcome ['Life-Impact']
['Life-Impact']

Myocardial O
contractility O
decreased O
in O
both O
groups O
but O
significantly O
less O
in O
the O
pH-corrected O
group O
( O
approximately O
10 O
% O
) O
than O
in O
the O
pH-uncorrected O
group O
( O
approximately O
18 O
% O
, O
p O
< O
0.05 O
) O
. O
[]

RESULTS O
Suture B-outcome ['Physiological-Clinical']
line I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
minutes I-outcome ['Physiological-Clinical']
was O
present O
in O
7 O
( O
14 O
% O
) O
of O
51 O
patients O
in O
the O
BP O
group O
and O
24 O
( O
55 O
% O
) O
of O
44 O
patients O
in O
the O
Dacron O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
We O
had O
demonstrated O
that O
a O
short O
course O
of O
acupuncture O
had O
efficacy O
in O
improving O
various O
developmental B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
aspects O
of O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Students O
( O
176 O
; O
25.35?1.03 O
years O
, O
63 O
% O
female O
) O
were O
alphabetically O
assigned O
to O
44 O
four-person O
teams O
that O
were O
then O
randomly O
( O
computer-generated O
) O
assigned O
to O
either O
CRM O
intervention O
( O
n=26 O
) O
, O
receiving O
interactive O
video-based O
CRM-training O
, O
or O
to O
control O
intervention O
( O
n=18 O
) O
, O
receiving O
an O
additional O
ALS-training O
. O
[]

After O
3 O
months O
, O
the O
index O
of O
portal-systemic O
encephalopathy O
significantly O
improved O
in O
patients O
on O
active O
treatment O
( O
from O
40 O
[ O
S.D O
. O
[]

Study O
participants O
in O
both O
arms O
of O
the O
CIGTS O
were O
treated O
aggressively O
in O
an O
effort O
to O
reduce B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
IOP B-outcome ['Physiological-Clinical']
) O
to O
a O
level O
at O
or O
below O
a O
predetermined O
, O
eye-specific O
target O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
After O
569 O
patients O
had O
undergone O
randomization O
, O
enrollment O
was O
stopped O
because O
of O
concerns O
about O
the O
safety O
of O
the O
patients O
who O
had O
been O
assigned O
to O
receive O
warfarin O
. O
[]

Overall O
, O
1 O
additional O
infant O
survived O
without O
chronic B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
for O
every O
14 O
to O
15 O
infants O
who O
received O
vitamin O
A O
supplements O
. O
['Physiological-Clinical']

FINDINGS O
189 O
patients O
were O
screened O
and O
130 O
randomly O
assigned O
to O
placebo O
( O
66 O
patients O
) O
or O
dalcetrapib O
( O
64 O
patients O
) O
. O
[]

CONCLUSIONS O
Consistent O
with O
findings O
of O
the O
epidemiological O
study O
, O
our O
study O
suggests O
that O
statins O
may O
prevent O
the O
development O
of O
a O
new O
brain B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
increase O
in O
the O
proportion O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted O
as O
DMA O
in O
the O
folic O
acid O
group O
( O
72 O
% O
before O
and O
79 O
% O
after O
supplementation O
) O
was O
significantly O
( O
P O
< O
0.0001 O
) O
greater O
than O
that O
in O
the O
placebo O
group O
, O
as O
was O
the O
reduction O
in O
the O
proportions O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted I-outcome ['Physiological-Clinical']
as O
MMA O
( O
13 O
% O
and O
10 O
% O
, O
respectively O
; O
P O
< O
0.0001 O
) O
and O
as O
InAs O
( O
15 O
% O
and O
11 O
% O
, O
respectively O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Calves O
were O
fed O
2 O
L O
of O
cow O
's O
milk O
containing O
acetaminophen O
( O
50 O
mg/kg O
body O
weight O
) O
30 O
minutes O
after O
each O
treatment O
was O
administered O
, O
and O
jugular O
venous O
blood O
samples O
were O
obtained O
periodically O
after O
suckling O
. O
[]

L-Ornithine-L-aspartate O
( O
LOLA O
) O
has O
been O
shown O
to O
reduce O
ammonia B-outcome ['Physiological-Clinical']
and O
improve O
psychometric B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
patients O
with O
hepatic O
encephalopathy O
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
Test O
the O
feasibility O
of O
Helping O
HAND O
( O
Healthy O
Activity O
and O
Nutrition O
Directions O
) O
, O
an O
obesity O
intervention O
for O
5- O
to O
8-year-old O
children O
in O
primary O
care O
clinics O
. O
[]

In O
this O
study O
, O
we O
assessed O
virologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
retreatment O
with O
peginterferon O
alfa-2a O
and O
ribavirin O
( O
RBV O
) O
, O
as O
a O
function O
of O
the O
baseline O
fibrosis O
score O
( O
Ishak O
staging O
) O
and O
platelet O
count O
, O
in O
1,046 O
patients O
enrolled O
in O
the O
Hepatitis O
C O
Antiviral O
Long-term O
Treatment O
against O
Cirrhosis O
( O
HALT-C O
) O
Trial O
. O
['Physiological-Clinical']

Secondary O
assessments O
examined O
the O
effects O
of O
the O
PGE1 O
infusion O
on O
plasma O
mediated O
suppression O
of O
PMN O
superoxide O
production O
and O
loss O
of O
PMN O
granule O
enzyme O
content O
. O
[]

FINDINGS O
204 O
patients O
were O
assigned O
to O
receive O
placebo O
, O
208 O
to O
daclizumab O
HYP O
150 O
mg O
, O
and O
209 O
to O
daclizumab O
HYP O
300 O
mg O
, O
of O
whom O
188 O
( O
92 O
% O
) O
, O
192 O
( O
92 O
% O
) O
, O
and O
197 O
( O
94 O
% O
) O
, O
respectively O
, O
completed O
follow-up O
to O
week O
52 O
. O
[]

Measures O
on O
child O
's O
anxiety O
using O
the O
Spence O
Child O
Anxiety O
Scale O
-- O
Child O
( O
SCAS-C O
) O
and O
the O
Clinical O
Global O
Impression-Severity O
scale O
( O
CGI O
-- O
S O
) O
were O
administered O
at O
pre- O
, O
post-treatment O
, O
and O
follow-ups O
( O
3- O
and O
6-month O
) O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
increased O
2.76 O
+/- O
0.63 O
to O
3.42 O
+/- O
0.72 O
liters/min/m2 O
) O
, O
pulmonary B-outcome ['Physiological-Clinical']
wedge I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
( O
19.5 O
+/- O
8.8 O
to O
14.6 O
+/- O
8.0 O
mm O
Hg O
) O
as O
did O
mean O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
101 O
+/- O
14.8 O
to O
85 O
+/- O
13.7 O
mm O
Hg O
) O
and O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( O
1,880 O
+/- O
573 O
to O
1,254 O
+/- O
383 O
dynes O
s O
cm-5 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
live O
and O
videotape O
ratings O
: O
clomipramine O
and O
haloperidol O
in O
autism O
. O
[]

Standardized O
artificial O
carious O
lesions O
were O
created O
and O
demineralized O
dentin O
was O
excavated O
. O
[]

The O
primary O
outcome O
measure O
was O
an O
instrument O
rating O
six O
repetitive B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
: O
need B-outcome ['Life-Impact']
to O
know B-outcome ['Life-Impact']
, O
repeating B-outcome ['Life-Impact']
, O
ordering B-outcome ['Life-Impact']
, O
need B-outcome ['Life-Impact']
to O
tell/ask B-outcome ['Life-Impact']
, O
self-injury B-outcome ['Life-Impact']
, O
and O
touching B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
The O
OPV O
( O
HDC O
) O
vaccine O
was O
safe O
and O
immunogenicity O
for O
the O
children O
> O
or O
=2 O
months O
old O
. O
[]

Clinical O
sites O
are O
international O
and O
include O
both O
primary O
care O
as O
well O
as O
specialists O
. O
[]

METHODS O
Sixty O
patients O
were O
assigned O
to O
one O
of O
the O
following O
therapeutic O
groups O
: O
control O
, O
treated O
with O
full-mouth O
scaling O
and O
root O
planing O
( O
SRP O
) O
; O
test O
1 O
, O
treated O
with O
SRP O
and O
400 O
mg O
systemically O
administered O
metronidazole O
( O
MET O
) O
three O
times O
per O
day O
for O
10 O
days O
; O
test O
2 O
, O
treated O
with O
SRP O
and O
professional O
supragingival O
plaque O
removal O
( O
PP O
) O
every O
week O
for O
3 O
months O
; O
and O
test O
3 O
, O
treated O
with O
SRP O
and O
MET O
plus O
PP O
. O
[]

Effects O
of O
psychosocial O
program O
for O
preparing O
long-term O
hospitalized O
patients O
with O
schizophrenia O
for O
discharge O
from O
hospital O
: O
randomized O
controlled O
trial O
. O
[]

The O
major O
efficacy O
criterion O
was O
plasma O
gamma-glutamyl O
transpeptidase O
( O
GGT O
) O
, O
as O
an O
indicator O
of O
recent O
alcohol O
ingestion O
. O
[]

In O
the O
Child O
Health O
outpatient O
setting O
, O
the O
'traditional O
' O
structured O
approach O
led O
to O
significantly O
greater O
knowledge B-outcome ['Life-Impact']
gain O
in O
comparison O
with O
the O
'novel O
' O
student-directed O
approach O
. O
['Life-Impact']

A O
spirometry O
substudy O
evaluates O
the O
bronchodilator O
efficacy O
. O
[]

No O
difference O
was O
observed O
between O
Isopaque O
Cerebral O
and O
Conray O
Meglumin O
, O
regardless O
of O
dosage O
. O
[]

According O
to O
investigator-based O
Wrinkle O
Severity O
Rating O
Scale O
assessments O
at O
6 O
and O
9 O
months O
after O
baseline O
, O
Perlane O
was O
superior O
in O
50.0 O
percent O
and O
48.8 O
percent O
of O
patients O
, O
respectively O
, O
whereas O
Zyplast O
was O
superior O
in O
10.3 O
percent O
and O
14.0 O
percent O
of O
patients O
, O
respectively O
( O
p O
< O
0.0004 O
) O
. O
[]

RESULTS O
There O
were O
no O
differences O
in O
any O
of O
the O
primary O
or O
secondary O
outcomes O
when O
fexofenadine O
was O
added O
to O
treatment O
with O
either O
fluticasone O
propionate-salmeterol O
or O
fluticasone O
propionate O
alone O
. O
[]

FINDINGS O
Annual O
occupational O
injury B-outcome ['Resource-use']
and I-outcome ['Resource-use']
illness I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
per O
farmer O
paid O
by O
insurers O
were O
45 O
% O
lower O
in O
the O
intervention O
cohort O
( O
$ O
183 O
) O
than O
in O
the O
control O
cohort O
( O
$ O
332 O
) O
. O
['Resource-use']

dal-PLAQUE O
is O
the O
first O
multicentre O
study O
using O
novel O
non-invasive O
multimodality O
imaging O
to O
assess O
structural O
and O
inflammatory O
indices O
of O
atherosclerosis O
as O
primary O
endpoints O
. O
[]

We O
sought O
to O
determine O
if O
the O
combination O
of O
tacrolimus O
and O
sirolimus O
( O
Tac/Sir O
) O
was O
more O
effective O
than O
tacrolimus O
and O
methotrexate O
( O
Tac/Mtx O
) O
in O
preventing O
acute O
GVHD O
and O
early O
mortality O
after O
allogeneic O
MRD O
HCT O
in O
a O
phase O
3 O
, O
multicenter O
trial O
. O
[]

There O
were O
no O
significant O
differences O
in O
[]

STUDY O
DESIGN O
The O
study O
was O
designed O
as O
a O
randomized O
controlled O
trial O
with O
neighborhood O
as O
the O
unit O
of O
randomization O
. O
[]

In O
conclusion O
, O
a O
substantial O
number O
of O
patients O
revealed O
evidence O
of O
cognitive O
deficits O
a O
long O
time O
after O
HSCT O
. O
[]

All O
patients O
received O
intermittent O
pneumatic O
compression O
. O
[]

The O
six-session O
intervention O
that O
emerged O
from O
the O
development O
process O
relied O
on O
both O
social-cognitive O
theories O
and O
peer O
influence O
models O
. O
[]

To O
avoid O
these O
organizational O
problems O
a O
prospective O
study O
was O
undertaken O
to O
analyze O
the O
effectiveness O
of O
preoperative O
irradiation O
on O
the O
day O
preceding O
surgery O
( O
16-20 O
h O
before O
operation O
) O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
risedronate O
treatment O
on O
the O
level O
of O
serum O
cytokines O
including O
receptor O
activator O
of O
nuclear O
factor-kappaB O
ligand O
( O
RANKL O
) O
and O
osteoprotegerin O
among O
postmenopausal O
women O
with O
osteoporosis O
. O
[]

Fidelity O
criteria O
were O
maintained O
throughout O
. O
[]

This O
study O
is O
registered O
at O
http O
: O
//clinicaltrials.gov O
as O
NCT00002744 O
. O
[]

The O
experimental O
group O
significantly O
improved O
the O
duration O
of O
the O
reception O
double O
stance O
on O
the O
paretic O
limb O
between O
JM O
and O
JM O
+ O
30 O
compared O
with O
the O
control O
group O
( O
P O
= O
0.03 O
) O
. O
[]

Intervention O
targeting O
development O
of O
socially O
synchronous O
engagement O
in O
toddlers O
with O
autism O
spectrum O
disorder O
: O
a O
randomized O
controlled O
trial O
. O
[]

We O
examined O
the O
hypothesis O
that O
amino O
acids O
, O
in O
the O
absence O
of O
glucose O
supply O
, O
spare O
protein O
while O
preventing O
hyperglycemia O
. O
[]

CONCLUSIONS O
Efforts O
to O
aid O
discharge O
decision O
making O
and O
optimize O
hospital O
resource O
planning O
could O
take O
advantage O
of O
our O
predictive O
model O
and O
the O
simplified O
scoring O
tool O
. O
[]

Induction O
of O
anesthesia O
consisted O
of O
midazolam O
, O
fentanyl O
, O
and O
pancuronium O
. O
[]

Safety O
evaluation O
of O
lasalocid O
use O
in O
Chinese O
ring-necked O
pheasants O
( O
Phasianus O
colchicus O
) O
. O
[]

Effect O
of O
fats O
high O
in O
individual O
saturated O
fatty O
acids O
on O
plasma B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
levels O
in O
young O
healthy O
men O
. O
['Physiological-Clinical']

Women O
with O
VDI B-outcome ['Physiological-Clinical']
were O
more O
likely O
to O
be O
black O
( O
17 O
% O
v. O
2 O
% O
, O
P O
< O
0.001 O
) O
, O
heavier O
( O
BMI O
33.0 O
( O
sd O
7 O
) O
kg/m2 O
v. O
29.0 O
( O
sd O
7 O
) O
kg/m2 O
, O
P O
< O
0.001 O
) O
and O
less O
likely B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tan I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
past I-outcome ['Life-Impact']
year I-outcome ['Life-Impact']
( O
49 O
% O
v. O
72 O
% O
, O
P O
< O
0.001 O
) O
, O
use O
sunscreen B-outcome ['Life-Impact']
( O
57 O
% O
v. O
72 O
% O
, O
P O
< O
0.001 O
) O
or O
report O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
in O
the O
last O
3 O
months O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

It O
has O
been O
shown O
that O
finasteride O
decreases O
bleeding O
in O
patients O
with O
hematuria O
of O
prostatic O
origin O
. O
[]

alpha-Interferon O
has O
antitumor O
activity O
in O
a O
variety O
of O
malignancies O
but O
is O
frequently O
associated O
with O
unacceptable O
toxic B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

RESULTS O
Tumors B-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
or O
the O
target O
tumor O
area O
was O
reduced O
in O
subjects O
in O
the O
4- O
and O
6-week O
dosing O
regimens O
. O
['Physiological-Clinical']

No O
patients O
had O
multiple O
foci O
of O
NPC O
. O
[]

PATIENTS O
AND O
METHODS O
Sixty O
patients O
between O
18 O
and O
65 O
years O
of O
age O
participated O
and O
completed O
the O
study O
. O
[]

OBJECTIVE O
The O
mechanisms O
underlying O
symptom O
improvement O
in O
gastric O
electrical O
stimulation O
( O
GES O
) O
are O
not O
fully O
understood O
. O
[]

DESIGN O
Men O
and O
women O
aged O
40-65 O
y O
( O
n O
= O
38 O
) O
underwent O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
trial O
of O
treatment O
with O
0.7 O
g O
DHA/d O
for O
3 O
mo O
. O
[]

METHODS O
The O
WRIST O
study O
randomized O
130 O
patients O
to O
double-blinded O
therapy O
with O
gamma O
irradiation O
( O
iridium-192 O
[ O
( O
192 O
) O
Ir O
] O
) O
versus O
placebo O
after O
interventional O
treatment O
of O
diffuse O
in-stent O
restenosis O
. O
[]

For O
patients O
with O
EjD O
at O
baseline O
, O
the O
mean O
change O
from O
baseline O
in O
ejaculatory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
with O
alfuzosin O
was O
comparable O
to O
that O
with O
placebo O
. O
['Physiological-Clinical']

Ten O
children O
were O
trained O
on O
theory O
of O
mind O
, O
whilst O
ten O
were O
trained O
in O
executive O
function O
. O
[]

Patients O
who O
did O
not O
convert O
to O
sinus O
rhythm O
after O
treatment O
with O
verapamil O
were O
treated O
with O
flecainide O
and O
observed O
for O
another O
hour O
. O
[]

The O
aim O
of O
this O
study O
is O
to O
assess O
whether O
obese O
patients O
with O
heart O
failure O
can O
benefit O
from O
losing O
weight O
via O
an O
orlistat-assisted O
diet O
. O
[]

Twenty O
children O
aged O
6 O
to O
9 O
years O
and O
their O
families O
began O
a O
program O
to O
modify O
the O
family O
diet O
toward O
a O
goal O
of O
70 O
mEq O
sodium O
per O
person O
per O
day O
. O
[]

Aside O
from O
anaemia B-outcome ['Physiological-Clinical']
in O
one O
cat O
treated O
with O
AZT O
, O
no O
adverse O
effects O
were O
observed O
. O
['Physiological-Clinical']

Heidelberg O
retinal O
angiography O
images O
showed O
the O
[]

METHOD O
This O
24-week O
, O
three-site O
, O
randomized O
, O
parallel-groups O
clinical O
trial O
enrolled O
124 O
children O
, O
aged O
4 O
through O
13 O
years O
, O
with O
PDDs O
, O
accompanied O
by O
frequent O
tantrums O
, O
self-injury O
, O
and O
aggression O
. O
[]

Thirty-five O
of O
the O
forty-one O
( O
85.4 O
% O
) O
children O
with O
a O
pathologic O
MII/pH O
presented O
with O
extraesophageal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
were O
treated O
with O
PPIs O
( O
omeprazole O
; O
n:19 O
) O
or O
H O
( O
2 O
) O
RAs O
( O
ranitidine O
; O
n:16 O
) O
for O
12 O
weeks O
. O
['Physiological-Clinical']

For O
the O
SCJ O
group O
( O
n O
= O
25 O
) O
, O
a O
median O
increase O
in O
BCVA O
started O
at O
day O
7 O
( O
5.0 O
letters O
) O
and O
was O
3.0 O
, O
4.0 O
, O
and O
4.0 O
letters O
at O
days O
14 O
, O
45 O
and O
90 O
, O
respectively O
. O
[]

The O
maximal O
plasma B-outcome ['Physiological-Clinical']
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
was O
significantly O
lower O
, O
and O
the O
time O
to O
reach O
Cmax B-outcome ['Physiological-Clinical']
as O
well O
as O
the O
time O
span O
during O
which O
the O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
difference O
between O
the O
two O
protocols O
was O
significant O
as O
indicated O
by O
the O
effect O
of O
group O
, O
the O
between O
subjects O
factor O
( O
F O
= O
5.85 O
, O
d.f O
. O
[]

Altered O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
growth O
hormone O
releasing O
hormone O
administration O
in O
chronic O
renal O
failure O
. O
['Physiological-Clinical']

The O
outcome O
measure O
was O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
at O
6 O
weeks O
. O
['Life-Impact']

BACKGROUND O
The O
effectiveness O
of O
the O
nonsteroidal O
anti-inflammatory O
drug O
ketorolac O
in O
reducing O
pulmonary O
morbidity O
after O
rib O
fractures O
remains O
largely O
unknown O
. O
[]

Long-term O
survival O
in O
a O
phase O
III O
, O
randomised O
study O
of O
topotecan O
versus O
paclitaxel O
in O
advanced O
epithelial O
ovarian O
carcinoma O
. O
[]

This O
study O
indicates O
that O
there O
is O
a O
highly O
significant O
reduction O
of O
Staphylococcus O
spp O
. O
( O
[]

Weekly O
intake O
of O
alendronate O
, O
whether O
conventional O
or O
enteric-coated O
; O
is O
associated O
with O
less O
heartburn B-outcome ['Physiological-Clinical']
and O
nausea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Steroid O
dependence O
was O
defined O
as O
use O
of O
prednisolone O
or O
prednisone O
( O
15-40 O
mg/day O
) O
or O
budesonide O
( O
9 O
mg/day O
) O
for O
> O
or O
=8 O
weeks O
, O
a O
previous O
failed O
attempt O
to O
decrease O
or O
discontinue O
steroids O
within O
8 O
weeks O
of O
screening O
, O
and O
a O
Crohn O
's O
Disease O
Activity O
Index O
score O
of O
< O
or O
=150 O
points O
. O
[]

The O
potential O
antioxidative O
effect O
of O
the O
rye O
bran O
intervention O
was O
investigated O
by O
measuring O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( O
LDL B-outcome ['Physiological-Clinical']
) O
susceptibility B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
copper I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
ex I-outcome ['Physiological-Clinical']
vivo B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Our O
purpose O
was O
to O
estimate O
costs B-outcome ['Resource-use']
and O
determine O
cost B-outcome ['Resource-use']
predictors O
. O
['Resource-use', 'Resource-use']

OBJECTIVE O
The O
Alcohol O
Dependence O
Scale O
( O
ADS O
) O
yields O
continuous O
scores O
purported O
to O
reflect O
the O
severity O
of O
the O
dependence O
syndrome O
. O
[]

We O
followed O
up O
each O
group O
at O
least O
for O
12 O
months O
after O
their O
restoration O
of O
regular O
cycle O
. O
[]

The O
only O
prognostic O
factor O
was O
presence O
of O
vascular B-outcome ['Physiological-Clinical']
permeation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PATIENTS O
Four O
hundred O
sixteen O
patients O
with O
severe O
injuries O
, O
assessed O
by O
Injury B-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
Score O
and O
degree O
of O
contamination B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
failed O
to O
show O
significant O
difference O
in O
intelligence B-outcome ['Life-Impact']
quotient I-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
scales O
with O
donepezil O
therapy O
over O
12 O
weeks O
. O
['Life-Impact', 'Life-Impact']

No O
significant O
differences O
were O
observed O
in O
the O
mean O
1-y O
change O
in O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
between O
the O
control O
, O
medium-dairy O
, O
and O
high-dairy O
groups O
( O
-0.5 O
+/- O
2.5 O
, O
0.3 O
+/- O
2.7 O
, O
and O
0.5 O
+/- O
3.5 O
kg O
, O
respectively O
; O
P O
= O
0.26 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
article O
examines O
the O
form O
and O
function O
of O
spontaneous O
communication O
and O
outcome O
predictors O
in O
nonverbal O
children O
with O
autism O
following O
classroom-based O
intervention O
( O
Picture O
Exchange O
Communication O
System O
[ O
PECS O
] O
training O
) O
. O
[]

Reactions B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
rabbit I-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
F I-outcome ['Physiological-Clinical']
( O
ab O
' O
) O
2 O
fractions O
were O
only O
obtained O
during O
hyposensitization O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
titanoreine O
on O
early O
postoperative O
symptoms O
after O
procedure O
for O
prolapse O
and O
hemorrhoids O
( O
PPH O
) O
. O
[]

RESULTS O
Early O
during O
treatment O
at O
TW8 O
, O
quality O
of O
life O
was O
not O
different O
between O
patients O
in O
the O
control O
and O
the O
amantadine O
group O
. O
[]

Clinicians O
involved O
in O
the O
intervention O
increased O
their O
use O
of O
handouts B-outcome ['Life-Impact']
, O
waiting O
room O
educational O
materials O
, O
and O
['Life-Impact']

Actuarial O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
analysis O
at O
5 O
years O
was O
95.7 O
% O
in O
the O
group O
of O
adjuvant-treated O
patients O
and O
82.8 O
% O
in O
the O
control O
group O
. O
['Mortality']

DESIGN O
Parallel O
, O
clinical O
intervention O
study O
of O
12 O
weeks O
energy O
restriction O
( O
6.5 O
MJ/day O
) O
and O
4 O
weeks O
energy O
balance O
( O
8.2 O
MJ/day O
) O
in O
two O
groups O
of O
subjects O
randomly O
assigned O
to O
either O
a O
high-protein O
( O
HP O
) O
diet O
( O
27 O
% O
of O
energy O
( O
% O
E O
) O
as O
protein O
, O
45 O
% O
E O
as O
carbohydrate O
) O
or O
a O
lower-protein O
( O
LP O
) O
diet O
( O
16 O
% O
E O
as O
protein O
, O
57 O
% O
E O
as O
carbohydrate O
) O
. O
[]

Quick O
change O
versus O
double O
pump O
while O
changing O
the O
infusion O
of O
inotropes O
: O
an O
experimental O
study O
. O
[]

BACKGROUND O
Hemorrhoidopexy O
using O
the O
circumferential O
stapler O
is O
an O
established O
method O
for O
surgical O
treatment O
of O
patients O
with O
prolapsing O
hemorrhoids O
. O
[]

KIU/hr O
. O
[]

The O
WL O
group O
received O
SSBT O
after O
a O
second O
baseline O
assessment O
. O
[]

Two O
groups O
of O
individuals O
were O
compared O
: O
( O
a O
) O
215 O
supported O
employees O
who O
were O
in O
sheltered O
workshops O
prior O
to O
entering O
supported O
employment O
and O
( O
b O
) O
215 O
supported O
employees O
who O
were O
not O
in O
sheltered O
workshops O
. O
[]

STUDY O
DESIGN O
Adults O
with O
uncomplicated O
acute O
appendicitis O
were O
randomized O
1:1 O
to O
either O
SILS O
or O
3-port O
laparoscopic O
appendectomy O
. O
[]

However O
, O
the O
total O
CD19+ B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
population I-outcome ['Physiological-Clinical']
from O
myeloma O
was O
not O
significantly O
different O
from O
the O
median O
of O
age-matched O
, O
normal O
controls O
. O
['Physiological-Clinical']

Postoperative O
iron O
, O
ferritin O
, O
and O
transferrin O
saturation O
levels O
were O
significantly O
higher O
in O
Group O
IE O
. O
[]

Measurements O
from O
Doppler O
sonography O
had O
lower O
reproducibility O
and O
sensitivity B-outcome ['Physiological-Clinical']
compared O
with O
the O
other O
applied O
methods O
. O
['Physiological-Clinical']

Adult O
inpatients O
who O
had O
received O
warfarin O
sodium O
10 O
mg O
daily O
for O
less O
than O
three O
days O
were O
eligible O
for O
the O
study O
. O
[]

Correlations O
between O
[]

Systematic O
data O
on O
the O
long-term O
course O
of O
and O
therapeutic O
options O
for O
these O
consequences O
are O
limited O
. O
[]

Tipping O
of O
the O
maxillary O
segments O
and O
increases O
in O
the O
retention B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
are O
equal O
in O
both O
groups O
. O
['Physiological-Clinical']

Both O
groups O
were O
followed O
for O
six O
months O
. O
[]

BACKGROUND O
Because O
the O
response O
to O
treatment O
is O
limited O
, O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
typically O
receive O
multiple O
treatments O
. O
[]

As O
a O
rule O
, O
their O
low O
serum O
gamma O
globulin O
levels O
at O
birth O
subsequently O
decline O
to O
hypogammaglobulinemic O
values O
; O
hence O
, O
prophylactic O
administration O
of O
intravenous O
immune O
globulin O
may O
reduce O
the O
rate O
of O
hospital-acquired O
infections O
. O
[]

Further O
studies O
are O
necessary O
to O
provide O
this O
information O
in O
order O
to O
assess O
the O
need O
for O
subsequent O
booster O
doses O
after O
primary O
immunization O
with O
both O
ADPT O
and O
WCDPT O
vaccines O
. O
[]

The O
reductions O
in O
FEV1 B-outcome ['Physiological-Clinical']
and O
FVC B-outcome ['Physiological-Clinical']
were O
comparable O
and O
were O
not O
symptomatic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
post-operative O
adjuvant O
therapy O
, O
4/48 O
( O
8 O
% O
) O
anastrozole O
and O
25/49 O
( O
51 O
% O
) O
tamoxifen O
patients O
experienced O
recurrence O
. O
[]

All O
methods O
of O
the O
treatment O
of O
severe O
sepsis O
are O
discussed O
with O
reference O
to O
treatment O
indications B-outcome ['Physiological-Clinical']
, O
efficacy O
, O
and O
outcome O
parameters O
. O
['Physiological-Clinical']

Mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
the O
first O
24 O
h O
post-treatment O
was O
similar O
in O
the O
desmopressin O
and O
placebo O
groups O
( O
582 O
vs O
465 O
ml O
, O
respectively O
; O
p O
= O
0.15 O
) O
. O
['Physiological-Clinical']

The O
treatment O
group O
's O
pain B-outcome ['Physiological-Clinical']
decreased O
during O
the O
last O
2 O
days O
of O
the O
study O
. O
['Physiological-Clinical']

In O
conclusion O
, O
this O
trial O
supports O
the O
hypothesis O
that O
acupuncture O
is O
more O
effective O
than O
advice O
and O
exercises O
in O
the O
symptomatic O
treatment O
of O
OA O
of O
the O
hip O
. O
[]

RESULTS O
Seventeen O
of O
20 O
( O
85 O
% O
) O
women O
in O
the O
control O
group O
developed O
preeclampsia B-outcome ['Physiological-Clinical']
, O
whereas O
9 O
of O
20 O
( O
45 O
% O
) O
in O
the O
treatment O
group O
developed O
preeclampsia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
28 O
subjects O
between O
8 O
and O
18 O
ages O
with O
autistic O
disorder O
were O
enrolled O
to O
the O
open O
label O
phase O
of O
the O
study O
. O
[]

Previous O
clinical O
trials O
have O
demonstrated O
the O
important O
influence O
of O
ethnicity O
and O
dietary O
salt O
on O
the O
antihypertensive O
efficacy O
of O
drugs O
that O
block O
the O
renin O
angiotensin O
system O
. O
[]

Warfarin O
was O
started O
on O
the O
day O
of O
the O
procedure O
and O
the O
dosage O
was O
adjusted O
to O
maintain O
the O
thromboplastin O
international O
normalised O
ratio O
greater O
than O
or O
equal O
to O
2.5 O
. O
[]

The O
duration O
of O
treatment O
was O
30 O
days O
, O
but O
this O
was O
extended O
to O
three O
months O
in O
3 O
patients O
in O
the O
cimetidine O
group O
and O
4 O
patients O
in O
the O
antacid O
group O
. O
[]

CONCLUSIONS O
Fructose-1,6-diphosphate O
produces O
a O
modest O
but O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
in O
patients O
with O
mild O
to O
moderate O
heart O
failure O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
median O
induction-to-abortion B-outcome ['Mortality']
interval I-outcome ['Mortality']
( O
sublingual O
: O
13.8 O
hours O
; O
vaginal O
: O
12.0 O
hours O
) O
. O
['Mortality']

PURPOSE O
This O
controlled O
clinical O
study O
was O
designed O
to O
simulate O
the O
dentin/composite O
cement O
interface O
immediately O
after O
cementation O
of O
a O
cast O
restoration O
. O
[]

Medical O
Research O
Council O
Working O
Party O
on O
Childhood O
Leukaemia O
. O
[]

SECONDARY O
OUTCOMES O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
evaluation O
of O
ECG B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
and O
QT B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
, O
hypoglycaemic B-outcome ['Resource-use']
and I-outcome ['Resource-use']
anti-hypertensive I-outcome ['Resource-use']
medication I-outcome ['Resource-use']
and O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
obtained O
at O
baseline O
, O
+0.333 O
; O
0.667 O
; O
1.00 O
; O
1.33 O
; O
1.67 O
; O
2.00 O
; O
2.33 O
; O
2.67 O
; O
3.00 O
; O
3.50 O
; O
4.00 O
; O
6.00 O
; O
8.00 O
; O
12.0 O
; O
24.0 O
; O
36.0 O
; O
48.0 O
and O
72.0 O
h O
post-administration O
. O
['Physiological-Clinical']

Diets O
high O
in O
C18 O
gave O
significantly O
higher O
levels O
of O
Lp B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
( O
51 O
( O
12-560 O
) O
mg/L O
) O
than O
diets O
high O
in O
C16 O
( O
38 O
( O
12-533 O
mg/L O
) O
( O
P O
= O
0.020 O
) O
and O
C12 O
+ O
C14 O
( O
34 O
( O
12-534 O
) O
mg/L O
) O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical']

A O
comparison O
of O
sclerotherapy O
with O
staple O
transection O
of O
the O
esophagus O
for O
the O
emergency O
control O
of O
bleeding B-outcome ['Physiological-Clinical']
from O
esophageal O
varices O
. O
['Physiological-Clinical']

Maternal O
dietary O
counseling O
in O
the O
first O
year O
of O
life O
is O
associated O
with O
a O
higher O
healthy B-outcome ['Life-Impact']
eating I-outcome ['Life-Impact']
index O
in O
childhood O
. O
['Life-Impact']

BACKGROUND O
Adverse O
events O
occur O
following O
non-ST O
elevation O
acute O
coronary O
syndromes O
( O
NSTE O
ACS O
) O
. O
[]

All O
patients O
received O
succinylcholine O
1 O
mg/kg O
i.v O
. O
[]

Use O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
facilities I-outcome ['Resource-use']
was O
assessed O
from O
diaries/questionnaires O
and O
Medicare B-outcome ['Resource-use']
reimbursement I-outcome ['Resource-use']
rates O
used O
to O
estimate O
costs O
. O
['Resource-use', 'Resource-use']

Under O
CW O
conditions O
, O
subjects O
are O
exposed O
to O
thermal O
stress O
caused O
by O
CW O
protective O
clothing O
. O
[]

Bladder O
sensation O
volumes O
were O
lower O
with O
rectal O
distention O
as O
follows O
: O
normal O
desire O
to O
void O
( O
139 O
ml O
SD O
, O
?114 O
vs. O
197 O
ml O
SD O
?150 O
, O
P O
= O
0.01 O
) O
, O
strong O
desire O
to O
void O
( O
260 O
ml O
SD O
?171 O
vs. O
330 O
ml O
SD O
?172 O
, O
P O
= O
0.01 O
) O
, O
and O
maximum O
cystometric O
capacity O
( O
326 O
ml O
SD O
?183 O
vs. O
403 O
ml O
SD O
?180 O
, O
P O
= O
0.0001 O
) O
. O
[]

Previous O
studies O
of O
home-based O
pulmonary O
rehabilitation O
in O
COPD O
have O
demonstrated O
improvement O
in O
exercise O
capacity O
and O
quality O
of O
life O
, O
but O
not O
all O
elements O
of O
the O
program O
were O
conducted O
in O
the O
home O
environment O
. O
[]

METHOD O
Each O
treatment O
was O
delivered O
to O
children O
for O
a O
maximum O
total O
of O
24 O
hr O
over O
a O
6-month O
period O
. O
[]

To O
compare O
the O
safety O
and O
efficacy O
of O
a O
topical O
diclofenac O
solution O
versus O
oral O
diclofenac O
in O
relieving O
the O
symptoms O
of O
primary O
osteoarthritis O
( O
OA O
) O
of O
the O
knee O
, O
in O
a O
randomized O
, O
double-blind O
, O
double-dummy O
equivalence O
trial O
. O
[]

Effects O
of O
losartan O
and O
enalapril O
on O
high-sensitivity O
C-reactive O
protein O
and O
total O
antioxidant O
in O
renal O
transplant O
recipients O
with O
Renin-Angiotensin O
system O
polymorphisms O
. O
[]

We O
subdivided O
the O
patients O
into O
age-related O
groups O
for O
each O
parameter O
. O
[]

METHODS O
A O
single O
blind O
placebo-controlled O
trial O
was O
carried O
out O
for O
two O
years O
in O
220 O
adolescents O
with O
higher O
blood O
pressure O
, O
aged O
18 O
- O
22 O
years O
, O
who O
were O
randomly O
divided O
into O
supplementary O
group O
( O
n O
= O
110 O
) O
and O
control O
group O
( O
n O
= O
110 O
) O
. O
[]

The O
most O
consistent O
data O
with O
respect O
to O
micronutrient O
antioxidants O
and O
atherosclerosis O
appear O
to O
relate O
to O
alpha-tocopherol O
( O
AT O
) O
, O
the O
predominant O
lipid-soluble O
antioxidant O
in O
LDL O
. O
[]

FDA O
review O
of O
a O
panitumumab O
( O
Vectibix O
) O
clinical O
trial O
for O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
both O
groups O
at O
the O
end O
of O
trial O
was O
equally O
and O
significantly O
reduced O
; O
systolic O
pressure O
22.2 O
mmHg O
and O
diastolic O
pressure O
15.5 O
mmHg O
in O
the O
supine O
position O
, O
and O
24.4 O
mmHg O
and O
18.4 O
mmHg O
, O
respectively O
, O
in O
the O
standing O
position O
in O
those O
on O
nicardipine O
, O
and O
by O
23.7 O
and O
16.2 O
mmHg O
and O
28.0 O
and O
19.2 O
mmHg O
, O
respectively O
, O
in O
the O
propranolol O
group O
. O
['Physiological-Clinical']

Statistical O
analyses O
were O
made O
using O
Friedman O
's O
and O
Wilcoxon O
's O
rank-sum O
tests O
. O
[]

Twelve O
male O
patients O
with O
stable O
effort O
angina O
and O
without O
previous O
myocardial O
infarction O
were O
studied O
. O
[]

Patients O
were O
randomized O
to O
receive O
either O
minidose O
succinylcholine O
( O
0.1 O
mg/kg O
) O
or O
pancuronium O
( O
0.03 O
mg/kg O
) O
IV O
one O
minute O
prior O
to O
the O
full O
paralytic O
dose O
of O
succinylcholine O
( O
1.5 O
mg/kg O
) O
IV O
. O
[]

A O
comparison O
of O
1- O
and O
3-minute O
lockout O
periods O
during O
patient-controlled O
sedation O
with O
midazolam O
. O
[]

SUBJECTS O
Parturients O
( O
ASA O
1 O
and O
2 O
) O
scheduled O
for O
elective O
caesarean O
section O
. O
[]

The O
relationship O
between O
two O
indices O
was O
linear O
in O
each O
subject O
, O
and O
the O
correlation O
coefficient O
was O
0.83 O
when O
evaluated O
using O
whole O
data O
. O
[]

In O
a O
double-blind O
, O
placebo-controlled O
study O
the O
effects O
of O
Actovegin O
on O
frontal O
and O
parietal O
electrical O
P300 O
sources O
revealed O
by O
low O
resolution O
electromagnetic O
tomography O
( O
LORETA O
) O
were O
studied O
in O
age-associated O
memory O
impairment O
( O
AAMI O
) O
patients O
. O
[]

Approximately O
30 O
% O
of O
patients O
in O
both O
groups O
had O
progression B-outcome ['Physiological-Clinical']
of O
their O
disease B-outcome ['Physiological-Clinical']
, O
and O
progression-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
was O
nearly O
identical O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Among O
them O
, O
86 O
% O
were O
successfully O
eradicated B-outcome ['Physiological-Clinical']
by O
the O
tinidazole O
, O
tetracycline O
, O
bismuth O
and O
rabeprazole O
therapy O
. O
['Physiological-Clinical']

Some O
patients O
of O
each O
group O
received O
an O
intravenous O
infusion O
of O
5 O
% O
glucose O
. O
[]

The O
results O
show O
the O
two O
media O
to O
be O
similar O
both O
in O
imaging B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
in O
the O
incidence O
of O
associated O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

DESIGN O
An O
observational O
substudy O
of O
an O
open-label O
randomized O
controlled O
trial O
of O
two O
alternative O
therapeutic O
regimens O
for O
MAC O
. O
[]

RESULTS O
The O
cumulative O
probability O
of O
cure O
was O
significantly O
( O
P O
< O
0.001 O
) O
different O
in O
children O
receiving O
GB O
for O
both O
acute O
[ O
hazard O
ratio O
( O
HR O
) O
= O
0.63 O
( O
95 O
% O
CI O
: O
0.56-0.67 O
) O
] O
and O
prolonged O
diarrhoea O
[ O
HR O
= O
0.38 O
( O
95 O
% O
CI O
: O
0.26-0.59 O
) O
] O
. O
[]

This O
study O
is O
registered O
at O
ClinicalTrials.gov O
, O
number O
NCT00370331 O
. O
[]

All O
patients O
engrafted O
. O
[]

What O
is O
the O
optimum O
maximal O
gonadotropin O
dosage O
used O
in O
microdose O
flare-up O
cycles O
in O
poor O
responders O
? O
[]

OBJECTIVE O
To O
study O
the O
clinical O
efficacy O
and O
mechanisms O
of O
Youdujing O
( O
YDJ O
) O
preparation O
in O
treating O
the O
cervical O
high-risk O
human O
papilloma O
virus O
( O
HR-HPV O
) O
infection O
. O
[]

Behavioral B-outcome ['Life-Impact']
ratings O
of O
the O
roleplays O
and O
participant B-outcome ['Life-Impact']
evaluations I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
motivational I-outcome ['Life-Impact']
interviewing I-outcome ['Life-Impact']
video I-outcome ['Life-Impact']
constituted O
the O
outcome O
measures O
. O
['Life-Impact', 'Life-Impact']

In O
the O
placebo O
group O
, O
the O
baseline O
value O
was O
1.56+/-0.27 O
kcal/kg/h O
; O
it O
changed O
to O
1.33+/-0.36 O
kcal/kg/h O
at O
the O
end O
of O
12 O
wk O
. O
[]

Although O
the O
intensive O
insulin O
therapy O
group O
had O
more O
glucose B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
performed O
than O
the O
control O
group O
, O
a O
similar O
proportion O
of O
values O
were O
within O
the O
target O
range O
( O
682 O
[ O
42.4 O
% O
] O
of O
1607 O
values O
in O
the O
5- O
to O
7-mmol/L O
range O
; O
250 O
[ O
38.7 O
% O
] O
of O
660 O
values O
in O
the O
8- O
to O
10-mmol/L O
range O
, O
P O
= O
.35 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Perioperative O
blood O
transfusions O
are O
reported O
to O
be O
related O
to O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
reduced O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

TRIAL O
REGISTRATION O
Current O
Controlled O
Trials O
ISRCTN18445519 O
. O
[]

Patients O
of O
good O
performance O
status O
receiving O
moderate O
dose O
radiation O
therapy O
have O
improved O
survival O
. O
[]

The O
healing O
rate O
of O
a O
high O
dose O
, O
2 O
week O
course O
is O
about O
70-75 O
% O
and O
the O
relapse O
rate O
after O
3 O
years O
is O
9.5 O
% O
. O
[]

Comparison O
of O
the O
renal O
and O
hepatic O
effects O
of O
enflurane O
and O
halothane O
. O
[]

Chlorthalidone O
does O
not O
increase O
the O
hypotensive B-outcome ['Physiological-Clinical']
effect O
of O
nifedipine O
in O
essential O
hypertensives O
: O
a O
crossover O
multicentre O
study O
. O
['Physiological-Clinical']

RESULTS O
In O
the O
analyses O
of O
time O
to O
PPMD O
recurrence O
, O
poor O
sleep O
quality O
, O
but O
none O
of O
the O
hormones O
, O
was O
associated O
with O
PPMD O
recurrence O
( O
p O
< O
.05 O
) O
after O
controlling O
for O
medication O
assignment O
. O
[]

DESIGN O
Twenty-five O
patients O
underwent O
overnight O
polysomnography O
with O
simultaneous O
and O
continuous O
impedance O
cardiographic O
monitoring O
. O
[]

Patients O
were O
sent O
the O
optimal O
recommendations O
by O
both O
the O
cellular O
phone O
and O
the O
Internet O
. O
[]

Influence O
of O
ibopamine O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
arrhythmic B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
in O
patients O
with O
congestive O
heart O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Special-effect O
contact O
lenses O
( O
opaque O
, O
tinted O
soft O
contact O
lenses O
that O
incorporate O
decorative O
images O
such O
as O
cateyes O
, O
stars O
, O
or O
hearts O
to O
alter O
eye O
color O
and O
structure O
) O
have O
become O
increasingly O
popular O
. O
[]

Results O
were O
analyzed O
overall O
in O
the O
cohort O
of O
893 O
patients O
with O
endocrine-responsive O
disease O
, O
and O
according O
to O
prospectively O
defined O
categories O
of O
ER O
, O
age O
and O
nodal O
status O
. O
[]

There O
was O
no O
significant O
difference O
when O
the O
Hi-Lo-Evac O
tube O
was O
used O
with O
or O
without O
a O
pack O
( O
P O
greater O
than O
0.2 O
) O
. O
[]

12 O
( O
6 O
% O
) O
patients O
in O
the O
placebo O
group O
, O
15 O
( O
7 O
% O
) O
of O
those O
in O
the O
daclizumab O
150 O
mg O
group O
, O
and O
19 O
( O
9 O
% O
) O
in O
the O
300 O
mg O
group O
had O
serious O
adverse O
events O
excluding O
multiple O
sclerosis O
relapse O
. O
[]

CONCLUSION O
TB1 O
has O
a O
good O
comprehensive O
effect O
in O
retarding B-outcome ['Physiological-Clinical']
aging I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
after O
2 O
years O
was O
89 O
% O
after O
stenting O
and O
70 O
% O
after O
angioplasty O
. O
['Physiological-Clinical']

During O
phase O
1 O
, O
a O
42-day O
open-label O
induction O
period O
, O
subjects O
wore O
only O
active O
transdermal O
nicotine O
systems O
. O
[]

Adjuvant O
goserelin O
and O
ovarian O
preservation O
in O
chemotherapy O
treated O
patients O
with O
early O
breast O
cancer O
: O
results O
from O
a O
randomized O
trial O
. O
[]

RESULTS O
Of O
the O
253 O
couples O
included O
, O
127 O
couples O
were O
allocated O
to O
IUI O
with O
COH O
and O
126 O
to O
expectant O
management O
. O
[]

PATIENTS O
AND O
METHODS O
From O
July O
2004 O
to O
April O
2006 O
, O
80 O
patients O
aged O
between O
10 O
and O
15 O
years O
, O
with O
tonsillectomy O
planned O
for O
chronic O
tonsillitis O
, O
were O
included O
in O
the O
study O
. O
[]

These O
experiments O
assessed O
the O
influence O
of O
two O
variables O
, O
age O
of O
subjects O
and O
time O
of O
drug O
administration O
, O
on O
the O
reinforcing O
properties O
of O
amphetamine O
and O
of O
diazepam O
in O
normal O
volunteers O
. O
[]

High-dose O
chemotherapy O
consisted O
of O
cyclophosphamide O
1.7 O
g/m2 O
days O
1-4 O
, O
BCNU O
150 O
mg/m2 O
days O
1-4 O
, O
etoposide O
400 O
mg/m2 O
days O
1-4 O
. O
[]

The O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
and O
hematocrit B-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
two O
groups O
until O
the O
third O
trimester O
but O
thereafter O
were O
higher O
( O
p O
< O
0.05 O
) O
in O
the O
hematinic O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Administration O
of O
VK2 O
was O
not O
an O
independent O
variable O
for O
the O
recurrence B-outcome ['Physiological-Clinical']
on O
univariate O
analysis O
. O
['Physiological-Clinical']

Opioid-immune O
interactions O
in O
autism O
: O
behavioural O
and O
immunological O
assessment O
during O
a O
double-blind O
treatment O
with O
naltrexone O
. O
[]

Assessment O
of O
response O
to O
induction O
therapy O
and O
its O
influence O
on O
5-year O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
group O
III O
rhabdomyosarcoma O
: O
the O
Intergroup O
Rhabdomyosarcoma O
Study-IV O
experience O
-- O
a O
report O
from O
the O
Soft O
Tissue O
Sarcoma O
Committee O
of O
the O
Children O
's O
Oncology O
Group O
. O
['Mortality']

A O
randomized O
double-blind O
clinical O
trial O
of O
griseofulvin O
treatment O
. O
[]

Data O
for O
high O
grade O
PIN O
and O
LSPC O
were O
gathered O
from O
each O
ERSPC O
centre O
. O
[]

Patients O
who O
received O
MOF-Strep O
experienced O
substantially O
greater O
vomiting B-outcome ['Physiological-Clinical']
and O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
than O
patients O
who O
received O
FU O
+ O
HU O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
risk O
reductions O
, O
achieved O
at O
a O
median O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
level O
difference O
of O
9.1 O
% O
for O
conventional O
treatment O
vs O
7.3 O
% O
for O
intensive O
treatment O
have O
been O
maintained O
through O
7 O
years O
of O
EDIC O
, O
even O
though O
the O
difference O
in O
mean O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
of O
the O
2 O
former O
randomized O
treatment O
groups O
was O
only O
0.4 O
% O
at O
1 O
year O
( O
P O
< O
.001 O
) O
( O
8.3 O
% O
in O
the O
former O
conventional O
treatment O
group O
vs O
7.9 O
% O
in O
the O
former O
intensive O
treatment O
group O
) O
, O
continued O
to O
narrow O
, O
and O
became O
statistically O
nonsignificant O
by O
5 O
years O
( O
8.1 O
% O
vs O
8.2 O
% O
, O
P O
=.09 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Gastrointestinal O
symptoms O
have O
been O
reported O
in O
association O
with O
myoelectrical O
dysrhythmia O
, O
where O
different O
types O
of O
gastric O
electrical O
activity O
have O
been O
described O
. O
[]

After O
adjustment O
, O
risk O
factors O
for O
follicular O
trachoma O
( O
TF O
) O
in O
both O
countries O
were O
[]

The O
two O
treatment O
groups O
showed O
no O
statistically O
significant O
differences O
in O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
except O
for O
increased O
incidence O
of O
diaphoresis B-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
) O
and O
diarrhea B-outcome ['Physiological-Clinical']
( O
P O
= O
.05 O
) O
in O
the O
rHuEPO-treated O
group O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
treatments O
consisted O
of O
( O
1 O
) O
one O
orally O
administered O
0.25-mg O
triazolam O
tablet O
after O
treatment O
with O
ranitidine O
; O
( O
2 O
) O
one O
orally O
administered O
0.25-mg O
triazolam O
tablet O
, O
with O
no O
ranitidine O
pretreatment O
; O
( O
3 O
) O
a O
0.25-mg O
intravenous O
dose O
of O
triazolam O
after O
treatment O
with O
ranitidine O
; O
and O
( O
4 O
) O
a O
0.25-mg O
intravenous O
dose O
of O
triazolam O
, O
with O
no O
ranitidine O
pretreatment O
. O
[]

Comparison O
of O
meloxicam O
and O
a O
glucosamine-chondroitin O
supplement O
in O
management O
of O
feline B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Data O
were O
obtained O
at O
age O
0-3 O
days O
( O
n O
= O
43 O
) O
or O
, O
when O
clinically O
stable O
, O
age O
3-5 O
days O
( O
n O
= O
49 O
) O
. O
[]

PTK2 O
expression O
and O
immunochemotherapy O
outcome O
in O
chronic O
lymphocytic O
leukemia O
. O
[]

Furthermore O
, O
the O
change O
in O
the O
fasting O
level O
of O
total O
factor O
VII O
after O
therapy O
was O
not O
associated O
with O
the O
change O
in O
the O
fasting O
level O
of O
active O
factor O
VII O
( O
r O
= O
0.27 O
; O
P O
= O
0.21 O
) O
. O
[]

METHODS O
We O
randomly O
assigned O
2079 O
men O
and O
women O
who O
were O
35 O
years O
of O
age O
or O
older O
and O
who O
had O
had O
one O
or O
more O
histologically O
confirmed O
colorectal O
adenomas O
removed O
within O
six O
months O
before O
randomization O
to O
one O
of O
two O
groups O
: O
an O
intervention O
group O
given O
intensive O
counseling O
and O
assigned O
to O
follow O
a O
diet O
that O
was O
low O
in O
fat O
( O
20 O
percent O
of O
total O
calories O
) O
and O
high O
in O
fiber O
( O
18 O
g O
of O
dietary O
fiber O
per O
1000 O
kcal O
) O
and O
fruits O
and O
vegetables O
( O
3.5 O
servings O
per O
1000 O
kcal O
) O
, O
and O
a O
control O
group O
given O
a O
standard O
brochure O
on O
healthy O
eating O
and O
assigned O
to O
follow O
their O
usual O
diet O
. O
[]

The O
diagnosis O
obtained O
from O
the O
limited O
sleep-recording O
device O
and O
polysomnography O
agreed O
in O
75 O
% O
of O
the O
interpretable O
home O
studies O
( O
89 O
% O
, O
if O
inconclusive O
home O
studies O
were O
excluded O
) O
. O
[]

The O
coadministration O
of O
cephalexin O
with O
ranitidine O
or O
omeprazole O
resulted O
in O
relatively O
minor O
changes O
in O
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
AUC O
( O
infinity O
) O
, O
t O
( O
1/2 O
) O
, O
or O
CL/F B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
secondary O
outcome O
measures O
are O
the O
Center O
for O
Epidemiological O
Studies O
Depression B-outcome ['Life-Impact']
Scale O
, O
the O
World O
Health O
Organization O
Quality O
of O
Life O
Scale O
26-item O
version O
, O
the O
Global O
Assessment O
of O
Functioning B-outcome ['Life-Impact']
, O
State-trait B-outcome ['Life-Impact']
Anxiety B-outcome ['Life-Impact']
Inventory O
, O
Social B-outcome ['Life-Impact']
Phobia I-outcome ['Life-Impact']
and O
Anxiety B-outcome ['Life-Impact']
Inventory O
, O
and O
['Life-Impact', 'Life-Impact']

Over O
the O
same O
period O
, O
the O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
achieved O
by O
the O
placebo O
group O
rose O
from O
58 O
% O
pre-infusion O
to O
56 O
% O
24 O
h O
post O
infusion O
and O
then O
50 O
% O
relief O
5 O
days O
later O
. O
['Physiological-Clinical']

During O
the O
night O
in O
the O
sleep O
laboratory O
at O
a O
mean O
room O
temperature O
of O
14 O
degrees O
C O
, O
less O
condensation B-outcome ['Physiological-Clinical']
formed O
with O
the O
controlled O
heated O
breathing O
tube O
humidifier O
( O
1.9 O
mL O
versus O
35.3 O
mL O
) O
in O
the O
delivery O
system O
. O
['Physiological-Clinical']

Aspirin O
and O
nonsteroidal O
antiinflammatory O
drugs O
( O
NSAIDs O
) O
damage O
the O
gastroduodenal O
epithelium O
by O
two O
mechanisms O
: O
direct O
toxic O
effects O
and O
effects O
related O
to O
the O
depletion O
of O
endogenous O
prostaglandins O
. O
[]

After O
4 O
years O
of O
study O
, O
the O
gain O
in O
H-SDSCA B-outcome ['Physiological-Clinical']
was O
1.4 O
+ O
or O
- O
01 O
in O
the O
TOTO O
group O
and O
1.6 O
+ O
or O
- O
0.2 O
in O
the O
TTOO O
group O
leading O
to O
a O
mean O
height B-outcome ['Physiological-Clinical']
of O
-2.0 O
+ O
or O
- O
1.0 O
SDS O
and O
-2.0 O
+ O
or O
- O
0.8 O
SDS O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Excimer O
laser O
trabeculotomy O
vs O
180 O
degrees O
selective O
laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
. O
[]

Significant O
improvements O
in O
behavior B-outcome ['Life-Impact']
and O
severity B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
were O
maintained O
for O
12 O
months O
by O
both O
groups O
. O
['Life-Impact']

A O
negative O
relationship O
was O
observed O
between O
minimum O
BG B-outcome ['Physiological-Clinical']
and O
adrenaline B-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
0.37 O
, O
P O
= O
0.01 O
) O
, O
ketone B-outcome ['Physiological-Clinical']
bodies I-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
-0.20 O
, O
P O
= O
0.05 O
) O
and O
NEFA B-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
-0.35 O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cyproheptadine O
in O
the O
treatment O
of O
autistic O
disorder O
: O
a O
double-blind O
placebo-controlled O
trial O
. O
[]

Patients O
randomized O
to O
medical O
management O
showed O
4 O
% O
clot B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
in O
a O
similar O
time O
window O
. O
['Physiological-Clinical']

Early O
phase O
factors O
associated O
with O
death O
included O
lower O
socioeconomic O
status O
( O
P O
= O
.01 O
) O
, O
obstructed O
pulmonary O
venous O
return O
( O
P O
< O
.001 O
) O
, O
smaller O
ascending O
aorta O
( O
P O
= O
.02 O
) O
, O
and O
anatomic O
subtype O
. O
[]

Safety O
was O
generally O
similar O
between O
groups O
, O
but O
posttransplant O
lymphoproliferative O
disorder O
was O
more O
common O
in O
the O
belatacept O
groups O
. O
[]

The O
outcome O
was O
overall B-outcome ['Resource-use']
length I-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
?32 O
vs O
< O
32 O
days O
) O
. O
['Resource-use']

This O
difference O
was O
statistically O
significant O
, O
p O
less O
than O
0.015 O
-- O
Fischer O
's O
exact O
test O
. O
[]

Its O
leakage B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
lower O
and O
quality O
of O
life O
was O
better O
. O
['Physiological-Clinical']

Ten O
patients O
received O
1,2,6-IP3 O
as O
an O
intravenous O
( O
i.v O
. O
) O
[]

To O
quantify O
these O
rules O
, O
we O
used O
stimuli O
composed O
of O
randomly O
oriented O
nonoverlapping O
line O
segments O
. O
[]

RESULTS O
Comparing O
the O
tooth B-outcome ['Physiological-Clinical']
widths I-outcome ['Physiological-Clinical']
of O
patients O
with O
unilateral O
canine O
displacement O
with O
the O
corresponding O
contralateral O
quadrants O
, O
we O
noted O
a O
statistically O
significant O
difference O
, O
namely O
that O
the O
central O
and O
lateral O
incisors O
and O
the O
canines O
of O
the O
affected O
side O
were O
narrower O
than O
those O
of O
the O
non-affected O
side O
in O
the O
same O
patient O
. O
['Physiological-Clinical']

Eleven O
of O
those O
who O
discussed O
their O
health O
with O
the O
doctor O
were O
referred B-outcome ['Resource-use']
to I-outcome ['Resource-use']
a I-outcome ['Resource-use']
specialist I-outcome ['Resource-use']
( O
2 O
% O
) O
. O
['Resource-use']

RESULTS O
Two O
patients O
( O
6.7 O
% O
) O
in O
E-PEG O
group O
had O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
i.e. O
, O
aspiration B-outcome ['Physiological-Clinical']
pneumonia I-outcome ['Physiological-Clinical']
and O
surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Including O
a O
'no O
active O
intervention O
' O
arm O
in O
surgical O
trials O
is O
possible O
: O
evidence O
from O
the O
CLasP O
randomised O
trial O
. O
[]

RESULTS O
Using O
multivariate O
analysis O
with O
several O
socioeconomic O
controls O
, O
the O
authors O
find O
that O
children O
in O
the O
treatment O
condition O
( O
receiving O
the O
intervention O
) O
report O
significant O
improvement O
in O
their O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
The O
clinical O
outcome O
was O
virtually O
identical O
in O
the O
two O
groups O
. O
[]

Expansion O
was O
performed O
using O
a O
bone-borne O
or O
tooth-borne O
device O
. O
[]

Acceptable O
and O
unacceptable O
reasons O
for O
not O
administering O
vaccines O
were O
assigned O
. O
[]

There O
were O
no O
differences O
in O
the O
final O
mean O
dose O
of O
salbutamol O
( O
6.3 O
+/- O
44.5 O
mg O
for O
the O
placebo O
group O
and O
5.8 O
+/- O
4.2 O
mg O
for O
the O
aminophylline O
group O
) O
, O
hospital O
admission O
rate O
( O
10.2 O
percent O
for O
the O
placebo O
group O
and O
9.0 O
percent O
for O
the O
aminophylline O
group O
) O
, O
and O
mean O
duration O
of O
Emergency O
Department O
treatment O
( O
2.5 O
+/- O
1.83 O
h O
for O
the O
placebo O
group O
and O
2.37 O
+/- O
1.75 O
h O
for O
the O
aminophylline O
group O
) O
. O
[]

Outcome O
measures O
included O
the O
SF-36 O
Health O
Survey O
Questionnaire O
and O
additional O
generic O
and O
specific O
scales O
. O
[]

The O
degree O
of O
anesthesia B-outcome ['Resource-use']
was O
comparable O
for O
the O
three O
solutions O
following O
the O
administration O
of O
3.6 O
ml O
of O
each O
solution O
. O
['Resource-use']

Thus O
, O
the O
benefits O
of O
6.5 O
years O
of O
intensive O
treatment O
extend O
well O
beyond O
the O
period O
of O
its O
most O
intensive O
implementation O
. O
[]

METHOD O
Eighty-nine O
suppressed O
patients O
> O
or O
=18 O
years O
old O
with O
CD4 O
counts O
> O
50 O
cells/mm O
( O
3 O
) O
were O
enrolled O
in O
this O
phase O
II O
, O
open-label O
, O
multicenter O
, O
randomized O
, O
stratified O
( O
by O
pretrial O
protease O
inhibitor O
[ O
PI O
] O
) O
, O
parallel-group O
clinical O
trial O
. O
[]

Impact O
of O
antioxidants O
, O
zinc O
, O
and O
copper O
on O
cognition O
in O
the O
elderly O
: O
a O
randomized O
, O
controlled O
trial O
. O
[]

Optimality B-outcome ['Physiological-Clinical']
analyses O
assess O
their O
efficiency O
. O
['Physiological-Clinical']

Effect O
of O
six-hour O
exposure O
to O
nitrogen O
dioxide O
on O
early-phase O
nasal B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
allergen O
challenge O
in O
patients O
with O
a O
history O
of O
seasonal O
allergic O
rhinitis O
. O
['Physiological-Clinical']

Fifty O
patients O
in O
each O
group O
were O
given O
placebo O
, O
omega-3 O
fatty O
acids O
2 O
g O
( O
most O
commonly O
used O
dosage O
in O
Korean O
patients O
) O
, O
or O
fenofibrate O
160 O
mg O
, O
respectively O
daily O
for O
2 O
months O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
measured O
, O
and O
transesophageal O
echocardiography O
( O
TEE O
) O
was O
used O
to O
determine O
myocardial O
contractility O
. O
['Physiological-Clinical']

Bile B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
was O
determined O
and O
the O
saturation O
index O
calculated O
before O
and O
after O
treatment O
, O
on O
samples O
collected O
by O
duodenal O
siphonage O
after O
caerulein O
stimulation O
, O
in O
both O
groups O
. O
['Physiological-Clinical']

The O
impact O
of O
different O
doses O
of O
medroxyprogesterone O
acetate O
on O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
sequential O
hormonal O
therapy O
. O
['Life-Impact']

Child O
and O
parent O
language O
were O
assessed O
using O
similar O
measures O
. O
[]

Papers O
were O
marked O
under O
blind O
conditions O
. O
[]

All O
the O
84 O
patients O
were O
classified O
at O
baseline O
with O
DGE B-outcome ['Physiological-Clinical']
( O
gastric O
retention O
> O
6.3 O
% O
at O
4 O
hours O
) O
or O
normal B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

1 O
. O
[]

BACKGROUND O
Telcagepant O
is O
an O
oral O
calcitonin O
gene-related O
peptide O
receptor O
antagonist O
with O
acute O
antimigraine B-outcome ['Resource-use']
efficacy O
comparable O
to O
oral O
triptans O
. O
['Resource-use']

RESULTS O
Primary O
: O
intent-to-treat O
random O
effects O
regression O
showed O
that O
COMB O
was O
superior O
to O
MED O
on O
HSQ B-outcome ['Physiological-Clinical']
( O
p O
= O
.006 O
) O
[ O
effect O
size O
at O
week O
24 O
( O
d O
) O
= O
0.34 O
] O
. O
['Physiological-Clinical']

METHODS O
Phase O
1 O
involved O
65 O
children O
who O
received O
one O
round O
of O
DMSA O
( O
3 O
days O
) O
. O
[]

Post-hoc O
analyses O
demonstrated O
that O
stride B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
was O
the O
gait O
parameter O
largely O
contributing O
to O
this O
overall O
group O
difference O
( O
p=0.033 O
) O
, O
and O
the O
HI O
group O
produced O
a O
significantly O
longer O
stride B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
than O
the O
C O
group O
( O
p=0.030 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Neither O
intervention O
significantly O
reduced O
polyp O
count O
in O
the O
rectum O
and O
sigmoid O
colon O
: O
aspirin O
relative O
risk O
= O
0.77 O
( O
95 O
% O
CI O
, O
0.54-1.10 O
; O
versus O
nonaspirin O
arms O
) O
; O
RS O
relative O
risk O
= O
1.05 O
( O
95 O
% O
CI O
, O
0.73-1.49 O
; O
versus O
non-RS O
arms O
) O
. O
[]

Psychosocial O
adjustment O
to O
their O
relative B-outcome ['Life-Impact']
's O
illness B-outcome ['Physiological-Clinical']
, O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
burden B-outcome ['Life-Impact']
, O
coping B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
and O
expenditures B-outcome ['Life-Impact']
were O
measured O
after O
6 O
months O
and O
1 O
year O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

In O
this O
study O
, O
we O
examined O
whether O
posterior O
ERP O
components O
associated O
with O
identity O
processing O
( O
P2 O
, O
N250 O
and O
face-N400 O
) O
and O
components O
associated O
with O
early-stage O
face O
processing O
( O
P1 O
and O
N170 O
) O
are O
atypical O
in O
ASD O
. O
[]

The O
present O
study O
used O
the O
physicochemical O
approach O
to O
characterize O
the O
changes O
in O
acid-base B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
occurring O
after O
oral O
NaAcetate/acetic O
acid O
( O
NAA O
) O
administration O
in O
horses O
. O
['Physiological-Clinical']

Crying B-outcome ['Life-Impact']
history I-outcome ['Life-Impact']
was O
determined O
from O
semistructured O
interviews O
and O
from O
diaries O
kept O
by O
the O
patients O
. O
['Life-Impact']

Mann-Whitney O
U O
test O
was O
used O
for O
significance O
of O
difference O
between O
both O
the O
groups O
. O
[]

A O
total O
of O
257 O
patients O
on O
TG O
( O
25 O
% O
) O
developed O
VOD B-outcome ['Physiological-Clinical']
or O
disproportionate B-outcome ['Physiological-Clinical']
thrombocytopenia I-outcome ['Physiological-Clinical']
and O
switched O
to O
MP O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
MATERIALS O
Patients O
( O
N O
= O
207 O
) O
with O
nonresectable O
rectal O
cancer O
were O
randomized O
to O
preoperative O
CRT O
or O
RT O
( O
2 O
Gy O
? O
[]

Differences O
in O
volume-pressure O
behavior O
of O
the O
excised O
lungs O
included O
greater O
distensibility B-outcome ['Physiological-Clinical']
in O
the O
infants O
from O
dexamethasone-treated O
dams O
( O
20.6 O
+/- O
7.1 O
ml/g O
dry O
lung O
versus O
14.7 O
+/- O
6.1 O
, O
p O
less O
than O
0.05 O
) O
and O
enhanced O
deflation B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
with O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
TWT O
or O
BET O
groups O
. O
[]

They O
had O
all O
had O
at O
least O
6 O
months O
of O
chronic O
LBP O
. O
[]

Peak O
ground B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
forces I-outcome ['Physiological-Clinical']
during O
exercise O
increased O
from O
2.5 O
to O
2.8 O
times O
body O
weight O
. O
['Physiological-Clinical']

Captopril O
significantly O
reduced O
both O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
154/90 O
+/- O
5/2 O
vs. O
144/86 O
+/- O
4/3 O
mmHg O
) O
without O
major O
side O
effects O
. O
['Physiological-Clinical']

The O
strongest O
correlation O
( O
R O
= O
0.74 O
, O
P O
< O
.0001 O
) O
was O
found O
between O
systolic B-outcome ['Physiological-Clinical']
PAP I-outcome ['Physiological-Clinical']
and O
the O
heart B-outcome ['Physiological-Clinical']
rate-corrected I-outcome ['Physiological-Clinical']
IVRT I-outcome ['Physiological-Clinical']
' O
derived O
from O
the O
basal O
RV O
free O
wall O
segment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CreaT B-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
not O
different O
between O
VEG O
and O
NVEG O
. O
['Physiological-Clinical']

Therefore O
, O
the O
estimates O
from O
the O
interaction O
between O
ODR O
and O
treatment O
on O
milk O
production O
were O
used O
to O
determine O
how O
well O
the O
ODR O
predicted O
the O
response O
of O
the O
treatment O
. O
[]

CONCLUSION O
In O
this O
study O
, O
efficacy O
and O
tolerability O
were O
comparable O
between O
C/A O
and O
H/A O
over O
23 O
days O
of O
treatment O
in O
these O
patients O
with O
moderate O
or O
severe O
, O
chronic O
, O
cancer-related O
pain O
. O
[]

Depending O
on O
tolerance O
and O
efficacy O
, O
they O
were O
treated O
for O
periods O
ranging O
from O
5 O
to O
150 O
days O
. O
[]

There O
was O
no O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
scores O
with O
intramuscular O
ketorolac O
compared O
with O
placebo O
. O
['Physiological-Clinical']

RESULTS O
Of O
59 O
patients O
, O
eight O
were O
excluded O
from O
randomization O
( O
a O
surgeon O
judged O
Steri-Strip O
S O
to O
be O
a O
nonviable O
closure O
technique O
for O
mismatched O
wound O
edges O
) O
. O
[]

Each O
dose O
was O
followed O
1 O
hour O
later O
by O
an O
egg-beater O
meal O
, O
labeled O
with O
Tc99m O
. O
[]

SD O
age O
: O
68.7 O
? O
[]

Further O
studies O
using O
long-term O
aging O
procedures O
should O
be O
conducted O
. O
[]

CONCLUSIONS O
Patients O
in O
our O
prospective O
randomized O
study O
who O
were O
treated O
with O
trochanteric O
nailing O
did O
not O
differ O
in O
hip B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
at O
one O
year O
postoperatively O
compared O
with O
patients O
treated O
with O
intramedullary O
nailing O
through O
the O
piriformis O
fossa O
. O
['Physiological-Clinical']

Relative O
changes O
in O
the O
concentration O
of O
oxyhemoglobin B-outcome ['Physiological-Clinical']
and O
deoxyhemoglobin B-outcome ['Physiological-Clinical']
were O
assessed O
in O
the O
prefrontal O
cortex O
using O
near-infrared O
spectroscopy O
during O
performance O
of O
nine O
computerized O
cognitive O
tasks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Symptoms O
of O
pain B-outcome ['Physiological-Clinical']
, O
discomfort B-outcome ['Life-Impact']
and O
nausea B-outcome ['Physiological-Clinical']
were O
compared O
using O
linear O
analogue O
scales O
and O
spirometry O
was O
used O
to O
examine O
pre-operative O
and O
postoperative O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

DISCUSSION O
Combined O
calcium O
and O
vitamin O
D O
supplementation O
proved O
superior O
to O
calcium O
alone O
in O
reducing O
the O
number O
of O
falls B-outcome ['Life-Impact']
and O
improving O
muscle O
function O
in O
community-dwelling O
older O
individuals O
. O
['Life-Impact']

The O
primary O
outcome O
of O
independent O
ratings O
of O
child B-outcome ['Physiological-Clinical']
goal I-outcome ['Physiological-Clinical']
attainment I-outcome ['Physiological-Clinical']
and O
several O
process O
measures O
( O
e.g. O
, O
consultant O
and O
teacher O
fidelity O
) O
were O
evaluated O
. O
['Physiological-Clinical']

Two O
minutes O
before O
the O
venepuncture O
, O
in O
the O
intervention O
arm O
, O
40 O
babies O
received O
5 O
ml O
of O
EBM O
, O
while O
41 O
babies O
in O
control O
group O
received O
5 O
ml O
of O
distilled O
water O
( O
DW O
) O
as O
placebo O
. O
[]

The O
Endometriosis O
Health O
Profile-30 O
( O
EHP-30 O
) O
endometriosis-specific B-outcome ['Life-Impact']
quality-of-life I-outcome ['Life-Impact']
questionnaire O
was O
completed O
at O
the O
beginning O
and O
at O
the O
end O
of O
the O
trial O
. O
['Life-Impact']

Internal O
consistency O
reliability O
was O
analyzed O
by O
Cronbach O
's O
alpha O
. O
[]

In O
the O
early O
and O
late O
groups O
, O
a O
mean O
of O
200.3 O
+/- O
68.7 O
x O
10 O
( O
6 O
) O
and O
194.8 O
+/- O
60.4 O
x O
10 O
( O
6 O
) O
stem B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
respectively O
, O
were O
delivered O
to O
the O
myocardium O
, O
and O
1.30 O
+/- O
0.68 O
x O
10 O
( O
9 O
) O
and O
1.29 O
+/- O
0.41 O
x O
10 O
( O
9 O
) O
cells O
, O
respectively O
, O
were O
delivered O
into O
the O
artery O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
suggests O
that O
young O
children O
with O
high O
functioning O
ASD O
may O
benefit O
from O
CBT O
to O
improve O
regulation O
of O
anger B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
, O
and O
parent O
training O
may O
improve O
parental B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Pursuant O
to O
promising O
appearing O
pilot O
data O
, O
the O
current O
study O
evaluated O
the O
use O
of O
vitamin O
E O
for O
the O
prevention O
of O
CIPN O
. O
[]

The O
efficacy O
end O
points O
were O
mean O
percent O
change O
in O
plasma B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
primary O
) O
, O
total O
['Physiological-Clinical']

The O
INT O
group O
received O
home O
visits O
and O
center-based O
educational O
interventions O
until O
36 O
months O
of O
age O
( O
corrected O
for O
gestational O
age O
when O
final O
assessments O
were O
completed O
) O
. O
[]

Placebo O
was O
sham O
ultrasound O
and O
light O
application O
of O
a O
non-therapeutic O
gel O
, O
followed O
by O
no O
treatment O
. O
[]

The O
purpose O
of O
our O
study O
was O
to O
prospectively O
investigate O
the O
incidence O
of O
esophageal B-outcome ['Physiological-Clinical']
ulcerations I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ESUL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
as O
well O
as O
the O
impact O
of O
energy O
settings O
, O
radiofrequency O
lesion O
sets O
, O
and O
direct O
visualization O
of O
the O
esophagus O
on O
esophageal O
wall O
injury O
. O
['Physiological-Clinical']

Further O
research O
will O
test O
how O
these O
results O
translate O
into O
clinical O
performance O
and O
patient O
outcome O
. O
[]

The O
combination O
of O
50 O
% O
followed O
by O
a O
second O
application O
of O
50 O
% O
produced O
the O
deepest B-outcome ['Physiological-Clinical']
peel I-outcome ['Physiological-Clinical']
, O
with O
necrosis O
into O
the O
papillary O
dermis O
. O
['Physiological-Clinical']

We O
conclude O
that O
prophylactic O
epidural O
blood O
patch O
is O
an O
effective O
method O
to O
reduce O
the O
development O
of O
post-dural O
puncture O
headache O
in O
obstetric O
patients O
. O
[]

We O
concluded O
that O
SSA O
was O
an O
effective O
alternative O
to O
DES O
for O
outpatient O
gynecological O
laparoscopy O
. O
[]

SH B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
increased O
eightfold O
when O
30 O
% O
of O
CGM B-outcome ['Physiological-Clinical']
values O
were O
? O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
need O
for O
assisted B-outcome ['Resource-use']
postoperative I-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
was O
significantly O
higher O
in O
the O
traditional O
group O
( O
33.3 O
% O
vs. O
5.4 O
% O
; O
p O
= O
0.011 O
) O
. O
['Resource-use']

The O
first O
21 O
cases O
of O
this O
cohort O
were O
compared O
in O
a O
randomized O
study O
with O
a O
comparable O
group O
of O
21 O
hydrocephalic O
patients O
who O
received O
a O
conventional O
differential-pressure O
( O
DP- O
) O
valve O
. O
[]

All O
participants O
completed O
a O
22-item O
test O
3 O
weeks O
later O
. O
[]

Twenty O
healthy O
subjects O
participated O
in O
this O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
pupil B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
explanation O
might O
be O
that O
in O
some O
patients O
an O
early O
spread O
of O
tumor O
cells O
has O
occurred O
which O
might O
not O
be O
curable O
by O
surgical O
means O
. O
[]

In O
both O
experiments O
, O
subjects O
were O
divided O
into O
two O
groups O
( O
serial O
CE O
and O
integrated O
CE O
) O
matched O
for O
initial O
physical O
condition O
and O
trained O
in O
a O
vigorous O
3-day O
per O
week O
CE O
program O
of O
9 O
( O
men O
) O
to O
11 O
( O
women O
) O
weeks O
. O
[]

This O
trial O
demonstrated O
short-term O
efficacy O
of O
smokeless B-outcome ['Physiological-Clinical']
tobacco B-outcome ['Physiological-Clinical']
in O
combination O
with O
group O
support O
for O
smoking O
cessation O
but O
no O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
this O
pilot O
study O
, O
the O
administration O
of O
food O
did O
not O
have O
any O
significant O
effect O
on O
the O
antiviral O
activity O
of O
ddI-EC O
capsules O
. O
[]

From O
a O
clinical O
point O
of O
view O
, O
important O
differences O
were O
found O
for O
five O
scales O
: O
two O
functioning O
scales O
( O
social B-outcome ['Life-Impact']
and O
role B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
) O
and O
three O
symptom O
scales O
( O
['Life-Impact', 'Life-Impact']

RESULTS O
Individuals O
receiving O
duloxetine O
as O
their O
initial O
5-week O
treatment O
reported O
a O
mean O
decrease O
in O
average O
pain O
of O
1.06 O
( O
95 O
% O
CI O
, O
0.72-1.40 O
) O
vs O
0.34 O
( O
95 O
% O
CI O
, O
0.01-0.66 O
) O
among O
those O
who O
received O
placebo O
( O
P O
= O
.003 O
; O
effect O
size O
, O
0.513 O
) O
. O
[]

Moreover O
, O
a O
low B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( O
< O
or O
= O
3 O
J O
) O
was O
observed O
in O
61 O
% O
of O
subjects O
in O
the O
lead O
configuration O
but O
in O
only O
36 O
% O
in O
the O
active O
can O
configuration O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Total O
AOFAS B-outcome ['Physiological-Clinical']
Ankle-Hindfoot I-outcome ['Physiological-Clinical']
score O
of O
OA B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Each O
patient O
was O
assigned O
on O
six O
separate O
days O
to O
receive O
one O
of O
the O
following O
drug O
regimens O
in O
random O
order O
: O
A O
. O
[]

PATIENTS O
AND O
METHODS O
A O
multicenter O
, O
randomized O
phase O
II O
trial O
evaluated O
the O
safety O
of O
combining O
bevacizumab O
with O
either O
chemotherapy O
( O
docetaxel O
or O
pemetrexed O
) O
or O
erlotinib O
and O
preliminarily O
assessed O
these O
combinations O
versus O
chemotherapy O
alone O
, O
as O
measured O
by O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

Effect O
of O
testosterone O
and O
a O
nutritional O
supplement O
, O
alone O
and O
in O
combination O
, O
on O
hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
in O
undernourished O
older O
men O
and O
women O
. O
['Resource-use']

CONCLUSIONS O
Transhiatal O
esophagectomy O
is O
a O
safe O
and O
fast O
procedure O
. O
[]

UNLABELLED O
It O
has O
been O
reported O
that O
cytarabine O
, O
acting O
by O
at O
least O
two O
different O
mechanisms O
, O
enhances O
the O
cytotoxic O
effect O
of O
cisplatin O
in O
in O
vitro O
systems O
. O
[]

Progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
also O
significantly O
longer O
for O
patients O
receiving O
marimastat O
compared O
to O
placebo O
( O
P=0.009 O
, O
hazard O
ratio=1.32 O
( O
1.07-1.63 O
) O
) O
. O
['Mortality']

Increased O
appetite B-outcome ['Physiological-Clinical']
and O
weight O
gain O
were O
common O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
examine O
if O
an O
acute O
nicotine O
infusion O
alters O
insulin O
sensitivity O
to O
a O
similar O
degree O
in O
type O
2 O
diabetic O
patients O
as O
in O
healthy O
control O
subjects O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
cysteine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
unchanged O
, O
whereas O
cystine O
concentrations O
increased O
. O
['Physiological-Clinical']

Fifty-six O
patients O
undergoing O
open O
abdominal O
surgery O
, O
at O
high O
risk O
of O
developing O
postoperative O
pulmonary O
complications O
, O
were O
randomised O
before O
operation O
to O
an O
early O
mobilisation-only O
group O
or O
an O
early O
mobilisation-plus-deep O
breathing O
and O
coughing O
group O
. O
[]

Group O
1 O
( O
n O
= O
14 O
) O
received O
the O
placebo O
, O
group O
2 O
( O
n O
= O
15 O
) O
received O
a O
dose O
of O
500 O
mg O
valacyclovir O
once O
daily O
, O
and O
group O
3 O
( O
n O
= O
16 O
) O
received O
a O
dose O
of O
500 O
mg O
valacyclovir O
once O
daily O
and O
350 O
mg O
aspirin O
twice O
daily O
for O
30 O
days O
. O
[]

Gabapentin O
reduced O
the O
need O
for O
additional O
postoperative B-outcome ['Resource-use']
pain I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
( O
PCA O
boluses O
of O
50 O
microg O
of O
fentanyl O
) O
by O
40 O
% O
during O
the O
first O
20 O
postoperative O
hours O
. O
['Resource-use']

To O
investigate O
if O
PSL-LBNP O
tolerance O
, O
heart O
rate O
, O
and O
blood O
pressure O
were O
repeatable O
, O
11 O
subjects O
were O
exposed O
to O
4 O
PSL-LBNP O
tests O
; O
each O
test O
occurring O
at O
the O
same O
time O
of O
day O
, O
separated O
by O
at O
least O
72 O
h O
, O
and O
using O
the O
same O
protocol O
. O
[]

METHOD O
This O
study O
was O
designed O
as O
a O
double-blind O
, O
prospective O
, O
for O
a O
12-week O
period O
. O
[]

HA O
may O
therefore O
be O
a O
useful O
additional O
therapy O
for O
symptomatic O
knee O
osteoarthritis O
and O
may O
have O
a O
long O
duration O
of O
action O
. O
[]

METHODS O
A O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
on O
26 O
asthma O
patients O
who O
randomly O
received O
vaccination O
or O
placebo O
for O
1 O
year O
. O
[]

We O
analyzed O
survival B-outcome ['Mortality']
of O
patients O
in O
the O
original O
trial O
. O
['Mortality']

FINDINGS O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
52.3 O
% O
( O
95 O
% O
CI O
40.4-64.1 O
) O
in O
the O
TH O
group O
and O
37.9 O
% O
( O
26.1-49.6 O
) O
in O
the O
LTA O
group O
. O
['Mortality']

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
link O
between O
work-related O
stress O
and O
early O
atherosclerosis O
as O
measured O
by O
common O
carotid O
artery O
intima-media O
thickness O
and O
focal O
lesions O
in O
the O
common O
carotid O
artery O
and O
bifurcation O
. O
[]

Surgery O
was O
always O
planned O
on O
treatment O
day O
3 O
. O
[]

We O
performed O
a O
prospective O
randomised O
controlled O
trial O
of O
the O
A-V O
Impulse O
System O
in O
82 O
patients O
treated O
by O
hemiarthroplasty O
for O
subcapital O
fracture O
of O
the O
femoral O
neck O
. O
[]

RESULTS O
Lowest O
pain B-outcome ['Physiological-Clinical']
scores O
were O
observed O
with O
the O
addition O
of O
midazolam O
to O
caudal O
bupivacaine O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

In O
the O
present O
study O
, O
we O
investigated O
mind O
reading O
abilities O
in O
a O
group O
of O
adults O
with O
Asperger O
Syndrome O
( O
AS O
) O
by O
using O
the O
faux O
pas O
task O
, O
an O
advanced O
test O
of O
theory O
of O
mind O
( O
Baron-Cohen O
et O
al O
. O
( O
[]

To O
assess O
whether O
lipid-lowering O
therapy O
and O
CCB O
treatment O
may O
have O
an O
additive O
or O
synergistic O
beneficial O
effect O
on O
human O
atherosclerosis B-outcome ['Physiological-Clinical']
, O
which O
is O
conceivable O
because O
their O
anti-atherosclerotic O
properties O
differ O
, O
data O
from O
the O
angiographic O
lipid-lowering O
trial O
REGRESS O
( O
pravastatin O
vs. O
placebo O
) O
were O
reviewed O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Twenty O
anemic O
sideropenic O
patients O
( O
hemoglobin O
< O
/=110 O
g/l O
; O
serum O
iron O
< O
600 O
microg/l O
) O
with O
cancer O
of O
the O
gastrointestinal O
tract O
were O
randomly O
allocated O
to O
two O
groups O
: O
the O
first O
( O
n O
= O
10 O
) O
received O
400 O
U/kg O
of O
r-Hu O
EPO O
divided O
in O
4 O
doses O
( O
100 O
U/kg O
each O
, O
every O
4 O
days O
) O
; O
the O
second O
( O
n O
= O
10 O
) O
received O
200 O
U/kg O
of O
r-HuEPO O
( O
50 O
U/kg O
each O
, O
every O
4 O
days O
) O
. O
[]

OBJECTIVE O
To O
examine O
the O
psychometric O
properties O
of O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
( O
CYBOCS O
) O
modified O
for O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

OBJECTIVE O
To O
study O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
laparoscopic O
surgery O
in O
combination O
of O
Quyu O
Jiedu O
Recipe O
( O
QYJDR O
) O
on O
endometriosis O
( O
EMs O
) O
-related O
infertility O
patients O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
use O
of O
distraction O
techniques O
is O
effective O
in O
reducing O
situational O
anxiety O
in O
older O
children O
and O
lowering O
parental O
perception O
of O
pain O
distress O
in O
younger O
children O
. O
[]

CONCLUSIONS O
Flow O
cytometry O
and O
magnetic O
bead O
isolation O
can O
be O
used O
to O
identify O
changes O
in O
numbers O
of O
circulating O
tumour O
cells O
in O
patients O
undergoing O
chemotherapy O
for O
SCLC O
and O
thereafter O
during O
follow-up O
periods O
. O
[]

AIM O
To O
measure O
the O
variations B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
delivered I-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
minute I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inspiratory I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
during O
a O
3-min O
period O
of O
mask O
ventilation O
comparing O
VDMV O
with O
three O
commonly O
used O
hand-delivered O
methods O
of O
bag O
and O
mask O
ventilation O
: O
Laerdal O
self-inflating O
bag O
( O
SIB O
) O
; O
anaesthetic O
bag O
and O
T-piece O
Neopuff O
. O
['Physiological-Clinical']

The O
plasma B-outcome ['Physiological-Clinical']
PLP I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
in O
maternal B-outcome ['Physiological-Clinical']
and O
cord B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
were O
highly O
correlated O
and O
indicated O
a O
dependence O
of O
fetal O
vitamin O
B6 O
nutrition O
on O
maternal O
circulating O
PLP O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

International O
prostate O
symptom O
scores O
( O
I-PSS O
) O
, O
uroflowmetry B-outcome ['Physiological-Clinical']
, O
measurement O
of O
residual O
urine B-outcome ['Physiological-Clinical']
amount I-outcome ['Physiological-Clinical']
and O
ultrasonography B-outcome ['Resource-use']
were O
performed O
for O
each O
patient O
both O
preoperatively O
and O
postoperatively O
( O
first O
month O
and O
first O
year O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

If O
the O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
exceeded O
25 O
cmH2O O
, O
it O
was O
manually O
released O
to O
20 O
cmH2O O
. O
['Physiological-Clinical']

The O
right O
adrenalectomy O
mean O
operative O
time O
( O
OpT O
) O
was O
51.8 O
mins O
( O
range O
40-90 O
mins O
) O
and O
68.6 O
mins O
( O
range O
50-130 O
mins O
) O
in O
group O
A O
and O
B O
, O
respectively O
( O
P O
not O
significant O
) O
. O
[]

During O
dietary O
treatment O
the O
relative O
content B-outcome ['Physiological-Clinical']
of O
saturated O
and O
monounsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
secreased O
and O
the O
polyunsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
increased O
with O
an O
increasing O
ratio O
between O
pulyunsaturated B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
saturated I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
( O
P/S B-outcome ['Physiological-Clinical']
ratio O
) O
in O
the O
cholesterol O
esters O
and O
triglycerides O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

plus O
tobramycin O
3 O
mg/kg O
per O
day O
( O
1.5 O
mg/kg O
b.i.d O
. O
) O
, O
[]

RESULTS O
Retention B-outcome ['Physiological-Clinical']
rates O
at O
1 O
year O
were O
similar O
for O
the O
lumiracoxib O
100 O
mg O
o.d. O
, O
lumiracoxib O
100 O
mg O
b.i.d O
. O
['Physiological-Clinical']

Hb B-outcome ['Physiological-Clinical']
, O
Hct B-outcome ['Physiological-Clinical']
, O
FEP B-outcome ['Physiological-Clinical']
, O
and O
ferritin B-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
with O
the O
exception O
of O
lower O
ferritin O
values O
at O
age O
365 O
d O
( O
p O
less O
than O
0.05 O
) O
in O
the O
group O
fed O
the O
nonfortified O
formula O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Convergent O
evidence O
from O
different O
assessments O
and O
raters O
confirms O
methylphenidate O
's O
efficacy O
in O
relieving O
ADHD B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
some O
children O
with O
PDD O
. O
['Life-Impact']

SETTING O
National O
Survey O
for O
Children O
's O
Health O
2003-2004 O
telephone O
interview O
. O
[]

0.002 O
) O
. O
[]

Patient O
and O
hematologic O
factors O
potentially O
associated O
with O
NC O
were O
evaluated O
. O
[]

MATERIAL O
AND O
METHODS O
In O
the O
first O
screening O
round O
, O
a O
total O
of O
56,294 O
men O
aged O
55-74 O
years O
were O
screened O
with O
serum O
prostate O
specific O
antigen O
( O
PSA O
) O
in O
five O
countries O
of O
the O
European O
Randomised O
Study O
of O
Screening O
for O
Prostate O
Cancer O
( O
ERSPC O
) O
with O
an O
overall O
detection O
rate O
( O
prevalence O
) O
of O
2.8 O
% O
( O
1972 O
prostate O
cancers O
) O
. O
[]

At O
both O
follow-ups O
, O
the O
intervention O
group O
showed O
within-group O
improvement O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
( O
P O
< O
0.02 O
; O
P O
< O
0.01 O
) O
and O
exercise B-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
( O
P O
< O
0.001 O
; O
P O
< O
0.001 O
) O
with O
differences O
in O
exercise B-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
favoring O
the O
intervention O
group O
( O
P O
< O
0.01 O
) O
at O
T O
( O
2 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

In O
about O
50 O
% O
of O
primarily O
inoperable O
stage O
3 O
ovarian O
cancers O
, O
the O
random O
treatment O
with O
cyclophosphamide O
( O
Endoxan O
) O
results O
in O
a O
clinical B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
LY450139 I-outcome ['Physiological-Clinical']
, O
Abeta B-outcome ['Physiological-Clinical']
( O
1-40 O
) O
and O
Abeta B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1-X I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Abeta I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
total O
) O
) O
were O
determined O
, O
and O
safety O
and O
tolerability O
were O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Targeting O
to O
remission O
with O
tight O
clinical O
controls O
results O
in O
low O
radiologic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
most O
RA O
patients O
. O
['Physiological-Clinical']

All O
pretreatment O
drugs O
were O
made O
in O
2 O
mL O
and O
were O
accompanied O
by O
manual O
venous O
occlusion O
for O
1 O
min O
. O
[]

Dose O
conformity O
requirements O
were O
then O
formulated O
based O
on O
these O
results O
. O
[]

Combination O
cyclopentolate O
and O
phenylephrine O
for O
mydriasis O
in O
premature O
infants O
with O
heavily O
pigmented O
irides O
. O
[]

Prospective O
randomised O
study O
of O
double O
hemi-body O
irradiation O
with O
and O
without O
subsequent O
maintenance O
recombinant O
alpha O
2b O
interferon O
on O
survival B-outcome ['Mortality']
in O
patients O
with O
relapsed O
multiple O
myeloma O
. O
['Mortality']

Baseline O
microalbuminuria O
predicted O
subsequent O
clinical B-outcome ['Physiological-Clinical']
proteinuria I-outcome ['Physiological-Clinical']
for O
the O
study O
participants O
overall O
( O
adjusted O
odds O
ratio O
[ O
OR O
] O
, O
17.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
12.6 O
to O
24.4 O
) O
, O
in O
participants O
without O
diabetes O
( O
OR O
, O
16.7 O
; O
95 O
% O
CI O
, O
8.6 O
to O
32.4 O
) O
, O
and O
in O
participants O
with O
diabetes O
( O
OR O
, O
18.2 O
; O
95 O
% O
CI O
, O
12.4 O
to O
26.7 O
) O
. O
['Physiological-Clinical']

The O
present O
study O
enrolled O
70 O
NHL O
patients O
who O
received O
either O
chlorambucil O
( O
CB O
; O
10 O
mg/day O
) O
or O
CB O
plus O
interferon O
alfa-2b O
( O
5 O
million O
units O
( O
MU O
) O
/m2 O
subcutaneously O
three O
times O
a O
week O
) O
. O
[]

Furthermore O
, O
multilevel O
analyses O
showed O
significant O
increases O
in O
joint B-outcome ['Physiological-Clinical']
attention B-outcome ['Life-Impact']
and O
symbolic B-outcome ['Physiological-Clinical']
play B-outcome ['Life-Impact']
skills B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
I O
group O
was O
divided O
into O
subgroups O
based O
on O
baseline O
behaviour O
and O
risk O
factor O
status O
. O
[]

A O
randomized O
trial O
. O
[]

Both O
active O
treatments O
were O
also O
associated O
with O
reduced O
weekly O
episodes B-outcome ['Physiological-Clinical']
of O
urticaria B-outcome ['Physiological-Clinical']
compared O
with O
placebo O
, O
which O
was O
significant O
after O
2 O
weeks O
' O
treatment O
( O
mizolastine O
: O
7.9 O
episodes O
, O
P O
= O
0.0061 O
; O
loratadine O
: O
8.3 O
, O
P O
= O
0.0221 O
; O
placebo O
: O
13.3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Chemotherapy O
was O
given O
before O
surgery O
in O
3 O
% O
of O
patients O
whilst O
97 O
% O
received O
adjuvant O
chemotherapy O
. O
[]

The O
mean O
satisfaction O
grading O
was O
9.2 O
on O
a O
visual O
analogue O
scale O
in O
the O
treatment O
group O
compared O
to O
8.1 O
in O
controls O
( O
p=0.004 O
) O
. O
[]

A O
randomized O
trial O
of O
chiropractic O
and O
medical O
care O
for O
patients O
with O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
: O
eighteen-month O
follow-up O
outcomes O
from O
the O
UCLA O
low O
back O
pain O
study O
. O
['Physiological-Clinical']

This O
study O
was O
specific O
for O
a O
patient O
group O
receiving O
prolonged O
courses O
of O
i.v O
. O
[]

After O
12 O
months O
, O
a O
significant O
reduction O
in O
HbA1c B-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
nateglinide O
group O
, O
whereas O
a O
significant O
increase O
of O
HbA1c B-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
untreated O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
respect O
of O
reactivity O
, O
reactance O
also O
had O
the O
highest O
values O
. O
[]

More O
risperidone-treated O
subjects O
( O
87 O
% O
) O
showed O
global O
improvement O
in O
their O
condition O
compared O
with O
the O
placebo O
group O
( O
40 O
% O
) O
. O
[]

Placebo O
and O
control O
groups O
were O
statistically O
similar O
on O
all O
measures O
. O
[]

Factor O
analysis O
confirmed O
the O
original O
domain O
structure O
of O
the O
CRQ O
but O
not O
of O
the O
SGRQ O
. O
[]

Is O
EEG-biofeedback O
an O
effective O
treatment O
in O
autism O
spectrum O
disorders O
? O
[]

4 O
. O
[]

The O
aim O
of O
this O
clinical O
study O
was O
to O
investigate O
the O
acid B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
enamel O
lesions O
remineralized O
in O
situ O
by O
a O
sugar-free O
chewing O
gum O
containing O
casein O
phosphopeptide-amorphous O
calcium O
phosphate O
nanocomplexes O
( O
CPP-ACP O
: O
Recaldent O
) O
. O
['Physiological-Clinical']

No O
overall O
trend O
for O
lower O
RU B-outcome ['Physiological-Clinical']
was O
associated O
with O
sibenadet O
therapy O
, O
which O
correlates O
with O
the O
lack O
of O
sustained O
clinical O
effect O
seen O
in O
studies O
conducted O
concurrently O
. O
['Physiological-Clinical']

The O
extent O
of O
defects B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
MCE I-outcome ['Physiological-Clinical']
was O
less O
than O
the O
extent O
of O
either O
abnormal O
wall O
motion O
or O
SPECT O
abnormalities O
. O
['Physiological-Clinical']

The O
TOM O
test O
: O
a O
new O
instrument O
for O
assessing O
theory O
of O
mind O
in O
normal O
children O
and O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

For O
six O
months O
36 O
U O
factor O
VIII O
concentrates O
per O
kg O
bodyweight O
and O
week O
were O
administered O
to O
six O
out-patients O
with O
severe O
haemophilia O
A O
. O
[]

CONCLUSIONS O
A O
surrogate O
PD O
model O
to O
assess O
retinoid B-outcome ['Physiological-Clinical']
bioequivalence I-outcome ['Physiological-Clinical']
has O
been O
developed O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
A O
randomized O
, O
controlled O
trial O
in O
the O
setting O
of O
a O
neurotological O
clinic O
in O
Thailand O
. O
[]

Antihypertensive B-outcome ['Resource-use']
effect O
of O
single O
doses O
of O
enalapril O
in O
hypertensive O
patients O
treated O
with O
bendrofluazide O
. O
['Resource-use']

In O
this O
study O
, O
we O
examine O
the O
efficacy O
of O
targeted O
interventions O
of O
joint O
attention O
and O
symbolic O
play O
. O
[]

RESULTS O
Thirty O
patients O
were O
randomized O
and O
followed O
up O
for O
six O
weeks O
. O
[]

More O
sophisticated O
methods O
of O
acquisition O
and O
interpretation O
are O
needed O
to O
enhance O
the O
feasibility O
of O
this O
technique O
in O
routine O
practice O
. O
[]

This O
tendency O
was O
also O
supported O
by O
moderate O
effect O
sizes O
and O
qualitative O
indications O
of O
likely O
harmful O
or O
detrimental O
effects O
associated O
with O
RSA-SS O
. O
[]

RESULTS O
The O
administration O
of O
ginseng O
extract O
resulted O
in O
a O
significant O
improvement O
of O
fertility B-outcome ['Physiological-Clinical']
parameters O
and O
testicular B-outcome ['Physiological-Clinical']
antioxidants I-outcome ['Physiological-Clinical']
together O
with O
a O
decrease O
in O
malondialdehyde B-outcome ['Physiological-Clinical']
and O
testicular B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
was O
generally O
the O
strongest O
single O
predictor O
. O
['Physiological-Clinical']

The O
overall O
clinical O
response O
rates O
( O
complete O
response O
plus O
partial O
response O
) O
were O
52 O
and O
63 O
% O
for O
CP O
and O
cisplatin O
, O
respectively O
( O
non-significant O
) O
. O
[]

AN O
subjects O
receiving O
aripiprazole O
had O
a O
larger O
change O
in O
weight O
from O
baseline O
to O
endpoint O
compared O
with O
those O
receiving O
placebo O
( O
1.9 O
vs. O
0.7 O
kg O
; O
treatment O
difference O
1.2 O
kg O
, O
95 O
% O
CI O
: O
0.5 O
, O
1.9 O
) O
than O
PAE O
subjects O
receiving O
aripiprazole O
compared O
with O
subjects O
receiving O
placebo O
( O
0.4 O
vs. O
-0.4 O
kg O
; O
treatment O
difference O
0.9 O
kg O
, O
95 O
% O
CI O
: O
-0.6 O
, O
2.4 O
) O
. O
[]

Moreover O
, O
the O
placebo-treated O
patients O
showed O
more O
improvement O
than O
the O
griseofulvin-treated O
patients O
. O
[]

The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
was O
17 O
% O
( O
5/30 O
) O
in O
the O
no-closure O
group O
, O
which O
was O
lower O
than O
that O
in O
the O
closure O
group O
( O
42 O
% O
, O
13/31 O
) O
, O
but O
not O
significantly O
so O
( O
P O
< O
0.1 O
) O
. O
['Physiological-Clinical']

Many O
etiologic O
factors O
cause O
a O
femoral O
head O
necrosis O
such O
as O
, O
for O
example O
, O
high-dose O
steroids O
, O
abuse O
of O
alcohol O
, O
defect O
of O
bone O
marrow O
and O
trauma O
of O
the O
hip O
. O
[]

Spearman O
's O
correlation O
coefficient O
between O
the O
satisfaction B-outcome ['Life-Impact']
questionnaire O
score O
and O
VAS O
score O
was O
0.58 O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact']

The O
intervention O
effect O
was O
greater O
among O
Medicaid-insured O
children O
and O
for O
broad-spectrum O
agents O
. O
[]

In O
HAL O
group O
, O
the O
effective O
rate O
was O
only O
5 O
% O
, O
the O
mean O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
was O
5.1 O
months O
, O
6 O
months O
survival B-outcome ['Mortality']
rate O
was O
35.8 O
% O
. O
['Mortality', 'Mortality']

Minimally O
invasive O
compared O
with O
traditional O
transgluteal O
approach O
for O
total O
hip O
arthroplasty O
: O
a O
comparative O
gait O
analysis O
. O
[]

Pre-operative O
radiochemotherapy O
for O
rectal O
cancer O
. O
[]

Selamectin O
also O
was O
100 O
% O
effective O
in O
preventing O
the O
development O
of O
canine O
heartworms O
and O
was O
safe O
for O
topical O
use O
in O
dogs O
and O
cats O
. O
[]

IMPLICATIONS O
FOR O
NURSING O
These O
data O
support O
the O
value-added O
role O
of O
nursing O
interventions O
for O
symptom O
management O
and O
improved O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
during O
the O
course O
of O
cancer O
treatment O
. O
['Life-Impact']

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
) O
; O
secondary O
end O
points O
included O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
an O
ECP O
for O
stroke O
patients O
in O
Latium O
( O
Italy O
) O
emergency O
system O
. O
[]

By O
week O
10 O
, O
patients O
in O
the O
celecoxib O
group O
showed O
significantly O
greater O
improvement O
in O
the O
Irritability O
( O
P O
< O
0.001 O
) O
, O
Lethargy/Social O
Withdrawal O
( O
P O
< O
0.001 O
) O
, O
and O
Stereotypic O
Behavior O
( O
P O
< O
0.00 O
) O
but O
not O
in O
Hyperactivity/Noncompliance O
( O
P O
= O
0.202 O
) O
and O
Inappropriate O
Speech O
( O
P O
= O
0.802 O
) O
subscales O
than O
the O
placebo O
group O
. O
[]

Although O
no O
statistical O
significance O
was O
achieved O
, O
it O
is O
remarkable O
that O
there O
was O
a O
clear O
trend O
for O
the O
superiority O
of O
Galphimia B-outcome ['Physiological-Clinical']
D6 I-outcome ['Physiological-Clinical']
while O
the O
Galphimia O
dilution O
10 O
( O
-6 O
) O
was O
about O
equally O
effective O
compared O
with O
placebo O
. O
['Physiological-Clinical']

Participants O
responded O
to O
the O
presence O
of O
a O
green O
K O
in O
an O
array O
of O
two O
, O
five O
, O
or O
nine O
distractor O
stimuli O
during O
a O
40-min O
vigil O
. O
[]

CONCLUSION O
These O
results O
suggest O
that O
an O
acute O
bout O
( O
4 O
min O
) O
of O
static O
stretching O
of O
the O
lower O
limbs O
during O
recovery O
periods O
between O
efforts O
may O
compromise O
RSA B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
but O
has O
less O
effect O
on O
CODS O
performance O
. O
['Physiological-Clinical']

An O
attempt O
was O
made O
to O
contact O
all O
patients O
at O
10 O
years O
to O
determine O
whether O
they O
had O
had O
a O
subsequent O
appendicectomy O
, O
or O
had O
been O
diagnosed O
with O
another O
abdominal O
condition O
that O
might O
be O
relevant O
to O
the O
initial O
presentation O
in O
1991-1992 O
. O
[]

Reducing O
sodium O
intake O
in O
the O
control O
diet O
group O
increased O
BP B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
2.3-fold O
( O
74 O
% O
vs. O
32 O
% O
; O
95 O
% O
confidence O
interval O
, O
1.7-3.2 O
) O
. O
['Physiological-Clinical']

A O
comparable O
decrease O
in O
colloid B-outcome ['Physiological-Clinical']
oncotic I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
in O
plasma B-outcome ['Physiological-Clinical']
albumin O
concentration O
was O
observed O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
dose-dependent O
decrease O
in O
ambulatory B-outcome ['Physiological-Clinical']
daytime I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
BP B-outcome ['Physiological-Clinical']
with O
the O
progestogen O
treatments O
compared O
with O
placebo O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pretreatment O
and O
month O
6 O
plasma O
specimens O
were O
designated O
EBV O
( O
- O
) O
or O
EBV O
( O
+ O
) O
by O
this O
cutoff O
. O
[]

In O
spite O
of O
the O
ability O
to O
tell O
whether O
a O
subject O
has O
normal O
or O
abnormal O
values O
, O
because O
of O
the O
lack O
of O
prospective O
mortality/morbidity O
data O
, O
home O
blood O
pressure O
monitoring O
can O
not O
be O
used O
to O
decide O
whether O
treatment O
is O
indicated O
. O
[]

RESULTS O
353 O
children O
with O
positive O
throat O
swabs O
for O
GABHS O
were O
randomised O
to O
amoxicillin O
( O
n O
= O
177 O
) O
or O
penicillin O
V O
( O
n O
= O
176 O
) O
. O
[]

Each O
primary O
endpoint O
utilizes O
a O
0-100 O
mm O
visual O
analog O
scale O
. O
[]

Since O
January O
1974 O
, O
95 O
patients O
with O
anterior O
tongue O
and O
floor O
of O
the O
mouth O
cancers O
were O
included O
in O
a O
randomized O
trial O
. O
[]

Subjects O
were O
then O
exposed O
to O
0.4 O
ppm O
O O
( O
3 O
) O
for O
2 O
h O
and O
underwent O
a O
second O
BAL O
. O
[]

CONCLUSIONS O
Data O
from O
this O
pilot O
investigation O
support O
the O
potential O
usefulness O
of O
NAC O
for O
treating O
irritability O
in O
children O
with O
autistic O
disorder O
. O
[]

This O
therapy O
may O
offer O
a O
novel O
adjunct O
treatment O
for O
patients O
presenting O
with O
ACS O
. O
[]

Secondary O
outcomes O
included O
microbiologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
follow-up O
, O
safety O
, O
and O
compliance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

The O
combined O
effects O
of O
these O
probiotic O
strains O
will O
guide O
infants O
through O
the O
weaning O
period O
, O
when O
sensitization O
to O
newly O
encountered O
antigens O
is O
initiated O
. O
[]

Twelve O
healthy O
volunteers O
( O
25.2 O
? O
[]

Before O
and O
after O
treatment O
, O
respiratory B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
forced I-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
s I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FEV I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
shuttle I-outcome ['Physiological-Clinical']
walking I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
distance O
and O
St. O
George O
's O
Respiratory B-outcome ['Physiological-Clinical']
Questionnaire O
scores O
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Objective O
response O
rates O
, O
time O
to O
progression B-outcome ['Physiological-Clinical']
, O
survival B-outcome ['Mortality']
and O
safety O
of O
the O
two O
regimens O
were O
compared O
. O
['Physiological-Clinical', 'Mortality']

OBJECTIVE O
To O
investigate O
the O
safety O
and O
tolerance B-outcome ['Life-Impact']
of O
adjuvant O
dose-dense O
chemotherapy O
with O
paclitaxel O
and O
epirubicin O
for O
high-risk O
breast O
cancer O
. O
['Life-Impact']

TRIAL O
REGISTRATION O
ClinicalTrials O
identifier O
: O
NCT01195025 O
. O
[]

Data O
were O
analyzed O
by O
using O
two-sample O
t O
tests O
, O
chi-square O
methods O
, O
and O
Fisher O
's O
exact O
test O
. O
[]

The O
method O
described O
here O
has O
proven O
to O
be O
sensitive O
enough O
to O
detect O
clinically O
relevant O
interactions O
with O
muscle B-outcome ['Resource-use']
relaxants I-outcome ['Resource-use']
. O
['Resource-use']

During O
surgery O
, O
fluid O
boluses O
of O
Voluven O
were O
given O
if O
the O
stroke O
volume O
variation O
was O
> O
10 O
% O
. O
[]

Direct O
renin O
inhibition O
offers O
a O
means O
for O
blocking O
the O
RAAS O
. O
[]

Calcium O
and O
fibre O
supplementation O
in O
prevention O
of O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
: O
a O
randomised O
intervention O
trial O
. O
['Physiological-Clinical']

We O
report O
week O
96 O
results O
from O
a O
phase O
3 O
trial O
of O
elvitegravir/cobicistat/emtricitabine/tenofovir O
disoproxil O
fumarate O
( O
EVG/COBI/FTC/TDF O
, O
n O
= O
348 O
) O
vs O
efavirenz/emtricitabine/tenofovir O
disoproxil O
fumarate O
( O
EFV/FTC/TDF O
, O
n O
= O
352 O
) O
. O
[]

BACKGROUND O
It O
has O
been O
claimed O
that O
patients O
with O
sick O
sinus O
syndrome O
have O
an O
increased O
risk O
of O
developing O
AV B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
, O
but O
this O
has O
never O
been O
assessed O
prospectively O
. O
['Physiological-Clinical']

BACKGROUND O
The O
degree O
to O
which O
human O
immunodeficiency O
virus O
( O
HIV O
) O
continues O
to O
replicate O
during O
antiretroviral O
therapy O
( O
ART O
) O
is O
controversial O
. O
[]

Tailoring O
was O
based O
on O
smoking-related O
beliefs O
, O
personal O
characteristics O
and O
smoking O
patterns O
, O
self-efficacy O
and O
outcome O
expectations O
. O
[]

MATERIALS O
AND O
METHODS O
One O
hundred O
and O
six O
consecutive O
patients O
with O
ureteric O
calculi O
at O
different O
levels O
were O
treated O
by O
ESWL O
using O
Siemens O
Lithostar O
2 O
machine O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
or O
presumed B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
was O
detected O
for O
97.3 O
% O
and O
96.3 O
% O
of O
S. O
pneumoniae O
, O
85.0 O
% O
and O
90.5 O
% O
of O
H. O
influenzae O
, O
88.9 O
% O
and O
90.9 O
% O
of O
S. O
aureus O
and O
100.0 O
% O
and O
83.3 O
% O
of O
M. O
catarrhalis O
in O
faropenem O
daloxate O
and O
cefuroxime O
axetil O
recipients O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Meta-analysis O
of O
randomized O
controlled O
trials O
. O
[]

Comparative O
dose O
efficacy O
study O
of O
atorvastatin O
versus O
simvastatin O
, O
pravastatin O
, O
lovastatin O
, O
and O
fluvastatin O
in O
patients O
with O
hypercholesterolemia O
( O
the O
CURVES O
study O
) O
The O
objective O
of O
this O
multicenter O
, O
randomized O
, O
open-label O
, O
parallel-group O
, O
8-week O
study O
was O
to O
evaluate O
the O
comparative O
dose O
efficacy O
of O
the O
3-hydroxy-3-methylglutaryl O
coenzyme O
A O
( O
HMG-CoA O
) O
reductase O
inhibitor O
atorvastatin O
10 O
, O
20 O
, O
40 O
, O
and O
80 O
mg O
compared O
with O
simvastatin O
10 O
, O
20 O
, O
and O
40 O
mg O
, O
pravastatin O
10 O
, O
20 O
, O
and O
40 O
mg O
, O
lovastatin O
20 O
, O
40 O
, O
and O
80 O
mg O
, O
and O
fluvastatin O
20 O
and O
40 O
mg. O
Investigators O
enrolled O
534 O
hypercholesterolemic O
patients O
( O
low-density O
lipoprotein O
[ O
LDL O
] O
cholesterol O
> O
or O
= O
160 O
mg/dl O
[ O
4.2 O
mmol/L O
] O
and O
triglycerides O
< O
or O
= O
400 O
mg/dl O
[ O
4.5 O
mmol/L O
] O
) O
. O
[]

OBJECTIVES O
We O
examined O
whether O
tomato O
paste O
-- O
rich O
in O
lycopene O
, O
a O
powerful O
antioxidant O
-- O
can O
protect O
human O
skin O
against O
UVR-induced O
effects O
partially O
mediated O
by O
oxidative O
stress O
, O
i.e O
. O
[]

No O
associated O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

METHODS O
Patients O
with O
cystic O
fibrosis O
receiving O
intermittent O
i.v O
. O
[]

METHODS O
Transthoracic O
contrast O
examinations O
were O
performed O
in O
a O
randomly O
selected O
group O
of O
70 O
patients O
( O
without O
previous O
history O
of O
cerebral O
or O
systemic O
embolus O
) O
undergoing O
cardiac O
catheterization O
. O
[]

kg O
( O
-1 O
) O
? O
[]

OBJECTIVES O
To O
determine O
the O
effectiveness O
of O
around-the-clock O
( O
ATC O
) O
analgesic O
administration O
, O
with O
or O
without O
nurse O
coaching O
, O
compared O
with O
standard O
care O
with O
as O
needed O
( O
PRN O
) O
dosing O
in O
children O
undergoing O
outpatient O
tonsillectomy O
. O
[]

Active O
symptom O
control O
with O
or O
without O
chemotherapy O
in O
the O
treatment O
of O
patients O
with O
malignant O
pleural O
mesothelioma O
( O
MS01 O
) O
: O
a O
multicentre O
randomised O
trial O
. O
[]

Reperfusion B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
, O
CK B-outcome ['Physiological-Clinical']
and O
CKMB B-outcome ['Physiological-Clinical']
, O
corrected O
TIMI O
frame O
count O
( O
CTFC B-outcome ['Physiological-Clinical']
) O
, O
wall B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
score O
index O
( O
WMSI O
) O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
by O
echocardiography O
were O
compared O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
With O
a O
mean O
follow-up O
of O
3.3 O
years O
, O
the O
primary O
outcome O
occurred O
in O
320 O
of O
1722 O
patients O
in O
the O
spironolactone O
group O
( O
18.6 O
% O
) O
and O
351 O
of O
1723 O
patients O
in O
the O
placebo O
group O
( O
20.4 O
% O
) O
( O
hazard O
ratio O
, O
0.89 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.77 O
to O
1.04 O
; O
P=0.14 O
) O
. O
[]

This O
study O
demonstrates O
for O
the O
first O
time O
that O
the O
efficiency O
of O
TIL O
in O
stage O
III O
melanoma O
( O
AJCC O
) O
is O
directly O
related O
to O
the O
number O
of O
invaded O
lymph O
nodes O
, O
indicating O
that O
tumor O
burden O
might O
be O
a O
crucial O
factor O
in O
the O
efficacy O
and/or O
in O
vitro O
expansion O
of O
T O
cells O
specific O
for O
autologous O
tumor O
antigen O
, O
a O
finding O
which O
could O
be O
of O
value O
in O
future O
vaccine O
development O
for O
the O
treatment O
of O
melanoma O
. O
[]

[ O
Effect O
of O
treatment O
of O
non-nephrotic O
syndrome O
IgA O
nephropathy O
with O
Shenyanning O
] O
. O
[]

CONCLUSIONS O
The O
Er O
, O
Cr O
: O
YSGG O
laser O
system O
is O
effective O
for O
preparation O
of O
Class O
I O
, O
III O
and O
V O
cavities O
and O
resin O
restorations O
are O
retained O
by O
lased O
tooth O
surfaces O
. O
[]

RESULTS O
No O
significant O
difference O
in O
the O
average O
time B-outcome ['Life-Impact']
spent I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
operating I-outcome ['Life-Impact']
room I-outcome ['Life-Impact']
or O
in O
the O
total O
irrigation B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
used O
between O
the O
two O
groups O
was O
observed O
. O
['Life-Impact', 'Physiological-Clinical']

Each O
subject O
received O
a O
single O
oral O
dose O
( O
650 O
mg O
) O
of O
enteric-coated O
ASA O
( O
ecASA O
) O
and O
compressed O
ASA O
tablets O
( O
cASA O
) O
, O
or O
ecASA O
and O
sodium O
salicylate O
( O
578 O
mg O
) O
separated O
by O
a O
minimum O
of O
5 O
weeks O
. O
[]

At O
the O
start O
and O
finish O
of O
each O
14-day O
period O
, O
fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
levels O
were O
estimated O
and O
oral O
status O
assessed O
by O
a O
plaque B-outcome ['Physiological-Clinical']
index O
( O
P1I B-outcome ['Physiological-Clinical']
) O
, O
a O
gingival B-outcome ['Physiological-Clinical']
index O
( O
GI B-outcome ['Physiological-Clinical']
) O
, O
and O
gingival B-outcome ['Physiological-Clinical']
exudate I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
meter O
( O
GEF B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Administration O
of O
relatively O
low O
pharmacological O
doses O
of O
prednisone O
for O
one O
week O
impaired O
insulin O
sensitivity O
in O
a O
dose-dependent O
manner O
in O
healthy O
males O
. O
[]

METHODS/DESIGN O
Phase O
III O
comprises O
a O
pragmatic O
, O
fast-track O
, O
single-blind O
randomised O
controlled O
trial O
of O
BIS O
versus O
standard O
care O
. O
[]

RESULTS O
A O
high O
rate O
of O
virologic B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
was O
sustained O
with O
both O
regimens O
throughout O
the O
trial O
. O
['Physiological-Clinical']

Fifty-four O
percent O
of O
the O
participants O
significantly O
reduced O
delta O
and/or O
theta O
power O
during O
EEG-biofeedback O
sessions O
and O
were O
identified O
as O
EEG-regulators O
. O
[]

Fadrozole O
HCL O
( O
CGS-16949A O
) O
versus O
megestrol O
acetate O
treatment O
of O
postmenopausal O
patients O
with O
metastatic O
breast O
carcinoma O
: O
results O
of O
two O
randomized O
double O
blind O
controlled O
multiinstitutional O
trials O
. O
[]

Declamping O
caused O
a O
more O
marked B-outcome ['Physiological-Clinical']
increase O
of O
paCO2 B-outcome ['Physiological-Clinical']
and O
a O
greater O
fall O
of O
pH B-outcome ['Physiological-Clinical']
in O
the O
NA O
group O
as O
compared O
to O
the O
epidural O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
each O
patient O
, O
one O
PCC O
was O
randomly O
assigned O
to O
insertion O
with O
RXU O
, O
the O
second O
PCC O
was O
assigned O
to O
insertion O
with O
RXU+E O
. O
[]

The O
other O
three O
discharge O
screens O
examined-abnormal O
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
, O
IV O
fluids B-outcome ['Physiological-Clinical']
or O
drugs B-outcome ['Resource-use']
, O
and O
wound B-outcome ['Resource-use']
drainage I-outcome ['Resource-use']
before O
discharge-were O
unrelated O
to O
postdischarge O
adverse O
outcomes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

For O
the O
topotecan O
group O
, O
median O
time O
to O
progression B-outcome ['Physiological-Clinical']
was O
18.9 O
weeks O
( O
range O
< O
1 O
to O
92.6+ O
weeks O
; O
25 O
% O
censored O
) O
, O
and O
, O
for O
paclitaxel O
, O
14.7 O
weeks O
( O
range O
< O
1 O
to O
137.3+ O
weeks O
; O
12.3 O
% O
censored O
) O
; O
P O
= O
0.076 O
. O
['Physiological-Clinical']

The O
F-box O
protein O
S-phase O
kinase-associated O
protein O
2 O
( O
Skp2 O
) O
positively O
regulates O
the O
G1-S O
transition O
by O
controlling O
the O
stability O
of O
several O
G1 O
regulators O
, O
such O
as O
the O
cell O
cycle O
inhibitor O
p27kip1 O
. O
[]

Methotrimeprazine O
7.5 O
mg O
i.m O
. O
[]

Interfering O
with O
the O
central O
executive O
by O
means O
of O
a O
random O
interval O
repetition O
task O
. O
[]

None O
of O
the O
patients O
treated O
with O
prednisone O
therapy O
responded O
completely O
but O
only O
two O
had O
a O
partial O
and O
two O
a O
minor O
response O
. O
[]

Both O
groups O
received O
2.5 O
mg O
of O
neostigmine O
simultaneously O
. O
[]

RESULTS O
The O
clinical O
outcome O
of O
the O
patients O
was O
similar O
in O
both O
groups O
. O
[]

RESULTS O
The O
ratio O
of O
fluorescence B-outcome ['Resource-use']
after I-outcome ['Resource-use']
incubation I-outcome ['Resource-use']
to O
that O
before O
incubation O
was O
6.1+/-1.2 O
in O
the O
non-prepared O
section O
. O
['Resource-use']

RESULTS O
The O
severity O
of O
negative O
symptoms B-outcome ['Physiological-Clinical']
at O
the O
time O
of O
assessment O
was O
associated O
with O
deficits O
in O
memory B-outcome ['Life-Impact']
, O
verbal B-outcome ['Life-Impact']
fluency I-outcome ['Life-Impact']
, O
psychomotor B-outcome ['Life-Impact']
speed B-outcome ['Life-Impact']
and O
executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

[ O
Protective O
effect O
of O
ischemia O
postconditioning O
on O
reperfusion O
injury O
in O
patients O
with O
ST-segment O
elevation O
acute O
myocardial O
infarction O
] O
. O
[]

With O
combined O
topical O
and O
oral O
therapy O
, O
significantly O
more O
ofloxacin O
was O
measured O
than O
ciprofloxacin O
( O
3.84 O
microg/mL O
vs O
0.35 O
microg/mL O
[ O
P O
< O
.001 O
] O
) O
. O
[]

However O
, O
the O
mean O
duration O
of O
therapeutic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
is O
significantly O
higher O
in O
the O
group O
II O
( O
p O
= O
0,01 O
) O
. O
['Physiological-Clinical']

The O
vaccine O
had O
no O
observable O
effect O
on O
somatic O
cell O
count O
or O
streptococcal O
infections O
. O
[]

None O
of O
the O
participants O
had O
taken O
a O
vitamin/mineral O
supplement O
in O
the O
two O
months O
prior O
to O
the O
start O
of O
the O
study O
. O
[]

Twenty-one O
patients O
completed O
PBSC O
collection O
, O
and O
six O
patients O
of O
the O
G-CSF O
group O
and O
nine O
of O
the O
GM-CSF O
group O
were O
autografted O
. O
[]

BACKGROUND O
Triple O
therapy O
including O
two O
antibiotics O
and O
a O
proton O
pump O
inhibitor O
is O
a O
rational O
approach O
to O
the O
treatment O
of O
Helicobacter O
pylori O
induced O
peptic O
ulcer O
disease O
. O
[]

Outcomes O
included O
incidence O
of O
clinically O
significant O
postoperative B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
, O
fever B-outcome ['Physiological-Clinical']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
restoration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Earlier O
instruction O
was O
provided O
for O
the O
critical O
operative O
steps O
, O
with O
additional O
intraoperative O
instruction O
when O
required O
. O
[]

PSK O
may O
suppress O
CD57 O
( O
+ O
) O
T O
cells O
to O
improve O
survival O
of O
advanced O
gastric O
cancer O
patients O
. O
[]

METHODS O
Using O
RT-PCR O
, O
expression O
of O
leptin O
genes O
and O
leptin O
receptor O
genes O
was O
studied O
in O
myomas O
and O
in O
the O
surrounding O
myometrium O
in O
women O
with O
uterine O
myomas O
, O
untreated O
or O
treated O
with O
GnRH O
analogue O
. O
[]

BACKGROUND O
Progress O
towards O
MDG4 O
for O
child O
survival O
in O
South O
Africa O
requires O
effective O
prevention O
of O
mother-to-child O
transmission O
( O
PMTCT O
) O
of O
HIV O
including O
increasing O
exclusive O
breastfeeding O
, O
as O
well O
as O
a O
new O
focus O
on O
reducing O
neonatal O
deaths O
. O
[]

RESULTS O
After O
12 O
weeks O
, O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
in O
the O
eccentric O
group O
was O
63 O
% O
compared O
with O
48 O
% O
in O
the O
night O
splint O
group O
. O
['Life-Impact']

In O
all O
patients O
, O
tacrolimus O
was O
used O
without O
induction O
therapy O
. O
[]

Comparison O
of O
four O
continuously O
administered O
progestogen O
plus O
oestradiol O
combinations O
for O
climacteric B-outcome ['Physiological-Clinical']
complaints I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

c O
) O
Pain B-outcome ['Physiological-Clinical']
in O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

Children O
with O
lower O
levels O
of O
Time O
1 O
object O
interest O
exhibited O
facilitated O
growth O
in O
communication O
; O
children O
with O
higher O
levels O
of O
object O
interest O
exhibited O
growth O
attenuation O
. O
[]

Approximately O
two-thirds O
of O
the O
subjects O
were O
receiving O
antipsychotic O
treatment O
at O
the O
time O
of O
assessment O
; O
however O
, O
the O
duration O
of O
treatment O
was O
limited O
to O
12 O
weeks O
or O
less O
. O
[]

Long-term O
results O
regarding O
the O
use O
of O
recombinant O
interferon O
alpha-2b O
in O
the O
treatment O
of O
II O
type O
mixed O
essential O
cryoglobulinemia O
. O
[]

Two O
breasts O
with O
smooth O
prostheses O
were O
contracted O
after O
6 O
months O
( O
Baker O
III O
or O
IV O
) O
. O
[]

Evaluation O
of O
additional O
amine O
fluoride/stannous O
fluoride-containing O
mouthrinse O
during O
supportive O
therapy O
in O
patients O
with O
generalized O
aggressive O
periodontitis O
. O
[]

Data O
from O
a O
prospective O
randomized O
clinical O
trial O
among O
22 O
premenopausal O
women O
, O
age O
32.6 O
( O
range O
20-45 O
years O
) O
, O
who O
were O
randomly O
assigned O
to O
either O
of O
two O
treatments O
with O
continuous O
progestogens O
for O
contraception O
were O
analyzed O
; O
depot-medroxyprogesterone O
acetate O
( O
DMPA O
) O
or O
continuous O
levonorgestrel O
treatment O
with O
subdermal O
implants O
( O
Norplant O
) O
, O
respectively O
. O
[]

Changes O
in O
morning B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
were O
also O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children B-outcome ['Physiological-Clinical']
's O
communication B-outcome ['Life-Impact']
and O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
were O
measured O
at O
each O
time O
point O
. O
['Physiological-Clinical', 'Life-Impact']

Sleep O
was O
also O
measured O
by O
using O
parent-report O
diaries O
. O
[]

Imipenem O
had O
a O
mean O
half-life O
of O
66.7 O
+/- O
10.4 O
min O
; O
that O
of O
meropenem O
was O
64.4 O
+/- O
6.9 O
min O
. O
[]

BACKGROUND O
A O
double-blind O
, O
randomized O
, O
parallel-group O
, O
placebo-controlled O
trial O
was O
conducted O
in O
patients O
with O
paroxysmal O
atrial O
fibrillation O
or O
flutter O
( O
PAF/PAFL O
) O
experiencing O
2 O
or O
more O
episodes O
of O
symptomatic O
PAF/PAFL O
during O
a O
28-day O
observation O
period O
to O
determine O
the O
dose-response O
effect O
and O
safety O
of O
flecainide O
. O
[]

The O
change O
was O
even O
more O
marked O
with O
regard O
to O
serum B-outcome ['Physiological-Clinical']
EPX I-outcome ['Physiological-Clinical']
( O
P=0.005 O
; O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

Intraoperative O
conditions O
were O
comparable O
in O
both O
groups O
. O
[]

All O
patients O
received O
750 O
mg O
m O
( O
-2 O
) O
day O
( O
-1 O
) O
5-FU O
for O
5 O
days O
by O
continuous O
intravenous O
( O
i.v O
. O
) O
[]

No O
additional O
diagnostic O
information O
was O
obtained O
using O
0.3 O
mM/kg O
gadodiamide O
injection O
compared O
to O
0.1 O
mM/kg O
gadopentate O
dimeglumine O
in O
the O
same O
patients O
. O
[]

The O
absolute O
bioavailability O
reaches O
24 O
% O
probably O
due O
to O
a O
first-pass O
effect O
. O
[]

DESIGN O
Prospective O
, O
randomized O
multicenter O
study O
. O
[]

Bovine O
pericardium O
vs O
dacron O
for O
patch O
angioplasty O
after O
carotid O
endarterectomy O
: O
a O
prospective O
randomized O
study O
. O
[]

The O
3 O
year O
survival B-outcome ['Mortality']
rate O
was O
100 O
% O
in O
group O
B O
, O
whereas O
it O
was O
76 O
% O
in O
group O
A O
. O
['Mortality']

The O
fed O
trials O
resulted O
in O
lower O
plasma O
PSE O
concentrations O
at O
all O
time O
points O
compared O
with O
the O
nonfed O
trials O
. O
[]

Navigation O
shortened O
the O
time O
for O
both O
colorectal B-outcome ['Physiological-Clinical']
( O
P O
= O
0.0017 O
) O
and O
prostate B-outcome ['Physiological-Clinical']
screening I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
( O
P O
= O
0.06 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Venous O
blood O
was O
sampled O
at O
30 O
, O
50 O
, O
and O
70 O
min O
and O
pre-warm-up O
and O
postexercise O
for O
the O
analysis O
of O
plasma O
PSE O
and O
catecholamine O
concentrations O
, O
and O
urine O
was O
also O
collected O
for O
the O
analysis O
of O
PSE O
concentration O
. O
[]

The O
primary O
outcomes O
( O
i.e. O
, O
6-month O
point O
prevalence O
) O
were O
23.1 O
% O
versus O
20.8 O
% O
, O
respectively O
( O
OR O
= O
1.31 O
, O
ns O
) O
. O
[]

BACKGROUND O
It O
is O
hypothesized O
that O
self-injurious O
behavior O
( O
SIB O
) O
and O
symptoms O
of O
autism O
may O
be O
due O
to O
overactivity O
in O
some O
opioid O
systems O
in O
the O
brain O
. O
[]

Serum B-outcome ['Physiological-Clinical']
was O
sampled O
before O
start O
of O
chemotherapy O
and O
every O
2nd O
week O
during O
8 O
weeks O
for O
CEA O
, O
TPA O
, O
TPS O
, O
CA72-4 O
, O
CA19-9 O
and O
CA242 O
measurements O
. O
['Physiological-Clinical']

METHOD O
The O
study O
was O
a O
between-subjects O
design O
( O
mindfulness O
intervention O
vs O
control O
) O
with O
difference O
between O
number O
of O
most O
and O
least O
chosen O
stimulus O
selections O
on O
an O
over-selectivity O
task O
as O
the O
dependent O
measure O
. O
[]

In O
this O
task O
, O
pleasure O
typically O
decreases O
with O
decreasing O
contrast O
of O
the O
positive O
images O
displayed O
. O
[]

The O
objective O
of O
the O
study O
was O
to O
investigate O
the O
central O
effects O
of O
GES O
, O
including O
the O
possible O
modulation O
of O
the O
visceral O
sensory O
nervous O
system O
. O
[]

The O
primary O
outcome O
is O
stroke B-outcome ['Physiological-Clinical']
( O
including O
hemorrhagic B-outcome ['Physiological-Clinical']
) O
or O
systemic B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
increase O
was O
mainly O
the O
result O
of O
increased O
Gram O
( O
+ O
) O
and O
anaerobic O
species O
. O
[]

[ O
Efficacy O
and O
immune B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
of O
plasma-derived O
hepatitis O
B O
vaccine O
11 O
years O
after O
primary O
immunization O
] O
. O
['Physiological-Clinical']

Eighteen O
healthy O
volunteers O
received O
a O
single O
oral O
dose O
of O
pantoprazole O
( O
40 O
mg O
) O
and O
serum O
concentrations O
were O
determined O
. O
[]

Response O
to O
rHuEPO O
therapy O
was O
assessed O
by O
measuring O
changes O
in O
hematocrit B-outcome ['Physiological-Clinical']
level O
, O
transfusion B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
and O
quality O
of O
life O
. O
['Physiological-Clinical', 'Resource-use']

6.08 O
, O
p O
= O
0.007 O
and O
basal O
citrulline O
group O
= O
41.4 O
? O
[]

No O
significant O
differences O
in O
language B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
autistic I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
measures O
were O
observed O
at O
the O
3-week O
follow-up O
between O
the O
groups O
. O
['Life-Impact']

RESULTS O
Glycaemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
deteriorated O
in O
patients O
on O
CIT O
, O
but O
improved O
significantly O
in O
patients O
allocated O
to O
IIT O
( O
p=0.007 O
) O
. O
['Physiological-Clinical']

Study O
results O
do O
not O
support O
the O
hypothesis O
that O
acustimulation O
bands O
are O
efficacious O
as O
an O
adjunct O
to O
pharmacological O
antiemetics O
for O
control O
of O
chemotherapy-related B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
female O
breast O
cancer O
patients O
. O
['Physiological-Clinical']

In O
each O
patient O
a O
euglycaemic O
glucose O
clamp O
with O
simultaneous O
indirect O
calorimetry O
allowed O
us O
to O
determine O
whole B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
disposal I-outcome ['Physiological-Clinical']
and O
substrate B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serious B-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rates O
were O
6 O
% O
for O
the O
daily O
regimen O
and O
22 O
% O
for O
the O
weekly O
schedule O
. O
['Adverse-effects']

METHODS O
Between O
1994 O
and O
2004 O
, O
we O
retrospectively O
reviewed O
122 O
patients O
with O
rectal O
cancer O
whose O
serum B-outcome ['Physiological-Clinical']
CEA I-outcome ['Physiological-Clinical']
levels O
were O
measured O
on O
the O
preoperative O
day O
and O
postoperative O
days O
7 O
and O
30 O
. O
['Physiological-Clinical']

We O
have O
investigated O
in O
30 O
patients O
the O
metabolic O
and O
hormonal O
responses O
to O
middle O
ear O
surgery O
using O
induced O
hypotension O
to O
a O
mean O
arterial O
pressure O
of O
55 O
mm O
Hg O
. O
[]

RESULTS O
A O
majority O
did O
not O
respond O
to O
omega O
3/6 O
treatment O
. O
[]

METHODS O
A O
cohort O
of O
795 O
adults O
with O
preneoplastic O
gastric O
lesions O
was O
randomised O
to O
receive O
anti-H O
pylori O
treatment O
and/or O
antioxidants O
. O
[]

Azimilide O
dihydrochloride O
was O
investigated O
as O
adjunctive O
treatment O
for O
reducing O
the O
frequency O
of O
VT O
and O
, O
thus O
, O
the O
need O
for O
ICD O
therapies O
, O
including O
ATP O
and O
cardioversion/defibrillation O
( O
ICD O
shocks O
) O
in O
patients O
with O
inducible O
monomorphic O
VT. O
METHODS O
A O
total O
of O
172 O
patients O
were O
randomized O
to O
daily O
treatment O
with O
placebo O
, O
35 O
mg O
, O
75 O
mg O
, O
or O
125 O
mg O
of O
oral O
AZ O
in O
this O
dose-ranging O
pilot O
study O
of O
patients O
with O
ICDs O
. O
[]

RESULTS O
In O
total O
, O
398 O
patients O
were O
recruited O
in O
the O
initial O
therapy O
group O
, O
among O
whom O
253 O
were O
included O
in O
on-demand O
therapy O
, O
with O
127 O
patients O
in O
the O
hydrotalcite O
group O
and O
the O
remaining O
126 O
in O
the O
esomeprazole O
group O
. O
[]

At O
weeks O
4 O
and O
8 O
, O
tolerability B-outcome ['Life-Impact']
was O
assessed O
using O
history O
taking O
and O
laboratory O
analysis O
, O
and O
compliance O
was O
assessed O
using O
pill O
counts O
. O
['Life-Impact']

However O
, O
the O
absence O
of O
correlations O
between O
EPA O
+ O
DHA O
intakes O
from O
different O
marine O
species O
suggests O
that O
a O
minimum O
EPA O
+ O
DHA O
intake O
is O
necessary O
to O
observe O
a O
relationship O
with O
RBC O
EPA O
+ O
DHA O
concentrations O
. O
[]

METHODS O
Thirty-one O
subjects O
with O
an O
ART-suppressed O
plasma O
HIV O
RNA O
level O
of O
< O
40 O
copies/mL O
and O
a O
CD4 O
( O
+ O
) O
T-cell O
count O
of O
?350 O
cells/mm O
( O
3 O
) O
for O
?1 O
year O
were O
randomly O
assigned O
to O
receive O
raltegravir O
400 O
mg O
twice O
daily O
or O
placebo O
for O
24 O
weeks O
. O
[]

A O
similar O
dose-response B-outcome ['Physiological-Clinical']
between O
the O
present O
study O
and O
Caucasian O
study O
was O
demonstrated O
. O
['Physiological-Clinical']

There O
were O
628 O
patients O
who O
were O
eligible O
for O
the O
clinical O
protocol O
E9486 O
, O
but O
of O
these O
521 O
were O
also O
entered O
on O
the O
companion O
laboratory O
study O
( O
E9487 O
) O
and O
had O
CD19 O
data O
. O
[]

Before O
treatment O
( O
Day O
0 O
) O
, O
peak O
improvement O
in O
PaO2/FIO2 B-outcome ['Physiological-Clinical']
was O
achieved O
at O
10 O
ppm O
for O
both O
control O
and O
NO-treated O
patients O
. O
['Physiological-Clinical']

We O
evaluated O
the O
effectiveness O
of O
IUI O
with O
COH O
relative O
to O
expectant O
management O
in O
couples O
with O
unexplained B-outcome ['Physiological-Clinical']
subfertility I-outcome ['Physiological-Clinical']
and O
an O
intermediate O
prognosis O
of O
a O
spontaneous B-outcome ['Physiological-Clinical']
ongoing I-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
To O
verify O
the O
preliminary O
results O
with O
EPI-NO O
in O
a O
prospective O
randomised O
trial O
. O
[]

Intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
respiratory B-outcome ['Physiological-Clinical']
functions B-outcome ['Life-Impact']
, O
including O
percent B-outcome ['Physiological-Clinical']
forced I-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
and O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
were O
then O
measured O
for O
3 O
hours O
after O
drug O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
a O
non-ionic O
dimer O
, O
iodixanol O
with O
a O
non-ionic O
monomer O
, O
iohexol O
in O
low O
dose O
intravenous O
urography O
. O
[]

The O
30-day O
operative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
the O
EVAR O
group O
was O
9 O
% O
( O
13 O
of O
150 O
, O
95 O
% O
CI O
5-15 O
) O
and O
the O
no O
intervention O
group O
had O
a O
rupture O
rate O
of O
9.0 O
per O
100 O
person O
years O
( O
95 O
% O
CI O
6.0-13.5 O
) O
. O
['Mortality']

Without O
further O
practice O
, O
both O
groups O
were O
asked O
to O
insert O
an O
LMA O
in O
a O
live O
patient O
in O
theatre O
3 O
months O
after O
initial O
training O
. O
[]

This O
randomized O
prospective O
study O
evaluates O
the O
need O
for O
hip O
restrictions O
following O
a O
modified O
anterolateral O
procedure O
. O
[]

Recombinant O
human O
TSH O
has O
been O
developed O
to O
facilitate O
monitoring O
for O
thyroid O
carcinoma O
recurrence O
or O
persistence O
without O
the O
attendant O
morbidity O
of O
hypothyroidism O
seen O
after O
thyroid O
hormone O
withdrawal O
. O
[]

OBJECTIVE O
To O
explore O
the O
efficacy O
of O
KGQG O
and O
its O
therapeutic O
mechanisms O
in O
chronic O
hepatitis O
B O
patients O
with O
liver O
fibrosis O
. O
[]

35.02 O
) O
pg/ml O
, O
t O
= O
4.97 O
- O
15.61 O
, O
P O
< O
0.01 O
) O
; O
renal O
blood O
flow O
was O
( O
175.15 O
? O
[]

The O
patients O
were O
allocated O
into O
two O
groups O
. O
[]

Risk O
factors O
for O
smoking O
following O
treatment O
identified O
in O
women O
only O
included O
treatment O
with O
the O
lower O
dose O
of O
bupropion O
SR O
, O
younger O
age O
, O
and O
higher O
perceived O
stress O
, O
whereas O
those O
that O
were O
unique O
to O
men O
included O
the O
presence O
of O
lifetime O
depression O
. O
[]

The O
children O
were O
randomized O
3:2 O
to O
COMB O
( O
n O
= O
75 O
) O
or O
MED O
( O
n O
= O
49 O
) O
. O
[]

NC B-outcome ['Physiological-Clinical']
were O
defined O
as O
an O
absolute B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
< O
or O
=1.5 O
x O
10 O
( O
9 O
) O
cells/L O
( O
ie O
, O
> O
or O
=grade O
II O
) O
before O
the O
next O
cycle O
, O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
or O
neutropenia B-outcome ['Physiological-Clinical']
with O
a O
documented B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
described O
here O
investigates O
the O
efficacy O
and O
safety O
of O
glycerol O
lidocaine O
eardrops O
for O
the O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
abacterial I-outcome ['Physiological-Clinical']
otitis I-outcome ['Physiological-Clinical']
externa I-outcome ['Physiological-Clinical']
( O
CAS O
No O
. O
['Physiological-Clinical']

All O
substances O
used O
in O
the O
local O
treatment O
for O
periarthropathies O
, O
such O
as O
local O
anesthetics O
, O
corticosteroids O
or O
botulinum O
toxin O
A O
, O
possess O
certain O
disadvantages O
. O
[]

A O
positive O
correlation O
was O
found O
between O
activated B-outcome ['Physiological-Clinical']
CECs I-outcome ['Physiological-Clinical']
and O
survivin O
in O
the O
chemotherapy O
group O
pre- O
and O
post-therapy O
( O
P O
= O
0.001 O
and O
0.021 O
, O
respectively O
) O
, O
but O
only O
in O
the O
chemotherapy O
with O
Endostar O
group O
pre-therapy O
( O
P O
= O
0.030 O
) O
rather O
than O
post-therapy O
. O
['Physiological-Clinical']

The O
effectiveness O
of O
nifedipine O
as O
first-line O
monotherapy O
for O
mild O
diastolic B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
( O
range O
: O
95 O
to O
105 O
mm O
Hg O
) O
was O
tested O
in O
this O
placebo-controlled O
, O
double-blind O
, O
randomized O
trial O
. O
['Physiological-Clinical']

The O
efficacy O
and O
safety O
of O
clarithromycin O
, O
roxithromycin O
and O
erythromycin O
stearate O
in O
mild O
pneumonia O
were O
compared O
in O
an O
open O
randomized O
trial O
. O
[]

The O
Folic O
Acid O
for O
Vascular O
Outcome O
Reduction O
In O
Transplantation O
( O
FAVORIT O
) O
trial O
is O
designed O
to O
evaluate O
whether O
lowering O
tHcy B-outcome ['Physiological-Clinical']
using O
vitamin O
supplementation O
reduces O
CVD B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
renal O
transplant O
recipients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
milticentre O
randomized O
clinical O
study O
of O
the O
efficiency O
of O
remaxol O
infusion O
solution O
( O
hepatoprotective O
medicine O
for O
chronic O
liver O
dysfunction O
) O
included O
494 O
patients O
with O
chronic O
hepatitis O
B O
and O
C. O
294 O
of O
them O
staying O
in O
7 O
clinics O
were O
given O
remaxol O
and O
200 O
ones O
received O
placebo O
. O
[]

RESULTS O
Both O
treatments O
increased O
HDL-cholesterol B-outcome ['Physiological-Clinical']
, O
but O
decreased O
LDL-cholesterol B-outcome ['Physiological-Clinical']
by O
a O
comparable O
extent O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Short-term O
metabolic B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
effects O
of O
metformin O
in O
markedly O
obese O
adolescents O
with O
normal O
glucose O
tolerance O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
impact O
of O
a O
multifaceted O
, O
community-wide O
intervention O
on O
overall O
antibiotic O
use O
for O
young O
children O
and O
on O
use O
of O
broad-spectrum O
agents O
. O
[]

DH O
was O
assessed O
for O
all O
groups O
with O
a O
visual O
analog O
scale O
. O
[]

Key O
secondary O
endpoints O
included O
target B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
TVF B-outcome ['Physiological-Clinical']
; O
including O
cardiac B-outcome ['Physiological-Clinical']
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
target B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
) O
and O
Academic B-outcome ['Physiological-Clinical']
Research I-outcome ['Physiological-Clinical']
Consortium-defined I-outcome ['Physiological-Clinical']
definite/probable I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
at O
the O
end O
of O
the O
study O
, O
patients O
treated O
with O
cyclical O
clodronate O
had O
higher O
spinal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
compared O
with O
those O
treated O
continuously O
( O
3.32 O
+/- O
0.71 O
versus O
0.43 O
+/- O
0.89 O
% O
, O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

PURPOSE O
Limited O
robust O
randomised O
controlled O
trials O
investigating O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
in O
people O
at O
risk O
of O
cardiovascular O
disease O
( O
CVD O
) O
exist O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
cardiorespiratory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
IV O
administration O
of O
propofol O
( O
4 O
mg/kg O
) O
, O
ketamine O
hydrochloride O
and O
propofol O
( O
2 O
mg/kg O
each O
; O
K-P O
) O
, O
or O
ketamine O
hydrochloride O
( O
5 O
mg/kg O
) O
and O
diazepam O
( O
0.2 O
mg/kg O
; O
K-D O
) O
before O
and O
after O
induction O
of O
anesthesia O
( O
IoA O
) O
in O
dogs O
sedated O
with O
acepromazine O
maleate O
and O
oxymorphone O
hydrochloride O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
single O
blind O
study O
was O
to O
evaluate O
effect O
of O
gluten O
and O
casein-free O
diet O
for O
children O
with O
autistic O
syndromes O
and O
urinary O
peptide O
abnormalities O
. O
[]

Demographic O
characteristics O
were O
similar O
in O
both O
treatment O
groups O
, O
as O
were O
results O
of O
the O
EORTC O
QOL-30 O
questionnaire O
. O
[]

Previous O
studies O
suggest O
that O
the O
antinociceptive O
action O
of O
paracetamol O
( O
acetaminophen O
, O
APAP O
) O
might O
involve O
descending O
inhibitory O
pain O
pathways O
and O
the O
opioidergic O
system O
: O
this O
study O
explores O
this O
issue O
in O
humans O
with O
naloxone O
, O
the O
opioid O
antagonist O
. O
[]

Cardiac O
tamponade O
secondary O
to O
cancer O
is O
a O
life-threatening O
complication O
requiring O
immediate O
treatment O
. O
[]

The O
alternative O
protocol O
was O
used O
then O
in O
a O
second O
cycle O
. O
[]

The O
following O
parameters O
were O
evaluated O
at O
the O
moment O
of O
provisional O
restoration O
( O
within O
48 O
h O
after O
implant O
placement O
) O
and O
at O
the O
2 O
years O
follow-up O
visit O
: O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
, O
papilla B-outcome ['Physiological-Clinical']
index O
, O
position O
of O
the O
mucosal B-outcome ['Physiological-Clinical']
margin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
88 O
tumors O
( O
9.3+/-3.2 O
) O
( O
5.0-14.5 O
) O
cm O
in O
diameter O
were O
detected O
, O
and O
the O
largest O
tumor O
in O
a O
specific O
patients O
with O
multiple O
lesions O
was O
selected O
for O
observation O
. O
[]

CONCLUSIONS O
Initiating O
oral O
nutrition O
after O
mild O
acute O
[]

Chronic O
vasodilator O
therapy O
with O
flosequinan O
in O
congestive O
heart O
failure O
. O
[]

Risk O
factors O
for O
failure O
include O
high B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
a O
short O
time O
interval O
after O
the O
last O
procedure O
involving O
a O
conjunctival O
incision O
, O
the O
number O
of O
procedures O
with O
conjunctival O
incisions O
, O
and O
Hispanic O
ethnicity O
. O
['Physiological-Clinical']

Effect O
of O
macronutrient O
composition O
of O
the O
diet O
on O
the O
regulation O
of O
lipolysis B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
adipose I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
at O
rest O
and O
during O
exercise O
: O
microdialysis O
study O
. O
['Physiological-Clinical']

Rapid O
injection O
facilitated O
LMA B-outcome ['Resource-use']
insertion I-outcome ['Resource-use']
, O
unlike O
slow O
injection O
with O
lidocaine O
0.5 O
mg/kg O
pretreatment O
, O
and O
was O
similarly O
successful O
to O
slow O
injection O
after O
pretreatment O
with O
lidocaine O
1.0 O
mg/kg O
. O
['Resource-use']

The O
effects O
on O
intraarterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
ran O
in O
parallel O
, O
a O
fall O
in O
supine O
resting O
pressure O
, O
but O
no O
reduction O
in O
BP B-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
during O
mental O
stress O
and O
a O
lack O
of O
fall O
in O
BP B-outcome ['Physiological-Clinical']
with O
tilting O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
vaginal O
insert O
, O
Cervidil O
, O
containing O
10 O
mg O
of O
dinoprostone O
in O
a O
timed-release O
preparation O
was O
placed O
in O
the O
posterior O
vaginal O
formix O
for O
a O
maximum O
period O
of O
24 O
hours O
. O
[]

Patients O
who O
tolerated O
only O
low O
6-mercaptopurine O
( O
6-MP O
) O
doses O
because O
of O
neutropaenia O
and O
those O
who O
randomly O
were O
prescribed O
higher O
doses O
of O
Mtx O
had O
a O
lower O
rate O
of O
leukaemia B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
after O
the O
completion O
of O
therapy O
. O
['Physiological-Clinical']

Individual O
differences O
in O
the O
efficacy O
of O
a O
short O
theory O
of O
mind O
intervention O
for O
children O
with O
autism O
spectrum O
disorder O
: O
a O
randomized O
controlled O
trial O
. O
[]

Moreover O
, O
in O
vitro O
studies O
have O
suggested O
the O
presence O
of O
anticoagulant O
effects O
of O
3-hydroxy-3-methylglutaryl O
coenzyme O
A O
reductase O
inhibitors O
, O
as O
lipopolysaccharide O
( O
LPS O
) O
-induced O
monocyte O
tissue O
factor O
( O
TF O
) O
was O
suppressed O
. O
[]

Ropivacaine O
versus O
lidocaine O
in O
digital O
nerve O
blocks O
: O
a O
prospective O
study O
. O
[]

Otherwise O
healthy O
abdominally O
obese O
subjects O
have O
low O
GH O
levels O
and O
show O
features O
of O
the O
metabolic O
syndrome O
as O
well O
. O
[]

Grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
in O
both O
arms O
was O
acceptable O
. O
['Adverse-effects']

antivenom O
restored O
normal B-outcome ['Physiological-Clinical']
coagulability I-outcome ['Physiological-Clinical']
permanently O
in O
all O
23 O
patients O
in O
one O
group O
, O
but O
in O
the O
other O
group O
receiving O
an O
average O
dose O
of O
37.9 O
ml O
Behringwerke O
antivenom O
normal B-outcome ['Physiological-Clinical']
clotting I-outcome ['Physiological-Clinical']
resulted O
in O
only O
18 O
out O
of O
23 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CGRP O
and O
SP O
are O
considered O
relevant O
in O
the O
genesis O
of O
migraine O
pain O
. O
[]

METHODS O
Thirty O
subjects O
( O
8 O
men O
and O
22 O
women O
) O
who O
had O
minor O
RAS O
at O
least O
once O
a O
month O
were O
randomly O
allocated O
to O
a O
soybean O
oil O
group O
or O
a O
perilla O
oil O
group O
in O
a O
double-blind O
manner O
( O
experimental O
phase O
) O
after O
a O
run-in O
phase O
of O
4 O
mo O
during O
which O
subjects O
used O
a O
reference O
oil O
, O
the O
most O
popular O
cooking O
oil O
in O
Japan O
, O
or O
a O
50/50 O
mixture O
of O
soybean O
oil O
and O
rapeseed O
oil O
. O
[]

CONCLUSION O
This O
free O
bednet O
distribution O
program O
achieved O
high O
levels O
of O
adherence O
after O
6 O
months O
. O
[]

Bitolterol O
has O
a O
much O
longer O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
and O
should O
be O
considered O
as O
a O
suitable O
bronchodilator O
for O
regular O
nebulizer O
treatment O
of O
chronic O
asthma O
. O
['Physiological-Clinical']

for O
14 O
days O
) O
followed O
by O
7 O
days O
of O
wash-out O
before O
repeating O
the O
TAM/MPA O
treatment O
. O
[]

Oral O
desensitization O
in O
papular O
urticaria O
in O
children O
. O
[]

A O
significant O
increase O
of O
initial O
claudication O
distance O
was O
found O
in O
the O
nebivolol O
group O
. O
[]

The O
effects O
of O
a O
new O
drug O
, O
N-2- O
( O
p-chlorophenoxy O
) O
-isobutyryl-N'-morpholinomethylurea O
( O
plafibride O
, O
ITA O
104 O
) O
, O
were O
studied O
in O
a O
double O
blind O
study O
lasting O
four O
months O
on O
a O
group O
of O
30 O
patients O
with O
a O
type O
IV O
hyperlipoproteinemia O
. O
[]

Leptin O
levels O
in O
protracted O
critical O
illness O
: O
effects O
of O
growth O
hormone-secretagogues O
and O
thyrotropin-releasing O
hormone O
. O
[]

Bacteroides O
bacteremia O
was O
significantly O
associated O
with O
performance O
of O
elective O
appendectomy O
at O
the O
time O
of O
transplantation O
( O
P O
less O
than O
0.01 O
) O
and O
with O
profound O
lymphocytopenia O
( O
P O
= O
0.01 O
) O
. O
[]

A O
pilot O
study O
of O
the O
Tele-Airway O
Management O
System O
in O
a O
hospital O
emergency O
department O
. O
[]

On O
multivariate O
analysis O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.02 O
) O
, O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.02 O
) O
, O
and O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
better O
( O
P O
=.06 O
) O
in O
younger O
children O
due O
to O
a O
lower O
relapse B-outcome ['Physiological-Clinical']
rate O
( O
P O
=.02 O
) O
especially O
in O
the O
bone O
marrow O
( O
P O
=.02 O
) O
. O
['Mortality', 'Mortality', 'Mortality', 'Physiological-Clinical']

The O
occlusal O
surface O
was O
ground O
flat O
and O
the O
teeth O
were O
sectioned O
mesio-distally O
. O
[]

Research O
shows O
that O
labels O
are O
variable O
, O
of O
poor O
quality O
, O
and O
not O
patient-centered O
. O
[]

In O
the O
first O
study O
the O
efficacy O
of O
the O
antidepressant O
paroxetine O
( O
20 O
mg O
daily O
) O
, O
the O
phosphodiesterase O
inhibitor O
pentoxifylline O
( O
1200 O
mg O
daily O
) O
and O
the O
glutamate O
release O
inhibitor O
riluzole O
( O
100 O
mg O
daily O
) O
was O
assessed O
. O
[]

The O
difference O
was O
largely O
explained O
by O
the O
greater O
proportion O
of O
virulent B-outcome ['Physiological-Clinical']
organisms I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tap I-outcome ['Physiological-Clinical']
eyes I-outcome ['Physiological-Clinical']
compared O
with O
biopsy O
eyes O
. O
['Physiological-Clinical']

BACKGROUND O
This O
study O
examined O
the O
nurse O
outcomes O
of O
a O
cancer O
pain O
education O
program O
for O
nurses O
of O
patients O
from O
11 O
different O
ethnic O
groups O
. O
[]

Despite O
practising O
with O
the O
expert-defined O
'timing-based O
' O
approach O
to O
murmur O
diagnosis O
( O
i.e O
. O
[]

[ O
Usage O
of O
titanoreine O
after O
procedure O
for O
prolapse O
and O
hemorrhoids O
] O
. O
[]

Fourteen O
animals O
were O
inoculated O
with O
virulent O
canine O
parvovirus O
; O
10 O
animals O
that O
developed O
clinical O
signs O
thereby O
meeting O
the O
inclusion O
criteria O
were O
admitted O
to O
the O
treatment O
phase O
in O
two O
randomly O
selected O
groups O
( O
placebo O
and O
IFN O
) O
of O
equal O
size O
. O
[]

RESULTS O
The O
RV O
pacing O
contributed O
to O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
end-systolic I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
LV B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
compared O
to O
BiV O
pacing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Findings O
suggest O
that O
some O
aspect O
of O
both O
auditory O
training O
and O
listening O
to O
selected O
unmodified O
music O
may O
have O
a O
beneficial O
effect O
on O
children O
with O
autism O
and O
sound O
sensitivity O
, O
and O
indicate O
a O
need O
for O
further O
research O
into O
the O
effects O
that O
led O
to O
these O
changes O
and O
the O
mechanisms O
involved O
in O
the O
sensory O
abnormalities O
commonly O
associated O
with O
autism O
. O
[]

The O
primary O
outcome O
measures O
were O
the O
changes O
in O
trough O
supine B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic O
blood O
pressure B-outcome ['Physiological-Clinical']
( O
sSBP O
, O
sDBP O
) O
between O
baseline O
and O
the O
last O
observation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
38 O
patients O
( O
19.3 O
% O
) O
had O
cesarean O
deliveries O
. O
[]

The O
response O
time O
was O
shortest O
in O
patients O
treated O
with O
azithromycin O
. O
[]

PURPOSE O
To O
compare O
the O
toxicity O
between O
hypofractionation O
vs. O
conventional O
fractionation O
schedules O
in O
patients O
with O
high-risk O
prostate O
cancer O
. O
[]

BACKGROUND O
Over O
the O
last O
two O
decades O
the O
incidence O
of O
allergic O
diseases O
has O
increased O
in O
industrialized O
countries O
, O
and O
consequently O
new O
approaches O
have O
to O
be O
explored O
. O
[]

Free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
were O
measured O
using O
electron O
spin O
resonance O
spectroscopy O
. O
['Physiological-Clinical']

Treatment O
with O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
was O
first O
used O
in O
glomerulonephritis O
( O
GN O
) O
in O
1966 O
but O
its O
efficiency O
is O
still O
debated O
. O
[]

On O
the O
other O
hand O
, O
children O
in O
the O
control O
condition O
( O
not O
receiving O
the O
intervention O
) O
report O
no O
changes O
on O
both O
measures O
. O
[]

Effect O
of O
esmolol O
pretreatment O
on O
EEG B-outcome ['Physiological-Clinical']
seizure I-outcome ['Physiological-Clinical']
morphology I-outcome ['Physiological-Clinical']
in O
RUL O
ECT O
. O
['Physiological-Clinical']

After O
24 O
weeks O
treatment O
, O
simvastatin O
induced O
a O
37 O
% O
reduction O
in O
cholesterol B-outcome ['Physiological-Clinical']
plasma O
levels O
, O
a O
9 O
% O
increase O
of O
HDL B-outcome ['Physiological-Clinical']
and O
a O
16 O
% O
reduction O
of O
LDL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
initial O
treatment O
period O
for O
group O
II O
, O
also O
consisting O
of O
four O
visits O
, O
included O
the O
same O
oral O
hygiene O
instructions O
as O
for O
group O
I O
. O
[]

Grades O
2-4 O
acute O
graft-versus-host O
disease O
( O
GVHD O
) O
occurs O
in O
approximately O
35 O
% O
of O
matched O
, O
related O
donor O
( O
MRD O
) O
allogeneic O
hematopoietic O
cell O
transplantation O
( O
HCT O
) O
recipients O
. O
[]

Safety O
and O
efficacy O
of O
a O
new O
3.3 O
g O
b.i.d O
. O
[]

The O
final O
diagnosis O
was O
adjudicated O
by O
a O
physician O
blinded O
to O
the O
BNP O
levels O
. O
[]

Use O
of O
antecedent O
aerobic O
exercise O
to O
reduce O
maladaptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
stereotypic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
of O
adults O
with O
both O
autism O
and O
mental O
retardation O
is O
supported O
. O
['Life-Impact']

Variables O
were O
measured O
for O
210 O
min O
after O
administration O
of O
capsules O
. O
[]

The O
patients O
were O
followed O
by O
cystoscopy O
and O
urinary O
cytology O
every O
3 O
months O
. O
[]

AIMS O
Scarcity O
of O
resources O
, O
expertise O
and O
evidence-based O
models O
have O
so O
far O
limited O
delivery O
of O
patient-centred O
diabetes O
education O
. O
[]

INTERPRETATION O
A O
low-intensity O
, O
7-week O
training O
protocol O
has O
a O
beneficial O
effect O
on O
the O
mechanical O
efficiency O
and O
metabolic B-outcome ['Physiological-Clinical']
cost I-outcome ['Physiological-Clinical']
of O
wheelchair O
propulsion O
in O
able-bodied O
participants O
. O
['Physiological-Clinical']

In O
the O
defect O
rats O
, O
increased O
trabecular B-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
metaphyseal I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
apposition I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
observed O
in O
propranolol-treated O
groups O
. O
['Physiological-Clinical']

The O
mean O
elimination O
half-lives O
of O
the O
[]

Postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
are O
common O
after O
recovery O
from O
anesthesia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
research O
measured O
naltrexone O
levels O
in O
plasma O
, O
to O
assess O
the O
relationship O
between O
behavioral O
response O
to O
naltrexone O
and O
plasma O
levels O
, O
and O
the O
effects O
of O
naltrexone O
on O
weight O
in O
hospitalized O
autistic O
children O
( O
n O
= O
41 O
) O
. O
[]

Nizatidine O
, O
administered O
as O
a O
300 O
mg O
nocte O
and O
as O
a O
150 O
mg O
b.d O
. O
[]

METHOD O
21 O
patients O
( O
age O
0-2 O
months O
) O
and O
40 O
healthy O
infants O
( O
age O
0-2 O
months O
) O
were O
investigated O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials O
NCT00779597 O
. O
[]

Insulin-mediated B-outcome ['Physiological-Clinical']
vasodilation I-outcome ['Physiological-Clinical']
and O
insulin-stimulated B-outcome ['Physiological-Clinical']
NO I-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
were O
well O
matched O
across O
groups O
by O
this O
approach O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
composite O
restoration O
of O
FRC O
posts O
combined O
with O
resin O
core O
and O
resin O
crown O
can O
improve O
the O
fracture B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
the O
pulpless O
roots O
. O
['Physiological-Clinical']

OBJECTIVE O
Our O
objective O
was O
to O
determine O
the O
effect O
of O
7-d O
aerobic O
exercise O
training O
on O
peripheral O
and O
hepatic O
insulin O
sensitivity O
during O
isoglycemic/hyperinsulinemic O
clamp O
conditions O
. O
[]

The O
92 O
males O
and O
28 O
females O
included O
in O
the O
study O
had O
a O
median O
age O
of O
62 O
years O
( O
range O
40-85 O
years O
) O
. O
[]

The O
safety O
evaluation O
was O
performed O
during O
the O
28-day O
follow-up O
and O
serum O
samples O
for O
anti-rabies O
antibody O
titration O
were O
collected O
on O
D0 O
( O
before O
injection O
) O
D3 O
, O
D7 O
, O
D14 O
and O
D28 O
. O
[]

Effect O
of O
intensive O
insulin O
therapy O
on O
the O
somatotropic O
axis O
of O
critically O
ill O
children O
. O
[]

The O
drug O
combination O
and O
administration O
periods O
in O
the O
PPI O
group O
were O
LPZ O
30 O
mg O
, O
CAM O
400 O
mg O
, O
MTZ O
500 O
mg O
( O
LCM O
group O
) O
. O
[]

Among O
men O
with O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
above O
the O
median O
, O
the O
ff O
genotype O
was O
no O
longer O
associated O
with O
risk O
. O
['Physiological-Clinical']

METHOD O
Patients O
were O
withdrawn O
from O
antidepressants O
and O
sedative/hypnotics O
, O
and O
then O
randomized O
to O
receive O
4.5 O
, O
6 O
, O
or O
9 O
g O
SXB O
or O
placebo O
nightly O
for O
8 O
weeks O
. O
[]

Coronary O
plaques O
can O
be O
reduced O
by O
some O
medications O
. O
[]

Health-related O
quality O
of O
life O
was O
assessed O
with O
the O
EQ-5D O
, O
and O
in O
combination O
with O
time O
used O
to O
calculate O
patients O
' O
quality-adjusted O
life O
years O
( O
QALYs O
) O
. O
[]

2 O
, O
piglets O
were O
weaned O
at O
21 O
d O
of O
age O
and O
then O
had O
free O
access O
to O
diets O
supplemented O
with O
1 O
% O
L-glutamine O
( O
wt O
: O
wt O
) O
or O
isonitrogenous O
L-alanine O
( O
control O
) O
. O
[]

Immediate O
or O
early O
use O
of O
proliferation O
signal O
inhibitor O
( O
PSI O
) O
/mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
inhibitor O
therapy O
can O
avoid O
high O
exposure O
to O
calcineurin O
inhibitors O
but O
concerns O
exist O
relating O
to O
the O
risk O
of O
delayed B-outcome ['Physiological-Clinical']
graft I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
DGF B-outcome ['Physiological-Clinical']
) O
and O
impaired B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
with O
the O
mTOR O
sirolimus O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
laryngoscopy O
and O
intubation O
, O
SAP B-outcome ['Physiological-Clinical']
and O
DAP O
increased O
secondary O
to O
an O
increase O
in O
SVR O
. O
['Physiological-Clinical']

However O
, O
fresh-start O
experiences O
, O
absence O
of O
new O
severe O
stressors O
and O
standard O
attachment O
style O
were O
more O
important O
predictors O
of O
remission O
. O
[]

Postoperatively O
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
was O
213+/-77 O
g/m2 O
( O
stentless O
) O
compared O
with O
202+/-72 O
( O
conventional O
group O
) O
g/m2 O
( O
NS O
) O
, O
whereas O
after O
6 O
months O
it O
was O
141+/-41 O
g/m2 O
in O
the O
stentless O
and O
170+/-43 O
g/m2 O
in O
the O
conventional O
group O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

METHODS O
Twenty O
drug-free O
adults O
with O
autistic O
disorder O
( O
16 O
men O
and O
4 O
women O
) O
( O
mean O
[ O
+/- O
SD O
] O
age O
, O
30.5 O
+/- O
8.5 O
years O
) O
underwent O
short-term O
tryptophan O
depletion O
in O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
crossover O
design O
. O
[]

This O
study O
examined O
the O
effectiveness O
of O
a O
30 O
week O
social O
competence O
and O
social O
skills O
group O
intervention O
program O
with O
children O
, O
ages O
7-11 O
, O
diagnosed O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

Effects O
of O
telmisartan O
and O
enalapril O
on O
renoprotection O
in O
patients O
with O
mild O
to O
moderate O
chronic O
kidney O
disease O
. O
[]

The O
tumor O
was O
not O
completely O
resected O
when O
the O
patient O
underwent O
TUR O
. O
[]

This O
manuscript O
presents O
the O
results O
of O
a O
randomized O
controlled O
trial O
testing O
the O
efficacy O
of O
interactive O
voice O
response O
( O
IVR O
) O
in O
recycling O
low O
income O
smokers O
who O
had O
previously O
used O
quitline O
( O
QL O
) O
support O
back O
to O
QL O
support O
for O
a O
new O
quit O
attempt O
. O
[]

Local O
therapy O
with O
glycerol O
lidocaine O
eardrops O
is O
a O
safe O
, O
and O
cost-effective O
treatment O
for O
the O
widely O
spread O
clinical O
picture O
of O
acute O
abacterial O
otitis O
externa O
. O
['Resource-use']

The O
results O
showed O
that O
preoperative O
chemotherapy O
caused O
no O
myelosuppression B-outcome ['Physiological-Clinical']
, O
but O
merely O
mild B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Each O
subject O
viewed O
the O
testing O
videotape O
, O
rating O
the O
performances O
and O
giving O
feedback O
commentary O
. O
[]

Comparison O
between O
the O
2 O
groups O
in O
terms O
of O
early B-outcome ['Adverse-effects']
postoperative I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
showed O
a O
higher O
incidence O
of O
cerebrovascular B-outcome ['Physiological-Clinical']
accidents I-outcome ['Physiological-Clinical']
in O
group O
2 O
( O
group O
1 O
= O
0 O
patients O
vs O
group O
2 O
= O
4 O
patients O
, O
5 O
% O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

An O
alternative O
stepwise O
model O
selection O
process O
including O
all O
fever-related B-outcome ['Physiological-Clinical']
measures O
from O
the O
preoperative O
and O
intraoperative O
period O
( O
e.g. O
, O
hydrocephalus O
, O
duration O
of O
surgery O
, O
intraoperative O
blood O
loss O
) O
resulted O
in O
the O
loss O
of O
significance O
for O
dichotomized O
Glasgow O
Outcome O
Scale O
, O
but O
significant O
associations O
between O
fever B-outcome ['Physiological-Clinical']
and O
several O
other O
outcome O
measures O
remained O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Maximal O
and O
integrated O
early O
( O
E O
, O
Ei O
) O
and O
late O
( O
A O
, O
Ai O
) O
diastolic B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocities O
and O
their O
ratio O
( O
E/A O
, O
Ei/Ai O
) O
were O
measured O
by O
pulsed O
Doppler O
over O
the O
mitral O
and O
tricuspid O
valves O
. O
['Physiological-Clinical']

No O
relationship O
was O
found O
between O
the O
maximum O
observed O
plasma O
ASA O
level O
and O
the O
maximum O
effect O
. O
[]

CONCLUSIONS O
We O
conclude O
that O
rHuEPO O
is O
safe O
and O
effective O
for O
reversing O
anemia B-outcome ['Physiological-Clinical']
related O
to O
advanced O
cancer O
or O
to O
chemotherapy O
for O
cancer O
. O
['Physiological-Clinical']

BACKGROUND O
Residual O
cardiovascular O
( O
CV O
) O
risk O
often O
remains O
high O
despite O
statin O
therapy O
to O
lower O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
therefore O
conducted O
a O
4-month O
double-blind O
clinical O
trial O
in O
28 O
obese O
[ O
mean O
body O
mass O
index O
( O
BMI O
) O
: O
40.3 O
+/- O
5.7 O
kg/m O
( O
2 O
) O
] O
, O
insulin-resistant O
[ O
homeostasis O
model O
assessment O
- O
insulin O
resistance O
: O
7.6 O
+/- O
2.8 O
and O
whole O
body O
insulin O
sensitivity O
index O
( O
WBISI O
) O
: O
1.5 O
+/- O
0.7 O
] O
adolescents O
( O
age O
15.0 O
+/- O
1.3 O
yr O
) O
randomized O
to O
MET O
( O
n O
= O
15 O
, O
dose O
1500 O
mg O
daily O
) O
or O
placebo O
( O
n O
= O
13 O
) O
. O
[]

Excluded O
were O
partially-erupted O
teeth O
and O
surfaces O
with O
caries O
or O
restorations O
that O
had O
to O
be O
measured O
. O
[]

Six O
patients O
then O
underwent O
placement O
of O
a O
LeVeen O
shunt O
. O
[]

Unfortunately O
, O
these O
antidepressant O
effects O
are O
short-lived O
and O
patients O
usually O
relapse O
to O
baseline O
depression O
levels O
within O
48 O
hours O
. O
[]

Previous O
studies O
have O
demonstrated O
that O
Xuezhikang O
, O
an O
extract O
of O
cholestin O
, O
available O
from O
Chinese O
red O
yeast O
rice O
, O
could O
effectively O
modify O
lipid O
profile O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
prothrombin I-outcome ['Physiological-Clinical']
and O
serum O
['Physiological-Clinical']

After O
a O
median O
follow-up O
of O
41 O
months O
, O
the O
response O
duration O
and O
time O
to O
progression O
( O
TTP O
) O
were O
significantly O
better O
with O
arm O
B O
, O
the O
longer O
regimen O
( O
P O
: O
=.012 O
and O
P O
: O
< O
10 O
( O
-3 O
) O
, O
respectively O
) O
. O
[]

This O
study O
evaluated O
the O
effectiveness O
of O
an O
internet B-outcome ['Resource-use']
accessed I-outcome ['Resource-use']
training I-outcome ['Resource-use']
program I-outcome ['Resource-use']
that O
included O
Theory O
of O
Mind-based O
guidance O
, O
video O
models O
, O
visual O
supports O
, O
and O
virtual O
reality O
practice O
sessions O
in O
teaching O
appropriate O
job O
interview O
skills O
to O
individuals O
with O
high O
functioning O
Autism O
Spectrum O
Disorders O
. O
['Resource-use']

The O
use O
of O
vasoconstrictors O
was O
the O
only O
variable O
that O
had O
a O
statistically O
significant O
change O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
associated O
with O
a O
change O
in O
position O
. O
['Physiological-Clinical']

In O
the O
US O
3 O
G O
group O
, O
3 O
g O
daily O
of O
stanol O
esters O
lowered O
TC B-outcome ['Physiological-Clinical']
and O
LDL-C B-outcome ['Physiological-Clinical']
levels O
by O
6.4 O
% O
and O
10.1 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Male O
and O
female O
Korean O
patients O
aged O
18 O
to O
75 O
years O
having O
uncomplicated O
, O
mild O
to O
moderate O
, O
essential O
hypertension O
( O
sitting O
diastolic O
blood O
pressure O
[ O
SiDBP O
] O
90- O
< O
110 O
mm O
Hg O
) O
and O
receiving O
no O
antihypertensives O
in O
the O
2 O
weeks O
before O
randomization O
were O
eligible O
. O
[]

The O
1-year O
mortality B-outcome ['Mortality']
rate O
was O
2.9 O
% O
for O
black O
patients O
and O
2.5 O
% O
for O
non-black O
patients O
( O
p O
= O
0.93 O
) O
. O
['Mortality']

In O
each O
case O
, O
the O
drug O
was O
administered O
intravenously O
, O
beginning O
1 O
to O
2 O
hours O
preoperatively O
and O
continued O
for O
the O
prescribed O
period O
. O
[]

METHODS O
A O
prospectively O
planned O
, O
combined O
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
analysis O
was O
performed O
, O
including O
data O
from O
two O
Phase O
III O
trials O
that O
compared O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
fulvestrant O
( O
250 O
mg O
monthly O
; O
n O
= O
428 O
) O
with O
anastrozole O
( O
1 O
mg O
daily O
; O
n O
= O
423 O
) O
in O
the O
treatment O
of O
postmenopausal O
women O
with O
advanced O
breast O
carcinoma O
who O
had O
disease O
progression O
after O
receipt O
of O
previous O
endocrine O
treatment O
. O
['Mortality', 'Life-Impact']

FINDINGS O
The O
intervention O
group O
did O
not O
differ O
from O
the O
control O
group O
on O
the O
primary O
outcome O
( O
9.1 O
% O
versus O
9.3 O
% O
; O
odds O
ratio O
= O
1.02 O
95 O
% O
confidence O
interval O
0.73-1.42 O
) O
or O
on O
any O
of O
the O
secondary O
outcomes O
. O
[]

In O
study O
group O
, O
the O
total O
scores O
of O
SDSS O
in O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
( O
5.9 O
? O
[]

Further O
studies O
of O
ascorbic O
acid O
to O
treat O
hypertension B-outcome ['Physiological-Clinical']
, O
with O
clinical O
endpoints O
, O
are O
warranted O
. O
['Physiological-Clinical']

3 O
. O
[]

No O
differences O
by O
racial O
group O
were O
documented O
. O
[]

Although O
there O
was O
no O
single O
cutoff O
in O
age O
, O
younger O
children O
were O
more O
likely O
to O
have O
intermediate O
risk O
and O
less O
likely O
to O
have O
favorable B-outcome ['Physiological-Clinical']
cytogenetics I-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
, O
and O
they O
had O
a O
higher O
incidence O
of O
translocations B-outcome ['Physiological-Clinical']
involving I-outcome ['Physiological-Clinical']
chromosome I-outcome ['Physiological-Clinical']
11q23 I-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Routine O
antibiotic O
use O
in O
preterm O
neonates O
: O
a O
randomised O
controlled O
trial O
. O
[]

There O
was O
a O
trend O
toward O
better O
EFS B-outcome ['Mortality']
with O
the O
addition O
of O
MTP O
( O
P O
= O
.08 O
) O
. O
['Mortality']

Satisfaction B-outcome ['Life-Impact']
was O
measured O
for O
attendees O
and O
referring O
doctors O
at O
follow-up O
. O
['Life-Impact']

Both O
drugs O
increase O
platelet B-outcome ['Physiological-Clinical']
5-HT I-outcome ['Physiological-Clinical']
in O
the O
first O
phase O
of O
treatment O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
fast-titration O
regimen O
had O
a O
similar O
adverse B-outcome ['Adverse-effects']
event O
['Adverse-effects']

Results O
show O
that O
sway B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
had O
returned O
to O
baseline O
values O
3 O
h O
after O
the O
end O
of O
anaesthesia O
in O
all O
children O
who O
had O
received O
propofol/alfentanil/N2O O
and O
in O
12 O
of O
the O
15 O
children O
who O
had O
received O
thiopentone/halothane/N2O O
. O
['Life-Impact']

Thirty O
postmenopausal O
women O
with O
reduced O
bone O
mineral O
density O
were O
divided O
randomly O
into O
two O
groups O
based O
on O
the O
chronological O
sequence O
of O
their O
first O
visit O
to O
the O
Osteoporosis O
Clinic O
of O
Katsuragi O
Hospital O
. O
[]

In O
the O
placebo O
, O
the O
eleutherococcus O
extract O
was O
substituted O
by O
additional O
wine O
, O
resulting O
in O
identical O
final O
concentrations O
of O
ethanol O
in O
both O
preparations O
. O
[]

In O
group O
2 O
, O
37 O
embryo O
transfers O
resulted O
in O
eight O
implantations B-outcome ['Physiological-Clinical']
( O
21.6 O
% O
) O
. O
['Physiological-Clinical']

Despite O
the O
psychosocial O
difficulties O
common O
among O
young O
adults O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
, O
little O
to O
no O
evidence-based O
social O
skills O
interventions O
exist O
for O
this O
population O
. O
[]

Diazepam O
and O
midazolam O
were O
rated O
as O
77 O
% O
and O
100 O
% O
successful B-outcome ['Physiological-Clinical']
, O
according O
to O
the O
overall O
behavior B-outcome ['Life-Impact']
evaluation O
criteria O
( O
P=.02 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

We O
have O
studied O
interactions O
between O
i.v O
. O
[]

At O
the O
end O
of O
the O
operation O
morphine O
( O
5 O
mg O
) O
or O
saline O
was O
injected O
periarticularly O
. O
[]

[ O
Clinical O
observations O
on O
the O
treatment O
of O
hookworm O
, O
Ascaris O
and O
Trichuris O
infection O
with O
oxibendazole O
] O
. O
[]

No O
difference O
in O
compliance B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
sustained I-outcome ['Physiological-Clinical']
virological I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
found O
between O
active O
and O
non-active O
IVDUs O
or O
between O
IVDU O
patients O
in O
or O
without O
a O
methadone O
maintenance O
program O
. O
['Physiological-Clinical']

Eighteen O
volunteers O
were O
randomly O
divided O
into O
two O
groups O
and O
allocated O
either O
an O
active O
corticosteroid O
preparation O
( O
Betamethasone O
valerate O
) O
or O
the O
basal O
formulation O
only O
( O
placebo O
) O
. O
[]

CONCLUSION O
These O
results O
indicate O
that O
the O
relation O
between O
DA O
and O
treatment O
response O
in O
chronic O
depression O
is O
complex O
, O
but O
suggest O
that O
greater O
DA O
may O
be O
associated O
with O
a O
steeper O
reduction O
and/or O
better O
response O
to O
pharmacotherapy O
. O
[]

Any O
angiographic O
assessment O
of O
thrombolytic O
drug O
efficacy O
should O
take O
these O
variations O
as O
well O
as O
interobserver O
variability O
into O
account O
. O
[]

Interest O
in O
equivalence O
trials O
has O
been O
increasing O
for O
many O
years O
, O
though O
the O
methodology O
which O
has O
been O
developed O
for O
such O
trials O
is O
mainly O
for O
uncensored O
data O
. O
[]

RESULTS O
The O
antihypertensive O
effect O
of O
captopril O
and O
atenolol O
was O
not O
influenced O
by O
concurrent O
administration O
of O
pravastatin O
. O
[]

For O
each O
subject O
, O
blood-alcohol O
levels O
measured O
via O
breathalyzer O
and O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
using O
the O
entire O
10/20 O
International O
System O
, O
were O
recorded O
both O
prior O
to O
and O
at O
intervals O
of O
35 O
, O
70 O
, O
105 O
, O
and O
140 O
minutes O
after O
P O
, O
LD O
, O
or O
HD O
administration O
. O
['Physiological-Clinical']

The O
accuracy O
of O
brushing B-outcome ['Resource-use']
cytology I-outcome ['Resource-use']
in O
patients O
with O
carcinoma B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
when O
the O
brushing B-outcome ['Physiological-Clinical']
was O
performed O
before O
biopsy O
than O
after O
biopsy O
( O
93.5 O
% O
versus O
82.6 O
% O
; O
P O
less O
than O
.01 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
present O
pilot O
study O
was O
compromised O
by O
several O
factors O
: O
a O
reliance O
on O
parental O
report O
to O
measure O
language O
, O
non-matching O
of O
the O
groups O
on O
initial O
IQ O
, O
and O
a O
lack O
of O
systematic O
checking O
regarding O
the O
implementation O
of O
the O
parent O
training O
intervention O
. O
[]

Physical O
effort O
stimulates O
the O
reninangiotensin O
system O
( O
RAS O
) O
. O
[]

A O
visual O
analogue O
scale O
( O
1-100 O
) O
was O
used O
to O
record O
pain B-outcome ['Physiological-Clinical']
, O
unpleasantness O
of O
taste O
and O
overall O
discomfort O
experienced O
. O
['Physiological-Clinical']

There O
was O
1 O
operative B-outcome ['Mortality']
death I-outcome ['Mortality']
. O
['Mortality']

In O
a O
substudy O
, O
89 O
% O
eyes O
( O
58 O
of O
65 O
) O
varied O
within O
+/- O
0.50 O
D O
over O
the O
course O
of O
a O
day O
. O
[]

Results O
including O
the O
culture O
at O
60 O
d O
after O
calving O
were O
21.2 O
and O
22.5 O
% O
, O
respectively O
, O
for O
combination O
therapy O
and O
cephapirin O
therapy O
only O
. O
[]

The O
results O
are O
discussed O
in O
relation O
to O
theories O
of O
pathogenesis O
of O
perioral B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
and O
steroid B-outcome ['Physiological-Clinical']
acne I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Double-blind O
efficacy O
study O
of O
selenium O
sulfide O
in O
tinea O
versicolor O
. O
[]

The O
positive O
response O
rate O
to O
the O
paclitaxel/cisplatin O
therapy O
was O
85 O
% O
vs O
61 O
% O
for O
the O
patients O
who O
received O
the O
cyclophosphamide/cisplatin O
regimen O
. O
[]

Seventy-five O
participants O
, O
25 O
per O
group O
, O
completed O
the O
study O
. O
[]

Aspirin O
infusion O
reduced O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of O
both O
metabolites O
greater O
than O
90 O
% O
, O
but O
excretion O
of O
2,3-dinor-6-oxo-PGF1 B-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
recovered O
more O
rapidly O
than O
did O
that O
of O
2,3-dinor-TXB2 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ketamine O
. O
[]

The O
mean O
+/- O
SD O
triglyceride O
level O
during O
the O
study O
was O
87 O
+/- O
79 O
mg/dl O
, O
with O
no O
significant O
difference O
between O
the O
two O
groups O
. O
[]

The O
two O
treatment O
groups O
were O
well-matched O
in O
age O
, O
sex O
, O
stage O
and O
performance O
status O
. O
[]

Trandolapril O
2 O
mg O
once O
daily O
is O
an O
effective O
antihypertensive O
agent O
, O
comparable O
to O
HCTZ O
. O
[]

Diarrhea B-outcome ['Physiological-Clinical']
occurred O
during O
both O
phases O
, O
but O
N-acetylcysteine O
was O
otherwise O
well O
tolerated B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Naltrexone O
reduced O
hyperactivity B-outcome ['Life-Impact']
and O
had O
no O
effect O
on O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
in O
the O
laboratory O
. O
['Life-Impact', 'Life-Impact']

Intravenous O
magnesium O
sulfate O
in O
acute B-outcome ['Physiological-Clinical']
severe I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
not O
responding O
to O
conventional O
therapy O
. O
['Physiological-Clinical']

The O
aims O
of O
this O
study O
were O
to O
examine O
in O
a O
randomised O
, O
double-blind O
fashion O
, O
the O
possible O
interaction O
between O
cyclosporin O
A O
and O
ticlopidine O
( O
250 O
mg O
per O
day O
) O
and O
the O
tolerability O
of O
this O
combination O
in O
heart-transplant O
recipients O
. O
[]

Length O
of O
observation O
and O
frequency O
of O
laboratory O
measures O
can O
be O
anticipated O
from O
these O
models O
. O
[]

Helping O
women O
make O
choices O
about O
mammography O
screening O
: O
an O
online O
randomized O
trial O
of O
a O
decision O
aid O
for O
40-year-old O
women O
. O
[]

This O
study O
found O
that O
SofScale O
is O
safe O
to O
gingival B-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
and O
does O
not O
promote O
tooth B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
impairment O
in O
three O
core O
symptom O
domains O
: O
socialization O
, O
communication O
, O
and O
repetitive/stereotyped O
behaviours O
. O
[]

Statistically O
significant O
differences O
between O
oral O
vaccine O
and O
placebo O
were O
not O
found O
in O
the O
clinical O
or O
the O
immunological O
variables O
tested O
. O
[]

BACKGROUND O
Many O
adults O
have O
not O
been O
screened O
for O
colon O
cancer O
, O
a O
potentially O
preventable O
cause O
of O
death O
. O
[]

CONCLUSIONS O
Pretreatment O
with O
lanreotide O
before O
transsphenoidal O
surgery O
improves O
surgical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
in O
patients O
with O
GH-secreting O
pituitary O
macroadenomas O
. O
['Physiological-Clinical']

The O
changes O
at O
the O
endpoint O
compared O
with O
baseline O
were O
: O
-11.90 O
+/- O
3.79 O
( O
mean O
+/- O
SD O
) O
and O
-5.15 O
+/- O
3.04 O
for O
group O
A O
and O
B O
respectively O
. O
[]

The O
platelet B-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
was O
higher O
( O
mean O
+/- O
SD O
, O
166,000 O
+/- O
51,000/microL O
after O
priming O
v O
151,000 O
+/- O
45,000/microL O
before O
priming O
, O
P O
=.007 O
) O
, O
and O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thrombocytopenia I-outcome ['Physiological-Clinical']
, O
ie O
, O
a O
platelet O
count O
less O
than O
150,000/microL O
, O
was O
shorter O
( O
1.5 O
+/- O
2.1 O
days O
v O
2.8 O
+/- O
2.9 O
days O
, O
P O
=.0025 O
) O
after O
priming O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
date O
, O
no O
study O
has O
examined O
the O
synergistic O
effects O
of O
a O
nutrition O
and O
combination O
of O
aerobic O
and O
strength O
training O
( O
CAST O
) O
on O
both O
adiposity B-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
in O
overweight O
Latina O
adolescent O
females O
. O
['Physiological-Clinical', 'Physiological-Clinical']

QS2c B-outcome ['Physiological-Clinical']
was O
unchanged O
after O
niguldipine O
. O
['Physiological-Clinical']

The O
program O
was O
designed O
to O
( O
a O
) O
improve O
students O
' O
distress-coping B-outcome ['Life-Impact']
, O
( O
b O
) O
prepare O
them O
as O
gatekeepers O
with O
regard B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
self-destructive I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
peers I-outcome ['Life-Impact']
and O
( O
c O
) O
assess O
the O
program O
's O
face O
validity O
and O
social B-outcome ['Life-Impact']
validity I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Combined O
infusion O
of O
amino O
acids O
and O
glucose O
increased O
protein B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
from O
-17+/-7 O
to O
7+/-5 O
micromol.kg O
( O
-1 O
) O
.h O
( O
-1 O
) O
. O
['Physiological-Clinical']

Methacholine B-outcome ['Physiological-Clinical']
PD20 I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
after O
run-in O
, O
first O
and O
second O
placebo O
were O
63 O
micro O
g O
, O
60 O
micro O
g O
and O
64 O
micro O
g O
, O
respectively O
( O
corresponding O
to O
2 O
, O
4 O
and O
6 O
weeks O
of O
ICS O
washout O
, O
respectively O
) O
. O
['Physiological-Clinical']

Generally O
speaking O
, O
responsibility B-outcome ['Life-Impact']
was O
even O
higher O
during O
couple-responsible O
episodes O
and O
even O
lower O
during O
therapist-responsible O
episodes O
when O
contrast O
was O
present O
. O
['Life-Impact']

Elderly O
neoplastic O
patients O
frequently O
may O
show O
hypertension O
and O
hyperuricemia O
, O
before O
and O
after O
chemotherapeutic O
treatments O
. O
[]

ECCE O
with O
PCL O
is O
burdened O
by O
frequent B-outcome ['Physiological-Clinical']
capsular I-outcome ['Physiological-Clinical']
fibrosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Immediately O
following O
balloon O
dilatation O
an O
intra-arterial O
bolus O
of O
either O
150 O
micrograms O
GTN O
, O
with O
or O
without O
a O
10 O
mg O
GTN O
patch O
for O
24 O
h O
, O
or O
a O
saline O
placebo O
was O
administered O
. O
[]

Anxiety O
disorders O
in O
typically O
developing O
youth O
: O
autism O
spectrum O
symptoms O
as O
a O
predictor O
of O
cognitive-behavioral O
treatment O
. O
[]

The O
area O
under O
the O
curve O
VAS O
and O
VRS B-outcome ['Physiological-Clinical']
scores O
were O
lower O
at O
4 O
, O
6 O
, O
12 O
and O
24 O
h O
in O
Group O
LM O
( O
p O
= O
0.001 O
, O
p O
= O
0.016 O
, O
respectively O
) O
. O
['Physiological-Clinical']

To O
test O
this O
hypothesis O
, O
psychoacoustic O
tasks O
were O
devised O
so O
as O
to O
use O
a O
signal O
detection O
methodology O
. O
[]

Moreover O
, O
women O
living O
with O
AIDS O
who O
demonstrated O
higher O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
scores O
at O
baseline O
had O
greater O
reduction O
in O
their O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
than O
women O
with O
lower O
scores O
. O
['Life-Impact', 'Life-Impact']

Mindfulness-based O
therapy O
( O
MBT O
) O
has O
been O
found O
effective O
in O
reducing O
anxiety B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
however O
research O
in O
autism O
is O
limited O
. O
['Life-Impact', 'Life-Impact']

The O
annual O
incidence O
of O
invasive O
plus O
noninvasive O
( O
ductal B-outcome ['Physiological-Clinical']
carcinoma B-outcome ['Physiological-Clinical']
in O
situ O
) O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
Finnish O
Diabetes O
Prevention O
Study O
is O
to O
assess O
the O
efficacy O
of O
an O
intensive O
diet-exercise O
programme O
in O
preventing O
or O
delaying O
type O
2 O
diabetes B-outcome ['Physiological-Clinical']
in O
individuals O
with O
impaired O
glucose O
tolerance O
( O
IGT O
) O
and O
to O
evaluate O
the O
effect O
of O
the O
programme O
on O
the O
risk O
factors O
of O
atherosclerotic O
vascular O
diseases O
and O
the O
incidence O
of O
cardiovascular O
events O
. O
['Physiological-Clinical']

Event-related O
potential O
indices O
of O
auditory O
selective O
attention O
in O
dependent O
amphetamine O
users O
. O
[]

In O
general O
, O
the O
degree O
of I-outcome ['Physiological-Clinical']
suppression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
HPA I-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
related O
to O
the O
daily O
dosage O
of O
steroid O
given O
, O
the O
duration O
of O
its O
administration O
, O
the O
extent O
of O
body O
surface O
covered O
, O
and O
the O
potency O
of O
the O
corticosteroid O
. O
['Physiological-Clinical']

A O
total O
of O
452 O
consecutive O
patients O
( O
240 O
with O
kidney O
disease O
and O
212 O
without O
kidney O
disease O
) O
were O
randomly O
assigned O
to O
a O
diagnostic O
strategy O
with O
( O
BNP O
group O
) O
or O
without O
( O
control O
group O
) O
the O
use O
of O
BNP O
levels O
provided O
by O
a O
rapid O
bedside O
assay O
. O
[]

There O
were O
significant O
interaction O
effects O
between O
sex O
and O
medication O
group O
-- O
women O
in O
the O
mefloquine O
group O
showed O
more O
fatigue B-outcome ['Physiological-Clinical']
( O
p= O
.011 O
) O
and O
confusion B-outcome ['Life-Impact']
( O
p= O
.011 O
) O
than O
men O
. O
['Physiological-Clinical', 'Life-Impact']

There O
were O
no O
significant O
improvements O
in O
the O
FTM O
total O
score O
or O
its O
subsections O
. O
[]

9 O
patients O
were O
classified O
as O
intermediate O
( O
1 O
had O
received O
placebo O
, O
5 O
low-dose O
, O
and O
3 O
high-dose O
) O
. O
[]

As O
for O
the O
parental O
report O
, O
the O
EA O
group O
also O
showed O
significantly O
better O
social B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
( O
p=0.01 O
) O
, O
receptive B-outcome ['Life-Impact']
language B-outcome ['Life-Impact']
( O
p=0.006 O
) O
, O
motor O
skills O
( O
p=0.034 O
) O
, O
coordination B-outcome ['Life-Impact']
( O
p=0.07 O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

In O
the O
study O
population O
with O
normal O
metabolic O
status O
the O
two O
oral O
formulations O
proved O
to O
be O
bioequivalent O
with O
regard O
to O
the O
pharmacokinetic O
parameters O
Cmax B-outcome ['Physiological-Clinical']
, O
AUC O
( O
0-Tlast O
) O
, O
AUC O
( O
0-infinity O
) O
and O
Ae B-outcome ['Adverse-effects']
( I-outcome ['Adverse-effects']
24h I-outcome ['Adverse-effects']
) I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

A O
total O
of O
79 O
patients O
were O
included O
. O
[]

Effects O
of O
a O
brief O
Early O
Start O
Denver O
model O
( O
ESDM O
) O
-based O
parent O
intervention O
on O
toddlers O
at O
risk O
for O
autism O
spectrum O
disorders O
: O
a O
randomized O
controlled O
trial O
. O
[]

RESULTS O
Participants O
randomised O
to O
receive O
an O
X-ray O
were O
more O
likely O
to O
report O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
at O
3 O
months O
( O
odds O
ratio O
( O
OR O
) O
= O
1.56 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
1.02 O
to O
2.40 O
) O
and O
had O
a O
lower O
overall O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
score O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
acute O
RAO O
after O
transradial O
catheterization O
can O
be O
recanalized O
by O
early O
1-hour O
homolateral O
ulnar O
artery O
compression O
. O
[]

Multiple O
secondary O
end O
points O
included O
clinician-assessed O
healing O
time O
and O
subject O
assessment O
of O
lesion O
protection O
, O
noticeability O
and O
social O
embarrassment O
. O
[]

RESULTS O
Eleven O
( O
65 O
% O
) O
of O
the O
17 O
patients O
who O
completed O
both O
test O
days O
showed O
a O
significant O
global O
worsening O
of O
behavioral O
symptoms O
with O
short-term O
tryptophan O
depletion O
, O
but O
none O
of O
the O
17 O
patients O
showed O
any O
significant O
change O
in O
clinical O
status O
from O
baseline O
after O
sham O
depletion O
( O
P O
= O
.001 O
) O
. O
[]

The O
rate O
[]

The O
influence O
of O
placebo O
awareness O
on O
stimulant O
drug O
response O
in O
a O
double-blind O
trial O
. O
[]

The O
NICE O
guidelines O
successfully O
triage O
those O
with O
a O
high O
breast O
cancer O
risk O
to O
be O
managed O
in O
cancer O
genetics O
clinics O
. O
[]

Our O
aim O
, O
therefore O
, O
was O
to O
ascertain O
whether O
pioglitazone O
reduces O
macrovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
high-risk O
patients O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical', 'Mortality']

Two O
tones O
were O
presented O
in O
random O
order O
, O
and O
subjects O
had O
to O
count O
the O
high-pitched O
tones O
. O
[]

One O
hundred O
and O
thirty-four O
subjects O
were O
randomized O
into O
exercise O
groups O
or O
a O
control O
group O
and O
130 O
completed O
the O
study O
. O
[]

OBJECTIVE O
Recent O
studies O
support O
the O
role O
of O
extracranial O
perivascular O
afferents O
in O
a O
substantial O
percentage O
of O
migraineurs O
. O
[]

METHODS O
Following O
assessment O
, O
individual O
profiles O
were O
developed O
and O
each O
week O
teachers O
and O
parents O
were O
given O
guidelines O
for O
working O
with O
the O
children O
and O
each O
child O
had O
three O
to O
four O
sessions O
a O
week O
lasting O
approximately O
for O
20 O
minutes O
. O
[]

For O
the O
24-h O
period O
after O
surgery O
, O
the O
number O
of O
emesis-free O
patients O
was O
significantly O
larger O
in O
the O
granisetron O
groups O
than O
in O
the O
control O
group O
( O
83 O
% O
, O
78 O
% O
, O
and O
20 O
% O
of O
patients O
receiving O
granisetron O
20 O
micrograms/kg O
and O
40 O
micrograms/kg O
, O
and O
saline O
, O
respectively O
) O
. O
[]

Treatment O
with O
ranitidine O
, O
but O
not O
placebo O
, O
was O
associated O
with O
a O
significant O
increase O
in O
CD4+ B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
( O
33 O
% O
to O
49 O
% O
; O
p O
< O
.05 O
) O
and O
a O
significant O
decrease O
in O
CD8+ B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
( O
41 O
% O
to O
27 O
% O
; O
p O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children O
responding O
to O
methylphenidate O
then O
entered O
8 O
weeks O
of O
open-label O
treatment O
at O
the O
individually O
determined O
best O
dose O
. O
[]

There O
was O
a O
significant O
difference O
in O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
the O
two O
groups O
( O
hazard O
ratio O
0.14 O
; O
95 O
% O
confidence O
interval O
0.05-0.41 O
; O
P O
= O
0.0003 O
) O
. O
['Mortality']

The O
training O
program O
lasted O
three O
months O
, O
and O
a O
22-week O
follow-up O
period O
examined O
the O
durability O
of O
the O
treatment O
effect O
. O
[]

During O
a O
9 O
week O
period O
, O
the O
patients O
were O
on O
a O
standard O
Na+ O
dialysate O
( O
Na+ O
= O
140 O
meq/L O
) O
basal O
period O
( O
B O
) O
; O
9 O
% O
( O
Na+ O
= O
149 O
meq/L O
) O
linear O
( O
L O
) O
; O
step O
drop O
( O
S O
) O
; O
and O
exponential O
drop O
( O
E O
) O
. O
[]

Effluent B-outcome ['Physiological-Clinical']
carcinogen I-outcome ['Physiological-Clinical']
antigen-125 I-outcome ['Physiological-Clinical']
levels O
were O
inversely O
correlated O
with O
peritoneal O
glucose O
exposure O
during O
lactate O
but O
not O
bicarbonate O
APD O
, O
indicating O
improved O
in O
vivo O
mesothelial O
cell O
tolerance O
of O
high-dose O
glucose O
with O
the O
neutral-pH O
PD O
fluid O
with O
reduced O
glucose O
degradation O
product O
content O
. O
['Physiological-Clinical']

We O
conclude O
that O
low-dose O
etoposide O
administered O
orally O
has O
a O
cytoreductive O
effect O
in O
relapsed O
ALL O
. O
[]

In O
contrast O
, O
pigs O
inoculated O
with O
strain O
Bartha O
or O
with O
the O
inactivated O
vaccine O
developed O
fever B-outcome ['Physiological-Clinical']
, O
had O
a O
period O
of O
growth B-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
, O
and O
excreted B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
after O
challenge O
exposure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
24 O
h O
fast O
more O
than O
doubled O
TSB B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
from O
baseline O
values O
in O
both O
the O
normal O
and O
high O
bilirubin O
groups O
. O
['Physiological-Clinical']

Subthreshold O
TENS O
did O
not O
increase O
the O
symptom O
relief O
produced O
by O
conservative O
treatment O
with O
the O
protocol O
used O
. O
[]

beta-Lactamase-producing O
[]

Arginine O
vasopressin O
reduced O
V B-outcome ['Physiological-Clinical']
( O
-58 O
% O
) O
and O
CH2O B-outcome ['Physiological-Clinical']
( O
-68 O
% O
) O
but O
did O
not O
alter O
UNaV B-outcome ['Physiological-Clinical']
or O
Ccr B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
cardiovascular O
( O
CV O
) O
responses O
to O
meal O
ingestion O
and O
orthostasis O
are O
well O
established O
. O
[]

Relationship O
of O
dietary O
intake O
to O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
children O
with O
autistic O
spectrum O
disorders O
. O
['Physiological-Clinical']

Differential O
effects O
of O
two O
dihydropyridine O
calcium O
antagonists O
in O
humans O
. O
[]

Breast O
conserving O
therapy O
( O
BCT O
) O
including O
postoperative O
irradiation O
of O
the O
remaining O
breast O
tissue O
is O
generally O
accepted O
as O
the O
best O
treatment O
for O
the O
majority O
of O
patients O
with O
early-stage O
breast O
cancer O
. O
[]

No O
signs O
of O
abrupt B-outcome ['Physiological-Clinical']
dissipation I-outcome ['Physiological-Clinical']
of O
the O
achieved O
clinical O
effects O
were O
observed O
during O
continued O
treatment O
, O
and O
no O
['Physiological-Clinical']

aureus O
. O
[]

There O
has O
been O
no O
secondary B-outcome ['Life-Impact']
graft I-outcome ['Life-Impact']
failure I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
leakage O
was O
measured O
with O
a O
filar O
micrometer O
eyepiece O
under O
a O
dissecting O
microscope O
. O
[]

Conjunctival O
hyperemia O
, O
hemorrhage O
, O
and O
edema O
were O
common O
after O
the O
SCJ O
injection O
procedure O
and O
conjunctival B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
was O
common O
after O
the O
IVT O
injection O
procedure O
. O
['Physiological-Clinical']

Herpes O
simplex O
virus O
vaccine O
in O
recurrent O
herpetic O
ocular O
infection O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
slightly O
( O
82 O
+/- O
17 O
to O
86 O
+/- O
14 O
beats/min O
) O
. O
['Physiological-Clinical']

They O
give O
the O
state O
of O
the O
results O
that O
have O
been O
obtained O
in O
603 O
patients O
using O
three O
protocols O
for O
treatment O
. O
[]

The O
remaining O
256 O
patients O
were O
divided O
into O
two O
groups O
according O
to O
the O
presence O
( O
group O
A O
, O
n O
= O
45 O
) O
or O
absence O
( O
group O
B O
, O
n O
= O
211 O
) O
of O
moderate O
dissection O
. O
[]

For O
Candida O
albicans O
, O
however O
, O
the O
maximum O
reduction O
was O
91 O
% O
on O
the O
first O
day O
and O
67 O
% O
on O
Day O
8 O
, O
maintained O
for O
30 O
minutes O
post-dosing O
. O
[]

METHODS O
201 O
patients O
with O
clinically O
definite O
multiple O
sclerosis O
were O
studied O
. O
[]

AIM O
To O
test O
the O
hypothesis O
that O
Helicobacter O
pylori O
eradication O
alone O
can O
reduce O
the O
incidence O
of O
gastric B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
in O
a O
subgroup O
of O
individuals O
with O
an O
increased O
risk O
for O
this O
fatal O
disease O
. O
['Physiological-Clinical']

The O
intervention O
focuses O
on O
lifestyle O
modification O
and O
takes O
12 O
months O
. O
[]

Median O
followup O
in O
the O
white O
light O
arm O
in O
103 O
cases O
was O
21.2 O
months O
( O
range O
4 O
to O
40 O
) O
compared O
with O
20.5 O
( O
range O
3 O
to O
40 O
) O
in O
the O
88 O
in O
the O
fluorescence O
diagnosis O
arm O
. O
[]

The O
absolute O
difference O
of O
aortic B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
between O
ultrasound O
and O
CT O
was O
< O
5 O
mm O
in O
88 O
% O
of O
patients O
. O
['Physiological-Clinical']

The O
study O
group O
consisted O
of O
61 O
postmenopausal O
women O
with O
osteoporosis O
. O
[]

In O
women O
with O
previous O
PMS O
the O
higher O
dose O
of O
MPA O
enhanced O
positive O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Social O
support O
may O
play O
an O
important O
role O
in O
helping O
drug O
users O
achieve O
abstinence B-outcome ['Life-Impact']
; O
however O
these O
benefits O
may O
depend O
on O
the O
type O
of O
support O
experienced O
. O
['Life-Impact']

SETTING O
Public O
rehabilitation O
center O
in O
France O
. O
[]

There O
was O
no O
significant O
difference O
in O
safety O
between O
the O
two O
regimens O
. O
[]

Marginal O
benefit/disadvantage O
of O
granulocyte O
colony-stimulating O
factor O
therapy O
after O
autologous O
blood O
stem O
cell O
transplantation O
in O
children O
: O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

AIM O
The O
research O
regards O
information O
on O
anesthesia O
to O
patients O
undergoing O
oral O
surgery O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
the O
supplemented O
group O
( O
n O
= O
9 O
) O
, O
which O
received O
one O
ampoule O
of O
Biostimine O
once O
daily O
for O
4 O
weeks O
, O
or O
to O
the O
placebo O
group O
( O
n O
= O
9 O
) O
. O
[]

OBJECTIVE O
To O
investigate O
the O
clinical O
usefulness O
of O
procalcitonin O
( O
PCT O
) O
for O
guiding O
duration O
of O
antibiotic O
therapy O
in O
patients O
with O
severe O
acute O
pancreatitis O
( O
SAP O
) O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
plaque B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
by O
B-mode O
ultrasound O
in O
the O
previous O
intervention O
study O
, O
and O
also O
to O
investigate O
the O
relationship O
between O
plaque B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
at O
baseline O
and O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
during O
the O
6-year O
follow-up O
in O
the O
two O
randomization O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Chi-square O
test O
was O
used O
for O
statistical O
analysis O
. O
[]

BACKGROUND O
Combining O
maintenance O
medications O
with O
different O
mechanisms O
of O
action O
may O
improve O
outcomes O
in O
COPD O
. O
[]

To O
determine O
limb B-outcome ['Physiological-Clinical']
lipid B-outcome ['Physiological-Clinical']
exchange B-outcome ['Physiological-Clinical']
, O
femoral O
arterial O
and O
venous O
blood O
samples O
drawn O
simultaneously O
at O
rest O
and O
during O
exercise O
were O
analyzed O
for O
total O
and O
individual O
FFA O
( O
e.g. O
, O
palmitate O
, O
oleate O
) O
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
HDL-C B-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
and O
limb B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
determined O
by O
thermodilution O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma O
Se O
, O
Zn O
, O
Cu O
and O
some O
enzymatic O
antioxidants O
activities O
were O
estimated O
in O
serum O
before O
and O
after O
the O
treatment O
. O
[]

Lead-time B-outcome ['Physiological-Clinical']
based O
on O
advanced O
['Physiological-Clinical']

These O
were O
used O
to O
compare O
trained O
( O
T.S O
. O
) O
[]

Infusion O
of O
fresh O
frozen O
plasma O
improved O
function O
more O
than O
did O
stored O
plasma O
and O
in O
addition O
returned O
a O
very O
low O
filtration O
fraction O
toward O
normal O
. O
[]

The O
success B-outcome ['Physiological-Clinical']
rate O
and O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
reach I-outcome ['Life-Impact']
cecum I-outcome ['Life-Impact']
were O
compared O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Life-Impact']

The O
exercise-induced B-outcome ['Life-Impact']
increase O
in O
EGC B-outcome ['Physiological-Clinical']
was O
higher O
during O
the O
HFD O
( O
AUC O
: O
HFD O
, O
1,641 O
+/- O
181 O
micromol/60 O
min O
; O
HCD O
, O
963 O
+/- O
156 O
micromol/60 O
min O
; O
P O
< O
.05 O
) O
and O
was O
associated O
with O
a O
higher O
exercise-induced B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
norepinephrine O
( O
P O
< O
.05 O
) O
and O
epinephrine O
( O
P O
=.056 O
) O
and O
lower O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Whereas O
nateglinide O
treatment O
also O
reduced O
triglyceride B-outcome ['Physiological-Clinical']
, O
highly-sensitive B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

After O
treatment O
, O
blood B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
two O
groups O
( O
both O
P O
< O
0.01 O
) O
, O
the O
observed O
group O
being O
lower O
than O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Chronic O
GVHD O
, O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
at O
2 O
years O
were O
no O
different O
between O
study O
arms O
( O
53 O
% O
vs O
45 O
% O
, O
P O
= O
.06 O
; O
53 O
% O
vs O
54 O
% O
, O
P O
= O
.77 O
; O
and O
59 O
% O
vs O
63 O
% O
, O
P O
= O
.36 O
) O
. O
['Mortality', 'Mortality']

INTERVENTION O
The O
treatment O
group O
received O
manual O
therapy O
, O
applied O
to O
the O
knee O
as O
well O
as O
to O
the O
lumbar O
spine O
, O
hip O
, O
and O
ankle O
as O
required O
, O
and O
performed O
a O
standardized O
knee O
exercise O
program O
in O
the O
clinic O
and O
at O
home O
. O
[]

Psychiatric B-outcome ['Physiological-Clinical']
assessment O
was O
made O
with O
the O
Hamilton O
depression B-outcome ['Life-Impact']
scale O
( O
HDS O
) O
, O
and O
unwanted B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
measured O
with O
the O
UKU O
side-effect B-outcome ['Adverse-effects']
scale O
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects', 'Adverse-effects']

Some O
investigations O
found O
that O
those O
side O
effects O
were O
less O
in O
FNB O
than O
in O
EA O
. O
[]

METHODS O
Eighty-two O
patients O
with O
tunneled O
CVCs O
were O
enrolled O
in O
the O
randomized O
controlled O
trial O
. O
[]

A O
randomized O
study O
comparing O
the O
use O
of O
the O
Ligaclip O
with O
bipolar O
energy O
to O
prevent O
lymphocele O
during O
laparoscopic O
pelvic O
lymphadenectomy O
for O
gynecologic O
cancer O
. O
[]

Statistical O
analyses O
of O
the O
measurements O
at O
T0 O
and O
T1 O
were O
undertaken O
with O
a O
paired O
t-test O
, O
and O
the O
difference O
between O
the O
groups O
assesed O
with O
a O
Student O
's O
t-test O
. O
[]

Effectiveness O
of O
active O
physical O
training O
as O
treatment O
for O
long-standing O
adductor-related O
groin O
pain O
in O
athletes O
: O
randomised O
trial O
. O
[]

The O
prostaglandin-depleted O
mucosa O
has O
increased O
susceptibility O
to O
luminal O
aggressive O
factors O
, O
yet O
the O
role O
of O
acid O
in O
the O
pathogenesis O
of O
the O
NSAID O
ulcer O
is O
controversial O
. O
[]

Although O
there O
were O
significant O
variations O
across O
sites O
in O
the O
management O
of O
post-CABG B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
, O
patterns O
of O
use O
of O
postoperative O
rhythm O
versus O
rate O
control O
and O
anticoagulation O
did O
not O
differ O
by O
geographic O
region O
or O
by O
whether O
or O
not O
the O
enrolling O
site O
was O
an O
academic O
institution O
. O
['Physiological-Clinical']

Each O
study O
group O
comprised O
25 O
patients O
. O
[]

The O
first O
was O
on O
a O
free O
sodium O
diet O
while O
the O
second O
was O
on O
a O
low-salt O
diet O
. O
[]

Metoclopramide O
increased O
LOSP B-outcome ['Physiological-Clinical']
significantly O
at O
3 O
min O
after O
administration O
i.v O
. O
( O
['Physiological-Clinical']

We O
describe O
here O
our O
findings O
in O
a O
further O
63 O
patients O
undergoing O
emergency O
abdominal O
surgery O
who O
were O
similarly O
allocated O
into O
either O
a O
cefotaxime O
or O
cephamandole O
antibiotic O
group O
. O
[]

The O
children O
who O
participated O
in O
this O
study O
were O
a O
heterogeneous O
group O
, O
and O
their O
apparent O
responses O
to O
the O
dimethylglycine O
varied O
. O
[]

We O
wished O
to O
assess O
the O
efficacy O
of O
inhaled O
salmeterol O
( O
SML O
; O
50 O
micrograms O
b.i.d O
. O
) O
[]

CONCLUSION O
No O
difference O
in O
the O
leak O
rate O
could O
be O
revealed O
. O
[]

Effects O
of O
vacuum-compression B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
on O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
: O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Terazosin O
was O
effective O
in O
lowering O
blood O
pressure O
when O
administered O
alone O
( O
in O
dosages O
of O
1 O
to O
80 O
mg/day O
) O
and O
when O
prescribed O
( O
in O
dosages O
of O
1 O
to O
20 O
mg/day O
) O
in O
combination O
with O
other O
antihypertensive O
agents O
. O
[]

Compared O
to O
conscious O
processing O
, O
unconscious O
processing O
significantly O
increased O
the O
number O
of O
correct B-outcome ['Life-Impact']
classifications I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
short-term O
cognitive-behavioural O
group O
therapy O
programme O
for O
pathological O
gamblers O
. O
[]

One-hundred-and-twelve O
subjects O
were O
enrolled O
and O
divided O
into O
two O
groups O
; O
those O
that O
consumed O
MLCT O
oil O
and O
those O
that O
consumed O
long-chain O
triglyceride O
( O
LCT O
) O
oil O
for O
8 O
weeks O
. O
[]

Volunteers O
displayed O
the O
expected O
rise O
in O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
but O
no O
other O
clinically B-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
hematology I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
spontaneous I-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
before I-outcome ['Physiological-Clinical']
37 I-outcome ['Physiological-Clinical']
weeks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
effects O
of O
both O
the O
early O
and O
the O
late O
block O
in O
UKALL O
X O
alone O
have O
been O
reported O
previously O
. O
[]

Double-blind O
comparison O
of O
ketazolam O
, O
diazepam O
and O
placebo O
in O
once-a-day O
vs O
t.i.d O
. O
[]

Nicorandil O
( O
30 O
mg O
) O
prevents O
ergometrine-induced B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
intensively O
treated O
adults O
with O
type O
1 O
diabetes O
, O
CGM O
use O
and O
benefit O
can O
be O
sustained O
for O
12 O
months O
. O
[]

Finally O
, O
in O
all O
studies O
, O
the O
TOM O
test O
was O
found O
to O
be O
reliable O
in O
terms O
of O
internal O
consistency O
. O
[]

STUDY O
OBJECTIVE O
to O
compare O
passive O
heat O
retention O
by O
low-flow O
anesthesia O
, O
alone O
and O
with O
additional O
thermal O
insulation O
by O
reflective O
blankets O
, O
with O
forced-air O
warming O
preventing O
intraoperative O
hypothermia O
during O
combined O
epidural-general O
anesthesia O
. O
[]

Among O
children O
undergoing O
APD O
, O
neutral-pH O
, O
bicarbonate-buffered O
PD O
fluid O
provides O
more O
effective O
correction O
of O
metabolic O
acidosis O
and O
better O
preservation O
of O
peritoneal O
cell O
mass O
than O
do O
conventional O
, O
acidic O
, O
lactate-based O
fluids O
. O
[]

In O
conclusion O
, O
an O
improved O
fibrinolytic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
was O
observed O
after O
statin O
treatment O
, O
most O
pronounced O
with O
atorvastatin O
. O
['Physiological-Clinical']

Although O
the O
IL-6 O
response O
to O
exercise O
has O
been O
extensively O
studied O
, O
little O
is O
known O
about O
the O
regulation O
of O
the O
IL-6R O
response O
. O
[]

Importantly O
, O
there O
were O
no O
interactions O
by O
FLT3/internal B-outcome ['Physiological-Clinical']
tandem I-outcome ['Physiological-Clinical']
duplications I-outcome ['Physiological-Clinical']
, O
NPM1 B-outcome ['Physiological-Clinical']
, O
or O
CEBPA B-outcome ['Physiological-Clinical']
mutation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
32 O
patients O
studied O
, O
18/19 O
receiving O
Cy O
and O
7/13 O
receiving O
MP O
responded O
to O
treatment O
( O
p O
< O
0.03 O
) O
. O
[]

Mesopic B-outcome ['Physiological-Clinical']
vision I-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
glare I-outcome ['Physiological-Clinical']
was O
reduced O
from O
1:2.5 O
to O
1:7.4 O
. O
['Physiological-Clinical']

The O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
at O
three O
years O
was O
also O
very O
similar O
in O
the O
two O
groups O
( O
86 O
percent O
in O
the O
laparoscopic-surgery O
group O
and O
85 O
percent O
in O
the O
open-colectomy O
group O
; O
P=0.51 O
; O
hazard O
ratio O
for O
death B-outcome ['Mortality']
in O
the O
laparoscopic-surgery O
group O
, O
0.91 O
; O
95 O
percent O
confidence O
interval O
, O
0.68 O
to O
1.21 O
) O
, O
with O
no O
significant O
difference O
between O
groups O
in O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
patients O
with O
any O
stage O
of O
cancer O
. O
['Mortality', 'Mortality', 'Physiological-Clinical', 'Mortality']

PATIENTS/PARTICIPANTS O
573 O
patients O
who O
had O
unrecognized O
and O
untreated O
anxiety O
identified O
from O
the O
approximately O
8,000 O
patients O
who O
completed O
the O
waiting O
room O
screening O
questionnaire O
. O
[]

Informed O
physicians O
counseled O
female O
patients O
, O
harmful O
but O
nondependent O
drinkers O
, O
and O
patients O
with O
inactive O
disorders O
more O
often O
than O
their O
uninformed O
colleagues O
, O
although O
only O
the O
last O
variable O
achieved O
statistical O
significance O
. O
[]

They O
were O
randomized O
to O
receive O
a O
periprostatic O
nerve O
block O
or O
no O
anesthesia O
. O
[]

Efficacy O
of O
patient O
education O
and O
supervised O
exercise O
vs O
patient O
education O
alone O
in O
patients O
with O
hip O
osteoarthritis O
: O
a O
single O
blind O
randomized O
clinical O
trial O
. O
[]

OBJECTIVE O
Determine O
the O
effect O
of O
a O
moderate O
dose O
multivitamin/mineral O
supplement O
on O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

This O
leads O
to O
the O
fact O
that O
the O
number O
of O
evaluable O
case O
studies O
is O
often O
appreciably O
lower O
than O
the O
number O
of O
test O
participants O
and O
that O
a O
meaningful O
therapy O
group O
comparison O
may O
even O
not O
be O
possible O
under O
certain O
circumstances O
. O
[]

Total O
cell B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
TCC B-outcome ['Physiological-Clinical']
) O
, O
differential O
cell B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
DCCs B-outcome ['Physiological-Clinical']
) O
and O
IL-8 B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
sputum B-outcome ['Physiological-Clinical']
were O
determined O
at O
the O
baseline O
and O
6 O
months O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Confocal O
microscopy O
assessments O
correlated O
well O
with O
tumor O
response O
to O
therapy O
, O
suggesting O
that O
confocal O
microscopy O
may O
help O
determine O
the O
need O
for O
surgery O
. O
[]

The O
use O
of O
thrombolytic O
agents O
in O
patients O
with O
suspected O
myocardial O
infarction O
has O
been O
shown O
to O
reduce O
early O
and O
long-term O
mortality O
by O
about O
20 O
% O
, O
and O
it O
has O
been O
suggested O
that O
since O
time O
is O
an O
important O
factor O
, O
pre-hospital O
treatment O
would O
give O
better O
results O
. O
[]

OBJECTIVE O
To O
study O
the O
symptomatology O
of O
early O
hemorrhoids O
and O
to O
compare O
injection O
sclerotherapy O
( O
IS O
) O
with O
electrocoagulation O
( O
EC O
) O
in O
the O
management O
outcome O
of O
early O
haemorrhoids O
with O
respect O
to O
pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
procedure I-outcome ['Physiological-Clinical']
, O
reduction O
in O
bleeding B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
, O
and O
overall B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Phase O
2 O
nonresponders O
( O
n O
= O
10 O
) O
were O
assigned O
to O
combined O
verapamil/lithium O
in O
Phase O
3 O
. O
[]

Nineteen O
children O
with O
autism O
spectrum O
disorders O
and O
an O
anxiety O
disorder O
( O
7-11 O
years O
old O
) O
were O
randomly O
assigned O
to O
16 O
sessions O
of O
CBT O
or O
a O
waitlist O
condition O
. O
[]

Kaplan-Meier O
analysis O
( O
mean+/-SD O
follow-up O
39+/-18 O
months O
) O
revealed O
equal O
survival B-outcome ['Mortality']
in O
both O
treatment O
groups O
. O
['Mortality']

At O
median O
follow-up O
of O
35 O
months O
, O
the O
estimated O
3-year O
overall O
survival O
was O
92 O
% O
for O
negative O
SLN O
, O
64 O
% O
for O
micrometastases O
, O
53 O
% O
for O
macrometastases O
, O
and O
100 O
% O
for O
submicrometastases O
( O
P O
< O
0.001 O
) O
. O
[]

After O
the O
acupuncture O
treatment O
, O
the O
percentages O
of O
OKT3+ B-outcome ['Physiological-Clinical']
, O
OKT4+ B-outcome ['Physiological-Clinical']
, O
OKT8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
obviously O
higher O
than O
those O
before O
acupuncture O
; O
the O
control O
group O
of O
patients O
showed O
no O
significant O
variation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
correlation O
between O
[]

3 O
. O
[]

Fifteen O
and O
two O
complete O
responders O
in O
the O
cauterization O
and O
interferon O
groups O
, O
respectively O
, O
experienced O
disease B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( O
P O
less O
than O
.01 O
) O
. O
['Physiological-Clinical']

Tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
t-PA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor-1 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAI-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
at O
the O
end O
of O
a O
2-week O
run-in O
period O
on O
the O
control O
diet O
and O
after O
each O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
categorized O
into O
three O
groups O
based O
on O
R O
( O
2 O
) O
values O
calculated O
through O
trend O
line O
, O
which O
indicates O
the O
correlation O
coefficient O
between O
exponential O
graph O
and O
measured O
CEA B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
: O
exponential O
decrease O
group O
( O
group O
1 O
: O
0.9 O
< O
R O
( O
2 O
) O
< O
or O
= O
1.0 O
) O
, O
nearly O
exponential O
decrease O
group O
( O
group O
2 O
: O
0.5 O
< O
R O
( O
2 O
) O
< O
or O
= O
0.9 O
) O
, O
and O
randomized O
clearance O
group O
( O
group O
3 O
: O
0.5 O
< O
or O
= O
R O
( O
2 O
) O
) O
. O
['Physiological-Clinical']

The O
incidences O
of O
symptomatic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
laboratory I-outcome ['Physiological-Clinical']
hypocalcemia I-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
in O
Groups O
A O
( O
2.0 O
% O
and O
8.2 O
% O
, O
respectively O
) O
and O
B O
( O
12.2 O
% O
and O
24.5 O
% O
, O
respectively O
) O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

They O
were O
randomly O
divided O
into O
two O
groups O
: O
controls O
( O
group O
1 O
) O
versus O
strict O
sodium O
diet O
( O
group O
2 O
; O
80 O
to O
100 O
mmol O
sodium O
daily O
) O
. O
[]

Urinary B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
was O
decreased O
in O
a O
dose-dependent O
fashion O
and O
its O
changes O
were O
largely O
independent O
fashion O
and O
its O
changes O
were O
largely O
independent O
of O
plasma O
renin O
activity O
. O
['Physiological-Clinical']

At O
the O
time O
of O
enrollment O
, O
patients O
were O
stratified O
according O
to O
diabetes O
status O
. O
[]

To O
assess O
the O
effects O
of O
modifying O
dietary O
sodium O
intake O
, O
80 O
school O
children O
with O
blood O
pressures O
above O
the O
95th O
percentile O
for O
age O
and O
sex O
but O
below O
130/90 O
mm O
Hg O
at O
school O
screening O
were O
randomized O
to O
a O
family O
intervention O
program O
or O
a O
control O
group O
. O
[]

BACKGROUND O
Three O
methods O
of O
treating O
chalazia O
were O
compared O
: O
intralesional O
triamcinolone O
acetonide O
injections O
( O
0.2 O
mL O
of O
10 O
mg/mL O
) O
, O
incision O
and O
curettage O
and O
advice O
regarding O
the O
application O
of O
hot O
compresses O
to O
the O
affected O
eyelid O
. O
[]

We O
observed O
a O
significantly O
decreased O
absolute B-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
number I-outcome ['Physiological-Clinical']
and O
percentage O
of O
CD3 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Usually O
this O
potentiation O
is O
done O
repeatedly O
and O
the O
final O
drug O
is O
labeled O
, O
e.g. O
, O
D6 O
which O
means O
a O
6 O
times O
decimal O
potentiation O
. O
[]

GE O
also O
had O
a O
within-group O
increase O
in O
mean O
vegetable B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
after O
3 O
months O
, O
but O
this O
increase O
was O
not O
different O
from O
changes O
in O
the O
other O
groups O
. O
['Life-Impact']

Analgesic B-outcome ['Resource-use']
efficacy O
of O
piroxicam O
in O
the O
treatment O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

The O
relative O
efficacy O
of O
HAI O
FUDR O
, O
HAI O
5-FU/FA O
, O
and O
i.v O
. O
[]

Incidence O
of O
side O
effects O
seems O
low O
and O
similar O
in O
different O
three-drug O
regimens O
used O
. O
[]

There O
was O
statistical O
difference O
in O
the O
KPS B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
after O
treatment O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Although O
other O
sleep O
parameters O
showed O
lesser O
, O
usually O
insignificant O
change O
, O
patients O
' O
subjective O
ratings O
of O
RLS B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

STUDY O
DESIGN O
In O
a O
randomized O
, O
double-blind O
trial O
97 O
patients O
with O
a O
first-trimester O
hemoglobin O
level O
> O
or O
= O
14.0 O
gm/dl O
received O
either O
iron O
and O
folic O
acid O
( O
hematinic O
group O
, O
n O
= O
53 O
) O
or O
a O
placebo O
( O
n O
= O
44 O
) O
. O
[]

In O
contrast O
to O
premature O
gestations O
with O
oligohydramnios O
, O
prophylactic O
amnioinfusion O
was O
not O
associated O
with O
a O
significant O
improvement O
in O
mean O
umbilical B-outcome ['Physiological-Clinical']
arterial B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
or O
a O
significant O
decrease O
in O
['Physiological-Clinical', 'Physiological-Clinical']

Kidney O
biopsies O
were O
examined O
with O
light O
and O
electron O
microscopy O
, O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma O
flow O
determined O
with O
inulin O
and O
para-aminohippuric O
acid O
clearances O
. O
[]

Efficacy O
and O
safety O
of O
mizolastine O
10 O
mg O
in O
a O
placebo-controlled O
comparison O
with O
loratadine O
in O
chronic O
idiopathic O
urticaria O
: O
results O
of O
the O
MILOR O
Study O
. O
[]

In O
group O
1 O
( O
risedronate O
plus O
calcium/vitamin O
D-treated O
patients O
) O
, O
serum O
levels O
of O
RANKL O
and O
IL-1beta O
significantly O
decreased O
and O
the O
level O
of O
osteoprotegerin B-outcome ['Physiological-Clinical']
significantly O
increased O
after O
three O
and O
6 O
months O
, O
but O
no O
significant O
difference O
was O
found O
in O
TNF-alpha B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fifty-seven O
patients O
comprised O
the O
study O
. O
[]

Between-group O
comparisons O
failed O
to O
reveal O
any O
significant O
differences O
on O
any O
rating O
[]

Hypothetically O
, O
the O
underlying O
mechanism O
might O
have O
been O
a O
stabilization O
of O
echolucent O
, O
instable O
, O
rupture-prone O
plaques O
. O
[]

Patient O
overall O
assessment O
showed O
a O
continuous O
benefit O
in O
both O
groups O
. O
[]

We O
also O
documented O
a O
decline O
in O
mid-arm O
muscle O
area O
, O
suggesting O
depletion O
of O
muscle O
mass O
, O
while O
triceps O
skinfold O
, O
a O
marker O
of O
fat O
stores O
, O
was O
unchanged O
. O
[]

This O
study O
examines O
the O
selective O
serotonin O
reuptake O
inhibitor O
liquid O
fluoxetine O
in O
the O
treatment O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
childhood O
and O
adolescent O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
['Life-Impact']

Mean O
followup O
was O
22.3 O
( O
range O
12 O
to O
36 O
) O
and O
21.3 O
months O
( O
range O
12 O
to O
35 O
) O
in O
groups O
1 O
and O
2 O
, O
respectively O
. O
[]

CONCLUSION O
Aflibercept O
4 O
mg/kg O
plus O
irinotecan-LV5FU2 O
every O
2 O
weeks O
had O
acceptable O
toxicity O
and O
pharmacokinetics O
, O
and O
showed O
promising O
antitumour O
activity O
. O
[]

Based O
on O
a O
serum B-outcome ['Physiological-Clinical']
Tg I-outcome ['Physiological-Clinical']
level O
of O
2 O
ng/mL O
or O
more O
, O
thyroid O
tissue O
or O
cancer O
was O
detected O
during O
thyroid O
hormone O
therapy O
in O
22 O
% O
, O
after O
recombinant O
human O
TSH O
stimulation O
in O
52 O
% O
, O
and O
after O
thyroid O
hormone O
withdrawal O
in O
56 O
% O
of O
patients O
with O
disease O
or O
tissue O
limited O
to O
the O
thyroid O
bed O
and O
in O
80 O
% O
, O
100 O
% O
, O
and O
100 O
% O
of O
patients O
, O
respectively O
, O
with O
metastatic O
disease O
. O
['Physiological-Clinical']

RESULTS O
BMI O
and O
hip-waist B-outcome ['Physiological-Clinical']
ratios O
of O
patients O
in O
groups O
1 O
, O
2 O
and O
3 O
did O
not O
significantly O
differ O
. O
['Physiological-Clinical']

Although O
women O
randomized O
to O
estradiol O
showed O
improvement O
in O
all O
the O
markers O
of O
carbohydrate O
metabolism O
, O
these O
factors O
did O
not O
play O
a O
significant O
role O
in O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
progression O
. O
['Physiological-Clinical']

The O
principal O
findings O
in O
our O
study O
show O
a O
strong O
correlation O
between O
PGC-1alpha B-outcome ['Physiological-Clinical']
and O
COX5B B-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
and O
between O
PGC-1alpha B-outcome ['Physiological-Clinical']
and O
MT-CO2 B-outcome ['Physiological-Clinical']
( O
p=0.017 O
) O
expression O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
changes O
were O
all O
independent O
of O
HbA1c O
level O
. O
[]

regimens O
were O
equivalent O
( O
HIV-1 O
RNA O
level O
< O
400 O
copies/mL O
, O
178 O
[ O
64 O
% O
] O
of O
278 O
vs. O
174 O
[ O
63 O
% O
] O
of O
276 O
; O
treatment O
difference O
, O
1 O
% O
[ O
95 O
% O
CI O
, O
-7.1 O
% O
to O
8.9 O
% O
] O
; O
HIV-1 O
RNA O
level O
< O
50 O
copies/mL O
, O
165 O
[ O
59 O
% O
] O
of O
278 O
vs. O
168 O
[ O
61 O
% O
] O
of O
276 O
; O
treatment O
difference O
, O
1.7 O
% O
[ O
95 O
% O
CI O
, O
-9.7 O
% O
to O
6.6 O
% O
] O
) O
. O
[]

The O
patients O
received O
regular O
and O
individualized O
counseling O
by O
dieticians O
. O
[]

The O
neonatal O
primary O
outcomes O
are O
need O
for O
[]

Analgesia/sedation O
was O
achieved O
by O
infusion O
of O
remifentanil O
( O
0.20 O
to O
0.25 O
microg/kg/min O
) O
and O
propofol O
in O
titrated O
doses O
. O
[]

Effects O
of O
fluoride O
and O
chlorhexidine O
on O
the O
microflora O
of O
dental B-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
and O
progression O
of O
root-surface O
caries O
. O
['Physiological-Clinical']

The O
intervention O
compared O
two O
formats O
, O
a O
1 O
day O
workshop O
and O
six O
individual O
sessions O
. O
[]

RESULTS O
Seventy O
percent O
( O
n O
= O
30 O
) O
of O
the O
sample O
population O
displayed O
a O
lower B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
in O
the O
45-degree O
upright O
position O
than O
that O
obtained O
in O
the O
supine O
position O
, O
with O
the O
decrease O
ranging O
from O
1 O
% O
to O
32 O
% O
( O
mean O
decrease O
11 O
% O
) O
. O
['Physiological-Clinical']

The O
overall O
incidence O
of O
BPAR O
was O
20.1 O
% O
. O
[]

Oral O
sodium O
phosphate O
is O
a O
cost-effective O
colonoscopy O
preparation O
that O
is O
better O
tolerated O
and O
more O
effective O
than O
the O
polyethylene O
glycol-electrolyte O
lavage O
solution O
or O
castor O
oil O
. O
[]

Patients O
in O
the O
intervention O
group O
received O
clinical O
pharmacy O
services O
that O
included O
a O
clinical O
pharmacist O
performing O
patient O
medication O
reviews O
, O
with O
emphasis O
on O
preventing O
or O
resolving O
medication-related O
problems O
and O
providing O
medication O
recommendations O
. O
[]

Two O
hundred O
and O
seventy O
one O
infants O
were O
enrolled O
in O
a O
study O
to O
compare O
six O
different O
methods O
of O
treating O
the O
umbilical O
cord O
. O
[]

Effect O
of O
adhesive O
system O
type O
and O
tooth O
region O
on O
the O
bond O
strength O
to O
dentin O
. O
[]

Medium O
correlations O
were O
found O
for O
the O
oscillatory B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
and O
Raw O
, O
whereas O
for O
tc-PO2 B-outcome ['Physiological-Clinical']
and O
Raw O
the O
correlation O
was O
markedly O
lower O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
blind O
study O
was O
to O
determine O
the O
effect O
of O
a O
two-stage O
chlorhexidine O
varnish O
, O
after O
three O
months O
, O
on O
the O
gingival O
status O
of O
11- O
to O
15-year-old O
children O
attending O
a O
school O
in O
Rio O
de O
Janeiro O
, O
Brazil O
. O
[]

RESULTS O
all-E-Zeaxanthin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
from O
0.048 O
+/- O
0.026 O
micro O
mol/L O
at O
baseline O
to O
0.20 O
+/- O
0.07 O
and O
0.92 O
+/- O
0.28 O
micro O
mol/L O
with O
1 O
and O
10 O
mg O
zeaxanthin O
, O
respectively O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
One O
hundred O
seventy-five O
patients O
, O
57.1 O
% O
paroxysmal O
AF O
, O
78.5 O
% O
male O
, O
underwent O
AF O
ablation O
and O
esophagoscopy O
24 O
hours O
thereafter O
. O
[]

Treatment O
was O
safe O
, O
and O
mortality O
was O
low O
( O
in O
fact O
33 O
% O
lower O
than O
in O
the O
remainder O
of O
the O
cohort O
) O
. O
( O
[]

In O
particular O
, O
[]

In O
the O
cluster O
group O
, O
serum O
levels O
of O
specific O
IgG O
( O
Mite O
) O
( O
p O
< O
0.001 O
) O
and O
specific B-outcome ['Physiological-Clinical']
IgG4 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Mite I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
significantly O
increased O
after O
8 O
weeks O
, O
while O
it O
took O
12 O
weeks O
in O
the O
classic O
SIT O
group O
. O
['Physiological-Clinical']

Auscultation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
epigastrium I-outcome ['Physiological-Clinical']
, O
right O
and O
left O
axilla O
is O
more O
reliable O
than O
auscultation O
of O
the O
chest O
, O
and O
the O
anaesthetist O
's O
feeling O
when O
he O
squeezes O
the O
bag O
. O
['Physiological-Clinical']

The O
preschool O
SCRPA O
Curriculum O
( O
ages O
2-5 O
) O
consisted O
of O
six O
1-hour O
classes O
scheduled O
twice O
a O
week O
for O
3 O
weeks O
. O
[]

The O
main O
factor O
that O
determined O
irreversibility O
of O
renal O
failure O
was O
the O
severity O
of O
myeloma O
cast O
formation O
. O
[]

CONCLUSION O
These O
results O
suggest O
that O
long-lasting O
analgesic O
effects O
of O
intrathecal O
0.5 O
mg O
morphine O
suppress O
the O
immune O
response O
following O
abdominal O
surgery O
. O
[]

The O
number O
of O
patients O
presenting O
a O
level O
of O
plateau O
increased O
in O
the O
active O
group O
( O
from O
two O
to O
four O
) O
and O
decreased O
in O
the O
placebo O
group O
( O
from O
two O
to O
one O
) O
. O
[]

Maprotiline O
was O
used O
as O
a O
reference O
drug O
: O
fourteen O
patients O
were O
assigned O
to O
receive O
diclofensine O
and O
thirteen O
to O
receive O
maprotiline O
in O
a O
double-blind O
design O
. O
[]

Polyunsaturated O
fatty O
acids O
( O
but O
not O
placebo O
) O
treatment O
also O
significantly O
increased O
R-R B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
total O
variance O
and O
low-frequency O
and O
high-frequency O
spectral O
powers O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVE O
In O
this O
study O
, O
our O
aim O
was O
to O
evaluate O
the O
effects O
of O
intravenous O
dexketoprofen O
trometamol O
with O
ilioinguinal O
and O
iliohypogastric O
nerve O
block O
on O
analgesic O
quality O
and O
morphine O
consumption O
after O
total O
abdominal O
hysterectomy O
operations O
. O
[]

= O
0.05 O
) O
. O
[]

METHODS O
Forty-one O
cases O
of O
PGS O
were O
randomly O
divided O
into O
3 O
groups O
in O
order O
of O
visiting O
. O
[]

Those O
subjects O
remaining O
on O
fluoxetine O
for O
a O
year O
had O
reduced O
relapse B-outcome ['Physiological-Clinical']
as O
determined O
by O
a O
significant O
increase O
in O
weight O
and O
reduction O
['Physiological-Clinical']

Cerebral O
structures O
specifically O
activated O
by O
nicotine O
( O
nicotine O
minus O
pepper O
, O
Z O
score O
> O
4.0 O
) O
included O
: O
left O
inferior O
frontal O
gyrus O
, O
left O
posterior O
cingulate O
gyrus O
and O
right O
thalamus O
. O
[]

CONCLUSIONS O
This O
study O
suggests O
that O
primary O
care-based O
AOD O
can O
be O
safely O
and O
effectively O
carried O
out O
by O
primary O
care O
providers O
and O
that O
clonidine/naltrexone O
may O
be O
more O
effective O
in O
this O
setting O
than O
is O
clonidine O
alone O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Hemodynamic O
, O
respiratory O
, O
and O
intraocular O
pressure O
monitoring O
was O
done O
. O
[]

PATIENTS O
AND O
METHODS O
We O
studied O
444 O
group O
III O
patients O
who O
received O
induction O
therapy O
, O
had O
response O
assessed O
at O
week O
8 O
by O
anatomic O
imaging O
, O
and O
continued O
with O
protocol O
therapy O
. O
[]

and O
anal O
manometry B-outcome ['Resource-use']
showed O
a O
significant O
postoperative O
decrease O
only O
in O
resting O
pressure O
after O
straight O
colo-anal O
anastomosis O
( O
p O
< O
0.001 O
) O
. O
['Resource-use']

It O
probably O
improves O
systemic O
and O
pulmonary O
hemodynamics O
, O
which O
could O
help O
in O
the O
treatment O
of O
diastolic O
heart O
failure O
. O
[]

A O
randomized O
, O
placebo- O
and O
active-controlled O
study O
of O
paliperidone O
extended-release O
as O
maintenance O
treatment O
in O
patients O
with O
bipolar O
I O
disorder O
after O
an O
acute O
manic O
or O
mixed O
episode O
. O
[]

Eliciting O
symptom O
and O
quality O
of O
life O
information O
from O
patients O
is O
an O
important O
component O
of O
medical O
and O
nursing O
care O
processes O
. O
[]

Compared O
with O
patients O
without O
LV O
hypertrophy O
, O
those O
patients O
with O
non-Q-wave O
AMI O
and O
LV O
hypertrophy O
had O
a O
2-fold O
higher O
incidence O
of O
reinfarction B-outcome ['Physiological-Clinical']
( O
24 O
vs O
12 O
% O
, O
p O
less O
than O
0.005 O
) O
and O
death O
( O
19 O
vs O
9 O
% O
, O
p O
= O
0.044 O
) O
during O
the O
first O
year O
of O
follow-up O
. O
['Physiological-Clinical']

The O
root O
canals O
of O
55 O
human O
maxillary O
anterior O
teeth O
were O
prepared O
using O
a O
step-back O
technique O
and O
the O
smear O
layer O
removed O
with O
17 O
% O
ethylenediaminetetraacetic O
acid O
. O
[]

The O
authors O
reported O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
results O
from O
these O
studies O
. O
['Mortality']

Those O
in O
mastectomy O
group O
received O
further O
excision O
or O
radiotherapy O
for O
locoregional O
recurrence O
and O
when O
local O
treatments O
had O
been O
exhausted O
or O
metastatic O
disease O
diagnosed O
they O
received O
tamoxifen O
. O
[]

The O
investigation O
was O
performed O
as O
a O
double-blind O
cross-over O
study O
in O
20 O
patients O
with O
ventricular O
arrhythmias O
( O
VA O
) O
of O
various O
origin O
. O
[]

Statistically O
significant O
( O
p O
less O
than O
0.01 O
) O
was O
the O
difference O
in O
postoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
evaluated I-outcome ['Physiological-Clinical']
with O
particular O
attention O
in O
patients O
of O
advanced O
age O
. O
['Physiological-Clinical']

The O
respective O
RBE B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
for O
early O
and O
late O
effects O
in O
the O
bowel O
are O
less O
than O
3.4 O
and O
3.8 O
. O
['Physiological-Clinical']

Volunteers O
were O
randomly O
assigned O
to O
one O
of O
three O
following O
groups O
: O
group O
A O
( O
receiving O
5*10 O
( O
9 O
) O
cfu/day O
of O
L. O
plantarum O
CECT O
7315/7316 O
in O
20 O
g O
powdered O
skim O
milk O
) O
, O
group O
B O
( O
receiving O
5*10 O
( O
8 O
) O
cfu/day O
of O
L. O
plantarum O
CECT O
7315/7316 O
in O
20 O
g O
powdered O
skim O
milk O
) O
and O
group O
C O
or O
placebo O
( O
20 O
g O
powered O
skim O
milk O
) O
. O
[]

Naltrexone O
and O
communication O
skills O
in O
young O
children O
with O
autism O
. O
[]

Postprandial B-outcome ['Physiological-Clinical']
AUC I-outcome ['Physiological-Clinical']
( O
0-2 O
h B-outcome ['Physiological-Clinical']
) O
of O
intact B-outcome ['Physiological-Clinical']
glucagon-like B-outcome ['Physiological-Clinical']
peptide-1 I-outcome ['Physiological-Clinical']
, O
the O
principal O
mediator O
of O
the O
biological O
effects O
of O
DPP4 O
inhibitors O
, O
was O
increased O
by O
3.90 O
+/- O
2.83 O
, O
11.63 O
+/- O
2.86 O
, O
16.42 O
+/- O
2.72 O
and O
15.75 O
+/- O
2.71 O
pmol/l O
x O
h O
, O
respectively O
, O
for O
placebo O
and O
100 O
, O
200 O
and O
400 O
mg O
( O
p O
= O
0.053 O
, O
0.001 O
and O
0.002 O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SEM O
) O
number O
of O
F O
& O
V O
portions/day O
consumed O
by O
the O
HF O
and O
LF O
groups O
at O
baseline O
( O
3.8 O
? O
[]

STUDY O
DESIGN O
A O
randomized O
, O
single-blinded O
study O
was O
designed O
. O
[]

Patients O
were O
evaluated O
for O
color O
at O
baseline O
, O
immediately O
after O
treatment O
and O
at O
one O
, O
two O
, O
four O
and O
six O
weeks O
after O
treatment O
using O
a O
colorimeter O
, O
shade O
guide O
and O
photos O
. O
[]

BACKGROUND O
Combined O
intracoronary O
and O
intramyocardial O
administration O
might O
improve O
outcomes O
for O
bone-marrow-derived O
stem O
cell O
therapy O
for O
acute O
myocardial O
infarction O
( O
AMI O
) O
. O
[]

During O
the O
initial O
, O
medication-free O
exercise O
all O
patients O
had O
increased O
pulmonary B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
wedge I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAWP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
31.4 O
+/- O
5.56 O
mmHg O
( O
mean O
+/- O
SD O
) O
, O
showing O
impaired O
left O
ventricular O
function O
, O
while O
mean O
arterial B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
( O
MAP O
) O
rose O
from O
112 O
+/- O
16.3 O
mmHg O
at O
rest O
to O
141 O
+/- O
15.9 O
mmHg O
during O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
pattern O
of O
ipilimumab-induced O
antibody O
titers O
to O
microbial O
flora O
and O
the O
histologic O
features O
and O
location O
of O
the O
inflammation O
were O
distinct O
from O
classic O
IBD O
. O
[]

Nerve B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
were O
significantly O
more O
frequent O
after O
open O
Shouldice O
and O
Lichtenstein O
repairs O
. O
['Physiological-Clinical']

PRL-8-53 O
: O
enhanced O
learning B-outcome ['Life-Impact']
and O
subsequent O
retention B-outcome ['Life-Impact']
in O
humans O
as O
a O
result O
of O
low O
oral O
doses O
of O
new O
psychotropic O
agent O
. O
['Life-Impact', 'Life-Impact']

Significant O
improvements O
in O
oxygenation B-outcome ['Physiological-Clinical']
( O
Pao2/Fio2 O
) O
occurred O
in O
EPA+GLA O
patients O
on O
study O
day O
4 O
as O
compared O
with O
controls O
. O
['Physiological-Clinical']

The O
combination O
gave O
a O
significantly O
greater O
reduction O
than O
either O
drug O
alone O
( O
-15.1 O
+/- O
1.13 O
mm O
Hg O
) O
. O
[]

Histopathologic O
examinations O
of O
nasopharyngeal O
biopsies O
were O
performed O
for O
all O
36 O
patients O
. O
[]

In O
two O
institutions O
, O
although O
the O
[]

Each O
patient O
contributed O
only O
once O
to O
each O
phase O
, O
but O
some O
entered O
both O
phases O
on O
separate O
occasions O
. O
[]

Solutions O
were O
used O
for O
skin O
disinfection O
before O
catheter O
insertion O
( O
2 O
consecutive O
30-second O
applications O
separated O
by O
a O
period O
sufficiently O
long O
to O
allow O
for O
dryness O
) O
and O
then O
as O
single O
applications O
during O
subsequent O
dressing O
changes O
( O
every O
72 O
hours O
, O
or O
earlier O
if O
soiled O
or O
wet O
) O
. O
[]

Two O
mothers O
were O
taught O
to O
use O
RIT O
to O
teach O
object O
imitation O
. O
[]

The O
formal O
, O
or O
'hard O
' O
, O
process O
of O
[]

Prevention O
of O
coronary O
spasm O
by O
nicorandil O
: O
comparison O
with O
nifedipine O
. O
[]

Hemolytic O
streptococcus O
preparation O
OK-432 O
; O
beneficial O
adjuvant O
therapy O
in O
recurrent O
gastric O
carcinoma O
. O
[]

CONCLUSIONS O
Valacyclovir O
treatment O
did O
not O
reduce O
the O
formation O
of O
active B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in O
patients O
with O
relapsing-remitting O
MS O
who O
had O
two O
or O
more O
relapses O
during O
the O
previous O
2-year O
period O
. O
['Physiological-Clinical']

PATIENTS O
Seven O
healthy O
men O
and O
women O
. O
[]

IIT O
was O
associated O
with O
significantly O
greater O
improvements O
in O
E-selectin B-outcome ['Physiological-Clinical']
( O
p O
< O
0.0001 O
) O
than O
CIT O
( O
group O
1 O
, O
p=0.026 O
and O
group O
2 O
, O
p=0.053 O
) O
. O
['Physiological-Clinical']

The O
incidence O
of O
secondary B-outcome ['Physiological-Clinical']
pneumonia I-outcome ['Physiological-Clinical']
was O
reduced O
from O
42 O
% O
to O
17.5 O
% O
( O
not O
significant O
) O
. O
['Physiological-Clinical']

Monitoring O
tumour O
cells O
in O
the O
peripheral O
blood O
of O
small O
cell O
lung O
cancer O
patients O
. O
[]

Two O
separate O
research O
laboratories O
undertook O
independent O
randomized O
repeated O
measures O
experiments O
, O
both O
designed O
to O
detect O
an O
effect O
of O
the O
rubber O
hand O
illusion O
on O
experimentally O
induced O
hand B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Hydrocodone O
7.5 O
mg O
with O
ibuprofen O
200 O
mg O
is O
the O
only O
approved O
fixed-dose O
combination O
analgesic O
containing O
an O
opioid O
and O
ibuprofen O
. O
[]

Three O
( O
6 O
% O
) O
first O
attempts O
failed B-outcome ['Physiological-Clinical']
in O
the O
active O
warming O
group O
compared O
with O
14 O
( O
28 O
% O
) O
in O
the O
passive O
insulation O
group O
( O
P=0.008 O
) O
. O
['Physiological-Clinical']

RESULTS O
alpha-Linolenic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
increased O
significantly O
in O
both O
groups O
during O
the O
experimental O
phase O
to O
a O
similar O
extent O
. O
['Physiological-Clinical']

INTERVENTION O
After O
pre-screening O
and O
a O
washout O
period O
of O
at O
least O
14 O
days O
, O
eligible O
volunteers O
received O
ASA O
81 O
mg O
with O
or O
without O
esomeprazole O
20 O
mg O
once O
daily O
for O
5 O
days O
in O
randomized O
order O
, O
with O
a O
14-day O
washout O
between O
treatments O
. O
[]

RESULTS O
The O
infiltrating O
growth O
pattern O
was O
significantly O
associated O
with O
histological O
subtype O
and O
lymphovascular O
invasion O
, O
while O
high-grade O
budding O
was O
significantly O
associated O
with O
tumor B-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
and O
lymphovascular B-outcome ['Physiological-Clinical']
invasion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
presence O
of O
cancer O
, O
infection O
, O
age O
over O
60 O
years O
, O
upper O
gastrointestinal O
disease O
, O
and O
longer O
length O
of O
hospital O
stay O
all O
negatively O
influenced O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
intravenous O
iron O
combined O
with O
low-dose O
recombinant O
human O
erythropoietin O
on O
transfusion B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
in O
iron-deficient O
patients O
undergoing O
bilateral O
total O
knee O
replacement O
arthroplasty O
. O
['Resource-use']

There O
are O
little O
data O
on O
the O
effect O
of O
compression O
on O
the O
accuracy O
of O
coronary O
angiography O
. O
[]

Randomized O
clinical O
trial O
comparing O
laparoscopic O
and O
open O
surgery O
in O
patients O
with O
rectal O
cancer O
. O
[]

A O
randomised O
, O
controlled O
study O
of O
dietary O
intervention O
in O
autistic O
syndromes O
. O
[]

PATIENTS O
OR O
OTHER O
PARTICIPANTS O
Twenty-seven O
healthy O
volunteers O
. O
[]

In O
conclusion O
, O
laparoscopic O
treatment O
of O
endometrial O
cancer O
is O
safe O
in O
the O
hands O
of O
experienced O
operators O
with O
minimal O
intraoperative O
and O
postoperative O
complications O
. O
[]

METHODS O
From O
September O
2002 O
to O
December O
2004 O
, O
68 O
closed O
fractures O
of O
the O
distal O
femur O
were O
treated O
by O
bridge O
plate O
osteosynthesis O
using O
DCS O
in O
31 O
and O
RIMSN O
in O
37 O
. O
[]

There O
are O
some O
benefits O
for O
eradicating O
Helicobacter O
pylori O
in O
patients O
with O
non-ulcer O
dyspepsia O
. O
[]

Patients O
are O
followed O
up O
every O
3 O
months O
for O
2 O
years O
to O
assess O
shock B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
efficacy O
of O
spontaneous B-outcome ['Physiological-Clinical']
arrhythmias B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
A O
few O
simple O
clinical O
variables O
measured O
on O
admission O
in O
patients O
with O
acute O
heart O
failure O
predict O
a O
variety O
of O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
with O
accuracy O
similar O
to O
more O
complex O
models O
. O
['Adverse-effects']

Sixty-three O
women O
with O
evidence O
of O
underlying O
hypertensive O
disease O
were O
followed O
prospectively O
throughout O
pregnancy O
. O
[]

METHODS O
In O
this O
randomised O
cross-over O
pilot O
study O
, O
participants O
performed O
a O
self-timed O
30 O
minute O
brisk O
walk O
in O
two O
different O
environments O
, O
park O
and O
urban O
, O
in O
Glasgow O
, O
Scotland O
( O
October O
2009 O
to O
January O
2010 O
) O
. O
[]

Between O
July O
1 O
, O
1971 O
and O
December O
31 O
, O
1978 O
, O
150 O
patients O
with O
favorable O
subtypes O
of O
non-Hodgkin O
's O
lymphoma O
[ O
nodular O
poorly O
differentiated O
lymphocytic O
( O
NLPD O
) O
, O
nodular O
mixed O
, O
or O
diffuse O
well O
differentiated O
lymphocytic O
] O
were O
entered O
into O
prospective O
randomized O
clinical O
trials O
at O
Stanford O
University O
. O
[]

Thirty O
alpacas O
, O
all O
positive O
for O
Chorioptes O
sp O
. O
[]

However O
, O
this O
effect O
lasts O
only O
12 O
hours O
without O
reducing O
the O
morphine B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
due O
to O
an O
increase O
of O
pain O
from O
the O
primary O
surgical O
site O
. O
['Life-Impact']

The O
drug O
conversion O
resulted O
in O
significant O
reduction O
of O
ALT/AST B-outcome ['Physiological-Clinical']
level O
from O
255.13+/-31.38/201.88+/-21.25 O
U/L O
to O
31.25+/-11.50/25.13+/-9.68 O
U/L O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Major O
Outcome O
Measure O
: O
We O
measured O
insulin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
response O
to O
iv B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
and O
arginine B-outcome ['Physiological-Clinical']
before O
and O
after O
treatment O
and O
after O
drug O
washout O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
In O
this O
prospective O
, O
randomized O
, O
single-center O
study O
, O
patients O
were O
randomly O
allocated O
to O
2 O
treatment O
arms O
: O
syncope O
unit O
evaluation O
and O
standard O
care O
. O
[]

Calcium O
acetate O
versus O
calcium O
carbonate O
as O
phosphate O
binders O
in O
hemodialysis O
patients O
. O
[]

Safety O
was O
satisfactory O
in O
all O
groups O
. O
[]

When O
observing O
responses O
were O
prompted O
, O
participants O
' O
accuracy O
scores O
improved O
. O
[]

The O
intervention O
aimed O
to O
increase O
knowledge O
about O
soil-transmitted O
helminths O
, O
induce O
behavioral B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
, O
and O
reduce O
the O
rate O
of O
infection B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Of O
the O
120 O
patients O
enrolled O
, O
112 O
completed O
the O
trial O
; O
58 O
in O
the O
treatment O
group O
and O
54 O
in O
the O
placebo O
group O
. O
[]

The O
mean O
period O
of O
interferon O
therapy O
, O
starting O
at O
a O
mean O
65 O
days O
( O
26-160 O
) O
post O
second O
hemi-body O
irradiation O
, O
is O
16.4 O
months O
( O
2-33.5 O
) O
. O
[]

During O
surgery O
, O
resected O
suburethral O
and O
hyperplastic O
prostate O
specimens O
were O
sent O
for O
histopathologic O
MVD O
determination O
separately O
. O
[]

However O
, O
its O
effects O
on O
the O
late O
phase O
remain O
unclear O
. O
[]

1.59 O
years O
, O
respectively O
. O
[]

For O
non-cued O
movements O
, O
abnormalities O
in O
MRPs O
for O
Parkinson O
's O
disease O
subjects O
consisted O
of O
delayed B-outcome ['Physiological-Clinical']
MRP I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
and O
peak O
times O
, O
and O
prolonged O
cortical O
activity O
following O
movement O
. O
['Physiological-Clinical']

Continuous O
chemotherapy O
in O
responsive O
metastatic O
breast O
cancer O
: O
a O
role O
for O
tumour O
markers O
? O
[]

OBJECTIVES O
To O
present O
clinical O
evidence O
with O
botulinum O
toxin O
A O
( O
BTX-A O
) O
suggesting O
an O
antinociceptive B-outcome ['Physiological-Clinical']
role I-outcome ['Physiological-Clinical']
in O
patients O
with O
interstitial O
cystitis O
( O
IC O
) O
. O
['Physiological-Clinical']

RESULTS O
Bednet B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
among O
the O
560 O
households O
in O
the O
study O
, O
increased O
from O
6 O
to O
91 O
% O
after O
6 O
months O
. O
['Life-Impact']

Vaccination O
of O
close O
household O
contacts O
is O
recommended O
to O
provide O
indirect O
protection O
to O
children O
< O
6 O
months O
of O
age O
. O
[]

CONCLUSION O
This O
study O
showed O
that O
LOLA O
ameliorated O
the O
deleterious O
psychometric B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
of O
glutamine O
in O
Child O
's O
grade O
B O
and O
C O
patients O
with O
cirrhosis O
without O
TIPS O
and O
supports O
its O
use O
in O
clinical O
practice O
in O
hepatic O
encephalopathy O
. O
['Life-Impact']

The O
toxicities O
of O
TG O
preclude O
its O
protracted O
use O
as O
given O
in O
this O
study O
. O
[]

PURPOSE O
To O
evaluate O
the O
effects O
of O
gaseous O
ozone O
application O
on O
enamel O
and O
dentin O
bond O
strength O
produced O
by O
two O
self-etching O
adhesive O
systems O
. O
[]

CONCLUSION O
Both O
study O
groups O
were O
effective O
in O
the O
prevention O
of O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
with O
respect O
to O
control O
( O
P O
< O
0.01 O
in O
Group O
1 O
and O
P O
< O
0.001 O
in O
Group O
2 O
) O
. O
['Physiological-Clinical']

INTERVENTION O
Uptitration O
of O
guideline-based O
treatments O
to O
reduce O
symptoms O
to O
NYHA O
class O
of O
II O
or O
less O
( O
symptom-guided O
therapy O
) O
and O
BNP O
level O
of O
2 O
times O
or O
less O
the O
upper O
limit O
of O
normal O
and O
symptoms O
to O
NYHA O
class O
of O
II O
or O
less O
( O
BNP-guided O
therapy O
) O
. O
[]

Conversely O
, O
interferon O
and O
5-fluorouracil O
are O
relatively O
ineffective O
as O
primary O
therapies O
. O
[]

Mild B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
to O
7vPnC O
were O
more O
common O
in O
the O
experimental O
group O
than O
the O
control O
group O
( O
100 O
% O
vs O
81.3 O
% O
; O
P O
= O
.002 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
There O
is O
an O
advantage O
to O
administering O
xylitol O
and O
fructose O
with O
regard O
to O
the O
intestinal B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
and O
concomitant O
symptoms O
as O
compared O
with O
sorbitol O
. O
['Physiological-Clinical']

Although O
there O
were O
significantly O
more O
babies O
in O
the O
vacuum O
extractor O
group O
with O
cephalhaematomata B-outcome ['Physiological-Clinical']
( O
9 O
% O
vs O
3 O
% O
, O
OR O
3.3 O
; O
95 O
% O
CI O
1.4-7.4 O
) O
there O
were O
fewer O
babies O
in O
the O
vacuum O
extractor O
group O
with O
other O
facial B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
selected O
high-risk O
individuals O
in O
group O
I O
developed O
0.25 O
new O
manifest O
caries O
lesions O
approximally/year O
, O
compared O
with O
0.27 O
for O
all O
children O
of O
the O
same O
age O
group O
in O
the O
area O
. O
[]

The O
acellular O
vaccines O
produced O
significantly O
fewer O
local B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
systemic I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Knowledge O
gain O
showed O
significant O
differences O
between O
the O
two O
learning O
approaches O
( O
student-directed O
16.5 O
( O
3.7 O
) O
; O
structured O
29.1 O
( O
3.8 O
) O
, O
difference O
= O
12.6 O
( O
95 O
% O
CI O
11.3 O
to O
13.9 O
) O
) O
. O
['Life-Impact']

Femoral O
vein O
delivery O
of O
contrast O
medium O
enhances O
transthoracic B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Only O
in O
Arkansas O
did O
the O
treatment-control O
difference O
in O
total O
cost B-outcome ['Resource-use']
shrink O
over O
time-to O
less O
than O
5 O
percent O
( O
and O
statistically O
insignificant O
) O
in O
year O
2 O
. O
['Resource-use']

RESULTS O
Compared O
with O
findings O
before O
IoA O
, O
dogs O
receiving O
the O
K-P O
or O
K-D O
treatment O
had O
increased O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
, O
oxygen B-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
2-year O
survival B-outcome ['Mortality']
figures O
were O
33 O
% O
for O
the O
daily O
fractionation O
technique O
and O
22 O
% O
for O
the O
weekly O
regimen O
. O
['Mortality']

Our O
data O
, O
in O
combination O
with O
data O
from O
other O
studies O
, O
suggest O
that O
SJW O
has O
little O
role O
in O
the O
treatment O
of O
tobacco O
dependence O
. O
[]

No O
drug-related B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
. O
['Adverse-effects']

RACOMIP O
is O
a O
population-based O
, O
randomized O
trial O
of O
the O
effectiveness O
and O
cost-effectiveness O
of O
different O
interventions O
aimed O
at O
increasing O
participation O
in O
a O
well-run O
cervical O
cancer O
screening O
program O
in O
western O
Sweden O
. O
['Resource-use']

The O
former O
can O
reflect O
more O
sensitively O
antiangiogenic O
efficacy O
and O
the O
latter O
is O
more O
sensitive O
to O
shrinkage O
or O
swelling O
of O
tumors O
. O
[]

This O
study O
compared O
the O
efficacy O
and O
safety O
of O
5-fluorouracil O
( O
5-FU O
) O
monotherapy O
to O
that O
of O
5-FU O
combined O
with O
natural O
human O
interferon-beta O
( O
IFN-beta O
) O
in O
patients O
with O
unresectable O
, O
advanced O
colorectal O
carcinoma O
. O
[]

We O
aimed O
to O
investigate O
the O
efficacy O
of O
sodium O
bicarbonate O
by O
comparing O
2 O
other O
regimens O
, O
including O
combination O
of O
N-acetylcysteine O
( O
NAC O
) O
plus O
sodium O
chloride O
and O
sodium O
chloride O
alone O
, O
to O
prevent O
CIN O
in O
patients O
undergoing O
cardiovascular O
procedures O
. O
[]

These O
models O
included O
a O
dichotomised O
version O
of O
DUP O
( O
short O
versus O
long O
duration O
) O
as O
a O
fixed O
effect O
, O
several O
adjusting O
variables O
to O
account O
for O
patient O
differences O
, O
and O
a O
random O
effect O
to O
incorporate O
the O
longitudinal O
structure O
of O
the O
data O
. O
[]

Fifty O
percent O
of O
the O
patients O
in O
each O
group O
were O
randomly O
assigned O
to O
receive O
prostheses O
oriented O
in O
a O
perpendicular O
or O
a O
parallel O
position O
with O
respect O
to O
the O
ventricular O
septum O
. O
[]

These O
women O
were O
also O
more O
dissatisfied B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
number I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
visits I-outcome ['Life-Impact']
they O
received O
( O
odds O
ratio O
2.50 O
; O
2.00 O
to O
3.11 O
) O
. O
['Life-Impact']

but O
moist O
desquamation O
developed O
in O
42 O
% O
of O
patients O
in O
the O
b.i.d O
. O
[]

This O
study O
evaluated O
the O
effects O
of O
low O
amounts O
of O
nitric O
oxide O
, O
iloprost O
( O
prostacyclin O
analog O
) O
, O
and O
their O
combination O
administered O
directly O
into O
the O
oxygenator O
on O
platelet O
function O
, O
platelet-leukocyte O
interactions O
, O
and O
postoperative O
blood O
loss O
in O
patients O
undergoing O
coronary O
artery O
bypass O
grafting O
. O
[]

Skin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
thromboxane O
synthetase O
inhibitor O
after O
topical O
application O
with O
bioelastic O
membrane O
. O
['Physiological-Clinical']

METHODS O
& O
MATERIALS O
This O
double-blind O
study O
at O
three O
centers O
enrolled O
60 O
subjects O
, O
injected O
with O
both O
products O
, O
randomly O
assigned O
to O
left O
or O
right O
nasolabial O
fold O
. O
[]

CONCLUSIONS O
Assisted O
vaginal O
delivery O
using O
the O
new O
vacuum O
extractor O
policy O
is O
associated O
with O
significantly O
less O
maternal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
than O
with O
forceps O
. O
['Physiological-Clinical']

CONCLUSION O
MEC O
therapy O
used O
in O
this O
study O
is O
promising O
in O
terms O
of O
the O
antitumor B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Detection O
of O
recurrent B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
persistent I-outcome ['Physiological-Clinical']
nasopharyngeal I-outcome ['Physiological-Clinical']
carcinomas I-outcome ['Physiological-Clinical']
after O
radiotherapy O
with O
technetium-99m O
methoxyisobutylisonitrile O
single O
photon O
emission O
computed O
tomography O
and O
computed O
tomography O
: O
comparison O
with O
18-fluoro-2-deoxyglucose O
positron O
emission O
tomography O
. O
['Physiological-Clinical']

Effect O
of O
exercise O
, O
training O
, O
and O
glycogen O
availability O
on O
IL-6 O
receptor O
expression O
in O
human O
skeletal O
muscle O
. O
[]

CLINICAL O
TRIAL O
REGISTRATION O
http O
: O
//www.clinicaltrials.gov O
. O
[]

Anhedonia B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
lack I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
pleasure I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
was O
assessed O
as O
one O
of O
the O
core O
symptoms O
of O
major O
depression O
and O
chronic B-outcome ['Physiological-Clinical']
depression O
( O
dysthymia O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Increasing O
the O
plasma O
glucose O
and O
insulin O
concentrations O
during O
prolonged O
variable O
intensity O
exercise O
by O
supplementing O
with O
carbohydrate O
has O
been O
found O
to O
spare O
muscle O
glycogen O
and O
increase O
aerobic B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Subjects O
were O
54 O
outpatients O
who O
met O
DSM O
III-R O
criteria O
for O
active O
cocaine O
dependence O
and O
who O
completed O
a O
minimum O
of O
2 O
weeks O
of O
treatment O
. O
[]

This O
study O
describes O
a O
computerized O
serial O
ECG O
classification O
program O
developed O
at O
the O
St. O
Louis O
University O
Core O
ECG O
Laboratory O
for O
use O
in O
the O
Bypass O
Angioplasty O
Revascularization O
Investigation O
( O
BARI O
) O
trial O
, O
in O
which O
patients O
with O
multivessel O
coronary O
artery O
disease O
were O
randomized O
to O
receive O
either O
coronary O
artery O
bypass O
grafting O
or O
percutaneous O
transluminal O
coronary O
angioplasty O
. O
[]

The O
diameters O
of O
RFA-induced B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
between O
the O
groups O
( O
group O
1 O
: O
27 O
, O
range O
23-37 O
mm O
; O
group O
2 O
: O
23 O
, O
0-42 O
mm O
) O
. O
['Physiological-Clinical']

RESULTS O
Mean O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
level O
at O
the O
end O
of O
washout O
was O
2.5 O
+/- O
0.5 O
mmol/l O
( O
7.7 O
+/- O
1.5 O
mg/dl O
; O
n=73 O
) O
, O
and O
there O
was O
no O
evidence O
of O
a O
difference O
in O
levels O
between O
the O
treatment O
groups O
pre-randomization O
. O
['Physiological-Clinical']

BACKGROUND O
Emergency O
Clinical O
Pathways O
( O
ECP O
) O
for O
stroke O
have O
never O
been O
tested O
in O
randomized O
controlled O
trials O
( O
RCTs O
) O
. O
[]

Repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
has O
shown O
promising O
results O
in O
improving B-outcome ['Life-Impact']
gait I-outcome ['Life-Impact']
, O
a O
major O
cause O
of O
disability B-outcome ['Life-Impact']
, O
and O
may O
provide O
a O
therapeutic O
alternative O
. O
['Life-Impact', 'Life-Impact']

However O
, O
the O
uremic O
patients O
did O
not O
show O
the O
habitual O
post-peak O
fall O
, O
remaining O
GH B-outcome ['Physiological-Clinical']
levels O
over O
10 O
micrograms/l O
till O
the O
end O
of O
the O
test O
. O
['Physiological-Clinical']

A O
higher O
percentage O
of O
patients O
in O
the O
intervention O
group O
, O
relative O
to O
the O
control O
group O
, O
were O
able O
to O
reduce O
the O
use O
of O
antihypertensive B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
( O
31 O
vs. O
8 O
% O
, O
P O
< O
0.0001 O
) O
, O
and O
fewer O
patients O
in O
this O
group O
required O
additional B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
or O
increases O
in O
dosage O
relative O
to O
the O
controls O
( O
11 O
vs. O
28 O
% O
, O
P O
= O
0.03 O
) O
. O
['Resource-use', 'Resource-use']

An O
inception O
cohort O
of O
patients O
enrolled O
in O
the O
Beta-Blocker O
in O
Heart O
Attack O
Trial O
( O
n O
= O
2830 O
) O
was O
included O
. O
[]

Our O
patients O
were O
twenty-one O
adult O
patients O
with O
common O
variable O
immunodeficiency O
. O
[]

Therefore O
, O
selection O
bias O
, O
with O
overestimation O
of O
the O
reference O
values O
, O
is O
a O
likely O
consequence O
. O
[]

Patients O
randomized O
to O
stent O
implantation O
were O
supported O
by O
selective O
pressure-regulated O
retroinfusion O
of O
the O
anterior O
cardiac O
vein O
during O
ischemia O
. O
[]

Pharmacokinetic B-outcome ['Physiological-Clinical']
data O
were O
analyzed O
using O
the O
NONMEM O
software O
program O
( O
GloboMax O
, O
Hanover O
, O
MD O
, O
USA O
) O
. O
['Physiological-Clinical']

During O
the O
48 O
hours O
prior O
to O
the O
study O
, O
351 O
( O
74.8 O
% O
) O
patients O
had O
been O
treated O
with O
opioid O
or O
opioid-nonopioid O
combination O
analgesics O
. O
[]

Daily O
diaries O
were O
used O
to O
record O
changes O
in O
narcolepsy B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Cognitive O
psychotherapy O
and O
family O
counselling O
improved O
both O
depression B-outcome ['Life-Impact']
and O
quality O
of O
life O
indexes O
compared O
with O
the O
control O
group O
. O
['Life-Impact']

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
for O
outpatient O
oral O
surgery O
. O
['Physiological-Clinical']

Mean O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
after O
bronchodilator O
remained O
significantly O
higher O
throughout O
the O
study O
with O
fluticasone O
propionate O
compared O
with O
placebo O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Speakers O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
( O
trained O
vs O
untrained O
) O
. O
[]

Among O
these O
patients O
, O
48 O
( O
47 O
% O
) O
had O
metastatic O
deposits O
> O
2 O
mm O
( O
macrometastasis O
) O
, O
49 O
( O
47 O
% O
) O
had O
metastatic O
deposits O
< O
or O
=2 O
mm O
but O
> O
0.2 O
mm O
( O
micrometastasis O
) O
, O
and O
6 O
( O
6 O
% O
) O
had O
metastatic O
deposits O
< O
or O
=0.2 O
mm O
( O
submicrometastasis O
) O
. O
[]

Acute O
and O
short-term O
effects O
of O
secondhand O
smoke O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
cytokine B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty-four O
healthy O
males O
( O
age O
, O
35-48 O
years O
) O
participated O
in O
the O
study O
. O
[]

After O
a O
total O
of O
15,000 O
protein O
nitrogen O
units O
( O
PNU O
) O
had O
been O
given O
, O
blocking B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
monomer O
group O
rose O
from O
a O
mean O
of O
170 O
ng O
AgE O
bound O
per O
ml O
to O
a O
mean O
of O
2,813 O
. O
['Physiological-Clinical']

Regimen O
B O
( O
continuous O
regimen O
) O
consisted O
of O
6MP O
( O
50 O
mg/m2/day O
by O
mouth O
) O
plus O
MTX O
( O
20 O
mg/m2/week O
by O
mouth O
) O
combined O
with O
pulses O
of O
PRD B-outcome ['Physiological-Clinical']
and O
VCR B-outcome ['Physiological-Clinical']
( O
the O
same O
dosages O
as O
Regimen O
A O
) O
every O
4 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Inadequate O
discharge O
planning O
following O
inpatient O
stays O
is O
a O
major O
issue O
in O
the O
provision O
of O
a O
high O
standard B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
for O
patients O
who O
receive O
psychiatric O
treatment O
. O
['Life-Impact']

OBJECTIVE O
To O
explore O
the O
short-term O
treatment O
effect O
of O
the O
auditory O
integrative O
training O
on O
autistic O
children O
and O
provide O
them O
with O
clinical O
support O
for O
rehabilitative O
treatment O
. O
[]

METHODS O
Eight O
normal O
volunteers O
were O
studied O
on O
2 O
separate O
days O
. O
[]

A O
double-blind O
, O
randomized O
, O
prospective O
trial O
of O
either O
enalapril O
( O
10-20 O
mg O
daily O
) O
or O
eprosartan O
( O
400-800 O
mg O
daily O
) O
over O
a O
10-week O
period O
was O
conducted O
in O
42 O
patients O
( O
27 O
males O
, O
15 O
females O
) O
. O
[]

Among O
these O
US O
physicians O
, O
the O
median O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
were O
25 O
ng/ml O
in O
the O
blood O
samples O
collected O
during O
the O
winter O
or O
spring O
and O
32 O
ng/ml O
in O
samples O
collected O
during O
the O
summer O
or O
fall O
. O
['Physiological-Clinical']

We O
suggest O
that O
additional O
screening O
at O
an O
interval O
of O
less O
than O
three O
years O
should O
be O
offered O
to O
women O
with O
a O
negative O
colposcopy O
or O
a O
biopsy O
without O
CIN O
. O
[]

CaCl O
( O
2 O
) O
pre-treatment O
before O
diltiazem O
in O
the O
treatment O
of O
AFF O
with O
RVR O
. O
[]

CONCLUSIONS O
Pimecrolimus O
application O
did O
not O
translate O
into O
clinically O
meaningful O
benefit O
for O
patients O
with O
cetuximab-related O
facial O
rash O
. O
[]

Randomized O
controlled O
study O
of O
chemoimmunotherapy O
with O
bestatin O
of O
acute O
nonlymphocytic O
leukemia O
in O
adults O
. O
[]

INTERVENTION O
During O
each O
interview O
, O
the O
patients O
' O
MCIDs O
were O
determined O
by O
using O
( O
1 O
) O
a O
pictorial O
flip O
chart O
to O
describe O
atrial O
fibrillation B-outcome ['Physiological-Clinical']
; O
the O
consequences O
of O
a O
minor O
stroke B-outcome ['Physiological-Clinical']
, O
a O
major B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
, O
and O
a O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
; O
the O
chance O
of O
stroke B-outcome ['Physiological-Clinical']
if O
not O
taking O
warfarin O
; O
the O
chance O
of O
a O
major O
bleeding B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
if O
taking B-outcome ['Resource-use']
warfarin I-outcome ['Resource-use']
; O
examples O
of O
the O
inconvenience B-outcome ['Life-Impact']
, O
minor B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
and O
costs O
of O
warfarin B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
; O
and O
then O
( O
2 O
) O
1 O
of O
the O
2 O
elicitation O
methods O
to O
determine O
their O
MCIDs O
( O
the O
smallest O
reduction O
in O
stroke B-outcome ['Physiological-Clinical']
risk O
at O
which O
the O
patients O
were O
willing B-outcome ['Life-Impact']
to O
take O
warfarin B-outcome ['Resource-use']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

However O
, O
for O
these O
inflamed O
eyes O
with O
low O
intraocular O
pressure O
, O
the O
influence O
of O
preoperative O
oral O
steroids O
on O
reattachment O
rates O
has O
not O
been O
elucidated O
yet O
. O
[]

On O
an O
intention-to-treat O
basis O
, O
the O
difference O
between O
the O
groups O
in O
the O
rate O
of O
H. O
pylori O
eradication O
was O
marginally O
significant O
( O
P O
= O
0.06 O
[ O
0.028-0.512 O
] O
) O
. O
[]

Twenty-five O
patients O
undergoing O
excision O
of O
an O
aortic O
abdominal O
aneurysm O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

After O
multivariable O
adjustment O
for O
clinical O
, O
laboratory O
, O
and O
angiographic O
variables O
, O
BNP O
remained O
a O
significant O
independent O
predictor O
of O
CI-AKI O
( O
1.29 O
[ O
1.10 O
, O
1.51 O
] O
; O
P O
< O
0.001 O
) O
. O
[]

Interrater O
reliability O
was O
calculated O
for O
the O
two O
groups O
and O
the O
precision O
of O
the O
feedback O
was O
assessed O
. O
[]

Outcome O
measures O
included O
time O
to O
response O
to O
verbal B-outcome ['Life-Impact']
command B-outcome ['Life-Impact']
, O
Aldrete B-outcome ['Physiological-Clinical']
score O
= O
9 O
, O
Postanesthesia O
Discharge O
Scoring O
System O
= O
7 O
, O
and O
assessment O
by O
the O
Digit O
Symbol B-outcome ['Physiological-Clinical']
Substitution O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Selective O
inhibitors O
of O
cathepsin O
K O
, O
which O
has O
a O
major O
role O
in O
the O
degradation O
of O
bone O
collagen O
, O
are O
potential O
new O
treatments O
for O
osteoporosis O
. O
[]

Levels O
of O
constitutive O
proteins O
and O
acute O
phase O
proteins O
were O
measured O
at O
admission O
; O
at O
discharge O
; O
and O
at O
6 O
, O
9 O
, O
and O
12 O
months O
after O
burn O
. O
[]

A O
leak O
occurred O
in O
8.3 O
% O
. O
[]

STUDY O
OBJECTIVE O
To O
compare O
2 O
procedures O
for O
metroplasty O
: O
resectoscopy O
with O
monopolar O
knife O
versus O
small-diameter O
hysteroscopy O
fitted O
with O
a O
Versapoint O
device O
. O
[]

The O
results O
suggest O
the O
need O
for O
improvements O
in O
colonoscopic O
technology O
. O
[]

During O
2000-2004 O
, O
125 O
Swedish O
primary-care O
patients O
with O
non-acute O
NSP O
, O
full-time O
sick-listed O
6 O
weeks-2 O
years O
, O
were O
included O
in O
a O
randomized O
controlled O
trial O
to O
compare O
a O
cognitive-behavioural O
programme O
with O
traditional O
primary O
care O
. O
[]

The O
improvement O
in O
HADS O
anxiety B-outcome ['Life-Impact']
score O
was O
significantly O
greater O
in O
both O
physiotherapy O
intervention O
groups O
than O
in O
home O
exercises O
alone O
. O
['Life-Impact']

Animal O
studies O
with O
SSRI O
's O
suggest O
that O
serotonergic O
modulation O
alters O
methamphetamine O
's O
behavioral B-outcome ['Life-Impact']
effects O
. O
['Life-Impact']

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
declined O
significantly O
in O
the O
two O
treatment O
groups O
, O
from O
147/98 O
mmHg O
in O
both O
the O
enalapril O
and O
lisinopril O
groups O
to O
126/82 O
and O
122/81 O
mmHg O
, O
respectively O
, O
at O
the O
end O
of O
treatment O
. O
['Physiological-Clinical']

After O
each O
study O
phase O
the O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RPF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Teleconferencing O
Supervision O
is O
a O
method O
for O
training O
community-based O
substance O
abuse O
clinicians O
in O
Motivational O
Interviewing O
( O
MI O
) O
. O
[]

25 O
? O
[]

In O
conclusion O
, O
high O
intakes O
of O
iTFA O
and O
CLA O
did O
not O
substantially O
affect O
plasma O
concentrations O
of O
inflammatory O
markers O
, O
but O
they O
increased O
the O
urine O
8-iso-PGF O
( O
2? O
) O
concentration O
. O
[]

The O
current O
recommended O
treatment O
for O
feline O
chlamydophilosis O
involves O
daily O
oral O
administration O
of O
antimicrobials O
to O
all O
cats O
within O
an O
affected O
group O
for O
a O
prolonged O
period O
of O
time O
( O
4-6 O
weeks O
) O
. O
[]

BACKGROUND O
XS0601 O
, O
consisting O
of O
active O
ingredients O
( O
Chuangxiongol O
and O
paeoniflorin O
) O
, O
has O
been O
shown O
to O
inhibit O
arterial O
neointimal O
hyperplasia O
in O
animal O
models O
and O
in O
preliminary O
human O
studies O
. O
[]

Percentages O
of O
the O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
the O
principal I-outcome ['Physiological-Clinical']
metabolites B-outcome ['Physiological-Clinical']
desacetyldiltiazem I-outcome ['Physiological-Clinical']
and O
N-desmethyldiltiazem B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
diltiazem I-outcome ['Physiological-Clinical']
were O
< O
15 O
% O
and O
< O
10 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

EEG/EMG B-outcome ['Resource-use']
monitoring O
recorded O
no O
pathologic O
increase O
of O
cortical B-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
epileptic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

RESULTS O
Three O
variables O
qualified O
, O
all O
of O
them O
represented O
in O
3 O
follow-ups O
: O
Low O
total O
prior O
sick-listing O
( O
including O
all O
diagnoses O
) O
was O
the O
strongest O
predictor O
in O
2 O
follow-ups O
, O
18 O
and O
24 O
months O
, O
OR O
4.8 O
[ O
1.9-12.3 O
] O
and O
3.8 O
[ O
1.6-8.7 O
] O
respectively O
, O
High O
[]

PARTICIPANTS O
Participants O
were O
195 O
Veterans O
. O
[]

CONCLUSIONS O
Body O
orientation O
influenced O
isometric B-outcome ['Physiological-Clinical']
arm O
strength B-outcome ['Physiological-Clinical']
, O
notably O
the O
constituents O
of O
['Physiological-Clinical', 'Physiological-Clinical']

A O
high O
intake O
of O
trans O
fatty O
acids O
has O
little O
effect O
on O
markers O
of O
inflammation B-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
diuresis O
during O
extracorporeal O
shockwave O
lithotripsy O
( O
ESWL O
) O
treatment O
of O
ureteric O
calculi O
. O
[]

We O
conclude O
that O
it O
is O
possible O
to O
induce O
quadriceps O
fatigue O
by O
local O
electrostimulation-induced O
contractions O
. O
[]

Two O
courses O
of O
consolidation O
therapy O
were O
followed O
by O
continuation O
therapy O
or O
hematopoietic O
stem O
cell O
transplantation O
. O
[]

In O
a O
second O
controlled O
crossover O
trial O
, O
20 O
autistic O
children O
received O
40 O
mg/day O
of O
the O
neuropeptide O
ORG O
2766 O
, O
a O
synthetic O
analog O
of O
ACTH O
( O
4-9 O
) O
, O
for O
8 O
weeks O
. O
[]

The O
occlusion O
was O
released O
after O
2 O
min O
and O
one-fourth O
of O
the O
total O
propofol O
dose O
was O
injected O
into O
the O
vein O
over O
a O
period O
of O
5 O
s. O
During O
the O
injection O
of O
both O
pretreatment O
solution O
and O
propofol O
, O
patients O
' O
pain B-outcome ['Physiological-Clinical']
was O
assessed O
and O
recorded O
as O
0-3 O
, O
corresponding O
to O
no O
, O
mild O
, O
moderate O
or O
severe O
pain O
, O
respectively O
. O
['Physiological-Clinical']

Significant O
differences O
between O
nurse O
specialist O
and O
day O
patients O
were O
seen O
in O
the O
following O
domains O
: O
waiting O
time O
during O
the O
treatment O
, O
autonomy B-outcome ['Life-Impact']
, O
coordination B-outcome ['Life-Impact']
, O
non-financial B-outcome ['Resource-use']
access I-outcome ['Resource-use']
, O
and O
quality B-outcome ['Life-Impact']
of O
['Life-Impact', 'Life-Impact', 'Resource-use', 'Life-Impact']

Subjects O
used O
a O
visual O
analog O
scale O
( O
0-10 O
) O
for O
pain O
assessment O
. O
[]

The O
0.3 O
% O
and O
0.6 O
% O
concentrations O
decreased O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
from O
baseline O
levels O
compared O
to O
placebo O
at O
one O
, O
two O
, O
and O
four O
hours O
after O
treatment O
. O
['Physiological-Clinical']

METHODS O
The O
Ventricular O
Tachycardia O
Ablation O
in O
Coronary O
Heart O
Disease O
( O
VTACH O
) O
study O
was O
a O
prospective O
, O
open O
, O
randomised O
controlled O
trial O
, O
undertaken O
in O
16 O
centres O
in O
four O
European O
countries O
. O
[]

RESULTS O
Covariation O
was O
found O
between O
fat O
and O
calories O
( O
r O
= O
.16 O
) O
, O
fiber O
and O
calories O
( O
r O
= O
.53 O
) O
, O
fiber B-outcome ['Life-Impact']
and O
fruit/vegetables B-outcome ['Life-Impact']
( O
r O
= O
.53 O
) O
, O
calories B-outcome ['Life-Impact']
and O
fruit/vegetables B-outcome ['Life-Impact']
( O
r O
= O
.34 O
) O
, O
and O
fruit B-outcome ['Life-Impact']
and O
vegetables B-outcome ['Life-Impact']
and O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
r O
= O
-.12 O
) O
for O
the O
total O
sample O
( O
all O
p O
values O
< O
.01 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

17 O
mg/dl O
; O
p O
= O
0.001 O
) O
. O
[]

Both O
reflex B-outcome ['Physiological-Clinical']
depressor I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
bradycardic I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
NS I-outcome ['Physiological-Clinical']
increased O
after O
PUFA O
( O
respectively O
from O
-0.09 O
+/- O
0.01 O
to O
-0.16 O
+/- O
0.01 O
mm O
Hg O
x O
mm O
Hg O
( O
-1 O
) O
, O
p O
< O
0.01 O
, O
and O
from O
1.25 O
+/- O
0.9 O
to O
1.76 O
+/- O
1.1 O
ms O
x O
mm O
Hg O
( O
-1 O
) O
, O
p O
< O
0.04 O
) O
but O
not O
after O
placebo O
. O
['Physiological-Clinical']

Secretin O
and O
autism O
: O
a O
two-part O
clinical O
investigation O
. O
[]

GLP-1 O
did O
not O
change O
perception O
of O
isobaric B-outcome ['Physiological-Clinical']
distension I-outcome ['Physiological-Clinical']
but O
reduced O
the O
perception B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Glycaemia B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
clonidine O
group O
( O
P O
< O
0.01 O
) O
and O
the O
median O
amount O
of O
['Physiological-Clinical']

With O
the O
first O
and O
eighth O
interventions O
, O
it O
was O
collected O
immediately O
before O
and O
after O
intervention O
. O
[]

RESULTS O
After O
1 O
year O
, O
group O
1 O
subjects O
reported O
a O
significantly O
lower O
incidence O
of O
declining B-outcome ['Physiological-Clinical']
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
and O
a O
significantly O
lower O
incidence O
of O
falls B-outcome ['Life-Impact']
than O
group O
3 O
subjects O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Nearly O
61.2 O
% O
of O
the O
subjects O
in O
experimental O
group O
became O
non-anaemic B-outcome ['Physiological-Clinical']
after O
the O
intervention O
when O
compared O
to O
control O
group O
A O
. O
['Physiological-Clinical']

The O
Pakistanis O
had O
higher O
levels O
of O
serum B-outcome ['Physiological-Clinical']
parathyroid I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
median O
2.6 O
vs O
1.6 O
pmol/l O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

However O
, O
median O
duration O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
from O
the O
first O
top-up O
was O
82 O
( O
range O
3-164 O
) O
min O
for O
S O
( O
- O
) O
-bupivacaine O
and O
76 O
( O
22-221 O
) O
min O
for O
RS-bupivacaine O
. O
['Physiological-Clinical']

The O
postoperative B-outcome ['Physiological-Clinical']
fibrinolytic I-outcome ['Physiological-Clinical']
shutdown I-outcome ['Physiological-Clinical']
, O
reflected O
by O
the O
decrease O
of O
fibrinolytic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
was O
unaffected O
by O
phenylbutazone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
, O
double-blind O
, O
double-dummy O
, O
multicenter O
, O
parallel-group O
study O
aimed O
at O
comparing O
the O
efficacy O
and O
safety O
of O
calcium O
carbasalate O
( O
equivalent O
to O
900 O
mg O
aspirin O
) O
plus O
metoclopramide O
10 O
mg O
( O
CM O
) O
with O
ergotamine O
tartrate O
1 O
mg O
plus O
caffeine O
100 O
mg O
( O
EC O
) O
administered O
in O
the O
treatment O
of O
2 O
acute O
migraine O
attacks O
. O
[]

The O
rate O
of O
clinical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
-- O
defined O
as O
the O
persistence O
of O
signs O
of O
acute B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
otoscopic I-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
-- O
was O
also O
lower O
among O
the O
children O
treated O
with O
amoxicillin-clavulanate O
than O
among O
those O
who O
received O
placebo O
: O
4 O
% O
versus O
23 O
% O
at O
or O
before O
the O
visit O
on O
day O
4 O
or O
5 O
( O
P O
< O
0.001 O
) O
and O
16 O
% O
versus O
51 O
% O
at O
or O
before O
the O
visit O
on O
day O
10 O
to O
12 O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Experimental O
and O
clinical O
application O
] O
. O
[]

Anaesthesia O
was O
maintained O
with O
67 O
% O
nitrous O
oxide O
in O
oxygen O
, O
and O
additional O
bolus O
doses O
of O
the O
test O
drug O
were O
given O
in O
a O
standardized O
fashion O
, O
if O
needed O
. O
[]

PATIENT O
( O
S O
) O
Infertile O
women O
with O
ovulatory O
dysfunction O
, O
aged O
18-35 O
years O
, O
and O
body O
mass O
index O
< O
35 O
kg/m O
( O
2 O
) O
. O
[]

RESULTS O
The O
mean O
survival O
over O
6 O
months O
was O
157+/-52 O
days O
in O
the O
levosimendan O
group O
and O
139+/-64 O
days O
in O
the O
dobutamine O
group O
( O
P O
< O
0.01 O
) O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
evaluate O
the O
hypothesis O
that O
testosterone O
treatment O
and O
a O
nutritional O
supplement O
have O
additive O
benefits O
. O
[]

Expectancies O
, O
not O
aroma O
, O
explain O
impact O
of O
lavender O
aromatherapy O
on O
psychophysiological O
indices O
of O
relaxation O
in O
young O
healthy O
women O
. O
[]

The O
study O
, O
however O
, O
failed O
to O
show O
a O
significant O
improvement O
in O
median O
[]

The O
apparatus O
was O
switched O
on O
for O
20 O
min O
every O
time O
and O
3 O
times O
a O
day O
. O
[]

Two O
weeks O
, O
6 O
weeks O
and O
6 O
months O
postdose O
2 O
, O
GMC O
was O
44.3 O
, O
42.9 O
, O
and O
36.5 O
, O
respectively O
. O
[]

DESIGN O
Randomized O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Responders O
( O
n O
= O
26 O
) O
continued O
treatment O
for O
another O
16 O
weeks O
, O
followed O
by O
a O
double-blind O
discontinuation O
( O
n O
= O
24 O
; O
two O
patients O
discontinued O
treatment O
because O
of O
weight O
gain O
) O
consisting O
of O
either O
3 O
weeks O
of O
taper O
and O
5 O
weeks O
of O
placebo O
only O
or O
continuing O
use O
of O
risperidone O
. O
[]

RESULTS O
In O
intent-to-treat O
analyses O
, O
78.5 O
% O
of O
the O
CBT O
group O
met O
Clinical O
Global O
Impressions-Improvement O
scale O
criteria O
for O
positive O
treatment O
response O
at O
posttreatment O
, O
as O
compared O
to O
only O
8.7 O
% O
of O
the O
waitlist O
group O
. O
[]

Trough O
and O
peak O
serum O
levels O
of O
propranolol O
were O
significantly O
lower O
when O
the O
patients O
were O
in O
a O
thyrotoxic O
state O
than O
when O
they O
were O
in O
a O
euthyroid O
state O
, O
whereas O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
nadolol O
were O
not O
appreciably O
altered O
by O
thyrotoxicosis O
. O
['Physiological-Clinical']

Furthermore O
, O
to O
ascertain O
the O
effect O
of O
administering O
a O
vasodilator O
, O
glyceryl O
trinitrate O
( O
GTN O
) O
, O
immediately O
following O
PTA O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Relative O
decreases O
occurred O
in O
cerebellum O
and O
right O
parahippocampal O
gyrus O
following O
the O
higher O
dose O
. O
[]

The O
half-life B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
T1/2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
decreasing O
Na O
intake O
to O
10 O
mmol/d O
was O
1.08 O
days O
in O
whites O
and O
1.65 O
days O
in O
blacks O
( O
p O
= O
not O
significant O
[ O
NS O
] O
) O
. O
['Physiological-Clinical']

A O
higher O
level O
of O
parental B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
was O
associated O
with O
an O
increased O
CAM B-outcome ['Physiological-Clinical']
use O
in O
ASD O
and O
DD O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Screening O
for O
cervical O
cancer O
based O
on O
testing O
for O
human O
papillomavirus O
( O
HPV O
) O
increases O
the O
sensitivity O
of O
detection O
of O
high-grade O
( O
grade O
2 O
or O
3 O
) O
cervical O
intraepithelial O
neoplasia O
, O
but O
whether O
this O
gain O
represents O
overdiagnosis O
or O
protection O
against O
future O
high-grade O
cervical O
epithelial O
neoplasia O
or O
cervical O
cancer O
is O
unknown O
. O
[]

We O
did O
a O
prospective O
randomised O
clinical O
trial O
to O
see O
how O
reduction O
mammaplasty O
affected O
macromastia O
patients O
' O
depression B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
and O
self-esteem B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
significant O
treatment O
effects O
for O
the O
PlayWisely O
measure O
on O
the O
Yellow O
Sets O
that O
examine O
recognition B-outcome ['Life-Impact']
; O
Purple O
Sets O
that O
examine O
brain B-outcome ['Physiological-Clinical']
region I-outcome ['Physiological-Clinical']
agility I-outcome ['Physiological-Clinical']
and O
early B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
; O
Blue O
Sets O
that O
examine O
phonemic B-outcome ['Life-Impact']
awareness B-outcome ['Life-Impact']
and O
recognition B-outcome ['Life-Impact']
; O
and O
for O
the O
Total O
Sets O
, O
with O
a O
similar O
trend O
toward O
improvement O
in O
the O
Green O
Sets O
that O
examine O
perception O
and O
Red O
Sets O
that O
examine O
attention B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Possibilities O
include O
sustained O
attention O
to O
the O
affected O
limb O
, O
in O
which O
case O
the O
order O
of O
MIP O
components O
would O
not O
alter O
the O
effect O
, O
and O
sequential O
activation O
of O
cortical O
motor O
networks O
, O
in O
which O
case O
it O
would O
. O
[]

METHODS O
The O
TSH B-outcome ['Physiological-Clinical']
response O
to O
TRH B-outcome ['Physiological-Clinical']
( O
25 O
micrograms B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
intravenous I-outcome ['Physiological-Clinical']
bolus I-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
peak O
peripheral B-outcome ['Physiological-Clinical']
CD34+ I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
increased O
with O
pegfilgrastim O
dose O
, O
but O
were O
significantly O
higher O
than O
filgrastim O
only O
at O
the O
18 O
mg O
dose O
( O
10.17 O
vs O
4.96 O
x O
10 O
( O
4 O
) O
/ml O
; O
P=0.014 O
) O
. O
['Physiological-Clinical']

We O
evaluated O
the O
focal B-outcome ['Physiological-Clinical']
therapeutic O
effect O
of O
oily O
carcinostatic O
agents O
administered O
by O
transcatheter O
arterial O
infusion O
( O
TAI O
) O
as O
the O
initial O
therapy O
in O
patients O
with O
hepatocellular O
carcinoma O
in O
a O
randomized O
controlled O
clinical O
trial O
. O
['Physiological-Clinical']

Multivariate O
analysis O
results O
indicated O
that O
the O
lower O
the O
tissue B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
percentage O
before O
treatment O
, O
the O
greater O
the O
increase O
in O
['Physiological-Clinical']

As O
compared O
with O
the O
effects O
of O
angiotensin O
II O
alone O
, O
indomethacin O
pre-treatment O
followed O
by O
angiotensin O
II O
infusion O
led O
to O
much O
greater O
falls O
in O
absolute B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
fractional B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
effective B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
all O
P O
< O
0.0001 O
vs O
placebo O
) O
associated O
with O
a O
significant O
reduction O
in O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
not O
observed O
with O
angiotensin O
II O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SUBJECTS O
Six O
male O
and O
female O
type O
2 O
diabetic O
patients O
[ O
DM2 O
; O
age O
54 O
+/- O
10 O
( O
mean O
+/- O
SD O
) O
years O
; O
body O
mass O
index O
( O
BMI O
) O
25.6 O
+/- O
2.9 O
kg O
m O
( O
-2 O
) O
] O
treated O
with O
diet O
or O
one O
oral O
hypoglycaemic O
agent O
and O
six O
age- O
and O
BMI-matched O
control O
subjects O
( O
Ctr O
) O
. O
[]

Patients O
with O
a O
preoperative O
indwelling O
catheter O
, O
positive O
urine O
culture O
, O
signs O
of O
active O
infection O
or O
preoperative O
antibiotic O
treatment O
were O
excluded O
. O
[]

The O
rebleeding B-outcome ['Physiological-Clinical']
and O
the O
mortality B-outcome ['Mortality']
rates O
did O
not O
differ O
between O
the O
treatment O
groups O
in O
both O
Group O
I O
and O
Group O
II O
. O
['Physiological-Clinical', 'Mortality']

OBJECTIVE O
We O
prospectively O
investigated O
the O
long-term O
effect O
of O
oral O
magnesium O
supplementation O
on O
respiratory B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
by O
using O
manuvacuometry O
and O
the O
Shwachman-Kulczycki O
( O
SK O
) O
score O
among O
children O
and O
adolescents O
with O
CF O
. O
['Physiological-Clinical']

Assessments O
were O
conducted O
pre-intervention O
, O
immediately O
post-intervention O
, O
and O
, O
to O
assess O
maintenance O
, O
at O
six-month O
follow-up O
. O
[]

RESULTS O
Risk O
of O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
was O
significantly O
reduced O
86 O
% O
by O
psychosocial O
therapy O
, O
p O
= O
.03 O
. O
['Mortality']

OBJECTIVES O
We O
postulated O
that O
femoral O
vein O
delivery O
of O
contrast O
medium O
because O
of O
streaming O
, O
might O
enhance O
precordial B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
of O
patent O
foramen O
ovale O
. O
['Physiological-Clinical']

Group O
I O
had O
normal O
GE O
and O
group O
II O
delayed O
GE O
. O
[]

This O
trial O
was O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00003389 O
. O
[]

Maximal B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
reduced O
further O
by O
a O
total O
daily O
dose O
of O
200 O
mg O
than O
by O
lower O
doses O
, O
but O
no O
extra O
benefit O
was O
derived O
by O
giving O
the O
drug O
twice O
daily O
. O
['Physiological-Clinical']

Data O
were O
collected O
during O
hospital O
admission O
and O
by O
telephone O
at O
one O
month O
after O
hospital O
discharge O
. O
[]

Clinical O
benefit O
was O
prospectively O
evaluated O
in O
this O
trial O
as O
a O
secondary O
end O
point O
. O
[]

Among O
the O
Pakistanis O
a O
correlation O
was O
found O
between O
the O
dietary O
intake O
of O
margarine O
, O
the O
main O
source O
of O
vitamin O
D O
in O
the O
diet O
, O
and O
the O
concentration O
of O
25-hydroxyvitamin O
D3 O
in O
serum O
, O
r O
= O
0.48 O
( O
P O
= O
0.01 O
) O
. O
[]

In O
all O
patients O
, O
wall O
motion O
score O
index O
( O
WMSI O
) O
( O
from O
1 O
= O
normal O
to O
4 O
= O
dyskinetic O
in O
a O
16- O
segment O
model O
of O
the O
left O
ventricle O
) O
was O
evaluated O
by O
echo O
at O
baseline O
and O
peak O
dobutamine O
. O
[]

Comparison O
of O
laser O
photocoagulation O
for O
diabetic O
retinopathy O
using O
532-nm O
standard O
laser O
versus O
multispot O
pattern O
scan O
laser O
. O
[]

Each O
patient O
was O
thus O
her O
own O
control O
. O
[]

Eleven O
( O
19 O
% O
) O
women O
experienced O
intermenstrual B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
judged O
to O
be O
probably O
or O
possibly O
related O
to O
gel O
use O
( O
four O
in O
the O
CS O
and O
seven O
in O
the O
placebo O
gel O
group O
) O
. O
['Physiological-Clinical']

Patients O
who O
were O
VKA-naive O
and O
experienced O
are O
included O
in O
balanced O
proportions O
. O
[]

Subsequent O
to O
the O
clinical O
study O
, O
evaluation O
of O
oral O
use O
of O
EGF O
may O
be O
expected O
as O
the O
next O
step O
in O
the O
treatment O
of O
ulcers O
. O
[]

The O
response O
of O
neuropathic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
in O
complex O
regional O
pain B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
I O
to O
carbamazepine O
and O
sustained-release O
morphine O
in O
patients O
pretreated O
with O
spinal O
cord O
stimulation O
: O
a O
double-blinded O
randomized O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
were O
trials O
of O
the O
Memorial O
Sloan-Kettering O
Cancer O
Center O
( O
MSKCC O
) O
, O
the O
U.S. O
Multicenter O
Study O
Group O
, O
and O
the O
Southeastern O
Cancer O
Study O
Group O
( O
SEG O
) O
. O
[]

Fewer O
children O
( O
26.6 O
% O
) O
required O
additional B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
in O
the O
combination O
group O
whereas O
in O
group O
B O
, O
60 O
% O
of O
the O
children O
received O
analgesic B-outcome ['Resource-use']
supplements I-outcome ['Resource-use']
within O
6 O
hours O
after O
surgery O
( O
p O
< O
0.05 O
) O
. O
['Resource-use', 'Resource-use']

The O
results O
are O
discussed O
in O
terms O
of O
their O
implication O
for O
hypotheses O
linking O
laterality O
and O
training O
. O
[]

GHBP O
was O
measured O
by O
ligand-mediated O
immunofunctional O
assay O
, O
and O
serum O
insulin-like O
growth O
factor O
I O
( O
IGF-I O
) O
was O
determined O
by O
RIA O
after O
acid-ethanol O
extraction O
, O
using O
a O
truncated O
IGF-I O
analog O
as O
the O
radioligand O
. O
[]

Treatment O
acceptability B-outcome ['Life-Impact']
was O
high O
for O
both O
support O
persons O
and O
smokers O
. O
['Life-Impact']

BACKGROUND O
AND O
AIM O
An O
oral O
glutamine O
load O
in O
cirrhotic O
patients O
awaiting O
liver O
transplantation O
was O
shown O
to O
cause O
a O
rise O
in O
blood B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
and O
psychometric B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
which O
were O
reversed O
by O
hepatic O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
histamine O
challenge O
, O
5 O
of O
10 O
subjects O
showed O
no O
reaction B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Multisite O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
porcine O
secretin O
in O
autism O
. O
[]

CONCLUSIONS O
A O
dose O
of O
2,500 O
IU O
enoxaparin/day O
does O
not O
cause O
more O
bleeding O
complications O
than O
SH O
5,000 O
IU O
three O
times O
daily O
when O
used O
to O
prevent O
thrombosis O
. O
[]

PATIENTS O
Adult O
( O
age O
> O
or=18 O
years O
) O
critically O
ill O
patients O
with O
hemoglobin O
< O
or=12 O
g/dL O
, O
expected O
hospitalization O
of O
> O
or=7 O
days O
, O
with O
no O
ongoing O
acute O
blood O
loss O
. O
[]

Both O
tests O
involved O
three O
sets O
of O
six O
maximal O
sprint O
repetitions O
, O
with O
a O
4-min O
recovery O
between O
sets O
. O
[]

Circulating O
levels O
of O
lactate O
, O
pyruvate B-outcome ['Physiological-Clinical']
, O
alanine B-outcome ['Physiological-Clinical']
, O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
and O
the O
ketone O
bodies O
were O
similar O
with O
the O
two O
agents O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Transscleral O
cryotherapy O
to O
the O
avascular O
retina O
was O
applied O
to O
one O
randomly O
selected O
eye O
when O
there O
was O
threshold O
disease O
( O
defined O
as O
five O
or O
more O
contiguous O
or O
eight O
cumulative O
30 O
degree O
sectors O
[ O
clock O
hours O
] O
of O
stage O
3 O
ROP O
in O
zone O
1 O
or O
2 O
in O
the O
presence O
of O
plus O
disease O
) O
. O
[]

All O
subjects O
received O
intradermal O
injections O
on O
the O
forearm O
of O
a O
0.05 O
ml O
saline O
solution O
containing O
5 O
micrograms O
of O
histamine O
before O
and O
at O
different O
times O
after O
drug O
intake O
. O
[]

Study O
2 O
: O
CBT O
components O
were O
compared O
by O
treatment O
and O
ASD O
symptom O
status O
. O
[]

Patients O
with O
impaired O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
also O
had O
significantly O
reduced O
osteocalcin B-outcome ['Physiological-Clinical']
levels O
( O
p O
< O
0.01 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
haemoglobin B-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
between O
PKVP O
and O
TURP O
( O
p O
= O
0.326 O
at O
2 O
hours O
; O
p O
= O
0.192 O
on O
day O
1 O
) O
and O
serum O
sodium O
( O
p O
= O
0.757 O
at O
2 O
hours O
; O
p O
= O
0.888 O
on O
day O
1 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Marked O
activation O
of O
the O
sympathetic O
nervous O
system O
occurs O
during O
and O
after O
noncardiac O
surgery O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
clinical O
efficacy O
of O
treating O
knee O
osteoarthritis O
( O
KOA O
, O
Bi O
syndrome O
of O
knee O
) O
by O
massage O
combined O
Chinese O
materia O
medica O
( O
CMM O
) O
footbath O
fumigation O
and O
washing O
, O
and O
to O
observe O
the O
changes O
of O
the O
Lysholm O
knee B-outcome ['Physiological-Clinical']
score O
( O
LKSS O
) O
. O
['Physiological-Clinical']

Correlation O
was O
demonstrated O
between O
GI B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

METHODS O
In O
total O
, O
75 O
healthy O
volunteers O
( O
8 O
subjects O
in O
each O
of O
the O
10 O
cohorts O
; O
5 O
subjects O
participated O
in O
two O
cohorts O
) O
were O
randomized O
( O
6:2 O
) O
to O
receive O
a O
single O
dose O
of O
GS-9620 O
( O
0.3 O
, O
1 O
, O
2 O
, O
4 O
, O
6 O
, O
8 O
or O
12 O
mg O
) O
or O
placebo O
. O
[]

Separately O
examined O
, O
an O
improved O
fibrinolytic O
profile O
was O
seen O
in O
the O
atorvastatin O
group O
with O
a O
significant O
increase O
in O
serum B-outcome ['Physiological-Clinical']
D-dimer I-outcome ['Physiological-Clinical']
( O
P=.005 O
) O
, O
a O
borderline O
increase O
in O
tPA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
P=.083 O
) O
and O
a O
borderline O
reduction O
in O
tPA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( O
P=.069 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

They O
were O
followed O
for O
another O
8 O
weeks O
before O
retesting O
hs-CRP O
and O
TA O
. O
[]

OBJECTIVE O
We O
sought O
to O
examine O
the O
prevalence O
of O
EEG O
abnormalities O
in O
Smith-Lemli-Opitz O
syndrome O
( O
SLOS O
) O
as O
well O
as O
the O
relationship O
between O
interictal O
epileptiform O
discharges O
( O
IEDs O
) O
and O
within-subject O
variations O
in O
attentional O
symptom O
severity O
. O
[]

Antimicrobial O
control O
was O
equal O
for O
all O
methods O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
ECMO O
circuit O
and O
samples O
of O
blood O
were O
evaluated O
hourly O
for O
phase O
separation O
, O
layering O
out O
of O
the O
emulsion O
from O
blood O
, O
agglutination O
, O
and O
blood O
clots O
. O
[]

The O
study O
population O
had O
a O
mortality B-outcome ['Mortality']
of O
23 O
% O
during O
the O
6 O
month O
period O
, O
the O
amputation B-outcome ['Resource-use']
rate O
was O
43.5 O
% O
for O
iloprost O
and O
50 O
% O
for O
placebo O
treated O
patients O
. O
['Mortality', 'Resource-use']

Angiotensin-converting O
enzyme O
inhibition O
does O
not O
suppress O
plasma O
angiotensin O
II O
increase O
during O
exercise O
in O
humans O
. O
[]

Post-treatment O
declines O
in O
prostate-specific B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
of O
> O
or O
= O
50 O
% O
were O
achieved O
in O
21 O
of O
44 O
patients O
( O
48 O
% O
; O
95 O
% O
CI O
, O
33 O
% O
to O
64 O
% O
) O
on O
the O
ixabepilone O
arm O
, O
and O
31 O
of O
45 O
patients O
( O
69 O
% O
; O
95 O
% O
CI O
, O
55 O
% O
to O
82 O
% O
) O
on O
the O
ixabepilone O
+ O
EMP O
arm O
. O
['Physiological-Clinical']

Of O
the O
23 O
completers O
in O
the O
MTX O
arm O
, O
21 O
( O
91.3 O
% O
) O
were O
ACR O
20 O
% O
responders O
, O
18 O
( O
78.3 O
% O
) O
were O
ACR O
50 O
% O
, O
and O
10 O
( O
43.5 O
% O
) O
were O
ACR O
70 O
% O
responders O
. O
[]

One O
researcher O
performed O
the O
ultrasonographic B-outcome ['Physiological-Clinical']
data O
collection O
. O
['Physiological-Clinical']

[ O
Comparison O
of O
fracture B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
pulpless O
teeth O
restored O
with O
fiber O
reinforced O
composite O
posts O
and O
three O
kinds O
of O
resin O
core O
material O
] O
. O
['Physiological-Clinical']

AIM O
A O
study O
was O
carried O
out O
to O
investigate O
people O
's O
interest O
in O
participating O
in O
health O
checks O
and O
in O
discussions O
about O
health O
with O
their O
own O
general O
practitioner O
, O
participants O
' O
health O
status O
, O
the O
proportion O
who O
received O
health O
advice O
following O
health O
checks O
, O
and O
the O
lifestyle O
goals O
they O
set O
following O
discussion O
with O
their O
general O
practitioner O
. O
[]

The O
microparticles O
were O
analyzed O
by O
flow O
cytometry O
for O
bound O
complement O
components O
C1q O
, O
C4 O
and O
C3 O
, O
and O
bound O
complement O
activator O
molecules O
C-reactive O
protein O
( O
CRP O
) O
, O
serum O
amyloid O
P-component O
( O
SAP O
) O
, O
immunoglobulin O
( O
Ig O
) O
M O
and O
IgG O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
treatment O
failure B-outcome ['Physiological-Clinical']
after O
14 O
days O
was O
significantly O
more O
frequent O
in O
the O
sulfadoxine/pyrimethamine O
group O
( O
38 O
of O
215 O
, O
18 O
% O
) O
compared O
with O
either O
the O
sulfadoxine/pyrimethamine O
plus O
amodiaquine O
group O
( O
two O
of O
164 O
, O
1 O
% O
; O
p O
< O
0.0001 O
) O
or O
sulfadoxine/pyrimethamine O
plus O
artesunate O
group O
( O
one O
of O
198 O
, O
1 O
% O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
cases O
of O
recurrent B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
in O
two O
prospective O
clinical O
trials O
: O
a O
randomized O
study O
of O
two O
regimens O
for O
the O
last O
4 O
months O
of O
treatment O
( O
n O
= O
1,075 O
) O
and O
a O
study O
of O
a O
twice-weekly O
rifabutin-containing O
regimen O
for O
human O
immunodeficiency O
virus-infected O
tuberculosis O
( O
n O
= O
169 O
) O
. O
['Physiological-Clinical']

The O
control O
group O
patients O
received O
standard O
hospital O
care O
and O
follow-up O
. O
[]

Response O
prediction O
in O
metastasised O
colorectal O
cancer O
using O
intratumoural O
thymidylate O
synthase O
: O
results O
of O
a O
randomised O
multicentre O
trial O
. O
[]

By O
comparison O
, O
the O
exercise O
MPI O
results O
were O
normal O
in O
91 O
% O
, O
mildly O
abnormal O
in O
3 O
% O
, O
and O
moderate O
to O
severely O
abnormal O
in O
6 O
% O
. O
[]

After O
each O
treatment O
the O
enamel O
slabs O
were O
removed O
and O
half O
of O
each O
lesion O
challenged O
with O
acid B-outcome ['Physiological-Clinical']
in O
vitro B-outcome ['Physiological-Clinical']
for O
8 O
or O
16 O
h. O
The O
level O
of O
remineralization B-outcome ['Physiological-Clinical']
was O
determined O
using O
microradiography B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
was O
aimed O
to O
investigate O
the O
effect O
of O
two O
different O
statins O
on O
the O
levels O
of O
haemostatic O
variables O
reflecting O
procoagulant O
and O
fibrinolytic O
activity O
in O
patients O
with O
coronary O
heart O
disease O
( O
CHD O
) O
, O
with O
the O
hypothesis O
that O
statins O
might O
beneficially O
modify O
these O
levels O
. O
[]

Quantitative O
and O
semiquantitative O
SPECT O
, O
wall O
motion O
and O
digitized O
echocardiographic O
data O
were O
interpreted O
independently O
. O
[]

OBJECTIVES O
To O
assess O
the O
SHS O
effects O
and O
their O
duration O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Induced B-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
was O
analysed O
before O
and O
after O
the O
allergen O
challenges O
for O
cell O
counts O
, O
ECP O
, O
IL-5 O
, O
INF-? O
, O
IL-8 O
, O
and O
the O
transcription O
factor O
Foxp3 O
. O
['Physiological-Clinical']

A O
total O
of O
35 O
healthy O
men O
were O
studied O
in O
a O
placebo-controlled O
, O
randomized O
, O
double-blind O
study O
. O
[]

RESULTS O
After O
12 O
weeks O
of O
therapy O
, O
there O
was O
a O
significant O
improvement O
in O
all O
the O
four O
study O
parameters O
, O
which O
correlated O
well O
with O
the O
improvement O
in O
symptoms O
of O
urogenital O
atrophy O
and O
sexual O
dysfunction O
in O
both O
the O
study O
groups O
as O
compared O
with O
the O
control O
group O
. O
[]

BACKGROUND O
The O
safety O
of O
the O
technique O
of O
uterine O
exteriorization O
at O
caesarean O
section O
though O
popular O
among O
obstetricians O
, O
remains O
controversial O
. O
[]

Infants O
weighing O
501 O
to O
1000 O
g O
at O
birth O
were O
given O
900 O
mg O
of O
immune O
globulin O
per O
kilogram O
of O
body O
weight O
, O
and O
infants O
weighing O
1001 O
to O
1500 O
g O
at O
birth O
were O
given O
a O
dose O
of O
700 O
mg O
per O
kilogram O
. O
[]

Results O
were O
not O
statistically O
significant O
different O
[ O
group O
I O
: O
mean O
decrease O
log O
MAR O
95 O
% O
CI O
( O
0.06 O
; O
0.32 O
) O
, O
group O
II O
: O
( O
-0.02 O
; O
0.11 O
) O
] O
. O
[]

Clonidine O
reduced O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
125/79 O
+/- O
13/8 O
to O
104/68 O
+/- O
9/7 O
mmHg O
( O
p O
less O
than O
0.01 O
) O
, O
urinary B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
from O
68 O
( O
31-369 O
) O
to O
46 O
( O
6-200 O
) O
micrograms/min O
( O
median O
and O
range O
) O
( O
p O
less O
than O
0.01 O
) O
, O
and O
fractional B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
in O
all O
patients O
( O
median O
29 O
% O
) O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
undertook O
a O
phase O
3 O
, O
double-blind O
, O
placebo-controlled O
study O
in O
adults O
with O
previously O
treated O
immune O
thrombocytopenia O
of O
more O
than O
6 O
months O
' O
duration O
who O
had O
baseline O
platelet O
counts O
lower O
than O
30,000 O
per O
?L O
. O
[]

= O
0.05 O
] O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
survival O
with O
a O
functional O
larynx O
( O
SFL O
) O
. O
['Mortality']

Baseline O
working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
and O
executive B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
also O
associated O
with O
depression O
improvement O
over O
time O
. O
['Life-Impact']

There O
were O
208 O
patients O
( O
229 O
eyes O
) O
with O
initial O
pterygium O
, O
and O
they O
were O
allocated O
to O
two O
groups O
: O
excision O
of O
pterygium O
with O
limbal O
epithelial O
autograft O
transplantation O
surgery O
( O
A O
group O
, O
106 O
cases O
and O
124 O
eyes O
) O
and O
simple O
pterygium O
excision O
( O
B O
group O
, O
102 O
cases O
and O
105 O
eyes O
) O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
median O
duration O
of O
[]

No O
statistically O
significant O
differences O
in O
donepezil B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
( O
Cmax O
, O
tmax O
, O
AUC O
( O
0-120 O
) O
, O
AUC O
( O
0-infinity O
) O
or O
t1/2 O
) O
were O
observed O
when O
donepezil O
administered O
alone O
was O
compared O
with O
donepezil O
administered O
in O
combination O
with O
digoxin O
. O
['Physiological-Clinical']

It O
is O
therefore O
essential O
to O
evaluate O
current O
drugs O
, O
one O
of O
which O
is O
the O
water O
extract O
of O
the O
bark O
of O
the O
tree O
Choerospondias O
axillaris O
. O
[]

In O
addition O
, O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TAC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
measured O
in O
plasma O
samples O
, O
and O
cytokine O
( O
IL-6 O
, O
IL-10 O
) O
concentrations O
were O
determined O
in O
the O
serum O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
eradication B-outcome ['Physiological-Clinical']
rate O
achieved O
with O
the O
sequential O
regimen O
was O
significantly O
greater O
than O
that O
obtained O
with O
the O
triple O
therapy O
. O
['Physiological-Clinical']

CONCLUSIONS O
Among O
children O
6 O
to O
23 O
months O
of O
age O
with O
acute O
otitis O
media O
, O
treatment O
with O
amoxicillin-clavulanate O
for O
10 O
days O
tended O
to O
reduce O
the O
time O
to O
resolution O
of O
symptoms O
and O
reduced O
the O
overall O
symptom O
burden O
and O
the O
rate O
of O
persistent O
signs O
of O
acute O
infection O
on O
otoscopic O
examination O
. O
( O
[]

BACKGROUND O
Therapy O
for O
chronic O
atrial O
fibrillation O
( O
AF O
) O
focuses O
on O
rate O
versus O
rhythm O
control O
, O
but O
little O
is O
known O
about O
the O
effects O
of O
common O
therapeutic O
interventions O
on O
exercise O
tolerance O
in O
AF O
. O
[]

BACKGROUND O
Plasma O
triglyceride O
concentration O
has O
been O
an O
inconsistent O
independent O
risk O
factor O
for O
coronary O
heart O
disease O
, O
perhaps O
because O
of O
the O
metabolic O
heterogeneity O
among O
VLDL O
particles O
, O
the O
main O
carriers O
of O
triglycerides O
in O
plasma O
. O
[]

Group O
versus O
individualized O
education O
did O
not O
affect O
outcome O
. O
[]

Iodixanol O
resulted O
in O
poorer B-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
distension I-outcome ['Physiological-Clinical']
than O
iohexol O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
investigation O
was O
to O
compare O
the O
efficacy O
of O
a O
low-dose O
antacid O
( O
Maalox O
70 O
, O
280 O
mmol/day O
) O
with O
that O
of O
the O
H2-receptor O
antagonist O
cimetidine O
( O
Tagamet O
, O
200 O
mg O
three O
times O
daily O
and O
400 O
mg/day O
) O
after O
14 O
and O
28 O
days O
in O
the O
treatment O
of O
duodenal O
ulcer O
. O
[]

Risk O
factors O
for O
malnutrition O
in O
patients O
undergoing O
gastroenterological O
and O
hernia O
surgery O
: O
an O
analysis O
of O
374 O
patients O
. O
[]

RESULTS O
Intention-to-treat O
analysis O
revealed O
significant O
differences O
( O
P O
< O
0.05 O
) O
in O
the O
respective O
eradication B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
LOAD I-outcome ['Physiological-Clinical']
therapies I-outcome ['Physiological-Clinical']
( O
88.9 O
% O
( O
80/90 O
) O
LOAD-10 O
, O
90 O
% O
( O
81/90 O
) O
LOAD-7 O
, O
89.4 O
% O
( O
161/180 O
) O
for O
combined O
LOAD O
) O
compared O
with O
those O
receiving O
LAC B-outcome ['Physiological-Clinical']
, O
73.3 O
% O
( O
66/90 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Each O
of O
the O
three O
therapeutic O
regimens O
was O
associated O
with O
similar O
and O
clinically O
important O
improvement O
over O
time O
that O
was O
considered O
superior O
to O
the O
expected O
natural O
history O
of O
long-standing O
CLBP O
. O
[]

The O
CI O
for O
each O
efficacy O
variable O
fell O
within O
the O
predefined O
equivalence O
ranges O
( O
pain O
, O
+/- O
75 O
mm O
; O
physical O
function O
, O
+/- O
255 O
mm O
; O
PGA O
, O
+/- O
20 O
mm O
) O
, O
indicating O
that O
no O
clinically O
relevant O
difference O
was O
found O
between O
the O
2 O
treatment O
arms O
. O
[]

For O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
the O
risk O
reduction O
in O
clinically O
significant O
symptoms O
did O
not O
reach O
statistical O
significance O
( O
5.7 O
% O
vs O
22.4 O
% O
; O
aRR O
, O
0.33 O
; O
95 O
% O
CI O
, O
0.10 O
to O
1.08 O
) O
; O
however O
, O
the O
reduction O
in O
mean O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
was O
statistically O
significant O
( O
Quick O
Inventory O
of O
Depressive O
Symptomatology O
score O
, O
4.6 O
with O
PSE O
vs O
6.9 O
with O
usual O
care O
; O
adjusted O
mean O
difference O
, O
-1.67 O
; O
95 O
% O
CI O
, O
-3.17 O
to O
-0.18 O
) O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
Oral O
magnesium O
supplementation O
helped O
improve O
both O
the O
SK O
score O
and O
respiratory B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

A O
significant O
increase O
in O
the O
number O
of O
[]

Clomipramine O
did O
not O
seem O
more O
effective O
on O
a O
measure O
of O
stereotypy O
, O
nor O
was O
it O
better O
tolerated O
. O
[]

Torasemide O
induced O
a O
remarkably O
higher O
natriuretic B-outcome ['Physiological-Clinical']
( O
120 O
+/- O
15 O
vs. O
33 O
+/- O
6 O
mmol/day O
, O
p O
< O
0.02 O
) O
and O
diuretic B-outcome ['Physiological-Clinical']
( O
1450 O
+/- O
63 O
vs. O
900 O
+/- O
58 O
ml O
, O
p O
< O
0.005 O
) O
effect O
than O
furosemide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plaque B-outcome ['Physiological-Clinical']
index O
( O
PI O
) O
, O
BOP B-outcome ['Physiological-Clinical']
, O
PD B-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
margin I-outcome ['Physiological-Clinical']
position O
( O
GMP O
) O
, O
relative B-outcome ['Physiological-Clinical']
vertical I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
horizontal I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level O
( O
RVCAL B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
RHCAL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
vertical B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
horizontal I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
level O
( O
VBL O
and O
HBL B-outcome ['Physiological-Clinical']
) O
and O
furcation O
closure O
were O
evaluated O
immediately O
before O
and O
2 O
, O
4 O
and O
6 O
months O
after O
the O
surgeries O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Some O
observers O
have O
argued O
that O
such O
therapist O
self-disclosure O
impedes O
treatment O
, O
whereas O
others O
have O
suggested O
that O
it O
enhances O
the O
effectiveness O
of O
therapy B-outcome ['Resource-use']
. O
['Resource-use']

CONCLUSION O
The O
addition O
of O
ifosfamide O
to O
cisplatin O
, O
doxorubicin O
, O
and O
methotrexate O
did O
not O
enhance O
EFS B-outcome ['Mortality']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
patients O
with O
osteosarcoma O
. O
['Mortality', 'Mortality']

In O
our O
study O
, O
there O
is O
some O
evidence O
of O
protective B-outcome ['Physiological-Clinical']
effect O
of O
goserelin B-outcome ['Resource-use']
on O
ovarian O
['Physiological-Clinical', 'Resource-use']

The O
prophylaxis O
group O
received O
on O
the O
3rd O
, O
4th O
and O
5th O
day O
a O
daily O
dose O
of O
10 O
g O
each O
. O
[]

RESULTS O
Sphincter-preserving O
surgery O
was O
performed O
in O
78.6 O
and O
76.2 O
per O
cent O
of O
patients O
in O
the O
open O
and O
laparoscopic O
groups O
respectively O
. O
[]

Venous B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
obtained O
before O
tracheal O
intubation O
to O
measure O
baseline O
concentrations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
, O
noradrenaline B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
ACTH B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
false-positive O
cytologic B-outcome ['Physiological-Clinical']
or O
histologic B-outcome ['Physiological-Clinical']
reports O
. O
['Physiological-Clinical']

At O
the O
3-month O
follow-up O
assessment O
, O
PSE O
mothers O
were O
significantly O
less O
likely O
than O
those O
serving O
as O
controls O
to O
have O
clinically O
significant O
parental B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
( O
3.8 O
% O
vs O
29.3 O
% O
; O
adjusted O
relative O
risk O
[ O
aRR O
] O
, O
0.17 O
; O
95 O
% O
CI O
, O
0.04 O
to O
0.65 O
) O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
Nineteen O
patients O
with O
extremity O
melanoma O
( O
n O
= O
16 O
) O
or O
sarcoma O
( O
n O
= O
3 O
) O
, O
underwent O
90-minute O
ILP O
with O
TNF-alpha O
, O
interferon O
gamma O
( O
0.2 O
mg O
) O
, O
and O
M O
( O
10 O
to O
13 O
mg/L O
of O
limb O
volume O
) O
( O
TNF/IFN/M O
) O
( O
n O
= O
12 O
) O
, O
or O
M O
alone O
( O
n O
= O
7 O
) O
. O
[]

A O
study O
on O
the O
effect O
of O
the O
duration O
of O
subcutaneous O
heparin O
injection O
on O
bruising O
and O
pain O
. O
[]

Enalapril O
therapy O
did O
not O
affect O
left O
ventricle B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Demographic O
and O
clinical O
characteristics O
of O
the O
two O
groups O
were O
not O
significantly O
different O
. O
[]

Eighteen O
patients O
( O
25 O
% O
) O
had O
partial O
response O
( O
PR O
) O
and O
21 O
patients O
had O
stable O
disease O
for O
at O
least O
4 O
months O
( O
SD4 O
) O
. O
[]

METHODS O
We O
collected O
baseline O
data O
on O
DUB O
symptoms O
and O
aspects O
of O
the O
financial O
and O
quality-of-life O
burden O
for O
237 O
women O
agreeing O
to O
surgery O
for O
DUB O
in O
a O
randomized O
trial O
comparing O
hysterectomy O
with O
endometrial O
ablation O
. O
[]

OBJECTIVE O
To O
optimize O
therapy O
of O
acupuncture O
and O
moxibustion O
for O
postsurgical O
gastroparesis O
syndrome O
( O
PGS O
) O
. O
[]

Participants O
in O
both O
groups O
made O
anticipatory O
judgements B-outcome ['Life-Impact']
regarding O
movement B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
( O
approximately O
100 O
ms O
) O
. O
['Life-Impact', 'Life-Impact']

[ O
Platelet O
serotonin O
in O
infantile O
autism O
. O
[]

RESULTS O
Median O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
all O
participants O
were O
well O
above O
plasma O
and O
RBC O
folate O
cut-off O
levels O
indicative O
of O
deficiency O
( O
6.7 O
and O
317 O
nmol/L O
, O
respectively O
) O
and O
all O
, O
except O
for O
2 O
subjects O
, O
were O
above O
the O
cut-off O
for O
NTD-risk O
reduction O
( O
> O
906 O
nmol/L O
) O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
case O
study O
. O
[]

For O
example O
, O
in O
the O
early O
phase O
of O
hypertension O
, O
diuretics O
usually O
worsen O
the O
metabolic B-outcome ['Physiological-Clinical']
equilibrium I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Fifty-six O
patients O
with O
valvular O
heart O
disease O
with O
or O
without O
AF O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

METHODS O
This O
multicentre O
, O
clinical O
trial O
was O
an O
investigation O
to O
compare O
the O
antiallergic O
efficacy O
, O
local O
tolerance O
and O
safety O
of O
Antazolin/Tetryzolin O
eye O
drops O
and O
Levocabastine O
eye O
drops O
. O
[]

RESULTS O
In O
total O
, O
131 O
individuals O
were O
randomized O
, O
of O
whom O
31 O
( O
24 O
% O
) O
had O
undergone O
upper O
endoscopy O
. O
[]

The O
main O
interest O
was O
centered O
on O
the O
rate O
of O
post-operative O
bone O
flap O
infections O
requiring O
operative O
revision O
. O
[]

A O
total O
of O
1443 O
patients O
experienced O
a O
recurrence B-outcome ['Physiological-Clinical']
and O
initiated O
treatment O
with O
ME-609 O
( O
n O
= O
601 O
) O
, O
acyclovir O
( O
n O
= O
610 O
) O
, O
or O
placebo O
( O
n O
= O
232 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
between O
groups O
in O
the O
amount O
of O
hydrocodone O
bitartrate O
consumption O
. O
[]

Radiofrequency O
procedure O
is O
useful O
in O
eradication O
of O
these O
concomitant O
pathologies O
. O
[]

Survival O
and O
resource O
utilisation O
data O
were O
collected O
for O
6 O
months O
; O
survival O
was O
extrapolated O
assuming O
a O
mean O
additional O
lifetime O
of O
3 O
years O
based O
on O
data O
from O
the O
Cooperative O
North O
Scandinavian O
Enalapril O
Survival O
Study O
trial O
. O
[]

These O
studies O
compared O
400 O
mg/day O
of O
imatinib O
with O
800 O
mg/day O
of O
imatinib O
. O
[]

There O
were O
63 O
patients O
( O
24 O
male O
, O
39 O
female O
, O
mean O
age O
70.5 O
years O
) O
with O
bilateral O
symptomatic O
knee O
osteoarthritis O
with O
effusion O
. O
[]

The O
area O
under O
the O
concentration-time O
curve O
( O
AUC O
) O
was O
determined O
for O
each O
subject O
, O
on O
each O
dosing O
occasion O
, O
for O
each O
compound O
. O
['Physiological-Clinical']

Based O
on O
the O
results O
of O
these O
two O
comparative O
studies O
, O
the O
power-driven O
inserts O
or O
the O
various O
ultrasonic O
scalers O
tested O
did O
not O
remove B-outcome ['Physiological-Clinical']
more I-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
than O
conventional O
hand O
instruments O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
evaluate O
, O
in O
low-income O
minority O
children O
, O
whether O
there O
is O
a O
relationship O
among O
the O
frequency O
of O
RTEC O
consumption O
and O
nutrient O
intakes O
measured O
at O
baseline O
, O
and O
whether O
there O
is O
a O
relationship O
between O
the O
frequency O
of O
RTEC O
and O
BMI O
controlling O
for O
age O
, O
sex O
, O
ethnicity O
, O
and O
energy O
intake O
. O
[]

Data O
were O
expressed O
as O
mean O
+/- O
SD O
, O
with O
P O
< O
0.05 O
being O
considered O
significant O
. O
[]

A O
single O
nasal O
allergen O
challenge O
increases O
induced O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
non-asthmatic O
subjects O
with O
seasonal O
allergic O
rhinitis O
: O
correlation O
with O
plasma O
interleukin-5 O
. O
['Physiological-Clinical']

Paraesthesia O
during O
the O
needle-through-needle O
and O
the O
double O
segment O
technique O
for O
combined O
spinal O
epidural O
anaesthesia O
. O
[]

Owner B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
scores O
at O
day O
14 O
( O
p=0.01 O
) O
and O
day O
42 O
( O
p=0.002 O
) O
were O
significantly O
improved O
compared O
to O
pre-treatment O
scores O
for O
the O
meloxicam O
group O
. O
['Physiological-Clinical']

In O
a O
prospective O
study O
84 O
patients O
with O
aphakic O
retinal O
detachment O
were O
treated O
either O
by O
local O
scleral O
buckling O
alone O
or O
combined O
with O
an O
encirclement O
. O
[]

The O
primary O
objective O
of O
the O
study O
was O
to O
compare O
the O
effects O
of O
methylphenidate O
( O
MP O
) O
with O
those O
of O
placebo O
( O
PL O
) O
on O
CRF O
as O
measured O
using O
the O
Functional O
Assessment O
of O
Chronic B-outcome ['Physiological-Clinical']
Illness I-outcome ['Physiological-Clinical']
Therapy-Fatigue I-outcome ['Physiological-Clinical']
( O
FACIT-F O
) O
fatigue O
subscale O
. O
['Physiological-Clinical']

Individuals O
from O
both O
groups O
were O
matched O
based O
on O
their O
primary O
diagnosis O
, O
secondary O
diagnosis O
( O
if O
present O
) O
, O
and O
gender O
. O
[]

METHODS O
Using O
a O
parallel O
, O
randomized O
, O
double-blind O
, O
controlled O
trial O
, O
we O
conducted O
an O
interventional O
study O
to O
evaluate O
the O
efficacy O
of O
a O
supplement O
of O
cocoa O
husk O
rich O
in O
dietary O
fiber O
on O
intestinal O
transit O
time O
and O
other O
indices O
of O
constipation B-outcome ['Physiological-Clinical']
in O
children O
with O
constipation O
. O
['Physiological-Clinical']

METHODS O
MARVEL O
is O
a O
randomized O
placebo-controlled O
trial O
of O
image-guided O
, O
catheter-based O
intramyocardial O
injection O
of O
placebo O
or O
myoblasts O
( O
400 O
or O
800 O
million O
) O
in O
patients O
with O
class O
II O
to O
IV O
HF O
and O
ejection O
fraction O
< O
35 O
% O
. O
[]

Group O
2 O
received O
midazolam O
0.03 O
mg/kg O
, O
remifentanil O
: O
propofol O
( O
1:500 O
) O
given O
at O
an O
initial O
propofol O
infusion O
rate O
of O
40 O
microg/kg/min O
. O
[]

RESULTS O
A O
total O
of O
189 O
patients O
were O
enrolled O
( O
mean O
age O
, O
53 O
years O
; O
105 O
women O
, O
84 O
men O
; O
mean O
body O
weight O
, O
65.8 O
kg O
) O
. O
[]

Local B-outcome ['Physiological-Clinical']
septic I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
occurred O
in O
12.5 O
% O
of O
patients O
after O
pouch-anal O
anastomosis O
compared O
to O
20.5 O
% O
after O
colo-anal O
anastomosis O
: O
stool O
frequency O
, O
after O
pouch-anal O
anastomosis O
was O
3.3 O
per O
24 O
h O
compared O
to O
5.2 O
per O
24 O
h O
after O
straight O
anastomosis O
within O
the O
first O
year O
after O
ileostomy O
closure O
( O
p O
= O
0.053 O
) O
; O
continence B-outcome ['Physiological-Clinical']
was O
slightly O
better O
in O
the O
pouch O
group O
( O
n.s O
. O
) O
; O
['Physiological-Clinical', 'Physiological-Clinical']

Risperidone-treated O
subjects O
also O
exhibited O
significantly O
greater O
decreases O
on O
the O
other O
4 O
subscales O
of O
the O
ABC O
; O
on O
the O
conduct O
problem O
, O
insecure/anxious B-outcome ['Life-Impact']
, O
hyperactive B-outcome ['Life-Impact']
, O
and O
overly B-outcome ['Life-Impact']
sensitive I-outcome ['Life-Impact']
subscales O
of O
the O
Nisonger O
Child O
Behavior O
Rating O
Form O
( O
parent O
version O
) O
; O
and O
on O
the O
Visual O
Analog O
Scale O
of O
the O
most O
troublesome O
symptom O
. O
['Life-Impact']

Goal O
attainment O
scaling O
( O
GAS O
) O
holds O
promise O
as O
an O
idiographic O
approach O
for O
measuring O
outcomes O
of O
psychosocial O
interventions O
in O
community O
settings O
. O
[]

Prior O
to O
caries O
elimination O
, O
and O
again O
after O
three O
months O
, O
the O
gingival O
index O
was O
used O
to O
assess O
the O
gingival B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
study O
subjects O
. O
['Physiological-Clinical']

Hypertension O
after O
treatment O
with O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
receptor O
inhibitors O
is O
associated O
with O
superior O
treatment O
outcomes O
for O
advanced O
cancer O
patients O
. O
[]

METHODS O
A O
randomized O
controlled O
study O
was O
conducted O
to O
assess O
the O
effects O
of O
fat O
gain O
on O
endothelial O
function O
. O
[]

The O
?TBS O
values O
were O
analyzed O
using O
one-way O
analysis O
of O
variance O
( O
ANOVA O
) O
and O
the O
Tukey O
test O
( O
p=0.05 O
) O
. O
[]

RESULTS O
At O
baseline O
, O
56 O
% O
of O
group O
condition O
( O
immediate O
intervention O
) O
and O
54 O
% O
of O
individual O
condition O
( O
delayed O
intervention O
) O
participants O
were O
nonadherent O
by O
pill B-outcome ['Life-Impact']
count I-outcome ['Life-Impact']
and O
23 O
% O
of O
group O
and O
26 O
% O
of O
individual O
condition O
participants O
self-reported O
skipping B-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
at O
least O
once O
over O
the O
last O
3 O
months O
. O
['Life-Impact', 'Life-Impact']

Per-protocol O
eradication B-outcome ['Physiological-Clinical']
rate O
of O
sequential O
therapy O
was O
92.4 O
% O
( O
95 O
% O
CI O
85.8-96.1 O
% O
) O
vs. O
81.8 O
% O
( O
95 O
% O
CI O
73.9-87.8 O
% O
) O
( O
p O
= O
0.027 O
) O
for O
standard O
drug O
therapy O
. O
['Physiological-Clinical']

RESULTS O
After O
12 O
months O
of O
SIT O
, O
the O
median O
daily B-outcome ['Life-Impact']
inhaled I-outcome ['Life-Impact']
corticosteroid I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ICS I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
, O
which O
controls O
the O
symptoms O
of O
asthma O
, O
was O
reduced O
by O
25 O
% O
in O
the O
steroid O
group O
. O
['Life-Impact']

Although O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
definitive I-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Age O
, O
race O
, O
performance B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
histologic B-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
( O
serous=S O
; O
clear B-outcome ['Physiological-Clinical']
cell=CC O
; O
endometrioid=E O
) O
, O
disease B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
, O
and O
prior B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
were O
evaluated O
using O
various O
analytic O
methods O
to O
evaluate O
the O
probability O
of O
response O
and O
identify O
independent O
predictors O
of O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality', 'Mortality']

SETTING O
The O
studies O
were O
conducted O
at O
the O
Boston O
VA O
Healthcare O
System O
and O
the O
Boston O
University O
School O
of O
Medicine O
Medication O
Development O
Research O
Unit O
( O
MDRU O
) O
. O
[]

Of O
the O
38 O
patients O
, O
who O
had O
technically O
valid O
recordings O
, O
22 O
underwent O
LAUP O
and O
16 O
UPPP O
. O
[]

These O
bleeding O
complications O
were O
severe O
in O
only O
4.5 O
% O
and O
3 O
% O
, O
respectively O
. O
( O
[]

Both O
the O
patients O
' O
( O
p O
less O
than O
0.05 O
) O
and O
the O
clinicians O
' O
( O
p O
less O
than O
0.01 O
) O
treatment O
opinions O
, O
and O
their O
treatment O
preferences B-outcome ['Life-Impact']
( O
p O
less O
than O
0.05 O
) O
, O
favoured O
sodium O
cromoglycate O
. O
['Life-Impact']

By O
this O
stage O
over O
half O
the O
stapled O
group O
patients O
reported O
no O
pain B-outcome ['Physiological-Clinical']
at O
all O
. O
['Physiological-Clinical']

Eyes O
treated O
with O
latanoprost O
, O
stored O
both O
at O
4 O
degrees O
C O
and O
30 O
degrees O
C O
, O
achieved O
statistically O
significantly O
lower O
mean O
IOPs B-outcome ['Physiological-Clinical']
than O
untreated O
eyes O
at O
all O
time O
points O
, O
except O
at O
21 O
hours O
treated O
by O
the O
drug O
stored O
at O
30 O
degrees O
C. O
We O
subtracted O
the O
IOP O
of O
eyes O
receiving O
latanoprost O
from O
the O
IOP O
of O
untreated O
eyes O
for O
each O
time O
point O
to O
evaluate O
the O
efficacy O
of O
the O
eye O
drops O
( O
delta O
IOP O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
between O
the O
intervention O
( O
N O
= O
13 O
) O
and O
control O
( O
N O
= O
10 O
) O
groups O
in O
baseline O
blood B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
or O
in O
the O
percentage O
of O
hypertensive O
patients O
. O
['Physiological-Clinical']

In O
order O
to O
compare O
the O
efficacy O
of O
different O
asthma O
treatment O
in O
subjects O
with O
mild-to-moderate O
asthma O
, O
three O
groups O
of O
11 O
patients O
were O
treated O
with O
nedocromil O
sodium O
( O
NS O
) O
, O
beclomethasone O
dipropionate O
( O
BDP O
) O
and O
beclomethasone O
dipropionate O
plus O
salmeterol O
( O
BDP O
+ O
S O
) O
in O
an O
open O
, O
randomized O
study O
. O
[]

Plasma O
levels O
of O
lysozyme O
, O
a O
characteristic O
product O
of O
PMN O
degranulation O
, O
did O
not O
show O
significant O
differences O
between O
the O
study O
groups O
. O
[]

Improvement O
in O
glucose O
tolerance O
was O
correlated O
to O
weight O
reduction O
( O
r O
= O
0.19 O
, O
p O
less O
than O
0.02 O
) O
and O
increased O
fitness B-outcome ['Physiological-Clinical']
( O
r O
= O
0.22 O
, O
p O
less O
than O
0.02 O
) O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Phase O
3 O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
, O
multicenter O
study O
of O
a O
single O
510-mg O
dose O
of O
ferumoxytol O
versus O
saline O
as O
placebo O
. O
[]

Adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
rarely O
observed O
during O
the O
infusions O
. O
['Adverse-effects']

Patients O
received O
a O
cumulative O
loading O
dose O
of O
0 O
, O
8 O
, O
or O
24 O
mg O
of O
sirolimus O
2 O
days O
before O
and O
the O
day O
of O
repeat O
intervention O
followed O
by O
maintenance O
therapy O
of O
2 O
mg/d O
for O
7 O
days O
. O
[]

20 O
female O
and O
20 O
male O
students O
( O
ages O
: O
17-34 O
years O
) O
were O
instructed O
, O
upon O
the O
reception O
of O
an O
aversive O
or O
nonaversive O
acoustic O
signal O
, O
to O
press O
with O
the O
right O
hand O
a O
device O
that O
displayed O
a O
slide O
. O
[]

Within O
two O
years O
the O
costs B-outcome ['Resource-use']
of O
the O
two O
approaches O
are O
equivalent O
. O
['Resource-use']

The O
aim O
of O
this O
study O
was O
to O
compare O
adverse O
mood B-outcome ['Life-Impact']
effects O
of O
two O
different O
doses O
of O
medroxyprogesterone O
acetate O
( O
MPA O
) O
during O
postmenopausal O
hormone O
replacement O
therapy O
( O
HRT O
) O
in O
women O
with O
and O
without O
a O
history O
of O
premenstrual O
syndrome O
( O
PMS O
) O
. O
['Life-Impact']

INTERVENTIONS O
Symptomatic O
and O
asymptomatic O
tendons O
were O
scanned O
using O
the O
UTC B-outcome ['Resource-use']
procedure I-outcome ['Resource-use']
. O
['Resource-use']

Overexpression O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
its O
cellular O
receptor O
KDR O
( O
VEGFR-2 O
) O
in O
the O
bone O
marrow O
of O
patients O
with O
acute O
myeloid O
leukemia O
. O
[]

Nephrotoxicity B-outcome ['Physiological-Clinical']
developed O
in O
4/37 O
( O
10.8 O
% O
) O
and O
3/39 O
( O
7.7 O
% O
) O
patients O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSION O
The O
curative O
effect O
of O
SYN O
in O
treating O
IgAN O
was O
obviously O
better O
than O
that O
of O
simple O
Western O
medicine O
. O
[]

LKB O
and O
logistic O
model O
fits O
resulted O
in O
similar O
values O
for O
the O
volume O
parameter O
. O
[]

Effect O
of O
inhaled O
heparin O
on O
adenosine-induced O
bronchial O
hyperreactivity O
. O
[]

The O
diagnosis O
included O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
( O
n O
= O
27 O
) O
, O
neuroblastoma O
( O
n O
= O
29 O
) O
, O
and O
miscellaneous O
solid O
tumors O
( O
n O
= O
18 O
) O
. O
[]

On O
placebo O
, O
adrenaline B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
was O
162 O
+/- O
27 O
ng/min O
( O
mean O
, O
SE O
) O
at O
rest O
, O
increased O
by O
77 O
+/- O
42 O
ng/min O
with O
mental O
stress O
( O
p=0.019 O
) O
and O
was O
unchanged O
with O
tilting O
. O
['Physiological-Clinical']

The O
findings O
provide O
evidence O
of O
reciprocal O
influences O
, O
but O
socialization O
was O
a O
more O
consistent O
influence O
than O
selection O
. O
[]

At O
month O
12 O
, O
zoledronic O
acid O
significantly O
increased O
LS O
BMD O
versus O
risedronate O
in O
both O
subpopulations O
irrespective O
of O
gender O
( O
all O
P O
< O
0.05 O
) O
, O
cumulative O
prednisone O
dose O
( O
all O
P O
< O
0.01 O
) O
, O
and O
postmenopausal O
status O
( O
all O
P O
< O
0.05 O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
Controversies O
exists O
with O
regard O
to O
target O
volumes O
as O
far O
as O
thoracic O
radiotherapy O
( O
TRT O
) O
is O
concerned O
in O
the O
multimodality O
treatment O
for O
limited-stage O
small O
cell O
lung O
cancer O
( O
LSCLC O
) O
. O
[]

Side O
effects O
of O
the O
drug O
included O
irritability B-outcome ['Life-Impact']
and O
lethargy B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Patients O
may O
be O
isolated O
both O
physically O
and O
socially O
and O
may O
lack O
the O
self-efficacy O
to O
report O
problems O
and O
participate O
as O
partners O
in O
their O
care O
. O
[]

Students O
will O
be O
randomised O
to O
four O
groups O
, O
completing O
the O
four O
VP O
topics O
in O
the O
same O
order O
, O
but O
with O
each O
group O
exposed O
to O
a O
different O
VP O
design O
sequentially O
. O
[]

OBJECTIVE O
To O
assess O
the O
effect O
of O
a O
12-week O
arm-cranking O
exercise O
program O
on O
reducing O
oxidative B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
in O
untrained O
adults O
with O
chronic O
spinal O
cord O
injury O
( O
SCI O
) O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
in O
the O
level O
of O
pain B-outcome ['Physiological-Clinical']
relief O
. O
['Physiological-Clinical']

Early O
behavioral O
intervention O
is O
associated O
with O
normalized O
brain B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
young O
children O
with O
autism O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
radiologic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
beyond O
that O
time O
in O
patients O
with O
early O
RA O
initially O
treated O
with O
a O
combination O
of O
three O
disease-modifying O
antirheumatic O
drugs O
( O
DMARDs O
) O
or O
a O
single O
DMARD O
. O
['Physiological-Clinical']

Comparison O
of O
the O
evolutional O
process O
of O
children O
with O
autism O
spectrum O
disorders O
in O
different O
language O
therapeutic O
interventions O
. O
[]

These O
tests O
showed O
a O
total O
failure O
of O
the O
benzimidazole B-outcome ['Resource-use']
, O
imidothiazole B-outcome ['Resource-use']
, O
macrocyclic B-outcome ['Physiological-Clinical']
lactone I-outcome ['Physiological-Clinical']
and O
salicylanilide B-outcome ['Resource-use']
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

The O
efficacy O
and O
safety O
of O
lamotrigine O
and O
carbamazepine O
as O
monotherapy O
in O
patients O
with O
untreated O
, O
newly O
diagnosed O
or O
recurrent O
partial O
and/or O
generalised O
tonic-clonic O
seizures O
, O
were O
compared O
in O
a O
randomised O
, O
open O
, O
multicentre O
study O
. O
[]

Rationale O
and O
design O
of O
RE-LY O
: O
randomized O
evaluation O
of O
long-term O
anticoagulant O
therapy O
, O
warfarin O
, O
compared O
with O
dabigatran O
. O
[]

After O
lymph O
node O
excision O
, O
patients O
without O
any O
detectable O
metastases O
were O
randomly O
assigned O
to O
receive O
either O
TIL O
plus O
interleukin-2 O
( O
IL-2 O
) O
for O
2 O
months O
, O
or O
IL-2 O
only O
. O
[]

Changes O
of O
activated O
circulating O
endothelial O
cells O
and O
survivin O
in O
patients O
with O
non-small O
cell O
lung O
cancer O
after O
antiangiogenesis O
therapy O
. O
[]

There O
were O
also O
no O
significant O
differences O
between O
treatment O
groups O
in O
cardiovascular B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
, O
laboratory B-outcome ['Physiological-Clinical']
values O
, O
or O
adverse B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

New O
hope O
for O
children O
with O
Kawasaki O
disease O
. O
[]

[ O
The O
sympatho-adrenergic O
stress O
reaction O
in O
ear O
surgery O
using O
various O
anesthesia O
technics O
] O
. O
[]

Analysis O
of O
the O
postoperative B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
intake I-outcome ['Resource-use']
did O
not O
show O
statistically O
significant O
differences O
between O
examined O
groups O
. O
['Resource-use']

[ O
Comparison O
between O
anterior O
rhinomanometry O
and O
impulse-oscillometric O
rhinometry O
found O
within O
nasal B-outcome ['Physiological-Clinical']
allergen I-outcome ['Physiological-Clinical']
provocation I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

Single-operation O
anatomic B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
was O
81.8 O
% O
( O
9/11 O
) O
among O
those O
patients O
who O
received O
preoperative O
oral O
steroids O
and O
was O
66.7 O
% O
( O
6/9 O
) O
among O
those O
who O
did O
not O
receive O
preoperative O
oral O
steroids O
. O
['Physiological-Clinical']

Clinical O
improvement O
was O
measured O
by O
the O
Clinical O
Global O
Impression O
scale O
( O
primary O
outcome O
measure O
) O
, O
the O
Global O
Assessment O
of O
Functioning O
Scale O
( O
GAF O
) O
and O
the O
Positive O
and O
Negative O
Symptom O
Scale O
( O
PANSS O
; O
secondary O
outcome O
measures O
) O
. O
[]

MATERIAL O
AND O
METHODS O
The O
hypersensitive O
root O
surfaces O
of O
selected O
teeth O
were O
randomized O
to O
receive O
1 O
of O
3 O
treatments O
: O
coating O
with O
a O
self-etching O
adhesive O
( O
Linkmax O
) O
and O
its O
respective O
cement O
, O
coating O
with O
a O
conventionally O
etched O
adhesive O
( O
RelyX O
ARC O
) O
and O
its O
cement O
, O
or O
no O
treatment O
( O
negative O
control O
) O
. O
[]

Spontaneous O
and O
stimulated O
GH O
secretion O
is O
blunted O
in O
hypercortisolemic O
states O
due O
to O
increased O
hypothalamic O
somatostatinergic O
tone O
. O
[]

The O
Steward O
recovery O
score O
was O
also O
recorded O
every O
five O
minutes O
during O
the O
first O
20 O
minutes O
postoperatively O
and O
then O
every O
10 O
to O
15 O
minutes O
. O
[]

There O
was O
wide O
individual O
variation O
in O
the O
ratio O
of O
serum B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
saliva I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
indicating O
that O
, O
even O
when O
individual O
serum O
to O
saliva O
ratios O
have O
been O
established O
, O
the O
use O
of O
saliva O
theophylline O
measurements O
alone O
is O
unreliable O
for O
the O
routine O
monitoring O
of O
theophylline O
therapy O
. O
['Physiological-Clinical']

The O
highest O
correlation O
with O
NFT O
was O
found O
for O
high O
accuracy O
TLV O
( O
direct O
orders O
) O
( O
p=0.06 O
) O
. O
[]

There O
were O
no O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Gonadotropin-releasing O
hormone O
( O
GnRH O
) O
agonists O
have O
been O
shown O
to O
reduce O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
premenstrual I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PMS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
second O
protocol O
, O
changes O
in O
CVC B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
after O
acupuncture O
stimulation O
did O
not O
differ O
significantly O
between O
treated O
sites O
with O
EMLA O
cream O
and O
untreated O
sites O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
In O
a O
multinational O
trial O
( O
V325 O
) O
, O
445 O
patients O
were O
randomly O
assigned O
and O
treated O
with O
either O
docetaxel O
plus O
cisplatin O
and O
fluorouracil O
( O
DCF O
) O
or O
cisplatin O
and O
fluorouracil O
( O
CF O
) O
. O
[]

RESULTS O
One O
week O
after O
recommendations O
were O
delivered O
, O
only O
patients O
in O
the O
experimental O
group O
had O
increased O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( O
25.8 O
% O
and O
14.3 O
% O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

The O
Intergroup O
Study O
was O
designed O
to O
determine O
if O
the O
addition O
of O
adriamycin O
( O
ADR O
) O
or O
bilateral O
pulmonary O
radiotherapy O
( O
RT O
) O
to O
vincristine O
, O
dactinomycin O
, O
and O
cyclophosphamide O
( O
VAC O
therapy O
) O
would O
improve O
survival B-outcome ['Mortality']
and O
reduce B-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
and O
metastases B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
HRT O
's O
significantly O
( O
p O
< O
0.01 O
) O
prevented O
the O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
from O
all O
skeletal O
sites O
irrespective O
of O
the O
weight-bearing O
or O
content O
of O
trabecular O
bone O
, O
and O
( O
for O
the O
weight-bearing O
bones O
) O
there O
was O
even O
a O
gain O
in O
calcanean B-outcome ['Physiological-Clinical']
BMC I-outcome ['Physiological-Clinical']
and O
BMD B-outcome ['Physiological-Clinical']
and O
spinal B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Improvements O
in O
mood B-outcome ['Life-Impact']
were O
associated O
with O
modest O
gains O
in O
verbal B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
and O
executive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
over O
the O
10-week O
treatment O
period O
and O
accounted O
for O
greater O
variance O
in O
neuropsychological B-outcome ['Physiological-Clinical']
outcomes O
at O
the O
end O
of O
treatment O
than O
other O
known O
correlates O
of O
cognitive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
PD O
, O
such O
as O
disease O
severity O
, O
age O
, O
and O
education O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

METHODOLOGY O
One O
hundred O
and O
ninety-three O
( O
193 O
) O
H. O
pylori-positive O
patients O
were O
randomly O
assigned O
to O
one O
of O
the O
following O
7-day O
treatments O
: O
Group O
A O
( O
N O
= O
64 O
) O
: O
amoxicillin O
, O
clarithromycin O
and O
rabeprazole O
; O
Group O
B O
( O
N O
= O
64 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
ranitidine O
bismuth O
citrate O
; O
Group O
C O
( O
N O
= O
65 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
rabeprazole O
Eradication O
was O
assessed O
by O
13C-Urea O
Breath O
Test O
6-8 O
weeks O
after O
the O
end O
of O
the O
therapy O
. O
[]

A O
total O
of O
282 O
participants O
( O
100 O
women O
, O
182 O
men O
) O
with O
substance O
use O
disorders O
were O
included O
in O
this O
secondary O
analysis O
. O
[]

Acute O
effects O
of O
different O
stretching O
durations O
on O
passive B-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
, O
mobility B-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact']

After O
a O
2-week O
familiarization O
period O
, O
the O
participants O
were O
assigned O
to O
either O
a O
reduced O
alcohol O
drinking O
group O
or O
a O
usual O
drinking O
group O
for O
3 O
weeks O
( O
experimental O
period O
1 O
) O
. O
[]

After O
10 O
weeks O
standard O
hypolipidemic O
diet O
and O
hydrochlorothiazide O
( O
25 O
mg O
od O
) O
therapy O
, O
30 O
patients O
whose O
cholesterol B-outcome ['Physiological-Clinical']
levels O
were O
still O
greater O
than O
or O
equal O
to O
250 O
mg/100 O
ml O
and O
whose O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure O
was O
less O
than O
95 O
mmHg O
were O
randomized O
to O
one O
of O
the O
following O
treatments O
: O
simvastatin O
, O
20 O
mg O
od O
, O
gemfibrozil O
, O
600 O
mg O
bid O
or O
placebo O
, O
while O
continuing O
dietetic O
and O
diuretic O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
prospective O
randomised O
controlled O
study O
of O
40 O
patients O
could O
not O
show O
a O
statistically O
significant O
advantage O
with O
6 O
months O
of O
pentoxifylline O
compared O
with O
standard O
measures O
for O
late B-outcome ['Physiological-Clinical']
radiation-induced I-outcome ['Physiological-Clinical']
rectal I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Probiotics O
prevent O
IgE-associated O
allergy O
until O
age O
5 O
years O
in O
cesarean-delivered O
children O
but O
not O
in O
the O
total O
cohort O
. O
[]

Leukotriene O
antagonist O
prevents O
exacerbation O
of O
asthma O
during O
reduction O
of O
high-dose O
inhaled O
corticosteroid O
. O
[]

In O
78 O
patients O
without O
HBV O
markers O
, O
we O
compared O
prednisone O
and O
PE O
to O
prednisone O
alone O
as O
the O
initial O
therapeutic O
regimen O
. O
[]

Tremor B-outcome ['Physiological-Clinical']
amplitude B-outcome ['Physiological-Clinical']
as O
assessed O
by O
accelerometry O
significantly O
improved O
in O
the O
ZNS O
group O
compared O
to O
the O
placebo O
group O
at O
endpoint O
relative O
to O
baseline O
( O
-0.50 O
+/- O
0.72 O
vs. O
0.30 O
+/- O
0.79 O
m/s O
( O
2 O
) O
; O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Multivariate O
regression O
was O
used O
to O
calculate O
rates O
of O
decline O
in O
estimated O
GFR O
for O
individuals O
administered O
gemfibrozil O
or O
placebo O
, O
controlling O
for O
prospectively O
determined O
potential O
confounders O
. O
[]

The O
study O
will O
investigate O
the O
effects O
on O
falls B-outcome ['Life-Impact']
, O
mobility B-outcome ['Life-Impact']
and O
quality O
of O
life O
of O
( O
i O
) O
movement O
strategy O
training O
combined O
with O
falls O
prevention O
education O
, O
( O
ii O
) O
progressive O
resistance O
strength O
training O
combined O
with O
falls O
prevention O
education O
, O
( O
iii O
) O
a O
generic O
life-skills O
social O
program O
( O
control O
group O
) O
. O
['Life-Impact', 'Life-Impact']

However O
, O
we O
argue O
that O
construct O
validity O
should O
be O
viewed O
in O
light O
of O
the O
application O
of O
a O
test O
, O
in O
that O
patients O
may O
also O
present O
with O
different O
cues O
and O
likelihoods O
of O
having O
hypertension O
. O
[]

The O
median O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
mitoxantrone O
group O
and O
in O
the O
doxorubicin O
group O
was O
22 O
and O
20 O
months O
, O
respectively O
( O
p=0.580 O
) O
. O
['Mortality']

Baseline O
[]

The O
following O
facts O
about O
the O
predictive O
factor O
for O
the O
prognosis O
of O
DU O
complication O
were O
found O
: O
the O
sensitivity B-outcome ['Physiological-Clinical']
of O
83.6 O
% O
, O
the O
specificity O
of O
92.8 O
% O
, O
the O
predictive O
accuracy O
of O
88.7 O
% O
, O
the O
relative O
risk O
of O
the O
predicted O
outcome O
of O
7.5 O
, O
the O
relative O
risk O
of O
a O
different O
outcome O
of O
0.11 O
, O
the O
odds O
ration O
of O
65.4 O
. O
['Physiological-Clinical']

CONCLUSION O
This O
study O
will O
provide O
unique O
and O
comprehensive O
nutritional O
data O
and O
its O
results O
will O
guide O
nutritional O
therapy O
for O
children O
undergoing O
HSCT O
and O
possibly O
other O
catabolic O
patients O
. O
[]

Comparative O
evaluation O
of O
calcium O
hydroxide O
and O
zinc O
oxide O
eugenol O
as O
root B-outcome ['Physiological-Clinical']
canal I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
materials I-outcome ['Physiological-Clinical']
for O
primary O
molars O
: O
a O
clinical O
and O
radiographic O
study O
. O
['Physiological-Clinical']

The O
test O
toothpastes O
were O
: O
1 O
) O
a O
low O
abrasion O
paste O
containing O
0.8 O
% O
sodium O
monofluorophosphate O
( O
MFP O
) O
, O
and O
2 O
) O
a O
paste O
containing O
3 O
% O
sodium O
trimetaphosphate O
( O
TMP O
) O
. O
[]

Fifty-nine O
junior O
high O
school O
students O
who O
volunteered O
to O
participate O
in O
treatment O
for O
interpersonal B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
were O
randomly O
assigned O
to O
rational-emotive O
therapy O
without O
imagery O
( O
RET O
) O
, O
rational-emotive O
therapy O
with O
imagery O
( O
REI O
) O
, O
relationship-oriented O
counseling O
( O
ROC O
) O
, O
and O
waiting-list O
control O
( O
WLC O
) O
groups O
. O
['Life-Impact']

HYPOTHESIS O
We O
hypothesized O
that O
azelnidipine O
treatment O
could O
limit O
renal O
injury O
partly O
by O
blocking O
the O
AGE-RAGE B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

It O
has O
also O
been O
reported O
that O
a O
single O
nucleotide O
polymorphism O
( O
SNP O
) O
in O
exon O
12 O
of O
HIF-1alpha O
gene O
is O
present O
in O
renal O
cell O
carcinoma O
and O
head O
and O
neck O
squamous O
cell O
carcinoma O
patients O
. O
[]

However O
, O
beyond O
safety O
and O
efficacy O
, O
the O
delivery O
system O
or O
vehicle O
used O
in O
topical O
treatment O
formulations O
is O
equally O
important O
in O
affecting O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
tolerability B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Clearance B-outcome ['Physiological-Clinical']
was O
3.91 O
+/- O
2.07 O
and O
3.62 O
+/- O
0.80 O
ml O
x O
min O
( O
-1 O
) O
x O
kg O
( O
-1 O
) O
in O
sevoflurane O
and O
fentanyl O
groups O
, O
respectively O
( O
P O
< O
0.65 O
) O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
Current O
Controlled O
Trials O
ISRCTN15427433 O
. O
[]

Targeted O
skills O
included O
conversational B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
peer B-outcome ['Life-Impact']
entry I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
developing O
friendship B-outcome ['Life-Impact']
networks O
, O
good B-outcome ['Life-Impact']
sportsmanship I-outcome ['Life-Impact']
, O
good B-outcome ['Life-Impact']
host I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
dates I-outcome ['Life-Impact']
, O
and O
handling B-outcome ['Life-Impact']
teasing I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
end O
point O
of O
CALGB O
8642 O
is O
to O
assess O
the O
difference O
in O
survival B-outcome ['Mortality']
, O
toxicity B-outcome ['Adverse-effects']
, O
and O
overall O
response B-outcome ['Physiological-Clinical']
when O
limited O
exposure O
to O
Phase O
II O
agents O
precedes O
standard O
chemotherapy O
. O
['Mortality', 'Adverse-effects', 'Physiological-Clinical']

The O
mean O
decrease O
in O
home B-outcome ['Physiological-Clinical']
morning I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
was O
not O
significantly O
greater O
than O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Tetrahydrobiopterin O
as O
a O
treatment O
for O
autism O
spectrum O
disorders O
: O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Gaze B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
and O
vocalization B-outcome ['Life-Impact']
served O
as O
dependent O
measures O
of O
engagement O
. O
['Life-Impact', 'Life-Impact']

PURPOSE O
To O
determine O
if O
inhibition O
of O
stem-cell O
activity O
induced O
by O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
[ O
GM-CSF O
] O
; O
Sargramostim O
; O
Immunex O
Corporation O
, O
Seattle O
, O
WA O
) O
withdrawal O
or O
priming O
protects O
hematopoietic O
stem O
cells O
from O
the O
cytotoxic O
effects O
of O
adjuvant O
chemotherapy O
for O
early-stage O
breast O
cancer O
. O
[]

Troponin O
T O
( O
TnT O
) O
measurements O
and O
electrocardiographic O
( O
ECG O
) O
recordings O
were O
performed O
at O
admission O
, O
before O
operation O
, O
and O
on O
the O
first O
and O
2nd O
postoperative O
days O
, O
which O
were O
used O
for O
diagnosis O
. O
[]

Beneficial O
effect O
of O
etidronate O
therapy O
in O
chronically O
hospitalized O
, O
disabled O
patients O
with O
stroke O
. O
[]

After O
induction O
of O
general O
anaesthesia O
, O
the O
devices O
were O
inserted O
, O
its O
correct O
placement O
was O
verified O
and O
airway O
leak O
pressure O
was O
measured O
. O
[]

Rationale O
and O
design O
of O
a O
randomized O
trial O
to O
evaluate O
an O
evidence-based O
prescription O
drug O
label O
on O
actual O
medication O
use O
. O
[]

The O
mean O
+/- O
SD O
time O
to O
eye O
opening O
was O
significantly O
longer O
in O
the O
thiopental-enflurane-N2O O
group O
( O
Group O
1 O
) O
than O
in O
the O
propofol-propofol-N2O O
group O
( O
Group O
3 O
) O
( O
6.1 O
+/- O
2.5 O
minutes O
vs. O
3.5 O
+/- O
2.8 O
minutes O
, O
respectively O
) O
. O
[]

BACKGROUND O
Long-term O
data O
comparing O
cemented O
and O
noncemented O
single-implant O
restorations O
has O
not O
been O
reported O
. O
[]

A O
controlled O
study O
of O
the O
effect O
of O
cognitive-behavioural O
group O
therapy O
for O
pathological O
gamblers O
. O
[]

Ventricular O
tachycardia O
may O
be O
provoked O
by O
myoblast O
injection O
but O
appears O
to O
be O
a O
transient O
and O
treatable O
problem O
. O
[]

Scaling O
clinical O
judgments O
of O
symptom O
pathology O
by O
means O
of O
the O
psychophysiological O
method O
of O
magnitude O
estimation O
. O
[]

Following O
a O
brief O
washout O
period O
between O
two O
additional O
visits O
, O
the O
above O
procedures O
were O
repeated O
with O
the O
two O
alternate O
toothbrushes O
. O
[]

Systemic O
antibiotics O
significantly O
accelerate O
the O
suppression O
of O
the O
periodontal B-outcome ['Physiological-Clinical']
microflora I-outcome ['Physiological-Clinical']
, O
but O
have O
limited O
effect O
on O
the O
elimination O
of O
target O
isolates O
during O
healing O
. O
['Physiological-Clinical']

CONCLUSION O
The O
findings O
of O
this O
study O
showed O
that O
the O
diode O
laser O
can O
perform O
a O
significant O
reduction O
in O
the O
hair B-outcome ['Physiological-Clinical']
amount I-outcome ['Physiological-Clinical']
without O
significant O
epidermal O
damage O
, O
at O
least O
for O
a O
short O
period O
. O
['Physiological-Clinical']

Portal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
was O
significantly O
different O
between O
protocols O
B O
and O
C O
( O
p O
= O
0.02 O
) O
in O
the O
first O
phase O
and O
between O
protocols O
B O
and O
C O
and O
protocols O
A O
and O
C O
( O
p O
< O
0.01 O
, O
p O
= O
0.02 O
) O
in O
the O
second O
phase O
. O
['Physiological-Clinical']

Calcium O
supplementation O
was O
associated O
( O
P O
< O
0.05 O
) O
with O
increased O
aBMD B-outcome ['Physiological-Clinical']
compared O
with O
placebo O
, O
adjusted O
for O
age O
, O
height O
, O
and O
weight O
at O
the O
following O
time O
points O
from O
baseline O
: O
total O
hip O
, O
6 O
months O
( O
1.9 O
% O
) O
, O
12 O
months O
( O
1.6 O
% O
) O
, O
and O
18 O
months O
( O
2.4 O
% O
) O
; O
lumbar O
spine O
, O
12 O
months O
( O
1.0 O
% O
) O
; O
femoral O
neck O
, O
6 O
months O
( O
1.9 O
% O
) O
. O
['Physiological-Clinical']

This O
could O
affect O
the O
esthetic O
appearance O
and O
the O
clinical O
choices O
made O
when O
using O
zirconia-based O
restorations O
. O
[]

Incidence O
of O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
of O
propofol O
in O
control O
, O
i.v O
. O
['Physiological-Clinical']

A O
total O
of O
86 O
healthy O
subjects O
received O
the O
vaccine O
in O
five O
groups O
using O
different O
doses O
and O
routes O
of O
administration O
. O
[]

Fatty B-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
and O
RBC B-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
were O
analyzed O
at O
0 O
, O
2 O
, O
and O
4 O
mo O
of O
treatment O
and O
at O
1 O
, O
2 O
, O
and O
3 O
mo O
of O
washout O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Introduction O
In O
patients O
on O
glucocorticoids O
, O
a O
single O
zoledronic O
acid O
infusion O
significantly O
increased O
BMD B-outcome ['Physiological-Clinical']
versus O
daily O
oral O
risedronate O
. O
['Physiological-Clinical']

Evaluating O
the O
impact O
of O
peer O
, O
nurse O
case-managed O
, O
and O
standard O
HIV O
risk-reduction O
programs O
on O
psychosocial B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
health-promoting I-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
outcomes O
among O
homeless O
women O
. O
['Life-Impact']

Urine B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
group O
2 O
than O
in O
group O
1 O
( O
0.7 O
+/- O
0.4 O
vs. O
1.4 O
+/- O
1.0 O
mL/min O
, O
respectively O
; O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

In O
conclusion O
, O
administration O
of O
RG-CMH O
to O
patients O
receiving O
chemotherapy/radiotherapy O
may O
have O
the O
capacity O
to O
delay O
, O
or O
ease O
, O
the O
reduction O
in O
levels O
of O
leucocytes O
and O
neutrophils O
that O
are O
experienced O
by O
patients O
during O
cancer O
treatment O
. O
[]

Children O
were O
randomized O
to O
a O
joint O
attention O
intervention O
, O
a O
symbolic O
play O
intervention O
, O
or O
control O
group O
. O
[]

RESULTS O
Patients O
( O
n O
= O
48 O
) O
enrolled O
at O
the O
beginning O
of O
our O
study O
had O
significantly O
increased O
osteocalcin B-outcome ['Physiological-Clinical']
levels O
( O
3.45 O
+/- O
0.93 O
-- O
> O
4.42 O
+/- O
1.39 O
ng/ml O
p O
< O
0.02 O
) O
after O
one O
year O
if O
inflammatory B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
decreased O
( O
> O
or O
= O
1 O
SD O
: O
erythrocyte B-outcome ['Physiological-Clinical']
sedimentation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ESR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
26.4 O
mm/h O
, O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
3.8 O
mg/dl O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
double-masked O
, O
placebo-controlled O
, O
parallel O
group O
multicenter O
study O
of O
6 O
weeks O
duration O
. O
[]

There O
was O
no O
difference O
between O
the O
two O
groups O
with O
respect O
to O
changes O
in O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Initial O
mean O
doses O
of O
CSA O
and O
AZA O
were O
4.2 O
mg/kg O
and O
1.7 O
mg/kg O
respectively O
. O
[]

In O
all O
studies O
selamectin O
was O
applied O
topically O
, O
once O
per O
month O
, O
in O
unit O
doses O
providing O
a O
minimum O
dosage O
of O
6mgkg O
( O
-1 O
) O
. O
[]

The O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
on O
the O
last O
dosage O
schedule O
was O
achieved O
during O
normal O
working O
. O
['Physiological-Clinical']

METHODS O
Two O
hundred O
and O
eighty-eight O
cases O
were O
randomized O
into O
a O
sticking O
needling O
group O
( O
150 O
cases O
) O
and O
an O
acupuncture O
group O
( O
138 O
cases O
) O
. O
[]

on O
day O
1 O
, O
and O
prednisone O
( O
50 O
mg/m O
( O
2 O
) O
) O
on O
days O
1-5 O
. O
[]

For O
the O
69 O
patients O
in O
each O
group O
who O
completed O
the O
healing O
phase O
of O
the O
trial O
, O
endoscopic O
ulcer O
healing O
was O
almost O
identical O
. O
[]

Body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
decreased O
relative O
to O
placebo O
after O
INCB13739 O
therapy O
. O
['Physiological-Clinical']

The O
effect O
of O
administered O
drug O
was O
determined O
by O
comparsion O
of O
values O
of O
red O
blood O
count O
recovered O
before O
the O
treatment O
, O
2nd O
or O
3rd O
day O
post O
administration O
and O
two O
weeks O
later O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
effects O
of O
aliskiren O
and O
perindopril O
. O
[]

There O
was O
no O
group O
by O
time O
interaction O
for O
WMI O
in O
the O
superior O
longitudinal O
fasciculus O
. O
[]

[ O
Pleural O
tent O
after O
upper O
lobectomy O
-- O
randomized O
study O
of O
it O
's O
efficacy O
and O
duration O
of O
the O
effect O
] O
. O
[]

The O
histopathological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
the O
chemotherapy O
and O
control O
groups O
( O
16 O
specimens O
) O
were O
different O
. O
['Physiological-Clinical']

In O
contrast O
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
levels O
, O
C-peptide B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

No O
statistically O
significant O
difference O
was O
observed O
between O
G1 O
( O
10.19 O
+/- O
3.1 O
MPa O
) O
and O
G2 O
( O
10.17 O
+/- O
3.1 O
MPa O
) O
( O
p=0.982 O
) O
( O
Student O
's O
t O
test O
; O
? O
[]

A O
shortened O
versus O
standard O
matched O
postpartum O
magnesium O
sulphate O
regimen O
in O
the O
treatment O
of O
eclampsia O
: O
a O
randomised O
controlled O
trial O
. O
[]

A O
multicenter O
study O
on O
the O
use O
of O
pulsed O
low-intensity O
direct O
current O
for O
healing O
chronic B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
decubitus I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
While O
there O
were O
no O
significant O
between-group O
differences O
in O
lexical B-outcome ['Life-Impact']
decision I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
patients O
with O
delusions O
showed O
selective B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
in O
both O
affective O
classification O
tasks O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
The O
respective O
in-hospital O
event O
rates O
for O
CABG O
and O
PTCA O
were O
1.3 O
percent O
and O
1.1 O
percent O
for O
mortality B-outcome ['Mortality']
, O
4.6 O
percent O
and O
2.1 O
percent O
for O
Q-wave B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
, O
and O
0.8 O
percent O
and O
0.2 O
percent O
for O
stroke B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

When O
the O
stigma O
manifests O
in O
the O
health O
care O
setting O
, O
people O
living O
with O
HIV O
receive O
substandard O
services O
or O
even O
be O
denied O
care O
altogether O
. O
[]

A O
workplace O
intervention O
for O
increasing O
outdoor O
workers O
' O
use O
of O
solar O
protection O
. O
[]

Quality O
assurance O
in O
the O
EORTC O
22921 O
trial O
on O
preoperative O
radiotherapy O
with O
or O
without O
chemotherapy O
for O
resectable O
rectal O
cancer O
: O
evaluation O
of O
the O
individual O
case O
review O
procedure O
. O
[]

However O
, O
the O
regimens O
' O
toxicity O
profiles O
differed O
. O
[]

Those O
indicating O
infrequent O
use O
of O
logical O
analysis O
coping O
skills O
showed O
benefits O
. O
[]

The O
Japanese O
Cooperative O
Study O
Group O
of O
PBSCT O
. O
[]

The O
other O
HCT O
group O
( O
HCTsub O
) O
exercised O
at O
70-85 O
% O
of O
RM O
. O
[]

Effect O
of O
extradural O
analgesia O
on O
stress O
responses B-outcome ['Physiological-Clinical']
to O
abdominal O
surgery O
in O
infants O
. O
['Physiological-Clinical']

Further O
studies O
to O
explore O
the O
efficacy O
of O
rHCNTF O
in O
the O
treatment O
of O
human O
motor O
neuron O
diseases O
are O
justified O
. O
[]

This O
article O
discusses O
why O
comparison O
anchors O
might O
be O
important O
in O
risk O
feedback O
situations O
and O
concludes O
with O
recommendations O
for O
professionals O
who O
wish O
to O
provide O
accurate O
risk O
information O
and O
have O
patients O
adopt O
that O
information O
. O
[]

A O
pilot O
study O
using O
low- O
versus O
high-dose O
photon O
bean O
radiation O
] O
. O
[]

DESIGN O
Women O
completed O
the O
Vitamin O
D O
& O
Sun O
( O
VIDSUN O
) O
questionnaire O
and O
we O
measured O
their O
serum B-outcome ['Physiological-Clinical']
25-hydrocyvitamin I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Nicotine O
0.3 O
microg O
kg-1 O
min O
( O
-1 O
) O
or O
NaCl O
was O
infused O
( O
2 O
h O
) O
during O
a O
euglycaemic O
hyperinsulinaemic O
clamp O
( O
4 O
h O
) O
to O
assess O
insulin O
sensitivity O
. O
[]

These O
findings O
support O
the O
use O
of O
a O
volume O
of O
infused O
colloid O
solution O
higher O
than O
that O
of O
withdrawn O
blood O
during O
preoperative O
hemodilution O
. O
[]

Previously O
validated O
measures O
were O
used O
to O
assess O
the O
remaining O
types O
of O
support O
. O
[]

The O
use O
of O
autologous O
blood O
is O
a O
well O
established O
and O
extremely O
popular O
technique O
to O
decrease O
the O
necessity O
for O
homologous O
transfusions O
and O
the O
attendant O
risks O
of O
hepatitis O
, O
HIV O
, O
and O
HTLV O
-- O
I/II O
infections O
. O
[]

The O
ID O
Group O
, O
following O
OK-432 O
injection O
, O
had O
a O
4.8 O
% O
incidence O
of O
fever B-outcome ['Physiological-Clinical']
and O
a O
52.4 O
% O
incidence O
of O
local B-outcome ['Physiological-Clinical']
abscess I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
at O
the O
injection O
site O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
the O
pharmacokinetics O
and O
selectivity O
of O
the O
photosensitizers O
were O
addressed O
by O
two-phase O
exponential O
function O
and O
specific O
uptake O
ratio O
, O
respectively O
. O
[]

The O
children O
were O
randomly O
assigned O
to O
treatment O
with O
an O
intravenous O
infusion O
of O
synthetic O
human O
secretin O
( O
0.4 O
microg O
per O
kilogram O
of O
body O
weight O
) O
or O
saline O
placebo O
. O
[]

The O
intervention O
consisted O
of O
24 O
caregiver-mediated O
sessions O
with O
follow-up O
1 O
year O
later O
. O
[]

cryoablation O
was O
associated O
with O
more O
acute B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
( O
mean O
PCI O
urinary O
function O
cryoablation=69.4 O
; O
mean O
EBRT=90.7 O
; O
P O
< O
.001 O
) O
, O
which O
resolved O
over O
time O
. O
['Physiological-Clinical']

Isometric O
contractions O
reduce O
plantar B-outcome ['Physiological-Clinical']
flexor I-outcome ['Physiological-Clinical']
moment O
, O
Achilles B-outcome ['Physiological-Clinical']
tendon I-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
the O
hypnotic O
state O
appears O
to O
be O
therapeutic O
for O
individuals O
who O
can O
enter O
medium O
or O
deep O
states O
of O
hypnosis O
. O
[]

PURPOSE O
To O
determine O
if O
the O
preoperative O
administration O
of O
tegafur O
and O
uracil O
( O
UFT O
) O
to O
patients O
with O
lung O
adenocarcinoma O
could O
induce O
apoptosis O
. O
[]

Although O
no O
statistical O
difference O
in O
mortality B-outcome ['Mortality']
rate O
was O
appreciated O
among O
the O
3 O
fluid O
resuscitation O
groups O
, O
a O
trend O
of O
decreased O
mortality B-outcome ['Mortality']
rate O
was O
observed O
in O
the O
HBOCS O
group O
. O
['Mortality', 'Mortality']

DESIGN O
In O
this O
12-week O
, O
randomized O
, O
double-blind O
, O
placebo- O
and O
active-comparator-controlled O
trial O
, O
548 O
patients O
( O
median O
age O
63 O
years O
) O
with O
OA O
of O
the O
hip O
or O
knee O
were O
randomized O
to O
receive O
placebo O
, O
etoricoxib O
30 O
mg O
q.d. O
, O
or O
ibuprofen O
800 O
mg O
t.i.d O
. O
[]

After O
the O
6-month O
training O
period O
, O
the O
SST O
Group O
made O
fewer O
errors O
in O
labeling O
anger O
on O
adult O
faces O
, O
whereas O
error O
rates O
in O
the O
LA O
Group O
remained O
stable O
. O
[]

BACKGROUND O
The O
sources O
and O
the O
impact O
of O
maternal O
bacteria O
on O
the O
initial O
inoculum O
of O
the O
intestinal O
microflora O
of O
newborn O
infants O
remain O
elusive O
. O
[]

After O
aspirin O
treatment O
, O
M-CSF B-outcome ['Physiological-Clinical']
, O
CRP B-outcome ['Physiological-Clinical']
, O
11-dehydro-TXB B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
changes O
in O
the O
percentage O
of O
sputum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
between O
LTD4 O
and O
methacholine O
( O
mean O
difference O
+/- O
SD O
, O
7.5 O
+/- O
12.5 O
% O
eosinophils O
; O
p O
= O
0.09 O
) O
. O
['Physiological-Clinical']

The O
time O
to O
extraction O
of O
the O
calculus O
from O
a O
convex O
based O
test O
tube O
caliceal O
model O
was O
recorded O
. O
[]

METHODS O
Eighteen O
patients O
were O
prospectively O
randomized O
to O
receive O
either O
epidural O
analgesia O
or O
PCA O
during O
the O
postoperative O
period O
. O
[]

The O
single O
modality O
approach O
. O
[]

Twenty-three O
subjects O
were O
given O
a O
plasma-derived O
vaccine O
( O
Hevac O
B O
) O
and O
27 O
received O
a O
recombinant O
HBsAg O
vaccine O
( O
yeast-derived O
; O
Engerix-B O
) O
. O
[]

AIMS O
Wind-up O
in O
central O
sensitisation O
induced O
human O
visceral O
pain O
hypersensitivity O
has O
not O
been O
explored O
. O
[]

Attitudes B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
influences I-outcome ['Life-Impact']
and O
self-efficacy B-outcome ['Life-Impact']
expectations I-outcome ['Life-Impact']
will O
be O
the O
content O
of O
these O
personalised O
feedback O
letters O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Only O
1 O
SILS O
case O
was O
converted O
to O
3-port O
. O
[]

Although O
both O
LOOH B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

likely O
to O
contact O
the O
EAP O
) O
than O
were O
supervisors O
who O
received O
a O
more O
didactic O
, O
informational O
training O
( O
n O
= O
23 O
) O
or O
a O
no-training O
control O
group O
( O
n O
= O
17 O
) O
. O
[]

METHODS O
This O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
involved O
81 O
full-term O
neonates O
, O
up O
to O
4 O
wk O
of O
postnatal O
age O
, O
who O
needed O
venepuncture O
for O
blood O
investigations O
. O
[]

Regarding O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
when O
anesthesia O
wore O
off O
on O
the O
day O
of O
the O
injection O
, O
20 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
14 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
indicate O
that O
VRE O
was O
superior O
to O
WL O
on O
all O
measures O
, O
including O
willingness B-outcome ['Life-Impact']
to O
fly O
on O
the O
posttreatment O
flight O
( O
76 O
% O
for O
VRE O
and O
SE O
; O
20 O
% O
for O
WL O
) O
. O
['Life-Impact']

Patients O
were O
removed O
from O
study O
if O
LVEF O
declined O
20 O
or O
more O
EF O
units O
from O
baseline O
to O
a O
final O
value O
of O
greater O
than O
or O
equal O
to O
50 O
% O
, O
or O
by O
10 O
or O
more O
units O
to O
a O
final O
value O
of O
less O
than O
50 O
% O
, O
or O
onset O
of O
clinical O
congestive O
heart O
failure O
( O
CHF O
) O
. O
[]

Pre-treatment O
disease B-outcome ['Physiological-Clinical']
scores O
were O
significantly O
higher O
in O
the O
meloxicam O
group O
for O
owner B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
( O
p=0.01 O
) O
and O
veterinary B-outcome ['Physiological-Clinical']
lameness I-outcome ['Physiological-Clinical']
( O
p=0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Long-term O
anticoagulant O
treatment O
after O
acute O
myocardial O
infarction O
. O
[]

Two O
or O
more O
parameters O
of O
the O
index O
improved O
in O
24 O
patients O
treated O
with O
amino O
acids O
( O
80 O
% O
; O
confidence O
limits O
, O
61-92 O
% O
) O
, O
and O
only O
in O
12 O
receiving O
casein O
( O
35 O
% O
; O
confidence O
limits O
, O
20-54 O
% O
; O
p O
less O
than O
0.001 O
) O
. O
[]

The O
evaluation O
of O
pulmonary O
hypertension O
using O
right O
ventricular O
myocardial O
isovolumic O
relaxation O
time O
. O
[]

OBJECTIVE O
The O
aims O
of O
the O
study O
were O
to O
determine O
1 O
) O
whether O
high-dose O
chemotherapy O
decreases O
concentrations O
of O
major O
circulating O
antioxidants O
in O
patients O
undergoing O
BMT O
and O
2 O
) O
whether O
administration O
of O
standard O
PN O
maintains O
systemic O
antioxidant O
concentrations O
compared O
with O
PN O
containing O
micronutrients O
and O
minimal O
lipids O
alone O
. O
[]

Fourty-four O
FeLV-infected O
cats O
in O
which O
free O
FeLV O
p27 O
antigen O
was O
detected O
in O
serum O
by O
enzyme-linked O
immunosorbent O
assay O
were O
included O
in O
the O
study O
. O
[]

CONCLUSION O
In O
our O
study O
, O
the O
H2O2 O
mouth O
rinse O
does O
not O
provide O
a O
better O
analgesic B-outcome ['Resource-use']
effect O
than O
the O
water O
rinse O
for O
post-tonsillectomy B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

This O
study O
has O
shown O
the O
superiority O
of O
LH O
compared O
to O
hCG O
in O
supporting O
FSH-induced O
follicular O
development O
in O
HH O
women O
. O
[]

Using O
Z O
rather O
than O
P O
could O
save O
busy O
cancer O
centres O
time O
and O
improve O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
A O
randomized O
prospective O
analysis O
of O
121 O
consecutive O
inguinal O
hernia O
repairs O
was O
performed O
over O
a O
12-month O
period O
. O
[]

Comparison O
of O
the O
efficacy O
of O
fluoxetine O
alone O
vs. O
fluoxetine O
plus O
local O
lidocaine O
ointment O
in O
the O
treatment O
of O
premature O
ejaculation O
. O
[]

Interactions O
of O
morphine O
and O
methotrimeprazine O
in O
mouse O
and O
man O
with O
respect O
to O
analgesia B-outcome ['Resource-use']
, O
respiration B-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Yohimbine O
in O
neurally O
mediated O
syncope O
. O
[]

The O
proportion O
of O
[]

Nine O
patients O
were O
attributed O
to O
the O
convulsion O
type O
, O
defined O
as O
a O
transient O
event O
of O
short O
duration O
with O
convulsions O
followed O
by O
a O
post-ictal O
phase O
, O
without O
signs O
of O
a O
generalized O
disease O
. O
[]

The O
starting O
dose O
of O
4 O
mg/24 O
h O
was O
increased O
every O
week O
by O
2 O
mg/24 O
h O
in O
the O
slow-titration O
group O
and O
4 O
mg/24 O
h O
in O
the O
fast-titration O
group O
. O
[]

The O
unaffected O
arm O
was O
restrained O
during O
the O
sessions O
. O
[]

RATIONALE O
The O
response O
characteristics O
of O
the O
6 O
minute O
walk O
test O
( O
6MWT O
) O
in O
studies O
of O
idiopathic O
pulmonary O
fibrosis O
( O
IPF O
) O
are O
only O
poorly O
understood O
, O
and O
the O
change O
in O
walk O
distance O
that O
constitutes O
the O
minimum O
important O
difference O
( O
MID O
) O
over O
time O
is O
unknown O
. O
[]

We O
followed O
up O
patients O
for O
time O
to O
recurrence O
, O
and O
recurrence-free O
and O
overall O
survival O
. O
[]

Interceed O
( O
TC7 O
) O
is O
a O
fabric O
composed O
of O
oxidized O
, O
regenerated O
cellulose O
that O
was O
designed O
to O
reduce O
the O
formation O
of O
postsurgical O
adhesions O
. O
[]

Patients O
completed O
a O
questionnaire O
before O
and O
1 O
year O
after O
surgery O
to O
evaluate O
symptoms O
, O
function O
, O
and O
overall O
satisfaction O
. O
[]

lipid O
emulsion O
( O
LCT O
, O
MCT O
, O
Olive-oil O
and O
Fish-oil O
) O
in O
patients O
undergoing O
elective O
gastrointestial O
surgery O
during O
the O
early O
postoperative O
period O
. O
[]

Supplementation O
of O
cardioplegic O
solutions O
with O
the O
high-energy O
compound O
creatine O
phosphate O
( O
10 O
mmol/L O
) O
compared O
to O
plain O
cardioplegic O
solutions O
was O
investigated O
in O
this O
study O
. O
[]

How O
to O
establish O
equivalence O
when O
data O
are O
censored O
: O
a O
randomized O
trial O
of O
treatments O
for O
B O
non-Hodgkin O
lymphoma O
. O
[]

Experiments O
2 O
and O
3 O
demonstrate O
that O
attitude B-outcome ['Life-Impact']
clarity I-outcome ['Life-Impact']
and O
attitude B-outcome ['Life-Impact']
correctness I-outcome ['Life-Impact']
can O
have O
distinct O
antecedents O
( O
repeated O
expression O
and O
consensus O
feedback O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

This O
randomized O
group O
experiment O
compared O
the O
efficacy O
of O
2 O
communication O
interventions O
( O
Responsive O
Education O
and O
Prelinguistic O
Milieu O
Teaching O
[ O
RPMT O
] O
and O
the O
Picture O
Exchange O
Communication O
System O
[ O
PECS O
] O
) O
in O
36 O
preschoolers O
with O
autism O
spectrum O
disorders O
. O
[]

The O
efficacy O
was O
assessed O
by O
serial O
Holter B-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Any O
blood B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
was O
documented O
. O
['Physiological-Clinical']

Streptokinase O
was O
given O
in O
a O
loading O
dose O
of O
250 O
000 O
IU O
and O
a O
maintenance O
dose O
of O
100 O
000 O
IU/hour O
for O
4 O
days O
as O
a O
mean O
. O
[]

The O
teeth O
restored O
with O
cast O
Ni-Cr O
dowel-cores O
and O
2.0 O
mm O
ferrules O
demonstrated O
significantly O
lower O
fracture B-outcome ['Physiological-Clinical']
strengths I-outcome ['Physiological-Clinical']
, O
p O
= O
0.04 O
. O
['Physiological-Clinical']

METHODS O
We O
studied O
40 O
patients O
who O
underwent O
myocardial O
revascularisation O
using O
extracorporeal O
circulation O
. O
[]

RESULTS O
Participating O
in O
the O
dietary O
intervention O
program O
reduced O
( O
mediated O
) O
the O
negative O
effect O
of O
poorer O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
on O
dietary B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
by O
15 O
% O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
There O
was O
no O
statistically O
significant O
difference O
in O
the O
mean O
DFT B-outcome ['Resource-use']
comparing O
VF O
durations O
of O
5 O
s O
( O
9.5+/-6.0 O
J O
) O
and O
10 O
s O
( O
10.8+/-7.0 O
J O
) O
( O
p=0.4 O
) O
. O
['Resource-use']

RESULTS O
SVR B-outcome ['Physiological-Clinical']
was O
achieved O
by O
9/13 O
patients O
( O
69 O
% O
) O
. O
['Physiological-Clinical']

Participants O
rated O
the O
pleasantness O
of O
the O
scent O
received O
. O
[]

In O
patients O
without O
a O
prior O
history O
of O
bleeding O
, O
bleeding O
risk O
was O
higher O
with O
more O
prolonged O
prothrombin O
time O
and O
lower O
when O
patients O
were O
receiving O
propranolol O
. O
[]

INTERVENTION O
All O
patients O
received O
either O
LE O
0.2 O
% O
or O
placebo O
( O
vehicle O
) O
four O
times O
a O
day O
in O
both O
eyes O
for O
42 O
days O
. O
[]

There O
were O
no O
differences O
between O
groups O
on O
the O
AIMS O
. O
[]

In O
acute O
HF O
, O
ischemic B-outcome ['Physiological-Clinical']
or O
nonischemic B-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
ventricles B-outcome ['Physiological-Clinical']
improved O
during O
3 O
months O
in O
about O
40 O
% O
of O
patients O
and O
remained O
unchanged O
or O
deteriorated O
in O
the O
rest O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adverse O
effects O
on O
blood O
pressure O
, O
electrolytes O
, O
and O
aldosterone O
levels O
, O
seen O
with O
another O
drug O
in O
this O
class O
, O
have O
not O
been O
noted O
in O
studies O
of O
anacetrapib O
to O
date O
. O
[]

The O
mean O
values O
of O
compound B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
M-wave I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
adjacent I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
( O
abductor O
digiti O
quinti O
and O
abductor O
hallucis O
) O
were O
above O
the O
predefined O
threshold O
of O
effect O
, O
indicating O
that O
there O
was O
no O
relevant O
diffusion-induced O
reduction O
of O
muscle B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

EGCG O
topical O
treatments O
influence O
HIF-1 O
? O
[]

There O
did O
appear O
to O
be O
a O
relative O
increase O
in O
mobilization B-outcome ['Life-Impact']
in O
the O
neighborhood O
with O
the O
highest O
level O
of O
intervention B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
effects O
of O
aerobic O
exercise O
on O
academic O
engagement O
in O
young O
children O
with O
autism O
spectrum O
disorder O
. O
[]

RESULTS O
The O
major O
finding O
of O
the O
study O
was O
the O
significant O
improvement O
in O
submaximal B-outcome ['Physiological-Clinical']
response O
to O
exercise B-outcome ['Life-Impact']
of O
experimental O
subjects O
, O
expressed O
by O
the O
reduction O
in O
HR B-outcome ['Physiological-Clinical']
, O
VO2 B-outcome ['Physiological-Clinical']
VE O
while O
VO2 B-outcome ['Physiological-Clinical']
max O
did O
not O
change O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
sought O
to O
examine O
the O
efficacy O
of O
a O
calendar/notebook O
rehabilitation O
intervention O
, O
the O
memory B-outcome ['Life-Impact']
support O
system O
( O
MSS O
) O
, O
for O
individuals O
with O
amnestic O
MCI O
. O
['Life-Impact']

BACKGROUND O
Greater O
body O
mass O
index O
( O
BMI O
) O
is O
associated O
with O
shorter O
time O
to O
prostate-specific O
antigen O
( O
PSA O
) O
failure O
following O
radical O
prostatectomy O
and O
radiation O
therapy O
( O
RT O
) O
. O
[]

The O
primary O
endpoint O
was O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

Short- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
long-term I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
tactile O
massage O
on O
salivary B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
Parkinson O
's O
disease O
: O
a O
randomised O
controlled O
pilot O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Health-related B-outcome ['Life-Impact']
QoL I-outcome ['Life-Impact']
was O
assessed O
at O
entry O
and O
after O
every O
cycle O
by O
the O
EORTC-QLQ-C30 O
and O
LC13 O
questionnaires O
, O
toxicity B-outcome ['Adverse-effects']
by O
the O
NCI-NCCN O
CTC O
vs O
2 O
, O
and O
intent-to-treat O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
by O
the O
Recist O
criteria O
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical']

Additionally O
, O
95 O
patients O
developed O
veno-occlusive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Both O
treatments O
were O
applied O
in O
a O
once O
daily O
dosage O
regimen O
of O
0.01-0.08 O
mg/kg/day O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
greater O
in O
those O
undergoing O
oophorectomy O
, O
though O
both O
treatments O
were O
['Adverse-effects']

Thoracoscopic O
talc O
insufflation O
versus O
talc O
slurry O
for O
symptomatic O
malignant O
pleural O
effusion O
. O
[]

OBJECTIVE O
Although O
metformin O
( O
MET O
) O
is O
an O
insulin O
sensitizer O
currently O
used O
as O
an O
adjunct O
to O
the O
treatment O
of O
some O
of O
the O
complications O
of O
childhood O
obesity O
besides O
type O
2 O
diabetes O
mellitus O
, O
few O
studies O
have O
comprehensively O
examined O
its O
metabolic O
and O
clinical O
effects O
in O
obese O
children O
with O
normal O
glucose O
tolerance O
( O
NGT O
) O
. O
[]

No O
clinically O
significant O
abnormal B-outcome ['Physiological-Clinical']
laboratory I-outcome ['Physiological-Clinical']
values O
or O
overall O
differences O
between O
treatment O
groups O
were O
noted O
. O
['Physiological-Clinical']

A O
double-blind O
, O
double-dummy O
, O
crossover O
study O
was O
carried O
out O
in O
8 O
centres O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
'controlled-release O
' O
ketoprofen O
tablets O
( O
200 O
mg O
) O
with O
that O
of O
indomethacin O
suppositories O
( O
100 O
mg O
) O
in O
out-patients O
with O
definite O
or O
classical O
rheumatoid O
arthritis O
. O
[]

Varicella-zoster B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VZV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
measured O
by O
a O
glycoprotein O
enzyme-linked O
immunosorbent O
assay O
( O
gpELISA O
) O
. O
['Physiological-Clinical']

RESULTS O
103 O
patients O
with O
acute O
ischaemic O
stroke O
were O
randomised O
to O
either O
treatment O
with O
AR-R15896AR O
( O
70 O
patients O
) O
or O
placebo O
( O
33 O
patients O
) O
. O
[]

One O
round O
of O
DMSA O
had O
nearly O
the O
same O
benefit O
as O
seven O
rounds O
. O
[]

Treatment O
groups O
did O
not O
differ O
significantly O
in O
terms O
of O
gestational B-outcome ['Physiological-Clinical']
age O
at O
membrane O
rupture B-outcome ['Physiological-Clinical']
, O
gestational B-outcome ['Physiological-Clinical']
age O
at O
delivery O
, O
birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
maternal O
or O
fetal B-outcome ['Physiological-Clinical']
infectious I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome O
, O
necrotizing B-outcome ['Physiological-Clinical']
enterocolitis B-outcome ['Physiological-Clinical']
, O
or O
perinatal B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

RESULTS O
The O
trial O
was O
planned O
for O
150 O
patients O
, O
but O
was O
halted O
after O
75 O
patients O
when O
planned O
interim O
analysis O
showed O
that O
SILS O
patients O
had O
more O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
pain O
score O
: O
4.4 O
? O
['Physiological-Clinical']

The O
degree O
of O
multivessel B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
was O
similar O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

No O
significant O
difference O
in O
the O
rate O
of O
catheter B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
was O
observed O
between O
the O
groups O
( O
14.6 O
% O
vs O
26.2 O
% O
, O
P O
= O
0.1371 O
) O
. O
['Physiological-Clinical']

We O
assessed O
whether O
sucrose O
administration O
reduces O
pain-specific B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
spinal I-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
after O
an O
acute O
noxious O
procedure O
in O
newborn O
infants O
. O
['Physiological-Clinical']

Choosing O
the O
'Usual O
Care O
' O
brief O
intervention O
over O
existing O
practice O
( O
Real O
Control O
) O
shows O
a O
lower O
cost O
per O
quality O
adjusted O
life O
year O
, O
but O
the O
lack O
of O
supporting O
evidence O
for O
efficacy O
or O
sustainability O
is O
an O
important O
consideration O
for O
decision O
makers O
. O
[]

Analysis O
is O
by O
intention O
to O
treat O
. O
[]

Feasibility O
of O
two O
dose-dense O
FEC O
regimens O
with O
growth O
factor O
support O
for O
adjuvant O
therapy O
in O
patients O
with O
early O
breast O
cancer O
: O
results O
from O
a O
randomised O
study O
of O
the O
Central O
European O
Cooperative O
Oncology O
Group O
( O
CECOG O
) O
. O
[]

Among O
the O
patients O
getting O
cardiovascular O
complications O
, O
these O
occurred O
within O
two O
months O
after O
the O
start O
of O
treatment O
in O
50 O
% O
and O
within O
one O
year O
in O
85 O
% O
of O
them O
. O
[]

Patients O
were O
randomly O
assigned O
in O
a O
single-blind O
fashion O
to O
treatment O
with O
either O
lovastatin O
, O
an O
HMG O
CoA O
reductase O
inhibitor O
( O
n O
= O
16 O
; O
mean O
dose O
30.0 O
+/- O
12.6 O
mg/day O
) O
or O
placebo O
( O
n O
= O
18 O
) O
for O
2 O
years O
. O
[]

A O
simplified O
approach O
to O
virtual O
colonoscopy O
using O
different O
intestinal O
preparations O
: O
preliminary O
experience O
with O
regard O
to O
quality O
, O
accuracy O
and O
patient O
acceptability O
. O
[]

The O
patient B-outcome ['Physiological-Clinical']
annulus I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
13.55 O
vs. O
13.46 O
mm O
; O
NS O
) O
measured O
intraoperatively O
was O
used O
as O
baseline O
for O
further O
comparison O
. O
['Physiological-Clinical']

One O
hundred O
patients O
were O
randomized O
to O
receive O
standard O
( O
CDA O
0.14 O
mg/kg/day O
day O
1-5 O
[ O
Arm O
A O
] O
) O
or O
experimental O
treatment O
( O
CDA O
0.14 O
mg/kg/day O
once O
weekly O
for O
5 O
weeks O
[ O
Arm O
B O
] O
) O
. O
[]

Response O
to O
familiar B-outcome ['Life-Impact']
faces I-outcome ['Life-Impact']
, O
newly O
familiar O
faces O
, O
and O
novel O
faces O
as O
assessed O
by O
ERPs O
is O
intact O
in O
adults O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

RESULTS O
There O
were O
significantly O
more O
responders O
in O
the O
acarbose-treated O
group O
compared O
with O
the O
placebo O
group O
( O
20/24 O
patients O
vs. O
10/19 O
patients O
; O
p O
< O
0.05 O
) O
. O
[]

OBJECTIVE O
To O
investigate O
the O
effect O
of O
exercise O
training O
and O
dietary O
macronutrient O
composition O
on O
24 O
h B-outcome ['Physiological-Clinical']
substrate I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
in O
male O
, O
obese O
subjects O
. O
['Physiological-Clinical']

Injections O
of O
3 O
ml O
of O
the O
local O
anesthetic O
were O
given O
, O
followed O
by O
the O
remainder O
of O
the O
local O
anesthetic O
at O
10 O
ml/min O
1 O
min O
later O
. O
[]

An O
AX O
continuous O
performance O
test O
( O
AX-CPT O
) O
was O
used O
to O
evaluate O
working O
memory O
and O
inhibitory O
control O
. O
[]

The O
mean O
CD4 O
( O
+/- O
SD O
) O
lymphocyte O
level O
was O
37 O
( O
+/- O
29 O
) O
/microL O
and O
39 O
( O
+/- O
44 O
) O
/microL O
in O
groups O
A O
and O
B O
, O
respectively O
. O
[]

The O
objective O
of O
the O
study O
was O
to O
investigate O
whether O
home B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
HBP O
) O
is O
a O
reliable O
alternative O
to O
ambulatory O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
ABP O
) O
for O
the O
detection O
of O
the O
white O
coat O
effect O
( O
WCE O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Early O
withdrawal O
of O
calcineurin O
inhibitors O
and O
everolimus O
monotherapy O
in O
de O
novo O
liver O
transplant O
recipients O
preserves O
renal O
function O
. O
[]

Therefore O
, O
we O
designed O
a O
protocol O
for O
repetitive O
high-dose O
bronchial O
allergen O
challenges O
to O
generate O
clinical O
symptoms O
and O
airway O
inflammation O
. O
[]

Secondary O
outcome O
measures O
were O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Effectiveness O
of O
web-based O
tailored O
smoking O
cessation O
advice O
reports O
( O
iQuit O
) O
: O
a O
randomized O
trial O
. O
[]

Beneficial O
effects O
were O
homogeneous O
for O
sex O
, O
race O
, O
diabetes O
and O
no O
diabetes O
, O
age O
, O
functional O
class O
, O
and O
etiology O
. O
[]

The O
rates O
of O
severe B-outcome ['Adverse-effects']
acute I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
were O
similar O
( O
4 O
% O
for O
q.d O
. O
['Adverse-effects']

RESULTS O
Both O
citalopram O
and O
reboxetine O
showed O
good O
safety O
and O
tolerability B-outcome ['Life-Impact']
. O
['Life-Impact']

This O
study O
aimed O
to O
elucidate O
the O
effects O
of O
concurrent O
activation O
of O
elbow O
muscles O
on O
the O
coordination O
between O
hand O
muscles O
performing O
a O
grip O
task O
. O
[]

However O
, O
this O
effect O
was O
only O
found O
in O
higher-functioning O
children O
, O
and O
not O
with O
more O
severely O
impaired O
children O
. O
[]

Limitations O
of O
the O
study O
and O
future O
research O
are O
discussed O
. O
[]

Patients O
were O
randomised O
to O
receive O
either O
four O
or O
eight O
courses O
of O
cytotoxic O
chemotherapy O
with O
cyclophosphamide O
, O
vincristine O
and O
etoposide O
and O
also O
randomised O
to O
receive O
, O
on O
disease O
progression O
, O
either O
second O
line O
chemotherapy O
( O
methotrexate O
and O
doxorubicin O
) O
or O
symptomatic O
treatment O
only O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
a O
short-course O
pretreatment O
with O
metformin O
on O
hyperandrogenism B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
cervical B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
, O
and O
pregnancy B-outcome ['Physiological-Clinical']
rates O
in O
women O
with O
clomiphene O
citrate O
( O
CC O
) O
-resistant O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

beta-Carotene O
has O
been O
reported O
to O
have O
an O
immunostimulatory O
effect O
. O
[]

METHODS O
In O
this O
multicenter O
clinical O
trial O
, O
213 O
patients O
with O
previous O
cataract O
surgery O
or O
previous O
failed O
filtering O
surgery O
were O
randomly O
assigned O
to O
receive O
either O
trabeculectomy O
alone O
or O
trabeculectomy O
with O
postoperative O
subconjunctival O
5-fluorouracil O
injections O
. O
[]

It O
is O
characterised O
by O
acute O
, O
potentially O
life-threatening O
neurological O
attacks O
that O
are O
precipitated O
by O
various O
drugs O
, O
reproductive O
hormones O
and O
other O
factors O
. O
[]

Comparison O
of O
analgesic O
effect O
of O
locally O
and O
systemically O
administered O
ketorolac O
in O
mastectomy O
patients O
. O
[]

A O
total O
of O
92.7 O
% O
indicated O
that O
they O
would O
rejoin O
the O
clinical O
trial O
if O
they O
had O
to O
do O
it O
all O
over O
again O
. O
[]

The O
primary O
safety O
endpoint O
was O
cardiotoxicity O
. O
[]

A O
new O
immunomodulating O
agent O
, O
bestatin O
( O
INN O
: O
Ubenimex O
has O
low O
toxicity O
even O
after O
long-term O
oral O
administration O
and O
has O
significant O
modifications O
in O
immunological B-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical']

Participants O
, O
classroom O
teachers O
, O
and O
research O
assistants O
who O
coded O
the O
data O
were O
blind O
as O
to O
the O
group O
to O
which O
the O
participants O
were O
assigned O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
psychological B-outcome ['Life-Impact']
aspect I-outcome ['Life-Impact']
of O
reduction O
mammaplasty O
is O
therefore O
an O
important O
consideration O
. O
['Life-Impact']

There O
was O
no O
association O
of O
nutrient O
intake O
to O
changes O
in O
stool O
consistency O
. O
[]

However O
the O
results O
need O
to O
be O
further O
confirmed O
by O
a O
larger O
randomized O
controlled O
trial O
. O
[]

RESULTS O
Of O
the O
68 O
patients O
who O
underwent O
transurethral O
prostate O
resection O
2 O
were O
withdrawn O
before O
surgery O
, O
and O
so O
32 O
received O
finasteride O
and O
36 O
received O
placebo O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

INTRODUCTION O
Adherence B-outcome ['Life-Impact']
to O
treatment O
in O
osteoporosis O
remains O
poor O
. O
['Life-Impact']

Omega-3 O
fatty O
acids O
supplementation O
in O
children O
with O
autism O
: O
a O
double-blind O
randomized O
, O
placebo-controlled O
pilot O
study O
. O
[]

BACKGROUND O
Fluticasone O
propionate O
, O
an O
inhaled O
corticosteroid O
with O
negligible O
systemic O
bioavailability O
via O
the O
oral O
route O
, O
is O
efficacious O
in O
the O
treatment O
of O
asthma O
when O
administered O
via O
metered-dose O
inhaler O
. O
[]

Acute O
intravenous O
L-arginine O
infusion O
decreases O
endothelin-1 B-outcome ['Physiological-Clinical']
levels O
and O
improves O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
angina O
pectoris O
and O
normal O
coronary O
arteriograms O
: O
correlation O
with O
asymmetric O
dimethylarginine B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Limited O
data O
are O
available O
regarding O
the O
direct O
comparison O
of O
angiographic O
and O
clinical O
outcomes O
after O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
with O
drug-eluting O
stents O
( O
DESs O
) O
for O
chronic O
total O
occlusion O
( O
CTO O
) O
. O
[]

Effects O
of O
irrigation O
fluid O
temperature O
on O
core O
body O
temperature O
during O
transurethral O
resection O
of O
the O
prostate O
. O
[]

Relapse B-outcome ['Physiological-Clinical']
after O
initial O
control O
of O
the O
disease O
was O
observed O
in O
7 O
patients O
( O
4 O
in O
group O
A O
and O
3 O
in O
group O
B O
) O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
During O
a O
2-year O
period O
101 O
men O
with O
benign O
prostatic O
hyperplasia O
were O
randomly O
assigned O
to O
PlasmaKinetic O
surgery O
or O
standard O
transurethral O
prostate O
resection O
( O
TURP O
) O
. O
[]

The O
use O
of O
( O
low-dose O
) O
CsA O
was O
not O
associated O
with O
lipid B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
or O
with O
disturbances O
in O
glucose B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

2 O
. O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
was O
inversely O
related O
to O
total O
and O
cardiovascular B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Data O
from O
eligible O
nonrandomized O
patients O
were O
analyzed O
separately O
. O
[]

Three O
groups O
of O
unimpaired O
participants O
trained O
with O
the O
target O
arm O
movement O
broken O
down O
in O
three O
ways O
: O
1 O
) O
elbow O
flexion/extension O
and O
the O
unified O
shoulder O
motion O
independently O
( O
anatomical O
decomposition O
) O
, O
2 O
) O
three O
component O
shoulder O
motions O
in O
Euler O
coordinates O
and O
elbow O
flexion/extension O
( O
Euler O
decomposition O
) O
, O
or O
3 O
) O
the O
motion O
of O
the O
tip O
of O
the O
elbow O
and O
motion O
of O
the O
hand O
with O
respect O
to O
the O
elbow O
, O
independently O
( O
visual O
decomposition O
) O
. O
[]

AIM O
The O
aim O
of O
our O
study O
was O
to O
assess O
the O
influence O
of O
oral O
corticosteroids O
and O
oral O
corticosteroids O
combined O
with O
vitamin O
D O
( O
3 O
) O
on O
the O
early O
clinical O
and O
immunological O
effects O
of O
SIT O
. O
[]

RESULTS O
Ten O
female O
subjects O
with O
mild O
to O
moderate O
facial O
photodamage O
were O
treated O
with O
one O
pass O
of O
either O
IPL O
or O
Er O
: O
YAG O
in O
a O
split-face O
fashion O
. O
[]

In O
contrast O
, O
VEGFR-1 O
staining O
levels O
in O
AML O
patients O
were O
in O
the O
same O
range O
as O
in O
the O
controls O
. O
[]

METHODS O
From O
January O
2002 O
through O
December O
2004 O
, O
600 O
patients O
with O
Neisseria O
gonorrhoeae O
or O
Chlamydia O
trachomatis O
were O
recruited O
from O
STI O
clinics O
and O
randomly O
assigned O
to O
either O
a O
standard-of-care O
group O
or O
a O
group O
that O
was O
counseled O
at O
the O
time O
of O
diagnosis O
and O
given O
additional O
follow-up O
contact O
. O
[]

The O
paroxetine O
352 O
bipolar O
trial O
: O
A O
study O
in O
medical O
ghostwriting O
. O
[]

DESIGN O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
single-center O
trial O
enrolling O
222 O
postmenopausal O
women O
45 O
years O
and O
older O
without O
cardiovascular O
disease O
and O
with O
low-density O
lipoprotein O
( O
LDL O
) O
cholesterol O
levels O
of O
3.37 O
mmol/L O
or O
greater O
( O
> O
or O
= O
130 O
mg/dL O
) O
. O
[]

The O
patients O
in O
different O
groups O
were O
treated O
with O
different O
doses O
of O
recombinant O
hepatitis O
B O
vaccine O
in O
combination O
with O
IFN O
alpha O
1b O
50 O
micrograms O
with O
3 O
times O
a O
week O
for O
24 O
weeks O
. O
[]

RESULTS O
Women O
in O
the O
educational O
book O
group O
had O
fewer O
risks O
in O
their O
homes O
and O
exercised O
more O
safety O
[]

Single-dose O
metronidazole O
treatment O
of O
the O
sexual O
partner O
of O
women O
with O
bacterial O
vaginosis O
improves O
initial O
bacterial B-outcome ['Physiological-Clinical']
vaginosis I-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
clarify O
the O
role O
of O
microembolization O
in O
the O
genesis O
of O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Chronic O
heart O
failure O
( O
CHF O
) O
accounts O
for O
significant O
morbidity O
, O
mortality O
and O
health O
expenditure O
. O
[]

A O
total O
of O
55 O
subjects O
gavetheir O
consent O
and O
27 O
were O
randomized O
in O
a O
1 O
: O
1 O
manner O
( O
mean O
age O
9.46+/-2.46 O
, O
mean O
nonverbal O
IQ O
63.3+/-23.9 O
) O
. O
[]

Strength O
of O
vital O
force O
in O
classical O
homeopathy O
: O
bio-psycho-social-spiritual O
correlates O
within O
a O
complex O
systems O
context O
. O
[]

Oxytocin O
infusion O
reduces O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
adults O
with O
autistic O
and O
Asperger O
's O
disorders O
. O
['Life-Impact']

The O
incidence O
of O
ephedrine B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
incidence O
of O
nausea/vomiting B-outcome ['Physiological-Clinical']
, O
and O
median O
total O
dose B-outcome ['Life-Impact']
of O
ephedrine B-outcome ['Resource-use']
were O
similar O
in O
all O
groups O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Baseline O
values O
were O
compared O
with O
data O
collected O
during O
the O
treatment O
period O
. O
[]

The O
prompt O
metabolic O
decompensation O
precipitated O
by O
insulin O
withdrawal O
suggests O
that O
insulin-deficient O
patients O
may O
benefit O
from O
insulin O
therapy O
and O
may O
need O
it O
to O
prevent O
symptomatic B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
values O
were O
calculated O
for O
groups O
of O
volunteers O
at O
each O
sampling O
time O
according O
to O
country O
, O
sex O
, O
and O
supplementation O
( O
between O
9 O
and O
24 O
individual O
samples O
contributing O
to O
each O
mean O
) O
. O
[]

The O
value O
of O
early O
tumour O
marker O
changes O
during O
palliative O
chemotherapy O
in O
patients O
with O
upper O
gastrointestinal O
adenocarcinoma O
( O
UGIA O
) O
is O
unclear O
. O
[]

Each O
subject O
received O
either O
100 O
microg O
of O
octreotide O
or O
10 O
mg O
of O
prochlorperazine O
intravenously O
for O
a O
2-minute O
period O
. O
[]

Five-year O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
registered O
in O
85.2 O
% O
of O
menopausal O
patients O
treated O
with O
tamoxifen O
versus O
71.1 O
% O
in O
control O
( O
P O
< O
0.05 O
) O
. O
['Mortality']

Renal O
plasma O
flow O
and O
MSA O
increased O
significantly O
during O
the O
insulin O
clamp O
, O
whereas O
renal O
NE O
and O
total O
body O
NE O
spillover O
remained O
unchanged O
, O
suggesting O
nonuniform O
regional O
sympathetic O
nerve O
responses O
to O
acute O
hyperinsulinemia O
. O
[]

CoQ O
( O
10 O
) O
main O
effect O
was O
: O
peak O
VO B-outcome ['Physiological-Clinical']
( O
2 O
) O
+9 O
% O
, O
EDDBA B-outcome ['Physiological-Clinical']
+38 O
% O
, O
systolic B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
thickening B-outcome ['Physiological-Clinical']
score O
index O
( O
SWTI B-outcome ['Physiological-Clinical']
) O
-12 O
% O
; O
ET O
produced O
comparable O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
Clinical O
study O
on O
dan O
shao O
tang O
in O
treating O
IgA O
nephropathy O
of O
deficiency O
of O
yin O
with O
damp-heat O
symptom O
] O
. O
[]

Vitamin O
C O
( O
pre O
, O
194.6+/-40.9 O
; O
post O
, O
137.2+/-34.1 O
; O
P O
< O
.05 O
) O
and O
a O
combination O
of O
vitamin O
C O
and O
E O
( O
pre O
, O
171.0+/-39.8 O
; O
post O
, O
133.5+/-29.6 O
P O
< O
.05 O
) O
suppressed O
urinary B-outcome ['Physiological-Clinical']
8-epi-PGF2 I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
, O
whereas O
vitamin O
E O
alone O
had O
no O
effect O
. O
['Physiological-Clinical']

There O
were O
no O
changes O
in O
the O
QTc B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
in O
the O
lidocaine O
group O
. O
['Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
challenge O
trial O
was O
performed O
in O
beagle O
pups O
( O
8-9 O
weeks O
) O
; O
clinical O
signs O
, O
body O
weight O
, O
hematologic O
parameters O
, O
and O
mortality O
were O
monitored O
for O
a O
period O
of O
14 O
days O
after O
challenge O
. O
[]

The O
number O
of O
very O
premature B-outcome ['Physiological-Clinical']
infants I-outcome ['Physiological-Clinical']
born B-outcome ['Physiological-Clinical']
( O
less O
than O
28 O
weeks O
' O
gestation O
) O
was O
unequal O
in O
the O
two O
groups O
( O
12 O
in O
the O
bed O
rest O
group O
and O
5 O
in O
the O
tocolysis O
group O
) O
and O
skewed O
the O
results O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effectiveness O
and O
safety O
of O
fixed-dose O
enoxaparin O
and O
adjusted O
dose O
warfarin O
in O
preventing O
venous O
thromboembolism O
after O
knee O
arthroplasty O
. O
[]

A O
quasi-experimental O
pretest-posttest O
control O
group O
design O
was O
used O
. O
[]

PATIENTS O
AND O
METHODS O
Women O
( O
n=509 O
) O
with O
MBC O
and O
normal O
cardiac O
function O
were O
randomized O
to O
receive O
either O
PLD O
50 O
mg/m2 O
( O
every O
4 O
weeks O
) O
or O
doxorubicin O
60 O
mg/m2 O
( O
every O
3 O
weeks O
) O
. O
[]

The O
AQ-J-21 B-outcome ['Physiological-Clinical']
( O
consisting O
of O
21 O
items O
['Physiological-Clinical']

This O
study O
evaluates O
the O
safety O
and O
efficacy O
of O
buspirone O
hydrochloride O
for O
the O
treatment O
of O
a O
patient O
with O
autism O
and O
hyperactivity O
disorder O
and O
determines O
the O
effect O
of O
buspirone O
on O
the O
number O
of O
performance O
tasks O
completed O
by O
the O
patient O
at O
school O
. O
[]

Despite O
the O
limitations O
of O
a O
small O
sample O
size O
in O
this O
study O
, O
ipratropium O
bromide O
nasal O
spray O
significantly O
reduced O
both O
the O
severity B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
in O
laryngectomized O
patients O
. O
['Physiological-Clinical']

Internal O
limiting O
membrane O
delamination O
vs O
posterior O
hyaloid O
removal O
. O
[]

Estimation O
was O
made O
on O
therapeutic O
effect O
and O
developing O
level O
of O
autism O
children O
with O
CARS O
and O
PEP O
. O
[]

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
quality O
of O
life O
improvement O
and O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
significantly O
favoured O
RFA O
. O
['Life-Impact', 'Resource-use']

A O
comparative O
study O
of O
ofloxacin O
and O
amoxycillin/clavulanate O
in O
hospitalized O
patients O
with O
lower O
respiratory B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
pathogens O
were O
Haemophilus O
influenzae O
type O
b O
( O
54 O
cases O
) O
, O
streptococci O
( O
9 O
cases O
) O
, O
meningococci O
( O
9 O
cases O
) O
, O
and O
unknown O
( O
6 O
cases O
) O
. O
[]

26,641 O
Anopheles O
punctulatus O
mosquitoes O
were O
caught O
during O
499 O
person-nights O
of O
landing O
catches O
. O
[]

The O
antiviral O
effect O
was O
not O
significant O
. O
[]

Surgery O
was O
reserved O
for O
persistent O
or O
recurrent O
disease O
. O
[]

Pentoxifylline O
treatment O
did O
not O
influence O
the O
concentration O
of O
plasma-TNF-alpha B-outcome ['Physiological-Clinical']
, O
subpopulations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
mononuclear B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
the O
proliferative O
responses B-outcome ['Physiological-Clinical']
nor O
the O
natural O
killer B-outcome ['Physiological-Clinical']
( O
NK B-outcome ['Physiological-Clinical']
) O
, O
and O
lymphokine B-outcome ['Physiological-Clinical']
activated B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
( O
LAK B-outcome ['Physiological-Clinical']
) O
cell B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Goldmann O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
displayed O
a O
significant O
constriction B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
isopters I-outcome ['Physiological-Clinical']
: O
III/4 O
, O
I/4 O
, O
and O
I/3 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
participants O
also O
performed O
a O
visual O
task O
, O
in O
which O
they O
rated O
the O
intensity O
of O
pleasure B-outcome ['Life-Impact']
they O
experienced O
in O
response O
to O
emotionally B-outcome ['Life-Impact']
positive O
and O
neutral B-outcome ['Life-Impact']
pictures I-outcome ['Life-Impact']
differing O
in O
luminance B-outcome ['Physiological-Clinical']
contrast I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Single O
Bond O
adhesive O
system O
was O
applied O
to O
the O
surfaces O
and O
light O
cured O
( O
40 O
s O
) O
. O
[]

Efficacy O
of O
second O
versus O
third O
generation O
oral O
contraceptives O
in O
the O
treatment O
of O
hirsutism O
. O
[]

This O
prospective O
, O
randomised O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
the O
two O
agents O
in O
the O
prevention O
of O
vomiting B-outcome ['Physiological-Clinical']
and O
nausea B-outcome ['Physiological-Clinical']
in O
children O
receiving O
highly O
emetogenic O
chemotherapy O
for O
various O
malignancies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Most O
patients O
needed O
only O
1-tablet O
doses O
following O
the O
initial O
2-tablet O
dose O
. O
[]

This O
study O
will O
assess O
whether O
yoga O
is O
effective O
for O
treating O
chronic B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
compared O
with O
self O
care O
and O
exercise O
and O
will O
explore O
the O
mechanisms O
responsible O
for O
any O
observed O
benefits O
. O
['Physiological-Clinical']

Reduction O
in O
the O
number O
of O
lesions B-outcome ['Physiological-Clinical']
was O
similar O
with O
both O
azithromycin O
and O
doxycycline O
treatments O
( O
27 O
+/- O
12 O
and O
30 O
+/- O
12 O
, O
respectively O
) O
in O
both O
groups O
. O
['Physiological-Clinical']

Half O
of O
the O
participants O
complained O
about O
deficiencies O
concerning O
the O
ergonomic B-outcome ['Physiological-Clinical']
hardware I-outcome ['Physiological-Clinical']
design I-outcome ['Physiological-Clinical']
of O
the O
AR O
system O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
number O
and O
appearance B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
evaluated O
before O
, O
during O
, O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
main O
reasons O
for O
this O
are O
avoidance O
of O
sun O
exposure O
, O
a O
low O
dietary O
intake O
of O
vitamin O
D O
, O
and O
no O
or O
little O
use O
of O
supplementation O
. O
[]

PURPOSE O
Survival O
of O
patients O
with O
completely O
resected O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
unsatisfactory O
, O
and O
in O
2002 O
, O
the O
benefit O
of O
adjuvant O
chemotherapy O
was O
not O
established O
. O
[]

Mean O
predialysis O
anti-Xa O
level O
20-24 O
hours O
after O
the O
third O
LMWH O
dose O
was O
0.37 O
? O
[]

Afterwards O
, O
8 O
transverse O
sections O
( O
1.5 O
mm O
) O
were O
cut O
from O
4 O
mm O
above O
the O
CEJ O
up O
to O
4 O
mm O
short O
of O
the O
root O
canal O
apex O
, O
comprising O
coronal O
and O
root O
canal O
dentin O
. O
[]

This O
study O
was O
performed O
to O
evaluate O
by O
echo-Doppler O
technique O
the O
hemodynamic B-outcome ['Physiological-Clinical']
effects O
of O
subcutaneous O
sumatriptan O
administration O
. O
['Physiological-Clinical']

BACKGROUND O
Fungal O
infection O
is O
a O
frequent O
and O
often O
fatal O
complication O
in O
patients O
undergoing O
remission O
induction O
therapy O
for O
acute O
leukemia O
. O
[]

A O
comparison O
of O
human O
papillomavirus O
testing O
of O
clinician-collected O
and O
self-collected O
samples O
during O
follow-up O
after O
screen-and-treat O
. O
[]

All O
34 O
patients O
completed O
the O
study O
. O
[]

Clinical O
efficacy O
of O
antazoline O
in O
rapid B-outcome ['Physiological-Clinical']
cardioversion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
paroxysmal I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
-- I-outcome ['Physiological-Clinical']
a O
protocol O
of O
a O
single O
center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
( O
the O
AnPAF O
Study O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
if O
sertraline O
is O
helpful O
in O
the O
management O
of O
depressive O
symptoms O
associated O
with O
ovarian O
suppression O
during O
GnRH O
agonist O
therapy O
as O
compared O
with O
a O
placebo-controlled O
group O
. O
[]

The O
net O
change O
in O
the O
VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
2.5 O
mL O
min/kg O
( O
95 O
% O
CI O
1.5 O
, O
3.5 O
) O
( O
8.7 O
% O
) O
in O
Group O
S1 O
and O
2.5 O
mL O
min/kg O
( O
95 O
% O
CI O
1.5 O
, O
3.5 O
) O
( O
8.8 O
% O
) O
in O
Group O
S2 O
. O
['Physiological-Clinical']

Previous O
studies O
of O
iron O
in O
relation O
to O
gastric O
cancer O
have O
not O
assessed O
subtype-specific O
relationships O
. O
[]

524 O
( O
90.2 O
% O
) O
of O
581 O
patients O
enrolled O
in O
the O
NMSG O
4/90 O
completed O
the O
first O
questionnaire O
, O
and O
484 O
( O
83.3 O
% O
) O
completed O
all O
questionnaires O
given O
to O
them O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
scores O
were O
significantly O
improved O
( O
P O
less O
than O
.01 O
) O
at O
ten O
and O
30 O
minutes O
following O
the O
treatment O
with O
racemic O
epinephrine O
but O
not O
at O
120 O
minutes O
. O
['Physiological-Clinical']

These O
interactions O
can O
cascade O
over O
larger O
distances O
provided O
the O
spacing O
of O
stimulus O
elements O
is O
kept O
within O
a O
limited O
range O
. O
[]

Seventy O
children O
( O
9-16 O
years O
old O
) O
were O
randomly O
assigned O
to O
either O
of O
the O
programs O
( O
n O
( O
CBT O
) O
= O
36 O
; O
n O
( O
SR O
) O
= O
34 O
) O
. O
[]

PURPOSE O
A O
previous O
dose-ranging O
study O
of O
foscarnet O
maintenance O
therapy O
for O
cytomegalovirus O
retinopathy O
showed O
a O
positive O
relationship O
between O
dose O
and O
survival O
but O
could O
not O
confirm O
a O
relationship O
between O
dose O
and O
time O
to O
first O
progression O
. O
[]

OBJECTIVE O
To O
examine O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
single O
intra-articular O
injection O
of O
rAAV2-TNFR O
: O
Fc O
, O
an O
adenoassociated O
virus O
serotype O
2 O
vector O
containing O
the O
cDNA O
for O
the O
human O
tumour O
necrosis O
factor-immunoglobulin O
Fc O
fusion O
gene O
( O
tgAAC94 O
) O
, O
in O
subjects O
with O
inflammatory O
arthritis O
. O
['Life-Impact']

The O
P-ASA O
injection O
was O
administered O
, O
utilizing O
the O
Wand O
Plus O
system O
, O
6 O
to O
10 O
mm O
into O
the O
incisive O
canal O
located O
lingual O
to O
the O
central O
incisors O
. O
[]

Safety O
and O
efficacy O
were O
compared O
over O
the O
first O
12 O
weeks O
of O
the O
yearlong O
trial O
between O
patients O
who O
had O
remained O
on O
CFC O
albuterol O
and O
those O
who O
had O
been O
switched O
to O
HFA O
albuterol O
. O
[]

No O
crystalloid O
was O
given O
during O
surgery O
. O
[]

A O
randomized O
placebo-controlled O
prevention O
trial O
of O
aspirin O
and/or O
resistant O
starch O
in O
young O
people O
with O
familial B-outcome ['Physiological-Clinical']
adenomatous I-outcome ['Physiological-Clinical']
polyposis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Our O
hypothesis O
was O
that O
bilateral O
TAP O
blocks O
decrease O
pain O
after O
laparoscopic O
cholecystectomy O
when O
compared O
with O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
. O
[]

These O
results O
support O
the O
use O
of O
this O
novel O
sealant O
for O
the O
intraoperative O
management O
of O
anastomotic O
bleeding O
during O
aortic O
reconstruction O
procedures O
. O
[]

Fasting O
venous O
blood O
draws O
for O
lipid O
measurement O
were O
obtained O
at O
baseline O
, O
towards O
the O
end O
of O
the O
run-in O
period O
and O
at O
the O
end O
of O
the O
intervention O
. O
[]

Although O
laser O
has O
definite O
advantages O
, O
cryotherapy O
can O
be O
considered O
as O
an O
alternative O
modality O
of O
treatment O
in O
developing O
countries O
due O
to O
economic O
reasons O
. O
[]

The O
study O
was O
designed O
as O
a O
randomized O
double-blind O
cross-over O
study O
and O
included O
36 O
postmenopausal O
women O
at O
three O
health O
care O
areas O
in O
northern O
Sweden O
. O
[]

PATIENTS O
All O
25 O
patients O
had O
clinically O
stable O
heart O
failure O
and O
left O
ventricular O
ejection O
fractions O
< O
40 O
% O
. O
[]

Three O
individualized O
goals O
( O
social O
, O
communication O
, O
and O
independence O
skills O
) O
were O
selected O
for O
intervention O
for O
each O
child O
. O
[]

Tissue-type B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
during O
the O
anhepatic O
phase O
but O
to O
a O
significantly O
lesser O
extent O
in O
the O
infusion O
group O
. O
['Physiological-Clinical']

In O
contrast O
, O
the O
control O
group O
demonstrated O
no O
significant O
improvements O
related O
to O
stress O
or O
quality O
of O
life O
. O
[]

Of O
these O
, O
116 O
were O
randomized O
to O
participate O
in O
a O
bedside-precepted O
visit O
with O
an O
oncology O
nurse O
specialist O
with O
pain O
specialization O
and O
a O
focus O
group O
to O
discuss O
attitudinal O
issues O
. O
[]

METHODS O
Twenty-four O
volunteers O
were O
recruited O
into O
an O
open-label O
, O
randomised O
, O
two-period O
, O
single-centre O
study O
with O
crossover O
design O
. O
[]

Streptococcus B-outcome ['Physiological-Clinical']
viridans I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
not O
attributable O
to O
luminal O
colonization O
. O
['Physiological-Clinical']

Lancet O
puncture O
to O
the O
side O
of O
the O
thumb O
resulted O
in O
less O
pain B-outcome ['Physiological-Clinical']
than O
lancet O
puncture O
to O
the O
finger O
or O
venepuncture O
at O
the O
elbow O
. O
['Physiological-Clinical']

Results O
of O
the O
two O
experiments O
suggest O
that O
manipulation B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
is O
retrieved O
without O
conscious O
effort O
and O
that O
manipulation B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
constitutes O
a O
part O
of O
the O
lexical-semantic O
representation O
of O
objects O
. O
['Life-Impact', 'Life-Impact']

Effect O
of O
clinical O
pharmacy O
services O
on O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
African-American O
renal O
transplant O
patients O
. O
['Physiological-Clinical']

From O
2,834 O
single O
pregnancies O
, O
1,415 O
were O
selected O
at O
random O
to O
receive O
ultrasound O
imaging O
and O
continuous O
wave O
Doppler O
flow O
studies O
at O
five O
points O
throughout O
pregnancy O
( O
Intensive O
) O
and O
1,419 O
to O
receive O
a O
single O
imaging O
scan O
at O
18 O
weeks O
( O
Regular O
) O
, O
with O
further O
scans O
only O
as O
indicated O
on O
clinical O
grounds O
. O
[]

The O
primary O
objective O
of O
the O
study O
was O
to O
demonstrate O
non-inferiority B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lumiracoxib I-outcome ['Physiological-Clinical']
at O
either O
dose O
compared O
with O
celecoxib O
200 O
mg O
o.d O
. O
['Physiological-Clinical']

We O
conclude O
that O
glibenclamide O
stimulates O
pancreatic O
insulin O
production O
even O
after O
6 O
months O
treatment O
. O
[]

METHODS O
Patients O
were O
randomly O
divided O
into O
2 O
groups O
; O
one O
group O
was O
treated O
with O
16 O
mg O
azelnidipine O
and O
the O
other O
with O
5 O
mg O
amlodipine O
once O
daily O
. O
[]

METHODS O
We O
carried O
out O
clinical O
and O
parasitological O
surveys O
in O
14 O
communities O
in O
matched O
pairs O
. O
[]

The O
effects O
of O
clopamide O
, O
pindolol O
and O
its O
combination O
on O
plasma O
lipids O
in O
49 O
hypertensive O
patients O
( O
WHO O
I-II O
) O
, O
divided O
into O
three O
parallel O
randomized O
groups O
, O
were O
studied O
over O
a O
6 O
months O
period O
. O
[]

PU O
was O
given O
in O
a O
single O
daily O
dose O
320 O
mg O
for O
36 O
months O
to O
50 O
patients O
with O
initial O
symptoms O
of O
prostatic O
adenoma O
( O
PA O
) O
in O
comparison O
with O
50 O
matched O
controls O
. O
[]

The O
measurement O
and O
quantification O
of O
saccadic O
eye O
movements O
is O
a O
powerful O
tool O
for O
assessing O
sensory O
, O
motor O
, O
and O
cognitive O
function O
. O
[]

OBJECTIVE O
To O
compare O
the O
effect O
of O
5 O
and O
10 O
mg O
of O
mifepristone O
on O
uterine B-outcome ['Physiological-Clinical']
leiomyoma I-outcome ['Physiological-Clinical']
size O
and O
symptoms B-outcome ['Physiological-Clinical']
, O
and O
to O
measure O
side O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Expression O
of O
VEGF B-outcome ['Physiological-Clinical']
and O
VEGFR-2 B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
patients O
with O
a O
high O
degree O
of O
microvessel O
density O
compared O
to O
those O
with O
a O
low O
degree O
( O
VEGF O
: O
P O
=0.024 O
; O
VEGFR-2 O
: O
P O
=0.040 O
) O
and O
correlated O
well O
with O
bone O
marrow O
microvessel O
density O
( O
r O
( O
s O
) O
=0.566 O
and O
0.609 O
, O
respectively O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
prospective O
randomized O
study O
concerning O
the O
point O
A O
dose O
in O
high-dose O
rate O
intracavitary O
therapy O
for O
carcinoma O
of O
the O
uterine O
cervix O
. O
[]

Gender O
difference O
in O
the O
response O
to O
an O
angiotensin-converting O
enzyme O
inhibitor O
and O
a O
diuretic O
in O
hypertensive O
patients O
of O
African O
descent O
. O
[]

There O
is O
increasing O
demand O
for O
more O
efficient O
and O
safe O
rehabilitation O
protocols O
. O
[]

There O
was O
no O
significant O
difference O
in O
elevation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
total O
protein B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
we O
tested O
the O
hypothesis O
that O
delusional O
schizophrenia O
patients O
are O
more O
likely O
than O
non-delusional O
schizophrenia O
patients O
and O
healthy O
participants O
to O
assign O
affective O
meanings O
to O
neutral O
stimuli O
. O
[]

Improved O
trends O
were O
noted O
on O
other O
outcome O
measures O
. O
[]

Neither O
H-2 O
receptor O
blockers O
nor O
antacids O
alter O
mucosal B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
or O
parietal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lack O
of O
efficacy O
of O
citalopram O
in O
children O
with O
autism O
spectrum O
disorders O
and O
high O
levels O
of O
repetitive O
behavior O
: O
citalopram O
ineffective O
in O
children O
with O
autism O
. O
[]

Oocyst O
excretion B-outcome ['Physiological-Clinical']
increased O
for O
the O
4 O
patients O
initially O
on O
placebo O
compared O
to O
a O
median O
decrease O
of O
128 O
x O
10 O
( O
6 O
) O
/24 O
h O
for O
the O
6 O
initially O
treated O
with O
drug O
( O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

AIM O
To O
determine O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
PHX1149 O
, O
a O
novel O
dipeptidyl O
peptidase-4 O
( O
DPP4 O
) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
. O
['Life-Impact']

9.2 O
years O
with O
angiographically O
diagnosed O
unilateral O
RAS O
( O
? O
[]

Photodynamic O
therapy O
with O
5-aminolaevulinic O
acid O
or O
placebo O
for O
recalcitrant O
foot B-outcome ['Physiological-Clinical']
and O
hand B-outcome ['Physiological-Clinical']
warts I-outcome ['Physiological-Clinical']
: O
randomised O
double-blind O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
treatment O
group O
were O
unable O
to O
work O
19 O
% O
of O
the O
observation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
were O
hospitalized O
for O
4.3 O
% O
of O
that O
time O
. O
['Life-Impact']

The O
injection O
of O
normal O
saline O
solution O
at O
a O
rate O
of O
5 O
mL/sec O
through O
an O
18-gauge O
needle O
was O
continued O
while O
the O
knee O
was O
moved O
through O
a O
range O
of O
motion O
until O
fluid O
extravasated O
from O
the O
iatrogenic O
laceration O
. O
[]

The O
correlation O
of O
the O
FE O
predicted O
failure O
load O
with O
the O
experimental O
failure O
load O
was O
r O
( O
2 O
) O
=64 O
% O
for O
the O
reconstruction O
FE O
model O
, O
which O
was O
significantly O
better O
( O
p O
< O
0.05 O
) O
than O
that O
for O
DXA O
( O
r O
( O
2 O
) O
=24 O
% O
) O
. O
[]

METHODS O
Between O
1999 O
and O
2002 O
, O
1397 O
antiretroviral-treatment-naive O
patients O
, O
presenting O
at O
18 O
clinical O
trial O
units O
with O
80 O
research O
sites O
in O
the O
USA O
, O
were O
randomly O
assigned O
in O
a O
ratio O
of O
1:1:1 O
to O
a O
protease O
inhibitor O
( O
PI O
) O
strategy O
( O
PI O
plus O
nucleoside O
reverse O
transcriptase O
inhibitor O
[ O
NRTI O
] O
; O
n=470 O
) O
, O
a O
non-nucleoside O
reverse O
transcriptase O
inhibitor O
( O
NNRTI O
) O
strategy O
( O
NNRTI O
plus O
NRTI O
; O
n=463 O
) O
, O
or O
a O
three-class O
strategy O
( O
PI O
plus O
NNRTI O
plus O
NRTI O
; O
n=464 O
) O
. O
[]

Similarly O
, O
a O
trend O
towards O
lower O
UVA O
dose O
required O
to O
achieve O
CCR O
in O
the O
combination O
arm O
( O
median O
55?8 O
J O
cm O
( O
-2 O
) O
) O
compared O
with O
the O
PUVA O
arm O
alone O
( O
median O
117?5 O
J O
cm O
( O
-2 O
) O
) O
( O
P O
= O
0?5 O
) O
was O
observed O
. O
[]

A O
formula O
that O
provides O
as O
much O
as O
2.1 O
mg/L O
of O
copper O
, O
however O
, O
may O
not O
always O
permit O
positive O
copper B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Over O
the O
trial O
duration O
, O
no O
significant O
differences O
between O
DHA O
and O
placebo O
groups O
were O
found O
for O
vitamin O
A O
, O
vitamin O
E O
, O
platelet O
aggregation O
, O
antioxidant O
activity O
, O
lipoprotein O
cholesterol O
, O
or O
oxidized O
LDL O
levels O
( O
all O
P O
> O
0.14 O
) O
. O
[]

It O
was O
hypothesized O
that O
food O
form O
is O
the O
most O
salient O
attribute O
. O
[]

Rewarming B-outcome ['Physiological-Clinical']
took O
place O
at O
a O
rate O
of O
0.7 O
+/- O
0.6 O
degrees O
C/h O
( O
range O
0.1-1.8 O
) O
in O
the O
hypothermic O
group O
. O
['Physiological-Clinical']

No O
statistically O
significant O
differences O
in O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
were O
found O
between O
the O
two O
treatment O
techniques O
. O
['Mortality']

The O
transition O
from O
rest O
to O
exercise O
resulted O
in O
a O
shift O
from O
net O
leg O
total O
FFA B-outcome ['Physiological-Clinical']
release B-outcome ['Physiological-Clinical']
( O
-44 O
+/- O
16 O
micromol/min O
) O
to O
uptake O
( O
193 O
+/- O
49 O
micromol/min O
) O
that O
was O
unaffected O
by O
either O
exercise O
intensity O
or O
endurance O
training O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
with O
the O
control O
period O
, O
nicotinic O
acid O
therapy O
reduced O
the O
plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
level O
by O
24 O
% O
, O
plasma B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
level O
by O
45 O
% O
, O
very-low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
by O
58 O
% O
, O
and O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
by O
15 O
% O
, O
and O
it O
increased O
the O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
level O
by O
34 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
controlled O
, O
randomized O
, O
double-blind O
trial O
to O
evaluate O
the O
effect O
of O
a O
supplement O
of O
cocoa O
husk O
that O
is O
rich O
in O
dietary O
fiber O
on O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
in O
constipated O
pediatric O
patients O
. O
['Physiological-Clinical']

The O
ultimate O
outcome O
measure O
was O
full O
return O
to O
sports O
at O
the O
same O
level O
without O
groin O
pain O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Epidural O
analgesia O
has O
been O
shown O
to O
provide O
superior O
pain O
control O
compared O
with O
intravenous O
( O
IV O
) O
opioids O
after O
major O
surgical O
procedures O
. O
[]

Serum O
prolactin O
was O
determined O
by O
immunoradiometric O
assay O
; O
dopamine B-outcome ['Physiological-Clinical']
type-2 I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
( O
DRD2 O
) O
polymorphisms B-outcome ['Physiological-Clinical']
were O
genotyped O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ANIMAL O
POPULATION O
Thirty-seven O
male O
Wistar O
rats O
were O
randomly O
allocated O
to O
one O
of O
six O
treatment O
groups O
. O
[]

Complications B-outcome ['Adverse-effects']
from I-outcome ['Adverse-effects']
MTX I-outcome ['Adverse-effects']
were O
mild O
and O
included O
anorexia B-outcome ['Physiological-Clinical']
, O
alopecia B-outcome ['Physiological-Clinical']
, O
and O
stomatitis B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
model O
for O
evaluating O
anticonvulsants O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
onset B-outcome ['Physiological-Clinical']
and O
average O
root B-outcome ['Physiological-Clinical']
mean O
square O
amplitude O
of O
EMG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Other O
cycle O
variables O
were O
generally O
similar O
between O
groups O
, O
as O
was O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

OBJECTIVE O
To O
highlight O
the O
differences O
in O
behaviors O
in O
children O
with O
diagnosis O
of O
Down O
syndrome O
. O
[]

At O
postassessment O
, O
both O
the O
RET O
and O
REI O
groups O
were O
rated O
on O
sociometric B-outcome ['Life-Impact']
measures O
as O
significantly O
less O
interpersonally O
anxious B-outcome ['Life-Impact']
than O
the O
WLC O
group O
. O
['Life-Impact', 'Life-Impact']

We O
investigated O
to O
compare O
the O
effects O
of O
the O
addition O
of O
tamoxifen O
to O
epirubicin O
versus O
epirubicin O
alone O
on O
VEGF O
and O
VEGFR2 O
expression O
in O
breast O
cancer O
patients O
. O
[]

Low-dose O
liquid O
fluoxetine O
( O
mean O
final O
dose O
: O
9.9+/-4.35 O
mg/day O
) O
was O
superior O
to O
placebo O
in O
the O
treatment O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
by O
CY-BOCS O
compulsion B-outcome ['Life-Impact']
scale O
. O
['Life-Impact', 'Life-Impact']

The O
improved O
mechanical O
efficiency O
seems O
to O
be O
the O
result O
of O
changes O
in O
propulsion O
technique O
that O
were O
found O
. O
[]

Neither O
cognitive O
therapy O
alone O
, O
nor O
associate O
therapy O
alone O
significantly O
reduced O
depression B-outcome ['Life-Impact']
, O
state B-outcome ['Life-Impact']
or O
trait B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
self-rated O
agoraphobia B-outcome ['Life-Impact']
or O
behavioral B-outcome ['Life-Impact']
avoidance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

PATIENTS O
Injection O
drug O
users O
( O
IDUs O
) O
seeking O
substance O
abuse O
treatment O
between O
the O
ages O
of O
18 O
and O
50 O
years O
who O
were O
addicted O
to O
opioids O
( O
e.g. O
, O
heroin O
) O
and O
not O
currently O
in O
drug O
treatment O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Dietary B-outcome ['Life-Impact']
calcium I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
osteoporosis B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
health B-outcome ['Life-Impact']
beliefs I-outcome ['Life-Impact']
, O
and O
self-efficacy B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Mean O
basal B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
was O
27 O
( O
SEM O
5 O
) O
micromol/l O
in O
non-TIPS O
and O
76 O
( O
10 O
) O
micromol/l O
in O
TIPS O
patients O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Further O
technical O
developments O
should O
aim O
at O
improvements O
of O
spatial O
and O
temporal O
coverage O
. O
[]

Results O
showed O
clearly O
that O
homogenisation O
of O
wolfberry O
in O
hot O
skimmed O
milk O
results O
in O
a O
formulation O
that O
has O
a O
3-fold O
enhanced O
bioavailability O
of O
zeaxanthin O
compared O
with O
both O
the O
'classical O
' O
hot O
water O
and O
warm O
skimmed O
milk O
treatment O
of O
the O
berries O
. O
[]

METHODS O
Sixteen O
patients O
( O
10 O
women O
and O
6 O
men O
) O
with O
a O
mean O
age O
of O
35 O
years O
( O
ranging O
from O
21 O
to O
49 O
years O
old O
) O
were O
treated O
from O
2004 O
to O
2005 O
for O
single-tooth O
replacement O
in O
the O
upper O
arch O
. O
[]

The O
European O
and O
Australian O
Stroke O
Prevention O
in O
Reversible O
Ischaemia O
Trial O
( O
ESPRIT O
) O
is O
a O
randomised O
clinical O
trial O
in O
which O
patients O
with O
cerebral O
ischaemia O
of O
arterial O
origin O
will O
be O
randomised O
between O
oral O
anticoagulation O
( O
international O
normalized O
ratio O
( O
INR O
) O
: O
2.0-3.0 O
) O
, O
the O
combination O
of O
acetylsalicylic O
acid O
( O
in O
any O
dose O
between O
30 O
and O
325 O
mg O
per O
day O
) O
plus O
dipyridamole O
( O
400 O
mg O
daily O
) O
and O
acetylsalicylic O
acid O
only O
( O
in O
any O
dose O
between O
30 O
and O
325 O
mg O
per O
day O
) O
. O
[]

No O
toxic B-outcome ['Mortality']
death I-outcome ['Mortality']
was O
observed O
. O
['Mortality']

Pemetrexed O
in O
combination O
with O
cisplatin O
versus O
cisplatin O
monotherapy O
in O
patients O
with O
recurrent O
or O
metastatic O
head O
and O
neck O
cancer O
: O
final O
results O
of O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
phase O
3 O
study O
. O
[]

Bronchoalveolar O
lavage O
was O
performed O
the O
following O
morning O
. O
[]

For O
14 O
patients O
treated O
with O
netilmicin-cefoxitin O
( O
N-C O
) O
, O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
favorable O
in O
13/13 O
( O
100 O
% O
) O
evaluable O
cases O
, O
and O
19/20 O
( O
95 O
% O
) O
organisms O
were O
eliminated O
or O
markedly O
reduced O
. O
['Physiological-Clinical']

The O
sample O
was O
composed O
of O
11 O
children O
diagnosed O
with O
Autism O
( O
n=6 O
) O
and O
Asperger O
syndrome O
( O
n=5 O
) O
by O
a O
multidisciplinary O
team O
, O
that O
attended O
specialized O
speech-language O
pathology O
therapy O
at O
the O
institution O
were O
the O
study O
was O
carried O
out O
. O
[]

Peroperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
transfusion I-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

METHODS O
Twenty O
eyes O
with O
combined O
RRD O
and O
CD O
that O
underwent O
primary O
vitrectomy O
were O
randomized O
to O
receive O
oral O
steroids O
( O
for O
1 O
week O
) O
or O
no O
oral O
steroids O
before O
surgery O
. O
[]

Subjects O
in O
this O
trial O
were O
slightly O
older O
and O
more O
likely O
to O
have O
complaints O
of O
repetitive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
than O
participants O
in O
RUPP O
trials O
. O
['Life-Impact']

In O
an O
open-label O
, O
randomized O
, O
multicenter O
, O
multiple-dose O
pharmacokinetic O
study O
, O
we O
determined O
the O
steady-state B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
of O
amprenavir O
with O
and O
without O
coadministration O
of O
indinavir O
, O
nelfinavir O
, O
or O
saquinavir O
soft O
gel O
formulation O
in O
31 O
human O
immunodeficiency O
virus O
type O
1-infected O
subjects O
. O
['Physiological-Clinical']

To O
test O
these O
competing O
positions O
, O
therapists O
at O
a O
university O
counseling O
center O
were O
instructed O
to O
increase O
the O
number O
of O
self-disclosures O
they O
made O
during O
treatment O
of O
one O
client O
and O
refrain O
from O
making O
self-disclosures O
during O
treatment O
of O
another O
client O
. O
[]

In O
a O
cross-over O
double-blind O
study O
, O
three O
dosages O
of O
naltrexone O
( O
0.5 O
, O
1 O
and O
2 O
mg/kg/day O
) O
and O
placebo O
were O
compared O
. O
( O
[]

BACKGROUND O
In O
familial O
hypercholesterolemia O
( O
FH O
) O
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
( O
LDL-C B-outcome ['Physiological-Clinical']
) O
-lowering O
therapy O
is O
important O
to O
avoid O
predisposition O
to O
coronary O
artery O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Time O
to O
awakening B-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
. O
['Physiological-Clinical']

There O
were O
four O
cases O
of O
posttransplant B-outcome ['Physiological-Clinical']
lymphoproliferative O
disorder B-outcome ['Physiological-Clinical']
( O
PTLD O
) O
from O
the O
beginning O
of O
the O
LTE O
to O
year O
5 O
( O
n O
= O
3 O
LI O
; O
n O
= O
1 O
CsA O
) O
; O
two O
of O
three O
PTLD O
cases O
in O
the O
LI O
group O
were O
in O
patients O
who O
were O
seronegative O
for O
Epstein-Barr O
virus O
( O
EBV O
( O
- O
) O
) O
at O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
rigorous O
statistical O
method O
of O
scale O
construction O
consisting O
of O
a O
modification O
of O
the O
scale O
discrimination O
technique O
was O
employed O
, O
resulting O
in O
a O
45-item O
questionnaire O
representing O
three O
orthogonally O
derived O
scales O
. O
[]

Compared O
to O
control O
, O
this O
therapeutic O
modality O
was O
found O
to O
increase O
the O
healing B-outcome ['Physiological-Clinical']
rate O
of O
recalcitrant O
, O
diabetic O
foot O
ulcers O
. O
['Physiological-Clinical']

BACKGROUND O
Actinic O
keratosis O
is O
a O
frequent O
lesion O
which O
occurs O
in O
sunlight O
exposed O
areas O
. O
[]

In O
dogs O
, O
CCM O
therapy O
increased O
LV B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
at O
2 O
hours O
( O
26 O
+/- O
1 O
versus O
31 O
+/- O
2 O
% O
, O
P O
= O
.001 O
) O
without O
increasing O
MVO B-outcome ['Physiological-Clinical']
( O
2 O
) O
( O
257 O
+/- O
41 O
versus O
180 O
+/- O
34 O
micromol/min O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
Sixteen O
patients O
who O
had O
chronic O
mitral O
regurgitation O
due O
to O
myxomatous O
degeneration O
were O
randomized O
to O
preservation O
( O
Pres O
group O
, O
n O
= O
8 O
) O
or O
no O
preservation O
( O
No O
Pres O
group O
, O
n O
= O
8 O
) O
of O
the O
chordae O
tendineae O
and O
papillary O
muscles O
during O
mitral O
valve O
replacement O
. O
[]

CONCLUSION O
L. O
plantarum O
CECT7315/7316 O
has O
an O
immunostimulating O
effect O
and O
could O
be O
used O
to O
improve O
the O
response O
to O
influenza O
vaccination O
in O
elderly O
. O
[]

When O
combined O
treatment O
is O
considered O
, O
seizure B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
achieved O
in O
17 O
( O
57 O
percent O
) O
of O
the O
neonates O
assigned O
to O
receive O
phenobarbital O
first O
and O
18 O
( O
62 O
percent O
) O
of O
those O
assigned O
to O
receive O
phenytoin O
first O
( O
P=0.67 O
) O
. O
['Physiological-Clinical']

A O
randomized O
control O
trial O
comparing O
two O
social-communication O
interventions O
in O
young O
children O
with O
autism O
examined O
far-transfer O
of O
the O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
picture I-outcome ['Life-Impact']
exchange I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
communicate I-outcome ['Life-Impact']
. O
['Life-Impact']

Secondary O
: O
muscle B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
( O
101-point O
numeric O
rating O
scale O
) O
, O
lateral B-outcome ['Physiological-Clinical']
trunk I-outcome ['Physiological-Clinical']
flexibility I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
fingertip-floor I-outcome ['Physiological-Clinical']
distance O
) O
, O
and O
Roland-Morris O
Disability O
Questionnaire O
over O
3 O
days O
of O
treatment O
and O
2 O
days O
of O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
change O
occurred O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
, O
apo B-outcome ['Physiological-Clinical']
B100/apo B-outcome ['Physiological-Clinical']
A1 B-outcome ['Physiological-Clinical']
ratio O
, O
plasminogen B-outcome ['Physiological-Clinical']
activator B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fourteen O
patients O
with O
Helicobacter O
pylori O
infection O
were O
treated O
with O
omeprazole O
capsules O
20 O
mg O
and O
amoxycillin O
capsules O
1000 O
mg O
twice O
daily O
for O
14 O
days O
and O
14 O
patients O
with O
omeprazole O
capsules O
20 O
mg O
and O
placebo O
twice O
daily O
for O
14 O
days O
. O
[]

Overall O
, O
postmenopausal O
women O
have O
lower O
levels O
of O
HRV O
than O
premenopausal O
women O
, O
which O
may O
be O
additionally O
complicated O
by O
lifestyle O
related O
behaviors O
such O
as O
physical O
inactivity O
and O
obesity O
. O
[]

METHODS O
Twenty O
patients O
received O
three O
cycles O
of O
C O
& O
D O
followed O
by O
imiquimod O
5 O
% O
or O
vehicle O
cream O
once O
daily O
for O
1 O
month O
as O
adjunctive O
therapy O
. O
[]

RA O
patients O
of O
Shen O
deficiency O
and O
cold O
invading O
syndrome O
in O
the O
treatment O
group O
( O
120 O
cases O
) O
were O
treated O
with O
BQZD O
and O
MTX O
( O
10 O
mg/week O
) O
, O
while O
those O
in O
the O
control O
group O
( O
120 O
cases O
) O
were O
treated O
with O
MTX O
( O
10 O
mg/week O
) O
alone O
. O
[]

RESULTS O
Baseline O
patient O
characteristics O
were O
comparable O
in O
both O
arms O
. O
[]

Nicotine O
infusion O
acutely O
impairs O
insulin O
sensitivity O
in O
type O
2 O
diabetic O
patients O
but O
not O
in O
healthy O
subjects O
. O
[]

RESULTS O
There O
were O
small O
and O
comparable O
reductions O
in O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin B-outcome ['Physiological-Clinical']
in O
both O
groups O
over O
3 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Treatment-seeking O
, O
alcohol-dependent O
individuals O
entering O
the O
Combining O
Pharmacotherapies O
and O
Behavioral O
Interventions O
for O
Alcohol O
Dependence O
( O
COMBINE O
) O
Study O
( O
N O
= O
1,372 O
; O
69 O
% O
men O
) O
completed O
the O
ADS O
, O
diagnostic O
interviews O
, O
and O
other O
measures O
before O
randomization O
. O
[]

PATIENTS O
Children O
diagnosed O
with O
CPP O
( O
n O
= O
84 O
) O
, O
who O
were O
either O
treatment O
naive O
or O
previously O
treated O
with O
GnRHa O
, O
were O
recruited O
. O
[]

For O
any O
given O
individual O
, O
a O
rise O
in O
Cr B-outcome ['Physiological-Clinical']
of O
< O
or O
= O
0.5 O
mg/dL O
in O
the O
first O
24 O
hours O
after O
contrast O
exposure O
predicted O
a O
favorable O
outcome O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
the O
overall O
response O
rate O
[ O
complete O
clinical O
response O
( O
CCR O
) O
plus O
partial O
response O
( O
PR O
) O
] O
. O
[]

Compared O
with O
placebo O
, O
nocturnal B-outcome ['Physiological-Clinical']
voiding I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
is O
reduced O
, O
duration O
of O
the O
first O
sleep O
period O
is O
increased O
, O
and O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
may O
be O
improved O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
a O
result O
, O
Parkinson O
's O
disease O
patients O
are O
more O
reliant O
on O
external O
cues O
and O
are O
unable O
to O
use O
predictive O
models O
to O
internally O
guide O
movement O
. O
[]

This O
randomized O
controlled O
trial O
was O
designed O
to O
demonstrate O
whether O
an O
implementation O
intention O
intervention O
involving O
the O
completion O
of O
a O
simple O
self-administered O
questionnaire O
linking O
the O
intention O
of O
taking O
medication O
with O
a O
particular O
time O
, O
place O
, O
and O
other O
activity O
can O
improve O
AED O
treatment O
schedule O
adherence O
. O
[]

Median O
reduction O
in O
HF B-outcome ['Physiological-Clinical']
score O
was O
49 O
% O
for O
venlafaxine O
and O
55 O
% O
for O
clonidine O
( O
ns O
) O
. O
['Physiological-Clinical']

As O
radiographic O
cortical O
continuity O
appears O
late O
in O
the O
healing O
process O
, O
perhaps O
too O
late O
for O
clinical O
relevance O
, O
we O
studied O
the O
qualitative O
appearance O
of O
the O
callus O
5 O
weeks O
after O
fracture O
. O
[]

However O
, O
to O
date O
, O
no O
studies O
have O
compared O
the O
clinical O
effectiveness O
of O
amlodipine O
camsylate O
and O
amlodipine O
besylate O
in O
treating O
hypertension O
. O
[]

Potentiation O
of O
bradykinin-induced O
tissue O
plasminogen O
activator O
release O
by O
angiotensin-converting O
enzyme O
inhibition O
. O
[]

and O
arm O
C O
( O
six O
males/15 O
females O
, O
aged O
41 O
+/- O
16 O
yrs O
) O
placebo O
dextrose O
tablets O
. O
[]

Ten O
drug-related B-outcome ['Mortality']
deaths I-outcome ['Mortality']
were O
reported O
for O
the O
experimental O
arm O
and O
seven O
for O
the O
control O
arm O
. O
['Mortality']

However O
, O
FMD O
and O
digital O
vasodilator O
response O
did O
not O
significantly O
change O
from O
baseline O
with O
long-term O
sulfasalazine O
treatment O
. O
[]

PURPOSE O
The O
aims O
of O
this O
pilot O
study O
were O
the O
following O
: O
1 O
) O
to O
examine O
patterns O
of O
adherence O
to O
a O
brisk O
walking O
program O
in O
women O
receiving O
adjuvant O
chemotherapy O
or O
radiation O
therapy O
for O
newly O
diagnosed O
breast O
cancer O
using O
a O
prospective O
, O
randomized O
, O
controlled O
experimental O
design O
; O
2 O
) O
to O
examine O
the O
influence O
of O
disease O
symptoms O
and O
treatment O
side O
effects O
on O
exercise O
levels O
; O
and O
3 O
) O
to O
suggest O
methods O
that O
may O
improve O
future O
clinical O
trials O
of O
moderate-intensity O
exercise O
in O
similar O
populations O
. O
[]

Primary O
outcome O
measures O
( O
9-hole O
Peg O
Test O
[ O
9HPT O
] O
, O
Jebsen O
Taylor O
Test O
[ O
JTT O
] O
, O
and O
grip O
and O
pinch-grip O
dynamometry O
) O
were O
assessed O
4 O
, O
30 O
, O
and O
90 O
days O
post O
treatment O
. O
[]

High-functioning O
children O
with O
ASD O
were O
compared O
with O
a O
group O
of O
typically O
developing O
children O
. O
[]

Divergence O
in O
student O
and O
educator O
conceptual O
structures O
during O
auscultation O
training O
. O
[]

Under O
40 O
mg O
nimodipine O
the O
subgroup O
with O
poor O
alpha-activity B-outcome ['Physiological-Clinical']
showed O
a O
shift B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
; O
the O
subgroup O
with O
abundant O
alpha-activity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
right I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Regarding O
safety O
, O
213 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
observed O
in O
the O
febuxostat O
group O
and O
220 O
events O
in O
the O
allopurinol O
group O
. O
['Adverse-effects']

CONCLUSION O
Laser-assisted O
topical O
anesthesia O
is O
fast O
, O
painless O
, O
and O
substantially O
more O
effective O
than O
conventional O
topical O
anesthesia O
but O
does O
not O
provide O
adequate O
anesthesia O
for O
full-face O
resurfacing O
in O
all O
subjects O
. O
[]

Subjects O
( O
128 O
boys O
, O
21 O
girls O
) O
had O
a O
mean O
age O
of O
9.3 O
( O
?3.12 O
) O
years O
; O
132 O
( O
88.6 O
% O
) O
were O
diagnosed O
with O
autistic O
disorder O
( O
4.7 O
% O
with O
Asperger O
's O
Disorder O
; O
6.7 O
% O
with O
PDD-not O
otherwise O
specified O
) O
. O
[]

CONCLUSION O
Findings O
from O
this O
study O
indicate O
generally O
that O
there O
are O
benefits O
to O
training B-outcome ['Life-Impact']
parents O
to O
implement O
naturalistic O
language O
intervention O
strategies O
with O
preschool O
children O
who O
have O
ID O
and O
significant O
language O
impairments O
. O
['Life-Impact']

HS O
was O
associated O
with O
increased O
responsiveness O
compared O
with O
a O
blunted O
LS B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
HS O
DeltaE O
' O
-1.4 O
+/- O
0.4 O
cm/s O
vs O
LS O
DeltaE O
' O
-0.1 O
+/- O
0.3 O
cm/s O
, O
P O
= O
0.02 O
; O
HS O
DeltaRBF O
-135.2 O
+/- O
13.2 O
vs O
LS O
DeltaRBF O
-62.5 O
+/- O
10.1 O
mL/min O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
data O
collected O
included O
heart O
rate O
, O
mean O
arterial O
pressure O
, O
respiratory O
rate O
, O
saturation O
of O
oxygen O
, O
amount O
of O
sedatives O
, O
awakening O
time O
and O
adverse O
effects O
. O
[]

RESULTS O
Results O
of O
intent-to-treat O
analyses O
are O
presented O
in O
this O
study O
. O
[]

Leuprolide O
reduced O
PMS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
to O
minimal O
levels O
where O
symptoms O
were O
limited O
to O
the O
luteal O
phase O
. O
['Physiological-Clinical']

All O
patients O
showed O
a O
classic O
stress O
response B-outcome ['Physiological-Clinical']
with O
an O
increase O
in O
circulating B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
and O
growth B-outcome ['Physiological-Clinical']
hormone B-outcome ['Physiological-Clinical']
concentrations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
There O
were O
no O
significant O
differences O
between O
the O
reconstruction O
groups O
for O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
( O
Roux-en-Y O
vs. O
Longmire-Interposition O
with O
and O
without O
pouch O
: O
30.4 O
% O
vs. O
28.6 O
% O
for O
the O
morbidity B-outcome ['Physiological-Clinical']
; O
4.3 O
% O
vs. O
4.1 O
% O
for O
the O
mortality B-outcome ['Mortality']
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Mortality']

In O
addition O
to O
having O
difficulties O
with O
social O
communications O
, O
individuals O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
often O
also O
experience O
impairment O
in O
higher-order O
, O
executive B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
studied O
clinical O
efficiency O
and O
IFN-inducing O
activity O
of O
anaferon O
in O
chronic O
recurrent O
genital O
herpes O
with O
high O
incidence O
of O
relapses O
. O
[]

[ O
Observation O
on O
therapeutic O
effect O
of O
acupuncture O
on O
early O
peripheral O
facial O
paralysis O
] O
. O
[]

OBJECTIVES O
Allopurinol O
protects O
the O
heart O
from O
reperfusion O
injury O
. O
[]

A O
randomised O
, O
controlled O
, O
single-blind O
study O
was O
performed O
on O
100 O
patients O
to O
investigate O
a O
new O
method O
of O
reducing O
pain B-outcome ['Physiological-Clinical']
on O
propofol O
injection O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
is O
the O
change O
in O
glycated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
A1c I-outcome ['Physiological-Clinical']
from O
baseline O
to O
week O
12 O
. O
['Physiological-Clinical']

45 O
kg O
. O
[]

METHODS O
A O
total O
of O
168 O
patients O
with O
previously O
untreated O
stage O
IIIB/IV O
NSCLC O
were O
randomized O
to O
arm O
A O
, O
cetuximab O
( O
400 O
mg/m O
( O
2 O
) O
day O
1 O
followed O
by O
weekly O
250 O
mg/m O
( O
2 O
) O
) O
+ O
paclitaxel O
( O
Taxol O
) O
( O
225 O
mg/m O
( O
2 O
) O
) O
/carboplatin O
( O
AUC6 O
) O
day O
1 O
every O
3 O
weeks O
or O
arm O
B O
, O
same O
cetuximab O
regimen O
plus O
paclitaxel O
( O
100 O
mg/m O
( O
2 O
) O
) O
days O
1 O
, O
8 O
, O
and O
15 O
every O
3 O
weeks O
and O
carboplatin O
( O
AUC6 O
) O
day O
1 O
every O
4 O
weeks O
. O
[]

RESULTS O
A O
reduction O
in O
severity B-outcome ['Physiological-Clinical']
was O
seen O
in O
both O
LE O
and O
placebo O
groups O
for O
bulbar B-outcome ['Physiological-Clinical']
conjunctival I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
( O
1.5 O
vs. O
1.0 O
units O
on O
a O
0-3 O
scale O
) O
and O
itching O
( O
3.4 O
vs. O
3.0 O
units O
on O
a O
0-4 O
scale O
) O
over O
the O
first O
2 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
investigate O
the O
applicability B-outcome ['Life-Impact']
and O
effectiveness O
of O
a O
peer-mentored O
exercise O
program O
, O
this O
study O
compared O
the O
retention B-outcome ['Life-Impact']
and O
participation B-outcome ['Life-Impact']
rates O
, O
and O
physical B-outcome ['Physiological-Clinical']
improvements I-outcome ['Physiological-Clinical']
of O
older O
adults O
trained O
by O
peer O
mentors O
( O
PM O
) O
to O
a O
group O
trained O
by O
young O
qualified O
student O
mentors O
( O
SM O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

We O
conducted O
a O
randomized O
, O
controlled O
, O
pilot-study O
to O
evaluate O
the O
need O
for O
diverting B-outcome ['Physiological-Clinical']
ileostomy I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
low O
anterior O
resection O
[ O
NCT00457327 O
] O
. O
['Physiological-Clinical']

The O
effect O
seemed O
greater O
among O
patients O
without O
metastases O
( O
hazard O
ratio O
= O
0.79 O
; O
P O
= O
.16 O
) O
than O
among O
those O
with O
metastases O
( O
hazard O
ratio O
= O
0.96 O
; O
P O
= O
.84 O
) O
. O
[]

Although O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
declined O
by O
26 O
% O
, O
the O
change O
was O
not O
statistically O
significant O
. O
['Life-Impact']

In O
addition O
, O
each O
patient O
subjectively O
evaluated O
efficacy O
of O
treatment O
by O
a O
visual O
analogue O
scale O
. O
[]

It O
was O
not O
possible O
to O
blind O
participants O
or O
research O
nurses O
to O
washout O
versus O
no O
intervention O
, O
but O
participants O
in O
the O
saline O
and O
washout O
solution O
groups O
were O
blinded O
to O
solution O
type O
. O
[]

RESULTS O
Three O
patients O
had O
relapse B-outcome ['Physiological-Clinical']
on O
phenytoin O
and O
nine O
had O
relapse O
on O
placebo O
. O
['Physiological-Clinical']

A O
beneficial O
effect O
in O
preventing O
acetaminophen O
absorption O
can O
be O
expected O
if O
it O
is O
given O
within O
one O
hour O
after O
ingestion O
. O
[]

To O
evaluate O
the O
effect O
they O
were O
scored O
according O
to O
4 O
grades O
, O
and O
evaluated O
every O
24 O
hours O
from O
the O
start O
of O
chemotherapy O
to O
5 O
days O
after O
its O
completion O
. O
[]

RESULTS O
Clinical B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rates O
were O
100 O
% O
in O
both O
arms O
. O
['Physiological-Clinical']

However O
, O
both O
social O
and O
non-social O
cues O
shifted O
attention B-outcome ['Life-Impact']
to O
the O
cued O
location O
in O
children O
with O
autism O
. O
['Life-Impact']

Effects O
of O
atropine O
and O
scopolamine O
on O
bradycardia B-outcome ['Physiological-Clinical']
and O
emetic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
otoplasty O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Incidences O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
comparable O
. O
['Adverse-effects']

One O
patient O
( O
3 O
% O
) O
in O
the O
13-CRA O
group O
and O
two O
patients O
( O
6 O
% O
) O
in O
the O
placebo O
group O
had O
a O
minor O
response O
. O
[]

Three O
doses O
of O
lornoxicam O
( O
2 O
mg O
, O
4 O
mg O
, O
and O
8 O
mg O
) O
were O
compared O
with O
aspirin O
650 O
mg O
and O
placebo O
. O
[]

The O
Exercise O
and O
Nutrition O
to O
Enhance O
Recovery O
and O
Good O
Health O
for O
You O
( O
ENERGY O
) O
study O
is O
a O
4-year O
randomized O
clinical O
trial O
of O
693 O
overweight/obese O
women O
aged O
?21years O
diagnosed O
with O
any O
early O
stage O
breast O
cancer O
( O
stages O
I O
[ O
?1cm O
] O
-III O
) O
within O
the O
previous O
five O
years O
, O
designed O
to O
demonstrate O
the O
feasibility O
of O
achieving O
sustained O
weight O
loss O
and O
to O
examine O
the O
impact O
of O
weight O
loss O
on O
quality O
of O
life O
and O
co-morbidities O
, O
and O
to O
enable O
future O
exploration O
of O
biochemical O
mechanisms O
linking O
obesity O
to O
lower O
likelihood O
of O
disease-free O
survival O
. O
[]

Significant O
differences O
were O
not O
identified O
between O
patients O
with O
similar O
current O
ages O
and O
cerebrovascular O
disease O
risk O
who O
had O
early-onset O
or O
late-onset O
depression O
. O
[]

The O
restenosis O
rate O
obtained O
from O
the O
vessel O
segment O
inclusive O
of O
the O
dose O
fall-off O
zones O
was O
the O
best O
correlate O
of O
TVR O
and O
should O
become O
a O
standard O
analysis O
site O
in O
all O
vascular O
brachytherapy O
trials O
. O
[]

Concern O
that O
this O
approach O
would O
compromise O
survival O
by O
failing O
to O
achieve O
a O
proper O
oncologic O
resection O
or O
adequate O
staging O
or O
by O
altering O
patterns O
of O
recurrence O
( O
based O
on O
frequent O
reports O
of O
tumor O
recurrences O
within O
surgical O
wounds O
) O
prompted O
a O
controlled O
trial O
evaluation O
. O
[]

Of O
the O
12 O
patients O
who O
suffered O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
eight O
relapsed B-outcome ['Physiological-Clinical']
and O
four O
died B-outcome ['Mortality']
of I-outcome ['Mortality']
toxicity I-outcome ['Mortality']
. O
['Adverse-effects', 'Physiological-Clinical', 'Mortality']

Nearly O
100 O
% O
of O
patients O
experience O
trauma O
to O
the O
trigeminal O
nerve O
during O
orthognathic O
surgery O
, O
impairing O
sensation O
and O
sensory O
function O
on O
the O
face O
. O
[]

Prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial O
infarction O
. O
[]

After O
12 O
weeks O
, O
the O
patients O
had O
a O
mean O
decrease O
of O
28.6 O
mg/dL O
in O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
78.4 O
mg/dL O
in O
2-hour B-outcome ['Physiological-Clinical']
postprandial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
levels O
and O
a O
mean O
increase O
in O
the O
care B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
control O
group O
's O
symptoms O
were O
monitored O
without O
study-related O
treatment O
. O
[]

The O
placebo O
group O
had O
lower O
diastolic B-outcome ['Physiological-Clinical']
and O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
after O
24 O
weeks O
than O
the O
EPA O
and O
DHA O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Silent O
ischemia O
is O
associated O
with O
a O
worse O
prognosis O
in O
patients O
with O
stable O
or O
unstable O
angina O
, O
survivors O
of O
myocardial O
infarction O
, O
and O
populations O
at O
risk O
for O
coronary O
disease O
. O
[]

The O
data O
are O
consistent O
with O
the O
results O
of O
earlier O
studies O
which O
indicate O
that O
the O
effects O
of O
tobacco O
administration O
and O
withdrawal O
are O
mediated O
by O
central O
actions O
of O
nicotine O
. O
[]

No O
significant O
intervention O
effects O
were O
found O
for O
any O
of O
the O
primary O
( O
language B-outcome ['Life-Impact']
) O
, O
secondary O
( O
global B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
improvement O
) O
, O
or O
mediating O
( O
child B-outcome ['Life-Impact']
engagement I-outcome ['Life-Impact']
, O
early B-outcome ['Life-Impact']
precursors I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
or O
parental B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
) O
outcome O
variables O
, O
suggesting O
that O
the O
'Focus O
parent O
training O
' O
was O
not O
of O
additional O
value O
to O
the O
more O
general O
care-as-usual O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

An O
update O
on O
a O
cohort O
of O
69 O
patients O
treated O
from O
1983 O
to O
1986 O
. O
[]

Females O
may O
show O
greater O
prolactin B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
than O
males O
. O
['Physiological-Clinical']

Utility O
of O
the O
bladder O
flap O
at O
cesarean O
delivery O
: O
a O
randomized O
controlled O
trial O
. O
[]

RESULTS O
Eighty O
nine O
percent O
of O
women O
at O
risk O
of O
breast O
cancer O
and O
76 O
% O
of O
women O
with O
breast O
cancer O
were O
interested O
in O
BRCA1 B-outcome ['Physiological-Clinical']
testing O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Effects O
of O
maternal O
glucose O
infusion O
on O
fetal O
acid-base O
status O
in O
human O
pregnancy O
. O
[]

OBJECTIVE O
We O
collected O
preliminary O
data O
on O
the O
safety O
and O
efficacy O
of O
supplemental O
arginine O
to O
improve O
natural O
killer O
cell O
cytotoxicity O
in O
a O
sample O
of O
persons O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
. O
[]

Butorphanol O
and O
meperidine O
compared O
in O
patients O
with O
acute O
ureteral O
colic O
. O
[]

BACKGROUND O
Different O
methods O
and O
propofol O
formulations O
have O
been O
used O
to O
decrease O
propofol B-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
but O
it O
remains O
an O
unresolved O
problem O
. O
['Physiological-Clinical']

Maximal B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
similarly O
improved O
after O
SP O
( O
4.9+/-1.8 O
% O
) O
and O
MX O
( O
4.9+/-1.4 O
% O
) O
, O
but O
there O
was O
no O
effect O
on O
ventilatory B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
two-group O
Wilcoxon O
test O
was O
used O
to O
analyze O
the O
mean O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
with O
the O
patient O
in O
the O
supine O
, O
flat O
position O
and O
in O
the O
45-degree O
upright O
position O
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
was O
carried O
out O
to O
measure O
the O
cost-effectiveness O
of O
realtime B-outcome ['Resource-use']
teledermatology I-outcome ['Resource-use']
compared O
with O
conventional O
outpatient O
dermatology O
care O
for O
patients O
from O
urban O
and O
rural O
areas O
. O
['Resource-use']

In O
the O
fish O
extract O
treatment O
group O
three O
patients O
withdrew O
from O
the O
study O
before O
the O
fourth O
month O
due O
to O
lack O
of O
therapeutic O
effect O
. O
[]

RESULTS O
Ten O
of O
16 O
( O
63 O
% O
) O
subjects O
remained O
on O
fluoxetine O
for O
a O
year O
, O
whereas O
only O
three O
of O
19 O
( O
16 O
% O
) O
remained O
on O
the O
placebo O
for O
a O
year O
( O
p O
=.006 O
) O
. O
[]

Our O
findings O
highlight O
the O
role O
of O
melatonin O
in O
priming O
sleep-associated O
brain O
activation O
patterns O
in O
anticipation O
of O
sleep O
. O
[]

Central O
venous O
catheter O
self-care O
increased O
patients O
' O
independence B-outcome ['Life-Impact']
from O
health O
professionals O
and O
supported O
perceived O
self-efficacy B-outcome ['Life-Impact']
and O
control O
. O
['Life-Impact', 'Life-Impact']

One O
patient O
developed O
troublesome O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
with O
C O
as O
compared O
with O
4 O
patients O
in O
the O
case O
of O
P. O
A O
more O
than O
20 O
per O
cent O
increase O
in O
QRS B-outcome ['Physiological-Clinical']
was O
seen O
in O
7 O
patients O
with O
C O
and O
in O
10 O
patients O
with O
P O
, O
the O
figures O
for O
PR O
being O
2 O
and O
6 O
patients O
respectively O
. O
['Adverse-effects', 'Physiological-Clinical']

Carious O
tissue O
was O
removed O
by O
hand B-outcome ['Life-Impact']
excavation I-outcome ['Life-Impact']
, O
bur B-outcome ['Resource-use']
excavation I-outcome ['Resource-use']
, O
air-abrasion O
, O
laser B-outcome ['Resource-use']
ablation I-outcome ['Resource-use']
, O
chemomechanical B-outcome ['Resource-use']
methods I-outcome ['Resource-use']
and O
sono-abrasion B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

Single-dose O
pharmacokinetics O
of O
delavirdine O
mesylate O
and O
didanosine O
in O
patients O
with O
human O
immunodeficiency O
virus O
infection O
. O
[]

In O
addition O
, O
CETP O
concentration O
had O
a O
highly O
positive O
correlation O
with O
serum B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
E O
( O
2 O
) O
( O
r=0.243 O
, O
P O
< O
0.001 O
) O
, O
while O
negative O
correlation O
of O
CETP B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
with O
serum B-outcome ['Physiological-Clinical']
concentration O
of O
FSH B-outcome ['Physiological-Clinical']
was O
found O
( O
r=-0.273 O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eighty-two O
percent O
of O
the O
complete O
or O
partial O
responses O
( O
18 O
of O
22 O
) O
occurred O
after O
the O
first O
course O
of O
AMSA O
. O
[]

Mean O
( O
range O
) O
Hb B-outcome ['Physiological-Clinical']
levels O
were O
11.35 O
( O
8.96-14.22 O
) O
g/dL O
and O
11.54 O
( O
8.74-13.84 O
) O
g/dL O
for O
patients O
receiving O
epoetin O
zeta O
and O
epoetin O
alfa O
, O
respectively O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
[ O
test-reference O
] O
: O
0.09-0.28 O
g/dL O
, O
within O
the O
predefined O
equivalence O
range O
of O
+/-0.6 O
g/dL O
) O
. O
['Physiological-Clinical']

Standardized O
effect O
size O
estimates O
were O
primarily O
in O
the O
medium O
and O
large O
ranges O
and O
favored O
the O
treatment O
group O
. O
[]

This O
effect O
was O
well O
maintained O
in O
the O
supine O
position O
, O
although O
during O
standing O
it O
tended O
to O
be O
less O
evident O
with O
increasing O
doses O
. O
[]

Treatment O
with O
risedronate O
is O
accompanied O
by O
significant O
changes O
in O
bone O
turnover O
and O
bone O
mineral O
density O
. O
[]

The O
practice O
group O
was O
encouraged O
to O
perform O
coping O
techniques O
of O
this O
type O
, O
whereas O
the O
no-practice O
group O
was O
told O
only O
that O
the O
intervention O
would O
help O
them O
during O
the O
inoculation O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
Randomized O
controlled O
multicenter O
Trial O
of O
Intensified O
vs O
Standard O
Medical O
Therapy O
in O
Elderly O
Patients O
With O
Congestive O
Heart O
Failure O
( O
TIME-CHF O
) O
of O
499 O
patients O
aged O
60 O
years O
or O
older O
with O
systolic O
heart O
failure O
( O
ejection O
fraction O
< O
or O
= O
45 O
% O
) O
, O
New O
York O
Heart O
Association O
( O
NYHA O
) O
class O
of O
II O
or O
greater O
, O
prior O
hospitalization O
for O
heart O
failure O
within O
1 O
year O
, O
and O
N-terminal O
BNP O
level O
of O
2 O
or O
more O
times O
the O
upper O
limit O
of O
normal O
. O
[]

Of O
the O
202 O
patients O
randomized O
to O
placebo O
, O
162 O
reached O
the O
add-on O
and O
only O
12 O
the O
monotherapy O
phase O
. O
[]

CONCLUSION O
The O
results O
of O
this O
study O
suggest O
that O
OCD O
can O
be O
treated O
effectively O
with O
a O
group O
format O
of O
CBT O
, O
thus O
sparing O
some O
therapist O
resources O
, O
although O
the O
four O
accomplished O
comparative O
studies O
do O
not O
rule O
out O
the O
possibility O
of O
a O
small O
superiority O
of O
individually O
conducted O
CBT O
. O
[]

CONCLUSION O
There O
does O
not O
appear O
to O
be O
any O
difference O
in O
discomfort B-outcome ['Physiological-Clinical']
scores O
between O
the O
ocular O
irrigation O
fluids O
when O
used O
without O
the O
MTL O
. O
['Physiological-Clinical']

The O
hardness B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
breasts I-outcome ['Physiological-Clinical']
was O
evaluated O
after O
0.5 O
, O
1 O
, O
and O
7.5 O
years O
using O
Baker O
grading O
and O
applanation B-outcome ['Resource-use']
tonometry I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

There O
was O
significantly O
less O
mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
irrigation I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
in O
the O
finasteride O
group O
than O
in O
the O
control O
group O
( O
43.6 O
versus O
69.3 O
gm O
. O
['Physiological-Clinical']

These O
findings O
were O
interpreted O
as O
support O
for O
the O
hypothesis O
that O
the O
PECS O
curriculum O
can O
successfully O
teach O
a O
generalized O
means O
of O
showing O
[]

The O
ultimate O
aim O
of O
the O
randomized O
projects O
is O
to O
demonstrate O
the O
effect O
of O
screening O
on O
breast O
cancer O
mortality B-outcome ['Mortality']
. O
['Mortality']

Effects O
of O
two O
different O
short-term O
training O
programs O
on O
the O
physical O
and O
technical O
abilities O
of O
adolescent O
basketball O
players O
. O
[]

Patients O
who O
developed O
avoidance B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
before O
the O
full O
syndrome O
of O
panic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
had O
less O
often O
a O
full O
agoraphobia B-outcome ['Life-Impact']
but O
were O
not O
different O
in O
their O
response O
to O
treatment O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

PURPOSE O
This O
study O
was O
designed O
to O
evaluate O
the O
clinical O
role O
of O
rHuEPO O
in O
reducing O
symptomatic B-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
in O
patients O
with O
advanced O
cancer O
who O
were O
receiving O
myelosuppressive O
chemotherapy O
( O
excluding O
cisplatin O
) O
. O
['Physiological-Clinical']

Pain O
scores O
for O
delivery O
of O
the O
anesthetic O
, O
using O
a O
numerical O
rating O
scale O
, O
produced O
a O
median O
score O
of O
1 O
for O
1-QST O
and O
2 O
for O
the O
retrobulbar O
technique O
. O
[]

It O
is O
concluded O
that O
a O
continuous O
oestradiol-progestogen O
combination O
can O
be O
used O
for O
long-term O
treatment O
of O
climacteric B-outcome ['Life-Impact']
complaints I-outcome ['Life-Impact']
in O
postmenopausal O
women O
and O
that O
after O
4 O
months O
the O
clinical O
efficacy O
is O
the O
same O
irrespective O
of O
the O
type O
and O
dose O
of O
progestogen O
administered O
. O
['Life-Impact']

The O
target O
administration O
period O
was O
5 O
years O
. O
[]

1.41 O
mg/L O
after O
1.75 O
h O
( O
0.75-4.00 O
) O
. O
[]

Stepping O
Stones O
Triple O
P O
( O
SSTP O
) O
is O
a O
parenting O
program O
designed O
for O
families O
of O
a O
child O
with O
a O
disability O
. O
[]

After O
this O
evaluation O
, O
while O
continuing O
the O
Na+ O
supplementation O
, O
patients O
were O
randomized O
to O
valsartan O
320 O
mg/day O
( O
n O
= O
28 O
) O
, O
or O
the O
addition O
of O
hydrochlorothiazide O
( O
HCTZ O
) O
12.5 O
mg/day O
( O
n O
= O
30 O
) O
, O
or O
benazepril O
20 O
mg/day O
to O
the O
valsartan O
160 O
mg/day O
for O
an O
additional O
6 O
weeks O
. O
[]

METHODS O
We O
compared O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
recurrent B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
during O
median O
follow-up O
of O
7.5 O
years O
in O
a O
heterogeneous O
cohort O
of O
patients O
with O
chronic O
illness O
initially O
exposed O
to O
a O
multidisciplinary O
, O
home-based O
intervention O
( O
HBI O
) O
( O
n O
= O
260 O
) O
or O
to O
usual O
postdischarge O
care O
( O
n O
= O
268 O
) O
. O
['Mortality', 'Resource-use']

Group O
1 O
, O
the O
control O
, O
received O
midazolam O
0.03 O
mg/kg O
, O
fentanyl O
1 O
microg/kg O
, O
and O
propofol O
initially O
at O
140 O
microg/kg/min O
. O
[]

The O
present O
study O
aimed O
to O
compare O
the O
outcomes O
of O
patients O
with O
PCOS O
undergoing O
controlled O
ovarian O
hyperstimulation O
( O
COH O
) O
with O
GnRH O
agonist O
versus O
GnRH O
antagonist O
protocols O
for O
assisted O
reproduction O
cycles O
. O
[]

However O
, O
electrophysiological O
studies O
typically O
fall O
short O
in O
revealing O
the O
neural O
generators O
of O
this O
activity O
. O
[]

The O
selected O
main O
points O
were O
Neiguan O
( O
PC O
6 O
) O
, O
Qu-chi O
( O
LI O
11 O
) O
, O
Waiguan O
( O
TE O
5 O
) O
, O
Hegu O
( O
LI O
4 O
) O
, O
Binao O
( O
LI O
14 O
) O
, O
Jianyu O
( O
LI O
15 O
) O
, O
Fengshi O
( O
GB O
31 O
) O
, O
Xuehai O
( O
SP O
10 O
) O
, O
Yinlingquan O
( O
SP O
9 O
) O
, O
Sanyinjiao O
( O
SP O
6 O
) O
, O
Taichong O
( O
LR O
3 O
) O
, O
etc.. O
The O
limb B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
evaluated O
with O
Fugl-Meyer B-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FMA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
scale O
before O
treatment O
and O
after O
10-week O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Standard-dose O
lansoprazole O
is O
better O
than O
high-dose O
ranitidine O
in O
moderately O
severe O
reflux O
oesophagitis O
. O
[]

SD O
133.5? O
? O
[]

Administration O
of O
PU O
significantly O
increased O
urinary B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
though O
in O
the O
controls O
urinary B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
decreased O
, O
size O
of O
the O
prostate B-outcome ['Physiological-Clinical']
diminished O
and O
increased O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
compare O
the O
advantages O
and O
disadvantages O
of O
potassium O
titanyl O
phosphate O
laser O
with O
those O
of O
bipolar O
radiofrequency O
techniques O
, O
in O
paediatric O
tonsillectomy O
. O
[]

In O
the O
initial O
2 O
weeks O
of O
active O
drug O
listlessness O
, O
food B-outcome ['Life-Impact']
refusal I-outcome ['Life-Impact']
, O
and O
stomach B-outcome ['Physiological-Clinical']
upset I-outcome ['Physiological-Clinical']
were O
frequently O
seen O
. O
['Life-Impact', 'Physiological-Clinical']

The O
therapeutic O
effects O
of O
each O
treatment O
were O
compared O
both O
clinically O
and O
microbiologically O
. O
[]

In O
response O
to O
the O
need O
to O
communicate O
more O
accurate O
risk O
information O
to O
these O
women O
, O
specialized O
programs O
for O
breast O
cancer O
risk O
counseling O
have O
been O
initiated O
in O
medical O
centers O
across O
the O
United O
States O
. O
[]

CONCLUSION O
Participants O
accumulated O
more O
moderate-to-vigorous O
physical O
activity O
in O
bouts O
? O
[]

The O
effect O
of O
values O
affirmation O
on O
race-discordant O
patient-provider O
communication O
. O
[]

Our O
study O
showed O
that O
the O
use O
of O
the O
Gantrez-NNP O
combination O
is O
safe O
with O
respect O
to O
dental B-outcome ['Life-Impact']
esthetics I-outcome ['Life-Impact']
in O
the O
control O
of O
S. O
mutans B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

A O
significant O
increase O
in O
86rubidium B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
present O
in O
boys O
as O
compared O
to O
girls O
. O
['Physiological-Clinical']

Obesity O
is O
a O
significant O
health O
issue O
worldwide O
and O
is O
associated O
with O
chronic O
, O
low-grade O
inflammation O
predisposing O
the O
individual O
to O
cardiovascular O
disease O
and O
impaired O
blood O
glucose O
homeostasis O
. O
[]

Early O
versus O
late O
replacement O
of O
autotransfused O
blood O
in O
elective O
spinal O
surgery O
. O
[]

Almost O
half O
had O
worries B-outcome ['Life-Impact']
and O
concerns B-outcome ['Life-Impact']
about O
CRC O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Few O
studies O
have O
compared O
treatment O
strategies O
in O
patients O
with O
asthma O
poorly O
controlled O
on O
low O
dose O
inhaled O
corticosteroids O
, O
and O
little O
is O
known O
about O
the O
effects O
of O
different O
treatments O
on O
airway O
inflammation O
. O
[]

However O
, O
a O
prospective O
evaluation O
of O
clinical O
benefit O
in O
AGGEC O
patients O
has O
never O
before O
been O
reported O
in O
a O
phase O
III O
setting O
. O
[]

OBJECTIVE O
To O
determine O
whether O
lower O
rates O
or O
incomplete O
resection O
of O
cervical O
intraepithelial O
neoplasia O
( O
CIN O
) O
may O
be O
achieved O
by O
needle O
excision O
of O
the O
transformation O
zone O
( O
NETZ O
) O
than O
with O
loop O
excision O
( O
LLETZ O
) O
. O
[]

RESULTS O
In O
the O
ER+ O
( O
Estrogen O
Receptor O
? O
[]

During O
the O
Sal O
trial O
, O
pH O
decreased O
from O
7.41?0.01 O
at O
rest O
to O
7.02?0.02 O
but O
only O
to O
7.36?0.02 O
( O
P O
< O
0.05 O
) O
during O
the O
Bicarb O
trial O
. O
[]

Clinic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
measured O
weekly O
with O
the O
mean O
values O
of O
weeks O
3 O
and O
4 O
of O
each O
phase O
used O
for O
analysis O
. O
['Physiological-Clinical']

Data O
were O
analysed O
using O
chi-square O
test O
, O
Mann-Whitney O
U O
, O
Wilcoxon O
signed O
ranks O
tests O
and O
correlation O
. O
[]

There O
were O
no O
group-by-time O
interactions O
for O
coping B-outcome ['Life-Impact']
confidence I-outcome ['Life-Impact']
( O
p-values O
> O
0.05 O
) O
. O
['Life-Impact']

Study O
of O
cytosine O
arabinoside O
( O
NSC-63878 O
) O
synchronization O
plus O
vincristine O
( O
NSC-67574 O
) O
, O
prednisone O
( O
NSC-10023 O
) O
, O
and O
L-asparaginase O
( O
NSC-109229 O
) O
for O
remission O
induction O
in O
advanced O
acute O
leukemia O
in O
children O
. O
[]

The O
present O
trial O
was O
aimed O
at O
evaluating O
the O
therapeutic O
efficacy O
of O
a O
recombinant O
feline O
interferon O
( O
type O
omega O
) O
preparation O
in O
the O
treatment O
of O
parvoviral O
enteritis O
in O
dogs O
. O
[]

The O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
from O
before O
to O
48 O
h O
after O
delivery O
, O
use O
of O
additional O
oxytocics O
and O
treatment O
related O
side O
effects O
were O
the O
main O
outcome O
measures O
. O
['Physiological-Clinical']

Therefore O
, O
it O
was O
not O
possible O
to O
investigate O
the O
influence O
of O
potentially O
contributing O
factors O
on O
the O
occurrence O
of O
radiation B-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
, O
such O
as O
interfraction B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
, O
cord B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fine O
needle O
aspiration O
coupled O
with O
real-time O
PCR O
: O
a O
painless O
methodology O
to O
study O
adaptive O
functional O
changes O
in O
skeletal O
muscle O
. O
[]

OBJECTIVE O
To O
consider O
the O
impact O
on O
primary O
care O
patient O
outcomes O
of O
using O
both O
a O
screener O
to O
determine O
elevated O
anxiety O
levels O
among O
patients O
with O
previously O
undetected O
anxiety O
and O
a O
physician O
intervention O
to O
inform O
physicians O
of O
their O
patients O
' O
conditions O
. O
[]

The O
cold O
stress O
resulted O
in O
a O
significant O
increase O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
the O
rate O
pressure O
product O
without O
a O
change O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
follow-up O
period O
was O
6.1 O
months O
( O
range O
1 O
day O
to O
20 O
months O
) O
. O
[]

To O
compare O
the O
effect O
of O
a O
Social O
Skills O
Training O
Group-based O
Program O
( O
SST-GP O
) O
and O
a O
Leisure O
Activities O
Group-based O
Program O
( O
LA-GP O
) O
on O
the O
perception O
of O
facial O
emotions O
and O
quality O
of O
life O
( O
QoL O
) O
in O
young O
people O
with O
HFA O
. O
[]

BBTW O
participants O
received O
an O
average O
of O
0.5 O
kg O
, O
less O
than O
1.5 O
% O
of O
any O
participant O
's O
body O
weight O
. O
[]

Increasing O
verbal O
responsiveness O
in O
parents O
of O
children O
with O
autism O
: O
a O
pilot O
study O
. O
[]

They O
also O
suggest O
that O
extinction O
of O
over-selected B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
may O
be O
a O
fruitful O
line O
of O
intervention O
for O
clinical O
intervention O
for O
some O
individuals O
. O
['Physiological-Clinical']

As O
nimodipine O
might O
have O
anticraving O
and O
mood-stabilizing O
properties O
and O
cardio- O
and O
neuroprotective O
properties O
in O
the O
face O
of O
cocaine O
intoxication O
and O
might O
possibly O
even O
reverse O
some O
cocaine-induced O
brain O
deficits O
, O
further O
investigation O
of O
the O
role O
of O
nimodipine O
( O
and O
other O
VSCCBs O
) O
in O
cocaine O
addiction O
appears O
an O
attractive O
avenue O
of O
future O
medication O
development O
. O
[]

CONCLUSIONS O
In O
a O
study O
conducted O
to O
test O
the O
feasibility O
of O
a O
four-treatment O
crossover O
tea O
trial O
, O
a O
high O
rate O
of O
dropout O
among O
smokers O
and O
non-smokers O
was O
observed O
. O
[]

of O
aminoglycosides O
, O
was O
significantly O
more O
often O
necessary O
in O
the O
control O
group O
. O
[]

METHODS O
Seventy-five O
postmenopausal O
women O
symptomatic O
for O
urogenital O
atrophy O
and O
sexual O
dysfunction O
were O
randomly O
divided O
into O
two O
study O
groups O
and O
one O
control O
group O
. O
[]

Of O
these O
, O
22 O
women O
with O
severe O
PE O
gave O
birth O
to O
neonates O
with O
VLBW O
( O
very O
low O
birth O
weight O
< O
or O
= O
1500 O
g O
) O
. O
[]

Statistical O
analysis O
was O
performed O
by O
linear O
models O
and O
standard O
F O
tests O
. O
[]

Parent O
management O
training O
and O
Asperger O
syndrome O
: O
a O
randomized O
controlled O
trial O
to O
evaluate O
a O
parent O
based O
intervention O
. O
[]

Day O
two O
serum B-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
after O
surgery O
were O
unchanged B-outcome ['Physiological-Clinical']
( O
P= O
0.45 O
) O
, O
compared O
with O
baseline O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
adverse O
effects O
between O
the O
M O
group O
( O
6.1 O
% O
) O
and O
E O
group O
( O
2.2 O
% O
) O
. O
[]

The O
primary O
outcome O
measure O
was O
mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
the O
target O
toenail B-outcome ['Physiological-Clinical']
at O
18 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
in O
the O
case O
of O
stimuli O
presented O
over O
headphones O
( O
Grantham O
& O
Wightman O
, O
1979 O
) O
, O
an O
auditory B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
aftereffect I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MAE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
occurred O
: O
subjects O
responded O
left O
to O
probes O
more O
often O
when O
the O
adaptor O
moved O
right O
than O
when O
it O
moved O
left O
. O
['Physiological-Clinical']

The O
children O
received O
a O
daily O
dose O
of O
3 O
mg O
tetrahydrobiopterin O
per O
kilogram O
during O
6 O
months O
alternating O
with O
placebo O
. O
[]

High-pressure O
, O
rapid-inflation O
compression O
produced O
significantly O
higher O
maximal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
in O
the O
popliteal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
veins I-outcome ['Physiological-Clinical']
in O
both O
healthy O
volunteers O
and O
patients O
who O
were O
post-thrombotic O
as O
compared O
with O
standard O
compression O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Medical O
College O
of O
Wisconsin O
Research O
facility O
. O
[]

Participants O
then O
completed O
the O
Reading O
the O
Mind O
in O
the O
Eyes O
Task O
, O
a O
widely O
used O
and O
reliable O
test O
of O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
. O
['Life-Impact']

Patients O
aged O
18-55 O
years O
with O
relapsing-remitting O
multiple O
sclerosis O
were O
randomly O
assigned O
( O
1:1:1 O
) O
, O
via O
a O
central O
interactive O
voice O
response O
system O
, O
to O
subcutaneous O
injections O
of O
daclizumab O
HYP O
150 O
mg O
or O
300 O
mg O
, O
or O
placebo O
, O
every O
4 O
weeks O
for O
52 O
weeks O
. O
[]

Hence O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
relative O
effects O
of O
RRR-AT O
and O
all-rac-AT O
on O
plasma O
antioxidant O
levels O
and O
LDL O
oxidation O
in O
healthy O
persons O
in O
a O
dose-response O
study O
. O
[]

Pain B-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
were O
higher O
in O
the O
control O
patients O
than O
in O
the O
NB-treated O
patients O
during O
the O
postanesthesia O
care O
unit O
stay O
. O
['Physiological-Clinical', 'Resource-use']

The O
meta-analysis O
of O
four O
accomplished O
comparative O
studies O
( O
including O
the O
present O
one O
) O
found O
a O
between-group O
mean O
effect O
size O
of O
( O
d= O
0.15 O
favouring O
individual O
over O
group O
CBT O
at O
posttreatment O
( O
95 O
% O
confidence O
interval O
, O
-0.12 O
, O
0.42 O
) O
. O
[]

PATIENTS O
AND O
METHODS O
Seventy-one O
postmenopausal O
patients O
were O
randomized O
to O
receive O
an O
i.m O
. O
[]

The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
significantly O
longer O
, O
and O
the O
leakage B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
transthoracic O
group O
( O
Student O
's O
t-test O
and O
Fischer O
's O
exact O
test O
, O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Although O
psychosocial O
therapy O
has O
been O
shown O
to O
reduce O
mortality B-outcome ['Mortality']
after O
myocardial O
infarction O
, O
it O
is O
unknown O
whether O
the O
benefits O
of O
psychosocial O
therapy O
on O
mortality O
reduction O
extend O
to O
out-of-hospital O
sudden O
cardiac O
arrest O
, O
a O
main O
cause O
of O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

In O
the O
low-risk O
group O
, O
65 O
of O
200 O
patients O
were O
transplanted O
( O
33 O
% O
) O
, O
30 O
( O
13 O
% O
) O
in O
the O
intermediate-risk O
group O
, O
and O
nine O
( O
10 O
% O
) O
in O
the O
high-risk O
group O
. O
[]

The O
effect O
on O
ICF B-outcome ['Physiological-Clinical']
and O
L-ICI B-outcome ['Physiological-Clinical']
significantly O
correlated O
with O
amantadine O
serum O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

1999 O
) O
. O
[]

BACKGROUND O
Randomized O
trials O
have O
demonstrated O
benefits O
of O
biventricular O
( O
BiV O
) O
pacing O
in O
patients O
with O
advanced O
heart O
failure O
, O
intraventricular O
conduction O
delay O
, O
and O
atrial O
fibrillation O
( O
AF O
) O
post-atrioventricular O
( O
AV O
) O
node O
ablation O
. O
[]

POG O
8625 O
: O
a O
randomized O
trial O
comparing O
chemotherapy O
with O
chemoradiotherapy O
for O
children O
and O
adolescents O
with O
Stages O
I O
, O
IIA O
, O
IIIA1 O
Hodgkin O
Disease O
: O
a O
report O
from O
the O
Children O
's O
Oncology O
Group O
. O
[]

The O
additional O
value O
of O
a O
night O
splint O
to O
eccentric O
exercises O
in O
chronic O
midportion O
Achilles O
tendinopathy O
: O
a O
randomised O
controlled O
trial O
. O
[]

The O
incidence O
of O
local O
hematoma O
was O
2.3 O
% O
and O
3.7 O
% O
in O
the O
2,000- O
and O
5,000-IU O
groups O
, O
respectively O
( O
p O
= O
0.42 O
) O
. O
[]

Warfarin O
versus O
aspirin O
for O
prevention O
of O
thromboembolism O
in O
atrial O
fibrillation O
: O
Stroke O
Prevention O
in O
Atrial O
Fibrillation O
II O
Study O
. O
[]

Patients O
received O
olmesartan O
medoxomil O
20 O
mg O
, O
losartan O
potassium O
50 O
mg O
, O
valsartan O
80 O
mg O
, O
or O
placebo O
once O
daily O
. O
[]

METHOD O
Forty O
children O
from O
the O
original O
study O
( O
n O
= O
58 O
) O
had O
complete O
data O
at O
the O
5-year O
follow-up O
. O
[]

The O
patients O
were O
assigned O
1 O
of O
3 O
prophylactic O
regimens O
: O
infusion O
of O
sodium O
bicarbonate O
, O
sodium O
chloride O
, O
sodium O
chloride O
plus O
oral O
NAC O
( O
600 O
mg O
bid O
) O
. O
[]

A O
refusal O
survey O
was O
provided O
for O
those O
who O
declined O
to O
join O
the O
study O
. O
[]

There O
were O
no O
mechanical B-outcome ['Physiological-Clinical']
or O
technical B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
such I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
disconnection I-outcome ['Life-Impact']
during O
use O
of O
the O
TAMS O
. O
['Physiological-Clinical', 'Life-Impact']

Confidential O
registration O
in O
health O
services O
: O
randomised O
controlled O
trial O
. O
[]

Measuring O
the O
TBPI O
increase O
during O
the O
first O
week O
following O
PTA O
underestimates O
total O
improvement O
, O
and O
may O
give O
false O
reassurance O
with O
respect O
to O
recurrent O
disease O
. O
[]

A O
total O
of O
285 O
premenopausal O
breast O
cancer O
patients O
, O
in O
a O
randomized O
adjuvant O
trial O
( O
Zoladex O
in O
premenopausal O
patients O
( O
ZIPP O
) O
) O
, O
were O
assigned O
to O
a O
study O
on O
ovarian O
function O
. O
[]

RESULTS O
The O
eradication B-outcome ['Physiological-Clinical']
rate O
of O
the O
cimetidine O
group O
the O
omeprazole O
group O
, O
and O
the O
CBS O
group O
were O
0 O
% O
, O
7.7 O
% O
, O
0 O
% O
, O
respectively O
, O
and O
that O
of O
the O
double O
therapy O
group O
and O
the O
triple O
therapy O
group O
were O
44.4 O
% O
and O
89.3 O
% O
, O
respectively O
. O
['Physiological-Clinical']

The O
TE B-outcome ['Physiological-Clinical']
event O
['Physiological-Clinical']

INTERVENTIONS O
Prior O
to O
randomization O
, O
subjects O
entered O
a O
1-week O
test-dose O
phase O
in O
which O
each O
subject O
received O
placebo O
for O
1 O
day O
followed O
by O
increasing O
doses O
of O
methylphenidate O
( O
low O
, O
medium O
, O
and O
high O
doses O
) O
that O
were O
each O
given O
for O
2 O
days O
. O
[]

At O
21 O
and O
28 O
days O
after O
treatment O
, O
none O
of O
the O
formulations O
killed O
significant O
numbers O
of O
fleas B-outcome ['Physiological-Clinical']
as O
compared O
to O
controls O
within O
6 O
hours O
of O
infestation O
. O
['Physiological-Clinical']

All O
families O
were O
compared O
at O
pre- O
and O
post-treatment O
on O
formal O
dependent O
measures O
. O
[]

Comparisons O
of O
itraconazole O
alone O
and O
itraconazole O
with O
simultaneous O
ddI O
were O
performed O
on O
days O
1 O
and O
15 O
. O
[]

Vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
electrocardiogram O
data O
, O
including O
corrected O
QT O
intervals O
( O
Bazett O
and O
Fridericia O
) O
, O
were O
similar O
across O
treatment O
groups O
. O
['Physiological-Clinical']

Although O
quality O
of O
tapping B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
differed O
between O
the O
single-task O
and O
the O
dual-task O
conditions O
, O
it O
was O
not O
related O
to O
recall B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

EBM O
RATING O
A-1b O
. O
[]

Patients O
have O
been O
randomized O
into O
two O
treatment O
groups O
. O
[]

Inflammatory O
response O
in O
humans O
exposed O
to O
2.0 O
ppm O
nitrogen O
dioxide O
. O
[]

BACKGROUND O
Intracoronary O
radiation O
therapy O
reduces O
recurrence O
of O
in-stent O
restenosis O
. O
[]

METHODS O
Sixty O
cases O
of O
GD O
were O
randomly O
divided O
into O
a O
treatment O
group O
( O
pricking O
therapy O
group O
) O
and O
a O
control O
group O
( O
medication O
group O
) O
. O
[]

Growth-curve O
and O
structural-equation O
modeling O
analyses O
assessed O
overall O
program O
effects O
on O
the O
emotional O
health O
outcomes O
as O
well O
as O
mediation O
of O
these O
effects O
via O
the O
program O
's O
impact O
on O
youths O
' O
social-emotional O
and O
character O
development O
. O
[]

RESULTS O
Several O
baseline O
predictors O
of O
response O
were O
identified O
, O
and O
a O
principal O
component O
analysis O
yielded O
3 O
composite O
measures O
( O
[]

Early O
screening O
for O
BV O
and O
treatment O
with O
clindamycin O
saved O
approximately O
27 O
euro O
per O
woman O
. O
[]

Signal-averaged B-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
were O
recorded O
in O
a O
subgroup O
of O
24 O
patients O
. O
['Physiological-Clinical']

As O
clarity O
and O
correctness O
increase O
, O
attitudes B-outcome ['Life-Impact']
become O
more O
resistant O
to O
counterattitudinal O
persuasive O
messages O
. O
['Life-Impact']

It O
was O
found O
that O
PU O
treatment O
relieved O
PA O
symptoms O
by O
IPSS O
, O
while O
these O
symptoms O
progressed O
in O
the O
controls O
. O
[]

PATIENTS O
AND O
METHODS O
Sixty-one O
patients O
were O
randomised O
to O
either O
HoLEP O
or O
TURP O
. O
[]

Operator O
and O
subject O
questionnaires O
were O
completed O
immediately O
after O
treatment O
to O
determine O
ease O
of O
the O
scaling O
procedure O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
decreased O
by O
an O
average O
22 O
% O
during O
treatment O
with O
either O
dl-norgestrel O
alone O
( O
123 O
+/- O
11 O
vs. O
160 O
+/- O
10 O
mg/dl O
, O
n O
= O
25 O
, O
P O
< O
0.005 O
) O
or O
combination O
therapy O
( O
126 O
+/- O
11 O
vs. O
162 O
+/- O
11 O
, O
n O
= O
25 O
, O
P O
< O
0.005 O
) O
as O
compared O
with O
control O
. O
['Physiological-Clinical']

Wound O
infiltration O
of O
iliac O
crest O
harvest O
site O
with O
local O
anaesthetic O
is O
an O
easy O
technique O
for O
postoperative O
analgesia O
. O
[]

H. O
pylori O
status O
was O
evaluated O
by O
( O
13 O
) O
C B-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
test O
5 O
weeks O
after O
anti-ulcer O
treatment O
completion O
. O
['Physiological-Clinical']

CONCLUSIONS O
Consistent O
with O
previously O
published O
efficacy O
results O
, O
these O
data O
suggest O
that O
150 O
mg/m O
( O
2 O
) O
qw O
3/4 O
may O
represent O
the O
most O
clinically O
efficacious O
nab-paclitaxel O
dosing O
regimen O
for O
patients O
with O
no O
previous O
chemotherapy O
for O
MBC O
. O
[]

In O
the O
absence O
of O
curative O
and O
effective O
treatments O
for O
this O
disabling O
condition O
, O
this O
information O
has O
created O
new O
hope O
among O
parents O
. O
[]

METHODS O
Eighty-four O
cases O
were O
randomly O
divided O
into O
3 O
groups O
, O
28 O
cases O
in O
each O
group O
. O
[]

Pharmacokinetic O
data O
were O
analyzed O
in O
accordance O
with O
the O
two O
1-sided O
test O
for O
bioequivalence O
. O
[]

Influence O
of O
diets O
rich O
in O
Maillard O
reaction O
products O
on O
calcium B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
Coriander O
oil O
is O
effective O
and O
well O
tolerated O
in O
the O
treatment O
of O
interdigital O
tinea O
pedis O
. O
[]

Median O
cumulative B-outcome ['Life-Impact']
doxorubicin I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
of O
cardiotoxicity B-outcome ['Physiological-Clinical']
was O
785 O
mg/m O
( O
2 O
) O
for O
TLC O
D-99 O
versus O
570 O
mg/m O
( O
2 O
) O
for O
doxorubicin O
( O
P O
= O
0.0001 O
; O
hazard O
ratio O
, O
3.56 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
We O
tested O
the O
hypothesis O
that O
dietary O
intervention O
can O
inhibit O
the O
development O
of O
recurrent B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
adenomas I-outcome ['Physiological-Clinical']
, O
which O
are O
precursors O
of O
most O
large-bowel O
cancers O
. O
['Physiological-Clinical']

Two O
study O
groups O
were O
randomly O
formed O
: O
enamel O
blocks O
brushed O
with O
( O
a O
) O
the O
Gantrez-NNP O
combination O
and O
( O
b O
) O
conventional O
toothpaste O
, O
for O
1 O
minute O
once O
daily O
for O
4 O
weeks O
, O
then O
rinsed O
with O
distilled O
water O
and O
placed O
in O
thymol O
solution O
. O
[]

Some O
children O
appeared O
to O
respond O
positively O
to O
the O
dimethylglycine O
, O
and O
there O
was O
a O
smaller O
proportion O
of O
negative O
changes O
in O
the O
dimethylglycine O
group O
, O
but O
the O
quantitative O
changes O
in O
the O
dimethylglycine O
behavioral O
assessments O
were O
not O
significantly O
different O
from O
what O
was O
observed O
among O
children O
who O
received O
placebo O
. O
[]

Adding O
chemotherapy O
reduced O
the O
relative O
risk O
of O
a O
disease-free O
survival O
event O
by O
19 O
% O
( O
P O
= O
0.02 O
) O
compared O
with O
ET O
alone O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
attributable O
to O
captopril O
were O
noted O
, O
except O
in O
one O
patient O
in O
whom O
proteinuria B-outcome ['Physiological-Clinical']
developed O
after O
seven O
weeks O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
ECV O
was O
elevated O
in O
the O
anthracycline-treated O
patients O
compared O
to O
the O
age- O
and O
gender-matched O
controls O
( O
0.36 O
? O
[]

PURPOSE O
To O
develop O
a O
simple O
pharmacodynamic O
( O
PD O
) O
assay O
for O
the O
evaluation O
of O
the O
bioequivalence O
of O
topically O
applied O
retinoid O
products O
. O
[]

Significant O
difference O
was O
observed O
in O
the O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
convalescence I-outcome ['Life-Impact']
too O
( O
group O
A O
9.3+/-7.2 O
days O
; O
group O
B O
12.1+/-7 O
. O
['Life-Impact']

No O
association O
was O
seen O
between O
RBC O
EPA O
and O
plasma O
TAG O
concentration O
or O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Acute O
sympathetic O
nervous O
activation O
is O
a O
proven O
trigger O
for O
adverse B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

[ O
Intravesical O
electrostimulation O
and O
magnetophoresis O
in O
overactive O
bladder O
in O
females O
: O
efficacy O
of O
Amus-01-Intramag O
device O
with O
Intrastim O
attachment O
] O
. O
[]

METHODS O
Eighty-eight O
patients O
with O
stroke O
were O
assigned O
randomly O
to O
receive O
a O
home-based O
program O
of O
( O
1 O
) O
TENS O
, O
( O
2 O
) O
TENS+TRT O
, O
( O
3 O
) O
placebo O
TENS+TRT O
, O
or O
( O
4 O
) O
no O
treatment O
( O
control O
) O
5 O
days O
a O
week O
for O
4 O
weeks O
. O
[]

Spontaneous B-outcome ['Physiological-Clinical']
menstruation B-outcome ['Physiological-Clinical']
resumed O
in O
five O
metformin O
treated O
patients O
and O
in O
six O
placebo O
treated O
women O
, O
P=0.63 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
8 O
years O
in O
The O
Netherlands O
, O
6 O
in O
Sweden O
and O
Finland O
, O
5 O
in O
Italy O
and O
4 O
in O
Belgium O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
rate O
of O
3 O
day O
, O
6 O
day O
and O
7 O
day O
miconazole O
courses O
for O
uncomplicated O
VVC O
at O
day O
35 O
was O
93.8 O
% O
, O
95.3 O
% O
, O
and O
89.8 O
% O
, O
respectively O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
40 O
non-carious O
human O
premolars O
were O
randomly O
divided O
into O
four O
groups O
. O
[]

The O
duration O
of O
nausea B-outcome ['Physiological-Clinical']
and O
anorexia B-outcome ['Physiological-Clinical']
after O
CDDP O
treatment O
was O
also O
shortened O
by O
high-dose O
metoclopramide O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Clinical O
benefits O
of O
normothermic O
cardiopulmonary O
bypass O
on O
postoperative O
systemic O
metabolism O
] O
. O
[]

There O
was O
an O
improvement O
of O
IIEF B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
for O
all O
domains O
in O
Cappra O
( O
? O
) O
['Physiological-Clinical']

10 O
adolescent O
or O
adult O
subjects O
with O
high-functioning O
autism O
or O
Asperger-syndrome O
were O
included O
in O
the O
investigation O
. O
[]

25 O
TM O
tibial O
components O
were O
fixed O
press-fit O
by O
2 O
hexagonal O
pegs O
( O
TM O
group O
) O
and O
25 O
Ti O
tibial O
components O
were O
fixed O
press-fit O
and O
by O
4 O
supplemental O
screws O
( O
Ti O
group O
) O
. O
[]

METHODS/DESIGN O
People O
with O
idiopathic O
Parkinson O
's O
disease O
who O
live O
at O
home O
will O
be O
recruited O
and O
randomly O
allocated O
to O
one O
of O
three O
groups O
. O
[]

These O
results O
provide O
direct O
evidence O
for O
spinal O
inhibition O
as O
one O
mechanism O
of O
placebo O
analgesia O
and O
highlight O
that O
psychological O
factors O
can O
act O
on O
the O
earliest O
stages O
of O
pain O
processing O
in O
the O
central O
nervous O
system O
. O
[]

Improved O
frontoparietal B-outcome ['Physiological-Clinical']
white I-outcome ['Physiological-Clinical']
matter I-outcome ['Physiological-Clinical']
integrity I-outcome ['Physiological-Clinical']
in O
overweight O
children O
is O
associated O
with O
attendance O
at O
an O
after-school O
exercise O
program O
. O
['Physiological-Clinical']

To O
determine O
whether O
the O
combination O
of O
nifedipine O
+ O
chlorthalidone O
exerts O
an O
additive B-outcome ['Resource-use']
antihypertensive I-outcome ['Resource-use']
effect O
when O
compared O
with O
single-drug O
treatment O
, O
we O
studied O
66 O
uncomplicated O
essential O
hypertensives O
, O
with O
diastolic O
blood O
pressure O
of O
greater O
than O
100 O
and O
less O
than O
115 O
mmHg O
. O
['Resource-use']

In O
the O
chemotherapy O
group O
, O
excessive B-outcome ['Physiological-Clinical']
keratinization I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
squamous I-outcome ['Physiological-Clinical']
component I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
esophageal I-outcome ['Physiological-Clinical']
cancerous I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
appeared O
in O
the O
resected O
specimens O
. O
['Physiological-Clinical']

Further O
improvements O
can O
be O
achieved O
with O
dose-dense O
regimens O
, O
but O
densification O
of O
fluorouracil/epirubicin/cyclophosphamide O
( O
FEC O
) O
has O
proved O
difficult O
, O
with O
FEC O
( O
60 O
) O
providing O
little O
benefit O
over O
standard O
chemotherapy O
and O
FEC O
( O
100 O
) O
associated O
with O
toxicity O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Timing B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
referrals I-outcome ['Life-Impact']
and O
discharge B-outcome ['Life-Impact']
planning I-outcome ['Life-Impact']
; O
total O
length O
of O
stay B-outcome ['Resource-use']
; O
and O
complication B-outcome ['Adverse-effects']
and O
readmission B-outcome ['Resource-use']
rates O
['Life-Impact', 'Resource-use', 'Adverse-effects', 'Resource-use']

The O
patients O
were O
assigned O
to O
5 O
groups O
: O
placebo O
, O
200 O
mg O
, O
400 O
mg O
, O
600 O
mg O
and O
800 O
mg O
of O
ebrotidine O
once O
daily O
. O
[]

RESULTS O
Patients O
reported O
similar O
median O
pain B-outcome ['Physiological-Clinical']
scores O
and O
were O
equally O
satisfied O
with O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
intention O
was O
to O
investigate O
if O
the O
biocompatibility O
benefits O
of O
heparin-coated O
CPB O
circuits O
apply O
to O
children O
. O
[]

METHODS O
One O
hundred O
twenty-one O
men O
with O
benign O
prostatic O
enlargement O
( O
BPE O
) O
and O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
underwent O
a O
pressure-flow O
study O
( O
PFS O
) O
at O
1 O
of O
11 O
clinical O
centers O
. O
[]

Practices O
were O
matched O
according O
to O
the O
numbers O
of O
pediatricians O
and O
the O
proportions O
of O
patients O
receiving O
Medicaid O
. O
[]

CONCLUSION O
WP-IMRT O
is O
associated O
with O
significantly O
less O
toxicity O
compared O
with O
WP-CRT O
and O
has O
a O
comparable O
clinical O
outcome O
. O
[]

P3 O
maxima O
elicited O
by O
rare O
non-targets O
were O
recorded O
more O
rostrally O
after O
fenfluramine O
treatment O
. O
[]

The O
average O
esmolol O
dosage O
producing O
a O
therapeutic O
response O
was O
97.5 O
micrograms/kg/min O
. O
[]

Analysis O
of O
treatment O
in O
childhood O
leukaemia O
. O
[]

Future O
studies O
with O
longer O
treatment O
duration O
and O
larger O
sample O
size O
are O
needed O
to O
further O
explore O
the O
potential O
role O
of O
rosiglitazone O
in O
improving O
cognitive O
function O
in O
patients O
with O
schizophrenia O
. O
[]

They O
were O
then O
crossed O
over O
to O
the O
alternative O
treatment O
for O
a O
further O
3 O
weeks O
. O
[]

Durable B-outcome ['Physiological-Clinical']
remissions I-outcome ['Physiological-Clinical']
were O
achieved O
in O
only O
a O
minority O
of O
the O
patients O
, O
and O
there O
was O
a O
high O
rate O
of O
treatment-related O
complications O
. O
['Physiological-Clinical']

HO B-outcome ['Physiological-Clinical']
was O
graded O
according O
to O
the O
1-year O
postoperative O
radiographs O
according O
to O
the O
Brooker O
classification O
. O
['Physiological-Clinical']

The O
second O
group O
of O
patients O
received O
1 O
gm O
of O
tetracycline O
by O
mouth O
per O
day O
for O
4 O
weeks O
, O
followed O
by O
500 O
mg/day O
for O
8 O
weeks O
, O
plus O
placebo O
for O
erythromycin O
. O
[]

The O
acquisition O
of O
novel B-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
was O
consistent O
for O
receptive O
and O
expressive O
tests O
for O
2 O
of O
the O
children O
, O
with O
varied O
results O
for O
the O
3rd O
. O
['Life-Impact']

Primary O
end-point O
was O
a O
difference O
of O
modified O
Boyarsky O
score O
between O
treatment O
groups O
after O
6 O
months O
; O
secondary O
end-points O
were O
changes O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
( O
IPSS O
) O
, O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
prostate B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Clomipramine O
was O
superior O
to O
both O
placebo O
and O
desipramine O
on O
ratings O
of O
autistic B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
including B-outcome ['Life-Impact']
stereotypies I-outcome ['Life-Impact']
) O
, O
anger B-outcome ['Life-Impact']
, O
and O
compulsive B-outcome ['Life-Impact']
, O
ritualized B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
P O
< O
.05 O
) O
, O
with O
no O
differences O
between O
desipramine O
and O
placebo O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Eighteen O
patients O
of O
colorectal O
cancer O
with O
metastases O
to O
the O
liver O
or O
lung O
or O
of O
unresectable O
hepatoma O
received O
a O
24 O
hour O
continuous O
infusion O
with O
low O
dose O
recombinant O
of O
IL-2 O
( O
mainly O
8 O
x O
10 O
( O
5 O
) O
JRU/day O
) O
for O
25-40 O
days O
. O
[]

Participants O
will O
be O
randomly O
allocated O
to O
hospital-based O
or O
home-based O
pulmonary O
rehabilitation O
. O
[]

In O
the O
International O
Breast O
Cancer O
Study O
Group O
( O
IBCSG O
) O
Trials O
VII O
and O
12-93 O
, O
postmenopausal O
women O
with O
node-positive O
, O
estrogen O
receptor O
( O
ER O
) O
-positive O
or O
ER-negative O
, O
operable O
breast O
cancer O
were O
randomized O
to O
receive O
either O
chemotherapy O
or O
endocrine O
therapy O
or O
combined O
chemoendocrine O
treatment O
. O
[]

The O
response O
rate O
to O
mitoxantrone O
was O
20.6 O
% O
, O
to O
doxorubicin O
29.3 O
% O
( O
P O
= O
.07 O
) O
. O
[]

The O
concomitant O
reduction O
of O
the O
urinary O
excretion O
of O
PGE-M O
( O
68 O
to O
85 O
% O
decrease O
) O
and O
prostaglandin O
E O
( O
73 O
to O
100 O
% O
decrease O
) O
after O
indomethacin O
treatment O
in O
each O
case O
( O
n=8 O
) O
is O
evidence O
that O
a O
diminished O
urinary O
PGE-M O
output O
reflects O
a O
decrease O
in O
prostaglandin O
E O
biosynthesis O
. O
[]

Ultrasonic O
evaluation O
showed O
mild B-outcome ['Physiological-Clinical']
residue I-outcome ['Physiological-Clinical']
in O
3 O
, O
1 O
and O
1 O
cases O
of O
groups O
A O
, O
B O
and O
C O
, O
respectively O
( O
P O
= O
0.2 O
) O
. O
['Physiological-Clinical']

Pretreatment O
levels O
of O
antigen O
E O
-- O
specific O
IgE O
and O
blocking O
antibody O
activity O
were O
similar O
in O
both O
groups O
. O
[]

OBJECTIVES O
To O
determine O
whether O
or O
not O
there O
was O
a O
significant O
difference O
between O
the O
methods O
of O
centrifugation O
( O
CF O
) O
and O
multiple-pass O
hemoconcentration O
( O
MPH O
) O
of O
the O
residual O
cardiopulmonary-bypass O
volume O
in O
relation O
to O
biochemical O
measurements O
and O
patient O
outcomes O
. O
[]

The O
therapy O
lasted O
for O
4 O
weeks O
; O
the O
dosage O
was O
300 O
mg O
three O
times O
daily O
. O
[]

The O
two O
groups O
had O
a O
similar O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
progression B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
i.e O
. O
['Mortality', 'Mortality', 'Mortality']

In O
a O
double-blind O
, O
randomised O
study O
of O
thromboprophylaxis O
in O
patients O
undergoing O
total O
hip O
replacement O
, O
we O
compared O
a O
low-molecular-weight O
heparin O
with O
a O
placebo O
. O
[]

We O
studied O
the O
effects O
of O
simvastatin O
( O
MK O
733 O
) O
, O
a O
new O
competitive O
inhibitor O
of O
HMG O
CoA O
reductase O
, O
alone O
and O
in O
combination O
with O
a O
bile O
acid O
sequestrant O
, O
cholestyramine O
, O
on O
serum O
levels O
of O
lipoproteins O
and O
apoproteins O
A1 O
and O
B O
, O
in O
24 O
patients O
with O
familial O
hypercholesterolemia O
. O
[]

Two O
incorrect O
randomisations O
in O
each O
group O
. O
[]

This O
randomized O
prospective O
investigation O
compared O
the O
patient-controlled O
administration O
of O
fentanyl O
with O
that O
of O
administration O
by O
nurses O
on O
request O
. O
[]

In O
order O
to O
study O
the O
plasma O
levels O
of O
factor O
XaI O
and O
IIaI O
activity O
an O
enzymatically O
depolymerized O
low O
molecular O
weight O
heparin O
( O
LMW-heparin O
; O
Logiparin O
) O
was O
given O
s.c. O
in O
a O
dose O
of O
35 O
XaI O
mu/kg O
b.w O
. O
[]

Bronchial O
provocation O
tests O
were O
performed O
in O
a O
single-blind O
, O
crossover O
, O
randomized O
order O
, O
and O
repeated O
45 O
minutes O
after O
placebo O
or O
aerosolized O
heparin O
inhalation O
( O
1,000 O
U/kg O
) O
. O
[]

Participants O
were O
randomized O
to O
the O
SST O
or O
LA O
group O
. O
[]

Observed O
medication O
and O
weekend O
diary O
cards O
were O
used O
to O
monitor O
adherence O
. O
[]

The O
present O
study O
investigated O
the O
effect O
of O
ANF O
on O
the O
increase O
in O
plasma B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
due O
to O
metoclopramide B-outcome ['Resource-use']
in O
man O
. O
['Physiological-Clinical', 'Resource-use']

The O
left O
ventricular O
mass O
index O
( O
LVMI O
) O
was O
calculated O
from O
two-dimensional O
M-mode O
echocardiography O
. O
[]

The O
incidence O
of O
the O
disease O
is O
rising O
rapidly O
in O
many O
countries O
, O
and O
there O
is O
no O
generally O
accepted O
standard O
treatment O
for O
patients O
with O
unresectable O
disease O
. O
[]

Measurements O
were O
taken O
pre- O
and O
post-programme O
. O
[]

Recently O
, O
nicotinic O
acid O
has O
been O
recommended O
as O
a O
first-line O
hypolipidemic O
drug O
. O
[]

Design O
of O
a O
randomized O
controlled O
trial O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
The O
primary O
endpoint O
was O
the O
ovulation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
the O
first O
treatment O
cycle O
( O
cycle O
1 O
) O
. O
['Physiological-Clinical']

The O
pain B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
needle I-outcome ['Physiological-Clinical']
insertion I-outcome ['Physiological-Clinical']
, O
needle B-outcome ['Resource-use']
placement I-outcome ['Resource-use']
, O
solution O
deposition O
and O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
were O
recorded O
on O
a O
Heft-Parker O
visual O
analog O
scale O
for O
the O
2 O
P-ASA O
injections O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

In O
the O
zoledronic O
acid O
group O
, O
bone O
marrow O
was O
not O
collected O
from O
one O
patient O
because O
of O
disease O
progression O
, O
one O
patient O
was O
taken O
off O
study O
because O
of O
severe O
diarrhoea O
, O
and O
two O
patients O
had O
not O
consented O
at O
the O
time O
of O
surgery O
. O
[]

Fifty-four O
heparin-resistant O
patients O
were O
randomized O
. O
[]

CONCLUSIONS O
Community O
psychiatric O
nurses O
can O
safely O
and O
effectively O
deliver O
a O
brief O
CBT O
intervention O
to O
patients O
with O
schizophrenia O
and O
their O
carers O
. O
[]

4 O
. O
[]

They O
then O
compared O
response O
rates O
for O
both O
groups O
. O
[]

The O
101 O
eligible O
cases O
( O
bestatin O
: O
48 O
, O
control O
: O
53 O
) O
were O
analyzed O
; O
the O
bestatin O
group O
achieved O
longer O
remission B-outcome ['Physiological-Clinical']
than O
the O
control O
group O
and O
a O
statistically O
significant O
longer O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
thermal O
destruction O
group O
( O
7.2 O
+/- O
2.8 O
mL O
vs O
89 O
+/- O
38 O
mL O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
a O
high-dose O
infusion O
of O
beta-endorphin O
, O
an O
opioid O
peptide O
, O
on O
blood O
pressure O
and O
on O
the O
hormonal O
profile O
in O
healthy O
subjects O
and O
in O
hypertensive O
patients O
and O
the O
mediation O
played O
by O
opioid O
receptor O
agonism O
. O
[]

Subjects O
were O
studied O
in O
the O
fasting O
state O
on O
the O
morning O
following O
days O
4 O
and O
5 O
of O
each O
diet O
. O
[]

With O
or O
without O
HBO O
pre-treatment O
, O
the O
rats O
were O
further O
divided O
into O
the O
following O
subgroups O
( O
n O
= O
6 O
) O
: O
( O
i O
) O
LPS O
injection O
, O
( O
ii O
) O
normal O
saline O
( O
N/S O
) O
injection O
, O
( O
iii O
) O
hemin O
( O
a O
HO-1 O
inducer O
) O
plus O
LPS O
, O
( O
iv O
) O
hemin O
alone O
, O
( O
v O
) O
tin O
protoporphyrin O
( O
SnPP O
; O
a O
HO-1 O
inhibitor O
) O
plus O
LPS O
, O
and O
( O
vi O
) O
SnPP O
alone O
. O
[]

Low O
intraoperative B-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
Index O
( O
BIS O
) O
values O
may O
be O
associated O
with O
increased O
mortality O
. O
['Physiological-Clinical']

Oral O
ondansetron O
in O
the O
prevention B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Eyes O
were O
randomized O
to O
receive O
sham O
injections O
plus O
prompt O
laser O
, O
intravitreal O
ranibizumab O
injections O
plus O
prompt O
laser O
, O
intravitreal O
ranibizumab O
injections O
plus O
deferred O
laser O
, O
or O
intravitreal O
triamcinolone O
acetonide O
injections O
plus O
prompt O
laser O
up O
to O
every O
16 O
weeks O
with O
sham O
injections O
intermittently O
. O
[]

Because O
of O
the O
low O
cost O
of O
oral O
sodium O
phosphate O
combined O
with O
the O
lowest O
repeat O
endoscopy O
rate O
for O
inadequate O
cleansing O
, O
patient B-outcome ['Life-Impact']
savings I-outcome ['Life-Impact']
were O
projected O
to O
be O
$ O
5000 O
per O
100 O
patients O
at O
this O
center O
. O
['Life-Impact']

They O
were O
then O
placed O
in O
the O
supine O
flat O
position O
, O
and O
after O
an O
additional O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

Baseline O
values O
showed O
that O
the O
7 O
patients O
who O
received O
placebo O
had O
more O
severe O
CHF B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Amenorrhea B-outcome ['Physiological-Clinical']
occurred O
in O
60-65 O
% O
of O
both O
groups O
. O
['Physiological-Clinical']

Best-case O
and O
stage-shift O
scenarios O
gave O
25 O
and O
19 O
deaths B-outcome ['Mortality']
prevented O
with O
ROCA O
, O
for O
RRs O
of O
0.90 O
( O
95 O
% O
CI O
: O
0.69-1.17 O
) O
and O
0.95 O
( O
95 O
% O
CI O
: O
0.74-1.23 O
) O
, O
respectively O
. O
['Mortality']

Synthesis O
of O
interleukin-1 O
beta O
in O
primary O
biliary O
cirrhosis O
: O
relationship O
to O
treatment O
with O
methotrexate O
or O
colchicine O
and O
disease O
progression O
. O
[]

After O
3 O
years O
, O
target B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
was O
7 O
% O
in O
the O
SES O
group O
versus O
27 O
% O
in O
the O
BMS O
group O
( O
P O
< O
.001 O
) O
; O
and O
target O
vessel B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
was O
seen O
in O
11 O
% O
in O
the O
SES O
group O
versus O
30 O
% O
in O
the O
BMS O
group O
( O
P O
= O
.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
distinguish O
various O
types O
of O
childhood O
severe O
cryptogenic/idiopathic O
generalised O
epilepsy O
on O
the O
basis O
of O
reproducible O
diagnostic O
criteria O
, O
using O
multiple O
correspondence O
analysis O
( O
MCA O
) O
. O
[]

The O
relationship O
of O
changes O
in O
EORTC O
QLQ-C30 O
scores O
to O
ratings O
on O
the O
Subjective O
Significance O
Questionnaire O
in O
men O
with O
localized O
prostate O
cancer O
. O
[]

Accordingly O
, O
the O
impact O
of O
kidney O
disease O
on O
the O
benefit O
of O
BNP O
testing O
needs O
to O
be O
scrutinized O
. O
[]

The O
pain-relieving B-outcome ['Physiological-Clinical']
effect O
of O
indomethacin O
phonophoresis O
on O
temporomandibular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TMJ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
a O
double-blind O
, O
placebo-controlled O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
at O
regular O
intervals O
. O
['Adverse-effects']

Despite O
the O
high O
prevalence O
of O
malnutrition B-outcome ['Physiological-Clinical']
, O
the O
medical O
teams O
only O
assessed O
the O
nutritional B-outcome ['Physiological-Clinical']
status O
of O
a O
few O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

About O
14/16 O
patients O
with O
encephalopathic O
syndrome O
of O
the O
coma O
type O
were O
infected O
with O
malaria O
. O
[]

RESULTS O
Forty-nine O
women O
were O
included O
in O
the O
EE30/LNG150 O
group O
and O
48 O
in O
the O
EE20/LNG100 O
group O
. O
[]

The O
sex O
of O
the O
patient O
, O
presence O
of O
diabetes O
, O
body O
surface O
area O
and O
smoking O
history O
appeared O
to O
play O
no O
role O
in O
predicting O
the O
occurrence O
of O
radial B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Dose O
dependent O
response O
of O
symptoms O
, O
pituitary O
, O
and O
bone O
to O
transdermal O
oestrogen O
in O
postmenopausal O
women O
. O
[]

In O
conclusion O
, O
introduction O
of O
everolimus O
immediately O
or O
early O
posttransplant O
in O
DGF-risk O
patients O
is O
associated O
with O
good O
efficacy O
, O
renal O
function O
and O
safety O
profile O
. O
[]

Effects O
of O
reducing O
dietary O
[ O
( O
Na+ O
+ O
K+ O
) O
- O
( O
Cl- O
+ O
SO4= O
) O
] O
on O
the O
rate O
of O
calcium O
mobilisation O
by O
dairy O
cows O
at O
parturition O
. O
[]

20 O
patients O
treated O
with O
basic O
therapy O
plus O
ozone O
therapy O
were O
taken O
as O
a O
treatment O
group O
. O
[]

The O
ESS-1 O
study O
was O
designed O
to O
evaluate O
the O
long-term O
effects O
of O
the O
angiotensin O
converting O
enzyme O
inhibitor O
( O
ACEI O
) O
enalapril O
( O
10 O
mg O
per O
day O
) O
on O
the O
cardio-pulmonary O
system O
in O
patients O
with O
scleroderma O
( O
SSc O
) O
. O
[]

The O
effectiveness O
of O
ES O
of O
the O
pelvic O
floor O
in O
urinary O
incontinent O
elderly O
women O
is O
low O
. O
[]

2 O
, O
168 O
crossbred O
steers O
( O
initial O
BW O
300 O
? O
[]

A O
controlled O
trial O
was O
undertaken O
to O
compare O
the O
efficacy O
of O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
with O
standard O
intramuscular O
opiate O
analgesia O
in O
the O
management O
of O
postoperative O
pain O
following O
appendicectomy O
. O
[]

Changes O
in O
liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
significantly O
correlated O
with O
concomitant O
changes O
in O
kidney B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
( O
r O
= O
0.67 O
) O
during O
octreotide O
but O
not O
during O
placebo O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similarly O
, O
whereas O
death B-outcome ['Mortality']
or O
MI O
increased O
with O
higher O
risk O
( O
11 O
% O
, O
14 O
% O
, O
and O
23 O
% O
, O
respectively O
) O
, O
the O
proportion O
of O
patients O
with O
this O
event O
beyond O
30 O
days O
did O
not O
differ O
in O
the O
three O
strata O
( O
22 O
% O
, O
20 O
% O
, O
and O
25 O
% O
, O
respectively O
) O
. O
['Mortality']

Results O
indicated O
an O
increase O
in O
components O
of O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
for O
the O
experimental O
group O
but O
not O
the O
control O
group O
. O
['Life-Impact']

The O
percentage O
of O
patients O
obstructed O
by O
Abrams-Griffiths O
classification O
decreased O
from O
76.2 O
% O
at O
baseline O
to O
66.7 O
% O
at O
month O
12 O
and O
59.6 O
% O
at O
month O
24 O
. O
[]

In O
comparison O
, O
the O
[]

AIM O
To O
compare O
the O
effectiveness O
of O
EMLA O
cream O
and O
Ametop O
gel O
in O
providing O
analgesia O
for O
venous O
cannulation O
. O
[]

METHODS O
Sixty-four O
male O
patients O
, O
mean O
age O
55.6 O
? O
[]

Long-term O
prospective O
, O
randomized O
, O
controlled O
study O
using O
repetitive O
education O
at O
six-month O
intervals O
and O
monitoring O
for O
adherence O
in O
heart O
failure O
outpatients O
: O
the O
REMADHE O
trial O
. O
[]

The O
total O
symptom O
score O
significantly O
decreased O
in O
all O
active O
groups O
compared O
with O
placebo O
( O
-18.8 O
% O
for O
placebo O
patients O
; O
-71.9 O
% O
, O
P O
= O
0.0022 O
for O
20 O
?g O
; O
-75.6 O
% O
, O
P O
= O
0.0007 O
for O
80 O
?g O
; O
-81.8 O
% O
, O
P O
= O
0.0009 O
for O
160 O
?g O
; O
-78.3 O
% O
, O
P O
= O
0.0003 O
for O
320 O
?g O
) O
. O
[]

OBJECTIVE O
To O
determine O
the O
feasibility O
of O
videotaped O
training O
for O
obstetric O
care O
practitioners O
in O
motivational O
interviewing O
skills O
that O
could O
be O
used O
in O
brief O
patient O
consultations O
on O
problem O
drinking O
. O
[]

We O
conclude O
that O
indomethacin O
can O
reduce O
the O
fever B-outcome ['Physiological-Clinical']
associated O
with O
interferon O
therapy O
in O
patients O
with O
malignant O
melanoma O
without O
interfering O
with O
its O
therapeutic B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
immunomodulatory I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
estimated O
for O
all O
patients O
with O
TP53 B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
in O
their O
tumours O
, O
a O
significant O
better O
outcome O
for O
the O
paclitaxel/cisplatin O
group O
was O
found O
compared O
with O
the O
patient O
group O
receiving O
cyclophosphamide O
and O
cisplatin O
therapy O
( O
P O
= O
0.002 O
) O
. O
['Mortality', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Institutional O
review O
committee O
approval O
and O
written O
informed O
consent O
were O
obtained O
. O
[]

The O
incidence O
of O
bacteriuria B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
anesthesia O
group O
. O
['Physiological-Clinical']

Volunteer O
subjects O
( O
N O
= O
37 O
) O
were O
studied O
using O
doses O
from O
5 O
to O
50 O
mg/day O
given O
for O
14 O
days O
. O
[]

Because O
brain O
metastases O
are O
a O
sign O
of O
systemic O
progression O
, O
and O
chemotherapy O
was O
found O
to O
be O
effective O
as O
well O
, O
it O
becomes O
questionable O
whether O
WBRT O
is O
the O
only O
appropriate O
therapy O
in O
this O
situation O
. O
[]

The O
incidence O
of O
extravertebral O
fractures O
and O
of O
new O
or O
progressive O
vertebral O
deformity O
tended O
to O
be O
lower O
in O
groups O
2 O
and O
3 O
than O
in O
group O
1 O
. O
[]

In O
one O
other O
case O
an O
urticarial B-outcome ['Physiological-Clinical']
rash B-outcome ['Physiological-Clinical']
appeared O
, O
but O
disappeared O
spontaneously O
when O
the O
drug O
was O
temporarily O
stopped O
and O
did O
not O
reappear O
when O
it O
was O
administered O
again O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
found O
statistically O
significant O
differences O
( O
p O
< O
0.05 O
) O
in O
duration O
of O
sensory B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
( O
120.92 O
+/- O
36.21 O
min O
with O
prilocaine O
and O
145.83 O
+/- O
35.81 O
min O
with O
mepivacaine O
) O
and O
in O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
( O
106.29 O
+/- O
38.16 O
min O
with O
prilocaine O
and O
133.16 O
+/- O
42.21 O
min O
with O
mepivacaine O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Half-side O
comparative O
pilot O
study O
on O
subjects O
with O
symmetric O
, O
bilateral O
interdigital O
tinea O
pedis O
. O
[]

In O
conclusion O
, O
long-term O
inhaled O
NO O
with O
constant O
doses O
of O
10 O
ppm O
leads O
to O
enhanced O
sensitivity O
after O
several O
days O
and O
does O
do O
not O
allow O
reduction O
of O
ventilation O
parameters O
. O
[]

There O
was O
no O
main O
effect O
for O
treatment O
condition B-outcome ['Physiological-Clinical']
after O
removing O
one O
subject O
with O
an O
extreme O
score O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Open-label O
randomized O
controlled O
trial O
. O
[]

Protein B-outcome ['Physiological-Clinical']
breakdown I-outcome ['Physiological-Clinical']
, O
protein B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
, O
protein B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
and O
glucose B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
were O
assessed O
by O
stable O
isotope O
tracer O
kinetics O
using O
l- O
[ O
1- O
( O
13 O
) O
C O
] O
leucine O
and O
[ O
6,6- O
( O
2 O
) O
H2 O
] O
glucose O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
mixture O
of O
C16:0 O
and O
C18:0 O
PAFs O
in O
a O
ratio O
of O
1:9 O
appeared O
to O
be O
more O
active O
than O
in O
a O
ratio O
of O
3:1 O
. O
[]

Both O
groups O
showed O
modest O
to O
moderate O
improvement O
, O
but O
differences O
between O
groups O
were O
negligible O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
and O
cost-effectiveness O
of O
simvastatin O
on O
erectile O
function O
and O
health-related O
quality O
of O
life O
in O
men O
aged O
?40 O
years O
with O
erectile O
dysfunction O
( O
ED O
) O
. O
[]

Heparin-coated O
cardiopulmonary O
bypass O
circuits O
reduce O
circulating O
complement O
factors O
and O
interleukin-6 O
in O
paediatric O
heart O
surgery O
. O
[]

Shock O
waves O
were O
given O
at O
a O
rate O
of O
90 O
shocks/minute O
with O
energy O
starting O
from O
10 O
up O
to O
18 O
KV O
. O
[]

These O
findings O
suggest O
that O
cocaine-using O
methadone O
patients O
with O
AD O
achieve O
greater O
cocaine B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
than O
their O
non-AD O
counterparts O
and O
should O
not O
necessarily O
be O
viewed O
as O
more O
difficult O
to O
treat O
. O
['Life-Impact']

Compliance O
was O
excellent O
. O
[]

Five O
randomized O
controlled O
trials O
regarding O
antenatal O
use O
of O
corticosteroids O
to O
prevent O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
could O
be O
combined O
meta-analytically O
and O
showed O
a O
reduction O
in O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
in O
the O
treatment O
group O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
OBJECTIVE O
; O
To O
observe O
the O
effects O
of O
early O
acupuncture O
on O
motor O
function O
of O
the O
limb O
in O
the O
severe O
head O
injury O
patients O
. O
[]

RESULTS O
Clinical O
benefit O
assessments O
were O
performed O
in O
more O
than O
75 O
% O
of O
patients O
throughout O
V325 O
. O
[]

BACKGROUND O
Imaging O
evidence O
indicates O
that O
brain O
alterations O
are O
primary O
to O
the O
full-blown O
onset O
of O
schizophrenia O
and O
seem O
to O
progress O
across O
time O
. O
[]

In O
only O
2 O
of O
the O
11 O
patients O
who O
received O
a O
third O
sclerotherapy O
injection O
was O
bleeding B-outcome ['Physiological-Clinical']
controlled I-outcome ['Physiological-Clinical']
for O
more O
than O
five O
days O
, O
and O
9 O
died O
. O
['Physiological-Clinical']

PURPOSE O
Minority O
patients O
with O
cancer O
experience O
worse O
control O
of O
their O
pain O
than O
do O
their O
white O
counterparts O
. O
[]

RESULTS O
Under O
placebo O
, O
the O
AS O
group O
showed O
decreased O
activity O
in O
the O
right B-outcome ['Physiological-Clinical']
amygdala I-outcome ['Physiological-Clinical']
, O
fusiform B-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
, O
and O
inferior B-outcome ['Physiological-Clinical']
occipital I-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
compared O
with O
the O
control O
group O
during O
face O
processing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
novel O
methodology O
for O
generating O
3D O
finite O
element O
models O
of O
the O
hip O
from O
2D O
radiographs O
. O
[]

Thirty-three O
patients O
aged O
18 O
to O
70 O
years O
were O
randomized O
to O
receive O
either O
desflurane O
or O
isoflurane O
following O
a O
standard O
intravenous O
induction O
with O
propofol O
. O
[]

METHODS O
Adults O
at O
moderate O
and O
high O
risk O
for O
skin O
cancer O
were O
recruited O
in O
primary O
health O
care O
settings O
in O
Honolulu O
, O
HI O
, O
and O
Long O
Island O
, O
NY O
. O
[]

The O
Nycomed O
NC100100 O
Investigators O
. O
[]

n O
= O
1,519 O
) O
or O
celecoxib O
200 O
mg O
o.d O
. O
( O
[]

A O
positive O
treatment O
effect O
was O
also O
observed O
in O
cases O
irradiated O
with O
36 O
Gy O
; O
however O
, O
a O
25 O
% O
incidence O
of O
radiation O
retinopathy O
seems O
unacceptable O
. O
[]

However O
, O
this O
study O
did O
not O
find O
significant O
differences O
in O
scaling O
time O
between O
product O
and O
placebo O
when O
using O
a O
2-minute O
gel O
contact O
time O
. O
[]

Although O
the O
effect O
was O
not O
significant O
during O
the O
whole O
time O
of O
the O
steady O
state O
it O
became O
evident O
by O
a O
negative O
correlation O
with O
lactate O
( O
r O
= O
-0.687 O
) O
and O
pyruvate O
( O
r O
= O
-0.843 O
) O
. O
[]

METHODS O
We O
studied O
the O
distribution O
of O
a O
Web-based O
and O
a O
print-delivered O
version O
of O
the O
Active O
Plus O
intervention O
in O
a O
clustered O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
[]

The O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
15 O
+/- O
4 O
mmol/l O
before O
and O
14 O
+/- O
5 O
mmol/l O
after O
clonidine O
injection O
. O
['Physiological-Clinical']

Where O
practical O
, O
later O
infusions O
were O
given O
at O
home O
( O
rather O
than O
in O
the O
clinic O
) O
and O
patients O
questioned O
on O
their O
preferred O
infusion O
location O
. O
[]

Twenty-five O
deaths B-outcome ['Mortality']
were O
not O
due O
to O
bleeding O
but O
were O
closely O
related O
to O
cirrhosis O
. O
['Mortality']

These O
data O
confirm O
preclinical O
findings O
. O
[]

Very O
few O
infants O
developed O
iron B-outcome ['Physiological-Clinical']
deficiency I-outcome ['Physiological-Clinical']
anaemia I-outcome ['Physiological-Clinical']
in O
either O
group O
but O
there O
was O
a O
tendency O
for O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
levels O
to O
fall O
between O
6 O
and O
18 O
months O
of O
age O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

GOALS O
OF O
WORK O
We O
set O
out O
to O
assess O
the O
preference O
of O
patients O
with O
common O
cancers O
involving O
bone O
receiving O
intravenous O
bisphosphonate O
therapy O
for O
either O
pamidronate O
( O
P O
) O
or O
zoledronic O
acid O
( O
Z O
) O
and O
their O
preference O
for O
the O
location O
of O
the O
infusion O
( O
clinic O
or O
home O
) O
. O
[]

Two O
hundred O
and O
twelve O
patients O
with O
previously O
untreated O
advanced O
squamous O
carcinoma O
of O
the O
larynx O
or O
hypopharynx O
were O
randomized O
to O
receive O
initial O
treatment O
with O
radiotherapy O
, O
50 O
Gy O
in O
20 O
fractions O
in O
28 O
days O
or O
split O
course O
radiotherapy O
and O
concurrent O
chemotherapy O
, O
25 O
Gy O
in O
10 O
fractions O
in O
14 O
days O
followed O
by O
a O
4 O
week O
rest O
and O
a O
further O
25 O
Gy O
in O
10 O
fractions O
in O
14 O
days O
starting O
on O
day O
43 O
; O
Mitomycin O
C O
was O
given O
on O
day O
1 O
and O
day O
43 O
and O
5FU O
continuous O
infusions O
on O
days O
1 O
-- O
4 O
and O
days O
43 O
-- O
46 O
. O
[]

Randomized O
prospective O
studies O
to O
quantify O
the O
effect O
of O
methylprednisolone O
on O
perioperative O
outcomes O
in O
neonatal O
cardiac O
surgery O
have O
not O
been O
performed O
. O
[]

BACKGROUND O
Subgroups O
of O
breast O
cancer O
that O
have O
an O
impaired O
response O
to O
endocrine O
treatment O
, O
despite O
hormone O
receptor O
positivity O
, O
are O
still O
poorly O
defined O
. O
[]

This O
study O
uses O
eye-tracking O
to O
explore O
the O
typicality O
of O
gaze O
patterns O
when O
children O
with O
ASD O
attend O
their O
own O
faces O
compared O
to O
other O
familiar O
and O
unfamiliar O
faces O
. O
[]

Blood B-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
changed O
little O
during O
operation O
, O
suggesting O
that O
tissue O
oxygenation O
was O
adequate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
presentation O
order O
of O
the O
heart B-outcome ['Physiological-Clinical']
sound I-outcome ['Physiological-Clinical']
was O
reversed O
for O
the O
other O
half O
of O
the O
subjects O
. O
['Physiological-Clinical']

PURPOSE O
To O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
with O
resected O
stage B-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
melanoma I-outcome ['Physiological-Clinical']
administered O
active O
specific O
immunotherapy O
and O
low-dose O
interferon O
alfa-2b O
( O
IFN-alpha-2b O
) O
with O
the O
OS O
achieved O
using O
high-dose O
IFN-alpha-2b O
. O
['Physiological-Clinical']

In O
this O
double-blind O
, O
three-arm O
study O
, O
105 O
patients O
diagnosed O
with O
acute O
abacterial O
otitis O
externa O
were O
included O
and O
randomized O
to O
receive O
either O
glycerol O
eardrops O
, O
glycerol O
eardrops O
with O
0.5 O
% O
lidocaine O
, O
or O
glycerol O
eardrops O
with O
2 O
% O
lidocaine O
for O
seven O
days O
. O
[]

Patients O
in O
whom O
at O
least O
seven O
clinic O
( O
6-month O
intervals O
) O
or O
at O
least O
three O
( O
yearly O
intervals O
) O
24-h O
values O
were O
available O
from O
the O
end O
of O
the O
drug O
titration O
phase O
to O
the O
end O
of O
the O
study O
were O
considered O
. O
[]

CONCLUSIONS O
Parent-implemented O
intervention O
studies O
for O
early O
ASD O
thus O
far O
have O
not O
demonstrated O
the O
large O
effects O
seen O
in O
intensive-treatment O
studies O
. O
[]

Primary O
care-based O
ambulatory O
opioid O
detoxification O
: O
the O
results O
of O
a O
clinical O
trial O
. O
[]

The O
cohort O
was O
followed O
through O
July O
2000 O
for O
development O
of O
breast O
diseases O
, O
and O
the O
breast O
cancer O
cases O
were O
followed O
through O
2001 O
for O
vital O
status O
. O
[]

Attitude O
certainty O
has O
been O
the O
subject O
of O
considerable O
attention O
in O
the O
attitudes O
and O
persuasion O
literature O
. O
[]

Overall O
survival B-outcome ['Mortality']
was O
greater O
with O
the O
implantable O
defibrillator O
, O
with O
unadjusted O
estimates O
of O
89.3 O
percent O
, O
as O
compared O
with O
82.3 O
percent O
in O
the O
antiarrhythmic-drug O
group O
at O
one O
year O
, O
81.6 O
percent O
versus O
74.7 O
percent O
at O
two O
years O
, O
and O
75.4 O
percent O
versus O
64.1 O
percent O
at O
three O
years O
( O
P O
< O
0.02 O
) O
. O
['Mortality']

In O
contrast O
, O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
after O
administration O
of O
450 O
mg O
were O
almost O
the O
same O
as O
after O
300 O
mg O
. O
['Physiological-Clinical']

Accordingly O
, O
the O
current O
study O
examined O
within-person O
covariation O
between O
time-varying O
abstinence O
and O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
in O
a O
multilevel O
model O
( O
MLM O
) O
, O
which O
allowed O
for O
transitions O
between O
smoking O
statuses O
within O
a O
participant O
. O
['Life-Impact']

Our O
study O
was O
designed O
to O
compare O
the O
efficacy O
, O
costs B-outcome ['Resource-use']
, O
and O
safety O
of O
oral O
ganciclovir O
and O
valacyclovir O
in O
the O
prophylaxis O
of O
CMV O
disease O
over O
the O
first O
6 O
months O
after O
RTx O
. O
['Resource-use']

After O
full O
recovery O
, O
acepromazine O
( O
0.02 O
mg/kg O
) O
and O
oxymorphone O
( O
0.05 O
mg/kg O
) O
were O
administered O
IV O
. O
[]

Effect O
of O
antacids O
on O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
and O
duodenal O
ulcer O
patients O
. O
['Physiological-Clinical']

Japanese O
Urothelial O
Cancer O
Research O
Group O
. O
[]

Beneficial O
effects O
of O
albumin O
therapy O
was O
apparent O
only O
in O
those O
infants O
with O
low O
RABC O
as O
determined O
by O
the O
sephadex O
gel O
filtration O
technique O
. O
[]

RESULTS O
Patients O
with O
short-term O
GHQ O
success O
were O
more O
likely O
to O
show O
mid-term B-outcome ['Physiological-Clinical']
GHQ I-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
( O
p O
< O
.001 O
) O
, O
marginally O
less O
likely O
to O
die O
of O
any O
causes O
( O
p O
= O
.087 O
) O
, O
less O
likely O
to O
die O
of O
cardiac O
causes O
( O
p O
= O
.043 O
) O
, O
less O
likely O
to O
be O
readmitted B-outcome ['Physiological-Clinical']
for O
any O
reason O
( O
p O
< O
.001 O
) O
and O
for O
cardiac O
reasons O
( O
p O
< O
.001 O
) O
, O
and O
less O
likely O
to O
have O
high O
depression B-outcome ['Life-Impact']
( O
p O
< O
.001 O
) O
and O
anxiety B-outcome ['Life-Impact']
( O
p O
< O
.001 O
) O
at O
1-year O
than O
patients O
with O
short-term O
unsuccessful O
GHQ B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Recrudescent O
and O
new O
infections O
were O
distinguished O
by O
comparison O
of O
polymorphisms O
in O
merozoite O
surface O
protein O
2 O
( O
MSP2 O
) O
. O
[]

The O
treatment O
did O
not O
alter O
outcome O
or O
the O
duration O
of O
ICU B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Resource-use']

STUDY O
OBJECTIVES O
To O
investigate O
the O
ability O
of O
a O
supranormal O
dose O
of O
N-acetylcysteine O
to O
overcome O
the O
effects O
of O
activated O
charcoal O
on O
N-acetylcysteine O
bioavailability O
and O
to O
determine O
the O
effects O
of O
activated O
charcoal O
on O
serum O
acetaminophen O
levels O
. O
[]

The O
improvement O
was O
defined O
as O
at O
least O
50 O
percent O
reduction O
of O
the O
Brief O
Psychiatric B-outcome ['Physiological-Clinical']
Rating O
Scale O
( O
BPRS O
) O
total O
score O
. O
['Physiological-Clinical']

Eleven O
patients O
in O
the O
riluzole O
group O
and O
five O
patients O
in O
the O
placebo O
group O
were O
classified O
as O
responders O
based O
on O
their O
CGI-I O
scores O
[ O
? O
( O
[]

As O
a O
group O
, O
the O
patients O
displayed O
greater O
UFC B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
ACTH I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
the O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Clomipramine O
, O
a O
serotonin O
reuptake O
blocker O
that O
has O
unique O
antiobsessional O
properties O
, O
was O
hypothesized O
to O
have O
a O
different O
effect O
from O
that O
of O
desipramine O
, O
a O
tricyclic O
antidepressant O
with O
selective O
adrenergic O
effects O
, O
for O
the O
stereotyped O
, O
repetitive O
behaviors O
in O
autism O
. O
[]

Treatments O
were O
administered O
4 O
times O
at O
weekly O
intervals O
. O
[]

Limitations O
of O
this O
study O
include O
small O
sample O
size O
, O
lack O
of O
an O
attention O
control O
group O
, O
and O
use O
of O
outcome O
measures O
normed O
with O
typically O
developing O
children O
[]

The O
administration O
of O
placebo O
with O
scopolamine O
caused O
significant O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
as O
assessed O
by O
the O
Computerized O
Neuropsychological O
Test O
Battery O
( O
CNTB O
) O
, O
and O
also O
decreased O
salivation B-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
randomized O
observer O
blind O
controlled O
trial O
of O
123 O
very O
preterm O
infants O
was O
conducted O
in O
the O
neonatal O
intensive O
care O
unit O
of O
the O
sole O
tertiary O
referral O
centre O
in O
Western O
Australia O
. O
[]

Trace O
element O
supplementation O
after O
major O
burns O
modulates O
antioxidant O
status O
and O
clinical O
course O
by O
way O
of O
increased O
tissue B-outcome ['Physiological-Clinical']
trace I-outcome ['Physiological-Clinical']
element I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Videotaped O
training O
in O
alcohol O
counseling O
for O
obstetric O
care O
practitioners O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
was O
statistically O
significant O
( O
p O
< O
0.02 O
) O
in O
placebo-treated O
patients O
at O
12 O
and O
24 O
months O
, O
and O
in O
the O
lovastatin O
group O
after O
24 O
months O
. O
['Physiological-Clinical']

Study O
of O
the O
vaginal O
tolerance O
to O
Acidform O
, O
an O
acid-buffering O
, O
bioadhesive O
gel O
. O
[]

The O
tented O
patients O
had O
statistically O
significant O
reduction O
of O
mean O
duration O
of O
air B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
in O
days O
( O
4.9 O
+/- O
1.79 O
vs O
8.2 O
+/- O
4.2 O
) O
, O
the O
number O
of O
days O
of O
a O
chest B-outcome ['Physiological-Clinical']
tube I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
( O
7.3 O
+/- O
1.14 O
vs O
12.46 O
+/- O
3.6 O
) O
, O
the O
length O
of O
postoperative O
in-hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in I-outcome ['Resource-use']
days I-outcome ['Resource-use']
( O
9.4 O
+/- O
1.86 O
vs O
13.6 O
+/- O
2.49 O
) O
, O
and O
the O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
cost B-outcome ['Resource-use']
per O
patient O
( O
leva O
, O
3840 O
+/- O
298 O
vs O
5160 O
+/- O
3890 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

These O
results O
demonstrate O
that O
stimulation O
of O
the O
metaboreflex O
activates O
, O
but O
does O
not O
sensitize O
the O
CC O
, O
and O
help O
explain O
the O
enhanced O
CC O
activity O
with O
exercise O
. O
[]

MRI O
signal O
hyperintensities O
and O
failure B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
remit I-outcome ['Physiological-Clinical']
following O
antidepressant O
treatment O
. O
['Physiological-Clinical']

DISCUSSION O
If O
ROMEO O
confirms O
that O
group O
care O
can O
be O
successfully O
implemented O
in O
different O
clinics O
, O
a O
novel O
clinico-pedagogic O
tool O
will O
have O
been O
acquired O
to O
support O
patient-centred O
education O
, O
improve O
lifestyle B-outcome ['Life-Impact']
and O
outcomes O
, O
support O
team B-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
enhance O
providers O
' O
attitudes B-outcome ['Life-Impact']
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

On O
the O
other O
hand O
, O
the O
levels O
of O
PAI B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
imidapril O
group O
decreased O
rapidly O
and O
those O
48 O
hours O
after O
administration O
were O
significantly O
lower O
than O
those O
in O
the O
placebo O
group O
( O
7.9 O
+/- O
1.9 O
IU/ml O
vs O
18.4 O
+/- O
3.5 O
IU/ml O
; O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Does O
waiting O
matter O
? O
[]

Changes O
in O
body B-outcome ['Physiological-Clinical']
weight O
, O
total O
fat B-outcome ['Physiological-Clinical']
intake I-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
and O
potassium B-outcome ['Physiological-Clinical']
did O
not O
have O
significant O
predictive O
power O
in O
any O
of O
the O
analyses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
experimental O
group O
received O
routine O
care O
and O
services O
that O
included O
rigorous O
follow-up O
, O
discussions O
with O
the O
mother O
about O
her O
plans O
for O
return O
to O
school O
and O
use O
of O
family O
planning O
methods O
, O
and O
extra O
health O
teaching O
. O
[]

AIMS O
To O
compare O
outcome O
of O
AF O
patients O
with O
effective O
rhythm O
control O
with O
patients O
treated O
with O
rate O
control O
. O
[]

To O
achieve O
a O
maintenance O
dose O
of O
allergen O
extract O
, O
cluster O
patients O
received O
14 O
injections O
of O
house O
dust O
mite O
allergen O
within O
6 O
weeks O
, O
whereas O
the O
classic O
SIT O
group O
received O
14 O
injections O
within O
14 O
weeks O
. O
[]

This O
pilot O
study O
tested O
the O
effect O
of O
cognitive O
behavioral O
therapy O
( O
CBT O
) O
on O
parent-reported O
autism O
symptoms O
. O
[]

Late O
patient-reported O
toxicity O
after O
preoperative O
radiotherapy O
or O
chemoradiotherapy O
in O
nonresectable O
rectal O
cancer O
: O
results O
from O
a O
randomized O
Phase O
III O
study O
. O
[]

Video O
sequences O
and O
participants` O
questionnaires O
showed O
instrument B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
as O
the O
major O
problem O
in O
the O
single-incision O
surgery O
groups O
. O
['Life-Impact']

Group O
A O
received O
prednisone O
plus O
'triple-treatment O
' O
( O
vitamin O
D2 O
45000 O
iu O
twice O
weekly O
, O
sodium O
fluoride O
50 O
mg O
and O
calcium O
phosphate O
4.5 O
g O
daily O
) O
, O
group O
B O
received O
only O
prednisone O
. O
[]

The O
sessions O
did O
not O
differ O
significant O
in O
terms O
of O
the O
Tsk O
time-course O
response B-outcome ['Life-Impact']
. O
['Life-Impact']

Low O
initial B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
and O
young O
patient O
age O
independently O
predicted O
increased O
blood B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
during O
bicarbonate B-outcome ['Physiological-Clinical']
APD I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adjustment O
for O
Helicobacter O
pylori O
and O
gastric O
atrophy O
had O
little O
effect O
on O
observed O
associations O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
at O
0 O
, O
6 O
, O
12 O
, O
and O
24 O
hours O
by O
using O
a O
visual O
analog O
scale O
( O
VAS O
) O
. O
['Physiological-Clinical']

Significant O
improvements O
were O
observed O
in O
waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
prognostic O
value O
of O
sialyl O
Lewis O
( O
a O
) O
expression O
in O
colon O
cancer O
is O
still O
controversial O
. O
[]

Atrial O
flutter O
cycle O
length O
and O
atrial O
monophasic O
action O
potential O
duration O
recorded O
from O
the O
right O
atrium O
during O
atrial O
flutter O
were O
measured O
at O
baseline O
and O
following O
infusion O
of O
ibutilide O
, O
procainamide O
, O
or O
placebo O
. O
[]

Five O
patients O
complained O
of O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Multifactor O
dimensionality O
reduction O
analysis O
was O
used O
to O
identify O
a O
genetic B-outcome ['Physiological-Clinical']
interaction O
profile O
for O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) O
. O
['Physiological-Clinical', 'Mortality']

Six O
ovulatory O
cycles O
were O
assessed O
. O
[]

Each O
group O
received O
identical O
dietary O
instructions O
. O
[]

Main O
outcome O
measures O
were O
Humphrey O
Field O
Analyzer O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
, O
30-Hz O
electroretinogram O
amplitude O
, O
and O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Ninety-six O
( O
95.0 O
% O
) O
parents O
returned O
the O
questionnaire O
. O
[]

Serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
was O
measured O
in O
the O
first O
trimester O
, O
at O
36 O
weeks O
' O
gestation O
, O
and O
in O
cord O
blood O
. O
['Physiological-Clinical']

Five O
iso-nitrogenous O
( O
356.3 O
? O
[]

RESULTS O
The O
morphometric O
analysis O
of O
histological O
sections O
of O
conjunctiva O
showed O
the O
following O
changes O
: O
squamous B-outcome ['Physiological-Clinical']
metaplasia I-outcome ['Physiological-Clinical']
( O
significant O
increases O
in O
the O
thickness B-outcome ['Physiological-Clinical']
and O
number O
of O
epithelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
layers I-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
a O
20-week O
parent O
education O
programme O
including O
skills O
training O
for O
parents O
of O
young O
children O
with O
autistic O
disorder O
provides O
significant O
improvements O
in O
child B-outcome ['Life-Impact']
adaptive I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
and O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
for O
low-functioning O
children O
. O
['Life-Impact', 'Life-Impact']

Phase O
III O
trial O
of O
satraplatin O
, O
an O
oral O
platinum O
plus O
prednisone O
vs. O
prednisone O
alone O
in O
patients O
with O
hormone-refractory O
prostate O
cancer O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
treatment O
with O
the O
antiherpes O
drug O
valacyclovir O
on O
MRI-evident O
lesions B-outcome ['Physiological-Clinical']
in O
patients O
with O
relapsing-remitting O
MS O
in O
a O
phase O
2 O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Two O
groups O
were O
built O
by O
randomization O
. O
[]

Genotypes O
were O
determined O
with O
respect O
to O
a O
functional O
polymorphism O
of O
the O
serotonin O
transporter O
gene O
promoter O
region O
( O
5HTTLPR O
) O
. O
[]

RESULTS O
Constitutive B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
prealbumin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
retinol-binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
increased O
( O
p O
< O
0.05 O
) O
, O
and O
acute O
phase O
proteins B-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
1-acid I-outcome ['Physiological-Clinical']
glycoprotein I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
C3 I-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
2-macroglobulin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
levels O
significantly O
decreased O
in O
the O
oxandrolone O
group O
compared O
with O
placebo O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

P O
less O
than O
0.05 O
) O
and O
this O
change O
was O
sustained O
for O
40 O
min O
. O
[]

Treatment O
with O
etidronate O
increases O
BMD B-outcome ['Physiological-Clinical']
in O
chronically O
hospitalized O
patients O
poststroke O
, O
and O
may O
prevent O
hip O
fracture O
. O
['Physiological-Clinical']

OBJECTIVE O
Stapled O
mucosectomy O
has O
been O
developed O
as O
an O
alternative O
to O
conventional O
haemorrhoidectomy O
for O
the O
elective O
treatment O
of O
haemorrhoids O
, O
but O
has O
not O
been O
assessed O
in O
the O
emergency O
setting O
. O
[]

We O
attempted O
to O
verify O
whether O
topical O
periarterial O
capsaicin O
could O
ameliorate O
pain O
in O
absence O
of O
and O
during O
a O
migraine B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Authors O
examined O
the O
effects O
of O
information O
source O
on O
peers O
' O
cognitive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
toward O
an O
unfamiliar O
child O
with O
autism O
. O
['Life-Impact']

METHODS O
One O
hundred O
twenty-five O
volunteers O
were O
randomly O
assigned O
to O
the O
treatment O
( O
n O
= O
100 O
) O
or O
control O
group O
( O
n O
= O
25 O
) O
after O
examination O
by O
the O
team O
neurologist O
to O
ensure O
a O
diagnosis O
of O
migraine B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additional O
investigations O
are O
warranted O
to O
determine O
the O
potential O
for O
interactions O
in O
elderly O
patients O
with O
dementia O
who O
may O
eliminate O
risperidone O
and O
donepezil O
more O
slowly O
and O
thus O
be O
more O
vulnerable O
to O
clinical O
drug O
interactions O
than O
the O
young O
healthy O
subjects O
examined O
in O
this O
study O
. O
[]

Three O
surgical O
subgroups O
were O
entered O
into O
the O
study O
: O
anterior/posterior O
( O
A/P O
) O
spinal O
fusion O
patients O
, O
posterior O
thoracolumbar O
scoliosis O
fusion O
patients O
( O
PSF O
) O
, O
and O
degenerative O
posterior O
lumbar O
fusion O
patients O
( O
LF O
) O
. O
[]

Of O
the O
components O
of O
the O
primary O
outcome O
, O
only O
hospitalization O
for O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
had O
a O
significantly O
lower O
incidence O
in O
the O
spironolactone O
group O
than O
in O
the O
placebo O
group O
( O
206 O
patients O
[ O
12.0 O
% O
] O
vs. O
245 O
patients O
[ O
14.2 O
% O
] O
; O
hazard O
ratio O
, O
0.83 O
; O
95 O
% O
CI O
, O
0.69 O
to O
0.99 O
, O
P=0.04 O
) O
. O
['Physiological-Clinical']

Erythropoietin O
can O
be O
combined O
safely O
with O
rhGM-CSF O
after O
autologous O
transplantation O
. O
[]

Subjects O
were O
1,504 O
police O
trainees O
( O
85 O
% O
male O
, O
15 O
% O
female O
) O
with O
an O
ethnic O
distribution O
of O
82 O
% O
white O
, O
16 O
% O
African O
American O
, O
and O
2 O
% O
other O
. O
[]

Group O
A O
subjects O
were O
placed O
supine O
, O
and O
after O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

In O
conclusion O
, O
in O
60-year-old O
subjects O
antioxidant O
supplementation O
had O
[]

No O
anti-aflibercept O
antibodies O
were O
detected O
. O
[]

The O
effectiveness O
of O
naltrexone O
in O
the O
treatment O
of O
autism O
and O
self-injurious O
behavior O
requires O
additional O
assessment O
in O
a O
sample O
of O
children O
with O
moderate O
to O
severe O
self-injurious O
behavior O
. O
[]

No O
differences O
were O
observed O
in O
glucose O
levels O
, O
insulin O
sensitivity O
index O
and O
lipid O
profile O
as O
well O
as O
in O
[]

Antibiotic O
therapy O
in O
the O
study O
group O
was O
not O
applied O
until O
clinical O
signs O
and O
symptoms O
of O
infection O
appeared O
( O
PCT O
value O
was O
> O
0.5ng/ml O
) O
. O
[]

Mean O
observed O
steady-state B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
arzoxifene O
were O
3.62 O
and O
7.48 O
ng/ml O
for O
the O
20 O
and O
50 O
mg O
doses O
, O
respectively O
. O
['Physiological-Clinical']

The O
plasma B-outcome ['Physiological-Clinical']
PAI I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
gradually O
to O
peak O
levels O
16 O
hours O
after O
the O
administration O
of O
imidapril O
and O
placebo O
. O
['Physiological-Clinical']

This O
report O
summarizes O
the O
entire O
blinded O
treatment O
period O
, O
which O
ended O
on O
January O
31 O
, O
1996 O
. O
[]

The O
right O
ventricle-to-pulmonary O
artery O
shunt O
demonstrated O
better O
survival B-outcome ['Mortality']
in O
the O
51 O
% O
of O
subjects O
who O
were O
full O
term O
with O
aortic O
atresia O
( O
P O
< O
.001 O
) O
. O
['Mortality']

Specifically O
, O
D-dimer B-outcome ['Physiological-Clinical']
levels O
at O
all O
four O
time O
points O
correlated O
with O
patients O
' O
long-term O
outcomes O
. O
['Physiological-Clinical']

By O
20 O
min O
, O
PI B-outcome ['Physiological-Clinical']
increased O
by O
326 O
% O
, O
compared O
with O
a O
10 O
% O
decrease O
and O
a O
3 O
% O
increase O
in O
MAP B-outcome ['Physiological-Clinical']
and O
toe B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recombinant O
human O
thyrotropin-stimulated O
radioiodine O
therapy O
of O
nodular O
goiter O
allows O
major O
reduction O
of O
the O
radiation B-outcome ['Resource-use']
burden I-outcome ['Resource-use']
with O
retained O
efficacy O
. O
['Resource-use']

Sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
and O
abnormal B-outcome ['Physiological-Clinical']
dreaming I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
were O
most O
frequent O
with O
pindolol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Gonorrhea B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
chlamydial I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
detected O
in O
6 O
% O
of O
intervention O
and O
11 O
% O
of O
control O
participants O
at O
follow-up O
( O
AOR O
= O
2.2 O
; O
95 O
% O
CI O
= O
1.1 O
, O
4.1 O
) O
, O
with O
greatest O
benefits O
seen O
among O
men O
( O
for O
gender O
interaction O
, O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

RESULTS O
Nineteen O
infants O
( O
33 O
eyes O
) O
were O
treated O
, O
ranging O
from O
485 O
to O
863 O
g O
birth O
weight O
( O
23 O
to O
27 O
weeks O
gestational O
age O
) O
; O
18 O
patients O
( O
32 O
eyes O
) O
were O
followed O
for O
3 O
months O
or O
longer O
. O
[]

After O
two O
years O
, O
they O
underwent O
a O
detailed O
interview O
by O
an O
independent B-outcome ['Life-Impact']
, O
masked O
investigator O
. O
['Life-Impact']

This O
study O
tests O
a O
formula O
for O
selecting O
appropriately O
sized O
cuffed O
endotracheal O
tubes O
and O
compares O
the O
use O
of O
cuffed O
versus O
uncuffed O
endotracheal O
tubes O
for O
patients O
whose O
lungs O
are O
mechanically O
ventilated O
during O
anesthesia O
. O
[]

The O
Clopidogrel O
in O
Unstable O
angina O
to O
prevent O
Recurrent O
Events O
( O
CURE O
) O
trial O
demonstrated O
the O
effectiveness O
of O
clopidogrel O
plus O
acetylsalicylic O
acid O
( O
ASA O
) O
compared O
with O
ASA O
alone O
in O
reducing O
cardiovascular O
events O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
, O
in O
addition O
, O
patients O
undergoing O
percutaneous O
coronary O
intervention O
in O
the O
Percutaneous O
Coronary O
Intervention O
in O
CURE O
( O
PCI-CURE O
) O
trial O
. O
[]

Perinatal O
outcomes O
and O
performance O
of O
skilled O
birth O
attendants O
on O
management O
of O
intrapartum-related B-outcome ['Physiological-Clinical']
neonatal I-outcome ['Physiological-Clinical']
hypoxia I-outcome ['Physiological-Clinical']
will O
be O
the O
main O
measurements O
. O
['Physiological-Clinical']

With O
nutritional B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
triceps B-outcome ['Physiological-Clinical']
skinfold I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
and O
mid-arm B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
increased O
( O
mean O
15 O
% O
, O
62 O
% O
, O
and O
95 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

About O
platelet B-outcome ['Physiological-Clinical']
5-HT I-outcome ['Physiological-Clinical']
, O
there O
is O
neither O
order O
x O
treatment O
interaction O
, O
nor O
treatment O
effect O
but O
a O
significant O
order B-outcome ['Physiological-Clinical']
effect O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Changing O
the O
target O
blood O
pressure O
to O
below O
130/85 O
, O
for O
subjects O
aged O
below O
60 O
, O
as O
recommended O
by O
WHO/ISH O
, O
affects O
predominantly O
low- O
and O
medium-risk O
groups O
. O
[]

Choice O
of O
vitreous O
sampling O
procedure O
must O
depend O
on O
the O
clinical O
judgment O
of O
the O
surgeon O
. O
[]

In O
non-TIPS O
patients O
, O
ammonia B-outcome ['Physiological-Clinical']
increased O
to O
36 O
( O
10 O
) O
micromol/l O
when O
LOLA O
was O
administered O
and O
to O
62 O
( O
13 O
) O
micromol/l O
with O
placebo O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

Diastolic O
blood O
pressure O
, O
respiration O
and O
pulse O
did O
vary O
significantly O
with O
position O
. O
[]

RESULTS O
The O
demographic O
data O
were O
not O
statistically O
different O
. O
[]

This O
study O
tested O
a O
modular O
cognitive O
behavioral O
therapy O
( O
CBT O
) O
program O
for O
children O
with O
this O
profile O
. O
[]

In O
the O
labetalol-treated O
patients O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
17 O
instances O
fell O
from O
198 O
+/- O
5/104 O
+/- O
4 O
mmHg O
to O
143 O
+/- O
7/89 O
+/- O
5 O
mmHg O
180 O
min O
following O
injection O
of O
labetalol O
50 O
mg O
. O
['Physiological-Clinical']

RESULTS O
The O
significantly O
raised O
levels O
of O
MDA B-outcome ['Physiological-Clinical']
and O
SOD B-outcome ['Physiological-Clinical']
, O
and O
decreased O
levels O
of O
reduced B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
during O
uncontrolled O
stage O
of O
diabetes O
indicated O
free O
radical O
stress O
induced O
lipid O
peroxidation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
both O
cohorts O
, O
quarterly O
calls O
over O
3 O
years O
were O
used O
to O
collect O
self-reported O
occupational O
injury O
and O
illness O
information O
, O
including O
costs O
to O
the O
farmers O
and O
their O
insurers O
. O
[]

Being O
65 O
and O
older O
decreased O
the O
chances O
of O
screening B-outcome ['Resource-use']
( O
OR=0.39 O
; O
CI O
: O
0.37-0.42 O
) O
, O
as O
well O
as O
living O
in O
high-size B-outcome ['Life-Impact']
households I-outcome ['Life-Impact']
( O
OR=0.73 O
; O
CI O
: O
0.68-0.78 O
) O
. O
['Resource-use', 'Life-Impact']

No O
change O
was O
evident O
in O
group O
2 O
. O
[]

Significant O
proportions O
of O
the O
variance O
in O
responsibility B-outcome ['Life-Impact']
, O
struggle B-outcome ['Life-Impact']
, O
and O
cooperation B-outcome ['Life-Impact']
, O
however O
, O
were O
not O
accounted O
for O
by O
therapist O
process O
alone O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

A O
significant O
reduction O
of O
61 O
% O
was O
seen O
within O
the O
first O
year O
( O
p O
= O
0.001 O
) O
. O
[]

Analyses O
were O
conducted O
on O
a O
final O
sample O
of O
67 O
children O
( O
lost O
to O
follow-up O
= O
8 O
) O
. O
[]

A O
randomized O
controlled O
design O
was O
employed O
to O
evaluate O
a O
social O
skills O
intervention O
for O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

Therefore O
, O
the O
aim O
of O
this O
study O
is O
to O
determine O
if O
the O
single O
injection O
SWI O
technique O
is O
no O
less O
effective O
than O
the O
routinely O
used O
four O
injection O
SWI O
method O
in O
reducing O
continuous O
lower O
back O
pain O
during O
labour O
. O
[]

Visual O
field O
progression O
was O
analyzed O
using O
repeated O
measures O
models O
. O
[]

BACKGROUND O
Mizolastine O
is O
a O
novel O
histamine O
H1-antagonist O
registered O
in O
Europe O
for O
the O
management O
of O
allergic O
rhinitis O
and O
urticaria O
. O
[]

The O
total O
transit B-outcome ['Life-Impact']
time O
decreased O
by O
45.4 O
+/- O
38.4 O
hours O
in O
the O
cocoa O
husk O
group O
and O
by O
8.7 O
+/- O
28.9 O
hours O
in O
the O
placebo O
group O
( O
-38.1 O
hours O
) O
. O
['Life-Impact']

Based O
on O
the O
results O
of O
combined O
data O
from O
three O
North O
American O
Phase O
II O
studies O
, O
a O
randomised O
Phase O
II O
study O
in O
the O
same O
patient O
population O
was O
performed O
, O
using O
combination O
chemotherapy O
with O
estramustine O
phosphate O
( O
EMP O
) O
and O
vinblastine O
( O
VBL O
) O
in O
hormone O
refractory O
prostate O
cancer O
patients O
. O
[]

SPACE O
study O
results O
] O
. O
[]

RESULTS O
The O
addition O
of O
FSC O
to O
TIO O
significantly O
improved O
lung O
function O
indices O
including O
AM O
pre-dose O
FEV O
( O
1 O
) O
, O
2 O
h O
post-dose O
FEV O
( O
1 O
) O
, O
AM O
pre-dose O
FVC O
, O
2 O
h O
post-dose O
FVC O
and O
AM O
pre-dose O
IC O
compared O
with O
TIO O
alone O
. O
[]

All O
cats O
were O
treated O
for O
6 O
weeks O
. O
[]

This O
study O
was O
therefore O
designed O
to O
compare O
the O
effectiveness O
of O
0.4 O
% O
Dexamethasone O
sodium O
phosphate O
( O
DEX-P O
) O
phonophoresis O
( O
PH O
) O
with O
0.4 O
% O
DEX-P O
iontophoresis O
( O
ION O
) O
therapy O
in O
the O
management O
of O
patients O
with O
knee O
joint O
OA O
. O
[]

OBJECTIVE O
To O
observe O
the O
therapeutic O
effect O
of O
shengxuening O
( O
SXN O
) O
in O
treating O
iron-deficiency O
anemia O
( O
IDA O
) O
and O
to O
explore O
its O
molecular O
mechanism O
on O
iron O
metabolism O
balance O
regulation O
. O
[]

The O
patient O
proportion O
who O
did O
not O
require O
additional O
bolus O
injections O
to O
start O
PCI O
was O
significantly O
higher O
in O
argatroban O
than O
in O
UFH O
( O
p O
? O
[]

Psychometric O
tests O
, O
including O
choice O
reaction O
time O
( O
CRT O
) O
and O
number O
connection O
test O
, O
were O
performed O
before O
and O
after O
glutamine O
, O
together O
with O
electroencephalography O
and O
blood O
ammonia O
. O
[]

CONCLUSIONS O
Antidepressant O
and O
antianxiety O
treatment O
is O
of O
benefit O
to O
the O
antihypertensive O
therapy O
in O
senile O
hypertensive O
patients O
with O
complications O
of O
depression O
and/or O
anxiety O
neurosis O
. O
[]

The O
effect O
of O
metronidazole O
on O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
elective O
colon O
surgery O
. O
['Physiological-Clinical']

From O
May O
1978 O
until O
November O
1980 O
, O
169 O
previously O
untreated O
patients O
with O
advanced O
epithelial O
ovarian O
cancer O
were O
entered O
into O
a O
prospective O
randomized O
clinical O
trial O
comparing O
the O
combination O
of O
hexamethylmelamine O
, O
Adriamycin O
, O
and O
cyclophosphamide O
( O
HAC O
) O
to O
a O
combination O
of O
melphalan O
and O
cis-platinum O
. O
[]

The O
type O
of O
deep O
vein O
thrombosis O
prophylaxis O
in O
this O
group O
was O
based O
on O
surgeon O
preference O
. O
[]

All O
patients O
also O
received O
ranitidine O
( O
300 O
mg O
each O
night O
) O
for O
6 O
or O
10 O
weeks O
. O
[]

The O
success O
of O
bismuth O
is O
probably O
due O
to O
its O
local B-outcome ['Physiological-Clinical']
antimicrobial I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
evaluated O
the O
additional O
use O
of O
B-type B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

There O
were O
significant O
differences O
between O
the O
control O
group O
and O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
groups O
( O
p O
< O
0.05 O
) O
. O
[]

Bisphosphonate O
infusions O
: O
patient B-outcome ['Life-Impact']
preference I-outcome ['Life-Impact']
, O
safety O
and O
clinic B-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

Computerized O
analysis O
of O
sleep O
recordings O
. O
[]

Actual O
or O
potential O
applications O
of O
this O
research O
include O
the O
design O
of O
interfaces O
in O
support O
of O
attention O
and O
interruption O
management O
in O
a O
wide O
range O
of O
event-driven O
environments O
. O
[]

Cost-effectiveness O
of O
clozapine O
compared O
with O
conventional O
antipsychotic O
medication O
for O
patients O
in O
state O
hospitals O
. O
[]

RESULTS O
After O
24 O
months O
, O
cortical O
thickness O
was O
increased O
compared O
with O
the O
controls O
( O
6.43 O
% O
, O
CI O
3.34 O
to O
9.61 O
% O
; O
p O
= O
0.0001 O
) O
and O
metacarpal O
index O
( O
MCI O
) O
( O
6.14 O
% O
, O
CI O
3.95 O
to O
8.38 O
% O
; O
p O
< O
0.0001 O
) O
, O
while O
the O
endosteal O
diameter O
decreased O
( O
-4.64 O
% O
, O
CI O
-7.15 O
to O
-2.05 O
; O
p O
< O
0.001 O
) O
. O
[]

Finally O
, O
we O
investigate O
whether O
there O
is O
a O
difference O
in O
compliance B-outcome ['Life-Impact']
between O
persons O
receiving O
supervised O
Nordic O
Walking O
and O
persons O
doing O
unsupervised O
Nordic O
Walking O
. O
['Life-Impact']

SETTING O
Rural O
Malawi O
. O
[]

Measures O
were O
taken O
on O
three O
occasions O
: O
pre-intervention O
, O
at O
4 O
weeks O
, O
and O
at O
3 O
month O
follow-up O
. O
[]

All O
patients O
who O
received O
TNF/IFN/M O
had O
significantly O
greater O
increases O
in O
systemic B-outcome ['Physiological-Clinical']
interleukin-6 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
than O
in O
patients O
with O
M O
alone O
( O
12,395 O
+/- O
10,374 O
pg/mL O
v O
79.4 O
+/- O
7.2 O
pg/mL O
, O
respectively O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Rates O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
three O
groups O
. O
['Physiological-Clinical']

Study O
2 O
assessed O
the O
efficacy O
of O
piroxicam O
20 O
mg O
or O
40 O
mg O
compared O
with O
aspirin O
648 O
mg O
and O
placebo O
. O
[]

A O
systems O
analysis O
of O
obstetric O
triage O
. O
[]

Group O
R O
received O
0.9 O
% O
saline O
10 O
ml O
and O
remifentanil O
1 O
microg/kg O
. O
[]

insulin O
. O
[]

Once O
a O
day O
lisinopril O
appeared O
to O
be O
a O
more O
effective O
antihypertensive O
regimen O
than O
twice O
a O
day O
captopril O
. O
[]

Further O
study O
is O
required O
to O
determine O
the O
optimal O
timing O
and O
dose O
duration O
to O
minimize O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
identify O
how O
relevant O
such O
a O
decrease O
in O
bleeding O
is O
in O
clinical O
practice O
. O
['Physiological-Clinical']

Thirty-seven O
surgical O
patients O
were O
evaluated O
for O
efficacy O
and O
46 O
patients O
were O
evaluated O
for O
toxicity O
. O
[]

RESULTS O
Aortic B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
was O
significantly O
different O
between O
protocols O
A O
and O
B O
( O
p O
= O
0.04 O
, O
p O
< O
0.0001 O
) O
and O
protocols O
B O
and O
C O
( O
p O
= O
0.02 O
, O
p O
< O
0.001 O
) O
in O
the O
first O
and O
second O
phases O
. O
['Physiological-Clinical']

Overall O
risk O
of O
cardiotoxicity B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
with O
doxorubicin O
than O
PLD O
( O
HR=3.16 O
; O
95 O
% O
CI O
1.58-6.31 O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

In O
32 O
patients O
with O
newly O
diagnosed O
untreated O
AML O
, O
we O
observed O
by O
immunohistochemical O
analysis O
of O
bone O
marrow O
biopsies O
significantly O
higher O
levels O
of O
VEGF O
and O
VEGFR-2 O
expression O
than O
in O
10 O
control O
patients O
( O
P O
< O
0.001 O
) O
. O
[]

The O
baseline O
and O
procedural O
characteristics O
were O
comparable O
in O
both O
groups O
. O
[]

Arsenic O
( O
As O
) O
testing O
could O
help O
22 O
million O
people O
, O
using O
drinking O
water O
sources O
that O
exceed O
the O
Bangladesh O
As O
standard O
, O
to O
identify O
safe O
sources O
. O
[]

Value O
of O
an O
anal O
dilator O
after O
anal O
stretch O
for O
haemorrhoids B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nitrogen O
dioxide O
( O
NO2 O
) O
is O
a O
common O
indoor O
air O
pollutant O
, O
especially O
in O
homes O
with O
unvented O
combustion O
appliances O
. O
[]

ET-1 B-outcome ['Physiological-Clinical']
flux I-outcome ['Physiological-Clinical']
across O
the O
leg O
was O
not O
augmented O
by O
insulin O
alone O
but O
was O
increased O
with O
the O
addition O
of O
BQ-123 O
to O
insulin O
( O
P O
= O
0.01 O
BQ-123 O
effect O
, O
P O
= O
not O
significant O
comparing O
groups O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Cancer O
patients O
prefer O
shorter O
bisphosphonate B-outcome ['Resource-use']
infusions-and O
at O
home O
, O
where O
practical O
. O
['Resource-use']

In O
this O
prospective O
trial O
, O
a O
total O
of O
74 O
children O
who O
were O
scheduled O
to O
undergo O
high-dose O
chemotherapy O
followed O
by O
autologous O
peripheral O
blood O
stem O
cell O
transplantation O
( O
PBSCT O
) O
were O
prospectively O
randomized O
at O
diagnosis O
to O
evaluate O
the O
effectiveness O
of O
exogenous O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
treatment O
in O
accelerating O
hematopoietic B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
after O
PBSCT O
. O
['Physiological-Clinical']

Evaluation O
of O
the O
approach O
includes O
specific O
intervention O
targets O
and O
functional B-outcome ['Life-Impact']
spoken I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
outcomes I-outcome ['Life-Impact']
( O
Tager-Flusberg O
et O
al. O
, O
J O
Speech O
Lang O
Hear O
Res O
52:643-652 O
, O
2009 O
) O
. O
['Life-Impact']

PARTICIPANTS O
270 O
adults O
with O
arm O
pain O
due O
to O
repetitive O
use O
that O
had O
lasted O
at O
least O
three O
months O
despite O
treatment O
and O
who O
scored O
> O
or O
=3 O
on O
a O
10 O
point O
pain O
scale O
. O
[]

Exploring O
the O
social B-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
of O
being O
a O
typical O
peer O
model O
for O
included O
children O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
This O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo O
controlled O
study O
. O
[]

Although O
root O
instrumentation O
has O
been O
accepted O
as O
the O
most O
important O
cause-related O
treatment O
of O
periodontal O
diseases O
, O
repeated O
scaling O
and O
root O
planing O
may O
over O
time O
result O
in O
substantive O
loss O
of O
tooth O
substance O
and O
increased O
sensitivity O
of O
the O
teeth O
. O
[]

From O
our O
study O
we O
believe O
that O
acupuncture O
can O
be O
used O
as O
one O
of O
the O
many O
treatments O
for O
patients O
with O
cancer O
. O
[]

The O
results O
reveal O
differential O
responding O
across O
ESM B-outcome ['Physiological-Clinical']
, O
with O
some O
variation O
related O
to O
the O
engagement O
metric O
employed O
. O
['Physiological-Clinical']

Both O
treatments O
were O
well O
tolerated O
. O
[]

A O
longitudinal O
epidemiological O
study O
suggests O
that O
statins O
may O
prevent O
development O
of O
SBI B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Prospective O
evaluation O
of O
the O
macrolide O
antibiotic O
dirithromycin O
for O
the O
treatment O
of O
Helicobacter O
pylori O
. O
[]

RESULTS O
The O
mixed-model O
analysis O
of O
variance O
for O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
among O
women O
with O
breast O
cancer O
revealed O
women O
's O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
scores O
decreased O
over O
time O
in O
all O
groups O
. O
['Life-Impact', 'Life-Impact']

Results O
were O
established O
on O
the O
basis O
of O
targeted O
questions O
asked O
prior O
to O
and O
after O
the O
learning O
phase O
, O
followed O
by O
an O
analysis O
of O
frequencies O
and O
significance O
testing O
by O
the O
Chi O
squared O
method O
. O
[]

Intradermal O
injection O
of O
the O
C16:0 O
and O
C18:0 O
PAF O
homologues O
induced O
dose-dependent O
increases O
in O
weal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
flare B-outcome ['Physiological-Clinical']
area O
responses B-outcome ['Physiological-Clinical']
which O
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eligible O
patients O
were O
children O
and O
adolescents O
with O
HFA O
. O
[]

Hypothermia B-outcome ['Physiological-Clinical']
did O
not O
delay O
emergence O
from O
anesthesia B-outcome ['Resource-use']
( O
20 O
+/- O
15 O
min O
) O
compared O
with O
normothermia O
( O
15 O
+/- O
15 O
min O
, O
P O
= O
.45 O
) O
. O
['Physiological-Clinical', 'Resource-use']

Results O
indicated O
markedly O
better O
outcomes O
for O
the O
CBT O
group O
. O
[]

Melatonin O
treatment O
was O
mainly O
effective O
in O
reducing O
insomnia B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
while O
cognitive-behavioural O
therapy O
had O
a O
light O
positive O
impact O
mainly O
on O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
, O
suggesting O
that O
some O
behavioural O
aspects O
might O
play O
a O
role O
in O
determining O
initial B-outcome ['Physiological-Clinical']
insomnia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
and O
secondary O
outcome O
results O
were O
similar O
in O
the O
two O
aspirin O
strata O
. O
[]

The O
primary O
outcome O
was O
a O
composite O
of O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
at O
30 O
days O
. O
['Mortality', 'Physiological-Clinical']

OBJECTIVE O
To O
study O
protective O
effect O
of O
Epimedium O
brevicornum O
( O
EB O
) O
on O
hypothalamus-pituitary-adrenal-thymus O
( O
HPAT O
) O
axis O
inhibited O
by O
exogenous O
glucocorticoid O
. O
[]

RESULTS O
Groups O
were O
comparable O
at O
the O
start O
of O
the O
trial O
. O
[]

RESULTS O
A O
total O
of O
170 O
participants O
( O
n O
= O
86 O
perindopril O
, O
n O
= O
84 O
placebo O
) O
were O
randomized O
. O
[]

[ O
Effect O
of O
acupuncture O
on O
T-lymphocyte B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
its I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
from O
the O
peripheral O
blood O
of O
patients O
with O
malignant O
neoplasm O
] O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
different O
intensities O
and O
durations O
of O
GWU O
on O
1RM O
performance O
. O
[]

Both O
regimens O
were O
well O
tolerated O
. O
[]

The O
strength O
of O
treatment O
courses O
received O
prior O
to O
randomization O
was O
classified O
using O
a O
validated O
method O
. O
[]

Patients O
have O
intrinsic O
differences O
in O
sensitivity O
to O
sorafenib O
's O
BP-elevating O
effects O
. O
[]

Ease B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
, O
quality O
of O
airway B-outcome ['Physiological-Clinical']
seal I-outcome ['Physiological-Clinical']
, O
fibre-optic B-outcome ['Life-Impact']
view I-outcome ['Life-Impact']
and O
postoperative B-outcome ['Physiological-Clinical']
pharyngeal I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
were O
examined O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Patient-reported O
outcomes O
( O
PRO O
) O
reflect O
the O
functional O
outcomes O
of O
inguinal O
herniorrhaphy O
. O
[]

Baseline O
factors O
were O
balanced O
between O
the O
arms O
. O
[]

CONCLUSIONS O
Weight O
gain O
was O
more O
pronounced O
in O
AN O
subjects O
and O
more O
likely O
to O
occur O
in O
younger O
subjects O
with O
a O
higher O
baseline O
weight O
z-score O
. O
[]

Sixty-seven O
subjects O
completed O
the O
study O
. O
[]

We O
conducted O
this O
study O
to O
compare O
surgical O
resection O
alone O
versus O
radiochemotherapy O
without O
resection O
for O
locally O
invasive O
pancreatic O
cancer O
using O
a O
multicenter O
randomized O
design O
. O
[]

Children O
who O
substituted O
active O
for O
sedentary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
had O
significantly O
greater O
z-BMI B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
at O
6 O
( O
-1.21 O
vs. O
-0.76 O
) O
and O
12 O
( O
-1.05 O
vs. O
-0.51 O
) O
months O
, O
respectively O
. O
['Life-Impact', 'Physiological-Clinical']

No O
infant O
had O
hemoglobin B-outcome ['Physiological-Clinical']
less O
than O
100 O
g/L O
. O
['Physiological-Clinical']

Maximal B-outcome ['Physiological-Clinical']
aerobic I-outcome ['Physiological-Clinical']
power O
( O
VO2max O
) O
, O
with O
simultaneous B-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
SV O
) O
and O
cardiac B-outcome ['Physiological-Clinical']
output B-outcome ['Physiological-Clinical']
( O
CO B-outcome ['Physiological-Clinical']
) O
, O
by O
impedance B-outcome ['Physiological-Clinical']
cardiography B-outcome ['Physiological-Clinical']
, O
was O
assessed O
pre- O
and O
post-training O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
crossover O
study O
was O
conducted O
of O
two O
gastric O
prokinetic O
drugs O
in O
23 O
patients O
with O
gastroesophageal O
reflux O
. O
[]

Participants O
were O
randomized O
to O
either O
immediate O
or O
delayed O
access O
to O
the O
online O
DA O
which O
( O
i O
) O
explained O
the O
benefits O
and O
harms O
, O
( O
ii O
) O
included O
a O
values O
clarification O
exercise O
and O
a O
worksheet O
to O
support O
decision O
making O
. O
[]

Design O
, O
implementation O
and O
results O
of O
the O
quality O
control O
program O
for O
the O
Australian O
government O
's O
point O
of O
care O
testing O
in O
general O
practice O
trial O
. O
[]

However O
, O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
levels O
bear O
little O
relationship O
to O
physiologic O
and O
clinical O
variables O
observed O
in O
HF O
, O
including O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
and O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

All O
patients O
received O
standardized O
premedication O
, O
intraoperative O
monitoring O
and O
oxygen O
therapy O
. O
[]

PCA O
was O
administered O
for O
each O
patient O
. O
[]

BACKGROUND O
Recent O
evidence O
shows O
that O
subjects O
diagnosed O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
have O
significantly O
lower O
levels O
of O
glutathione O
than O
typically O
developing O
children O
. O
[]

Evaluation O
in O
heifers O
. O
[]

The O
target B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
phosphorous I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
P O
) O
=5.5 O
mg/dL O
and O
the O
corrected B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
concentration O
( O
Ca B-outcome ['Physiological-Clinical']
) O
was O
9.0-10.0 O
mg/dL O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
LifeMasters O
Supported O
SelfCare O
demonstration O
program O
provides O
disease O
management O
( O
DM O
) O
services O
to O
Florida O
Medicare O
beneficiaries O
who O
are O
also O
enrolled O
in O
Medicaid O
and O
have O
congestive O
heart O
failure O
( O
CHF O
) O
, O
diabetes O
, O
or O
coronary O
artery O
disease O
( O
CAD O
) O
. O
[]

Bacteremia O
caused O
by O
Bacteroides O
fragilis O
occurred O
in O
four O
of O
75 O
children O
after O
renal O
transplantation O
, O
and O
B. O
fragilis O
was O
the O
most O
common O
cause O
of O
postoperative O
bacteremia O
. O
[]

Each O
patient O
also O
received O
ibuprofen O
; O
acetaminophen O
with O
codeine O
( O
30 O
mg O
) O
; O
and O
a O
7-day O
diary O
to O
record O
pain B-outcome ['Physiological-Clinical']
, O
percussion B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
number O
and O
type O
of O
pain B-outcome ['Physiological-Clinical']
medication B-outcome ['Resource-use']
taken B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

Safety O
evaluation O
data O
included O
recording O
device B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
procedure B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
intracranial B-outcome ['Physiological-Clinical']
events/overall I-outcome ['Physiological-Clinical']
neurologic I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
, O
which O
could O
be O
either O
device-related O
, O
procedure-related O
, O
or O
both O
. O
['Adverse-effects', 'Adverse-effects', 'Physiological-Clinical']

[ O
The O
effect O
of O
indobufen O
on O
aortocoronary O
bypass O
patency O
after O
1 O
week O
and O
after O
1 O
year O
] O
. O
[]

BACKGROUND O
Following O
the O
dose-escalation O
stage O
, O
this O
double-blind O
expansion O
stage O
of O
the O
phase O
I O
study O
evaluated O
the O
safety O
, O
pharmacodynamics O
, O
pharmacokinetics O
, O
anti-vascular O
effects O
and O
antitumour O
activity O
of O
aflibercept O
4 O
mg/kg O
with O
irinotecan O
, O
5-fluorouracil O
and O
leucovorin O
( O
LV5FU2 O
) O
. O
[]

RESULTS O
Of O
36 O
patients O
in O
the O
control O
group O
, O
14 O
with O
positive O
urine B-outcome ['Physiological-Clinical']
cytology I-outcome ['Physiological-Clinical']
had O
more O
frequent O
recurrence B-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
22 O
patients O
with O
negative O
cytology O
( O
P O
= O
0.004 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adoptive O
immunotherapy O
is O
thought O
to O
be O
an O
effective O
method O
to O
lower O
recurrence O
and O
metastasis O
rates O
of O
malignant O
tumors O
. O
[]

This O
study O
sought O
to O
determine O
whether O
early O
treatment O
with O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitors O
in O
patients O
with O
acute O
myocardial O
infarction O
( O
AMI O
) O
is O
useful O
for O
the O
improvement O
of O
fibrinolytic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

5.1 O
kg O
, O
and O
V?O2max O
= O
64.8 O
? O
[]

RESULTS O
Analyses O
of O
self-reported O
daily O
activity O
levels O
revealed O
a O
diffusion O
of O
treatment O
effect O
. O
[]

Patients O
following O
an O
sVLPD O
started O
dialysis O
therapy O
in O
the O
case O
of O
malnutrition O
, O
intractable O
fluid O
overload O
, O
hyperkalemia O
, O
or O
appearance O
of O
uremic O
symptoms O
. O
[]

PARTICIPANTS O
N/A O
. O
[]

bradykinin O
in O
21 O
salt-replete O
normal-to-high O
renin O
hypertensive O
patients O
. O
[]

Primary O
endpoint O
was O
the O
ADHD O
Rating O
Scale O
( O
ADHD-RS O
) O
. O
[]

Each O
toothbrush O
was O
found O
to O
be O
safe O
and O
significantly O
reduced O
plaque B-outcome ['Physiological-Clinical']
levels O
after O
a O
single O
brushing O
. O
['Physiological-Clinical']

Patient B-outcome ['Life-Impact']
demographics I-outcome ['Life-Impact']
, O
stratification O
, O
and O
prognostic O
factors O
were O
well O
balanced O
between O
treatments O
. O
['Life-Impact']

Here O
, O
we O
investigated O
the O
relationship O
between O
gaze B-outcome ['Life-Impact']
onto I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
eye I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
mouth I-outcome ['Life-Impact']
regions I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
faces I-outcome ['Life-Impact']
, O
and O
the O
visual O
information O
that O
was O
present O
within O
those O
regions O
. O
['Life-Impact']

The O
patients O
were O
randomized O
into O
2 O
homogeneous O
groups O
of O
15 O
and O
treated O
for O
12 O
weeks O
with O
L-5-HTP O
( O
100 O
mg/day O
) O
and O
placebo O
as O
per O
the O
following O
design O
: O
placebo O
- O
L-5-HTP O
( O
group O
A O
) O
and O
L-5-HTP O
- O
placebo O
( O
group O
B O
) O
. O
[]

An O
increasing O
body O
of O
literature O
has O
indicated O
that O
social O
stories O
are O
an O
effective O
way O
to O
teach O
individuals O
diagnosed O
with O
autism O
appropriate O
social O
behavior O
. O
[]

OBJECTIVE O
The O
authors O
rated O
periventricular O
and O
subcortical O
signal O
hyperintensities O
on O
magnetic O
resonance O
imaging O
( O
MRI O
) O
scans O
in O
elderly O
patients O
with O
depression O
and O
in O
normal O
subjects O
with O
similar O
demographic O
features O
to O
examine O
whether O
such O
changes O
discriminate O
patients O
with O
depression O
from O
normal O
subjects O
and O
whether O
they O
are O
associated O
with O
any O
clinical O
variables O
. O
[]

Determinants O
of O
the O
effect O
of O
estrogen O
on O
the O
progression O
of O
subclinical B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
: O
Estrogen O
in O
the O
Prevention O
of O
Atherosclerosis O
Trial O
. O
['Physiological-Clinical']

More O
patients O
in O
the O
conventional O
group O
complained O
of O
persistent B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
bleeding B-outcome ['Physiological-Clinical']
and O
discharge B-outcome ['Physiological-Clinical']
at O
2 O
week O
and O
6 O
week O
review O
with O
20 O
% O
requiring O
readmission O
compared O
with O
none O
in O
the O
stapled O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
are O
consistent O
with O
EI O
theory O
, O
showing O
that O
craving B-outcome ['Life-Impact']
is O
reduced O
by O
loading O
the O
visuospatial O
sketchpad O
of O
working O
memory O
but O
not O
by O
loading O
the O
phonological O
loop O
. O
['Life-Impact']

Ambulatory B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP I-outcome ['Physiological-Clinical']
after O
3 O
months O
of O
aspirin O
treatment O
were O
similar O
to O
baseline O
: O
deltaSBP O
-0.5 O
mmHg O
( O
95 O
% O
confidence O
intervals O
[ O
CI O
] O
from O
-1.9 O
to O
+2.9 O
mm O
Hg O
) O
and O
deltaDBP O
-1.1 O
mm O
Hg O
( O
95 O
% O
CI O
from O
-2.5 O
to O
+0.3 O
mm O
Hg O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Due O
to O
easy O
handling O
of O
the O
nasal-spray O
a O
good O
compliance B-outcome ['Life-Impact']
was O
confirmed O
. O
['Life-Impact']

These O
findings O
underline O
the O
need O
to O
take O
altered O
central O
pain O
processing O
into O
account O
when O
managing O
the O
pain O
of O
chronic O
pancreatitis O
. O
[]

A O
total O
of O
1367 O
patients O
participated O
in O
the O
study O
; O
mean O
age O
was O
52.5 O
years O
, O
40.8 O
% O
were O
male O
, O
76.5 O
% O
were O
black O
, O
50.8 O
% O
graduated O
from O
high O
school O
, O
26 O
% O
were O
married O
, O
and O
54.1 O
% O
had O
income O
< O
$ O
5,000 O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
surface O
preparation O
on O
the O
local O
uptake B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ALA I-outcome ['Life-Impact']
by O
recording O
fluorescence O
from O
accumulated O
protoporphyrin O
IX O
( O
PPIX O
) O
. O
['Life-Impact']

Effect O
of O
topical O
rh-TGF-beta O
1 O
on O
second B-outcome ['Physiological-Clinical']
intention I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
in O
horses O
. O
['Physiological-Clinical']

Endpoint O
analysis O
revealed O
no O
significant O
differences O
across O
treatment O
groups O
on O
a O
modified O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
scale O
( O
validated O
in O
irritable B-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
studies O
) O
, O
number B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
daily I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
, O
days B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
, O
or O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
problem I-outcome ['Physiological-Clinical']
behaviors I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Supplementation O
with O
iron O
and O
riboflavin O
enhances O
dark O
adaptation O
response O
to O
vitamin O
A-fortified O
rice O
in O
iron-deficient O
, O
pregnant O
, O
nightblind O
Nepali O
women O
. O
[]

Acute O
cardiac O
effects O
of O
nicotine O
in O
healthy O
young O
adults O
. O
[]

Fasting O
levels O
of O
intact O
neurotensin O
were O
unchanged O
by O
surgery O
, O
whereas O
levels O
of O
NH2-terminal B-outcome ['Physiological-Clinical']
immunoreactivity I-outcome ['Physiological-Clinical']
were O
higher O
in O
bypass O
patients O
with O
a O
long O
ileal O
segment O
( O
37.5 O
cm O
) O
than O
in O
unoperated O
patients O
and O
in O
those O
with O
a O
short O
ileal O
segment O
( O
12.5 O
cm O
) O
. O
['Physiological-Clinical']

These O
values O
were O
reversed O
when O
compared O
with O
Groups O
1 O
and O
2 O
when O
sodium O
ascorbate O
was O
used O
. O
[]

DISCUSSION O
The O
proposed O
post-discharge O
network O
coordination O
program O
intervenes O
during O
the O
critical O
post-discharge O
period O
. O
[]

In O
all O
, O
92 O
patients O
were O
randomised O
into O
a O
Phase O
II O
study O
of O
oral O
EMP O
( O
10 O
mg O
kg O
day O
continuously O
) O
or O
oral O
EMP O
in O
combination O
with O
intravenous O
VBL O
( O
4 O
mg O
m O
( O
2 O
) O
week O
for O
6 O
weeks O
, O
followed O
by O
2 O
weeks O
rest O
) O
. O
[]

CONTEXT O
The O
opioid O
system O
is O
involved O
in O
blood O
pressure O
regulation O
in O
both O
normal O
humans O
and O
patients O
with O
essential O
hypertension O
. O
[]

OBJECTIVE O
To O
observe O
the O
effect O
of O
ischemia O
postconditioning O
during O
the O
first O
minutes O
of O
reperfusion O
for O
the O
myocardial O
reperfusion O
injury O
in O
ST-segment O
elevation O
acute O
myocardial O
infarction O
( O
STEMI O
) O
patients O
undergoing O
emergency O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

RESULTS O
Of O
the O
160 O
subjects O
in O
whom O
efficacy O
could O
be O
evaluated O
, O
the O
OC O
group O
showed O
a O
statistically O
significantly O
greater O
improvement O
than O
the O
placebo O
group O
for O
all O
primary O
efficacy O
measures O
. O
[]

Deceased-donor O
kidney O
transplant O
patients O
at O
protocol-specified O
risk O
of O
DGF O
were O
randomized O
to O
start O
everolimus O
on O
day O
1 O
( O
immediate O
everolimus O
, O
IE O
; O
n O
= O
65 O
) O
or O
week O
5 O
( O
delayed O
everolimus O
, O
DE O
; O
n O
= O
74 O
) O
. O
[]

All O
patients O
were O
treated O
with O
a O
standardized O
regimen O
. O
[]

PURPOSE O
Deep O
vein O
thrombosis O
( O
DVT O
) O
is O
a O
preventable O
cause O
of O
morbidity O
and O
mortality O
in O
patients O
who O
are O
hospitalized O
. O
[]

Six O
healthy O
male O
volunteers O
were O
evaluated O
, O
each O
on O
three O
separate O
days O
in O
random O
order O
. O
[]

RESULTS O
Both O
therapeutics O
regimens O
reduced O
significantly O
the O
levels O
of O
the O
SAM O
tested O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
Yufeining O
, O
a O
traditional O
Chinese O
medicine O
, O
on O
induced B-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
interleukin-8 I-outcome ['Physiological-Clinical']
( O
IL-8 B-outcome ['Physiological-Clinical']
) O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
at O
the O
stable O
phase O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
evaluate O
this O
possibility O
we O
adapted O
an O
infusion O
test O
of O
somatostatin O
in O
10 O
normal O
persons O
( O
age O
26 O
+/- O
3 O
years O
, O
relative O
body O
weight O
26 O
+/- O
10 O
% O
according O
to O
Broca O
) O
in O
a O
randomized O
cross-over O
therapy O
with O
bezafibrate O
( O
3 O
X O
200 O
mg/die O
) O
. O
[]

Pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
immediately O
and O
24 O
h O
after O
each O
intervention O
was O
assessed O
by O
a O
five-point O
scale O
. O
['Physiological-Clinical']

In O
the O
screening O
practices O
, O
high-risk O
individuals O
were O
invited O
to O
take O
part O
in O
a O
stepwise O
screening O
programme O
. O
[]

CONCLUSION O
The O
eradication O
of O
H. O
pylori O
in O
patients O
with O
DU O
reduces O
the O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DU I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intervention O
in O
the O
TDM O
group O
involved O
patient O
follow-up O
by O
a O
clinical O
pharmacist O
to O
obtain O
and O
pharmacokinetically O
interpret O
serum O
vancomycin O
concentrations O
for O
dosage O
individualization O
. O
[]

BACKGROUND O
Tobacco O
use O
adversely O
affects O
oral O
health O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
survival B-outcome ['Mortality']
whether O
treatment O
was O
administered O
to O
the O
prostate O
or O
prostate O
and O
pelvic O
lymph O
nodes O
. O
['Mortality']

Rapid O
dissolution O
in O
the O
intestinal O
fluids O
accounts O
for O
the O
high O
digoxin B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
the O
tablets O
. O
['Physiological-Clinical']

Jessner O
's O
solution O
peel O
vs. O
the O
topical O
mixture O
of O
hydroquinone O
2 O
% O
and O
kojic O
acid O
. O
[]

Massively O
elevated O
levels O
of O
beta-endorphin B-outcome ['Physiological-Clinical']
were O
observed O
in O
all O
children O
with O
assays O
using O
C-terminal O
antibody O
but O
not O
with O
an O
N-terminal O
antibody O
assay O
. O
['Physiological-Clinical']

Iron O
sulphate O
100 O
mg O
was O
prescribed O
orally O
twice O
a O
day O
. O
[]

Patients O
then O
were O
taken O
immediately O
to O
the O
catheterization O
laboratory O
, O
and O
those O
with O
suitable O
coronary O
anatomy O
underwent O
immediate O
PTCA O
. O
[]

The O
washout O
period O
between O
Parts O
A O
and O
B O
was O
2 O
weeks O
. O
[]

151 O
patients O
with O
locally O
advanced O
prostatic O
cancer O
( O
T3-4 O
M0 O
) O
, O
representing O
38 O
% O
of O
the O
404 O
cancer O
patients O
in O
a O
Finnish O
multicenter O
study O
, O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
arms O
: O
orchiectomy O
, O
estrogens O
or O
radiotherapy O
. O
[]

UNLABELLED O
Cod-liver O
oil O
and O
other O
marine O
products O
containing O
polyunsaturated O
fatty O
acids O
have O
anti-inflammatory O
, O
anti-bacterial O
and O
anti-viral O
effects O
and O
may O
be O
useful O
in O
the O
treatment O
of O
various O
inflammatory O
and O
infectious O
diseases O
. O
[]

50 O
patients O
in O
treatment O
group O
were O
treated O
with O
DST O
and O
western O
medicine O
and O
40 O
patients O
in O
control O
group O
were O
treated O
only O
with O
western O
medicine O
. O
[]

Interictal O
EEG O
showed O
short O
sequences O
of O
irregular B-outcome ['Physiological-Clinical']
3-Hz I-outcome ['Physiological-Clinical']
spike-waves I-outcome ['Physiological-Clinical']
. O
( O
['Physiological-Clinical']

At O
the O
beginning O
and O
the O
end O
of O
the O
experimentation O
period O
, O
glucose B-outcome ['Physiological-Clinical']
, O
HbA1c B-outcome ['Physiological-Clinical']
, O
triglyceride B-outcome ['Physiological-Clinical']
, O
cholesterol B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
thiamine B-outcome ['Physiological-Clinical']
pyrophosphate I-outcome ['Physiological-Clinical']
, O
pyridoxal B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
AGE- I-outcome ['Physiological-Clinical']
peptides I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
and O
controls O
had O
similar O
routine O
care O
during O
the O
study O
period O
and O
there O
were O
no O
study O
dropouts O
after O
treatment O
had O
started O
. O
[]

OBJECTIVE O
To O
define O
the O
relationship O
between O
skin B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
( O
as O
well O
as O
other O
cutaneous O
manifestations B-outcome ['Physiological-Clinical']
) O
and O
inhaled O
corticosteroid O
( O
ICS O
) O
therapy O
vs O
placebo O
in O
subjects O
with O
COPD O
who O
were O
participating O
in O
a O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mild O
to O
moderate O
adverse B-outcome ['Adverse-effects']
clinical I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
2 O
of O
103 O
maternal O
and O
2 O
of O
25 O
infant O
infusions O
. O
['Adverse-effects']

METHOD O
Hundred O
and O
twelve O
carers O
and O
68 O
adolescents O
with O
BN/EDNOS O
completed O
self-report O
measures O
( O
General O
Health O
Questionnaire O
, O
Experience O
of O
Caregiving O
Inventory O
, O
Level O
of O
Expressed O
Emotion O
, O
Self-report O
Family O
Inventory O
, O
Inventory O
of O
Interpersonal O
Problems O
) O
. O
[]

The O
sense O
of O
body O
ownership O
can O
be O
easily O
disrupted O
during O
illusions O
and O
the O
most O
common O
illusion O
is O
the O
rubber O
hand O
illusion O
. O
[]

There O
were O
no O
spill-over O
effects O
of O
the O
program O
to O
non-targeted O
students O
. O
[]

Perioperative O
myocardial O
infarctions O
are O
common O
and O
often O
unrecognized O
in O
patients O
undergoing O
hip O
fracture O
surgery O
. O
[]

The O
influence O
of O
prostaglandin O
inhibition O
by O
indomethacin O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
treated O
with O
cilazapril O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Clomipramine O
was O
superior O
to O
desipramine O
and O
placebo O
, O
as O
indicated O
by O
standardized O
ratings O
of O
autism B-outcome ['Life-Impact']
and O
anger B-outcome ['Life-Impact']
as O
well O
as O
ratings O
of O
repetitive B-outcome ['Life-Impact']
and O
compulsive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
distribution O
of O
HIF-1alpha B-outcome ['Physiological-Clinical']
genotypes I-outcome ['Physiological-Clinical']
in O
controls O
was O
89 O
C/C O
( O
89 O
% O
) O
, O
11 O
C/T O
( O
11 O
% O
) O
, O
and O
0 O
T/T O
( O
0 O
% O
) O
. O
['Physiological-Clinical']

Ongoing O
Telmisartan O
Alone O
and O
in O
Combination O
With O
Ramipril O
Global O
Endpoint O
Trial O
( O
ONTARGET O
) O
: O
implications O
for O
reduced O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical']

It O
is O
concluded O
that O
SQ29,852 O
is O
an O
effective O
antihypertensive O
drug O
without O
adverse B-outcome ['Adverse-effects']
effect O
on O
lipid O
metabolism O
. O
['Adverse-effects']

Four O
( O
7 O
% O
) O
patients O
taking O
placebo O
had O
serious B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
compared O
with O
one O
( O
< O
1 O
% O
) O
patient O
treated O
with O
eltrombopag O
. O
['Physiological-Clinical']

Clinical O
data O
comparing O
the O
renal O
effects O
of O
ACEIs O
and O
ARBs O
, O
either O
singly O
or O
in O
combination O
, O
are O
scarce O
and O
usually O
concern O
the O
use O
of O
standard O
or O
high O
doses O
. O
[]

In O
the O
two O
groups O
significant O
improvement O
of O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
ESR B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

10 O
min O
; O
number O
of O
walking O
breaks O
; O
and O
duration O
. O
[]

METHODS O
Fifty-five O
cases O
of O
patients O
with O
ocular O
burns O
( O
in O
88 O
eyes O
) O
were O
randomly O
divided O
into O
treatment O
and O
control O
groups O
. O
[]

Unreamed B-outcome ['Physiological-Clinical']
nails I-outcome ['Physiological-Clinical']
do O
not O
protect O
the O
patient O
from O
pulmonary O
embolization O
of O
marrow O
contents O
. O
['Physiological-Clinical']

Days O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
for I-outcome ['Resource-use']
CHF I-outcome ['Resource-use']
exacerbations I-outcome ['Resource-use']
in O
the O
6 O
month O
follow-up O
were O
significantly O
greater O
in O
the O
intervention O
group O
( O
IRR O
= O
2.34 O
95 O
% O
CI O
: O
1.80-3.05 O
P O
= O
0.000 O
) O
. O
['Resource-use']

The O
MCR O
and O
E/I O
ratio O
assess O
parasympathetic O
function O
. O
[]

The O
endometrium B-outcome ['Physiological-Clinical']
was O
atrophied O
in O
nearly O
all O
biopsies B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

HRs O
( O
three-class O
vs O
combined O
two-class O
) O
for O
AIDS B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
and O
virological B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
1.15 O
( O
0.91-1.45 O
) O
and O
0.87 O
( O
0.75-1.00 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

OBJECTIVE O
To O
find O
the O
optimal O
dose O
of O
a O
new O
hypoallergenic O
folding O
variant O
of O
recombinant O
Bet O
v O
1 O
( O
rBet O
v O
1-FV O
) O
as O
SIT O
for O
patients O
with O
birch O
pollen O
allergy O
. O
[]

The O
endpoint O
was O
the O
frequency O
of O
testing O
. O
[]

Twenty-four O
children O
diagnosed O
with O
autism O
from O
Kowloon O
, O
Hong O
Kong O
were O
assessed O
for O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
and O
spatial B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
abilities O
. O
['Life-Impact', 'Life-Impact']

There O
was O
evidence O
of O
variation O
in O
sensitivity B-outcome ['Physiological-Clinical']
between O
endoscopists O
, O
but O
significant O
miss O
rates O
for O
small O
adenomas O
were O
found O
among O
essentially O
all O
endoscopists O
. O
['Physiological-Clinical']

We O
report O
a O
12 O
month O
double-blind O
randomized O
crossover O
trial O
of O
fenfluramine O
in O
20 O
children O
with O
the O
syndrome O
of O
autism O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
oral O
treatment O
with O
amlodipine O
camsylate O
or O
amlodipine O
besylate O
. O
[]

In O
13 O
patients O
with O
stable O
angina O
pectoris O
, O
single-pass O
studies O
of O
left O
ventricular O
function O
with O
indium O
113 O
under O
double-blind O
, O
placebo-controlled O
conditions O
similarly O
showed O
acebutolol O
to O
have O
no O
clinically O
significant O
negative O
inotropic O
effects O
. O
[]

D-dimer O
predicts O
outcome O
after O
aneurysmal O
subarachnoid O
hemorrhage O
: O
no O
effect O
of O
thromboprophylaxis O
on O
coagulation B-outcome ['Physiological-Clinical']
activity O
. O
['Physiological-Clinical']

Use O
of O
recombinant O
human O
granulocyte O
colony-stimulating O
factor O
to O
increase O
chemotherapy O
dose-intensity O
: O
a O
randomized O
trial O
in O
very O
high-risk O
childhood O
acute O
lymphoblastic O
leukemia O
. O
[]

Ten O
regression O
algorithms O
were O
generated O
designed O
to O
estimate O
GAI O
. O
[]

RESULTS O
In O
one O
patient O
, O
nasal B-outcome ['Physiological-Clinical']
insertion I-outcome ['Physiological-Clinical']
failed O
, O
and O
she O
was O
excluded O
from O
further O
analysis O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
cognitive-behavioral O
therapy O
( O
CBT O
) O
and O
standard O
medical O
care O
( O
SMC O
) O
as O
treatments O
for O
psychogenic O
nonepileptic O
seizures O
( O
PNES O
) O
. O
[]

OBJECTIVE O
Describe O
efficacy O
of O
psychosocial O
therapy O
on O
two-year O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
sudden O
cardiac O
arrest O
survivors O
. O
['Mortality']

There O
was O
no O
difference O
between O
the O
two O
groups O
in O
the O
quantity O
of O
milk B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
but O
the O
amounts O
taken O
lessened O
between O
6 O
and O
18 O
months O
of O
age O
. O
['Life-Impact']

BACKGROUND O
The O
primary O
aim O
and O
central O
hypothesis O
of O
the O
study O
are O
that O
a O
designated O
syncope O
unit O
in O
the O
emergency O
department O
improves O
diagnostic O
yield O
and O
reduces O
hospital O
admission O
for O
patients O
with O
syncope O
who O
are O
at O
intermediate O
risk O
for O
an O
adverse O
cardiovascular O
outcome O
. O
[]

The O
size O
of O
the O
polyps O
that O
recurred O
was O
estimated O
at O
different O
time-intervals O
by O
the O
examining O
doctor O
. O
[]

This O
is O
a O
randomized O
controlled O
trial O
that O
aimed O
to O
evaluate O
the O
effect O
of O
the O
Seven-star O
Needle O
Stimulation O
treatment O
on O
children O
with O
Autistic O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

BACKGROUND O
The O
VIOS O
( O
Vascular O
Improvement O
with O
Olmesartan O
medoxomil O
Study O
) O
study O
is O
a O
randomized O
, O
parallel O
study O
to O
determine O
the O
relative O
effects O
of O
suppressing O
the O
renin-angiotensin O
system O
( O
RAS O
) O
with O
the O
angiotensin O
receptor O
antagonist O
olmesartan O
medoxomil O
versus O
suppressing O
sympathetic O
drive O
with O
the O
beta-adrenoceptor O
antagonist O
atenolol O
on O
remodeling O
of O
the O
subcutaneous O
small O
resistance O
vessel O
. O
[]

Spinal B-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
was O
investigated O
by O
distal O
latencies O
and O
M-amplitudes B-outcome ['Physiological-Clinical']
of O
the O
abductor O
digiti O
minimi O
muscle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
TEE O
, O
valve B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
was O
normal O
in O
all O
patients O
. O
['Physiological-Clinical']

Human O
sensitivity O
to O
first-order O
modulations O
is O
well O
described O
by O
a O
computational O
model O
involving O
spatially O
localized O
filters O
that O
are O
selective O
for O
orientation O
and O
spatial O
frequency O
( O
SF O
) O
. O
[]

Training O
of O
physicians O
, O
nurses O
and O
dietitians O
included O
preparation O
of O
operating O
manual O
and O
videos O
, O
interactive O
sessions O
, O
and O
evaluation O
of O
local O
facilities O
and O
resources O
. O
[]

Rationale O
and O
study O
design O
of O
the O
increase O
of O
vagal O
tone O
in O
heart O
failure O
study O
: O
INOVATE-HF O
. O
[]

The O
number O
of O
brain B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
as O
detected O
by O
MRI O
was O
recorded O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

Individuals O
in O
the O
intervention O
group O
received O
30 O
mL O
of O
MgCl2 O
5 O
% O
solution O
( O
equivalent O
to O
382 O
mg O
of O
magnesium O
) O
and O
individuals O
in O
the O
control O
group O
30 O
mL O
of O
placebo O
solution O
, O
once O
daily O
during O
4 O
months O
. O
[]

RESULTS O
The O
main O
differences O
were O
found O
at O
maximal B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
opening I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
analysed O
anthropometric O
and O
metabolic O
parameters O
in O
five O
groups O
of O
10 O
males O
: O
four O
receiving O
testosterone O
undecanoate O
( O
TU O
: O
1000 O
mg O
) O
plus O
norethisterone O
enanthate O
( O
NETE O
: O
200 O
mg O
) O
at O
different O
intervals O
( O
every O
8 O
weeks O
: O
NETE-8 O
; O
every O
12 O
weeks O
: O
NETE-12 O
; O
every O
6 O
weeks O
for O
12 O
weeks O
and O
then O
every O
12 O
weeks O
: O
NETE-6/12 O
; O
every O
6 O
weeks O
for O
12 O
weeks O
and O
then O
TU O
plus O
placebo O
every O
12 O
weeks O
: O
NETE-6/12/0 O
) O
and O
one O
placebo O
( O
NETE-0/0 O
) O
for O
a O
total O
of O
48 O
weeks O
. O
[]

induction O
doss O
were O
0.7 O
+/- O
0.1 O
mg.kg-1 O
( O
group O
E1 O
) O
, O
0.8 O
+/- O
0.1 O
mg.kg-1 O
( O
group O
E2 O
) O
and O
4.0 O
+/- O
0.0 O
mg.kg-1 O
( O
group O
T O
) O
. O
[]

This O
study O
examined O
the O
relatively O
unexplored O
contribution O
of O
the O
therapist O
's O
performance B-outcome ['Life-Impact']
in O
determining O
outcomes O
of O
treatment O
. O
['Life-Impact']

Patients O
were O
assessed O
at O
baseline O
, O
12 O
weeks O
, O
24 O
weeks O
, O
and O
48 O
weeks O
. O
[]

Incentives O
may O
undermine O
motivation B-outcome ['Life-Impact']
in O
studies O
in O
which O
the O
intrinsic O
motivation O
of O
the O
respondents O
is O
already O
high O
. O
['Life-Impact']

In O
the O
presplint O
group O
, O
teeth O
were O
splinted O
to O
at O
least O
two O
rigid O
teeth O
before O
surgery O
, O
in O
the O
postsplint O
group O
, O
teeth O
were O
splinted O
at O
suture O
removal O
, O
and O
in O
the O
nonsplint O
group O
, O
the O
treated O
teeth O
were O
not O
splinted O
at O
all O
. O
[]

Differences O
in O
tolerability O
between O
the O
2 O
treatment O
groups O
were O
not O
identified O
. O
[]

In O
both O
training O
groups O
training B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
set O
at O
86 O
% O
of O
individual O
maximum O
heart O
rate O
. O
['Physiological-Clinical']

HADS O
scores O
significantly O
improved O
during O
the O
course O
of O
treatment O
( O
P O
< O
.001 O
) O
. O
[]

Combination O
chemotherapy O
was O
more O
myelotoxic B-outcome ['Physiological-Clinical']
than O
MPH-P O
and O
, O
in O
particular O
, O
caused O
more O
non-haematological B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

When O
aerobic O
exercise O
preceded O
the O
vocational O
task O
, O
similar O
reductions O
were O
observed O
. O
[]

Also O
, O
parents O
of O
adolescent O
treatment O
responders O
experienced O
a O
decrease O
in O
their O
own O
trait O
anxiety O
. O
[]

Patients O
who O
met O
remission O
criteria O
at O
2 O
consecutive O
weekly O
visits O
during O
6 O
to O
12 O
weeks O
of O
open-label O
olanzapine O
treatment O
were O
randomly O
assigned O
to O
olanzapine O
or O
placebo O
treatment O
for O
48 O
weeks O
. O
[]

This O
finding O
supports O
the O
results O
of O
previous O
US O
and O
European O
studies O
, O
which O
have O
also O
shown O
that O
lanthanum O
carbonate O
treatment O
effectively O
controls O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
HDL-cholesterol B-outcome ['Physiological-Clinical']
, O
LDL-cholesterol B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
protein B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
the O
number O
of O
podocytes B-outcome ['Physiological-Clinical']
were O
measured O
before O
treatment O
and O
at O
3 O
and O
6 O
months O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Subjects O
in O
the O
CM O
( O
attendance O
) O
and O
in O
the O
CM O
( O
weight O
) O
group O
lost O
a O
mean O
of O
1.16 O
kg O
and O
1.23 O
kg O
, O
respectively O
, O
while O
subjects O
in O
the O
CON O
gained O
a O
mean O
of O
0.68 O
kg O
. O
[]

Action O
observation O
treatment O
improves O
recovery O
of O
postsurgical O
orthopedic O
patients O
: O
evidence O
for O
a O
top-down O
effect O
? O
[]

Levels O
of O
many B-outcome ['Physiological-Clinical']
vitamins I-outcome ['Physiological-Clinical']
, O
minerals B-outcome ['Physiological-Clinical']
, O
and O
biomarkers B-outcome ['Physiological-Clinical']
improved/increased O
showing O
good O
compliance B-outcome ['Life-Impact']
and O
absorption B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

In O
conclusion O
, O
buflomedil O
is O
as O
effective O
or O
more O
effective O
than O
dihydrogenated O
ergot O
alkaloids O
in O
the O
treatment O
of O
senile B-outcome ['Physiological-Clinical']
dementia I-outcome ['Physiological-Clinical']
associated O
with O
cerebrovascular O
insufficiency O
and O
could O
prove O
a O
valuable O
addition O
to O
long-term O
therapy O
if O
further O
studies O
support O
the O
trend O
shown O
in O
this O
study O
. O
['Physiological-Clinical']

Leg B-outcome ['Physiological-Clinical']
press O
1RM O
values O
were O
higher O
( O
on O
average O
3 O
% O
) O
when O
subjects O
performed O
LDLI O
( O
367.8 O
? O
['Physiological-Clinical']

Prolonged O
theophylline O
use O
is O
, O
however O
, O
associated O
with O
emergence O
of O
tolerance O
. O
[]

A O
prospective O
randomized O
trial O
compared O
anal O
stretch O
with O
or O
without O
continued O
dilatation O
for O
three O
months O
in O
89 O
consecutive O
patients O
with O
haemorrhoids O
. O
[]

Our O
trial O
examined O
the O
HRQOL O
effects O
of O
adjuvant O
pegylated O
IFN-alpha-2b O
( O
PEG-IFN-alpha-2b O
) O
versus O
observation O
in O
patients O
with O
stage O
III O
melanoma O
. O
[]

In O
conclusion O
, O
granisetron O
was O
found O
to O
be O
more O
effective O
than O
tropisetron O
in O
controlling O
nausea B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

Atropine O
and O
glycopyrrolate O
induced O
a O
significant O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
a O
simultaneous O
decrease O
in O
pressure B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRQ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
while O
scopolamine O
caused O
a O
significant O
decrease O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
a O
simultaneous O
increase O
in O
PRQ B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Phosphate O
binder O
impact O
on O
bone B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
and O
coronary B-outcome ['Physiological-Clinical']
calcification I-outcome ['Physiological-Clinical']
-- O
results O
from O
the O
BRiC O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thromboxane B-outcome ['Physiological-Clinical']
B2 I-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
was O
also O
significantly O
less O
( O
p O
= O
0.05 O
) O
in O
group O
II O
( O
33.6 O
pg/min O
) O
than O
in O
group O
I O
( O
67.0 O
pg/min O
) O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
prospective O
randomized O
study O
. O
[]

Dose-response O
comparison O
of O
RRR-alpha-tocopherol O
and O
all-racemic O
alpha-tocopherol O
on O
LDL O
oxidation O
. O
[]

Patients O
had O
to O
have O
histologically O
documented O
measurable O
breast O
cancer O
and O
a O
performance O
status O
of O
0-1 O
. O
[]

Fasting O
concentrations O
of O
serum O
free O
fatty O
acids O
( O
S-FFA O
) O
and O
plasma O
gastric O
inhibitory O
polypeptide O
( O
P-GIP O
) O
were O
also O
recorded O
during O
the O
three O
study O
periods O
. O
[]

Larger O
controlled O
trials O
will O
be O
necessary O
to O
detect O
possible O
therapeutic O
effects O
. O
[]

The O
patients O
completed O
the O
RBDI O
questionnaire O
( O
Raitasalo O
's O
modification O
of O
the O
short O
form O
of O
the O
Beck O
Depression B-outcome ['Life-Impact']
Inventory O
) O
. O
['Life-Impact']

METHODS O
The O
subjects O
were O
17 O
healthy O
male O
volunteers O
. O
[]

There O
were O
42 O
patients O
in O
the O
experimental O
group O
, O
including O
16 O
males O
and O
26 O
females O
, O
ranging O
in O
age O
from O
41 O
to O
63 O
years O
, O
with O
an O
average O
of O
( O
53.62 O
+/- O
6.53 O
) O
years O
; O
the O
disease O
course O
ranged O
from O
8 O
to O
24 O
months O
, O
with O
an O
average O
of O
( O
10.35 O
+/- O
6.42 O
) O
months O
. O
[]

The O
control O
group O
listened O
to O
music O
and O
used O
no O
other O
therapeutic O
device O
. O
[]

BACKGROUND O
The O
prevalence O
of O
allergic O
rhinoconjunctivitis O
has O
increased O
significantly O
over O
the O
past O
decades O
with O
grass O
pollen O
being O
a O
common O
trigger O
. O
[]

All O
patients O
received O
the O
Spectron O
EF O
stem O
. O
[]

During O
the O
follow-up O
, O
blood O
pressure O
was O
significantly O
lower O
in O
the O
CCB O
group O
than O
in O
the O
ARB O
group O
( O
P O
< O
0.001 O
) O
. O
[]

This O
observed O
decline O
in O
spirochetes O
was O
then O
used O
to O
determine O
which O
patients O
had O
been O
compliant O
in O
a O
double-blind O
clinical O
trial O
involving O
the O
unsupervised O
usage O
of O
metronidazole O
. O
[]

Parametric O
time-to-event O
modeling O
and O
bootstrapping O
were O
used O
to O
identify O
independent O
predictors O
. O
[]

This O
effect O
was O
fully O
reversed O
when O
the O
patients O
returned O
to O
lactate O
fluid O
. O
[]

Side O
effects O
, O
such O
as O
hypotension B-outcome ['Physiological-Clinical']
and O
emesis B-outcome ['Physiological-Clinical']
were O
negligible O
, O
severe O
bradycardia B-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
did O
not O
occur O
, O
and O
none O
of O
the O
patients O
in O
the O
two O
groups O
reported O
transient B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
over O
24 O
h. O
In O
conclusion O
, O
plain O
mepivacaine O
in O
a O
60- O
or O
80-mg O
dose O
is O
a O
suitable O
local O
anesthetic O
choice O
for O
ambulatory O
spinal O
anesthesia O
with O
respect O
to O
anesthetic O
, O
as O
well O
as O
recovery O
profiles O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
Group O
IT0.5 O
, O
the O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
lower O
on O
postoperative O
day O
1 O
( O
23.9 O
+/- O
8.4 O
% O
) O
than O
the O
baseline O
level O
( O
45.7 O
+/- O
13 O
% O
) O
before O
surgery O
, O
and O
recovered O
on O
postoperative O
day O
2 O
. O
['Physiological-Clinical']

It O
is O
usually O
caused O
by O
ruptured O
pleural O
blebs O
. O
[]

Pupillary B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
was O
recorded O
at O
four O
time O
points O
during O
surgery O
. O
['Physiological-Clinical']

Follow O
up O
examinations B-outcome ['Resource-use']
were O
performed O
at O
the O
15th O
, O
30th O
and O
60th O
day O
after O
surgery O
. O
['Resource-use']

There O
was O
a O
10 O
% O
to O
15 O
% O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
at O
the O
onset O
of O
ischemia O
associated O
with O
a O
30 O
% O
higher O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Investigators O
of O
the O
Children O
's O
Cancer O
Study O
Group O
entered O
73 O
children O
with O
previously O
untreated O
localized O
non-Hodgkin O
's O
lymphoma O
on O
a O
prospective O
randomized O
trial O
of O
systemic O
treatment O
with O
either O
a O
four-drug O
program O
( O
cyclophosphamide O
, O
vincristine O
, O
methotrexate O
, O
prednisone O
[ O
COMP O
] O
) O
or O
a O
10-drug O
( O
LSA2-L2 O
modified O
) O
program O
of O
18 O
months O
duration O
. O
[]

Behavior B-outcome ['Life-Impact']
, O
attention B-outcome ['Life-Impact']
, O
and O
orientation B-outcome ['Life-Impact']
were O
evaluated O
at O
1 O
1/2 O
months O
, O
2 O
months O
, O
3 O
months O
, O
and O
4 O
months O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
no O
statistically O
significant O
differences O
between O
the O
delta O
IOPs O
with O
the O
drug O
stored O
at O
4 O
degrees O
C O
and O
30 O
degrees O
C. O
During O
the O
study O
, O
no O
subject O
developed O
a O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event O
. O
['Adverse-effects']

CONCLUSIONS O
In O
patients O
undergoing O
laparoscopic O
cholecystectomy O
, O
the O
intraperitoneal O
administration O
of O
morphine O
plus O
bupivacaine O
0.25 O
% O
reduced O
the O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
during O
the O
first O
6 O
postoperative O
hours O
compared O
with O
the O
control O
group O
. O
['Resource-use']

Amaferm O
resulted O
in O
a O
greater O
( O
P=0.07 O
) O
G O
: O
F. O
In O
Exp O
. O
[]

Irregular B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
aggravated O
in O
one O
patient O
during O
the O
first O
month O
of O
treatment O
with O
rhGH O
, O
but O
was O
overcome O
by O
a O
-blocking O
agent O
. O
['Physiological-Clinical']

Pioglitazone O
slowed O
progression O
compared O
with O
glimepiride O
in O
this O
population O
. O
[]

CONCLUSION O
Metoprolol O
CR/XL O
once O
daily O
in O
addition O
to O
standard O
therapy O
improved O
both O
diastolic B-outcome ['Physiological-Clinical']
and O
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
heart O
failure O
and O
decreased O
ejection O
fraction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
are O
expected O
in O
2009 O
. O
[]

By O
immunohistochemistry O
a O
minimal O
nodal B-outcome ['Physiological-Clinical']
spread O
of O
tumor B-outcome ['Physiological-Clinical']
cells B-outcome ['Physiological-Clinical']
was O
detected O
in O
21 O
out O
of O
94 O
patients O
( O
LS O
, O
n=10 O
( O
24 O
% O
) O
; O
LA O
, O
n=11 O
( O
21 O
% O
) O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
2 O
weeks O
' O
treatment O
, O
the O
severity O
of O
pruritus B-outcome ['Physiological-Clinical']
( O
visual O
analogue O
score O
( O
VAS O
) O
assessed O
by O
patients O
) O
decreased O
significantly O
in O
both O
the O
mizolastine O
and O
loratadine O
groups O
compared O
with O
placebo O
( O
mizolastine O
: O
-36.7 O
mm O
, O
P O
= O
0.0001 O
; O
loratadine O
: O
-29.8 O
, O
P O
= O
0.0071 O
; O
placebo O
: O
-16.3 O
) O
; O
this O
improvement O
with O
both O
active O
treatments O
was O
maintained O
throughout O
the O
treatment O
period O
, O
the O
difference O
being O
significant O
only O
for O
the O
mizolastine O
group O
( O
P O
= O
0.0090 O
) O
. O
['Physiological-Clinical']

A O
randomized O
multicenter O
phase O
III O
trial O
with O
a O
target O
sample O
size O
of O
380 O
patients O
was O
initiated O
in O
men O
with O
HRPC O
. O
[]

To O
determine O
the O
safety O
and O
efficacy O
of O
a O
new O
, O
non-contact O
, O
kilohertz O
ultrasound O
therapy O
for O
the O
healing O
of O
recalcitrant B-outcome ['Physiological-Clinical']
diabetic I-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
- O
as O
well O
as O
to O
evaluate O
the O
impact O
on O
total O
closure O
and O
quantitative O
bacterial O
cultures O
and O
the O
effect O
on O
healing O
of O
various O
levels O
of O
sharp/surgical O
debridement O
- O
a O
randomized O
, O
double-blinded O
, O
sham-controlled O
, O
multicenter O
study O
was O
conducted O
in O
hospital-based O
and O
private O
wound O
care O
clinics O
. O
['Physiological-Clinical']

The O
difference O
in O
median O
percentage O
change O
between O
D O
and O
C O
was O
statistically O
significant O
[ O
-4.0 O
( O
D O
) O
vs. O
4.7 O
( O
C O
) O
; O
P O
= O
0.005 O
, O
n O
= O
39 O
] O
. O
[]

Both O
the O
number O
of O
vanishing B-outcome ['Physiological-Clinical']
warts I-outcome ['Physiological-Clinical']
and O
the O
difference O
in O
relative O
wart B-outcome ['Physiological-Clinical']
area O
of O
persisting O
warts B-outcome ['Physiological-Clinical']
at O
week O
14 O
and O
18 O
were O
significant O
( O
p O
< O
0.05 O
) O
in O
favour O
of O
ALA-PDT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

They O
completed O
pre- O
and O
posttest O
assessments O
that O
included O
both O
self-reported B-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
( O
on O
diet B-outcome ['Life-Impact']
, O
exercise B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

APPLICATIONS/CONCLUSIONS O
Understanding O
and O
using O
instruments O
to O
assess O
the O
physical O
and O
emotional O
status O
of O
a O
target O
population O
will O
help O
dietetic O
professionals O
promote O
healthful O
dietary O
change O
and O
maintenance O
. O
[]

We O
advocate O
the O
use O
of O
a O
more O
cost-effective O
all-polyethylene O
tibial O
component O
in O
elderly O
patients O
( O
> O
70 O
years O
old O
) O
who O
are O
not O
likely O
to O
need O
the O
versatility O
of O
exchange O
of O
a O
modular O
polyethylene O
insert O
because O
of O
wear O
. O
[]

Laser O
Doppler O
flowmetry O
discovered O
that O
the O
above O
combined O
treatment O
corrects O
microcirculation O
in O
bladder O
mucosa O
. O
[]

The O
authors O
tested O
this O
hypothesis O
. O
[]

METHODS O
Forty O
autistic O
children O
receiving O
rehabilitation O
training O
were O
divided O
into O
a O
control O
group O
and O
a O
treatment O
group O
, O
20 O
cases O
in O
each O
group O
. O
[]

Steroid O
treatment O
, O
during O
allergen O
exposure O
, O
increased O
the O
mean O
density O
of O
the O
PGS B-outcome ['Physiological-Clinical']
biglycan I-outcome ['Physiological-Clinical']
and O
versican B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Measurements O
were O
compared O
against O
those O
obtained O
with O
the O
Reichert O
Xpert O
Plus O
, O
Goldmann O
applanation O
tonometer O
and O
Perkins O
tonometer O
. O
[]

Young O
beef O
cattle O
( O
n O
= O
270 O
) O
weighing O
approximately O
400 O
kg O
were O
allocated O
to O
batches O
of O
five O
, O
which O
were O
randomly O
assigned O
to O
receive O
ivermectin O
+ O
clorsulon O
injection O
, O
ivermectin O
+ O
closantel O
injection O
, O
or O
levamisole O
+ O
triclabendazole O
oral O
drench O
. O
[]

Mastication O
and O
late O
mandibular O
fracture O
after O
surgery O
of O
impacted O
third O
molars O
associated O
with O
no O
gross O
pathology O
. O
[]

Outcome O
measures O
were O
the O
Fugl-Meyer O
Assessment O
( O
FMA O
) O
and O
muscle O
tone O
measured O
by O
Myoton-3 O
for O
motor B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and O
the O
Box O
and O
Block O
Test O
( O
BBT O
) O
and O
10-Meter O
Walk O
Test O
( O
10 O
MWT O
) O
for O
motor O
function O
. O
['Life-Impact']

A O
magnetic O
resonance O
study O
. O
[]

Participants O
in O
the O
peer-mentored O
and O
nurse O
case-managed O
groups O
did O
not O
differ O
significantly O
from O
the O
standard O
group O
in O
self-esteem B-outcome ['Life-Impact']
, O
life B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
noninjection I-outcome ['Life-Impact']
drugs I-outcome ['Life-Impact']
, O
sex B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
multiple I-outcome ['Life-Impact']
partners I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Participants O
who O
had O
high O
urinary O
excretion O
of O
toxic O
metals O
were O
selected O
to O
continue O
on O
to O
phase O
2 O
. O
[]

CONCLUSIONS O
Regular O
intake O
of O
lime O
juice O
may O
be O
of O
great O
therapeutic O
and O
nutritional O
relevance O
in O
children O
with O
SCA O
. O
[]

Nimodipine O
pharmacotherapeutic O
adjuvant O
therapy O
for O
inpatient O
treatment O
of O
cocaine O
dependence O
. O
[]

There O
were O
no O
significant O
differences O
in O
mean O
peak O
CD34+ B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
between O
pegfilgrastim O
and O
filgrastim O
, O
but O
there O
was O
an O
advantage O
for O
pegfilgrastim O
18 O
mg O
in O
the O
relevant O
period O
of O
days O
7-12 O
( O
3.14 O
vs O
1.19 O
x O
10 O
( O
4 O
) O
/ml O
; O
P=0.043 O
) O
. O
['Physiological-Clinical']

The O
250-mg O
naproxen O
tablets O
, O
tablet O
I O
from O
AFI O
, O
Oslo O
, O
Norway O
, O
and O
tablet O
II O
Naprosyn O
, O
Astra-Syntex O
, O
were O
taken O
by O
12 O
healthy O
volunteers O
in O
a O
randomized O
two-period O
crossover O
study O
. O
[]

RESULTS O
Using O
an O
intent-to-treat O
approach O
, O
findings O
replicated O
earlier O
results O
with O
a O
very O
large O
effect O
size O
( O
d O
= O
1.41 O
) O
for O
the O
FF O
group O
and O
a O
large O
effect O
size O
( O
d O
= O
1.12 O
) O
for O
the O
WEB O
group O
relative O
to O
the O
PBO O
group O
. O
[]

BACKGROUND O
Glucocorticosteroids O
are O
effective O
in O
the O
treatment O
of O
allergic O
rhinitis O
, O
a O
disease O
characterized O
by O
a O
variety O
of O
symptoms O
, O
e.g O
. O
[]

In O
particular O
, O
changes O
in O
positive O
[]

Group O
50 O
received O
0.3 O
mg O
kg-1 O
diazepam O
with O
50 O
ml O
of O
water O
2 O
h O
before O
surgery O
. O
[]

Event-related B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
potentials I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ERPs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
obtained O
in O
seven O
subjects O
on O
an O
auditory O
choice O
reaction O
time O
task O
. O
['Physiological-Clinical']

The O
capsule O
form O
of O
paricalcitol O
was O
developed O
to O
provide O
a O
convenient O
dosage O
form O
for O
patients O
with O
stages O
3 O
and O
4 O
CKD O
. O
[]

Data O
from O
over O
100 O
healthy O
adults O
revealed O
a O
relationship O
between O
these O
two O
factors O
as O
multisensory O
timing O
perception O
correlated O
with O
symptoms O
of O
autism O
. O
[]

This O
strategy O
could O
make O
vaccines O
more O
acceptable O
to O
children O
and O
may O
improve O
child-doctor O
relationships O
and O
contribute O
to O
a O
decrease O
in O
child O
fear O
about O
health O
care O
. O
[]

Both O
groups O
increased O
their O
walk B-outcome ['Life-Impact']
distance I-outcome ['Life-Impact']
( O
by O
29.6 O
m O
perindopril O
, O
36.4 O
m O
placebo O
group O
) O
at O
20 O
weeks O
, O
but O
there O
was O
no O
statistically O
significant O
treatment O
effect O
between O
groups O
( O
-8.6m O
[ O
95 O
% O
confidence O
interval O
: O
-30.1 O
, O
12.9 O
] O
, O
p O
= O
.43 O
) O
. O
['Life-Impact']

Withdrawals O
from O
the O
study O
because O
of O
excessive O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
levels O
were O
about O
eight O
times O
less O
frequent O
among O
the O
subjects O
treated O
with O
clonidine O
, O
either O
alone O
or O
with O
chlorthalidone O
. O
['Physiological-Clinical']

The O
net O
fat B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
was O
-2.1 O
% O
( O
95 O
% O
CI-2.7 O
, O
-1.4 O
) O
in O
Group O
S1 O
and O
-1.7 O
% O
( O
95 O
% O
CI-2.3 O
, O
-1.0 O
) O
in O
Group O
S2 O
. O
['Physiological-Clinical']

This O
study O
investigates O
the O
role O
of O
oral O
sildenafil O
in O
decreasing O
pulmonary B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
after O
congenital O
heart O
surgery O
. O
['Physiological-Clinical']

Variability O
in O
language B-outcome ['Life-Impact']
, O
NVIQ O
and O
symptom B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
increased O
over O
time O
. O
['Life-Impact', 'Life-Impact']

Bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
was O
quantified O
by O
measurement O
of O
the O
provocative B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
methacholine I-outcome ['Life-Impact']
causing O
a O
20 O
% B-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
forced I-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PD20 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Thus O
, O
paced O
patients O
were O
significantly O
less O
likely O
to O
fall B-outcome ['Life-Impact']
( O
odds O
ratio O
0.42 O
; O
95 O
% O
confidence O
interval O
: O
0.23 O
, O
0.75 O
) O
than O
were O
controls O
. O
['Life-Impact']

Lorazepam O
was O
liked O
better O
than O
were O
other O
drugs O
only O
at O
1 O
hour O
and O
only O
compared O
with O
buspirone O
20 O
and O
placebo O
. O
[]

RESULTS O
There O
was O
a O
significant O
improvement O
in O
the O
FMA B-outcome ['Physiological-Clinical']
score O
in O
the O
two O
groups O
after O
the O
treatment O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

At O
the O
end O
of O
the O
3-month O
trial O
, O
there O
was O
significantly O
higher O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
self-care I-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

5 O
. O
[]

Incidence O
and O
severity O
of O
side O
effects O
were O
examined O
. O
[]

In O
study O
group O
, O
the O
total O
scores O
of O
SDSS O
in O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
( O
5.93 O
? O
[]

Itching B-outcome ['Physiological-Clinical']
, O
a O
pathophysiologically O
complex O
sensation O
, O
is O
favourably O
influenced O
by O
steroids O
within O
10 O
min O
, O
therefore O
presumably O
via O
nongenomic O
mechanisms O
. O
['Physiological-Clinical']

A O
secondary O
aim O
was O
to O
identify O
complications O
requiring O
provider O
interventions O
. O
[]

None O
of O
the O
between-group O
differences O
in O
response O
rates O
were O
significant O
. O
[]

19.2 O
vs. O
42.24 O
? O
[]

Amantadine O
was O
well O
tolerated O
. O
[]

Toxicity O
and O
supportive O
care O
requirements O
were O
not O
increased O
. O
[]

Walking O
trials O
in O
postmenopausal O
women O
: O
effect O
of O
one O
vs O
two O
daily O
bouts O
on O
aerobic B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
differences O
are O
statistically O
significant O
. O
[]

This O
paper O
reports O
the O
final O
results O
in O
terms O
of O
survival O
, O
local O
control O
and O
complications O
. O
[]

Based O
on O
these O
data O
, O
an O
open O
, O
randomized O
controlled O
trial O
was O
started O
. O
[]

The O
mean O
birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
of O
all O
infants O
of O
the O
treated O
group O
was O
significantly O
higher O
than O
in O
those O
of O
the O
control O
group O
( O
3111.9 O
+/- O
905 O
gm O
versus O
2680 O
+/- O
813.4 O
gm O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

The O
results O
of O
this O
study O
demonstrate O
striking O
differences O
in O
the O
ability O
of O
breast-pumping O
methods O
to O
produce O
an O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sustained I-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
in O
breast-feeding O
mothers O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
did O
not O
increase O
in O
any O
group O
during O
the O
one O
year O
therapy O
. O
['Physiological-Clinical']

A O
single O
dose O
of O
gabapentin O
reduces O
acute B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
allodynia B-outcome ['Physiological-Clinical']
in O
patients O
with O
herpes O
zoster O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Most O
patients O
had O
stage O
II O
or O
III O
disease O
, O
and O
received O
neoadjuvant O
therapy O
with O
oral O
capecitabine O
and O
50-54 O
Gy O
external O
beam O
radiotherapy O
. O
[]

Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
high-resolution O
vascular O
ultrasound O
. O
['Physiological-Clinical']

A O
statistically O
significant O
improvement O
( O
p O
less O
than O
0.05 O
) O
, O
evaluated O
by O
a O
four-stage O
scale O
on O
pains O
, O
infirmity O
, O
and O
consumption B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
, O
was O
observed O
in O
the O
actively O
treated O
patients O
. O
['Resource-use']

RESULTS O
Tumor B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
( O
complete O
and O
partial O
responses O
) O
were O
seen O
in O
16 O
patients O
( O
26 O
% O
) O
in O
arm O
A O
and O
19 O
patients O
( O
29 O
% O
) O
in O
arm O
B O
. O
['Physiological-Clinical']

Various O
large O
volume O
cuffed O
endotracheal O
tubes O
were O
studied O
, O
including O
Portex O
Profile O
, O
Searle O
Sensiv O
, O
Mallinkrodt O
Hi-Lo O
, O
and O
Lanz O
. O
[]

There O
were O
no O
serious B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
or O
abnormal O
laboratory O
tests O
in O
both O
treatment O
groups O
. O
['Adverse-effects']

Patients O
were O
followed O
for O
a O
3-month O
period O
of O
active O
weight O
loss O
and O
a O
10-week O
period O
of O
weight O
maintenance O
. O
[]

There O
were O
22 O
patients O
in O
the O
drug O
treatment O
group O
( O
20.0 O
% O
) O
and O
29 O
patients O
in O
the O
placebo O
group O
( O
24.0 O
% O
) O
with O
opposite-side B-outcome ['Physiological-Clinical']
amputations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Safety O
and O
tolerability B-outcome ['Life-Impact']
were O
also O
assessed O
. O
['Life-Impact']

The O
salivary O
glands O
were O
dissected O
from O
all O
female O
anophelines O
caught O
to O
identify O
sporozoites O
by O
microscopy O
. O
[]

Participants O
were O
randomized O
into O
a O
fed O
or O
nonfed O
condition O
and O
orally O
ingested O
2.8 O
mg?kg O
BM O
of O
PSE O
or O
a O
placebo O
( O
PLA O
) O
90 O
min O
before O
exercise O
; O
in O
the O
fed O
trials O
, O
they O
consumed O
a O
meal O
providing O
1.5 O
g?kg O
BM O
of O
CHO O
. O
[]

Drinking O
water O
and O
brushing O
with O
toothpaste O
B O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
dynamometry O
and O
spirometry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
purpose O
of O
this O
study O
was O
to O
test O
the O
effectiveness O
of O
timely O
patient O
feedback O
in O
the O
form O
of O
a O
letter O
providing O
recent O
patient-specific O
symptoms O
, O
medication O
, O
and O
health O
service O
use O
combined O
with O
guideline-based O
recommendations O
for O
changes O
in O
therapy O
on O
improving O
the O
quality O
of O
asthma O
care O
by O
inner-city O
primary O
care O
providers O
and O
on O
resultant O
asthma O
morbidity O
. O
[]

METHODS O
AND O
RESULTS O
To O
compare O
and O
contrast O
the O
relative O
importance O
of O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
CRP B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

C. O
albicans O
was O
isolated O
most O
frequently O
90.3 O
% O
( O
271/300 O
) O
, O
followed O
by O
C. O
glabrata O
( O
7.3 O
% O
) O
, O
C. O
tropicalis O
( O
1.3 O
% O
) O
, O
C. O
krusei O
( O
0.7 O
% O
) O
, O
and O
C. O
parapsilosis O
( O
0.3 O
% O
) O
. O
[]

In O
the O
study O
group O
, O
there O
was O
a O
significant O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
and O
an O
improvement O
in O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.06 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

Changes O
in O
arm O
muscle B-outcome ['Physiological-Clinical']
area O
correlated O
with O
energy O
, O
but O
not O
protein O
intake O
. O
['Physiological-Clinical']

Control O
condition O
participants O
watched O
a O
20-minute O
docudrama O
of O
a O
pregnant O
problem O
drinker O
. O
[]

Thirty-two O
patients O
( O
4 O
% O
) O
experienced O
recurrent B-outcome ['Physiological-Clinical']
ulceration I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
at O
6 O
months-2 O
years O
( O
mean O
, O
15 O
mo O
) O
. O
['Physiological-Clinical']

POPULATION O
A O
total O
of O
18 O
hypertensive O
and O
hyperinsulinemic O
( O
= O
10 O
U/mL O
or O
more O
) O
men O
and O
women O
completed O
the O
trial O
. O
[]

The O
histamine-induced O
wheal O
area O
was O
measured O
and O
, O
after O
drug O
administration O
, O
the O
percent O
decrease O
of O
the O
wheal B-outcome ['Physiological-Clinical']
area O
was O
calculated O
. O
['Physiological-Clinical']

There O
was O
a O
decrease O
in O
IPSS B-outcome ['Physiological-Clinical']
( O
-7.4 O
[ O
3.8 O
] O
points O
in O
the O
beta-sitosterol-treated O
group O
vs O
-2.1 O
[ O
3.8 O
] O
points O
in O
the O
placebo O
group O
) O
and O
changes O
in O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
parameters O
: O
beta-sitosterol O
treatment O
resulted O
in O
increasing O
peak O
flow B-outcome ['Physiological-Clinical']
( O
15.2 O
[ O
5.7 O
] O
mL/s O
from O
9.9 O
[ O
2.5 O
] O
mL/s O
) O
, O
and O
decrease O
of O
mean O
residual O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
designed O
to O
investigate O
the O
influence O
of O
a O
lighter O
ball O
( O
Tachikara O
Volley O
Lite O
) O
on O
72 O
seventh-grade O
girls O
' O
tournament O
game O
play O
and O
pretest-to-posttest O
improvement O
for O
a O
16-day O
volleyball O
practice O
period O
. O
[]

At O
the O
completion O
of O
locoregional O
treatment O
, O
76 O
% O
( O
42 O
of O
55 O
) O
of O
patients O
in O
the O
experimental O
group O
were O
in O
CR O
compared O
to O
89 O
% O
( O
54 O
of O
61 O
) O
in O
the O
control O
group O
. O
[]

This O
study O
evaluated O
the O
safety O
and O
efficacy O
of O
a O
sirolimus O
, O
corticosteroid O
, O
and O
cyclosporine O
reduction O
regimen O
in O
an O
open-label O
, O
12-month O
trial O
of O
420 O
de O
novo O
renal O
allograft O
recipients O
at O
49 O
European O
transplant O
centers O
. O
[]

METHODS O
The O
374 O
patients O
evaluated O
in O
this O
study O
were O
a O
subgroup O
of O
a O
larger O
multicenter O
, O
cross-sectional O
, O
randomized O
study O
that O
was O
carried O
out O
in O
1996 O
. O
[]

RESULTS O
The O
results O
show O
that O
intrathecal O
LV/hIL-10 O
reverses O
enhanced O
pain O
states O
. O
[]

After O
removal O
of O
the O
connected O
vasculature O
the O
remaining O
objects O
are O
considered O
possible O
red O
lesions O
. O
[]

CONCLUSION O
Subcutaneous O
IL-2 O
was O
well O
tolerated B-outcome ['Life-Impact']
for O
6 O
months O
in O
patients O
with O
surgically O
resected O
RCC O
at O
high O
risk O
of O
recurrence O
. O
['Life-Impact']

CONCLUSIONS O
Patient O
navigation O
positively O
impacts O
time O
to O
resolution B-outcome ['Physiological-Clinical']
of O
abnormal O
screening O
tests O
for O
breast O
, O
colorectal O
, O
and O
prostate O
cancers O
in O
a O
medically O
underserved O
population O
. O
['Physiological-Clinical']

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
AmB I-outcome ['Physiological-Clinical']
were O
investigated O
in O
20 O
children O
who O
received O
AmB O
in O
dextrose O
and O
15 O
children O
who O
received O
AmB O
in O
lipid O
emulsion O
. O
['Physiological-Clinical']

The O
implant B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
moment O
of O
implant O
placement O
and O
at O
the O
moment O
of O
the O
delivery O
of O
the O
definitive O
restoration O
. O
['Physiological-Clinical']

Children O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
, O
8 O
and O
10 O
wk O
of O
starting O
medication O
protocol O
. O
[]

OBJECTIVES O
To O
compare O
the O
safety O
and O
plaque B-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
efficacy O
of O
two O
oscillating/rotating/pulsating O
toothbrushes O
( O
Oral-B O
ProfessionalCare O
7000 O
[ O
PC O
7000 O
] O
and O
Oral-B O
3D O
Excel O
[ O
3DE O
] O
) O
and O
a O
high-frequency O
toothbrush O
( O
Sonicare O
Advance O
, O
Philips O
Oral O
Healthcare O
; O
SA O
) O
in O
a O
single-use O
, O
examiner-blind O
, O
three O
period O
crossover O
study O
. O
['Physiological-Clinical']

Induction O
chemotherapy O
consisted O
of O
two O
cycles O
of O
carboplatin O
area O
under O
time-concentration O
curve O
6 O
mg/mL O
. O
[]

It O
remains O
unclear O
whether O
the O
addition O
of O
myocardial O
perfusion O
imaging O
( O
MPI O
) O
to O
the O
standard O
ECG O
exercise O
treadmill O
test O
( O
ETT O
) O
provides O
incremental O
information O
to O
improve O
clinical O
decision O
making O
in O
women O
with O
suspected O
CAD O
. O
[]

At O
entry O
, O
systolic/diastolic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
averaged O
176/86 O
mm O
Hg O
in O
the O
clinic O
and O
149/80 O
mm O
Hg O
on O
24-hour O
ambulatory O
monitoring O
. O
['Physiological-Clinical']

When O
corrected O
for O
differences O
in O
blood O
glucose O
control O
it O
appeared O
that O
in O
three O
out O
of O
nine O
patients O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
had O
not O
completely O
returned O
to O
the O
reference O
range O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
explore O
the O
better O
therapy O
for O
chronic B-outcome ['Physiological-Clinical']
tension-type I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CTTH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Antiinflammatory B-outcome ['Physiological-Clinical']
effects O
of O
the O
phosphodiesterase-4 O
inhibitor O
cilomilast O
( O
Ariflo O
) O
in O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical']

To O
resolve O
the O
drawbacks O
in O
the O
traditional O
methodology O
of O
bioequivalence O
evaluation O
, O
the O
use O
of O
partial O
areas O
in O
lieu O
of O
total O
AUC O
, O
Tmax B-outcome ['Physiological-Clinical']
, O
and O
Cmax B-outcome ['Physiological-Clinical']
is O
suggested O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fear O
on O
the O
part O
of O
patients O
that O
providers O
stereotype O
them O
negatively O
might O
be O
one O
cause O
of O
this O
poorer O
communication O
. O
[]

BACKGROUND O
In O
cemented O
THA O
, O
aseptic O
loosening O
of O
the O
cup O
is O
more O
common O
than O
loosening O
of O
the O
stem O
, O
while O
periprosthetic O
osteolysis O
of O
the O
socket O
resulting O
in O
difficult O
reconstruction O
problems O
has O
emerged O
as O
the O
most O
significant O
problem O
with O
cementless O
cup O
fixation O
. O
[]

The O
current O
study O
aimed O
to O
test O
alternative O
explanations O
for O
this O
apparent O
lack O
of O
reputation O
management O
. O
[]

BACKGROUND O
Coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
is O
effective O
in O
relieving O
angina O
and O
improving O
survival O
and O
quality O
of O
life O
in O
patients O
with O
obstructive O
coronary O
artery O
disease O
; O
however O
, O
recurrent O
angina O
, O
myocardial O
infarction O
, O
neurological O
injury O
, O
and O
death O
can O
occur O
in O
the O
perioperative O
and O
postoperative O
period O
. O
[]

This O
study O
demonstrated O
the O
favorable O
risk O
: O
benefit O
ratio O
of O
zoledronic O
acid O
for O
the O
prevention O
of O
skeletal O
complications O
. O
[]

Group O
5 O
received O
placebo O
plus O
G-CSF O
5 O
microg/kg/day O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
unexpectedly O
high O
in O
both O
treatment O
arms O
and O
led O
to O
treatment O
withdrawal O
or O
refusal O
in O
49 O
% O
of O
all O
patients O
, O
predominantly O
already O
during O
the O
first O
treatment O
cycle O
. O
['Adverse-effects']

Most O
patients O
without O
a O
stoma O
( O
7 O
of O
12 O
in O
CRT O
group O
and O
9 O
of O
16 O
in O
RT O
group O
) O
had O
incontinence O
for O
liquid O
stools O
or O
gas O
. O
[]

End O
point O
analysis O
was O
possible O
in O
109 O
patients O
( O
85.2 O
% O
) O
. O
[]

In O
addition O
, O
the O
influence O
of O
regression O
on O
resting O
diastolic O
filling O
and O
on O
cardiac O
output O
and O
ejection O
fraction O
during O
rest O
and O
mild O
upright O
bicycle O
exercise O
were O
determined O
. O
[]

Fifteen O
minutes O
later O
( O
before O
IoA O
) O
, O
each O
dog O
received O
treatment O
IV O
with O
propofol O
, O
K-P O
, O
or O
K-D. O
Cardiorespiratory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
were O
assessed O
before O
, O
immediately O
after O
, O
and O
5 O
minutes O
after O
IoA O
. O
['Physiological-Clinical']

Control O
group O
received O
regular O
paediatric O
care O
and O
was O
wait-listed O
for O
Helping O
HAND O
. O
[]

The O
two O
groups O
were O
compared O
for O
operative O
and O
hospitalization O
times O
and O
postoperative O
course O
. O
[]

Subcutaneous O
low-molecular-weight O
heparin O
compared O
with O
continuous O
intravenous O
unfractionated O
heparin O
in O
the O
treatment O
of O
proximal O
deep O
vein O
thrombosis O
. O
[]

The O
percentage O
of O
patients O
in O
whom O
control O
of O
home B-outcome ['Physiological-Clinical']
morning I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
achieved O
was O
53 O
% O
in O
the O
intervention O
group O
and O
47 O
% O
in O
the O
control O
group O
( O
P O
= O
0.40 O
) O
. O
['Physiological-Clinical']

Exercise O
stimulates O
release O
of O
renin O
; O
this O
action O
was O
greater O
with O
captopril O
administration O
( O
treatment O
effect O
: O
p O
< O
10 O
( O
-4 O
) O
, O
indicating O
blockade O
of O
the O
RAS O
. O
[]

The O
use O
of O
a O
PSA-D O
threshold O
value O
of O
0 O
. O
[]

Though O
no O
detailed O
mechanisms O
can O
be O
derived O
from O
this O
study O
, O
steroid O
interaction O
with O
receptors O
in O
the O
central O
nervous O
system O
may O
play O
an O
important O
role O
in O
mediating O
this O
effect O
. O
[]

Unfortunately O
, O
no O
recommendations O
can O
be O
drawn O
from O
these O
studies O
that O
would O
alter O
presently O
accepted O
methods O
of O
management O
. O
[]

Phenobarbital O
compared O
with O
phenytoin O
for O
the O
treatment O
of O
neonatal O
seizures O
. O
[]

The O
patients O
with O
ECCE O
and O
PCL O
showed O
capsular B-outcome ['Physiological-Clinical']
fibrosis I-outcome ['Physiological-Clinical']
in O
48 O
( O
28 O
% O
) O
making O
it O
the O
most O
frequent O
complication O
of O
the O
whole O
study O
. O
['Physiological-Clinical']

Patients O
were O
stratified O
according O
to O
esophageal O
size O
, O
based O
on O
the O
diameter O
of O
the O
divided O
esophagus O
( O
< O
or O
> O
or O
= O
30 O
mm O
) O
and O
then O
were O
randomized O
to O
have O
either O
a O
hand-sewn O
or O
a O
stapled O
anastomosis O
. O
[]

Efficacy O
of O
radiochemotherapy O
of O
malignantly-converted O
brain O
gliomas O
using O
teniposide O
was O
evaluated O
in O
a O
randomized O
prospective O
study O
. O
[]

Study O
3 O
demonstrated O
for O
a O
sample O
of O
children O
with O
PDDs O
( O
n O
= O
10 O
) O
that O
the O
interrater O
reliability O
of O
the O
TOM O
test O
is O
good O
. O
[]

Enhancing O
attitudes B-outcome ['Life-Impact']
and O
intentions B-outcome ['Life-Impact']
in O
prospective O
blood O
donors O
: O
evaluation O
of O
a O
new O
donor O
recruitment O
brochure O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVES O
Reducing O
unnecessary O
antibiotic O
use O
, O
particularly O
among O
children O
, O
continues O
to O
be O
a O
public O
health O
priority O
. O
[]

To O
what O
extent O
a O
reduction O
in O
the O
AER O
could O
ameliorate O
diabetic O
patients O
is O
, O
at O
present O
, O
unknown O
. O
[]

A O
total O
of O
747 O
febrile O
granulocytopenic O
patients O
with O
cancer O
were O
randomized O
to O
receive O
ceftazidime O
plus O
amikacin O
( O
CA O
) O
with O
or O
without O
vancomycin O
( O
V O
) O
as O
initial O
empirical O
therapy O
. O
[]

RESULTS O
Although O
preoperative O
Hb O
and O
the O
amount O
of O
postoperative O
bleeding O
were O
comparable O
in O
the O
two O
groups O
, O
Hb O
levels O
at O
1 O
, O
2 O
, O
and O
3 O
days O
and O
at O
2 O
and O
6 O
weeks O
postoperation O
were O
significantly O
higher O
in O
Group O
IE O
. O
[]

We O
assessed O
genome-wide B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of O
300 O
pretreatment O
specimens O
from O
a O
subset O
of O
552 O
patients O
in O
REACH O
, O
a O
study O
of O
FC O
or O
R-FC O
in O
relapsed O
CLL O
. O
['Physiological-Clinical']

Improved O
survival O
with O
early O
intensification O
: O
combined O
results O
from O
the O
Medical O
Research O
Council O
childhood O
ALL O
randomised O
trials O
, O
UKALL O
X O
and O
UKALL O
XI O
. O
[]

We O
compared O
the O
onset O
of O
neuromuscular B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
with O
succinylcholine O
( O
1 O
mg O
kg-1 O
) O
and O
two O
doses O
of O
rocuronium O
( O
0.6 O
and O
0.9 O
mg O
kg-1 O
) O
at O
the O
adductor O
pollicis O
muscle O
using O
electromyography O
( O
EMG O
) O
and O
acceleromyography O
( O
AMG O
) O
, O
and O
at O
the O
adductor O
laryngeal O
muscles O
with O
a O
new O
electromyographic O
method O
using O
a O
disposable O
surface O
electrode O
attached O
to O
the O
cuff O
of O
a O
tracheal O
tube O
. O
['Physiological-Clinical']

The O
effects O
of O
improvisational O
music O
therapy O
on O
joint O
attention O
behaviors O
in O
autistic O
children O
: O
a O
randomized O
controlled O
study O
. O
[]

or O
by O
Behringwerke O
( O
North O
and O
West O
African O
polyvalent O
antivenom O
) O
. O
[]

Somatic O
comorbidity O
and O
an O
increased O
mortality O
related O
to O
the O
lifestyle O
among O
persons O
with O
psychiatric O
disabilities O
are O
well O
known O
. O
[]

The O
outcome O
variables O
were O
total O
scores O
on O
the O
Childhood O
Autism O
Rating O
Scale O
( O
CARS O
) O
and O
the O
Children O
's O
Global O
Assessment O
Scale O
( O
CGAS O
) O
after O
6 O
months O
. O
[]

National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
's O
Breast O
Cancer O
Prevention O
Trial O
. O
[]

The O
most O
common O
related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
after O
each O
treatment O
included O
symptoms B-outcome ['Physiological-Clinical']
related O
to O
the O
injection/infusion O
site O
, O
dizziness B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cardiac O
function O
was O
monitored O
by O
multiple-gated O
radionuclide O
cardioangiography O
scan O
, O
and O
the O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
was O
scored O
at O
a O
central O
laboratory O
. O
[]

From O
1981 O
to O
1983 O
, O
131 O
previously O
untreated O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
standard-risk O
group O
were O
entered O
to O
the O
protocol O
JCCLSG-S811 O
. O
[]

The O
addition O
of O
IFN-3 O
to O
5-FU O
significantly O
improved O
response O
rate O
( O
33.3 O
% O
vs O
4.5 O
% O
for O
evaluable O
patients O
; O
P O
= O
0.021 O
) O
, O
time O
to O
progression B-outcome ['Physiological-Clinical']
( O
median O
7.2 O
vs O
4.2 O
months O
; O
P O
= O
0.0435 O
) O
, O
and O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
( O
median O
15.9 O
vs O
7.2 O
months O
; O
P O
= O
0.038 O
) O
without O
significantly O
increasing O
toxicity B-outcome ['Adverse-effects']
compared O
to O
5-FU O
alone O
. O
['Physiological-Clinical', 'Mortality', 'Adverse-effects']

BACKGROUND O
Routine O
oral O
calcium O
and O
vitamin O
D O
supplementation O
may O
prevent O
hypocalcemic O
crisis O
, O
but O
its O
efficacy O
has O
not O
been O
studied O
in O
patients O
undergoing O
thyroidectomy O
plus O
central O
neck O
dissection O
( O
CND O
) O
. O
[]

METHODS O
Fresh O
venous O
blood O
was O
taken O
throughout O
treatment O
and O
follow-up O
. O
[]

During O
the O
first O
4 O
days O
these O
changes O
were O
significant O
( O
p O
< O
0.05 O
) O
. O
[]

As O
a O
consequence O
, O
baseline O
VEGF B-outcome ['Physiological-Clinical']
had O
a O
negative O
prognostic O
role O
in O
patients O
who O
received O
epirubicin O
alone O
but O
not O
in O
patients O
receiving O
epirubicin O
plus O
tamoxifen O
( O
interaction O
test O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
tramadol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Risperidone-treated O
subjects O
experienced O
statistically O
significantly O
greater O
increases O
in O
weight O
( O
2.7 O
vs O
1.0 O
kg O
) O
, O
pulse B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

Estrone O
decreased O
in O
55.56 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
42.86 O
% O
in O
the O
placebo O
group O
. O
[]

In O
comparison O
to O
aR O
IOS O
is O
not O
dependent O
on O
the O
patients O
cooperation O
. O
[]

UNLABELLED O
An O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
can O
have O
profound O
and O
lasting O
adverse O
effects O
on O
a O
patient O
's O
physical O
and O
psychological O
well-being O
. O
[]

Bronchial O
carcinoma O
. O
[]

Preinjection O
mean O
( O
+/- O
SD O
) O
IOP B-outcome ['Physiological-Clinical']
wer O
12.9 O
+/- O
3.7 O
mmHg O
in O
the O
retrobulbar O
and O
13.4 O
+/- O
3.2 O
mmHg O
in O
the O
1-QST O
patients O
. O
['Physiological-Clinical']

Twenty-five O
microgram O
tablets O
of O
misoprostol O
were O
placed O
in O
the O
posterior O
vaginal O
fornix O
every O
4 O
hours O
for O
a O
maximum O
of O
six O
doses O
. O
[]

This O
study O
assessed O
the O
diagnostic B-outcome ['Life-Impact']
accuracy O
of O
coronary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
evaluation O
obtained O
by O
three O
readers O
at O
different O
levels O
of O
training O
or O
at O
different O
points O
of O
the O
learning O
curve O
proposed O
by O
the O
international O
guidelines O
. O
['Life-Impact', 'Physiological-Clinical']

Comparison O
of O
three O
methods O
to O
increase O
knowledge B-outcome ['Life-Impact']
about O
breast O
cancer O
and O
breast O
cancer O
screening O
in O
screening O
mammography O
patients O
. O
['Life-Impact']

RESULTS O
No O
significant O
differences O
were O
found O
between O
the O
two O
in-person O
interview O
modes O
for O
subject O
age O
, O
weight O
, O
body O
mass O
index O
, O
percentage O
of O
body O
fat O
, O
total O
energy O
expenditure O
, O
rEI O
, O
and O
misreporting O
of O
energy O
intake O
. O
[]

The O
assessment O
measures O
correlated O
reasonably O
with O
one O
another O
at O
the O
beginning O
of O
the O
study O
( O
r O
= O
0.60-0.87 O
) O
and O
even O
better O
at O
the O
end O
of O
the O
study O
( O
r O
= O
0.63-0.94 O
) O
. O
[]

Parents O
of O
children O
who O
receive O
the O
diagnosis O
of O
autistic O
spectrum O
disorder O
( O
ASD O
) O
experience O
a O
situational O
crisis O
related O
to O
receiving O
the O
diagnosis O
, O
which O
causes O
feelings O
of O
distress O
and O
urgency O
to O
access O
services O
for O
the O
affected O
child O
. O
[]

Fifty-two O
patients O
and O
48 O
controls O
were O
included O
with O
a O
mean O
age O
of O
12.13 O
? O
[]

Combined O
use O
of O
cytostatics O
and O
irradiation O
appeared O
safe O
, O
tolerable O
and O
significantly O
more O
effective O
than O
radiotherapy O
alone O
as O
assessed O
by O
local B-outcome ['Physiological-Clinical']
control O
of O
tumor B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
One O
hundred O
ASA O
I-II O
patients O
, O
aged O
18-60 O
yr O
undergoing O
elective O
minor O
surgery O
, O
were O
randomized O
to O
receive O
either O
an O
LTS O
( O
n O
= O
50 O
) O
or O
PLMA O
( O
n O
= O
50 O
) O
for O
airway O
management O
. O
[]

BACKGROUND O
Pharmacogenetic O
markers O
related O
to O
drug O
metabolism O
and O
mechanisms O
of O
action O
could O
help O
to O
better O
select O
patients O
with O
metastatic O
colorectal O
cancer O
( O
mCRC O
) O
for O
treatment O
. O
[]

Safety O
was O
assessed O
by O
evaluation O
of O
adverse O
events O
, O
vital O
signs O
, O
and O
laboratory O
data O
. O
[]

PURPOSE O
To O
assess O
the O
efficacy O
and O
safety O
of O
botulinum O
toxin O
type O
A O
( O
BoNT-A O
) O
injection O
in O
patients O
suffering O
from O
intractable O
periorbital O
pain O
after O
acute O
angle O
closure O
glaucoma O
( O
AACG O
) O
. O
[]

Human O
platelet O
response O
to O
three O
salicylate O
dosage O
forms O
. O
[]

METHODS O
A O
series O
of O
blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
collected O
over O
a O
period O
of O
48 O
h O
after O
i.v O
. O
['Physiological-Clinical']

Screening B-outcome ['Resource-use']
accuracy O
was O
comparably O
limited O
based O
on O
ADS O
subscales O
reflecting O
psychoperceptual O
or O
psychophysical O
withdrawal O
. O
['Resource-use']

In O
cured O
patients O
taking O
750 O
mg O
mefloquine O
, O
peak O
plasma B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
Cmax B-outcome ['Physiological-Clinical']
) O
and O
area O
under O
the O
plasma B-outcome ['Physiological-Clinical']
concentration-time O
curve O
( O
AUC O
) O
were O
significantly O
greater O
than O
in O
the O
patients O
for O
whom O
treatment O
failed O
( O
p O
less O
than O
0.0005 O
and O
p O
less O
than O
0.01 O
, O
respectively O
) O
, O
and O
plasma B-outcome ['Physiological-Clinical']
mefloquine I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
from O
8 O
hours O
to O
18 O
days O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
wondered O
whether O
anabolic O
treatment O
with O
oxandrolone O
would O
affect O
these O
proteins O
. O
[]

Participants O
with O
2 O
study O
eyes O
had O
1 O
eye O
randomized O
to O
sham O
plus O
prompt O
laser O
and O
1 O
eye O
randomized O
to O
a O
real O
injection O
group O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Both O
drugs O
were O
equally O
effective O
in O
lowering O
blood O
pressure O
. O
[]

In O
stratum O
1 O
, O
CBRs O
were O
50.5 O
% O
with O
gefitinib O
and O
45.5 O
% O
with O
placebo O
. O
[]

This O
result O
did O
not O
alter O
in O
post O
hoc O
analyses O
, O
when O
patients O
not O
achieving O
target B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
( O
< O
10 O
breaths/min O
) O
or O
non-compliant O
patients O
were O
excluded O
. O
['Physiological-Clinical']

Available O
data O
are O
not O
sufficient O
to O
serve O
as O
a O
basis O
for O
firm O
dietary O
advice O
. O
[]

At O
24 O
months O
, O
IL-2-induced B-outcome ['Physiological-Clinical']
IL-1 I-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
was O
increased O
in O
patients O
treated O
with O
methotrexate O
, O
whereas O
S O
epidermidis-induced B-outcome ['Physiological-Clinical']
IL-1 I-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
was O
enhanced O
in O
colchicine-treated O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Coronary O
angiography O
using O
multidetector O
computed O
tomography O
( O
MDCT-CA O
) O
is O
a O
recent O
technique O
for O
the O
nonivasive O
study O
of O
coronary O
arteries O
. O
[]

40 O
patients O
with O
the O
irresectable O
hepatocellular O
carcinoma O
( O
HCC O
) O
admitted O
to O
the O
department O
of O
HPB O
surgery O
in O
the O
First O
Affiliated O
Hospital O
of O
SUMS O
were O
randomized O
into O
two O
groups O
: O
( O
20 O
each O
) O
from O
Feb. O
1994 O
to O
April O
, O
1995 O
. O
[]

Increased O
appetite B-outcome ['Physiological-Clinical']
and O
skin B-outcome ['Physiological-Clinical']
rash B-outcome ['Physiological-Clinical']
were O
significant O
side O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
white O
women O
were O
less O
likely O
to O
benefit O
than O
African-American O
women O
( O
OR O
= O
0.34 O
; O
95 O
% O
CI O
= O
0.11-0.99 O
; O
P O
= O
.05 O
) O
. O
[]

Autonomy O
was O
usually O
recovered O
rapidly O
, O
but O
the O
degree O
of O
recovery O
depended O
on O
the O
patient O
's O
previous O
autonomy O
( O
p O
< O
0.0001 O
) O
. O
[]

Intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

No O
interaction O
was O
found O
between O
aspirin O
and O
the O
most O
used O
antihypertensive O
drug O
classes O
( O
angiotensin O
converting O
enzyme O
inhibitors O
and O
calcium O
antagonists O
) O
. O
[]

The O
major O
dose-limiting B-outcome ['Physiological-Clinical']
toxicity B-outcome ['Adverse-effects']
for O
both O
drugs O
was O
leukopenia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

The O
countries O
' O
corresponding O
Amplicor B-outcome ['Physiological-Clinical']
positive O
prevalences O
were O
0.8 O
% O
and O
21.9 O
% O
. O
['Physiological-Clinical']

Hypogammaglobulinemia O
at O
D15 O
was O
not O
associated O
with O
an O
increased O
risk O
of O
infections O
during O
the O
first O
year O
. O
[]

This O
article O
describes O
the O
design O
of O
the O
study O
and O
the O
participant O
flow O
until O
and O
including O
randomization O
. O
[]

TTCW B-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
for O
100-mg O
sitaxsentan O
patients O
than O
placebo O
( O
P O
= O
0.090 O
) O
. O
['Physiological-Clinical']

Detection O
rates O
of O
subsequent B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
in O
the O
first O
re-biopsy O
after O
these O
diagnoses O
were O
determined O
. O
['Physiological-Clinical']

A O
total O
of O
89 O
patients O
were O
enrolled O
, O
and O
71 O
completed O
the O
10-week O
treatment O
period O
. O
[]

A O
randomized O
trial O
of O
radiation O
therapy O
compared O
to O
split O
course O
radiation O
therapy O
combined O
with O
mitomycin O
C O
and O
5 O
fluorouracil O
as O
initial O
treatment O
for O
advanced O
laryngeal O
and O
hypopharyngeal O
squamous O
carcinoma O
. O
[]

They O
were O
instructed O
to O
follow O
the O
American O
Heart O
Association O
Step O
One O
diet O
. O
[]

RESULTS O
As O
the O
drop-out O
rate O
after O
crossover O
was O
high O
( O
17 O
of O
79 O
patients O
[ O
22 O
% O
] O
) O
, O
we O
analyzed O
the O
trial O
as O
a O
parallel O
clinical O
trial O
, O
using O
data O
of O
the O
first O
half O
of O
the O
crossover O
phase O
only O
. O
[]

Variables O
associated O
with O
non-adherence O
were O
diagnosis O
by O
screening B-outcome ['Resource-use']
( O
OR O
1.88 O
, O
95 O
% O
CI O
1.26-2.82 O
, O
P O
= O
0.001 O
) O
, O
illegal B-outcome ['Physiological-Clinical']
immigration O
status O
( O
OR O
1.48 O
, O
95 O
% O
CI O
1.01-2.15 O
, O
P O
= O
0.03 O
) O
, O
unemployment B-outcome ['Life-Impact']
( O
OR O
1.91 O
, O
95 O
% O
CI O
1.28-2.85 O
, O
P O
= O
0.0008 O
) O
, O
illiteracy B-outcome ['Life-Impact']
( O
OR O
1.73 O
, O
95 O
% O
CI O
1.04-2.88 O
, O
P O
= O
0.02 O
) O
, O
lack O
of O
family B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
( O
OR O
3.7 O
, O
95 O
% O
CI O
2.54-5.4 O
, O
P O
= O
0.001 O
) O
and O
the O
6-month O
treatment O
['Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

A O
comparative O
study O
of O
caudal O
bupivacaine O
and O
midazolam-bupivacaine O
mixture O
for O
post-operative O
analgesia O
in O
children O
undergoing O
genitourinary O
surgery O
. O
[]

Sixty-six O
patients O
with O
poorly O
responsive O
tumors O
such O
as O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
, O
bladder O
cancer O
, O
gastrointestinal O
cancers O
, O
kidney O
cancer O
, O
melanoma O
and O
metastatic O
carcinoma O
of O
unknown O
origin O
entered O
the O
study O
. O
[]

METHODS O
119 O
asthmatics O
were O
randomized O
( O
64 O
in O
the O
intervention O
and O
55 O
in O
the O
reference O
group O
) O
. O
[]

Segmental B-outcome ['Physiological-Clinical']
maxillary I-outcome ['Physiological-Clinical']
tipping I-outcome ['Physiological-Clinical']
occurred O
in O
both O
groups O
and O
did O
not O
affect O
relapse B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Solid B-outcome ['Physiological-Clinical']
cancers I-outcome ['Physiological-Clinical']
developed O
in O
six O
patients O
in O
the O
etanercept O
group O
, O
as O
compared O
with O
none O
in O
the O
control O
group O
( O
P=0.01 O
) O
. O
['Physiological-Clinical']

Analysis O
of O
clinical O
and O
laboratory O
data O
showed O
no O
significant O
difference O
between O
either O
group O
of O
patients O
as O
to O
the O
evolution O
of O
their O
illness O
except O
for O
a O
significantly O
higher O
incidence O
of O
anuria B-outcome ['Physiological-Clinical']
and O
a O
significantly O
faster B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
in O
the O
treated O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
were O
interested O
in O
the O
potential O
role O
of O
filgrastim O
( O
recombinant O
methionyl O
human O
granulocyte O
colony-stimulating O
factor O
, O
r-metHuG-CSF O
) O
in O
the O
reduction O
of O
mucositis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Hyperbaric O
oxygen O
in O
the O
treatment O
of O
childhood O
autism O
: O
a O
randomised O
controlled O
trial O
. O
[]

Patients O
were O
randomly O
assigned O
to O
treatment O
( O
n O
= O
61 O
) O
with O
aerosolized O
pentamidine O
once O
every O
month O
or O
to O
no O
treatment O
( O
n O
= O
60 O
) O
. O
[]

Accelerated O
production B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
material I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
phospholipids I-outcome ['Physiological-Clinical']
in O
infants O
from O
dexamethasone-treated O
dams O
was O
indicated O
by O
increases O
in O
total O
lung B-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
84.5 O
+/- O
8.1 O
mg/g O
dry O
lung O
versus O
75.1 O
+/- O
9.9 O
, O
p O
less O
than O
0.025 O
) O
, O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
5.65 O
+/- O
3.33 O
mg/g O
dry O
lung O
versus O
3.01 O
+/- O
1.84 O
, O
p O
less O
than O
0.05 O
) O
, O
and O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
disaturated I-outcome ['Physiological-Clinical']
phosphatidylcholine I-outcome ['Physiological-Clinical']
( O
DPC B-outcome ['Physiological-Clinical']
) O
( O
2.47 O
+/- O
1.84 O
mg/g O
dry O
lung O
versus O
1.06 O
+/- O
1.05 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
From O
November O
2002 O
to O
July O
2003 O
, O
80 O
patients O
who O
received O
PPH O
were O
randomly O
divided O
in O
to O
titanoreine O
group O
( O
n=42 O
) O
and O
control O
group O
without O
titanoreine O
( O
n=38 O
) O
. O
[]

on O
retention O
on O
treatment O
over O
1 O
year O
. O
[]

Biomarker O
analysis O
suggested O
that O
in O
stratum O
1 O
there O
was O
greater O
benefit O
with O
gefitinib O
in O
patients O
who O
were O
ER-negative O
or O
had O
lower O
levels O
of O
ER O
protein O
. O
[]

Assessment O
included O
recording O
of O
: O
visual O
analog O
scores O
( O
VAS O
) O
for O
pain O
; O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
; O
range O
of O
movement B-outcome ['Physiological-Clinical']
; O
joint B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
; O
local B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
; O
synovial B-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
; O
joint-line B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
periarticular I-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
role O
of O
intensive O
induction O
chemotherapy O
in O
small O
cell O
cancer O
of O
the O
lung O
remains O
unclear O
. O
[]

The O
Spearman O
correlation O
coefficients O
for O
pain B-outcome ['Physiological-Clinical']
, O
stiffness B-outcome ['Physiological-Clinical']
and O
function B-outcome ['Life-Impact']
were O
0.88 O
, O
0.77 O
and O
0.87 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Analysis O
was O
on O
an O
intention O
to O
treat O
basis O
. O
[]

Intrathecal O
lentivirus-mediated O
transfer O
of O
interleukin-10 O
attenuates O
chronic B-outcome ['Physiological-Clinical']
constriction I-outcome ['Physiological-Clinical']
injury-induced I-outcome ['Physiological-Clinical']
neuropathic I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
through O
modulation O
of O
spinal O
high-mobility O
group O
box O
1 O
in O
rats O
. O
['Physiological-Clinical']

Feedlot B-outcome ['Physiological-Clinical']
performance O
showed O
an O
advantage O
( O
P O
< O
.10 O
) O
to O
feeding O
SMB O
during O
the O
first O
84 O
d O
of O
the O
trial O
and O
an O
advantage O
to O
feeding O
SBM-U O
during O
the O
last O
98 O
d O
of O
the O
trial O
. O
['Physiological-Clinical']

To O
investigate O
this O
aim O
, O
we O
randomized O
30 O
subjects O
to O
2.0 O
g/d O
ginger O
or O
placebo O
for O
28 O
days O
. O
[]

The O
less O
favourable O
improvement O
in O
periodontal O
function O
of O
postsplint O
or O
nonsplint O
teeth O
seemed O
to O
be O
due O
to O
the O
loss O
of O
BRG B-outcome ['Physiological-Clinical']
material I-outcome ['Physiological-Clinical']
caused O
by O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
total O
298 O
consecutive O
patients O
68 O
? O
[]

We O
investigated O
whether O
( O
a O
) O
cigarette O
smoking O
is O
linked O
to O
increased O
cytokine O
production O
, O
which O
may O
mediate O
platelet O
activation O
and O
thrombin O
generation O
in O
chronic O
coronary O
artery O
disease O
( O
CAD O
) O
, O
and O
( O
b O
) O
aspirin O
treatment O
inhibits O
smoking-related O
changes O
on O
cytokines O
, O
platelets O
, O
and O
thrombin O
. O
[]

The O
impaired O
hemostasis O
of O
aspirin-treated O
patients O
is O
an O
annoying O
problem O
during O
and O
after O
cardiopulmonary O
bypass O
. O
[]

METHODS O
Forty-three O
patients O
suffering O
from O
premature O
ejaculation O
were O
studied O
. O
[]

Opposite O
results O
for O
the O
two O
subgroups O
were O
also O
obtained O
for O
the O
left-right B-outcome ['Physiological-Clinical']
relations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
alpha-power I-outcome ['Physiological-Clinical']
over O
the O
anterior O
regions O
. O
['Physiological-Clinical']

Comparison O
of O
methods O
for O
intravenous O
infusion O
of O
fat O
emulsion O
during O
extracorporeal O
membrane O
oxygenation O
. O
[]

Five O
cases O
of O
hypotension B-outcome ['Physiological-Clinical']
and O
4 O
of O
bradycardia B-outcome ['Physiological-Clinical']
occurred O
in O
each O
group O
and O
one O
patient O
in O
the O
mepivacaine O
group O
suffered O
slight O
postoperative O
cephalea O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
sensitivity O
of O
the O
index O
and O
area O
recordings B-outcome ['Physiological-Clinical']
to O
detect O
plaque O
removed O
by O
brushing O
was O
then O
evaluated O
. O
['Physiological-Clinical']

29.1 O
( O
LI O
) O
and O
44.6 O
? O
[]

OBJECTIVE O
The O
effectiveness O
of O
influenza O
vaccination O
in O
preventing O
illness O
is O
lower O
in O
the O
elderly O
; O
this O
is O
why O
the O
ability O
of O
Lactobacillus O
plantarum O
CECT O
7315/7316 O
to O
stimulate O
the O
response O
to O
influenza B-outcome ['Physiological-Clinical']
vaccination I-outcome ['Physiological-Clinical']
in O
elderly O
was O
evaluated O
. O
['Physiological-Clinical']

CONCLUSIONS O
Defibrillation B-outcome ['Physiological-Clinical']
efficacy O
decreases O
with O
increasing O
VF O
duration O
using O
biphasic O
waveforms O
in O
humans O
. O
['Physiological-Clinical']

Validity O
was O
assessed O
by O
correlating O
the O
DD-CGAS O
with O
measures O
of O
functioning O
and O
symptoms O
in O
83 O
youngsters O
with O
PDD O
. O
[]

[ O
Clinical O
study O
on O
treatment O
of O
endometriosis-related O
infertility O
patients O
by O
laparoscopic O
surgery O
in O
combination O
of O
quyu O
jiedu O
recipe O
] O
. O
[]

ATRA O
has O
no O
overall O
effect O
on O
treatment O
outcomes O
in O
this O
group O
of O
patients O
. O
[]

In O
agreement O
with O
findings O
in O
animal O
studies O
, O
our O
results O
suggest O
that O
microalbuminuria O
is O
to O
a O
large O
extent O
pressure-dependent O
, O
probably O
because O
of O
glomerular O
hypertension O
, O
and O
that O
autoregulation O
of O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
is O
normal O
in O
most O
patients O
with O
incipient O
diabetic O
nephropathy O
. O
['Physiological-Clinical']

The O
accuracy O
of O
the O
system O
is O
usually O
sufficient O
for O
clinical O
purposes O
, O
provided O
the O
calibration O
is O
checked O
every O
4 O
h O
. O
[]

CONCLUSIONS O
This O
patient-based O
sexual O
partner O
notification O
program O
can O
help O
reduce O
risks O
for O
subsequent O
STIs O
among O
urban O
, O
minority O
patients O
presenting O
for O
care O
at O
STI O
clinics O
. O
[]

After O
2 O
months O
, O
a O
significant O
improvement O
in O
skin B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
occurred O
in O
patients O
given O
probiotic-supplemented O
formulas O
, O
as O
compared O
to O
the O
unsupplemented O
group O
; O
chi O
( O
2 O
) O
= O
12.27 O
, O
P O
= O
0.002 O
. O
['Physiological-Clinical']

Data O
from O
epidemiologic O
studies O
suggest O
that O
hookworm O
infections O
, O
in O
establishing O
an O
immunologic O
phenotype O
conducive O
to O
parasite O
survival O
, O
may O
protect O
against O
the O
development O
of O
allergic O
disease O
. O
[]

The O
ratio O
between O
GH B-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
GHRH I-outcome ['Physiological-Clinical']
plus I-outcome ['Physiological-Clinical']
arginine I-outcome ['Physiological-Clinical']
and O
after O
GHRH B-outcome ['Physiological-Clinical']
plus O
saline B-outcome ['Resource-use']
was O
significantly O
greater O
in O
patients O
than O
in O
controls O
( O
751 O
+/- O
531 O
% O
vs. O
81 O
+/- O
45 O
% O
; O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Rates O
of O
prothrombin O
and O
factor O
V O
activation O
( O
FVa O
) O
, O
fibrinogen B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Fbg I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cleavage I-outcome ['Physiological-Clinical']
and O
FVa B-outcome ['Physiological-Clinical']
inactivation I-outcome ['Physiological-Clinical']
showed O
that O
both O
quinapril O
and O
atorvastatin O
decreased O
the O
rates O
of O
: O
formation O
of O
thrombin B-outcome ['Physiological-Clinical']
B-chain I-outcome ['Physiological-Clinical']
( O
by O
30.6 O
% O
, O
P=0.007 O
; O
and O
by O
34.3 O
% O
, O
P=0.003 O
) O
, O
formation O
of O
thrombin-antithrombin B-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
( O
by O
30.4 O
% O
, O
P=0.0002 O
; O
and O
by O
40 O
% O
, O
P=0.001 O
) O
, O
FV B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
( O
by O
19.1 O
% O
, O
P=0.03 O
; O
and O
by O
21.8 O
% O
, O
P=0.005 O
) O
and O
Fbg B-outcome ['Physiological-Clinical']
depletion I-outcome ['Physiological-Clinical']
( O
by O
29.2 O
% O
, O
P=0.004 O
; O
and O
by O
32.7 O
% O
, O
P=0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

During O
the O
mitigated O
behavior O
, O
oxytocin O
increased O
the O
originally O
diminished O
brain O
activity O
in O
the O
medial O
prefrontal O
cortex O
( O
P O
< O
.001 O
) O
. O
[]

EXPERIMENTAL O
APPROACH O
A O
haplotype O
analysis O
of O
eight O
single-nucleotide O
polymorphisms O
of O
ADORA2A O
was O
performed O
in O
82 O
volunteers O
. O
[]

A O
biomicroscopic O
examination O
and O
a O
test O
of O
tolerability O
on O
instillation O
were O
also O
performed O
, O
and O
adverse O
events O
were O
recorded O
. O
[]

12.2 O
vs. O
22.8 O
? O
[]

Our O
study O
shows O
that O
use O
of O
a O
small O
dose O
of O
subconjunctival O
5-FU O
provides O
significantly O
lower O
postoperative B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
than O
does O
no O
antimetabolite O
treatment O
. O
['Physiological-Clinical']

METHODS O
Blood B-outcome ['Physiological-Clinical']
samples O
to O
measure O
activation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
and O
fibrinolysis B-outcome ['Physiological-Clinical']
were O
collected O
from O
42 O
patients O
participating O
in O
the O
enoxaparin O
trial O
for O
acute O
aneurysmal O
SAH O
at O
four O
time O
points O
: O
1 O
) O
at O
hospital O
admission O
; O
2 O
) O
12 O
to O
24 O
hours O
after O
aneurysm O
surgery O
but O
before O
initiation O
of O
enoxaparin O
therapy O
; O
3 O
) O
3 O
hours O
after O
the O
first O
dose O
; O
and O
4 O
) O
at O
the O
conclusion O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Gestational B-outcome ['Physiological-Clinical']
age O
was O
29.9 O
weeks O
( O
25.4-32.5 O
) O
in O
Group O
A O
, O
28.6 O
weeks O
( O
26.6-33.4 O
) O
in O
Group O
B O
and O
27.3 O
weeks O
( O
26.7-31.1 O
) O
in O
Group O
C O
( O
median O
and O
range O
) O
. O
['Physiological-Clinical']

RESULTS O
Thirty-six O
patients O
received O
a O
TKI O
after O
everolimus O
: O
sunitinib O
in O
17 O
patients O
, O
sorafenib O
in O
15 O
, O
and O
dovitinib O
( O
TKI258 O
) O
in O
4 O
. O
[]

A O
comparison O
of O
the O
effects O
of O
anticholinergic O
and O
beta O
2-agonist O
and O
combination O
therapy O
on O
respiratory O
impedance O
in O
COPD O
. O
[]

Overall O
satisfaction O
with O
pain B-outcome ['Resource-use']
management I-outcome ['Resource-use']
was O
better O
in O
COX-2-treated O
patients O
( O
very O
satisfied O
vs. O
satisfied O
) O
. O
['Resource-use']

Using O
the O
stringent O
SDAI O
and O
CDAI O
criteria O
, O
however O
, O
remission O
rates O
in O
patients O
treated O
with O
tocilizumab O
were O
in O
the O
same O
range O
as O
those O
seen O
in O
patients O
treated O
with O
tumor O
necrosis O
factor O
inhibitors O
. O
[]

RESULTS O
One O
hundred O
thirty-one O
( O
23 O
% O
[ O
131/577 O
] O
) O
screened O
women O
were O
found O
to O
have O
MPC O
. O
[]

OBJECTIVE O
We O
sought O
to O
investigate O
the O
effects O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
diphenhydramine O
( O
50 O
mg O
) O
, O
and O
placebo O
on O
memory B-outcome ['Life-Impact']
and O
psychomotor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
after O
acute O
( O
day O
1 O
) O
and O
subchronic O
( O
day O
4 O
) O
daily O
administration O
in O
48 O
healthy O
volunteers O
( O
24 O
men O
and O
24 O
women O
) O
. O
['Life-Impact', 'Life-Impact']

Granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
as O
adjunct O
therapy O
in O
relapsed O
Hodgkin O
disease O
. O
[]

The O
overall O
results O
indicated O
that O
improvisational O
music O
therapy O
was O
more O
effective O
at O
facilitating O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
non-verbal B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
children O
than O
play O
. O
['Life-Impact', 'Life-Impact']

We O
conclude O
that O
nebulized O
racemic O
epinephrine O
is O
effective O
treatment O
for O
the O
acute O
signs O
of O
croup O
. O
[]

The O
aim O
of O
this O
double-blind O
, O
placebo-controlled O
, O
single O
ascending-dose O
study O
was O
to O
investigate O
the O
safety O
, O
tolerability B-outcome ['Life-Impact']
, O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
pharmacodynamics B-outcome ['Physiological-Clinical']
of O
GS-9620 O
in O
healthy O
volunteers O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
randomized O
clinical O
trial O
of O
comprehensive O
care O
for O
hypertensive O
young O
urban O
black O
men O
, O
factors O
potentially O
associated O
with O
care O
and O
control O
were O
assessed O
at O
baseline O
for O
the O
309 O
enrolled O
men O
. O
[]

STUDY O
OBJECTIVES O
Cheyne-Stokes O
respirations O
occur O
in O
40 O
% O
of O
patients O
with O
heart O
failure O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
was O
recorded O
using O
radiotelemetric B-outcome ['Physiological-Clinical']
technique O
( O
Heidelberg O
capsule O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Arm O
A O
was O
started O
at O
the O
26th O
postoperative O
day O
and O
arm O
B O
at O
the O
21st O
day O
on O
average O
. O
[]

The O
CD4 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
the O
SH O
group O
at O
week O
12 O
and O
thereafter O
were O
significantly O
increased O
from O
the O
baseline O
value O
. O
['Physiological-Clinical']

There O
is O
a O
very O
high O
prevalence O
of O
hypertension O
in O
diabetic O
subjects O
, O
which O
makes O
it O
necessary O
to O
use O
an O
antihypertensive O
drug O
with O
the O
least O
possible O
metabolic O
interference O
. O
[]

World O
Health O
Organization O
performance O
status O
( O
WHO O
PS O
) O
for O
CLIP O
or O
alpha-fetoprotein O
for O
BCLC O
allowed O
a O
significant O
improvement O
of O
prognostic O
information O
. O
[]

A O
significant O
difference O
of O
average O
values O
of O
CRP B-outcome ['Physiological-Clinical']
between O
the O
3rd O
and O
21st O
day O
in O
both O
groups O
of O
patients O
was O
established O
, O
as O
well O
as O
the O
similarity O
in O
average O
values O
of O
CRP B-outcome ['Physiological-Clinical']
, O
which O
points O
to O
the O
fact O
that O
the O
mechanical O
effect O
of O
through O
drainage O
is O
dominant O
, O
speaking O
about O
rinsing O
focus O
of O
infection B-outcome ['Physiological-Clinical']
and O
eliminating O
necrotic O
tissues O
and O
small O
sequesters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
statistical O
difference O
in O
pH B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
between O
the O
groups O
. O
['Physiological-Clinical']

METHODS O
One O
third O
of O
the O
patients O
of O
the O
international O
trial O
were O
treated O
at O
Link?ping O
University O
Hospital O
. O
[]

METHOD O
Seventy-seven O
children O
were O
randomly O
assigned O
to O
2 O
treatments O
( O
parent O
+ O
therapist O
EMT O
or O
therapist-only O
EMT O
) O
and O
received O
36 O
intervention O
sessions O
. O
[]

However O
, O
no O
field O
data O
exist O
on O
the O
impact O
of O
chemotherapy O
alone O
on O
vector O
efficiency O
and O
transmission O
intensity O
of O
W O
bancrofti O
. O
[]

No O
difference O
in O
clinical O
outcomes O
could O
be O
demonstrated O
except O
that O
the O
percentage O
of O
patients O
with O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
study O
group O
( O
1.2 O
% O
versus O
5.4 O
% O
, O
p O
= O
0.035 O
) O
. O
['Physiological-Clinical']

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
VF I-outcome ['Physiological-Clinical']
was O
longer O
in O
the O
ablation O
group O
( O
median O
18.6 O
months O
[ O
lower O
quartile O
2.4 O
, O
upper O
quartile O
not O
determinable O
] O
) O
than O
in O
the O
control O
group O
( O
5.9 O
months O
[ O
IQR O
0.8-26.7 O
] O
) O
. O
['Physiological-Clinical']

When O
we O
analyzed O
the O
evolution O
of O
the O
intestinal B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time O
throughout O
the O
study O
of O
children O
whose O
total O
basal B-outcome ['Physiological-Clinical']
intestinal I-outcome ['Physiological-Clinical']
transit B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
> O
50th O
percentile O
, O
significant O
differences O
were O
observed O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

But O
EA O
seems O
to O
have O
little O
influence O
on O
the O
stress O
reaction O
to O
major O
abdominal O
surgery O
. O
[]

The O
role O
of O
pneumatic O
compression O
in O
the O
treatment O
of O
postmastectomy O
lymphedema O
. O
[]

After O
treatment O
with O
chlorhexidine O
varnish O
, O
significantly O
more O
initial B-outcome ['Physiological-Clinical']
root-surface I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
had I-outcome ['Physiological-Clinical']
hardened I-outcome ['Physiological-Clinical']
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

The O
ultrasound O
head O
was O
moved O
over O
a O
10-cm2 O
area O
using O
small O
, O
continuous O
, O
circular O
movements O
. O
[]

Comparison O
was O
made O
with O
a O
delayed O
treatment O
control O
group O
( O
DTC O
) O
. O
[]

It O
focuses O
primarily O
on O
promoting O
the O
integration O
of O
the O
patients O
into O
their O
social B-outcome ['Life-Impact']
networks I-outcome ['Life-Impact']
, O
and O
additionally O
to O
coordinating O
outpatient B-outcome ['Resource-use']
care I-outcome ['Resource-use']
and O
addressing B-outcome ['Life-Impact']
concerns I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

The O
mean O
times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stabilization I-outcome ['Physiological-Clinical']
were O
6.8 O
days O
in O
the O
analog-computer O
group O
, O
7.3 O
days O
in O
the O
linear-regression O
group O
, O
and O
8.4 O
days O
in O
the O
empiric-dosing O
group O
; O
these O
times O
were O
not O
significantly O
different O
. O
['Physiological-Clinical']

The O
study O
consisted O
of O
20 O
subjects O
who O
received O
two O
tablets O
of O
ViviScal O
once O
daily O
and O
20 O
who O
received O
two O
tablets O
of O
fish O
extract O
once O
daily O
for O
6 O
months O
. O
[]

This O
strategy O
offers O
the O
possibility O
to O
improve O
markedly O
morbidity O
and O
mortality B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
, O
presently O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
North O
American O
men O
. O
['Mortality']

Finally O
, O
a O
placebo-controlled O
discontinuation O
study O
tested O
the O
need O
for O
continuous O
treatment O
. O
[]

It O
will O
provide O
the O
information O
needed O
for O
planning O
a O
definitive O
trial O
to O
test O
home-based O
RTG O
training O
. O
[]

No O
control O
group O
was O
examined O
and O
probably O
the O
changes O
reflect O
some O
effects O
of O
sexual B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
cation I-outcome ['Physiological-Clinical']
handling I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Rationale O
and O
design O
of O
the O
Folic O
Acid O
for O
Vascular B-outcome ['Physiological-Clinical']
Outcome I-outcome ['Physiological-Clinical']
Reduction O
In O
Transplantation O
( O
FAVORIT O
) O
trial O
. O
['Physiological-Clinical']

MANCOVA O
, O
ANCOVA O
and O
Post O
Hoc O
analyses O
were O
utilized O
to O
test O
for O
significant O
differences O
among O
the O
three O
groups O
. O
[]

Grades B-outcome ['Physiological-Clinical']
2-4 I-outcome ['Physiological-Clinical']
GVHD I-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
Tac/Sir O
and O
Tac/Mtx O
arms O
( O
26 O
% O
vs O
34 O
% O
, O
P O
= O
.48 O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
changing O
the O
rate O
of O
infusion O
of O
propofol O
for O
induction O
of O
anaesthesia B-outcome ['Resource-use']
was O
studied O
in O
60 O
elderly O
patients O
. O
['Resource-use']

Primary O
endpoints O
of O
abstinence B-outcome ['Life-Impact']
were O
previously O
reported O
. O
['Life-Impact']

Effects O
of O
fish O
oil O
supplementation O
on O
markers O
of O
the O
metabolic O
syndrome O
. O
[]

The O
effect O
of O
the O
MIP O
seems O
to O
be O
dependent O
on O
the O
order O
of O
components O
, O
which O
suggests O
that O
it O
is O
not O
due O
to O
sustained O
attention O
to O
the O
affected O
limb O
, O
but O
is O
consistent O
with O
sequential O
activation O
of O
cortical O
motor O
networks O
. O
[]

The O
State O
Trait O
Anxiety O
Inventory O
for O
Children O
was O
performed O
in O
children O
> O
or O
= O
10 O
years O
of O
age O
. O
[]

[ O
Intra-arterial O
( O
5-FU/FA O
and O
FUDR O
) O
versus O
systemic O
chemotherapy O
( O
5-FU/FA O
) O
of O
non-resectable B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

Influence O
of O
Aloe O
arborescens O
Mill O
. O
[]

Measurements O
for O
both O
parameters O
were O
taken O
at O
0 O
, O
1 O
, O
2 O
and O
3 O
months O
of O
treatment O
. O
[]

In O
many O
previous O
studies O
NTG O
has O
been O
found O
to O
be O
effective O
in O
controlling O
hypertension B-outcome ['Physiological-Clinical']
; O
ISDN O
offers O
and O
alternative O
approach O
in O
reducing O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Stapled O
mucosectomy O
for O
acute O
thrombosed O
circumferential O
piles O
is O
feasible O
and O
may O
result O
in O
less O
pain B-outcome ['Physiological-Clinical']
, O
a O
more O
rapid O
resolution O
of O
symptoms O
and O
an O
earlier O
return O
to O
work O
compared O
with O
a O
conventional O
procedure O
. O
['Physiological-Clinical']

Little O
evidence O
has O
been O
published O
for O
the O
nondiabetic O
population O
. O
[]

After O
a O
2-wk O
run-in O
period O
, O
the O
doses O
of O
BDI O
were O
halved O
, O
while O
the O
patients O
were O
assigned O
to O
receive O
orally O
ONO-1078 O
, O
450 O
mg O
twice O
daily O
, O
or O
placebo O
. O
[]

BACKGROUND O
Treatment O
of O
short O
children O
born O
small O
for O
gestational O
age O
SGA O
with O
recombinant O
human O
growth O
hormone O
r-hGH O
increases O
growth B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
during O
childhood O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
data O
do O
not O
show O
that O
one O
intervention O
is O
better O
than O
the O
other O
. O
[]

METHOD O
Weight O
change O
was O
measured O
for O
63 O
children O
and O
adolescents O
with O
autism O
treated O
with O
risperidone O
for O
6 O
months O
. O
[]

BACKGROUND O
It O
has O
been O
suggested O
that O
the O
use O
of O
adjunctive O
hyperbaric O
oxygen O
therapy O
improves O
the O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
, O
and O
decreases O
the O
risk O
of O
lower B-outcome ['Resource-use']
extremity I-outcome ['Resource-use']
amputations I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

This O
study O
aimed O
to O
evaluate O
the O
efficacy O
of O
an O
emotion O
training O
programme O
for O
a O
group O
of O
young O
children O
with O
autism O
with O
a O
range O
of O
intellectual O
ability O
. O
[]

Differences O
( O
silodosin O
vs O
placebo O
) O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
and O
subscores O
increased O
by O
week O
12 O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Rates O
of O
responses B-outcome ['Physiological-Clinical']
in O
patients O
adequately O
dosed O
( O
i.e. O
, O
with O
significant O
hematotoxicity O
) O
with O
amonafide O
ranged O
from O
35 O
to O
50 O
% O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
groups O
. O
[]

METHODS O
AND O
RESULTS O
In O
this O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
study O
, O
20 O
healthy O
, O
male O
subjects O
were O
randomized O
to O
receive O
either O
simvastatin O
( O
80 O
mg/d O
) O
or O
placebo O
for O
4 O
days O
before O
intravenous O
administration O
of O
LPS O
( O
20 O
IU/kg O
IV O
) O
. O
[]

When O
a O
randomized O
trial O
( O
NMSG O
4/90 O
) O
comparing O
treatment O
with O
melphalan/prednisone O
to O
melphalan/ O
prednisone O
+ O
interferon O
alpha-2b O
in O
newly O
diagnosed O
multiple O
myeloma O
was O
initiated O
in O
1990 O
, O
a O
quality-of-life B-outcome ['Life-Impact']
assessment O
was O
integrated O
into O
the O
study O
. O
['Life-Impact']

Evidence O
of O
radiographic B-outcome ['Physiological-Clinical']
benefit O
of O
treatment O
with O
infliximab O
plus O
methotrexate O
in O
rheumatoid O
arthritis O
patients O
who O
had O
no O
clinical O
improvement O
: O
a O
detailed O
subanalysis O
of O
data O
from O
the O
anti-tumor O
necrosis O
factor O
trial O
in O
rheumatoid O
arthritis O
with O
concomitant O
therapy O
study O
. O
['Physiological-Clinical']

The O
emergence B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
the O
D O
group O
was O
significantly O
faster O
than O
the O
I O
group O
( O
D O
: O
14.9 O
+/- O
2.4 O
min O
vs O
I O
: O
29.2 O
+/- O
2.4 O
min O
for O
eye-opening O
) O
. O
['Physiological-Clinical']

We O
found O
no O
evidence O
for O
increased O
nonlinearity O
as O
loads O
became O
perceptible O
. O
[]

No O
severe O
adverse O
effect O
was O
reported O
in O
either O
group O
. O
[]

No O
large O
surveys O
of O
side O
effects O
of O
this O
drug O
have O
been O
reported O
in O
autistic O
children O
. O
[]

OBJECTIVE O
Postprandial O
hyperglycemia O
observed O
in O
type O
2 O
diabetes O
mellitus O
is O
a O
risk O
factor O
for O
atherosclerosis O
. O
[]

GABHS O
isolates O
were O
serotyped O
to O
distinguish O
bacteriological B-outcome ['Physiological-Clinical']
treatment O
failures B-outcome ['Physiological-Clinical']
( O
and O
relapses B-outcome ['Physiological-Clinical']
) O
from O
new O
acquisitions O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Outcome O
after O
4 O
years O
of O
treatment O
, O
including O
cognitive B-outcome ['Life-Impact']
, O
language B-outcome ['Life-Impact']
, O
adaptive B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
with O
benign O
gastric O
ulcer O
were O
treated O
for O
four O
weeks O
with O
carbenoxolone O
sodium O
as O
Biogastrone O
tablets O
100 O
mg O
three O
times O
a O
day O
, O
and O
if O
the O
ulcers O
were O
not O
healed O
at O
4 O
weeks O
treatment O
was O
continued O
for O
a O
further O
4 O
weeks O
. O
[]

RESULTS O
A O
total O
of O
474 O
patients O
were O
treated O
( O
239 O
PLD O
and O
235 O
topotecan O
) O
. O
[]

Pulmonary B-outcome ['Physiological-Clinical']
diffusing I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
did O
not O
change O
during O
parenteral O
nutrition O
regardless O
of O
the O
amount O
of O
parenteral B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
supplied O
by O
lipid O
, O
but O
arterial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
decreased O
( O
mean O
of O
93.5 O
% O
to O
91.5 O
% O
; O
P O
less O
than O
0.005 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

The O
trial O
had O
three O
1-month O
treatment O
periods O
using O
metoclopramide O
10 O
mg O
q.i.d. O
, O
domperidone O
20 O
mg O
q.i.d. O
, O
or O
placebo O
on O
a O
random O
basis O
. O
[]

SPEM O
is O
a O
multicenter O
randomized O
double-blind O
study O
performed O
to O
test O
the O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
electrophysiological I-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
of O
three O
different O
ventricular O
leads O
: O
( O
1 O
) O
an O
ion O
exchange O
membrane O
with O
30-microgram O
dexamethasone O
elution O
in O
a O
contoured O
activated O
carbon O
tip O
lead O
( O
Membrane O
1400T O
, O
30 O
patients O
) O
; O
( O
2 O
) O
the O
same O
lead O
design O
without O
steroid O
( O
Membrane O
1401T O
, O
24 O
patients O
) O
; O
and O
( O
3 O
) O
the O
same O
lead O
design O
without O
steroid O
or O
membrane O
( O
control O
group O
, O
27 O
patients O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Renewed O
insight O
into O
dose-related O
effects O
of O
sertindole O
and O
haloperidol O
was O
sought O
by O
re-analysing O
published O
data O
for O
antipsychotic O
effect O
, O
extrapyramidal O
effect O
, O
and O
patient O
wellbeing O
- O
i.e. O
, O
the O
important O
pharmacopsychometric O
triangle O
domains O
. O
[]

CONCLUSIONS O
Simultaneous O
oral O
administration O
of O
ddI O
significantly O
decreases O
[]

Sensory B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
was O
determined O
by O
the O
pinprick O
method O
and O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
by O
the O
Bromage O
method O
at O
2-min O
intervals O
for O
the O
first O
20 O
min O
, O
at O
5-min O
intervals O
for O
the O
next O
10 O
min O
, O
and O
then O
every O
15 O
min O
to O
a O
total O
of O
240 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Forty-nine O
children O
with O
AS O
were O
recruited O
to O
participate O
and O
randomly O
assigned O
to O
intervention O
( O
n O
= O
26 O
) O
or O
wait-list O
control O
( O
n O
= O
23 O
) O
conditions O
. O
[]

We O
hypothesized O
that O
pulse O
oximeter O
PI O
provides O
an O
earlier O
and O
clearer O
indication O
of O
sympathectomy O
following O
epidural O
anesthesia O
than O
skin O
temperature O
and O
arterial O
pressure O
. O
[]

The O
majority O
of O
parents O
( O
56 O
% O
) O
were O
unable B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
report I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
retrospect I-outcome ['Life-Impact']
when O
their O
child O
had O
received O
auditory O
integration O
training O
. O
['Life-Impact']

This O
has O
implications O
for O
falls O
risk O
, O
fractures O
, O
and O
interventions O
. O
[]

There O
was O
no O
significant O
rise O
in O
PA O
pressure O
following O
discontinuation O
of O
the O
drug O
( O
26.30 O
+/- O
6.66 O
vs O
28.49 O
+/- O
10.93 O
mm O
Hg O
, O
p O
= O
0.366 O
) O
. O
[]

Provision O
for O
these O
children O
is O
usually O
made O
via O
a O
paediatrician O
through O
occupational O
or O
physiotherapy O
though O
, O
with O
a O
prevalence O
rate O
of O
5 O
% O
, O
regular O
provision O
is O
not O
possible O
due O
to O
limited O
professional O
resources O
. O
[]

In O
control O
subjects O
, O
compared O
with O
saline O
infusion O
, O
L-arginine O
infusion O
did O
not O
modify O
any O
parameter O
. O
[]

Three O
hundred O
children O
aged O
between O
3-5 O
years O
from O
twenty O
randomly O
selected O
long O
day O
care O
services O
in O
the O
Hunter O
Region O
of O
New O
South O
Wales O
, O
Australia O
will O
be O
invited O
to O
participate O
in O
the O
trial O
. O
[]

Data O
from O
30 O
infants O
, O
matched O
for O
birth O
weight O
and O
gestational O
age O
, O
receiving O
PN O
during O
the O
first O
5 O
days O
after O
birth O
were O
also O
obtained O
. O
[]

A O
field O
trial O
of O
production O
and O
financial O
consequences O
of O
helminthosis O
control O
in O
sheep O
production O
in O
Ethiopia O
. O
[]

Although O
the O
reach O
of O
the O
Web-based O
intervention O
is O
lower O
, O
Web-based O
interventions O
can O
be O
a O
good O
channel O
to O
reach O
high-risk O
populations O
( O
lower O
PA O
intention O
and O
higher O
BMI O
) O
. O
[]

Multiple B-outcome ['Physiological-Clinical']
sclerosis I-outcome ['Physiological-Clinical']
risk O
after O
optic O
neuritis O
: O
final O
optic O
neuritis O
treatment O
trial O
follow-up O
. O
['Physiological-Clinical']

In O
experiment O
1 O
, O
observers O
threw O
darts O
at O
targets O
that O
were O
fixated O
either O
monocularly O
or O
binocularly O
. O
[]

No O
significant O
difference O
in O
the O
prevalence O
of O
PONV O
was O
found O
between O
patients O
receiving O
propofol O
and O
those O
receiving O
droperidol O
, O
and O
propofol O
and O
droperidol O
were O
associated O
with O
significantly O
lower O
prevalences O
of O
PONV O
compared O
with O
metoclopramide O
( O
P O
= O
0.022 O
and O
P O
= O
0.043 O
, O
respectively O
) O
. O
[]

Children O
with O
ASD O
perceive O
important O
linguistic O
information O
embedded O
in O
music O
stimuli O
organized O
by O
principles O
of O
pattern O
perception O
, O
and O
produce O
the O
functional O
speech O
. O
[]

RESULTS O
The O
health-promotion O
group O
maintained O
their O
ADL B-outcome ['Life-Impact']
level O
despite O
a O
significant O
decrease O
in O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
while O
the O
individual O
intervention O
group O
increased O
its O
dependence O
in O
ADL B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
immature O
immune O
system O
of O
preterm O
neonates O
puts O
them O
at O
higher O
risk O
of O
neonatal O
sepsis O
. O
[]

The O
absolute O
CD4 B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
absolute O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
and O
total O
and O
B-lymphocytes O
all O
increased O
on O
carotene O
and O
fell O
during O
placebo O
, O
but O
these O
differences O
did O
not O
reach O
statistical O
significance O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Granisetron O
was O
administered O
at O
40 O
micrograms/kg O
during O
chemotherapy O
, O
and O
methylprednisolone O
was O
administered O
concomitantly O
at O
125 O
mg/body O
for O
3 O
days O
or O
more O
in O
the O
combination O
group O
. O
[]

The O
parent O
training O
group O
( O
7 O
with O
autism O
, O
6 O
with O
pervasive O
developmental O
disorder O
NOS O
) O
received O
3 O
to O
9 O
months O
of O
parent O
training O
. O
[]

The O
high O
dose O
( O
0.3 O
mM/kg O
) O
gadodiamide O
injection O
in O
7 O
patients O
did O
not O
shorten O
the O
T2 O
value O
sufficiently O
to O
overwhelm O
the O
T1 B-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
and O
leave O
pathologic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
hypointense I-outcome ['Physiological-Clinical']
compared O
to O
precontrast O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
nasopharyngeal I-outcome ['Physiological-Clinical']
primary I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in O
groups O
B O
and O
C O
was O
significantly O
higher O
than O
that O
in O
group O
A O
, O
with O
also O
significantly O
higher O
complete O
remission B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
lymph I-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
A O
change O
in O
dietary B-outcome ['Life-Impact']
calcium I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
may O
be O
a O
useful O
measure O
as O
part O
of O
an O
overall O
approach O
to O
prevent O
the O
occurrence O
of O
overweight O
and O
obesity O
among O
postmenopausal O
women O
. O
['Life-Impact']

Besides O
, O
the O
integral O
difference O
between O
before O
and O
after O
drug O
therapy O
was O
higher O
in O
the O
test O
group O
than O
in O
the O
control O
group O
[ O
( O
9.12 O
+/- O
6.16 O
) O
score O
vs O
( O
3.48 O
+/- O
2.06 O
) O
score O
) O
] O
, O
showing O
statistical O
difference O
( O
P O
< O
0.05 O
) O
. O
[]

Pinprick B-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
, O
motor B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
tolerance O
to O
electrical B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
and O
thigh O
tourniquet B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
time O
to O
ambulation B-outcome ['Life-Impact']
were O
assessed O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Joint B-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
was O
normal O
during O
and O
after O
completion O
of O
therapy O
in O
all O
patients O
. O
['Physiological-Clinical']

The O
present O
findings O
support O
the O
potential O
application O
of O
Chinese O
Chan-based O
mind-body O
exercises O
as O
a O
form O
of O
neuropsychological O
rehabilitation O
for O
patients O
with O
self-control O
problems O
. O
[]

The O
control O
group O
consisted O
of O
19 O
patients O
( O
19 O
eyes O
) O
who O
received O
only O
antimicrobial O
therapy O
. O
[]

Left O
ventricular O
performance O
was O
assessed O
by O
radionuclide O
ventriculography O
at O
baseline O
and O
within O
60 O
minutes O
after O
the O
fourth O
infusion O
. O
[]

RESULTS O
The O
incidence O
of O
pruritus B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
only O
when O
the O
control O
group O
. O
( O
['Physiological-Clinical']

OBJECTIVE O
To O
improve O
the O
voice O
quality O
of O
female O
laryngectomees O
and/or O
laryngectomees O
with O
a O
hypotonic O
pharyngoesophageal O
( O
PE O
) O
segment O
by O
means O
of O
a O
pneumatic B-outcome ['Physiological-Clinical']
artificial I-outcome ['Physiological-Clinical']
source I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
voice I-outcome ['Physiological-Clinical']
incorporated I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
regular I-outcome ['Physiological-Clinical']
tracheoesophageal I-outcome ['Physiological-Clinical']
( O
TE B-outcome ['Physiological-Clinical']
) O
shunt B-outcome ['Physiological-Clinical']
valve O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
patients O
who O
healed B-outcome ['Physiological-Clinical']
, O
5 O
of O
16 O
patients O
in O
the O
Grenz O
ray O
only O
group O
and O
4 O
of O
13 O
patients O
in O
the O
combination O
group O
remained B-outcome ['Physiological-Clinical']
healed I-outcome ['Physiological-Clinical']
at O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Rational-emotive O
therapy O
and O
the O
reduction O
of O
interpersonal B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
in O
junior O
high O
school O
students O
. O
['Life-Impact']

On O
two O
patients O
with O
smooth O
prostheses O
and O
one O
patient O
with O
a O
textured O
prosthesis O
, O
the O
capsule O
around O
the O
implant O
hardened O
between O
6 O
and O
12 O
months O
. O
[]

The O
secondary O
endpoints O
are O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
proportion O
of O
laparoscopy-assisted B-outcome ['Resource-use']
distal I-outcome ['Resource-use']
gastrectomy I-outcome ['Resource-use']
completion O
, O
proportion O
of O
conversion B-outcome ['Resource-use']
to I-outcome ['Resource-use']
open I-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
short-term B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
['Mortality', 'Resource-use', 'Resource-use', 'Adverse-effects', 'Physiological-Clinical', 'Life-Impact']

CONCLUSION O
Mifepristone O
in O
doses O
of O
5 O
mg O
or O
10 O
mg O
results O
in O
comparable O
leiomyoma B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
, O
improvement O
in O
symptoms O
, O
and O
few O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

CONCLUSION O
There O
appears O
to O
be O
some O
activity O
and O
tolerable O
toxicity O
at O
1,000-2,000 O
mg/day O
doses O
of O
American O
ginseng O
with O
regard O
to O
cancer-related O
fatigue O
. O
[]

NCT00784550 O
. O
[]

Gamma-hydroxybutyric O
acid O
versus O
clomethiazole O
for O
the O
treatment O
of O
alcohol B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
in O
a O
medical O
intensive O
care O
unit O
: O
an O
open O
, O
single-center O
randomized O
study O
. O
['Life-Impact']

Analysis O
between O
treatment O
groups O
revealed O
a O
highly O
significant O
difference O
at O
T3 O
and O
T4 O
for O
the O
total O
VAS O
score O
( O
p O
= O
0.007 O
and O
p O
= O
0.001 O
, O
respectively O
) O
in O
favor O
of O
the O
active O
combination O
treatment O
. O
[]

Much O
of O
the O
research O
that O
spurred O
the O
introduction O
of O
foam O
earplugs O
indicated O
little O
change O
in O
speech O
intelligibility O
in O
persons O
with O
normal O
hearing O
. O
[]

A O
second O
challenge O
of O
3-h O
duration O
, O
carried O
out O
at O
least O
12 O
h O
after O
the O
final O
dose O
, O
was O
undertaken O
after O
1 O
week O
( O
mean O
) O
of O
twice-daily O
treatment O
to O
assess O
residual O
effects O
of O
the O
formulation O
after O
achievement O
of O
steady O
state O
. O
[]

419 O
patients O
were O
evaluated O
after O
a O
median O
follow-up O
of O
57 O
months O
. O
[]

BACKGROUND O
In O
several O
non-randomised O
trials O
training O
with O
EPI-NO O
increased O
the O
rate O
of O
intact O
perineum O
and O
decreased O
episiotomy O
rates O
, O
shortened O
the O
second O
stage O
of O
labour O
and O
lowered O
use O
of O
pain O
killers O
. O
[]

VDMV O
achieved O
PIP B-outcome ['Physiological-Clinical']
and O
PEEP B-outcome ['Physiological-Clinical']
closest O
to O
that O
targeted O
and O
significantly O
lower O
variation O
in O
all O
measured O
parameters O
( O
p O
< O
0.001 O
) O
other O
than O
with O
PIP O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Effects O
of O
electroacupuncture O
combined O
with O
behavior O
therapy O
on O
intelligence O
and O
behavior O
of O
children O
of O
autism O
] O
. O
[]

Two O
patients O
in O
the O
placebo O
group O
but O
none O
in O
the O
steroid O
group O
experienced O
chronic B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
( O
p O
= O
0.257 O
) O
. O
['Physiological-Clinical']

The O
centres O
represented O
England O
, O
Scotland O
and O
Wales O
, O
and O
were O
randomly O
selected O
from O
groups O
ranked O
by O
different O
levels O
of O
clinical O
activity O
in O
cancer O
genetics O
practice O
. O
[]

Before O
and O
after O
the O
program O
, O
all O
subjects O
participated O
in O
DTI O
scans O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
on O
other O
routine O
laboratory O
values O
were O
observed O
. O
['Adverse-effects']

Comparative O
clinical O
study O
] O
. O
[]

It O
can O
be O
used O
for O
prolonged O
operations O
( O
> O
1.5 O
hours O
) O
without O
additional O
injections O
and O
can O
provide O
long-lasting O
postoperative O
analgesia O
. O
[]

All O
positive O
SLN O
and O
randomly O
selected O
negative O
cases O
were O
reviewed O
by O
two O
pathologists O
. O
[]

INTERVENTION O
A O
12-week O
arm-cranking O
exercise O
program O
, O
3 O
sessions/wk O
, O
consisting O
of O
warming-up O
( O
10-15min O
) O
followed O
by O
a O
main O
part O
in O
arm-crank O
( O
20-30min O
[ O
increasing O
2min O
and O
30s O
every O
3wk O
] O
) O
at O
a O
moderate O
work O
intensity O
of O
50 O
% O
to O
65 O
% O
of O
the O
heart O
rate O
reserve O
( O
starting O
at O
50 O
% O
and O
increasing O
5 O
% O
every O
3 O
weeks O
) O
and O
by O
a O
cooling-down O
period O
( O
5-10min O
) O
. O
[]

Furthermore O
, O
this O
combination O
was O
superior O
to O
TIO O
alone O
in O
reducing O
rescue B-outcome ['Resource-use']
albuterol I-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
['Resource-use']

BACKGROUND O
Long-chain O
n-3 O
polyunsaturated O
fatty O
acids O
have O
variable O
effects O
on O
LDL O
cholesterol O
, O
and O
the O
effects O
of O
docosahexaenoic O
acid O
( O
DHA O
) O
are O
uncertain O
. O
[]

INTERVENTIONS O
Assignment O
in O
a O
1 O
: O
1 O
ratio O
to O
a O
diagnostic O
strategy O
including O
point-of-care O
measurement O
of O
BNP O
( O
n O
= O
163 O
) O
or O
standard O
assessment O
without O
BNP O
( O
n O
= O
160 O
) O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
of O
valproate O
for O
aggression O
in O
youth O
with O
pervasive O
developmental O
disorders O
. O
[]

Effect O
of O
antioxidant O
supplementation O
on O
ozone-induced O
lung O
injury O
in O
human O
subjects O
. O
[]

PURPOSE O
Endotracheal O
suctioning O
causes O
significant O
lung O
derecruitment O
. O
[]

One O
of O
the O
causes O
of O
death O
of O
severe O
hepatitis O
is O
complication O
of O
renal B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
or O
hepatorenal B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
value O
of O
transbronchial B-outcome ['Resource-use']
lung I-outcome ['Resource-use']
biopsy I-outcome ['Resource-use']
using O
jumbo O
forceps O
via O
rigid O
bronchoscope O
in O
diffuse O
lung O
disease O
. O
['Resource-use']

The O
development O
of O
symptoms B-outcome ['Physiological-Clinical']
, O
number O
of O
episodes O
of O
ulcer-related B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
, O
total O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
Previous O
uncontrolled O
studies O
have O
suggested O
an O
interaction O
between O
ticlopidine O
, O
a O
major O
antiplatelet O
agent O
, O
and O
cyclosporin O
in O
heart- O
and O
kidney-transplant O
recipients O
. O
[]

RESULTS O
Over O
1 O
year O
the O
3M O
group O
reported O
a O
decrease O
in O
the O
number O
of O
snacks B-outcome ['Life-Impact']
whereas O
the O
3+3M O
group O
reported O
an O
increase O
( O
-1.1 O
vs O
+0.4 O
snacks/day O
, O
respectively O
, O
P O
< O
0.0001 O
) O
. O
['Life-Impact']

Feedback O
from O
the O
usability O
testing O
on O
the O
length O
, O
presentation O
, O
and O
content O
of O
the O
materials O
was O
incorporated O
into O
the O
final O
versions O
of O
the O
booklet O
and O
website O
. O
[]

After O
CIK O
cell O
infusions O
, O
the O
percentages O
of O
CD3+ B-outcome ['Physiological-Clinical']
, O
CD4+ B-outcome ['Physiological-Clinical']
, O
CD56+ B-outcome ['Physiological-Clinical']
, O
CD3+CD56+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
the O
effects O
of O
soy O
in O
36 O
premenopausal O
women O
, O
20 O
of O
whom O
used O
OC O
. O
[]

Exercise O
participants O
were O
scheduled O
to O
attend O
exercise O
sessions O
lasting O
45 O
minutes O
, O
including O
warm-up O
and O
cool-down O
, O
3 O
times O
a O
week O
for O
8 O
weeks O
( O
24 O
sessions O
) O
. O
[]

13 O
, O
age O
68+/-3 O
yr O
, O
mean+/-SEM O
) O
or O
observation O
( O
no O
. O
[]

The O
neutrophil B-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
was O
similar O
with O
and O
without O
priming O
( O
mean O
+/- O
SD O
, O
490 O
+/- O
310/microL O
v O
550 O
+/- O
350/microL O
, O
respectively O
; O
P O
=.2 O
) O
; O
however O
, O
on O
day O
16 O
the O
mean O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
was O
higher O
( O
mean O
+/- O
SD O
, O
1030 O
+/- O
580/microL O
v O
690 O
+/- O
370/microL O
, O
P O
=.004 O
) O
, O
and O
the O
proportion O
of O
patients O
with O
a O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
less O
than O
500/microL O
was O
lower O
after O
priming O
than O
before O
( O
six O
of O
35 O
or O
17 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Five O
, O
chosen O
at O
random O
, O
received O
post-operatively O
1-2 O
units O
insulin/kg O
body O
weight/24 O
h O
with O
their O
feed O
, O
while O
the O
other O
five O
received O
the O
feed O
only O
. O
[]

The O
influence O
of O
adult O
intervention O
on O
infants O
' O
level O
of O
attention O
. O
[]

BACKGROUND O
No O
studies O
have O
been O
published O
comparing O
the O
U- O
and O
H-type O
methods O
of O
the O
TVT O
SECUR O
( O
TVT-S O
) O
procedure O
. O
[]

Medical O
treatments O
have O
become O
available O
for O
benign O
hypertrophy O
of O
the O
prostate O
, O
including O
alpha-receptor O
blocking O
agents O
and O
5-alpha-reductase O
inhibitors O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
three O
long-acting O
local O
anesthetics O
( O
bupivacaine O
0.75 O
% O
, O
ropivacaine O
1 O
% O
and O
etidocaine O
1 O
% O
) O
and O
to O
try O
, O
with O
reference O
to O
previous O
studies O
, O
to O
make O
some O
statement O
about O
the O
equipotency O
of O
ropivacaine O
relative O
to O
bupivacaine O
and O
etidocaine O
. O
[]

The O
hypothesis O
was O
that O
the O
DP O
method O
could O
be O
the O
most O
effective O
in O
achieving O
haemodynamic B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
addition O
, O
we O
evaluated O
whether O
an O
intravenous O
infusion O
of O
L-arginine O
would O
improve O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
these O
subjects O
. O
['Physiological-Clinical']

A O
similar O
number O
of O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
were O
reported O
by O
the O
patients O
on O
amiprilose O
( O
67 O
% O
) O
and O
on O
placebo O
( O
63 O
% O
) O
. O
['Adverse-effects']

The O
scores O
of O
IQ B-outcome ['Life-Impact']
or O
DQ O
had O
increased O
and O
scores O
of O
ABC O
had O
dropped O
. O
['Life-Impact']

Study O
1 O
: O
children O
with O
moderate O
autistic O
symptomology O
( O
per O
SRS-P O
) O
were O
significantly O
more O
likely O
to O
improve O
from O
family O
CBT O
( O
FCBT O
) O
than O
individual O
CBT O
( O
ICBT O
; O
OR O
= O
8.67 O
) O
. O
[]

Making O
the O
connection O
: O
randomized O
controlled O
trial O
of O
social O
skills O
at O
school O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

Plaque B-outcome ['Physiological-Clinical']
, O
BOP B-outcome ['Physiological-Clinical']
, O
and O
PPD B-outcome ['Physiological-Clinical']
were O
recorded O
on O
all O
implant O
surfaces O
at O
baseline O
, O
and O
after O
3 O
and O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
mean O
hospital B-outcome ['Resource-use']
stays I-outcome ['Resource-use']
in O
groups O
1 O
and O
2 O
were O
3.1 O
and O
1.6 O
days O
, O
respectively O
( O
P O
= O
0.003 O
) O
. O
['Resource-use']

BACKGROUND O
The O
consumption O
of O
non-ready-to-eat O
cereal O
and O
ready-to-eat O
cereal O
( O
RTEC O
) O
breakfasts O
have O
been O
associated O
with O
increased O
nutrient B-outcome ['Physiological-Clinical']
intakes I-outcome ['Physiological-Clinical']
and O
lower O
body O
mass O
index O
( O
BMI O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
lower O
mean O
drainage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
in O
the O
custom-fit O
group O
( O
391 O
ml O
vs. O
603 O
ml O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

RESULTS O
No O
statistically O
significant O
difference O
in O
TTP B-outcome ['Physiological-Clinical']
was O
observed O
between O
treatments O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
DPP-4 I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
was O
integrated O
in O
the O
model O
by O
relating O
the O
model-predicted O
DPP-4 O
occupancy O
with O
linagliptin O
linearly O
to O
DPP-4 O
inhibition O
. O
['Physiological-Clinical']

CONCLUSION O
Based O
on O
known O
minimum O
inhibitory O
concentration O
data O
, O
the O
uterine B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
moxifloxacin O
achieved O
over O
24 O
hours O
would O
be O
sufficient O
to O
eradicate O
the O
range O
of O
bacterial O
pathogens O
responsible O
for O
PID O
. O
['Physiological-Clinical']

BACKGROUND O
Fulvestrant O
is O
an O
estrogen O
receptor O
antagonist O
with O
no O
agonist O
effects O
. O
[]

Olanzapine-treated O
patients O
also O
experienced O
longer O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
depressive I-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
( O
85 O
versus O
22 O
days O
, O
p=0.001 O
) O
and O
manic B-outcome ['Life-Impact']
symptomatic I-outcome ['Life-Impact']
relapse I-outcome ['Life-Impact']
( O
too O
few O
relapses O
to O
calculate O
versus O
42 O
days O
, O
p O
< O
0.001 O
) O
than O
did O
placebo-treated O
patients O
. O
['Physiological-Clinical', 'Life-Impact']

The O
therapeutic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
esmolol O
during O
the O
initial O
treatment O
period O
( O
72 O
% O
) O
was O
similar O
to O
that O
obtained O
when O
esmolol O
was O
given O
as O
a O
second O
agent O
. O
['Physiological-Clinical']

30.2 O
mm? O
at O
6 O
months O
: O
4.8 O
% O
decrease O
, O
p O
= O
0.002 O
, O
respectively O
) O
. O
[]

For O
this O
purpose O
, O
a O
placebo-controlled O
, O
double-blind O
, O
three-time O
cross-over O
study O
using O
17beta-estradiol O
combined O
with O
norethisterone O
acetate O
for O
replacement O
therapy O
and O
as O
an O
adjunct O
to O
a O
naturalistic O
maintenance O
antipsychotic O
treatment O
was O
carried O
out O
over O
a O
period O
of O
8 O
months O
. O
[]

Sustained O
benefit O
of O
continuous O
glucose O
monitoring O
on O
A1C O
, O
glucose O
profiles O
, O
and O
hypoglycemia O
in O
adults O
with O
type O
1 O
diabetes O
. O
[]

[ O
Effect O
analysis O
on O
non-and-low O
response O
infants O
after O
revaccinated O
hepatitis O
B O
vaccine O
] O
. O
[]

Symptoms O
were O
assessed O
over O
a O
four-week O
period O
starting O
with O
a O
run-in O
period O
of O
one O
week O
. O
[]

BACKGROUND O
& O
AIMS O
Patients O
with O
cirrhosis O
undergoing O
selective O
intestinal O
decontamination O
with O
norfloxacin O
show O
a O
reduction O
in O
serum O
cytokine O
levels O
, O
probably O
because O
of O
a O
combined O
effect O
of O
norfloxacin O
on O
bowel O
flora O
and O
neutrophils O
. O
[]

2.9 O
) O
( O
t O
= O
-4.49 O
, O
P O
< O
0.05 O
) O
. O
[]

No O
resected O
patients O
received O
any O
adjuvant O
treatments O
. O
[]

UNLABELLED O
Growth O
hormone O
( O
GH O
) O
treatment O
in O
young O
adults O
with O
childhood-onset O
GH O
deficiency O
has O
beneficial O
effects O
on O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
multicentre O
trial O
( O
10 O
centres O
) O
of O
urokinase O
( O
UK O
) O
was O
performed O
in O
patients O
with O
acute O
severe O
pulmonary O
embolism O
( O
PE O
) O
. O
[]

Participants O
were O
children O
aged O
2-59 O
months O
of O
age O
, O
who O
received O
either O
oral O
amoxycillin O
( O
31-54 O
mg/Kg/day O
, O
in O
three O
divided O
doses O
for O
three O
days O
) O
or O
placebo O
, O
and O
standard O
bronchodilator O
therapy O
. O
[]

The O
observed O
marginal O
cost B-outcome ['Resource-use']
per O
patient O
of O
the O
initial O
realtime O
teledermatology O
consultation O
was O
52.85 O
Pounds O
for O
those O
in O
urban O
areas O
and O
59.93 O
Pounds O
per O
patient O
for O
those O
from O
rural O
areas O
. O
['Resource-use']

RESULTS O
Remifentanil O
had O
prototypic O
micro-like O
opioid O
subjective O
effects O
, O
impaired B-outcome ['Life-Impact']
psychomotor I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
produced O
['Life-Impact']

Physician-pharmacist O
cooperation O
program O
for O
blood O
pressure O
control O
in O
patients O
with O
hypertension O
: O
a O
randomized-controlled O
trial O
. O
[]

The O
neurotoxic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
in O
humans O
are O
less O
clear O
and O
little O
is O
known O
about O
the O
functional O
consequences O
, O
although O
some O
studies O
suggest O
memory O
impairment O
. O
['Physiological-Clinical']

Deficiency O
of O
serum B-outcome ['Physiological-Clinical']
ionized I-outcome ['Physiological-Clinical']
magnesium I-outcome ['Physiological-Clinical']
in O
patients O
receiving O
hemodialysis O
or O
peritoneal O
dialysis O
. O
['Physiological-Clinical']

Randomized O
clinical O
trial O
of O
balance-based O
torso O
weighting O
for O
improving O
upright B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
in O
people O
with O
multiple O
sclerosis O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
This O
study O
involved O
prospective O
randomization O
of O
82 O
patients O
in O
a O
traditional O
and O
a O
fast-track O
treatment O
arm O
. O
[]

CONCLUSIONS O
After O
controlled O
exposure O
to O
grass O
pollen O
, O
CC O
and O
AT O
treatment O
showed O
a O
therapeutic O
effect O
on O
the O
signs O
and O
symptoms O
of O
allergic O
conjunctivitis O
. O
[]

RESULTS O
The O
free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
in O
the O
ischaemic O
preconditioning O
group O
was O
9.7 O
and O
16.6 O
% O
after O
the O
ischaemic O
preconditioning O
protocol O
and O
10 O
min O
after O
declamping O
, O
6.8 O
and O
13.3 O
% O
in O
the O
controls O
. O
['Physiological-Clinical']

5-fluorouracil O
plus O
folinic O
acid O
with O
or O
without O
ifosfamide O
in O
advanced O
colorectal O
cancer O
: O
a O
phase O
II O
randomized O
trial O
. O
[]

No O
subject O
reacted O
to O
placebo O
. O
[]

At O
4 O
years O
post-randomisation O
, O
median O
survival B-outcome ['Mortality']
in O
the O
topotecan O
group O
was O
63.0 O
weeks O
( O
range O
< O
1 O
to O
238.4+ O
weeks O
; O
20.5 O
% O
censored O
) O
and O
, O
for O
paclitaxel O
, O
53.0 O
weeks O
( O
range O
< O
1 O
to O
226.3+ O
weeks O
; O
12.3 O
% O
censored O
) O
; O
P O
= O
0.44 O
. O
['Mortality']

METHODS O
LSCLC O
patients O
received O
2 O
cycles O
of O
etoposide O
and O
cisplatin O
( O
EP O
) O
induction O
chemotherapy O
and O
were O
randomly O
assigned O
to O
receive O
TRT O
to O
either O
the O
post- O
or O
pre-chemotherapy O
tumor O
extent O
( O
GTV-T O
) O
as O
study O
arm O
and O
control O
arm O
, O
CTV-N O
included O
the O
positive O
nodal O
drainage O
area O
for O
both O
arms O
. O
[]

Recombinant O
human O
granulocyte O
colony-stimulating O
factor O
( O
rhG-CSF O
) O
is O
effective O
in O
countering O
chemotherapy-induced O
neutropenia O
. O
[]

We O
chose O
to O
test O
valproate O
due O
to O
its O
well O
documented O
effect O
as O
a O
migraine O
prophylactic O
drug O
. O
[]

Those O
in O
group O
B O
visited O
the O
clinic O
only O
to O
measure O
BP B-outcome ['Physiological-Clinical']
and O
later O
underwent O
the O
same O
BF O
. O
['Physiological-Clinical']

We O
conclude O
that O
cyclo-oxygenase O
is O
rapidly B-outcome ['Physiological-Clinical']
synthesised I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bradykinin-responsive I-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
in O
vivo O
and O
that O
this O
reflects O
similarly O
rapid O
enzyme O
biosynthesis O
in O
tissues O
that O
produce O
PGI2 O
under O
basal O
conditions O
. O
['Physiological-Clinical']

The O
periprosthetic B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
5 O
ROIs O
positioned O
around O
the O
acetabular O
component O
. O
['Physiological-Clinical']

One O
patient O
given O
daclizumab O
HYP O
150 O
mg O
who O
was O
recovering O
from O
a O
serious O
rash O
died O
because O
of O
local O
complication O
of O
a O
psoas O
abscess O
. O
[]

Three O
randomized O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
2 O
patients O
received O
less O
than O
50 O
mL O
of O
study O
solution O
due O
to O
an O
interstitial O
intravenous O
line O
and O
1 O
lost O
randomization O
identification O
. O
[]

No O
significant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
any O
patient O
. O
['Adverse-effects']

CONCLUSIONS O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
of O
at O
least O
6 O
weeks O
duration O
is O
not O
associated O
with O
improved O
functioning O
, O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
or O
overall O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
is O
associated O
with O
an O
increase O
in O
GP B-outcome ['Resource-use']
workload I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Dose-response O
relationship O
of O
sertindole O
and O
haloperidol O
using O
the O
pharmacopsychometric O
triangle O
. O
[]

RESULTS O
None O
of O
the O
participants O
experienced O
any O
adverse B-outcome ['Adverse-effects']
clinical I-outcome ['Adverse-effects']
, O
virologic B-outcome ['Physiological-Clinical']
, O
or O
['Adverse-effects', 'Physiological-Clinical']

METHODS O
Patients O
with O
autism O
( O
N O
= O
101 O
, O
5-17 O
years O
of O
age O
) O
were O
randomized O
to O
an O
8-week O
trial O
of O
risperidone O
or O
placebo O
and O
63 O
then O
took O
part O
in O
a O
4-month O
open-label O
follow-up O
phase O
. O
[]

OBJECTIVE O
The O
short-term O
benefit O
of O
risperidone O
in O
ameliorating O
severe B-outcome ['Life-Impact']
disruptive I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
pediatric O
patients O
with O
autism O
spectrum O
disorders O
is O
well O
established O
; O
however O
, O
only O
one O
placebo-controlled O
, O
long-term O
study O
of O
efficacy O
is O
available O
. O
['Life-Impact']

Relative O
increases O
in O
[]

RESULTS O
For O
the O
first O
surveillance O
test O
, O
risk O
of O
non-attendance O
was O
significantly O
higher O
in O
younger O
women O
, O
those O
without O
post-secondary O
education O
, O
and O
non-users O
of O
prescribed O
contraception O
. O
[]

To O
explore O
the O
relationship O
between O
easy B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
and O
other O
systemic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ICS I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
, O
including O
adrenal B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
and O
loss O
of O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
6 O
months O
follow-up O
, O
tape O
group O
patients O
reported O
positive O
attitudes B-outcome ['Life-Impact']
to O
the O
audiotape O
and O
were O
shown O
to O
recall B-outcome ['Life-Impact']
significantly O
more O
information O
about O
their O
illness B-outcome ['Physiological-Clinical']
than O
did O
controls O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
overall O
response O
rate O
was O
51 O
% O
in O
arm O
A O
and O
38 O
% O
in O
arm O
B O
( O
p O
= O
0.147 O
) O
. O
[]

CONCLUSION O
The O
[]

During O
the O
first O
two O
months O
of O
the O
trial O
only O
a O
diet O
was O
prescribed O
. O
[]

Mean O
change O
in O
CD4 B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
at O
or O
after O
32 O
months O
was O
+234 O
cells O
per O
mm3 O
and O
+227 O
cells O
per O
mm3 O
for O
the O
three-class O
and O
the O
combined O
two-class O
strategies O
( O
p=0.62 O
) O
, O
respectively O
. O
['Physiological-Clinical']

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
We O
enrolled O
100 O
hospitalized O
preterm O
infants O
with O
birth O
weights O
of O
500 O
to O
1300 O
g O
into O
a O
randomized O
clinical O
trial O
comparing O
2 O
levels O
of O
hematocrit O
threshold O
for O
RBC O
transfusion O
. O
[]

Weight O
gain O
was O
similar O
in O
both O
groups O
. O
[]

Low-intensity O
back-strengthening O
exercise O
was O
effective O
in O
improving O
the O
quality O
of O
life O
and O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
median O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
was O
13.5 O
months O
( O
range O
, O
1-49 O
months O
) O
in O
arm O
A O
and O
16 O
months O
( O
range O
, O
1-43 O
months O
) O
in O
arm O
B O
. O
['Mortality']

Because O
these O
behaviors O
may O
be O
chronic O
, O
there O
is O
a O
need O
to O
establish O
the O
efficacy O
and O
safety O
of O
longer-term O
treatment O
with O
this O
agent O
. O
[]

No O
appreciable O
effect O
of O
10 O
mg O
prednisone O
was O
observed O
. O
[]

In O
the O
risperidone O
group O
, O
12 O
of O
19 O
children O
showed O
improvement O
in O
the O
total O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
score O
and O
17 O
of O
19 O
children O
in O
the O
Children B-outcome ['Physiological-Clinical']
's O
Global B-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Scale O
score O
compared O
with O
0 O
of O
20 O
children O
for O
the O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
score O
and O
2 O
of O
20 O
children O
for O
the O
Children B-outcome ['Physiological-Clinical']
's O
Global B-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Scale O
score O
in O
the O
placebo O
group O
( O
P O
< O
.001 O
and O
P O
= O
.035 O
, O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Multiple O
courses O
of O
rituximab O
produce O
sustained O
clinical O
and O
radiographic O
efficacy O
and O
safety O
in O
patients O
with O
rheumatoid O
arthritis O
and O
an O
inadequate O
response O
to O
1 O
or O
more O
tumor O
necrosis O
factor O
inhibitors O
: O
5-year O
data O
from O
the O
REFLEX O
study O
. O
[]

Further O
studies O
on O
the O
safety O
of O
such O
supplements O
are O
suggested O
. O
[]

OBJECTIVE O
To O
compare O
the O
therapeutic O
effects O
of O
acupuncture O
combined O
with O
drug O
and O
simple O
drug O
for O
treatment O
of O
male O
osteoporosis O
. O
[]

Fifty-seven O
patients O
with O
amyotrophic O
lateral O
sclerosis O
( O
ALS O
) O
were O
randomly O
assigned O
to O
receive O
0.5 O
, O
1 O
, O
3 O
, O
7 O
, O
10 O
, O
or O
30 O
micrograms/kg O
recombinant O
human O
ciliary O
neurotrophic O
factor O
( O
rHCNTF O
) O
or O
placebo O
subcutaneously O
3 O
times O
a O
week O
for O
2 O
weeks O
. O
[]

A O
tester O
who O
was O
blinded O
to O
group O
assignment O
made O
group O
comparisons O
at O
the O
initial O
visit O
( O
before O
initiation O
of O
treatment O
) O
, O
4 O
weeks O
, O
8 O
weeks O
, O
and O
1 O
year O
. O
[]

Comparison O
of O
self-administered O
vaginal O
misoprostol O
versus O
placebo O
for O
cervical O
ripening O
prior O
to O
operative O
hysteroscopy O
using O
a O
sequential O
trial O
design O
. O
[]

The O
measure O
of O
the O
outcome O
was O
the O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
. O
['Life-Impact']

The O
outcome O
of O
the O
evaluation O
was O
teachers O
' O
implementation B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Smart I-outcome ['Life-Impact']
Choices B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

In O
the O
first O
week O
of O
remission O
induction O
therapy O
, O
patients O
received O
etoposide O
( O
50 O
mg/m O
( O
2 O
) O
per O
day O
) O
administered O
orally O
as O
a O
single O
agent O
once O
or O
twice O
daily O
. O
[]

A O
significant O
( O
P O
= O
.006 O
) O
improvement O
in O
the O
nasal O
index O
occurred O
as O
early O
as O
12 O
hours O
after O
the O
first O
dose O
of O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
. O
[]

The O
Breathlessness O
Intervention O
Service O
( O
BIS O
) O
seeks O
to O
improve O
the O
care O
of O
breathless B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
with O
advanced O
disease O
( O
regardless O
of O
cause O
) O
through O
the O
use O
of O
evidence-based O
practice O
and O
working O
with O
other O
healthcare O
providers O
. O
['Physiological-Clinical']

Learning O
curve O
in O
multidetector O
CT O
coronary O
angiography O
( O
MDCT-CA O
) O
. O
[]

METHODS O
Two O
hundred O
twenty-five O
consecutive O
patients O
with O
sick O
sinus O
syndrome O
and O
intact O
AV O
conduction O
were O
randomized O
to O
undergo O
single-chamber O
atrial O
pacing O
( O
110 O
patients O
) O
or O
single-chamber O
ventricular O
pacing O
( O
115 O
patients O
) O
. O
[]

Groups O
1 O
and O
2 O
had O
12 O
( O
44.4 O
% O
) O
of O
27 O
and O
8 O
( O
27.6 O
% O
) O
of O
29 O
patients O
, O
respectively O
, O
who O
demonstrated O
an O
elevation O
in O
their O
core B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Long-term O
effects O
of O
risperidone O
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
placebo O
discontinuation O
study O
. O
[]

Ventilation O
was O
then O
immediately O
re-established O
. O
[]

The O
objective O
of O
the O
present O
study O
was O
prospectively O
and O
randomly O
to O
evaluate O
the O
role O
of O
L-arginine O
in O
improving O
uterine B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
follicular I-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
in O
improving O
ovarian B-outcome ['Physiological-Clinical']
response O
to O
gonadotrophin B-outcome ['Physiological-Clinical']
in O
poor O
responder O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Drawing O
on O
the O
psychological O
principle O
that O
proximal O
consequences O
influence O
behavior O
more O
strongly O
than O
distal O
consequences O
, O
the O
authors O
tested O
the O
hypothesis O
that O
criminal O
suspects O
exhibit O
a O
short-sightedness O
during O
police O
interrogation O
that O
increases O
their O
risk O
for O
confession B-outcome ['Life-Impact']
. O
['Life-Impact']

To O
our O
knowledge O
however O
, O
no O
studies O
have O
investigated O
the O
effect O
of O
NPT O
in O
patients O
with O
generalized O
osteoarthritis O
( O
GOA O
) O
. O
[]

They O
prepared O
Class O
I O
, O
III O
and O
V O
cavities O
, O
placed O
resin O
restorations O
and O
evaluated O
subjects O
on O
the O
day O
of O
the O
procedure O
and O
30 O
days O
and O
six O
months O
postoperatively O
for O
pulp B-outcome ['Physiological-Clinical']
vitality I-outcome ['Physiological-Clinical']
, O
recurrent B-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
and O
discomfort B-outcome ['Physiological-Clinical']
, O
and O
restoration B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Experiment O
2 O
, O
64 O
vitrified O
embryos O
were O
transferred O
to O
5 O
recipient O
gilts O
, O
and O
8 O
healthy O
piglets O
were O
produced O
from O
3 O
recipients O
in O
the O
MVAC O
group O
. O
[]

Mean O
Ferriman-Gallwey O
scores O
decreased O
significantly O
in O
both O
treatment O
groups O
. O
[]

Thirty O
ASA O
I-II O
adult O
patients O
undergoing O
selective O
surgery O
were O
allocated O
randomly O
into O
two O
groups O
to O
receive O
one O
of O
the O
following O
agents O
: O
midazolam O
0.3 O
mg/kg O
, O
thiopental O
5 O
mg/kg O
, O
or O
diazepam O
0.4 O
mg/kg O
. O
[]

METHODS O
We O
prospectively O
studied O
five O
regimens O
( O
four O
intravenous O
, O
one O
local O
; O
40 O
patients O
each O
) O
with O
a O
control O
group O
( O
no O
tranexamic O
acid O
) O
. O
[]

METHODS O
This O
prospective O
, O
comparative O
study O
was O
conducted O
with O
healthy O
males O
and O
females O
between O
the O
ages O
of O
19 O
and O
24 O
. O
[]

BMS-181101 O
was O
well O
tolerated B-outcome ['Life-Impact']
both O
with O
and O
without O
ingestion O
of O
food O
. O
['Life-Impact']

Randomized O
trial O
of O
early O
developmental O
intervention O
on O
outcomes O
in O
children O
after O
birth B-outcome ['Physiological-Clinical']
asphyxia I-outcome ['Physiological-Clinical']
in O
developing O
countries O
. O
['Physiological-Clinical']

BACKGROUND O
Advanced O
pancreatic O
cancer O
has O
a O
poor O
prognosis O
, O
and O
the O
current O
standard O
of O
care O
( O
gemcitabine O
based O
chemotherapy O
) O
provides O
a O
small O
survival O
advantage O
. O
[]

Of O
54 O
patients O
with O
normal O
fasting O
glucose O
levels O
, O
18 O
showed O
impaired O
glucose O
tolerance O
and O
36 O
patients O
with O
normal O
glucose O
tolerance O
were O
randomized O
to O
30-day O
treatment O
with O
pioglitazone O
( O
45 O
mg O
) O
or O
placebo O
in O
addition O
to O
optimal O
medical O
therapy O
. O
[]

Comparisons O
of O
sensitivity B-outcome ['Physiological-Clinical']
, O
positive O
and O
negative O
predictive O
values O
, O
between O
the O
two O
tests O
, O
however O
, O
did O
not O
reveal O
any O
significant O
differences O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
Few O
studies O
of O
topical O
microbicides O
have O
assessed O
their O
safety O
in O
HIV-infected B-outcome ['Physiological-Clinical']
women O
. O
['Physiological-Clinical']

0.4 O
, O
4.5 O
? O
[]

PATIENTS O
135 O
consecutive O
patients O
with O
breast O
cancer O
aged O
over O
70 O
with O
operable O
tumours O
( O
less O
than O
5 O
cm O
maximum O
diameter O
) O
; O
68 O
were O
allocated O
to O
tamoxifen O
group O
and O
67 O
to O
mastectomy O
group O
. O
[]

No O
clinically O
relevant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
elicited O
in O
either O
group O
. O
['Adverse-effects']

METHODS O
Forty-five O
patients O
with O
type O
2 O
DM O
initially O
were O
compared O
with O
15 O
healthy O
controls O
matched O
for O
age O
and O
sex O
. O
[]

Some O
children O
who O
have O
PLI O
also O
show O
mild O
social O
impairments O
associated O
with O
high-functioning O
autism O
or O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Responses O
were O
evaluated O
in O
164 O
patients O
. O
[]

Mastoiditis B-outcome ['Physiological-Clinical']
developed O
in O
one O
child O
who O
received O
placebo O
. O
['Physiological-Clinical']

Attitudes O
toward O
autism O
differ O
depending O
on O
who O
provides O
information O
about O
the O
disability O
. O
[]

RESULTS O
The O
proportion O
of O
children O
with O
effective O
analgesia O
during O
the O
operation O
was O
similar O
among O
groups O
. O
[]

However O
, O
these O
results O
should O
be O
corroborated O
by O
additional O
studies O
. O
[]

OBJECTIVE O
To O
determine O
the O
impact O
of O
a O
parent O
education O
and O
behavior O
management O
intervention O
( O
PEBM O
) O
on O
the O
mental O
health O
and O
adjustment O
of O
parents O
with O
preschool O
children O
with O
autism O
. O
[]

Oral O
and O
parenteral O
glutamine O
in O
bone O
marrow O
transplantation O
: O
a O
randomized O
, O
double-blind O
study O
. O
[]

The O
effect O
of O
an O
early O
education O
program O
on O
adult O
health O
: O
the O
Carolina O
Abecedarian O
Project O
randomized O
controlled O
trial O
. O
[]

Results O
showed O
that O
the O
experimental O
group O
patients O
decreased O
their O
pain O
levels O
more O
than O
the O
control O
group O
patients O
did O
over O
time O
. O
[]

However O
, O
WL O
alone O
did O
not O
alter O
C1 O
and O
C2 O
. O
[]

PATIENTS O
Thirty O
patients O
admitted O
to O
the O
intensive O
care O
unit O
who O
had O
a O
thermodilution O
pulmonary O
artery O
catheter O
in O
place O
. O
[]

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
, O
8 O
and O
10 O
weeks O
of O
starting O
medication O
. O
[]

negative O
) O
subgroup O
YAP1 O
expression O
correlated O
positively O
to O
proliferation O
( O
p O
= O
0.005 O
) O
. O
[]

The O
gastrointestinal O
dysfunction O
score O
in O
P+EN O
, O
EN O
, O
PN O
groups O
14 O
days O
after O
nutritional O
intervention O
was O
0.28 O
? O
[]

The O
incidence O
of O
side-effects B-outcome ['Adverse-effects']
in O
this O
trial O
was O
high O
but O
proper O
comparison O
of O
the O
two O
products O
could O
not O
be O
made O
because O
of O
the O
small O
number O
of O
patients O
. O
['Adverse-effects']

PATIENTS O
AND O
METHODS O
Since O
July O
1996 O
, O
198 O
patients O
with O
non-operable O
NSCLC O
and O
measurable O
disease O
without O
previous O
chemotherapy O
entered O
the O
trial O
. O
[]

Patients O
are O
required O
to O
return O
to O
the O
study O
centre O
every O
week O
for O
an O
additional O
6 O
weeks O
of O
follow-up O
for O
wound O
evaluation O
and O
management O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
The O
resources O
used O
for O
intensive O
and O
conventional O
therapy O
and O
to O
deal O
with O
the O
side O
effects O
of O
therapy O
were O
assessed O
at O
each O
of O
the O
29 O
DCCT O
clinics O
and O
summarized O
. O
[]

INTERVENTIONS O
The O
intervention O
group O
received O
two O
1-hour O
training O
sessions O
that O
followed O
the O
Wheelchair O
Skills O
Training O
Program O
( O
WSTP O
) O
protocol O
. O
[]

RESULTS O
A O
total O
of O
2,321 O
children O
were O
screened O
, O
with O
980 O
having O
a O
positive O
result O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
[]

After O
that O
, O
additional O
3 O
cycles O
of O
EP O
consolidation O
were O
administered O
. O
[]

At O
early O
vaccination O
, O
4-12 O
months O
after O
stem O
cell O
transplantation O
, O
these O
responses O
were O
more O
pronounced O
. O
[]

78 O
U/L O
; O
LDH O
: O
21.8 O
? O
[]

In O
school-aged O
children O
a O
combination O
of O
galacto-oligosaccharides O
and O
Lactobacillus O
GG O
increases O
bifidobacteria O
more O
than O
Lactobacillus O
GG O
on O
its O
own O
. O
[]

However O
, O
the O
cognitive O
benefit O
of O
off-pump O
surgery O
remains O
unclear O
. O
[]

Residual O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
in O
groups O
L O
, O
M O
and O
H O
after O
instillation O
of O
saline O
into O
the O
bladder O
( O
p O
less O
than O
0.01 O
) O
but O
not O
in O
group O
P. O
The O
maximum O
and O
average O
flow B-outcome ['Physiological-Clinical']
rates O
were O
significantly O
increased O
in O
groups O
L O
, O
M O
and O
H O
( O
p O
less O
than O
0.01 O
) O
but O
not O
in O
group O
P. O
Average O
flow B-outcome ['Physiological-Clinical']
rate O
showed O
significant O
differences O
between O
groups O
M O
or O
H O
versus O
group O
P. O
Neither O
orthostatic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
nor O
a O
decrease O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Improving O
maternal B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
after O
a O
child O
's O
diagnosis O
of O
autism O
spectrum O
disorder O
: O
results O
from O
a O
randomized O
clinical O
trial O
. O
['Life-Impact']

Myocardial O
extracellular O
volume O
by O
cardiac O
magnetic O
resonance O
imaging O
in O
patients O
treated O
with O
anthracycline-based O
chemotherapy O
. O
[]

The O
95 O
% O
confidence O
interval O
for O
the O
difference O
in O
the O
percentage O
variation O
of O
MAP B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
was O
( O
-3.1 O
, O
+3.7 O
) O
. O
['Physiological-Clinical']

In O
study O
3 O
comparing O
lansoprazole O
and O
esomeprazole O
, O
consumption B-outcome ['Life-Impact']
of O
the O
former O
was O
85 O
% O
that O
of O
the O
latter O
. O
['Life-Impact']

They O
considered O
P O
< O
.05 O
to O
be O
statistically O
significant O
. O
[]

Difficulties O
regulating O
emotions O
have O
implications O
for O
the O
development O
, O
maintenance O
, O
and O
recovery O
from O
alcohol O
problems O
. O
[]

1 O
Prizidilol O
hydrochloride O
( O
SK O
& O
F O
92657 O
) O
is O
a O
new O
compound O
which O
causes O
both O
arteriolar O
dilatation O
and O
beta-adrenoceptor B-outcome ['Resource-use']
blockade I-outcome ['Resource-use']
. O
['Resource-use']

BACKGROUND O
Dietary O
intake O
of O
soy O
protein O
with O
isoflavones O
may O
be O
associated O
with O
reductions O
in O
serum O
cholesterol O
. O
[]

Age O
( O
P O
< O
0.05 O
) O
and O
baseline O
GHBP B-outcome ['Physiological-Clinical']
level O
( O
P O
< O
0.01 O
) O
were O
inversely O
correlated O
with O
the O
increase O
in O
LBM O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
therapeutic O
efficacy O
and O
safety O
of O
epoetin O
zeta O
, O
compared O
with O
epoetin O
alfa O
, O
in O
maintaining O
target O
haemoglobin O
( O
Hb O
) O
concentrations O
in O
patients O
with O
anaemia O
and O
chronic O
kidney O
disease O
( O
CKD O
) O
maintained O
on O
haemodialysis O
. O
[]

Increased O
macular O
zeaxanthin O
is O
suggested O
to O
lower O
the O
risk O
of O
age-related B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
degeneration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
conclude O
that O
the O
5h O
AUC O
is O
a O
more O
relevant O
parameter O
to O
establish O
naproxen O
bioequivalence O
than O
[]

Flutamide-metformin O
plus O
ethinylestradiol-drospirenone O
for O
lipolysis B-outcome ['Physiological-Clinical']
and O
antiatherogenesis B-outcome ['Physiological-Clinical']
in O
young O
women O
with O
ovarian O
hyperandrogenism O
: O
the O
key O
role O
of O
early O
, O
low-dose O
flutamide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thirty O
healthy O
volunteers O
were O
randomized O
either O
to O
a O
study O
group O
administrating O
30 O
% O
FFA O
suppositories O
and O
applying O
30 O
% O
FFA O
ointment O
to O
the O
perianal O
region O
twice O
per O
day O
for O
two O
weeks O
, O
or O
to O
a O
control O
group O
using O
placebo O
suppositories O
and O
ointment O
in O
a O
double O
blinded O
manner O
. O
[]

The O
assessment O
of O
erythema B-outcome ['Physiological-Clinical']
and O
thickness B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
burn I-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
during O
pressure O
garment O
therapy O
as O
a O
preventive O
measure O
for O
hypertrophic O
scarring O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Local B-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
transfused O
than O
non-transfused O
patients O
( O
11.9 O
versus O
7.6 O
per O
cent O
; O
P O
= O
0.09 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
patients O
with O
CHF O
are O
often O
on O
numerous O
pharmacological O
agents O
for O
their O
comorbidities O
. O
[]

Considering O
patients O
on O
treatment O
or O
within O
28 O
days O
after O
discontinuing O
the O
test O
medication O
, O
92 O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
, O
as O
compared O
with O
60 O
of O
the O
warfarin-treated O
patients O
, O
a O
risk O
reduction O
of O
35 O
% O
( O
P O
= O
0.005 O
) O
. O
['Mortality']

There O
was O
a O
mean O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
associated O
with O
CSA O
; O
no O
persons O
were O
withdrawn O
from O
the O
study O
for O
this O
reason O
. O
['Physiological-Clinical']

Further O
studies O
should O
be O
conducted O
to O
develop O
a O
protocol O
for O
standardised O
use O
of O
saline O
solution O
irrigation O
in O
various O
nasal O
pathologies O
. O
[]

The O
study O
involved O
141 O
children O
and O
adults O
with O
autism O
, O
and O
pre O
and O
post O
symptoms O
of O
autism O
were O
assessed O
. O
[]

Children O
with O
autistic O
spectrum O
disorders O
. O
[]

Cats O
were O
assigned O
to O
one O
of O
four O
treatment O
groups O
that O
received O
either O
high O
dose O
huIFN-?2a O
( O
10 O
( O
5 O
) O
IU/kg O
q24h O
; O
12 O
cats O
) O
, O
AZT O
( O
5 O
mg/kg O
q12h O
; O
10 O
cats O
, O
both O
of O
these O
treatments O
( O
12 O
cats O
) O
or O
placebo O
( O
10 O
cats O
) O
. O
[]

Follow-up O
was O
a O
median O
of O
12 O
years O
and O
a O
maximum O
of O
16 O
years O
. O
[]

SD O
1.8 O
? O
[]

The O
total O
of O
120 O
patients O
studied O
in O
the O
two O
series O
showed O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
to O
occur O
in O
13 O
per O
cent O
of O
the O
62 O
patients O
receiving O
cefotaxime O
and O
30 O
per O
cent O
of O
the O
58 O
patients O
receiving O
cephamandole O
. O
['Physiological-Clinical']

Cerebrospinal O
fluid O
( O
CSF O
) O
samples O
were O
collected O
during O
surgical O
plane O
anesthesia O
and O
the O
collected O
CSF O
samples O
were O
used O
to O
assay O
for O
human O
IL-10 O
, O
rat O
IL-1? O
, O
rat O
IL-6 O
, O
and O
rat O
TNF-? O
by O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O
[]

In O
the O
intravenous O
study O
, O
enoximone O
was O
delivered O
over O
5 O
minutes O
and O
hemodynamic O
data O
were O
measured O
for O
up O
to O
12 O
hours O
after O
. O
[]

An O
evaluation O
model O
is O
presented O
here O
in O
order O
to O
fully O
exploit O
the O
obtained O
data O
; O
in O
this O
the O
percentile O
changes O
of O
the O
function O
parameters O
( O
estimated O
by O
linear O
regression O
) O
at O
a O
defined O
dose O
of O
the O
provocation O
substance O
are O
analyzed O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
international O
trial O
( O
the O
initial O
Heart O
Outcomes O
Prevention O
Evaluation O
[ O
HOPE O
] O
trial O
conducted O
between O
December O
21 O
, O
1993 O
, O
and O
April O
15 O
, O
1999 O
) O
of O
patients O
at O
least O
55 O
years O
old O
with O
vascular O
disease O
or O
diabetes O
mellitus O
was O
extended O
( O
HOPE-The O
Ongoing O
Outcomes O
[ O
HOPE-TOO O
] O
) O
between O
April O
16 O
, O
1999 O
, O
and O
May O
26 O
, O
2003 O
. O
[]

More O
surgical O
procedures O
( O
including O
debridement O
) O
were O
required O
in O
the O
MWT O
group O
( O
120 O
vs O
43 O
NPWT O
, O
P O
< O
.001 O
) O
. O
[]

All O
patients O
were O
clinically O
examined O
, O
informed O
about O
their O
back O
pain O
, O
and O
encouraged O
to O
stay O
active O
and O
exercise O
according O
to O
specific O
instructions O
based O
on O
clinical O
evaluation O
. O
[]

CONCLUSIONS O
Combined O
administration O
of O
remifentanil O
and O
propofol O
for O
colonoscopy O
provides O
sufficient O
[]

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer B-outcome ['Physiological-Clinical']
Quality O
of O
Life O
( O
EORTC O
QOL B-outcome ['Life-Impact']
) O
-C30 O
questionnaire O
was O
also O
used O
to O
measure O
eight O
symptoms O
at O
baseline O
and O
during O
each O
course O
( O
pain B-outcome ['Physiological-Clinical']
, O
anorexia B-outcome ['Physiological-Clinical']
, O
diarrhoea B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
, O
dyspnea B-outcome ['Physiological-Clinical']
, O
constipation B-outcome ['Physiological-Clinical']
and O
insomnia B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparative O
study O
of O
administration O
methods O
of O
granisetron O
injection O
used O
to O
treat O
nausea/vomiting O
induced O
by O
cancer O
chemotherapy O
without O
cisplatin O
in O
tumors O
of O
hematopoietic O
organs O
. O
[]

We O
could O
not O
, O
however O
, O
demonstrate O
significant O
differences O
between O
the O
placebo O
and O
active O
treatments O
. O
[]

Participant O
demographics O
included O
72 O
% O
minority O
, O
49 O
% O
with O
annual O
household O
income O
less O
than O
$ O
10,000 O
, O
and O
36 O
% O
uninsured O
. O
[]

This O
information O
is O
not O
available O
for O
many O
early O
measurements O
. O
[]

A O
statistically O
significant O
variation O
in O
body B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
reported O
on O
the O
seventh O
day O
. O
['Physiological-Clinical']

The O
rate O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
the O
3 O
groups O
. O
['Adverse-effects']

Uvulopalatopharyngoplasty O
versus O
laser O
assisted O
uvulopalatoplasty O
for O
the O
treatment O
of O
snoring O
: O
an O
objective O
randomised O
clinical O
trial O
. O
[]

There O
were O
no O
significant O
differences O
between O
treatment O
arms O
for O
time O
to O
onset O
of O
neuropathy O
( O
P O
= O
0.58 O
) O
, O
for O
chemotherapy O
dose O
reductions O
due O
to O
neuropathy O
( O
P O
= O
0.21 O
) O
, O
or O
for O
secondary O
endpoints O
derived O
from O
patient-reported O
neuropathy O
symptom O
assessments O
. O
[]

The O
cumulative O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
significantly O
( O
p O
less O
than O
0.007 O
) O
greater O
in O
patients O
healed O
with O
cimetidine O
than O
with O
sucralfate O
, O
50 O
% O
relapse O
occurring O
at O
6 O
and O
12 O
mo O
, O
respectively O
. O
['Physiological-Clinical']

The O
present O
study O
investigated O
the O
effects O
of O
oral O
ENT O
administration O
on O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
in O
subjects O
with O
a O
preference O
for O
a O
high-fat O
diet O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

During O
delayed O
intensification O
, O
all O
patients O
received O
a O
dexamethasone O
dosage O
of O
10 O
mg/m O
( O
2 O
) O
/d O
for O
21 O
days O
, O
with O
taper O
. O
[]

The O
routine O
treatment O
including O
anti-infection O
and O
anti-acid O
agents O
, O
and O
that O
of O
inhibition O
of O
pancreatic O
secretion O
were O
given O
, O
except O
for O
the O
different O
nutritional O
interventions O
in O
all O
groups O
. O
[]

As O
such O
, O
testicular O
biopsies O
may O
be O
clinically O
useful O
. O
[]

This O
may O
produce O
poor O
automatic O
preferential O
processing O
of O
relevant O
information O
and O
increase O
load O
on O
limited O
attentional O
resources O
. O
[]

Effects O
of O
cuff O
inflation O
on O
self-recorded B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
A O
randomised O
group O
comparison O
design O
involving O
a O
parent O
education O
and O
counselling O
intervention O
and O
a O
parent O
education O
and O
behaviour O
management O
intervention O
to O
control O
for O
parent O
skills O
training O
and O
a O
control O
sample O
. O
[]

Schizophrenic O
children O
showed O
both O
positive O
and O
negative O
signs B-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
and O
both O
improved O
with O
neuroleptic B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Results O
showed O
significantly O
reduced O
pain B-outcome ['Physiological-Clinical']
during O
the O
first O
five O
postoperative O
days O
in O
patients O
treated O
with O
1,2,6-IP3 O
, O
as O
measured O
by O
using O
a O
VAS O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Differences O
in O
complications O
( O
choroidal O
detachment O
, O
hyphema O
, O
leakage O
) O
seen O
between O
the O
two O
groups O
were O
statistically O
nonsignificant O
. O
[]

The O
FemCap O
was O
believed O
to O
be O
safe O
and O
was O
associated O
with O
significantly O
fewer O
[]

Logistic O
regression O
analysis O
confirmed O
that O
TDM O
independently O
reduced O
the O
incidence O
of O
nephrotoxicity B-outcome ['Physiological-Clinical']
in O
this O
patient O
population O
. O
['Physiological-Clinical']

Anhedonia B-outcome ['Life-Impact']
was O
defined O
to O
be O
present O
if O
the O
participants O
reported O
having O
suffered O
a O
major O
loss O
of O
interest O
during O
the O
previous O
month O
. O
['Life-Impact']

METHODS O
After O
consuming O
a O
run-in O
diet O
[ O
37 O
% O
of O
energy O
( O
E O
% O
) O
fat O
, O
18 O
E O
% O
saturated O
fat O
] O
for O
three O
weeks O
, O
subjects O
were O
randomly O
assigned O
either O
to O
a O
MUFA-diet O
( O
40 O
E O
% O
fat O
, O
19 O
E O
% O
monounsaturated O
fatty O
acids O
) O
or O
a O
PUFA-diet O
( O
34 O
E O
% O
fat O
, O
10 O
E O
% O
polyunsaturated O
fat O
) O
for O
eight O
weeks O
. O
[]

Early O
intervention O
for O
autism O
with O
a O
parent-delivered O
Qigong O
massage O
program O
: O
a O
randomized O
controlled O
trial O
. O
[]

Birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
groups O
and O
13 O
of O
the O
22 O
infants O
weighed O
below O
1000 O
g. O
There O
was O
a O
tendency O
to O
lower O
Apgar B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
at O
five O
minutes O
in O
the O
hydralazine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
endpoints O
included O
infection B-outcome ['Physiological-Clinical']
, O
dehiscence B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
closure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
other O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

Lack O
of O
benefit O
of O
an O
active O
pectoral O
pulse O
generator O
on O
atrial O
defibrillation O
thresholds O
. O
[]

A O
foscarnet O
maintenance O
therapy O
dose O
of O
120 O
mg/kg O
of O
body O
weight/day O
instead O
of O
90 O
mg/kg O
of O
body O
weight/day O
may O
help O
to O
preserve O
vision O
in O
patients O
with O
cytomegalovirus O
retinopathy O
. O
[]

Patients O
received O
a O
24-hour O
, O
low-tryptophan O
diet O
followed O
the O
next O
morning O
by O
an O
amino O
acid O
drink O
. O
[]

RESULTS O
One O
hundred O
eighteen O
patients O
were O
randomized O
to O
receive O
either O
ALVAC O
before O
and O
concomitantly O
with O
chemotherapy O
( O
n O
= O
39 O
) O
, O
ALVAC O
with O
tetanus O
adjuvant O
before O
and O
concomitantly O
with O
chemotherapy O
( O
n O
= O
40 O
) O
, O
or O
chemotherapy O
followed O
by O
ALVAC O
( O
n O
= O
39 O
) O
. O
[]

CONCLUSIONS O
This O
preliminary O
investigation O
showing O
a O
decrease O
in O
BALF O
levels O
of O
IL-8 O
and O
leukotriene O
B4 O
and O
the O
associated O
reduction O
of O
BALF O
neutrophils O
and O
alveolar O
membrane O
protein O
permeability O
in O
acute O
respiratory O
distress O
syndrome O
patients O
fed O
EPA+GLA O
support O
, O
in O
part O
, O
the O
potential O
mechanisms O
underlying O
the O
previously O
described O
clinical O
improvements O
with O
this O
diet O
. O
[]

Our O
results O
also O
revealed O
significant O
gender O
differences O
of O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use O
in O
its O
associated O
individual- O
and O
school-level O
factors O
. O
['Life-Impact']

Subjects O
entered O
the O
study O
after O
undergoing O
complete O
colonoscopy O
and O
removal O
of O
adenomatous O
polyps O
; O
they O
remained O
in O
the O
study O
for O
approximately O
four O
years O
, O
undergoing O
colonoscopy O
one O
and O
four O
years O
after O
randomization O
. O
[]

Sun O
protection O
counseling O
for O
children O
: O
primary O
care O
practice O
patterns O
and O
effect O
of O
an O
intervention O
on O
clinicians O
. O
[]

It O
was O
postulated O
that O
this O
would O
result O
in O
more O
rapid O
onset O
of O
effect O
. O
[]

Both O
therapies O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

This O
study O
assessed O
whether O
these O
findings O
generalize O
from O
children O
to O
adults O
with O
autism O
. O
[]

In O
particular O
, O
type O
3 O
Anthonisens B-outcome ['Physiological-Clinical']
's O
exacerbations B-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
by O
flunisolide O
( O
p O
= O
0.044 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
somatization B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
showed O
large O
decreases O
. O
['Life-Impact']

RESULTS O
Mean O
BCVA B-outcome ['Physiological-Clinical']
over O
6 O
months O
remained O
unchanged O
in O
85 O
% O
of O
patients O
of O
group O
II O
, O
and O
decreased O
in O
53 O
% O
of O
patients O
of O
group O
I O
. O
['Physiological-Clinical']

A O
need O
exists O
for O
further O
studies O
to O
rigorously O
evaluate O
the O
effectiveness O
of O
more O
intensive O
report O
card O
interventions O
. O
[]

2398 O
children O
were O
enrolled O
and O
received O
at O
least O
one O
dose O
of O
RRV-TV O
( O
n=1191 O
) O
or O
placebo O
( O
n=1207 O
) O
. O
[]

This O
was O
done O
, O
prospectively O
, O
to O
determine O
doses O
of O
these O
agents O
that O
would O
increase O
or O
decrease O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
levels O
by O
> O
/= O
30 O
% O
. O
['Physiological-Clinical']

Twenty-five O
percent O
of O
the O
patients O
tested O
positive O
for O
M O
pneumoniae O
. O
[]

The O
associations O
between O
exercise O
capacity O
, O
symptoms O
and O
specific O
aspects O
of O
quality O
of O
life O
were O
examined O
in O
subjects O
participating O
in O
a O
trial O
of O
the O
treatment O
of O
heart O
failure O
. O
[]

Viewing O
either O
of O
the O
videotapes O
also O
resulted O
in O
significantly O
less O
dietary B-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
1 O
month O
after O
hospital O
release B-outcome ['Life-Impact']
compared O
with O
controls O
. O
['Life-Impact', 'Life-Impact']

METHODS O
Postmenopausal O
women O
( O
age O
65 O
years O
or O
older O
) O
were O
enrolled O
in O
a O
randomized O
clinical O
trial O
and O
underwent O
every-other-day O
ES O
of O
the O
pelvic O
floor O
, O
or O
a O
daily O
Kegel O
exercise O
( O
KE O
) O
program O
. O
[]

We O
conclude O
that O
in O
our O
open O
label O
pilot O
study O
, O
the O
antihypertensive O
activity O
of O
valsartan O
is O
not O
significantly O
attenuated O
by O
supplemented O
salt O
diet O
in O
hypertensive O
African O
Americans O
. O
[]

This O
study O
indicates O
that O
participating O
in O
an O
exercise O
intervention O
improves O
WMI O
in O
children O
as O
compared O
to O
a O
sedentary O
after-school O
program O
. O
[]

Acustimulation O
wrist O
bands O
are O
not O
effective O
for O
the O
control O
of O
chemotherapy-induced B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
women O
with O
breast O
cancer O
. O
['Physiological-Clinical']

BACKGROUND O
Flow O
cytometry O
was O
used O
to O
enumerate O
tumour O
cells O
in O
longitudinal O
studies O
of O
peripheral O
blood O
from O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
patients O
, O
together O
with O
magnetic O
bead O
selection O
to O
isolate O
and O
identify O
these O
cells O
. O
[]

The O
scars O
of O
all O
treated O
and O
untreated O
patients O
were O
evaluated O
at O
monthly O
intervals O
. O
[]

DATA O
COLLECTION/EXTRACTION O
METHODS O
Youth O
surveys O
were O
self-administered O
during O
school O
hours O
. O
[]

Group O
I O
( O
n O
= O
19 O
patients O
) O
underwent O
surgical O
induction O
of O
posterior O
vitreous O
detachment O
( O
PVD O
) O
, O
group O
II O
( O
n O
= O
20 O
patients O
) O
PVD O
and O
removal O
of O
the O
ILM O
. O
[]

Prethreshold O
ROP O
was O
defined O
as O
any O
stage O
of O
ROP O
in O
zone O
I O
with O
plus O
disease O
; O
or O
stage O
3 O
with O
three O
or O
more O
contiguous O
clock O
hours O
or O
five O
or O
more O
total O
clock O
hours O
of O
involvement O
of O
retina O
in O
zone O
II O
with O
plus O
disease O
but O
less O
than O
threshold O
disease O
. O
[]

Men O
currently O
using B-outcome ['Life-Impact']
illicit I-outcome ['Life-Impact']
drugs I-outcome ['Life-Impact']
were O
2.64 O
times O
less O
likely O
to O
have O
controlled B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
compared O
with O
their O
counterparts O
who O
did O
not O
use O
illicit O
drugs O
, O
and O
men O
currently O
taking B-outcome ['Resource-use']
HBP I-outcome ['Resource-use']
medication I-outcome ['Resource-use']
were O
63 O
times O
more O
likely O
have O
controlled B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
compared O
with O
men O
not O
taking O
HBP O
medication O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Eighteen O
patients O
in O
arm O
1 O
( O
30 O
% O
) O
and O
17 O
patients O
( O
28.3 O
% O
) O
in O
arm O
2 O
had O
partial O
response O
on O
therapy O
. O
[]

RESULTS O
Of O
381 O
patients O
who O
underwent O
SLN O
biopsy O
, O
103 O
( O
27 O
% O
) O
were O
positive O
. O
[]

All O
patients O
received O
the O
same O
cementless O
implant O
, O
inserted O
with O
use O
of O
standard O
instruments O
, O
and O
all O
operations O
were O
performed O
by O
a O
single O
, O
experienced O
surgeon O
. O
[]

MATERIALS O
AND O
METHODS O
This O
is O
the O
first O
report O
to O
our O
knowledge O
on O
cardiovascular O
safety O
data O
from O
a O
completed O
1-year O
randomized O
controlled O
trial O
of O
leuprolide O
acetate O
vs O
degarelix O
. O
[]

PURPOSE O
Sulindac O
is O
a O
nonsteroidal O
anti-inflammatory O
drug O
( O
NSAID O
) O
effective O
in O
regressing O
adenomas O
in O
patients O
with O
familial O
adenomatous O
polyposis O
( O
FAP O
) O
. O
[]

This O
failed O
to O
influence O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
plasma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Significantly O
fewer O
drug-related B-outcome ['Adverse-effects']
clinical I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
after O
rizatriptan O
10 O
mg O
( O
33 O
% O
, O
P O
= O
0.014 O
) O
compared O
with O
sumatriptan O
100 O
mg O
( O
41 O
% O
) O
. O
['Adverse-effects']

There O
were O
no O
statistically O
significant O
differences O
in O
mortality B-outcome ['Mortality']
( O
4 O
% O
in O
telemedicine O
and O
11 O
% O
in O
telephone O
) O
or O
rates O
of O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
4 O
% O
in O
telemedicine O
and O
0 O
% O
in O
telephone O
) O
. O
['Mortality', 'Physiological-Clinical']

CONCLUSION O
Sentinel O
lymph O
node O
detection O
and O
analysis O
is O
feasible B-outcome ['Life-Impact']
, O
technique O
is O
relatively O
['Life-Impact']

Deterioration O
in O
morphological B-outcome ['Physiological-Clinical']
parameters O
observed O
in O
earlier O
studies O
of O
our O
patients O
did O
not O
become O
worse O
during O
treatment O
with O
candesartan O
or O
placebo O
. O
['Physiological-Clinical']

The O
healing B-outcome ['Physiological-Clinical']
rate O
did O
not O
differ O
significantly O
between O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

We O
aimed O
to O
determine O
the O
benefits O
of O
regular O
replacement O
of O
extended O
wear O
RGP O
contact O
lenses O
. O
[]

METHODS O
We O
conducted O
a O
prospective O
study O
of O
300 O
patients O
who O
had O
small-cell O
lung O
cancer O
that O
was O
in O
complete O
remission O
. O
[]

There O
was O
significant O
statistical O
difference O
between O
them O
. O
[]

METHODS O
This O
was O
a O
randomized O
trial O
of O
897 O
women O
from O
three O
racial O
groups O
( O
white O
, O
African O
American O
, O
Native O
American O
) O
living O
in O
a O
rural O
county O
in O
North O
Carolina O
. O
[]

DESIGN/METHODS O
Twenty-four O
patients O
with O
primary O
biliary O
cirrhosis O
and O
17 O
healthy O
subjects O
were O
studied O
. O
[]

4.6 O
vs. O
170.0 O
? O
[]

The O
primary O
outcome O
was O
a O
hematocrit B-outcome ['Physiological-Clinical']
drop I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
or O
greater O
24 O
h O
postpartum O
. O
['Physiological-Clinical']

Patients O
treated O
with O
placebo O
subsequently O
received O
a O
12-week O
open-label O
trial O
of O
risperidone O
. O
[]

Although O
the O
differences O
in O
these O
three O
parameters O
were O
statistically O
significant O
, O
they O
were O
very O
small O
and O
are O
of O
no O
clinical O
importance O
. O
[]

Infrared O
LED O
irradiation O
applied O
during O
high-intensity O
treadmill O
training O
improves O
maximal B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
: O
a O
6-month O
longitudinal O
study O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
cholesterols I-outcome ['Physiological-Clinical']
, O
LDL/HDL B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
, O
LDL B-outcome ['Physiological-Clinical']
cholesterols I-outcome ['Physiological-Clinical']
, O
and O
triglyceride B-outcome ['Physiological-Clinical']
determinations I-outcome ['Physiological-Clinical']
in O
male O
tobacco O
users O
significantly O
exceeded O
those O
in O
nonsmoking O
males O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BFST-D O
significantly O
improved O
quality O
of O
family B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
compared O
to O
SC O
( O
10 O
of O
12 O
comparisons O
) O
and O
ES O
( O
6 O
of O
12 O
comparisons O
) O
. O
['Life-Impact']

Subjects O
then O
underwent O
mental O
stress O
testing O
. O
[]

PURPOSE O
To O
compare O
once-daily O
radiation O
therapy O
( O
qdRT O
) O
with O
hyperfractionated O
accelerated O
radiation O
therapy O
( O
HART O
) O
after O
two O
cycles O
of O
induction O
chemotherapy O
. O
[]

Although O
one O
subject O
appeared O
to O
have O
partial O
decreases O
in O
maladaptive B-outcome ['Life-Impact']
behaviors B-outcome ['Life-Impact']
associated O
with O
naltrexone O
use O
, O
the O
drugs O
, O
as O
administered O
in O
this O
study O
, O
did O
not O
reduce O
the O
['Life-Impact', 'Life-Impact']

Microparticles O
were O
isolated O
from O
systemic O
blood O
collected O
before O
anesthesia O
( O
T1 O
) O
and O
at O
the O
end O
of O
CPB O
( O
T2 O
) O
, O
and O
from O
pericardial O
blood O
. O
[]

Protein O
ingestion O
further O
augments O
S6K1 O
phosphorylation O
in O
skeletal O
muscle O
following O
resistance O
type O
exercise O
in O
males O
. O
[]

The O
relationship O
of O
alexithymia O
to O
emotional O
dysregulation O
within O
an O
alcohol O
dependent O
treatment O
sample O
. O
[]

The O
use O
of O
memory O
aids O
to O
improve O
respondent O
recall O
is O
becoming O
increasingly O
popular O
in O
health O
surveys O
. O
[]

An O
analysis O
for O
group O
mean O
differences O
between O
the O
NC O
and O
the O
FB O
instructions O
yielded O
significant O
differences O
across O
the O
basic O
TOVA O
variables O
across O
the O
four O
quarters O
, O
two O
halves O
and O
total O
score O
. O
[]

In O
a O
prospective O
study O
, O
20 O
patients O
with O
endoscopically O
proven O
duodenal O
ulcers O
were O
randomised O
to O
be O
treated O
with O
cimetidine O
1 O
g O
daily O
or O
with O
antacids O
350 O
mmol O
daily O
. O
[]

These O
results O
indicate O
that O
the O
[]

The O
risk O
increased O
to O
44.9 O
% O
( O
36.0-53.9 O
% O
) O
and O
60.1 O
% O
( O
48.5-71.7 O
% O
) O
, O
respectively O
, O
after O
96 O
months O
. O
[]

Women O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
a O
computer O
generated O
random O
sequence O
to O
either O
triple O
antiretroviral O
prophylaxis O
( O
a O
combination O
of O
300 O
mg O
zidovudine O
, O
150 O
mg O
lamivudine O
, O
and O
400 O
mg O
lopinavir O
plus O
100 O
mg O
ritonavir O
twice O
daily O
until O
cessation O
of O
breastfeeding O
to O
a O
maximum O
of O
6?5 O
months O
post O
partum O
) O
or O
zidovudine O
and O
single-dose O
nevirapine O
( O
300 O
mg O
zidovudine O
twice O
daily O
until O
delivery O
and O
a O
dose O
of O
600 O
mg O
zidovudine O
plus O
200 O
mg O
nevirapine O
at O
the O
onset O
of O
labour O
and O
, O
after O
a O
protocol O
amendment O
in O
December O
, O
2006 O
, O
1 O
week O
post-partum O
zidovudine O
300 O
mg O
twice O
daily O
and O
lamivudine O
150 O
mg O
twice O
daily O
) O
. O
[]

267/890 O
patients O
( O
30 O
% O
) O
were O
within O
24 O
h O
of O
an O
ST-segment O
elevation O
MI O
. O
[]

CONCLUSION O
Tubeless O
PCNL O
seems O
to O
be O
accompanied O
by O
better O
outcome O
. O
[]

Gemcitabine O
combined O
with O
either O
pemetrexed O
or O
paclitaxel O
in O
the O
treatment O
of O
advanced O
non-small O
cell O
lung O
cancer O
: O
a O
randomized O
phase O
II O
SICOG O
trial O
. O
[]

The O
results O
of O
this O
investigation O
indicate O
that O
the O
sedation O
regimen O
of O
propofol O
alone O
has O
the O
least O
impact O
on O
postprocedure O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
significant O
decrease O
in O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
at O
the O
end O
of O
the O
post-stimulation O
period O
was O
also O
demonstrated O
. O
['Physiological-Clinical']

In O
six O
patients O
( O
5.6 O
% O
) O
therapy O
was O
discontinued O
as O
a O
result O
of O
adverse O
experiences O
. O
[]

Parents O
of O
children O
with O
more O
advanced O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
may O
require O
intervention O
strategies O
that O
go O
beyond O
FPI O
's O
focus O
on O
responsive B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

PARTICIPANTS O
Eighteen O
subjects O
( O
mean O
age O
, O
29.5?11.0 O
years O
) O
allergic O
to O
grass O
pollen O
. O
[]

Prolonged O
infusion O
of O
low-dose O
gemcitabine O
and O
cisplatin O
( O
GC O
) O
proved O
to O
be O
an O
effective O
treatment O
for O
patients O
with O
advanced O
bladder O
cancer O
. O
[]

At O
12 O
month O
follow-up O
, O
the O
rate O
of O
target B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
conventional O
group O
( O
29 O
% O
versus O
13 O
% O
, O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

Other O
measures O
of O
chorea B-outcome ['Physiological-Clinical']
( O
UHDRS O
chorea B-outcome ['Physiological-Clinical']
score O
, O
video O
ratings O
) O
showed O
no O
improvement O
. O
['Physiological-Clinical']

Re-examinations O
of O
the O
stool O
were O
performed O
after O
the O
treatment O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
( O
n O
= O
240 O
) O
were O
randomly O
assigned O
to O
receive O
either O
ED O
( O
epirubicin O
75 O
mg/m O
( O
2 O
) O
and O
docetaxel O
75 O
mg/m O
( O
2 O
) O
) O
or O
EC O
( O
epirubicin O
90 O
mg/m O
( O
2 O
) O
and O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
) O
. O
[]

Many O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
participate O
in O
social O
skills O
or O
Theory O
of O
Mind O
( O
ToM O
) O
treatments O
. O
[]

The O
question O
of O
differential O
effects O
on O
bone O
density O
by O
two O
different O
types O
of O
progestogen-only O
methods O
for O
contraception O
in O
premenopausal O
women O
was O
addressed O
. O
[]

10 O
years O
old O
( O
31 O
% O
> O
75 O
years O
old O
) O
underwent O
stent O
implantation O
and O
received O
prasugrel O
therapy O
. O
[]

Onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
was O
determined O
to O
have O
taken O
place O
the O
first O
time O
that O
the O
effects O
of O
ciclesonide O
, O
as O
reflected O
in O
the O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
, O
were O
significantly O
greater O
than O
those O
of O
placebo O
at O
a O
particular O
hourly O
assessment O
, O
provided O
that O
the O
subsequent O
hourly O
assessment O
also O
showed O
a O
statistically O
significant O
difference O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Large O
forceps O
are O
expected O
to O
result O
in O
larger O
specimens O
and O
improve O
diagnostic O
yield O
. O
[]

No O
intergroup O
differences O
were O
found O
with O
respect O
to O
the O
number O
of O
punctures B-outcome ['Physiological-Clinical']
( O
mean O
value O
1.6 O
+/- O
0.83 O
) O
and O
the O
incidence O
of O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

BACKGROUND O
CETP O
plays O
an O
important O
role O
in O
HDL O
metabolism O
and O
in O
the O
reverse O
cholesterol O
transport O
pathway O
. O
[]

Clinical O
pathway O
for O
fractured O
neck O
of O
femur O
: O
a O
prospective O
, O
controlled O
study O
. O
[]

From O
this O
study O
, O
a O
low-dose O
test O
( O
MEG-X O
concentration O
30 O
minutes O
after O
50 O
mg O
lidocaine O
intravenously O
[ O
MEG-X30min O
] O
normalized O
to O
standard O
MEG-X O
test O
results O
) O
was O
developed O
. O
[]

Pimecrolimus O
, O
an O
inhibitor O
of O
calcineurin O
, O
has O
been O
used O
successfully O
in O
one O
patient O
with O
seborrhoeic O
dermatitis O
. O
[]

INTERVENTION O
All O
participants O
received O
usual O
care O
. O
[]

RESULTS O
The O
operative B-outcome ['Resource-use']
resection I-outcome ['Resource-use']
, O
anal B-outcome ['Physiological-Clinical']
preservation I-outcome ['Physiological-Clinical']
and O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rates O
were O
86.66 O
% O
, O
33.33 O
% O
, O
15.38 O
% O
in O
group O
A O
and O
100 O
% O
, O
83.33 O
% O
, O
0 O
% O
in O
group O
B O
( O
P O
< O
0.05 O
and O
P O
< O
0.01 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Induction O
of O
anesthesia O
with O
propofol O
is O
associated O
with O
a O
more O
rapid B-outcome ['Physiological-Clinical']
emergence I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
anesthesia I-outcome ['Physiological-Clinical']
than O
induction O
with O
thiopental O
. O
['Physiological-Clinical']

AIM O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
circulatory B-outcome ['Physiological-Clinical']
AGE-peptide I-outcome ['Physiological-Clinical']
levels O
in O
diabetic O
nephropathy O
and O
to O
observe O
the O
effects O
of O
thiamine O
( O
vitamin O
B1 O
) O
and O
pyridoxine O
( O
vitamin O
B6 O
) O
therapy O
. O
['Physiological-Clinical']

Five O
of O
six O
in O
the O
olanzapine O
group O
and O
three O
of O
six O
in O
the O
haloperidol O
group O
were O
rated O
as O
responders O
according O
to O
the O
CGI O
Improvement O
item O
. O
[]

All O
give O
symptomatic O
improvement O
in O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
in O
the O
control O
group O
received O
routine O
clinic O
services O
, O
but O
had O
no O
clinical O
pharmacist O
interaction O
. O
[]

This O
led O
to O
a O
significant O
increase O
( O
P O
= O
0.02 O
) O
in O
the O
dose O
intensity O
actually O
administered O
in O
the O
third O
, O
fourth O
and O
sixth O
cycles O
: O
+28 O
% O
, O
+25 O
% O
, O
+20 O
% O
respectively O
. O
[]

The O
serial B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
endotoxin I-outcome ['Physiological-Clinical']
, O
IL-1 B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
at O
12 O
, O
36 O
and O
60 O
h O
after O
treatment O
compared O
with O
Control O
groups O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
randomly O
assigned O
83 O
first- O
, O
second- O
, O
and O
third-year O
medical O
residents O
to O
receive O
or O
not O
to O
receive O
diagnostic O
information O
and O
counseling O
directives O
on O
214 O
patients O
who O
reported O
at O
least O
one O
symptom O
of O
alcohol O
impairment O
as O
defined O
in O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Third O
Edition O
. O
[]

Outcome O
analyses O
were O
performed O
at O
a O
median O
follow-up O
interval O
of O
4.4 O
years O
. O
[]

Transplacental O
passage O
occurred O
. O
[]

RESULTS O
Tramadol O
and O
placebo O
had O
no O
statistical O
significances O
in O
analgesic B-outcome ['Resource-use']
properties O
, O
assessed O
by O
the O
means O
of O
pain B-outcome ['Physiological-Clinical']
rating O
at O
the O
different O
time O
intervals O
. O
['Resource-use', 'Physiological-Clinical']

We O
performed O
an O
open O
trial O
with O
naltrexone O
in O
2 O
autistic O
girls O
, O
displaying O
serious O
self-injurious O
behavior O
, O
reduced O
crying O
and O
a O
marked O
preference O
for O
salty O
and O
spicy O
foods O
, O
symptoms O
that O
could O
be O
related O
to O
a O
dysfunction O
of O
the O
opioid O
system O
. O
[]

Isolates O
at O
diagnosis O
and O
from O
positive O
cultures O
after O
treatment O
completion O
underwent O
genotyping O
using O
IS6110 O
( O
with O
secondary O
genotyping O
for O
isolates O
with O
less O
than O
six O
copies O
of O
IS6110 O
) O
. O
[]

During O
this O
time O
, O
the O
safety O
, O
anti-plaque B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

Mean O
( O
? O
[]

Given O
the O
acceptability B-outcome ['Life-Impact']
curve O
, O
there O
is O
a O
92.4 O
% O
chance O
that O
the O
CBT O
, O
compared O
with O
the O
SET O
, O
is O
['Life-Impact']

In O
this O
study O
, O
vincristine O
was O
administered O
by O
bolus O
injection O
followed O
by O
a O
3-day O
continuous O
intravenous O
( O
IV O
) O
infusion O
( O
total O
dose O
of O
2.0 O
mg/m2 O
every O
other O
week O
) O
; O
the O
maximum O
dose O
of O
vincristine O
was O
not O
arbitrarily O
limited O
. O
[]

Administration O
of O
cefotiam O
was O
randomized O
for O
patients O
undergoing O
major O
craniotomies O
. O
[]

Concentrations O
of O
[]

Endurance B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
ventilatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
CWT O
were O
compared O
between O
fatigued O
and O
fresh O
state O
. O
['Life-Impact', 'Physiological-Clinical']

For O
the O
movement B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
crying I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
midazolam O
also O
proved O
to O
be O
significantly O
more O
effective O
from O
the O
start O
of O
treatment O
through O
the O
35- O
and O
40-min O
markers O
, O
respectively O
( O
P O
< O
.05 O
) O
. O
['Life-Impact']

It O
was O
hypothesized O
that O
muscle B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
caused O
by O
FES O
could O
be O
reduced O
by O
randomly O
modulating O
parameters O
of O
the O
electrical O
stimulus O
. O
['Physiological-Clinical']

MEASURES O
Key O
outcome O
measures O
were O
the O
Autism B-outcome ['Life-Impact']
Relevant O
Subscale O
of O
the O
Children O
's O
Psychiatric B-outcome ['Physiological-Clinical']
Rating O
Scale O
, O
the O
Modified O
Comprehensive O
Psychopathological O
Rating O
Scale-Obsessive-Compulsive O
Disorder I-outcome ['Life-Impact']
Subscale O
, O
and O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Ambulatory O
activity O
was O
measured O
during O
1 O
week O
with O
a O
StepWatch O
activity O
monitor O
as O
steps O
per O
day O
, O
and O
time O
spent O
at O
medium O
and O
high O
step O
rates O
. O
[]

For O
these O
reasons O
, O
PTCA O
therapy O
of O
acute O
MI O
should O
not O
be O
routinely O
performed O
with O
adjunctive O
intravenous O
streptokinase O
therapy O
. O
[]

By O
8 O
weeks O
, O
average O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distances I-outcome ['Life-Impact']
had O
improved O
by O
13.1 O
% O
and O
WOMAC O
scores O
had O
improved O
by O
55.8 O
% O
over O
baseline O
values O
in O
the O
treatment O
group O
( O
P O
< O
0.05 O
) O
. O
['Life-Impact']

The O
degree O
of O
soleus B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
appeared O
directly O
proportional O
to O
the O
speed O
of O
the O
arm O
swing O
. O
['Physiological-Clinical']

Placental B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
( O
PlGF O
) O
, O
a O
member O
of O
the O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
family O
, O
acts O
via O
the O
flt-1 O
receptor O
and O
promotes O
endothelial O
activation O
and O
macrophage O
recruitment O
into O
atherosclerotic O
lesions O
. O
['Physiological-Clinical']

On O
a O
phone O
interview O
they O
had O
to O
evaluate O
their O
appreciation O
of O
the O
anxiolytic O
technique O
, O
their O
perception O
during O
loco-regional O
anesthesia O
and O
incidence O
of O
pain O
and O
edema O
. O
[]

A O
randomized O
comparison O
of O
acyclovir O
and O
vidarabine O
. O
[]

CONCLUSIONS O
This O
study O
is O
among O
the O
first O
randomized O
trials O
comparing O
2 O
active O
interventions O
with O
a O
large O
sample O
of O
low-resourced O
families O
. O
[]

RESULTS O
Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
This O
double-blind O
placebo-controlled O
paralleled O
study O
randomized O
302 O
patients O
with O
type O
2 O
diabetes O
( O
mean O
A1C O
8.3 O
% O
) O
on O
metformin O
monotherapy O
( O
mean O
1.5 O
g/day O
) O
to O
receive O
one O
of O
five O
INCB13739 O
doses O
or O
placebo O
once O
daily O
for O
12 O
weeks O
. O
[]

DGF O
and O
wound O
healing O
complications O
were O
similar O
between O
groups O
. O
[]

The O
influence O
of O
fidelity B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
on O
teacher-student O
interaction O
quality B-outcome ['Life-Impact']
in O
the O
context O
of O
a O
randomized O
controlled O
trial O
of O
the O
Responsive O
Classroom O
approach O
. O
['Life-Impact', 'Life-Impact']

Objective B-outcome ['Physiological-Clinical']
stabilization I-outcome ['Physiological-Clinical']
occurred O
, O
respectively O
, O
in O
14 O
% O
and O
44 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

At O
the O
second O
examination O
, O
the O
patients O
who O
had O
been O
operated O
on O
, O
had O
significantly O
less O
depression B-outcome ['Life-Impact']
( O
p O
< O
0.01 O
) O
and O
better O
self-esteem B-outcome ['Life-Impact']
( O
p=0.03 O
) O
than O
the O
conservative O
group O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Characterization O
of O
fatal O
and O
non-fatal O
reactions O
to O
food O
indicates O
that O
the O
majority O
of O
reactions O
are O
due O
to O
the O
ingestion O
of O
prepared O
foods O
rather O
than O
the O
non-processed O
allergen O
. O
[]

Early O
after O
surgery O
, O
the O
No O
Pres O
group O
had O
lower B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
and O
stroke B-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
by O
repeated-measures O
[ O
rm O
] O
ANOVA O
) O
than O
the O
Pres O
group O
did O
at O
similar O
end-diastolic O
volume O
indexes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SAMPLE O
Premenopausal O
and O
postmenopausal O
women O
referred O
to O
outpatient O
resectoscopy O
. O
[]

CONCLUSION O
This O
study O
, O
based O
on O
a O
limited O
number O
of O
patients O
, O
indicates O
that O
adjuvant O
immunochemotherapy O
( O
BCG O
+ O
FAM O
) O
may O
prolong O
the O
survival B-outcome ['Mortality']
of O
gastric O
cancer O
patients O
after O
curative O
gastrectomy O
; O
in O
particular O
, O
in O
patients O
with O
pT2/T3 O
tumors O
and O
intestinal-type O
primary O
tumors O
. O
['Mortality']

However O
, O
long-term O
exposure O
to O
low O
protein O
provision O
in O
mink O
reduces O
their O
growth B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
and O
induces B-outcome ['Physiological-Clinical']
transient I-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
lipidosis I-outcome ['Physiological-Clinical']
and O
modified B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
antibiotic O
combination O
permitted O
a O
dramatic O
decrease O
in O
[]

We O
suggest O
that O
intraumbilical O
vein O
injection O
of O
prostaglandin O
F2 O
alpha O
might O
be O
a O
beneficial O
, O
non-surgical O
method O
for O
treating O
retained O
placenta O
. O
[]

Treatment O
of O
familial O
hypercholesterolemia O
with O
a O
combination O
of O
bezafibrate O
and O
guar O
. O
[]

Steers O
fed O
diets O
containing O
SBM-U O
had O
12 O
% O
less O
( O
P O
< O
.10 O
) O
fat B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
than O
those O
fed O
diets O
containing O
SBM O
. O
['Physiological-Clinical']

Pretrial O
USG O
was O
1.022 O
? O
[]

Total O
cholesterol B-outcome ['Physiological-Clinical']
, O
LDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
were O
all O
significantly O
decreased O
in O
hyperlipidemic O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Experiment O
2 O
used O
a O
modified O
training O
protocol O
that O
promoted O
attention O
to O
context O
cues O
. O
[]

Between O
May O
1988 O
and O
June O
2000 O
, O
698 O
children O
were O
treated O
in O
the O
Medical O
Research O
Council O
acute O
myeloid O
leukemia O
10 O
and O
12 O
trials O
. O
[]

No O
cases O
in O
the O
other O
two O
groups O
encountered O
this O
problem O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
mainly O
limited O
to O
WHO O
grades O
1 O
or O
2 O
. O
['Adverse-effects']

The O
overall O
mean O
number O
of I-outcome ['Life-Impact']
daily B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
study I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
was O
significantly O
less O
in O
the O
HI2 O
group O
( O
2.94+/-0.99 O
) O
than O
in O
the O
HI1 O
group O
( O
3.23+/-0.76 O
) O
( O
P O
= O
0.036 O
) O
or O
the O
CA O
group O
( O
3.26+/-0.75 O
) O
( O
P O
= O
0.014 O
) O
. O
['Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Of O
624 O
nursing O
home O
patients O
with O
dementia O
, O
446 O
completed O
follow-up O
assessments O
. O
[]

Glycemic O
control O
was O
assessed O
by O
HbA O
( O
1c O
) O
, O
self-reported O
hypoglycemic O
events O
, O
and O
blood O
glucose O
memory O
meter O
read O
outs O
. O
[]

RESULTS O
After O
1 O
cycle O
, O
BMI O
, O
total O
T B-outcome ['Physiological-Clinical']
level O
, O
and O
percentage O
of O
participants O
with O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
in O
the O
metformin O
group O
, O
without O
any O
significant O
decrease O
in O
LH B-outcome ['Physiological-Clinical']
, O
FSH B-outcome ['Physiological-Clinical']
, O
and O
DHEAS B-outcome ['Physiological-Clinical']
levels O
; O
and O
in O
the O
second O
cycle O
, O
CC O
treatment O
resulted O
in O
a O
higher O
ovulation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
a O
thicker B-outcome ['Physiological-Clinical']
endometrium I-outcome ['Physiological-Clinical']
in O
the O
metformin O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
RESULTS O
Mortality B-outcome ['Mortality']
from O
metastatic O
cancer O
in O
tamoxifen O
group O
was O
7 O
( O
10.6 O
% O
) O
and O
in O
mastectomy O
group O
10 O
( O
15.3 O
% O
) O
( O
NS O
) O
. O
['Mortality']

Times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
two-segment I-outcome ['Physiological-Clinical']
and O
T-10 B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
were O
comparable O
in O
the O
two O
groups O
( O
112 O
+/- O
26 O
min O
in O
Group O
1 O
versus O
122 O
+/- O
28 O
min O
in O
Group O
2 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
pharmacologic O
effects O
of O
lorazepam O
( O
2 O
mg O
) O
, O
buspirone O
( O
20 O
mg O
, O
10 O
mg O
) O
, O
secobarbital O
( O
100 O
mg O
) O
, O
and O
placebo O
were O
compared O
in O
15 O
male O
, O
experienced O
, O
intermittent O
nontherapeutic O
drug O
users O
. O
[]

A O
lower O
PSA B-outcome ['Physiological-Clinical']
cut-off O
level O
of O
3 O
ng/ml O
used O
in O
Sweden O
and O
The O
Netherlands O
prolonged O
the O
mean O
lead-time O
by O
approximately O
1 O
year O
. O
['Physiological-Clinical']

Micronized O
flavonoids O
in O
pain B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
after O
hemorrhoidectomy O
: O
a O
prospective O
randomized O
controlled O
study O
. O
['Physiological-Clinical']

By O
a O
double-blind O
, O
placebo-controlled O
, O
balanced O
randomization O
, O
subjects O
received O
GM-CSF O
priming O
on O
days O
5 O
to O
1 O
for O
courses O
1 O
and O
3 O
or O
courses O
2 O
and O
4 O
. O
[]

RESULTS O
Spearman O
's O
correlation O
coefficient O
between O
intake O
of O
EPA O
, O
DHA O
and O
EPA O
+ O
DHA O
and O
their O
corresponding O
concentration O
in O
RBC O
was O
0.46 O
, O
0.40 O
and O
0.42 O
, O
respectively O
( O
all O
P O
< O
0.05 O
) O
. O
[]

They O
were O
followed O
up O
for O
6 O
months O
. O
[]

Furthermore O
, O
they O
suggest O
that O
these O
effects O
of O
insulin O
are O
reinforced O
when O
the O
hormone O
is O
administered O
in O
an O
intermittent O
manner O
in O
an O
attempt O
to O
reproduce O
the O
pulsatile B-outcome ['Physiological-Clinical']
physiological I-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Midazolam O
vs O
ondansetron O
for O
preventing O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
: O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
total O
effective O
rate O
in O
the O
treatment O
group O
was O
obviously O
higher O
than O
that O
in O
the O
control O
group O
( O
77.1 O
% O
vs. O
54.3 O
% O
, O
P O
< O
0.05 O
) O
. O
[]

After O
28 O
days O
, O
the O
mean O
HIV-1 O
RNA O
reduction O
was O
0.99 O
log O
( O
10 O
) O
copies/mL O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.45-1.53 O
] O
for O
group O
1 O
and O
0.89 O
log O
( O
10 O
) O
copies/mL O
( O
95 O
% O
CI O
0.38-1.40 O
) O
for O
group O
2 O
. O
[]

Performance O
of O
a O
modified O
starch O
hydrophilic O
matrix O
for O
the O
sustained O
release O
of O
theophylline O
in O
healthy O
volunteers O
. O
[]

The O
secondary O
objective O
is O
to O
compare O
the O
cost-effectiveness O
of O
both O
interventions O
. O
[]

Dosing O
was O
continued O
for O
8 O
consecutive O
days O
on O
each O
treatment O
with O
an O
intervening O
wash-out O
period O
of O
1 O
week O
. O
[]

Although O
pre-course O
scores O
were O
similar O
( O
student-directed O
25.3 O
( O
7.3 O
) O
; O
structured O
24.8 O
( O
7.5 O
) O
) O
the O
structured O
approach O
resulted O
in O
higher O
post-course O
scores O
in O
comparison O
with O
the O
student-directed O
approach O
( O
student-directed O
41.8 O
( O
9.4 O
) O
; O
structured O
53.8 O
( O
8.8 O
) O
; O
p O
< O
0.01 O
) O
. O
[]

Psychoeducational O
group O
intervention O
for O
wives O
of O
men O
with O
prostate O
cancer O
. O
[]

OUTCOME O
MEASURES O
Severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gagging I-outcome ['Physiological-Clinical']
was O
rated O
on O
a O
visual-analogue O
scale O
. O
['Physiological-Clinical']

With O
a O
median O
of O
4.7 O
years O
of O
follow-up O
( O
range O
, O
0.1 O
to O
6.3 O
years O
) O
, O
there O
was O
no O
difference O
in O
OS B-outcome ['Mortality']
( O
hazard O
ratio O
[ O
HR O
] O
, O
1.24 O
; O
95 O
% O
CI O
, O
0.94 O
to O
1.64 O
; O
P O
= O
.14 O
) O
or O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.22 O
; O
95 O
% O
CI O
, O
0.93 O
to O
1.61 O
; O
P O
= O
.15 O
) O
between O
the O
arms O
. O
['Mortality', 'Mortality']

Preoperative O
and O
postoperative B-outcome ['Physiological-Clinical']
International I-outcome ['Physiological-Clinical']
Prostate I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
( O
IPSS B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Early O
reperfusion O
and O
late O
clinical O
outcomes O
in O
patients O
presenting O
with O
acute O
myocardial O
infarction O
randomly O
assigned O
to O
primary O
percutaneous O
coronary O
intervention O
or O
streptokinase O
. O
[]

Scar O
development O
was O
investigated O
in O
45 O
young O
patients O
who O
had O
undergone O
thoracic O
surgery O
. O
[]

The O
reported O
feelings O
of O
relaxation B-outcome ['Life-Impact']
were O
negatively O
correlated O
to O
the O
directionality O
of O
temperature O
change O
and O
were O
primarily O
attributed O
to O
nonspecific O
expectancies O
. O
['Life-Impact']

AIMS O
To O
assess O
the O
effectiveness O
and O
safety O
of O
a O
brief O
cognitive-behavioural O
therapy O
( O
CBT O
) O
intervention O
in O
a O
representative O
community O
sample O
of O
patients O
with O
schizophrenia O
in O
secondary O
care O
settings O
. O
[]

CONCLUSIONS/SIGNIFICANCE O
This O
modelling O
study O
shows O
that O
a O
decision O
to O
adopt O
a O
Telephone O
Counselling O
program O
over O
existing O
practice O
( O
Real O
Control O
) O
is O
likely O
to O
be O
cost-effective O
. O
['Resource-use']

Rocuronium O
PK O
was O
described O
by O
a O
two-compartment O
model O
and O
PD O
parameters O
were O
estimated O
using O
effect O
compartment O
and O
sigmoidal O
E O
( O
max O
) O
models O
. O
[]

The O
response O
rate O
after O
HAI O
treatment O
was O
significantly O
higher O
as O
compared O
to O
i.v O
. O
[]

Patients O
are O
randomized O
to O
a O
multivitamin O
that O
includes O
either O
a O
high-dose O
or O
low-dose O
of O
folic O
acid O
( O
5 O
or O
0 O
mg O
) O
, O
vitamin O
B6 O
( O
50 O
or O
1.4 O
mg O
) O
, O
and O
vitamin O
B12 O
( O
1000 O
or O
2 O
microg O
) O
. O
[]

RESULTS O
The O
mean O
area O
under O
the O
curve O
of O
improvement O
for O
scaling/hypertrophy B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
itching O
and O
global B-outcome ['Physiological-Clinical']
patient I-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
was O
significantly O
better O
for O
the O
actively O
treated O
patients O
as O
compared O
with O
placebo O
( O
scaling/hypertrophy O
, O
P O
= O
0.0262 O
; O
pain O
, O
P O
= O
0.0238 O
; O
itching O
, O
P O
= O
0.0135 O
; O
global O
patient O
assessment O
, O
P O
= O
0.045 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inspection O
by O
direct B-outcome ['Physiological-Clinical']
palpation I-outcome ['Physiological-Clinical']
, O
conventional B-outcome ['Resource-use']
instruments I-outcome ['Resource-use']
, O
and O
laparoscopic B-outcome ['Resource-use']
instruments I-outcome ['Resource-use']
was O
performed O
on O
all O
objects O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

The O
children O
on O
both O
regimens O
were O
comparable O
for O
sex O
, O
race O
, O
age O
at O
initial O
ALL O
diagnosis O
, O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
ALL I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CNS I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
, O
systemic O
therapy O
both O
before O
and O
after O
CNS I-outcome ['Physiological-Clinical']
relapse O
, O
and O
number O
of I-outcome ['Physiological-Clinical']
blasts O
in O
the O
spinal O
fluid O
at O
diagnosis I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CNS I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
groups O
appeared O
similar O
at O
intake O
on O
all O
measures O
; O
however O
, O
at O
follow-up O
the O
intensive O
treatment O
group O
outperformed O
the O
parent O
training O
group O
on O
measures O
of O
intelligence B-outcome ['Life-Impact']
, O
visual-spatial B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
language B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
outcome O
was O
assessed O
by O
means O
of O
direct O
observations O
( O
n O
= O
11 O
) O
and O
on O
the O
basis O
of O
scores O
on O
a O
list O
of O
target B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
, O
and O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
difference O
is O
probably O
due O
to O
the O
reduction O
of O
wave B-outcome ['Physiological-Clinical']
reflection I-outcome ['Physiological-Clinical']
caused O
by O
enalapril O
. O
['Physiological-Clinical']

RESULTS O
Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O
[]

Recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
longer O
in O
the O
dexmedetomidine O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Four O
patients O
assigned O
to O
sclerotherapy O
and O
12 O
assigned O
to O
staple O
transection O
did O
not O
actually O
undergo O
those O
procedures O
, O
but O
all O
analyses O
were O
made O
on O
an O
intention-to-treat O
basis O
. O
[]

RESULTS O
A O
total O
of O
55 O
patients O
completed O
the O
study O
. O
[]

METHOD O
Twenty-six O
children O
diagnosed O
with O
autism O
at O
age O
2 O
were O
re-assessed O
at O
ages O
3 O
and O
7 O
years O
. O
[]

Phase O
1 O
was O
from O
19 O
to O
58 O
wk O
, O
and O
phase O
2 O
was O
from O
59 O
to O
68 O
wk O
. O
[]

Elevated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
62.6 O
% O
) O
was O
, O
among O
risk O
factors O
, O
most O
common O
in O
the O
study O
population O
, O
followed O
by O
central B-outcome ['Physiological-Clinical']
obesity I-outcome ['Physiological-Clinical']
( O
53.4 O
% O
) O
, O
and O
hyperglycemia B-outcome ['Physiological-Clinical']
( O
52.2 O
% O
) O
defined O
using O
the O
NCEP O
2005 O
criteria O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
conducted O
a O
prospective O
, O
single-center O
, O
controlled O
, O
double-masked O
study O
of O
39 O
RGP O
lens O
wearers O
. O
[]

Tailored O
group O
participants O
demonstrated O
significantly O
greater O
positive O
changes O
in O
prevention B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
after O
the O
intervention O
, O
including O
['Life-Impact']

Level O
of O
intervention O
was O
controlled O
by O
systematically O
varying O
the O
manner O
and O
frequency O
with O
which O
objects O
were O
presented O
, O
the O
extent O
to O
which O
the O
experimenter O
talked O
to O
the O
infant O
, O
and O
physical O
proximity O
. O
[]

PATIENTS O
AND O
METHODS O
Eight O
cirrhotics O
( O
Child O
's O
B O
or O
C O
) O
without O
transjugular O
intrahepatic O
portosystemic O
shunts O
( O
TIPS O
) O
and O
seven O
with O
TIPS O
underwent O
two O
oral O
glutamine O
( O
20 O
g O
) O
challenges O
, O
receiving O
LOLA O
( O
5 O
g O
intravenously O
) O
on O
one O
occasion O
and O
placebo O
on O
the O
other O
in O
random O
order O
. O
[]

There O
was O
no O
observed O
effect O
on O
newborn B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
electrolyte I-outcome ['Physiological-Clinical']
levels O
with O
amnioinfusion O
, O
nor O
was O
there O
any O
apparent O
benefit O
of O
infusion O
of O
warmed O
saline O
compared O
with O
room-temperature O
saline O
. O
['Physiological-Clinical']

PROCLAIM O
: O
pilot O
study O
to O
examine O
the O
effects O
of O
clopidogrel O
on O
inflammatory O
markers O
in O
patients O
with O
metabolic O
syndrome O
receiving O
low-dose O
aspirin O
. O
[]

Three-year O
clinical O
outcome O
after O
primary O
stenting O
of O
totally O
occluded O
native O
coronary O
arteries O
: O
a O
randomized O
comparison O
of O
bare-metal O
stent O
implantation O
with O
sirolimus-eluting O
stent O
implantation O
for O
the O
treatment O
of O
total O
coronary O
occlusions O
( O
Primary O
Stenting O
of O
Totally O
Occluded O
Native O
Coronary O
Arteries O
[ O
PRISON O
] O
II O
study O
) O
. O
[]

The O
etiology O
of O
this O
pathophysiological O
problem O
is O
multifactorial O
, O
and O
patient O
positioning O
may O
be O
a O
contributing O
factor O
. O
[]

The O
length O
of O
postoperative B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
similar O
, O
with O
an O
average O
of O
19,8 O
+/- O
8,5 O
days O
. O
['Resource-use']

These O
effects O
are O
probably O
mediated O
by O
genetic O
variations O
within O
the O
OT O
system O
. O
[]

Mean O
free B-outcome ['Physiological-Clinical']
testosterone I-outcome ['Physiological-Clinical']
and O
3alpha-androstanediol B-outcome ['Physiological-Clinical']
glucuronide I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
group O
receiving O
ethinyl O
estradiol/desogestrel O
but O
not O
in O
the O
ethinyl O
estradiol/levonorgestrel O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
This O
study O
aimed O
to O
evaluate O
the O
feasibility O
of O
non-contrast-enhanced O
4D O
magnetic O
resonance O
angiography O
( O
NCE O
4D O
MRA O
) O
with O
signal O
targeting O
with O
alternative O
radiofrequency O
( O
STAR O
) O
spin O
labeling O
and O
variable O
flip O
angle O
( O
VFA O
) O
sampling O
in O
the O
assessment O
of O
dural O
arteriovenous O
fistula O
( O
DAVF O
) O
in O
the O
transverse O
sinus O
. O
[]

PURPOSE O
To O
evaluate O
the O
effect O
on O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
switching O
from O
timolol O
to O
latanoprost O
or O
adding O
latanoprost O
to O
timolol O
in O
patients O
with O
open O
angle O
glaucoma O
or O
ocular O
hypertension O
where O
IOP B-outcome ['Physiological-Clinical']
is O
not O
adequately O
controlled O
with O
timolol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
response O
between O
stings B-outcome ['Physiological-Clinical']
scraped I-outcome ['Physiological-Clinical']
or O
pinched B-outcome ['Physiological-Clinical']
off O
after O
2 O
s. O
INTERPRETATION O
These O
data O
suggest O
that O
advice O
to O
patients O
on O
the O
immediate O
treatment O
of O
bee B-outcome ['Physiological-Clinical']
stings I-outcome ['Physiological-Clinical']
should O
emphasise O
quick O
removal O
, O
without O
concern O
for O
the O
method O
of O
removal O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
aged O
between O
5 O
years O
and O
16 O
years O
10 O
months O
, O
with O
a O
confirmed O
ASD O
diagnosis O
and O
severe O
sleep O
problems O
, O
refractory O
to O
community-based O
interventions O
. O
[]

POPULATION O
Sixty-two O
patients O
, O
who O
were O
not O
suitable O
for O
a O
vaginal O
hysterectomy O
, O
requiring O
treatment O
for O
uterine O
fibroids O
. O
[]

Funded O
by O
the O
National O
Institute O
of O
Allergy O
and O
Infectious O
Diseases O
; O
ClinicalTrials.gov O
number O
, O
NCT00377260 O
. O
) O
. O
[]

Effects O
of O
an O
antimicrobial O
additive O
to O
toothbrushes O
on O
residual O
periodontal B-outcome ['Physiological-Clinical']
pathogens I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
arterial O
pressure O
was O
reduced O
20 O
% O
to O
60-65 O
mm O
Hg O
with O
use O
of O
either O
isoflurane O
( O
less O
than O
or O
equal O
to O
4 O
% O
) O
, O
sodium O
nitroprusside O
( O
less O
than O
or O
equal O
to O
8 O
micrograms.kg-1.min-1 O
) O
, O
or O
esmolol O
( O
less O
than O
or O
equal O
to O
24 O
mg/min O
) O
. O
[]

The O
concentric B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
increased O
statistically O
in O
both O
groups O
after O
the O
treatments O
. O
['Physiological-Clinical']

Fifty O
patients O
of O
uncontrolled O
type O
2 O
diabetes O
were O
divided O
in O
to O
two O
groups O
. O
[]

Changes O
obtained O
at O
the O
end O
of O
the O
treatment O
persisted O
to O
the O
3-month O
follow-up O
. O
[]

DESIGN O
Double-blind O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
of O
triamcinolone O
acetonide O
( O
1200 O
microg O
daily O
) O
vs O
placebo O
in O
participants O
with O
mild-to-moderate O
COPD O
. O
[]

BACKGROUND O
It O
is O
desirable O
to O
establish O
evidence O
for O
the O
selection O
of O
antipsychotics O
from O
the O
viewpoint O
of O
recovery O
of O
social O
activity O
in O
individual O
patient O
with O
schizophrenia O
receiving O
medication O
. O
[]

Recombinant O
human O
granulocyte O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
G-CSF O
and O
GM-CSF O
) O
administered O
following O
cytotoxic O
chemotherapy O
have O
a O
similar O
ability O
to O
mobilize O
peripheral O
blood O
stem O
cells O
. O
[]

Median O
random O
assignment O
to O
balloon B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
82 O
( O
55 O
, O
100 O
) O
minutes O
, O
and O
median O
random O
assignment O
to O
needle B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
15 O
( O
10 O
, O
26 O
) O
minutes O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
absorbable O
clips O
seem O
to O
be O
as O
effective O
as O
metal O
clips O
in O
providing O
hemostasis B-outcome ['Physiological-Clinical']
in O
cystic O
artery O
and O
in O
cystic O
duct O
ligation O
. O
['Physiological-Clinical']

This O
analysis O
was O
completed O
by O
criteria O
concordance O
analysis O
on O
a O
number O
of O
indicators O
of O
alcohol O
intake O
. O
[]

CONCLUSION O
This O
trial O
found O
that O
taking O
20 O
mg O
pravastatin O
for O
2 O
years O
had O
no O
significant O
effect O
on O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
patients O
with O
ADPKD O
. O
['Physiological-Clinical']

Minimising O
TTI O
increases O
the O
chances O
of O
successful O
defibrillation O
. O
[]

CONCLUSIONS O
These O
results O
are O
consistent O
with O
studies O
linking O
oxytocin O
to O
social B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
in O
rodents O
as O
well O
as O
studies O
linking O
oxytocin O
to O
['Life-Impact']

appetite B-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Study O
1 O
: O
dirithromycin O
500 O
mg O
q.d.s. O
, O
dirithromycin O
500 O
mg O
q.d.s O
. O
[]

A O
standardized O
postoperative O
fluid O
regime O
with O
Hartmann O
solution O
was O
prescribed O
at O
1.5 O
mL O
? O
[]

Patients O
with O
a O
score O
at O
or O
beyond O
this O
threshold O
would O
be O
considered O
at O
[]

Treatment O
of O
peptic B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
with O
furazolidone O
. O
['Physiological-Clinical']

The O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fits I-outcome ['Physiological-Clinical']
and O
other O
maternal B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Adverse-effects']

Thereby O
, O
GH O
shows O
a O
triphasic O
action O
on O
BMD B-outcome ['Physiological-Clinical']
: O
an O
initial O
decrease O
in O
BMD B-outcome ['Physiological-Clinical']
during O
the O
1st O
year O
, O
followed O
by O
a O
continuous O
increase O
in O
BMD B-outcome ['Physiological-Clinical']
with O
buildup O
of O
a O
stable O
plateau O
after O
60 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
NCX-4016 O
on O
gastrointestinal O
mucosa O
and O
platelet B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
healthy O
human O
volunteers O
. O
['Physiological-Clinical']

Thirty-three O
patients O
received O
mitoxantrone O
, O
whereas O
30 O
patients O
used O
doxorubicin O
. O
[]

Analyses O
were O
based O
on O
the O
intent-to-treat O
population O
. O
[]

However O
, O
it O
is O
possible O
that O
standardised O
measures O
are O
insensitive O
to O
dimensions O
of O
child O
behaviour O
that O
are O
nonetheless O
detectable O
by O
parents O
. O
[]

CONCLUSION O
Vagal O
nerve O
stimulation O
with O
CardioFit O
as O
a O
treatment O
for O
symptomatic O
heart O
failure O
is O
under O
active O
investigation O
as O
a O
novel O
approach O
to O
restore O
balance O
between O
the O
sympathetic O
and O
parasympathetic O
nervous O
systems O
. O
[]

Children O
responded O
to O
measures O
of O
attitudes O
( O
Adjective B-outcome ['Life-Impact']
Checklist O
) O
and O
behavioral O
intentions O
( O
['Life-Impact']

Some O
serial B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
was O
noted O
in O
25 O
% O
of O
the O
total O
patient O
population O
and O
in O
49 O
% O
of O
all O
reperfusion O
patients O
. O
['Physiological-Clinical']

The O
training B-outcome ['Life-Impact']
attrition I-outcome ['Life-Impact']
from O
the O
Internet-based O
training O
was O
even O
higher O
at O
64.4 O
% O
. O
['Life-Impact']

Rest O
and O
exercise O
nuclear O
ventriculograms O
were O
performed O
early O
( O
3 O
months O
) O
and O
late O
( O
5 O
years O
) O
after O
surgery O
. O
[]

CONCLUSIONS O
Differences O
in O
fT4 O
and O
TSH O
concentration O
, O
even O
within O
the O
reference O
range O
, O
may O
be O
a O
determinant O
of O
psychological O
well-being O
in O
treated O
hypothyroid O
patients O
although O
not O
necessarily O
with O
symptoms O
typical O
of O
anxiety O
or O
depression O
. O
[]

A O
comparative O
trial O
of O
liver O
biopsy O
needles O
. O
[]

Parameters O
discriminating O
the O
development O
of O
ESUL B-outcome ['Physiological-Clinical']
in O
a O
specific O
patient O
were O
type O
of O
AF B-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
delivered I-outcome ['Physiological-Clinical']
, O
usage O
of O
a O
nasogastric O
tube O
, O
and O
additional O
left O
atrial O
lines O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ANIMALS O
Five O
adult O
Beagles O
with O
periodontitis O
. O
[]

OBJECTIVE O
We O
hypothesized O
that O
IIT O
reactivates O
the O
somatotropic O
axis O
and O
anabolism B-outcome ['Physiological-Clinical']
in O
PICU O
patients O
. O
['Physiological-Clinical']

Corresponding O
values O
for O
the O
control O
group O
were O
5469 O
and O
4246 O
. O
[]

We O
administered O
measures O
of O
pseudoword B-outcome ['Life-Impact']
reading I-outcome ['Life-Impact']
, O
phonological B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
, O
phonological B-outcome ['Life-Impact']
word I-outcome ['Life-Impact']
decoding I-outcome ['Life-Impact']
and O
orthographical B-outcome ['Life-Impact']
word I-outcome ['Life-Impact']
decoding I-outcome ['Life-Impact']
tasks O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Pseudoephedrine O
and O
preexercise O
feeding O
: O
influence O
on O
performance B-outcome ['Life-Impact']
. O
['Life-Impact']

No O
significant O
changes O
were O
seen O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
low-density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
in O
either O
group O
. O
['Physiological-Clinical']

All O
hearts B-outcome ['Physiological-Clinical']
functioned I-outcome ['Physiological-Clinical']
adequately O
in O
both O
groups O
. O
['Physiological-Clinical']

In O
addition O
, O
there O
was O
no O
significant O
difference O
in O
the O
reduction O
of O
plaque O
volume O
achieved O
by O
these O
2 O
medications O
. O
[]

71 O
U/L O
, O
P O
> O
0.05 O
) O
. O
[]

A O
significantly O
higher O
proportion O
of O
ICS O
than O
placebo O
participants O
who O
complied O
with O
using O
their O
inhaler O
reported O
easy B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
( O
11.2 O
% O
vs O
3.5 O
% O
, O
respectively O
) O
and O
the O
slow B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cuts I-outcome ['Physiological-Clinical']
or O
sores B-outcome ['Physiological-Clinical']
( O
2.4 O
% O
vs O
0.5 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

when O
novel O
stimuli O
were O
presented O
during O
an O
instructional O
task O
. O
[]

One O
hundred O
seventy-seven O
women O
aged O
41 O
+/- O
8 O
( O
mean O
+/- O
SD O
) O
years O
, O
referred O
for O
evaluation O
of O
excessive O
uterine O
bleeding O
, O
were O
enrolled O
in O
an O
open-label O
randomized O
trial O
to O
evaluate O
the O
efficacy O
of O
local O
anesthesia O
before O
hysteroscopy B-outcome ['Physiological-Clinical']
in O
an O
outpatient O
population O
. O
['Physiological-Clinical']

In O
group O
I O
, O
the O
[]

The O
model O
predicts O
that O
mean O
plasma B-outcome ['Physiological-Clinical']
diltiazem I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
79 O
, O
172 O
, O
and O
294 O
ng/ml O
are O
required O
to O
produce O
a O
20 O
% O
, O
30 O
% O
, O
and O
40 O
% O
reduction O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
examinations O
indicate O
in O
general O
the O
difficulty O
of O
the O
judgement O
of O
efficacy O
of O
non-medicamentous O
therapeutic O
measures O
in O
connection O
with O
a O
rational O
dose-reduced O
long-term O
therapy O
with O
antihypertensive O
drugs O
. O
[]

Clinical O
cure O
or O
improvement O
was O
observed O
in O
100 O
and O
99 O
% O
of O
the O
ciprofloxacin O
and O
ceftriaxone O
groups O
, O
respectively O
. O
[]

There O
were O
31 O
deaths O
( O
55 O
% O
) O
in O
the O
dialysis O
group O
and O
28 O
deaths B-outcome ['Mortality']
( O
50 O
% O
) O
in O
the O
diet O
group O
. O
['Mortality']

However O
, O
clinician-rated O
improvements O
in O
behavioral B-outcome ['Life-Impact']
ratings O
following O
treatment O
with O
amantadine O
suggest O
that O
further O
studies O
with O
this O
or O
other O
drugs O
acting O
on O
the O
glutamatergic O
system O
are O
warranted O
. O
['Life-Impact']

Registration O
accuracy O
of O
153Gd O
transmission O
images O
of O
the O
brain O
. O
[]

TSAb B-outcome ['Physiological-Clinical']
was O
determined O
on O
whole O
serum O
in O
29 O
patients O
before O
and O
at O
the O
end O
of O
treatment O
, O
and O
in O
26 O
patients O
at O
the O
end O
of O
treatment O
only O
. O
['Physiological-Clinical']

Renal O
function O
was O
assessed O
by O
serially O
measuring O
the O
serum O
creatinine O
, O
glomerular O
filtration O
rate O
( O
using O
Cr51-EDTA O
) O
, O
and O
24-h O
urinary O
protein O
excretion O
. O
[]

The O
use O
of O
low O
dose O
heparin O
in O
MARS O
improves O
the O
disorder O
of O
hypercoagulable O
state O
during O
the O
high O
coaguation O
period O
, O
while O
heparin-free O
during O
low O
coagulation O
period O
can O
effectively O
prevent O
the O
occurrence O
of O
bleeding O
and O
improve O
the O
mechanism O
of O
blood O
coagulation O
by O
reducing O
heparin-like O
substance O
in O
the O
blood O
. O
[]

A O
feasibility O
study O
exploring O
the O
role O
of O
Chinese O
herbal O
medicine O
in O
the O
treatment O
of O
endometriosis O
. O
[]

SETTING O
Seven O
trials O
from O
Mexico O
, O
Haiti O
, O
the O
United O
States O
, O
Zambia O
, O
Uganda O
and O
Kenya O
. O
[]

Descriptive O
statistics O
were O
used O
to O
answer O
the O
research O
questions O
. O
[]

AIM O
In O
the O
present O
study O
, O
the O
effect O
of O
chemo O
and O
radio O
therapies O
on O
serum O
trace O
elements O
content O
and O
antioxidant B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
blood O
serum O
of O
cervical O
cancer O
patients O
was O
evaluated O
. O
['Physiological-Clinical']

A O
total O
of O
165 O
infertile O
patients O
with O
CC-resistant O
PCOS O
who O
attended O
for O
treatment O
were O
the O
target O
population O
for O
this O
study O
. O
[]

Impaired O
secretion O
of O
GH O
in O
obesity O
results O
in O
the O
consequent O
loss O
of O
the O
lipolytic B-outcome ['Physiological-Clinical']
effect O
of O
GH B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ondansetron O
8 O
mg O
three O
times O
daily O
was O
also O
significantly O
better O
than O
placebo O
in O
the O
second O
study O
. O
[]

Pancuronium O
was O
given O
for O
neuromuscular O
block O
. O
[]

1.4 O
, O
p O
< O
0.05 O
) O
. O
[]

CONCLUSIONS O
These O
results O
do O
not O
support O
the O
hypothesis O
that O
water-washed O
soy O
protein O
has O
an O
effect O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additional O
studies O
to O
evaluate O
the O
antileukemic O
efficacy O
of O
Clo O
? O
[]

Effects O
of O
preoperative O
intentional O
hemodilution O
on O
the O
extravasation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
After O
training O
with O
EPI-NO O
we O
observed O
a O
significant O
increase O
in O
the O
incidence O
of O
intact B-outcome ['Physiological-Clinical']
perineum I-outcome ['Physiological-Clinical']
( O
37.4 O
% O
vs O
25.7 O
% O
; O
P O
= O
0.05 O
) O
and O
a O
tendency O
towards O
lower O
episiotomy B-outcome ['Physiological-Clinical']
rates O
( O
41.9 O
% O
vs O
50.5 O
% O
; O
P O
= O
0.11 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Poor O
adherence O
with O
prescribed O
asthma O
medication O
is O
a O
major O
barrier O
to O
positive O
treatment O
outcomes O
. O
[]

Etomidate O
with O
or O
without O
flumazenil O
anesthesia O
for O
stem O
cell O
transplantation O
in O
autistic O
children O
. O
[]

Differences O
between O
food O
forms O
were O
not O
significant O
. O
[]

In O
one O
patient O
in O
group O
II O
the O
IJV O
and O
CA O
could O
not O
be O
distinguished O
as O
one O
was O
overlying O
the O
other O
. O
[]

No O
significant O
main O
effect O
of O
[]

METHODS O
Chemotherapy O
was O
performed O
for O
72 O
h O
before O
gastrectomy O
in O
63 O
gastric O
cancer O
patients O
. O
[]

PURPOSE O
Nasopharyngeal O
carcinoma O
( O
NPC O
) O
is O
a O
radiosensitive O
and O
chemosensitive O
tumor O
. O
[]

The O
number O
of O
anginal B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
similarly O
fell O
parallel O
to O
dose O
. O
['Physiological-Clinical']

CONCLUSION O
Aerobic O
physical O
activity O
with O
sleep O
hygiene O
education O
is O
an O
effective O
treatment O
approach O
to O
improve O
sleep O
quality O
, O
mood O
and O
quality O
of O
life O
in O
older O
adults O
with O
chronic O
insomnia O
. O
[]

Isoflurane O
was O
added O
as O
needed O
. O
[]

Bradykinin-induced O
cough O
reflex O
markedly O
increases O
in O
patients O
with O
cough O
associated O
with O
captopril O
and O
enalapril O
. O
[]

CONCLUSIONS O
In O
this O
randomized O
trial O
, O
SJW O
did O
not O
increase O
smoking O
abstinence B-outcome ['Life-Impact']
rates O
. O
['Life-Impact']

Of O
the O
81 O
patients O
with O
epilepsy O
who O
were O
randomized O
, O
69 O
completed O
a O
1-month O
monitoring O
period O
with O
an O
objective O
measure O
of O
tablet O
taking O
( O
electronic O
registration O
of O
pill O
bottle O
openings O
, O
Medication O
Event O
Monitoring O
System O
[ O
MEMS O
] O
) O
. O
[]

in O
the O
SMT/TSE O
group O
. O
[]

Influence O
of O
occlusal O
access O
on O
demineralized B-outcome ['Physiological-Clinical']
dentin I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
in O
the O
atraumatic O
restorative O
treatment O
( O
ART O
) O
approach O
. O
['Physiological-Clinical']

The O
first O
molar O
, O
first O
premolar O
, O
lateral O
incisor O
, O
and O
contralateral O
canine O
( O
control O
) O
were O
blindly O
tested O
with O
an O
Analytic O
Technology O
pulp O
tester O
at O
3-min O
cycles O
for O
50 O
min O
. O
[]

Participants O
( O
N O
= O
22 O
) O
performed O
the O
TGMD-2 O
under O
three O
different O
protocols O
( O
traditional O
protocol O
, O
picture O
task O
card O
protocol O
, O
and O
picture O
activity O
schedule O
protocol O
) O
. O
[]

While O
subjects O
were O
seated O
, O
FES O
was O
applied O
to O
quadriceps O
and O
tibialis O
anterior O
muscles O
bilaterally O
using O
surface O
electrodes O
. O
[]

AIMS O
To O
evaluate O
the O
effectiveness O
of O
an O
intensive O
manualized O
social O
communication O
intervention O
( O
SCIP O
) O
for O
children O
who O
have O
PLI O
with O
or O
without O
features O
of O
ASD O
. O
[]

Clindamycin O
applied O
in O
a O
single O
preoperative O
dose O
of O
600 O
mg O
with O
or O
without O
subsequent O
5-day O
therapy O
does O
not O
demonstrate O
efficacy O
in O
prophylaxis O
for O
postoperative O
inflammatory O
complications O
after O
third O
molar O
surgery O
. O
[]

Three O
dosage-prediction O
methods O
for O
initial O
in-hospital O
stabilization O
of O
warfarin O
therapy O
were O
evaluated O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
ibuprofen O
on O
gastric B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
and O
enzymes B-outcome ['Physiological-Clinical']
involved I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
gastroprotection I-outcome ['Physiological-Clinical']
in O
healthy O
volunteers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
oil O
supplementation O
had O
no O
effect O
on O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
effective B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
filtration B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
which O
does O
not O
exclude O
effects O
of O
the O
cyclosporin-induced O
rigidified O
erythrocytes O
in O
the O
acute O
phase O
of O
renal O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
5.2 O
months O
( O
95 O
% O
CI O
: O
2.8-13.7 O
) O
on O
the O
satraplatin O
plus O
prednisone O
arm O
as O
compared O
to O
2.5 O
months O
( O
95 O
% O
CI O
: O
2.1- O
4.7 O
) O
on O
the O
prednisone O
alone O
arm O
( O
HR O
= O
0.50 O
, O
95 O
% O
CI O
: O
0.28-0.92 O
) O
. O
['Mortality']

At O
3 O
weeks O
, O
all O
pramipexole O
doses O
reduced O
the O
median O
for O
PLM B-outcome ['Physiological-Clinical']
while I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
to O
levels O
considered O
normal O
( O
< O
5PLM/h O
) O
. O
['Physiological-Clinical']

The O
current O
study O
investigated O
the O
extent O
to O
which O
the O
lag O
effect O
on O
the O
durability O
of O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
is O
due O
to O
interference O
or O
to O
the O
loss O
of O
memory O
strength O
with O
time O
. O
['Life-Impact']

The O
patients O
underwent O
hysteroscopy B-outcome ['Physiological-Clinical']
and O
endometrial O
biopsy O
with O
paracervical O
block O
by O
10 O
mL O
of O
1 O
% O
mepivacaine O
hydrochloride O
solution O
( O
n O
= O
87 O
) O
or O
no O
local O
anesthesia O
( O
n O
= O
90 O
) O
and O
assessed O
lower O
abdominal O
and O
pelvic O
pain O
according O
to O
a O
10-point O
linear O
analog O
scale O
. O
['Physiological-Clinical']

Effects O
of O
individualized O
breast O
cancer O
risk O
counseling O
: O
a O
randomized O
trial O
. O
[]

Pentoxifylline O
therapy O
was O
particularly O
useful O
in O
restoring O
the O
PBPI O
in O
men O
with O
the O
pelvic O
steal O
syndrome O
; O
six O
of O
seven O
such O
subjects O
improved O
into O
the O
normal O
range O
. O
[]

SCFA B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
( O
except O
butyrate O
) O
and O
excretions B-outcome ['Physiological-Clinical']
were O
higher O
for O
males O
than O
for O
females O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recent O
studies O
indeed O
showed O
that O
electrophysiological B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Mu-rhythm I-outcome ['Physiological-Clinical']
in O
the O
10-12Hz O
range O
is O
weaker O
when O
individuals O
with O
Asperger O
's O
syndrome O
observe O
actions O
performed O
by O
others O
compared O
to O
controls O
. O
['Physiological-Clinical']

Tirasemtiv O
was O
given O
as O
a O
single O
daily O
dose O
up O
to O
375 O
mg O
for O
two O
weeks O
, O
with O
and O
without O
concomitant O
riluzole O
. O
[]

This O
is O
likely O
to O
be O
due O
to O
a O
placebo O
effect O
. O
[]

13 O
patients O
( O
22 O
% O
) O
[ O
8 O
of O
31 O
( O
26 O
% O
) O
controls O
, O
5 O
of O
28 O
( O
18 O
% O
) O
in O
the O
interferon O
arm O
] O
received O
single O
hemi-body O
irradiation O
alone O
due O
to O
progressive O
disease O
and/or O
persistent O
cytopoenias O
following O
the O
initial O
procedure O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
measured O
weekly O
. O
['Physiological-Clinical']

RESULTS O
The O
total O
effective O
rate O
of O
the O
trial O
group O
was O
83.3 O
% O
( O
25/30 O
) O
, O
better O
than O
66.7 O
% O
( O
20/30 O
) O
of O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
Speech B-outcome ['Life-Impact']
Alone I-outcome ['Life-Impact']
, O
Sign O
Alone O
, O
Simultaneous O
Presentation O
of O
Sign O
and O
Speech B-outcome ['Life-Impact']
, O
and O
Alternating B-outcome ['Life-Impact']
Presentation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Sign I-outcome ['Life-Impact']
and O
Speech B-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Most O
complications B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
experienced O
were O
managed O
with O
additional O
medication O
or O
surgical O
intervention O
, O
resulting O
in O
a O
favorable O
outcome O
for O
subjects O
. O
['Adverse-effects']

European O
Group O
for O
the O
Investigation O
of O
Valsartan O
in O
Chronic O
Renal O
Disease O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
between O
children O
with O
ASD O
and O
typically O
matched O
groups O
for O
fixation B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
Eye I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
Mouth I-outcome ['Life-Impact']
areas I-outcome ['Life-Impact']
of O
all O
face O
types O
( O
familiar O
, O
unfamiliar O
and O
self O
) O
. O
['Life-Impact']

Pretreatment O
and O
co-administration O
of O
oral O
anti-diabetic O
agent O
with O
clomiphene O
citrate O
or O
rFSH O
for O
ovulation O
induction O
in O
clomiphene-citrate-resistant O
polycystic O
ovary O
syndrome O
. O
[]

To O
reduce O
the O
lidocaine-induced O
side O
effects O
, O
we O
evaluated O
the O
MEG-X O
formation O
after O
0.5 O
and O
1 O
mg/kg O
lidocaine O
intravenously O
in O
subjects O
with O
normal O
( O
n O
= O
5 O
) O
and O
severely O
impaired O
liver O
function O
( O
n O
= O
7 O
) O
( O
study O
I O
) O
. O
[]

There O
was O
no O
difference O
between O
the O
groups O
in O
the O
percentage O
of O
infants B-outcome ['Physiological-Clinical']
who I-outcome ['Physiological-Clinical']
avoided I-outcome ['Physiological-Clinical']
transfusions I-outcome ['Physiological-Clinical']
altogether I-outcome ['Physiological-Clinical']
( O
12 O
% O
in O
the O
liberal-transfusion O
group O
versus O
10 O
% O
in O
the O
restrictive-transfusion O
group O
) O
. O
['Physiological-Clinical']

All O
patients O
received O
nebulized O
salbutamol O
at O
0.15 O
mg/kg O
every O
4 O
hours O
for O
the O
first O
24 O
hours O
. O
[]

Four O
patients O
reported O
a O
complete O
reversion O
of O
RLS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
during O
ropinirole O
treatment O
at O
doses O
ranging O
from O
0.25-2 O
mg/d O
. O
['Physiological-Clinical']

Effect O
of O
a O
carbohydrate-protein O
supplement O
on O
endurance B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
during O
exercise O
of O
varying O
intensity O
. O
['Physiological-Clinical']

For O
this O
intervention O
group O
compared O
with O
the O
usual O
care O
group O
there O
was O
a O
highly O
significant O
improvement O
in O
the O
level O
of O
advice B-outcome ['Life-Impact']
recorded I-outcome ['Life-Impact']
as O
having O
been O
given O
on O
drug B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
, O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
driving B-outcome ['Life-Impact']
, O
alcohol B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

Pain O
following O
traumatic O
injuries O
is O
common O
, O
can O
impair O
injury O
recovery O
and O
is O
often O
inadequately O
treated O
. O
[]

The O
primary O
efficacy O
parameters O
were O
total O
American O
Urological B-outcome ['Physiological-Clinical']
Association O
( O
AUA O
) O
symptom B-outcome ['Physiological-Clinical']
score O
and O
maximum B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
Qmax O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
were O
randomly O
assigned O
to O
receive O
standard O
care O
or O
transfusions O
to O
reduce O
the O
hemoglobin O
S O
concentration O
to O
less O
than O
30 O
percent O
of O
the O
total O
hemoglobin O
concentration O
. O
[]

In O
a O
multivariate O
Cox O
regression O
model O
, O
the O
quantitative O
FLT3ITD O
mRNA O
level O
showed O
an O
independent O
prognostic O
impact O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
) O
and O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
RFS O
) O
only O
in O
the O
NPM1+ O
subgroup O
( O
OS O
: O
hazard O
ratio O
, O
5.9 O
; O
[ O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
3.1-11.2 O
] O
; O
RFS O
: O
hazard O
ratio O
, O
7.5 O
[ O
95 O
% O
CI O
: O
3.4-16.5 O
] O
) O
. O
['Mortality', 'Mortality']

Inhaled O
treprostinil O
was O
discontinued O
in O
4 O
patients O
because O
of O
symptoms O
including O
cough B-outcome ['Physiological-Clinical']
and O
bronchospasm B-outcome ['Physiological-Clinical']
( O
n O
= O
3 O
) O
and O
progression O
of O
PAH O
( O
n O
= O
1 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']
